FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Horsewill, AJ
   Jones, NH
   Caciuffo, R
AF Horsewill, AJ
   Jones, NH
   Caciuffo, R
TI RETRACTED: Evidence for coherent proton tunneling in a hydrogen bond
   network (Retracted article. See vol 298, pg 1171, 2002)
SO SCIENCE
LA English
DT Article; Retracted Publication
ID SOLID-STATE; DYNAMICS; PYRAZOLES; RESONANCE; NMR
AB We observed coherent proton tunneling in the cyclic network of four hydrogen bonds in calix[4]arene. The tunneling frequency of 35 megahertz was revealed by a peak in the magnetic field dependence of the proton spin-lattice relaxation rate measured with field-cycling nuclear magnetic resonance in the solid state at temperatures below 80 kelvin. The amplitude of the coherent tunneling peak grows with temperature according to a Boltzmann law with energy D/k(B) = (125 +/- 10) kelvin (where k(B) is Boltzmann's constant). The tunneling peak can be interpreted in the context of Level crossings in the region where the tunneling frequency matches the proton Larmor frequency. The tunneling spectrum reveals fine structure that we attribute to coupling between the hydrogen bonds in the network The characteristics of the tunneling peak are interpreted in the context of the potential energy surface experienced by the hydrogen atoms in the network.
C1 Univ Nottingham, Sch Phys & Astron, Nottingham NG7 2RD, England.
   Univ Ancona, Dipartimento Sci Mat & Terra, Ist Nazl Fis Mat, I-60131 Ancona, Italy.
RP Horsewill, AJ (reprint author), Univ Nottingham, Sch Phys & Astron, Nottingham NG7 2RD, England.
OI Caciuffo, Roberto G. M./0000-0002-8708-6219; Horsewill,
   Anthony/0000-0002-8086-1374
CR AGUILARPARRILLA F, 1992, J AM CHEM SOC, V114, P9657, DOI 10.1021/ja00050a055
   BAUGHCUM SL, 1981, J AM CHEM SOC, V103, P6296, DOI 10.1021/ja00411a005
   BERNHARD T, 1990, J CHEM PHYS, V92, P2178, DOI 10.1063/1.458009
   BLOEMBERGEN N, 1948, PHYS REV, V73, P679, DOI 10.1103/PhysRev.73.679
   Brougham DF, 1997, CHEM PHYS LETT, V272, P69, DOI 10.1016/S0009-2614(97)00493-4
   Brougham DF, 1999, NATURE, V397, P241
   CHENG CP, 1979, J AM CHEM SOC, V101, P2327, DOI 10.1021/ja00503a015
   dePaz JLG, 1997, J CHEM SOC PERK T 2, P101, DOI 10.1039/a603035a
   Diamond D, 1996, CHEM SOC REV, V25, P15, DOI 10.1039/cs9962500015
   HAUPT J, 1971, Z NATURFORSCH PT A, VA 26, P1578
   Horsewill AJ, 1999, PROG NUCL MAG RES SP, V35, P359, DOI 10.1016/S0079-6565(99)00016-3
   Kohen A, 1999, NATURE, V399, P496
   KUBO R, 1954, J PHYS SOC JPN, V9, P888, DOI 10.1143/JPSJ.9.888
   OPPENLANDER A, 1989, PHYS REV LETT, V63, P1432, DOI 10.1103/PhysRevLett.63.1432
   SAENGER W, 1982, NATURE, V296, P581, DOI 10.1038/296581a0
   Scrutton NS, 1999, EUR J BIOCHEM, V264, P666, DOI 10.1046/j.1432-1327.1999.00645.x
   Torkar M, 2000, J MAGN RESON, V144, P13, DOI 10.1006/jmre.2000.2051
NR 17
TC 35
Z9 35
U1 2
U2 27
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
J9 SCIENCE
JI Science
PD JAN 5
PY 2001
VL 291
IS 5501
BP 100
EP 103
DI 10.1126/science.291.5501.100
PG 4
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 389VJ
UT WOS:000166259100041
PM 11141555
DA 2018-12-27
ER

PT J
AU Davis, ST
   Benson, BG
   Bramson, HN
   Chapman, DE
   Dickerson, SH
   Dold, KM
   Eberwein, DJ
   Edelstein, M
   Frye, SV
   Gampe, RT
   Griffin, RJ
   Harris, PA
   Hassell, AM
   Holmes, WD
   Hunter, RN
   Knick, VB
   Lackey, K
   Lovejoy, B
   Luzzio, MJ
   Murray, D
   Parker, P
   Rocque, WJ
   Shewchuk, L
   Veal, JM
   Walker, DH
   Kuyper, LF
AF Davis, ST
   Benson, BG
   Bramson, HN
   Chapman, DE
   Dickerson, SH
   Dold, KM
   Eberwein, DJ
   Edelstein, M
   Frye, SV
   Gampe, RT
   Griffin, RJ
   Harris, PA
   Hassell, AM
   Holmes, WD
   Hunter, RN
   Knick, VB
   Lackey, K
   Lovejoy, B
   Luzzio, MJ
   Murray, D
   Parker, P
   Rocque, WJ
   Shewchuk, L
   Veal, JM
   Walker, DH
   Kuyper, LF
TI RETRACTED: Prevention of chemotherapy-induced alopecia in rats by CDK
   inhibitors (Retracted Article. See vol 298, pg 2327, 2002)
SO SCIENCE
LA English
DT Article; Retracted Publication
ID CYCLIN-DEPENDENT KINASE; CELL-CYCLE; 1,25-DIHYDROXYVITAMIN D-3;
   PROTEIN-KINASE; PROTECTION; GROWTH; ACTIVATION; APOPTOSIS; RECEPTOR;
   DESIGN
AB Most traditional cytotoxic anticancer agents ablate the rapidly dividing epithelium of the hair follicle and induce alopecia (hair Loss). Inhibition of cyclin-dependent kinase 2 (CDK2), a positive regulator of eukaryotic cell cycle progression, may represent a therapeutic strategy for prevention of chemotherapy-induced alopecia (CIA) by arresting the cell cycle and reducing the sensitivity of the epithelium to many cell cycle-active antitumor agents. Potent small-molecule inhibitors of CDK2 were developed using structure-based methods. Topical application of these compounds in a neonatal rat model of CIA reduced hair loss at the site of application in 33 to 50% of the animals. Thus, inhibition of CDK2 represents a potentially useful approach for the prevention of CIA in cancer patients.
C1 Glaxo Wellcome Inc, Res & Dev, Dept Canc Biol, Res Triangle Pk, NC 27709 USA.
   Glaxo Wellcome Inc, Res & Dev, Dept Discovery Genet, Res Triangle Pk, NC 27709 USA.
   Glaxo Wellcome Inc, Res & Dev, Dept Mol Biochem, Res Triangle Pk, NC 27709 USA.
   Glaxo Wellcome Inc, Res & Dev, Dept Biomet Res Support, Res Triangle Pk, NC 27709 USA.
   Glaxo Wellcome Inc, Res & Dev, Dept Med Chem, Res Triangle Pk, NC 27709 USA.
   Glaxo Wellcome Inc, Res & Dev, Dept Struct Chem, Res Triangle Pk, NC 27709 USA.
   Glaxo Wellcome Inc, Res & Dev, Dept Mol Sci, Res Triangle Pk, NC 27709 USA.
RP Davis, ST (reprint author), Glaxo Wellcome Inc, Res & Dev, Dept Canc Biol, 5 Moore Dr, Res Triangle Pk, NC 27709 USA.
EM std41085@glaxowellcome.com
RI ID, IMCACAT/D-5867-2014
CR Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254
   BRUNO S, 1992, CANCER RES, V52, P470
   BuquetFagot C, 1997, ANTI-CANCER DRUG, V8, P623, DOI 10.1097/00001813-199707000-00011
   Chen G, 1998, INT J CANCER, V75, P303, DOI 10.1002/(SICI)1097-0215(19980119)75:2<303::AID-IJC21>3.0.CO;2-C
   Chen YNP, 1999, P NATL ACAD SCI USA, V96, P4325, DOI 10.1073/pnas.96.8.4325
   DARZYNKIEWICZ Z, 1995, J CELL BIOCHEM, V58, P151, DOI 10.1002/jcb.240580204
   DOLD KM, UNPUB
   Dorr VJ, 1998, SEMIN ONCOL, V25, P562
   Duvic M, 1996, J AM ACAD DERMATOL, V35, P74, DOI 10.1016/S0190-9622(96)90500-9
   HARRIS JR, 1993, CANC PRINCIPLES PRAC, P1264
   Hidalgo M, 1999, ANTI-CANCER DRUG, V10, P393, DOI 10.1097/00001813-199904000-00007
   JIMENEZ JJ, 1992, CANCER RES, V52, P5123
   Kim SH, 1998, PURE APPL CHEM, V70, P555, DOI 10.1351/pac199870030555
   Levkau B, 1998, MOL CELL, V1, P553, DOI 10.1016/S1097-2765(00)80055-6
   LOBE DC, UNPUB
   McCormack ES, 1997, BIOCHEM PHARMACOL, V53, P1149, DOI 10.1016/S0006-2952(97)00094-4
   MEHTA S, UNPUB
   Mohammadi M, 1997, SCIENCE, V276, P955, DOI 10.1126/science.276.5314.955
   Munstedt K, 1997, SUPPORT CARE CANCER, V5, P139, DOI 10.1007/s005200050056
   OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612
   Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X
   Paus R, 1999, NEW ENGL J MED, V341, P491, DOI 10.1056/NEJM199908123410706
   Russo AA, 1996, NAT STRUCT BIOL, V3, P696, DOI 10.1038/nsb0896-696
   SchulzeGahmen U, 1996, J MED CHEM, V39, P4540, DOI 10.1021/jm960402a
   Shewchuk L, 2000, J MED CHEM, V43, P133, DOI 10.1021/jm990401t
   Sun L, 1998, J MED CHEM, V41, P2588, DOI 10.1021/jm980123i
   Sundberg JP, 1996, DERMATOL CLIN, V14, P619, DOI 10.1016/S0733-8635(05)70389-2
   VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103
   WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2
   ZerfassThome K, 1997, MOL CELL BIOL, V17, P407, DOI 10.1128/MCB.17.1.407
NR 30
TC 135
Z9 139
U1 2
U2 16
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
J9 SCIENCE
JI Science
PD JAN 5
PY 2001
VL 291
IS 5501
BP 134
EP 137
DI 10.1126/science.291.5501.134
PG 4
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 389VJ
UT WOS:000166259100052
PM 11141566
DA 2018-12-27
ER

PT J
AU Fujii, Y
   Tanaka, H
   Kawasaki, T
AF Fujii, Y
   Tanaka, H
   Kawasaki, T
TI RETRACTED: Prophylaxis with oral granisetron for the prevention of
   nausea and vomiting after laparoscopic cholecystectomy - A prospective
   randomized study (Retracted article. See vol. 147, pg. 681, 2012)
SO ARCHIVES OF SURGERY
LA English
DT Article; Retracted Publication
ID 5-HT3 RECEPTOR ANTAGONIST; EFFICACY
AB Hypothesis: Laparoscopic cholecystectomy is associated with a relatively high incidence of postoperative nausea and vomiting when no prophylactic antiemetic is given. This study assesses the efficacy and safety of oral granisetron hydrochloride for the prevention of nausea and vomiting after laparoscopic cholecystectomy.
   Design: A prospective, randomized, double-blind, placebo-controlled study.
   Setting: University teaching hospital.
   Patients: The study comprised 120 patients, 92 women and 28 men, undergoing laparoscopic cholecystectomy.
   Interventions: Patients received orally either placebo or granisetron at 3 different doses (1 mg, 2 mg, and 4 mg; n=30 of each) 60 minutes before surgery. A standard general anesthetic technique and postoperative analgesia were used.
   Main Outcome Measures: Emetic episodes were recorded during the first 24 hours after anesthesia.
   Results: The incidence of patients who were emesis-free 24 hours after anesthesia was 60% with 1 mg of granisetron (P =.40), 83% with 2 mg of granisetron (P = .01), and 83% with 4 mg of granisetron (P = .01), compared with placebo (53%). No clinically important adverse effects were observed in any of the groups.
   Conclusion: Preoperative oral granisetron in doses higher than 2 mg is effective for the prevention of nausea and vomiting after laparoscopic cholecystectomy.
C1 Toride Kyodo Gen Hosp, Dept Anesthesiol, Toride, Ibaraki, Japan.
   Toride Kyodo Gen Hosp, Dept Surg, Toride, Ibaraki, Japan.
RP Fujii, Y (reprint author), Univ Tsukuba, Inst Clin Med, Dept Anesthesiol, 2-1-1 Amakubo, Tsukuba, Ibaraki 305, Japan.
CR Andrews PL, 1992, EJC SUPPL, V28A, P2
   BERMUDEZ J, 1988, BRIT J CANCER, V58, P644, DOI 10.1038/bjc.1988.277
   CARMICHAEL J, 1989, CANCER CHEMOTH PHARM, V24, P45
   Fujii Y, 1997, CAN J ANAESTH, V44, P396, DOI 10.1007/BF03014460
   Fujii Y, 1998, EUR J ANAESTH, V15, P166, DOI 10.1111/j.0265-0215.1998.00267.x
   Iitomi T, 1995, Masui, V44, P1627
   LEESER J, 1991, ANESTH ANALG, V72, P751
   Maisano R, 1995, ANTICANCER RES, V15, P2287
   SANTON JM, 1991, ANAESTHESIA, V46, P317
   WATCHA MF, 1992, ANESTHESIOLOGY, V77, P162, DOI 10.1097/00000542-199207000-00023
   Watcha MF, 1997, ANESTHESIOLOGY, V86, P1170, DOI 10.1097/00000542-199705000-00021
   YARKER YE, 1994, DRUGS, V48, P761, DOI 10.2165/00003495-199448050-00008
NR 12
TC 8
Z9 8
U1 4
U2 9
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0004-0010
EI 1538-3644
J9 ARCH SURG-CHICAGO
JI Arch. Surg.
PD JAN
PY 2001
VL 136
IS 1
BP 101
EP 104
DI 10.1001/archsurg.136.1.101
PG 4
WC Surgery
SC Surgery
GA 390QH
UT WOS:000166307500023
PM 11146789
DA 2018-12-27
ER

PT J
AU Saitoh, Y
   Kaneda, K
   Fujii, Y
   Oshima, T
AF Saitoh, Y
   Kaneda, K
   Fujii, Y
   Oshima, T
TI RETRACTED: Nicorandil accelerates recovery of neuromuscular block caused
   by vecuronium (Retracted article. See vol. 62, pg. 942, 2015)
SO CANADIAN JOURNAL OF ANAESTHESIA-JOURNAL CANADIEN D ANESTHESIE
LA English
DT Article; Retracted Publication
ID SKELETAL-MUSCLE; IN-VITRO; STIMULATION; CHANNELS
AB Purpose: To examine the effect of nicorandil, a K-ATP, channel agonist, on neuromuscular block caused by vecuronium in patients anesthetized with nitrous oxide, oxygen. isoflurane, and fentanyl.
   Methods: Sixty adult patients were allocated to four groups of 15: nicorandil-post-tetanic count (N-PTC), nicorandil-train-of-four (N-TOF), control-post-tetanic count (C-PTC) or control-train-of-four (C-TOF) group. In the N-PTC and N-TOF groups. 0.1 mg.kg(-1) nicorandil was given as a bolus followed by an infusion at mug.kg(-1) min(-1) Two minutes after the bolus, 0.1 mg.kg(-1) vecuronium was administered, In the C-PTC or C-TOF group normal saline was given instead of nicorandil. PTC and TOF responses were measured mechanically using a force displacement transducer.
   Results: Time from the administration of vecuronium to the onset of neuromuscular block in the N-PTC or N-TOF group did not differ from that in the C-PTC or C-TOF group (241 +/- 33 vs 225 +/- 32 sec, mean +/- SD), Times from vecuronium injection to the return of PTC in the N-PTC and C-PTC groups, and those of T1, T2, T3, and T4 (first, second, third, and fourth stimulation of TOF) in the N-TOF and C-TOF groups did not differ. Recoveries of PTC in the N-PTC and C-PTC groups followed similar time course. T1/control twitch height and TOF ratio (T4/T1) in the N-TOF group were higher than those in the C-TOF group 80-120 min and 100-120 min after administration of vecuronium, respectively.
   Conclusion: Nicorandil accelerates recovery of neuromuscular block caused by vecuronium.
C1 Fukushima Med Univ, Sch Med, Dept Anesthesiol, Fukushima, Fukushima 9601295, Japan.
   Toride Kyodo Gen Hosp, Ibaraki, Osaka, Japan.
   Univ Tsukuba, Dept Anesthesiol, Inst Clin Med, Tsukuba, Ibaraki, Japan.
   Gifu Univ, Sch Med, Dept Anesthesiol & Crit Care Med, Gifu 500, Japan.
RP Saitoh, Y (reprint author), Fukushima Med Univ, Sch Med, Dept Anesthesiol, 1 Hikarigaoka, Fukushima, Fukushima 9601295, Japan.
EM ys@m6.people.or.jp
CR ALLARD B, 1993, EUR J PHARMACOL, V236, P419, DOI 10.1016/0014-2999(93)90480-6
   COLQUHOUN D, 1979, J PHYSIOL-LONDON, V293, P247, DOI 10.1113/jphysiol.1979.sp012888
   DONATI F, 1988, CAN J ANAESTH, V35, P1, DOI 10.1007/BF03010535
   HONG SJ, 1991, J PHARMACOL EXP THER, V259, P932
   KOPMAN AF, 1984, ANESTHESIOLOGY, V61, P83, DOI 10.1097/00000542-198461010-00015
   KOYAMA K, 1998, ANESTH ANALG, V846, pS77
   Lee GC, 1997, ANESTHESIOLOGY, V86, P48, DOI 10.1097/00000542-199701000-00008
   MCCOY EP, 1995, ANESTH ANALG, V80, P364, DOI 10.1097/00000539-199502000-00027
   MUOZ HR, 1997, ANESTH ANALG, V85, P437
   Murayama S, 1997, AM J CARDIOL, V79, P1685, DOI 10.1016/S0002-9149(97)00225-7
   Oyanagi S, 1995, Masui, V44, P986
   Sakata Y, 1997, AM HEART J, V133, P616, DOI 10.1016/S0002-8703(97)70162-5
   Santanen OAP, 1999, ACTA ANAESTH SCAND, V43, P338, DOI 10.1034/j.1399-6576.1999.430316.x
   SPULER A, 1989, N-S ARCH PHARMACOL, V339, P327
   TSUTAMOTO T, 1994, AM HEART J, V127, P866, DOI 10.1016/0002-8703(94)90555-X
   UTOH J, 1995, AM J EMERG MED, V13, P610, DOI 10.1016/0735-6757(95)90188-4
   VibyMogensen J, 1996, ACTA ANAESTH SCAND, V40, P59, DOI 10.1111/j.1399-6576.1996.tb04389.x
   WESELCOUCH EO, 1993, J PHARMACOL EXP THER, V267, P410
NR 18
TC 1
Z9 1
U1 2
U2 7
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0832-610X
J9 CAN J ANAESTH
JI Can. J. Anaesth.-J. Can. Anesth.
PD JAN
PY 2001
VL 48
IS 1
BP 28
EP 33
DI 10.1007/BF03019810
PG 6
WC Anesthesiology
SC Anesthesiology
GA 395MW
UT WOS:000166585000004
PM 11212045
DA 2018-12-27
ER

PT J
AU Koch, CA
AF Koch, CA
TI RETRACTED: Rapid increase in bone mineral density in a child with
   osteoporosis and autoimmune hypoparathyroidism treated with PTH 1-34
   (Retracted Article. See vol 110, pg 100, 2002)
SO EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES
LA English
DT Article; Retracted Publication
DE hypoparathyroidism; osteoporosis; autoimmune polyglandular syndrome;
   bone densitometry
ID PARATHYROID-HORMONE; IDIOPATHIC HYPOPARATHYROIDISM; ANTICONVULSANT
   THERAPY; ANABOLIC ACTIONS; TRABECULAR BONE; DEFICIENCY;
   HISTOMORPHOMETRY; OSTEOMALACIA; RESORPTION; CALCIUM
AB We describe a 16-year-old girl with autoimmune polyglandular syndrome type I including hypoparathyroidism, who had osteoporosis that improved rapidly with parathyroid hormone replacement therapy. Patients with hypoparathyroidism usually have high bone mass. Our, patient developed vertebral compression fractures at age 10, shortly after hypoparathyroidism was diagnosed. She continued to have low lumbar bone mass until age 16, when a dual energy x-ray absorptiometry (DEXA) gy revealed a Z score of -2.2 SD. Several factors including decreased physical activity, total body magnesium depletion, and intermittent ketoconazole and short-term prednisone treatment, may have contributed to the development and progression of osteoporosis. Therapy with synthetic human parathyroid hormone (PTH) 1-34 rapidly normalized lumbar bone mass, as assessed by DEXA..
C1 NICHHD, Pediat & Reprod Endocrinol Branch, NIH, Bethesda, MD 20892 USA.
RP Koch, CA (reprint author), NICHHD, Pediat & Reprod Endocrinol Branch, NIH, Bldg 10,Rm 9D42, Bethesda, MD 20892 USA.
EM Kochc@exchange.nih.gov
OI Koch, Christian/0000-0003-0678-1242
CR ABUGASSA S, 1993, J CLIN ENDOCR METAB, V76, P1617, DOI 10.1210/jc.76.6.1617
   AHONEN P, 1990, NEW ENGL J MED, V322, P1829, DOI 10.1056/NEJM199006283222601
   ALBRIGHT F, 1956, J CLIN ENDOCR METAB, V16, P419, DOI 10.1210/jcem-16-3-419
   Betterle C, 1998, J CLIN ENDOCR METAB, V83, P1049, DOI 10.1210/jc.83.4.1049
   DEMPSTER DW, 1993, ENDOCR REV, V14, P690, DOI 10.1210/er.14.6.690
   DEMPSTER DW, 1995, ENDOCRINE REV MONOGR, V4, P247
   DIMICH A, 1967, ARCH INTERN MED, V120, P449, DOI 10.1001/archinte.120.4.449
   DREZNER MK, 1977, J CLIN ENDOCR METAB, V45, P114, DOI 10.1210/jcem-45-1-114
   Duan YB, 1999, J CLIN ENDOCR METAB, V84, P718, DOI 10.1210/jc.84.2.718
   Emerson K, 1941, ANN INTERN MED, V14, P1256, DOI 10.7326/0003-4819-14-7-1256
   Feldkamp J, 2000, EXP CLIN ENDOCR DIAB, V108, P37
   FUJIYAMA K, 1995, J CLIN ENDOCR METAB, V80, P2135, DOI 10.1210/jc.80.7.2135
   GLASS AR, 1988, J CLIN ENDOCR METAB, V66, P934, DOI 10.1210/jcem-66-5-934
   HAHN TJ, 1972, NEW ENGL J MED, V287, P900, DOI 10.1056/NEJM197211022871803
   HARRIS M, 1974, ARCH ORAL BIOL, V19, P981, DOI 10.1016/0003-9969(74)90083-1
   Koch CA, 2000, NEUROSURG REV, V23, P171, DOI 10.1007/PL00011952
   Kurland ES, 2000, J CLIN ENDOCR METAB, V85, P3069, DOI 10.1210/jc.85.9.3069
   Langdahl BL, 1996, BONE, V18, P103, DOI 10.1016/8756-3282(95)00443-2
   Lindsay R, 1997, LANCET, V350, P550, DOI 10.1016/S0140-6736(97)02342-8
   MITHAL A, 1989, Indian Journal of Pediatrics, V56, P267, DOI 10.1007/BF02726623
   OLIVERI MB, 1991, BONE MINER, V12, P91, DOI 10.1016/0169-6009(91)90038-2
   ORRWALKER B, 1990, POSTGRAD MED J, V66, P1061, DOI 10.1136/pgmj.66.782.1061
   REID IR, 1991, AM J MED, V90, P63, DOI 10.1016/0002-9343(91)90507-T
   Rude RK, 1998, MINER ELECTROL METAB, V24, P314, DOI 10.1159/000057389
   Rude RK, 1999, MAGNESIUM RES, V12, P257
   SCHULMAN JL, 1955, PEDIATRICS, V16, P848
   SCHUTTAINE JC, 1982, J PEDIAT, V106, P255
   SEEMAN E, 1982, J CLIN INVEST, V69, P1302, DOI 10.1172/JCI110570
   Selye H, 1932, ENDOCRINOLOGY, V16, P547, DOI 10.1210/endo-16-5-547
   SMITH R, 1995, BRIT J RHEUMATOL, V34, P68
   STEINBERG H, 1952, MEDICINE, V31, P133, DOI 10.1097/00005792-195205000-00001
   TOULIATOS JS, 1995, AM J MED SCI, V310, P56, DOI 10.1097/00000441-199508000-00003
   WHITFIELD JF, 1995, CALCIFIED TISSUE INT, V56, P227, DOI 10.1007/BF00298615
   Winer KK, 1998, J CLIN ENDOCR METAB, V83, P3480, DOI 10.1210/jc.83.10.3480
   Winer KK, 1996, JAMA-J AM MED ASSOC, V276, P631, DOI 10.1001/jama.276.8.631
NR 35
TC 5
Z9 5
U1 4
U2 10
PU JOHANN AMBROSIUS BARTH VERLAG MEDIZINVERLAGE HEIDELBERG GMBH
PI STUTTGART
PA RUEDIGERSTR 14, D-70469 STUTTGART, GERMANY
SN 0947-7349
EI 1439-3646
J9 EXP CLIN ENDOCR DIAB
JI Exp. Clin. Endocrinol. Diabet.
PY 2001
VL 109
IS 6
BP 350
EP 354
DI 10.1055/s-2001-17398
PG 5
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 474UE
UT WOS:000171124600008
PM 11571675
DA 2018-12-27
ER

PT J
AU Takahashi, H
AF Takahashi, H
TI RETRACTED: A SADS defect in tumor cells provides optimism (Retracted
   Article. See vol 7, pg 749, 2001)
SO NATURE MEDICINE
LA English
DT Editorial Material; Retracted Publication
ID APOPTOSIS
AB SADS, a new component of the Fas-mediated apoptotic pathway, is downregulated in patients with colon carcinoma. Could this downregulation be a widespread mechanism of tumor cell immune evasion?
C1 Jikei Univ, Sch Med, Inst Clin Med & Res, Minato Ku, Tokyo 1058461, Japan.
RP Takahashi, H (reprint author), Jikei Univ, Sch Med, Inst Clin Med & Res, Minato Ku, 3-25-8 Nishi Shinbashi, Tokyo 1058461, Japan.
EM takahashi@jikei.ac.jp
CR BERKE G, 1995, CELL, V81, P9, DOI 10.1016/0092-8674(95)90365-8
   Enari M, 1998, NATURE, V391, P43
   Imai Y, 1999, NATURE, V398, P777
   Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1
   MARTIN PJ, 1975, BRIT MED J, V1, P17, DOI 10.1136/bmj.1.5948.17
   Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675
   Shiraki K, 1997, P NATL ACAD SCI USA, V94, P6420, DOI 10.1073/pnas.94.12.6420
   Suzuki A, 2001, NAT MED, V7, P88, DOI 10.1038/83401
   THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464
NR 9
TC 4
Z9 4
U1 3
U2 9
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1078-8956
EI 1546-170X
J9 NAT MED
JI Nat. Med.
PD JAN
PY 2001
VL 7
IS 1
BP 26
EP 27
DI 10.1038/83306
PG 2
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
   Experimental
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
   Medicine
GA 389MX
UT WOS:000166243100024
PM 11135609
DA 2018-12-27
ER

PT J
AU Suzuki, A
   Obata, S
   Hayashida, M
   Kawano, H
   Nakano, T
   Shiraki, K
AF Suzuki, A
   Obata, S
   Hayashida, M
   Kawano, H
   Nakano, T
   Shiraki, K
TI RETRACTED: SADS: A new component of Fas-DISC is the accelerator for cell
   death signaling and is downregulated in patients with colon carcinoma
   (Retracted Article. See vol 7, pg 749, 2001)
SO NATURE MEDICINE
LA English
DT Article; Retracted Publication
ID MEDIATED APOPTOSIS; PROTEIN; RECEPTOR; ANTIGEN; FADD; INVOLVEMENT;
   CASPASE-8; ACTIVATION; PROTEASES; PATHWAYS
AB Fas is the death receptor, transducing cell death signaling upon stimulation by Fas ligand. During Fas-initiated cell death signaling, the formation of Fas-death inducing signaling complex (Fas-DISC) is the first step. Here we have identified a new component of Fas-DISC which we call 'small-accelerator for death signaling' (SADS). SADS cDNA encodes a 150 amino acid polypeptide (Mr = 16,700). During Fas-mediated cell death, SADS enhances the interaction of Fas-death domain-interactive factors (FADD) and procaspase-8, and deletion mutant analysis has identified FADD- and caspase-8-interactive domains in SADS. Inhibition or removal of SADS delays Fas-mediated cell death. In addition, we demonstrate the deletion or mutation of SADS in patients with colon carcinoma and that exogenous SADS expression in human colon carcinoma SW480 cells that lack SADS leads to re-acquisition of Fas-mediated cell death. Here, we propose that SADS is one of the cell death-associated factors and enhances Fas-DISC formation, especially FADD and procaspase-8 recruitment.
C1 Daiichi Pharmaceut Co Ltd, Basic Technol Res Lab, Project Cell Death Res, Tokyo R&D Ctr,Edogawa Ku, Tokyo 1348630, Japan.
   Kishida Chem Co Ltd, Sanda Factory, Res & Dev Grp, Biochem Lab, Sanda, Hyogo 6691339, Japan.
   Mie Univ, Sch Med, Dept Internal Med 1, Tsu, Mie 5148507, Japan.
RP Suzuki, A (reprint author), Daiichi Pharmaceut Co Ltd, Basic Technol Res Lab, Project Cell Death Res, Tokyo R&D Ctr,Edogawa Ku, Kitakasai 1-16-13, Tokyo 1348630, Japan.
EM LEB00373@nifty.ne.jp
CR Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3
   Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9
   CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3
   Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0
   FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761
   Hasegawa J, 1996, CANCER RES, V56, P1713
   Imai Y, 1999, NATURE, V398, P777
   ITOH N, 1993, J BIOL CHEM, V268, P10932
   ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5
   KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x
   Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5
   LAZEBNIK YA, 1995, P NATL ACAD SCI USA, V92, P9042, DOI 10.1073/pnas.92.20.9042
   Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X
   Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0
   NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326
   Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7
   Sahara S, 1999, NATURE, V401, P168
   Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675
   Shiraki K, 1997, P NATL ACAD SCI USA, V94, P6420, DOI 10.1073/pnas.94.12.6420
   Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3
   Suzuki A, 1999, P SOC EXP BIOL MED, V221, P72, DOI 10.1046/j.1525-1373.1999.d01-56.x
   TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3
   Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907
   WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0
   Wyllie A H, 1980, Int Rev Cytol, V68, P251
   YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747
NR 26
TC 14
Z9 14
U1 3
U2 10
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1078-8956
EI 1546-170X
J9 NAT MED
JI Nat. Med.
PD JAN
PY 2001
VL 7
IS 1
BP 88
EP 93
DI 10.1038/83401
PG 6
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
   Experimental
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
   Medicine
GA 389MX
UT WOS:000166243100040
PM 11135621
DA 2018-12-27
ER

PT J
AU Smith, T
   McCracken, J
   Shin, YK
   DeWitt, D
AF Smith, T
   McCracken, J
   Shin, YK
   DeWitt, D
TI RETRACTED: Arachidonic acid and nonsteroidal anti-inflammatory drugs
   induce conformational changes in the human prostaglandin endoperoxide
   H-2 synthase-2 (cyclooxygenase-2) (Retracted Article. See vol 279, pg
   6204, 2004)
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article; Retracted Publication
ID H-SYNTHASE; CRYSTAL-STRUCTURE; DNA DUPLEX; SITE; ACTIVATION; BINDING;
   PROTEIN; AGENTS; PROTEOLYSIS; INHIBITION
AB By using the technique of site-directed spin labeling combined with EPR spectroscopy, we have observed that binding of arachidonic acid and nonsteroidal antiinflammatory drugs induces conformational changes in the human prostaglandin endoperoxide H-2 synthase enzyme (PGHS-2), Line shape broadening resulting from spin-spin coupling of nitroxide pairs introduced into the membrane-binding helices of PGHS-2 was used to calculate the inter-helical distances and changes in these distances that occur in response to binding various ligands, The inter-residue distances determined for the PGHS-2 holoenzyme using EPR were 1-7.9 Angstrom shorter than those of the crystal structure of the PGHS-8 holoenzyme, However, inter-helical distances calculated and determined by EPR for PGHS-S complexed with arachidonic acid, flurbiprofen, and CS-58125 were in close agreement with those obtained from the cognate crystal structures. These results indicate that the structure of the solubilized PGHS-S holoenzyme measured in solution differs from the crystal structure of PGHS-2 holoenzyme obtained by x-ray analysis. Furthermore, binding of ligands induces a conformational change in the holo-PGHS-2, converting it to a structure similar to those obtained by x-ray analysis. Proteolysis protection assays had previously provided circumstantial evidence that binding of heme and non-steroidal anti-inflammatory drugs alters the conformation of PGHS, but the present experiments are the first to directly measure such changes. The finding that arachidonate can also induce a conformational change in PGHS-2 was unexpected, and the magnitude of changes suggests this structural flexibility may be integral to the cyclooxygenase catalytic mechanism.
C1 Michigan State Univ, Dept Biochem, E Lansing, MI 48824 USA.
   Michigan State Univ, Dept Chem, E Lansing, MI 48824 USA.
   Iowa State Univ Sci & Technol, Dept Biochem & Biophys, Ames, IA 50011 USA.
RP DeWitt, D (reprint author), Michigan State Univ, Dept Biochem, 519 Biochem, E Lansing, MI 48824 USA.
EM dewittd@msu.edu
FU NIGMS NIH HHS [GM57323]
CR CHEN YNP, 1987, J BIOL CHEM, V262, P16892
   DeWitt DL, 1999, MOL PHARMACOL, V55, P625
   Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768
   FEIX JB, 1998, BIO MAGN RE, V14, P251
   Gross A, 1999, BIOCHEMISTRY-US, V38, P10324, DOI 10.1021/bi990856k
   Hall JA, 1997, J BIOL CHEM, V272, P17610, DOI 10.1074/jbc.272.28.17610
   HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384
   JOSHUATOR L, 1988, NATURE, V334, P82, DOI 10.1038/334082a0
   Kalgutkar AS, 1996, BIOCHEMISTRY-US, V35, P9076, DOI 10.1021/bi9605752
   KULMACZ RJ, 1989, J BIOL CHEM, V264, P14136
   KULMACZ RJ, 1982, BIOCHEM BIOPH RES CO, V104, P758, DOI 10.1016/0006-291X(82)90702-1
   Kurumbail RG, 1996, NATURE, V384, P644, DOI 10.1038/384644a0
   Luong C, 1996, NAT STRUCT BIOL, V3, P927, DOI 10.1038/nsb1196-927
   Malkowski MG, 2000, SCIENCE, V289, P1933, DOI 10.1126/science.289.5486.1933
   Marnett LJ, 1998, CURR OPIN CHEM BIOL, V2, P482, DOI 10.1016/S1367-5931(98)80124-5
   MILLER M, 1988, NATURE, V334, P85, DOI 10.1038/334085a0
   Ottemann KM, 1998, BIOCHEMISTRY-US, V37, P7062, DOI 10.1021/bi980305e
   Perozo E, 1999, SCIENCE, V285, P73, DOI 10.1126/science.285.5424.73
   PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0
   RABENSTEIN MD, 1995, P NATL ACAD SCI USA, V92, P8239, DOI 10.1073/pnas.92.18.8239
   Smith T, 2000, ARCH BIOCHEM BIOPHYS, V375, P195, DOI 10.1006/abbi.1999.1659
   Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157
   SMITH WL, 1996, THERAPEUTIC IMMUNOLO, P119
   So OY, 1998, J BIOL CHEM, V273, P5801, DOI 10.1074/jbc.273.10.5801
   Thuresson ED, 2000, J BIOL CHEM, V275, P8501, DOI 10.1074/jbc.275.12.8501
NR 25
TC 18
Z9 18
U1 3
U2 12
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD DEC 22
PY 2000
VL 275
IS 51
BP 40407
EP 40415
DI 10.1074/jbc.M005563200
PG 9
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 386BD
UT WOS:000166039500083
PM 11006278
OA Bronze
DA 2018-12-27
ER

PT J
AU Schon, JH
   Kloc, C
   Batlogg, B
AF Schon, JH
   Kloc, C
   Batlogg, B
TI RETRACTED: Perylene: A promising organic field-effect transistor
   material (Retracted Article. See vol 82, pg 1313, 2003)
SO APPLIED PHYSICS LETTERS
LA English
DT Article; Retracted Publication
ID THIN-FILM TRANSISTORS; RING OSCILLATORS
AB Field-effect transistors based on single crystalline perylene have been prepared and analyzed in the temperature range from 50 to 300 K. Room temperature electron mobilities as high as 5.5 cm(2)/V s have been achieved. In addition, ambipolar device operation, i.e., n- and p-channel activity, is observed. The temperature dependence of the electron and hole mobilities is discussed in the limits of hopping and band-like transport mechanisms. (C) 2000 American Institute of Physics. [S0003-6951(00)00749-X].
C1 Bell Labs, Lucent Technol, Murray Hill, NJ 07974 USA.
RP Schon, JH (reprint author), Bell Labs, Lucent Technol, 600 Mt Ave,POB 636, Murray Hill, NJ 07974 USA.
EM hendrik@lucent.com
RI Kloc, Christian/A-2255-2011
CR Bao ZA, 1998, J AM CHEM SOC, V120, P207, DOI 10.1021/ja9727629
   BROWN AR, 1995, SCIENCE, V270, P972, DOI 10.1126/science.270.5238.972
   Crone B, 2000, NATURE, V403, P521, DOI 10.1038/35000530
   DODABALAPUR A, 1995, SCIENCE, V269, P1560, DOI 10.1126/science.269.5230.1560
   Dodabalapur A, 1998, APPL PHYS LETT, V73, P142, DOI 10.1063/1.121736
   HADDON RC, 1995, APPL PHYS LETT, V67, P121, DOI 10.1063/1.115503
   Jackson TN, 1998, IEEE J SEL TOP QUANT, V4, P100, DOI 10.1109/2944.669475
   Karl N., 1990, DEFECT CONTROL SEMIC, P1725
   Katz HE, 2000, NATURE, V404, P478, DOI 10.1038/35006603
   Kloc C, 1997, J CRYST GROWTH, V182, P416, DOI 10.1016/S0022-0248(97)00370-9
   Landolt-Bornstein Karl N., 1985, LANDOLTBORNSTEIN, V17, P106
   Lin YY, 1999, APPL PHYS LETT, V74, P2714, DOI 10.1063/1.123946
   NEUDECK GW, 1987, IEEE T ELECTRON DEV, V34, P344, DOI 10.1109/T-ED.1987.22928
   Schon JH, 2000, SCIENCE, V287, P1022, DOI 10.1126/science.287.5455.1022
   SCHON JH, 1999, P MRS FALL M BOST
   Silinsh E. A., 1994, ORGANIC MOL CRYSTALS
   Sirringhaus H, 1998, SCIENCE, V280, P1741, DOI 10.1126/science.280.5370.1741
   SZE SM, 1981, PHYSICS SEMICONDUCTO
   WARTA W, 1985, APPL PHYS A-MATER, V36, P163, DOI 10.1007/BF00624938
NR 19
TC 54
Z9 57
U1 5
U2 20
PU AMER INST PHYSICS
PI MELVILLE
PA CIRCULATION & FULFILLMENT DIV, 2 HUNTINGTON QUADRANGLE, STE 1 N O 1,
   MELVILLE, NY 11747-4501 USA
SN 0003-6951
J9 APPL PHYS LETT
JI Appl. Phys. Lett.
PD DEC 4
PY 2000
VL 77
IS 23
BP 3776
EP 3778
AR PII [S0003-6951(00)00749-X]
DI 10.1063/1.1329634
PG 3
WC Physics, Applied
SC Physics
GA 378KZ
UT WOS:000165584700032
DA 2018-12-27
ER

PT J
AU Zheng, XM
AF Zheng, XM
TI RETRACTED: Regional cerebral blood flow changes in drug-resistant
   depressed patients following treatment with transcranial magnetic
   stimulation: a statistical parametric mapping analysis (Retracted
   article. See vol 115, pg 91, 2002)
SO PSYCHIATRY RESEARCH-NEUROIMAGING
LA English
DT Article; Retracted Publication
DE brain perfusion; major depression; left dorsolateral prefrontal cortex;
   Tc-99m-hexamethylpropyleneamine oxime; SPECT
ID EMISSION-COMPUTED-TOMOGRAPHY; UNIPOLAR DEPRESSION; MAJOR DEPRESSION;
   CONNECTIVITY; DISORDERS; CORTEX; MOOD
AB Changes of regional cerebral blood flow (rCBF) in five drug-resistant depressed patients were examined by single photon emission computed tomography (SPECT) with Tc-99m-hexamethylpropyleneamine oxime (Tc-99m-HMPAO) before and after treatment with transcranial magnetic stimulation (TMS). The SPECT images were analysed with the Statistical Parametric Mapping (SPM) package. TMS administered in the region of the left dorsolateral prefrontal cortex (DLPFC) of the depressed patients was associated with an increase of rCBF at a focal region some distance from the stimulation site. No change was observed at any other remote region. (C) 2000 Elsevier Science Ireland Ltd. All rights reserved.
C1 Charles Sturt Univ, Fac Hlth Studies, Sch Clin Sci, Wagga Wagga, NSW 2678, Australia.
RP Zheng, XM (reprint author), Charles Sturt Univ, Fac Hlth Studies, Sch Clin Sci, Locked Bag 588, Wagga Wagga, NSW 2678, Australia.
EM xzheng@csu.edu.au
CR AMSTERDAM JD, 1992, J AFFECT DISORDERS, V24, P43, DOI 10.1016/0165-0327(92)90059-F
   ANDREASEN NC, 1992, J NEUROPSYCH CLIN N, V4, P125
   ARDEKANI BA, 1995, J COMPUT ASSIST TOMO, V19, P615, DOI 10.1097/00004728-199507000-00022
   BENCH CJ, 1995, PSYCHOL MED, V25, P247, DOI 10.1017/S0033291700036151
   DRESSLER D, 1990, NEUROSCI LETT, V119, P153, DOI 10.1016/0304-3940(90)90821-P
   DREVETS WC, 1992, J NEUROSCI, V12, P3628
   Ebmeier KP, 1997, BRIT J PSYCHIAT, V170, P77, DOI 10.1192/bjp.170.1.77
   Fox P, 1997, NEUROREPORT, V8, P2787, DOI 10.1097/00001756-199708180-00027
   Frackowiak R., 1997, HUMAN BRAIN FUNCTION
   Friston K. J., 1995, HUMAN BRAIN MAPPING, V2, P189, DOI DOI 10.1002/HBM.460020402
   George MS, 1999, ARCH GEN PSYCHIAT, V56, P300, DOI 10.1001/archpsyc.56.4.300
   Hornig M, 1997, PROG NEURO-PSYCHOPH, V21, P1097, DOI 10.1016/S0278-5846(97)00100-0
   Kimbrell TA, 1999, BIOL PSYCHIAT, V46, P1603, DOI 10.1016/S0006-3223(99)00195-X
   KIMBRELL TA, 1997, BIOL PSYCHIAT, V41, pS108
   Loo C, 1999, AM J PSYCHIAT, V156, P946, DOI 10.1176/ajp.156.6.946
   MAES M, 1993, PSYCHIAT RES-NEUROIM, V50, P77, DOI 10.1016/0925-4927(93)90012-7
   MAYBERG HS, 1994, J NUCL MED, V35, P929
   Mozley PD, 1996, PROG NEURO-PSYCHOPH, V20, P443, DOI 10.1016/0278-5846(96)00008-5
   Paus T, 1997, J NEUROSCI, V17, P3178
   Paus T, 1998, J NEUROPHYSIOL, V79, P1102
   Post RM, 1999, J ECT, V15, P39
   SACKEIM HA, 1990, ARCH GEN PSYCHIAT, V47, P60
   Siebner HR, 1998, NEUROREPORT, V9, P943, DOI 10.1097/00001756-199803300-00033
   Talairach J., 1988, COPLANAR STEREOTAXIC
   Tutus A, 1998, PSYCHIAT RES-NEUROIM, V83, P169, DOI 10.1016/S0925-4927(98)00037-7
NR 25
TC 21
Z9 21
U1 2
U2 10
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0925-4927
EI 1872-7506
J9 PSYCHIAT RES-NEUROIM
JI Psychiatry Res. Neuroimaging
PD DEC 4
PY 2000
VL 100
IS 2
BP 75
EP 80
DI 10.1016/S0925-4927(00)00073-1
PG 6
WC Clinical Neurology; Neuroimaging; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 387PE
UT WOS:000166130300002
PM 11114493
DA 2018-12-27
ER

PT J
AU Sato, Y
   Asoh, T
   Kaji, M
   Oizumi, K
AF Sato, Y
   Asoh, T
   Kaji, M
   Oizumi, K
TI RETRACTED: Beneficial effect of intermittent cyclical etidronate therapy
   in hemiplegic patients following an acute stroke(Retracted article. See
   vol.31,pg.1911,2016)
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article; Retracted Publication
DE acute stroke; etidronate; hemiplegia; hypercalcemia; osteopenia
ID VITAMIN-D DEFICIENCY; X-RAY DENSITOMETRY; STROKE PATIENTS; BONE MASS;
   CALCIUM HOMEOSTASIS; HYPOVITAMINOSIS D; HIP-FRACTURES; ELDERLY-WOMEN;
   IMMOBILIZATION; OSTEOPENIA
AB Significant decreases in bone mineral density (BMD) occur on the hemiplegic side in chronic stroke patients, which correlate with the degree of paralysis and hypovitaminosis D. In this double-blind, randomized, and prospective study of 98 patients with hemiplegia involving both an upper and lower extremity (55 males and 53 females; mean age, 71.4 +/- 0.6 years) after an acute stroke, 49 were given etidronate for 56 weeks and 49 received a placebo. The BMD was measured by computed X-ray densitometry (CXD) of the second metacarpal bone bilaterally. Forty age-matched control subjects were followed for 56 weeks. At baseline, both groups had 25-hydroxyvitamin D [25(OH)D] insufficiency, increased serum ionized calcium and pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen (ICTP), and low serum concentrations of parathyroid hormone (PTH) and 1,25-dihydroxyvitamin D [1,25(OH)(2)D], suggesting immobilization-induced hypercalcemia and inhibition of renal synthesis of 1,25(OH)(2)D. The BMD on the hemiplegic side decreased by 2.3% and 4.8% in the etidronate and placebo groups, respectively (p = 0.0003). After treatment, the serum 1,25(OH)(2)D concentration increased by 62.2% in the etidronate group and decreased by 12.4% in the placebo group. The etidronate group had significant decreases in the serum ionized calcium and ICTP and increases in PTH and bone Gla protein (BGP), whereas the placebo group had higher serum calcium and ICTP concentrations but stable PTH. These results suggest that etidronate can prevent decreases in the BMD in hemiplegic stroke patients because it decreases the serum calcium through inhibition of bone resorption and causes a subsequent increase in the serum 1,25(OH)(2)D concentration.
C1 Kurume Univ, Futase Social Insurance Hosp, Sch Med, Dept Neurol, Kurume, Fukuoka 830, Japan.
   Kurume Univ, Sch Med, Dept Internal Med 1, Kurume, Fukuoka 830, Japan.
RP Sato, Y (reprint author), Kurume Univ, Futase Social Insurance Hosp, Sch Med, Dept Neurol, Kurume, Fukuoka 830, Japan.
CR Adachi JD, 1997, NEW ENGL J MED, V337, P382, DOI 10.1056/NEJM199708073370603
   [Anonymous], 1985, Stroke, V16, P885
   CHAPUY MC, 1992, NEW ENGL J MED, V327, P1637, DOI 10.1056/NEJM199212033272305
   CHIU KY, 1992, INJURY, V23, P297, DOI 10.1016/0020-1383(92)90171-N
   DawsonHughes B, 1997, NEW ENGL J MED, V337, P670, DOI 10.1056/NEJM199709043371003
   ERIKSEN EF, 1993, J BONE MINER RES, V8, P127
   FLEISCH H, 1981, METAB BONE DIS RELAT, V3, P279, DOI 10.1016/0221-8747(81)90044-8
   HOLICK MF, 1990, J NUTR, V120, P1464, DOI 10.1093/jn/120.suppl_11.1464
   HOOPER G, 1979, INJURY, V10, P281, DOI 10.1016/0020-1383(79)90044-5
   KOMAR L, 1993, J AM GERIATR SOC, V41, P1057, DOI 10.1111/j.1532-5415.1993.tb06452.x
   MAHONEY F I, 1965, Md State Med J, V14, P61
   MATSUMOTO C, 1994, CALCIFIED TISSUE INT, V55, P324, DOI 10.1007/BF00299308
   ORIMO H, 1992, SHINYAKU TO RINSHYO, V41, P1249
   ORIMO H, 1982, VITAMIN D CHEM BIOCH, P1239
   POPLINGHER AR, 1985, ACTA ORTHOP SCAND, V56, P226
   Ramnemark A, 1998, OSTEOPOROSIS INT, V8, P92, DOI 10.1007/s001980050053
   Ramnemark A, 1999, STROKE, V30, P755, DOI 10.1161/01.STR.30.4.755
   ROSS P, 1995, BONE, V16, P325, DOI 10.1016/8756-3282(94)00045-X
   Sato Y, 1998, J NEUROL SCI, V156, P205, DOI 10.1016/S0022-510X(98)00041-0
   Sato Y, 1998, BONE, V23, P555, DOI 10.1016/S8756-3282(98)00134-3
   Sato Y, 1998, BONE, V23, P291, DOI 10.1016/S8756-3282(98)00108-2
   Sato Y, 2000, J NEUROL SCI, V175, P135, DOI 10.1016/S0022-510X(00)00298-7
   Sato Y, 1999, STROKE, V30, P414, DOI 10.1161/01.STR.30.2.414
   Sato Y, 1996, EUR NEUROL, V36, P278, DOI 10.1159/000117272
   Sato Y, 1999, AM J PHYS MED REHAB, V78, P457, DOI 10.1097/00002060-199909000-00008
   Sato Y, 1997, STROKE, V28, P736, DOI 10.1161/01.STR.28.4.736
   Sato Y, 1998, STROKE, V29, P1373, DOI 10.1161/01.STR.29.7.1373
   Sato Y, 1999, BONE, V24, P271, DOI 10.1016/S8756-3282(98)00185-9
   Sato Y, 1996, STROKE, V27, P2183, DOI 10.1161/01.STR.27.12.2183
   SEO GS, 1994, BONE MINER, V27, P173, DOI 10.1016/S0169-6009(08)80191-2
   STEWART AF, 1982, NEW ENGL J MED, V306, P1136, DOI 10.1056/NEJM198205133061903
   STROM T, 1990, NEW ENGL J MED, V322, P1265
   Thomas MK, 1998, NEW ENGL J MED, V338, P777, DOI 10.1056/NEJM199803193381201
NR 33
TC 56
Z9 57
U1 1
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0884-0431
EI 1523-4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD DEC
PY 2000
VL 15
IS 12
BP 2487
EP 2494
DI 10.1359/jbmr.2000.15.12.2487
PG 8
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 376NH
UT WOS:000165463300022
PM 11127214
OA Bronze
DA 2018-12-27
ER

PT J
AU Heck, M
   Kumle, B
   Boldt, J
   Lang, J
   Lehmann, A
   Saggau, W
AF Heck, M
   Kumle, B
   Boldt, J
   Lang, J
   Lehmann, A
   Saggau, W
TI RETRACTED: Electroencephalogram bispectral index predicts hemodynamic
   and arousal reactions during induction of anesthesia in patients
   undergoing cardiac surgery (Retracted article. See vol. 25, pg. 755,
   2011)
SO JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA
LA English
DT Article; Retracted Publication
DE electroencephalogram; bispectral index; hemodynamics; intubation; depth
   of anesthesia
ID SPECTRAL EDGE FREQUENCY; MEDIAN FREQUENCY; NITROUS-OXIDE; PROPOFOL;
   DEPTH; ISOFLURANE; EEG; INTUBATION; LARYNGOSCOPY; ALFENTANIL
AB Objective:To evaluate hemodynamic and clinical responses to induction of anesthesia and intubation at 3 different values of the electroencephalogram bispectral index (BIS).
   Design: Prospective randomized trial.
   Setting: University-affiliate hospital.
   Participants: Forty-five patients undergoing elective coronary artery bypass graft surgery.
   Interventions: Patients were assigned to 3 groups (n = 15 for each group). Anesthesia was induced with midazolam, sufentanil, and pancuronium. In each group, sufentanil was titrated to a BIS value of 60, 50, or 40 before intubation. Mean arterial blood pressure, heart rate, incidence of coughing, tearing, and need for fluid replacement or injections of norepinephrine were recorded before intubation as well as immediately and 1 and 2 minutes after intubation.
   Measurements and Main Results: Thirteen patients intubated at a BIS value of 60 coughed and 14 experienced tearing after intubation, whereas no patient of the other groups showed signs of arousal. Mean arterial blood pressure remained stable in the BIS 60 and 50 groups, whereas in the BIS 40 group it decreased significantly to lower values before and after intubation, Patients in the BIS 40 group needed significantly more fluid replacement and injections of norepinephrine compared with the other groups. No significant changes in heart rate were detected.
   Conclusions: Electroencephalogram BIS predicts hemodynamic and arousal reaction resulting from induction of anesthesia and endotracheal intubation. BIS value should be kept at 50 before intubation to ensure safe hemodynamic conditions during induction of anesthesia in cardiac surgical patients. Copyright (C) 2000 by W.B. Saunders Company.
C1 Klinikum Stadt Ludwigshafen, Klin Anaesthesiol & Operat Intens Med, Dept Anesthesiol & Operat Intens Care, D-67063 Ludwigshafen, Germany.
   Klinikum Stadt Ludwigshafen, Clin Cardiac Surg, D-67063 Ludwigshafen, Germany.
RP Boldt, J (reprint author), Klinikum Stadt Ludwigshafen, Klin Anaesthesiol & Operat Intens Med, Dept Anesthesiol & Operat Intens Care, Bremserstr 79, D-67063 Ludwigshafen, Germany.
CR Doi M, 1997, BRIT J ANAESTH, V78, P180
   DRUMMOND JC, 1991, ACTA ANAESTH SCAND, V35, P693, DOI 10.1111/j.1399-6576.1991.tb03374.x
   DWYER RC, 1994, ANESTHESIOLOGY, V81, P403, DOI 10.1097/00000542-199408000-00019
   FREYE E, 1995, OPIOIDE MED, P155
   Glass PS, 1997, ANESTHESIOLOGY, V86, P836, DOI 10.1097/00000542-199704000-00014
   Heier T, 1996, ACTA ANAESTH SCAND, V40, P1087, DOI 10.1111/j.1399-6576.1996.tb05570.x
   Hoffman WE, 1996, J NEUROSURG ANESTH, V8, P15, DOI 10.1097/00008506-199601000-00005
   KEARSE LA, 1994, ANESTHESIOLOGY, V81, P1365, DOI 10.1097/00000542-199412000-00010
   Kobayashi T, 1996, Masui, V45, P1335
   Kovac AL, 1996, J CLIN ANESTH, V8, P63, DOI 10.1016/0952-8180(95)00147-6
   Liu J, 1997, ANESTH ANALG, V84, P185, DOI 10.1097/00000539-199701000-00033
   Masuda T, 1999, Masui, V48, P621
   Mi WD, 1998, CAN J ANAESTH, V45, P19, DOI 10.1007/BF03011986
   Pavlin DJ, 1999, ANESTH ANALG, V88, pU51
   PRYSROBERTS C, 1971, BRIT J ANAESTH, V43, P122, DOI 10.1093/bja/43.2.122
   RAMPIL IJ, 1987, ANESTHESIOLOGY, V67, P139, DOI 10.1097/00000542-198707000-00033
   Rampil IJ, 1998, ANESTHESIOLOGY, V89, P980, DOI 10.1097/00000542-199810000-00023
   SCHWILDEN H, 1987, BRIT J ANAESTH, V59, P738, DOI 10.1093/bja/59.6.738
   Sebel PS, 1997, ANESTH ANALG, V84, P891, DOI 10.1097/00000539-199704000-00035
   SIGL JC, 1994, J CLIN MONITOR, V10, P392, DOI 10.1007/BF01618421
   Sleigh JW, 1999, BRIT J ANAESTH, V82, P666
   Sleigh JW, 1999, ANESTH ANALG, V88, P659, DOI 10.1097/00000539-199903000-00035
   VERNON JM, 1995, ANESTH ANALG, V80, P780, DOI 10.1097/00000539-199504000-00023
NR 23
TC 23
Z9 26
U1 3
U2 16
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 1053-0770
EI 1532-8422
J9 J CARDIOTHOR VASC AN
JI J. Cardiothorac. Vasc. Anesth.
PD DEC
PY 2000
VL 14
IS 6
BP 693
EP 697
DI 10.1053/jcan.2000.18447
PG 5
WC Anesthesiology; Cardiac & Cardiovascular Systems; Respiratory System;
   Peripheral Vascular Disease
SC Anesthesiology; Cardiovascular System & Cardiology; Respiratory System
GA 381NT
UT WOS:000165770000013
PM 11139111
DA 2018-12-27
ER

PT J
AU Trapasso, F
   Iuliano, R
   Boccia, A
   Stella, A
   Visconti, R
   Bruni, P
   Baldassarre, G
   Santoro, M
   Viglietto, G
   Fusco, A
AF Trapasso, F
   Iuliano, R
   Boccia, A
   Stella, A
   Visconti, R
   Bruni, P
   Baldassarre, G
   Santoro, M
   Viglietto, G
   Fusco, A
TI RETRACTED: Rat protein tyrosine phosphatase eta suppresses the
   neoplastic phenotype of retrovirally transformed thyroid cells through
   the stabilization of p27(Kip1) (Retracted article. See vol. 38, 2018)
SO MOLECULAR AND CELLULAR BIOLOGY
LA English
DT Article; Retracted Publication
ID BANNAYAN-ZONANA-SYNDROME; TUMOR-SUPPRESSOR; GERMLINE MUTATIONS;
   MOLECULAR-CLONING; EPITHELIAL-CELLS; KINASE-ACTIVITY; COWDEN-DISEASE;
   INHIBITOR P27; NEU ONCOGENE; RECEPTOR
AB The r-PTP eta gene encodes a rat receptor-type protein tyrosine phosphatase whose expression is negatively regulated by neoplastic cell transformation, Here we first demonstrate a dramatic reduction in DEP-1/HPTP eta (the human homolog of r-PTP eta) expression in a panel of human thyroid carcinomas. Subsequently, we show that the reexpression of the r-PTP eta gene in highly malignant rat thyroid cells transformed by retroviruses carrying the v-mos and v-ms-Ki oncogenes suppresses their malignant phenotype. Cell cycle analysis demonstrated that r-PTP eta caused G(1) growth arrest and increased the cyclin-dependent kinase inhibitor p27(Kip1) protein level by reducing the proteasome-dependent degradation rate. We propose that the r-PTP eta tumor suppressor activity is mediated by p27(Kip1) protein stabilization, because suppression of p27(Kip1) protein synthesis using p27-specific antisense oligonucleotides blocked the growth-inhibitory effect induced by r-PTP eta, Furthermore, we provide evidence that in v-mos- or v-ras-Ki-transformed thyroid cells, the p27(Kip1) protein level was regulated by the mitogen-activated protein (MAP) kinase pathway and that r-PTP eta regulated p27(Kip1) stability by preventing v-mos- or v-ras-Ki-induced MAP kinase activation.
C1 Univ Naples Federico II, Fac Med & Chirurg, Dipartimento Biol & Patol Cellulare & Mol, Ctr Endocrinol & Oncol Sperimentale,CNR, I-80131 Naples, Italy.
   Univ Catanzaro Magna Graecia, Fac Med & Chirurg, Dipartimento Med Sperimentale & Clin, I-88100 Catanzaro, Italy.
   Ist Tumori Napoli, Naples, Italy.
RP Fusco, A (reprint author), Univ Naples Federico II, Fac Med & Chirurg, Dipartimento Biol & Patol Cellulare & Mol, Ctr Endocrinol & Oncol Sperimentale,CNR, Via Pansini 5, I-80131 Naples, Italy.
EM afusco@napoli.com
RI Baldassarre, Gustavo/K-1350-2016; Visconti, Roberta/C-5299-2009
OI Baldassarre, Gustavo/0000-0002-9750-8825; Fusco,
   Alfredo/0000-0003-3332-5197
CR Baldassarre G, 1999, J CLIN INVEST, V104, P865, DOI 10.1172/JCI6443
   BERLINGIERI MT, 1995, MOL CELL BIOL, V15, P1545
   BRADYKALNAY SM, 1995, J CELL BIOL, V130, P977, DOI 10.1083/jcb.130.4.977
   BROWNSHIMER S, 1992, CANCER RES, V52, P478
   Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877
   DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0
   Fuchs M, 1996, J BIOL CHEM, V271, P16712, DOI 10.1074/jbc.271.28.16712
   Furnari FB, 1997, P NATL ACAD SCI USA, V94, P12479, DOI 10.1073/pnas.94.23.12479
   FUSCO A, 1985, J VIROL, V56, P284
   FUSCO A, 1987, MOL CELL BIOL, V7, P3365, DOI 10.1128/MCB.7.9.3365
   Goldsmith BA, 1997, INT J ONCOL, V11, P825
   GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3
   Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177
   HONDA H, 1994, BLOOD, V84, P4186
   HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.bi.54.070185.004341
   Kawada M, 1997, ONCOGENE, V15, P629, DOI 10.1038/sj.onc.1201228
   Keane MM, 1996, CANCER RES, V56, P4236
   KRISHAN A, 1975, J CELL BIOL, V66, P188, DOI 10.1083/jcb.66.1.188
   Kuramochi S, 1996, FEBS LETT, V378, P7, DOI 10.1016/0014-5793(95)01415-2
   LAFORGIA S, 1991, P NATL ACAD SCI USA, V88, P5036, DOI 10.1073/pnas.88.11.5036
   Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943
   Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64
   Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231
   MACPHERSON I, 1964, VIROLOGY, V23, P291, DOI 10.1016/0042-6822(64)90301-0
   MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8
   Marsh DJ, 1998, HUM MOL GENET, V7, P507, DOI 10.1093/hmg/7.3.507
   Marsh DJ, 1997, NAT GENET, V16, P333, DOI 10.1038/ng0897-333
   Martelli ML, 1998, EXP CELL RES, V245, P195, DOI 10.1006/excr.1998.4257
   Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052
   OKAZAKI K, 1995, EMBO J, V14, P5048, DOI 10.1002/j.1460-2075.1995.tb00187.x
   OSTMAN A, 1994, P NATL ACAD SCI USA, V91, P9680, DOI 10.1073/pnas.91.21.9680
   PAGANO M, 1995, SCIENCE, V267, P1024
   POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9
   Pulido R, 1998, EMBO J, V17, P7337, DOI 10.1093/emboj/17.24.7337
   ROBBINS DJ, 1992, P NATL ACAD SCI USA, V89, P6924, DOI 10.1073/pnas.89.15.6924
   Sambrook J, 1989, MOL CLONING LAB MANU
   SANTORO M, 1995, EUR J ENDOCRINOL, V133, P513, DOI 10.1530/eje.0.1330513
   SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149
   Soos TJ, 1996, CELL GROWTH DIFFER, V7, P135
   Sorio C, 1997, BLOOD, V90, P49
   Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356
   THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N
   Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4
   TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8
   ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K
   VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251
   ZANNINI M, 1992, MOL CELL BIOL, V12, P4230, DOI 10.1128/MCB.12.9.4230
   ZHAI YF, 1995, MOL CARCINOGEN, V14, P103, DOI 10.1002/mc.2940140206
   Zhang L, 1997, EXP CELL RES, V235, P62, DOI 10.1006/excr.1997.3659
NR 49
TC 92
Z9 93
U1 1
U2 1
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0270-7306
EI 1098-5549
J9 MOL CELL BIOL
JI Mol. Cell. Biol.
PD DEC
PY 2000
VL 20
IS 24
BP 9236
EP 9246
DI 10.1128/MCB.20.24.9236-9246.2000
PG 11
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 426UE
UT WOS:000168366100014
PM 11094075
OA Bronze
DA 2018-12-27
ER

PT J
AU Ramalingam, TS
   West, AP
   Lebron, JA
   Nangiana, JS
   Hogan, TH
   Enns, CA
   Bjorkman, PJ
AF Ramalingam, TS
   West, AP
   Lebron, JA
   Nangiana, JS
   Hogan, TH
   Enns, CA
   Bjorkman, PJ
TI RETRACTED: Binding to the transferrin receptor is required for
   endocytosis of HFE and regulation of iron homeostasis (Retracted
   article. See vol 5, pg 680, 2003)
SO NATURE CELL BIOLOGY
LA English
DT Article; Retracted Publication
ID HEREDITARY HEMOCHROMATOSIS PROTEIN; CELL-SURFACE EXPRESSION;
   CRYSTAL-STRUCTURE; HELA-CELLS; HLA-H; ASSOCIATION; SIGNALS;
   BETA(2)-MICROGLOBULIN; ENDOSOME; GENE
AB HFE, the protein that is mutated in hereditary haemochromatosis, binds to the transferrin receptor (TfR). Here we show that wild-type HFE and TfR localize in endosomes and at the basolateral membrane of a polarized duodenal epithelial cell line, whereas the primary haemochromatosis HFE mutant, and another mutant with impaired TfR-binding ability accumulate in the ER/Golgi and at the basolateral membrane, respectively. Levels of the iron-storage protein ferritin are greatly reduced and those of TfR ave slightly increased in cells expressing wild-type HFE, but not in cells expressing either mutant. Addition of an endosomal-targeting sequence derived from the human low-density lipoprotein receptor (LDLR) to the TfR-binding-impaired mutant restores its endosomal localization but not ferritin reduction or TfR elevation. Thus, binding to TfR is required for transport of HFE to endosomes and regulation of intracellular iron homeostasis, but not for basolateral surface expression of HFE.
C1 CALTECH, Div Biol 156 29, Pasadena, CA 91125 USA.
   CALTECH, Howard Hughes Med Inst, Pasadena, CA 91125 USA.
   Oregon Hlth & Sci Univ, Dept Cell & Dev Biol L215, Portland, OR 97201 USA.
RP Bjorkman, PJ (reprint author), CALTECH, Div Biol 156 29, Pasadena, CA 91125 USA.
EM bjorkman@cco.caltech.edu
CR Alvarez-Hernandez X, 1998, BLOOD, V91, P3974
   Bennett MJ, 2000, NATURE, V403, P46, DOI 10.1038/47417
   COLLAWN JF, 1991, EMBO J, V10, P3247, DOI 10.1002/j.1460-2075.1991.tb04888.x
   Corsi B, 1999, FEBS LETT, V460, P149, DOI 10.1016/S0014-5793(99)01330-7
   Cullen LM, 1999, ANNU REV MED, V50, P87
   Demaurex N, 1998, J BIOL CHEM, V273, P2044, DOI 10.1074/jbc.273.4.2044
   DUNN KW, 1989, J CELL BIOL, V109, P3303, DOI 10.1083/jcb.109.6.3303
   Feder JN, 1998, P NATL ACAD SCI USA, V95, P1472, DOI 10.1073/pnas.95.4.1472
   Feder JN, 1996, NAT GENET, V13, P399, DOI 10.1038/ng0896-399
   Feder JN, 1997, J BIOL CHEM, V272, P14025, DOI 10.1074/jbc.272.22.14025
   FUTTER CE, 1995, J BIOL CHEM, V270, P10999, DOI 10.1074/jbc.270.18.10999
   Gross CN, 1998, J BIOL CHEM, V273, P22068, DOI 10.1074/jbc.273.34.22068
   Heilker R, 1999, BIOESSAYS, V21, P558, DOI 10.1002/(SICI)1521-1878(199907)21:7<558::AID-BIES4>3.0.CO;2-R
   Hicke L, 1996, CELL, V84, P277, DOI 10.1016/S0092-8674(00)80982-4
   KAIN SR, 2000, LIVING COLOR PROTOCO, P199
   Lebron JA, 1998, CELL, V93, P111, DOI 10.1016/S0092-8674(00)81151-4
   Lebron JA, 1999, J MOL BIOL, V294, P239, DOI 10.1006/jmbi.1999.3252
   Lebron JA, 1999, J MOL BIOL, V289, P1109, DOI 10.1006/jmbi.1999.2842
   MAYOR S, 1993, J CELL BIOL, V121, P1257, DOI 10.1083/jcb.121.6.1257
   Mukherjee S, 1997, PHYSIOL REV, V77, P759
   Parkkila S, 1997, P NATL ACAD SCI USA, V94, P2534, DOI 10.1073/pnas.94.6.2534
   Parkkila S, 1997, P NATL ACAD SCI USA, V94, P13198, DOI 10.1073/pnas.94.24.13198
   Richardson DR, 1997, BBA-REV BIOMEMBRANES, V1331, P1, DOI 10.1016/S0304-4157(96)00014-7
   Riedel HD, 1999, BLOOD, V94, P3915
   Roy CN, 1999, J BIOL CHEM, V274, P9022, DOI 10.1074/jbc.274.13.9022
   Waheed A, 1997, P NATL ACAD SCI USA, V94, P12384, DOI 10.1073/pnas.94.23.12384
   Waheed A, 1999, P NATL ACAD SCI USA, V96, P1579, DOI 10.1073/pnas.96.4.1579
   WEISZ OA, 1992, J BIOL CHEM, V267, P22282
   WILLIAMS AM, 1991, J BIOL CHEM, V266, P17648
NR 29
TC 39
Z9 40
U1 3
U2 14
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1465-7392
EI 1476-4679
J9 NAT CELL BIOL
JI Nat. Cell Biol.
PD DEC
PY 2000
VL 2
IS 12
BP 953
EP 957
PG 5
WC Cell Biology
SC Cell Biology
GA 382GK
UT WOS:000165814500020
PM 11146662
DA 2018-12-27
ER

PT J
AU Schon, JH
   Kloc, C
   Batlogg, B
AF Schon, JH
   Kloc, C
   Batlogg, B
TI RETRACTED: Superconductivity at 52 K in hole-doped C-60 (Retracted
   article. See vol 422 pg 93 2003)
SO NATURE
LA English
DT Article; Retracted Publication
ID ELECTRICAL-RESISTIVITY; FULLERENES; FULLERIDES; VOLUME; K3C60
AB Superconductivity in electron-doped C-60 was first observed almost ten years ago. The metallic state and superconductivity result from the transfer of electrons from alkaline or alkaline-earth ions to the C-60 molecule, which is known to be a strong electron acceptor. For this reason, it is very difficult to remove electrons from C-60-yet one might expect to see superconductivity at higher temperatures in hole-doped than in electron-doped C-60, because of the higher density of electronic states in the valence band than in the conduction band. We have used the technique of gate-induced doping in a reld-effect transistor conrguration to introduce signircant densities of holes into C-60. We observe superconductivity over an extended range of hole density, with a smoothly varying transition temperature T-c that peaks at 52 K. By comparison with the well established dependence of T-c on the lattice parameter in electron-doped C-60, we anticipate that T-c values signircantly in excess of 100 K should be achievable in a suitably expanded, hole-doped C-60 lattice.
C1 Bell Labs, Lucent Technol, Murray Hill, NJ 07974 USA.
RP Batlogg, B (reprint author), Bell Labs, Lucent Technol, 600 Mt Ave, Murray Hill, NJ 07974 USA.
EM batlogg@lucent.com
RI Kloc, Christian/A-2255-2011
CR CRESPI VH, 1992, PHYS REV B, V46, P12064, DOI 10.1103/PhysRevB.46.12064
   DODABALAPUR A, 1995, SCIENCE, V268, P270, DOI 10.1126/science.268.5208.270
   ERWIN SC, 1992, BUCKMINISTERFULLEREN, P217
   Gunnarsson O, 1997, REV MOD PHYS, V69, P575, DOI 10.1103/RevModPhys.69.575
   HADDON RC, 1993, PHILOS T ROY SOC A, V343, P53, DOI 10.1098/rsta.1993.0040
   HADDON RC, 1995, J MATER CHEM, V5, P1719, DOI 10.1039/jm9950501719
   Han JE, 2000, PHYS REV LETT, V84, P1276, DOI 10.1103/PhysRevLett.84.1276
   HEBARD AF, 1991, NATURE, V350, P600, DOI 10.1038/350600a0
   HEINEY PA, 1992, PHYS REV B, V45, P4544, DOI 10.1103/PhysRevB.45.4544
   Hesper R, 2000, PHYS REV LETT, V85, P1970, DOI 10.1103/PhysRevLett.85.1970
   HIRSCH JE, 1989, PHYSICA C, V158, P326, DOI 10.1016/0921-4534(89)90225-6
   KLEIN O, 1992, PHYS REV B, V46, P11247, DOI 10.1103/PhysRevB.46.11247
   Kloc C, 1997, J CRYST GROWTH, V182, P416, DOI 10.1016/S0022-0248(97)00370-9
   KOCHANSKI GP, 1992, SCIENCE, V255, P184, DOI 10.1126/science.255.5041.184
   MAZIN II, 1992, PHYS REV B, V45, P5114, DOI 10.1103/PhysRevB.45.5114
   Ramirez A. P., 1994, Superconductivity Review, V1, P1
   Reed CA, 2000, SCIENCE, V289, P101, DOI 10.1126/science.289.5476.101
   Rosseinsky MJ, 1998, CHEM MATER, V10, P2665, DOI 10.1021/cm980226p
   Schon JH, 2000, SCIENCE, V288, P656, DOI 10.1126/science.288.5466.656
   SCHON JH, 2000, NATURE, V406, P704
   SEITZ F, 1994, SOLID STATE PHYSICS, V48
   SONG LW, 1993, SOLID STATE COMMUN, V87, P387, DOI 10.1016/0038-1098(93)90782-I
   VAREKA WA, 1994, PHYS REV LETT, V72, P4121, DOI 10.1103/PhysRevLett.72.4121
   VARMA CM, 1991, SCIENCE, V254, P989, DOI 10.1126/science.254.5034.989
   Yildirim T, 1996, PHYS REV LETT, V77, P167, DOI 10.1103/PhysRevLett.77.167
NR 25
TC 211
Z9 217
U1 6
U2 63
PU MACMILLAN PUBLISHERS LTD
PI LONDON
PA PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
J9 NATURE
JI Nature
PD NOV 30
PY 2000
VL 408
IS 6812
BP 549
EP 552
DI 10.1038/35046008
PG 4
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 377WE
UT WOS:000165548600108
PM 11117735
DA 2018-12-27
ER

PT J
AU Lee, HC
   Kim, SJ
   Kim, KS
   Shin, HC
   Yoon, JW
AF Lee, HC
   Kim, SJ
   Kim, KS
   Shin, HC
   Yoon, JW
TI RETRACTED: Remission in models of type 1 diabetes by gene therapy using
   a single-chain insulin analogue (Retracted Article. See vol 458, pg 660,
   2009)
SO NATURE
LA English
DT Article; Retracted Publication
ID PYRUVATE-KINASE GENE; ADENOASSOCIATED VIRUS; CYCLIC-AMP; BETA-CELLS;
   MELLITUS; MICE; INTEGRATION; EXPRESSION; PROMOTER; GLUCOSE
AB A cure for diabetes has long been sought using several different approaches, including islet transplantation, regeneration of beta cells and insulin gene therapy(1). However, permanent remission of type 1 diabetes has not yet been satisfactorily achieved. The development of type 1 diabetes results from the almost total destruction of insulin-producing pancreatic beta cells by autoimmune responses specific to beta cells(2-6). Standard insulin therapy may not maintain blood glucose concentrations within the relatively narrow range that occurs in the presence of normal pancreatic beta cells(7). We used a recombinant adeno-associated virus (rAAV) that expresses a single-chain insulin analogue (SIA), which possesses biologically active insulin activity without enzymatic conversion, under the control of hepatocyte-specific L-type pyruvate kinase (LPK) promoter, which regulates SIA expression in response to blood glucose levels. Here we show that SIA produced from the gene construct rAAV-LPK-SIA caused remission of diabetes in streptozotocin-induced diabetic rats and autoimmune diabetic mice for a prolonged time without any apparent side effects. This new SIA gene therapy may have potential therapeutic value for the cure of autoimmune diabetes in humans.
C1 Yonsei Univ, Coll Med, Dept Internal Med, Div Endocrinol, Seoul 120752, South Korea.
   Yonsei Univ, Coll Med, Inst Genet Sci, Dept Biochem & Mol Biol, Seoul 120752, South Korea.
   Univ Calgary, Fac Med,Lab Viral & Immunopathogenesis Diabet, Dept Microbiol & Infect Dis, Julia McFarlane Diabet Res Ctr, Calgary, AB T2N 4N1, Canada.
RP Lee, HC (reprint author), Yonsei Univ, Coll Med, Dept Internal Med, Div Endocrinol, Seoul 120752, South Korea.
EM endohclee@yumc.yonsei.ac.kr
CR BACH JF, 1995, J AUTOIMMUN, V8, P439, DOI 10.1016/0896-8411(95)90001-2
   BERGOT MO, 1992, NUCLEIC ACIDS RES, V20, P1871, DOI 10.1093/nar/20.8.1871
   CAMERON NE, 1991, AM J PHYSIOL, V261, pE1
   CHEN RH, 1995, FEBS LETT, V365, P223, DOI 10.1016/0014-5793(95)00472-L
   Clark KR, 1999, HUM GENE THER, V10, P1031, DOI 10.1089/10430349950018427
   Cuif MH, 1997, FEBS LETT, V417, P81, DOI 10.1016/S0014-5793(97)01260-X
   CUIF MH, 1993, J BIOL CHEM, V268, P13769
   DECAUX JF, 1989, J BIOL CHEM, V264, P11584
   *DIAB CONTR COMPL, 1993, NEW ENGL J MED, V329, P977, DOI DOI 10.1056/NEJM199309303291401
   FROST SC, 1985, J BIOL CHEM, V260, P2646
   GIRAUD C, 1994, P NATL ACAD SCI USA, V91, P10039, DOI 10.1073/pnas.91.21.10039
   HEATH WF, 1992, J BIOL CHEM, V267, P419
   Hirasawa K, 1997, J VIROL, V71, P4024
   KOTIN RM, 1992, EMBO J, V11, P5071, DOI 10.1002/j.1460-2075.1992.tb05614.x
   Levine F, 1999, MOL MED TODAY, V5, P165, DOI 10.1016/S1357-4310(98)01425-7
   Ma ZM, 1997, CLIN CHEM, V43, P1732
   MUZYCZKA N, 1992, CURR TOP MICROBIOL, V158, P97
   POLLET RJ, 1977, J BIOL CHEM, V252, P5828
   ROSSINI AA, 1993, DIABETES REV, V1, P43
   Roth J, 1975, Methods Enzymol, V37, P66
   SAMULSKI RJ, 1993, CURR OPIN GENET DEV, V3, P74, DOI 10.1016/S0959-437X(05)80344-2
   Schranz DB, 1998, DIABETES METAB REV, V14, P3, DOI 10.1002/(SICI)1099-0895(199803)14:1<3::AID-DMR206>3.0.CO;2-T
   STUDIER FW, 1990, METHOD ENZYMOL, V185, P60
   Tisch R, 1996, CELL, V85, P291, DOI 10.1016/S0092-8674(00)81106-X
   Yoon J-W, 1998, ENCY IMMUNOLOGY, P1390
   YOON JW, 1982, NATURE, V296, P566, DOI 10.1038/296566a0
   YOON JW, 1976, NATURE, V264, P178, DOI 10.1038/264178a0
   Yoon JW, 1999, SCIENCE, V284, P1183, DOI 10.1126/science.284.5417.1183
NR 28
TC 178
Z9 188
U1 2
U2 17
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
EI 1476-4687
J9 NATURE
JI Nature
PD NOV 23
PY 2000
VL 408
IS 6811
BP 483
EP 488
DI 10.1038/35044106
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 375YD
UT WOS:000165429800051
PM 11100731
DA 2018-12-27
ER

PT J
AU Schon, JH
   Dodabalapur, A
   Kloc, C
   Batlogg, B
AF Schon, JH
   Dodabalapur, A
   Kloc, C
   Batlogg, B
TI RETRACTED: A light-emitting field-effect transistor (Retracted Article.
   See vol 298, pg 961, 2002)
SO SCIENCE
LA English
DT Article; Retracted Publication
ID STIMULATED-EMISSION; SINGLE-CRYSTAL; SEXITHIOPHENE; LASERS
AB We report here on the structure and operating characteristics of an ambipolar Light-emitting field-effect transistor based on single crystals of the organic semiconductor alpha -sexithiophene, Electrons and holes are injected from the source and drain electrodes, respectively. Their concentrations are controlled by the applied gate and drain-source voltages. Excitons are generated, Leading to radiative recombination. Moreover, above a remarkably Low threshold current, coherent light is emitted through amplified spontaneous emission. Hence, this three-terminal device is the basis of a very promising architecture for electrically driven laser action in organic semiconductors.
C1 Bell Labs, Lucent Technol, Murray Hill, NJ 07974 USA.
RP Schon, JH (reprint author), Bell Labs, Lucent Technol, 600 Mt Ave, Murray Hill, NJ 07974 USA.
EM hendrik@lucent.com; ananth@lucent.com
RI Kloc, Christian/A-2255-2011; Dodabalapur, Ananth/H-3043-2012
CR Berggren M, 1997, NATURE, V389, P466
   CASPERSON LW, 1972, IEEE J QUANTUM ELECT, VQE 8, P80, DOI 10.1109/JQE.1972.1076944
   DODABALAPUR A, 1995, SCIENCE, V269, P1560, DOI 10.1126/science.269.5230.1560
   Dodabalapur A, 1996, APPL PHYS LETT, V68, P1108, DOI 10.1063/1.115728
   Dodabalapur A., 1996, Advanced Materials, V8, P853, DOI 10.1002/adma.19960081021
   Fichou D, 1997, ADV MATER, V9, P1178, DOI 10.1002/adma.19970091512
   Garnier F, 1998, APPL PHYS LETT, V72, P2087, DOI 10.1063/1.121284
   HOROWITZ G, 1994, ADV MATER, V6, P752, DOI 10.1002/adma.19940061007
   Kloc C, 1997, J CRYST GROWTH, V182, P416, DOI 10.1016/S0022-0248(97)00370-9
   Mekis A, 2000, OPT LETT, V25, P942, DOI 10.1364/OL.25.000942
   Muccini M, 1998, J CHEM PHYS, V108, P7327, DOI 10.1063/1.476151
   NEUDECK GW, 1987, IEEE T ELECTRON DEV, V34, P344, DOI 10.1109/T-ED.1987.22928
   PFLEIDERER H, 1986, IEEE T ELECTRON DEV, V33, P145, DOI 10.1109/T-ED.1986.22451
   Rogers JA, 1999, APPL PHYS LETT, V74, P3257, DOI 10.1063/1.123312
   Schon JH, 2000, SCIENCE, V287, P1022, DOI 10.1126/science.287.5455.1022
   SCHON JH, 2000, IN PRESS P EUR MAT R
   SCHON JH, 2000, SCIENCE, V289, P589
   Zou Z, 2000, IEEE PHOTONIC TECH L, V12, P1, DOI 10.1109/68.817427
NR 18
TC 113
Z9 115
U1 4
U2 48
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
J9 SCIENCE
JI Science
PD NOV 3
PY 2000
VL 290
IS 5493
BP 963
EP 965
DI 10.1126/science.290.5493.963
PG 3
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 370BV
UT WOS:000165103200043
PM 11062124
DA 2018-12-27
ER

PT J
AU Amaral, DG
AF Amaral, DG
TI RETRACTED: Organization of connections of the basal and accessory basal
   nuclei in the monkey amygdala (Retracted article. See vol. 43, pg. 859,
   2016)
SO EUROPEAN JOURNAL OF NEUROSCIENCE
LA English
DT Article; Retracted Publication
ID IN-SITU HYBRIDIZATION; LATERAL NUCLEUS; INTRINSIC CONNECTIONS; MACAQUE
   MONKEY; TEMPORAL-LOBE; PHA-L; COMPLEX; PROJECTIONS; FIBERS; CELLS
C1 MIND Inst, Dept Psychiat, Ctr Neurosci, Davis, CA 95616 USA.
   MIND Inst, Calif Reg Primate Res Ctr, Davis, CA 95616 USA.
RP Amaral, DG (reprint author), MIND Inst, Dept Psychiat, Ctr Neurosci, 1544 Newton Court, Davis, CA 95616 USA.
EM dgamaral@ucdavis.edu
CR AMARAL DG, 1992, EXP BRAIN RES, V88, P375, DOI 10.1007/BF02259113
   Bonda E, 2000, EUR J NEUROSCI, V12, P1971, DOI 10.1046/j.1460-9568.2000.00082.x
   Jongen-Relo AL, 1998, EUR J NEUROSCI, V10, P2924, DOI 10.1111/j.1460-9568.1998.00299.x
   PITKANEN A, 1991, EXP BRAIN RES, V83, P465
   PITKANEN A, 1993, J COMP NEUROL, V331, P199, DOI 10.1002/cne.903310205
   PITKANEN A, 1994, J NEUROSCI, V14, P2200
   PITKANEN A, 1995, J COMP NEUROL, V356, P288, DOI 10.1002/cne.903560211
   Pitkanen A, 1998, J COMP NEUROL, V398, P431, DOI 10.1002/(SICI)1096-9861(19980831)398:3<431::AID-CNE9>3.0.CO;2-0
   PITKANEN A, 1991, J COMP NEUROL, V313, P326, DOI 10.1002/cne.903130209
   PITKANEN A, 1993, J COMP NEUROL, V331, P14, DOI 10.1002/cne.903310103
   Stefanacci L, 2000, J COMP NEUROL, V421, P52, DOI 10.1002/(SICI)1096-9861(20000522)421:1<52::AID-CNE4>3.0.CO;2-O
   Stefanacci L, 1996, J COMP NEUROL, V375, P552
   STEFANACCI L, 1992, J COMP NEUROL, V323, P586, DOI 10.1002/cne.903230411
NR 13
TC 1
Z9 1
U1 3
U2 15
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0953-816X
EI 1460-9568
J9 EUR J NEUROSCI
JI Eur. J. Neurosci.
PD NOV
PY 2000
VL 12
IS 11
BP 4153
EP 4153
DI 10.1046/j.1460-9568.2000.00330.x
PG 1
WC Neurosciences
SC Neurosciences & Neurology
GA 378XD
UT WOS:000165609900036
PM 11069612
DA 2018-12-27
ER

PT J
AU Inoue, A
   Zhang, T
   Saida, J
   Matsushita, M
AF Inoue, A
   Zhang, T
   Saida, J
   Matsushita, M
TI RETRACTED: Enhancement of strength and ductility in Zr-based bulk
   amorphous alloys by precipitation of quasicrystalline phase (Retracted
   article)
SO MATERIALS TRANSACTIONS JIM
LA English
DT Article; Retracted Publication
DE bulk quasicrystalline alloy; zirconium-based bulk amorphous alloy;
   two-stage crystallization; mechanical property; polymorphous mode;
   diffusion-controlled mode; nucleation frequency; growth rate
ID SUPERCOOLED LIQUID REGION; NI-AL ALLOYS; METALLIC-GLASS;
   MAGNETIC-PROPERTIES; ICOSAHEDRAL PHASE; TRANSFORMATION; KINETICS;
   GROWTH; AU; AG
AB The crystallization mode of the Zr-Al-Ni-Cu amorphous alloys is found to change from a single stage to two stages on adding Ag or Pd. Furthermore, the first-stage exothermic reaction is found to result from the precipitation of nanoscale icosahedral particles in the size range of 20 to 50 nm. The precipitation is found to occur with high nucleation and low growth rates in a polymorphous mode for the Ag-containing alloys and a diffusion-controlled mode for the Pd-containing alloys. These alloys with a mixed nanoscale structure exhibit enhanced strength and ductility as compared with those for the corresponding amorphous single phase alloys. The findings of the dispersion strengthening as well as the dispersion ductilization arising from the finely dispersed icosahedral entities promise opportunities to fabricate new bulk nonequilibrium phase alloys.
C1 Tohoku Univ, Inst Mat Res, Sendai, Miyagi 9808577, Japan.
   Japan Sci & Technol Corp, Inoue Superliquid Project, Exploratory Res Adv Technol, Sendai, Miyagi 9820807, Japan.
RP Inoue, A (reprint author), Tohoku Univ, Inst Mat Res, Sendai, Miyagi 9808577, Japan.
RI Saida, Junji/C-1912-2009; Zhang, Tao/O-4911-2014; Inoue,
   Akihisa/E-5271-2015
CR CHEN LC, 1988, NATURE, V336, P366, DOI 10.1038/336366a0
   Chen MW, 1999, APPL PHYS LETT, V75, P1697, DOI 10.1063/1.124793
   Drehman A. J., 1986, Journal of Materials Research, V1, P741, DOI 10.1557/JMR.1986.0741
   HOLZER JC, 1991, ACTA METALL MATER, V39, P1833, DOI 10.1016/0956-7151(91)90152-Q
   Inoue A, 2000, J MATER RES, V15, P2195, DOI 10.1557/JMR.2000.0316
   Inoue A, 1999, MATER T JIM, V40, P1137, DOI 10.2320/matertrans1989.40.1137
   Inoue A, 1999, MATER T JIM, V40, P1382, DOI 10.2320/matertrans1989.40.1382
   Inoue A, 2000, MATER T JIM, V41, P362, DOI 10.2320/matertrans1989.41.362
   Inoue A, 2000, ACTA MATER, V48, P279, DOI 10.1016/S1359-6454(99)00300-6
   Inoue A, 2000, APPL PHYS LETT, V76, P967, DOI 10.1063/1.125907
   INOUE A, 1988, JPN J APPL PHYS 2, V27, pL2248, DOI 10.1143/JJAP.27.L2248
   Inoue A, 1997, MATER T JIM, V38, P359, DOI 10.2320/matertrans1989.38.359
   INOUE A, 1989, MATER T JIM, V30, P965, DOI 10.2320/matertrans1989.30.965
   Inoue A, 1995, MATER T JIM, V36, P1427, DOI 10.2320/matertrans1989.36.1427
   INOUE A, 1995, MATER T JIM, V36, P866, DOI 10.2320/matertrans1989.36.866
   Inoue A, 1999, MATER T JIM, V40, P1181, DOI 10.2320/matertrans1989.40.1181
   INOUE A, 1994, MAT SCI ENG A-STRUCT, V178, P255, DOI 10.1016/0921-5093(94)90551-7
   INOUE A, 1990, MATER T JIM, V31, P177, DOI 10.2320/matertrans1989.31.177
   Inoue A, 1996, MATER T JIM, V37, P181, DOI 10.2320/matertrans1989.37.181
   Inoue A., 1998, BULK AMORPHOUS ALLOY, P1
   Johnson WA, 1939, T AM I MIN MET ENG, V135, P416
   Johnson WL, 1999, MRS BULL, V24, P42, DOI 10.1557/S0883769400053252
   KOSTER U, 1993, KEY ENG MAT, V81-3, P647
   Koster U, 1997, MAT SCI ENG A-STRUCT, V226, P995, DOI 10.1016/S0921-5093(97)80100-1
   Koster U, 1996, APPL PHYS LETT, V69, P179, DOI 10.1063/1.117364
   MASUMOTO T, 1989, Patent No. 7122120
   Matsushita M, 2000, PHIL MAG LETT, V80, P79, DOI 10.1080/095008300176335
   MATSUSHITA M, 1999, UNPUB
   Murty BS, 2000, APPL PHYS LETT, V76, P55, DOI 10.1063/1.125654
   OHNUGI M, 1999, MAT JAPAN, V38, P251
   PEKER A, 1993, APPL PHYS LETT, V63, P2342, DOI 10.1063/1.110520
   SAIDA J, IN PRESS PHILOS MAG
   Shen BL, 2000, MATER T JIM, V41, P873, DOI 10.2320/matertrans1989.41.873
   Wang XM, 1999, MATER T JIM, V40, P1130, DOI 10.2320/matertrans1989.40.1130
   Wang XM, 2000, MATER T JIM, V41, P539, DOI 10.2320/matertrans1989.41.539
   Xing LQ, 1999, APPL PHYS LETT, V74, P664, DOI 10.1063/1.122980
NR 36
TC 36
Z9 36
U1 5
U2 10
PU JAPAN INST METALS
PI SENDAI
PA 1-14-32, ICHIBANCHO, AOBA-KU, SENDAI, 980-8544, JAPAN
SN 0916-1821
J9 MATER T JIM
JI Mater. Trans. JIM
PD NOV
PY 2000
VL 41
IS 11
BP 1511
EP 1520
DI 10.2320/matertrans1989.41.1511
PG 10
WC Materials Science, Multidisciplinary; Metallurgy & Metallurgical
   Engineering
SC Materials Science; Metallurgy & Metallurgical Engineering
GA 395BU
UT WOS:000166559500028
OA Bronze
DA 2018-12-27
ER

PT J
AU Schon, JH
   Kloc, C
   Bao, ZN
   Batlogg, B
AF Schon, JH
   Kloc, C
   Bao, ZN
   Batlogg, B
TI RETRACTED: Electron transport in fluorinated copper-phthalocyanine
   (Retracted Article. See vol 15, pg 478, 2003)
SO ADVANCED MATERIALS
LA English
DT Article; Retracted Publication
ID FIELD-EFFECT TRANSISTORS; RETRACTED ARTICLE. SEE; THIN-FILM TRANSISTORS;
   ORGANIC TRANSISTORS; ALPHA-HEXATHIOPHENE; RING OSCILLATORS;
   SINGLE-CRYSTALS; EFFECT MOBILITY; POLYCRYSTALLINE; SEMICONDUCTORS
C1 Bell Labs, Lucent Technol, Murray Hill, NJ 07974 USA.
RP Schon, JH (reprint author), Bell Labs, Lucent Technol, 600 Mt Ave, Murray Hill, NJ 07974 USA.
RI Kloc, Christian/A-2255-2011
CR Bao ZA, 1998, J AM CHEM SOC, V120, P207, DOI 10.1021/ja9727629
   BROWN AR, 1995, SCIENCE, V270, P972, DOI 10.1126/science.270.5238.972
   Brown AR, 1997, SYNTHETIC MET, V88, P37, DOI 10.1016/S0379-6779(97)80881-8
   Crone B, 2000, NATURE, V403, P521, DOI 10.1038/35000530
   Dimitrakopoulos CD, 1999, SCIENCE, V283, P822, DOI 10.1126/science.283.5403.822
   DODABALAPUR A, 1995, SCIENCE, V268, P270, DOI 10.1126/science.268.5208.270
   HOROWITZ G, 1995, J PHYS III, V5, P355, DOI 10.1051/jp3:1995132
   Horowitz G, 2000, J APPL PHYS, V87, P4456, DOI 10.1063/1.373091
   Jackson TN, 1998, IEEE J SEL TOP QUANT, V4, P100, DOI 10.1109/2944.669475
   Karl N., 1990, DEFECT CONTROL SEMIC, V2, P1725
   KATZ HE, UNPUB
   Kloc C, 1997, J CRYST GROWTH, V182, P416, DOI 10.1016/S0022-0248(97)00370-9
   Laquindanum JG, 1996, J AM CHEM SOC, V118, P11331, DOI 10.1021/ja962461j
   Lin YY, 1999, APPL PHYS LETT, V74, P2714, DOI 10.1063/1.123946
   ORTON JW, 1980, REP PROG PHYS, V43, P1263, DOI 10.1088/0034-4885/43/11/001
   Schon JH, 1999, APPL PHYS LETT, V75, P1556, DOI 10.1063/1.124753
   Schon JH, 1998, APPL PHYS LETT, V73, P3574, DOI 10.1063/1.122828
   Schon JH, 2000, SCIENCE, V287, P1022, DOI 10.1126/science.287.5455.1022
   Schon JH, 1998, PHYS REV B, V58, P12952, DOI 10.1103/PhysRevB.58.12952
   SETO JYW, 1975, J APPL PHYS, V46, P5247, DOI 10.1063/1.321593
   Tada H, 1999, J PORPHYR PHTHALOCYA, V3, P667, DOI 10.1002/(SICI)1099-1409(199908/10)3:6/7<667::AID-JPP191>3.0.CO;2-Y
   WARTA W, 1985, PHYS REV B, V32, P1172, DOI 10.1103/PhysRevB.32.1172
NR 22
TC 30
Z9 30
U1 5
U2 24
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA PO BOX 10 11 61, D-69451 WEINHEIM, GERMANY
SN 0935-9648
J9 ADV MATER
JI Adv. Mater.
PD OCT 16
PY 2000
VL 12
IS 20
BP 1539
EP 1542
DI 10.1002/1521-4095(200010)12:20<1539::AID-ADMA1539>3.0.CO;2-S
PG 4
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied;
   Physics, Condensed Matter
SC Chemistry; Science & Technology - Other Topics; Materials Science;
   Physics
GA 372QF
UT WOS:000165244300019
DA 2018-12-27
ER

PT J
AU Reese, EL
   Haimo, LT
AF Reese, EL
   Haimo, LT
TI RETRACTED: Dynein, dynactin, and kinesin II's interaction with
   microtubules is regulated during bidirectional organelle transport
   (Retracted Article. See vol 160, 2000)
SO JOURNAL OF CELL BIOLOGY
LA English
DT Article; Retracted Publication
DE dynein; kinesin; melanophores; microtubules; phosphorylation
ID PROTEIN-KINASE; FLAGELLAR DYNEIN; PIGMENT DISPERSION; AXONAL-TRANSPORT;
   XENOPUS-LAEVIS; LIGHT-CHAIN; CELL-CYCLE; IN-VIVO; PHOSPHORYLATION; MOTOR
AB The microtubule motors, cytoplasmic dynein and kinesin II, drive pigmented organelles in opposite directions in Xenopus melanophores, but the mechanism by which these or other motors are regulated to control the direction of organelle transport has not been previously elucidated. We find that cytoplasmic dynein, dynactin, and kinesin II remain on pigment granules during aggregation and dispersion in melanophores, indicating that control of direction is not mediated by a cyclic association of motors with these organelles. However, the ability of dynein, dynactin, and kinesin II to bind to microtubules varies as a function of the state of aggregation or dispersion of the pigment in the cells from which these molecules are isolated. Dynein and dynactin bind to microtubules when obtained from cells with aggregated pigment, whereas kinesin II binds to microtubules when obtained from cells with dispersed pigment. Moreover. the microtubule binding activity of these motors/dynactin can be reversed in vitro by the kinases and phosphatase that regulate the direction of pigment granule transport in vivo. These findings suggest that phosphorylation controls the direction of pigment granule transport by altering the ability of dynein, dynactin, and kinesin II to interact with microtubules.
C1 Univ Calif Riverside, Dept Biol, Riverside, CA 92521 USA.
RP Haimo, LT (reprint author), Univ Calif Riverside, Dept Biol, Riverside, CA 92521 USA.
EM lhaimo@ucrac1.ucr.edu
CR ALLAN V, 1995, J CELL BIOL, V128, P879, DOI 10.1083/jcb.128.5.879
   DAHLSTROM AB, 1991, ACTA PHYSIOL SCAND, V141, P469, DOI 10.1111/j.1748-1716.1991.tb09107.x
   De Vos K, 2000, J CELL BIOL, V149, P1207, DOI 10.1083/jcb.149.6.1207
   DILLMAN JF, 1994, J CELL BIOL, V127, P1671, DOI 10.1083/jcb.127.6.1671
   GILLE JJP, 1991, MEMBRANE LIPID OXIDA, V3, P1
   Goldstein LSB, 1999, ANNU REV CELL DEV BI, V15, P141, DOI 10.1146/annurev.cellbio.15.1.141
   Habermacher G, 1997, J CELL BIOL, V136, P167, DOI 10.1083/jcb.136.1.167
   Habermacher G, 1996, J CELL SCI, V109, P1899
   HAMASAKI T, 1991, P NATL ACAD SCI USA, V88, P7918, DOI 10.1073/pnas.88.18.7918
   HEUSER J, 1989, J CELL BIOL, V108, P855, DOI 10.1083/jcb.108.3.855
   HIROKAWA N, 1991, J CELL BIOL, V114, P295, DOI 10.1083/jcb.114.2.295
   HIROKAWA N, 1990, J CELL BIOL, V111, P1027, DOI 10.1083/jcb.111.3.1027
   Hirokawa N, 1996, TRENDS CELL BIOL, V6, P135, DOI 10.1016/0962-8924(96)10003-9
   HOWARD DR, 1994, J CELL BIOL, V127, P1683, DOI 10.1083/jcb.127.6.1683
   King SJ, 2000, NAT CELL BIOL, V2, P20
   KUMAR S, 2000, IN PRESS J BIOL CHEM
   Lane JD, 1999, MOL BIOL CELL, V10, P1909, DOI 10.1091/mbc.10.6.1909
   LEE KD, 1995, J BIOL CHEM, V270, P5600, DOI 10.1074/jbc.270.10.5600
   LIN SXH, 1994, J CELL BIOL, V127, P1009, DOI 10.1083/jcb.127.4.1009
   Lindesmith L, 1997, J BIOL CHEM, V272, P22929, DOI 10.1074/jbc.272.36.22929
   LIPPINCOTTSCHWARTZ J, 1995, J CELL BIOL, V128, P293, DOI 10.1083/jcb.128.3.293
   Marlowe KJ, 1998, EUR J CELL BIOL, V75, P140, DOI 10.1016/S0171-9335(98)80056-3
   MATTHIES HJG, 1993, J BIOL CHEM, V268, P11176
   McClintock TS, 1996, J CELL PHYSIOL, V167, P1
   MCILVAIN JM, 1994, J BIOL CHEM, V269, P19176
   Muresan V, 1996, J CELL BIOL, V135, P383, DOI 10.1083/jcb.135.2.383
   Niclas J, 1996, J CELL BIOL, V133, P585, DOI 10.1083/jcb.133.3.585
   Nilsson H, 1996, CELL MOTIL CYTOSKEL, V33, P183, DOI 10.1002/(SICI)1097-0169(1996)33:3<183::AID-CM3>3.0.CO;2-C
   Nilsson H, 1997, CELL MOTIL CYTOSKEL, V38, P397, DOI 10.1002/(SICI)1097-0169(1997)38:4<397::AID-CM9>3.3.CO;2-5
   OKADA Y, 1995, J NEUROSCI, V15, P3053
   POTENZA MN, 1991, PIGM CELL RES, V4, P186, DOI 10.1111/j.1600-0749.1991.tb00437.x
   PRYER NK, 1986, CELL MOTIL CYTOSKEL, V6, P537, DOI 10.1002/cm.970060602
   REBHUN LI, 1964, PRIMITIVE MOTILE SYS, P503
   Reilein AR, 1998, J CELL BIOL, V142, P803, DOI 10.1083/jcb.142.3.803
   RODIONOV VI, 1991, P NATL ACAD SCI USA, V88, P4956, DOI 10.1073/pnas.88.11.4956
   Rogers SL, 1999, J CELL BIOL, V146, P1265, DOI 10.1083/jcb.146.6.1265
   Rogers SL, 1997, P NATL ACAD SCI USA, V94, P3720, DOI 10.1073/pnas.94.8.3720
   Rogers SL, 1998, CURR BIOL, V8, P161, DOI 10.1016/S0960-9822(98)70063-6
   Rogers SL, 1998, METHOD ENZYMOL, V298, P361, DOI 10.1016/S0076-6879(98)98032-6
   ROZDZIAL MM, 1986, CELL, V47, P1061, DOI 10.1016/0092-8674(86)90821-4
   Runnegar MT, 1999, BIOCHEM J, V342, P1, DOI 10.1042/0264-6021:3420001
   SATOYOSHITAKE R, 1992, J BIOL CHEM, V267, P23930
   SHEETZ MP, 1989, TRENDS NEUROSCI, V12, P474, DOI 10.1016/0166-2236(89)90099-4
   SUGDEN D, 1992, J CELL BIOL, V119, P1515, DOI 10.1083/jcb.119.6.1515
   THALER CD, 1990, J CELL BIOL, V111, P1939, DOI 10.1083/jcb.111.5.1939
   Tuma MC, 1999, PIGM CELL RES, V12, P283, DOI 10.1111/j.1600-0749.1999.tb00762.x
   Tuma MC, 1998, J CELL BIOL, V143, P1547, DOI 10.1083/jcb.143.6.1547
   Vaisberg EA, 1996, J CELL BIOL, V133, P831, DOI 10.1083/jcb.133.4.831
   VALE RD, 1992, J CELL BIOL, V119, P1589, DOI 10.1083/jcb.119.6.1589
   VALLEE RB, 1986, METHOD ENZYMOL, V134, P89
   Verhey KJ, 1998, J CELL BIOL, V143, P1053, DOI 10.1083/jcb.143.4.1053
   WATERMANSTORER CM, 1995, P NATL ACAD SCI USA, V92, P1634, DOI 10.1073/pnas.92.5.1634
   WEISS DG, 1986, CELL MOTIL CYTOSKEL, V6, P128, DOI 10.1002/cm.970060210
NR 53
TC 49
Z9 50
U1 2
U2 10
PU ROCKEFELLER UNIV PRESS
PI NEW YORK
PA 950 THIRD AVE, 2ND FLR, NEW YORK, NY 10022 USA
SN 0021-9525
EI 1540-8140
J9 J CELL BIOL
JI J. Cell Biol.
PD OCT 2
PY 2000
VL 151
IS 1
BP 155
EP 165
DI 10.1083/jcb.151.1.155
PG 11
WC Cell Biology
SC Cell Biology
GA 361DM
UT WOS:000089707400013
PM 11018061
OA Bronze, Green Published
DA 2018-12-27
ER

PT J
AU Fujii, Y
   Hoshi, T
   Takahashi, S
   Toyooka, H
AF Fujii, Y
   Hoshi, T
   Takahashi, S
   Toyooka, H
TI RETRACTED: The effect of sedative drugs on diaphragmatic contractility
   in dogs: Propofol versus midazolam (Retracted article. See vol. 116, pg.
   745, 2013)
SO ANESTHESIA AND ANALGESIA
LA English
DT Article; Retracted Publication
ID VOLUNTARY; FATIGUE
C1 Univ Tsukuba, Inst Clin Med, Dept Anesthesiol, Tsukuba, Ibaraki 305, Japan.
RP Fujii, Y (reprint author), Univ Tsukuba, Inst Clin Med, Dept Anesthesiol, 2-1-1 Amakubo, Tsukuba, Ibaraki 305, Japan.
CR AUBIER M, 1981, J APPL PHYSIOL, V50, P538
   EDWARDS RHT, 1978, CLIN SCI MOL MED, V54, P463, DOI 10.1042/cs0540463
   Fujii Y, 1999, ANESTH ANALG, V89, P1557, DOI 10.1097/00000539-199912000-00046
   GRASSINO A, 1978, J APPL PHYSIOL, V44, P829
   JONES DA, 1979, EXP NEUROL, V64, P401, DOI 10.1016/0014-4886(79)90279-6
   MOXHAM J, 1981, CIBA F S 82, P197
   REVES JG, 1985, ANESTHESIOLOGY, V62, P310, DOI 10.1097/00000542-198503000-00017
   Sanchez-Izquierdo-Riera JA, 1998, ANESTH ANALG, V86, P1219, DOI 10.1097/00000539-199806000-00016
   SMITH I, 1994, ANESTHESIOLOGY, V81, P1005
NR 9
TC 6
Z9 6
U1 1
U2 9
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0003-2999
J9 ANESTH ANALG
JI Anesth. Analg.
PD OCT
PY 2000
VL 91
IS 4
BP 1035
EP 1037
DI 10.1097/00000539-200010000-00052
PG 3
WC Anesthesiology
SC Anesthesiology
GA 357LT
UT WOS:000089503700052
PM 11004073
DA 2018-12-27
ER

PT J
AU Huang, GF
   Chou, YL
   Su, FC
AF Huang, GF
   Chou, YL
   Su, FC
TI RETRACTED: Gait analysis and energy consumption of below-knee amputees
   wearing three different prosthetic feet (Retracted Article. See vol 18,
   pg 124, 2003)
SO GAIT & POSTURE
LA English
DT Article; Retracted Publication
DE below-knee amputees; gait analysis; energy consumption
ID SACH FOOT; COST; AMPUTATION; WALKING; LEVEL
AB This study scientifically measures the dynamic gait characteristics and energy consumption of 16 male below-knee amputees, eight vascular and eight traumatic, while wearing solid ankle cushion heel (SACH), single axis and multiple axis prosthetic feet via six-camera motion analysis, metabolic measurement cart and heavy-duty treadmill. Subjective results are additionally determined via questionnaire after testing. Motion analysis showed statistically significant differences at P < 0.05 between the SACH, single axis and multiple axis foot in the velocity, cadence, stride length and single limb stance. Significant differences were found in energy consumption between the traumatic and vascular groups, and significant changes in walking under different speeds and different inclines. Results provide quantitative and qualitative information about the dynamic performance of the various feet, which can be helpful in prescribing the optimal prosthetic foot for individual amputees. (C) 2000 Elsevier Science B.V. All rights reserved.
C1 Natl Cheng Kung Univ, Dept Inst Biomed Engn, Tainan 70148, Taiwan.
RP Chou, YL (reprint author), Natl Cheng Kung Univ, Dept Inst Biomed Engn, 1 Ta Hsueh Rd, Tainan 70148, Taiwan.
EM ylchou@mail.ncku.edu.tw
CR BARTH DG, 1992, J PROSTHET ORTHOT, V4, P63, DOI DOI 10.1097/00008526-199200420-00001
   CULHAM EG, 1986, PROSTHET ORTHOT INT, V10, P15
   GAGE JR, 1985, CLIN PROSTHET ORTHOT, V9, P17
   HANNAH RE, 1984, ARCH PHYS MED REHAB, V65, P159
   KADABA MP, 1990, J ORTHOP RES, V8, P383, DOI 10.1002/jor.1100080310
   LEHMANN JF, 1993, ARCH PHYS MED REHAB, V74, P853, DOI 10.1016/0003-9993(93)90013-Z
   LESLIE T, 1995, J REHABIL RES DEV, V32, P111
   LONDEREE BR, 1982, RES Q EXERCISE SPORT, V53, P297, DOI 10.1080/02701367.1982.10605252
   NIELSEN DH, 1988, J PROSTHET ORTHOT, V1, P24, DOI 10.1097/00008526-198810000-00006
   PAGLIARULO MA, 1979, PHYS THER, V59, P539
   VANLEEUWEN JL, 1990, J BIOMECH, V23, P441, DOI 10.1016/0021-9290(90)90299-I
   WAGNER J, 1987, CLIN PROSTHETICS ORT, V11, P55
   WATERS RL, 1976, J BONE JOINT SURG AM, V58, P42, DOI 10.2106/00004623-197658010-00007
   WILLIAM DM, 1991, EXERCISE PHYSL, P254
NR 14
TC 22
Z9 23
U1 2
U2 20
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0966-6362
J9 GAIT POSTURE
JI Gait Posture
PD OCT
PY 2000
VL 12
IS 2
BP 162
EP 168
DI 10.1016/S0966-6362(00)00069-2
PG 7
WC Neurosciences; Orthopedics; Sport Sciences
SC Neurosciences & Neurology; Orthopedics; Sport Sciences
GA 359WZ
UT WOS:000089636200011
PM 10998614
DA 2018-12-27
ER

PT J
AU Handa, A
   Brown, KE
AF Handa, A
   Brown, KE
TI RETRACTED: GB virus C/hepatitis G virus replicates in human
   haematopoietic cells and vascular endothelial cells (Retracted Article.
   See vol 82, pg 2837, 2001)
SO JOURNAL OF GENERAL VIROLOGY
LA English
DT Article; Retracted Publication
ID HEPATITIS-G VIRUS; BLOOD MONONUCLEAR-CELLS; LOW-DENSITY-LIPOPROTEIN; C
   VIRUS; FULMINANT-HEPATITIS; CLINICAL-IMPLICATIONS; C/HGV-RNA; INFECTION;
   LIVER; SERUM
AB A novel flavivirus, GB virus C (GBV-C)/hepatitis G virus (HGV), has been detected in chronic liver disease patients. It is known that: the viral RNA can be detected in similar to 5% of American blood donors. However, the implications for liver disease and the sites of virus replication remain unknown. Possible sites of virus replication were studied by using cell lines and/or primary cells derived from human lymphoid cells, myeloid cells, hepatocytes and endothelial cells. RNA was detected by virus strand-specific RT-PCR and GBV-C/HGV antigen was detected with a rabbit polyclonal anti-E2 (envelope 2) antibody by Western blot analysis. Negative-strand RNA, representative of replicating virus, was detected in lymphoid and megakaryocytoid cell lines and primary vascular endothelial cells. In addition, an increase in virus titre over time was demonstrated and viral antigen was detected, and virus could be passaged to infect fresh cells. However, viral RNA or antigen could not be detected in any of the hepatocyte lines tested. These results indicate that the replication site of GBV-C/HGV is not primarily in hepatocytes and that detection of replicating virus in hepatic tissue may reflect virus replication in haematopoietic cells and/or vascular endothelial cells present in the liver.
C1 NHLBI, Hematol Branch, NIH, Bethesda, MD 20892 USA.
RP Handa, A (reprint author), NHLBI, Hematol Branch, NIH, Bldg 10,Room 7C218,9000 Rockville Pike, Bethesda, MD 20892 USA.
EM handaa@nih.gov
CR Agnello V, 1999, P NATL ACAD SCI USA, V96, P12766, DOI 10.1073/pnas.96.22.12766
   Brown KE, 1997, NEW ENGL J MED, V336, P1059, DOI 10.1056/NEJM199704103361504
   BUDD TJ, 1991, BIOSCIENCE REP, V11, P15, DOI 10.1007/BF01118601
   Cabrerizo M, 1999, KIDNEY INT, V56, P1120, DOI 10.1046/j.1523-1755.1999.00628.x
   Cantaloube JF, 1999, TRANSFUSION, V39, P95, DOI 10.1046/j.1537-2995.1999.39199116900.x
   Emilia G, 1997, J MED VIROL, V53, P182, DOI 10.1002/(SICI)1096-9071(19971003)53:2<182::AID-JMV12>3.0.CO;2-L
   Feucht HH, 1999, J CLIN MICROBIOL, V37, P1294
   Fogeda M, 1999, J VIROL, V73, P4052
   Francesconi R, 1997, J HEPATOL, V26, P1165, DOI 10.1016/S0168-8278(97)80448-5
   Gutierrez RA, 1997, J MED VIROL, V53, P167, DOI 10.1002/(SICI)1096-9071(199710)53:2<167::AID-JMV10>3.0.CO;2-G
   Hanazono Y, 1999, BLOOD, V94, P2263
   Heringlake S, 1996, LANCET, V348, P1626, DOI 10.1016/S0140-6736(96)04413-3
   Hernandez F, 1998, ACTA HAEMATOL-BASEL, V99, P217, DOI 10.1159/000040842
   Ikeda M, 1997, BIOCHEM BIOPH RES CO, V235, P505, DOI 10.1006/bbrc.1997.6818
   Kanda T, 1997, HEPATOLOGY, V25, P1261, DOI 10.1002/hep.510250534
   Kao JH, 1999, ARCH VIROL, V144, P2173, DOI 10.1007/s007050050631
   Khudyakov YE, 1997, J VIROL, V71, P6875
   Laras A, 1999, J HEPATOL, V30, P383, DOI 10.1016/S0168-8278(99)80094-4
   Laskus T, 1998, J VIROL, V72, P3072
   Laskus T, 1997, J VIROL, V71, P7804
   Leary TP, 1996, J MED VIROL, V48, P60, DOI 10.1002/(SICI)1096-9071(199601)48:1<60::AID-JMV10>3.3.CO;2-E
   Lindenbach BD, 1997, J VIROL, V71, P9608
   Linnen J, 1996, SCIENCE, V271, P505, DOI 10.1126/science.271.5248.505
   Madejon A, 1997, GASTROENTEROLOGY, V113, P573, DOI 10.1053/gast.1997.v113.pm9247478
   Mellor J, 1998, J GEN VIROL, V79, P705, DOI 10.1099/0022-1317-79-4-705
   Menendez C, 1999, J CLIN MICROBIOL, V37, P2333
   Mushahwar IK, 1998, J MED VIROL, V56, P1, DOI 10.1002/(SICI)1096-9071(199809)56:1<1::AID-JMV1>3.0.CO;2-3
   Pessoa MG, 1998, HEPATOLOGY, V27, P877, DOI 10.1002/hep.510270335
   Sawamura T, 1997, NATURE, V386, P73, DOI 10.1038/386073a0
   Schleicher S, 1996, J MED VIROL, V50, P71, DOI 10.1002/(SICI)1096-9071(199609)50:1<71::AID-JMV12>3.0.CO;2-0
   Seipp S, 1996, VIRUS RES, V46, P81, DOI 10.1016/S0168-1702(96)01377-9
   Seipp S, 1999, J HEPATOL, V30, P570, DOI 10.1016/S0168-8278(99)80186-X
   Sheng L, 1997, THROMB HAEMOSTASIS, V77, P868
   Shimizu YK, 1999, J VIROL, V73, P8411
   SIMONS JN, 1995, NAT MED, V1, P564, DOI 10.1038/nm0695-564
   Take H, 2000, BIOCHEM BIOPH RES CO, V268, P321, DOI 10.1006/bbrc.2000.2147
   Tameda Y, 1996, J HEPATOL, V25, P842, DOI 10.1016/S0168-8278(96)80287-X
   Tepper JL, 1998, J RHEUMATOL, V25, P925
   Tsuda F, 1996, J MED VIROL, V49, P248, DOI 10.1002/(SICI)1096-9071(199607)49:3<248::AID-JMV15>3.0.CO;2-8
   Wang JT, 1996, BLOOD, V88, P1881
   Wang JT, 1998, TRANSFUSION, V38, P290, DOI 10.1046/j.1537-2995.1998.38398222874.x
   YOSHIBA M, 1995, LANCET, V346, P1131, DOI 10.1016/S0140-6736(95)91802-7
NR 42
TC 14
Z9 15
U1 3
U2 7
PU MICROBIOLOGY SOC
PI LONDON
PA CHARLES DARWIN HOUSE, 12 ROGER ST, LONDON WC1N 2JU, ERKS, ENGLAND
SN 0022-1317
EI 1465-2099
J9 J GEN VIROL
JI J. Gen. Virol.
PD OCT
PY 2000
VL 81
BP 2461
EP 2469
DI 10.1099/0022-1317-81-10-2461
PN 10
PG 9
WC Biotechnology & Applied Microbiology; Virology
SC Biotechnology & Applied Microbiology; Virology
GA 358KJ
UT WOS:000089557000012
PM 10993934
OA Bronze
DA 2018-12-27
ER

PT J
AU Inoue, A
   Zhang, T
   Chen, MW
   Sakurai, T
   Saida, J
   Matsushita, M
AF Inoue, A
   Zhang, T
   Chen, MW
   Sakurai, T
   Saida, J
   Matsushita, M
TI RETRACTED: Formation and properties of Zr-based bulk quasicrystalline
   alloys with high strength and good ductility (Retracted article. See
   vol. 33, pg. 1698, 2018)
SO JOURNAL OF MATERIALS RESEARCH
LA English
DT Article; Retracted Publication
ID SUPERCOOLED LIQUID REGION; NI AMORPHOUS-ALLOYS; METALLIC-GLASS;
   MAGNETIC-PROPERTIES; ICOSAHEDRAL PHASE; AL ALLOYS; TRANSFORMATION;
   KINETICS; GROWTH; AU
AB The crystallization mode of the Zr-Al-Ni-Cu amorphous alloys changed from a single stage to become two stages by the addition of Ag or Pd, and the first-stage exothermic reaction was found to result from the precipitation of nanoscale icosahedral particles with a size of 20 to 50 nm. The precipitation took place by high nucleation and low growth rates in a polymorphous mode for the Ag-containing alloys, and a diffusion-controlled mode for the Pd-containing alloys. The nanoscale mixed structure alloys exhibited improved strength and ductility as compared with the corresponding amorphous single-phase alloys. The findings of the dispersion strengthening as well as the dispersion ductilization gave a future opportunity to fabricate a new bulk nonequilibrium phase alloy by use of the new phenomenon.
C1 Tohoku Univ, Inst Mat Res, Sendai, Miyagi 9808577, Japan.
   Japan Sci & Technol Corp, Inoue Superliquid Glass Project, Sendai, Miyagi 9820807, Japan.
RP Inoue, A (reprint author), Tohoku Univ, Inst Mat Res, Sendai, Miyagi 9808577, Japan.
EM ainoue@imr.tohoku.ac.jp
RI CHEN, Mingwei/A-4855-2010; Zhang, Tao/O-4911-2014; Inoue,
   Akihisa/E-5271-2015; Saida, Junji/C-1912-2009
OI CHEN, Mingwei/0000-0002-8274-3099; Chen, Mingwei/0000-0002-2850-8872
CR CHEN LC, 1988, NATURE, V336, P366, DOI 10.1038/336366a0
   Chen MW, 1999, APPL PHYS LETT, V75, P1697, DOI 10.1063/1.124793
   Drehman A. J., 1986, Journal of Materials Research, V1, P741, DOI 10.1557/JMR.1986.0741
   HOLZER JC, 1991, ACTA METALL MATER, V39, P1833, DOI 10.1016/0956-7151(91)90152-Q
   Inoue A, 1999, MATER T JIM, V40, P1137, DOI 10.2320/matertrans1989.40.1137
   Inoue A, 1999, MATER T JIM, V40, P1382, DOI 10.2320/matertrans1989.40.1382
   Inoue A, 2000, MATER T JIM, V41, P362, DOI 10.2320/matertrans1989.41.362
   Inoue A, 2000, ACTA MATER, V48, P279, DOI 10.1016/S1359-6454(99)00300-6
   Inoue A, 2000, APPL PHYS LETT, V76, P967, DOI 10.1063/1.125907
   INOUE A, 1988, JPN J APPL PHYS 2, V27, pL2248, DOI 10.1143/JJAP.27.L2248
   Inoue A, 1997, MATER T JIM, V38, P359, DOI 10.2320/matertrans1989.38.359
   INOUE A, 1989, MATER T JIM, V30, P965, DOI 10.2320/matertrans1989.30.965
   Inoue A, 1995, MATER T JIM, V36, P1427, DOI 10.2320/matertrans1989.36.1427
   INOUE A, 1995, MATER T JIM, V36, P866, DOI 10.2320/matertrans1989.36.866
   Inoue A, 1999, MATER T JIM, V40, P1181, DOI 10.2320/matertrans1989.40.1181
   INOUE A, 1994, MAT SCI ENG A-STRUCT, V178, P255, DOI 10.1016/0921-5093(94)90551-7
   INOUE A, 1990, MATER T JIM, V31, P177, DOI 10.2320/matertrans1989.31.177
   Inoue A, 1996, MATER T JIM, V37, P181, DOI 10.2320/matertrans1989.37.181
   Inoue A., 1998, BULK AMORPHOUS ALLOY, P1
   INOUE A, IN PRESS MAT T JIM
   Johnson WA, 1939, T AM I MIN MET ENG, V135, P416
   Johnson WL, 1999, MRS BULL, V24, P42, DOI 10.1557/S0883769400053252
   KOSTER U, 1993, KEY ENG MAT, V81-3, P647
   Koster U, 1997, MAT SCI ENG A-STRUCT, V226, P995, DOI 10.1016/S0921-5093(97)80100-1
   Koster U, 1996, APPL PHYS LETT, V69, P179, DOI 10.1063/1.117364
   MASUMOTO T, 1989, Patent No. 7122120
   Matsushita M, 2000, PHIL MAG LETT, V80, P79, DOI 10.1080/095008300176335
   Murty BS, 2000, APPL PHYS LETT, V76, P55, DOI 10.1063/1.125654
   OHNUGI M, 1999, MAT JAPAN, V38, P251
   PEKER A, 1993, APPL PHYS LETT, V63, P2342, DOI 10.1063/1.110520
   SAIDA J, IN PRESS PHILOS MAG
   SAIDA J, IN PRESS MAT T JIM
   Shen BL, 2000, MATER T JIM, V41, P873, DOI 10.2320/matertrans1989.41.873
   Wang XM, 1999, MATER T JIM, V40, P1130, DOI 10.2320/matertrans1989.40.1130
   Wang XM, 2000, MATER T JIM, V41, P539, DOI 10.2320/matertrans1989.41.539
   Xing LQ, 1999, APPL PHYS LETT, V74, P664, DOI 10.1063/1.122980
NR 36
TC 99
Z9 100
U1 2
U2 15
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 0884-2914
EI 2044-5326
J9 J MATER RES
JI J. Mater. Res.
PD OCT
PY 2000
VL 15
IS 10
BP 2195
EP 2208
DI 10.1557/JMR.2000.0316
PG 14
WC Materials Science, Multidisciplinary
SC Materials Science
GA 360PM
UT WOS:000089676500023
DA 2018-12-27
ER

PT J
AU Hawthorne, G
   Irgens, LM
   Lie, RT
AF Hawthorne, G
   Irgens, LM
   Lie, RT
TI RETRACTED: Outcome of pregnancy in diabetic women in northeast England
   and in Norway, 1994-7 (Retracted Article. See vol 327, pg 905, 2003)
SO BMJ-BRITISH MEDICAL JOURNAL
LA English
DT Article; Retracted Publication
AB In northeast England, perinatal mortality is five times higher and congenital malformation is four times higher for pregnancies in diabetic women than for those in women who do not have diabetes.' The same is true in other regions in the United Kingdom,(2 3) but this is not the case in Norway.(4) Why is the outcome of pregnancy in diabetic women better in Norway? Does Norway use the same definitions and record the same outcome data as the United Kingdom? If the data are standardised will these differences disappear! If not, what is causing the difference in the outcome of pregnancy in diabetic women?
   The methodology for data collection needs to be standardised between the two countries to determine whether differences in outcome are real before looking for explanations in the healthcare systems of the two countries. We compare the outcome of pregnancy in women with diabetes based on prospective population data collected in Norway and northeast England.
C1 No Diabet Pregnancy Survey, Reg Matern Survey Off, Newcastle Upon Tyne NE2 4AA, Tyne & Wear, England.
   Hauletend Hosp, Med Birth Registry Norway, N-5021 Bergen, Norway.
RP Hawthorne, G (reprint author), No Diabet Pregnancy Survey, Reg Matern Survey Off, Newcastle Upon Tyne NE2 4AA, Tyne & Wear, England.
EM gillian.hawthorne@nth.northy.nhs.uk
CR Casson IF, 1997, BRIT MED J, V315, P275, DOI 10.1136/bmj.315.7103.275
   Diabetes Care and Research in Europe, 1990, DIABETIC MED, V7, P360
   HADDEN DR, 1998, DIABETIC MED S1, V15, pS16
   HAWTHORNE G, 1994, BRIT MED J, V315, P279
   Hellesen Harald Bjarne, 1996, Tidsskrift for den Norske Laegeforening, V116, P3465
NR 5
TC 26
Z9 26
U1 3
U2 11
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 1756-1833
J9 BMJ-BRIT MED J
JI BMJ-British Medical Journal
PD SEP 23
PY 2000
VL 321
IS 7263
BP 730
EP 731
DI 10.1136/bmj.321.7263.730
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA 358FE
UT WOS:000089546600019
PM 10999902
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Xu, J
   Love, LM
   Singh, I
   Zhang, QX
   Dewald, J
   Wang, DA
   Fischer, DJ
   Tigyi, G
   Berthiaume, LG
   Waggoner, DW
   Brindley, DN
AF Xu, J
   Love, LM
   Singh, I
   Zhang, QX
   Dewald, J
   Wang, DA
   Fischer, DJ
   Tigyi, G
   Berthiaume, LG
   Waggoner, DW
   Brindley, DN
TI RETRACTED: Lipid phosphate phosphatase-1 and Ca2+ control
   lysophosphatidate signaling through EDG-2 receptors (Retracted Article.
   See vol 278, pg 38104, 2003)
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article; Retracted Publication
ID CELL-PERMEABLE CERAMIDES; SPHINGOSINE 1-PHOSPHATE; ACID
   PHOSPHOHYDROLASE; MOLECULAR-CLONING; DNA-SYNTHESIS; GROWTH-FACTOR;
   G-PROTEINS; FIBROBLASTS; IDENTIFICATION; MOBILIZATION
AB The serum-derived phospholipid growth factor, lysophosphatidate (LPA), activates cells through the EDG family of G protein-coupled receptors, The present study investigated mechanisms by which dephosphorylation of exogenous LPA by lipid phosphate phosphatase-1 (LPP-1) controls cell signaling. Overexpressing LPP-1 decreased the net specific cell association of LPA with Rats fibroblasts by approximately 50% at 37 degrees C when less than 10% of LPA was dephosphorylated. This attenuated cell activation as indicated by diminished responses, including cAMP, Ca2+, activation of phospholipase D and ERK, DNA synthesis, and cell division. Conversely, decreasing LPP-1 expression increased net LPA association, ERK stimulation, and DNA synthesis. Whereas changing LPP-1 expression did not alter the apparent K-d and B-max for LPA binding at 4 degrees C, increasing Ca2+ from 0 to 50 mu M increased the K-d from 40 to 900 nM. Decreasing extracellular Ca2+ from 1.8 mM to 10 mu M increased LPA binding by 20-fold, shifting the threshold for ERK activation to the nanomolar range. Hence the Ca2+ dependence of the apparent K-d values explains the long-standing discrepancy of why micromolar LPA is often needed to activate cells at physiological Ca2+ levels. In addition, the work demonstrates that LPP-1 can regulate specific LPA association with cells without significantly depleting bulk LPA concentrations in the extracellular medium. This identifies a novel mechanism for controlling EDG-2 receptor activation.
C1 Univ Alberta, Dept Biochem, Signal Transduct Labs, Edmonton, AB T6G 2S2, Canada.
   Univ Alberta, Dept Biochem, Lipid Biol Res Grp, Edmonton, AB T6G 2S2, Canada.
   Univ Alberta, Dept Cell Biol, Edmonton, AB T6G 2S2, Canada.
   Univ Tennessee, Dept Physiol, Memphis, TN 38163 USA.
   Cell Therapeut Inc, Seattle, WA 98119 USA.
RP Brindley, DN (reprint author), Univ Alberta, Dept Biochem, Signal Transduct Labs, 357 Heritage Med Res Ctr, Edmonton, AB T6G 2S2, Canada.
EM david.brindley@ualberta.ca
OI Berthiaume, Luc/0000-0003-0926-059X
FU NHLBI NIH HHS [HL 61459]; PHS HHS [R01 61751]
CR An SZ, 1998, MOL PHARMACOL, V54, P881
   An SZ, 1998, J BIOL CHEM, V273, P7906, DOI 10.1074/jbc.273.14.7906
   An SZ, 1997, BIOCHEM BIOPH RES CO, V231, P619, DOI 10.1006/bbrc.1997.6150
   Bandoh K, 1999, J BIOL CHEM, V274, P27776, DOI 10.1074/jbc.274.39.27776
   Brindley DN, 1998, J BIOL CHEM, V273, P24281, DOI 10.1074/jbc.273.38.24281
   English D, 1997, BIOCHEM J, V324, P941, DOI 10.1042/bj3240941
   Fischer DJ, 1998, MOL PHARMACOL, V54, P979
   FOURCADE O, 1995, CELL, V80, P919, DOI 10.1016/0092-8674(95)90295-3
   Frankel A, 1996, CLIN CANCER RES, V2, P1307
   Fukushima N, 1998, P NATL ACAD SCI USA, V95, P6151, DOI 10.1073/pnas.95.11.6151
   Goetzl EJ, 1998, FASEB J, V12, P1589
   GOMEZMUNOZ A, 1994, J BIOL CHEM, V269, P8937
   GOMEZMUNOZ A, 1995, MOL PHARMACOL, V47, P883
   Guo Z, 1996, P NATL ACAD SCI USA, V93, P14367, DOI 10.1073/pnas.93.25.14367
   Hecht JH, 1996, J CELL BIOL, V135, P1071, DOI 10.1083/jcb.135.4.1071
   ITO T, 1974, BIOCHIM BIOPHYS ACTA, V352, P29, DOI 10.1016/0005-2736(74)90176-X
   JALINK K, 1995, BIOCHEM J, V307, P609, DOI 10.1042/bj3070609
   JALINK K, 1990, J BIOL CHEM, V265, P12232
   Jasinska R, 1999, BIOCHEM J, V340, P677, DOI 10.1042/0264-6021:3400677
   Kai M, 1996, J BIOL CHEM, V271, P18931, DOI 10.1074/jbc.271.31.18931
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   Liliom K, 1998, AM J PHYSIOL-CELL PH, V274, pC1065
   MARTIN A, 1987, BIOCHEM J, V245, P347, DOI 10.1042/bj2450347
   MOOLENAAR WH, 1995, J BIOL CHEM, V270, P12949, DOI 10.1074/jbc.270.22.12949
   NEWTON C, 1978, BIOCHIM BIOPHYS ACTA, V506, P281, DOI 10.1016/0005-2736(78)90398-X
   PAGANO RE, 1985, J BIOL CHEM, V260, P1909
   PERRY DK, 1993, J BIOL CHEM, V268, P25302
   Picotto G, 1999, BIOCHEM J, V339, P71, DOI 10.1042/0264-6021:3390071
   Rizza C, 1999, LAB INVEST, V79, P1227
   Roberts R, 1998, J BIOL CHEM, V273, P22059, DOI 10.1074/jbc.273.34.22059
   Sasagawa T, 1999, LIPIDS, V34, P17, DOI 10.1007/s11745-999-332-5
   Shahrestanifar M, 1999, J BIOL CHEM, V274, P3828, DOI 10.1074/jbc.274.6.3828
   Shen Z, 1997, CLIN CHEM, V43, P577
   Tabata MJ, 1996, DEVELOPMENT, V122, P1243
   Tigyi G, 1996, J NEUROCHEM, V66, P537
   Valet P, 1998, J CLIN INVEST, V101, P1431, DOI 10.1172/JCI806
   VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4
   VANDERBEND RL, 1992, BIOCHIM BIOPHYS ACTA, V1125, P110, DOI 10.1016/0005-2760(92)90163-P
   Waggoner DW, 1996, J BIOL CHEM, V271, P16506, DOI 10.1074/jbc.271.28.16506
   Waggoner DW, 1999, BBA-MOL CELL BIOL L, V1439, P299, DOI 10.1016/S1388-1981(99)00102-X
   Xu Y, 1998, JAMA-J AM MED ASSOC, V280, P719, DOI 10.1001/jama.280.8.719
   Yazaki T, 1996, MOL PHARMACOL, V50, P236
   Young KW, 1999, BIOCHEM J, V343, P45, DOI 10.1042/0264-6021:3430045
   Zhang QX, 2000, BIOCHEM J, V345, P181, DOI 10.1042/0264-6021:3450181
NR 44
TC 44
Z9 44
U1 0
U2 9
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD SEP 8
PY 2000
VL 275
IS 36
BP 27520
EP 27530
PG 11
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 352CN
UT WOS:000089197100004
PM 10849424
DA 2018-12-27
ER

PT J
AU Wakefield, AJ
   Anthony, A
   Murch, SH
   Thomson, M
   Montgomery, SM
   Davies, S
   O'Leary, JJ
   Berelowitz, M
   Walker-Smith, JA
AF Wakefield, AJ
   Anthony, A
   Murch, SH
   Thomson, M
   Montgomery, SM
   Davies, S
   O'Leary, JJ
   Berelowitz, M
   Walker-Smith, JA
TI RETRACTED: Enterocolitis in children with developmental disorders
   (Retracted article. See vol. 105, pg. 1214, 2010)
SO AMERICAN JOURNAL OF GASTROENTEROLOGY
LA English
DT Article; Retracted Publication
ID NODULAR LYMPHOID HYPERPLASIA; COMMON VARIABLE IMMUNODEFICIENCY;
   NONSPECIFIC COLITIS; LYMPHONODULAR HYPERPLASIA; SMALL-INTESTINE;
   MEASLES-VIRUS; T-CELLS; AUTISM; HYPOGAMMAGLOBULINEMIA; INFECTION
AB OBJECTIVE: Intestinal pathology, i.e., ileocolonic lymphoid nodular hyperplasia (LNH) and mucosal inflammation, has been described in children with developmental disorders. This study describes some of the endoscopic and pathological characteristics in a group of children with developmental disorders (affected children) that are associated with behavioral regression and bowel symptoms, and compares them with pediatric controls.
   METHODS: Ileocolonoscopy and biopsy were performed on 60 affected children (median age 6 yr, range 3-16; 53 male). Developmental diagnoses were autism (50 patients), Asperger's syndrome (five), disintegrative disorder (two), attention deficit hyperactivity disorder (ADHD) (one), schizophrenia (one), and dyslexia (one). Severity of ileal LNH was graded (0-3) in both affected children and 37 developmentally normal controls (median age 11 yr, range 2-13 yr) who were investigated for possible inflammatory bowel disease (IBD). Tissue sections were reviewed by three pathologists and scored on a standard proforma. Data were compared with ileocolonic biopsies from 22 histologically normal children (controls) and 20 children with ulcerative colitis (UC), scored in an identical manner. Gut pathogens were sought routinely.
   RESULTS: Ileal LNH was present in 54 of 58 (93%) affected children and in five of 35 (14.3%) controls (p < 0.001). Colonic LNH was present in 18 of 60 (30%) affected children and in two of 37 (5.4%) controls (p < 0.01). Histologically, reactive follicular hyperplasia was present in 46 of 52 (88.5%) ileal biopsies from affected children and in four of 14 (29%) with UC, but not in non-IBD controls (p < 0.01). Active ileitis was present in four of 51 (8%) affected children but not in controls. Chronic colitis was identified in 53 of 60 (88%) affected children compared with one of 22 (4.5%) controls and in 20 of 20 (100%) with UC. Scores of frequency and severity of inflammation were significantly greater in both affected children and those with UC, compared with controls (p < 0.001).
   CONCLUSIONS: A new variant of inflammatory bowel disease is present in this group of children with developmental disorders. (Am J Gastroenterol 2000;95:2285-2295. (C) 2000 by Am. Cell. of Gastroenterology).
C1 Univ London, Royal Free & Univ Coll, Sch Med, Dept Med,Inflammatory Bowel Dis Study Grp, London NW3 2QG, England.
   Univ London, Royal Free & Univ Coll, Sch Med, Dept Histopathol, London NW3 2QG, England.
   Univ London, Royal Free & Univ Coll, Sch Med, Dept Paediat Gastroenterol, London NW3 2QG, England.
   Univ London, Royal Free & Univ Coll, Sch Med, Dept Paediat Psychiat, London NW3 2QG, England.
   Coombe Womens Hosp, Univ Dept Pathol, Dublin, Ireland.
   Trinity Coll Dublin, Dublin, Ireland.
RP Wakefield, AJ (reprint author), Univ London, Royal Free & Univ Coll, Sch Med, Dept Med,Inflammatory Bowel Dis Study Grp, Royal Free Campus, London NW3 2QG, England.
CR AJDUKIEWICZ AB, 1972, GUT, V13, P589, DOI 10.1136/gut.13.8.589
   American Psychiatric Association, 1994, DIAGN STAT MAN MENT
   Anthony A, 1998, GUT, V42, pA24
   BASTLEIN C, 1988, ENDOSCOPY, V20, P272, DOI 10.1055/s-2007-1018192
   BHARDWAJ N, 1997, J EXP MED, V186, P759
   FERRARI P, 1988, Encephale, V14, P339
   FIBER SS, 1983, GASTROENTEROLOGY, V50, P83
   Fujimura Y, 1996, GUT, V38, P724, DOI 10.1136/gut.38.5.724
   GRIFFEN DE, 1996, FIELDS VIROLOGY, P1280
   Gupta S, 1998, J NEUROIMMUNOL, V85, P106, DOI 10.1016/S0165-5728(98)00021-6
   HERMANS PE, 1966, AM J MED, V40, P78, DOI 10.1016/0002-9343(66)90189-6
   Horvath K, 1999, J PEDIATR-US, V135, P559, DOI 10.1016/S0022-3476(99)70052-1
   Katz A J, 1977, Ciba Found Symp, P243
   LEVENDOGLU H, 1992, AM J GASTROENTEROL, V87, P1200
   PANKSEPP J, 1979, TRENDS NEUROSCI, V2, P174, DOI 10.1016/0166-2236(79)90071-7
   Reichelt K L, 1981, Adv Biochem Psychopharmacol, V28, P627
   Sabra A, 1998, LANCET, V352, P234, DOI 10.1016/S0140-6736(05)77837-5
   SHATTOCK P, 1990, Brain Dysfunction, V3, P328
   Singh VK, 1998, CLIN IMMUNOL IMMUNOP, V89, P105, DOI 10.1006/clin.1998.4588
   SINGH VK, 1993, BRAIN BEHAV IMMUN, V7, P97, DOI 10.1006/brbi.1993.1010
   STUBBS EG, 1977, J AUTISM CHILD SCHIZ, V7, P49, DOI 10.1007/BF01531114
   VANDENBRANDE P, 1988, J CLIN IMMUNOL, V8, P296, DOI 10.1007/BF00916558
   vanGent T, 1997, J CHILD PSYCHOL PSYC, V38, P337
   Wakefield AJ, 1998, LANCET, V351, P637, DOI 10.1016/S0140-6736(97)11096-0
   Wakefield AJ, 1998, GUT, V42, pA86
   WARREN RP, 1987, J AM ACAD CHILD PSY, V26, P333, DOI 10.1097/00004583-198705000-00008
   WARREN RP, 1990, IMMUNOL INVEST, V19, P245, DOI 10.3109/08820139009041839
   WEBSTER ADB, 1977, GUT, V18, P364, DOI 10.1136/gut.18.5.364
   WEIZMAN A, 1982, AM J PSYCHIAT, V139, P1462
NR 29
TC 149
Z9 156
U1 3
U2 27
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0002-9270
J9 AM J GASTROENTEROL
JI Am. J. Gastroenterol.
PD SEP
PY 2000
VL 95
IS 9
BP 2285
EP 2295
PG 11
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 354BR
UT WOS:000089310400022
PM 11007230
DA 2018-12-27
ER

PT J
AU Sparac, V
   Kupesic, S
   Kurjak, A
AF Sparac, V
   Kupesic, S
   Kurjak, A
TI RETRACTED: What do contrast media add to three-dimensional power Doppler
   evaluation of adnexal masses? (Retracted Article. See vol 48, pg 145,
   2007)
SO CROATIAN MEDICAL JOURNAL
LA English
DT Article; Retracted Publication
DE adnexa uteri; contrast media; Doppler ultrasonography; color; ovarian
   neoplasms; ultrasonogrophy; Doppler; color; visual contrast sensitivity
ID OVARIAN-CANCER; ANGIOGENESIS; SONOGRAPHY; ULTRASOUND; CARCINOMA; LESIONS
AB Aim. To investigate the potential usefulness of contrast-enhanced three-dimensional (3D) power Doppler sonography in the differentiation of benign and malignant adnexal lesions.
   Methods. Thirty one patients with complex adnexal lesions of uncertain malignancy at transvaginal B-mode and/or color Doppler sonography were prospectively evaluated with three-dimensional power Doppler sonography before and after injection of a contrast agent. Presence of a penetrating pattern and a mixed penetrating and/or peripheral pattern suggested adnexal malignancy. The results were compared with histopathology
   Results. There were 10 cases of ovarian malignancy and 21 benign adnexal lesions. Of the 10 ovarian cancers, 6 showed vascular distribution suggestive of malignancy at nonenhanced 3D power Doppler sonography. After injection of a contrast agent, a penetrating Vascular pattern and/or a mixed penetrating and peripheral pattern were detected in all cases of ovarian malignancy as well as in 2 benign lesions (fibroma and cystadenofibroma), which were misdiagnosed as malignant. The use of a contrast agent with three-dimensional power Doppler sonography showed diagnostic efficiency of 96.7%, superior to that of nonenhanced 3D power Doppler sonography (93.5%).
   Conclusion. Contrast-enhanced 3D power Doppler sonography provides better visualization of tumor Vascularity in complex adnexal masses. If used together with 3D morphological ultrasound assessment, enhanced 3D power Doppler imaging may precisely discriminate benign from malignant adnexal lesions.
C1 Univ Zagreb, Holly Ghost Hosp, Sch Med, Dept Obstet & Gynecol, Zagreb 10000, Croatia.
RP Sparac, V (reprint author), Univ Zagreb, Holly Ghost Hosp, Sch Med, Dept Obstet & Gynecol, Sveti Duh 64, Zagreb 10000, Croatia.
EM asim.kurjak@public.srce.hr
CR Albrecht T, 1998, RADIOLOGY, V207, P339, DOI 10.1148/radiology.207.2.9577478
   BOURNE T, 1989, BRIT MED J, V299, P1367, DOI 10.1136/bmj.299.6712.1367
   BOURNE TH, 1994, ULTRASOUND OBST GYN, V4, P357, DOI 10.1046/j.1469-0705.1994.04050355-2.x
   DOWNEY DB, 1995, AM J ROENTGENOL, V165, P665, DOI 10.2214/ajr.165.3.7645492
   Fleischer AC, 1996, AM J OBSTET GYNECOL, V174, P101, DOI 10.1016/S0002-9378(96)70380-0
   FOLKMAN J, 1898, J NATL CANCER I, V82, P4
   Hosten N, 1999, J CLIN ULTRASOUND, V27, P107, DOI 10.1002/(SICI)1097-0096(199903/04)27:3<107::AID-JCU2>3.0.CO;2-Y
   Kim AY, 1999, J ULTRAS MED, V18, P581
   Kurjak A, 1999, CROAT MED J, V40, P413
   KURJAK A, 1993, ULTRASOUND OBST GYN, V3, P195, DOI 10.1046/j.1469-0705.1993.03030195.x
   KURJAK A, 1991, J ULTRAS MED, V10, P295
   RAK JW, 1995, ANTI-CANCER DRUG, V6, P3, DOI 10.1097/00001813-199502000-00001
   SCULLY RE, 1975, NATL CANCER I MONOGR, P5
   Skobe M, 1997, NAT MED, V3, P1222, DOI 10.1038/nm1197-1222
NR 14
TC 6
Z9 8
U1 2
U2 8
PU MEDICINSKA NAKLADA
PI ZAGREB
PA VLASKA 69, HR-10000 ZAGREB, CROATIA
SN 0353-9504
EI 1332-8166
J9 CROAT MED J
JI Croat. Med. J.
PD SEP
PY 2000
VL 41
IS 3
BP 257
EP 261
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA 355BT
UT WOS:000089366300007
PM 10962043
DA 2018-12-27
ER

PT J
AU Brodie, SJ
AF Brodie, SJ
TI RETRACTED: Nonlymphoid reservoirs of HIV replication in children with
   chronic-progressive disease (Retracted Article. See vol 83, pg 797,
   2008)
SO JOURNAL OF LEUKOCYTE BIOLOGY
LA English
DT Article; Proceedings Paper; Retracted Publication
CT 4th International Workshop on HIV and Cells of Macrophage Lineage and
   Other Reservoirs
CY DEC 01-04, 1999
CL DONNINI, ITALY
SP Minist Univ, Inst Super Sanita, Australian Natl Ctr HIV Virol Res, Glaxo Wellcome, Bristol Myers Squibb, Merck & Co, Pharmacia Upjohn, SmithKline Beecham Int, Perkin Elmer Europe, Bechman Coulter
DE BALT; GALT; macrophages; follicular dendritic cells; peripheral blood
   lymphocytes
ID HUMAN-IMMUNODEFICIENCY-VIRUS; FOLLICULAR DENDRITIC CELLS;
   EPSTEIN-BARR-VIRUS; LYMPHOCYTIC INTERSTITIAL PNEUMONIA; MULTINUCLEATED
   GIANT-CELLS; ANTIRETROVIRAL THERAPY; LYMPHOID-TISSUES; T-CELLS; IN-VIVO;
   PERIPHERAL-BLOOD
AB Autopsy tissues from 2 cohorts of age-matched HIV-infected children with similar plasma viral load (>10(5) HIV RNA copies/ml), but with distinct AIDS-associated disease manifestations, were examined for sites of persistent HIV replication. One group consisted of 3 children with severe lymphoid atrophy and peripheral blood CD4(+) T cell counts of <10/mm(3). Another group was composed of 6 children with extensive hyperplasia of mucosal-associated lymphoid tissues and blood CD4(+) T cell counts >500/mm(3). Hyperplastic bronchiole- and gut-associated lymphoid tissues were characterized by extensive networks of germinal center follicular dendritic cells (FDC) containing large amounts of immune-complexed virion RNA. Conversely, pulmonary and gastrointestinal tissues from children with severe CD4(+) T cell depletion were devoid of any secondary lymphoid structures, yet these tissues also harbored high concentrations of HIV RNA. Dual in situ procedures showed that only macrophage (M phi) within these sites contained tat fusion transcripts, a product of post-transcriptional splicing and a correlate of productive infection. When examining explant cultures of M phi and FDC, only M phi harbored HIV tat mRNA and only M phi demonstrated budding retroviral particles. Hence, germinal center FDC in secondary lymphoid tissues are key reservoirs of immune-complexed HIV RNA and are likely to contribute to AIDS-associated lymphoproliferations; however, these cells do not support HIV replication, and failure to do so results from a post-transcriptional block in the virus life cycle. Moreover, gut and pulmonary M phi represent a lineage of cells that are permissive to HIV replication and contribute significantly to the high viral load in children with severe CD4(+) T cell depletion. It will be important to identify the molecular mechanisms that allow for these highly productive infections of M phi.
C1 Univ Washington, Sch Med, Div Virol, Retrovirol Lab, Seattle, WA USA.
RP Brodie, SJ (reprint author), Univ Washington, Sch Med, Dept Lab Med, Vaccine Virol Div, Room T293X, Seattle, WA 98195 USA.
FU NIAID NIH HHS [AI30731, AI36613, AI41535]
CR An SF, 1999, J NEUROPATH EXP NEUR, V58, P1156, DOI 10.1097/00005072-199911000-00005
   Anderson JM, 2000, CURR OPIN HEMATOL, V7, P40, DOI 10.1097/00062752-200001000-00008
   ANDIMAN WA, 1985, LANCET, V2, P1390
   Arber DA, 1996, AM J SURG PATHOL, V20, P1426, DOI 10.1097/00000478-199611000-00016
   ARBER DA, 1995, HUM PATHOL, V26, P1093, DOI 10.1016/0046-8177(95)90271-6
   Ayehunie S, 1997, BLOOD, V90, P1379
   BARBERA JA, 1992, AM REV RESPIR DIS, V145, P940, DOI 10.1164/ajrccm/145.4_Pt_1.940
   BIRX DL, 1986, NEW ENGL J MED, V314, P874, DOI 10.1056/NEJM198604033141403
   Brodie Scott J., 2000, P97
   Brodie SJ, 1999, AM J PATHOL, V154, P1453, DOI 10.1016/S0002-9440(10)65400-4
   Brodie SJ, 1998, J VIROL, V72, P5599
   BRODIE SJ, 1995, AM J PATHOL, V146, P250
   Brodie SJ, 1999, NAT MED, V5, P34
   BRODIE SJ, 1994, J IMMUNOL, V153, P5790
   BRODIE SJ, 2000, IN PRESS J CLIN INVE
   BRODIE SJ, 2000, 7 C RETR OPP INF SAN, P561
   Cameron P, 1996, J LEUKOCYTE BIOL, V59, P158
   CAMERON PU, 1992, SCIENCE, V257, P383, DOI 10.1126/science.1352913
   CARBONE A, 1994, AM J CLIN PATHOL, V101, P768, DOI 10.1093/ajcp/101.6.768
   Cavert W, 1997, SCIENCE, V276, P960, DOI 10.1126/science.276.5314.960
   Collier AC, 1996, NEW ENGL J MED, V334, P1011, DOI 10.1056/NEJM199604183341602
   Coombs RW, 1998, J INFECT DIS, V177, P320, DOI 10.1086/514213
   Desrosiers RC, 1997, J VIROL, V71, P9764
   Diamond C, 1998, J VIROL, V72, P6223
   EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0
   FOX CH, 1992, IMMUNOL TODAY, V13, P353, DOI 10.1016/0167-5699(92)90171-3
   FOX CH, 1994, NATURE, V370, P256, DOI 10.1038/370256a0
   FOX CH, 1991, J INFECT DIS, V164, P1051, DOI 10.1093/infdis/164.6.1051
   FURTADO MR, 1991, VIROLOGY, V185, P258, DOI 10.1016/0042-6822(91)90773-5
   Furtado MR, 1999, NEW ENGL J MED, V340, P1614, DOI 10.1056/NEJM199905273402102
   Gluckman JC, 1997, CYTOKINES CELL MOL T, V3, P187
   Hausser GA, 1995, ADV EXP MED BIOL, V378, P477
   HEATH SL, 1995, NATURE, V377, P740, DOI 10.1038/377740a0
   Hockett RD, 1999, J EXP MED, V189, P1545, DOI 10.1084/jem.189.10.1545
   Kotler DP, 1999, J INFECT DIS, V179, pS454, DOI 10.1086/314803
   Kraehenbuhl JP, 1998, TRENDS MICROBIOL, V6, P419, DOI 10.1016/S0966-842X(98)01393-6
   LAURENCE J, 1991, P NATL ACAD SCI USA, V88, P7635, DOI 10.1073/pnas.88.17.7635
   Lewin-Smith M, 1999, MODERN PATHOL, V12, P75
   LINDHOUT E, 1994, J EXP MED, V179, P1173, DOI 10.1084/jem.179.4.1173
   Nagira M, 1999, VIROLOGY, V264, P422, DOI 10.1006/viro.1999.0011
   Orenstein JM, 1997, SCIENCE, V276, P1857, DOI 10.1126/science.276.5320.1857
   Orenstein JM, 1997, AM J PATHOL, V151, P1173
   Palucka KA, 1998, J IMMUNOL, V160, P4587
   PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0
   Patterson BK, 1998, CYTOMETRY, V31, P265, DOI 10.1002/(SICI)1097-0320(19980401)31:4<265::AID-CYTO6>3.0.CO;2-I
   PATTERSON BK, 2000, 7 C RETR OPP INF SAN, P183
   Perelson AS, 1997, NATURE, V387, P188, DOI 10.1038/387188a0
   Petito CK, 1999, J NEUROVIROL, V5, P327, DOI 10.3109/13550289909029474
   PITT J, 1991, CLIN PERINATOL, V18, P227
   Rubbert A, 1998, J IMMUNOL, V160, P3933
   Schacker T, 1996, ANN INTERN MED, V125, P257, DOI 10.7326/0003-4819-125-4-199608150-00001
   SCHMITZ J, 1994, J IMMUNOL, V153, P1352
   SCHMITZ J, 1994, ADV EXP MED BIOL, V355, P165
   SCHRAGER LK, 1995, NATURE, V377, P680, DOI 10.1038/377680a0
   Shek TWH, 1996, AM J SURG PATHOL, V20, P900, DOI 10.1097/00000478-199607000-00017
   SPIEGEL H, 1992, AM J PATHOL, V140, P15
   SPRENGER R, 1995, MED MICROBIOL IMMUN, V184, P129
   Tacchetti C, 1997, AM J PATHOL, V150, P533
   TENNERRACZ K, 1994, RES VIROLOGY, V145, P177, DOI 10.1016/S0923-2516(07)80020-3
   TennerRacz K, 1995, CURR TOP MICROBIOL, V201, P141
   Triozzi PL, 1997, J LEUKOCYTE BIOL, V61, P600
   Tscherning-Casper C, 1999, J VIROL, V73, P9673
   van Furth R, 1989, Curr Top Pathol, V79, P125
   Veazey RS, 1998, SCIENCE, V280, P427, DOI 10.1126/science.280.5362.427
   Wahl SM, 1999, J INFECT DIS, V179, pS457, DOI 10.1086/314814
   Weck KE, 1997, NAT MED, V3, P1346, DOI 10.1038/nm1297-1346
   Weissman D, 1997, CLIN MICROBIOL REV, V10, P358, DOI 10.1128/CMR.10.2.358
   Weissman D, 1997, ADV EXP MED BIOL, V417, P401
   Wong JK, 1997, SCIENCE, V278, P1291, DOI 10.1126/science.278.5341.1291
   Worgall S, 1999, J VIROL, V73, P5865
   ZHAN GL, 1999, NEW ENGL J MED, V340, P1605
   Zhang H, 1998, NEW ENGL J MED, V339, P1803, DOI 10.1056/NEJM199812173392502
   Zhang ZQ, 1998, P NATL ACAD SCI USA, V95, P1154, DOI 10.1073/pnas.95.3.1154
   Zhang ZQ, 1999, SCIENCE, V286, P1353, DOI 10.1126/science.286.5443.1353
   ZHU T, 2000, 7 C RETR OPP INF SAN, P136
NR 75
TC 15
Z9 15
U1 3
U2 11
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0741-5400
EI 1938-3673
J9 J LEUKOCYTE BIOL
JI J. Leukoc. Biol.
PD SEP
PY 2000
VL 68
IS 3
BP 351
EP 359
PG 9
WC Cell Biology; Hematology; Immunology
SC Cell Biology; Hematology; Immunology
GA 352FA
UT WOS:000089202800009
PM 10985251
DA 2018-12-27
ER

PT J
AU Matsubara, H
   Moriguchi, Y
   Mori, Y
   Masaki, H
   Tsutsumi, Y
   Shibasaki, Y
   Uchiyama-Tanaka, Y
   Fujiyama, S
   Koyama, Y
   Nose-Fujiyama, A
   Iba, S
   Tateishi, E
   Iwasaka, T
AF Matsubara, H
   Moriguchi, Y
   Mori, Y
   Masaki, H
   Tsutsumi, Y
   Shibasaki, Y
   Uchiyama-Tanaka, Y
   Fujiyama, S
   Koyama, Y
   Nose-Fujiyama, A
   Iba, S
   Tateishi, E
   Iwasaka, T
TI RETRACTED: Transactivation of EGF receptor induced by angiotensin II
   regulates fibronectin and TGF-beta gene expression via transcriptional
   and post-transcriptional mechanisms (Retracted Article. See vol 251, pg
   167, 2003)
SO MOLECULAR AND CELLULAR BIOCHEMISTRY
LA English
DT Article; Retracted Publication
DE angiotensin II receptors; angiotensin II type 1 receptor; angiotensin II
   type 2 receptor; angiotensin II; AT1 receptor; epidermal growth factor
   receptor
ID VASCULAR SMOOTH-MUSCLE; RAT CARDIAC FIBROBLASTS; GROWTH-FACTOR RECEPTOR;
   PROTEIN-KINASE ACTIVATION; TYROSINE PHOSPHORYLATION; C-JUN;
   SIGNAL-TRANSDUCTION; COUPLED RECEPTORS; TYPE-1A RECEPTOR; MESSENGER-RNAS
AB The signaling cascade elicited by angiotensin II (Ang II) resembles that characteristic of growth factor, and recent evidence indicates transactivation of epidermal growth factor receptor (EGF-R) by G protein-coupled receptors. Here, we report the involvement of EGF-R in Ang II-induced synthesis of fibronectin and TGF-beta in cardiac fibroblasts. Ang II stimulated fibronectin mRNA levels dose-dependently with a maximal increase (similar to5-fold) observed after 12 h of incubation. Ang II-, or calcium ionophore-induced fibronectin synthesis was completely abolished by tyrosine kinase inhibitors and intracellular Ca2+ chelating agents. Ang II-induced fibronectin mRNA was not affected by PKC inhibitors or PKC depletion, whereas specific inhibition of EGF-R function by a dominant negative EGF-R mutant and tyrphostin AG1478 abolished induction of fibronectin mRNA. We isolated the rat fibronectin gene including the 5'-flanking region and found that the AP-1 binding site present in the promoter region was responsible for the Ang II responsiveness of this gene. Gel retardation assay revealed the binding of nuclear protein to the AP-1 site, which was supershifted with anti-c-fos and anti-c-jun but not anti-ATF-2 antibodies. Conditioned medium from Ang II-treated cells contained TGF-beta bioactivity and addition of neutralizing TGF-beta antibody modestly (46%) inhibited induction of fibronectin. Ang II-induced synthesis of TGF-beta was also abolished by inhibition of EGF-R function. The effect of TGF-beta was exerted by stabilizing fibronectin mRNA without affecting the promoter activity and required de novo protein synthesis. We concluded that Ang II-induced expression of fibronectin and TGF-beta is mediated by downstream signaling of EGF-R transactivated by Ca2+-dependent tyrosine kinase, and that Ang II-induced fibronectin mRNA expression is regulated by two different mechanisms ; transcriptional control by binding of c-fos/c-jun complex to the AP-1 site, and post-transcriptional control by mRNA stabilization due to autocrine and/or paracrine effects of TGF-beta. Thus, this study suggested that the action of Ang II on extracellular matrix formation should be interpreted in association with the EGF-R signaling cascade.
C1 Kansai Med Univ, Dept Med 2, Osaka 5708507, Japan.
RP Matsubara, H (reprint author), Kansai Med Univ, Dept Med 2, Fumizonocho 10-15, Osaka 5708507, Japan.
CR Ali MS, 1997, J BIOL CHEM, V272, P12373, DOI 10.1074/jbc.272.19.12373
   ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8
   Berk BC, 1997, CIRC RES, V80, P607, DOI 10.1161/01.RES.80.5.607
   Bernstein KE, 1996, TRENDS CARDIOVAS MED, V6, P179, DOI 10.1016/S1050-1738(96)00053-9
   BHAT GJ, 1994, J BIOL CHEM, V269, P31443
   BOOZ GW, 1994, AM J PHYSIOL-CELL PH, V267, pC1308
   CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x
   Clarke N, 1998, MOL CELL BIOL, V18, P1065, DOI 10.1128/MCB.18.2.1065
   CONE JL, 1998, ANAL BIOCHEM, V168, P71
   CRABOS M, 1994, J CLIN INVEST, V93, P2372, DOI 10.1172/JCI117243
   Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0
   Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032
   Dostal DE, 1996, MOL CELL BIOCHEM, V157, P15
   EGHBALI M, 1991, CIRC RES, V69, P483, DOI 10.1161/01.RES.69.2.483
   Eguchi S, 1998, J BIOL CHEM, V273, P8890, DOI 10.1074/jbc.273.15.8890
   Eguchi S, 1996, J BIOL CHEM, V271, P14169, DOI 10.1074/jbc.271.24.14169
   FISHER SA, 1995, AM J PHYSIOL-CELL PH, V268, pC910
   Force T, 1996, CIRC RES, V78, P947, DOI 10.1161/01.RES.78.6.947
   GIBBONS GH, 1992, J CLIN INVEST, V90, P456, DOI 10.1172/JCI115881
   GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x
   HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0
   HYNES RO, 1989, FIBRONECTIN, P181
   INAGAMI T, HYPERTENS RES, V17, P87
   KAGAMI S, 1994, J CLIN INVEST, V93, P2431, DOI 10.1172/JCI117251
   KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483
   KESKIOJA J, 1988, J BIOL CHEM, V263, P3111
   KOJIMA K, 1994, CIRC RES, V79, P887
   KOVACICMILIVOJEVIC B, 1992, MOL CELL BIOL, V12, P292, DOI 10.1128/MCB.12.1.292
   Kudoh S, 1997, CIRC RES, V80, P139, DOI 10.1161/01.RES.80.1.139
   LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601
   LINSEMAN DA, 1995, J BIOL CHEM, V270, P12563, DOI 10.1074/jbc.270.21.12563
   Logan SK, 1997, MOL CELL BIOL, V17, P5784, DOI 10.1128/MCB.17.10.5784
   Luttrell LM, 1997, J BIOL CHEM, V272, P4637, DOI 10.1074/jbc.272.7.4637
   MAMUYA WS, 1992, J CLIN INVEST, V89, P392, DOI 10.1172/JCI115598
   MARRERO MB, 1995, NATURE, V375, P247, DOI 10.1038/375247a0
   Matsubara H, 1998, ENDOCR J, V45, P137, DOI 10.1507/endocrj.45.137
   MATSUBARA H, 1994, J CLIN INVEST, V93, P1592, DOI 10.1172/JCI117139
   MOLLOY CJ, 1993, J BIOL CHEM, V268, P7338
   MURASAWA S, 1993, J BIOL CHEM, V268, P26996
   Murasawa S, 1996, Hypertens Res, V19, P271, DOI 10.1291/hypres.19.271
   MURASAWA S, 1995, J BIOL CHEM, V270, P24282, DOI 10.1074/jbc.270.41.24282
   Murasawa S, 1998, HYPERTENSION, V32, P668, DOI 10.1161/01.HYP.32.4.668
   Murasawa S, 1998, CIRC RES, V82, P1338, DOI 10.1161/01.RES.82.12.1338
   NIO Y, 1995, J CLIN INVEST, V95, P46, DOI 10.1172/JCI117675
   Ohkubo N, 1997, CIRCULATION, V96, P3954
   PATEL RS, 1987, EMBO J, V6, P2565, DOI 10.1002/j.1460-2075.1987.tb02545.x
   Rosen LB, 1996, P NATL ACAD SCI USA, V93, P1113, DOI 10.1073/pnas.93.3.1113
   ROSSI P, 1988, CELL, V52, P405, DOI 10.1016/S0092-8674(88)80033-3
   Sadoshima J, 1996, EMBO J, V15, P775, DOI 10.1002/j.1460-2075.1996.tb00413.x
   SADOSHIMA J, 1995, CIRC RES, V76, P1
   SCHORB W, 1993, CIRC RES, V72, P1245, DOI 10.1161/01.RES.72.6.1245
   SCHORB W, 1994, J BIOL CHEM, V269, P19626
   SHIRAISHI T, 1989, CANCER RES, V49, P2374
   SUZUKI J, 1993, CIRC RES, V73, P439, DOI 10.1161/01.RES.73.3.439
   TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3
   Tsai W, 1997, EMBO J, V16, P4597, DOI 10.1093/emboj/16.15.4597
   TSUDA T, 1992, CIRC RES, V71, P620, DOI 10.1161/01.RES.71.3.620
   VILLARREAL FJ, 1993, CIRCULATION, V88, P2849, DOI 10.1161/01.CIR.88.6.2849
   WEBER KT, 1991, CIRCULATION, V83, P1849, DOI 10.1161/01.CIR.83.6.1849
   Zou YZ, 1996, J BIOL CHEM, V271, P33592, DOI 10.1074/jbc.271.52.33592
   Zwick E, 1997, J BIOL CHEM, V272, P24767, DOI 10.1074/jbc.272.40.24767
NR 61
TC 17
Z9 19
U1 2
U2 13
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0300-8177
EI 1573-4919
J9 MOL CELL BIOCHEM
JI Mol. Cell. Biochem.
PD SEP
PY 2000
VL 212
IS 1-2
BP 187
EP 201
DI 10.1023/A:1007189828584
PG 15
WC Cell Biology
SC Cell Biology
GA 372ZV
UT WOS:000165264700023
PM 11108151
DA 2018-12-27
ER

PT J
AU Murthy, HMK
   Judge, K
   DeLucas, L
   Padmanabhan, R
AF Murthy, HMK
   Judge, K
   DeLucas, L
   Padmanabhan, R
TI RETRACTED: Crystal structure of dengue virus NS3 protease in complex
   with a Bowman-Birk inhibitor: Implications for flaviviral polyprotein
   processing and drug design (Retracted article. See vol. 397, pg. 1119,
   2010)
SO JOURNAL OF MOLECULAR BIOLOGY
LA English
DT Article; Retracted Publication
DE Bowman-Birk inhibitor; conformational change; dengue virus; drug-design;
   substrate recognition
ID HEPATITIS-C VIRUS; SERINE PROTEASES; ACTIVE-SITE; TRYPSIN; PROTEINASE;
   DOMAIN; SPECIFICITY; INSIGHTS; PEPTIDE; PESTIVIRUSES
AB Dengue viruses are members of the Flaviviridae and cause dengue fever and the more severe dengue hemorrhagic fever. Although nearly 40 % of the world's population is at risk of dengue infection, there is currently no effective vaccine or chemotherapy for the disease. Processing of the dengue polyprotein into structural and non-structural proteins in a host, which is essential for assembly of infective virions, is carried out by the combined action of host proteases and the trypsin-like, two-component viral NS2B/NS3 serine protease. Although NS2B strongly stimulates the catalytic NS3 protease domain, the latter is fully active against small substrates and possesses detectable activity against larger substrates, making both forms of the enzyme possible targets for drug design. Ln the crystal structure of a complex of the protease with a Bowman-Birk inhibitor reported here, an Arg residue at the P1 position of the inhibitor is bound in a manner distinctly different from that in other serine proteases of comparable specificity. However, because the regulatory component, NS2B, is not present in the complex, the physiological implications of this observations are currently unclear. The redundant nature of interaction of P1 Arg and Lys residues with Asp129, Tyr150 and Ser163 of the enzyme provides an explanation for the observed behavior of several site-specific mutants of Asp129 in the protease. The strong level of conservation of residues in the protease that interact with the P1 Arg, along with conservation of Arg at P1 of most cleavage sites in other flaviviruses, suggests that observations from this structure are likely to be applicable to many flaviviruses. The structure provides a starting point for design of site-specific mutations to probe the mechanism of catalysis by the catalytic domain, its activation by the regulatory domain and for design of specific inhibitors of enzymatic activity. (C) 2000 Academic Press.
C1 Univ Alabama Birmingham, Ctr Macromol Crystallog, Birmingham, AL 35294 USA.
   Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, Kansas City, KS 66160 USA.
RP Murthy, HMK (reprint author), Univ Alabama Birmingham, Ctr Macromol Crystallog, 1918 Univ Blvd,79 THT MCLM 244, Birmingham, AL 35294 USA.
EM murthy@onyx.cmc.uab.edu
RI ID, IMCACAT/D-5867-2014
CR Banner DW, 1996, NATURE, V380, P41, DOI 10.1038/380041a0
   BAZAN JF, 1989, VIROLOGY, V171, P637, DOI 10.1016/0042-6822(89)90639-9
   BODE W, 1992, EUR J BIOCHEM, V204, P433, DOI 10.1111/j.1432-1033.1992.tb16654.x
   BONE R, 1989, NATURE, V341, P462
   BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0
   BRUNGER AT, 1990, XPLOR MANUAL
   BURLEY SK, 1988, ADV PROTEIN CHEM, V39, P125
   CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3
   CHEN P, 1992, J BIOL CHEM, V267, P1990
   CHI CW, 1982, PROTEINS BIOL MED, P427
   Cowtan K, 1994, JOINT CCP4 ESF EACBM, V31, P34
   DiMarco S, 1997, STRUCTURE, V5, P1465
   Ding JZ, 1996, EMBO J, V15, P1778, DOI 10.1002/j.1460-2075.1996.tb00526.x
   FALGOUT B, 1993, J VIROL, V67, P2034
   FALGOUT B, 1991, J VIROL, V65, P2467
   GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P3889, DOI 10.1093/nar/17.10.3889
   GUBLER DJ, 1995, EMERG INFECT DIS, V1, P55
   HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561
   IKENAKA T, 1986, PROTEASES
   JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224
   Kennedy AR, 1998, AM J CLIN NUTR, V68, p1406S, DOI 10.1093/ajcn/68.6.1406S
   Kim JL, 1996, CELL, V87, P343, DOI 10.1016/S0092-8674(00)81351-3
   KRAUT J, 1977, ANNU REV BIOCHEM, V46, P331, DOI 10.1146/annurev.bi.46.070177.001555
   LASKOWSKI M, 1980, ANNU REV BIOCHEM, V49, P593, DOI 10.1146/annurev.bi.49.070180.003113
   LIN GD, 1993, EUR J BIOCHEM, V212, P549, DOI 10.1111/j.1432-1033.1993.tb17692.x
   Love RA, 1996, CELL, V87, P331, DOI 10.1016/S0092-8674(00)81350-1
   Martin PD, 1997, STRUCTURE, V5, P1681, DOI 10.1016/S0969-2126(97)00314-6
   Mittl PRE, 1997, STRUCTURE, V5, P253, DOI 10.1016/S0969-2126(97)00183-4
   MONATH TP, 1994, P NATL ACAD SCI USA, V91, P2395, DOI 10.1073/pnas.91.7.2395
   Murthy HMK, 1999, J BIOL CHEM, V274, P5573, DOI 10.1074/jbc.274.9.5573
   Murthy HMK, 1999, ACTA CRYSTALLOGR D, V55, P1370
   NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407
   OTWINOWSKI Z, 1991, ISOMORPHOUS REPLACEM, P101
   PERONA JJ, 1995, PROTEIN SCI, V4, P337
   Ramachandra M, 1996, METHOD ENZYMOL, V275, P168
   Renatus M, 1997, J BIOL CHEM, V272, P21713, DOI 10.1074/jbc.272.35.21713
   RUHLMANN A, 1973, J MOL BIOL, V77, P417, DOI 10.1016/0022-2836(73)90448-8
   Ryan MD, 1998, J GEN VIROL, V79, P947, DOI 10.1099/0022-1317-79-5-947
   SARDANA VV, 1994, J BIOL CHEM, V269, P14337
   SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X
   TERWILLIGER TC, 1987, ACTA CRYSTALLOGR A, V43, P1, DOI 10.1107/S0108767387099999
   TSUNOGAE Y, 1986, J BIOCHEM-TOKYO, V100, P1637, DOI 10.1093/oxfordjournals.jbchem.a121872
   Valle RPC, 1998, J VIROL, V72, P624
   Yan YW, 1998, PROTEIN SCI, V7, P837
   ZHANG LW, 1992, J VIROL, V66, P7549
   1994, ACTA CRYSTALLOG D, V50, P760
NR 46
TC 76
Z9 82
U1 3
U2 19
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0022-2836
EI 1089-8638
J9 J MOL BIOL
JI J. Mol. Biol.
PD AUG 25
PY 2000
VL 301
IS 4
BP 759
EP 767
DI 10.1006/jmbi.2000.3924
PG 9
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 354WC
UT WOS:000089351800002
PM 10966782
DA 2018-12-27
ER

PT J
AU Schon, JH
   Kloc, C
   Batlogg, B
AF Schon, JH
   Kloc, C
   Batlogg, B
TI RETRACTED: Superconductivity in molecular crystals induced by charge
   injection (Retracted article. See vol 422 pg 93 2003)
SO NATURE
LA English
DT Article; Retracted Publication
ID FIELD; TRANSISTORS; POLYACENE; FILMS
AB Progress in the field of superconductivity is often linked to the discovery of new classes of materials, with the layered copper oxides(1) being a particularly impressive example. The superconductors known today include a wide spectrum of materials, ranging in complexity from simple elemental metals, to alloys and binary compounds of metals, to multi-component compounds of metals and chalcogens or metalloids, doped fullerenes and organic charge-transfer salts. Here we present a new class of superconductors: insulating organic molecular crystals that are made metallic through charge injection. The first examples are pentacene, tetracene and anthracene, the last having the highest transition temperature, at 4 K. We anticipate that many other organic molecular crystals can also be made superconducting by this method, which will lead to surprising findings in the vast composition space of molecular crystals.
C1 Bell Labs, Lucent Technol, Murray Hill, NJ 07974 USA.
RP Batlogg, B (reprint author), Bell Labs, Lucent Technol, 600 Mt Ave, Murray Hill, NJ 07974 USA.
EM batlogg@bell-labs.com
RI Kloc, Christian/A-2255-2011
CR Ahn CH, 1999, SCIENCE, V284, P1152, DOI 10.1126/science.284.5417.1152
   BEDNORZ JG, 1986, Z PHYS B CON MAT, V64, P189, DOI 10.1007/BF01303701
   Devos A, 1998, PHYS REV B, V58, P8236, DOI 10.1103/PhysRevB.58.8236
   DODABALAPUR A, 1995, SCIENCE, V268, P270, DOI 10.1126/science.268.5208.270
   GINZBURG VL, 1968, CONTEMP PHYS, V9, P355, DOI 10.1080/00107516808220090
   GLOVER RE, 1960, PHYS REV LETT, V5, P248, DOI 10.1103/PhysRevLett.5.248
   Ishiguro T., 1998, ORGANIC SUPERCONDUCT
   Jerome D., 1980, J PHYS LETT, V31, P95, DOI DOI 10.1051/JPHYSLET:0198000410409500
   KIVELSON S, 1983, PHYS REV B, V28, P7236, DOI 10.1103/PhysRevB.28.7236
   Kloc C, 1997, J CRYST GROWTH, V182, P416, DOI 10.1016/S0022-0248(97)00370-9
   Konsin P, 1998, PHYS REV B, V58, P5795, DOI 10.1103/PhysRevB.58.5795
   MANNHART J, 1993, APPL PHYS LETT, V62, P630, DOI 10.1063/1.108877
   MISHIMA A, 1985, SYNTHETIC MET, V11, P75, DOI 10.1016/0379-6779(85)90176-6
   Schon JH, 2000, SCIENCE, V288, P656, DOI 10.1126/science.288.5466.656
   Schon JH, 2000, SCIENCE, V288, P2338, DOI 10.1126/science.288.5475.2338
   Schon JH, 2000, SCIENCE, V287, P1022, DOI 10.1126/science.287.5455.1022
   Silinsh E. A., 1994, ORGANIC MOL CRYSTALS
   WARTA W, 1985, PHYS REV B, V32, P1172, DOI 10.1103/PhysRevB.32.1172
   WARTA W, 1985, APPL PHYS A-MATER, V36, P163, DOI 10.1007/BF00624938
NR 19
TC 161
Z9 162
U1 3
U2 48
PU MACMILLAN PUBLISHERS LTD
PI LONDON
PA PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
J9 NATURE
JI Nature
PD AUG 17
PY 2000
VL 406
IS 6797
BP 702
EP 704
DI 10.1038/35021011
PG 4
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 344PH
UT WOS:000088767700036
PM 10963589
DA 2018-12-27
ER

PT J
AU Visvanathan, S
   Geczy, CL
   Harmer, JA
   McNeil, HP
AF Visvanathan, S
   Geczy, CL
   Harmer, JA
   McNeil, HP
TI RETRACTED: Monocyte tissue factor induction by activation of
   beta(2)-glycoprotein-I-specific T lymphocytes is associated with
   thrombosis and fetal loss in patients with antiphospholipid antibodies
   (Retracted Article. See vol 169, pg 1135, 2002)
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article; Retracted Publication
ID ANTICARDIOLIPIN ANTIBODIES; SUCCESSFUL PREGNANCY; I ANTIBODIES;
   COAGULATION; IMMUNITY
AB Antiphospholipid (aPL) syndrome (APS) is characterized by thromboembolic events, thrombocytopenia, or recurrent miscarriage associated with aPL Abs with specificity for beta(2)-glycoprotein-I (beta 2GPI). We recently reported that at least 44% of patients with the APS possess circulating type 1 (Th1) CD4(+) T cells that proliferate and secrete IFN-gamma when stimulated with beta 2GPI in vitro. In this study, we show that stimulation of PBMCs from 20 APS patients with beta 2GPI induced substantial monocyte tissue factor (TF) (80 +/- 11 TF stimulation index (TF-SI)), whereas no induction was observed using PBMCs from 13 patients with aPL Abs without APS (6 +/- 1 TF-SI) or 7 normal and 7 autoimmune controls (5 +/- 1 and 3 +/- 1 TF-SI, respectively) (p < 0.0001). TF induction on monocytes by beta 2GPI was dose dependent and required CD4(+) T lymphocytes and class II MHC molecules. Because monocyte TF induction by beta 2GPI was observed in all patients with APS, but not in any patient with aPL Abs without APS, this response is a potentially useful predictor for APS in patients with aPL Abs, as well as providing mechanistic insight into thrombosis and fetal loss in these patients.
C1 Univ New S Wales, Sch Pathol, Inflammat Res Unit, Sydney, NSW 2052, Australia.
   Univ New S Wales, Sch Pathol, Cytokine Res Unit, Sydney, NSW 2052, Australia.
   Prince Wales Hosp, Dept Rheumatol, Sydney, NSW, Australia.
RP McNeil, HP (reprint author), Univ New S Wales, Sch Pathol, Inflammat Res Unit, Sydney, NSW 2052, Australia.
EM P.McNeil@unsw.edu.au
OI McNeil, Hugh Patrick/0000-0003-4336-2960
CR Amengual O, 1998, THROMB HAEMOSTASIS, V79, P276
   Cuadrado MJ, 1997, ARTHRITIS RHEUM, V40, P834, DOI 10.1002/art.1780400509
   DELPRETE G, 1995, BLOOD, V86, P250
   EDWARDS RL, 1978, SCIENCE, V200, P541, DOI 10.1126/science.644314
   GECZY CL, 1994, INT REV CYTOL, V152, P49, DOI 10.1016/S0074-7696(08)62554-1
   GINSBURG KS, 1992, ANN INTERN MED, V117, P997, DOI 10.7326/0003-4819-117-12-997
   Guerin J, 1997, CLIN EXP IMMUNOL, V109, P304, DOI 10.1046/j.1365-2249.1997.4601357.x
   HARRIS EN, 1986, ARCH INTERN MED, V146, P2153, DOI 10.1001/archinte.146.11.2153
   KHAMASHTA MA, 1995, NEW ENGL J MED, V332, P993, DOI 10.1056/NEJM199504133321504
   MCNEIL HP, 1991, ADV IMMUNOL, V49, P193
   MCNEIL HP, 1990, P NATL ACAD SCI USA, V87, P4120, DOI 10.1073/pnas.87.11.4120
   MORITA T, 1977, J BIOCHEM-TOKYO, V82, P1495, DOI 10.1093/oxfordjournals.jbchem.a131840
   Raghupathy R, 1997, IMMUNOL TODAY, V18, P478, DOI 10.1016/S0167-5699(97)01127-4
   Roubey RAS, 1996, ARTHRITIS RHEUM-US, V39, P1444, DOI 10.1002/art.1780390903
   Sanmarco M, 1997, J LAB CLIN MED, V129, P499, DOI 10.1016/S0022-2143(97)90004-4
   Tincani A, 1998, CLIN EXP RHEUMATOL, V16, P396
   VIARD JP, 1992, AM J MED, V93, P181, DOI 10.1016/0002-9343(92)90049-H
   Visvanathan S, 1999, J IMMUNOL, V162, P6919
   WEGMANN TG, 1993, IMMUNOL TODAY, V14, P353, DOI 10.1016/0167-5699(93)90235-D
NR 19
TC 20
Z9 20
U1 3
U2 10
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
EI 1550-6606
J9 J IMMUNOL
JI J. Immunol.
PD AUG 15
PY 2000
VL 165
IS 4
BP 2258
EP 2262
DI 10.4049/jimmunol.165.4.2258
PG 5
WC Immunology
SC Immunology
GA 342BW
UT WOS:000088626200068
PM 10925314
OA Bronze
DA 2018-12-27
ER

PT J
AU van Son, JAM
   Hambsch, J
   Mohr, FW
AF van Son, JAM
   Hambsch, J
   Mohr, FW
TI RETRACTED: Anatomical reconstruction of aorta and pulmonary trunk in
   patients with an aortopulmonary window (Retracted article. See vol 70,
   pg 2184, 2000)
SO ANNALS OF THORACIC SURGERY
LA English
DT Article; Retracted Publication
ID MANAGEMENT; CLOSURE; DEFECT
AB We report a modified technique for repair of aortopulmonary window in which a native pulmonary artery flap is created and the aortopulmonary window is completely divided. The pulmonary artery nap is used to reconstruct the ascending aorta, and the defect in the pulmonary trunk is closed with an autologous pericardial patch. This repair avoids the use of a fabric patch with its inherent disadvantages and allows anatomical reconstruction of both the ascending aorta and the pulmonary trunk with low risk of early or late distortion of the aortic and pulmonary root structures. (C) 2000 by The Society of Thoracic Surgeons.
C1 Univ Leipzig, Herzzentrum, D-04289 Leipzig, Germany.
RP van Son, JAM (reprint author), Univ Leipzig, Herzzentrum, Russenstr 19, D-04289 Leipzig, Germany.
CR Chang AC, 1998, PEDIAT CARDIAC INTEN, P201
   CLARKE CP, 1976, J THORAC CARDIOV SUR, V72, P48
   DEVERALL PB, 1969, J THORAC CARDIOV SUR, V57, P479
   Di Bella I, 1998, ANN THORAC SURG, V65, P768, DOI 10.1016/S0003-4975(97)01418-5
   GROSS RE, 1952, CIRCULATION, V5, P858, DOI 10.1161/01.CIR.5.6.858
   JOHANSSON L, 1978, ANN THORAC SURG, V25, P564, DOI 10.1016/S0003-4975(10)63611-9
   KUTSCHE LM, 1987, AM J CARDIOL, V59, P443, DOI 10.1016/0002-9149(87)90953-2
   MATSUKI O, 1992, ANN THORAC SURG, V54, P991, DOI 10.1016/0003-4975(92)90672-Q
   MESSMER BJ, 1994, ANN THORAC SURG, V57, P498, DOI 10.1016/0003-4975(94)91036-7
   RICHARDSON JV, 1979, J THORAC CARDIOV SUR, V78, P21
   TAKAHASHI K, 1995, EUR J PEDIATR, V154, P878, DOI 10.1007/BF01957496
   VANSON JAM, 1993, MAYO CLIN PROC, V68, P128, DOI 10.1016/S0025-6196(12)60159-1
NR 12
TC 5
Z9 5
U1 2
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0003-4975
EI 1552-6259
J9 ANN THORAC SURG
JI Ann. Thorac. Surg.
PD AUG
PY 2000
VL 70
IS 2
BP 674
EP 675
DI 10.1016/S0003-4975(00)01485-5
PG 2
WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery
SC Cardiovascular System & Cardiology; Respiratory System; Surgery
GA 346TC
UT WOS:000088886300075
PM 10969707
DA 2018-12-27
ER

PT J
AU Lehmann, A
   Zeitler, C
   Thaler, E
   Isgro, F
   Boldt, J
AF Lehmann, A
   Zeitler, C
   Thaler, E
   Isgro, F
   Boldt, J
TI RETRACTED: Comparison of two different anesthesia regimens in patients
   undergoing aortocoronary bypass grafting surgery: Sufentanil-midazolam
   versus remifentanil-propofol (Retracted article. See vol. 25, pg. 755,
   2011)
SO JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA
LA English
DT Article; Retracted Publication
DE cardiac surgery; propofol; remifentanil; midazolam; sufentanil; elective
   aortocoronary bypass graft surgery; hemodynamics; depth of anesthesia
ID TOTAL INTRAVENOUS ANESTHESIA; LEFT-VENTRICULAR FUNCTION;
   ABDOMINAL-SURGERY; BISPECTRAL INDEX; ALFENTANIL; ISOFLURANE;
   PHARMACOKINETICS; ANALGESIA; VARIABLES; EMERGENCE
AB Objective: To compare intraoperative hemodynamics and depth of anesthesia using sufentanil-midazolam (SM) versus remifentanil-propofol (RP) anesthesia.
   Design: Prospective, randomized study.
   Setting: Clinical investigation in an urban, university affiliated hospital.
   Participants: Forty patients undergoing elective first-time coronary artery bypass graft surgery.
   Interventions: Twenty patients were anesthetized using SM and 20 patients using RP.
   Measurements and Main Results: Hemodynamic monitoring included a 5-lead electrocardiogram, a radial artery catheter, and a pulmonary artery catheter. Depth of anesthesia was assessed using bispectral index (BIS). Data were obtained after induction of anesthesia (Tl), after sternotomy (T2), after pericardiotomy (T3), 5 minutes after cardiopulmonary bypass (CPB) (T4), after closure of thorax (T5), and at the end of surgery (T6). The 2 groups were comparable with regard to demographic and perioperative data. There were no significant differences of any hemodynamic parameter at any time between the 2 groups. In both groups, systemic vascular resistance increased at T2 and decreased at T4 from baseline value (p < 0.05). Cardiac index increased at T4 in both groups from baseline value (p < 0.05): 55% of the patients of both groups needed low-dose dobutamine after CPB. During CPB, 40% of the RP patients needed norepinephrine versus 35% of the SM patients. BIS was lower in the RP than in the SM group at T2 and T3 (p < 0.05). sis values indicating intraoperative awareness were not noted.
   Conclusion: Both anesthesia regimens provided stable hemodynamics and adequate anesthesia in patients undergoing coronary artery bypass graft surgery. Copyright (C) 2000 by W.B. Saunders Company.
C1 Klinikum Stadt Ludwigshafen, Dept Anesthesiol & Intens Care Med, D-67063 Ludwigshafen, Germany.
   Klinikum Stadt Ludwigshafen, Dept Cardiac Surg, D-67063 Ludwigshafen, Germany.
RP Boldt, J (reprint author), Klinikum Stadt Ludwigshafen, Dept Anesthesiol & Intens Care Med, Bremserstr 79, D-67063 Ludwigshafen, Germany.
CR Apitzsch H, 1999, ANAESTHESIST, V48, P301, DOI 10.1007/s001010050705
   Bailey JM, 1996, ANESTHESIOLOGY, V84, P1288, DOI 10.1097/00000542-199606000-00003
   Boldt J, 1998, ANESTH ANALG, V86, P504, DOI 10.1097/00000539-199803000-00010
   Bowdle TA, 1997, EUR J ANAESTH, V14, P374, DOI 10.1046/j.1365-2346.1997.t01-1-00109.x
   DAttellis N, 1997, J CARDIOTHOR VASC AN, V11, P467, DOI 10.1016/S1053-0770(97)90057-4
   Doi M, 1997, ANAESTHESIA, V52, P1048, DOI 10.1111/j.1365-2044.1997.229-az0364.x
   Doi M, 1997, BRIT J ANAESTH, V78, P180
   EGAN TD, 1995, CLIN PHARMACOKINET, V29, P80, DOI 10.2165/00003088-199529020-00003
   Flaishon R, 1997, ANESTHESIOLOGY, V86, P613, DOI 10.1097/00000542-199703000-00013
   FREYE E, 1999, OPIOIDS MED, P225
   FREYE E, 1999, OPIOIDS MED, P122
   Gan TJ, 1997, ANESTHESIOLOGY, V87, P808, DOI 10.1097/00000542-199710000-00014
   Glass PS, 1997, ANESTHESIOLOGY, V86, P836, DOI 10.1097/00000542-199704000-00014
   Hogue CW, 1996, ANESTH ANALG, V83, P279, DOI 10.1097/00000539-199608000-00014
   Howie M B, 1991, J Cardiothorac Vasc Anesth, V5, P485, DOI 10.1016/1053-0770(91)90124-C
   Kleinschmidt S, 1998, EUR J ANAESTH, V15, P559, DOI 10.1046/j.1365-2346.1998.00353.x
   Kovac AL, 1997, J CLIN ANESTH, V9, P532, DOI 10.1016/S0952-8180(97)00140-2
   Lehmann A, 1999, J CARDIOTHOR VASC AN, V13, P15, DOI 10.1016/S1053-0770(99)90166-0
   Myles PS, 1997, ANESTH ANALG, V84, P12, DOI 10.1097/00000539-199701000-00003
   Newman M, 1993, J Cardiothorac Vasc Anesth, V7, P615, DOI 10.1016/1053-0770(93)90325-F
   PHILLIPS AS, 1993, ANAESTHESIA, V48, P661, DOI 10.1111/j.1365-2044.1993.tb07173.x
   RAZA SMA, 1988, CAN J ANAESTH, V35, P518, DOI 10.1007/BF03026904
   Schuttler J, 1997, ANAESTHESIA, V52, P307, DOI 10.1111/j.1365-2044.1997.24-az0051.x
   SEBEL PS, 1995, ANESTH ANALG, V80, P990, DOI 10.1097/00000539-199505000-00024
   SHERRY KM, 1995, J CARDIOTHOR VASC AN, V9, P368, DOI 10.1016/S1053-0770(05)80089-8
   Struys M, 1998, ANAESTHESIA, V53, P4, DOI 10.1046/j.1365-2044.1998.00279.x
   Thomson IR, 1999, J CARDIOTHOR VASC AN, V13, P9, DOI 10.1016/S1053-0770(99)90165-9
   Tuman K J, 1990, J Cardiothorac Anesth, V4, P308, DOI 10.1016/0888-6296(90)90036-F
   Yarmush J, 1997, ANESTHESIOLOGY, V87, P235, DOI 10.1097/00000542-199708000-00009
NR 29
TC 27
Z9 34
U1 2
U2 12
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 1053-0770
EI 1532-8422
J9 J CARDIOTHOR VASC AN
JI J. Cardiothorac. Vasc. Anesth.
PD AUG
PY 2000
VL 14
IS 4
BP 416
EP 420
DI 10.1053/jcan.2000.7945
PG 5
WC Anesthesiology; Cardiac & Cardiovascular Systems; Respiratory System;
   Peripheral Vascular Disease
SC Anesthesiology; Cardiovascular System & Cardiology; Respiratory System
GA 345BD
UT WOS:000088794800011
PM 10972607
DA 2018-12-27
ER

PT J
AU Hanson, MA
   Stevens, RC
AF Hanson, MA
   Stevens, RC
TI RETRACTED: Cocrystal structure of synaptobrevin-II bound to botulinum
   neurotoxin type B at 2.0 angstrom resolution (Retracted article. See vol
   16, pg 795, 2009)
SO NATURE STRUCTURAL BIOLOGY
LA English
DT Article; Retracted Publication
ID ELECTRON-DENSITY MAPS; TOXIN TYPE-A; TETANUS TOXIN; CLOSTRIDIAL
   NEUROTOXINS; CRYSTAL-STRUCTURE; LOW PH; PROTEIN; CLEAVAGE; LIGHT;
   MOLSCRIPT
AB Botulinum neurotoxin serotype B is a zinc protease that disrupts neurotransmitter release by cleaving synaptobrevin-II (Sb2), one of three SNARE proteins involved in neuronal synaptic vesicle fusion. The three-dimensional crystal structure of the apo botulinum neurotoxin serotype B catalytic domain (BoNT/B-LC) has been determined to 2.2 Angstrom resolution, and the complex of cleaved Sb2 with the catalytic domain (Sb2-BoNT/B-LC) has been determined to 2.0 Angstrom resolution. A comparison of the holotoxin catalytic domain and the isolated BoNT/B-LC structure shows a rearrangement of three active site loops. This rearrangement exposes the BoNT/B active site. The Sb2-BoNT/B-LC structure illustrates two distinct binding regions, which explains the specificity of each botulinum neurotoxin for its synaptic vesicle protein. This observation provides an explanation for the proposed cooperativity between binding of full-length substrate and catalysis and suggest a mechanism of synaptobrevin proteolysis employed by the clostridial neurotoxins.
C1 Scripps Res Inst, Dept Chem & Mol Biol, La Jolla, CA 92037 USA.
RP Stevens, RC (reprint author), Scripps Res Inst, Dept Chem & Mol Biol, La Jolla, CA 92037 USA.
EM stevens@scripps.edu
OI Stevens, Raymond/0000-0002-4522-8725
CR BINZ T, 1994, J BIOL CHEM, V269, P1617
   BLASI J, 1993, NATURE, V365, P160, DOI 10.1038/365160a0
   BOQUET P, 1984, EUR J BIOCHEM, V144, P339, DOI 10.1111/j.1432-1033.1984.tb08469.x
   BOQUET P, 1982, P NATL ACAD SCI-BIOL, V79, P7614, DOI 10.1073/pnas.79.24.7614
   Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254
   *COLL COMP PROJ 4, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI DOI 10.1107/S0907444994003112
   Cornille F, 1997, J BIOL CHEM, V272, P3459, DOI 10.1074/jbc.272.6.3459
   Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363
   Fasshauer D, 1998, P NATL ACAD SCI USA, V95, P15781, DOI 10.1073/pnas.95.26.15781
   Hanson PI, 1997, CURR OPIN NEUROBIOL, V7, P310, DOI 10.1016/S0959-4388(97)80057-8
   Hazzard J, 1999, J BIOMOL NMR, V14, P203, DOI 10.1023/A:1008382027065
   JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224
   KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399
   KRIEGLSTEIN KG, 1994, J PROTEIN CHEM, V13, P49, DOI 10.1007/BF01891992
   KURAZONO H, 1992, J BIOL CHEM, V267, P14721
   Lacy DB, 1999, J MOL BIOL, V291, P1091, DOI 10.1006/jmbi.1999.2945
   Lacy DB, 1998, NAT STRUCT BIOL, V5, P898, DOI 10.1038/2338
   LEBEDA FJ, 1994, PROTEINS, V20, P293, DOI 10.1002/prot.340200402
   MATTHEWS BW, 1988, ACCOUNTS CHEM RES, V21, P333, DOI 10.1021/ar00153a003
   Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9
   Montecucco C, 1995, Q REV BIOPHYS, V28, P423, DOI 10.1017/S0033583500003292
   NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597
   Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X
   Pellizzari R, 1996, J BIOL CHEM, V271, P20353, DOI 10.1074/jbc.271.34.20353
   SCHIAVO G, 1992, J BIOL CHEM, V267, P23479
   SHONE CC, 1993, EUR J BIOCHEM, V217, P965, DOI 10.1111/j.1432-1033.1993.tb18327.x
   SIMPSON LL, 1980, J PHARMACOL EXP THER, V212, P16
   Simpson LL, 1989, BOTULINUM NEUROTOXIN
   SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0
   SUDHOF TC, 1993, CELL, V75, P1
   Sutton RB, 1998, NATURE, V395, P347
   Swaminathan S, 2000, NAT STRUCT BIOL, V7, P693, DOI 10.1038/78005
   YAMASAKI S, 1994, J BIOL CHEM, V269, P12764
NR 33
TC 119
Z9 126
U1 3
U2 8
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1072-8368
J9 NAT STRUCT BIOL
JI Nat. Struct. Biol.
PD AUG
PY 2000
VL 7
IS 8
BP 687
EP 692
DI 10.1038/77997
PG 6
WC Biochemistry & Molecular Biology; Biophysics; Cell Biology
SC Biochemistry & Molecular Biology; Biophysics; Cell Biology
GA 340RJ
UT WOS:000088548400019
PM 10932255
DA 2018-12-27
ER

PT J
AU Schon, JH
   Kloc, C
   Dodabalapur, A
   Batlogg, B
AF Schon, JH
   Kloc, C
   Dodabalapur, A
   Batlogg, B
TI RETRACTED: An organic solid state injection laser (Retracted Article.
   See vol 298, pg 961, 2002)
SO SCIENCE
LA English
DT Article; Retracted Publication
ID STIMULATED-EMISSION; CONJUGATED POLYMER; CRYSTALS
AB We report on electrically driven amplified spontaneous emission and Lasing in tetracene single crystals using field-effect electrodes for efficient electron and hole injection. For Laser action, feedback is provided by reflections at the cleaved edges of the crystal resulting in a Fabry-Perot resonator. Increasing the injected current density above a certain threshold value results in the decreasing of the spectral width of the emission from 120 millielectron volts to Less than 1 millielectron volt because of gain narrowing and eventually Laser action. High electron and hole mobilities as well as balanced charge carrier injection Lead to improved exciton generation in these gate-controlled devices. Moreover, the effect of charge-induced absorption is substantially reduced in high-quality single crystals compared with amorphous organic materials.
C1 Lucent Technol, Bell Labs, Murray Hill, NJ 07974 USA.
RP Batlogg, B (reprint author), Lucent Technol, Bell Labs, 600 Mt Ave, Murray Hill, NJ 07974 USA.
EM batlogg@lucent.com
RI Kloc, Christian/A-2255-2011; Dodabalapur, Ananth/H-3043-2012
CR AVANESJAN OS, 1974, MOL CRYST LIQ CRYST, V29, P165, DOI 10.1080/15421407408083197
   AVANESYAN HS, 1975, PHYS STATUS SOLIDI A, V30, P781, DOI 10.1002/pssa.2210300239
   AVANESYAN OS, 1973, PHYS STATUS SOLIDI A, V19, pK121
   Berggren M, 1997, APPL PHYS LETT, V71, P2230, DOI 10.1063/1.120065
   Blom PWM, 1998, IEEE J SEL TOP QUANT, V4, P105, DOI 10.1109/2944.669477
   Dodabalapur A, 1998, IEEE J SEL TOP QUANT, V4, P67, DOI 10.1109/2944.669469
   Fichou D, 1997, ADV MATER, V9, P1178, DOI 10.1002/adma.19970091512
   Frolov SV, 2000, IEEE J QUANTUM ELECT, V36, P2, DOI 10.1109/3.817632
   Garnier F, 1998, APPL PHYS LETT, V72, P2087, DOI 10.1063/1.121284
   Hide F, 1997, LASER FOCUS WORLD, V33, P151
   Jabbour GE, 2000, IEEE J QUANTUM ELECT, V36, P12, DOI 10.1109/3.817633
   KALINOWSKI J, 1976, MOL CRYST LIQ CRYST, V33, P247, DOI 10.1080/15421407608084300
   Kallinger C, 1998, ADV MATER, V10, P920, DOI 10.1002/(SICI)1521-4095(199808)10:12<920::AID-ADMA920>3.0.CO;2-7
   KARL N, 1972, PHYS STATUS SOLIDI A, V13, P651, DOI 10.1002/pssa.2210130237
   Kloc C, 1997, J CRYST GROWTH, V182, P416, DOI 10.1016/S0022-0248(97)00370-9
   Kolendritskii D. D., 1978, Optics and Spectroscopy, V44, P162
   Kozlov VG, 1999, APPL PHYS LETT, V74, P1057, DOI 10.1063/1.123480
   Kozlov VG, 2000, IEEE J QUANTUM ELECT, V36, P18, DOI 10.1109/3.817634
   LEE TP, 1982, IEEE J QUANTUM ELECT, V18, P1101, DOI 10.1109/JQE.1982.1071656
   NELSON RJ, 1981, IEEE J QUANTUM ELECT, V17, P202, DOI 10.1109/JQE.1981.1071067
   Schon JH, 2000, SCIENCE, V287, P1022, DOI 10.1126/science.287.5455.1022
   SCHON JH, IN PRESS SCIENCE
   Tessler N., 1997, Laser und Optoelektronik, V29, P54
   Tessler N, 1999, ADV MATER, V11, P363, DOI 10.1002/(SICI)1521-4095(199903)11:5<363::AID-ADMA363>3.0.CO;2-Y
   Zenz C, 1997, APPL PHYS LETT, V71, P2566, DOI 10.1063/1.119332
NR 25
TC 232
Z9 242
U1 2
U2 6
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
EI 1095-9203
J9 SCIENCE
JI Science
PD JUL 28
PY 2000
VL 289
IS 5479
BP 599
EP 601
DI 10.1126/science.289.5479.599
PG 3
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 338XD
UT WOS:000088447800046
PM 10915617
DA 2018-12-27
ER

PT J
AU Baglia, FA
   Walsh, PN
AF Baglia, FA
   Walsh, PN
TI RETRACTED: Thrombin-mediated feedback activation of factor XI on the
   activated platelet surface is preferred over contact activation by
   factor XIIa or factor XIa (Retracted article. see vol 282, pg 29067,
   2007)
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article; Retracted Publication
ID MOLECULAR-WEIGHT KININOGEN; COAGULATION-FACTOR-XI; PLASMA THROMBOPLASTIN
   ANTECEDENT; BLOOD-COAGULATION; BINDING-SITE; HAGEMAN-FACTOR;
   HEAVY-CHAIN; DOMAIN; PTA; RADIOIMMUNOASSAY
AB To study the pathways for initiation of intrinsic blood coagulation, activated human platelets were compared with dextran sulfate as surfaces for factor XI activation by factor XIIa, factor XIa, or thrombin. Activated gel-filtered platelets promoted the activation of factor XI (60 nM) by thrombin (0.02-10 nM, EC50 similar to 100 pM, threshold concentration similar to 10 pM) at initial rates 2- to 5-fold greater than those obtained with dextran sulfate in the presence of either high molecular weight kininogen (45 nM) and ZnCl2 (25 mu M) or prothrombin (1.2 mu M) and CaCl2 (2 mM). The maximum rates of factor XI activation achieved in the presence of activated gel-filtered platelets were 30 nM.min(-1) with thrombin, 6 nM.min(-1) with factor XIIa and 2 nM.min(-1) with factor XIa. Values of turnover number calculated at various enzyme concentrations (0.05-1 nM) were 24-167 (mean = 86) min(-1) for thrombin, 4.6-50 (mean = 21) min(-1) for factor XIIa, and 1.3-14 (mean = 8) min(-1) for factor XIa. A physiological concentration of fibrinogen (9.0 mu M) inhibited factor XI activation by thrombin (but not by factor XIIa) in the presence of dextran sulfate but not in the presence of gel-filtered platelets. Compared with factors XIIa and XIa, thrombin is the preferred factor XI activator, and activated platelets are a relevant physiological surface for thrombin-mediated initiation of intrinsic coagulation in vivo.
C1 Temple Univ, Sol Sherry Thrombosis Res Ctr, Sch Med, Philadelphia, PA 19140 USA.
   Temple Univ, Sch Med, Dept Med, Philadelphia, PA 19140 USA.
   Temple Univ, Sch Med, Dept Biochem, Philadelphia, PA 19140 USA.
RP Walsh, PN (reprint author), Temple Univ, Sol Sherry Thrombosis Res Ctr, Sch Med, 3400 N Broad St, Philadelphia, PA 19140 USA.
EM pnw@astro.ocis.temple.edu
FU NHLBI NIH HHS [HL56153, HL46213, HL56914]
CR BAGLIA FA, 1995, J BIOL CHEM, V270, P6734, DOI 10.1074/jbc.270.12.6734
   BAGLIA FA, 1992, J BIOL CHEM, V267, P4247
   BAGLIA FA, 1990, J BIOL CHEM, V265, P4149
   Baglia FA, 1996, J BIOL CHEM, V271, P3652
   BAGLIA FA, 1993, J BIOL CHEM, V268, P3838
   Baglia FA, 1998, BIOCHEMISTRY-US, V37, P2271, DOI 10.1021/bi972113+
   BAGLIA FA, 1989, BLOOD, V74, P244
   BOUMA BN, 1977, J BIOL CHEM, V252, P6432
   BRUNNEE T, 1993, BLOOD, V81, P580
   FUJIKAWA K, 1986, BIOCHEMISTRY-US, V25, P2417, DOI 10.1021/bi00357a018
   GAILANI D, 1991, SCIENCE, V253, P909, DOI 10.1126/science.1652157
   GREENGARD JS, 1986, BIOCHEMISTRY-US, V25, P3884, DOI 10.1021/bi00361a022
   GRIFFIN JH, 1976, P NATL ACAD SCI USA, V73, P2554, DOI 10.1073/pnas.73.8.2554
   HARMON JT, 1988, BIOCHEMISTRY-US, V27, P2151, DOI 10.1021/bi00406a050
   HECK LW, 1974, J EXP MED, V140, P1615, DOI 10.1084/jem.140.6.1615
   Ho DH, 1998, J BIOL CHEM, V273, P16382, DOI 10.1074/jbc.273.26.16382
   KERBIRIOU DM, 1979, J BIOL CHEM, V254, P2020
   KURACHI K, 1977, BIOCHEMISTRY-US, V16, P5831, DOI 10.1021/bi00645a030
   LEIBA H, 1965, BRIT J HAEMATOL, V11, P654, DOI 10.1111/j.1365-2141.1965.tb00114.x
   LUNDBLAD RL, 1984, J BIOL CHEM, V259, P6991
   MCMULLEN BA, 1991, BIOCHEMISTRY-US, V30, P2056, DOI 10.1021/bi00222a008
   MEIER HL, 1977, J CLIN INVEST, V60, P18, DOI 10.1172/JCI108754
   MOVAT HZ, 1974, J LAB CLIN MED, V84, P861
   NAITO K, 1991, J BIOL CHEM, V266, P7353
   Oliver JA, 1999, ARTERIOSCL THROM VAS, V19, P170, DOI 10.1161/01.ATV.19.1.170
   PROCTOR RR, 1961, AM J CLIN PATHOL, V36, P212
   RAGNI MV, 1985, BLOOD, V65, P719
   RAPAPORT SI, 1961, BLOOD, V18, P149
   RATNOFF OD, 1961, J CLIN INVEST, V40, P803, DOI 10.1172/JCI104314
   SAITO H, 1977, BLOOD, V50, P377
   Scandura JM, 1996, BIOCHEMISTRY-US, V35, P8890, DOI 10.1021/bi9525029
   SCOTT CF, 1984, BLOOD, V63, P42
   SCOTT CF, 1992, P NATL ACAD SCI USA, V89, P11189, DOI 10.1073/pnas.89.23.11189
   SINHA D, 1985, J BIOL CHEM, V260, P714
   THOMPSON RE, 1977, J CLIN INVEST, V60, P1376, DOI 10.1172/JCI108898
   WALSH PN, 1981, BLOOD, V57, P106
NR 36
TC 75
Z9 80
U1 1
U2 10
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD JUL 7
PY 2000
VL 275
IS 27
BP 20514
EP 20519
DI 10.1074/jbc.M000464200
PG 6
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 332QG
UT WOS:000088084500042
PM 10781579
OA Bronze
DA 2018-12-27
ER

PT J
AU van Son, JAM
   Hambsch, J
   Kinzel, P
   Haas, GS
   Mohr, FW
AF van Son, JAM
   Hambsch, J
   Kinzel, P
   Haas, GS
   Mohr, FW
TI RETRACTED: Urgency of operation in infracardiac total anomalous
   pulmonary venous connection (Retracted article. See vol 70, pg 2184,
   2000)
SO ANNALS OF THORACIC SURGERY
LA English
DT Article; Retracted Publication
ID DRAINAGE
AB Background. Because the tendency for pulmonary venous obstruction in the infracardiac type of total anomalous pulmonary venous connection may be partially dependent on the connection of the descending vein to the portal vein, the inferior vena cava, or one of their tributary vessels, we reviewed our surgical experience with various subtypes of infracardiac total anomalous pulmonary venous connection.
   Methods. The urgency of operation in 4 neonates with infracardiac total anomalous pulmonary venous connection was reviewed.
   Results. Two patients with pulmonary venous obstruction in whom the descending vein connected to the portal vein were operated on immediately with successful outcome. One patient who had become critically ill after the ductus venosus had closed died before operation could be undertaken. One patient in whom the descending vein connected to the left hepatic vein was operated on electively with successful outcome.
   Conclusions. In hemodynamically stable patients with no clinical or echocardiographic signs of pulmonary venous obstruction, some form of differentiation with regard to urgency of operation may be appropriate. When the descending vein connects to the inferior vena cava or a hepatic vein, the operation may be performed on a semi-elective basis. In contrast, when the descending vein connects to the portal vein or the ductus venosus, operation should generally not be delayed because of the high likelihood of obstruction. (Ann Thorac Surg 2000;70:128-30) (C) 2000 by The Society of Thoracic Surgeons.
C1 Univ Leipzig, Herzzentrum, D-04289 Leipzig, Germany.
RP van Son, JAM (reprint author), Univ Leipzig, Herzzentrum, Russenstr 19, D-04289 Leipzig, Germany.
CR ARCIPRETE P, 1986, J THORAC CARDIOV SUR, V92, P146
   CARTER REB, 1969, BRIT HEART J, V31, P45
   DELISLE G, 1976, AM HEART J, V91, P99, DOI 10.1016/S0002-8703(76)80440-1
   DUFF DF, 1977, BRIT HEART J, V39, P619
   SANO S, 1989, J THORAC CARDIOV SUR, V97, P886
   SERRAF A, 1991, J THORAC CARDIOV SUR, V101, P601
   TURLEY K, 1980, AM J CARDIOL, V45, P92, DOI 10.1016/0002-9149(80)90225-8
   VANDEWAL HJCM, 1992, EUR J CARDIO-THORAC, V6, P545, DOI 10.1016/1010-7940(92)90006-J
   VANSON JAM, 1997, ASIAN CARDIOVASC THO, V5, P121
NR 9
TC 12
Z9 14
U1 3
U2 11
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0003-4975
EI 1552-6259
J9 ANN THORAC SURG
JI Ann. Thorac. Surg.
PD JUL
PY 2000
VL 70
IS 1
BP 128
EP 130
DI 10.1016/S0003-4975(00)01350-3
PG 3
WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery
SC Cardiovascular System & Cardiology; Respiratory System; Surgery
GA 336TB
UT WOS:000088318100031
PM 10921696
DA 2018-12-27
ER

PT J
AU Drazan, KE
AF Drazan, KE
TI RETRACTED: Molecular biology of hepatitis C infection (Retracted
   Article. See vol 7, pg 1008, 2001)
SO LIVER TRANSPLANTATION
LA English
DT Review; Retracted Publication
ID VIRUS CORE PROTEIN; NON-B-HEPATITIS; DENSITY-LIPOPROTEIN RECEPTOR;
   NONSTRUCTURAL 5A PROTEIN; HYPERVARIABLE REGION 1; DOUBLE-STRANDED-RNA;
   IN-VITRO; CELL-LINE; NON-A; MIXED CRYOGLOBULINEMIA
AB Hepatitis C infection (HCV) is an emerging epidemic. Liver specialists are managing this disease with limited scientific information about the underlying pathogenesis and treatment. The current review offers a molecular dissection of infection, a snapshot of the HCV life cycle, and emerging strategies for antiviral therapy.
C1 Stanford Univ, Liver Transplant Program, Palo Alto, CA 94304 USA.
RP Drazan, KE (reprint author), 750 Welch Rd,Suite 319, Palo Alto, CA 94304 USA.
EM kdrazan@leland.standford.edu
CR AGNELLO V, 1995, SCAND J IMMUNOL, V42, P179, DOI 10.1111/j.1365-3083.1995.tb03643.x
   Agnello V, 1997, SPRINGER SEMIN IMMUN, V19, P111, DOI 10.1007/BF00945029
   Barba G, 1997, P NATL ACAD SCI USA, V94, P1200, DOI 10.1073/pnas.94.4.1200
   BARRY CWS, 1999, 25 ANN M AM SOC TRAN
   BARTLETT J, 2001, FAMILIAR QUOTATIONS
   BATES P, 1993, CELL, V74, P1043, DOI 10.1016/0092-8674(93)90726-7
   Berenguer M, 1999, GUT, V45, P159, DOI 10.1136/gut.45.2.159
   Berkhout B, 1999, J BIOMED SCI, V6, P298, DOI 10.1007/BF02253518
   BERTOLINI L, 1993, RES VIROLOGY, V144, P281, DOI 10.1016/S0923-2516(06)80041-5
   BRADLEY D, 1991, J MED VIROL, V34, P206, DOI 10.1002/jmv.1890340315
   BRADLEY DW, 1983, J INFECT DIS, V148, P254, DOI 10.1093/infdis/148.2.254
   Brillanti S, 1995, J HEPATOL, V23, P13
   BROWN EA, 1992, NUCLEIC ACIDS RES, V20, P5041, DOI 10.1093/nar/20.19.5041
   BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311
   Brown MS, 1997, NATURE, V388, P629, DOI 10.1038/41672
   Brown-Driver V, 1999, ANTISENSE NUCLEIC A, V9, P145, DOI 10.1089/oli.1.1999.9.145
   BUKH J, 1995, SEMIN LIVER DIS, V15, P41, DOI 10.1055/s-2007-1007262
   BUKH J, 1992, P NATL ACAD SCI USA, V89, P4942, DOI 10.1073/pnas.89.11.4942
   Castelli J, 1998, BIOMED PHARMACOTHER, V52, P386, DOI 10.1016/S0753-3322(99)80006-7
   CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562
   Clemens MJ, 1999, INT J BIOCHEM CELL B, V31, P1, DOI 10.1016/S1357-2725(98)00127-7
   Dammacco F, 1998, LEUKEMIA LYMPHOMA, V31, P463, DOI 10.3109/10428199809057606
   Davis GL, 1998, HEPATOLOGY, V28, p390A
   DAVIS GL, 1989, NEW ENGL J MED, V321, P1501, DOI 10.1056/NEJM198911303212203
   DHILLON AP, 1995, HISTOPATHOLOGY, V26, P297, DOI 10.1111/j.1365-2559.1995.tb00191.x
   El-Serag HB, 1999, NEW ENGL J MED, V340, P745, DOI 10.1056/NEJM199903113401001
   Enomoto N, 1996, NEW ENGL J MED, V334, P77, DOI 10.1056/NEJM199601113340203
   ENOMOTO N, 1995, J CLIN INVEST, V96, P224, DOI 10.1172/JCI118025
   Eren R, 1998, IMMUNOLOGY, V93, P154
   Farci P, 1996, P NATL ACAD SCI USA, V93, P15394, DOI 10.1073/pnas.93.26.15394
   Flint M, 1999, J VIROL, V73, P6235
   Furione M, 1999, J CLIN VIROL, V13, P121, DOI 10.1016/S1386-6532(99)00036-0
   Gale M, 1998, MOL CELL BIOL, V18, P5208, DOI 10.1128/MCB.18.9.5208
   Gale MJ, 1998, CLIN DIAGN VIROL, V10, P157
   Gale MJ, 1997, VIROLOGY, V230, P217, DOI 10.1006/viro.1997.8493
   Gallinari P, 1998, J VIROL, V72, P6758
   GALUN E, 2000, 7 INT S HEP C REL VI
   Glenn JS, 1998, J VIROL, V72, P9303
   Glue P, 1999, SEMIN LIVER DIS, V19, P17
   GRAKOUI A, 1993, J VIROL, V67, P2832
   HAHM B, 1995, J VIROL, V69, P2534
   HAN JH, 1991, P NATL ACAD SCI USA, V88, P1711, DOI 10.1073/pnas.88.5.1711
   HE LF, 1987, J INFECT DIS, V156, P636, DOI 10.1093/infdis/156.4.636
   HIJIKATA M, 1993, P NATL ACAD SCI USA, V90, P10773, DOI 10.1073/pnas.90.22.10773
   HIJIKATA M, 1993, J VIROL, V67, P1953
   HIJIKATA MK, 1991, J VIROL, V67, P4665
   HOFER F, 1994, P NATL ACAD SCI USA, V91, P1839, DOI 10.1073/pnas.91.5.1839
   Houghton M., 1996, HEPATITIS C VIRUSES
   IACOVACCI S, 1993, RES VIROLOGY, V144, P275, DOI 10.1016/S0923-2516(06)80040-3
   Ito T, 1996, J GEN VIROL, V77, P1043, DOI 10.1099/0022-1317-77-5-1043
   Jacobs BL, 1996, VIROLOGY, V219, P339, DOI 10.1006/viro.1996.0259
   Jagus R, 1999, INT J BIOCHEM CELL B, V31, P123, DOI 10.1016/S1357-2725(98)00136-8
   Jones PS, 1998, ANTIVIR CHEM CHEMOTH, V9, P283
   KAITO M, 1994, J GEN VIROL, V75, P1755, DOI 10.1099/0022-1317-75-7-1755
   KAMER G, 1984, NUCLEIC ACIDS RES, V12, P7269, DOI 10.1093/nar/12.18.7269
   KANAI A, 1995, FEBS LETT, V376, P221, DOI 10.1016/0014-5793(95)01283-X
   KIM DW, 1995, BIOCHEM BIOPH RES CO, V215, P160, DOI 10.1006/bbrc.1995.2447
   Kim JL, 1996, CELL, V87, P343, DOI 10.1016/S0092-8674(00)81351-3
   Kolykhalov AA, 1996, J VIROL, V70, P3363
   KUMAR U, 1994, GASTROENTEROLOGY, V106, P1072, DOI 10.1016/0016-5085(94)90770-6
   KUMAR U, 1993, J INFECT DIS, V167, P726, DOI 10.1093/infdis/167.3.726
   KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467
   Kwong AD, 1999, ANTIVIR RES, V41, P65
   Lai MMC, 1998, VIROLOGY, V244, P1, DOI 10.1006/viro.1998.9098
   LANFORD RE, 1994, VIROLOGY, V202, P606, DOI 10.1006/viro.1994.1381
   Large MK, 1999, J IMMUNOL, V162, P931
   Lavanchy D, 1999, J HEPATOL, V31, P146, DOI 10.1016/S0168-8278(99)80392-4
   Lemon SM, 1997, SEMIN VIROL, V8, P274, DOI 10.1006/smvy.1997.0129
   Levy S, 1998, ANNU REV IMMUNOL, V16, P89, DOI 10.1146/annurev.immunol.16.1.89
   Lieber A, 1996, J VIROL, V70, P8782
   Lindsay KL, 1997, HEPATOLOGY, V26, pS71, DOI 10.1002/hep.510260713
   Lohmann V, 1999, SCIENCE, V285, P110, DOI 10.1126/science.285.5424.110
   Maecker HT, 1997, J EXP MED, V185, P1505, DOI 10.1084/jem.185.8.1505
   Matsumoto M, 1997, J VIROL, V71, P1301
   Mizutani T, 1996, J VIROL, V70, P7219
   Neumann AU, 1998, SCIENCE, V282, P103, DOI 10.1126/science.282.5386.103
   Oh JW, 1999, J VIROL, V73, P7694
   OKAMOTO H, 1991, J GEN VIROL, V72, P2697, DOI 10.1099/0022-1317-72-11-2697
   Pileri P, 1998, SCIENCE, V282, P938, DOI 10.1126/science.282.5390.938
   Prince AM, 1996, J VIRAL HEPATITIS, V3, P11, DOI 10.1111/j.1365-2893.1996.tb00075.x
   Ray RB, 1997, J BIOL CHEM, V272, P10983
   RICE CM, 1996, FLAVIVIRIDAE VIRUSES
   Rosa D, 1996, P NATL ACAD SCI USA, V93, P1759, DOI 10.1073/pnas.93.5.1759
   Sachs AB, 1997, CELL, V89, P831, DOI 10.1016/S0092-8674(00)80268-8
   SAITO I, 1990, P NATL ACAD SCI USA, V87, P6547, DOI 10.1073/pnas.87.17.6547
   SANTOLINI E, 1994, J VIROL, V68, P3631
   SANTOLINI E, 1995, J VIROL, V69, P7461
   Seipp S, 1997, J GEN VIROL, V78, P2467, DOI 10.1099/0022-1317-78-10-2467
   SHIH CM, 1993, J VIROL, V67, P5823
   SHIMIZU YK, 1992, P NATL ACAD SCI USA, V89, P5477, DOI 10.1073/pnas.89.12.5477
   Shimizu YK, 1996, VIROLOGY, V223, P409, DOI 10.1006/viro.1996.0497
   SHIMIZU YK, 1993, P NATL ACAD SCI USA, V90, P6037, DOI 10.1073/pnas.90.13.6037
   Srinivas RV, 1996, VIRUS RES, V45, P87, DOI 10.1016/S0168-1702(96)01361-5
   Sugiyama K, 1997, J GEN VIROL, V78, P329, DOI 10.1099/0022-1317-78-2-329
   SUN BGM, 1999, 6 INT S HEP C REL VI
   Tai CL, 1996, J VIROL, V70, P8477
   Tanaka T, 1996, J VIROL, V70, P3307
   Taylor DR, 1999, SCIENCE, V285, P107, DOI 10.1126/science.285.5424.107
   THOMSSEN R, 1992, MED MICROBIOL IMMUN, V181, P293, DOI 10.1007/BF00198849
   TSUKIYAMAKOHARA K, 1992, J VIROL, V66, P1476
   WEINER AJ, 1991, VIROLOGY, V180, P842, DOI 10.1016/0042-6822(91)90104-J
   Williams BRG, 1997, BIOCHEM SOC T, V25, P509, DOI 10.1042/bst0250509
   Xie ZC, 1998, VIROLOGY, V244, P513, DOI 10.1006/viro.1998.9127
   Yanagi M, 1999, P NATL ACAD SCI USA, V96, P2291, DOI 10.1073/pnas.96.5.2291
   ZIBERT A, 1995, VIROLOGY, V208, P653, DOI 10.1006/viro.1995.1196
   ZIGNEGO AL, 1992, J HEPATOL, V15, P382, DOI 10.1016/0168-8278(92)90073-X
NR 106
TC 18
Z9 23
U1 4
U2 12
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1527-6465
EI 1527-6473
J9 LIVER TRANSPLANT
JI Liver Transplant.
PD JUL
PY 2000
VL 6
IS 4
BP 396
EP 406
DI 10.1053/jlts.2000.6449
PG 11
WC Gastroenterology & Hepatology; Surgery; Transplantation
SC Gastroenterology & Hepatology; Surgery; Transplantation
GA 340FU
UT WOS:000088523100002
PM 10915159
OA Bronze
DA 2018-12-27
ER

PT J
AU Schon, JH
   Kloc, C
   Batlogg, B
AF Schon, JH
   Kloc, C
   Batlogg, B
TI RETRACTED: Fractional quantum Hall effect in organic molecular
   semiconductors (Retracted Article. See vol 298, pg 961, 2002)
SO SCIENCE
LA English
DT Article; Retracted Publication
ID PHYSICAL VAPOR GROWTH; HIGH-FIELD; TETRACENE SUPERLATTICES; PENTACENE;
   CRYSTALS; ALPHA-(BEDT-TTF)(2)TLHG(SCN)(4); TRANSISTORS; TRANSPORT
AB High-quality crystals of the organic molecular semiconductors tetracene and pentacene were used to prepare metal-insulator-semiconductor (MIS) structures exhibiting hole and electron mobilities exceeding 10(4) square centimeters per volt per second, The carrier concentration in the channel region of these ambipolar field-effect devices was controlled by the applied gate voltage. Well-defined Shubnikov-de Haas oscillations and quantized Hall plateaus were observed for two-dimensional carrier densities in the range of 10(11) per square centimeter. Fractional quantum Hall states were observed in tetracene crystals at temperatures as high as similar to 2 kelvin.
C1 Bell Labs, Lucent Technol, Murray Hill, NJ 07974 USA.
RP Schon, JH (reprint author), Bell Labs, Lucent Technol, 600 Mt Ave, Murray Hill, NJ 07974 USA.
RI Kloc, Christian/A-2255-2011
CR AKIMICHI H, 1993, APPL PHYS LETT, V63, P3158, DOI 10.1063/1.110234
   BURLAND DM, 1977, J CHEM PHYS, V67, P319, DOI 10.1063/1.434527
   CHAIKIN PM, 1992, PHYSICA B, V177, P353, DOI 10.1016/0921-4526(92)90128-F
   CHAMBERLIN RV, 1988, PHYS REV LETT, V60, P1189, DOI 10.1103/PhysRevLett.60.1189
   CORNIL J, COMMUNICATION
   DODABALAPUR A, 1995, SCIENCE, V268, P270, DOI 10.1126/science.268.5208.270
   HADDON RC, COMMUNICATION
   Harrison N, 1996, PHYS REV LETT, V77, P1576, DOI 10.1103/PhysRevLett.77.1576
   Honold MM, 1999, PHYS REV B, V59, P10417, DOI 10.1103/PhysRevB.59.R10417
   KARL N, 1991, SYNTHETIC MET, V42, P2473, DOI 10.1016/0379-6779(91)91407-2
   Kloc C, 1997, J CRYST GROWTH, V182, P416, DOI 10.1016/S0022-0248(97)00370-9
   KRAVCHENKO SV, 1994, PHYS REV B, V50, P8039, DOI 10.1103/PhysRevB.50.8039
   Laudise RA, 1998, J CRYST GROWTH, V187, P449, DOI 10.1016/S0022-0248(98)00034-7
   LITTLEWOOD PB, COMMUNICATION
   MINAKATA T, 1995, POLYM ADVAN TECHNOL, V6, P611, DOI 10.1002/pat.1995.220060904
   RIBAULT M, 1984, J PHYS LETT-PARIS, V45, pL935
   Schon JH, 2000, SCIENCE, V287, P1022, DOI 10.1126/science.287.5455.1022
   SINGH DC, 1974, MOL CRYST LIQ CRYST, V27, P55, DOI 10.1080/15421407408083120
   SO FF, 1991, PHYS REV LETT, V66, P2649, DOI 10.1103/PhysRevLett.66.2649
   Stormer HL, 1999, REV MOD PHYS, V71, P875, DOI 10.1103/RevModPhys.71.875
   TSUI DC, 1982, PHYS REV B, V25, P1408
   VONKLITZING K, 1986, REV MOD PHYS, V58, P519, DOI 10.1103/RevModPhys.58.519
   VONKLITZING K, 1980, PHYS REV LETT, V45, P494
   WARTA W, 1985, PHYS REV B, V32, P1172, DOI 10.1103/PhysRevB.32.1172
NR 24
TC 116
Z9 119
U1 3
U2 49
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
J9 SCIENCE
JI Science
PD JUN 30
PY 2000
VL 288
IS 5475
BP 2338
EP 2340
DI 10.1126/science.288.5475.2338
PG 5
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 329NP
UT WOS:000087913400030
PM 17769842
DA 2018-12-27
ER

PT J
AU Thomas, JM
   Eckhoff, DE
   Contreras, JL
   Lobashevsky, AL
   Hubbard, WJ
   Moore, JK
   Cook, WJ
   Thomas, FT
   Neville, DM
AF Thomas, JM
   Eckhoff, DE
   Contreras, JL
   Lobashevsky, AL
   Hubbard, WJ
   Moore, JK
   Cook, WJ
   Thomas, FT
   Neville, DM
TI RETRACTED: Durable donor-specific T and B cell tolerance in rhesus
   macaques induced with peritransplantation anti-CD3 immunotoxin and
   deoxyspergualin - Absence of chronic allograft nephropathy (Retracted
   Article. See vol 82, pg 577, 2006)
SO TRANSPLANTATION
LA English
DT Article; Retracted Publication
ID TRANSPLANT RECIPIENTS; CHRONIC REJECTION; BONE-MARROW;
   KIDNEY-TRANSPLANTS; NONHUMAN-PRIMATES; RENAL-ALLOGRAFTS;
   GRAFT-REJECTION; INDUCTION; MONKEYS; ANTIGEN
AB Tolerance induction can prevent acute kidney allograft rejection without chronic immunosuppression. It is uncertain whether specific tolerance can prevent chronic allograft nephropathy (CAN), which involves both nonimmune and immune injury. This report provides evidence that immunologically tolerant macaques, induced with immunotoxin and deoxyspergualin, developed neither acute rejection nor CAN. Long survivors, bearing MHC-mismatched grafts without chronic immunosuppression for 0.8 to 3.4 years, exhibited general immune competence with donor-specific T and B cell tolerance and no functional or histological evidence of CAN. Stringent criteria for tolerance were satisfied by specific prolongation of donor skin grafts with rapid rejection of third-party skin, followed by indefinite acceptance of a second donor kidney graft and establishment of microchimerism. Primate tolerance with documented absence of CAN may give impetus to the clinical application of tolerance.
C1 Univ Alabama Birmingham, Transplant Ctr, Dept Surg & Pathol, Birmingham, AL 35294 USA.
   NIMH, NIH, Bethesda, MD 20892 USA.
RP Thomas, JM (reprint author), Univ Alabama Birmingham, Transplant Ctr, Dept Surg & Pathol, Birmingham, AL 35294 USA.
EM jthomas@uab.edu
FU NIDDK NIH HHS [1U19 DK57958]; NIAID NIH HHS [AI 22293]
CR Albert ML, 1998, NATURE, V392, P86, DOI 10.1038/32183
   Benichou Gilles, 1999, Frontiers in Bioscience, V4, pD476, DOI 10.2741/Benichou
   Cecka J M, 1997, Clin Transpl, P1
   Contreras JL, 1999, TRANSPLANTATION, V68, P215, DOI 10.1097/00007890-199907270-00009
   Contreras JL, 1998, TRANSPLANTATION, V65, P1159, DOI 10.1097/00007890-199805150-00003
   Ehl S, 1998, NAT MED, V4, P1015, DOI 10.1038/2001
   Fechner JH, 1997, TRANSPLANTATION, V63, P1339, DOI 10.1097/00007890-199705150-00023
   Halloran PF, 1999, J AM SOC NEPHROL, V10, P167
   Hamawy MM, 1998, CURR OPIN IMMUNOL, V10, P513, DOI 10.1016/S0952-7915(98)80216-1
   HANCOCK WH, 1993, TRANSPLANTATION, V56, P643, DOI 10.1097/00007890-199309000-00028
   Hancock WW, 1998, NAT MED, V4, P1392, DOI 10.1038/3982
   Harlan DM, 1999, JAMA-J AM MED ASSOC, V282, P1076, DOI 10.1001/jama.282.11.1076
   HARLAN WR, 1967, NEW ENGL J MED, V277, P769, DOI 10.1056/NEJM196710122771501
   HAYRY P, 1998, GRAFT, V1, P154
   HUBBARD WJ, 1997, CURR OPIN ORGAN TRAN, V2, P36
   Kawai T, 1999, TRANSPLANTATION, V68, P1767, DOI 10.1097/00007890-199912150-00022
   Kawai T, 1999, CURR OPIN IMMUNOL, V11, P516, DOI 10.1016/S0952-7915(99)00009-6
   Kerby JD, 1997, TRANSPLANTATION, V63, P988, DOI 10.1097/00007890-199704150-00015
   Kirk AD, 1999, NAT MED, V5, P686, DOI 10.1038/9536
   Knechtle SJ, 1998, SURGERY, V124, P438, DOI 10.1016/S0039-6060(98)70151-5
   Lobashevsky A, 1999, TISSUE ANTIGENS, V54, P254, DOI 10.1034/j.1399-0039.1999.540306.x
   Matas AJ, 1999, ANN SURG, V230, P493, DOI 10.1097/00000658-199910000-00005
   MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991, DOI 10.1146/annurev.iy.12.040194.005015
   Mellman I, 1998, TRENDS CELL BIOL, V8, P231, DOI 10.1016/S0962-8924(98)01276-8
   MOSELEY ROGER V., 1966, TRANSPLANTATION, V4, P678, DOI 10.1097/00007890-196611000-00003
   NADLER SG, 1995, THER DRUG MONIT, V17, P700, DOI 10.1097/00007691-199512000-00026
   Nagano H, 1997, AM J MED SCI, V313, P305, DOI 10.1097/00000441-199705000-00010
   Nemoto K, 1997, EXP HEMATOL, V25, P1339
   Neville DM, 1996, J IMMUNOTHER, V19, P85, DOI 10.1097/00002371-199603000-00001
   Opelz G, 1997, TRANSPLANTATION, V64, P1473, DOI 10.1097/00007890-199711270-00017
   Paul LC, 1999, KIDNEY INT, V56, P783, DOI 10.1046/j.1523-1755.1999.00611.x
   PENNOCK JL, 1981, TRANSPLANTATION, V32, P467, DOI 10.1097/00007890-198112000-00003
   Racusen LC, 1999, KIDNEY INT, V55, P713, DOI 10.1046/j.1523-1755.1999.00299.x
   Rescigno M, 1998, J EXP MED, V188, P2175, DOI 10.1084/jem.188.11.2175
   Rose SM, 1998, TRANSPLANTATION, V66, P1123, DOI 10.1097/00007890-199811150-00001
   Russell PS, 1997, TRANSPLANTATION, V64, P1531, DOI 10.1097/00007890-199712150-00005
   Sanfilippo F, 1998, NEW ENGL J MED, V339, P1700, DOI 10.1056/NEJM199812033392310
   Shirwan H, 1999, TRANSPLANTATION, V68, P715, DOI 10.1097/00007890-199909270-00001
   Steinmuller D., 1998, TRANSPLANT REV, V12, P42
   STEVENS HPJD, 1991, TRANSPLANT P, V23, P623
   THOMAS J, 1992, TRANSPLANTATION, V53, P247, DOI 10.1097/00007890-199202010-00001
   THOMAS JM, 1989, TRANSPLANTATION, V47, P209, DOI 10.1097/00007890-198902000-00002
   Thomas JM, 1999, TRANSPLANTATION, V68, P1660, DOI 10.1097/00007890-199912150-00009
   THOMAS JM, 1995, TRANSPLANTATION, V59, P245, DOI 10.1097/00007890-199501270-00017
   Thomas JM, 1997, TRANSPLANTATION, V64, P124, DOI 10.1097/00007890-199707150-00022
   TRAN CD, 1989, ANAL CHEM, V61, P928, DOI 10.1021/ac00183a031
   Vella JP, 1997, TRANSPLANTATION, V64, P795, DOI 10.1097/00007890-199709270-00001
NR 47
TC 73
Z9 74
U1 3
U2 13
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0041-1337
EI 1534-6080
J9 TRANSPLANTATION
JI Transplantation
PD JUN 27
PY 2000
VL 69
IS 12
BP 2497
EP 2503
DI 10.1097/00007890-200006270-00007
PG 7
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 335HU
UT WOS:000088238700007
PM 10910269
DA 2018-12-27
ER

PT J
AU Mizutani, A
   Okajima, K
   Uchiba, M
   Noguchi, T
AF Mizutani, A
   Okajima, K
   Uchiba, M
   Noguchi, T
TI RETRACTED: Activated protein C reduces ischemia/reperfusion-induced
   renal injury in rats by inhibiting leukocyte activation (Retracted
   article. See vol. 122, pg. 302, 2013)
SO BLOOD
LA English
DT Article; Retracted Publication
ID DISSEMINATED INTRAVASCULAR COAGULATION; PULMONARY VASCULAR INJURY;
   BLOOD-COAGULATION; NEUTROPHIL ELASTASE; ESCHERICHIA-COLI; FAILURE;
   PREVENTS; ISCHEMIA; GAMMA; SHOCK
AB We examined whether activated protein C (APC) reduces ischemia/reperfusion (VR)induced renal injury by inhibiting leukocyte activation, In a rat model, intravenous administration of APC markedly reduced VR-induced renal dysfunction and histological changes, whereas intravenous administration of dansyl glutamyl-glycylarginyl chloromethyl ketone-treated factor Xa (DEGR-FXa; active-site-blocked factor Xa), heparin or diisopropyl fluorophosphate-treated APC (DIP-APC; inactive derivative of ARC) had no effect. Furthermore, APC significantly inhibited the IIR-induced decrease in renal tissue blood flow and the increase in the vascular permeability, whereas neither DEGR-FXa, heparin, nor DIP-APC produced such effects. Renal IIR-induced increases in plasma levels of fibrin degradation products were significantly inhibited by APC, DEGR-FXa, and heparin, These observations suggest that APC reduces IIR-induced renal injury independently of its anticoagulant effects but in a manner dependent on its serine protease activity. Renal levels of tumor necrosis factor-alpha (TNF-alpha), rat interleukin-8, and myeloperoxidase were significantly increased after renal I/R, These increases were significantly inhibited by APC but not by DEGR-FXa, heparin, or DIP-APC. Leukocytopenia produced effects similar to those of APC, These findings strongly suggest that APC protects against I/R-induced renal injury not by inhibiting coagulation abnormalities but by inhibiting activation of leukocytes that play an important role in I/R-induced renal injury, Inhibition of leukocyte activation by APC could be explained by the inhibitory activity of TNF-alpha. (C) 2000 by The American Society of Hematology.
C1 Kumamoto Univ, Sch Med, Dept Lab Med, Kumamoto 8600811, Japan.
   Oita Med Univ, Dept Anesthesiol, Kumamoto, Japan.
RP Okajima, K (reprint author), Kumamoto Univ, Sch Med, Dept Lab Med, Honjo 1-1-1, Kumamoto 8600811, Japan.
EM whynot@kaiju.medic.kumamoto-u.ac.jp
CR BAJAJ SP, 1981, PREP BIOCHEM, V11, P397, DOI 10.1080/00327488108065531
   Bonventre J V, 1996, Curr Opin Nephrol Hypertens, V5, P254, DOI 10.1097/00041552-199605000-00011
   BONVENTRE JV, 1993, KIDNEY INT, V43, P1160, DOI 10.1038/ki.1993.163
   Chiao H, 1997, J CLIN INVEST, V99, P1165, DOI 10.1172/JCI119272
   Daemen MARC, 1999, TRANSPLANTATION, V67, P792, DOI 10.1097/00007890-199903270-00003
   Druid H, 1998, INT J EXP PATHOL, V79, P55, DOI 10.1046/j.1365-2613.1998.00055.x
   ESMON CT, 1992, ARTERIOSCLER THROMB, V12, P135, DOI 10.1161/01.ATV.12.2.135
   GREY S, 1993, TRANSPLANT P, V25, P2913
   GREY ST, 1994, J IMMUNOL, V153, P3664
   Gurbanov K, 1996, AM J PHYSIOL-RENAL, V271, pF1166
   HANSELL P, 1990, ACTA PHYSIOL SCAND, V139, P15, DOI 10.1111/j.1748-1716.1990.tb08892.x
   INAUEN W, 1990, AM J PHYSIOL, V259, pG134
   KAWABATA K, 1991, BIOCHEM BIOPH RES CO, V177, P814, DOI 10.1016/0006-291X(91)91862-7
   KELLY KJ, 1994, P NATL ACAD SCI USA, V91, P812, DOI 10.1073/pnas.91.2.812
   Kelly KJ, 1996, J CLIN INVEST, V97, P1056, DOI 10.1172/JCI118498
   Liu WG, 1998, J LAB CLIN MED, V132, P432, DOI 10.1016/S0022-2143(98)90114-7
   LOSONCZY G, 1985, ACTA PHYSIOL HUNG, V66, P183
   MANN KG, 1984, PROG HEMOST THROMB, V7, P1
   MORITA T, 1986, J BIOL CHEM, V261, P4008
   Murakami K, 1997, AM J PHYSIOL-LUNG C, V272, pL197
   Murakami K, 1996, BLOOD, V87, P642
   NESHEIM ME, 1981, J BIOL CHEM, V256, P6537
   OKAJIMA K, 1989, THROMB HAEMOSTASIS, V61, P20
   OKAJIMA K, 1990, AM J HEMATOL, V33, P277, DOI 10.1002/ajh.2830330413
   OKAJIMA K, 1990, THROMB HAEMOSTASIS, V63, P48
   PLANTE GE, 1992, J CLIN INVEST, V89, P2030, DOI 10.1172/JCI115813
   POBER JS, 1990, PHYSIOL REV, V70, P427
   RABB H, 1995, BIOCHEM BIOPH RES CO, V211, P67, DOI 10.1006/bbrc.1995.1779
   Remick DG, 1996, J LEUKOCYTE BIOL, V59, P471
   STJOHN RC, 1993, CHEST, V103, P932, DOI 10.1378/chest.103.3.932
   Taoka Y, 1998, J NEUROSCI, V18, P1393
   TAYLOR FB, 1987, J CLIN INVEST, V79, P918, DOI 10.1172/JCI112902
   TAYLOR FB, 1991, BLOOD, V78, P364
   Thadhani R, 1996, NEW ENGL J MED, V334, P1448, DOI 10.1056/NEJM199605303342207
   WALKER FJ, 1979, BIOCHIM BIOPHYS ACTA, V571, P333, DOI 10.1016/0005-2744(79)90103-7
NR 35
TC 179
Z9 185
U1 0
U2 12
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD JUN 15
PY 2000
VL 95
IS 12
BP 3781
EP 3787
PG 7
WC Hematology
SC Hematology
GA 325ME
UT WOS:000087678700020
PM 10845910
DA 2018-12-27
ER

PT J
AU Horninger, W
   Reissigl, A
   Rogatsch, H
   Volgger, H
   Studen, M
   Klocker, H
   Bartsch, G
AF Horninger, W
   Reissigl, A
   Rogatsch, H
   Volgger, H
   Studen, M
   Klocker, H
   Bartsch, G
TI RETRACTED: Prostate cancer screening in the Tyrol, Austria: experience
   and results (Retracted article. See vol. 48, pg. 286, 2012)
SO EUROPEAN JOURNAL OF CANCER
LA English
DT Article; Proceedings Paper; Retracted Publication
CT 1st International Conference on Tumour Genetics and Prevention
CY FEB 17-19, 2000
CL UNIV ST GALLEN, ST GALLEN, SWITZERLAND
SP European Journal Canc, Journal Clin Oncol
HO UNIV ST GALLEN
DE prostate specific antigen; free prostate specific antigen; prostate
   specific antigen transition zone density transitional zone cancer; stage
   migration; organ confined tumours; PSA-screening; probability of
   prostate cancer
ID REFERENCE RANGES; PSA LEVELS; ANTIGEN; SERUM; MEN; CARCINOMA; AGE;
   ADENOCARCINOMA; POPULATION
AB This article summarises the experience and results of different prostate carcinoma screening projects using total prostate specific antigen (PSA) and per cent free PSA as the initial test. Of the 21 078 volunteers 1618 (8%) had elevated PSA levels. Of these men 778 (48%) underwent biopsies: 197 (25%) biopsies were positive for prostate carcinoma and 135 (17%) underwent radical prostatectomy. 95 were found to be organ-confined. A PSA cut-off of 2.5 ng/ml in men aged 45-49 years and of 3.5 ng/ml in men aged 50-59 years resulted in an 8% increase in the detection rate of organ-confined disease. 284/2272 men (13 %) had elevated PSA levels and prostate carcinoma was detected in 62 men (3 %). All patients underwent radical prostatectomy and histological examination revealed organ-confined tumour in all but 8 men. 98/340 men (29 %) had biopsies positive for carcinoma: 28 of these patients (29%) had carcinoma that originated in the transition zone only. In the retrospective study, receiver operating characteristic curve analysis showed that by using a per cent free PSA of less than 18% as a biopsy criterion, 37% of the negative biopsies could be eliminated although 94% of all carcinomas would still be detected. In the first prospective study, 106/158 men (67%) with elevated PSA levels below 10.0 ng/ml were further evaluated and 37 (35%) prostate carcinomas were detected. By using 3 per cent free PSA of <22% as a biopsy criterion. 30% of the negative biopsies could be eliminated although 98% of the carcinomas would still be detected. in the second prospective study, 120/465 men (26%) with total PSA levels between 1.25 and 6.49 ng/ml and a per cent free PSA < 18% were further evaluated and 27 (23%) were found to have prostate carcinomas. Receiver operating characteristic curve analysis for PSA transition zone (TZ) density showed that by using a PSA transition zone density of > 22 nd/ml/cc as a biopsy criterion, 24.4% of negative biopsies could be avoided without missing a single carcinoma. In the prescreening era the incidence of Tla Grade 1 and 3 carcinomas was 3.1% and the incidence of Tla and Tlb Grade 3 carcinoma was 2.3% whereas in the years after the establishment of PSA-based screening the incidence was 4.6 and 1.03% respectively. The rate of organ-confined tumours increased from 28.7% in 1993 to 65.7% in 1997. In this evaluation a new approach, to proceed with a prostate biopsy bused upon the: individual risk of having prostate cancer rather than a single PSA cut-off point was developed. High total PSA levels, PSA density and PSA transition zone density correlated significantly with high Gleason scores, capsular penetration, a high percentage of cancer in the prostatectomy specimen and a high cancer volume. In this evaluation all of the 95 patients with PSA levels below 3.99 ng/ml who underwent radical prostatectomy showed clinically significant, organ-confined prostate cancer with negative surgical margins. The results of this evaluation suggest that older men have larger tumour volumes compared with younger men with the same PSA levels. These data suggest that PSA-based screening with low PSA cut-off values increase the detection rate of clinically significant, organ confined and potentially curable prostate cancer. Per cent free PSA and PSA transition zone density provide an additional diagnostic benefit over total PSA. (C) 2000 Elsevier Science Ltd. All rights reserved.
C1 Univ Innsbruck, Dept Urol, A-6020 Innsbruck, Austria.
RP Horninger, W (reprint author), Univ Innsbruck, Dept Urol, Anichstr 35, A-6020 Innsbruck, Austria.
EM wolfganghorninger@uibk.ac.at
CR BRAWER MK, 1992, J UROLOGY, V147, P841, DOI 10.1016/S0022-5347(17)37401-3
   Carter HB, 1998, J UROLOGY, V159, P74
   CATALONA WJ, 1991, NEW ENGL J MED, V324, P1156, DOI 10.1056/NEJM199104253241702
   EPSTEIN JI, 1986, J UROLOGY, V136, P837, DOI 10.1016/S0022-5347(17)45097-X
   Gilliland FD, 1996, UROLOGY, V48, P67, DOI 10.1016/S0090-4295(96)00083-0
   Hoedemaeker RF, 1997, WORLD J UROL, V15, P339, DOI 10.1007/BF01300181
   HUDSON MA, 1989, J UROLOGY, V142, P1011, DOI 10.1016/S0022-5347(17)38972-3
   IMAI K, 1995, J UROLOGY, V154, P1085, DOI 10.1016/S0022-5347(01)66983-0
   Jewett H J, 1975, Urol Clin North Am, V2, P105
   LABRIE F, 1992, J UROLOGY, V147, P846, DOI 10.1016/S0022-5347(17)37402-5
   LANGE PH, 1989, J UROLOGY, V141, P873
   Littrup PJ, 1997, CANCER-AM CANCER SOC, V80, P1864
   MCNEAL JE, 1988, AM J SURG PATHOL, V12, P897, DOI 10.1097/00000478-198812000-00001
   OESTERLING JE, 1995, J UROLOGY, V153, P1160, DOI 10.1016/S0022-5347(01)67538-4
   OESTERLING JE, 1993, JAMA-J AM MED ASSOC, V270, P860, DOI 10.1001/jama.270.7.860
   Perrotti M, 1998, UROLOGY, V52, P106, DOI 10.1016/S0090-4295(98)00154-X
   RAINWATER LM, 1990, MAYO CLIN PROC, V65, P1118, DOI 10.1016/S0025-6196(12)62725-6
   REISSIGL A, 1995, UROLOGY, V46, P662, DOI 10.1016/S0090-4295(99)80297-0
   Reissigl A, 1996, UROLOGY, V48, P62, DOI 10.1016/S0090-4295(96)00612-7
   Reissigl A, 1997, PROSTATE, V30, P243
   STAMEY TA, 1989, J UROLOGY, V141, P1067
NR 21
TC 49
Z9 50
U1 4
U2 12
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0959-8049
EI 1879-0852
J9 EUR J CANCER
JI Eur. J. Cancer
PD JUN
PY 2000
VL 36
IS 10
BP 1322
EP 1335
DI 10.1016/S0959-8049(00)00113-1
PG 14
WC Oncology
SC Oncology
GA 327KJ
UT WOS:000087792800022
PM 10882875
DA 2018-12-27
ER

PT J
AU Piper, SN
   Boldt, J
   Schmidt, CC
   Brosch, C
   Maleck, WH
   Berchtold, C
AF Piper, SN
   Boldt, J
   Schmidt, CC
   Brosch, C
   Maleck, WH
   Berchtold, C
TI RETRACTED: Influence of dopexamine on hemodynamics, intramucosal pH, and
   regulators of the macrocirculation and microcirculation in patients
   undergoing abdominal aortic surgery (Retracted article. See vol. 25, pg.
   755, 2011)
SO JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA
LA English
DT Article; Retracted Publication
DE aortic surgery; dopexamine; hemodynamics; intramucosal pH; regulators of
   circulation
ID RISK SURGICAL PATIENTS; ATRIAL-NATRIURETIC-PEPTIDE; OXYGEN DELIVERY;
   CRITICALLY ILL; BLOOD-FLOW; HYDROCHLORIDE; PERMEABILITY; CIRCULATION;
   TRIAL; HEART
AB Objective: To investigate whether dopexamine hydrochloride beneficially influences splanchnic perfusion and regulators of the macrocirculation and microcirculation in patients undergoing surgery of the abdominal aorta.
   Design: Prospective, blinded, and randomized study.
   Setting: University-affiliated hospital.
   Participants: Twenty patients undergoing elective abdominal aortic surgery.
   Interventions: The patients were randomized to one of two groups. In the dopexamine group (DOP, n = 10), dopexamine, 1 mu g/kg/min, was started before surgery and continued for 24 hours. In the control group (COG, n = 10), patients received saline solution as placebo. Extensive hemodynamic monitoring was carried out using a pulmonary artery catheter, and intramucosal pH was measured using a gastric tonometer. From arterial blood samples, important regulators of the circulation were measured before dopexamine was administered (T0), before aortic clamping (T1). 20 minutes after aortic clamping (T2), after declamping the first leg (T3), at the end of surgery (T4), 1 hour postoperatively (T5), and 24 hours postoperatively (T6).
   Measurements and Main Results: Heart rate increased significantly in DOP(63 +/- 16 to 84 +/- 18 beats/min). At T5, mean pulmonary artery pressure was significantly lower in DOP (15 +/- 6 mmHg) than in COG (22 +/- 6 mmHg). During aortic clamping, pulmonary capillary wedge pressure increased significantly in both groups. Cardiac index increased significantly from baseline only in the dopexamine patients. No significant differences between the groups were seen with regard to oxygenation parameters and intramucosal pH. Renin plasma levels increased significantly only in COG (46 +/- 32 to 99 +/- 55 mu U/mL). Endothelin and atrial natriuretic peptide plasma levels showed no significant differences between the two groups. Atrial natriuretic peptide increased significantly only in DOP (366 +/- 171 pg/mL; COG, 159 +/- 71 pg/mL). Antidiuretic hormone, norepinephrine, and epinephrine plasma levels increased significantly from baseline in both groups, without showing significant differences between the groups.
   Conclusions: In patients undergoing abdominal aortic surgery, prophylactic perioperative administration of dopexamine hydrochloride produced effects on hemodynamics but without improving oxygenation and intramucosal pH. From the measured regulators of the circulation, only renin was beneficially affected. Copyright (C) 2000 by W.B. Saunders Company.
C1 Johannes Gutenberg Univ Mainz, Dept Anesthesiol & Intens Care Med & Surg, Klinikum Stadt Ludwigshafen, Akad Lehrkrankenhaus, Ludwigshafen, Germany.
RP Piper, SN (reprint author), Klinikum Ludwigshafen, Dept Anesthesiol & Intens Med, Bremserstr 79, D-67063 Ludwigshafen, Germany.
CR ATLAS SA, 1986, RECENT PROG HORM RES, V42, P207
   BENNETT ED, 1995, CLIN INTENSIVE CAR S, V6, P39
   BERGLUND H, 1990, BRIT HEART J, V64, P9
   Boldt J, 1997, BRIT J ANAESTH, V79, P733
   BOYD O, 1993, JAMA-J AM MED ASSOC, V270, P2699, DOI 10.1001/jama.270.22.2699
   BOYD O, 1995, ANAESTH INTENS CARE, V23, P478
   BURNS A, 1991, CLIN INT CARE S, V2, P50
   CHOWDREY HS, 1989, J CARDIOVASC PHARM, V13, P451, DOI 10.1097/00005344-198903000-00014
   COLSON P, 1992, ANESTH ANALG, V74, P481
   DAWSON JR, 1985, BRIT HEART J, V54, P313
   FITTON A, 1990, DRUGS, V39, P308, DOI 10.2165/00003495-199039020-00009
   FOULDS RA, 1988, AM J CARDIOL, V62, pC41, DOI 10.1016/S0002-9149(88)80066-3
   GANDHI CR, 1994, ANESTHESIOLOGY, V80, P892, DOI 10.1097/00000542-199404000-00023
   GELMAN S, 1988, AM J SURG, V155, P578, DOI 10.1016/S0002-9610(88)80413-6
   Gomersall CD, 1997, ANAESTHESIA, V52, P619, DOI 10.1111/j.1365-2044.1997.146-az0150.x
   GOSH S, 1991, J CARDIOTHOR VASC AN, V5, P382
   HUTCHISON J, 1991, CLIN INTENSIVE CAR S, V2, P18
   KHANNA S, 1994, AM J PHYSIOL-REG I, V267, pR1142
   LATERRE PF, 1996, INTENS CARE MED, V22, pS311
   LEIER CV, 1988, AM J CARDIOL, V62, pE86, DOI 10.1016/S0002-9149(88)80019-5
   LUND N, 1995, J TRAUMA, V38, P767, DOI 10.1097/00005373-199505000-00016
   MADORIN WS, 1996, INTENS CARE MED, V22, pS442
   MAYNARD ND, 1995, CHEST, V108, P1648, DOI 10.1378/chest.108.6.1648
   McGinley J, 1998, ANESTH ANALG, V86, pU68
   MULLER M, 1997, INTENS CARE MED, V23, pS85
   OMLAND T, 1993, EUR HEART J, V14, P1022, DOI 10.1093/eurheartj/14.8.1022
   PHELAN D, 1991, CLIN INTENSIVE CARE, V2, P37
   QUINTIN L, 1991, BRIT J ANAESTH, V66, P108, DOI 10.1093/bja/66.1.108
   Schmidt H, 1996, CRIT CARE MED, V24, P1233, DOI 10.1097/00003246-199607000-00028
   SHOEMAKER WC, 1988, CHEST, V94, P1176, DOI 10.1378/chest.94.6.1176
   Sinclair DG, 1997, INTENS CARE MED, V23, P510, DOI 10.1007/s001340050366
   SIVERSTEIN PR, 1979, ANESTHESIOLOGY, V50, P462
   Soong CV, 1997, CRIT CARE MED, V25, P1472, DOI 10.1097/00003246-199709000-00013
   Sutcliffe NP, 1996, ANAESTHESIA, V51, P37, DOI 10.1111/j.1365-2044.1996.tb07651.x
   TRINDER TJ, 1995, ANAESTH INTENS CARE, V23, P178
   WELCH M, 1995, ANN VASC SURG, V9, P488, DOI 10.1007/BF02143865
   WU X, 1997, BR J ANAESTH S, V78, P25
   YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0
NR 38
TC 5
Z9 5
U1 3
U2 9
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 1053-0770
EI 1532-8422
J9 J CARDIOTHOR VASC AN
JI J. Cardiothorac. Vasc. Anesth.
PD JUN
PY 2000
VL 14
IS 3
BP 281
EP 287
DI 10.1016/S1053-0770(00)90126-5
PG 7
WC Anesthesiology; Cardiac & Cardiovascular Systems; Respiratory System;
   Peripheral Vascular Disease
SC Anesthesiology; Cardiovascular System & Cardiology; Respiratory System
GA 325ZK
UT WOS:000087707000011
PM 10890482
DA 2018-12-27
ER

PT J
AU Canellos, GP
AF Canellos, GP
TI RETRACTED: The policing of clinical trials (Retracted Article. See vol
   19, pg 2973, 2001)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Editorial Material; Retracted Publication
ID HIGH-DOSE CHEMOTHERAPY; METASTATIC BREAST-CANCER; RANDOMIZED-TRIAL
CR BEZWODA WR, 1995, J CLIN ONCOL, V13, P2483, DOI 10.1200/JCO.1995.13.10.2483
   Rodenhuis S, 1998, LANCET, V352, P515, DOI 10.1016/S0140-6736(98)01350-6
   Stadtmauer EA, 2000, NEW ENGL J MED, V342, P1069, DOI 10.1056/NEJM200004133421501
   Weiss RB, 2000, LANCET, V355, P999, DOI 10.1016/S0140-6736(00)90024-2
NR 4
TC 5
Z9 5
U1 5
U2 10
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD JUN
PY 2000
VL 18
IS 12
BP 2353
EP 2353
DI 10.1200/JCO.2000.18.12.2353
PG 1
WC Oncology
SC Oncology
GA 325ZY
UT WOS:000087708300001
PM 10856093
DA 2018-12-27
ER

PT J
AU Santos, MS
   Barbosa, J
   Kushmerick, C
   Gomez, MV
   Prado, VF
   Prado, MAM
AF Santos, MS
   Barbosa, J
   Kushmerick, C
   Gomez, MV
   Prado, VF
   Prado, MAM
TI RETRACTED: Visualization and trafficking of the vesicular acetylcholine
   transporter in living cholinergic cells (Retracted article. See vol 75,
   pg 1332, 2000)
SO JOURNAL OF NEUROCHEMISTRY
LA English
DT Article; Retracted Publication
DE vesicular acetylcholine transporter; synaptic vesicle; endocytosis;
   cholinergic neurons; vesicular trafficking; synaptic proteins
ID CULTURED HIPPOCAMPAL-NEURONS; VESICLE TARGETING SIGNAL; SYNAPTIC
   VESICLE; MONOAMINE TRANSPORTER; AXONAL-TRANSPORT; SORTING SIGNALS;
   PLASMA-MEMBRANE; PC12 CELLS; SYNAPTOPHYSIN; LOCALIZATION
AB The present experiments investigated the trafficking of the vesicular acetylcholine transporter (VAChT) tagged with the enhanced green fluorescent protein (EGFP) in living cholinergic cells (SN56). The EGFP-VAChT chimera was located in endosomal-like compartments in the soma of SN56 cells, and it was also targeted to varicosities of neurites. In contrast, EGFP alone in cells was soluble in the cytoplasm. The C-terminal cytoplasmic tail of VAChT has been implicated in targeting of VAChT to synaptic vesicles; thus, we have examined the role of the C-terminal region in the trafficking to varicosities. A C-terminal fragment tagged with EGFP appeared to be selectively accumulated in varicosities when expressed in SN56 cells. Interestingly, the protein was not freely soluble in the cytosol, and it presented a punctate pattern of expression. However, EGFP-C terminus did not present this peculiar pattern of expression in a nonneuronal cell line (HEK 293). Moreover, the C-terminal region of VAChT did not seem to be essential for VAChT trafficking, as a construct that lacks the C-terminal tail was, similar to EGFP-VAChT, partially targeted to endocytic organelles in the soma and sorted to varicosities. These experiments visualize VAChT for the first time in living cells and suggest that there might be multiple signals that participate in trafficking of VAChT to sites of synaptic vesicle accumulation.
C1 Univ Fed Minas Gerais, ICB, Dept Farmacol, Lab Neurofarmacol, BR-31270901 Belo Horizonte, MG, Brazil.
   Univ Fed Minas Gerais, ICB, Dept Bioquim Imunol, BR-31270901 Belo Horizonte, MG, Brazil.
RP Prado, MAM (reprint author), Univ Fed Minas Gerais, ICB, Dept Farmacol, Lab Neurofarmacol, Av Antonio Carlos 6627, BR-31270901 Belo Horizonte, MG, Brazil.
RI Gomez, Marcus Vinicius/I-4081-2012; Kushmerick, Christopher/G-3578-2012
OI Prado, Marco Antonio Maximo/0000-0002-3028-5778; Prado,
   Vania/0000-0003-4994-6393
CR Barbosa J, 1997, J NEUROCHEM, V69, P2608
   Barbosa J, 1999, J NEUROCHEM, V73, P1881
   BLUSZTAJN JK, 1992, J NEUROSCI, V12, P793
   Bonifacino JS, 1999, J CELL BIOL, V145, P923, DOI 10.1083/jcb.145.5.923
   CAMERON PL, 1991, J CELL BIOL, V115, P151, DOI 10.1083/jcb.115.1.151
   Fon EA, 1997, NEURON, V19, P1271, DOI 10.1016/S0896-6273(00)80418-3
   Gilmor ML, 1996, J NEUROSCI, V16, P2179
   GLICKMAN JN, 1989, EMBO J, V8, P1041, DOI 10.1002/j.1460-2075.1989.tb03471.x
   GROTE E, 1995, CELL, V81, P581, DOI 10.1016/0092-8674(95)90079-9
   Grote E, 1996, J CELL BIOL, V132, P537, DOI 10.1083/jcb.132.4.537
   HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997
   HAMMOND DN, 1990, BRAIN RES, V512, P190, DOI 10.1016/0006-8993(90)90626-M
   Hannah MJ, 1999, ANNU REV CELL DEV BI, V15, P733, DOI 10.1146/annurev.cellbio.15.1.733
   JOHNSTON PA, 1989, EMBO J, V8, P2863, DOI 10.1002/j.1460-2075.1989.tb08434.x
   Krantz DE, 1997, J BIOL CHEM, V272, P6752, DOI 10.1074/jbc.272.10.6752
   Liu YJ, 1999, TRENDS CELL BIOL, V9, P356, DOI 10.1016/S0962-8924(99)01605-0
   Liu YJ, 1997, J CELL BIOL, V139, P907, DOI 10.1083/jcb.139.4.907
   Maletic-Savatic M, 1998, J NEUROSCI, V18, P6803
   Marks MS, 1996, J CELL BIOL, V135, P341, DOI 10.1083/jcb.135.2.341
   Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575
   Nakata T, 1998, J CELL BIOL, V140, P659, DOI 10.1083/jcb.140.3.659
   OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928
   OKADA Y, 1995, CELL, V81, P769, DOI 10.1016/0092-8674(95)90538-3
   Ray K, 1999, J CELL BIOL, V147, P507, DOI 10.1083/jcb.147.3.507
   REGNIERVIGOUROUX A, 1991, EMBO J, V10, P3589, DOI 10.1002/j.1460-2075.1991.tb04925.x
   Sambrook J., 1989, MOL CLONING LAB MANU
   SANGER F, 1977, P NATL ACAD SCI USA, V74, P463
   Song HJ, 1997, NEURON, V18, P815, DOI 10.1016/S0896-6273(00)80320-7
   Tan PK, 1998, J BIOL CHEM, V273, P17351, DOI 10.1074/jbc.273.28.17351
   Tao-Cheng J H, 1998, Adv Pharmacol, V42, P250
   Varoqui H, 1998, J BIOL CHEM, V273, P9094, DOI 10.1074/jbc.273.15.9094
   Wang YM, 1997, NEURON, V19, P1285, DOI 10.1016/S0896-6273(00)80419-5
   Weihe E, 1996, P NATL ACAD SCI USA, V93, P3547, DOI 10.1073/pnas.93.8.3547
   West AE, 1997, J CELL BIOL, V139, P917, DOI 10.1083/jcb.139.4.917
   Yelin R, 1998, J NEUROCHEM, V71, P2518
NR 35
TC 3
Z9 4
U1 2
U2 10
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0022-3042
J9 J NEUROCHEM
JI J. Neurochem.
PD JUN
PY 2000
VL 74
IS 6
BP 2425
EP 2435
DI 10.1046/j.1471-4159.2000.0742425.x
PG 11
WC Biochemistry & Molecular Biology; Neurosciences
SC Biochemistry & Molecular Biology; Neurosciences & Neurology
GA 312XG
UT WOS:000086968800022
PM 10820203
DA 2018-12-27
ER

PT J
AU Jorge-Rivera, JC
   McIntyre, KL
   Henderson, LP
AF Jorge-Rivera, JC
   McIntyre, KL
   Henderson, LP
TI RETRACTED: Anabolic steroids induce region- and subunit-specific rapid
   modulation of GABA(A) receptor-mediated currents in the rat forebrain
   (Retracted Article. See vol 98, pg 1841, 2007)
SO JOURNAL OF NEUROPHYSIOLOGY
LA English
DT Article; Retracted Publication
ID AMINOBUTYRIC ACID(A) RECEPTOR; BENZODIAZEPINE-RECEPTORS;
   HIPPOCAMPAL-NEURONS; SYNAPTIC INHIBITION; DESENSITIZED STATES; SEXUAL
   RECEPTIVITY; GAMMA-1 SUBUNIT; MINI AMPLITUDE; MESSENGER-RNAS;
   ESTROUS-CYCLE
AB Anabolic-androgenic steroids (AAS) have become significant drugs of abuse in recent years with the highest increase reported in adolescent girls. In spite of the increased use of AAS, the CNS effects of these steroids are poorly understood. We report that in prepubertal female rats, three commonly abused AAS, 17 alpha-methyltestosterone, stanozolol, and nandrolone, induced rapid and reversible modulation of GABAergic currents in neurons of two brain regions known to be critical for the expression of reproductive behaviors: the ventromedial nucleus of the hypothalamus (VMN) and the medial preoptic area (mPOA). All three AAS significantly enhanced peak synaptic current amplitudes and prolonged synaptic current decays in neurons of the VMN. Conversely all three AAS significantly diminished peak current amplitudes of synaptic currents from neurons of the mPOA. The endogenous neuroactive steroids, 3 alpha-hydroxy-5 alpha-pregnan-20-one and 5 alpha-androstane-3 alpha,17 beta-diol, potentiated currents in the VMN as did the AAS. In contrast to the negative modulation induced by AAS in the mPOA, the endogenous steroids potentiated responses in this region. To determine the concentration response relationships, modulation by the AAS, 17 alpha-methyltestosterone (17 alpha-meT), was assessed for currents evoked by ultrafast perfusion of brief pulses of GABA to acutely isolated neurons. Half-maximal effects on currents elicited by 1 mM GABA were elicited by submicromolar concentrations of AAS for neurons from both brain regions. In addition, the efficacy of 10(-5) to 10(-2) M GABA was significantly increased by 1 mM 17 alpha-meT. Previous studies have demonstrated a striking dichotomy in receptor composition between the VMN and the mPOA with regard to gamma subunit expression. To determine if the preferential expression of gamma(2) subunit-containing receptors in the VMN and of gamma(1) subunit-containing receptors in the mPOA could account for the region-specific effects of AAS in the two regions, responses elicited by ultrafast perfusion of GABA to human embryonic kidney 293 cells transfected with alpha(2), beta(3), and gamma(2) or alpha(2), beta(3), and gamma(1) subunit cDNAs were analyzed. As with native VMN neurons, positive modulation of GABA responses was elicited for alpha(2)beta(3)gamma(2) recombinant receptors, while negative modulation was induced at alpha(2)beta(3)gamma(1) receptors as in the mPOA. Our data demonstrate that AAS in doses believed to occur in steroid abusers can induce significant modulation of GABAergic transmission in brain regions essential for neuroendocrine function. In addition, the effects of these steroids can vary significantly between brain regions in a manner that appears to depend on the subunit composition of GABA(A) receptors expressed.
C1 Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Dept Physiol, Hanover, NH 03755 USA.
   Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Dept Biochem, Hanover, NH 03755 USA.
RP Henderson, LP (reprint author), Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Dept Physiol, Hanover, NH 03755 USA.
FU NINDS NIH HHS [NS-28668]
CR BAHKRE MS, 1998, CHILD ADOL PSYCH CL, V7, P821
   BITRAN D, 1993, HORM BEHAV, V27, P568, DOI 10.1006/hbeh.1993.1041
   Blasberg ME, 1997, PHYSIOL BEHAV, V61, P265, DOI 10.1016/S0031-9384(96)00409-X
   Blasberg ME, 1998, HORM BEHAV, V34, P283, DOI 10.1006/hbeh.1998.1484
   BORMANN J, 1988, P NATL ACAD SCI USA, V85, P9336, DOI 10.1073/pnas.85.23.9336
   Brickley SG, 1996, J PHYSIOL-LONDON, V497, P753, DOI 10.1113/jphysiol.1996.sp021806
   Bronson F. H., 1996, Physiology and Behavior, V59, P49, DOI 10.1016/0031-9384(95)02027-6
   Bronson FH, 1996, PHARMACOL BIOCHEM BE, V53, P329, DOI 10.1016/0091-3057(95)02030-6
   Brussaard AB, 1997, NEURON, V19, P1103, DOI 10.1016/S0896-6273(00)80401-8
   Chery N, 1999, J NEUROSCI, V19, P7342, DOI 10.1523/JNEUROSCI.19-17-07342.1999
   Clark AS, 1998, P ROY SOC B-BIOL SCI, V265, P1853, DOI 10.1098/rspb.1998.0512
   Clark AS, 1998, PHYSIOL BEHAV, V63, P287, DOI 10.1016/S0031-9384(97)00443-5
   Cooper EJ, 1999, J PHYSIOL-LONDON, V521, P437, DOI 10.1111/j.1469-7793.1999.00437.x
   Davies PA, 1997, NATURE, V385, P820, DOI 10.1038/385820a0
   Davis AM, 2000, DEV BRAIN RES, V119, P127, DOI 10.1016/S0165-3806(99)00150-9
   Franke WW, 1997, CLIN CHEM, V43, P1262
   FREEMAN ME, 1994, PHYSL REPRODUCTION, V2, P613
   FRERKING M, 1995, NEURON, V15, P885, DOI 10.1016/0896-6273(95)90179-5
   FRITSCHY JM, 1995, J COMP NEUROL, V359, P154, DOI 10.1002/cne.903590111
   Frye CA, 1996, BEHAV BRAIN RES, V79, P109, DOI 10.1016/0166-4328(96)00004-6
   HERBISON AE, 1995, J NEUROSCI, V15, P2328
   HICKSON RC, 1986, CLIN SPORT MED, V5, P461
   Hill MW, 1998, J NEUROSCI, V18, P5103
   Honour JW, 1997, CURR OPIN OBSTET GYN, V9, P181
   JOHNSON MD, 1990, PEDIATR CLIN N AM, V37, P1111
   Jonas Peter, 1995, P231
   JONES MV, 1995, NEURON, V15, P181, DOI 10.1016/0896-6273(95)90075-6
   KAMMERER R, 1993, ANABOLIC STEROIDS SP, P283
   Kochakian C.D., 1993, ANABOLIC STEROIDS SP, P3
   LAMBERT JJ, 1995, TRENDS PHARMACOL SCI, V16, P295, DOI 10.1016/S0165-6147(00)89058-6
   LAMBERT JJ, 1999, J PHYSL LOND, V518
   Lavoie AM, 1996, NEUROPHARMACOLOGY, V35, P1383, DOI 10.1016/S0028-3908(96)00077-9
   LESTER RAJ, 1992, J NEUROSCI, V12, P635
   Maitra R, 1998, CAN J PHYSIOL PHARM, V76, P909, DOI 10.1139/cjpp-76-9-909
   MAJEWSKA MD, 1987, INTEGRATIVE PSYCHIAT, V5, P258
   MASONIS AET, 1995, NEUROSCI LETT, V189, P35
   Masonis AET, 1996, J PHARMACOL EXP THER, V279, P186
   MCCARTHY MM, 1995, HORM BEHAV, V29, P131, DOI 10.1006/hbeh.1995.1010
   MODY I, 1994, TRENDS NEUROSCI, V17, P517, DOI 10.1016/0166-2236(94)90155-4
   Moss HB, 1992, AM J ADDICTION, V1, P315, DOI DOI 10.1111/J.1521-0391.1992.TB00357.X
   Nett ST, 1999, J NEUROPHYSIOL, V81, P192
   Nusser Z, 1997, NEURON, V19, P697, DOI 10.1016/S0896-6273(00)80382-7
   OJEDA SR, 1994, PHYSL REPRODUCTION, V2, P363
   PFAFF DW, 1994, PHYSL REPRODUCTION, V2, P107
   POPE HG, 1988, AM J PSYCHIAT, V145, P487
   PUIA G, 1993, RECEPTOR CHANNEL, V1, P135
   PUIA G, 1991, MOL PHARMACOL, V39, P691
   Rossi DJ, 1998, NEURON, V20, P783, DOI 10.1016/S0896-6273(00)81016-8
   ROVIRA C, 1993, J NEUROPHYSIOL, V70, P1076
   SATHER W, 1992, J PHYSIOL-LONDON, V450, P643, DOI 10.1113/jphysiol.1992.sp019148
   SIEGHART W, 1995, PHARMACOL REV, V47, P181
   SIGEL E, 1990, NEURON, V5, P703, DOI 10.1016/0896-6273(90)90224-4
   Smith ST, 1996, NEUROENDOCRINOLOGY, V64, P103, DOI 10.1159/000127105
   Stevenson A, 1995, MOL PHARMACOL, V48, P965
   STRAUSS RH, 1993, ANABOLIC STEROIDS SP, P151
   WAFFORD KA, 1993, MOL PHARMACOL, V44, P437
   Whiting PJ, 1997, J NEUROSCI, V17, P5027
   WISDEN W, 1992, J NEUROSCI, V12, P1040
   Wu FCW, 1997, CLIN CHEM, V43, P1289
   Yesalis CE, 1997, ARCH PEDIAT ADOL MED, V151, P1197, DOI 10.1001/archpedi.1997.02170490023005
   YMER S, 1990, EMBO J, V9, P3261, DOI 10.1002/j.1460-2075.1990.tb07525.x
   ZHANG P, 1991, COMPUT POLYMER SCI, V1, P3
   Zhu WJ, 1996, J NEUROSCI, V16, P6648
   Zhu WJ, 1997, J NEUROSCI, V17, P4022
NR 64
TC 44
Z9 44
U1 3
U2 13
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-3077
EI 1522-1598
J9 J NEUROPHYSIOL
JI J. Neurophysiol.
PD JUN
PY 2000
VL 83
IS 6
BP 3299
EP 3309
PG 11
WC Neurosciences; Physiology
SC Neurosciences & Neurology; Physiology
GA 323PK
UT WOS:000087574000011
PM 10848550
DA 2018-12-27
ER

PT J
AU Shin, SG
AF Shin, SG
TI RETRACTED: Experimental and simulation studies on grain growth in TiC-
   and WC-based cermets during liquid phase sintering (Retracted article.
   See vol. 24, pg. 433, 2018)
SO METALS AND MATERIALS INTERNATIONAL
LA English
DT Article; Retracted Publication
DE cemented carbides; cermets; tungsten carbide; titanium carbide; grain
   growth; simulation; Monte Carlo method; liquid phase sintering; Ostwald
   ripening
ID COMPUTER-SIMULATION; VOLUME FRACTION; KINETICS
AB The grain growth behaviors of TiC and WC particles in TiC-Ni, TiC-Mo2C-Ni, WC-Co and WC-VC-Co alloys during liquid phase sintering were investigated for different Ni or Co contents and compared with the results of Monte Carlo simulations. in the experimental study, TiC-Ni and WC-Co alloys had a maximum grain size at a certain liquid volume fraction, while the grain size in TiC-Mo2C-Ni and WC-VC-Co alloys increased monotonically with an increasing liquid volume fraction. These results mean that the grain growth of these alloys cannot be explained by the conventional mechanisms for Ostwald ripening, namely diffusion or reaction controlled processes. Monte Carlo simulations with different energy relationships between solid-liquid interfaces predicted the effect of the liquid volume fraction on grain size similar to the experimental results, The contiguous boundaries between solid (carbide) particles appear to influence the grain growth behavior in TiC- and WC-based alloys during liquid phase sintering.
C1 Japan Fine Ceram Ctr, R&D Lab, Atsuta Ku, Nagoya, Aichi 4568587, Japan.
RP Shin, SG (reprint author), Japan Fine Ceram Ctr, R&D Lab, Atsuta Ku, 2-4-1 Mutsuno, Nagoya, Aichi 4568587, Japan.
CR ANDERSON MP, 1984, ACTA METALL MATER, V32, P783, DOI 10.1016/0001-6160(84)90151-2
   ARDELL AJ, 1972, ACTA METALL MATER, V20, P61, DOI 10.1016/0001-6160(72)90114-9
   CHEN IW, 1990, J AM CERAM SOC, V73, P2865, DOI 10.1111/j.1151-2916.1990.tb06687.x
   DOI H, 1984, SCI HARD MATERIALS, P312
   EXNER HE, 1983, SCI HARD MAT, P233
   GERMAN RM, 1985, LIQUID PHASE SINTERI, P223
   GREENWOOD GW, 1956, ACTA METALL MATER, V4, P243, DOI 10.1016/0001-6160(56)90060-8
   GREST GS, 1985, ACTA METALL MATER, V33, P509, DOI 10.1016/0001-6160(85)90093-8
   HASSOLD GN, 1990, J AM CERAM SOC, V73, P2857, DOI 10.1111/j.1151-2916.1990.tb06686.x
   HUMENIK M, 1956, J AM CERAM SOC, V39, P60, DOI 10.1111/j.1151-2916.1956.tb15624.x
   LIFSHITZ IM, 1961, J PHYS CHEM SOLIDS, V19, P35, DOI 10.1016/0022-3697(61)90054-3
   LINDAU L, 1976, POWDER METALL, V19, P210, DOI 10.1179/pom.1976.19.4.210
   MATSUBARA H, 1991, MATER T JIM, V32, P951, DOI 10.2320/matertrans1989.32.951
   MATSUBARA H, 1997, P 6 INT S MET COMP E, P654
   MATSUBARA H, 1996, CERAM T, V71, P403
   Moskowitz D., 1966, MODERN DEV POWDER ME, V3, P83
   Okamoto Y, 1999, J CERAM SOC JPN, V107, P109, DOI 10.2109/jcersj.107.109
   PARIKH NM, 1957, J AM CERAM SOC, V40, P457
   PETZOW G, 1985, ACTA METALL, V33, P509
   SARIAN S, 1966, J APPL PHYS, V37, P1675, DOI 10.1063/1.1708583
   SHIN SG, 1996, SINTERING TECHNOLOGY, P157
   Snell P.-O., 1974, Planseeberichte fur Pulvermetallurgie, V22, P91
   STOVER ER, 1959, T AM I MIN MET ENG, V215, P127
   SUZUKI H, 1971, J JPN I MET, V35, P146
   Tajika M, 1997, J CERAM SOC JPN, V105, P928, DOI 10.2109/jcersj.105.928
   VOORHEES PW, 1984, METALL TRANS A, V15, P1081, DOI 10.1007/BF02644701
   WAGNER C, 1961, Z ELEKTROCHEM, V65, P581
   WARREN R, 1972, POWDER METALL, V15, P166, DOI 10.1179/pom.1972.15.30.005
NR 28
TC 20
Z9 20
U1 2
U2 11
PU KOREAN INST METALS MATERIALS
PI SEOUL
PA KIM BLDG 6TH FLOOR, SEOCHO-DAERO 56 GIL 38, SEOCHO-GU, SEOUL 137-881,
   SOUTH KOREA
SN 1598-9623
EI 2005-4149
J9 MET MATER INT
JI Met. Mater.-Int.
PD JUN
PY 2000
VL 6
IS 3
BP 195
EP 201
DI 10.1007/BF03028212
PG 7
WC Materials Science, Multidisciplinary; Metallurgy & Metallurgical
   Engineering
SC Materials Science; Metallurgy & Metallurgical Engineering
GA 331HD
UT WOS:000088012000004
DA 2018-12-27
ER

PT J
AU Tanaka, K
   Matsumoto, Y
   Nakatani, F
   Iwamoto, Y
   Yamada, Y
AF Tanaka, K
   Matsumoto, Y
   Nakatani, F
   Iwamoto, Y
   Yamada, Y
TI RETRACTED: A zinc finger transcription factor, alpha A-crystallin
   binding protein 1, is a negative regulator of the chondrocyte-specific
   enhancer of the alpha 1(II) collagen gene (Retracted Article)
SO MOLECULAR AND CELLULAR BIOLOGY
LA English
DT Article; Retracted Publication
ID MAJOR HISTOCOMPATIBILITY COMPLEX; AUTOSOMAL SEX REVERSAL; SRY-RELATED
   GENE; II COLLAGEN; CAMPOMELIC DYSPLASIA; FACTOR PRDII-BF1; CELL-LINE;
   MOUSE; SOX9; EXPRESSION
AB Transcription of the type II collagen gene (Col2a1) is regulated by multiple cis-acting sites, The enhancer element, which is located in the first intron, is necessary for high-level and cartilage-specific expression of Col2a1. A mouse limb bud cDNA expression library was screened by the Saccharomyces cerevisiae one hybrid screening method to identify protein factors bound to the enhancer. A zinc finger protein, alpha A-crystallin binding protein 1 (CRYBP1), which had been reported to bind to the mouse alpha A-crystallin gene promoter, was isolated. We herein demonstrate that CRYBP1 is involved in the negative regulation of Col2a1 enhancer activity, CRYBP1 mRNA expression was downregulated during chondrocyte differentiation in vitro. In situ hybridization analysis of developing mouse cartilage showed that CRYBP1 mRNA was also downregulated during mesenchymal condensation and that CRYBP1 mRNA was highly expressed by hypertrophic chondrocytes, but at very low levels by resting and proliferating chondrocytes, Expression of recombinant CRYBP1 in a transfected rat chondrosarcoma cell line inhibited Col2a1 enhancer activity. Electrophoretic mobility shift assays showed that CRYBP1 bound a specific sequence within the Col2a1 enhancer and inhibited the binding of Sox9, an activator for Col2a1, to the enhancer. Cotransfection of CRYBP1 with Sox9 into BALB/c 3T3 cells inhibited activation of the Col2a1 enhancer by Sox9. These results suggest a novel mechanism that negatively regulates cartilage-specific expression of Col2a1.
C1 NIDCR, Craniofacial Dev Biol & Regenerat Branch, NIH, Bethesda, MD 20892 USA.
   Kyushu Univ, Grad Sch Med Sci, Dept Orthopaed Surg, Fukuoka 8128582, Japan.
RP Yamada, Y (reprint author), NIDCR, Craniofacial Dev Biol & Regenerat Branch, NIH, Bldg 30,Room 405, Bethesda, MD 20892 USA.
EM yoshi.yamada@nih.gov
RI Matsumoto, Yoichiro/M-4093-2014
CR Arnosti DN, 1996, DEVELOPMENT, V122, P205
   ARORA K, 1995, CELL, V81, P781, DOI 10.1016/0092-8674(95)90539-1
   BALDWIN AS, 1990, MOL CELL BIOL, V10, P1406, DOI 10.1128/MCB.10.4.1406
   Basson M, 1996, GENE DEV, V10, P1953, DOI 10.1101/gad.10.15.1953
   Bell DM, 1997, NAT GENET, V16, P174, DOI 10.1038/ng0697-174
   Bi WM, 1999, NAT GENET, V22, P85
   BRADY JP, 1995, J BIOL CHEM, V270, P1221, DOI 10.1074/jbc.270.3.1221
   Chamberlin HM, 1999, GENETICS, V153, P731
   CHEAH KSE, 1991, DEVELOPMENT, V111, P945
   FAN CM, 1990, GENE DEV, V4, P29, DOI 10.1101/gad.4.1.29
   FOSTER JW, 1994, NATURE, V372, P525, DOI 10.1038/372525a0
   GENETTA T, 1994, MOL CELL BIOL, V14, P6153, DOI 10.1128/MCB.14.9.6153
   GRAY S, 1994, GENE DEV, V8, P1829, DOI 10.1101/gad.8.15.1829
   Gray S, 1996, CURR OPIN CELL BIOL, V8, P358
   GRIEDER NC, 1995, CELL, V81, P791, DOI 10.1016/0092-8674(95)90540-5
   HARLEY VR, 1994, NUCLEIC ACIDS RES, V22, P1500, DOI 10.1093/nar/22.8.1500
   Henderson KD, 1999, DEV BIOL, V205, P10, DOI 10.1006/dbio.1998.9113
   HIROTA S, 1992, MOL BRAIN RES, V15, P47, DOI 10.1016/0169-328X(92)90150-A
   IP YT, 1992, GENE DEV, V6, P1728, DOI 10.1101/gad.6.9.1728
   JOHNSON AD, 1995, CELL, V81, P655, DOI 10.1016/0092-8674(95)90524-3
   KAMACHI Y, 1993, MOL CELL BIOL, V13, P5206, DOI 10.1128/MCB.13.9.5206
   KANTOROW M, 1993, GENE, V131, P159, DOI 10.1016/0378-1119(93)90289-F
   Krebsbach PH, 1996, J BIOL CHEM, V271, P4298
   Kuivaniemi H, 1997, HUM MUTAT, V9, P300, DOI 10.1002/(SICI)1098-1004(1997)9:4<300::AID-HUMU2>3.0.CO;2-9
   Lefebvre V, 1998, EMBO J, V17, P5718, DOI 10.1093/emboj/17.19.5718
   Lefebvre V, 1997, MOL CELL BIOL, V17, P2336, DOI 10.1128/MCB.17.4.2336
   LI JJ, 1993, SCIENCE, V262, P1870, DOI 10.1126/science.8266075
   MAEKAWA T, 1989, J BIOL CHEM, V264, P14591
   METSARANTA M, 1991, J BIOL CHEM, V266, P16862
   MITCHELMORE C, 1991, NUCLEIC ACIDS RES, V19, P141, DOI 10.1093/nar/19.1.141
   MUCHARDT C, 1992, J VIROL, V66, P244
   MUKHOPADHYAY K, 1995, J BIOL CHEM, V270, P27711, DOI 10.1074/jbc.270.46.27711
   NAKAMURA T, 1990, MOL CELL BIOL, V10, P3700, DOI 10.1128/MCB.10.7.3700
   Ng LJ, 1997, DEV BIOL, V183, P108, DOI 10.1006/dbio.1996.8487
   RAHUEL C, 1992, EMBO J, V11, P4095, DOI 10.1002/j.1460-2075.1992.tb05502.x
   Sambrook J, 1989, MOL CLONING LAB MANU
   SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712
   SEELER JS, 1994, J VIROL, V68, P1002
   Shukunami C, 1996, J CELL BIOL, V133, P457, DOI 10.1083/jcb.133.2.457
   SIMON AM, 1993, MOL CELL BIOL, V13, P5133, DOI 10.1128/MCB.13.9.5133
   STAEHLINGHAMPTON K, 1995, DEVELOPMENT, V121, P3393
   WAGNER T, 1994, CELL, V79, P1111, DOI 10.1016/0092-8674(94)90041-8
   WANG MM, 1993, NATURE, V364, P121, DOI 10.1038/364121a0
   Wirth J, 1996, HUM GENET, V97, P186, DOI 10.1007/BF02265263
   WRIGHT E, 1995, NAT GENET, V9, P15, DOI 10.1038/ng0195-15
   WRIGHT EM, 1993, NUCLEIC ACIDS RES, V21, P744, DOI 10.1093/nar/21.3.744
   Zhao Q, 1997, DEV DYNAM, V209, P377, DOI 10.1002/(SICI)1097-0177(199708)209:4<377::AID-AJA5>3.0.CO;2-F
   Zhou G, 1998, J BIOL CHEM, V273, P14989, DOI 10.1074/jbc.273.24.14989
NR 48
TC 51
Z9 54
U1 3
U2 13
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0270-7306
EI 1098-5549
J9 MOL CELL BIOL
JI Mol. Cell. Biol.
PD JUN
PY 2000
VL 20
IS 12
BP 4428
EP 4435
DI 10.1128/MCB.20.12.4428-4435.2000
PG 8
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 318NF
UT WOS:000087289700024
PM 10825206
OA Bronze
DA 2018-12-27
ER

PT J
AU Romagni, JG
   Duke, SO
   Dayan, FE
AF Romagni, JG
   Duke, SO
   Dayan, FE
TI RETRACTED: Inhibition of plant asparagine synthetase-by monoterpene
   cineoles (Retracted Article. See vol 137, pg 1487, 2005)
SO PLANT PHYSIOLOGY
LA English
DT Article; Retracted Publication
ID ARABIDOPSIS-THALIANA; CINMETHYLIN; HERBICIDES; CONSTITUENTS; ACTIVATION;
   EXPRESSION; GROWTH; LEAVES; OIL
AB Asparagine (Asn) synthetase (AS) is the key enzyme in Asn biosynthesis and plays an important role in nitrogen mobilization. Despite its important physiological function, little research has been done documenting inhibitors of plant AS. Plant growth inhibition caused by the natural monoterpene 1,4-cineole and its structurally related herbicide cinmethylin was reversed 65% and 55%, respectively, by providing 100 mu M Asn exogenously. Reversion of the phytotoxic effect was dependent on the concentration of Asn. The presence of either 1,4-cineole or cinmethylin stimulated root uptake of [C-14]Asn by lettuce (Lactuca sativa) seedlings. Although the physiological responses suggested that both compounds affected Asn biosynthesis, biochemical analysis of AS activity showed that the natural monoterpene was a potent inhibitor (I-50 = approximately 0.5 mu M) of the enzyme, whereas the commercial product was not inhibitory up to levels of 10 mM. Analysis of the putative metabolite, 2-hydroxy-1,4-cineole, showed that the cis-enantiomer was much more active than the trans-enantiomer, suggesting that the hydroxyl group was involved in the specific ligand/active site interaction. This is the first report that AS is a suitable herbicide target site, and that cinmethylin is apparently a proherbicide that requires metabolic bioactivation via cleavage of the benzyl-ether side chain.
C1 USDA, Agr Res Serv, Nat Prod Utilizat Res Unit, University, MS 38677 USA.
RP Dayan, FE (reprint author), USDA, Agr Res Serv, Nat Prod Utilizat Res Unit, POB 8048, University, MS 38677 USA.
EM fdayan@ag.gov
RI Dayan, Franck/A-7592-2009
OI Dayan, Franck/0000-0001-6964-2499
CR AHMAD A, 1994, PHYTOCHEMISTRY, V37, P183, DOI 10.1016/0031-9422(94)85021-6
   AMAGASA T, 1994, PESTIC BIOCHEM PHYS, V49, P37, DOI 10.1006/pest.1994.1032
   ANDRULIS IL, 1987, MOL CELL BIOL, V7, P2435, DOI 10.1128/MCB.7.7.2435
   ASPLUND RO, 1968, PHYTOCHEMISTRY, V7, P1995, DOI 10.1016/S0031-9422(00)90758-1
   Baum SF, 1998, J PLANT GROWTH REGUL, V17, P107, DOI 10.1007/PL00007015
   BIRCH AJ, 1959, TETRAHEDRON LETT, P1
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   COONEY DA, 1976, CANCER TREAT REP, V60, P1493
   Dayan F., 1999, Pesticide Outlook, V10, P185
   Dembinski E, 1996, PHYSIOL PLANTARUM, V96, P66
   Devine M, 1993, PHYSL HERBICIDE ACTI
   DITOMASO JM, 1991, PESTIC BIOCH PHYSL, V39, P402
   DUKE SO, 1995, ACS SYM SER, V582, P348
   GRAYSON BT, 1987, PESTIC SCI, V21, P143, DOI 10.1002/ps.2780210207
   HAAGENSMIT JJ, 1958, ENCY PLATN PHYSL, V10, P52
   HALLIGAN JP, 1975, ECOLOGY, V56, P999, DOI 10.2307/1936312
   HEISEY RM, 1984, AM J BOT, V71, P821, DOI 10.2307/2443473
   HOGG JW, 1974, PHYTOCHEMISTRY, V13, P868, DOI 10.1016/S0031-9422(00)91156-7
   IRELAND RJ, 1999, PLANT AMINO ACIDS BI, P78
   JOY KW, 1983, PLANT PHYSIOL, V73, P165, DOI 10.1104/pp.73.1.165
   KUMAR N, 1986, PHYTOCHEMISTRY, V3, P663
   LAM HM, 1994, PLANT PHYSIOL, V106, P1347, DOI 10.1104/pp.106.4.1347
   LEA PJ, 1978, PHYTOCHEMISTRY, V17, P217, DOI 10.1016/S0031-9422(00)94149-9
   LEE PW, 1986, J AGR FOOD CHEM, V34, P162, DOI 10.1021/jf00068a003
   MANNS D, 1995, PHYTOCHEMISTRY, V39, P1115, DOI 10.1016/0031-9422(95)00108-J
   MULLER CH, 1964, SCIENCE, V143, P471, DOI 10.1126/science.143.3605.471
   MULLER WALTER H., 1964, BULL TORREY BOT CLUB, V91, P327, DOI 10.2307/2483297
   MULLER WH, 1965, BOT GAZ, V126, P195, DOI 10.1086/336319
   NAVES YR, 1950, MEM SOC CHIM, P673
   ORIHARA Y, 1994, PHYTOCHEMISTRY, V35, P641, DOI 10.1016/S0031-9422(00)90578-8
   RAMOS F, 1979, EUR J BIOCHEM, V94, P409, DOI 10.1111/j.1432-1033.1979.tb12908.x
   REITZER LJ, 1983, BIOTECHNOLOGY, V3, P133
   Richards NGJ, 1998, ADV ENZYMOL RAMB, V72, P145
   ROGNES SE, 1975, PHYTOCHEMISTRY, V14, P1975, DOI 10.1016/0031-9422(75)83108-6
   ROGNES SE, 1980, PHYTOCHEMISTRY, V19, P2287, DOI 10.1016/S0031-9422(00)91013-6
   Romagni JG, 2000, J CHEM ECOL, V26, P303, DOI 10.1023/A:1005414216848
   ROMAGNI JG, 2000, IN PRESS J AGR FOOD
   RUSSELL SG, 1991, WEED SCI, V39, P402
   SIECIECHOWICZ KA, 1988, PHYTOCHEMISTRY, V27, P663, DOI 10.1016/0031-9422(88)84071-8
   SINGH BK, 1995, PESTIC SCI, V43, P221, DOI 10.1002/ps.2780430307
   TSAI FY, 1990, EMBO J, V9, P323, DOI 10.1002/j.1460-2075.1990.tb08114.x
   VAUGHN SF, 1993, WEED SCI, V41, P114
   Vaughn SF, 1996, WEED SCI, V44, P7
NR 43
TC 62
Z9 68
U1 2
U2 10
PU AMER SOC PLANT BIOLOGISTS
PI ROCKVILLE
PA 15501 MONONA DRIVE, ROCKVILLE, MD 20855 USA
SN 0032-0889
EI 1532-2548
J9 PLANT PHYSIOL
JI Plant Physiol.
PD JUN
PY 2000
VL 123
IS 2
BP 725
EP 732
DI 10.1104/pp.123.2.725
PG 8
WC Plant Sciences
SC Plant Sciences
GA 325FX
UT WOS:000087666500031
PM 10859202
OA Bronze
DA 2018-12-27
ER

PT J
AU Yung, YV
   Yao, Z
   Hanoch, T
   Seger, R
AF Yung, YV
   Yao, Z
   Hanoch, T
   Seger, R
TI RETRACTED: ERK1b, a 46-kDa ERK isoform that is differentially regulated
   by MEK (Retracted article. See vol. 292, pg. 8854, 2017)
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article; Retracted Publication
ID ACTIVATED PROTEIN-KINASE; MAP KINASE; SIGNAL-TRANSDUCTION; NUCLEAR
   TRANSLOCATION; TYROSINE-PHOSPHATASE; NIH 3T3-CELLS; PC12 CELLS;
   PHOSPHORYLATION; EXPRESSION; IDENTIFICATION
AB We identified a 46-kDa ERK, whose kinetics of activation was similar to that of ERK1 and ERK2 in most cell lines and conditions, but showed higher fold activation in response to osmotic shock and epidermal growth factor treatments of Ras-transformed cells. We purified and cloned this novel ERK (ERK1b), which is an alternatively spliced form of ERK1 with a 26-amino acid insertion between residues 340 and 341 of ERK1. When expressed in COS7 cells, ERK1b exhibited kinetics of activation and kinase activity similar to those of ERK1. Unlike the uniform pattern of expression of ERK1 and ERK2, ERK1b was detected only in some of the tissues examined and seems to be abundant in the rat and human heart. Interestingly, in has-transformed Rat1 cells, there was a 7-fold higher expression of ERK1b, which was also more responsive than ERK1 and ERK2 to various extracellular treatments. Unlike ERK1 and ERK2, ERK1b failed to interact with MEK1 as judged from its nuclear localization in resting cells overexpressing ERK1b together with MEK1 or by lack of coimmunoprecipitation of the two proteins. Thus, ERK1b is a novel 46-kDa ERK isoform, which seems to be the major ERK isoform that responds to exogenous stimulation in Ras-transformed cells probably due to its differential regulation by MEK.
C1 Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel.
RP Seger, R (reprint author), Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel.
EM bmseger@weizmann.weizmann.ac.il
CR ALESSI DR, 1995, CURR BIOL, V5, P283, DOI 10.1016/S0960-9822(95)00059-5
   Berman DE, 1998, J NEUROSCI, V18, P10037
   BOULTON TG, 1991, CELL REGUL, V2, P357
   BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J
   Camps M, 1998, SCIENCE, V280, P1262, DOI 10.1126/science.280.5367.1262
   Canagarajah BJ, 1997, CELL, V90, P859, DOI 10.1016/S0092-8674(00)80351-7
   CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915
   Cobb MH, 1999, PROG BIOPHYS MOL BIO, V71, P479, DOI 10.1016/S0079-6107(98)00056-X
   COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3
   ENGLISH JM, 1995, J BIOL CHEM, V270, P28897, DOI 10.1074/jbc.270.48.28897
   ERIKSON RL, 1991, J BIOL CHEM, V266, P6007
   Fukuda M, 1997, J BIOL CHEM, V272, P32642, DOI 10.1074/jbc.272.51.32642
   Fukuda M, 1997, EMBO J, V16, P1901, DOI 10.1093/emboj/16.8.1901
   Fukunaga R, 1997, EMBO J, V16, P1921, DOI 10.1093/emboj/16.8.1921
   GOBERT S, 1995, EUR J BIOCHEM, V234, P75, DOI 10.1111/j.1432-1033.1995.075_c.x
   GONZALEZ FA, 1992, FEBS LETT, V304, P170, DOI 10.1016/0014-5793(92)80612-K
   Gopalbhai K, 1998, J CELL PHYSIOL, V174, P35, DOI 10.1002/(SICI)1097-4652(199801)174:1<35::AID-JCP5>3.0.CO;2-H
   Gotoh I, 1999, J BIOL CHEM, V274, P11874, DOI 10.1074/jbc.274.17.11874
   Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x
   Jaaro H, 1997, P NATL ACAD SCI USA, V94, P3742, DOI 10.1073/pnas.94.8.3742
   JUCKER M, 1992, ONCOGENE, V7, P943
   Kanopka A, 1998, NATURE, V393, P185
   Keyse SM, 1998, SEMIN CELL DEV BIOL, V9, P143, DOI 10.1006/scdb.1997.0219
   Khokhlatchev AV, 1998, CELL, V93, P605, DOI 10.1016/S0092-8674(00)81189-7
   Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4
   LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E
   MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K
   MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8
   Michael D, 1998, P NATL ACAD SCI USA, V95, P1864, DOI 10.1073/pnas.95.4.1864
   Misteli T, 1999, CURR BIOL, V9, pR198, DOI 10.1016/S0960-9822(99)80128-6
   PAGES G, 1995, J BIOL CHEM, V270, P26986, DOI 10.1074/jbc.270.45.26986
   PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x
   Peng X, 1996, J NEUROCHEM, V66, P1191
   RESZKA AA, 1995, P NATL ACAD SCI USA, V92, P8881, DOI 10.1073/pnas.92.19.8881
   Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0
   Rong X, 1996, IMMUNOL LETT, V54, P105, DOI 10.1016/S0165-2478(96)02657-0
   Rubinfeld H, 1999, J BIOL CHEM, V274, P30349, DOI 10.1074/jbc.274.43.30349
   Sadot E, 1998, J NEUROCHEM, V70, P428
   Salh B, 1999, ANTICANCER RES, V19, P731
   Schaeffer HJ, 1998, SCIENCE, V281, P1668, DOI 10.1126/science.281.5383.1668
   SEGER R, 1994, J BIOL CHEM, V269, P25699
   SEGER R, 1992, J BIOL CHEM, V267, P25628
   SEGER R, 1995, FASEB J, V9, P726
   SEGER R, 1992, J BIOL CHEM, V267, P14373
   Silverman MA, 1999, J BIOL CHEM, V274, P2631, DOI 10.1074/jbc.274.5.2631
   SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2
   Tolwinski NS, 1999, J BIOL CHEM, V274, P6168, DOI 10.1074/jbc.274.10.6168
   Tournier C, 1999, MOL CELL BIOL, V19, P1569
   Wang J, 1997, CURR OPIN GENET DEV, V7, P205, DOI 10.1016/S0959-437X(97)80130-X
   Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909
   Widmann C, 1999, PHYSIOL REV, V79, P143
   WU J, 1994, FEBS LETT, V353, P9, DOI 10.1016/0014-5793(94)01000-5
   Yung Y, 1997, FEBS LETT, V408, P292, DOI 10.1016/S0014-5793(97)00442-0
   ZHENG CF, 1993, J BIOL CHEM, V268, P23933
NR 54
TC 60
Z9 63
U1 2
U2 6
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD MAY 26
PY 2000
VL 275
IS 21
BP 15799
EP 15808
DI 10.1074/jbc.M910060199
PG 10
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 318NX
UT WOS:000087291400028
PM 10748187
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU de Pomerai, D
   Daniells, C
   David, H
   Allan, J
   Duce, I
   Mutwakil, M
   Thomas, D
   Sewell, P
   Tattersall, J
   Jones, D
   Candido, P
AF de Pomerai, D
   Daniells, C
   David, H
   Allan, J
   Duce, I
   Mutwakil, M
   Thomas, D
   Sewell, P
   Tattersall, J
   Jones, D
   Candido, P
TI RETRACTED: Cell biology - Non-thermal heat-shock response to microwaves
   (Retracted Article. See vol 440, pg 437, 2006)
SO NATURE
LA English
DT Article; Retracted Publication
ID CAENORHABDITIS-ELEGANS; NEMATODE; STRESS
C1 Univ Nottingham, Sch Biol Sci, Mol Toxicol Div, Nottingham NG7 2RD, England.
   Univ Nottingham, Sch Elect & Elect Engn, Nottingham NG7 2RD, England.
   Med Countermeasures, Salisbury SP4 0JQ, Wilts, England.
   Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada.
RP de Pomerai, D (reprint author), Univ Nottingham, Sch Biol Sci, Mol Toxicol Div, Nottingham NG7 2RD, England.
CR *ANSI IEEE, 1992, C9511992 ANSI IEEE
   CANDIDO E, 1996, TRENDS BIOTECHNOL, V40, P125
   Daniells C, 1998, MUTAT RES-FUND MOL M, V399, P55, DOI 10.1016/S0027-5107(97)00266-2
   Dennis JL, 1997, AQUAT TOXICOL, V40, P37, DOI 10.1016/S0166-445X(97)00043-X
   Gandhi OP, 1996, IEEE T MICROW THEORY, V44, P1884, DOI 10.1109/22.539947
   Jewitt N, 1999, ENZYME MICROB TECH, V25, P349, DOI 10.1016/S0141-0229(99)00052-6
   Nishizawa J, 1999, CIRCULATION, V99, P934, DOI 10.1161/01.CIR.99.7.934
   PARSELL DA, 1993, ANNU REV GENET, V27, P437, DOI 10.1146/annurev.ge.27.120193.002253
   SNUTCH TP, 1983, CAN J BIOCHEM CELL B, V61, P480, DOI 10.1139/o83-064
   WILLIAMS PL, 1990, ENVIRON TOXICOL CHEM, V9, P1285, DOI 10.1897/1552-8618(1990)9[1285:ATTUTN]2.0.CO;2
NR 10
TC 144
Z9 150
U1 3
U2 31
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
J9 NATURE
JI Nature
PD MAY 25
PY 2000
VL 405
IS 6785
BP 417
EP 418
DI 10.1038/35013144
PG 2
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 317DX
UT WOS:000087212000036
PM 10839528
DA 2018-12-27
ER

PT J
AU Barbaro, G
   Di Lorenzo, G
   Soldini, M
   Giancaspro, G
   Grisorio, B
   Pellicelli, AM
   D'Amati, G
   Barbarini, G
AF Barbaro, G
   Di Lorenzo, G
   Soldini, M
   Giancaspro, G
   Grisorio, B
   Pellicelli, AM
   D'Amati, G
   Barbarini, G
CA GISCA
TI RETRACTED: Clinical course of cardiomyopathy in HIV-infected patients
   with or without encephalopathy related to the myocardial expression of
   tumour necrosis factor-alpha and nitric oxide synthase (Retracted
   Article. See vol 18, pg 1087, 2004)
SO AIDS
LA English
DT Article; Retracted Publication
DE HIV; encephalopathy; dilated cardiomyopathy; tumour necrosis
   factor-alpha; inducible nitric oxide synthase
ID HUMAN-IMMUNODEFICIENCY-VIRUS; POLYMERASE-CHAIN-REACTION; DILATED
   CARDIOMYOPATHY; CEREBROSPINAL-FLUID; NEUROLOGIC MANIFESTATIONS; POSITIVE
   PATIENTS; CYTOKINES; HEART; INDUCTION; CHILDREN
AB Objective: To define whether the development of encephalopathy influences the clinical course of HIV-associated cardiomyopathy (HIV-DCM) in relation to the myocardial expression of tumour necrosis factor-alpha (TNF-alpha) and inducible nitric oxide synthase (iNOS).
   Design: Prospective study.
   Setting: University hospitals and AIDS centres.
   Methods: 115 HIV-infected patients with echocardiographic diagnosis of HIV-associated cardiomyopathy (34 with encephalopathy and 81 without encephalopathy) were followed for a mean of 24 +/- 3.2 months. All patients underwent endomyocardial biopsy for determination of myocardial immunostaining intensity of TNF-alpha and iNOS. Cerebrospinal fluid (CSF) from patients with encephalopathy was examined for the presence of viruses. Patients underwent clinical examination every 3 months and echocardiographic examination every 6 months. The intensity of TNF-alpha and iNOS immunostaining was also evaluated on postmortem cerebral tissue of patients who died of congestive heart failure (CHF).
   Results: A greater impairment of echocardiographic parameters was observed in patients with HIV-associated cardiomyopathy after development of encephalopathy. These parameters tended to worsen progressively during the follow-up period and were inversely correlated with HIV-1 viral load, CD4 cell count, mini mental status score and the intensity of myocardial and cerebral TNF-alpha and iNOS staining. CSF specimens were available in 29 patients with encephalopathy. HIV-1 sequences were detected in CSF of all these patients with cytomegalovirus sequences in two. The mortality rate for CHF was greater among patients with encephalopathy (73% versus 12%).
   Conclusions: The development of encephalopathy has an adverse effect on the clinical course of HIV-associated cardiomyopathy. In the relationship between cardiomyopathy and encephalopathy, the activation of iNOS by TNF-alpha may have a significant pathogenetic role in HIV disease. (C) 2000 Lippincott Williams & Wilkins.
C1 Univ Roma La Sapienza, Dept Emergency Med, Rome, Italy.
   Univ Roma La Sapienza, Dept Expt Med & Pathol, Rome, Italy.
   Spallanzani Hosp, Div Infect Dis 2, Rome, Italy.
   Gen Hosp, Div Infect Dis, Foggia, Italy.
   Univ Pavia, Policlin San Matteo, Dept Infect & Trop Med, I-27100 Pavia, Italy.
RP Barbaro, G (reprint author), Viale Anicio Gallo 63, I-00174 Rome, Italy.
RI Soldini, Maurizio/F-9433-2012
CR Adamson DC, 1999, MOL MED, V5, P98, DOI 10.1007/BF03402144
   ARETZ HT, 1987, HUM PATHOL, V18, P619
   Armitage P., 1994, STAT METHODS MED RES
   Barbaro G, 1997, SCAND J GASTROENTERO, V32, P1261, DOI 10.3109/00365529709028157
   Barbaro G, 1998, AIDS RES HUM RETROV, V14, P1071, DOI 10.1089/aid.1998.14.1071
   Barbaro G, 1998, NEW ENGL J MED, V339, P1093, DOI 10.1056/NEJM199810153391601
   Barbaro G, 1999, EUR HEART J, V20, P629
   BARBARO G, 1999, AIDS HIV INFEKTIONEN, V4, P1
   BARBARO G, 1999, CIRCULATION, V100, P633
   BESCHORNER WE, 1990, AM J PATHOL, V137, P1365
   Boller AM, 1998, CARDIOLOGY IN AIDS, P77
   BUKRINSKY MI, 1995, J EXP MED, V181, P735, DOI 10.1084/jem.181.2.735
   Caves P K, 1973, Ann Thorac Surg, V16, P325
   *CDCP, 1992, MMWR-MORBID MORTAL W, V41, P1
   Cinque P, 1996, AIDS, V10, P951, DOI 10.1097/00002030-199610090-00004
   CONRAD AJ, 1995, J ACQ IMMUN DEF SYND, V10, P425, DOI 10.1097/00042560-199512000-00005
   Cooper ER, 1998, J PEDIATR-US, V132, P808, DOI 10.1016/S0022-3476(98)70308-7
   EHRENREICH H, 1993, J IMMUNOL, V150, P4601
   Fiala M, 1996, J NEUROVIROL, V2, P158, DOI 10.3109/13550289609146878
   FINKEL MS, 1992, SCIENCE, V257, P387, DOI 10.1126/science.1631560
   FREEMAN GL, 1998, AM J PHYSIOL, V274, P249
   Ghanekar S, 1996, J IMMUNOL, V157, P4028
   GRODY WW, 1990, AM J CARDIOL, V66, P203, DOI 10.1016/0002-9149(90)90589-S
   Habib FM, 1996, LANCET, V347, P1151, DOI 10.1016/S0140-6736(96)90610-8
   HIMELMAN RB, 1989, J AM COLL CARDIOL, V13, P1030, DOI 10.1016/0735-1097(89)90256-8
   Kasten-Sportes C, 1998, CARDIOLOGY IN AIDS, P265
   KRONCKE KD, 1995, BIOL CHEM H-S, V376, P327
   LEVY RM, 1990, AM FAM PHYSICIAN, V41, P517
   Lipshultz SE, 1998, CIRCULATION, V97, P1246, DOI 10.1161/01.CIR.97.13.1246
   Lipshultz SE, 1998, NEW ENGL J MED, V339, P1153, DOI 10.1056/NEJM199810153391609
   LUGINBUHL LM, 1993, JAMA-J AM MED ASSOC, V269, P2869, DOI 10.1001/jama.269.22.2869
   Matsumori A, 1996, CURR OPIN CARDIOL, V11, P302, DOI 10.1097/00001573-199605000-00011
   MCARTHUR JC, 1987, MEDICINE, V66, P407, DOI 10.1097/00005792-198711000-00001
   Meldrum DR, 1998, AM J PHYSIOL-REG I, V274, pR577, DOI 10.1152/ajpregu.1998.274.3.R577
   Merrill JE, 1997, J NEUROSCI RES, V48, P372, DOI 10.1002/(SICI)1097-4547(19970515)48:4<372::AID-JNR9>3.0.CO;2-8
   MONCADA S, 1991, PHARMACOL REV, V43, P109
   Monno L, 1998, AIDS, V12, P581, DOI 10.1097/00002030-199806000-00006
   PHILIPPON V, 1994, VIROLOGY, V205, P519, DOI 10.1006/viro.1994.1673
   Plein D, 1999, CLIN CARDIOL, V22, P33, DOI 10.1002/clc.4960220112
   PORTEGIES P, 1994, TRANSCRIPT, V36, P12
   Rostasy K, 1999, ANN NEUROL, V46, P207, DOI 10.1002/1531-8249(199908)46:2<207::AID-ANA10>3.3.CO;2-W
   Satoh M, 1997, J AM COLL CARDIOL, V29, P716, DOI 10.1016/S0735-1097(96)00567-0
   SCHAG CC, 1984, J CLIN ONCOL, V2, P187, DOI 10.1200/JCO.1984.2.3.187
   Schrager LK, 1998, JAMA-J AM MED ASSOC, V280, P67, DOI 10.1001/jama.280.1.67
   SCHULZ R, 1992, BRIT J PHARMACOL, V105, P575, DOI 10.1111/j.1476-5381.1992.tb09021.x
   SIMPSON DM, 1994, ANN INTERN MED, V121, P769, DOI 10.7326/0003-4819-121-10-199411150-00008
   UNGUREANULONGROIS D, 1995, CIRC RES, V77, P494, DOI 10.1161/01.RES.77.3.494
   Woods G, 1993, DIAGNOSTIC PATHOLOGY
   YEUNG MC, 1995, AIDS, V9, P137
   YOKOYAMA T, 1993, J CLIN INVEST, V92, P2303, DOI 10.1172/JCI116834
   Zaragoza C, 1998, P NATL ACAD SCI USA, V95, P2469, DOI 10.1073/pnas.95.5.2469
NR 51
TC 24
Z9 25
U1 2
U2 13
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0269-9370
J9 AIDS
JI Aids
PD MAY 5
PY 2000
VL 14
IS 7
BP 827
EP 838
DI 10.1097/00002030-200005050-00009
PG 12
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 312XK
UT WOS:000086969100009
PM 10839591
DA 2018-12-27
ER

PT J
AU Muenchen, HJ
   Lin, DL
   Walsh, MA
   Keller, ET
   Pienta, KJ
AF Muenchen, HJ
   Lin, DL
   Walsh, MA
   Keller, ET
   Pienta, KJ
TI RETRACTED: Tumor necrosis factor-alpha-induced apoptosis in prostate
   cancer cells through inhibition of nuclear factor-kappa B by an I kappa
   B alpha "super-repressor" (Retracted Article. See vol 8, pg 3961, 2002)
SO CLINICAL CANCER RESEARCH
LA English
DT Article; Retracted Publication
ID ADENOVIRUS-MEDIATED EXPRESSION; TRANSCRIPTION FACTOR; ANDROGEN RECEPTOR;
   ACTIVATION; CYTOTOXICITY; PHOSPHORYLATION; INTERLEUKIN-6; MECHANISMS;
   CARCINOMA; SIGNAL
AB Prostate cancer patients experiencing a relapse in disease often express high serum tumor necrosis factor-alpha (TNF-alpha) levels. Many androgen-insensitive prostate cancer cells are TNF-alpha insensitive because of the expression of antiapoptotic genes as part of the nuclear factor-kappa B (NF-kappa B) family of transcription factors. NF-kappa B stimulates gene transcription when expressed in the nucleus; however, in resting cells, this nuclear import is prevented by association with the cytoplasmic inhibitor I kappa B alpha, This cytoplasmic retention of NF-kappa B is uncoupled by many extracellular signals including low levels of TNF-alpha. During normal cell activation, nuclear translocation of NF-kappa B is preceded by phosphorylation and degradation of I kappa B alpha, When phosphorylation is blocked, I kappa B alpha remains intact, thereby blocking NF-kappa B translocation to the nucleus and subsequent activation of antiapoptotic genes that cause TNF-alpha insensitivity. We tested whether a "super-repressor" of NF-kappa B activity could be transfected into prostate cancer cells and make them TNF-alpha sensitive. PC-3 and LNCaP cells were stimulated with TNF-alpha (10 ng/ml) for 24 h in the presence or absence of the I kappa B alpha "super-repressor" (p6R-I kappa B(S32A) + (S36A)) NF-kappa B activity was measured by electrophoretic mobility shift assay and the steady state levels of the cytoplasmic I kappa B alpha protein were measured by Western blot. Secretory IL-6 and IL-6 mRNA were measured by ELISA, p6R-I kappa B(S32A + S36A) blocked the stimulation of NF-kappa B activity by TNF-alpha in prostate cancer cells. It also subsequently decreased IL-6 production by TNF-alpha. We conclude that these data demonstrate that inhibition of NF-kappa B selectively sensitizes previously insensitive prostate cancer cells to TNF-alpha.
C1 Univ Michigan, Sch Med, Dept Internal Med, Div Hematol Oncol, Ann Arbor, MI 48109 USA.
   Univ Michigan, Sch Med, Dept Anim Med, Div Pathol, Ann Arbor, MI 48109 USA.
   Univ Michigan, Sch Med, Dept Surg, Div Urol, Ann Arbor, MI 48109 USA.
RP Muenchen, HJ (reprint author), Univ Michigan, Sch Med, Dept Internal Med, Div Hematol Oncol, 1500 E Med Ctr Dr,7303 CCGC, Ann Arbor, MI 48109 USA.
EM muenchen@umich.edu
RI Keller, Evan/M-1446-2016
OI Keller, Evan/0000-0002-7592-7535; Pienta, Kenneth/0000-0002-4138-2186
FU NCI NIH HHS [P50 CA69568]
CR AKDAS A, 1990, International Urology and Nephrology, V22, P501, DOI 10.1007/BF02549736
   AKIRA S, 1993, ADV IMMUNOL, V54, P1, DOI 10.1016/S0065-2776(08)60532-5
   BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0
   BAEUERLE PA, 1989, GENE DEV, V3, P1689, DOI 10.1101/gad.3.11.1689
   BALLARD DW, 1992, P NATL ACAD SCI USA, V89, P1875, DOI 10.1073/pnas.89.5.1875
   Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506
   BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301
   BORSELLINO N, 1995, CANCER RES, V55, P4633
   BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809
   BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466
   Claudio E, 1996, EXP CELL RES, V224, P63, DOI 10.1006/excr.1996.0111
   DEALTRY GB, 1987, EUR J IMMUNOL, V17, P689, DOI 10.1002/eji.1830170517
   DEVALCK D, 1993, EUR J BIOCHEM, V212, P491
   DiDonato J, 1996, MOL CELL BIOL, V16, P1295
   DOUHERTY GJ, 1988, EUR J IMMUNOL, V18, P35
   Hellerbrand C, 1998, HEPATOLOGY, V27, P1285, DOI 10.1002/hep.510270514
   HELSON L, 1979, EXP CELL BIOL, V47, P53
   Hobisch A, 1998, CANCER RES, V58, P4640
   Ikebe T, 1998, INT J CANCER, V77, P578
   IMAMURA K, 1988, J BIOL CHEM, V263, P10247
   Irie A, 1999, Nihon Hinyokika Gakkai Zasshi, V90, P502
   Jobin C, 1998, J IMMUNOL, V160, P410
   Kitamura M, 2000, KIDNEY INT, V57, P709, DOI 10.1046/j.1523-1755.2000.00893.x
   Kurokouchi K, 1998, J BONE MINER RES, V13, P1290, DOI 10.1359/jbmr.1998.13.8.1290
   LASTER SM, 1988, J IMMUNOL, V141, P2629
   Li NX, 1998, P NATL ACAD SCI USA, V95, P13012, DOI 10.1073/pnas.95.22.13012
   Miagkov AV, 1998, P NATL ACAD SCI USA, V95, P13859, DOI 10.1073/pnas.95.23.13859
   MIELE L, 1988, NATURE, V335, P726, DOI 10.1038/335726a0
   Muenchen HJ, 1998, ANTICANCER RES, V18, P2631
   Muenchen HJ, 1997, ANTI-CANCER DRUG, V8, P323, DOI 10.1097/00001813-199704000-00003
   Muenchen HJ, 1997, ANTI-CANCER DRUG, V8, P784, DOI 10.1097/00001813-199709000-00008
   Nakajima Y, 1996, PROSTATE, V29, P296
   Nakashima J, 1998, CLIN CANCER RES, V4, P1743
   NAKASHIMA J, 1995, CANCER RES, V55, P4881
   Pajonk F, 1999, J NATL CANCER I, V91, P1956, DOI 10.1093/jnci/91.22.1956
   Read MA, 1996, J IMMUNOL, V157, P3472
   Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X
   Sato N, 1997, J BIOL CHEM, V272, P17485, DOI 10.1074/jbc.272.28.17485
   Soares MP, 1998, J IMMUNOL, V161, P4572
   SUGARMAN BJ, 1985, SCIENCE, V230, P943, DOI 10.1126/science.3933111
   van Hogerlinden M, 1999, CANCER RES, V59, P3299
   WATANABE N, 1988, CANCER RES, V48, P2179
   Wrighton CJ, 1996, J EXP MED, V183, P1013, DOI 10.1084/jem.183.3.1013
NR 43
TC 66
Z9 68
U1 1
U2 7
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD MAY
PY 2000
VL 6
IS 5
BP 1969
EP 1977
PG 9
WC Oncology
SC Oncology
GA 312LY
UT WOS:000086945800048
PM 10815922
DA 2018-12-27
ER

PT J
AU Brodie, SJ
   Patterson, BK
   Lewinsohn, DA
   Diem, K
   Spach, D
   Greenberg, PD
   Riddell, SR
   Corey, L
AF Brodie, SJ
   Patterson, BK
   Lewinsohn, DA
   Diem, K
   Spach, D
   Greenberg, PD
   Riddell, SR
   Corey, L
TI RETRACTED: HIV-specific cytotoxic T lymphocytes traffic to lymph nodes
   and localize at sites of HIV replication and cell death (Retracted
   article. See vol. 120, pg. 3401, 2010)
SO JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Article; Retracted Publication
ID BLOOD MONONUCLEAR-CELLS; VIRUS TYPE-1 INFECTION; PERIPHERAL-BLOOD;
   ANTIRETROVIRAL THERAPY; MESSENGER-RNA; BONE-MARROW; GENE; APOPTOSIS;
   RESPONSES; DISEASE
AB We have tracked the in vivo migration and have identified in vivo correlates of cytotoxic T-lymphocyte (CTL) activity in HIV-seropositive subjects infused with autologous gene-marked CD8(+) HIV-specific CTL. The number of circulating gene-marked CTL ranged from 1.6 to 3.5% shortly after infusion to less than 0.5% 2 weeks later. Gene-marked CTL were present in the lymph node at 4.5- to 11-fold excess and colocalized within parafollicular regions of the lymph node adjacent to cells expressing HN fat fusion transcripts, a correlate of virus replication. The CTL clones expressed the CCR5 receptor and localized among HIV-infected cells expressing the ligands MIP-1 alpha and MIP-1 beta, CC-chemokines produced at sites of virus replication. Aggregates of apoptotic cells and cells expressing granzyme-B localized within these same sites. III contrast, lymph node sections from untreated HIV-seropositive subjects, all with significant viral burden (> 50,000 HIV RNA copies/mL plasma), showed no CC-chemokine expression and exhibited only sporadic and randomly distributed cells expressing granzymes and/or apoptotic cells. These studies show that the infused CTL specifically migrate to sites of HIV replication and retain their antigen-specific cytolytic potential. Moreover, these studies provide a methodology that will facilitate studies of both the magnitude and functional phenotype of Ag-specific CD8(+) T cells in vivo.
C1 Univ Washington, Dept Lab Med, Vaccine Virol Div, Seattle, WA 98195 USA.
   Northwestern Univ, Sch Med, Dept Obstet & Gynecol, Chicago, IL USA.
   Univ Washington, Dept Med, Seattle, WA USA.
   Fred Hutchinson Canc Res Ctr, Program Immunol, Seattle, WA 98104 USA.
   Univ Washington, Dept Immunol, Seattle, WA 98195 USA.
   Fred Hutchinson Canc Res Ctr, Program Infect Dis, Seattle, WA 98104 USA.
RP Brodie, SJ (reprint author), Univ Washington, Dept Lab Med, Vaccine Virol Div, Room T293X, Seattle, WA 98195 USA.
EM sjbrodie@u.washington.edu
FU NIAID NIH HHS [AI-41535, P01 AI030731, AI-36613, AI-30731]
CR ABE T, 1998, EXP HEMATOL, V26, P185
   BERREY MM, 2000, IN PRESS J INFECT DI
   BORROW P, 1994, J VIROL, V68, P6103
   Brodie SJ, 1999, AM J PATHOL, V154, P1453, DOI 10.1016/S0002-9440(10)65400-4
   Brodie SJ, 1998, J VIROL, V72, P5599
   Brodie SJ, 1999, NAT MED, V5, P34
   Brodie SJ, 1998, J VIROL, V72, P3863
   BRODIE SJ, 1995, AM J PATHOL, V146, P1
   Contassot E, 1998, HUM GENE THER, V9, P73, DOI 10.1089/hum.1998.9.1-73
   Cyster JG, 1999, SCIENCE, V286, P2098, DOI 10.1126/science.286.5447.2098
   Diamond C, 1998, J VIROL, V72, P6223
   DUNBAR CE, 1995, BLOOD, V85, P3048
   EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0
   FINKEL TH, 1995, NAT MED, V1, P129, DOI 10.1038/nm0295-129
   FURTADO MR, 1991, VIROLOGY, V185, P258, DOI 10.1016/0042-6822(91)90773-5
   Furtado MR, 1999, NEW ENGL J MED, V340, P1614, DOI 10.1056/NEJM199905273402102
   GROUX H, 1992, J EXP MED, V175, P331, DOI 10.1084/jem.175.2.331
   Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986
   Heslop HE, 1996, NAT MED, V2, P551, DOI 10.1038/nm0596-551
   KLEIN MR, 1995, J EXP MED, V181, P1365, DOI 10.1084/jem.181.4.1365
   KOHN DB, 1995, NAT MED, V1, P1017, DOI 10.1038/nm1095-1017
   KOUP RA, 1994, J VIROL, V68, P4650
   LEWIS DE, 1994, J IMMUNOL, V153, P412
   Lisziewicz J, 1999, NEW ENGL J MED, V340, P1683, DOI 10.1056/NEJM199905273402114
   McMichael A, 1998, CELL, V93, P673, DOI 10.1016/S0092-8674(00)81428-2
   MERROUCHE Y, 1995, J CLIN ONCOL, V13, P410, DOI 10.1200/JCO.1995.13.2.410
   MILLER AD, 1992, NATURE, V357, P455, DOI 10.1038/357455a0
   Musey L, 1997, NEW ENGL J MED, V337, P1267, DOI 10.1056/NEJM199710303371803
   OYAIZU N, 1993, BLOOD, V82, P3392
   Patterson BK, 1999, LANCET, V353, P211, DOI 10.1016/S0140-6736(05)77222-6
   PATTERSON BK, 1993, SCIENCE, V260, P976, DOI 10.1126/science.8493534
   Riddell SR, 1996, NAT MED, V2, P216, DOI 10.1038/nm0296-216
   Roskrow MA, 1998, HUM GENE THER, V9, P1237, DOI 10.1089/hum.1998.9.8-1237
   Rowland-Jones SL, 1999, IMMUNOL LETT, V66, P9, DOI 10.1016/S0165-2478(98)00179-5
   Schmitz JE, 1999, SCIENCE, V283, P857, DOI 10.1126/science.283.5403.857
   Spiegel HML, 2000, J VIROL, V74, P1018, DOI 10.1128/JVI.74.2.1018-1022.2000
   Tan RS, 1999, BLOOD, V93, P1506
   TERAI C, 1991, J CLIN INVEST, V87, P1710, DOI 10.1172/JCI115188
   WALTER EA, 1995, NEW ENGL J MED, V333, P1038, DOI 10.1056/NEJM199510193331603
   Zajac AJ, 1998, J EXP MED, V188, P2205, DOI 10.1084/jem.188.12.2205
NR 40
TC 82
Z9 84
U1 3
U2 12
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA
SN 0021-9738
J9 J CLIN INVEST
JI J. Clin. Invest.
PD MAY
PY 2000
VL 105
IS 10
BP 1407
EP 1417
DI 10.1172/JCI8707
PG 11
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 314UE
UT WOS:000087075300012
PM 10811848
OA Bronze
DA 2018-12-27
ER

PT J
AU Xu, Y
   Zhu, K
   Hong, GY
   Wu, WH
   Baudhuin, LM
   Xiao, YJ
   Damron, DS
AF Xu, Y
   Zhu, K
   Hong, GY
   Wu, WH
   Baudhuin, LM
   Xiao, YJ
   Damron, DS
TI RETRACTED: Sphingosylphosphorylcholine is a ligand for ovarian cancer
   G-protein-coupled receptor 1 (Retracted Article. See vol 8, pg 299,
   2006)
SO NATURE CELL BIOLOGY
LA English
DT Article; Retracted Publication
ID PHOSPHOLIPASE-C ACTIVATION; SPHINGOSINE 1-PHOSPHATE; CA2+ MOBILIZATION;
   LYSOPHOSPHATIDIC ACID; HUMAN KERATINOCYTES; KINASE ACTIVATION; BINDING
   PROTEIN; T-CELLS; MITOGEN; INHIBITION
AB Sphingosylphosphorylcholine (SPC) is a bioactive lipid that acts as an intracellular and extracellular signalling molecule in numerous biological processes. Many of the cellular actions of SPC are believed to be mediated by the activation of unidentified G-protein-coupled receptors. Here we show that SPC is a high-affinity ligand for an orphan receptor, ovarian cancer G-protein-coupled receptor 1 (OGR1). In OGR1-transfected cells, SPC binds to OGR1 with high affinity (K-d = 33.3 nM) and high specificity and transiently increases intracellular calcium. The specific binding of SPC to OGR1 also activates p42/44 mitogen-activated protein kinases (MAP kinases) and inhibits cell proliferation. In addition, SPC causes internalization of OGR1 in a structurally specific manner.
C1 Cleveland Clin Fdn, Dept Canc Biol, Div Anesthesiol & Crit Care Med, Cleveland, OH 44195 USA.
   Cleveland Clin Fdn, Dept Gynecol & Obstet, Div Anesthesiol & Crit Care Med, Cleveland, OH 44195 USA.
   Cleveland Clin Fdn, Ctr Anesthesiol Res, Div Anesthesiol & Crit Care Med, Cleveland, OH 44195 USA.
RP Xu, Y (reprint author), Cleveland Clin Fdn, Dept Canc Biol, Div Anesthesiol & Crit Care Med, 9500 Euclid Ave, Cleveland, OH 44195 USA.
EM xuy@ccf.org
CR An SZ, 1997, FEBS LETT, V417, P279, DOI 10.1016/S0014-5793(97)01301-X
   An SZ, 1998, J BIOL CHEM, V273, P7906, DOI 10.1074/jbc.273.14.7906
   Ancellin N, 1999, J BIOL CHEM, V274, P18997, DOI 10.1074/jbc.274.27.18997
   BERGER A, 1995, P NATL ACAD SCI USA, V92, P5885, DOI 10.1073/pnas.92.13.5885
   BITAR KN, 1995, AM J PHYSIOL-GASTR L, V269, pG370
   BOGOYEVITCH MA, 1995, BIOCHEM J, V309, P437, DOI 10.1042/bj3090437
   Bunemann M, 1996, EMBO J, V15, P5527, DOI 10.1002/j.1460-2075.1996.tb00937.x
   CASILLAS AM, 1993, BIOCHEM J, V290, P545, DOI 10.1042/bj2900545
   Cobb MH, 1999, PROG BIOPHYS MOL BIO, V71, P479, DOI 10.1016/S0079-6107(98)00056-X
   DESAI NN, 1991, BIOCHEM BIOPH RES CO, V181, P361, DOI 10.1016/S0006-291X(05)81427-5
   Graler MH, 1998, GENOMICS, V53, P164, DOI 10.1006/geno.1998.5491
   GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440
   Hamada H, 1997, CIRC RES, V81, P812
   HAWES BE, 1995, J BIOL CHEM, V270, P17148, DOI 10.1074/jbc.270.29.17148
   Hecht JH, 1996, J CELL BIOL, V135, P1071, DOI 10.1083/jcb.135.4.1071
   IISMAA T P, 1992, Current Opinion in Cell Biology, V4, P195, DOI 10.1016/0955-0674(92)90033-9
   Imokawa G, 1999, J INVEST DERMATOL, V112, P91, DOI 10.1046/j.1523-1747.1999.00462.x
   KEEN M, 1997, PROTOCOLS RECEPTOR S, P1
   Lee MJ, 1998, SCIENCE, V279, P1552, DOI 10.1126/science.279.5356.1552
   Liu CH, 1999, MOL BIOL CELL, V10, P1179, DOI 10.1091/mbc.10.4.1179
   Munsch N, 1998, BIOMED PHARMACOTHER, V52, P180, DOI 10.1016/S0753-3322(98)80208-4
   Murata Y, 1996, J INVEST DERMATOL, V106, P1242, DOI 10.1111/1523-1747.ep12348937
   OKAJIMA F, 1995, J BIOL CHEM, V270, P26332, DOI 10.1074/jbc.270.44.26332
   Okamoto H, 1999, BIOCHEM BIOPH RES CO, V260, P203, DOI 10.1006/bbrc.1999.0886
   Okamoto H, 1998, J BIOL CHEM, V273, P27104, DOI 10.1074/jbc.273.42.27104
   PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585
   Rodriguez-Lafrasse C, 1999, NEUROCHEM RES, V24, P199, DOI 10.1023/A:1022501702403
   Sato K, 1999, FEBS LETT, V443, P25, DOI 10.1016/S0014-5793(98)01676-7
   Sekiguchi K, 1999, CIRC RES, V85, P1000
   SEUFFERLEIN T, 1995, J BIOL CHEM, V270, P24343, DOI 10.1074/jbc.270.41.24343
   SEUFFERLEIN T, 1995, J BIOL CHEM, V270, P24334, DOI 10.1074/jbc.270.41.24334
   Spangelo BL, 1996, ENDOCRINOLOGY, V137, P4419, DOI 10.1210/en.137.10.4419
   SPIEGEL S, 1995, J MEMBRANE BIOL, V146, P225
   STRASBERG PM, 1988, BIOCHEM CELL BIOL, V66, P1322, DOI 10.1139/o88-153
   SUGIYAMA E, 1993, J BIOCHEM-TOKYO, V113, P467, DOI 10.1093/oxfordjournals.jbchem.a124068
   Sun LY, 1996, J INVEST DERMATOL, V106, P232, DOI 10.1111/1523-1747.ep12340570
   Tokura Y, 1999, J INVEST DERM SYMP P, V4, P184, DOI 10.1038/sj.jidsp.5640206
   Van Brocklyn JR, 1999, J BIOL CHEM, V274, P4626, DOI 10.1074/jbc.274.8.4626
   van den Brink MRM, 1999, J BIOL CHEM, V274, P11178, DOI 10.1074/jbc.274.16.11178
   vanKoppen CJ, 1996, MOL PHARMACOL, V49, P956
   Wakita H, 1998, J INVEST DERMATOL, V110, P253, DOI 10.1046/j.1523-1747.1998.00120.x
   WINDH RT, 1999, J BIOL CHEM, V274, P27531
   Xu Y, 1996, GENOMICS, V35, P397, DOI 10.1006/geno.1996.0377
   XU Y, 1995, J CELL PHYSIOL, V163, P441, DOI 10.1002/jcp.1041630303
   XU Y, 1995, BIOCHEM J, V309, P933, DOI 10.1042/bj3090933
   XU Y, IN PRESS METH MOL ME
   Yamada T, 1997, CELL MOL LIFE SCI, V53, P435, DOI 10.1007/s000180050052
   YATOMI Y, 1992, EUR J BIOCHEM, V205, P1003, DOI 10.1111/j.1432-1033.1992.tb16867.x
   Zhu L, 1999, IMMUNOLOGY, V97, P26
   ZUHERINGDORF DM, 1998, EUR J PHARMACOL, V354, P113
NR 50
TC 155
Z9 165
U1 2
U2 18
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1465-7392
EI 1476-4679
J9 NAT CELL BIOL
JI Nat. Cell Biol.
PD MAY
PY 2000
VL 2
IS 5
BP 261
EP 267
DI 10.1038/35010529
PG 7
WC Cell Biology
SC Cell Biology
GA 313FX
UT WOS:000086990600014
PM 10806476
OA Bronze
DA 2018-12-27
ER

PT J
AU Schon, JH
   Kloc, C
   Haddon, RC
   Batlogg, B
AF Schon, JH
   Kloc, C
   Haddon, RC
   Batlogg, B
TI RETRACTED: A superconducting field-effect switch (Retracted Article. See
   vol 298, pg 961, 2002)
SO SCIENCE
LA English
DT Article; Retracted Publication
ID C-60; TRANSISTORS; CRYSTALS
AB We report here on a novel realization of a field-effect device that allows switching between insulating and superconducting states, which is the widest possible variation of electrical properties of a material. We chose C(60) as the active material because of its Low surface state density and observed superconductivity in alkali metal-doped C(60). We induced three electrons per C(60) molecule in the topmost molecular Layer of a crystal with the field-effect device, creating a superconducting switch operating up to 11 kelvin. An insulator was thereby transformed into a superconductor. This technique offers new opportunities for the study of superconductivity as a function of carrier concentration.
C1 Bell Labs, Lucent Technol, Murray Hill, NJ 07974 USA.
   Univ Kentucky, Dept Chem, Lexington, KY 40506 USA.
   Univ Kentucky, Dept Phys, Lexington, KY 40506 USA.
   Univ Kentucky, Ctr Adv Mat, Lexington, KY 40506 USA.
RP Schon, JH (reprint author), Bell Labs, Lucent Technol, 600 Mt Ave, Murray Hill, NJ 07974 USA.
RI Kloc, Christian/A-2255-2011
CR ATALLA MM, 1959, BELL SYST TECH J, V28, P749
   DRESSELHAUS MS, 1994, PHYSICAL PROPERTIES, V4, P571
   FRANKEVICH E, 1993, CHEM PHYS LETT, V214, P39, DOI 10.1016/0009-2614(93)85452-T
   GLOVER RE, 1960, PHYS REV LETT, V5, P248, DOI 10.1103/PhysRevLett.5.248
   HADDON RC, 1995, APPL PHYS LETT, V67, P121, DOI 10.1063/1.115503
   Hebard AF, 1996, PHYS REV B, V54, P14052, DOI 10.1103/PhysRevB.54.14052
   HEBARD AF, 1991, NATURE, V350, P600, DOI 10.1038/350600a0
   Kloc C, 1997, J CRYST GROWTH, V182, P416, DOI 10.1016/S0022-0248(97)00370-9
   Lilienfeld J. E., 1926, U. S. Patent, Patent No. [1 745 175 A, 1745175]
   MANNHART J, 1993, APPL PHYS LETT, V62, P630, DOI 10.1063/1.108877
   MANNHART J, 1993, J ALLOY COMPD, V195, P519, DOI 10.1016/0925-8388(93)90791-K
   Ramirez A. P., 1994, Superconductivity Review, V1, P1
   SCHLUTER M, 1992, PHYS REV LETT, V68, P526, DOI 10.1103/PhysRevLett.68.526
   Schon JH, 2000, SCIENCE, V287, P1022, DOI 10.1126/science.287.5455.1022
   Schon JH, 1998, PHYS REV B, V58, P12952, DOI 10.1103/PhysRevB.58.12952
   SZE SM, 1981, PHYSICS SEMICONDUCTO
   VARMA CM, 1991, SCIENCE, V254, P989, DOI 10.1126/science.254.5034.989
   Yildirim T, 1996, PHYS REV LETT, V77, P167, DOI 10.1103/PhysRevLett.77.167
NR 18
TC 132
Z9 136
U1 3
U2 34
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
J9 SCIENCE
JI Science
PD APR 28
PY 2000
VL 288
IS 5466
BP 656
EP 658
DI 10.1126/science.288.5466.656
PG 3
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 308RR
UT WOS:000086727100039
PM 10784445
DA 2018-12-27
ER

PT J
AU Schon, JH
   Kloc, C
   Batlogg, B
AF Schon, JH
   Kloc, C
   Batlogg, B
TI RETRACTED: Mobile iodine dopants in organic semiconductors (Retracted
   article. See vol B 66, art. no. 249905, 2002)
SO PHYSICAL REVIEW B
LA English
DT Article; Retracted Publication
ID ALKYL-SUBSTITUTED OLIGOTHIOPHENES; PHYSICAL VAPOR GROWTH;
   SINGLE-CRYSTALS; THIN-FILMS; ELECTRICAL-PROPERTIES; PENTACENE;
   TRANSISTORS; TRANSPORT
AB The electrical properties of alpha-quaterthiophene, alpha-hexathiophene, and pentacene single crystals have been studied for low iodine dopant concentrations. The electronic and ionic (I-3(-)) currents have been separated experimentally, providing quantitative information on the ion mobility. The mobility of the I-3(-) ions in these layered structures is strongly anisotropic. Parallel to the molecular layers the mobility is of order of 10(-6) to 10(-7) cm(2)/V s, whereas perpendicular to the layers it is smaller by about 4 orders of magnitude. In addition, the activation energy for diffusion parallel to the layers is also much smaller (0.2-0.3 eV) than far diffusion perpendicular to the layers (0.85 eV).
C1 Bell Labs, Lucent Technol, Murray Hill, NJ 07974 USA.
RP Schon, JH (reprint author), Bell Labs, Lucent Technol, 600 Mt Ave,POB 636, Murray Hill, NJ 07974 USA.
EM hendrik@lucent.com
RI Kloc, Christian/A-2255-2011
CR AKIMICHI H, 1991, APPL PHYS LETT, V58, P1500, DOI 10.1063/1.105158
   Antolini L, 1998, ADV MATER, V10, P382, DOI 10.1002/(SICI)1521-4095(199803)10:5<382::AID-ADMA382>3.0.CO;2-Y
   BARBE DF, 1970, J CHEM PHYS, V52, P4046, DOI 10.1063/1.1673607
   CAMPBELL RB, 1961, ACTA CRYSTALLOGR, V14, P705, DOI 10.1107/S0365110X61002163
   CAMPBELL RB, 1962, ACTA CRYSTALLOGR, V15, P289, DOI 10.1107/S0365110X62000699
   CAO Y, 1987, SYNTHETIC MET, V18, P189, DOI 10.1016/0379-6779(87)90876-9
   Dimitrakopoulos CD, 1996, J APPL PHYS, V80, P2501, DOI 10.1063/1.363032
   DODABALAPUR A, 1995, SCIENCE, V268, P270, DOI 10.1126/science.268.5208.270
   HADDON RC, 1995, J MATER CHEM, V5, P1719, DOI 10.1039/jm9950501719
   HOROWITZ G, 1995, CHEM MATER, V7, P1337, DOI 10.1021/cm00055a010
   HOROWITZ G, 1989, SOLID STATE COMMUN, V72, P381, DOI 10.1016/0038-1098(89)90121-X
   HOTTA S, 1991, J MATER CHEM, V1, P835, DOI 10.1039/jm9910100835
   KIESS H, 1980, J ELECTRON MATER, V9, P763, DOI 10.1007/BF02652895
   Kloc C, 1997, J CRYST GROWTH, V182, P416, DOI 10.1016/S0022-0248(97)00370-9
   Laudise RA, 1998, J CRYST GROWTH, V187, P449, DOI 10.1016/S0022-0248(98)00034-7
   Lin YY, 1997, IEEE T ELECTRON DEV, V44, P1325, DOI 10.1109/16.605476
   MINAKATA T, 1991, J APPL PHYS, V69, P7354, DOI 10.1063/1.347594
   MINAKATA T, 1992, J APPL PHYS, V72, P4178, DOI 10.1063/1.352227
   MINAKATA T, 1992, J APPL PHYS, V72, P5220, DOI 10.1063/1.352004
   Nelson SF, 1998, APPL PHYS LETT, V72, P1854, DOI 10.1063/1.121205
   SAKAI H, 1985, B CHEM SOC JPN, V58, P926, DOI 10.1246/bcsj.58.926
   Schauer F, 1997, J APPL PHYS, V81, P1244, DOI 10.1063/1.364445
   Schon JH, 2000, NATURE, V403, P408, DOI 10.1038/35000172
   Schon JH, 1998, PHYS REV B, V58, P12952, DOI 10.1103/PhysRevB.58.12952
   SCHON JH, IN PRESS SYNTH MET
   SHIBAEVA RP, 1985, MOL CRYST LIQ CRYST, V119, P361, DOI 10.1080/00268948508075186
   Siegrist T, 1998, ADV MATER, V10, P379, DOI 10.1002/(SICI)1521-4095(199803)10:5<379::AID-ADMA379>3.0.CO;2-A
   YAMAMOTO T, 1992, MACROMOLECULES, V25, P1214, DOI 10.1021/ma00030a003
NR 28
TC 6
Z9 6
U1 1
U2 9
PU AMER PHYSICAL SOC
PI COLLEGE PK
PA ONE PHYSICS ELLIPSE, COLLEGE PK, MD 20740-3844 USA
SN 1098-0121
EI 1550-235X
J9 PHYS REV B
JI Phys. Rev. B
PD APR 15
PY 2000
VL 61
IS 16
BP 10803
EP 10806
DI 10.1103/PhysRevB.61.10803
PG 4
WC Materials Science, Multidisciplinary; Physics, Applied; Physics,
   Condensed Matter
SC Materials Science; Physics
GA 309EP
UT WOS:000086755600041
DA 2018-12-27
ER

PT J
AU Bulfone-Paus, S
   Ruckert, R
   Krause, H
   von Bernuth, H
   Notter, M
   Pohl, T
   Tran, TH
   Paus, R
   Kunzendorf, U
AF Bulfone-Paus, S
   Ruckert, R
   Krause, H
   von Bernuth, H
   Notter, M
   Pohl, T
   Tran, TH
   Paus, R
   Kunzendorf, U
TI RETRACTED: An interleukin-2-IgG-Fas ligand fusion protein suppresses
   delayed-type hypersensitivity in mice by triggering apoptosis in
   activated T cells as a novel strategy for immunosuppression (Retracted
   article. See vol. 92, pg. E68, 2011)
SO TRANSPLANTATION
LA English
DT Article; Retracted Publication
ID DEATH; LYMPHOCYTES; MECHANISMS; REJECTION; INDUCTION; RESPONSES;
   RECEPTOR; GAMMA; IL-2
AB Background. Cell-mediated immune responses can be down-regulated by induction of apoptosis of immunoreactive lymphocytes, In the present study, we have tested the feasibility of a strategy for immunosuppression by the selective induction of apoptosis in activated, interleukin (IL)-2 receptor-positive lymphocytes, using a triple IL-2-IgG-FasL fusion protein. The IL-2-IgG-FasL fusion protein combines IL-2 for the selection of activated T cells, with the extracellular domain of the Fast molecule for inducing T-cell apoptosis, These components were separated by the Fc part of IgG1 serving as a spacer as well as for half-life prolongation.
   Methods. The gene for the chimeric protein was created by fusing DNA sequences encoding for the three functional components: human IL-2, the Fc part of human IgG1, and the extracellular domain of murine Fast. When the fusion gene was expressed in murine J558L cells, we obtained soluble dimeric immunoglobulin-like proteins in the supernatant. After analyzing the function of the IL-2 and Fast portions individually in vitro, a delayed-type hypersensitivity (DTH) reaction to sheep red blood cells as model for cell-mediated immune responses was investigated to evaluate the IL-2-IgG-FasL-mediated immunosuppression in vivo.
   Results. In vitro, the IL-2-IgG-FasL fusion protein supported IL-a-dependent proliferation of Fas-resistant CTLL-2 cells, whereas concanavalin A-T blasts were induced to undergo apoptosis by the Fast portion. in vivo, this fusion protein potently inhibited a murine DTH. This was associated with an increased rate of apoptosis in activated lymphocytes in the spleen, even at very low doses of the fusion protein. Furthermore, a second antigen challenge 10 days after IL-2-IgG-FasL treatment still failed to elicit a DTH response.
   Conclusion. The abrogation of a standard T cell-dependent immune response in vivo demonstrates that IL-2-IgC-FasL can be successfully exploited to trigger the death of deleterious T cells, presenting a potentially useful strategy in the management of autoimmune diseases and allotransplant rejections.
C1 Univ Erlangen Nurnberg, Med Klin & Poliklin 4, Dept Nephrol, D-91054 Erlangen, Germany.
   Free Univ Berlin, Univ Hosp Benjamin Franklin, Inst Immunol, D-1000 Berlin, Germany.
   Free Univ Berlin, Univ Hosp Benjamin Franklin, Dept Urol, D-1000 Berlin, Germany.
   Free Univ Berlin, Dept Internal Med, D-1000 Berlin, Germany.
   Humboldt Univ, Charite, Dept Dermatol, Berlin, Germany.
RP Kunzendorf, U (reprint author), Univ Erlangen Nurnberg, Med Klin & Poliklin 4, Dept Nephrol, Krankenhausstr 12, D-91054 Erlangen, Germany.
EM ulrich.kunzendorf@rzmail.uni-erlangen.de
RI Kunzendorf, Ulrich/A-8257-2010
CR Abbas AK, 1996, CELL, V84, P655, DOI 10.1016/S0092-8674(00)81042-9
   ASHKENAZI A, 1997, CURR OPIN IMMUNOL, V9, P95
   Bulfone-Paus S, 1998, CANCER RES, V58, P2707
   BulfonePaus S, 1997, CYTOKINE, V9, P507, DOI 10.1006/cyto.1996.0194
   BulfonePaus S, 1997, NAT MED, V3, P1124, DOI 10.1038/nm1097-1124
   Constant SL, 1997, ANNU REV IMMUNOL, V15, P297, DOI 10.1146/annurev.immunol.15.1.297
   Cotter T., 1996, TECHNIQUES APOPTOSIS
   GILLIS S, 1977, NATURE, V268, P154, DOI 10.1038/268154a0
   HOCK H, 1993, P NATL ACAD SCI USA, V90, P2774, DOI 10.1073/pnas.90.7.2774
   Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657
   KNEITZ B, 1995, EUR J IMMUNOL, V25, P2572, DOI 10.1002/eji.1830250925
   Kunzendorf U, 1996, J CLIN INVEST, V97, P1204, DOI 10.1172/JCI118534
   LANZAVECCHIA A, 1993, SCIENCE, V260, P937, DOI 10.1126/science.8493532
   LENARDO MJ, 1991, NATURE, V353, P858, DOI 10.1038/353858a0
   LUO Y, 1993, CURRENT PROTOCOLS IM
   NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326
   NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O
   OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0
   OI VT, 1983, P NATL ACAD SCI-BIOL, V80, P825, DOI 10.1073/pnas.80.3.825
   PAUL WE, 1993, FUNDAMENTAL IMMUNOLO
   Refaeli Y, 1998, IMMUNITY, V8, P615, DOI 10.1016/S1074-7613(00)80566-X
   TAKAHASHI T, 1994, CELL, V76, P969, DOI 10.1016/0092-8674(94)90375-1
   TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559
   Thomson AW, 1994, IMMUNOSUPPRESSIVE DR
   VANPARIJS L, 1997, J IMMUNOL, V158, P2738
NR 25
TC 7
Z9 7
U1 4
U2 11
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0041-1337
J9 TRANSPLANTATION
JI Transplantation
PD APR 15
PY 2000
VL 69
IS 7
BP 1386
EP 1391
DI 10.1097/00007890-200004150-00030
PG 6
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 307YM
UT WOS:000086681800031
PM 10798759
DA 2018-12-27
ER

PT J
AU Le Page, F
   Kwoh, EE
   Avrutskaya, A
   Gentil, A
   Leadon, SA
   Sarasin, A
   Cooper, PK
AF Le Page, F
   Kwoh, EE
   Avrutskaya, A
   Gentil, A
   Leadon, SA
   Sarasin, A
   Cooper, PK
TI RETRACTED: Transcription-coupled repair of 8-oxoGuanine: Requirement for
   XPG, TFIIH, and CSB and implications for Cockayne syndrome (Retracted
   Article. See vol 123, pg 711, 2005)
SO CELL
LA English
DT Article; Retracted Publication
ID NUCLEOTIDE EXCISION-REPAIR; RNA-POLYMERASE-II; OXIDATIVE DNA-DAMAGE;
   GROUP-B CELLS; XERODERMA-PIGMENTOSUM; ESCHERICHIA-COLI; MAMMALIAN-CELLS;
   IN-VITRO; SACCHAROMYCES-CEREVISIAE; HUMAN HOMOLOG
AB Analysis of transcription-coupled repair (TCR) of oxidative lesions here reveals strand-specific removal of 8-oxo-guanine (8-oxoG) and thymine glycol both in normal human cells and xeroderma pigmentosum (XP) cells defective in nucleotide excision repair. In contrast, Cockayne syndrome (CS) cells including CS-B, XP-B/CS, XP-D/CS, and XP-G/CS not only lack TCR but cannot remove 8-oxoG in a transcribed sequence, despite its proficient repair when not transcribed. The XP-G/CS defect uniquely slows lesion removal in nontranscribed sequences. Defective TCR leads to a mutation frequency at 8-oxoG of 30%-40% compared to the normal 1%-4%. Surprisingly, unrepaired 8-oxoG blocks transcription by RNA polymerase II. These data imply that TCR is required for polymerase release to allow repair and that CS results from defects in TCR of oxidative lesions.
C1 Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Berkeley, CA 94720 USA.
   CNRS, UPR42, Mol Genet Lab, F-94801 Villejuif, France.
   Univ N Carolina, Sch Med, Dept Radiat Oncol, Chapel Hill, NC 27599 USA.
RP Sarasin, A (reprint author), Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Berkeley, CA 94720 USA.
EM sarasin@infobiogen.fr; pkcooper@lbl.gov
FU NCI NIH HHS [CA63503, CA40453]
CR ABOUSSEKHRA A, 1995, CELL, V80, P859, DOI 10.1016/0092-8674(95)90289-9
   Aspinwall R, 1997, P NATL ACAD SCI USA, V94, P109, DOI 10.1073/pnas.94.1.109
   Balajee AS, 1997, P NATL ACAD SCI USA, V94, P4306, DOI 10.1073/pnas.94.9.4306
   Bessho T, 1999, NUCLEIC ACIDS RES, V27, P979, DOI 10.1093/nar/27.4.979
   BODEPUDI V, 1992, CHEM RES TOXICOL, V5, P608, DOI 10.1021/tx00029a004
   Boiteux S, 1999, BIOCHIMIE, V81, P59, DOI 10.1016/S0300-9084(99)80039-X
   BROUGHTON BC, 1995, AM J HUM GENET, V56, P167
   CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2
   Cooper PK, 1997, SCIENCE, V275, P990, DOI 10.1126/science.275.5302.990
   DAYAGROSJEAN L, 1987, MUTAT RES, V183, P185, DOI 10.1016/0167-8817(87)90061-7
   de Laat WL, 1999, GENE DEV, V13, P768, DOI 10.1101/gad.13.7.768
   Dianov G, 1999, NUCLEIC ACIDS RES, V27, P1365, DOI 10.1093/nar/27.5.1365
   Dianov GL, 1997, NUCLEIC ACIDS RES, V25, P3636, DOI 10.1093/nar/25.18.3636
   DONAHUE BA, 1994, P NATL ACAD SCI USA, V91, P8502, DOI 10.1073/pnas.91.18.8502
   Evans E, 1997, EMBO J, V16, P625, DOI 10.1093/emboj/16.3.625
   Evans E, 1997, EMBO J, V16, P6559, DOI 10.1093/emboj/16.21.6559
   EVANS J, 1993, MUTAT RES, V299, P147, DOI 10.1016/0165-1218(93)90092-R
   Fortini P, 1999, J BIOL CHEM, V274, P15230, DOI 10.1074/jbc.274.21.15230
   Fortini P, 1998, BIOCHEMISTRY-US, V37, P3575, DOI 10.1021/bi972999h
   FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES
   GILINGER G, 1993, J VIROL, V67, P6682
   Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009
   Habraken Y, 1996, P NATL ACAD SCI USA, V93, P10718, DOI 10.1073/pnas.93.20.10718
   HANAWALT PC, 1994, SCIENCE, V266, P1957, DOI 10.1126/science.7801121
   HATAHET Z, 1994, ANN NY ACAD SCI, V726, P346, DOI 10.1111/j.1749-6632.1994.tb52847.x
   Hazra IK, 1998, NUCLEIC ACIDS RES, V26, P5116, DOI 10.1093/nar/26.22.5116
   Iyer N, 1996, BIOCHEMISTRY-US, V35, P2157, DOI 10.1021/bi9524124
   KLEIN B, 1990, EXP CELL RES, V191, P256, DOI 10.1016/0014-4827(90)90012-Y
   Klungland A, 1999, P NATL ACAD SCI USA, V96, P13300, DOI 10.1073/pnas.96.23.13300
   Klungland A, 1997, EMBO J, V16, P3341, DOI 10.1093/emboj/16.11.3341
   Klungland A, 1999, MOL CELL, V3, P33, DOI 10.1016/S1097-2765(00)80172-0
   Le Page F, 1998, NUCLEIC ACIDS RES, V26, P1276, DOI 10.1093/nar/26.5.1276
   Le XC, 1998, SCIENCE, V280, P1066, DOI 10.1126/science.280.5366.1066
   LEADON SA, 1992, J BIOL CHEM, V267, P23175
   Leadon SA, 1997, CANCER RES, V57, P3784
   LEADON SA, 1993, P NATL ACAD SCI USA, V90, P10499, DOI 10.1073/pnas.90.22.10499
   LEADON SA, 1988, DNA REPAIR LAB MANUA, P311
   Lindahl T, 1999, SCIENCE, V286, P1897, DOI 10.1126/science.286.5446.1897
   Lindahl T, 1997, CURR OPIN GENET DEV, V7, P158, DOI 10.1016/S0959-437X(97)80124-4
   MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6
   Mu D, 1996, J BIOL CHEM, V271, P8285, DOI 10.1074/jbc.271.14.8285
   Nouspikel T, 1997, P NATL ACAD SCI USA, V94, P3116, DOI 10.1073/pnas.94.7.3116
   Radicella JP, 1997, P NATL ACAD SCI USA, V94, P8010, DOI 10.1073/pnas.94.15.8010
   Reardon JT, 1997, P NATL ACAD SCI USA, V94, P9463, DOI 10.1073/pnas.94.17.9463
   RoldanArjona T, 1997, P NATL ACAD SCI USA, V94, P8016, DOI 10.1073/pnas.94.15.8016
   Rosenquist TA, 1997, P NATL ACAD SCI USA, V94, P7429, DOI 10.1073/pnas.94.14.7429
   SATOH MS, 1993, P NATL ACAD SCI USA, V90, P6335, DOI 10.1073/pnas.90.13.6335
   SCHERLY D, 1993, NATURE, V363, P182, DOI 10.1038/363182a0
   Selby CP, 1997, NUCLEIC ACIDS RES, V25, P787, DOI 10.1093/nar/25.4.787
   SHIBUTANI S, 1994, CANCER LETT, V83, P315, DOI 10.1016/0304-3835(94)90335-2
   STARY A, 1992, MUTAT RES, V272, P101, DOI 10.1016/0165-1161(92)90038-N
   Stucki M, 1998, ONCOGENE, V17, P835, DOI 10.1038/sj.onc.1202001
   Tantin D, 1998, J BIOL CHEM, V273, P27794, DOI 10.1074/jbc.273.43.27794
   THOMPSON LH, 1998, DNA DAMAGE REPAIR, V2, P335
   Tijsterman M, 1997, P NATL ACAD SCI USA, V94, P8027, DOI 10.1073/pnas.94.15.8027
   Tijsterman M, 1999, J BIOL CHEM, V274, P1199, DOI 10.1074/jbc.274.3.1199
   Tirode F, 1999, MOL CELL, V3, P87, DOI 10.1016/S1097-2765(00)80177-X
   Tornaletti S, 1999, BIOCHIMIE, V81, P139, DOI 10.1016/S0300-9084(99)80046-7
   Tu YQ, 1997, J BIOL CHEM, V272, P20747, DOI 10.1074/jbc.272.33.20747
   van Hoffen A, 1999, NUCLEIC ACIDS RES, V27, P2898, DOI 10.1093/nar/27.14.2898
   vanderHorst GTJ, 1997, CELL, V89, P425, DOI 10.1016/S0092-8674(00)80223-8
   vanGool AJ, 1997, EMBO J, V16, P4155, DOI 10.1093/emboj/16.14.4155
   VERMEULEN W, 1993, AM J HUM GENET, V53, P185
   Viswanathan A, 1998, J BIOL CHEM, V273, P21276, DOI 10.1074/jbc.273.33.21276
   Wagner J, 1997, J MOL BIOL, V265, P302, DOI 10.1006/jmbi.1996.0740
   Wakasugi M, 1997, J BIOL CHEM, V272, P16030, DOI 10.1074/jbc.272.25.16030
   Wilson DM, 1997, P NATL ACAD SCI USA, V94, P12754, DOI 10.1073/pnas.94.24.12754
   You ZY, 1998, MOL CELL BIOL, V18, P2668, DOI 10.1128/MCB.18.5.2668
NR 68
TC 271
Z9 272
U1 2
U2 14
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 0092-8674
EI 1097-4172
J9 CELL
JI Cell
PD APR 14
PY 2000
VL 101
IS 2
BP 159
EP 171
DI 10.1016/S0092-8674(00)80827-2
PG 13
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 305DP
UT WOS:000086524400003
PM 10786832
OA Bronze
DA 2018-12-27
ER

PT J
AU Mori, N
   Vada, A
   Hirayama, T
   Parks, TP
   Stratowa, C
   Yamamoto, N
AF Mori, N
   Vada, A
   Hirayama, T
   Parks, TP
   Stratowa, C
   Yamamoto, N
TI RETRACTED: Activation of intercellular adhesion molecule 1 expression by
   Helicobacter pylori is regulated by NF-kappa B in gastric epithelial
   cancer cells (Retracted article. See vol. 79, pg. 542, 2011)
SO INFECTION AND IMMUNITY
LA English
DT Article; Retracted Publication
ID HUMAN ENDOTHELIAL-CELLS; NECROSIS-FACTOR-ALPHA; INTERLEUKIN-8
   PRODUCTION; INDUCED INFLAMMATION; ANTRAL GASTRITIS; GENE-EXPRESSION;
   LINES; INFECTION; DISEASE; ICAM-1
AB Interactions between leukocytes and epithelial cells may play a key role in Helicobacter pylori-associated gastric mucosal inflammation. This process is mediated by various cell adhesion molecules. The present study examined the molecular mechanisms leading to H. pylori-induced epithelial cell intercellular adhesion molecule-1 (ICAM-1; also called CD54) expression. Coculture of epithelial cells dth cytotoxin-associated gene pathogenicity island-positive (cag PAI(+)) H. pylori strains, but not with a cag PAI(-) strain or H. pylori culture supernatants, resulted in upregulation of steady-state mRNA levels and cell surface expression of ICAM-1. Coculture with H. pylori induced an increase in luciferase activity in cells which were transfected with a luciferase reporter gene linked to the 5'-flanking region of the ICAM-1 gene. H. pylori activated the ICAM-1 promoter via the NF-kappa B binding site. An inducible nuclear protein complex bound to the ICAM-1 NF-kappa B site and was identified as the NF-kappa B p50-p65 heterodimer, H. pylori induced the degradation of I kappa B-alpha, a major cytoplasmic inhibitor of NF-kappa B, and stimulated the expression of I kappa B-alpha mRNA Pretreatment of epithelial cells with pyrrolidine dithiocarbamate, which blocks NF-kappa B activation, inhibited RT, pylori-induced ICAM-1 expression. THP-1 macrophagic cells, peripheral blood mononuclear cells, and purified neutrophils adhered to RI. pylori-infected epithelial cells to a greater extent than to uninfected cells. These results show that H. pylori directly induces expression of ICAM-1 on gastric epithelial cells in an NF-kappa B-dependent manner that may support leukocyte attachment during inflammation.
C1 Nagasaki Univ, Inst Trop Med, Dept Prevent & AIDS Res, Nagasaki 8528523, Japan.
   Nagasaki Univ, Inst Trop Med, Dept Bacteriol, Nagasaki 8528523, Japan.
   Boehringer Ingelheim Pharmaceut Inc, Dept Inflammatory Dis, Ridgefield, CT 06877 USA.
   Ernst Boehringer Inst Arzneimittelforsch, A-1121 Vienna, Austria.
RP Mori, N (reprint author), Nagasaki Univ, Inst Trop Med, Dept Prevent & AIDS Res, 1-12-4 Sakamoto, Nagasaki 8528523, Japan.
EM n-mori@net.nagasaki-u.ac.jp
CR Aihara M, 1997, INFECT IMMUN, V65, P3218
   ANTALIS TM, 1991, NUCLEIC ACIDS RES, V19, P4301, DOI 10.1093/nar/19.15.4301
   BENHAM FJ, 1984, EMBO J, V3, P2635, DOI 10.1002/j.1460-2075.1984.tb02186.x
   BLASER MJ, 1992, GASTROENTEROLOGY, V102, P720, DOI 10.1016/0016-5085(92)90126-J
   Brennan P, 1996, BIOCHEM J, V320, P975, DOI 10.1042/bj3200975
   Censini S, 1996, P NATL ACAD SCI USA, V93, P14648, DOI 10.1073/pnas.93.25.14648
   COVER TL, 1992, ANNU REV MED, V43, P135, DOI 10.1146/annurev.med.43.1.135
   CRABTREE JE, 1995, J CLIN PATHOL, V48, P41, DOI 10.1136/jcp.48.1.41
   CRABTREE JE, 1994, J CLIN PATHOL, V47, P61, DOI 10.1136/jcp.47.1.61
   CRABTREE JE, 1994, J CLIN PATHOL, V47, P945, DOI 10.1136/jcp.47.10.945
   CRABTREE JE, 1991, GUT, V32, P1473, DOI 10.1136/gut.32.12.1473
   El Kaissouni J, 1998, DIGESTION, V59, P53, DOI 10.1159/000007467
   GIONCHETTI P, 1994, AM J GASTROENTEROL, V89, P883
   GRAHAM DY, 1992, EUR J GASTROEN HEPAT, V4, pS9
   HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q
   Hatz RA, 1997, GASTROENTEROLOGY, V112, P1908, DOI 10.1053/gast.1997.v112.pm9178683
   Higuchi K, 1997, J CLIN GASTROENTEROL, V25, pS215, DOI 10.1097/00004836-199700001-00034
   HOU JZ, 1994, P NATL ACAD SCI USA, V91, P11641, DOI 10.1073/pnas.91.24.11641
   HUANG JZ, 1995, INFECT IMMUN, V63, P1732
   KAISERLIAN D, 1991, EUR J IMMUNOL, V21, P2415, DOI 10.1002/eji.1830211018
   KAWAI M, 1995, J IMMUNOL, V154, P2333
   Keates S, 1997, GASTROENTEROLOGY, V113, P1099, DOI 10.1053/gast.1997.v113.pm9322504
   KVALE D, 1992, SCAND J IMMUNOL, V35, P669, DOI 10.1111/j.1365-3083.1992.tb02973.x
   LEBAIL O, 1993, EMBO J, V12, P5043, DOI 10.1002/j.1460-2075.1993.tb06197.x
   LEDEBUR HC, 1995, J BIOL CHEM, V270, P933, DOI 10.1074/jbc.270.2.933
   LOOK DC, 1994, J BIOL CHEM, V269, P8952
   MOSS SF, 1994, GUT, V35, P1567, DOI 10.1136/gut.35.11.1567
   Munoz C, 1996, BLOOD, V88, P3482
   NOACH LA, 1994, SCAND J GASTROENTERO, V29, P425, DOI 10.3109/00365529409096833
   NOMURA A, 1991, NEW ENGL J MED, V325, P1132, DOI 10.1056/NEJM199110173251604
   Sharma SA, 1998, J IMMUNOL, V160, P2401
   SHARMA SA, 1995, INFECT IMMUN, V63, P1681
   SUZUKI T, 1995, ONCOGENE, V10, P1199
   YAMADA T, 1994, JAMA-J AM MED ASSOC, V272, P65, DOI 10.1001/jama.1994.03520010077036
NR 34
TC 27
Z9 31
U1 1
U2 7
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0019-9567
J9 INFECT IMMUN
JI Infect. Immun.
PD APR
PY 2000
VL 68
IS 4
BP 1806
EP 1814
DI 10.1128/IAI.68.4.1806-1814.2000
PG 9
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 296EP
UT WOS:000086010300008
PM 10722567
OA Bronze
DA 2018-12-27
ER

PT J
AU Ziman, MR
   Pelham, JT
   Mastaglia, FL
   Kay, PH
AF Ziman, MR
   Pelham, JT
   Mastaglia, FL
   Kay, PH
TI RETRACTED: Characterization of the alternate allelic forms of human PAX7
   (Retracted Article. See vol 12, pg 943, 2001)
SO MAMMALIAN GENOME
LA English
DT Article; Retracted Publication
ID INCLUSION-BODY MYOSITIS; PAIRED BOX TRANSCRIPTS; SKELETAL-MUSCLE; ADULT
   MICE; GENE; EXPRESSION; PROTEIN; CONSERVATION; DOMAIN
AB Six different allelic forms of the human neurogenic and myogenic developmental gene, PAX7, have been identified. They are distinguished by the number of tandem tetranucleotide, GAAG, repeats at a polymorphic site within the second intron of the paired box. Within the same intron, a second polymorphic site was found to have variable numbers of a dinucleotide TG repeat. The alleles are identified by a PCR-based method with oligo primers that span the variable regions of the intron. Several of the alleles include a duplicate copy of the entire paired box. Segregation studies demonstrate that the PAX7 alleles are inherited in a Mendelian fashion and that the duplicate copies of the PAX7 paired box region present in some of the alleles are closely linked, This initial study identified differences in the distribution of PAX7 alleles in DNA from patients with the skeletal muscle myopathy, dermatomyositis. Recognition of genetic polymorphism of PAX7 allows new approaches to understanding the role of PAX7 in myogenesis, neurogenesis, and neuromuscular disorders.
C1 Univ Western Australia, Dept Pathol, Nedlands, WA 6907, Australia.
   Univ Western Australia, Dept Med, Nedlands, WA 6907, Australia.
RP Ziman, MR (reprint author), Univ Western Australia, Dept Pathol, Nedlands, WA 6907, Australia.
EM mziman@cyllene.uwa.edu.au
RI Ziman, Mel/A-2272-2008
OI Ziman, Mel/0000-0001-7527-3538
CR Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389
   Balczarek KA, 1997, MOL BIOL EVOL, V14, P829, DOI 10.1093/oxfordjournals.molbev.a025824
   BOPP D, 1986, CELL, V47, P1033, DOI 10.1016/0092-8674(86)90818-4
   BURRI M, 1989, EMBO J, V8, P1183, DOI 10.1002/j.1460-2075.1989.tb03490.x
   Cox R, 1997, P NATL ACAD SCI USA, V94, P5237, DOI 10.1073/pnas.94.10.5237
   DALAKAS MC, 1991, NEW ENGL J MED, V325, P1487, DOI 10.1056/NEJM199111213252107
   FICKENSCHER HR, 1993, DNA CELL BIOL, V12, P381, DOI 10.1089/dna.1993.12.381
   Fox SA, 1996, MUSCLE NERVE, V19, P23, DOI 10.1002/(SICI)1097-4598(199601)19:1<23::AID-MUS4>3.3.CO;2-Y
   GOULDING MD, 1993, DEVELOPMENT, V117, P1001
   GRUSS P, 1992, CELL, V69, P719, DOI 10.1016/0092-8674(92)90281-G
   Hol FA, 1996, J MED GENET, V33, P655, DOI 10.1136/jmg.33.8.655
   JOSTES B, 1990, MECH DEVELOP, V33, P27, DOI 10.1016/0925-4773(90)90132-6
   KARPATI G, 1993, BAILLIERE CLIN NEUR, V2, P527
   Kay PH, 1998, INT J BIOCHEM CELL B, V30, P261, DOI 10.1016/S1357-2725(97)00108-8
   KAY PH, 1995, GENE, V163, P171, DOI 10.1016/0378-1119(95)00368-G
   Kay PH, 1997, GENE, V184, P45, DOI 10.1016/S0378-1119(96)00572-0
   Kay PH, 1999, GENE, V230, P55, DOI 10.1016/S0378-1119(99)00049-9
   KRAUSS S, 1991, DEVELOPMENT, V113, P1193
   Maniatis T., 1982, MOL CLONING LAB MANU
   SANYANUSIN P, 1995, NAT GENET, V9, P358, DOI 10.1038/ng0495-358
   SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0
   STOYKOVA A, 1994, J NEUROSCI, V14, P1395
   Vorobyov E, 1997, GENOMICS, V45, P168, DOI 10.1006/geno.1997.4915
   WALTHER C, 1991, DEVELOPMENT, V113, P1435
   Ziman MR, 1997, INT J BIOCHEM CELL B, V29, P1029, DOI 10.1016/S1357-2725(97)00023-X
   Ziman MR, 1998, GENE, V217, P77, DOI 10.1016/S0378-1119(98)00353-9
NR 26
TC 4
Z9 4
U1 2
U2 9
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0938-8990
EI 1432-1777
J9 MAMM GENOME
JI Mamm. Genome
PD APR
PY 2000
VL 11
IS 4
BP 332
EP 337
DI 10.1007/s003350010061
PG 6
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity
GA 305LQ
UT WOS:000086541900013
PM 10754111
DA 2018-12-27
ER

PT J
AU Sogawa, K
   Yamada, T
   Sumida, T
   Hamakawa, H
   Kuwabara, H
   Matsuda, M
   Muramatsu, Y
   Kose, H
   Matsumoto, K
   Sasaki, Y
   Okutani, K
   Kondo, K
   Monden, Y
AF Sogawa, K
   Yamada, T
   Sumida, T
   Hamakawa, H
   Kuwabara, H
   Matsuda, M
   Muramatsu, Y
   Kose, H
   Matsumoto, K
   Sasaki, Y
   Okutani, K
   Kondo, K
   Monden, Y
TI RETRACTED: Induction of apoptosis and inhibition of DNA topoisomerase-I
   in K-562 cells by a marine microalgal polysaccharide (Retracted Article.
   See vol 71, pg 2575, 2002)
SO LIFE SCIENCES
LA English
DT Article; Retracted Publication
DE microalgal polysaccharide; apoptosis; topoisomerase-I; K562 cells
ID CAMPTOTHECIN
AB We have previously purified an extracellular polysaccharide, D-galactan sulfate associated with L(+)-lactic acid, produced from a marine microalga Dinoflagellate Gymnodinium sp. A(3) (GA3). The GA3 polysaccharide, irrespective of presence or absence of lactic acid, exhibited significant cytotoxicity, which is based on an induction of apoptotic cell death, toward human myeloid leukemia K562 cells. Furthermore, we found that the GA3 polysaccharide with or without lactic acid possesses an inhibitory effect on topoisomerase-I (topo-I). The potent cytotoxic effect of GA3 polysaccharide may result from its inhibitory effect on topo-I, because the topo-I inhibition is known to trigger apoptotic cell death. (C) 2000 Elsevier Science Inc.
C1 Kyoto Univ, Grad Sch Agr, Dept Anim Genet & Breeding, Sakyo Ku, Kyoto 6068502, Japan.
   Univ Tokushima, Sch Med, Dept Surg 2, Tokushima 7700042, Japan.
   Univ Tokushima, Sch Med, Inst Anim Experimentat, Tokushima 7700042, Japan.
   Ehime Univ, Sch Med, Dept Oral Surg, Matsuyama, Ehime 7910204, Japan.
   Kagawa Med Coll, Dept Pathol, Kagawa 7610701, Japan.
   Kagawa Univ, Fac Agr, Dept Bioresource Sci, Kagawa 7610701, Japan.
RP Yamada, T (reprint author), Kyoto Univ, Grad Sch Agr, Dept Anim Genet & Breeding, Sakyo Ku, Kyoto 6068502, Japan.
EM tyamada@jkans.jkans.kais.kyoto-u.ac.jp
RI Kondo, Kazuya/J-9163-2012
CR HASUI M, 1995, FISHERIES SCI, V61, P321, DOI 10.2331/fishsci.61.321
   HSIANG YH, 1985, J BIOL CHEM, V260, P4873
   ISHII K, 1983, J BIOL CHEM, V258, P2728
   ISHII K, 1987, BIOCHEM J, V241, P111, DOI 10.1042/bj2410111
   Morris EJ, 1996, J CELL BIOL, V134, P757, DOI 10.1083/jcb.134.3.757
   Sogawa K, 1998, RES COMMUN MOL PATH, V99, P259
   Sogawa K, 1998, J MAR BIOTECHNOL, V6, P35
   WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665
NR 8
TC 4
Z9 5
U1 3
U2 13
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0024-3205
J9 LIFE SCI
JI Life Sci.
PD MAR 10
PY 2000
VL 66
IS 16
BP PL227
EP PL231
DI 10.1016/S0024-3205(00)00473-2
PG 5
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA 293TU
UT WOS:000085870100011
PM 10794503
DA 2018-12-27
ER

PT J
AU Lezcano, N
   Mrzljak, L
   Eubanks, S
   Levenson, R
   Goldman-Rakic, P
   Bergson, C
AF Lezcano, N
   Mrzljak, L
   Eubanks, S
   Levenson, R
   Goldman-Rakic, P
   Bergson, C
TI RETRACTED: Dual signaling regulated by calcyon, a D1 dopamine receptor
   interacting protein (Retracted Article. See vol 314, pg 1681, 2006)
SO SCIENCE
LA English
DT Article; Retracted Publication
ID PREFRONTAL CORTEX; GOLGI-APPARATUS; CEREBRAL-CORTEX; PRIMATE BRAIN;
   MESSENGER-RNA; LOCALIZATION; RAT; D-1; MODULATION; NEURONS
AB The synergistic response of cells to the stimulation of multiple receptors has been ascribed to receptor cross talk: however, the specific molecules that mediate the resultant signal amplification have not been defined. Here a 24-kilodalton single transmembrane protein, designated calcyon, we functionally characterize that interacts with the D1 dopamine receptor. Calcyon Localizes to dendritic spines of D1 receptor-expressing pyramidal cells in prefrontal cortex. These studies delineate a mechanism of G(q)- and G(s)-coupled heterotrimeric CTP-binding protein-coupled receptor cross talk by which D1 receptors can shift effector coupling to stimulate robust intracellular calcium (Ca(i)(2+)) release as a result of interaction with calcyon. The role of calcyon in potentiating Ca(2+)-dependent signaling should provide insight into the D1 receptor-modulated cognitive functions of prefrontal cortex.
C1 Med Coll Georgia, Dept Pharmacol & Toxicol, Augusta, GA 30912 USA.
   Yale Univ, Sch Med, Neurobiol Sect, New Haven, CT 06510 USA.
   Penn State Univ, Coll Med, Dept Pharmacol, Hershey, PA 17033 USA.
RP Bergson, C (reprint author), Med Coll Georgia, Dept Pharmacol & Toxicol, Augusta, GA 30912 USA.
EM cbergson@mail.mcg.edu
FU NIMH NIH HHS [MH56608, R01 MH063271, P50 MH44866, P50 MH068789]
CR Bergson C, 1995, J NEUROSCI, V15, P7821
   CASTNER SA, IN PRESS SCIENCE
   CEPEDA C, 1992, SYNAPSE, V11, P330, DOI 10.1002/syn.890110408
   DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555
   FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0
   GOLDMANRAKIC PS, 1990, J NEUROSCI, V10, P2125
   GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440
   Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669
   HUANG YY, 1995, P NATL ACAD SCI USA, V92, P2446, DOI 10.1073/pnas.92.7.2446
   Konradi C, 1996, J NEUROSCI, V16, P4231
   KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   LEZCANO N, UNPUB
   MRZLJAK L, 1993, P NATL ACAD SCI USA, V90, P5194, DOI 10.1073/pnas.90.11.5194
   Mrzljak L, 1998, J COMP NEUROL, V390, P112
   Mrzljak L, 1996, NATURE, V381, P245, DOI 10.1038/381245a0
   Richards F. M., 1971, ENZYMES, V4, P647
   Saberan-Djoneidi D, 1998, J BIOL CHEM, V273, P3909, DOI 10.1074/jbc.273.7.3909
   SABERANDJONEIDI D, 1995, J BIOL CHEM, V270, P1888, DOI 10.1074/jbc.270.4.1888
   SMILEY JF, 1994, P NATL ACAD SCI USA, V91, P5720, DOI 10.1073/pnas.91.12.5720
   SUTCLIFFE JG, 1983, CELL, V33, P671, DOI 10.1016/0092-8674(83)90010-7
   TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350
   UNDIE AS, 1990, J PHARMACOL EXP THER, V253, P987
   UNDIE AS, 1994, J NEUROCHEM, V62, P2045
   UNDIE AS, 1994, J NEUROCHEM, V63, P222
   Wang HY, 1995, MOL PHARMACOL, V48, P988
   Wang JQ, 1997, J PHARMACOL EXP THER, V281, P972
   Wang Q, 1997, J BIOL CHEM, V272, P26040, DOI 10.1074/jbc.272.41.26040
   WILLIAMS GV, 1995, NATURE, V376, P572, DOI 10.1038/376572a0
   YU PY, 1995, J CLIN INVEST, V95, P304, DOI 10.1172/JCI117656
   YUNG KKL, 1995, NEUROSCIENCE, V65, P709, DOI 10.1016/0306-4522(94)00536-E
   ZHOU QY, 1990, NATURE, V347, P76, DOI 10.1038/347076a0
NR 32
TC 134
Z9 141
U1 3
U2 14
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
J9 SCIENCE
JI Science
PD MAR 3
PY 2000
VL 287
IS 5458
BP 1660
EP 1664
DI 10.1126/science.287.5458.1660
PG 5
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 289NE
UT WOS:000085628200041
PM 10698743
DA 2018-12-27
ER

PT J
AU Tahmaz, L
   Gokalp, A
   Kibar, Y
   Kocak, I
   Yalcin, O
   Ozercan, Y
AF Tahmaz, L
   Gokalp, A
   Kibar, Y
   Kocak, I
   Yalcin, O
   Ozercan, Y
TI RETRACTED: Effect of hypothyroidism on the testes in mature rats and
   treatment with levothyroxine and zinc (Retracted article. See vol. 41,
   pg. 392, 2009)
SO ANDROLOGIA
LA English
DT Article; Retracted Publication
DE hypothyroidism; levothyroxine; rat; zinc
ID PROPYLTHIOURACIL; GROWTH
AB This study was performed to investigate the effect of propylthiouracil (PTU) on rat testis, and to compare the results of the different treatment regimens of levothyroxine and zinc. Twenty sexually mature Wistar albino rats were subjected to PTU for 14 days intraperitoneally to make them hypothyroidic. The effect of PTU on testicular function was assessed histopathologically after unilateral orchiectomy on day 15, and treatment was evaluated by measuring serum thyroid-stimulating hormone (TSH), T3, T4, and zinc levels on days 0, 7, and 15. The rats were then divided into five groups which were given levothyroxine and/or zinc treatment for 15 days. Orchiectomies were repeated on day 30, and specimens were evaluated histopathologically. Although serum T3, T4 and zinc levels decreased, serum TSH levels increased in PTU-treated rats, and the difference to the control group was statistically significant (P < 0.001). Maturation arrest of spermatogenesis, a reduced number of Sertoli and Leydig cells, a decreased tubular diameter, interstitial oedema, and thickening of basal membrane were observed in hypothyroidic testicles. After treatment, testicular histology and spermatogenesis gradually recovered in all groups with hypothyroidism, but maximum improvement was achieved in the levothyroxine + zinc sulphate replacement group, indicating a possible role of zinc in testicular function.
C1 Gulhane Mil Med Acad, Dept Urol, TR-06010 Ankara, Turkey.
   Adnan Menderes Univ, Fac Med, Dept Urol, Aydin, Turkey.
   Fyrat Univ, Med Ctr, Dept Urol & Pathol, Elazig, Turkey.
RP Tahmaz, L (reprint author), Gulhane Mil Med Acad, Dept Urol, TR-06010 Ankara, Turkey.
EM agokalp@gara.edu.tr
CR BEDWAL RS, 1994, EXPERIENTIA, V50, P626, DOI 10.1007/BF01952862
   CHAN WY, 1995, J EXP ZOOL, V273, P160, DOI 10.1002/jez.1402730209
   COOKE PS, 1992, BIOL REPROD, V46, P146, DOI 10.1095/biolreprod46.1.146
   DEFRANCA LR, 1995, ANAT REC, V242, P57, DOI 10.1002/ar.1092420108
   DOLEV E, 1988, METABOLISM, V37, P61, DOI 10.1016/0026-0495(88)90030-3
   LEBONDEL G, 1992, BIO TRACE ELEMENT RE, V32, P281
   MEISAMI E, 1994, CELL TISSUE RES, V275, P503, DOI 10.1007/BF00318819
   Nair Neena, 1995, Indian Journal of Experimental Biology, V33, P655
   PALMERO S, 1995, J ENDOCRINOL, V145, P355, DOI 10.1677/joe.0.1450355
   STAUB JJ, 1992, AM J MED, V92, P631, DOI 10.1016/0002-9343(92)90782-7
   Utiger R. D., 1995, ENDOCRINOL METAB, P435
NR 11
TC 24
Z9 25
U1 3
U2 12
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0303-4569
EI 1439-0272
J9 ANDROLOGIA
JI Andrologia
PD MAR
PY 2000
VL 32
IS 2
BP 85
EP 89
DI 10.1046/j.1439-0272.2000.00324.x
PG 5
WC Andrology
SC Endocrinology & Metabolism
GA 296HP
UT WOS:000086019200002
PM 10755190
DA 2018-12-27
ER

PT J
AU Fujii, Y
   Tanaka, H
   Kawasaki, T
AF Fujii, Y
   Tanaka, H
   Kawasaki, T
TI RETRACTED: Randomized clinical trial of granisetron, droperidol and
   metoclopramide for the treatment of nausea and vomiting after
   laparoscopic cholecystectomy (Retracted article. See vol. 100, pg. 844,
   2013)
SO BRITISH JOURNAL OF SURGERY
LA English
DT Article; Retracted Publication
ID POSTOPERATIVE NAUSEA; RECEPTOR ANTAGONIST; PREVENTION; ONDANSETRON
AB Background: Patients undergoing laparoscopic cholecystectomy (LC) may be especially at risk of experiencing postoperative nausea and vomiting (PONV). This study was undertaken to evaluate the efficacy of granisetron, droperidol and metoclopramide for the treatment of PONV after LC.
   Methods: After experiencing PONV during the first 3 h after recovery from anaesthesia, 120 patients (78 women) received, in a randomized double-blind manner, granisetron 40 mu g/kg, droperidol 20 mu g/kg or metoclopramide 0.2 mg/kg (n=40 per group) intravenously. Patients were then observed for 24 h after administration of the study drug.
   Results: Complete control of established PONV, defined as no emetic symptoms and no need for another rescue antiemetic medication, was achieved in 88 per cent of patients with granisetron, 60 per cent with droperidol and 55 per cent with metoclopramide (P<0.05). No clinically adverse events were observed in any of the groups.
   Conclusion: A high dose of granisetron (40 mu g/kg) was more effective than droperidol 20 mu g/kg or metoclopramide 0.2 mg/kg for the treatment of established PONV after LC.
C1 Toride Kyodo Gen Hosp, Dept Anaesthesiol, Toride, Ibaraki, Japan.
   Toride Kyodo Gen Hosp, Dept Surg, Toride, Ibaraki, Japan.
RP Fujii, Y (reprint author), Univ Tsukuba, Inst Clin Med, Dept Anaesthesiol, 2-1-1 Amakubo, Tsukuba, Ibaraki 305, Japan.
CR ADREWS PLR, 1992, EJC SUPPL, V28, pS2
   BERMUDEZ J, 1988, BRIT J CANCER, V58, P644, DOI 10.1038/bjc.1988.277
   CARMICHAEL J, 1989, CANCER CHEMOTH PHARM, V24, P45
   COHEN SE, 1984, ANESTHESIOLOGY, V60, P67, DOI 10.1097/00000542-198401000-00015
   Diemunsch P, 1997, BRIT J ANAESTH, V79, P322, DOI 10.1093/bja/79.3.322
   Fujii Y, 1997, CAN J ANAESTH, V44, P396, DOI 10.1007/BF03014460
   Fujii Y, 1998, EUR J ANAESTH, V15, P287, DOI 10.1017/S0265021598000556
   Furue H, 1990, J CLIN THERAPEUTIC M, V6, P49
   Iitomi T, 1995, Masui, V44, P1627
   KORTTILA K, 1979, ANESTH ANALG, V58, P396
   MCKENZIE R, 1993, ANESTHESIOLOGY, V78, P21, DOI 10.1097/00000542-199301000-00005
   SANTON JM, 1991, ANAESTHESIA, V46, P317
   WATCHA MF, 1992, ANESTHESIOLOGY, V77, P162, DOI 10.1097/00000542-199207000-00023
NR 13
TC 21
Z9 22
U1 3
U2 10
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0007-1323
J9 BRIT J SURG
JI Br. J. Surg.
PD MAR
PY 2000
VL 87
IS 3
BP 285
EP 288
DI 10.1046/j.1365-2168.2000.01393.x
PG 4
WC Surgery
SC Surgery
GA 300HU
UT WOS:000086247900006
PM 10718795
DA 2018-12-27
ER

PT J
AU Schuchmann, S
   Heinemann, U
AF Schuchmann, S
   Heinemann, U
TI RETRACTED: Diminished glutathione levels cause spontaneous and
   mitochondria-mediated cell death in neurons from trisomy 16 mice: A
   model of Down's syndrome (Retracted article. See vol. 122, pg. 483,
   2012)
SO JOURNAL OF NEUROCHEMISTRY
LA English
DT Article; Retracted Publication
DE Down's syndrome; glutathione; mitochondria; cyclosporin A; tocopherol
ID PERMEABILITY TRANSITION PORE; OXIDATIVE STRESS; HIPPOCAMPAL-NEURONS;
   NEURODEGENERATIVE DISORDERS; SUPEROXIDE-DISMUTASE; CALCIUM HOMEOSTASIS;
   RECEPTOR ACTIVATION; FOREBRAIN NEURONS; AMINO-ACIDS; GLIAL-CELLS
AB It has been suggested that the increased neuronal death in cultures from trisomy 16 (Ts16) mice, a model of Down's syndrome, might result from a diminished concentration of reduced glutathione (GSH). In this study we used microfluorometric techniques to investigate the effect of GSH levels on neuronal survival in diploid and Ts16 cultures. Addition of the GSH precursors cysteine and cystine and the antioxidant tocopherol to the culture medium increased the GSH concentration up to 126.0% in diploid and up to 111.9% in Ts16 neurons. Moreover, we observed a reduced spontaneous neuronal death rate in diploid and Ts16 cultures, Following the application of 50-100 mu M glutamate to culture medium, we found a GSH increase in the presence of cysteine, cystine, tocopherol, and cyclosporin A, an inhibitor of mitochondrial permeability transition (diploid, 105.8-110.8%; Ts16, 83.1-96.3%). However, only tocopherol and cyclosporin A had a protective effect on glutamate-induced neuronal death, The results suggest that reduced GSH levels affect the increase of a spontaneous and a mitochondria-mediated, cyclosporin A-sensitive type of neuronal cell death, Therefore, elevating intracellular GSH concentration may have neuroprotective effects in Down's syndrome and Alzheimer's disease.
C1 Humboldt Univ, Inst Physiol, D-10117 Berlin, Germany.
RP Schuchmann, S (reprint author), Humboldt Univ, Inst Physiol, Tucholskystr 2, D-10117 Berlin, Germany.
EM sebastian.schuchmann@charite.de
CR ANDERSON ME, 1985, METHOD ENZYMOL, V113, P548
   AVRAHAM KB, 1988, CELL, V54, P823, DOI 10.1016/S0092-8674(88)91153-1
   Bains JS, 1997, BRAIN RES REV, V25, P335, DOI 10.1016/S0165-0173(97)00045-3
   BAMBRICK LL, 1995, P NATL ACAD SCI USA, V92, P9692, DOI 10.1073/pnas.92.21.9692
   BANNAI S, 1986, J MEMBRANE BIOL, V89, P1, DOI 10.1007/BF01870891
   BEHL C, 1994, CELL, V77, P817, DOI 10.1016/0092-8674(94)90131-7
   BENRARDI P, 1996, BIOCHIM BIOPHYS ACTA, V1275, P5
   Brookes PS, 1998, J NEUROCHEM, V70, P2195
   BUSCIGLIO J, 1995, NATURE, V378, P776, DOI 10.1038/378776a0
   CHOI DW, 1995, TRENDS NEUROSCI, V18, P58
   CLARKE DD, 1991, NEUROCHEM RES, V16, P1055, DOI 10.1007/BF00965850
   COLTON CA, 1990, BRAIN RES, V519, P236, DOI 10.1016/0006-8993(90)90083-N
   Cooper AJL, 1997, BIOL CHEM, V378, P793
   COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908
   Dringen R, 1996, J NEUROCHEM, V67, P1375, DOI 10.1046/j.1471-4159.1996.67041375.x
   Dringen R, 1999, J NEUROSCI, V19, P562
   DUBINSKY JM, 1995, NEUROPHARMACOLOGY, V34, P701, DOI 10.1016/0028-3908(95)00041-4
   Duchen MR, 1999, J PHYSIOL-LONDON, V516, P1, DOI 10.1111/j.1469-7793.1999.001aa.x
   DUGAN LL, 1995, J NEUROSCI, V15, P6377
   EPSTEIN CJ, 1986, NEUROBIOLOGY DOWN SY
   FERNANDEZCHECA JC, 1990, ANAL BIOCHEM, V190, P212, DOI 10.1016/0003-2697(90)90183-A
   GALDZICKI Z, 1993, BRAIN RES, V604, P69, DOI 10.1016/0006-8993(93)90353-O
   GRONER Y, 1994, BIOMED PHARMACOTHER, V48, P231, DOI 10.1016/0753-3322(94)90138-4
   GUNTER TE, 1994, AM J PHYSIOL, V267, pC313
   HULBERT PB, 1983, J PHARM PHARMACOL, V35, P384, DOI 10.1111/j.2042-7158.1983.tb02962.x
   JAIN A, 1991, P NATL ACAD SCI USA, V88, P1913, DOI 10.1073/pnas.88.5.1913
   KATO S, 1993, NEUROSCIENCE, V57, P473, DOI 10.1016/0306-4522(93)90080-Y
   Kowaltowski AJ, 1996, FEBS LETT, V378, P150, DOI 10.1016/0014-5793(95)01449-7
   Kranich O, 1996, NEUROSCI LETT, V219, P211, DOI 10.1016/S0304-3940(96)13217-1
   Lane NJ, 1996, CELL BIOL INT, V20, P673, DOI 10.1006/cbir.1996.0089
   MAKAR TK, 1994, J NEUROCHEM, V62, P45
   MATTSON MP, 1992, J NEUROSCI, V12, P376
   MATTSON MP, 1995, METHOD CELL BIOL, V46, P187
   MATTSON MP, 1993, EXP NEUROL, V121, P1, DOI 10.1006/exnr.1993.1066
   MEISTER A, 1988, J BIOL CHEM, V263, P17205
   MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431
   MURPHY TH, 1989, NEURON, V2, P1547, DOI 10.1016/0896-6273(89)90043-3
   NEUSCHWANDERTETRI BA, 1989, ANAL BIOCHEM, V179, P236, DOI 10.1016/0003-2697(89)90121-8
   Nicolli A, 1996, J BIOL CHEM, V271, P2185, DOI 10.1074/jbc.271.4.2185
   NIEMINEN AL, 1990, OPTICAL MICROSCOPY FOR BIOLOGY, P323
   Nieminen AL, 1996, NEUROSCIENCE, V75, P993
   PEACOCK JH, 1979, BRAIN RES, V169, P231, DOI 10.1016/0006-8993(79)91027-8
   REED DJ, 1995, BBA-MOL BASIS DIS, V1271, P43, DOI 10.1016/0925-4439(95)00008-R
   REYNOLDS IJ, 1995, J NEUROSCI, V15, P3318
   RICHARDS SJ, 1991, EMBO J, V10, P297, DOI 10.1002/j.1460-2075.1991.tb07950.x
   RICHTER C, 1991, CHEM-BIOL INTERACT, V77, P1, DOI 10.1016/0009-2797(91)90002-O
   RICHTER C, 1995, BBA-MOL BASIS DIS, V1271, P67, DOI 10.1016/0925-4439(95)00012-S
   SAGARA J, 1993, J NEUROCHEM, V61, P1672, DOI 10.1111/j.1471-4159.1993.tb09802.x
   SAVAGE MK, 1994, ARCH BIOCHEM BIOPHYS, V315, P142, DOI 10.1006/abbi.1994.1483
   Scanlon JM, 1998, J NEUROCHEM, V71, P2392
   Schinder AF, 1996, J NEUROSCI, V16, P6125
   Schuchmann S, 1998, J NEUROSCI, V18, P7216
   SINET PM, 1982, ANN NY ACAD SCI, V396, P83, DOI 10.1111/j.1749-6632.1982.tb26845.x
   StabelBurow J, 1997, BRAIN RES, V765, P313, DOI 10.1016/S0006-8993(97)00480-0
   VANDEWATER B, 1994, J BIOL CHEM, V269, P14546
   White RJ, 1996, J NEUROSCI, V16, P5688
   YIM MB, 1993, J BIOL CHEM, V268, P4099
   Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533
   ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367
NR 59
TC 22
Z9 22
U1 3
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-3042
EI 1471-4159
J9 J NEUROCHEM
JI J. Neurochem.
PD MAR
PY 2000
VL 74
IS 3
BP 1205
EP 1214
PG 10
WC Biochemistry & Molecular Biology; Neurosciences
SC Biochemistry & Molecular Biology; Neurosciences & Neurology
GA 284ME
UT WOS:000085335500035
PM 10693953
DA 2018-12-27
ER

PT J
AU Ma, ZX
   Liao, XB
   Kong, GL
   Chu, JH
AF Ma, ZX
   Liao, XB
   Kong, GL
   Chu, JH
TI RETRACTED: Absorption spectra of nanocrystalline silicon embedded in
   SiO2 matrix (Retracted article. See vol. 120, pg. 299, 2014)
SO MATERIALS LETTERS
LA English
DT Article; Retracted Publication
DE nanocrystalline silicon; absorption coefficient; photoluminescence
ID POROUS SILICON
AB Nanocrystalline silicon (nc-Si) embedded SiO2 matrix has been formed by annealing the SiOx films fabricated by plasma-enhanced chemical vapor deposition (PECVD) technique. Absorption coefficient and photoluminescence of the films have been measured at room temperature. The experimental results show that there is an "aUrbach-like" b exponential absorption in the spectral range of 2.0-3.0 eV. The relationship of (alpha hv)(1/2) proportional to(hv - E-g) demonstrates that the luminescent nc-Si have an indirect band structure. The existence of Stokes shift between photoluminescence and absorption edge indicates that radiative combination can take place not only between electron states and hole states but also between shallow trap states of electrons and holes. (C) 2000 Elsevier Science B.V. All rights reserved.
C1 Chinese Acad Sci, Shanghai Inst Tech Phys, Natl Lab Infrared Phys, Shanghai 200083, Peoples R China.
   Chinese Acad Sci, Inst Semicond, State Key Lab Surface Phys, Ctr Condensed Matter Phys, Beijing 100083, Peoples R China.
RP Ma, ZX (reprint author), Chinese Acad Sci, Shanghai Inst Tech Phys, Natl Lab Infrared Phys, Shanghai 200083, Peoples R China.
EM zxma@mail.sitp.ac.cn
CR CAMPBELL IH, 1986, SOLID STATE COMMUN, V58, P739, DOI 10.1016/0038-1098(86)90513-2
   CANBAM LT, 1990, APPL PHYS LETT, V57, P1046
   Hill NA, 1996, J ELECTRON MATER, V25, P269, DOI 10.1007/BF02666256
   Kanemitsu Y, 1996, PHYS REV B, V53, P13515, DOI 10.1103/PhysRevB.53.13515
   Kovalev D, 1996, J APPL PHYS, V80, P5978, DOI 10.1063/1.363595
   LEHMANN V, 1991, APPL PHYS LETT, V58, P856, DOI 10.1063/1.104512
   LEY L, TOP APPL PHYS, P56
   Ma ZX, 1998, J APPL PHYS, V83, P7934, DOI 10.1063/1.367973
   Nakajima A, 1996, J APPL PHYS, V80, P4006, DOI 10.1063/1.363359
   Pankove J. I, 1975, OPTICAL PROCESSES SE
   XIE YH, 1994, PHYS REV B, V49, P5386, DOI 10.1103/PhysRevB.49.5386
NR 11
TC 10
Z9 10
U1 3
U2 7
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0167-577X
EI 1873-4979
J9 MATER LETT
JI Mater. Lett.
PD MAR
PY 2000
VL 42
IS 6
BP 367
EP 370
DI 10.1016/S0167-577X(99)00206-2
PG 4
WC Materials Science, Multidisciplinary; Physics, Applied
SC Materials Science; Physics
GA 291DC
UT WOS:000085718000005
DA 2018-12-27
ER

PT J
AU Kugler, A
   Stuhler, G
   Walden, P
   Zoller, G
   Zobywalski, A
   Brossart, P
   Trefzer, U
   Ullrich, S
   Muller, CA
   Becker, V
   Gross, AJ
   Hemmerlein, B
   Kanz, L
   Muller, GA
   Ringert, RH
AF Kugler, A
   Stuhler, G
   Walden, P
   Zoller, G
   Zobywalski, A
   Brossart, P
   Trefzer, U
   Ullrich, S
   Muller, CA
   Becker, V
   Gross, AJ
   Hemmerlein, B
   Kanz, L
   Muller, GA
   Ringert, RH
TI RETRACTED: Regression of human metastatic renal cell carcinoma after
   vaccination with tumor cell-dendritic cell hybrids (Retracted article.
   See vol. 9, p. 1221, 2003)
SO NATURE MEDICINE
LA English
DT Article; Retracted Publication
ID T-LYMPHOCYTES; IMMUNITY; ANTIGEN; FUSION; CANCER
C1 Univ Gottingen, Dept Nephrol & Rheumatol, D-3400 Gottingen, Germany.
   Univ Gottingen, Dept Urol, D-3400 Gottingen, Germany.
   Univ Tubingen, Med Clin, Dept 2, Sect Transplantat Immunol & Immunohaematol, Tubingen, Germany.
   Humboldt Univ, Charite, Dept Dermatol, Berlin, Germany.
   Univ Gottingen, Dept Pathol, D-3400 Gottingen, Germany.
RP Muller, GA (reprint author), Univ Gottingen, Dept Nephrol & Rheumatol, D-3400 Gottingen, Germany.
EM gmueller@med.uni-goettingen.de; akugler@gwdg.de
CR ANICHINI A, 1989, J IMMUNOL, V142, P3692
   Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588
   Brossart P, 1999, BLOOD, V93, P4309
   Brossart P, 1998, CANCER RES, V58, P732
   Fujita K, 1999, BRIT J CANCER, V80, P301, DOI 10.1038/sj.bjc.6690355
   Gong JL, 1997, NAT MED, V3, P558, DOI 10.1038/nm0597-558
   Gong JL, 1998, P NATL ACAD SCI USA, V95, P6279, DOI 10.1073/pnas.95.11.6279
   GUO YJ, 1994, SCIENCE, V263, P518, DOI 10.1126/science.7507262
   Jantzer P, 1998, CANCER RES, V58, P3078
   Jayson GC, 1998, BRIT J CANCER, V78, P366, DOI 10.1038/bjc.1998.500
   Kugler A, 1998, BRIT J UROL, V82, P487
   Lokich J, 1997, AM J CLIN ONCOL-CANC, V20, P416, DOI 10.1097/00000421-199708000-00020
   SALLUSTO F, 1994, J EXP MED, V179, P110
   Stuhler G, 1999, P NATL ACAD SCI USA, V96, P1532, DOI 10.1073/pnas.96.4.1532
   STUHLER G, 1994, CANCER IMMUNOL IMMUN, V39, P342, DOI 10.1007/BF01519989
   Wang JL, 1998, J IMMUNOL, V161, P5516
NR 16
TC 523
Z9 563
U1 5
U2 30
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1078-8956
J9 NAT MED
JI Nat. Med.
PD MAR
PY 2000
VL 6
IS 3
BP 332
EP 336
PG 5
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
   Experimental
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
   Medicine
GA 288TL
UT WOS:000085580500045
PM 10700237
DA 2018-12-27
ER

PT J
AU Schon, JH
   Berg, S
   Kloc, C
   Batlogg, B
AF Schon, JH
   Berg, S
   Kloc, C
   Batlogg, B
TI RETRACTED: Ambipolar pentacene field-effect transistors and inverters
   (Retracted article. See vol 298, pg 961, 2002)
SO SCIENCE
LA English
DT Article; Retracted Publication
ID THIN-FILM TRANSISTORS; RING OSCILLATORS; CIRCUITS; CRYSTALS; MOBILITY;
   DEVICES
AB Organic field-effect transistors based on pentacene single crystals, prepared with an amorphous aluminum oxide gate insulator, are capable of ambipolar operation and can be used for the preparation of complementary inverter circuits. The field-effect mobilities of carriers in these transistors increase from 2.7 and 1.7 square centimeters per volt per second at room temperature up to 1200 and 320 square centimeters per volt per second at Low temperatures for hole and electron transport, respectively, following a power-law dependence. The possible simplification of the fabrication process of complementary Logic circuits with these transistors, together with the high carrier mobilities, may be seen as another step toward applications of plastic electronics.
C1 Lucent Technol, Bell Labs, Murray Hill, NJ 07974 USA.
RP Schon, JH (reprint author), Lucent Technol, Bell Labs, Mt Ave, Murray Hill, NJ 07974 USA.
EM hendrik@lucent.com
RI Kloc, Christian/A-2255-2011
OI Berg, Steffen/0000-0003-2441-7719
CR BROWN AR, 1995, SCIENCE, V270, P972, DOI 10.1126/science.270.5238.972
   de Leeuw D, 1999, PHYS WORLD, V12, P31
   Dimitrakopoulos CD, 1999, SCIENCE, V283, P822, DOI 10.1126/science.283.5403.822
   Dimitrakopoulos CD, 1998, SYNTHETIC MET, V92, P47, DOI 10.1016/S0379-6779(98)80021-0
   DODABALAPUR A, 1995, SCIENCE, V269, P1560, DOI 10.1126/science.269.5230.1560
   Dodabalapur A, 1996, APPL PHYS LETT, V68, P1108, DOI 10.1063/1.115728
   Dodabalapur A, 1998, APPL PHYS LETT, V73, P142, DOI 10.1063/1.121736
   Drury CJ, 1998, APPL PHYS LETT, V73, P108, DOI 10.1063/1.121783
   Garnier F, 1996, SYNTHETIC MET, V81, P163, DOI 10.1016/S0379-6779(96)03761-7
   Horowitz G, 1998, ADV MATER, V10, P365, DOI 10.1002/(SICI)1521-4095(199803)10:5<365::AID-ADMA365>3.0.CO;2-U
   Katz H. E., 1998, HDB OLIGO POLYTHIOPH, P459
   Klauk H, 1999, IEEE T ELECTRON DEV, V46, P1258, DOI 10.1109/16.766895
   Klauk H, 1999, IEEE ELECTR DEVICE L, V20, P289, DOI 10.1109/55.767101
   Kloc C, 1997, J CRYST GROWTH, V182, P416, DOI 10.1016/S0022-0248(97)00370-9
   Landolt-Bornstein Karl N., 1985, LANDOLTBORNSTEIN, V17, P106
   Lin YY, 1997, IEEE T ELECTRON DEV, V44, P1325, DOI 10.1109/16.605476
   Lin YY, 1999, APPL PHYS LETT, V74, P2714, DOI 10.1063/1.123946
   MATSUMURA M, 1980, J APPL PHYS, V51, P6443, DOI 10.1063/1.327599
   Nelson SF, 1998, APPL PHYS LETT, V72, P1854, DOI 10.1063/1.121205
   NEUDECK GW, 1987, IEEE T ELECTRON DEV, V34, P344, DOI 10.1109/T-ED.1987.22928
   Schon JH, 1999, APPL PHYS LETT, V74, P260, DOI 10.1063/1.123274
   Schon JH, 1998, PHYS REV B, V58, P12952, DOI 10.1103/PhysRevB.58.12952
   Sirringhaus H, 1998, SCIENCE, V280, P1741, DOI 10.1126/science.280.5370.1741
   Sze S. M., 1981, PHYS SEMICONDUCTOR D, P442
   WARTA W, 1985, PHYS REV B, V32, P1172, DOI 10.1103/PhysRevB.32.1172
NR 25
TC 333
Z9 341
U1 7
U2 156
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
J9 SCIENCE
JI Science
PD FEB 11
PY 2000
VL 287
IS 5455
BP 1022
EP 1023
DI 10.1126/science.287.5455.1022
PG 2
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 282WU
UT WOS:000085245400042
PM 10669410
DA 2018-12-27
ER

PT J
AU Altamirano, MM
   Blackburn, JM
   Aguayo, C
   Fersht, AR
AF Altamirano, MM
   Blackburn, JM
   Aguayo, C
   Fersht, AR
TI RETRACTED: Directed evolution of new catalytic activity using the
   alpha/beta-barrel scaffold (Retracted article. See vol 417, pg 468,
   2002)
SO NATURE
LA English
DT Article; Retracted Publication
ID PHOSPHORIBOSYL ANTHRANILATE ISOMERASE; INDOLEGLYCEROL-PHOSPHATE
   SYNTHASE; IN-VITRO RECOMBINATION; MUCONATE LACTONIZING ENZYME;
   BETA-SHEET BARRELS; ESCHERICHIA-COLI; MOLECULAR EVOLUTION; BIFUNCTIONAL
   ENZYME; TRYPTOPHAN BIOSYNTHESIS; MANDELATE RACEMASE
AB In biological systems, enzymes catalyse the efficient synthesis of complex molecules under benign conditions, but widespread industrial use of these biocatalysts depends crucially on the development of new enzymes with useful catalytic functions. The evolution of enzymes in biological systems often involves the acquisition of new catalytic or binding properties by an existing protein scaffold. Here we mimic this strategy using the most common fold in enzymes, the alpha/beta-barrel, as the scaffold. By combining an existing binding site for structural elements of phosphoribosylanthranilate with a catalytic template required for isomerase activity, we are able to evolve phosphoribosylanthranilate isomerase activity from the scaffold of indole-3-glycerolphosphate synthase, We find that targeting the catalytic template for in vitro mutagenesis and recombination, followed by in vivo selection, results in a new phosphoribosylanthranilate isomerase that has catalytic properties similar to those of the natural enzyme, with an even higher specificity constant. Our demonstration of divergent evolution and the widespread occurrence of the alpha/beta-barrel suggest that this scaffold may be a fold of choice for the directed evolution of new biocatalysts.
C1 Cambridge Ctr Prot Engn, Cambridge CB2 2QH, England.
   Univ Cambridge, Chem Lab, MRC Ctr, Cambridge CB2 2QH, England.
   Univ Nacl Autonoma Mexico, Fac Med, Dept Bioquim, Mexico City 04510, DF, Mexico.
RP Fersht, AR (reprint author), Cambridge Ctr Prot Engn, Hills Rd, Cambridge CB2 2QH, England.
EM arf10@cam.ac.uk
CR Altamirano MM, 1997, P NATL ACAD SCI USA, V94, P3576, DOI 10.1073/pnas.94.8.3576
   ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2
   Arnold FH, 1999, CURR OPIN CHEM BIOL, V3, P54, DOI 10.1016/S1367-5931(99)80010-6
   BISSWANGER H, 1979, BIOCHEMISTRY-US, V18, P5946, DOI 10.1021/bi00593a029
   Branden C., 1999, INTRO PROTEIN STRUCT
   Branden CI, 1991, CURR OPIN STRUC BIOL, V1, P978, DOI 10.1016/0959-440X(91)90094-A
   CHOTHIA C, 1992, NATURE, V357, P543, DOI 10.1038/357543a0
   CLARKE L, 1980, P NATL ACAD SCI-BIOL, V77, P2173, DOI 10.1073/pnas.77.4.2173
   Crameri A, 1996, NAT BIOTECHNOL, V14, P315, DOI 10.1038/nbt0396-315
   Crameri A, 1996, NAT MED, V2, P100, DOI 10.1038/nm0196-100
   Crameri A, 1998, NATURE, V391, P288
   Darimont B, 1998, PROTEIN SCI, V7, P1221, DOI 10.1002/pro.5560070518
   EBERHARD M, 1995, BIOCHEMISTRY-US, V34, P5419, DOI 10.1021/bi00016a013
   Gerlt JA, 1998, CURR OPIN CHEM BIOL, V2, P607, DOI 10.1016/S1367-5931(98)80091-4
   Giver L, 1998, CURR OPIN CHEM BIOL, V2, P335, DOI 10.1016/S1367-5931(98)80006-9
   Hasson MS, 1998, P NATL ACAD SCI USA, V95, P10396, DOI 10.1073/pnas.95.18.10396
   Henikoff S, 1997, SCIENCE, V278, P609, DOI 10.1126/science.278.5338.609
   Holm L, 1997, PROTEINS, V28, P72, DOI 10.1002/(SICI)1097-0134(199705)28:1<72::AID-PROT7>3.0.CO;2-L
   HOMMEL U, 1995, BIOCHEMISTRY-US, V34, P5429, DOI 10.1021/bi00016a014
   Kauffman S. A., 1993, ORIGINS ORDER
   KIRSCHNER K, 1987, METHOD ENZYMOL, V142, P386
   Knochel TR, 1996, J MOL BIOL, V262, P502, DOI 10.1006/jmbi.1996.0531
   LUGER K, 1989, SCIENCE, V243, P206, DOI 10.1126/science.2643160
   MURZIN AG, 1994, J MOL BIOL, V236, P1382, DOI 10.1016/0022-2836(94)90065-5
   MURZIN AG, 1994, J MOL BIOL, V236, P1369, DOI 10.1016/0022-2836(94)90064-7
   NEIDHART DJ, 1990, NATURE, V347, P692, DOI 10.1038/347692a0
   PATTHY L, 1999, PROTEIN EVOLUTION
   Shao ZX, 1998, NUCLEIC ACIDS RES, V26, P681, DOI 10.1093/nar/26.2.681
   Stehlin C, 1997, FEBS LETT, V403, P268, DOI 10.1016/S0014-5793(97)00066-5
   STEMMER WPC, 1994, NATURE, V370, P389, DOI 10.1038/370389a0
   STEMMER WPC, 1994, P NATL ACAD SCI USA, V91, P10747, DOI 10.1073/pnas.91.22.10747
   STERNBERG N, 1995, P NATL ACAD SCI USA, V92, P1609, DOI 10.1073/pnas.92.5.1609
   Sterner R, 1996, PROTEIN SCI, V5, P2000, DOI 10.1002/pro.5560051006
   Tawfik DS, 1998, NAT BIOTECHNOL, V16, P652, DOI 10.1038/nbt0798-652
   WILMANNS M, 1991, BIOCHEMISTRY-US, V30, P9161, DOI 10.1021/bi00102a006
   WILMANNS M, 1992, J MOL BIOL, V223, P477, DOI 10.1016/0022-2836(92)90665-7
   WINTER G, 1991, NATURE, V349, P293, DOI 10.1038/349293a0
   YANOFSKY C, 1994, J BACTERIOL, V176, P6245, DOI 10.1128/jb.176.20.6245-6254.1994
   YANOFSKY C, 1971, J AMER MED ASSOC, V218, P1026, DOI 10.1001/jama.218.7.1026
   YANOFSKY C, 1971, GENETICS, V69, P409
   Zhao HM, 1997, NUCLEIC ACIDS RES, V25, P1307, DOI 10.1093/nar/25.6.1307
   Zhao HM, 1998, NAT BIOTECHNOL, V16, P258, DOI 10.1038/nbt0398-258
NR 42
TC 143
Z9 148
U1 5
U2 32
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
EI 1476-4687
J9 NATURE
JI Nature
PD FEB 10
PY 2000
VL 403
IS 6770
BP 617
EP 622
DI 10.1038/35001001
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 283RD
UT WOS:000085288200041
PM 10688189
DA 2018-12-27
ER

PT J
AU Gilbert, T
   Pfab, R
   Fischer, I
   Chen, P
AF Gilbert, T
   Pfab, R
   Fischer, I
   Chen, P
TI RETRACTED: The zero kinetic energy photoelectron spectrum of the
   propargyl radical, C3H3 (Retracted Article. See vol 131, ARTN 159904,
   2009)
SO JOURNAL OF CHEMICAL PHYSICS
LA English
DT Article; Retracted Publication
ID PHOTODISSOCIATION DYNAMICS; SPECTROSCOPY; RESOLUTION; ABSORPTION;
   PHOTOLYSIS; CHEMISTRY; ALLENE; FLAMES; H2CCCH; CATION
AB We report the zero kinetic energy photoelectron spectrum of the propargyl radical, C3H3. From the spectrum an ionization energy of 69 953 +/- 10 cm(-1) (8.673 eV) is deduced. Vibrational frequencies are obtained for the totally symmetric normal modes of the propargyl cation, as well as some combination and overtone bands. Both the frequencies and the relative intensities agree well with the predictions from recent ab initio calculations. (C) 2000 American Institute of Physics. [S0021-9606(00)02006-7].
C1 Swiss Fed Inst Technol, Organ Chem Lab, CH-8092 Zurich, Switzerland.
RP Gilbert, T (reprint author), Swiss Fed Inst Technol, Organ Chem Lab, Univ Str 16, CH-8092 Zurich, Switzerland.
EM Fischer@org.chem.ethz.ch; chen@org.chem.ethz.ch
RI Chen, Peter/L-5824-2016
OI Chen, Peter/0000-0002-9280-4369
CR Barckholtz TA, 1999, J AM CHEM SOC, V121, P2576, DOI 10.1021/ja9832461
   BLUSH JA, 1992, ACCOUNTS CHEM RES, V25, P385, DOI 10.1021/ar00021a001
   BLUSH JA, 1993, J CHEM PHYS, V98, P3557, DOI 10.1063/1.464077
   BOTSCHWINA P, 1993, J CHEM SOC FARADAY T, V89, P2219, DOI 10.1039/ft9938902219
   BOTSCHWINA P, 1995, Z PHYS CHEM, V188, P29, DOI 10.1524/zpch.1995.188.Part_1_2.029
   COCKETT MCR, 1993, J CHEM PHYS, V98, P7763, DOI 10.1063/1.464584
   Deyerl HJ, 1999, J CHEM PHYS, V111, P3441, DOI 10.1063/1.479629
   EIDEN GC, 1991, J CHEM PHYS, V95, P8665, DOI 10.1063/1.461249
   Fahr A, 1997, CHEM PHYS, V215, P59, DOI 10.1016/S0301-0104(96)00334-5
   FISCHER I, 1993, CHEM PHYS LETT, V202, P542, DOI 10.1016/0009-2614(93)90045-3
   FISCHER I, 1992, J CHEM PHYS, V96, P7171, DOI 10.1063/1.462551
   GOODINGS JM, 1979, COMBUST FLAME, V36, P27, DOI 10.1016/0010-2180(79)90044-0
   HUANG JW, 1990, J CHEM PHYS, V93, P1583, DOI 10.1063/1.459137
   JACOX ME, 1974, CHEM PHYS, V4, P45, DOI 10.1016/0301-0104(74)80047-9
   KOHN DW, 1992, REV SCI INSTRUM, V63, P4003, DOI 10.1063/1.1143254
   LOSSING FP, 1972, CAN J CHEM, V50, P3973, DOI 10.1139/v72-629
   MERKT F, 1993, INT REV PHYS CHEM, V12, P205, DOI 10.1080/01442359309353282
   MINSEK DW, 1990, J PHYS CHEM-US, V94, P8399, DOI 10.1021/j100385a007
   MULLERDETHLEFS K, 1984, Z NATURFORSCH A, V39, P1089
   MULLERDETHLEFS K, 1991, ANNU REV PHYS CHEM, V42, P109, DOI 10.1146/annurev.pc.42.100191.000545
   MULLERDETHLEFS K, 1998, ANGEW CHEM, V110, P1415
   Panov SI, 1998, J CHEM PHYS, V108, P1335, DOI 10.1063/1.475506
   RAMSAY DA, 1966, CAN J PHYS, V44, P1381, DOI 10.1139/p66-116
   REISER G, 1993, J PHYS CHEM-US, V97, P4335, DOI 10.1021/j100119a015
   REISER G, 1988, CHEM PHYS LETT, V152, P119, DOI 10.1016/0009-2614(88)87340-8
   Stein S. E., 1990, 23 S INT COMB COMB I, V23, P85
   STROBEL A, 1994, J PHYS CHEM-US, V98, P2024, DOI 10.1021/j100059a008
   Tanaka K, 1997, J CHEM PHYS, V107, P2728, DOI 10.1063/1.474631
   TANAKA K, 1995, J CHEM PHYS, V103, P6450, DOI 10.1063/1.470422
   VRTILEK JM, 1990, ASTROPHYS J, V364, pL53, DOI 10.1086/185873
   WESTMORELAND PR, 1989, J PHYS CHEM-US, V93, P8171, DOI 10.1021/j100362a008
   YERETZIAN C, 1995, CHEM PHYS LETT, V239, P61, DOI 10.1016/0009-2614(95)00441-6
   Yuan L, 1998, J MOL SPECTROSC, V187, P102, DOI 10.1006/jmsp.1997.7487
NR 33
TC 55
Z9 57
U1 6
U2 26
PU AMER INST PHYSICS
PI MELVILLE
PA CIRCULATION & FULFILLMENT DIV, 2 HUNTINGTON QUADRANGLE, STE 1 N O 1,
   MELVILLE, NY 11747-4501 USA
SN 0021-9606
J9 J CHEM PHYS
JI J. Chem. Phys.
PD FEB 8
PY 2000
VL 112
IS 6
BP 2575
EP 2578
DI 10.1063/1.480830
PG 4
WC Chemistry, Physical; Physics, Atomic, Molecular & Chemical
SC Chemistry; Physics
GA 279KM
UT WOS:000085043000001
DA 2018-12-27
ER

PT J
AU Piper, SN
   Suttner, SW
   Schmidt, CC
   Kumle, B
   Maleck, WH
   Boldt, J
AF Piper, SN
   Suttner, SW
   Schmidt, CC
   Kumle, B
   Maleck, WH
   Boldt, J
TI RETRACTED: Acute phase response to nitroprusside-induced controlled
   hypotension in patients undergoing radical prostatectomy (Retracted
   article. See vol. 66, pg. 647, 2011)
SO ANAESTHESIA
LA English
DT Article; Retracted Publication
DE controlled hypotension, sodium nitroprusside; acute phase response,
   radical prostatectomy
ID C-REACTIVE PROTEIN; SYSTEMIC INFLAMMATORY RESPONSE;
   SODIUM-NITROPRUSSIDE; GRANULOCYTE ELASTASE; ORTHOGNATHIC SURGERY; SERUM
   INTERLEUKIN-6; ANESTHESIA; ISOFLURANE; BLOOD; HEMODILUTION
AB This study evaluated the effects of sodium nitroprusside-induced controlled hypotension on the acute phase response in patients undergoing radical prostatectomy. Thirty patients were randomly allocated to two groups, a hypotension group (mean arterial blood pressure was adjusted to 50 mmHg) and a control group (mean arterial blood pressure > 70 mmHg). C-reactive protein increased significantly in the hypotension group from 0.13 (0.23) to 9.85 (2.84) mu g.ml(-1) and in the control group from 0.15 (0.27) to 7.38 (3.02) mu g.ml(-1). In both groups, serum amyloid A increased significantly, but levels were higher in the hypotension group [585 (125) mu g.l(-1)] than in the control group [460 (187) mu g.l(-1)] Interleukin-6 increased significantly in both groups, but was higher in the hypotension group [139 (123) pg.ml(-1)] than the control group [56 (27) pg.ml(-1)]. Elastase showed no significant changes in the control group but in the hypotension group there was a significant increase from 65 (51) to 122 (75) ng.ml(-1). Sodium nitroprusside-induced hypotension was associated with a more pronounced acute phase reaction.
C1 Hosp City Ludwigshafen, Dept Anaesthesiol & Intens Care Med, D-67063 Ludwigshafen, Germany.
RP Piper, SN (reprint author), Hosp City Ludwigshafen, Dept Anaesthesiol & Intens Care Med, D-67063 Ludwigshafen, Germany.
CR ABDULATIF M, 1994, ANAESTH INTENS CARE, V22, P155
   ADAMS HA, 1990, ANAESTHESIST, V39, P158
   BERGER D, 1995, CLIN CHIM ACTA, V239, P121, DOI 10.1016/0009-8981(95)06105-M
   BERNARD JM, 1989, ANESTH ANALG, V69, P467
   Bistrian BR, 1999, CRIT CARE MED, V27, P452, DOI 10.1097/00003246-199903000-00004
   Boldt J, 1999, BRIT J ANAESTH, V82, P170, DOI 10.1093/bja/82.2.170
   Braun J, 1997, INTENS CARE MED, V23, P170, DOI 10.1007/s001340050312
   CRUICKSHANK AM, 1990, CLIN SCI, V79, P161, DOI 10.1042/cs0790161
   Cunze T, 1998, GYNECOL OBSTET INVES, V45, P89, DOI 10.1159/000009932
   DONATI A, 1997, CRITICAL CARE, V1, P48
   Enlund MG, 1997, SCAND J PLAST RECONS, V31, P311, DOI 10.3109/02844319709008977
   FEHR J, 1988, THER UMSCH, V45, P85
   Fukusaki M, 1998, J CLIN ANESTH, V10, P222, DOI 10.1016/S0952-8180(98)00010-5
   GOLDBERG ME, 1990, ANESTH ANALG, V70, P537
   GROSS V, 1990, DIGEST DIS SCI, V35, P97, DOI 10.1007/BF01537230
   HEESEN M, 1995, ANESTH ANALG, V81, P1250
   HEESEN M, 1995, ANAESTHESIST, V44, P328, DOI 10.1007/s001010050160
   Jochum M, 1999, ANASTH INTENSIVMED, V40, P44
   KRISTIANSSON M, 1993, INTENS CARE MED, V19, P395, DOI 10.1007/BF01724879
   Kushimoto S, 1996, CRIT CARE MED, V24, P1908, DOI 10.1097/00003246-199611000-00023
   Lake Carol L., 1995, P395
   LESSARD MR, 1989, ANESTH ANALG, V69, P379
   LIUZZO G, 1994, NEW ENGL J MED, V331, P417, DOI 10.1056/NEJM199408183310701
   MURATA A, 1990, IMMUNOL INVEST, V19, P271, DOI 10.3109/08820139009041842
   Orem A, 1997, CLIN CHIM ACTA, V264, P49, DOI 10.1016/S0009-8981(97)00072-7
   OWALL A, 1991, ACTA ANAESTH SCAND, V35, P216
   Preckel MP, 1998, ANESTH ANALG, V87, P1002, DOI 10.1097/00000539-199811000-00004
   SCHANDENE L, 1992, IMMUNOLOGY, V76, P30
   SCHEFFE H, 1953, BIOMETRIKA, V40, P87, DOI 10.2307/2333100
   Sheeran P, 1997, BRIT J ANAESTH, V78, P201
   SUTTORP N, 1993, INT J MICROCIRC, V13, P187
   Tao W, 1997, CRIT CARE MED, V25, P1458, DOI 10.1097/00003246-199709000-00009
   VELLENGA E, 1991, BRIT J HAEMATOL, V78, P14, DOI 10.1111/j.1365-2141.1991.tb04375.x
   WHITWAM JG, 1993, CURRENT OPINION ANAE, V6, pS1
   YENTIS SM, 1995, INTENS CARE MED, V21, P602, DOI 10.1007/BF01700168
   YOUNG B, 1991, PATHOLOGY, V23, P118, DOI 10.3109/00313029109060809
NR 36
TC 7
Z9 8
U1 3
U2 12
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0003-2409
EI 1365-2044
J9 ANAESTHESIA
JI Anaesthesia
PD FEB
PY 2000
VL 55
IS 2
BP 131
EP 136
DI 10.1046/j.1365-2044.2000.055002131.x
PG 6
WC Anesthesiology
SC Anesthesiology
GA 286RV
UT WOS:000085460100006
PM 10651673
OA Bronze
DA 2018-12-27
ER

PT J
AU Fujii, Y
   Saitoh, Y
   Tanaka, H
   Toyooka, H
AF Fujii, Y
   Saitoh, Y
   Tanaka, H
   Toyooka, H
TI RETRACTED: Ramosetron for preventing postoperative nausea and vomiting
   in women undergoing gynecological surgery (Retracted article. See vol.
   116, pg. 745, 2013)
SO ANESTHESIA AND ANALGESIA
LA English
DT Article; Retracted Publication
ID GRANISETRON; DROPERIDOL
AB In a prospective, randomized, double-blinded, placebo-controlled trial, we evaluated the efficacy of ramosetron at three different doses (0.15, 0.3, and 0.6 mg) for the prevention of postoperative nausea and vomiting (PONV) after gynecological surgery. One hundred twenty women, ASA physical status I or II, aged 21-63 yr, received IV either placebo or ramosetron 0.15, 0.3, or 0.6 mg (n = 30 of each) at the completion of surgery. A standard general anesthetic technique and postoperative analgesia were used. A complete response, defined as no PONV and no need for another rescue antiemetic, during 0-3 h after anesthesia occurred in 40%, 47%, 87%, and 90% of patients who had received placebo and ramosetron 0.15, 0.3, and 0.6 mg, respectively. Corresponding results during 3-24 h after anesthesia were 43%, 50%, 87%, and 90%, and 24-48 h after anesthesia were 50%, 53%, 90%, and 93% (P < 0.05). Patients who had received. ramosetron 0.3 or 0.6 mg were satisfied compared with those who had received placebo (P < 0.05). There were no serious clinical adverse events caused by the study drug in any of the groups. In conclusion, ramosetron 0.3 mg is an effective antiemetic for preventing PONV during 0-48 h after anesthesia in female patients undergoing gynecological surgery. Increasing the dose to 0.6 mg provided no further benefit. Implications: This randomized, double-blinded, placebo-controlled trial in 120 women found the effective dose of ramosetron for preventing postoperative nausea and vomiting after gynecological surgery to be 0.3 mg.
C1 Univ Tsukuba, Inst Clin Med, Dept Anesthesiol, Tsukuba, Ibaraki 305, Japan.
   Toride Kyodo Gen Hosp, Dept Anesthesiol, Toride, Ibaraki, Japan.
RP Fujii, Y (reprint author), Univ Tsukuba, Inst Clin Med, Dept Anesthesiol, 2-1-1 Amakubo, Tsukuba, Ibaraki 305, Japan.
CR FUJIHARA A, 1996, LAB CLIN, V30, P1965
   Fujii Y, 1999, ANESTH ANALG, V89, P476, DOI 10.1097/00000539-199908000-00043
   FUJII Y, 1995, CAN J ANAESTH, V42, P852, DOI 10.1007/BF03011030
   FUJII Y, 1994, CAN J ANAESTH, V41, P291, DOI 10.1007/BF03009906
   MADEJ TH, 1986, BRIT J ANAESTH, V58, P879, DOI 10.1093/bja/58.8.879
   NODA K, 1994, JPN J CLIN EXP MED, V71, P2765
   WATCHA MF, 1992, ANESTHESIOLOGY, V77, P162, DOI 10.1097/00000542-199207000-00023
NR 7
TC 25
Z9 25
U1 2
U2 9
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0003-2999
J9 ANESTH ANALG
JI Anesth. Analg.
PD FEB
PY 2000
VL 90
IS 2
BP 472
EP 475
DI 10.1097/00000539-200002000-00043
PG 4
WC Anesthesiology
SC Anesthesiology
GA 278KX
UT WOS:000084989900043
PM 10648342
DA 2018-12-27
ER

PT J
AU Tchernof, A
   Poehlman, ET
   Despres, JP
AF Tchernof, A
   Poehlman, ET
   Despres, JP
TI RETRACTED: Body fat distribution, the menopause transition, and hormone
   replacement therapy (Retracted Article. See vol 32, pg 285, 2006)
SO DIABETES & METABOLISM
LA English
DT Review; Retracted Publication
DE menopause; hormone replacement therapy; estrogen; androgen; regional fat
   metabolism; abdominal adipose tissue; cardiovascular disease risk
ID ADIPOSE-TISSUE DISTRIBUTION; CARDIOVASCULAR RISK-FACTORS; EARLY
   POSTMENOPAUSAL WOMEN; ISCHEMIC-HEART-DISEASE; WAIST-HIP RATIO;
   INSULIN-RESISTANCE; ANTHROPOMETRIC INDEXES; REPRODUCTIVE FACTORS;
   LIPOPROTEIN-LIPASE; ABDOMINAL FAT
AB Endocrine changes resulting from the menopause transition dramatically modify women's hormonal milieu. The consequences of these changes not only lead to cessation of reproduction and accompanying symptoms in women, but also dramatically impact long-term health. Loss of estrogen has been associated with the development of cardiovascular disease. Central distribution and accumulation of adipose tissue, and the concomitant insulin resistant dyslipidemic state have emerged as important components of a cluster of metabolic abnormalities that are strongly related to coronary heart disease. Thus, estrogen deficiency may affect cardiovascular disease risk by mediating changes in body fat distribution. This article is an update of the literature in the area of menopause, hormone replacement therapy, and body fat distribution. Cross-sectional studies using anthropometric measurements of abdominal fat distribution most often failed to detect an effect of the menopause transition that was independent of advancing age and degree of obesity. The use of radiologic techniques such as DEXA and computed tomography, however, led to the conclusion that the menopause transition accelerates the selective deposition of intra-abdominal fat. Available longitudinal data also support an increase in central body fatness occurring with menopause. Most intervention trials on hormone replacement therapy and body fat distribution showed that the treatment prevented the increase in central adiposity that was noted in postmenopausal women receiving no treatment or placebo. These results are supported by retrospective studies that showed a lower WHR in hormone users vs non-users. Mechanisms potentially explaining the menopause-related acceleration in abdominal fat accumulation include changes in regional adipose tissue metabolism in the face of a positive energy imbalance. As some inconsistencies were found among studies, further investigations using longitudinal and intervention designs, as well as more precise methodologies to measure body fat distribution, are needed to clearly establish the effects of menopause and hormone replacement on abdominal body fat distribution and the concomitant increase in cardiovascular disease risk.
C1 Univ Vermont, Dept Med, Burlington, VT 05401 USA.
   Univ Laval, Med Res Ctr, CHUQ, Lipid Res Ctr, Quebec City, PQ, Canada.
RP Tchernof, A (reprint author), Quebec Heart Inst, Lipid Res Ctr, 2725 Chemin St Foy,Pavillon U,2nd Floor, Ste Foy, PQ G1V 4G5, Canada.
FU NCRR NIH HHS [RR109]; NIA NIH HHS [AG-07587, AG-13978]
CR ALOIA JF, 1995, AM J OBSTET GYNECOL, V172, P896, DOI 10.1016/0002-9378(95)90018-7
   Barrett-Connor E, 1993, Int J Fertil Menopausal Stud, V38 Suppl 1, P6
   Bjorkelund C, 1996, INT J OBESITY, V20, P213
   BJORNTORP P, 1984, EUR J CLIN INVEST, V14, P239, DOI 10.1111/j.1365-2362.1984.tb01174.x
   BJORNTORP P, 1990, ARTERIOSCLEROSIS, V10, P493, DOI 10.1161/01.ATV.10.4.493
   BURGER HG, 1994, AUST NZ J OBSTET GYN, V34, P293, DOI 10.1111/j.1479-828X.1994.tb01076.x
   CALLESESCANDON J, 1995, J APPL PHYSIOL, V78, P266
   CallesEscandon J, 1997, AGING-CLIN EXP RES, V9, P57, DOI 10.1007/BF03340128
   CAMPOS H, 1991, ARTERIOSCLER THROMB, V11, P1077, DOI 10.1161/01.ATV.11.4.1077
   Davis SR, 1996, J CLIN ENDOCR METAB, V81, P2759, DOI 10.1210/jc.81.8.2759
   DENTONKELAAR I, 1990, INT J OBESITY, V14, P753
   DENTONKELAAR I, 1989, INT J OBESITY, V13, P817
   Despres Jean-Pierre, 1994, Current Opinion in Lipidology, V5, P274, DOI 10.1097/00041433-199408000-00006
   DESPRES JP, 1989, ARTERIOSCLEROSIS, V9, P203, DOI 10.1161/01.ATV.9.2.203
   DESPRES JP, 1989, DIABETES, V38, P304, DOI 10.2337/diabetes.38.3.304
   DESPRES JP, 1989, ARTERIOSCLEROSIS, V9, P485, DOI 10.1161/01.ATV.9.4.485
   DESPRES JP, 1993, NUTRITION, V9, P452
   DESPRES JP, 1991, AM J CLIN NUTR, V54, P471
   Despres JP, 1996, NEW ENGL J MED, V334, P952, DOI 10.1056/NEJM199604113341504
   DESPRES JP, 1991, CURR OPIN LIPIDOL, V2, P5
   DONAHUE RP, 1987, LANCET, V1, P821
   DUCIMETIERE P, 1986, INT J OBESITY, V10, P229
   Espeland MA, 1997, J CLIN ENDOCR METAB, V82, P1549, DOI 10.1210/jc.82.5.1549
   EVANS DJ, 1983, J CLIN ENDOCR METAB, V57, P304, DOI 10.1210/jcem-57-2-304
   FERLAND M, 1989, BRIT J NUTR, V61, P139, DOI 10.1079/BJN19890104
   FLATT JP, 1987, AM J CLIN NUTR, V45, P296, DOI 10.1093/ajcn/45.1.296
   FOLSOM AR, 1993, JAMA-J AM MED ASSOC, V269, P483, DOI 10.1001/jama.269.4.483
   FUJIOKA S, 1991, INT J OBESITY, V15, P853
   Gambacciani M, 1997, J CLIN ENDOCR METAB, V82, P414, DOI 10.1210/jc.82.2.414
   Gambacciani M, 1999, Climacteric, V2, P37
   Greendale GA, 1997, ENDOCRIN METAB CLIN, V26, P261, DOI 10.1016/S0889-8529(05)70246-2
   HAARBO J, 1991, METABOLISM, V40, P1323, DOI 10.1016/0026-0495(91)90037-W
   HAARBO J, 1990, ATHEROSCLEROSIS, V84, P239, DOI 10.1016/0021-9150(90)90096-2
   HEISS CJ, 1995, J CLIN ENDOCR METAB, V80, P1591, DOI 10.1210/jc.80.5.1591
   HENNES MMI, 1990, INT J OBESITY, V14, P831
   Hunter GR, 1996, INT J OBESITY, V20, P860
   JENSEN J, 1985, BRIT J OBSTET GYNAEC, V92, P260, DOI 10.1111/j.1471-0528.1985.tb01092.x
   KAYE SA, 1991, INT J EPIDEMIOL, V20, P151, DOI 10.1093/ije/20.1.151
   KAYE SA, 1990, INT J OBESITY, V14, P583
   KIRCHENGAST S, 1993, ANN HUM BIOL, V20, P47, DOI 10.1080/03014469300002492
   KISSEBAH AH, 1982, J CLIN ENDOCR METAB, V54, P254, DOI 10.1210/jcem-54-2-254
   KISSEBAH AH, 1989, DIABETES METAB REV, V5, P83, DOI 10.1002/dmr.5610050202
   KISSEBAH AH, 1994, PHYSIOL REV, V74, P761
   KISSEBAH AH, 1989, MED CLIN N AM, V73, P111, DOI 10.1016/S0025-7125(16)30695-2
   Kohrt WM, 1998, J APPL PHYSIOL, V84, P1506
   KOTANI K, 1994, INT J OBESITY, V18, P207
   KritzSilverstein D, 1996, JAMA-J AM MED ASSOC, V275, P46
   LABRIE F, 1991, MOL CELL ENDOCRINOL, V78, pC113, DOI 10.1016/0303-7207(91)90116-A
   Lamarche B, 1998, JAMA-J AM MED ASSOC, V279, P1955, DOI 10.1001/jama.279.24.1955
   Lamarche B, 1997, CIRCULATION, V95, P69, DOI 10.1161/01.CIR.95.1.69
   Lamarche B, 1996, CIRCULATION, V94, P273, DOI 10.1161/01.CIR.94.3.273
   LANSKA DJ, 1985, INT J OBESITY, V9, P29
   LAPIDUS L, 1984, BRIT MED J, V289, P1257, DOI 10.1136/bmj.289.6454.1257
   LARSSON B, 1984, BRIT MED J, V288, P1401, DOI 10.1136/bmj.288.6428.1401
   Lemieux S, 1996, DIABETES CARE, V19, P983, DOI 10.2337/diacare.19.9.983
   Lemieux S, 1996, AM J CLIN NUTR, V64, P685
   LEY CJ, 1992, AM J CLIN NUTR, V55, P950
   LINDBERG UB, 1990, HORM METAB RES, V22, P345, DOI 10.1055/s-2007-1004917
   Marin P, 1996, J CLIN ENDOCR METAB, V81, P1018, DOI 10.1210/jc.81.3.1018
   MARIN P, 1985, J CLIN ENDOCR METAB, V80, P239
   MOLE PA, 1989, ANN NUTR METAB, V33, P246, DOI 10.1159/000177541
   O'Sullivan AJ, 1998, J CLIN INVEST, V102, P1035, DOI 10.1172/JCI2773
   OBrien SN, 1997, OBSTET GYNECOL, V90, P244, DOI 10.1016/S0029-7844(97)00212-3
   OHLSON LO, 1985, DIABETES, V34, P1055, DOI 10.2337/diabetes.34.10.1055
   Panotopoulos G, 1996, MATURITAS, V25, P11, DOI 10.1016/0378-5122(96)01119-X
   PASQUALI R, 1994, INT J OBESITY, V18, P614
   Pasquali R, 1997, METABOLISM, V46, P5, DOI 10.1016/S0026-0495(97)90159-1
   Perry AC, 1998, OBES RES, V6, P40, DOI 10.1002/j.1550-8528.1998.tb00313.x
   POEHLMAN ET, 1995, ANN INTERN MED, V123, P673, DOI 10.7326/0003-4819-123-9-199511010-00005
   POEHLMAN ET, 1995, ARCH INTERN MED, V155, P2443, DOI 10.1001/archinte.155.22.2443
   POULIOT MC, 1994, AM J CARDIOL, V73, P460, DOI 10.1016/0002-9149(94)90676-9
   POULIOT MC, 1991, EUR J CLIN INVEST, V21, P398, DOI 10.1111/j.1365-2362.1991.tb01387.x
   Price TM, 1998, AM J OBSTET GYNECOL, V178, P101, DOI 10.1016/S0002-9378(98)70634-9
   Prior JC, 1998, ENDOCR REV, V19, P397, DOI 10.1210/er.19.4.397
   RAVUSSIN E, 1988, NEW ENGL J MED, V318, P467, DOI 10.1056/NEJM198802253180802
   RAZAY G, 1992, Q J MED, V85, P889
   REBUFFESCRIVE M, 1987, INT J OBESITY, V11, P347
   REBUFFESCRIVE M, 1986, METABOLISM, V35, P792, DOI 10.1016/0026-0495(86)90217-9
   REUBINOFF BE, 1995, FERTIL STERIL, V64, P963, DOI 10.1016/S0015-0282(16)57910-2
   Schreiner PJ, 1996, AM J EPIDEMIOL, V144, P335
   SIMONEAU JA, 1998, HDB OBESITY, P539
   SIMPSON ER, 1989, ENDOCR REV, V10, P136, DOI 10.1210/edrv-10-2-136
   SJOSTROM L, 1986, AM J PHYSIOL, V250, pE736
   Sotelo MM, 1997, ENDOCRIN METAB CLIN, V26, P313, DOI 10.1016/S0889-8529(05)70249-8
   SVEDBERG J, 1990, DIABETES, V39, P570, DOI 10.2337/diabetes.39.5.570
   SVENDSEN OL, 1993, INT J OBESITY, V17, P459
   Svendsen Ole Lander, 1995, Metabolism Clinical and Experimental, V44, P369
   Tchernof A, 1998, CORONARY ARTERY DIS, V9, P503, DOI 10.1097/00019501-199809080-00006
   Tchernof A, 1998, OBES RES, V6, P246, DOI 10.1002/j.1550-8528.1998.tb00344.x
   TERRY RB, 1991, METABOLISM, V40, P733, DOI 10.1016/0026-0495(91)90093-C
   TOTH MJ, 1999, IN PRESS INT J OBES
   Tremollieres FA, 1996, AM J OBSTET GYNECOL, V175, P1594, DOI 10.1016/S0002-9378(96)70111-4
   TROISI RJ, 1995, OBES RES, V3, P143
   VANDERKOOY K, 1993, AM J CLIN NUTR, V57, P327
   VERMEULEN A, 1980, MATURITAS, V2, P81, DOI 10.1016/0378-5122(80)90040-7
   WANG QL, 1994, AM J CLIN NUTR, V60, P843
   *WHO, 1991, RES MEN 90S REP WHO
   *WHO, 1981, REP WHO SCI GROUP RE
   WICH BK, 1995, ENDOCRIN METAB CLIN, V24, P273, DOI 10.1016/S0889-8529(18)30042-2
   Williams MJ, 1997, AM J CLIN NUTR, V65, P855
   WING RR, 1991, ARTERIOSCLER THROMB, V11, P1250, DOI 10.1161/01.ATV.11.5.1250
   Wise PM, 1996, SCIENCE, V273, P67, DOI 10.1126/science.273.5271.67
   XU XF, 1991, ENDOCRINOLOGY, V128, P379, DOI 10.1210/endo-128-1-379
   ZAMBONI M, 1992, INT J OBESITY, V16, P495
   ZURLO F, 1990, AM J PHYSIOL, V259, pE650
NR 105
TC 95
Z9 99
U1 4
U2 16
PU MASSON EDITEUR
PI MOULINEAUX CEDEX 9
PA 21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE
SN 1262-3636
EI 1878-1780
J9 DIABETES METAB
JI Diabetes Metab.
PD FEB
PY 2000
VL 26
IS 1
BP 12
EP 20
PG 9
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 293ZR
UT WOS:000085885900001
PM 10705099
DA 2018-12-27
ER

PT J
AU Iwamoto, M
   Sato, M
   Kono, M
   Hirooka, Y
   Sakai, K
   Takeshita, A
   Imaizumi, K
AF Iwamoto, M
   Sato, M
   Kono, M
   Hirooka, Y
   Sakai, K
   Takeshita, A
   Imaizumi, K
TI RETRACTED: Walnuts lower serum cholesterol in Japanese men and women
   (Retracted article. See vol 130, pg 2407, 2000)
SO JOURNAL OF NUTRITION
LA English
DT Article; Retracted Publication
DE blood pressure; Japanese diet; cholesterol; walnuts; humans
ID CORONARY HEART-DISEASE; LOW-DENSITY-LIPOPROTEIN; ALPHA-LINOLENIC ACID;
   BLOOD-PRESSURE; FATTY-ACIDS; NUT CONSUMPTION; LDL RECEPTOR; DIETARY
   FATS; FOLLOW-UP; RICH DIET
AB Recent studies have shown that incorporating moderate quantities of walnuts into the recommended cholesterol-lowering diet in the U.S. decreased serum concentrations of total cholesterol in normal American men. To explore whether walnut consumption would also prove effective as part of the Japanese diet, we studied the effects of walnut consumption on serum lipids and blood pressure in Japanese subjects. We randomly assigned 20 men and 20 women to two mixed natural diets, each to be consumed for 4 wk in a crossover design. Both diets conformed to the average Japanese diet (reference diet) and contained identical foods and macronutrients, except that 12.5% of the energy of the walnut diet was derived from walnuts (43-57 g/d) (offset by lesser amounts of fatty foods, meat and visible fat). Total cholesterol concentration was 0.16 mmol/L lower for men (P = 0.05) and 0.21 mmol/L lower for women (P < 0.01) when they consumed the walnut diet than when they consumed the reference diet. The LDL cholesterol concentrations were 0.18 mmol/L lower for men (P = 0.13) and 0.22 mmol/L lower for women (P < 0.01) when they consumed the walnut diet. The ratio of LDL cholesterol to HDL cholesterol and the apolipoprotein B concentration were also lowered by the walnut diet (P < 0.05). Blood pressures did not differ between the walnut and reference diet periods. Incorporating moderate quantities of walnuts into the average Japanese diet while maintaining the intake of total dietary fat and energy decreases serum total cholesterol concentrations and favorably modifies the lipoprotein profile in Japanese, particularly in women.
C1 Kyushu Univ, Grad Sch, Div Bioresource & Bioenvironm Sci, Nutr Chem Lab, Fukuoka 8128581, Japan.
   Kyushu Univ, Sch Med, Angiocardiol Res Inst, Fukuoka 8128581, Japan.
   Kyushu Univ, Sch Med, Cardiovasc Clin, Fukuoka 8128581, Japan.
RP Imaizumi, K (reprint author), Kyushu Univ, Grad Sch, Div Bioresource & Bioenvironm Sci, Nutr Chem Lab, Fukuoka 8128581, Japan.
RI U-ID, Kyushu/C-5291-2016
CR ABBEY M, 1994, AM J CLIN NUTR, V59, P995
   ALLAIN CC, 1974, CLIN CHEM, V20, P470
   Ascherio A, 1996, BMJ-BRIT MED J, V313, P84, DOI 10.1136/bmj.313.7049.84
   *ASS OFF AN CHEM, 1987, OFF METH AN
   CHAN JK, 1991, AM J CLIN NUTR, V53, P1230
   de Lorgeril M, 1999, CIRCULATION, V99, P779, DOI 10.1161/01.CIR.99.6.779
   DELORGERIL M, 1994, LANCET, V343, P1454, DOI 10.1016/S0140-6736(94)92580-1
   Dreher ML, 1996, NUTR REV, V54, P241
   Fleiss J., 1986, DESIGN ANAL CLIN EXP
   FRASER GE, 1992, ARCH INTERN MED, V152, P1416, DOI 10.1001/archinte.152.7.1416
   FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499
   *HLTH SERV BUR, 1995, REC DIET ALL JAP
   Hu FB, 1998, BMJ-BRIT MED J, V317, P1341, DOI 10.1136/bmj.317.7169.1341
   Ikeda I, 1998, LIPIDS, V33, P897, DOI 10.1007/s11745-998-0286-7
   IKEDA T, 1991, J CLIN LAB ANAL, V5, P90, DOI 10.1002/jcla.1860050204
   KESTIN M, 1990, AM J CLIN NUTR, V51, P1028
   KEYS A, 1965, METABOLIS, V14, P776, DOI 10.1016/0026-0495(65)90004-1
   KRITCHEVSKY D, 1982, ATHEROSCLEROSIS, V41, P429, DOI 10.1016/0021-9150(82)90208-8
   MANTZIORIS E, 1995, AM J CLIN NUTR, V61, P320
   *NAT NUTR SURV JAP, 1997, ANN REP HLTH SERV BU
   PARTHASARATHY S, 1987, P NATL ACAD SCI USA, V84, P537, DOI 10.1073/pnas.84.2.537
   PRINEAS RJ, 1993, NEW ENGL J MED, V328, P603
   REAVEN P, 1991, AM J CLIN NUTR, V54, P701
   Rudel LL, 1998, ARTERIOSCL THROM VAS, V18, P1818, DOI 10.1161/01.ATV.18.11.1818
   SABATE J, 1993, NEW ENGL J MED, V328, P603, DOI 10.1056/NEJM199303043280902
   SACKS FM, 1989, NUTR REV, V47, P291
   SALONEN JT, 1988, AM J CLIN NUTR, V48, P1226
   SPAYD RW, 1978, CLIN CHEM, V24, P1343
   Spiller GA, 1998, J AM COLL NUTR, V17, P285, DOI 10.1080/07315724.1998.10718761
   STAMLER J, 1986, JAMA-J AM MED ASSOC, V256, P2823, DOI 10.1001/jama.256.20.2823
   VERSCHUREN WMM, 1995, JAMA-J AM MED ASSOC, V274, P131
   WARNICK GR, 1982, CLIN CHEM, V28, P1379
NR 32
TC 32
Z9 33
U1 3
U2 14
PU AMER INST NUTRITION
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-3166
J9 J NUTR
JI J. Nutr.
PD FEB
PY 2000
VL 130
IS 2
BP 171
EP 176
PG 6
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 281NP
UT WOS:000085167600008
PM 10720165
DA 2018-12-27
ER

PT J
AU Schon, JH
   Kloc, C
   Bucher, E
   Batiogg, B
AF Schon, JH
   Kloc, C
   Bucher, E
   Batiogg, B
TI RETRACTED: Efficient organic photovoltaic diodes based on doped
   pentacene (Retracted article. See vol 422 pg 93 2003)
SO NATURE
LA English
DT Article; Retracted Publication
ID SOLAR-CELLS; THIN-FILM; TRANSISTORS; HETEROJUNCTIONS; SEMICONDUCTORS;
   VAPOR
AB Recent work on solar cells based on interpenetrating polymer networks(1-3) and solid-state dye-sensitized devices' shows that efficient solar-energy conversion is possible using organic materials. Further, it has been demonstrated that the performance of photovoltaic devices based on small molecules can be effectively enhanced by doping the organic material with electron-accepting molecules'. But as inorganic solar cells show much higher efficiencies, well above 15 per cent, the practical utility of organic-based cells will require their fabrication by lower-rest techniques, ideally on flexible substrates. Here we demonstrate efficiency enhancement by molecular doping in Schottky-type photovoltaic diodes based on pentacene-an organic semiconductor that has received much attention as a promising material for organic thin-film transistors(6-8), but relatively little attention for use in photovoltaic devices(9,10). The incorporation of the dopant improves the internal quantum efficiency by more than five orders of magnitude and yields an external energy conversion efficiency as high as 2.4 per cent for a standard solar spectrum. Thin-film devices based on doped pentacene therefore appear promising for the production of efficient 'plastic' solar cells.
C1 Lucent Technol, Bell Labs, Murray Hill, NJ 07974 USA.
   Univ Konstanz, Fac Phys, D-78457 Constance, Germany.
RP Schon, JH (reprint author), Lucent Technol, Bell Labs, 600 Mt Ave, Murray Hill, NJ 07974 USA.
EM hendrik@lucent.com
RI Kloc, Christian/A-2255-2011
CR Bach U, 1998, NATURE, V395, P583, DOI 10.1038/26936
   CHAMBERLAIN GA, 1981, NATURE, V289, P45, DOI 10.1038/289045a0
   CHAMBERLAIN GA, 1982, J APPL PHYS, V53, P6262, DOI 10.1063/1.331544
   Dimitrakopoulos CD, 1999, SCIENCE, V283, P822, DOI 10.1126/science.283.5403.822
   Granstrom M, 1998, NATURE, V395, P257
   HALLS JJM, 1995, NATURE, V376, P498, DOI 10.1038/376498a0
   HOVEL HJ, 1975, SEMICONDUCT SEMIMET, V11, P71
   Landolt-Bornstein Karl N., 1985, LANDOLTBORNSTEIN, V17, P106
   Laudise RA, 1998, J CRYST GROWTH, V187, P449, DOI 10.1016/S0022-0248(98)00034-7
   Lin YY, 1997, IEEE T ELECTRON DEV, V44, P1325, DOI 10.1109/16.605476
   MINAKATA T, 1991, J APPL PHYS, V69, P7354, DOI 10.1063/1.347594
   MINITAKA T, 1992, J APPL PHYS, V72, P5220
   Nelson SF, 1998, APPL PHYS LETT, V72, P1854, DOI 10.1063/1.121205
   Schon JH, 1998, PHYS REV B, V58, P12952, DOI 10.1103/PhysRevB.58.12952
   Signerski R, 1998, SYNTHETIC MET, V94, P135, DOI 10.1016/S0379-6779(97)04160-X
   TANG CW, 1986, APPL PHYS LETT, V48, P183, DOI 10.1063/1.96937
   Videlot C, 1998, J CHIM PHYS PCB, V95, P1335, DOI 10.1051/jcp:1998277
   Videlot C, 1999, SYNTHETIC MET, V102, P885, DOI 10.1016/S0379-6779(98)00377-4
   WOHRLE D, 1995, J MATER CHEM, V5, P1819, DOI 10.1039/jm9950501819
   WOHRLE D, 1991, ADV MATER, V3, P129, DOI 10.1002/adma.19910030303
   YU G, 1995, SCIENCE, V270, P1789, DOI 10.1126/science.270.5243.1789
NR 21
TC 161
Z9 163
U1 6
U2 80
PU MACMILLAN MAGAZINES LTD
PI LONDON
PA PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
J9 NATURE
JI Nature
PD JAN 27
PY 2000
VL 403
IS 6768
BP 408
EP 410
DI 10.1038/35000172
PG 3
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 280UA
UT WOS:000085121100044
PM 10667788
DA 2018-12-27
ER

PT J
AU Arichi, T
   Saito, T
   Major, ME
   Belyakov, IM
   Shirai, M
   Engelhard, VH
   Feinstone, SM
   Berzofsky, JA
AF Arichi, T
   Saito, T
   Major, ME
   Belyakov, IM
   Shirai, M
   Engelhard, VH
   Feinstone, SM
   Berzofsky, JA
TI RETRACTED: Prophylactic DNA vaccine for hepatitis C virus (HCV)
   infection: HCV-specific cytotoxic T lymphocyte induction and protection
   from HCV-recombinant vaccinia infection in an HLA-A2.1 transgenic mouse
   model (Retracted Article. See vol 98, pg 5943, 2001)
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article; Retracted Publication
ID HUMAN-IMMUNODEFICIENCY-VIRUS; IMMUNE-RESPONSES; PLASMID DNA; CELL
   MEMORY; B-VIRUS; STRUCTURAL PROTEINS; CTL RESPONSES; CORE PROTEIN;
   IN-VIVO; MICE
AB DNA vaccines express antigens intracellularly and effectively induce cellular immune responses. Because only chimpanzees can be used to model human hepatitis C virus (HCV) infections, we developed a small-animal model using HLA-A2.1-transgenic mice to test induction of HLA-A2.1-restricted cytotoxic T lymphocytes (CTLs) and protection against recombinant vaccinia expressing HCV-core, A plasmid encoding the HCV-core antigen induced CD8(+) CTLs specific for three conserved endogenously expressed core peptides presented by human HLA-A2.1, When challenged, DNA-immunized mice showed a substantial (5-12 log(10)) reduction in vaccinia virus titer compared with mock-immunized controls. This protection, lasting at least 14 mo, was shown to be mediated by CD8+ cells. Thus, a DNA vaccine expressing HCV-core is a potential candidate for a prophylactic vaccine for HLA-A2.1(+) humans.
C1 NCI, Mol Immunogenet & Vaccine Res Sect, Metab Branch, NIH, Bethesda, MD 20892 USA.
   US FDA, Ctr Biol Evaluat & Res, Lab Hepatitis Viruses, Div Viral Prod, Bethesda, MD 20892 USA.
   Yamaguchi Univ, Sch Med, Dept Microbiol, Ube, Yamaguchi 755, Japan.
   Univ Virginia, Dept Microbiol, Charlottesville, VA 22908 USA.
RP Berzofsky, JA (reprint author), NCI, Mol Immunogenet & Vaccine Res Sect, Metab Branch, NIH, Bldg 10,Room 6B-12,MSC 1578, Bethesda, MD 20892 USA.
EM berzofsk@helix.nih.gov
CR Alexander J, 1998, HUM IMMUNOL, V59, P776, DOI 10.1016/S0198-8859(98)00080-9
   AlexanderMiller MA, 1996, P NATL ACAD SCI USA, V93, P4102, DOI 10.1073/pnas.93.9.4102
   Alter MJ, 1997, HEPATOLOGY, V26, pS62, DOI 10.1002/hep.510260711
   BATTEGAY M, 1995, J VIROL, V69, P2462
   Belyakov IM, 1998, J CLIN INVEST, V102, P2072, DOI 10.1172/JCI5102
   Belyakov IM, 1998, P NATL ACAD SCI USA, V95, P1709, DOI 10.1073/pnas.95.4.1709
   Berzofsky JA, 1999, IMMUNOL REV, V170, P151, DOI 10.1111/j.1600-065X.1999.tb01336.x
   Boyer JD, 1997, NAT MED, V3, P526, DOI 10.1038/nm0597-526
   BUKH J, 1994, P NATL ACAD SCI USA, V91, P8239, DOI 10.1073/pnas.91.17.8239
   CEREDIG R, 1985, NATURE, V314, P98, DOI 10.1038/314098a0
   CERNY A, 1995, J CLIN INVEST, V95, P521, DOI 10.1172/JCI117694
   Chang KM, 1999, J IMMUNOL, V162, P1156
   CHOO QL, 1994, P NATL ACAD SCI USA, V91, P1294, DOI 10.1073/pnas.91.4.1294
   Cooper S, 1999, IMMUNITY, V10, P439, DOI 10.1016/S1074-7613(00)80044-8
   Davis HL, 1997, SPRINGER SEMIN IMMUN, V19, P195, DOI 10.1007/BF00870268
   DOHERTY PC, 1994, CURR OPIN IMMUNOL, V6, P545, DOI 10.1016/0952-7915(94)90139-2
   DRILLIEN R, 1988, P NATL ACAD SCI USA, V85, P1252, DOI 10.1073/pnas.85.4.1252
   Encke J, 1998, J IMMUNOL, V161, P4917
   ENGELHARD VH, 1991, J IMMUNOL, V146, P1226
   FARCI P, 1992, SCIENCE, V258, P135, DOI 10.1126/science.1279801
   FYNAN EF, 1993, P NATL ACAD SCI USA, V90, P11478, DOI 10.1073/pnas.90.24.11478
   Gurunathan S, 1997, J EXP MED, V186, P1137, DOI 10.1084/jem.186.7.1137
   HARRIS N, 1995, J VIROL, V69, P910
   HOU S, 1994, NATURE, V369, P652, DOI 10.1038/369652a0
   HSU HH, 1993, HEPATOLOGY, V17, P763, DOI 10.1016/0270-9139(93)90149-H
   INCHAUSPE G, 1991, P NATL ACAD SCI USA, V88, P10292, DOI 10.1073/pnas.88.22.10292
   Katz E, 1997, J VIROL, V71, P3178
   Kolykhalov AA, 1997, SCIENCE, V277, P570, DOI 10.1126/science.277.5325.570
   Kowalski H, 1996, J EXP MED, V183, P1761, DOI 10.1084/jem.183.4.1761
   Large MK, 1999, J IMMUNOL, V162, P931
   LAU LL, 1994, NATURE, V369, P648, DOI 10.1038/369648a0
   Li XM, 1998, J EXP MED, V188, P681, DOI 10.1084/jem.188.4.681
   Livingston BD, 1997, J IMMUNOL, V159, P1383
   Major ME, 1999, J VIROL, V73, P3317
   MAN S, 1995, INT IMMUNOL, V7, P597, DOI 10.1093/intimm/7.4.597
   Newberg MH, 1996, J IMMUNOL, V156, P2473
   NEWBERG MH, 1992, J IMMUNOL, V149, P136
   PERKUS ME, 1989, J VIROL, V63, P3829
   Prince AM, 1997, VACCINE, V15, P916, DOI 10.1016/S0264-410X(96)00248-4
   PRINCE AM, 1992, J INFECT DIS, V165, P438, DOI 10.1093/infdis/165.3.438
   RESSING ME, 1995, J IMMUNOL, V154, P5934
   Saito T, 1997, GASTROENTEROLOGY, V112, P1321, DOI 10.1016/S0016-5085(97)70146-X
   SARMIENTO M, 1980, J IMMUNOL, V125, P2665
   Sarobe P, 1998, J CLIN INVEST, V102, P1239, DOI 10.1172/JCI3714
   SEDEGAH M, 1994, P NATL ACAD SCI USA, V91, P9866, DOI 10.1073/pnas.91.21.9866
   SHIRAI M, 1994, J VIROL, V68, P3334
   SHIRAI M, 1995, J IMMUNOL, V154, P2733
   SIMMONDS P, 1994, HEPATOLOGY, V19, P1321, DOI 10.1016/0270-9139(94)90887-7
   Tanghe A, 1999, J IMMUNOL, V162, P1113
   ULMER JB, 1993, SCIENCE, V259, P1745, DOI 10.1126/science.8456302
   VITIELLO A, 1991, J EXP MED, V173, P1007, DOI 10.1084/jem.173.4.1007
   WANG B, 1993, P NATL ACAD SCI USA, V90, P4156, DOI 10.1073/pnas.90.9.4156
   Wang RB, 1998, SCIENCE, V282, P476, DOI 10.1126/science.282.5388.476
   WEINER AJ, 1992, P NATL ACAD SCI USA, V89, P3468, DOI 10.1073/pnas.89.8.3468
   Wentworth PA, 1996, EUR J IMMUNOL, V26, P97, DOI 10.1002/eji.1830260115
   Wentworth PA, 1996, INT IMMUNOL, V8, P651, DOI 10.1093/intimm/8.5.651
   YANKAUCKAS MA, 1993, DNA CELL BIOL, V12, P771, DOI 10.1089/dna.1993.12.771
   Zinkernagel RM, 1996, ANNU REV IMMUNOL, V14, P333, DOI 10.1146/annurev.immunol.14.1.333
NR 58
TC 25
Z9 26
U1 2
U2 10
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD JAN 4
PY 2000
VL 97
IS 1
BP 297
EP 302
DI 10.1073/pnas.97.1.297
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 271ZA
UT WOS:000084624500055
PM 10618412
OA Bronze, Green Published
DA 2018-12-27
ER

PT J
AU Fujii, Y
   Tanaka, H
   Somekawa, Y
AF Fujii, Y
   Tanaka, H
   Somekawa, Y
TI RETRACTED: Granisetron, droperidol, and metoclopramide for the treatment
   of established postoperative nausea and vomiting in women undergoing
   gynecologic surgery (Retracted article. See vol. 218, pg. 621, 2018)
SO AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY
LA English
DT Article; Retracted Publication
DE droperidol; granisetron; gynecologic; metoclopramide; vomiting
ID RECEPTOR ANTAGONIST; ONDANSETRON; PREVENTION
AB OBJECTIVE: The aim of this study was to evaluate granisetron, droperidol, and metoclopramide for efficacy and safety in the treatment of established postoperative nausea and vomiting after major gynecologic surgery.
   STUDY DESIGN: One hundred twenty postoperative female patients were monitored for the first 3 hours after anesthesia in the postanesthesia care unit and for the next 24 hours after anesthesia in the ward. Patients who had postoperative nausea and vomiting within the first 3 hours after anesthesia received intravenously, in a randomized double-blind manner, 40 mu g/kg granisetron, 20 mu g/kg droperidol, or 0.2 mg/kg metoclopramide. Patients were then observed for 24 hours after drug administration.
   RESULTS: Complete control of established postoperative nausea and vomiting, defined as no emesis and no need for another rescue antiemetic medication, was more frequent among the patients who had received granisetron (88%) than among those who had received droperidol (55%) or metoclopramide (50%) (P < .05). The severity of nausea was less in patients who had received granisetron than in those who had received droperidol or metoclopramide (P < .05). No clinically adverse events were observed in any of the groups.
   CONCLUSION: Granisetron is more effective than droperidol or metoclopramide for the treatment of established postoperative nausea and vomiting during the first 3 hours after anesthesia in patients undergoing major gynecologic operations.
C1 Toride Kyodo Gen Hosp, Dept Anesthesiol, Toride, Ibaraki, Japan.
   Toride Kyodo Gen Hosp, Dept Obstet & Gynecol, Toride, Ibaraki, Japan.
RP Fujii, Y (reprint author), Univ Tsukuba, Inst Clin Med, Dept Anesthesiol, 2-1-1 Amakubo, Tsukuba, Ibaraki 305, Japan.
CR Andrews PL, 1992, EJC SUPPL, V28A, P2
   BERMUDEZ J, 1988, BRIT J CANCER, V58, P644, DOI 10.1038/bjc.1988.277
   CARMICHAEL J, 1989, CANCER CHEMOTH PHARM, V24, P45
   COHEN SE, 1984, ANESTHESIOLOGY, V60, P67, DOI 10.1097/00000542-198401000-00015
   Diemunsch P, 1997, BRIT J ANAESTH, V79, P322, DOI 10.1093/bja/79.3.322
   FUJII Y, 1994, CAN J ANAESTH, V41, P794, DOI 10.1007/BF03011585
   FUJII Y, 1994, CAN J ANAESTH, V41, P291, DOI 10.1007/BF03009906
   Furue H, 1990, J CLIN THERAPEUTIC M, V6, P49
   KORTTILA K, 1979, ANESTH ANALG, V58, P396
   MCKENZIE R, 1993, ANESTHESIOLOGY, V78, P21, DOI 10.1097/00000542-199301000-00005
   WATCHA MF, 1992, ANESTHESIOLOGY, V77, P162, DOI 10.1097/00000542-199207000-00023
NR 11
TC 11
Z9 12
U1 1
U2 1
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9378
EI 1097-6868
J9 AM J OBSTET GYNECOL
JI Am. J. Obstet. Gynecol.
PD JAN
PY 2000
VL 182
IS 1
BP 13
EP 16
DI 10.1016/S0002-9378(00)70484-4
PN 1
PG 4
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA 278JR
UT WOS:000084987100003
PM 10649150
DA 2018-12-27
ER

PT J
AU Maio, GR
   Esses, VM
   Bell, DW
AF Maio, GR
   Esses, VM
   Bell, DW
TI RETRACTED: Examining conflict between components of attitudes:
   Ambivalence and inconsistency are distinct constructs (Retracted
   article. See vol. 44, pg. 92, 2012)
SO CANADIAN JOURNAL OF BEHAVIOURAL SCIENCE-REVUE CANADIENNE DES SCIENCES DU
   COMPORTEMENT
LA English
DT Article; Proceedings Paper; Retracted Publication
CT 105th Annual Meeting of the American-Psychological-Association
CY AUG 15-19, 1997
CL CHICAGO, IL
SP Amer Psychol Assoc
ID OPEN-ENDED MEASURES; IMMIGRANT GROUPS; NATIVE PEOPLES; SOCIAL-GROUPS;
   STEREOTYPES; CONSISTENCY; INFORMATION; INDEXES; BASES
AB Past research has indicated that attitudes can be based on different types of psychological information or components, such as emotions and beliefs. It has also been suggested that the amount of ambivalence and inconsistency between and within these components are important aspects of attitude structure. In this paper, we discuss the relation between ambivalence and inconsistency, and their effects on message processing. Based on past theorizing and research, and on our reanalyses of previous data (Maio, Bell, & Esses, 1996), we conclude that ambivalence and inconsistency are distinct constructs, which are empirically unrelated and produce different effects on message processing.
C1 Cardiff Univ, Sch Psychol, Cardiff CF10 3YG, S Glam, Wales.
   Univ Western Ontario, London, ON N6A 3K7, Canada.
RP Maio, GR (reprint author), Cardiff Univ, Sch Psychol, POB 901, Cardiff CF10 3YG, S Glam, Wales.
EM maio@cardiff.ac.uk
RI Maio, Gregory/D-1632-2009
OI Maio, Gregory/0000-0001-5408-5829
CR Bassili JN, 1996, J PERS SOC PSYCHOL, V71, P637, DOI 10.1037/0022-3514.71.4.637
   Bell DW, 1996, CAN J BEHAV SCI, V28, P12, DOI 10.1037/0008-400X.28.1.12
   Bell DW, 1997, J APPL SOC PSYCHOL, V27, P1063, DOI 10.1111/j.1559-1816.1997.tb00287.x
   Berlyne D, 1960, CONFLICT AROUSAL CUR
   BRECKLER SJ, 1994, EDUC PSYCHOL MEAS, V54, P350, DOI 10.1177/0013164494054002009
   Cacioppo J T, 1997, Pers Soc Psychol Rev, V1, P3, DOI 10.1207/s15327957pspr0101_2
   CAMPBELL A, 1971, WHITE ATTITUDES BLAC
   CHAIKEN S, 1989, P212
   CHAIKEN S, 1981, J PERS SOC PSYCHOL, V41, P1, DOI 10.1037/0022-3514.41.1.1
   Chaiken S., 1995, ATTITUDE STRENGTH AN, P387
   EAGLY AH, 1989, PERS SOC PSYCHOL B, V15, P543, DOI 10.1177/0146167289154008
   EAGLY AH, 1994, J EXP SOC PSYCHOL, V30, P113, DOI 10.1006/jesp.1994.1006
   Eagly AH, 1998, HDB SOCIAL PSYCHOL, P269
   Erber MW, 1995, ATTITUDE STRENGTH AN, P433
   Esses Victoria M., 1993, AFFECT COGNITION STE, P137
   ESSES VM, 1994, ONT SYMP P, V7, P77
   ESSES VM, 1997, MULTIPLE PERSPECTIVE
   Festinger L., 1964, CONFLICT DECISION DI
   Fincham FD, 1997, J FAM PSYCHOL, V11, P489, DOI 10.1037/0893-3200.11.4.489-502
   FREUD S, 1948, INHIBITIONS SYMPTOMS
   Gaertner S. L., 1986, PREJUDICE DISCRIMINA, P61
   Haddock G, 1998, BRIT J SOC PSYCHOL, V37, P129, DOI 10.1111/j.2044-8309.1998.tb01161.x
   HADDOCK G, 1993, J PERS SOC PSYCHOL, V65, P1105, DOI 10.1037//0022-3514.65.6.1105
   HADDOCK G, 1994, BRIT J SOC PSYCHOL, V33, P83, DOI 10.1111/j.2044-8309.1994.tb01012.x
   Jamieson D. W., 1993, ANN M AM PSYCH ASS T
   Jonas K, 1997, J EXP SOC PSYCHOL, V33, P190, DOI 10.1006/jesp.1996.1317
   KAPLAN KJ, 1972, PSYCHOL BULL, V77, P361, DOI 10.1037/h0032590
   KATZ I, 1988, J PERS SOC PSYCHOL, V55, P893, DOI 10.1037/0022-3514.55.6.893
   MacDonald TK, 1998, PERS SOC PSYCHOL B, V24, P427, DOI 10.1177/0146167298244009
   Maio GR, 1996, J EXP SOC PSYCHOL, V32, P513, DOI 10.1006/jesp.1996.0023
   MAIO GR, 1994, J APPL SOC PSYCHOL, V24, P1762, DOI 10.1111/j.1559-1816.1994.tb01573.x
   MAIO GR, IN PRESS PERSONALITY
   MAIO GR, 1997, ANN M SOC EXP SOC PS
   NISBETT RE, 1977, PSYCHOL REV, V84, P231, DOI 10.1037//0033-295X.84.3.231
   OLSON JM, 1993, ANNU REV PSYCHOL, V44, P117, DOI 10.1146/annurev.psych.44.1.117
   Petty R. E., 1995, ATTITUDE STRENGTH AN
   Petty Richard E, 1986, ADV EXPT SOCIAL PSYC, V19, P123, DOI DOI 10.1016/S0065-2601(08)60214-2
   Priester JR, 1996, J PERS SOC PSYCHOL, V71, P431, DOI 10.1037/0022-3514.71.3.431
   Rosenberg M. J., 1968, THEORIES COGNITIVE C, P73
   ROSS M, 1989, PSYCHOL REV, V96, P341, DOI 10.1037//0033-295X.96.2.341
   Schwarz N., 1996, SOCIAL PSYCHOL HDB B, P433
   STANGOR C, 1991, SOC COGNITION, V9, P359, DOI 10.1521/soco.1991.9.4.359
   THOMPSON MM, 1995, ATTITUDE STRENGTH AN, P361, DOI DOI 10.4324/9781315807041
   Trafimow D, 1998, J EXP SOC PSYCHOL, V34, P378, DOI 10.1006/jesp.1998.1356
   Zanna M. P., 1988, SOCIAL PSYCHOL KNOWL, P315
NR 45
TC 18
Z9 22
U1 2
U2 6
PU CANADIAN PSYCHOLOGICAL  ASSOC
PI OTTAWA
PA 141 LAURIER AVE WEST, STE 702, OTTAWA, ONTARIO K1P 5J3, CANADA
SN 0008-400X
EI 1879-2669
J9 CAN J BEHAV SCI
JI Can. J. Behav. Sci.-Rev. Can. Sci. Comport.
PD JAN
PY 2000
VL 32
IS 1
BP 58
EP 70
DI 10.1037/h0087101
PG 13
WC Psychology, Multidisciplinary
SC Psychology
GA 277QC
UT WOS:000084943400007
DA 2018-12-27
ER

PT J
AU Verlinden, S
   Hersen, M
   Thomas, J
AF Verlinden, S
   Hersen, M
   Thomas, J
TI RETRACTED: Risk factors in school shootings (Retracted Article. See vol
   21, pg 159, 2001)
SO CLINICAL PSYCHOLOGY REVIEW
LA English
DT Review; Retracted Publication
ID AGGRESSIVE-BEHAVIOR; ANTISOCIAL-BEHAVIOR; COGNITIVE-PROCESSES;
   THREATENED EGOTISM; YOUTH VIOLENCE; UNITED-STATES; SELF-ESTEEM;
   DELINQUENCY; CHILDREN; PREDICTORS
AB Nine incidents of multiple-victim homicide in American secondary schools are examined and common risk factors are identified. The literature dealing with individual, family, social, societal, and situational risk factors for youth violence and aggression is reviewed along with existing risk assessment methods. Checklists of risk factors for serious youth violence and school violence are used in reviewing each school shooting case. Commonalties among the cases and implications for psychologists practicing in clinical and school settings are discussed. (C) 2000 Elsevier Science Ltd.
C1 Pacific Univ, Sch Profess psychol Program, Forest Grove, OR 97116 USA.
RP Verlinden, S (reprint author), Pacific Univ, Sch Profess psychol Program, 2004 Pacific Ave, Forest Grove, OR 97116 USA.
CR ABRAMS J, 1997, LOUISVILLE COUR 1203
   ACHENBACH J, 1999, WASHINGTON POST 0428
   ALEXANDER K, 1997, TRICITY HERALD
   *AM AC CHILD AD PS, 1999, CHILDR TEL VIOL
   *AM PSYCH ASS, 1999, B FAM
   ANTON M, 1999, DENVER ROCKY MO 0502
   BARNARD J, 1998, SEATTLE TIMES   0525
   BARTLEMAN B, 1998, PADUCAH SUN     1217
   Bates JE, 1998, DEV PSYCHOL, V34, P982, DOI 10.1037//0012-1649.34.5.982
   Baumeister RF, 1996, PSYCHOL REV, V103, P5, DOI 10.1037/0033-295X.103.1.5
   Beale D, 1999, J Occup Health Psychol, V4, P233, DOI 10.1037/1076-8998.4.3.233
   BECKER G, 1998, DETROIT FREE PR 1002
   Bjerregaard B, 1995, J CRIM LAW CRIM, V86, P37, DOI 10.2307/1143999
   Blank J., 1998, US NEWS ONLINE  1012
   BOOTH W, 1998, WASHINGTON POST 0405
   Borum R, 1996, AM PSYCHOL, V51, P945, DOI 10.1037/0003-066X.51.9.945
   BORUM R, IN PRESS BEHAV SCI L, V17
   BOWLES S, 1997, US TODAY        1203
   BRANDON K, 1998, CHICAGO TRIBUNE 0524
   BREED AG, 1998, ABC NEWS ONLINE 0326
   BRIDIS T, 1997, SEATTLE TIMES   1202
   BRIDIS T, 1997, ASS PRESS ONLIN 1203
   BRIGGS B, 1999, DENVER POST     0502
   Bronfrenbrenner U., 1979, ECOLOGY HUMAN DEV EX
   BROOK J, 1999, NY TIMES        0505
   Bushman BJ, 1998, J PERS SOC PSYCHOL, V75, P219, DOI 10.1037//0022-3514.75.1.219
   BUTCHER JN, 1992, MMPI A MINNESOTA MUL
   Cairns RB, 1994, LIFE LINES RISKS PAT
   CAIRNS RB, 1996, AGGRESSION VIOLENCE, P337
   Campbell J. C., 1995, ASSESSING DANGEROUSN
   CAREY G, 1996, AGGRESSION VIOLENCE
   CARLSON M, 1990, J PERS SOC PSYCHOL, V58, P622, DOI 10.1037/0022-3514.58.4.622
   CATALANO R, 1999, SOCIAL DEV MODEL THE
   *CDC, 1999, PREV VIOL SUIC ENH F
   *CDC, 1999, MEDIA RELATIONS, P404
   CHRISTIAN SE, 1998, CHICAGO TRIBUNE 0326
   Cohen D, 1998, J PERS SOC PSYCHOL, V75, P408, DOI 10.1037//0022-3514.75.2.408
   COHEN S, 1999, SPOKANE NEWS    0426
   Crick NR, 1998, J CONSULT CLIN PSYCH, V66, P337, DOI 10.1037//0022-006X.66.2.337
   CROWELL DH, 1987, CHILDHOOD AGGRESSION
   DODGE KA, 1990, CHILD DEV, V61, P1289, DOI 10.2307/1130743
   DODGE KA, 1980, CHILD DEV, V51, P162, DOI 10.2307/1129603
   DODGE L, 1998, ABC NEWS COM
   DOTSON B, 1999, MSNBC NEWS      0530
   Douglas KS, 1999, CRIM JUSTICE BEHAV, V26, P3, DOI 10.1177/0093854899026001001
   DUBE J, 1999, ABC NEWS COM    0423
   Dwyer K, 1998, EARLY WARNING TIMELY
   Eddy S, 1998, EMERGENCIES IN MENTAL HEALTH PRACTICE, P217
   Elliott D, 1998, VIOLENCE AM SCH
   Elliott D. S., 1996, DELINQUENCY CRIME CU, P28
   ELLIOTT DS, 1994, CRIMINOLOGY, V32, P1, DOI 10.1111/j.1745-9125.1994.tb01144.x
   ERON LD, 1994, REASON HOPE PSYCHOSO
   FAINARU S, 1998, BOSTON GUIDE    1108
   Farrington D P, 1989, Violence Vict, V4, P79
   FARRINGTON DP, 1995, J CHILD PSYCHOL PSYC, V36, P929, DOI 10.1111/j.1469-7610.1995.tb01342.x
   FARRINGTON DP, 1994, AGGRESSIVE BEHAV CUR
   Fein RA, 1999, J FORENSIC SCI, V44, P321, DOI 10.1520/JFS14457J
   FIRESTONE D, 1999, NY TIMES        0521
   FITTEN RK, 1997, SEATTLE TIMES   0927
   FURLONG M, 1999, SCH VIOLENCE SOCIAL
   GARBARINO J, 1991, AM PSYCHOL, V46, P376, DOI 10.1037//0003-066X.46.4.376
   GARBARINO J, 1999, 1999 DA JON MEM C VI
   Garbarino J., 1999, LOST BOYS WHY OUR SO
   Garmezy N., 1985, J CHILD PSYCHOL PS S, V4, P213
   Giancola PR, 1998, J ABNORM PSYCHOL, V107, P629, DOI 10.1037/0021-843X.107.4.629
   GOTTMAN JM, 1977, CHILD DEV, V48, P513, DOI 10.1111/j.1467-8624.1977.tb01191.x
   GREEN AS, 1998, OREGONIAN       0522
   GREEN C, 1998, DENVER POST     0524
   GRISSO T, 1992, LAW HUMAN BEHAV, V16, P71
   HARE RD, 1991, HAVE PSYCHOPATHY CHE
   HARPOLD JA, 1998, LESSONS LEARNED FBI
   HARRIS P, 1998, ARKANSAS DEMOCR 0811
   HAWKINS JD, 1998, SERIOUS VIOLENT JUVE, P106
   HAYS K, 1999, ASS PRESS ARCHI 0522
   HAYS K, 1998, ASS PRESS ARCHI 0426
   HAYS K, 1999, ASS PRESS ARCHI 0309
   HEARD K, 1998, ARKANSAS DEMOCR 0327
   HEARD K, 1998, ARKANSAS DEMOCR 0324
   HEARD K, 1998, ARKANSAS DEMOCR 0328
   HENDREN J, 1999, DETROIT FREE PR 0425
   Henry B, 1996, DEV PSYCHOL, V32, P614
   HOLLAND G, 1997, SUN HERALD
   HOROWITZ TR, 1987, SCHOOL PSYCHOL INT, V8, P141
   Howell J. C., 1997, JUVENILE JUSTICE YOU
   HUESMAN LR, 1994, DEV PSYCHOL, V20, P1120
   HUESMANN LR, 1984, AGGRESSIVE BEHAV, V10, P243, DOI 10.1002/1098-2337(1984)10:3<243::AID-AB2480100308>3.0.CO;2-6
   HUGHES J, 1998, ABC NEWS COM    0612
   *HUM SOC US, 1999, HUM SOC B
   JETER J, 1998, WASHINGTON POST 0330
   JOHNSON EM, 1999, C VIOL YOUTH PORTL O
   JOSEPH J, 1999, ABC NEWS COM    0421
   Kachur SP, 1996, JAMA-J AM MED ASSOC, V275, P1729, DOI 10.1001/jama.275.22.1729
   KAISER RL, 1998, CHICAGO TRIBUNE 0522
   KANDEL E, 1991, CRIMINOLOGY, V29, P515
   Katz R. C., 1996, CRIMINAL BEHAV MENTA, V6, P339
   Kaufman P., 1998, 98251 NCES US DEP ED
   Kellermann AL, 1998, ANNU REV PUBL HEALTH, V19, P271, DOI 10.1146/annurev.publhealth.19.1.271
   Kelly B., 1997, EPIDEMIOLOGY SERIOUS
   KING P, 1998, NEWSWEEK        0601
   KINGSTON L, 1995, J AM ACAD CHILD PSY, V34, P348, DOI 10.1097/00004583-199503000-00021
   Kropp PR, 1994, MANUAL SPOUSAL ASSAU
   LAUB JH, 1998, VIOLENCE AM SCH, P127
   LeBlanc Marc, 1998, SERIOUS VIOLENT JUVE
   Lipsey M. W., 1998, SERIOUS VIOLENT JUVE, P86
   LOCHMAN JE, 1994, J CONSULT CLIN PSYCH, V62, P366, DOI 10.1037/0022-006X.62.2.366
   LOEBER R, 1986, CRIME JUSTICE, V7, P29, DOI 10.1086/449112
   Monahan J, 1996, AM PSYCHOL, V51, P931, DOI 10.1037/0003-066X.51.9.931
   OSBORN SG, 1978, J ADOLESCENCE, V1, P101, DOI 10.1016/S0140-1971(78)80024-4
   PATTERSON GR, 1992, ANTISOCIAL BOYS
   PEPLER DJ, 1994, THEORETICAL DEV PERS
   PHELAN M, 1999, CNN INTERACTIVE 0809
   PILCHER J, 1999, ASS PRESS ARCHI 0522
   PRESSLEY SA, 1997, WASHINGTON POST 1022
   PRESSLEY SA, 1999, WASHINGTON POST 0523
   QUENSEY V, 1998, VIOLENT OFFENDERS AP
   RAINE A, 1987, J ABNORM CHILD PSYCH, V15, P583, DOI 10.1007/BF00917243
   ROBINS LN, 1975, J CHILD PSYCHOL PSYC, V16, P125, DOI 10.1111/j.1469-7610.1975.tb01262.x
   RUTTER M, 1985, BRIT J PSYCHIAT, V147, P598, DOI 10.1192/bjp.147.6.598
   *SAF SCH COAL WASH, 1999, UND HAR VIOL SCH REP
   SALADINO T, 1999, ASS PRESS ARCHI 0521
   SALADINO T, 1999, ABC NEWS COM    0521
   SALTERS L, 1998, GOOD MORNING AM 0426
   SALVATORE S, 1999, CNN INTERACTIVE 0429
   Sampson R., 1994, UNDERSTANDING PREVEN, V3, P311
   Saner H, 1996, J ADOLESCENT HEALTH, V19, P94, DOI 10.1016/1054-139X(96)00131-0
   SCHADLER J, 1998, ABC PRIMETIME LIVE
   SCOTT CL, 1999, FORENSIC PSYCHOL, V22, P71
   SHINOHARA R, 1997, ANCHORAGE DAILY 0921
   SMITH C, 1995, CRIMINOLOGY, V33, P451, DOI 10.1111/j.1745-9125.1995.tb01186.x
   Spielberger C. D., 1983, ADV PERSONALITY ASSE, V2
   Sprague J. R., 1998, HDB CHILD BEHAV THER, P451
   STRASBURGER VC, 1995, ADOLESCENTS MEDIA
   TOOMEY S, 1998, ANCHORAGE DAILY 0222
   TOOMEY S, 1998, ANCHORAGE DAILY 0124
   TOOMEY S, 1998, ANCHORAGE DAILY 0130
   TRONE J, 1998, BLAME PANIC I STRATE
   Twemlow SW, 1996, B MENNINGER CLIN, V60, P296
   Valois RF, 1998, AM J HEALTH BEHAV, V22, P8
   WADSWORTH MEJ, 1976, BRIT J CRIMINOL, V16, P245, DOI 10.1093/oxfordjournals.bjc.a046738
   WALKER H, 1997, VIOLENCE PREVENTION
   Webber J, 1997, REM SPEC EDUC, V18, P94, DOI 10.1177/074193259701800203
   Webster C, 1995, COPING PSYCHIAT PSYC
   WEICZOREK R, 1984, SUICIDE WILL LIVE VS
   WELLER R, 1999, TIMES RECORD NE 0501
   WELLS LE, 1988, CRIMINOLOGY, V26, P263, DOI 10.1111/j.1745-9125.1988.tb00841.x
   West D. J, 1977, DELINQUENT WAY LIFE
   WILGOREN J, 1999, NY TIMES        0423
   WILLIAMS JH, 1994, THESIS U WASHINGTON
   WOLD M, 1997, REUTERS INFORMA 0825
   WOOD W, 1991, PSYCHOL BULL, V109, P371, DOI 10.1037//0033-2909.109.3.371
   ZUCKER RA, 1987, NEBR S MOT, V34
   1998, KOIN 6 NEWS     1001
   1998, KOIN 6 NEWS     0522
   1998, ARKANSAS DEMOCR 0901
   1998, BBC NEWS ONLINE 0326
   1998, LEXINGTON HERAL 1219
   1999, ELECT LIB
   1998, ARKANSAS DEMOCR 0330
   1998, KOIN 6 NEWS     0525
NR 159
TC 99
Z9 101
U1 4
U2 31
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0272-7358
J9 CLIN PSYCHOL REV
JI Clin. Psychol. Rev.
PD JAN
PY 2000
VL 20
IS 1
BP 3
EP 56
DI 10.1016/S0272-7358(99)00055-0
PG 54
WC Psychology, Clinical
SC Psychology
GA 275TV
UT WOS:000084837000002
PM 10660827
DA 2018-12-27
ER

PT J
AU Bax, M
AF Bax, M
TI RETRACTED: Warlords, priests and the politics of ethnic cleansing: a
   case-study from rural Bosnia Hercegovina (Retracted article. See vol.
   37, pg. 2491, 2014)
SO ETHNIC AND RACIAL STUDIES
LA English
DT Article; Retracted Publication
DE Bosnia Hercegovina; war; violence; ethnic cleansing; decivilization;
   Franciscans
AB There is a tendency among social scientists and others to interpret the ethnic cleansing in Bosnia Hercegovina as the result of a political policy carefully orchestrated from above and systematically carried out. Whatever eruptions of war violence might deviate from this interpretation are generally viewed as primitive balkanism, pointless acts, banditism or mental aberrations. Terms of this kind reflect an uncritical acceptance of a central or national leader perspective, dismissing as deviant everything that fails to go according to plan, and denying the significance of specific local and regional circumstances or failing at any rate to problematize and examine them. This article describes a process the final result of which can be seen as the ethnic homogenization of a region, but only part of its dynamics can be attributed to a policy implemented from above. Rather, its course can largely be traced back to local vendettas and a long-standing conflict between Franciscan friars and diocesan priests. The case illustrates that a systematic study "from below" is crucial to a better understanding of the dynamics and the developmental logic of the processes of ethnic cleansing. The article concludes with some theoretical thoughts which fit into the current debate on civilizing and decivilizing processes.
C1 Free Univ Amsterdam, Dept Anthropol, NL-1081 HV Amsterdam, Netherlands.
RP Bax, M (reprint author), Free Univ Amsterdam, Dept Anthropol, De Boelelaan 1081C, NL-1081 HV Amsterdam, Netherlands.
CR AARONS M, 1991, RATLINES
   Alexander S., 1987, TRIPLE MYTH LIFE ARC
   Alexander S., 1979, CHURCH STATE YUGOSLA
   *ASSISI, 1993, GIOV PAOL II PAC BOS
   BALIC S, 1992, UNBEKANNTE BOSNIEN E
   Bax M, 1997, ANTHROPOL QUART, V70, P11, DOI 10.2307/3317798
   Bax M., 1995, MEDJUGORJE RELIG POL
   BAX M, 1996, J MEDITERRANEN STUDI, V6, P1
   BAX M, 1989, ANTHR Q, V62, P231
   Bax Mart, 1991, RELIG REGIMES STATE, P7
   BRINGA T, 1993, ANTHR E EUROPE REV, V11, P69
   Bringa T, 1995, BEING MUSLIM BOSNIAN
   BROUCEK P, 1988, GEN ZWIELICHT ERINNE
   BUTLER Hubert, 1990, SUBPREFECT SHOULD HA
   CIGAR N, 1996, GENOCIDE EMOTION POS, P51
   Cigar Norman, 1995, GENOCIDE BOSNIA POLI
   COXSEDGE J, 1989, ROOTED SECREACY CLAN
   DENICH B, 1994, AM ETHNOL, V21, P367, DOI 10.1525/ae.1994.21.2.02a00080
   DENICH B, 1991, AM ANTHR ASS ANN M C, P1
   DENITCH B, 1996, ETHNIC NATL TRAGIC D
   DESWAAN A, 1997, AMSTERDAMS SOCIOLOGI, V24, P3
   Djilas A., 1991, CONTESTED COUNTRY YU
   Donia R. J., 1994, BOSNIA HERCEGOVINA T
   DUIJZINGS G, 1991, ISLAMITISCHE PELGRIM, P113
   FALCONI C, 1970, SILENCE PIUS 12
   FLETCHER J, 1995, AMSTERDAMS SOCIOLOGI, V22, P283
   Fletcher J., 1997, VIOLENCE CIVILIZATIO
   GEISS I, 1995, JUGOSLAWIENKRIEG
   Goudsblom J., 1988, TAAL SOCIALE WERKELI, P104
   GOUDSBLOM J, 1987, SOCIOLOGIE N ELIAS
   Hory Ladislaus, 1964, KROATISCHE USTASCHA
   Jelic Ivo, 1978, HRVATSKA RATU REVOLU
   Jelic-Butic Fikreta., 1986, CETNICI HRVATSKOJ
   JELICBUTIC F, 1983, HRVATSKA SELJACKA ST
   Koljevic Svetozar, 1980, EPIC MAKING
   KRALJICA M, 1978, KRALJICA MIRA HRASNO
   KRIZMAN B, 1983, USTASE TRECI REICH, V2
   KRIZMAN B, 1986, PAVELIC BJEKSTVU
   KRIZMAN B, 1980, PAVELIC IZMEDJU HITL
   Malcolm N., 1994, BOSNIA SHORT HIST
   MENNELL S, 1990, INT SOCIOL, V5, P205, DOI 10.1177/026858090005002006
   MENNELL S, 1995, INAUGURAL LECT
   MENNELL S, 1995, SOCIAL THEORY POLITI, P175
   Mennell S, 1989, HUMAN HIST SOCIAL PR, P93
   Mennell Stephen, 1989, N ELIAS CIVILIZATION
   Mestrovic S. G., 1996, GENOCIDE EMOTION POS
   Mojzes P., 1994, YUGOSLAVIAN INFERNO
   Novak Viktor, 1948, MAGNUM CRIMEN POLA V
   NUHANOVIC G, 1995, GLOBUS, V259
   OREC L, 1989, MEDJUGORJE
   Paris Edmond, 1961, GENOCIDE SATELLITE C
   Pasic A., 1994, ISLAMIC ARCHITECTURE
   PERIC R, 1977, PRIJESTOLJE MUDROSTI
   *QUAESTIO, 1979, QUAST HERC
   RAMET P, 1985, SLAVIC REV, V44, P298, DOI 10.2307/2497752
   RIEDLMAYER A, 1994, KILLING MEMORY BOSNI
   SCHENK G, 1993, GOD US ROLE RELIG CO
   Sells Michael Anthony, 1996, BRIDGE BETRAYED RELI
   Silber L., 1996, DEATH YUGOSLAVIA
   SOLDO J, 1964, CITLUK BROTNJO ISTOR
   Sorabji Cornelia, 1995, WAR CRUEL NECESSITY, P80
   SPIER F, 1994, RELIG REGIMES PERU
   Spier Fred, 1996, STRUCTURE BIG HIST B
   STEINBERG J, 1990, ALL NOTHING
   TOMASEVICH J, 1969, CONT YUGOSLAVIA
   TOMASEVICH J, 1978, WAR REVOLUTION YUGOS
   Tomasevich Jozo, 1975, CHETNIKS
   VEGO M, 1981, HIST BROTNJA
   VOJINOVIT N, 1991, GENOCID HRVATSKH KLE
   VULLIAMY E, 1994, SEASONS HELL
   West R, 1996, TITO RISE FALL YUGOS
   Wilson D., 1979, TITOS YUGOSLAVIA
   WILTERDINK N, 1993, ONGELIJKHEID INTERDE
NR 73
TC 32
Z9 33
U1 1
U2 8
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 0141-9870
EI 1466-4356
J9 ETHNIC RACIAL STUD
JI Ethn. Racial Stud.
PD JAN
PY 2000
VL 23
IS 1
BP 16
EP 36
DI 10.1080/014198700329114
PG 21
WC Ethnic Studies; Sociology
SC Ethnic Studies; Sociology
GA 274QA
UT WOS:000084775500002
OA Green Published
DA 2018-12-27
ER

PT J
AU Gelband, CH
   Wang, HW
   Gardon, ML
   Keene, K
   Goldberg, DS
   Reaves, PY
   Katovich, MJ
   Raizada, MK
AF Gelband, CH
   Wang, HW
   Gardon, ML
   Keene, K
   Goldberg, DS
   Reaves, PY
   Katovich, MJ
   Raizada, MK
TI RETRACTED: Angiotensin I-converting enzyme antisense prevents altered
   renal vascular reactivity, but not high blood pressure, in spontaneously
   hypertensive rats (Retracted Article. See vol 40, pg 566, 2002)
SO HYPERTENSION
LA English
DT Article; Proceedings Paper; Retracted Publication
CT 53rd Annual Fall Conference and Scientific Sessions of the
   American-Heart-Association-Council-for-High-Blood-Pressure-Research
CY SEP 13-16, 1999
CL ORLANDO, FL
SP Amer Heart Assoc Council High Blood Pressure Res
DE hypertension, renal; calcium channels; potassium channels; arterioles;
   gene therapy
ID TYPE-1 RECEPTOR ANTISENSE; GENE-THERAPY; NERVOUS-SYSTEM; ACE-INHIBITORS;
   HEART-FAILURE; DELIVERY; CHANNELS
AB The renin-angiotensin system plays a critical role in the control of blood pressure, and its hyperactivity is associated with the development of human primary hypertension. Because low-dose angiotensin I-converting enzyme (ACE) inhibitors cause small reductions in blood pressure that are associated with the complete reversal of altered vascular pathophysiology, our objective in this study was to determine whether ACE antisense (ACE-AS) gene delivery prevents alterations in renal vascular physiology in the parents and F-1 offspring of AS-treated spontaneously hypertensive rats (SHR). A single bolus intracardiac injection of ACE-AS (2X10(8) colony-forming units) in SHR neonates caused a modest (18+/-3 mm Hg, n=7 to 9) lowering of blood pressure, which was maintained in the F-1 generation offspring (n=7 to 9). Alterations in renal vascular reactivity, electrophysiology, and [Ca2+](i) homeostasis are underlying mechanisms associated with the development and establishment of hypertension. Renal resistance arterioles from truncated ACE sense-treated SHR showed a significantly enhanced contractile response to KCl and phenylephrine (n=24 rings from 6 animals, P<0.01) and significantly attenuated acetylcholine-induced relaxations (n=24 rings from 6 animals, P<0.01) compared with arterioles from ACE-AS-treated SHR. In addition, compared with cells dissociated from arterioles of ACE-AS-treated SHR, cells from truncated ACE sense-treated animal vessels had a resting membrane potential that was 22+/-4 mV more depolarized (n=38, P<0.01), an enhanced L-type Ca2+ current density (2.2+/-0.3 versus 1.2+/-0.2 pA/pF, n=23, P<0.01), a decreased Ky current density (16.2+/-1.3 versus 5.4+/-2.2 pA/pF, n=34, P<0.01), and increased Ang II-dependent changes in [Ca2+](i) (n=142, P<0.01). Similar effects of ACE-AS treatment were observed in the F-1 offspring. These results demonstrate that ACE-AS permanently prevents alterations in renal vascular pathophysiology in spite of the modest effect that ACE-AS had on high blood pressure in SHR.
C1 Univ Florida, Coll Med, Dept Physiol, Gainesville, FL 32610 USA.
   Univ Florida, Coll Pharm, Dept Pharmacodynam, Gainesville, FL 32611 USA.
   Univ Florida, Inst Brain, Gainesville, FL USA.
RP Gelband, CH (reprint author), Univ Florida, Coll Med, Dept Physiol, POB 100274, Gainesville, FL 32610 USA.
EM Gelband@phys.med.ufl.edu
FU NHLBI NIH HHS [HL-56921, HL-52189]
CR Ambrosioni E, 1994, Cardiologia, V39, P401
   BARBAGALLO M, 1993, INT ANGIOL, V12, P365
   Burnett JC, 1997, J HUM HYPERTENS, V11, P45, DOI 10.1038/sj.jhh.1000400
   Chung O, 1999, J HUM HYPERTENS, V13, pS11, DOI 10.1038/sj.jhh.1000744
   CHUNG O, 1999, J HUM HYPERTENS S1, V13, pS33
   Cosenzi A, 1999, CLIN EXP HYPERTENS, V21, P223, DOI 10.3109/10641969909068663
   Danser AHJ, 1996, MOL CELL BIOCHEM, V157, P211
   Gelband CH, 1999, HYPERTENSION, V33, P360, DOI 10.1161/01.HYP.33.1.360
   HRICIK DE, 1983, NEW ENGL J MED, V308, P373, DOI 10.1056/NEJM198302173080706
   ISRAILI ZH, 1992, ANN INTERN MED, V117, P234, DOI 10.7326/0003-4819-117-3-234
   Iyer SN, 1996, P NATL ACAD SCI USA, V93, P9960, DOI 10.1073/pnas.93.18.9960
   Lu D, 1997, HYPERTENSION, V30, P363, DOI 10.1161/01.HYP.30.3.363
   Mancini G. B. John, 1998, American Journal of Medicine, V105, p40S, DOI 10.1016/S0002-9343(98)00210-1
   Martens JR, 1998, P NATL ACAD SCI USA, V95, P2664, DOI 10.1073/pnas.95.5.2664
   Martens JR, 1996, CIRC RES, V79, P295, DOI 10.1161/01.RES.79.2.295
   Martens JR, 1998, P SOC EXP BIOL MED, V218, P192
   Mulvany MJ, 1998, METABOLISM, V47, P20, DOI 10.1016/S0026-0495(98)90366-3
   Parmley William W., 1998, American Journal of Medicine, V105, p27S, DOI 10.1016/S0002-9343(98)00208-3
   Phillips MI, 1998, REGUL PEPTIDES, V78, P1, DOI 10.1016/S0167-0115(98)00122-0
   Pitt B, 1997, CARDIOVASC DRUG THER, V11, P285, DOI 10.1023/A:1007795915009
   Roman O, 1998, REV MED CHILE, V126, P1238
   Rothermund L, 1998, BASIC RES CARDIOL, V93, P1
   Stroth U, 1999, J CARDIOVASC PHARM, V33, pS21, DOI 10.1097/00005344-199900001-00005
   Stroth U, 1999, J CARDIOVASC PHAR S1, pS41
   Wang HW, 1999, CIRC RES, V85, P614, DOI 10.1161/01.RES.85.7.614
NR 25
TC 7
Z9 8
U1 1
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0194-911X
EI 1524-4563
J9 HYPERTENSION
JI Hypertension
PD JAN
PY 2000
VL 35
IS 1
SU S
BP 209
EP 213
DI 10.1161/01.HYP.35.1.209
PN 2
PG 5
WC Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 279XP
UT WOS:000085070600010
PM 10642299
OA Bronze
DA 2018-12-27
ER

PT J
AU Assimakopoulos, NA
AF Assimakopoulos, NA
TI RETRACTED: Work-flow management with systems approach: anticipated and
   ad-hoc workflow for scientific applications (Retracted Article. See vol
   41, pg 271, 2002)
SO ISA TRANSACTIONS
LA English
DT Article; Retracted Publication
DE workflow modeling; workflow management; systems approach
AB While workflow management has mostly been considered in business applications so far, the focus of the Workflow Management with Systems Approach (WOMASA) is on scientific applications such as geoprocessing, molecular biology, or laboratory environments. In particular, WOMASA aims at flexible and platform-indepented workflow support, with respect to both specification and execution of workflows. It turns out that the modeling and execution of workflows in traditional and in scientific applications exhibit significant differences. In particular, the need for dynamic modifications of workflow models while workflows are running is an important feature in scientific applications. The conceptual design and functionality of a WOMASA prototype is outlined, in particular that of its core workflow engine, and it is shown how the requirements of flexibility in modeling and executing workflows, imposed by scientific applications, are met. (C) 2000 Elsevier Science Ltd. All rights reserved.
C1 Univ Piraeus, Dept Informat, GR-18534 Piraeus, Greece.
RP Assimakopoulos, NA (reprint author), Univ Piraeus, Dept Informat, 80 Karaoli & Dimitriou Str, GR-18534 Piraeus, Greece.
EM assinik@unipi.gr
CR ASSIMAKOPOULOS N, IN PRESS J COMPUTER
   ASSIMAKOPOULOS N, IN PRESS MIDDLE E FO
   ASSIMAKOPOULOS N, IN PRESS STUDIES REG
   ASSIMAKOPOULOSS N, P 3 INT C COM ANT SY
   BRAYNER A, 1996, EMISA FORUM, V2, P14
   BUSSLER C, 1996, ACM SIGOSIS B, V17, P17
   CELLARY W, 1994, ENG COMPUT, V10, P230, DOI 10.1007/BF01202368
   CELLARY W, 1990, P 16 INT C VER LARG, P432
   EDER J, 1994, P CON 94 WORKFL MAN, P249
   ELLIS C, 1995, P C ORG COMP SYST, P10
   GOODMAN N, 1995, MODERN DATABASE SYST, P216
   KAMEL NN, 1993, DISTRIB PARALLEL DAT, V1, P303, DOI 10.1007/BF01263335
   LEYMANN F, 1994, IBM SYST J, V33, P326, DOI 10.1147/sj.332.0326
   Medeiros C. B., 1996, Proceedings of the Seventh Israeli Conference on Computer Systems and Software Engineering, P129, DOI 10.1109/ICCSSE.1996.554918
   MEIDANIS J, 1996, P 1 INT C COOP INF S
   Mesrobian E, 1996, SIXTH INTERNATIONAL WORKSHOP ON RESEARCH ISSUES IN DATA ENGINEERING, PROCEEDINGS, P107, DOI 10.1109/RIDE.1996.492248
   ORFALI R, 1996, ESSENTIAL DISTRIBUTE
   STEIN L, P 1994 C COMP MED
   VOSSEN G, 1996, BUSINESS PROCESS MOD
   WESKE M, 1996, 0396I WASA
   Wodtke D, 1996, PROC INT CONF DATA, P556, DOI 10.1109/ICDE.1996.492206
NR 21
TC 6
Z9 6
U1 3
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0019-0578
EI 1879-2022
J9 ISA T
JI ISA Trans.
PY 2000
VL 39
IS 2
BP 153
EP 167
DI 10.1016/S0019-0578(00)00014-8
PG 15
WC Automation & Control Systems; Engineering, Multidisciplinary;
   Instruments & Instrumentation
SC Automation & Control Systems; Engineering; Instruments & Instrumentation
GA 322DG
UT WOS:000087494500005
PM 10871211
DA 2018-12-27
ER

PT J
AU Feifel, D
   Moutier, CY
   Perry, W
AF Feifel, D
   Moutier, CY
   Perry, W
TI RETRACTED: Safety and tolerability of a rapidly escalating dose-loading
   regimen for risperidone (Retracted Article. See vol 63, pg 169, 2002)
SO JOURNAL OF CLINICAL PSYCHIATRY
LA English
DT Article; Retracted Publication
ID DOSING STRATEGIES; SCHIZOPHRENIA; PHARMACOLOGY; CLOZAPINE; EFFICACY
AB Background: Risperidone is an "atypical" antipsychotic with strong binding affinity for dopamine-2 and serotonin-2 receptors. Risperidone is often used to treat hospitalized patients who have acute psychotic decompensation, and the therapeutic target dose commonly used is 2 to 6 mg/day. The most common clinical practice is to titrate the dose of risperidone to the target therapeutic dose over several days. This study investigated the safety and tolerability of a rapid oral-loading regimen for risperidone developed to achieve therapeutic doses of this antipsychotic within 24 hours.
   Method: Rapid-loaded risperidone was initiated with 1 mg. Subsequent doses were increased by 1 mg every 6 to 8 hours up to 3 mg. Dose increases were contingent on tolerance of last administered dose.
   Results: Of a sample of 11 consecutive inpatients admitted to an acute psychiatric facility who were treated with this protocol, 7 tolerated the most rapid titration, achieving a standing dose of 3 mg b.i.d. in 16 hours. Three required a slightly slower titration and achieved this target dose in 24 hours. One patient could not tolerate the 3-mg dose but tolerated a standing regimen of 2 mg t.i.d. No patient experienced serious extrapyramidal side effects, sedation, or any other adverse event during the rapid titration, and in no case did risperidone have to be discontinued.
   Conclusion: These results suggest that aggressive dosing of risperidone is well tolerated in most psychiatric inpatients.
C1 Univ Calif San Diego, Med Ctr, Neuropsychiat & Behav Med Unit, San Diego, CA 92103 USA.
RP Feifel, D (reprint author), Univ Calif San Diego, Med Ctr, Neuropsychiat & Behav Med Unit, 200 W Arbor Dr, San Diego, CA 92103 USA.
FU PHS HHS [R374228]
CR American Psychiatric Association, 1994, DIAGN STAT MAN MENT
   Casey DE, 1997, J CLIN PSYCHIAT, V58, P55
   CZOBOR P, 1995, J CLIN PSYCHOPHARM, V15, P243, DOI 10.1097/00004714-199508000-00002
   Davies A, 1998, CLIN THER, V20, P58, DOI 10.1016/S0149-2918(98)80034-9
   Kapur S, 1999, AM J PSYCHIAT, V156, P286
   Lane HY, 1999, J CLIN PSYCHIAT, V60, P487, DOI 10.4088/JCP.v60n0711c
   Lane HY, 2000, J CLIN PSYCHIAT, V61, P209, DOI 10.4088/JCP.v61n0311
   Love RC, 1999, J CLIN PSYCHIAT, V60, P771, DOI 10.4088/JCP.v60n1110
   MCEVOY JP, 1994, J CLIN PSYCHIAT, V55, P18
   Richelson E, 1996, J CLIN PSYCHIAT, V57, P4
   1997, RISPERDAL RISPERIDON, P1348
NR 11
TC 10
Z9 10
U1 3
U2 9
PU PHYSICIANS POSTGRADUATE PRESS
PI MEMPHIS
PA P O BOX 752870, MEMPHIS, TN 38175-2870 USA
SN 0160-6689
EI 1555-2101
J9 J CLIN PSYCHIAT
JI J. Clin. Psychiatry
PY 2000
VL 61
IS 12
BP 909
EP 911
DI 10.4088/JCP.v61n1203
PG 3
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA 394QG
UT WOS:000166534300003
PM 11206594
DA 2018-12-27
ER

PT J
AU Thomas, F
   Ray, P
   Thomas, JM
AF Thomas, F
   Ray, P
   Thomas, JM
TI RETRACTED: Immunological tolerance as an adjunct to allogeneic tissue
   grafting (Retracted article. See vol. 29, pg. 86, 2009)
SO MICROSURGERY
LA English
DT Article; Proceedings Paper; Retracted Publication
CT 2nd International Symposium on Composite Tissue Allotransplantation
CY MAY 17-18, 2000
CL LOUISVILLE, KY
ID DONOR BONE-MARROW; POSTTRANSPLANT ANTITHYMOCYTE GLOBULIN; INCOMPATIBLE
   ALLOGRAFT ACCEPTANCE; RHESUS-MONKEYS; CHRONIC IMMUNOSUPPRESSION;
   TRANSPLANTATION; PERITRANSPLANT; INDUCTION; SURVIVAL;
   ANTI-CD3-IMMUNOTOXIN
AB Since its clinical inception, our group has worked in clinical and experimental transplantation. The exciting early results of composite tissue allografts (CTA) attracted our attention during the 1980s, when some of the first experimental CTA literature appeared. The recent extraordinary results of clinical CTA grafts, primarily the Louisville and Lyon results, have been highlighted at this meeting. Interestingly, this success followed not long after the first International meeting in Louisville in 1997. This is clearly an exciting new application of transplant techniques to one of the newest and most unique types of transplants. Previous studies used immunosuppression for skin allografting, Early results seem quite exciting and we expect to see a rapid growth of interest and activity in this area. We believe that the entire field would benefit from the novel, highly effective and minimally toxic immune tolerance induction using CD3-immunotoxin (CD3-IT) and deoxyspergualin (DSG). (C) 2000 Wiley-Liss, Inc.
C1 Univ Alabama Birmingham, Dept Surg, Div Transplant Immunol, Birmingham, AL 35294 USA.
RP Thomas, F (reprint author), Univ Alabama Birmingham, Dept Surg, Div Transplant Immunol, Suite 557,Boshell Diabet Res & Educ Bldg,1808 7th, Birmingham, AL 35294 USA.
FU NIDDK NIH HHS [U19-DKS7958]
CR CLARK GT, 1989, J SURG RES, V46, P401, DOI 10.1016/0022-4804(89)90151-0
   Contreras JL, 1998, TRANSPLANTATION, V65, P1159, DOI 10.1097/00007890-199805150-00003
   GARRISON JL, 1990, J SURG RES, V49, P390, DOI 10.1016/0022-4804(90)90185-5
   Hewitt CW, 1998, TRANSPLANT P, V30, P2704, DOI 10.1016/S0041-1345(98)00792-1
   Jensen JN, 2000, J RECONSTR MICROSURG, V16, P235
   JENSEN JN, J RECONSTR MICROSURG, V6, P57
   Kanitakis J, 2000, TRANSPLANTATION, V69, P1380, DOI 10.1097/00007890-200004150-00029
   Lee WPA, 1999, J HAND SURG-AM, V24A, P906
   MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991, DOI 10.1146/annurev.iy.12.040194.005015
   Neville DM, 1996, J IMMUNOTHER, V19, P85, DOI 10.1097/00002371-199603000-00001
   Rose SM, 1998, TRANSPLANTATION, V66, P1123, DOI 10.1097/00007890-199811150-00001
   THOMAS F, 1981, INT J PRIMATOL, V22, P105
   THOMAS F, 1991, MIN CHIR, V46, P51
   Thomas FT, 1999, TRANSPLANTATION, V67, P846, DOI 10.1097/00007890-199903270-00011
   THOMAS FT, 1993, ANN NY ACAD SCI, V685, P175, DOI 10.1111/j.1749-6632.1993.tb35863.x
   THOMAS FT, 1983, ANN SURG, V198, P370, DOI 10.1097/00000658-198309000-00013
   THOMAS FT, 1993, IMMUNOLOGY RENAL TRA, P129
   THOMAS J, 1992, TRANSPLANTATION, V53, P247, DOI 10.1097/00007890-199202010-00001
   THOMAS J, 1982, CLIN EXP IMMUNOL, V47, P457
   THOMAS J, 1987, TRANSPLANTATION, V43, P332, DOI 10.1097/00007890-198703000-00002
   THOMAS JM, 1989, TRANSPLANTATION, V47, P209, DOI 10.1097/00007890-198902000-00002
   Thomas JM, 1999, TRANSPLANTATION, V68, P1660, DOI 10.1097/00007890-199912150-00009
   THOMAS JM, 1983, TRANSPLANTATION, V36, P104
   THOMAS JM, 1994, CLIN TRANSPLANT, V8, P195
   Thomas JM, 1997, TRANSPLANTATION, V64, P124, DOI 10.1097/00007890-199707150-00022
   THOMAS JM, 1981, TRANSPLANT P, V13, P599
   THOMAS JM, 1994, IMMUNOMETHODS
   THOMAS JM, 1993, TRANSPLANT SCI, V3, P60
   THOMAS JM, 2000, IN PRESS TRANSPLANTA, P69
   THOMAS JM, 1991, TRANSPLANT REV, V5, P209
   TRAN CD, 1989, ANAL CHEM, V61, P928, DOI 10.1021/ac00183a031
   Ustuner ET, 1998, TRANSPLANTATION, V66, P1581
NR 32
TC 10
Z9 12
U1 3
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0738-1085
EI 1098-2752
J9 MICROSURG
JI Microsurgery
PY 2000
VL 20
IS 8
BP 435
EP 440
DI 10.1002/1098-2752(2000)20:8<435::AID-MICR15>3.0.CO;2-2
PG 6
WC Surgery
SC Surgery
GA 389MV
UT WOS:000166242900014
PM 11150996
DA 2018-12-27
ER

PT J
AU Fujii, Y
   Saitoh, Y
   Tanaka, H
   Toyooka, H
AF Fujii, Y
   Saitoh, Y
   Tanaka, H
   Toyooka, H
TI RETRACTED: Pretreatment with oral clonidine attenuates cardiovascular
   responses to tracheal extubation in children (Retracted article. See
   vol. 23, pg. 377, 2013)
SO PAEDIATRIC ANAESTHESIA
LA English
DT Article; Retracted Publication
DE complications, tachycardia, hypertension; pharmacology, clonidine,
   diazepam
ID PREMEDICATION
AB This study was designed to evaluate the effects of diazepam and clonidine orally given preoperatively on cardiovascular responses to tracheal extubation in children. Fifty children, ASA physical status I, aged 4-10 years, undergoing minor elective surgery (inguinal hernia, phimosis) received orally, in a randomized, double-blind manner, diazepam 0.4 mg.kg(-1) or clonidine 4 mu g.kg(-1) (n = 25 of each). These drugs were administered 105 min before an inhalational induction of anaesthesia. The same standard general anaesthetic technique was employed throughout. The maximum changes in heart rate (HR), systolic blood pressure (SBP) and diastolic blood pressure (DBP) were less in patients who had received clonidine than in those who had received diazepam (HR, 12 vs 24; SEP, 14 vs 26; DBP, 9 vs 16; mean, P < 0.05). In conclusion, compared to diazepam given orally, pretreatment with oral clonidine attenuates haemodynamic changes associated with tracheal extubation in children.
C1 Univ Tsukuba, Inst Clin Med, Dept Anaesthesiol, Tsukuba, Ibaraki 305, Japan.
   Toride Kyodo Gen Hosp, Dept Anaesthesiol, Toride, Ibaraki, Japan.
RP Fujii, Y (reprint author), Univ Tsukuba, Inst Clin Med, Dept Anaesthesiol, 2-1-1 Amakubo, Tsukuba, Ibaraki 305, Japan.
CR Fujii Y, 1997, CAN J ANAESTH, V44, P1082, DOI 10.1007/BF03019230
   HARTLEY M, 1993, BRIT J ANAESTH, V71, P561, DOI 10.1093/bja/71.4.561
   LOWRIE A, 1992, BRIT J ANAESTH, V68, P261, DOI 10.1093/bja/68.3.261
   MIKAWA K, 1993, ANESTHESIOLOGY, V79, P926, DOI 10.1097/00000542-199311000-00009
   Mikawa K, 1996, ANESTH ANALG, V82, P225, DOI 10.1097/00000539-199602000-00001
   MIKAWA K, 1995, CAN J ANAESTH, V42, P869, DOI 10.1007/BF03011033
   MILLER KA, 1995, ANESTH ANALG, V80, P149, DOI 10.1097/00000539-199501000-00025
   STEWARD DJ, 1989, PEDIATRIC ANESTHESIA, P523
NR 8
TC 23
Z9 27
U1 3
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1155-5645
J9 PAEDIATR ANAESTH
JI Paediatr. Anaesth.
PD JAN
PY 2000
VL 10
IS 1
BP 65
EP 67
DI 10.1046/j.1460-9592.2000.00441.x
PG 3
WC Anesthesiology; Pediatrics
SC Anesthesiology; Pediatrics
GA 278LN
UT WOS:000084991400011
PM 10632912
DA 2018-12-27
ER

PT J
AU Piscureanu, M
   Manaila-Maximean, D
AF Piscureanu, M
   Manaila-Maximean, D
TI RETRACTED: Optical solitons in resonant and nonresonant nonlinear media
   in the presence of perturbations (Retracted Article. See vol E67, ARTN
   029901, 2003)
SO PHYSICAL REVIEW E
LA English
DT Article; Retracted Publication
ID PROPAGATION
AB We studied the optical solitons in nonlinear resonant and nonresonant media in the presence of perturbations, assuming that the transient effects are stimulated by the light scanning beam. We treated a slight deviation from the exact necessary condition for the soliton existence (2 beta nu= 1), as a small perturbation for the integrable system, studying its influence upon the soliton propagation conditions. The approximation is constructed by the help of an algebraic version of the soliton perturbation theory using a Riemann boundary problem in connection with the inverse scattering method. We have obtained the soliton equation and we have solved it in the presence of a small perturbation in the adiabatic approximation. In this case we have demonstrated that: for a Lorentz profile line the amplitude of the soliton remains unchanged, the only effect of the perturbation results in a phase shift PACS number(s): 42.65.Tg, 42.81.Dp.
C1 Univ Politehn Bucuresti, Dept Phys, Bucharest 77206, Romania.
RP Piscureanu, M (reprint author), Univ Politehn Bucuresti, Dept Phys, Splaiul Independentei 313, Bucharest 77206, Romania.
CR BASHAROV AM, 1989, OPT SPEKTROSK+, V66, P167
   Boyd RW., 1992, NONLINEAR OPTICS
   DOKTOROV EV, 1983, OPT ACTA, V30, P223, DOI 10.1080/713821151
   FADDEEV LD, 1988, HAMILTONIAN APPROACH
   KARPMAN VI, 1979, PHYS SCRIPTA, V20, P462, DOI 10.1088/0031-8949/20/3-4/023
   KAUP DJ, 1976, SIAM J APPL MATH, V31, P121, DOI 10.1137/0131013
   MAIMISTOV AI, 1983, ZH EKSP TEOR FIZ+, V85, P1177
   MATULIC L, 1988, J OPT SOC AM B, V5, P1673, DOI 10.1364/JOSAB.5.001673
   PORSEZIAN K, 1995, PHYS REV LETT, V74, P2941, DOI 10.1103/PhysRevLett.74.2941
   VLASOV RA, 1982, DOKL AKAD NAUK BELAR, V26, P322
NR 10
TC 1
Z9 1
U1 3
U2 9
PU AMER PHYSICAL SOC
PI COLLEGE PK
PA ONE PHYSICS ELLIPSE, COLLEGE PK, MD 20740-3844 USA
SN 2470-0045
EI 2470-0053
J9 PHYS REV E
JI Phys. Rev. E
PD JAN
PY 2000
VL 61
IS 1
BP 880
EP 885
DI 10.1103/PhysRevE.61.880
PG 6
WC Physics, Fluids & Plasmas; Physics, Mathematical
SC Physics
GA 277LN
UT WOS:000084935200113
PM 11046336
DA 2018-12-27
ER

PT J
AU Shan, RJ
   Price, JO
   Gaarde, WA
   Monia, BP
   Krantz, SB
   Zhao, ZHJ
AF Shan, RJ
   Price, JO
   Gaarde, WA
   Monia, BP
   Krantz, SB
   Zhao, ZHJ
TI RETRACTED: Distinct roles of JNKs/p38 MAP kinase and ERKs in apoptosis
   and survival of HCD-57 cells induced by withdrawal or addition of
   erythropoietin (Retracted Article. See vol 97, pg 843, 2001)
SO BLOOD
LA English
DT Article; Retracted Publication
ID ACTIVATED PROTEIN-KINASE; ERYTHROID PROGENITOR CELLS; TYROSINE
   PHOSPHORYLATION; IN-VIVO; SIGNAL-TRANSDUCTION; MITOGEN; PATHWAY; DEATH;
   PROLIFERATION; RECEPTOR
AB Erythropoietin (EPO), a major regulator of erythroid progenitor cells, is essential for the survival, proliferation, and differentiation of immature erythroid cells. To gain insight into the molecular mechanism by which EPO functions, we analyzed the activation of Jun N-terminal kinases (JNKs) and extracellular signal-regulated kinases (ERKs) in HCD-57 cells, a murine erythroid progenitor cell line that requires EPO for survival and proliferation. Withdrawal of EPO from the cell culture medium resulted in sustained activation of JNKs plus p38 MAP kinase, and inactivation of ERKs, preceding apoptosis of the cells. Addition of EPO to the EPO-deprived cells caused activation of ERKs accompanied by inactivation of JNKs and p38 MAP kinase and rescued the cells from apoptosis. Phorbol 12-myristate 13-acetate, which activated ERKs by a different mechanism, also suppressed the activation of JNKs and significantly retarded apoptosis of the cells caused by withdrawal of EPO. Furthermore, MEK inhibitor PD98059, which inhibited activation of ERKs, caused activation of JNKs, whereas suppression of JNK expression by antisense oligonucleotides and inhibition of p38 MAP kinase by SB203580 caused attenuation of the apoptosis that occurs upon withdrawal of EPO. Finally, the activation of JNKs and p38 MAP kinase and concurrent inactivation of ERKs upon withdrawal of EPO were also observed in primary human erythroid colony-forming cells. Taken together, the data suggest that activation of ERKs promotes cell survival, whereas activation of JNKs and p38 MAP kinase leads to apoptosis and EPO functions by controlling the dynamic balance between ERKs and JNKs. (C) 1999 by The American Society of Hematology.
C1 Vanderbilt Univ, Dept Med, Div Hematol Oncol, Nashville, TN USA.
   Vanderbilt Univ, Dept Pathol, Nashville, TN USA.
   Vanderbilt Univ, Dept Vet Affairs Med Serv, Nashville, TN USA.
   Vanderbilt Univ, Vanderbilt Ingram Canc Ctr, Nashville, TN USA.
   ISIS Pharmaceut, Dept Mol Pharmacol, Carlsbad, CA 92008 USA.
RP Krantz, SB (reprint author), 457,MRB II,2220 Pierce Ave, Nashville, TN 37232 USA.
EM joe.zhao@mcmail.vanderbilt.edu
FU NHLBI NIH HHS [HL-57393]; NIDDK NIH HHS [2 T32-DK-07186, DK-15555]
CR Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322
   Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305
   Barber DL, 1997, BLOOD, V89, P55
   Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6
   Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5
   delPeso L, 1997, SCIENCE, V278, P687
   Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317
   Graves JD, 1998, EMBO J, V17, P2224, DOI 10.1093/emboj/17.8.2224
   GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300
   Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309
   Horiuchi M, 1997, J BIOL CHEM, V272, P19022, DOI 10.1074/jbc.272.30.19022
   Ito T, 1997, J BIOL CHEM, V272, P11671, DOI 10.1074/jbc.272.18.11671
   Jacobs-Helber SM, 1998, MOL CELL BIOL, V18, P3699, DOI 10.1128/MCB.18.7.3699
   Klingmuller U, 1997, P NATL ACAD SCI USA, V94, P3016, DOI 10.1073/pnas.94.7.3016
   Klingmuller U, 1997, EUR J BIOCHEM, V249, P637, DOI 10.1111/j.1432-1033.1997.t01-1-00637.x
   KOURY MJ, 1990, SCIENCE, V248, P378, DOI 10.1126/science.2326648
   KRANTZ SB, 1991, BLOOD, V77, P419
   Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708
   Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4
   Maundrell K, 1997, J BIOL CHEM, V272, P25238, DOI 10.1074/jbc.272.40.25238
   MIURA Y, 1994, J BIOL CHEM, V269, P29962
   Monia BP, 1997, ANTI-CANCER DRUG DES, V12, P327
   Moriyama M, 1997, ONCOGENE, V14, P2465, DOI 10.1038/sj.onc.1201084
   Nagata Y, 1997, BLOOD, V89, P2664
   Nagata Y, 1998, BLOOD, V92, P1859
   OGAWA M, 1993, BLOOD, V81, P2844
   Paul A, 1997, CELL SIGNAL, V9, P403, DOI 10.1016/S0898-6568(97)00042-9
   SAWADA K, 1987, J CLIN INVEST, V80, P357, DOI 10.1172/JCI113080
   SEGER R, 1995, FASEB J, V9, P726
   SPIVAK JL, 1991, BLOOD, V77, P1228
   Sui XW, 1998, BLOOD, V92, P1142
   SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2
   SUN H, 1994, TRENDS BIOCHEM SCI, V19, P480, DOI 10.1016/0968-0004(94)90134-1
   Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312
   Verdier F, 1997, J BIOL CHEM, V272, P26173, DOI 10.1074/jbc.272.42.26173
   WANG ZD, 1992, J MATER CHEM, V2, P629, DOI 10.1039/jm9920200629
   WASKIEWICZ AJ, 1995, CURR OPIN CELL BIOL, V7, P798, DOI 10.1016/0955-0674(95)80063-8
   Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063
   WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366
   XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326
   Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3
   ZHAO ZZ, 1995, J BIOL CHEM, V270, P11765, DOI 10.1074/jbc.270.20.11765
NR 42
TC 38
Z9 39
U1 0
U2 7
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 15
PY 1999
VL 94
IS 12
BP 4067
EP 4076
PG 10
WC Hematology
SC Hematology
GA 263TD
UT WOS:000084140600013
PM 10590051
DA 2018-12-27
ER

PT J
AU Thomas, JM
   Contreras, JL
   Jiang, XL
   Eckhoff, DE
   Wang, PX
   Hubbard, WJ
   Lobashevsky, AL
   Wang, WL
   Asiedu, C
   Stavrou, S
   Cook, WJ
   Robbin, ML
   Thomas, FT
   Neville, DM
AF Thomas, JM
   Contreras, JL
   Jiang, XL
   Eckhoff, DE
   Wang, PX
   Hubbard, WJ
   Lobashevsky, AL
   Wang, WL
   Asiedu, C
   Stavrou, S
   Cook, WJ
   Robbin, ML
   Thomas, FT
   Neville, DM
TI RETRACTED: Peritransplant tolerance induction in macaques: Early events
   reflecting the unique synergy between immunotoxin and deoxyspergualin
   (Retracted article. See vol 86, pg. 482, 2008)
SO TRANSPLANTATION
LA English
DT Article; Proceedings Paper; Retracted Publication
CT 17th Annual Meeting of the American-Society-of-Transplant-Physicians
CY MAY 09-13, 1998
CL CHICAGO, IL
SP Amer Soc Transplant Physicians
ID TOTAL LYMPHOID IRRADIATION; RENAL-ALLOGRAFT REJECTION; KAPPA-B
   ACTIVATION; DONOR BONE-MARROW; T-CELL DEPLETION; DENDRITIC CELLS;
   ORGAN-TRANSPLANTATION; KIDNEY ALLOGRAFTS; RHESUS-MONKEYS; IN-VIVO
AB Background. Day of transplant T cell depletion with anti-CDS immunotoxin or F(Ab)(2) immunotoxin induces stable tolerance to renal allografts in rhesus monkeys given 15-deoxyspergualin (DSG), a NF-kappa B inhibitor that suppresses proinflammatory cytokine (PC) production. Because PC and NF-kappa B are involved in dendritic cell (DC) maturation, we asked if impaired DC maturation and Th2-type cytokine deviation might be related to the synergistic effect of DSG in this novel model.
   Methods. Immunosuppression was initialed 4 hr before transplanting a major histocompatibility complex mismatched renal allograft, Some groups received a supplemental 5-day course of cyclosporine A or DSG or a 15-day course of DSG. Peripheral lymph nodes were sequentially examined for presence of mature DC. In vitro effects of DSG on PC-induced maturation of DC were also examined.
   Results. Allografts survived without rejection in 87% of recipients given immunotoxin or F(Ab)(2) immunotoxin with DSG x 15 days, in 50% with DSG x 5 days, and 0% with cyclosporine A. The longest DSG survivors are >1000 days with normal graft function and tolerance validated, including acceptance of challenge second donor kidneys without treatment. DSG-treated recipients were unique in developing polarized Th2-type plasma cytokines, In DSG recipients, mature DC were significantly reduced in day +5 lymph node biopsies, with complete repopulation by 30 days. In vitro studies verified an inhibitory effect of DSG on DC maturation,
   Conclusions, The study suggests DSG arrests DC maturation. The unusual synergy of immunotoxin and DSG: apparently involves coincidental reduction in lymph node T cell mass and mature DC, a transient circumstance favoring development of stable tolerance.
C1 Univ Alabama, Dept Surg, Div Transplantat Immunobiol, Birmingham, AL 35294 USA.
   Univ Alabama, Dept Pathol, Birmingham, AL 35294 USA.
   Univ Alabama, Dept Radiol, Birmingham, AL 35294 USA.
   NIMH, NIH, Mol Biol Lab, Bethesda, MD 20800 USA.
RP Thomas, JM (reprint author), Div Transplantat Immunol, 531 Boshell Diabet Bldg,1808 7th Ave S, Birmingham, AL 35294 USA.
FU NIAID NIH HHS [AI RO1-AI122293]
CR Armstrong N, 1998, TRANSPLANTATION, V66, P5, DOI 10.1097/00007890-199807150-00002
   AUSTYN JM, 1990, TRANSPLANTATION, V49, P1, DOI 10.1097/00007890-199001000-00001
   Azuma H, 1996, P NATL ACAD SCI USA, V93, P12439, DOI 10.1073/pnas.93.22.12439
   Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588
   Bender A, 1997, ADV EXP MED BIOL, V417, P383
   BILLINGHAM RE, 1953, NATURE, V172, P603, DOI 10.1038/172603a0
   Cella M, 1997, CURR OPIN IMMUNOL, V9, P10, DOI 10.1016/S0952-7915(97)80153-7
   Cobbold SP, 1996, IMMUNOL REV, V149, P5, DOI 10.1111/j.1600-065X.1996.tb00897.x
   Contreras JL, 1998, TRANSPLANTATION, V65, P1159, DOI 10.1097/00007890-199805150-00003
   COULOMBE M, 1994, TRANSPLANTATION, V57, P1195, DOI 10.1097/00007890-199404270-00010
   Demetris A J, 1995, Adv Nephrol Necker Hosp, V24, P341
   Fechner JH, 1997, TRANSPLANTATION, V63, P1339, DOI 10.1097/00007890-199705150-00023
   FIELD EH, 1995, TRANSPLANTATION, V60, P695, DOI 10.1097/00007890-199510150-00014
   Field EH, 1997, TRANSPLANTATION, V64, P1, DOI 10.1097/00007890-199707150-00002
   GarciaMorales R, 1997, TRANSPLANT P, V29, P2179, DOI 10.1016/S0041-1345(97)00282-0
   Goumy L, 1996, TRANSPLANTATION, V61, P83, DOI 10.1097/00007890-199601150-00017
   Hamano K, 1996, TRANSPLANTATION, V62, P856, DOI 10.1097/00007890-199609270-00026
   Hisanaga M, 1996, TRANSPLANTATION, V61, P40, DOI 10.1097/00007890-199601150-00010
   HOEGER PH, 1994, J IMMUNOL, V153, P3908
   HUBBARD WJ, 1997, CURR OPIN ORGAN TRAN, V2, P36
   KAWAI T, 1995, TRANSPLANTATION, V59, P256, DOI 10.1097/00007890-199501270-00018
   Kimikawa M, 1997, TRANSPLANTATION, V64, P709, DOI 10.1097/00007890-199709150-00008
   Kirk AD, 1997, P NATL ACAD SCI USA, V94, P8789, DOI 10.1073/pnas.94.16.8789
   Knechtle SJ, 1997, TRANSPLANTATION, V63, P1, DOI 10.1097/00007890-199701150-00002
   Lafferty K J, 1986, Prog Clin Biol Res, V224, P87
   LAU H, 1984, SCIENCE, V223, P607, DOI 10.1126/science.6420888
   LECHLER RI, 1982, J EXP MED, V155, P31, DOI 10.1084/jem.155.1.31
   LECHLER RI, 1983, TRANSPLANT P, V15, P316
   LeitedeMoraes MC, 1997, EUR CYTOKINE NETW, V8, P229
   Lobashevsky AL, 1998, HUM IMMUNOL, V59, P363, DOI 10.1016/S0198-8859(98)00024-X
   Lu LN, 1997, TRANSPLANTATION, V64, P1808, DOI 10.1097/00007890-199712270-00031
   Mantovani A, 1998, RES IMMUNOL, V149, P639, DOI 10.1016/S0923-2494(99)80030-3
   Markees TG, 1996, TRANSPLANTATION, V61, P111, DOI 10.1097/00007890-199601150-00022
   MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991, DOI 10.1146/annurev.iy.12.040194.005015
   Mellman I, 1998, TRENDS CELL BIOL, V8, P231, DOI 10.1016/S0962-8924(98)01276-8
   Meng G, 1998, TRANSPL IMMUNOL, V6, P53, DOI 10.1016/S0966-3274(98)80035-X
   Meyer S, 1997, FEBS LETT, V413, P354, DOI 10.1016/S0014-5793(97)00930-7
   MONACO AP, 1966, ANN NY ACAD SCI, V129, P190, DOI 10.1111/j.1749-6632.1966.tb12851.x
   MOSELEY ROGER V., 1966, TRANSPLANTATION, V4, P678, DOI 10.1097/00007890-196611000-00003
   MYBURGH JA, 1984, J IMMUNOL, V132, P1019
   NADLER SG, 1995, THER DRUG MONIT, V17, P700, DOI 10.1097/00007691-199512000-00026
   Nemoto K, 1997, EXP HEMATOL, V25, P1339
   Neville DM, 1996, J IMMUNOTHER, V19, P85, DOI 10.1097/00002371-199603000-00001
   NICKERSON P, 1994, CURR OPIN IMMUNOL, V6, P757, DOI 10.1016/0952-7915(94)90081-7
   Nikolic B, 1997, CURR OPIN IMMUNOL, V9, P634, DOI 10.1016/S0952-7915(97)80042-8
   ODoherty U, 1997, J IMMUNOL METHODS, V207, P185, DOI 10.1016/S0022-1759(97)00119-1
   Pardoux C, 1997, J IMMUNOL, V158, P136
   PAUL WE, 1994, CELL, V76, P241, DOI 10.1016/0092-8674(94)90332-8
   POWELL TJ, 1990, J IMMUNOL, V144, P854
   REICHENSPURNER H, 1990, TRANSPLANTATION, V50, P181, DOI 10.1097/00007890-199008000-00001
   Ridge JP, 1996, SCIENCE, V271, P1723, DOI 10.1126/science.271.5256.1723
   Robert C, 1999, J EXP MED, V189, P627, DOI 10.1084/jem.189.4.627
   Rogge L, 1997, CHEM IMMUNOL, V68, P38
   Saleem S, 1996, TRANSPLANTATION, V62, P1908, DOI 10.1097/00007890-199612270-00039
   Seddon B, 1999, J EXP MED, V189, P279, DOI 10.1084/jem.189.2.279
   Seder RA, 1998, J IMMUNOL, V160, P5719
   Smith JP, 1997, CELL TRANSPLANT, V6, P369, DOI 10.1016/S0963-6897(97)00005-5
   STARZL TE, 1993, IMMUNOL TODAY, V14, P326, DOI 10.1016/0167-5699(93)90054-O
   Steinman RM, 1997, ADV EXP MED BIOL, V417, P1
   TEPPER MA, 1995, J IMMUNOL, V155, P2427
   THOMAS FT, 1993, ANN NY ACAD SCI, V685, P175, DOI 10.1111/j.1749-6632.1993.tb35863.x
   THOMAS FT, 1983, ANN SURG, V198, P370, DOI 10.1097/00000658-198309000-00013
   THOMAS J, 1992, TRANSPLANTATION, V53, P247, DOI 10.1097/00007890-199202010-00001
   THOMAS JM, 1995, TRANSPLANTATION, V59, P245, DOI 10.1097/00007890-199501270-00017
   THOMAS JM, 1994, TRANSPLANTATION, V57, P101, DOI 10.1097/00007890-199401000-00018
   Thomas JM, 1997, TRANSPLANTATION, V64, P124, DOI 10.1097/00007890-199707150-00022
   THOMAS JM, 1995, CHIMERISM TOLERANCE, P143
   Wood K, 1996, IMMUNOL TODAY, V17, P584, DOI 10.1016/S0167-5699(96)10069-4
   Wu L, 1998, IMMUNITY, V9, P839, DOI 10.1016/S1074-7613(00)80649-4
   Zeng DF, 1996, TRANSPLANTATION, V62, P510, DOI 10.1097/00007890-199608270-00014
   Zeng DF, 1999, J EXP MED, V189, P1073, DOI 10.1084/jem.189.7.1073
   ZHU XF, 1994, TRANSPLANTATION, V58, P1104
NR 72
TC 106
Z9 109
U1 3
U2 15
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0041-1337
J9 TRANSPLANTATION
JI Transplantation
PD DEC 15
PY 1999
VL 68
IS 11
BP 1660
EP 1673
DI 10.1097/00007890-199912150-00009
PG 14
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 266NJ
UT WOS:000084305800009
PM 10609942
DA 2018-12-27
ER

PT J
AU Urs, UK
   Murali, R
   Murthy, HMK
AF Urs, UK
   Murali, R
   Murthy, HMK
TI RETRACTED: Structure of Tag DNA polymerase shows a new orientation for
   the structure-specific nuclease domain (Retracted article. See vol. 66,
   pg. 222, 2010)
SO ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY
LA English
DT Article; Retracted Publication
ID X-RAY-DIFFRACTION; THERMUS-AQUATICUS; CRYSTAL-STRUCTURES;
   CHAIN-REACTION; MACROMOLECULAR STRUCTURES; ANOMALOUS DIFFRACTION;
   TERNARY COMPLEXES; ESCHERICHIA-COLI; LARGE FRAGMENT; PROTEIN
AB Thermus aquaticus DNA polymerase I consists of the polymerase, the structure-specific nuclease and the vestigial editing nuclease domains. Three-dimensional structures of the native enzyme and its complex with DNA have already been reported, The structure of a complex with an inhibitory antibody has also been determined. The structure of the native enzyme in a different crystal form determined at 2.6 Angstrom is reported here. Optimized anomalous diffraction measurements made at the holmium LIII edge were valuable in validating solutions obtained through molecular replacement. The structure of the polymerase domain is similar to those reported previously, while the relative orientation of the structure-specific nuclease domain is significantly different from those of the native enzyme and the DNA complex; it is, however, identical to that observed in the structure of the Fab complex, In the structures of the native enzyme and of the DNA complex reported previously, the active site of the structure-specific nuclease domain is too far from that of the polymerase domain, making it difficult to propose a structural model for the in vivo primer-excision and nick-translation activities of the enzyme. In the present structure, the two active sites are considerably closer. Taken together, the reported structure of the native enzyme, that of the Fab complex and the present structure imply that the different orientation of the structure-specific nuclease domain is probably a consequence of intrinsically high relative mobility between these two domains in this enzyme.
C1 Indian Inst Sci, Mol Biophys Unit, Bangalore 560012, Karnataka, India.
   Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA.
   Univ Alabama Birmingham, Ctr Macromol Crystallog, Birmingham, AL 35294 USA.
RP Murthy, HMK (reprint author), Indian Inst Sci, Mol Biophys Unit, Bangalore 560012, Karnataka, India.
EM murthy@onyx.cmc.uab.edu
CR ARNHEIM N, 1992, ANNU REV BIOCHEM, V61, P131, DOI 10.1146/annurev.bi.61.070192.001023
   Artymiuk PJ, 1997, NUCLEIC ACIDS RES, V25, P4224, DOI 10.1093/nar/25.21.4224
   BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x
   Brautigam CA, 1998, CURR OPIN STRUC BIOL, V8, P54, DOI 10.1016/S0959-440X(98)80010-9
   BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0
   BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355
   CHIEN A, 1976, J BACTERIOL, V127, P1550
   *COLL COMP PROJ 4, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI DOI 10.1107/S0907444994003112
   CONNOLLY ML, 1983, SCIENCE, V221, P709, DOI 10.1126/science.6879170
   DECORTE R, 1993, J MED GENET, V30, P625, DOI 10.1136/jmg.30.8.625
   Doublie S, 1998, NATURE, V391, P251
   ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071
   Eom SH, 1996, NATURE, V382, P278, DOI 10.1038/382278a0
   Hayward S, 1998, PROTEINS, V30, P144, DOI 10.1002/(SICI)1097-0134(19980201)30:2<144::AID-PROT4>3.0.CO;2-N
   HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561
   Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669
   HUBBARD SJ, 1993, NACCESS PROGRAM
   Hutchinson EG, 1996, PROTEIN SCI, V5, P212
   JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224
   JOYCE CM, 1995, J BACTERIOL, V177, P6321, DOI 10.1128/jb.177.22.6321-6329.1995
   KALEDIN AS, 1979, BIOCHEMISTRY-MOSCOW, V129, P47
   Kiefer JR, 1998, NATURE, V391, P304
   KIM Y, 1995, NATURE, V376, P612, DOI 10.1038/376612a0
   KOROLEV S, 1995, P NATL ACAD SCI USA, V92, P9264, DOI 10.1073/pnas.92.20.9264
   KRISHNAMURTHY HM, 1988, J BIOL CHEM, V263, P18430
   LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944
   LAWYER FC, 1989, J BIOL CHEM, V264, P6427
   Li Y, 1998, PROTEIN SCI, V7, P1116, DOI 10.1002/pro.5560070505
   Li Y, 1998, EMBO J, V17, P7514, DOI 10.1093/emboj/17.24.7514
   LYAMICHEV V, 1993, SCIENCE, V260, P778, DOI 10.1126/science.7683443
   MARIANS KJ, 1992, ANNU REV BIOCHEM, V61, P673, DOI 10.1146/annurev.bi.61.070192.003325
   MCPHERSON A, 1980, BIOPHYS J, V32, P155, DOI 10.1016/S0006-3495(80)84931-9
   Murali R, 1998, P NATL ACAD SCI USA, V95, P12562, DOI 10.1073/pnas.95.21.12562
   MURTHY HMK, 1996, METH MOL B, V56, P127
   NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597
   NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407
   Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X
   PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580
   READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622
   Sawaya MR, 1997, BIOCHEMISTRY-US, V36, P11205, DOI 10.1021/bi9703812
   TICKLE IJ, 1992, P CCP4 STUD WEEK MOL, P20
   URS UK, 1995, PROTEINS, V23, P111, DOI 10.1002/prot.340230112
   WRIGHT PA, 1990, J PATHOL, V162, P99, DOI 10.1002/path.1711620203
NR 43
TC 15
Z9 15
U1 1
U2 7
PU INT UNION CRYSTALLOGRAPHY
PI CHESTER
PA 2 ABBEY SQ, CHESTER, CH1 2HU, ENGLAND
SN 2059-7983
J9 ACTA CRYSTALLOGR D
JI Acta Crystallogr. Sect. D-Struct. Biol.
PD DEC
PY 1999
VL 55
BP 1971
EP 1977
PN 12
PG 7
WC Biochemical Research Methods; Biochemistry & Molecular Biology;
   Biophysics; Crystallography
SC Biochemistry & Molecular Biology; Biophysics; Crystallography
GA 268WD
UT WOS:000084440000002
PM 10666572
DA 2018-12-27
ER

PT J
AU Tang, YJ
   Zhao, YK
   Jiang, WY
   Zhu, ZH
   Liu, YQ
AF Tang, YJ
   Zhao, YK
   Jiang, WY
   Zhu, ZH
   Liu, YQ
TI RETRACTED: Liquid hydrogen isotopes layer profile inside a cryogenic
   inertia confinement fusion capsule for an isothermal environment
   (Retracted Article)
SO ACTA PHYSICA SINICA
LA Chinese
DT Article; Retracted Publication
AB It has been shown that the Young-Laplace equation based on the balance of the gravitational force and interfacial tension alone cannot produce a valid solution for the profile of a continuous liquid hydrogen layer inside an inertia confinement fusion capsule shell. In the calculated results, the London-van der Waals forces between the liquid and solid (shell) molecules must be included in the equation. The retardation effect of the London-van der Waals forces needs to be taken into account for thick liquid hydrogen isotopes layers. It has been also shown that, in an isothermal environment, a continuous liquid hydrogen isotopes layer with a uniform thickness can only be achieved inside the capsule shell, such as the spherical glass when the gravity is zero or the London constant between the solid and liquid molecules is infinity.
C1 SW Inst Nucl Phys & Chem, Mianyang 621900, Peoples R China.
   Sichuan Univ, Inst Atom & Mol Phys, Chengdu 610065, Peoples R China.
RP Tang, YJ (reprint author), SW Inst Nucl Phys & Chem, Mianyang 621900, Peoples R China.
CR BERNAT TP, 1981, UCRL86168 L LIV NAT
   CASIMIR HBG, 1948, PHYS REV, V73, P360, DOI 10.1103/PhysRev.73.360
   CONCUS P, 1968, J FLUID MECH, V34, P481, DOI 10.1017/S002211206800203X
   GOOD RJ, 1963, ADV CRYO ENG, V8, P306
   Gregory J., 1970, ADV COLLOID INTERFAC, V2, P396
   HILDBRAND FB, 1965, METHODS APPL MATH, P139
   LI T, 1962, J CHEM PHYS, V36, P2369, DOI 10.1063/1.1732891
   MCCRORY RL, 1988, NATURE, V335, P225, DOI 10.1038/335225a0
   MCLACHLAN AD, 1963, PROC R SOC LON SER-A, V271, P387, DOI 10.1098/rspa.1963.0025
   MOHANTY KK, 1979, 3 INT C SURF COLL SC
   OVERBEEK JTG, 1952, INTERACTION COLLOIDA
   RENK F, 1978, J COLLOID INTERF SCI, V67, P408, DOI 10.1016/0021-9797(78)90229-1
   SCHROENCAREY D, 1995, J VAC SCI TECHNOL A, V13, P2564, DOI 10.1116/1.579450
   Tang Yongjian, 1998, High Power Laser and Particle Beams, V10, P155
NR 14
TC 1
Z9 1
U1 3
U2 6
PU CHINESE PHYSICAL SOC
PI BEIJING
PA P O BOX 603, BEIJING 100080, PEOPLES R CHINA
SN 1000-3290
J9 ACTA PHYS SIN-CH ED
JI Acta Phys. Sin.
PD DEC
PY 1999
VL 48
IS 12
BP 2208
EP 2214
PG 7
WC Physics, Multidisciplinary
SC Physics
GA 262KM
UT WOS:000084066400011
DA 2018-12-27
ER

PT J
AU Fujii, Y
   Hoshi, T
   Takahashi, S
   Toyooka, H
AF Fujii, Y
   Hoshi, T
   Takahashi, S
   Toyooka, H
TI RETRACTED: Propofol decreases diaphragmatic contractility in dogs
   (Retracted article. See vol. 116, pg. 744, 2013)
SO ANESTHESIA AND ANALGESIA
LA English
DT Article; Retracted Publication
ID BLOOD-FLOW; RESPIRATORY MUSCLES; CANINE DIAPHRAGM; SKELETAL-MUSCLE;
   FATIGUE; VOLUNTARY; ACIDOSIS
AB Volatile anesthetics depress diaphragmatic muscle function; however, no data are available regarding the effect of propofol on diaphragmatic contractility. We therefore studied this effect in dogs. Pentobarbital anesthetized animals were divided into three groups of 10 each. Group I received only maintenance fluid; Group II was infused with a subhypnotic dose of propofol (0.1-mg/kg initial dose plus 1.5-mg.kg(-1).h(-1) maintenance dose); Group III was infused with an anesthetic dose of propofol (0.1-mg/kg initial dose plus 6.0-mg.kg(-1) maintenance dose). We assessed diaphragmatic contractility by transdiaphragmatic pressure (Pdi). With an infusion of propofol in Groups II and III, Pdi at low-frequency (20-Hz) stimulation decreased from the baseline values (P < 0.05), whereas Pdi at high-frequency (100-Hz) stimulation did not change. Compared with Group I, Pdi at 20-Hz stimulation decreased during propofol administration in Groups II and III (P < 0.05). Thf decrease in Pdi was more in Group III than in Group II (P < 0.05). We conclude that propofol is associated with a dose-related inhibitory effect on diaphragmatic contractility in dogs. Implications: Propofol is an effective IV anesthetic for the induction and maintenance of anesthesia. Subhypnotic and anesthetic doses of propofol decrease diaphragmatic contractility in dogs.
C1 Univ Tsukuba, Inst Clin Med, Dept Anesthesiol, Tsukuba, Ibaraki 305, Japan.
RP Fujii, Y (reprint author), Univ Tsukuba, Inst Clin Med, Dept Anesthesiol, 2-1-1 Amakubo, Tsukuba, Ibaraki 305, Japan.
CR AUBIER M, 1981, J APPL PHYSIOL, V50, P538
   CLERGUE F, 1986, ANESTHESIOLOGY, V84, P181
   EDWARDS RHT, 1978, CLIN SCI MOL MED, V54, P463, DOI 10.1042/cs0540463
   EDWARDS RHT, 1977, J PHYSIOL-LONDON, V272, P769, DOI 10.1113/jphysiol.1977.sp012072
   ESAU SA, 1989, AM REV RESPIR DIS, V139, P1410, DOI 10.1164/ajrccm/139.6.1410
   GRASSINO A, 1978, J APPL PHYSIOL, V44, P829
   HOWELL S, 1985, J APPL PHYSIOL, V59, P1376
   HUSSAIN SNA, 1988, J APPL PHYSIOL, V64, P329
   IDE T, 1992, ANESTH ANALG, V74, P739
   JONES DA, 1979, EXP NEUROL, V64, P401, DOI 10.1016/0014-4886(79)90279-6
   KOCHI T, 1990, ANESTH ANALG, V70, P362
   Moxham J, 1981, Ciba Found Symp, V82, P197
   REID MB, 1983, J APPL PHYSIOL, V54, P763
   ROBERTSON CH, 1977, J CLIN INVEST, V59, P31, DOI 10.1172/JCI108619
   ROUSSOS C, 1982, NEW ENGL J MED, V307, P786, DOI 10.1056/NEJM198209233071304
   SMITH I, 1994, ANESTHESIOLOGY, V81, P1005
   VEBER B, 1989, ANESTHESIOLOGY, V70, P684, DOI 10.1097/00000542-198904000-00024
NR 17
TC 23
Z9 23
U1 1
U2 9
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0003-2999
J9 ANESTH ANALG
JI Anesth. Analg.
PD DEC
PY 1999
VL 89
IS 6
BP 1557
EP 1560
DI 10.1097/00000539-199912000-00046
PG 4
WC Anesthesiology
SC Anesthesiology
GA 260ZB
UT WOS:000083982400046
PM 10589648
DA 2018-12-27
ER

PT J
AU Saitoh, Y
   Fujii, Y
   Oshima, T
AF Saitoh, Y
   Fujii, Y
   Oshima, T
TI RETRACTED: The ulinastatin-induced effect on neuromuscular block caused
   by vecuronium (Retracted article. See vol. 115, pg. 976, 2012)
SO ANESTHESIA AND ANALGESIA
LA English
DT Article; Retracted Publication
ID URINARY TRYPSIN-INHIBITOR; ORG NC 45; PROTEASE INHIBITOR; RENAL-FAILURE;
   PHARMACOKINETICS; ELIMINATION; PANCURONIUM; RATS
AB We examined the effect of ulinastatin, a protease inhibitor purified from human urine, on neuromuscular block caused by vecuronium. Sixty adult patients were randomly divided into four groups of 15 patients each: ulinastatin-posttetanic count (U-PTC), ulinastatin-train-of-four (U-TOF), control-posttetanic count (C-PTC) or control-train-of-four (C-TOF) group. In the U-PTC and U-TOF groups, a bolus dose of ulinastatin 5000 U/kg was administered 2 min before the injection of vecuronium 0.1 mg/kg. In the C-PTC and C-TOF groups, normal saline was administered instead of ulinastatin. The onset of neuromuscular block in the U-PTC and U-TOF groups was significantly slower than in the C-PTC and C-TOF groups (250 +/- 49 vs 214 +/- 35 s, mean +/- SD, P < 0.05). The time from the vecuronium injection to the return of PTC in the U-PTC group was significantly shorter than in the C-PTC group (11.0 +/- 2.8 vs 17.6 +/- 6.8 min, P < 0.05). Similarly, times to the returns of T1, T2 T3, and T4 (first, second, third, and fourth stimulation of TOF) in the U-TOF group were significantly shorter than in the C-TOF group (18.5 +/- 5.0 vs 28.0 +/- 9.1 min for T1, P < 0.05). PTC in the U-PTC group was significantly higher than in the C-PTC Group 10-30 min after the administration of vecuronium (P < 0.05). T1/control twitch height and TOF ratios in the U-TOF group were significantly higher than those in the C-TOF Group 30-70 min and 40-70 min after the administration of vecuronium, respectively (P < 0.05). Ulinastatin delays the onset of neuromuscular block and hastens its recovery caused by vecuronium. Implications: Ulinastatin delays the onset of neuromuscular block and hastens its recovery caused by vecuronium. This is because ulinastatin may release acetylcholine at the neuromuscular junction and increase hepatic and/or renal clearance of vecuronium.
C1 Toride Kyodo Gen Hosp, Dept Anesthesiol, Toride, Ibaraki 3020022, Japan.
   Univ Tsukuba, Inst Clin Med, Dept Anesthesiol, Tsukuba, Ibaraki 305, Japan.
   Gifu Univ, Sch Med, Dept Anesthesiol & Crit Care Med, Gifu 500, Japan.
RP Saitoh, Y (reprint author), Toride Kyodo Gen Hosp, Dept Anesthesiol, 2-1-1 Hongo, Toride, Ibaraki 3020022, Japan.
EM 69481654@people.or.jp
CR AOIKE I, 1989, NEPHRON, V52, P368, DOI 10.1159/000185683
   BENCINI AF, 1985, BRIT J ANAESTH, V57, P782, DOI 10.1093/bja/57.8.782
   CHAUVIN M, 1987, ANESTH ANALG, V66, P117
   FAHEY MR, 1981, BRIT J ANAESTH, V53, P1049, DOI 10.1093/bja/53.10.1049
   HARVEY AL, 1982, BRIT J PHARMACOL, V77, P153, DOI 10.1111/j.1476-5381.1982.tb09281.x
   JONSSONBERLING BM, 1991, SCAND J CLIN LAB INV, V51, P549, DOI 10.3109/00365519109104564
   LEBRAULT C, 1985, ANESTHESIOLOGY, V62, P601, DOI 10.1097/00000542-198505000-00010
   Matsumoto N, 1989, Masui, V38, P531
   MILLER RD, 1972, ANESTHESIOLOGY, V37, P573, DOI 10.1097/00000542-197212000-00001
   MIZUNO Y, 1988, JPN PHARMACOL THER, V16, P243
   OHNISHI H, 1985, JPN J PHARMACOL, V39, P137, DOI 10.1254/jjp.39.137
   Ota K, 1989, Masui, V38, P540
   SUGIKI M, 1991, INFLAMMATION, V15, P281, DOI 10.1007/BF00917313
   UPTON RA, 1982, ANESTH ANALG, V61, P313
NR 14
TC 5
Z9 6
U1 2
U2 10
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0003-2999
J9 ANESTH ANALG
JI Anesth. Analg.
PD DEC
PY 1999
VL 89
IS 6
BP 1565
EP 1569
DI 10.1097/00000539-199912000-00048
PG 5
WC Anesthesiology
SC Anesthesiology
GA 260ZB
UT WOS:000083982400048
PM 10589650
DA 2018-12-27
ER

PT J
AU Van Parijs, L
   Refaeli, Y
   Abbas, AK
   Baltimore, D
AF Van Parijs, L
   Refaeli, Y
   Abbas, AK
   Baltimore, D
TI RETRACTED: Autoimmunity as a consequence of retrovirus-mediated
   expression of c-FLIP in lymphocytes (Retracted article. See vol. 30, pg.
   612, 2009)
SO IMMUNITY
LA English
DT Article; Retracted Publication
ID T-CELL ACTIVATION; FAS-LIGAND; B-CELLS; LYMPHOPROLIFERATIVE SYNDROME;
   DEATH RECEPTORS; TRANSGENIC MICE; APOPTOSIS; DISEASE; MUTATIONS; PROTEIN
AB The induction of apoptosis by death receptors serves to regulate immune responses by eliminating unwanted and harmful cells. Mature lymphocytes express FLICE inhibitory proteins (FLIPs) that block death receptor-induced cell death. Here, we show that both B and T cells downregulate c-FLIP upon activation in vitro. Retrovirus-mediated expression of c-FLIP blocks Pas-induced apoptosis of activated lymphocytes but does not affect cell death resulting from cytokine withdrawal. In vivo, c-FLIP expression results in defective superantigen-mediated elimination of T cells, the accumulation of activated B cells, the production of autoantibodies, and the development of autoimmune disease. No effect was seen on negative selection of thyomocytes. These results suggest that activation-dependent downregulation of c-FLIP renders mature lymphocytes sensitive to death receptor-mediated apoptosis and is required to maintain self-tolerance.
C1 CALTECH, Dept Biol, Pasadena, CA 91125 USA.
   Harvard Univ, Sch Med, Dept Pathol, Div Immunol, Boston, MA 02115 USA.
   Brigham & Womens Hosp, Boston, MA 02115 USA.
RP Baltimore, D (reprint author), CALTECH, Dept Biol, Pasadena, CA 91125 USA.
EM baltimo@cco.caltech.edu
FU NCI NIH HHS [CA54162]; NIAID NIH HHS [AI42100]
CR ADACHI M, 1995, NAT GENET, V11, P294, DOI 10.1038/ng1195-294
   Amakawa R, 1996, CELL, V84, P551, DOI 10.1016/S0092-8674(00)81031-4
   BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795
   Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9
   BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0
   Chervonsky AV, 1997, CELL, V89, P17, DOI 10.1016/S0092-8674(00)80178-6
   CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3
   COHEN PL, 1991, ANNU REV IMMUNOL, V9, P243, DOI 10.1146/annurev.iy.09.040191.001331
   Collins KL, 1998, NATURE, V391, P397, DOI 10.1038/34929
   DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0
   FISHER GH, 1995, CELL, V81, P935, DOI 10.1016/0092-8674(95)90013-6
   Fukuyama H, 1998, J IMMUNOL, V160, P3805
   Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657
   Itoh N, 1997, J EXP MED, V186, P613, DOI 10.1084/jem.186.4.613
   JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0
   Kabra NH, 1999, J IMMUNOL, V162, P2766
   KAPPLER JW, 1987, CELL, V49, P273, DOI 10.1016/0092-8674(87)90568-X
   Kataoka T, 1998, J IMMUNOL, V161, P3936
   Khoruts A, 1998, J EXP MED, V187, P225, DOI 10.1084/jem.187.2.225
   Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0
   NAGATA S, 1995, IMMUNOL TODAY, V16, P39, DOI 10.1016/0167-5699(95)80069-7
   Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7
   Newton K, 1998, EMBO J, V17, P706, DOI 10.1093/emboj/17.3.706
   PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392
   RATHMELL JC, 1995, NATURE, V376, P181, DOI 10.1038/376181a0
   Refaeli Y, 1998, IMMUNITY, V8, P615, DOI 10.1016/S1074-7613(00)80566-X
   RIEUXLAUCAT F, 1995, SCIENCE, V268, P1347, DOI 10.1126/science.7539157
   Roman CAJ, 1997, IMMUNITY, V7, P13, DOI 10.1016/S1074-7613(00)80506-3
   ROTHSTEIN TL, 1995, NATURE, V374, P163, DOI 10.1038/374163a0
   Sabelko KA, 1997, J IMMUNOL, V159, P3096
   SETHNA MP, 1994, IMMUNITY, V1, P415, DOI 10.1016/1074-7613(94)90072-8
   Shresta S, 1998, CURR OPIN IMMUNOL, V10, P581, DOI 10.1016/S0952-7915(98)80227-6
   Smith KGC, 1996, EMBO J, V15, P5167, DOI 10.1002/j.1460-2075.1996.tb00901.x
   Thome M, 1997, NATURE, V386, P517, DOI 10.1038/386517a0
   Tschopp J, 1998, CURR OPIN GENET DEV, V8, P82, DOI 10.1016/S0959-437X(98)80066-X
   Van Parijs L, 1999, IMMUNITY, V11, P281, DOI 10.1016/S1074-7613(00)80103-X
   Van Parijs L, 1998, SCIENCE, V280, P243
   Waldner H, 1997, J IMMUNOL, V159, P3100
   Walsh CM, 1998, IMMUNITY, V8, P439, DOI 10.1016/S1074-7613(00)80549-X
   WANG JKM, 2000, IN PRESS EUR J IMMUN
   WHITE J, 1989, CELL, V56, P27, DOI 10.1016/0092-8674(89)90980-X
   Zhang JK, 1998, NATURE, V392, P296
NR 42
TC 137
Z9 139
U1 2
U2 9
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1074-7613
J9 IMMUNITY
JI Immunity
PD DEC
PY 1999
VL 11
IS 6
BP 763
EP 770
DI 10.1016/S1074-7613(00)80150-8
PG 8
WC Immunology
SC Immunology
GA 271UX
UT WOS:000084612900012
PM 10626898
OA Bronze
DA 2018-12-27
ER

PT J
AU Fujii, Y
   Tanaka, H
   Kobayashi, N
AF Fujii, Y
   Tanaka, H
   Kobayashi, N
TI RETRACTED: Prevention of nausea and vomiting after middle ear surgery:
   Granisetron versus ramnosetron (Retracted article. See vol. 127, pg
   E333, 2017)
SO LARYNGOSCOPE
LA English
DT Article; Retracted Publication
DE vomiting; antiemetics; ramosetron; granisetron; middle ear surgery
ID POSTOPERATIVE NAUSEA; RECEPTOR ANTAGONIST; GENERAL-ANESTHESIA;
   ONDANSETRON; THERAPY
AB Objective/Hypothesis: Middle ear surgery is associated with a relatively high incidence of postoperative nausea and vomiting. This study was undertaken to compare the efficacy of ramosetron with granisetron for preventing: nausea and vomiting after middle ear surgery. Study Design: Prospective, randomized, double-blind study. Methods: In a randomized, double-blind manner, 100 ASA I patients (69 women), aged 23 to 65 years, received either ramosetron 0.3 mg or granisetron 3 mg intravenously (n = 50 of each) immediately before the induction of anesthesia. A standard general anesthetic technique and postoperative analgesia were used. Postoperative nausea and vomiting and safety assessments were performed continuously during the first 24 hours (0-24 h) and the next 24 hours (24-48 h) after anesthesia. Results: A complete response, defined as no nausea and vomiting and no need for another rescue medication, during the first 24 hours after anesthesia (0-24 h) occurred in 90% of patients receiving ramosetron and in 86% of patients receiving granisetron, respectively (P = .379); the corresponding incidence rates in the second 24 hours after anesthesia (24-48 h) were 90% and 66% (P = .003). No clinically important adverse events were observed in either group. Conclusion: Prophylactic use of ramosetron is more effective than granisetron for long-term prevention of nausea and vomiting after middle ear surgery.
C1 Univ Tsukuba, Inst Clin Med, Dept Anesthesiol, Tsukuba, Ibaraki 305, Japan.
   Toride Kyodo Gen Hosp, Dept Anesthesiol, Toride, Ibaraki, Japan.
   Toride Kyodo Gen Hosp, Dept Otolaryngol, Toride, Ibaraki, Japan.
RP Fujii, Y (reprint author), Univ Tsukuba, Inst Clin Med, Dept Anesthesiol, 2-1-1 Amakubo, Tsukuba, Ibaraki 305, Japan.
CR ASPINALL RL, 1995, BRIT MED J, V311, P844, DOI 10.1136/bmj.311.7009.844
   BERMUDEZ J, 1988, BRIT J CANCER, V58, P644, DOI 10.1038/bjc.1988.277
   CARMICHAEL J, 1989, CANCER CHEMOTH PHARM, V24, P45
   FUJIHARA A, 1996, LAB CLIN, V30, P1965
   Fujii Y, 1998, ANAESTHESIA, V53, P1165, DOI 10.1046/j.1365-2044.1998.00633.x
   Fujii Y, 1998, BRIT J ANAESTH, V80, P764, DOI 10.1093/bja/80.6.764
   Fujii Y, 1997, BRIT J ANAESTH, V79, P539
   HONKAVAARA P, 1994, BRIT J ANAESTH, V73, P763, DOI 10.1093/bja/73.6.763
   Honkavaara P, 1996, BRIT J ANAESTH, V76, P316
   NODA K, 1994, JPN J CLIN EXP MED, V71, P2765
   REINHART DJ, 1994, ANESTH ANALG, V79, P281
   WATCHA MF, 1992, ANESTHESIOLOGY, V77, P162, DOI 10.1097/00000542-199207000-00023
   YARKER YE, 1994, DRUGS, V48, P761, DOI 10.2165/00003495-199448050-00008
NR 13
TC 13
Z9 14
U1 4
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0023-852X
EI 1531-4995
J9 LARYNGOSCOPE
JI Laryngoscope
PD DEC
PY 1999
VL 109
IS 12
BP 1988
EP 1990
DI 10.1097/00005537-199912000-00017
PG 3
WC Medicine, Research & Experimental; Otorhinolaryngology
SC Research & Experimental Medicine; Otorhinolaryngology
GA 261VN
UT WOS:000084030700017
PM 10591360
DA 2018-12-27
ER

PT J
AU Etheredge, JA
   Perez, SM
   Taylor, OR
   Jander, R
AF Etheredge, JA
   Perez, SM
   Taylor, OR
   Jander, R
TI RETRACTED: Monarch butterflies (Danaus plexippus L.) use a magnetic
   compass for navigation (Retracted article. See vol 97, pg 3782, 2000)
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article; Retracted Publication
ID ORIENTATION
AB Fall migratory monarch butterflies, tested for their directional responses to magnetic cues under three conditions, amagnetic, normal, and reversed magnetic: fields, showed three distinct patterns. in the absence of a magnetic field, monarchs lacked directionality as a group. in the normal magnetic field, monarchs oriented to the southwest with a group pattern typical for migrants. When the horizontal component of the magnetic field was reversed, the butterflies oriented to the northeast. In contrast, nonmigratory monarchs lacked directionality in the normal magnetic field. The results are a direct demonstration of magnetic compass orientation in migratory insects.
C1 Univ Kansas, Dept Entomol, Lawrence, KS 66045 USA.
   Univ Arizona, Dept Ecol & Evolutionary Biol, Tucson, AZ 85721 USA.
RP Taylor, OR (reprint author), Univ Kansas, Dept Entomol, 7005 Haworth Hall, Lawrence, KS 66045 USA.
EM monarch@ukans.edu
CR Beason RC, 1997, AUK, V114, P405, DOI 10.2307/4089242
   GIBO DL, 1979, CAN J ZOOL, V57, P1393, DOI 10.1139/z79-180
   JUNGREIS SA, 1987, FLA ENTOMOL, V70, P277, DOI 10.2307/3495160
   KIRSCHVINK JL, 1981, BIOSYSTEMS, V13, P181, DOI 10.1016/0303-2647(81)90060-5
   MacFadden B. J., 1985, MAGNETITE BIOMINERAL, P407
   Perez SM, 1997, NATURE, V387, P29, DOI 10.1038/387029a0
   Perez SM, 1999, NATURWISSENSCHAFTEN, V86, P140, DOI 10.1007/s001140050587
   ROGG KA, 1999, IN PRESS N AM C MON
   RZEDOWSKI J., 1957, ACTA ZOOL MEXICANA, V2, P1
   SCHMIDTKOENIG K, 1993, BIOL CONSERVATION MO, P275
   WALKER MM, 1998, NATURE, V320, P371
   Wiltschko R, 1995, MAGNETIC ORIENTATION
   WILTSCHKO W, 1994, EXPERIENTIA, V50, P697, DOI 10.1007/BF01952877
NR 13
TC 22
Z9 28
U1 1
U2 20
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD NOV 23
PY 1999
VL 96
IS 24
BP 13845
EP 13846
DI 10.1073/pnas.96.24.13845
PG 2
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 259AY
UT WOS:000083872900046
PM 10570160
OA Bronze, Green Published
DA 2018-12-27
ER

PT J
AU Reaves, PY
   Gelband, CH
   Wang, HW
   Yang, H
   Berecek, KH
   Katovich, MJ
   Raizada, MK
AF Reaves, PY
   Gelband, CH
   Wang, HW
   Yang, H
   Berecek, KH
   Katovich, MJ
   Raizada, MK
TI RETRACTED: Permanent cardiovascular protection from hypertension by the
   AT(1) receptor antisense gene therapy in hypertensive rat offspring
   (Retracted Article. See vol 94, pg E14, 2004)
SO CIRCULATION RESEARCH
LA English
DT Article; Retracted Publication
DE AT(1) receptor antisense; gene therapy; hypertension; SHR; antisense
   transmission to offspring
ID ANGIOTENSIN-CONVERTING ENZYME; GERM-LINE TRANSMISSION; HIGH
   BLOOD-PRESSURE; HEART-FAILURE; MYOCARDIAL-INFARCTION; RETROVIRAL VECTOR;
   ACE-INHIBITORS; POLYMORPHISM; SYSTEM; HYPERTROPHY
AB Our previous studies have demonstrated that the introduction of angiotensin II type I receptor antisense (AT(1)R-AS) cDNA by a retrovirally mediated delivery system prevents the development of hypertension in the spontaneously hypertensive rat (SHR), an animal model for primary hypertension in humans. These results have led us to propose the hypothesis that an interruption of the renin-angiotensin system (RAS) activity at a genetic level would prevent hypertension on a permanent basis. F-1 and F-2 generations of offspring from a retroviral vector, LNSV- and LNSV-AT(1)R-AS-treated SHR, were generated, and various physiological parameters indicative of hypertension were studied and compared with those of their parents to investigate this hypothesis. Both F-1 and F-2 generations of LNSV-AT(1)R-AS-treated SHR expressed a persistently lower blood pressure, decreased cardiac hypertrophy and fibrosis, decreased medial thickness, and normalization of renal artery excitation-contraction coupling, Ca2+ current, and [Ca2+](i) when compared with offspring derived from the LNSV-treated SHR. In fact, the magnitude of the prevention of these pathophysiological alterations was similar to that observed in the LNSV-AT(1)R-AS-treated SHR parent. The prevention of cardiovascular pathophysiology and expression of normotensive phenotypes are, at least in part, a result of integration and subsequent transmission of AT(1)R-AS from the SHR parents to offspring. These data demonstrate that a single intracardiac injection of LNSV-AT(1)R-AS causes a permanent cardiovascular protection against hypertension as a result of a genomic integration and germ line transmission of the AT(1)R-AS in the SHR offspring. The full text of this article is available at http://www.circresaha.org.
C1 Univ Florida, Coll Med, Dept Physiol, Gainesville, FL 32610 USA.
   Univ Florida, Coll Pharm, Dept Pharmacodynam, Gainesville, FL 32610 USA.
   Univ Alabama, Dept Physiol & Biophys, Birmingham, AL 35294 USA.
RP Raizada, MK (reprint author), Univ Florida, Coll Med, Dept Physiol, POB 100274, Gainesville, FL 32610 USA.
EM mraizada@phys.med.ufl.edu
FU NHLBI NIH HHS [HL52189, HL56921]
CR BERECEK KH, 1980, AM J PHYSIOL, V238, pH287
   Cambien F, 1995, EUR HEART J, V16, P13, DOI 10.1093/eurheartj/16.suppl_K.13
   Deedwania PC, 1997, AM J HYPERTENS, V10, pS280, DOI 10.1016/S0895-7061(97)00335-X
   FOULT JM, 1989, EUR HEART J, V10, P97, DOI 10.1093/eurheartj/10.suppl_F.97
   Gaiano N, 1996, P NATL ACAD SCI USA, V93, P7777, DOI 10.1073/pnas.93.15.7777
   Gelband CH, 1999, HYPERTENSION, V33, P360, DOI 10.1161/01.HYP.33.1.360
   GUYTON AC, 1991, SCIENCE, V252, P1813, DOI 10.1126/science.2063193
   HECKMANN U, 1987, NEPHRON, V47, P138, DOI 10.1159/000184573
   HIRSCH AT, 1991, CIRC RES, V69, P475, DOI 10.1161/01.RES.69.2.475
   Hu K, 1998, J AM COLL CARDIOL, V31, P692, DOI 10.1016/S0735-1097(97)00527-5
   ITO N, 1994, J MOL CELL CARDIOL, V26, P49, DOI 10.1006/jmcc.1994.1007
   Iyer SN, 1996, P NATL ACAD SCI USA, V93, P9960, DOI 10.1073/pnas.93.18.9960
   Katovich MJ, 1999, AM J PHYSIOL-HEART C, V277, pH1260, DOI 10.1152/ajpheart.1999.277.3.H1260
   KAWAGUCHI H, 1995, J MOL CELL CARDIOL, V27, P201, DOI 10.1016/S0022-2828(08)80019-3
   LIN S, 1994, SCIENCE, V265, P666, DOI 10.1126/science.8036514
   LU D, 1995, P NATL ACAD SCI USA, V92, P1162, DOI 10.1073/pnas.92.4.1162
   Lu D, 1997, HYPERTENSION, V30, P363, DOI 10.1161/01.HYP.30.3.363
   LU D, 1995, P NATL ACAD SCI USA, V92, P2914, DOI 10.1073/pnas.92.7.2914
   Lu JK, 1997, MOL MAR BIOL BIOTECH, V6, P289
   MANIATIS T, 1989, MOL CLONING LAB MANU
   Martens JR, 1998, P NATL ACAD SCI USA, V95, P2664, DOI 10.1073/pnas.95.5.2664
   McCarty Richard, 1996, Physiology and Behavior, V59, P71, DOI 10.1016/0031-9384(95)02034-9
   MCMURTRY JP, 1981, SCIENCE, V211, P1173, DOI 10.1126/science.7466389
   Megarry SG, 1997, DRUGS, V54, P48, DOI 10.2165/00003495-199700545-00008
   MOHABIR R, 1994, J CARDIOVASC PHARM, V23, P291, DOI 10.1097/00005344-199402000-00017
   Moser M, 1997, J AM COLL CARDIOL, V29, P1414, DOI 10.1016/S0735-1097(97)00096-X
   PAUL M, 1993, J CLIN INVEST, V91, P2058, DOI 10.1172/JCI116428
   Pitt B, 1997, CARDIOVASC DRUG THER, V11, P285, DOI 10.1023/A:1007795915009
   Pontremoli R, 1996, J AM SOC NEPHROL, V7, P2550
   Regan CP, 1997, CLIN EXP HYPERTENS, V19, P1161, DOI 10.3109/10641969709083210
   Ruilope L, 1997, J HYPERTENS, V15, pS15
   RUILOPE LM, 1994, HYPERTENSION, V23, P3, DOI 10.1161/01.HYP.23.1.3
   RUTLEDGE DR, 1995, BIOCHEM MOL BIOL INT, V35, P661
   Ruzicka M, 1997, CURR OPIN CARDIOL, V12, P347, DOI 10.1097/00001573-199707000-00002
   Sasaki M, 1996, J HYPERTENS, V14, P1403, DOI 10.1097/00004872-199612000-00003
   Teunissen KE, 1997, J HYPERTENS, V15, P1791, DOI 10.1097/00004872-199715120-00091
   WANG H, 1999, METHODS ENZYMOLOGY A, V314, P581
   WHELTON PK, 1994, LANCET, V344, P101, DOI 10.1016/S0140-6736(94)91285-8
NR 38
TC 16
Z9 18
U1 0
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0009-7330
J9 CIRC RES
JI Circ.Res.
PD NOV 12
PY 1999
VL 85
IS 10
BP E44
EP E50
PG 7
WC Cardiac & Cardiovascular Systems; Hematology; Peripheral Vascular
   Disease
SC Cardiovascular System & Cardiology; Hematology
GA 255TZ
UT WOS:000083687400015
PM 10559146
DA 2018-12-27
ER

PT J
AU Miyoshi, T
   Ooki, G
   Murata, M
   Hayakawa, H
   Tomita, K
   Imai, M
   Suzuki, M
AF Miyoshi, T
   Ooki, G
   Murata, M
   Hayakawa, H
   Tomita, K
   Imai, M
   Suzuki, M
TI RETRACTED: Expression of an mNSC1 in mammalian cells (Retracted Article.
   See vol 336, pg 730, 2005)
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article; Retracted Publication
DE nonselective cation channel; MIN6; beta-cell; niflumic acid
ID NONSELECTIVE CATION CHANNELS; RAT EXOCRINE PANCREAS; BASOLATERAL
   MEMBRANE; ACTIVATION; ACID; TRP
AB We have cloned a cDNA inducing a cation-permeable current (mNSC1) from pancreatic beta-cells, which shows niflumate-sensitive current in Xenopus oocytes. To elucidate the expression in mammalian cells, mNSC1 was expressed in CHO cells. The reversal potential by mNSC1 was shifted toward positive which was significantly reversed by flufenamic acid. Single-channel analysis showed a characteristic of a Ca-activated nonselective cation channel. Therefore, we may conclude that mNSC1 expresses a fenamates-sensitive cation channel, inducing membrane depolarization in a mammalian cell. (C) 1999 Academic Press.
C1 Jichi Med Sch, Dept Pharmacol, Minami Kawachi, Tochigi, Japan.
   Kumamoto Univ, Dept Internal Med 3, Kumamoto, Japan.
   Jichi Med Sch, Dept Cardiol, Minami Kawachi, Tochigi, Japan.
   Jichi Med Sch, Dept Internal Med 2, Minami Kawachi, Tochigi, Japan.
RP Suzuki, M (reprint author), Jichi Med Sch, Dept Pharmacol, Minami Kawachi, Tochigi, Japan.
EM macsuz@jichi.ac.jp
CR CONLEY EC, 1996, ION CHANNEL FACTS BO, V2, P248
   DAVIS MJ, 1992, AM J PHYSIOL, V263, pH1292
   GOGELEIN H, 1990, FEBS LETT, V268, P79, DOI 10.1016/0014-5793(90)80977-Q
   GOGELEIN H, 1989, PFLUG ARCH EUR J PHY, V413, P287, DOI 10.1007/BF00583543
   MARUYAMA Y, 1982, NATURE, V300, P61, DOI 10.1038/300061a0
   Niemeyer BA, 1996, CELL, V85, P651, DOI 10.1016/S0092-8674(00)81232-5
   PORONNIK P, 1991, CELL CALCIUM, V12, P441, DOI 10.1016/0143-4160(91)90070-U
   SIEMER C, 1992, PFLUG ARCH EUR J PHY, V420, P319, DOI 10.1007/BF00374465
   STURGESS NC, 1987, PFLUG ARCH EUR J PHY, V410, P169, DOI 10.1007/BF00581911
   Suzuki M, 1998, BIOCHEM BIOPH RES CO, V242, P191, DOI 10.1006/bbrc.1997.7931
   SUZUKI M, 1991, J CLIN INVEST, V88, P735, DOI 10.1172/JCI115370
   VANDENABBEELE T, 1994, PFLUG ARCH EUR J PHY, V427, P56, DOI 10.1007/BF00585942
   Zhu X, 1996, CELL, V85, P661, DOI 10.1016/S0092-8674(00)81233-7
NR 13
TC 2
Z9 2
U1 1
U2 11
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD NOV 11
PY 1999
VL 265
IS 1
BP 13
EP 17
DI 10.1006/bbrc.1999.1622
PG 5
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 256JB
UT WOS:000083721200003
PM 10548483
DA 2018-12-27
ER

PT J
AU Fujii, Y
   Saitoh, Y
   Tanaka, H
   Toyooka, H
AF Fujii, Y
   Saitoh, Y
   Tanaka, H
   Toyooka, H
TI RETRACTED: Prevention of postoperative vomiting with granisetron in
   paediatric patients with and without a history of motion sickness
   (Retracted article. See vol. 23, pg. 378, 2013)
SO PAEDIATRIC ANAESTHESIA
LA English
DT Article; Retracted Publication
DE vomiting : antiemetics; granisetron; motion sickness; surgery :
   tonsillectomy
ID RECEPTOR ANTAGONIST; ANESTHESIA; EMESIS
AB A history of motion sickness is one of the patient-related factors associated with postoperative emesis. This prospective, randomized, double-blind, placebo-controlled study was undertaken to assess the efficacy of granisetron, a selective 5-hydroxytryptamine type 3 receptor antagonist, for preventing postoperative vomiting after tonsillectomy in 120 children with (n = 60) and without (n = 60) a history of motion sickness. Patients received a single dose of granisetron (40 mu g.kg(-1)) or placebo (saline) (n = 30 of each) intravenously after an inhalation induction of anaesthesia. A complete response, defined as no vomiting, no retching and no need for another rescue medication, during the first 24 h after anaesthesia was 77% and 13% in patients with a history of motion sickness who had received granisetron or placebo, respectively; the corresponding incidence was 83% and 40% in those without it (P < 0.05; chi(2) test with Yates' continuity correction). No clinically serious adverse effects due to the study drug were observed in any of the groups. In conclusion, prophylactic antiemetic therapy with granisetron is effective for preventing postoperative emesis in children with a history of motion sickness as well as in those without it.
C1 Univ Tsukuba, Inst Clin Med, Dept Anaesthesiol, Tsukuba, Ibaraki 3050005, Japan.
   Toride Kyodo Gen Hosp, Dept Anaesthesiol, Toride, Ibaraki, Japan.
RP Fujii, Y (reprint author), Univ Tsukuba, Inst Clin Med, Dept Anaesthesiol, 2-1-1 Amakubo, Tsukuba, Ibaraki 3050005, Japan.
CR ANDREWS PLR, 1992, EJC SUPPL, V28, P52
   BERMUDEZ J, 1988, BRIT J CANCER, V58, P644, DOI 10.1038/bjc.1988.277
   CARMICHAEL J, 1989, CANCER CHEMOTH PHARM, V24, P45
   COHEN MM, 1990, ANESTH ANALG, V70, P160
   Fujii Y, 1996, CAN J ANAESTH, V43, P660, DOI 10.1007/BF03017947
   Fujii Y, 1996, CAN J ANAESTH, V43, P35, DOI 10.1007/BF03015955
   KAMATH B, 1990, BRIT J ANAESTH, V64, P728, DOI 10.1093/bja/64.6.728
   WATCHA MF, 1992, ANESTHESIOLOGY, V77, P162, DOI 10.1097/00000542-199207000-00023
NR 8
TC 12
Z9 12
U1 1
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1155-5645
J9 PAEDIATR ANAESTH
JI Paediatr. Anaesth.
PD NOV
PY 1999
VL 9
IS 6
BP 527
EP 530
DI 10.1046/j.1460-9592.1999.00414.x
PG 4
WC Anesthesiology; Pediatrics
SC Anesthesiology; Pediatrics
GA 252VL
UT WOS:000083522900010
PM 10597557
DA 2018-12-27
ER

PT J
AU Duckmanton, L
   Tellier, R
   Richardson, C
   Petric, M
AF Duckmanton, L
   Tellier, R
   Richardson, C
   Petric, M
TI RETRACTED: The novel hemagglutinin-esterase genes of human torovirus and
   Breda virus (Retracted Article. See vol 81, pg 167, 2001)
SO VIRUS RESEARCH
LA English
DT Article; Retracted Publication
DE novel hemagglutinin-esterase genes; human torovirus; Breda virus
ID INFLUENZA-C VIRUS; FECAL SPECIMENS; RNA RECOMBINATION; BOVINE TOROVIRUS;
   HEPATITIS-A; GLYCOPROTEIN; DIARRHEA; CORONAVIRUSES; CALVES;
   AMPLIFICATION
AB Human torovirus (HTV) and Breda virus (BRV), members of the genus torovirus in the family Coronaviridae, are established infectious agents of humans and cattle, respectively. The hemagglutinin-esterase (HE) gene of Breda virus serotype 2 (BRV-2) has been identified and the nucleotide sequence for BRV serotype 1 (BRV-1) genome which contains the open reading frames for the viral structural proteins has been reported revealing the presence of a 1.25 kb gene whose nucleotide sequence is identical to that of the BRV-2 HE gene. In this study, we amplified the 1.2kb HE gene from the HTV genome using long RT-PCR and sequenced the amplicon directly. At the nucleotide level, the HTV HE gene manifests 85% sequence identity to the HE genes of BRV-1 and BRV-2 and 89% identity with the X pseudogene sequence of BEV. The 1.25 kb amplicons which contained the HE genes of BRV-1 and HTV were cloned and expressed in a baculovirus system and the proteins purified by sodium dodecyl sulphate-polyacrylamide gel electrophoresis. Hyperimmune sera prepared in guinea pigs against these proteins were reactive with both bovine torovirus (BTV) and human torovirus (HTV) antigens. By immunoblot, they reacted specifically with a 65 kDa protein corresponding in size to the torovirus HE protein. Furthermore, the hyperimmune sera but not the preimmune sera reacted with a series of BTV-positive and HTV-positive fecal specimens by immunoblot and dot blot analysis. By immunoelectron microscopy (IEM) torovirus particles from BTV-positive specimens from calves with diarrhea and HTV-positive specimens from patients were aggregated by the hyperimmune sera. Human convalescent sera and gnotobiotic calf post-infection sera reacted by immunoblot with the expressed 65 kDa protein. The expressed HE protein of HTV has important diagnostic potential. (C) 1999 Elsevier Science B.V. All rights reserved.
C1 Univ Toronto, Dept Microbiol & Med Genet, Toronto, ON, Canada.
   Hosp Sick Children, Div Microbiol, Toronto, ON M5G 1X8, Canada.
   Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada.
   Princess Margaret Hosp, Ontario Canc Inst, Dept Med Biophys, Toronto, ON M4X 1K9, Canada.
RP Petric, M (reprint author), Univ Toronto, Dept Microbiol & Med Genet, Toronto, ON, Canada.
CR BEARDS GM, 1984, LANCET, V1, P1050
   BROWN DWG, 1987, J CLIN MICROBIOL, V25, P637
   Cavanagh D, 1997, ARCH VIROL, V142, P629
   Cavanagh D., 1995, CORONAVIRIDAE, P73
   Cornelissen LAHM, 1997, J VIROL, V71, P5277
   Duckmanton L, 1998, J CLIN MICROBIOL, V36, P1266
   Duckmanton L, 1997, VIROLOGY, V239, P158, DOI 10.1006/viro.1997.8879
   Duckmanton LM, 1998, VIRUS RES, V58, P83, DOI 10.1016/S0168-1702(98)00104-X
   GAGNETEN S, 1995, J VIROL, V69, P889
   HERRLER G, 1988, J GEN VIROL, V69, P839, DOI 10.1099/0022-1317-69-4-839
   HORZINEK MC, 1987, INTERVIROLOGY, V27, P17, DOI 10.1159/000149710
   Jamieson FB, 1998, J INFECT DIS, V178, P1263, DOI 10.1086/314434
   KOOPMANS M, 1989, VET MICROBIOL, V19, P233, DOI 10.1016/0378-1135(89)90069-2
   KOOPMANS M, 1993, J CLIN MICROBIOL, V31, P2738
   Koopmans MPG, 1997, PEDIATR INFECT DIS J, V16, P504, DOI 10.1097/00006454-199705000-00010
   Kroneman A, 1998, J VIROL, V72, P3507
   LUYTJES W, 1988, VIROLOGY, V166, P415, DOI 10.1016/0042-6822(88)90512-0
   PARKER MD, 1989, J GEN VIROL, V70, P155, DOI 10.1099/0022-1317-70-1-155
   Sambrook J, 1989, MOL CLONING LAB MANU
   SNIJDER EJ, 1991, VIROLOGY, V180, P448, DOI 10.1016/0042-6822(91)90056-H
   SUGIYAMA K, 1981, ARCH VIROL, V67, P241, DOI 10.1007/BF01318134
   Tellier R, 1996, J CLIN MICROBIOL, V34, P3085
   Tellier R, 1996, P NATL ACAD SCI USA, V93, P4370, DOI 10.1073/pnas.93.9.4370
   VLASAK R, 1988, P NATL ACAD SCI USA, V85, P4526, DOI 10.1073/pnas.85.12.4526
   VLASAK R, 1987, VIROLOGY, V160, P419, DOI 10.1016/0042-6822(87)90013-4
   WEISS M, 1987, ARCH VIROL, V92, P1, DOI 10.1007/BF01310058
   WOODE GN, 1982, VET MICROBIOL, V7, P221, DOI 10.1016/0378-1135(82)90036-0
   WOODE GN, 1985, AM J VET RES, V46, P1003
NR 28
TC 11
Z9 12
U1 1
U2 7
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-1702
EI 1872-7492
J9 VIRUS RES
JI Virus Res.
PD NOV
PY 1999
VL 64
IS 2
BP 137
EP 149
DI 10.1016/S0168-1702(99)00088-X
PG 13
WC Virology
SC Virology
GA 249QU
UT WOS:000083344400004
PM 10518710
DA 2018-12-27
ER

PT J
AU Cressman, VL
   Backlund, DC
   Avrutskaya, AV
   Leadon, SA
   Godfrey, V
   Koller, BH
AF Cressman, VL
   Backlund, DC
   Avrutskaya, AV
   Leadon, SA
   Godfrey, V
   Koller, BH
TI RETRACTED: Growth retardation, DNA repair defects, and lack of
   spermatogenesis in BRCA1-deficient mice (Retracted Article. See vol 26,
   pg 9571, 2006)
SO MOLECULAR AND CELLULAR BIOLOGY
LA English
DT Article; Retracted Publication
ID EMBRYONIC CELLULAR PROLIFERATION; TRANSCRIPTION-COUPLED REPAIR; RNA
   POLYMERASE-II; BREAST-CANCER; BRCA1 GENE; NUCLEAR PHOSPHOPROTEIN;
   PREFERENTIAL REPAIR; P53-DEFICIENT MICE; COCKAYNE-SYNDROME; FAMILIAL
   BREAST
AB BRCA1 is a nuclear phosphoprotein expressed in a broad spectrum of tissues during cell division. The inheritance of a mutant BRCA1 allele dramatically increases a woman's lifetime risk for developing both breast and ovarian cancers. A number of mouse lines carrying mutations in the Brca1 gene have been generated, and mice homozygous for these mutations generally die before day 10 of embryonic development. We report here the survival of a small number of mice homozygous for mutations in both the p53 and Brca1 genes, The survival of these mice is likely due to additional unknown mutations or epigenetic effects. Analysis of the Brca1(-/-) p53(-/-) animals indicates that BRCA1 is not required for the development of most organ systems. However, these mice are growth retarded, males are infertile due to meiotic failure, and the mammary gland of the female mouse is underdeveloped. Growth deficiency due to loss of BRCA1 was more thoroughly examined in an analysis of primary fibroblast lines obtained from these animals, Like p53(-/-) fibroblasts, Brca1(-/-) p53(-/-) cells proliferate more rapidly than wild-type cells; however, a high level of cellular death in these cultures results in reduced overall growth rates in comparison to p53(-/-) fibroblasts. Brca1(-/-) p53(-/-) fibroblasts are also defective in transcription-coupled repair and display increased sensitivity to DNA-damaging agents. We show, however, that after continued culture, and perhaps accelerated by the loss of BRCA1 repair functions, populations of Brca1(-/-) p53(-/-) fibroblasts with increased growth rates can be isolated, The increased survival of BRCA1-deficient fibroblasts in the absence of p53, and with the subsequent accumulation of additional growth-promoting changes, may mimic the events that occur during malignant transformation of BRCA1-deficient epithelia.
C1 Univ N Carolina, Dept Med, Chapel Hill, NC 27599 USA.
   Univ N Carolina, Curriculum Genet & Mol Biol, Chapel Hill, NC 27599 USA.
   Univ N Carolina, Dept Pathol, Chapel Hill, NC 27599 USA.
   Univ N Carolina, Dept Radiat Oncol, Chapel Hill, NC 27599 USA.
RP Koller, BH (reprint author), Univ N Carolina, Dept Med, 7007 Thurston-Bowles Bldg,CB 7248, Chapel Hill, NC 27599 USA.
EM Treawouns@aol.com
FU NCI NIH HHS [CA40453, P50 CA058223, R01 CA040453, IP50CA58223, CA70490]
CR AKASHI M, 1995, J BIOL CHEM, V270, P19181, DOI 10.1074/jbc.270.32.19181
   Blackshear PE, 1998, ONCOGENE, V16, P61, DOI 10.1038/sj.onc.1201506
   Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9
   Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0
   Chen CF, 1996, J BIOL CHEM, V271, P32863, DOI 10.1074/jbc.271.51.32863
   Chen YM, 1996, CANCER RES, V56, P3168
   Connor F, 1997, NAT GENET, V17, P423, DOI 10.1038/ng1297-423
   Couch FJ, 1996, HUM MUTAT, V8, P8, DOI 10.1002/humu.1380080102
   Cressman VL, 1999, CELL GROWTH DIFFER, V10, P1
   Crook T, 1997, LANCET, V350, P638, DOI 10.1016/S0140-6736(05)63327-2
   CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434
   DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X
   Dix DJ, 1996, P NATL ACAD SCI USA, V93, P3264, DOI 10.1073/pnas.93.8.3264
   DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0
   EASTON DF, 1993, AM J HUM GENET, V52, P678
   Friedman LS, 1998, CANCER RES, V58, P1338
   GAME JC, 1983, YEAST GENETICS FUNDA, P109
   Gowen LC, 1996, NAT GENET, V12, P191, DOI 10.1038/ng0296-191
   Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009
   Grade K, 1996, J CANCER RES CLIN, V122, P702, DOI 10.1007/BF01209036
   Hakem R, 1997, NAT GENET, V16, P298, DOI 10.1038/ng0797-298
   Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1
   HARVEY M, 1993, NAT GENET, V5, P225, DOI 10.1038/ng1193-225
   HARVEY M, 1993, ONCOGENE, V8, P2457
   HOGAN B, 1986, MANIPULATING MOUSE E, P17
   JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6
   LANE TF, 1995, GENE DEV, V9, P2712, DOI 10.1101/gad.9.21.2712
   LEADON SA, 1991, MUTAT RES, V255, P67, DOI 10.1016/0921-8777(91)90019-L
   LEADON SA, 1992, J BIOL CHEM, V267, P23175
   LEADON SA, 1993, P NATL ACAD SCI USA, V90, P10499, DOI 10.1073/pnas.90.22.10499
   Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1
   Liu CY, 1996, GENE DEV, V10, P1835, DOI 10.1101/gad.10.14.1835
   Ludwig T, 1997, GENE DEV, V11, P1226, DOI 10.1101/gad.11.10.1226
   MARQUIS ST, 1995, NAT GENET, V11, P17, DOI 10.1038/ng0995-17
   MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954
   Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4
   *NAT I DIAB DIG KI, 1999, BIOL MAMM GLAND
   Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302
   PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329
   Patel KJ, 1998, MOL CELL, V1, P347, DOI 10.1016/S1097-2765(00)80035-0
   Phillips KW, 1997, LAB INVEST, V76, P419
   Ruffner H, 1997, P NATL ACAD SCI USA, V94, P7138, DOI 10.1073/pnas.94.14.7138
   Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4
   Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6
   Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0
   SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K
   Snouwaert JN, 1998, CURRENT TOPICS ON BRCA1, P33, DOI 10.3233/BD-1998-101-206
   Somasundaram K, 1997, NATURE, V389, P187
   Suzuki A, 1997, GENE DEV, V11, P1242, DOI 10.1101/gad.11.10.1242
   Thakur S, 1997, MOL CELL BIOL, V17, P444, DOI 10.1128/MCB.17.1.444
   vanderHorst GTJ, 1997, CELL, V89, P425, DOI 10.1016/S0092-8674(00)80223-8
   Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430
   Zabludoff SD, 1996, ONCOGENE, V13, P649
   Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932
   ZHANG W, 1995, CANCER RES, V55, P668
NR 56
TC 79
Z9 81
U1 1
U2 8
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0270-7306
EI 1098-5549
J9 MOL CELL BIOL
JI Mol. Cell. Biol.
PD OCT
PY 1999
VL 19
IS 10
BP 7061
EP 7075
PG 15
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 237MM
UT WOS:000082660200057
PM 10490643
DA 2018-12-27
ER

PT J
AU Jayachandra, S
   Low, KG
   Thlick, AE
   Yu, J
   Ling, PD
   Chang, Y
   Moore, PS
AF Jayachandra, S
   Low, KG
   Thlick, AE
   Yu, J
   Ling, PD
   Chang, Y
   Moore, PS
TI RETRACTED: Three unrelated viral transforming proteins (vIRF, EBNA2, and
   E1A) induce the MYC oncogene through the interferon-responsive PRF
   element by using different transcription coadaptors (Retracted article.
   See vol 98, pg 12313, 2001)
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article; Retracted Publication
ID EPSTEIN-BARR-VIRUS; HUMAN PAPILLOMAVIRUS TYPE-16; RETINOBLASTOMA
   GENE-PRODUCT; NF-KAPPA-B; C-MYC; REGULATORY FACTOR; BINDING PROTEIN;
   BETA ENHANCEOSOME; FACTOR IRF-1; IFN-ALPHA
AB Kaposi sarcoma-associated herpesvirus vIRF is a viral transcription factor that inhibits interferon signaling and transforms NIH 3T3 cells, but does not bind interferon-stimulated response element (ISRE) DNA sequences. Here me show that induction of the MYC protooncogene is required for cell transformation by vIRF, and that vIRF increases MYC transcription up to 15-fold through specific promoter interactions at an ISRE sequence called the plasmacytoma repressor factor (PRF) element. These effects are resistant to cycloheximide but are inhibited by a dominant-negative ISRE binding protein, indicating that vIRF acts together with a cellular cofactor at the PRF element to directly transactivate MYC, The coadaptor CREB-binding protein (CBP) binds vIRF and synergizes transactivation of MYC, but, unexpectedly, closely related histone acetyltransferases p300 and P/CAF potently suppress vIRF transactivation. On the basis of the prediction that other interferon-inhibiting viral transforming proteins behave similarly, we found that Epstein-Barr virus-induced nuclear antigen 2 (EBNA2) also binds p300/CBP, and that both EBNA2 and adenovirus E1A transactivate MYC through the PRF element, For E1A, P/CAF coactivates MYC, whereas both p300 and CBP suppress E1A transactivation. For EBNA2, both P/CAF and CBP coactivate the MYC promoter, whereas p300 suppresses EBNA2 transactivation. These findings demonstrate that viral transforming proteins can activate as well as inhibit transcription through coadaptor interactions, At some promoters CBP and p300 have previously unrecognized, competitive antagonism to each other. While all three viral proteins target the same promoter element, each has a different coadaptor use profile. These findings are consistent with cellular MYC repression playing a role in innate immunity as well as in control of cell proliferation.
C1 Columbia Univ Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA.
   Columbia Univ Coll Phys & Surg, Div Epidemiol, New York, NY 10032 USA.
   Columbia Univ Coll Phys & Surg, Dept Microbiol, New York, NY 10032 USA.
   Baylor Coll Med, Div Mol Virol, Houston, TX 77030 USA.
RP Moore, PS (reprint author), Columbia Univ Coll Phys & Surg, Dept Pathol, P&S 14-442,630 W 168th St, New York, NY 10032 USA.
FU NCI NIH HHS [R01 CA76586, R01 CA67391, R01 CA067391]
CR ALEXANDROVA NM, 1990, FEBS LETT, V265, P67, DOI 10.1016/0014-5793(90)80885-M
   ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0
   Bhattacharya S, 1996, NATURE, V383, P344, DOI 10.1038/383344a0
   Chang Y, 1996, NATURE, V382, P410, DOI 10.1038/382410a0
   DUYAO MP, 1992, J BIOL CHEM, V267, P16288
   DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532
   Flowers CC, 1998, MOL MED, V4, P402, DOI 10.1007/BF03401747
   Gao SJ, 1997, ONCOGENE, V15, P1979, DOI 10.1038/sj.onc.1201571
   Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927
   GILL G, 1988, NATURE, V334, P721, DOI 10.1038/334721a0
   HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4
   He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509
   HENKEL T, 1994, SCIENCE, V265, P92, DOI 10.1126/science.8016657
   Hobeika AC, 1997, ONCOGENE, V14, P1165, DOI 10.1038/sj.onc.1200939
   JONAK GJ, 1984, P NATL ACAD SCI-BIOL, V81, P1747, DOI 10.1073/pnas.81.6.1747
   Kaiser C, 1999, J VIROL, V73, P4481
   KAKKIS E, 1989, NATURE, V339, P718, DOI 10.1038/339718a0
   Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6
   KANDA K, 1992, MOL CELL BIOL, V12, P4930, DOI 10.1128/MCB.12.11.4930
   Kawasaki H, 1998, NATURE, V393, P284
   Kempkes B, 1995, VIROLOGY, V214, P675, DOI 10.1006/viro.1995.0084
   Kim TK, 1998, P NATL ACAD SCI USA, V95, P12191, DOI 10.1073/pnas.95.21.12191
   Kwok RPS, 1996, NATURE, V380, P642, DOI 10.1038/380642a0
   Li MT, 1998, J VIROL, V72, P5433
   Lin Y, 1997, SCIENCE, V276, P596, DOI 10.1126/science.276.5312.596
   LING PD, 1995, J VIROL, V69, P1944
   LING PD, 1993, P NATL ACAD SCI USA, V90, P9237, DOI 10.1073/pnas.90.20.9237
   LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9
   LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686
   MacGregor D, 1996, J CELL PHYSIOL, V167, P95, DOI 10.1002/(SICI)1097-4652(199604)167:1<95::AID-JCP11>3.0.CO;2-O
   Masumi A, 1999, MOL CELL BIOL, V19, P1810
   Matikainen S, 1999, BLOOD, V93, P1980
   MCCORMICK F, 1980, J VIROL, V34, P213
   Merika M, 1998, MOL CELL, V1, P277, DOI 10.1016/S1097-2765(00)80028-3
   Moore PS, 1998, TRENDS GENET, V14, P144, DOI 10.1016/S0168-9525(98)01408-5
   Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523
   Pitha PM, 1998, BIOCHIMIE, V80, P651, DOI 10.1016/S0300-9084(99)80018-2
   REICH N, 1988, J VIROL, V62, P114
   Reid JL, 1998, EMBO J, V17, P4469, DOI 10.1093/emboj/17.15.4469
   RIGGS KJ, 1993, MOL CELL BIOL, V13, P7487, DOI 10.1128/MCB.13.12.7487
   Sangfelt O, 1997, ONCOGENE, V14, P415, DOI 10.1038/sj.onc.1200832
   Sarid R, 1998, J VIROL, V72, P1005
   SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8
   Shikama N, 1997, TRENDS CELL BIOL, V7, P230, DOI 10.1016/S0962-8924(97)01048-9
   SINCLAIR AJ, 1994, EMBO J, V13, P3321, DOI 10.1002/j.1460-2075.1994.tb06634.x
   TANAKA N, 1994, CANCER LETT, V83, P191, DOI 10.1016/0304-3835(94)90318-2
   TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5
   TANIGUCHI T, 1997, BIOCHIM BIOPHYS ACTA, V1333, pM9
   WANG HGH, 1993, J VIROL, V67, P4804
   WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286
   WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0
   Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0
   Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4
   Zhang JJ, 1996, P NATL ACAD SCI USA, V93, P15092, DOI 10.1073/pnas.93.26.15092
   Zimring JC, 1998, J VIROL, V72, P701
NR 55
TC 78
Z9 80
U1 2
U2 12
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD SEP 28
PY 1999
VL 96
IS 20
BP 11566
EP 11571
DI 10.1073/pnas.96.20.11566
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 241DY
UT WOS:000082868500116
PM 10500217
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Fujii, Y
   Takahashi, S
   Toyooka, H
AF Fujii, Y
   Takahashi, S
   Toyooka, H
TI RETRACTED: The effect of olprinone compared with milrinone on
   diaphragmatic muscle function in dogs (Retracted article. See vol. 116,
   pg. 745, 2013)
SO ANESTHESIA AND ANALGESIA
LA English
DT Article; Retracted Publication
ID CARBONITRILE HYDROCHLORIDE MONOHYDRATE; FATIGUED DIAPHRAGM; CANINE
   DIAPHRAGM; BLOOD-FLOW; CONTRACTILITY; DOBUTAMINE; ACIDOSIS
AB We compared the effect of olprinone with milrinone On the contractility of fatigued diaphragms in dogs. Animals were divided into four groups of 10 each. In each group, diaphragmatic fatigue was induced by intermittent supramaximal bilateral electrophrenic stimulation at a frequency of 20 Hz applied for 30 min. After producing fatigue, Group I received only maintenance fluids; Group II was given a bolus injection (50 mu g/kg) followed by continuous infusion (0.5 mu g . kg(-1) . min(-1)) of milrinone; Group In: was infused with olprinone (10 mu g/kg initial dose plus 0.3 mu g . kg(-1) . min(-1) maintenance dose); Group IV was infused with nicardipine (5 mu g . kg(-1) . min(-1)) during olprinone administration. After the fatigue-producing period in each group, transdiaphragmatic pressure (Pdi) at low-frequency (20 Hz) stimulation decreased from the prefatigued values (P < 0.05), whereas there was no change in Pdi at high-frequency (100-Hz) stimulation. In Groups II and III, during study drug infusion, Pdi at both stimuli increased from fatigued values (P < 0.05). The increase in Pdi was larger in Group III than in Group II (P < 0.05). In Group IV, the augmentation of Pdi by olprinone was abolished in the fatigued diaphragm with an infusion of nicardipine. We conclude that olprinone is more effective than milrinone for the improvement of contractility in he fatigued diaphragm and that the potentiating mechanism of olprinone may be closely related to the transmembrane calcium movement. Implications: Diaphragmatic fatigue may contribute to the development of respiratory failure. Compared with milrinone, olprinone improves the contractility in fatigued diaphragm in dogs.
C1 Univ Tsukuba, Inst Clin Med, Dept Anesthesiol, Tsukuba, Ibaraki 305, Japan.
RP Fujii, Y (reprint author), Univ Tsukuba, Inst Clin Med, Dept Anesthesiol, 2-1-1 Amakubo, Tsukuba, Ibaraki 305, Japan.
CR AUBIER M, 1981, NEW ENGL J MED, V305, P249, DOI 10.1056/NEJM198107303050503
   EBATA T, 1992, CAN J ANAESTH, V39, P375, DOI 10.1007/BF03009049
   EICHHORN EJ, 1987, AM J CARDIOL, V60, P1329, DOI 10.1016/0002-9149(87)90616-3
   ESAU SA, 1989, AM REV RESPIR DIS, V139, P1410, DOI 10.1164/ajrccm/139.6.1410
   FUJII Y, 1995, CAN J ANAESTH, V42, P80, DOI 10.1007/BF03010577
   Fujii Y, 1998, ANESTH ANALG, V87, P1077, DOI 10.1097/00000539-199811000-00018
   FUJII Y, 1993, CAN J ANAESTH, V40, P453, DOI 10.1007/BF03009517
   FUJII Y, 1994, CAN J ANAESTH, V41, P435, DOI 10.1007/BF03009869
   GRASSINO A, 1978, J APPL PHYSIOL, V44, P829
   HOWELL S, 1984, AM REV RESPIR DIS, V129, P118
   HOWELL S, 1985, J APPL PHYSIOL, V59, P1376
   HUSSAIN SNA, 1988, J APPL PHYSIOL, V64, P329
   KIMATA S, 1992, JPN J CLIN EXP MED, V69, P2260
   OGAWA T, 1989, ARZNEIMITTEL-FORSCH, V39-1, P33
   OHHARA H, 1989, ARZNEIMITTELFORSCH, V39-1, P38
   REID MB, 1983, J APPL PHYSIOL, V54, P763
   ROUSSOS C, 1982, NEW ENGL J MED, V307, P786, DOI 10.1056/NEJM198209233071304
NR 17
TC 11
Z9 11
U1 2
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0003-2999
J9 ANESTH ANALG
JI Anesth. Analg.
PD SEP
PY 1999
VL 89
IS 3
BP 781
EP 785
DI 10.1097/00000539-199909000-00048
PG 5
WC Anesthesiology
SC Anesthesiology
GA 230KE
UT WOS:000082249700048
PM 10475325
DA 2018-12-27
ER

PT J
AU Bulfone-Paus, S
   Bulanova, E
   Pohl, T
   Budagian, V
   Durkop, H
   Ruckert, R
   Kunzendorf, U
   Paus, R
   Krause, H
AF Bulfone-Paus, S
   Bulanova, E
   Pohl, T
   Budagian, V
   Durkop, H
   Ruckert, R
   Kunzendorf, U
   Paus, R
   Krause, H
TI RETRACTED: Death deflected: IL-15 inhibits TNF-alpha-mediated apoptosis
   in fibroblasts by TRAF2 recruitment to the IL-15R alpha chain (Retracted
   Article. See vol 25, pg 1118, 2011)
SO FASEB JOURNAL
LA English
DT Article; Retracted Publication
DE cell death; TNFR1; L929; I kappa B
ID NF-KAPPA-B; NECROSIS-FACTOR RECEPTOR; SIGNALS CELL-DEATH; BETA-CHAIN;
   IMMUNE-RESPONSES; KILLER-CELLS; KINASE RIP; DOMAIN; PROTEIN; INTERACTS
AB Interleukin-15 (IL-15) is a potent inhibitor of several apoptosis pathways. One prominent path toward apoptosis is the ligand-induced association of TNF receptor 1 (TNFR1) with death domain adaptor proteins. Studying if and how IL-15 blocks TNFR1-mediated apoptosis in a murine fibroblast cell line (L929), we show here that IL-15 blocks TNFR1-induced apoptosis tia IL-15R alpha chain signaling. The intracellular tail of IL-15R alpha shows sequence homologies to the TRAF2 binding motifs of CD30 and CD40. Most important, binding of IL-15 to IL-15R alpha successfully competes with the TNFR1 complex for TRAF2 binding, which may impede assembly of key adaptor proteins to the TNFR1 complex, and induces I kappa B alpha phosphorylation, Thus, IL-15R alpha chain stimulation is a powerful deflector of cell death very early in the apoptosis signaling cascade, while TNF-alpha and IL-15 surface as major opponents in apoptosis control.
C1 Free Univ Berlin, Hosp Benjamin Franklin, Inst Immunol, D-12200 Berlin, Germany.
   Free Univ Berlin, Hosp Benjamin Franklin, Dept Urol, D-12200 Berlin, Germany.
   Free Univ Berlin, Hosp Benjamin Franklin, Dept Pathol, D-12200 Berlin, Germany.
   Univ Hamburg, Hosp Eppendorf, Dept Dermatol, D-20246 Hamburg, Germany.
   Univ Erlangen Nurnberg, Dept Internal Med 4, D-8520 Erlangen, Germany.
RP Bulfone-Paus, S (reprint author), Free Univ Berlin, Hosp Benjamin Franklin, Inst Immunol, Hindenburgdamm 30, D-12200 Berlin, Germany.
EM bulfone@zedat.fu-berlin.de
RI Kunzendorf, Ulrich/A-8257-2010
CR ANDERSON DM, 1995, J BIOL CHEM, V270, P29862
   ARMITAGE RJ, 1995, J IMMUNOL, V154, P483
   BAEUERLE PA, 1989, GENE DEV, V3, P1689, DOI 10.1101/gad.3.11.1689
   Baichwal VR, 1997, CURR BIOL, V7, P94
   Baker SJ, 1996, ONCOGENE, V12, P1
   Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649
   BAMFORD RN, 1994, P NATL ACAD SCI USA, V91, P4940, DOI 10.1073/pnas.91.11.4940
   Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782
   BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795
   Boucher LM, 1997, BIOCHEM BIOPH RES CO, V233, P592, DOI 10.1006/bbrc.1997.6509
   BulfonePaus S, 1997, CYTOKINE, V9, P507, DOI 10.1006/cyto.1996.0194
   BulfonePaus S, 1997, NAT MED, V3, P1124, DOI 10.1038/nm1097-1124
   CARSON WE, 1994, J EXP MED, V180, P1395, DOI 10.1084/jem.180.4.1395
   CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3
   CHINNAIYAN AM, 1996, SCIENCE, V264, P707
   CLEVELAND JL, 1995, CELL, V81, P479, DOI 10.1016/0092-8674(95)90068-3
   COLIGAN JE, 1994, CURRENT PROTOCOLS IM
   DiSanto JP, 1997, CURR BIOL, V7, pR424, DOI 10.1016/S0960-9822(06)00208-9
   Duckett CS, 1997, GENE DEV, V11, P2810, DOI 10.1101/gad.11.21.2810
   Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3
   Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225
   Girard D, 1996, BLOOD, V88, P3176
   GIRI JG, 1995, EMBO J, V14, P3654, DOI 10.1002/j.1460-2075.1995.tb00035.x
   GIRI JG, 1994, EMBO J, V13, P2822, DOI 10.1002/j.1460-2075.1994.tb06576.x
   GRABSTEIN KH, 1994, SCIENCE, V264, P965, DOI 10.1126/science.8178155
   HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5
   Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6
   Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8
   ITOH N, 1993, J BIOL CHEM, V268, P10932
   Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5
   Jacobson MD, 1998, CURR BIOL, V8, pR418, DOI 10.1016/S0960-9822(98)70267-2
   Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X
   Kitson J, 1996, NATURE, V384, P372, DOI 10.1038/384372a0
   Kunzendorf U, 1996, J CLIN INVEST, V97, P1204, DOI 10.1172/JCI118534
   LEWIS M, 1991, P NATL ACAD SCI USA, V88, P2830, DOI 10.1073/pnas.88.7.2830
   LINDNER G, 1998, J INVEST DERMATOL, V141, P101
   Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6
   Marsters SA, 1996, CURR BIOL, V6, P1669, DOI 10.1016/S0960-9822(02)70791-4
   NAGATA S, 1995, IMMUNOL TODAY, V16, P39, DOI 10.1016/0167-5699(95)80069-7
   Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7
   NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O
   Onu A, 1997, J IMMUNOL, V158, P255
   ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0
   STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1
   Tagaya Y, 1996, IMMUNITY, V4, P329, DOI 10.1016/S1074-7613(00)80246-0
   TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O
   TARTAGLIA LA, 1993, CELL, V73, P213, DOI 10.1016/0092-8674(93)90222-C
   TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2
   THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464
   VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787
   Wallach D, 1997, NATURE, V388, P123, DOI 10.1038/40516
   Wallach D, 1997, TRENDS BIOCHEM SCI, V22, P107, DOI 10.1016/S0968-0004(97)01015-3
   Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784
   White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1
   XIE KP, 1993, INT J ONCOL, V3, P1043
NR 55
TC 128
Z9 130
U1 3
U2 16
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD SEP
PY 1999
VL 13
IS 12
BP 1575
EP 1585
PG 11
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA 232CF
UT WOS:000082347600013
PM 10463949
DA 2018-12-27
ER

PT J
AU Van Parijs, L
   Refaeli, Y
   Lord, JD
   Nelson, BH
   Abbas, AK
   Baltimore, D
AF Van Parijs, L
   Refaeli, Y
   Lord, JD
   Nelson, BH
   Abbas, AK
   Baltimore, D
TI RETRACTED: Uncoupling IL-2 signals that regulate T cell proliferation,
   survival, and Fas-mediated activation-induced cell death (Retracted
   article. See vol. 30, pg. 611, 2009)
SO IMMUNITY
LA English
DT Article; Retracted Publication
ID INTERLEUKIN-2 RECEPTOR-BETA; IMMUNE-RESPONSES; CHAIN; INDUCTION;
   APOPTOSIS; GROWTH; BCL-2; PHOSPHORYLATION; LYMPHOCYTES; BINDING
AB IL-2 is an important growth and survival factor for T lymphocytes but also sensitizes these cells to Fas-mediated activation-induced cell death (AICD). The molecular basis of these different effects of IL-2 was studied by introducing wild-type and mutant forms of the IL-2 receptor beta (IL-2R beta) chain that lacked specific signaling capacities into receptor-deficient T cells by retroviral gene transfer. Activation of Stat5 by IL-2 was found to be involved in T cell proliferation and promoted Pas ligand (FasL) expression and AICD. T cell survival was dependent on a receptor region that activated Akt and the expression of Bcl-2. Thus, distinct IL-2R beta chain signaling modules regulate T cell fate by stimulating growth and survival or by promoting apoptosis.
C1 CALTECH, Dept Biol, Pasadena, CA 91125 USA.
   Brigham & Womens Hosp, Div Immunol Res, Dept Pathol, Boston, MA 02115 USA.
   Harvard Univ, Sch Med, Boston, MA 02115 USA.
   Univ Washington, Virginia Mason Res Ctr, Seattle, WA 98195 USA.
   Univ Washington, Dept Immunol, Seattle, WA 98195 USA.
RP Baltimore, D (reprint author), CALTECH, Dept Biol, Pasadena, CA 91125 USA.
EM baltimo@caltech.edu
RI Nelson, Brad/K-2622-2014
FU NIAID NIH HHS [AI35297, AI42100]; NIGMS NIH HHS [GM57931]
CR Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322
   Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627
   Akbar AN, 1996, EUR J IMMUNOL, V26, P294, DOI 10.1002/eji.1830260204
   Brennan P, 1997, IMMUNITY, V7, P679, DOI 10.1016/S1074-7613(00)80388-X
   Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318
   Collins KL, 1998, NATURE, V391, P397, DOI 10.1038/34929
   Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5
   Friedman MC, 1996, P NATL ACAD SCI USA, V93, P2077, DOI 10.1073/pnas.93.5.2077
   Fujii H, 1998, EMBO J, V17, P6551, DOI 10.1093/emboj/17.22.6551
   FUJII H, 1995, P NATL ACAD SCI USA, V92, P5482, DOI 10.1073/pnas.92.12.5482
   HATAKEYAMA M, 1989, CELL, V59, P837, DOI 10.1016/0092-8674(89)90607-7
   HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859
   HAWLEY RG, 1994, GENE THER, V1, P136
   IHLE JN, 1995, ANNU REV IMMUNOL, V13, P369, DOI 10.1146/annurev.iy.13.040195.002101
   Imada K, 1998, J EXP MED, V188, P2067, DOI 10.1084/jem.188.11.2067
   Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657
   Johnson E W, 1995, J Back Musculoskelet Rehabil, V5, P3, DOI 10.3233/BMR-1995-5103
   KEEGAN AD, 1994, CELL, V76, P811, DOI 10.1016/0092-8674(94)90356-5
   Khoruts A, 1998, J EXP MED, V187, P225, DOI 10.1084/jem.187.2.225
   KUNDIG TM, 1993, SCIENCE, V262, P1059, DOI 10.1126/science.8235625
   LENARDO MJ, 1991, NATURE, V353, P858, DOI 10.1038/353858a0
   Leonard WJ, 1996, ANNU REV MED, V47, P229
   Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293
   Lord JD, 1998, J IMMUNOL, V161, P4627
   Miyazaki T, 1998, GENE DEV, V12, P770, DOI 10.1101/gad.12.6.770
   MIYAZAKI T, 1995, CELL, V81, P223, DOI 10.1016/0092-8674(95)90332-1
   MIYAZAKI T, 1994, SCIENCE, V266, P1045, DOI 10.1126/science.7973659
   Moriggl R, 1999, IMMUNITY, V10, P249, DOI 10.1016/S1074-7613(00)80025-4
   Moriggl R, 1996, MOL CELL BIOL, V16, P5691
   NABHOLZ M, 1995, IMMUNOBIOLOGY, V193, P259, DOI 10.1016/S0171-2985(11)80552-8
   Nakajima H, 1997, IMMUNITY, V7, P691, DOI 10.1016/S1074-7613(00)80389-1
   Nelms K, 1999, ANNU REV IMMUNOL, V17, P701, DOI 10.1146/annurev.immunol.17.1.701
   PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392
   Ravichandran KS, 1996, P NATL ACAD SCI USA, V93, P5275, DOI 10.1073/pnas.93.11.5275
   Refaeli Y, 1998, IMMUNITY, V8, P615, DOI 10.1016/S1074-7613(00)80566-X
   RUSSELL SM, 1994, SCIENCE, V266, P1042, DOI 10.1126/science.7973658
   SADLACK B, 1993, CELL, V75, P253, DOI 10.1016/0092-8674(93)80067-O
   SMITH KA, 1988, SCIENCE, V240, P1169, DOI 10.1126/science.3131876
   SUZUKI H, 1995, SCIENCE, V268, P1472, DOI 10.1126/science.7770771
   TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517
   TANIGUCHI T, 1993, CELL, V73, P5, DOI 10.1016/0092-8674(93)90152-G
   Van Parijs L, 1998, SCIENCE, V280, P243
   vanParijs L, 1996, CURR OPIN IMMUNOL, V8, P355, DOI 10.1016/S0952-7915(96)80125-7
   VanParijs L, 1997, J IMMUNOL, V158, P3738
   Wang DM, 1996, MOL CELL BIOL, V16, P6141
   WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354
   Wang RD, 1996, EUR J IMMUNOL, V26, P2263, DOI 10.1002/eji.1830260944
   WILLERFORD DM, 1995, IMMUNITY, V3, P521, DOI 10.1016/1074-7613(95)90180-9
   Zheng LX, 1998, J IMMUNOL, V160, P763
NR 49
TC 356
Z9 358
U1 6
U2 18
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1074-7613
J9 IMMUNITY
JI Immunity
PD SEP
PY 1999
VL 11
IS 3
BP 281
EP 288
DI 10.1016/S1074-7613(00)80103-X
PG 8
WC Immunology
SC Immunology
GA 242BN
UT WOS:000082918500003
PM 10514006
OA Bronze
DA 2018-12-27
ER

PT J
AU Venters, HD
   Tang, QS
   Liu, Q
   VanHoy, RW
   Dantzer, R
   Kelley, KW
AF Venters, HD
   Tang, QS
   Liu, Q
   VanHoy, RW
   Dantzer, R
   Kelley, KW
TI RETRACTED: A new mechanism of neurodegeneration: A proinflammatory
   cytokine inhibits receptor signaling by a survival peptide (Retracted
   article. See vol 106, pg 13636, 2009)
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article; Retracted Publication
ID GROWTH-FACTOR-I; TUMOR-NECROSIS-FACTOR; CENTRAL-NERVOUS-SYSTEM;
   CEREBELLAR GRANULE NEURONS; HYPOXIC-ISCHEMIC INJURY; FOCAL
   CEREBRAL-ISCHEMIA; METHYL-D-ASPARTATE; INSULIN-RECEPTOR; FACTOR-ALPHA;
   IGF-I
AB Heightened expression of both a proinflammatory cytokine, tumor necrosis factor alpha (TNF-alpha), and a survival peptide, insulin-like growth factor I (IGF-I), occurs in diverse diseases of the central nervous system, including Alzheimer's disease, multiple sclerosis, the AIDS-dementia complex, and cerebral ischemia, Conventional roles for these two proteins are neuroprotection by IGF-I and neurotoxicity by TNF-alpha. Although the mechanisms of action for IGF-I and TNF-alpha in the central nervous system originally were established as disparate and unrelated, we hypothesized that the signaling pathways of these two cytokines may interact during neurodegeneration, Here we show that concentrations of TNF-alpha as low as 10 pg/ml markedly reduce the capacity of IGF-I to promote survival of primary murine cerebellar granule neurons, TNF-alpha suppresses IGF-I-induced tyrosine phosphorylation of insulin receptor substrate 2 (IRS-2) and inhibits IRS-2-precipitable phosphatidylinositol 3'-kinase activity. These experiments indicate that TNF-alpha promotes IGF-I receptor resistance in neurons and inhibits the ability of the IGF-I receptor to tyrosine-phosphorylate the IRS-2 docking molecule and to subsequently activate the critical downstream enzyme phosphatidylinositol 3'-kinase. This intracellular crosstalk between discrete cytokine receptors reveals a novel pathway that leads to neuronal degeneration whereby a proinflammatory cytokine inhibits receptor signaling by a survival peptide.
C1 Univ Illinois, Dept Anim Sci, Immunophysiol Lab, Edward R Madigan Lab 207, Urbana, IL 61801 USA.
   Natl Sun Yat Sen Univ, Ctr Canc, Dept Hematol Oncol, Guangzha 510060, Peoples R China.
   Inst Francois Magendie, INSERM, U394, INRA, F-33077 Bordeaux, France.
RP Kelley, KW (reprint author), Univ Illinois, Dept Anim Sci, Immunophysiol Lab, Edward R Madigan Lab 207, 1207 W Gregory Dr, Urbana, IL 61801 USA.
EM kwkelley@uiuc.edu
OI Dantzer, Robert/0000-0001-9399-6107
FU NIDDK NIH HHS [DK-49311]; NIA NIH HHS [AG-06246]; NIMH NIH HHS
   [MH-51569, R01 MH051569]
CR Bark TH, 1998, AM J PHYSIOL-ENDOC M, V275, pE118, DOI 10.1152/ajpendo.1998.275.1.E118
   Barone FC, 1997, STROKE, V28, P1233, DOI 10.1161/01.STR.28.6.1233
   Bogdan I, 1997, J INFECT DIS, V176, P693, DOI 10.1086/514092
   Botchkina GI, 1997, MOL MED, V3, P765, DOI 10.1007/BF03401714
   Breese CR, 1996, J COMP NEUROL, V369, P388
   Carlson NG, 1998, J NEUROBIOL, V35, P29, DOI 10.1002/(SICI)1097-4695(199804)35:1<29::AID-NEU3>3.0.CO;2-D
   CARSON MJ, 1993, NEURON, V10, P729, DOI 10.1016/0896-6273(93)90173-O
   CHENG B, 1994, NEURON, V12, P139, DOI 10.1016/0896-6273(94)90159-7
   Connor B, 1997, MOL BRAIN RES, V49, P283, DOI 10.1016/S0169-328X(97)00192-7
   D'MELLO SR, 1993, P NATL ACAD SCI USA, V90, P10989, DOI 10.1073/pnas.90.23.10989
   Dantzer R, 1999, NEUROREPORT, V10, P289, DOI 10.1097/00001756-199902050-00015
   Dore S, 1997, TRENDS NEUROSCI, V20, P326
   Dore S, 1997, P NATL ACAD SCI USA, V94, P4772, DOI 10.1073/pnas.94.9.4772
   Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661
   Feldman EL, 1997, NEUROBIOL DIS, V4, P201, DOI 10.1006/nbdi.1997.0156
   FILLIT H, 1991, NEUROSCI LETT, V129, P318, DOI 10.1016/0304-3940(91)90490-K
   Folli F, 1996, MOL NEUROBIOL, V13, P155, DOI 10.1007/BF02740639
   FOLLI F, 1994, J NEUROSCI, V14, P6412
   Foster M, 1998, CELL MOL LIFE SCI, V54, P1076, DOI 10.1007/s000180050236
   Frost RA, 1997, ENDOCRINOLOGY, V138, P4153, DOI 10.1210/en.138.10.4153
   GarciaSegura LM, 1997, J NEUROCYTOL, V26, P479, DOI 10.1023/A:1018581407804
   GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493
   Guan J, 1996, NEUROREPORT, V7, P632, DOI 10.1097/00001756-199601310-00061
   Haviv R, 1998, J NEUROSCI RES, V52, P380, DOI 10.1002/(SICI)1097-4547(19980515)52:4<380::AID-JNR2>3.0.CO;2-5
   HOFMAN FM, 1989, J EXP MED, V170, P607, DOI 10.1084/jem.170.2.607
   Houzen H, 1997, J NEUROSCI RES, V50, P990, DOI 10.1002/(SICI)1097-4547(19971215)50:6<990::AID-JNR9>3.0.CO;2-8
   Jiang YP, 1999, SCIENCE, V283, P543, DOI 10.1126/science.283.5401.543
   Johnston BM, 1996, J CLIN INVEST, V97, P300, DOI 10.1172/JCI118416
   Kim BS, 1998, J BIOL CHEM, V273, P34543, DOI 10.1074/jbc.273.51.34543
   Liu Q, 1997, J IMMUNOL, V159, P829
   Loddick SA, 1998, P NATL ACAD SCI USA, V95, P1894, DOI 10.1073/pnas.95.4.1894
   Minshall C, 1996, J IMMUNOL, V156, P939
   Minshall C, 1999, J IMMUNOL, V162, P4542
   Munoz-Fernandez MA, 1998, PROG NEUROBIOL, V56, P307
   Natoli G, 1997, SCIENCE, V275, P200, DOI 10.1126/science.275.5297.200
   Nawashiro H, 1997, BRAIN RES, V778, P265, DOI 10.1016/S0006-8993(97)00981-5
   New DR, 1998, J BIOL CHEM, V273, P17852, DOI 10.1074/jbc.273.28.17852
   Nuovo GJ, 1996, MOL MED, V2, P358, DOI 10.1007/BF03401633
   Paz K, 1997, J BIOL CHEM, V272, P29911, DOI 10.1074/jbc.272.47.29911
   Peraldi P, 1996, J BIOL CHEM, V271, P13018, DOI 10.1074/jbc.271.22.13018
   Pettmann B, 1998, NEURON, V20, P633, DOI 10.1016/S0896-6273(00)81004-1
   Probert L, 1997, J NEUROIMMUNOL, V72, P137, DOI 10.1016/S0165-5728(96)00184-1
   Rothwell N, 1997, J CLIN INVEST, V100, P2648, DOI 10.1172/JCI119808
   Russell JW, 1998, J NEUROBIOL, V36, P455, DOI 10.1002/(SICI)1097-4695(19980915)36:4<455::AID-NEU1>3.0.CO;2-V
   *SAS I, 1996, SAS STAT REL 6 11
   SCHUMACHER R, 1993, J BIOL CHEM, V268, P1087
   Sipe KJ, 1996, MOL BRAIN RES, V38, P222, DOI 10.1016/0169-328X(95)00310-O
   Valverde AM, 1998, ENDOCRINOLOGY, V139, P1229, DOI 10.1210/en.139.3.1229
   van Buul-Offers SC, 1998, CELL MOL LIFE SCI, V54, P1083, DOI 10.1007/s000180050237
   Viviani B, 1998, TOXICOL APPL PHARM, V150, P271, DOI 10.1006/taap.1998.8406
   Weigent DA, 1997, CHEM IMMUNOL, V69, P1
   WERNER H, 1995, INT J BIOCHEM CELL B, V27, P987, DOI 10.1016/1357-2725(95)00074-Y
   White MF, 1998, RECENT PROG HORM RES, V53, P119
   Wickelgren I, 1998, SCIENCE, V280, P517, DOI 10.1126/science.280.5363.517
   Yamada M, 1997, J BIOL CHEM, V272, P30334, DOI 10.1074/jbc.272.48.30334
   Zhang FX, 1998, J BIOL CHEM, V273, P26596, DOI 10.1074/jbc.273.41.26596
   ZHU CZ, 1994, J CEREBR BLOOD F MET, V14, P237, DOI 10.1038/jcbfm.1994.30
NR 57
TC 160
Z9 164
U1 3
U2 3
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD AUG 17
PY 1999
VL 96
IS 17
BP 9879
EP 9884
DI 10.1073/pnas.96.17.9879
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 227UN
UT WOS:000082098500079
PM 10449788
OA Bronze, Green Published
DA 2018-12-27
ER

PT J
AU Rao, KR
AF Rao, KR
TI RETRACTED: New elements discovered and the island of stability sighted
   (Retracted article. See vol 83, pg 357, 2002)
SO CURRENT SCIENCE
LA English
DT Editorial Material; Retracted Publication
RP Rao, KR (reprint author), Gokula 29-2,11th Cross,111 Main, Bangalore 560003, Karnataka, India.
CR ARMBRUSTER P, 1989, SCI AM, V260, P66, DOI 10.1038/scientificamerican0589-66
   GHIORSO A, 1956, SCI AM, V195, P66, DOI 10.1038/scientificamerican1256-66
   NINOV V, 1999, IN PRESS PHYS REV LE, V83
   SEABORG GT, 1963, SCI AM, V208, P68, DOI 10.1038/scientificamerican0463-68
   SEABORG GT, 1950, SCI AM, V182, P38
   Service RF, 1999, SCIENCE, V284, P1751, DOI 10.1126/science.284.5421.1751
   Stone R, 1999, SCIENCE, V283, P474, DOI 10.1126/science.283.5401.474
NR 7
TC 1
Z9 1
U1 2
U2 4
PU INDIAN ACAD SCIENCES
PI BANGALORE
PA C V RAMAN AVENUE, SADASHIVANAGAR, P B #8005, BANGALORE 560 080, INDIA
SN 0011-3891
J9 CURR SCI INDIA
JI Curr. Sci.
PD AUG 10
PY 1999
VL 77
IS 3
BP 328
EP 330
PG 3
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 227HT
UT WOS:000082075600009
OA DOAJ Gold
DA 2018-12-27
ER

PT J
AU Fujii, Y
   Saitoh, Y
   Tanaka, H
   Toyooka, H
AF Fujii, Y
   Saitoh, Y
   Tanaka, H
   Toyooka, H
TI RETRACTED: Comparison of ramosetron and granisetron for preventing
   postoperative nausea and vomiting after gynecologic surgery (Retracted
   article. See vol. 116, pg. 744, 2013)
SO ANESTHESIA AND ANALGESIA
LA English
DT Article; Retracted Publication
ID RECEPTOR ANTAGONIST; DROPERIDOL
AB In a prospective, randomized, double-blinded study, we evaluated the efficacy of granisetron and ramosetron for preventing postoperative nausea and vomiting (PONV) in major gynecologic surgery. One hundred twenty patients, ASA physical status I or II, aged 23-65 yr,received TV granisetron 2.5 mg or ramosetron 0.3 mg (n = 60 each) at the end of surgery. A standard general anesthetic technique and postoperative analgesia were used. The incidence of a complete response, defined as no PONV and no need for another rescue medication, 0-3 h after anesthesia was 87% with granisetron and 90% with ramosetron; the corresponding incidence 3-24 h after anesthesia was 85% and 90%; the corresponding incidence 24-48 h after anesthesia was 70% and 92% (P < 0.05). No clinically serious adverse events due to the drugs were observed in any of the groups. In conclusion, prophylactic therapy with ramosetron is more effective than granisetron for the longterm prevention of PONV after major gynecologic surgery. Implications: We compared the efficacy of granisetron and ramosetron for preventing postoperative nausea and vomiting in major gynecologic surgery. Prophylactic therapy with ramosetron was more effective than granisetron for preventing postoperative nausea and vomiting 24-48 h after anesthesia.
C1 Univ Tsukuba, Inst Clin Med, Dept Anesthesiol, Tsukuba, Ibaraki 305, Japan.
   Toride Kyodo Gen Hosp, Toride, Ibaraki, Japan.
RP Fujii, Y (reprint author), Univ Tsukuba, Inst Clin Med, Dept Anesthesiol, 2-1-1 Amakubo, Tsukuba, Ibaraki 305, Japan.
CR ASPINALL RL, 1995, BRIT MED J, V311, P844, DOI 10.1136/bmj.311.7009.844
   BERMUDEZ J, 1988, BRIT J CANCER, V58, P644, DOI 10.1038/bjc.1988.277
   CARMICHAEL J, 1989, CANCER CHEMOTH PHARM, V24, P45
   FUJIHARA A, 1996, LAB CLIN, V30, P1965
   FUJIHARA A, 1996, LAB CLIN, V30, P1955
   FUJII Y, 1995, CAN J ANAESTH, V42, P852, DOI 10.1007/BF03011030
   FUJII Y, 1994, CAN J ANAESTH, V41, P794, DOI 10.1007/BF03011585
   FUJII Y, 1994, CAN J ANAESTH, V41, P291, DOI 10.1007/BF03009906
   Furue H, 1990, J CLIN THERAPEUTIC M, V6, P49
   KAMATO T, 1993, EUR J PHARMACOL, V238, P369, DOI 10.1016/0014-2999(93)90868-I
   Kawabata Y, 1994, NISHINIHON J UROL, V56, P1445
   KUMAKURA H, 1990, J CLIN THER MED, V5, P25
   LERMAN J, 1995, CAN J ANAESTH, V42, P263, DOI 10.1007/BF03010699
   MADEJ TH, 1986, BRIT J ANAESTH, V58, P879, DOI 10.1093/bja/58.8.879
   NODA K, 1994, JPN J CLIN EXP MED, V71, P2765
   WATCHA MF, 1992, ANESTHESIOLOGY, V77, P162, DOI 10.1097/00000542-199207000-00023
   WHITE PF, 1993, ANESTHESIOLOGY, V78, P2, DOI 10.1097/00000542-199301000-00002
   YARKER YE, 1994, DRUGS, V48, P761, DOI 10.2165/00003495-199448050-00008
NR 18
TC 26
Z9 26
U1 1
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0003-2999
J9 ANESTH ANALG
JI Anesth. Analg.
PD AUG
PY 1999
VL 89
IS 2
BP 476
EP 479
DI 10.1097/00000539-199908000-00043
PG 4
WC Anesthesiology
SC Anesthesiology
GA 222DD
UT WOS:000081767400043
PM 10439770
DA 2018-12-27
ER

PT J
AU Matsumura, Y
   Taira, S
   Kitano, R
   Hashimoto, N
   Kuro, T
AF Matsumura, Y
   Taira, S
   Kitano, R
   Hashimoto, N
   Kuro, T
TI RETRACTED: Selective antagonism of endothelin ETA or ETB receptor in
   renal hemodynamics and function of deoxycorticosterone
   acetate-salt-induced hypertensive rats (Retracted article. See vol. 37,
   pg. 1080, 2014)
SO BIOLOGICAL & PHARMACEUTICAL BULLETIN
LA English
DT Article; Retracted Publication
DE endothelin-1; endothelin receptor; ETA antagonist; ETB antagonist;
   deoxycorticosterone acetate-salt hypertension; renal function
ID ET(A) RECEPTOR; BLOOD-VESSELS; FAILURE; HYPERTROPHY; INJURY
AB Effects of acute and chronic blockade of endothelin ETA or ETB receptors on renal hemodynamics and function were investigated using deoxycorticosterone acetate (DOCA)-salt-induced hypertensive rats. At 4 weeks after initiating DOCA-salt treatment, intravenous bolus injection of ABT-627 (1 mg/kg), a selective ETA receptor antagonist, produced a sustained and significant hpotension. which was accompanied by potent renal vasodilation, When the selective ETB receptor antagonist A-192621 (3 mg/kg) was intravenously administered, there were marked decreases in renal blood dow and glomerular filtration rate, and increases in renal vascular resistance. A slight hypertensive effect was observed after the injection of A-192621, Next,,ve examined the effects of chronic treatment with ABT-627 (10 mg/kg/d, p.o., b.i.d.) or A-192621 (30 mg/kg/d, p.o., b.i.d.) for 2 weeks on renal function of animals at 2 weeks after initiating DOCA-salt treatment. In the 2-week-treated DOCA-salt animals, the levels of creatinine clearance (C-cr), urinary excretion of protein (UproteinV) and blood urea nitrogen (BUN) were not significantly different compared with those of sham-operated control animals. These parameters did show statistically significant differences over the 3 to 4 weeks treatment period, between the DOCA-salt and the control animals (decrease in C-cr, and increase in UproteinV and BUN in DOCA-salt rats), thereby indicating the gradual establishment of renal dysfunction in this hypertensive model. The DOCA-salt-induced changes in renal functional parameters were markedly attenuated by daily administration of ABT-627, in contrast, treatment with A-192621 augmented the above renal dysfunction, Our findings clearly indicate that selective blockade of the ETB receptor is detrimental to renal hemodynamics and the function of the hypertensive condition, and support the view that a selective ETA receptor antagonist is useful for treatment of subjects with mineralocorticoid-dependent hypertension.
C1 Osaka Univ Pharmaceut Sci, Dept Pharmacol, Takatsuki, Osaka 5691094, Japan.
RP Matsumura, Y (reprint author), Osaka Univ Pharmaceut Sci, Dept Pharmacol, 4-20-1 Nasahara, Takatsuki, Osaka 5691094, Japan.
CR BENIGNI A, 1993, KIDNEY INT, V44, P440, DOI 10.1038/ki.1993.263
   CHAN L, 1994, AM J PHYSIOL, V266, pF135
   Clozel M, 1996, FEBS LETT, V383, P42, DOI 10.1016/0014-5793(96)00212-8
   CLOZEL M, 1992, BIOCHEM BIOPH RES CO, V175, P556
   Fujita K, 1996, JPN J PHARMACOL, V70, P313, DOI 10.1254/jjp.70.313
   FUJITA K, 1995, BRIT J PHARMACOL, V114, P925, DOI 10.1111/j.1476-5381.1995.tb13292.x
   Fujita Katsuya, 1996, Life Sciences, V58, pPL1
   GELLAI M, 1994, J CLIN INVEST, V93, P900, DOI 10.1172/JCI117046
   GELLAI M, 1994, KIDNEY INT, V46, P1287, DOI 10.1038/ki.1994.396
   Hashimoto N, 1998, BIOL PHARM BULL, V21, P800
   Kassab S, 1998, HYPERTENSION, V31, P397, DOI 10.1161/01.HYP.31.1.397
   Kohan DE, 1996, CLIN EXP PHARMACOL P, V23, P337, DOI 10.1111/j.1440-1681.1996.tb02834.x
   LARIVIERE R, 1993, HYPERTENSION, V21, P916, DOI 10.1161/01.HYP.21.6.916
   LARIVIERE R, 1993, HYPERTENSION, V21, P294, DOI 10.1161/01.HYP.21.3.294
   LI JS, 1994, HYPERTENSION, V24, P183, DOI 10.1161/01.HYP.24.2.183
   Li JS, 1998, AM J HYPERTENS, V11, P554, DOI 10.1016/S0895-7061(97)00405-6
   Matsumura Y, 1997, EUR J PHARMACOL, V319, P65, DOI 10.1016/S0014-2999(96)00915-6
   Matsumura Y, 1999, HYPERTENSION, V33, P759, DOI 10.1161/01.HYP.33.2.759
   MINO N, 1992, EUR J PHARMACOL, V221, P77
   Opgenorth TJ, 1996, J PHARMACOL EXP THER, V276, P473
   OPGENORTH TJ, 1997, 5 INT C END
   Orth SR, 1998, HYPERTENSION, V31, P995, DOI 10.1161/01.HYP.31.4.995
   Shimizu T, 1998, J PHARMACOL EXP THER, V286, P977
   VUREK GG, 1966, ANAL BIOCHEM, V16, P409, DOI 10.1016/0003-2697(66)90222-3
   YAMASHITA Y, 1991, J PHARMACOL EXP THER, V259, P1256
   YUKIMURA T, 1994, EUR J PHARMACOL, V264, P399, DOI 10.1016/0014-2999(94)00501-X
NR 26
TC 9
Z9 9
U1 2
U2 8
PU PHARMACEUTICAL SOC JAPAN
PI TOKYO
PA 2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN
SN 0918-6158
J9 BIOL PHARM BULL
JI Biol. Pharm. Bull.
PD AUG
PY 1999
VL 22
IS 8
BP 858
EP 862
DI 10.1248/bpb.22.858
PG 5
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 228XJ
UT WOS:000082162400016
PM 10480326
OA Bronze
DA 2018-12-27
ER

PT J
AU Mori, N
   Oishi, K
   Sar, B
   Mukaida, N
   Nagatake, T
   Matsushima, K
   Yamamoto, N
AF Mori, N
   Oishi, K
   Sar, B
   Mukaida, N
   Nagatake, T
   Matsushima, K
   Yamamoto, N
TI RETRACTED: Essential role of transcription factor nuclear factor-kappa B
   in regulation of interleukin-8 gene expression by nitrite reductase from
   Pseudomonas aeruginosa in respiratory epithelial cells (Retracted
   article. See vol. 79, pg. 3473, 2011)
SO INFECTION AND IMMUNITY
LA English
DT Article; Retracted Publication
ID VIRUS TYPE-I; INFLAMMATORY CYTOKINES; COOPERATIVE INTERACTION;
   CYTOCHROME OXIDASE; AIRWAY EPITHELIUM; CYSTIC-FIBROSIS; BINDING-SITES;
   PROMOTER; ACTIVATION; INHIBITOR
AB Persistent infection with Pseudomonas aeruginosa increases interleukin-8 (IL-8) levels and causes dense neutrophil infiltrations in the airways of patients with chronic airway diseases. Recently, we have reported that nitrite reductase from P. aeruginosa induces the production of IL-8 in respiratory cells, including bronchial epithelial cells. To determine the molecular mechanism(s) of nitrite reductase-induced IL-8 expression in respiratory cells, A549 epithelial cells were transfected with plasmids containing serial deletions of the 5'-flanking region of the IL-8 gene and then exposed to nitrite reductase. Nitrite reductase significantly enhanced IL-8 gene promoter-driven reporter activity. This increased IL-8 gene expression was inhibited by mutating the nuclear factor-kappa B (NF-kappa B) binding element. Nitrite reductase enhanced nuclear localization of the NF-kappa B binding complex. Furthermore, nitrite reductase induced the degradation of I kappa B alpha, the major cytoplasmic inhibitor of NF-kappa B, and the expression of I kappa B alpha mRNA. These data support the critical role of the activation of NF-kappa B in nitrite reductase-induced IL-8 gene expression in airway epithelium.
C1 Nagasaki Univ, Inst Trop Med, Dept Prevent Med & AIDS Res, Nagasaki 8528523, Japan.
   Nagasaki Univ, Inst Trop Med, Dept Internal Med, Nagasaki 8528523, Japan.
   Kanazawa Univ, Canc Res Inst, Dept Pharmacol, Kanazawa, Ishikawa 9200934, Japan.
   Univ Tokyo, Sch Med, Dept Mol Prevent Med, Bunkyo Ku, Tokyo 1130033, Japan.
RP Mori, N (reprint author), Nagasaki Univ, Inst Trop Med, Dept Prevent Med & AIDS Res, 1-12-4 Sakamoto, Nagasaki 8528523, Japan.
EM n-mori@net.nagasaki-u.ac.jp
RI Mukaida, Naofumi/D-7623-2011
OI Mukaida, Naofumi/0000-0002-4193-1851
CR ANTALIS TM, 1991, NUCLEIC ACIDS RES, V19, P4301, DOI 10.1093/nar/19.15.4301
   BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141
   BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380
   CARRE PC, 1991, J CLIN INVEST, V88, P1802, DOI 10.1172/JCI115501
   DIMANGO E, 1995, J CLIN INVEST, V96, P2204, DOI 10.1172/JCI118275
   FICK RB, 1989, CHEST, V96, P158, DOI 10.1378/chest.96.1.158
   Hoiby N., 1977, ACTA PATHOL MICROB S, V262, P1
   INOUE H, 1994, AM J RESP CELL MOL, V11, P651, DOI 10.1165/ajrcmb.11.6.7946394
   KADOTA J, 1993, AM REV RESPIR DIS, V147, P153, DOI 10.1164/ajrccm/147.1.153
   KUNSCH C, 1993, MOL CELL BIOL, V13, P6137, DOI 10.1128/MCB.13.10.6137
   KUNSCH C, 1994, J IMMUNOL, V153, P153
   LEBAIL O, 1993, EMBO J, V12, P5043, DOI 10.1002/j.1460-2075.1993.tb06197.x
   Lee LF, 1997, MOL CELL BIOL, V17, P5097, DOI 10.1128/MCB.17.9.5097
   LIEBER M, 1976, INT J CANCER, V17, P62, DOI 10.1002/ijc.2910170110
   MAHE Y, 1991, J BIOL CHEM, V266, P13759
   MASSION PP, 1994, J CLIN INVEST, V93, P26, DOI 10.1172/JCI116954
   Mastronarde JG, 1998, J INFECT DIS, V177, P1275, DOI 10.1086/515279
   MATSUSAKA T, 1993, P NATL ACAD SCI USA, V90, P10193, DOI 10.1073/pnas.90.21.10193
   MCELVANEY NG, 1992, J CLIN INVEST, V90, P1296, DOI 10.1172/JCI115994
   Mori N, 1996, BLOOD, V87, P3410
   MORI N, 1995, CANCER RES, V55, P3592
   MUKAIDA N, 1990, J BIOL CHEM, V265, P21128
   MUKAIDA N, 1994, J LEUKOCYTE BIOL, V56, P554
   Murayama T, 1997, J VIROL, V71, P5692
   NAKAMURA H, 1991, J BIOL CHEM, V266, P19611
   Oishi K, 1997, INFECT IMMUN, V65, P2648
   OISHI K, 1994, INFECT IMMUN, V62, P4145
   OISHI K, UNPUB
   OKAMOTO SI, 1994, J BIOL CHEM, V269, P8582
   OLIVEIRA IC, 1994, MOL CELL BIOL, V14, P5300, DOI 10.1128/MCB.14.8.5300
   PENNINGT.JE, 1973, AM J MED, V55, P155, DOI 10.1016/0002-9343(73)90163-0
   ROLFE MW, 1991, AM J RESP CELL MOL, V5, P493, DOI 10.1165/ajrcmb/5.5.493
   Sar B, 1999, ANTIMICROB AGENTS CH, V43, P794, DOI 10.1128/AAC.43.4.794
   SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201
   SILVESTRINI MC, 1989, FEBS LETT, V254, P33, DOI 10.1016/0014-5793(89)81004-X
   TAKIZAWA H, 1995, INT ARCH ALLERGY IMM, V108, P260, DOI 10.1159/000237162
   TANIMOTO H, 1991, ANTIBIOT CHEMOTHER, V44, P94
   YAMANAKA T, 1963, J BIOCHEM-TOKYO, V53, P416, DOI 10.1093/oxfordjournals.jbchem.a127716
   YAMANAKA T, 1963, BIOCHIM BIOPHYS ACTA, V67, P379
   YASUMOTO K, 1992, J BIOL CHEM, V267, P22506
   YOSHIMURA T, 1987, J IMMUNOL, V139, P788
NR 41
TC 35
Z9 38
U1 0
U2 8
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0019-9567
J9 INFECT IMMUN
JI Infect. Immun.
PD AUG
PY 1999
VL 67
IS 8
BP 3872
EP 3878
PG 7
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 219ZA
UT WOS:000081637400025
PM 10417151
DA 2018-12-27
ER

PT J
AU Endoh, H
   Maruyama, K
   Masuhiro, Y
   Kobayashi, Y
   Goto, M
   Tai, H
   Yanagisawa, J
   Metzger, D
   Hashimoto, S
   Kato, S
AF Endoh, H
   Maruyama, K
   Masuhiro, Y
   Kobayashi, Y
   Goto, M
   Tai, H
   Yanagisawa, J
   Metzger, D
   Hashimoto, S
   Kato, S
TI RETRACTED: Purification and identification of p68 RNA helicase acting as
   a transcriptional coactivator specific for the activation function 1 of
   human estrogen receptor alpha (Retracted article. See vol. 34, pg. 915,
   2014)
SO MOLECULAR AND CELLULAR BIOLOGY
LA English
DT Article; Retracted Publication
ID STEROID-HORMONE RECEPTORS; VITAMIN-D-RECEPTOR; NUCLEAR RECEPTORS;
   HISTONE ACETYLTRANSFERASE; BINDING-PROTEIN; THYROID-HORMONE; RETINOIC
   ACID; FUNCTION AF-2; BETA; PHOSPHORYLATION
AB The estrogen receptor (ER) regulates the expression of target genes in a ligand-dependent manner. The ligand-dependent activation function AF-2 of the ER is located in the ligand binding domain (LBD), while the N-terminal A/B domain (AF-1) functions in a ligand-independent manner when isolated from the LED. AF-1 and AF-2 exhibit cell type and promoter context specificity. Furthermore, the AF-1 activity of the human ER alpha (hER alpha) is enhanced through phosphorylation of the Ser(118) residue by mitogen-activated protein kinase (MAPK). From MCF-7 cells, we purified and cloned a 68-kDa protein (p68) which interacted with the A/B domain but not with the LBD of hER alpha. Phosphorylation of hER alpha Ser(118) potentiated the interaction with p68. We demonstrate that p68 enhanced the activity of AF-1 but not AF-2 and the estrogen-induced as well as the anti-estrogen-induced transcriptional activity of the full-length ER alpha in a cell-type-specific manner. However, it did not potentiate AF-1 or AF-2 of ERP, androgen receptor, retinoic acid receptor alpha, or mineralocorticoid receptor. We also show that the RNA helicase activity previously ascribed to p68 is dispensable for the ER alpha AF-1 coactivator activity and that p68 binds to CBP in vitro. Furthermore, the interaction region for p68 in the ER alpha A/B domain was essential for the full activity of hER alpha AF-1. Taken together, these findings show that p68 acts as a coactivator specific far the ER alpha AF-1 and strongly suggest that the interaction between p68 and the hER alpha A/B domain is regulated by MAPK-induced phosphorylation of Ser(118).
C1 Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan.
   Yamanouchi Pharmaceut Co Ltd, Inst Drug Discovery Res, Mol Med Labs, Tsukuba, Ibaraki 3058585, Japan.
   Japan Sci & Technol, CREST, Kawaguchi, Saitama 3320012, Japan.
   Coll France, ULP, CNRS, INSERM,IGBMC, F-67404 Illkirch Graffenstaden, CU Strasbourg, France.
RP Kato, S (reprint author), Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Yayoi 1-1-1, Tokyo 1130032, Japan.
EM uskato@hongo.ecc.u-tokyo.ac.jp
CR ALI S, 1993, EMBO J, V12, P1153, DOI 10.1002/j.1460-2075.1993.tb05756.x
   Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965
   ARONICA SM, 1993, MOL ENDOCRINOL, V7, P743, DOI 10.1210/me.7.6.743
   BANIAHMAD A, 1993, P NATL ACAD SCI USA, V90, P8832, DOI 10.1073/pnas.90.19.8832
   Baur EV, 1996, EMBO J, V15, P110, DOI 10.1002/j.1460-2075.1996.tb00339.x
   BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5
   BERRY M, 1990, EMBO J, V9, P2811, DOI 10.1002/j.1460-2075.1990.tb07469.x
   BUELT MK, 1994, J BIOL CHEM, V269, P29367
   Bunone G, 1996, EMBO J, V15, P2174, DOI 10.1002/j.1460-2075.1996.tb00571.x
   CAVAILLES V, 1994, P NATL ACAD SCI USA, V91, P10009, DOI 10.1073/pnas.91.21.10009
   Chambon P, 1996, FASEB J, V10, P940
   Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4
   FORD MJ, 1988, NATURE, V332, P736, DOI 10.1038/332736a0
   Gross CH, 1998, J VIROL, V72, P4729
   HALACHMI S, 1994, SCIENCE, V264, P1455, DOI 10.1126/science.8197458
   Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750
   HIRLING H, 1989, NATURE, V339, P562, DOI 10.1038/339562a0
   Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167
   IGGO RD, 1989, EMBO J, V8, P1827, DOI 10.1002/j.1460-2075.1989.tb03577.x
   IGNARTROWBRIDGE DM, 1993, MOL ENDOCRINOL, V7, P992, DOI 10.1210/me.7.8.992
   Imai T, 1997, BIOCHEM BIOPH RES CO, V233, P765, DOI 10.1006/bbrc.1997.6531
   IWAMATSU A, 1992, ELECTROPHORESIS, V13, P142, DOI 10.1002/elps.1150130129
   JACQ X, 1994, CELL, V79, P107, DOI 10.1016/0092-8674(94)90404-9
   Kalkhoven E, 1998, EMBO J, V17, P232, DOI 10.1093/emboj/17.1.232
   Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6
   KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491
   KATO S, 1992, CELL, V68, P731, DOI 10.1016/0092-8674(92)90148-6
   Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925
   LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x
   LeDouarin B, 1996, EMBO J, V15, P6701, DOI 10.1002/j.1460-2075.1996.tb01060.x
   LEES JA, 1989, NUCLEIC ACIDS RES, V17, P5477, DOI 10.1093/nar/17.14.5477
   LEMAIRE L, 1993, LIFE SCI, V52, P917, DOI 10.1016/0024-3205(93)90526-9
   MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X
   Maruyama K, 1998, BIOCHEM BIOPH RES CO, V246, P142, DOI 10.1006/bbrc.1998.8590
   McInerney EM, 1996, P NATL ACAD SCI USA, V93, P10069, DOI 10.1073/pnas.93.19.10069
   Mengus G, 1997, GENE DEV, V11, P1381, DOI 10.1101/gad.11.11.1381
   MENGUS G, 1995, EMBO J, V14, P1520, DOI 10.1002/j.1460-2075.1995.tb07138.x
   MEYER ME, 1989, CELL, V57, P433, DOI 10.1016/0092-8674(89)90918-5
   Mosselman S, 1996, FEBS LETT, V392, P49, DOI 10.1016/0014-5793(96)00782-X
   ONATE SA, 1995, SCIENCE, V270, P1354
   Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5
   SADOVSKY Y, 1995, MOL CELL BIOL, V15, P1554
   Spencer TE, 1997, NATURE, V389, P194
   Takeyama K, 1997, SCIENCE, V277, P1827, DOI 10.1126/science.277.5333.1827
   Takeyama KI, 1999, MOL CELL BIOL, V19, P1049
   TASSET D, 1990, CELL, V62, P1177, DOI 10.1016/0092-8674(90)90394-T
   TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7
   Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x
   Webb P, 1998, MOL ENDOCRINOL, V12, P1605, DOI 10.1210/me.12.10.1605
   Yanagisawa J, 1999, SCIENCE, V283, P1317, DOI 10.1126/science.283.5406.1317
   Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0
   Yeh SY, 1996, P NATL ACAD SCI USA, V93, P5517, DOI 10.1073/pnas.93.11.5517
NR 52
TC 294
Z9 304
U1 0
U2 17
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0270-7306
EI 1098-5549
J9 MOL CELL BIOL
JI Mol. Cell. Biol.
PD AUG
PY 1999
VL 19
IS 8
BP 5363
EP 5372
PG 10
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 217RY
UT WOS:000081513800013
PM 10409727
DA 2018-12-27
ER

PT J
AU Contreras, JL
   Eckhoff, DE
   Cartner, S
   Frenette, L
   Thomas, FT
   Robbin, ML
   Neville, DM
   Thomas, JM
AF Contreras, JL
   Eckhoff, DE
   Cartner, S
   Frenette, L
   Thomas, FT
   Robbin, ML
   Neville, DM
   Thomas, JM
TI RETRACTED: Tolerability and side effects of anti-CD3-immunotoxin in
   preclinical testing in kidney and pancreatic islet transplant recipients
   (Retracted article. See vol 86, pg. 482, 2008)
SO TRANSPLANTATION
LA English
DT Article; Retracted Publication
ID IMMUNOTOXIN; TOLERANCE; PERITRANSPLANT; ALLOGRAFTS; INDUCTION; BLOOD
AB Introduction, Anti-CD3-immunotoxin (alpha-CD3-IT) promotes allograft tolerance in nonhuman primates owing to efficient depletion of sessile and circulating T cells. Common side effects of vascular leak syndrome, hepatotoxicity, and nephrotoxicity have limited tolerability of other immunotoxins. We report on preclinical studies of alpha-CD3-IT-related side effects.
   Methods. Normal rhesus monkeys received a kidney transplant and alpha-CD3-IT alone (on day -to +2) or in combination with brief peritransplant adjunctive immunosuppressive therapy. Some received donor CD34(+) cells. Blood chemistries, complete blood count, weight, liver, and kidney biopsies were examined for immunotoxin-related changes. Five spontaneously diabetic primates also received alpha-CD3-IT, three of whom had a pancreas islet transplant.
   Results. The main side effect of alpha-CD3-IT, vascular leak syndrome, was entirely prevented by adjunctive immunosuppressive therapy. Renal and liver function tests and biopsies revealed a lack of nephrotoxicity and hepatotoxicity, All had transient weight loss (14+/-5%). Without infusion of donor CD34(+) cells, 97% had full weight recovery. Of those given donor CD34(+) cells, 50% were euthanized for wasting.
   Conclusions. Side effects of alpha-CD3-IT are manageable and should not prevent therapeutic application.
C1 Univ Alabama, Dept Surg, Div Transplantat Immunol, Birmingham, AL 35294 USA.
   Univ Alabama, Dept Comparat Med, Birmingham, AL 35294 USA.
   Univ Alabama, Dept Anesthesia, Birmingham, AL 35294 USA.
   Univ Alabama, Dept Radiol, Birmingham, AL 35294 USA.
   NIMH, Mol Biol Lab, Bethesda, MD 20892 USA.
RP Thomas, JM (reprint author), Univ Alabama, Dept Surg, Div Transplantat Immunol, BDB 802,1808 7th Ave S, Birmingham, AL 35294 USA.
FU NIAID NIH HHS [R0I AI39793, R0I AII22293]
CR Contreras JL, 1998, TRANSPLANTATION, V65, P1159, DOI 10.1097/00007890-199805150-00003
   Knechtle SJ, 1997, TRANSPLANTATION, V63, P1, DOI 10.1097/00007890-199701150-00002
   NEVILLE DM, 1992, P NATL ACAD SCI USA, V89, P2585, DOI 10.1073/pnas.89.7.2585
   Neville DM, 1996, J IMMUNOTHER, V19, P85, DOI 10.1097/00002371-199603000-00001
   NEVILLE DM, 1993, J CONTROL RELEASE, V24, P133, DOI 10.1016/0168-3659(93)90173-3
   PASTAN IH, 1995, ANN NY ACAD SCI, V758, P345, DOI 10.1111/j.1749-6632.1995.tb24840.x
   Smit WM, 1998, BONE MARROW TRANSPL, V21, P553, DOI 10.1038/sj.bmt.1701135
   Storek J, 1997, BLOOD, V90, P4705
   Thomas FT, 1999, TRANSPLANTATION, V67, P846, DOI 10.1097/00007890-199903270-00011
   Thomas JM, 1997, TRANSPLANTATION, V64, P124, DOI 10.1097/00007890-199707150-00022
   THOMPSON J, 1995, J BIOL CHEM, V270, P28037
   Thrush GR, 1996, ANNU REV IMMUNOL, V14, P49, DOI 10.1146/annurev.immunol.14.1.49
   Vallera DA, 1997, PROTEIN ENG, V10, P1071, DOI 10.1093/protein/10.9.1071
NR 13
TC 21
Z9 21
U1 3
U2 10
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0041-1337
J9 TRANSPLANTATION
JI Transplantation
PD JUL 27
PY 1999
VL 68
IS 2
BP 215
EP 219
DI 10.1097/00007890-199907270-00009
PG 5
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 224RB
UT WOS:000081911100009
PM 10440390
DA 2018-12-27
ER

PT J
AU Murthy, HMK
   Judge, K
   DeLucas, L
   Clum, S
   Padmanabhan, R
AF Murthy, HMK
   Judge, K
   DeLucas, L
   Clum, S
   Padmanabhan, R
TI RETRACTED: Crystallization, characterization and measurement of MAD data
   on crystals of dengue virus NS3 serine protease complexed with mung-bean
   Bowman-Birk inhibitor (Retracted article. See vol. 66, pg. 222, 2010)
SO ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY
LA English
DT Article; Retracted Publication
ID CRYSTALLOGRAPHIC ANALYSIS; NONSTRUCTURAL PROTEINS; POLYPROTEIN
   PRECURSOR; TERNARY COMPLEX; ACTIVE-SITE; TYPE-2; TRYPSIN; NS2B;
   REPLACEMENT; MACROMOLECULES
AB Crystallization and preliminary characterization of the essential dengue virus NS3 serine protease complexed with a Bowman-Birk-type inhibitor from mung beans are reported. As the structure proved resistant to solution by molecular replacement and multiple isomorphous replacement methods, multi-wavelength anomalous diffraction data at the L-III edge of a holmium derivative have been measured. Promising Bijvoet and dispersive signals which are largely consistent with expected values have been extracted from the data. The structure, when determined, will provide a structural basis for the design, synthesis and evaluation of inhibitors of the protease for chemotherapy of dengue infections.
C1 Univ Alabama, Ctr Macromol Crystallog, Birmingham, AL 35294 USA.
   Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, Kansas City, KS 66160 USA.
RP Murthy, HMK (reprint author), Univ Alabama, Ctr Macromol Crystallog, 79-THT,MCLM-244,1918 Univ Blvd, Birmingham, AL 35294 USA.
EM murthy@onyx.cmc.uab.edu
RI ID, IMCACAT/D-5867-2014
CR ABDELMEGUID SS, 1993, BIOCHEMISTRY-US, V32, P7972, DOI 10.1021/bi00082a019
   ABDELMEGUID SS, 1994, BIOCHEMISTRY-US, V33, P11671, DOI 10.1021/bi00205a001
   CHAMBERS TJ, 1990, ANNU REV MICROBIOL, V44, P649, DOI 10.1146/annurev.mi.44.100190.003245
   CHEN P, 1992, J BIOL CHEM, V267, P1990
   CHI CW, 1982, PROTEINS BIOL MED
   Clum S, 1997, J BIOL CHEM, V272, P30715, DOI 10.1074/jbc.272.49.30715
   *COLL COMP PROJ 4, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI DOI 10.1107/S0907444994003112
   EVANS G, 1996, REV SCI INSTRUM, V67, P47
   FALGOUT B, 1993, J VIROL, V67, P2034
   FALGOUT B, 1991, J VIROL, V65, P2467
   GAIER JR, 1981, J BIOL CHEM, V256, P1417
   GUBLER DJ, 1995, EMERG INFECT DIS, V1, P55
   HOPE H, 1990, ANNU REV BIOPHYS BIO, V19, P107
   HOWARD AJ, 1995, XGEN USERS GUIDE REL
   Ikenaka T, 1986, PROTEINASE INHIBITOR, P361
   IRIE K, 1989, GENE, V75, P197, DOI 10.1016/0378-1119(89)90266-7
   KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903
   KAPOOR M, 1995, J BIOL CHEM, V270, P19100, DOI 10.1074/jbc.270.32.19100
   Kennedy AR, 1998, PHARMACOL THERAPEUT, V78, P167, DOI 10.1016/S0163-7258(98)00010-2
   KENNEDY AR, 1998, AM J CLIN NUTR, V68, P1406
   KRAUT J, 1977, ANNU REV BIOCHEM, V46, P331, DOI 10.1146/annurev.bi.46.070177.001555
   KRISHNAMURTHY HM, 1988, J BIOL CHEM, V263, P18430
   LASKOWSKI M, 1980, ANNU REV BIOCHEM, V49, P593, DOI 10.1146/annurev.bi.49.070180.003113
   LIN GD, 1993, EUR J BIOCHEM, V212, P549, DOI 10.1111/j.1432-1033.1993.tb17692.x
   MATTHEWS BW, 1985, METHOD ENZYMOL, V114, P176
   MCPHERSON A, 1985, METHOD ENZYMOL, V114, P112
   MONATH TP, 1994, P NATL ACAD SCI USA, V91, P2395, DOI 10.1073/pnas.91.7.2395
   Murthy HMK, 1999, J BIOL CHEM, V274, P5573, DOI 10.1074/jbc.274.9.5573
   MURTHY HMK, 1996, METH MOL B, V56, P127
   MURTHY HMK, 1992, J BIOL CHEM, V267, P22770
   NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597
   PREUGSCHAT F, 1990, J VIROL, V64, P4364
   Ramachandra M, 1996, METHOD ENZYMOL, V275, P168
   ROGERS DW, 1994, STRUCTURE, V2, P1135
   Ryan MD, 1998, J GEN VIROL, V79, P947, DOI 10.1099/0022-1317-79-5-947
   SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X
   STEITZ TA, 1982, ANNU REV BIOPHYS BIO, V11, P419, DOI 10.1146/annurev.bb.11.060182.002223
   SUZUKI A, 1987, J BIOCHEM-TOKYO, V101, P267
   TERWILLIGER TC, 1987, ACTA CRYSTALLOGR A, V43, P1, DOI 10.1107/S0108767387099999
   Terwilliger TC, 1996, ACTA CRYSTALLOGR D, V52, P749, DOI 10.1107/S0907444996000832
   THOMPSON SK, 1994, J MED CHEM, V37, P3100, DOI 10.1021/jm00045a015
   TSUNOGAE Y, 1986, J BIOCHEM-TOKYO, V100, P1637, DOI 10.1093/oxfordjournals.jbchem.a121872
   Valle RPC, 1998, J VIROL, V72, P624
   WEI CH, 1983, J BIOL CHEM, V258, P9357
   ZHANG L, 1993, GENE, V129, P197, DOI 10.1016/0378-1119(93)90269-9
   ZHANG LW, 1992, J VIROL, V66, P7549
NR 46
TC 4
Z9 5
U1 1
U2 7
PU INT UNION CRYSTALLOGRAPHY
PI CHESTER
PA 2 ABBEY SQ, CHESTER, CH1 2HU, ENGLAND
SN 2059-7983
J9 ACTA CRYSTALLOGR D
JI Acta Crystallogr. Sect. D-Struct. Biol.
PD JUL
PY 1999
VL 55
BP 1370
EP 1372
PN 7
PG 3
WC Biochemical Research Methods; Biochemistry & Molecular Biology;
   Biophysics; Crystallography
SC Biochemistry & Molecular Biology; Biophysics; Crystallography
GA 218HL
UT WOS:000081547100022
DA 2018-12-27
ER

PT J
AU Piper, SN
   Suttner, SW
   Schmidt, CC
   Maleck, WH
   Kumle, B
   Boldt, J
AF Piper, SN
   Suttner, SW
   Schmidt, CC
   Maleck, WH
   Kumle, B
   Boldt, J
TI RETRACTED: Nefopam and clonidine in the prevention of postanaesthetic
   shivering (Retracted article. See vol. 66, pg. 647, 2011)
SO ANAESTHESIA
LA English
DT Article; Retracted Publication
DE anaesthesia, recovery; complications, shivering; pharmacology,
   clonidine, nefopam
ID GENERAL-ANESTHESIA; DOUBLE-BLIND; PETHIDINE; MEPERIDINE; HYDROCHLORIDE;
   DOXAPRAM
AB Postanaesthetic shivering affects up to 70% of patients after general anaesthesia, and may be very distressing. Various drugs have been used to treat or prevent postanaesthetic shivering, but the ideal one has not yet been found. Sixty patients undergoing elective abdominal or orthopaedic surgery under general anaesthesia were included in a randomised, double-blind study. Patients received clonidine (3 mu g.kg(-1)), nefopam (0.15 mg.kg(-1)) or saline 0.9% as a placebo at the end of surgery, prior to extubation. Nefopam and clonidine significantly reduced the incidence and severity of shivering in comparison with the placebo. The recovery time, between the end of anaesthesia and extubation, was significantly longer in the clonidine-treated patients [13.6 (5.2) min] than in either the nefopam [9.6 (2.8) min] or the placebo [10.0 (5.4) min] groups. Mean arterial blood pressure and heart rate were significantly lower in the clonidine group compared with both other groups. Our results suggest that nefopam and clonidine are effective in the prevention of postanaesthetic shivering. However, following clonidine administration the recovery time was prolonged and hypotension was significantly greater than after nefopam.
C1 Hosp City Ludwigshafen, Dept Anaesthesiol & Intens Care Med, D-67063 Ludwigshafen, Germany.
RP Piper, SN (reprint author), Hosp City Ludwigshafen, Dept Anaesthesiol & Intens Care Med, D-67063 Ludwigshafen, Germany.
CR Alfonsi P, 1998, ANESTHESIOLOGY, V89, P43, DOI 10.1097/00000542-199807000-00009
   Buggy D, 1997, CAN J ANAESTH, V44, P263, DOI 10.1007/BF03015363
   CONWAY M, 1982, CURR MED RES OPIN, V7, P580, DOI 10.1185/03007998209110102
   CROSSLEY AWA, 1992, ANAESTHESIA, V47, P193, DOI 10.1111/j.1365-2044.1992.tb02114.x
   De Witte JL, 1998, ANESTH ANALG, V87, P173, DOI 10.1097/00000539-199807000-00036
   GOOLD JE, 1984, ANAESTHESIA, V39, P35, DOI 10.1111/j.1365-2044.1984.tb09451.x
   Gotz E, 1995, Anasthesiol Intensivmed Notfallmed Schmerzther, V30, P28, DOI 10.1055/s-2007-996442
   Grundmann U, 1997, ANASTH INTENSIV NOTF, V32, P36, DOI 10.1055/s-2007-995005
   Horn EP, 1998, ANESTHESIOLOGY, V88, P108, DOI 10.1097/00000542-199801000-00018
   Horn EP, 1997, ANESTH ANALG, V84, P613, DOI 10.1097/00000539-199703000-00028
   HORN EP, 1998, ANESTH ANALG, V86, pS33
   Ikeda T, 1998, ANESTHESIOLOGY, V88, P858, DOI 10.1097/00000542-199804000-00003
   JORIS J, 1993, ANESTHESIOLOGY, V79, P532, DOI 10.1097/00000542-199309000-00017
   KAPLAN JA, 1985, ANESTH ANALG, V64, P235
   KULKA PJ, 1993, ANAESTHESIST, V42, P630
   MAHAJAN RP, 1987, ANESTHESIOLOGY, V66, P419, DOI 10.1097/00000542-198703000-00030
   Monso A, 1996, BRIT J CLIN PHARMACO, V42, P307, DOI 10.1046/j.1365-2125.1996.04124.x
   Pillans PI, 1995, NZ MED J, V108, P832
   ROSA G, 1995, ACTA ANAESTH SCAND, V39, P90, DOI 10.1111/j.1399-6576.1995.tb05598.x
   Rosa G, 1997, ARCH INTERN MED, V157, P1589, DOI 10.1001/archinte.157.14.1589
   ROSLAND JH, 1990, J PHARM PHARMACOL, V42, P437, DOI 10.1111/j.2042-7158.1990.tb06587.x
   SARMA V, 1991, ANAESTHESIA, V46, P460, DOI 10.1111/j.1365-2044.1991.tb11683.x
   SESSLER DI, 1990, ANESTHESIOLOGY, V72, P816, DOI 10.1097/00000542-199005000-00008
   SESSLER DI, 1988, ANESTHESIOLOGY, V68, P843, DOI 10.1097/00000542-198806000-00003
   SIA S, 1998, BRIT J ANAESTH, V80, P121
   STRIEBEL HW, 1993, ANAESTHESIST, V42, P131
   Tempia A, 1992, Minerva Anestesiol, V58, P547
   TRYBA M, 1991, ANESTHESIOLOGY, V75, pA1085
   Vanderstappen I, 1996, ANAESTHESIA, V51, P351, DOI 10.1111/j.1365-2044.1996.tb07747.x
   Wrench IJ, 1997, ANAESTHESIA, V52, P32, DOI 10.1111/j.1365-2044.1997.006-az006.x
NR 30
TC 41
Z9 45
U1 2
U2 12
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0003-2409
EI 1365-2044
J9 ANAESTHESIA
JI Anaesthesia
PD JUL
PY 1999
VL 54
IS 7
BP 695
EP 699
DI 10.1046/j.1365-2044.1999.00849.x
PG 5
WC Anesthesiology
SC Anesthesiology
GA 221BB
UT WOS:000081703400016
PM 10417466
OA Bronze
DA 2018-12-27
ER

PT J
AU Fujii, Y
   Saitoh, Y
   Tanaka, H
   Toyooka, H
AF Fujii, Y
   Saitoh, Y
   Tanaka, H
   Toyooka, H
TI RETRACTED: Combination of granisetron and droperidol for the prevention
   of vomiting after paediatric strabismus surgery (Retracted article. See
   vol. 23, pg. 378, 2013)
SO PAEDIATRIC ANAESTHESIA
LA English
DT Article; Retracted Publication
DE vomiting; antiemetics; granisetron; droperidol; surgery; strabismus
   repair
ID POSTOPERATIVE NAUSEA; RECEPTOR ANTAGONIST; CHILDREN
AB This study was undertaken to compare the efficacy of granisetron plus droperidol with each antiemetic alone for the prevention of vomiting after paediatric strabismus surgery. In a prospective, randomized, double-blinded trial, 120 ASA physical status I children, aged 4-10 years, received granisetron 40 mu g.kg(-1), droperidol 50 mu g.kg(-1), granisetron 40 mu g.kg(-1) plus droperidol 50 mu g.kg(-1) (n = 40 of each) intravenously after an inhalation induction of anaesthesia. A complete response, defined as no vomiting, no retching and no need for another rescue antiemetic medication, curing 0-3 h after anaesthesia was 80% with granisetron, 45% with droperidol and 98% with granisetron plus droperidol, respectively; the corresponding incidence during 3-24 h after anaesthesia was 78%, 38% and 98% (P < 0.05; overall chi-squared test with Yates continuity correction). No clinically important adverse events were observed in any of the groups. In conclusion, a, combination of granisetron and droperidol was more effective than granisetron or droperidol as a sole antiemetic for the prevention of postoperative vomiting in children undergoing strabismus repair.
C1 Univ Tsukuba, Inst Clin Med, Dept Anaesthesiol, Tsukuba, Ibaraki 305, Japan.
   Tokyo Med & Dent Univ, Sch Med, Dept Anaesthesiol & Crit Care Med, Bunkyo Ku, Tokyo 113, Japan.
   Toride Kyodo Gen Hosp, Dept Anaesthesiol, Toride, Ibaraki, Japan.
RP Fujii, Y (reprint author), Univ Tsukuba, Inst Clin Med, Dept Anaesthesiol, 2-1-1 Amakubo, Tsukuba, Ibaraki 305, Japan.
CR ABRAMOWITZ MD, 1983, ANESTHESIOLOGY, V59, P579, DOI 10.1097/00000542-198312000-00021
   Andrews PL, 1992, EJC SUPPL, V28A, P2
   BERMUDEZ J, 1988, BRIT J CANCER, V58, P644, DOI 10.1038/bjc.1988.277
   CARMICHAEL J, 1989, CANCER CHEMOTH PHARM, V24, P45
   Fujii Y, 1998, ANESTH ANALG, V86, P613, DOI 10.1097/00000539-199803000-00033
   Fujii Y, 1996, CAN J ANAESTH, V43, P660, DOI 10.1007/BF03017947
   Fujii Y, 1996, CAN J ANAESTH, V43, P35, DOI 10.1007/BF03015955
   Furue H, 1990, J CLIN THERAPEUTIC M, V6, P49
   LERMAN J, 1995, CAN J ANAESTH, V42, P263, DOI 10.1007/BF03010699
   LERMAN J, 1986, ANESTHESIOLOGY, V65, P322
   ROWBOTHAM DJ, 1992, BRIT J ANAESTH, V69, pS46, DOI 10.1093/bja/69.supplement_1.46S
   TRAMER M, 1995, BRIT J ANAESTH, V75, P556, DOI 10.1093/bja/75.5.556
   WARNER LO, 1988, ANESTHESIOLOGY, V68, P618, DOI 10.1097/00000542-198804000-00026
   WATCHA MF, 1992, ANESTHESIOLOGY, V77, P162, DOI 10.1097/00000542-199207000-00023
   WHITE PF, 1993, ANESTHESIOLOGY, V78, P2, DOI 10.1097/00000542-199301000-00002
NR 15
TC 10
Z9 10
U1 3
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1155-5645
J9 PAEDIATR ANAESTH
JI Paediatr. Anaesth.
PD JUL
PY 1999
VL 9
IS 4
BP 329
EP 333
DI 10.1046/j.1460-9592.1999.00376.x
PG 5
WC Anesthesiology; Pediatrics
SC Anesthesiology; Pediatrics
GA 214MD
UT WOS:000081331000009
PM 10411769
DA 2018-12-27
ER

PT J
AU Dhillon, HS
   Prasad, RM
AF Dhillon, HS
   Prasad, RM
TI RETRACTED: Kynurenate attenuates the accumulation of diacylglycerol and
   free fatty acids after experimental brain injury in the rat (Retracted
   Article. See vol 965, pg 299, 2003)
SO BRAIN RESEARCH
LA English
DT Article; Retracted Publication
DE fluid percussion brain injury; excitatory amino acid receptor;
   diacylglycerol; free fatty acid; rat
ID SIGNAL-TRANSDUCTION PATHWAY; EXCITATORY AMINO-ACIDS;
   PHOSPHATIDYLINOSITOL BISPHOSPHATE; ARACHIDONIC-ACID; NEURONAL INJURY;
   CEREBRAL EDEMA; RECEPTOR; ACTIVATION; ANTAGONIST; PERMEABILITY
AB This study examined the effects of the administration of kynurenate, a non-specific excitatory amino acid (EAA) receptor subtype antagonist, on the regional accumulation of diacylglycerol (DG) and free fatty acids (FFAs) after lateral fluid percussion (FP) brain injury in the rat. After brain injury of moderate severity (2.0 atm), rats were treated with either kynurenate (200 mg/kg, i.v.) or saline at 5 min after injury. In the saline-treated brain-injured rats, levels of all individual DG-fatty acids (palmitic, stearic, oleic and arachidonic acids) and total DG-fatty acids were increased in the ipsilateral left cortex and hippocampus at 30 min and 60 min after injury. Kynurenate administration attenuated increases of individual and total DG-fatty acids in the ipsilateral cortex at 30 and 60 min and in the ipsilateral hippocampus at 30 min after FP brain injury. At 30 and 60 min after FP brain injury, increases in the levels of individual FFAs (palmitic, stearic, oleic and arachidonic acids) and of total FFAs were also observed in the ipsilateral cortex and hippocampus of the saline-treated injured rats. Kynurenate administration attenuated increases of all individual and total FFAs in the ipsilateral cortex and hippocampus either at 30 min alone or at both 30 min and 60 min after FP brain injury. In the contralateral cortex, levels of both DG-fatty acids and FFAs were not increased in the saline-treated injured rats and were also not affected by the administration of kynurenate. These results support the role of EAA receptor subtypes in the phospholipases-catalyzed formation of DG and FFAs in the ipsilateral cortex and hippocampus after lateral FP brain injury. (C) 1999 Elsevier Science B.V. All rights reserved.
C1 Univ Kentucky, Albert B Chandler Med Ctr, Dept Surg, Lexington, KY 40536 USA.
RP Prasad, RM (reprint author), Univ Kentucky, Albert B Chandler Med Ctr, Dept Surg, Lexington, KY 40536 USA.
FU NINDS NIH HHS [NS 34264]
CR BABA T, 1991, J CEREBR BLOOD F MET, V11, P638, DOI 10.1038/jcbfm.1991.115
   Bazan N G, 1976, Adv Exp Med Biol, V72, P317
   CHAN PH, 1984, FED PROC, V43, P210
   COOPER PR, 1985, CENTRAL NERVOUS SYST, P217
   DELAHUNTY TM, 1992, BRAIN RES, V594, P307, DOI 10.1016/0006-8993(92)91140-A
   Dhillon HS, 1996, J NEUROTRAUM, V13, P781, DOI 10.1089/neu.1996.13.781
   DHILLON HS, 1994, J NEUROTRAUM, V11, P405, DOI 10.1089/neu.1994.11.405
   Dhillon HS, 1997, EXP NEUROL, V146, P240, DOI 10.1006/exnr.1997.6524
   DHILLON HS, 1995, BRAIN RES, V698, P100, DOI 10.1016/0006-8993(95)00840-M
   Dhillon HS, 1995, J NEUROTRAUM, V12, P1035, DOI 10.1089/neu.1995.12.1035
   FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056
   FRANDSEN A, 1993, J NEUROCHEM, V60, P1202, DOI 10.1111/j.1471-4159.1993.tb03278.x
   GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704
   GONG QZ, 1995, BRAIN RES, V700, P299, DOI 10.1016/0006-8993(95)01081-6
   GORMAN LK, 1989, J NEUROTRAUM, V6, P203
   Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259
   HAYES RL, 1992, J NEUROTRAUM, V9, pS173
   Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421
   HICKS RR, 1995, BRAIN RES, V678, P151, DOI 10.1016/0006-8993(95)00179-T
   Homayoun P, 1997, J NEUROCHEM, V69, P199
   HOVDA DA, 1992, J NEUROTRAUM, V9, pS7
   Kampfl A, 1997, J NEUROTRAUM, V14, P121, DOI 10.1089/neu.1997.14.121
   Kampfl A, 1996, J NEUROCHEM, V67, P1575
   KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889
   KATSURA K, 1993, J NEUROCHEM, V61, P1677, DOI 10.1111/j.1471-4159.1993.tb09803.x
   KAWAMATA T, 1995, BRAIN RES, V674, P196, DOI 10.1016/0006-8993(94)01444-M
   Lyeth BG, 1996, BRAIN RES, V742, P63, DOI 10.1016/S0006-8993(96)01002-5
   MCINTOSH TK, 1990, J NEUROCHEM, V55, P1170, DOI 10.1111/j.1471-4159.1990.tb03122.x
   McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247
   Mukhin A, 1996, J NEUROSCI, V16, P6012
   NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115
   Okiyama K, 1998, BRAIN RES, V792, P291, DOI 10.1016/S0006-8993(98)00158-9
   PADMAPERUMA B, 1995, NEUROSCI RES COMMUN, V16, P121
   PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x
   PRASAD MR, 1994, J NEUROCHEM, V63, P773
   Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010
   SIMON RP, 1986, NEUROSCI LETT, V71, P361, DOI 10.1016/0304-3940(86)90648-8
   SMITH DH, 1993, J NEUROSCI, V13, P5383
   SOARES HD, 1992, J NEUROCHEM, V58, P1845, DOI 10.1111/j.1471-4159.1992.tb10061.x
   TAFT WC, 1992, J NEUROTRAUM, V9, P281, DOI 10.1089/neu.1992.9.281
   UNTERBERG A, 1987, ACTA NEUROPATHOL, V73, P209, DOI 10.1007/BF00686613
   WEI EP, 1982, J NEUROSURG, V56, P695, DOI 10.3171/jns.1982.56.5.0695
NR 42
TC 5
Z9 5
U1 3
U2 9
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0006-8993
EI 1872-6240
J9 BRAIN RES
JI Brain Res.
PD JUN 19
PY 1999
VL 832
IS 1-2
BP 7
EP 12
DI 10.1016/S0006-8993(99)01437-7
PG 6
WC Neurosciences
SC Neurosciences & Neurology
GA 209UG
UT WOS:000081066800002
PM 10375646
DA 2018-12-27
ER

PT J
AU Liaw, UH
   Su, YK
AF Liaw, UH
   Su, YK
TI RETRACTED: 1/f noise measurements on indium antimonide
   metal-oxide-semiconductor field-effect transistors (Retracted article.
   See vol. 109, artn no. 109905, 2011)
SO JOURNAL OF APPLIED PHYSICS
LA English
DT Article; Retracted Publication
ID FLICKER NOISE; PHOTO-DIODES; HG1-XCDXTE; JUNCTIONS; SILICON
AB We performed the 1/f noise measurements on n-channel indium antimonide (InSb) metal-oxide-semiconductor field-effect transistors (MOSFETs) biased in linear and saturation regions operated at 77 K. Through the investigation of the dependence of drain voltage noise power spectral density on gate and drain bias, we have estimated the oxide-semiconductor interface trap density as a function of energy. In this analysis, both the noise magnitude and the spectral shape were studied. In this study, the frequency span was performed from 150 Hz to 5 kHz. The noise behavior of the device was modeled using the modified McWhorter Model, originally developed for silicon FETs. The interface trap concentration values computed from the low-frequency noise measurements using the previous model were found to agree closely with InSb/SiO2 interface properties measured by capacitance and conductance methods. (C) 1999 American Institute of Physics. [S0021-8979(99)05911-3].
C1 Natl Cheng Kung Univ, Dept Elect Engn, Tainan 70101, Taiwan.
RP Liaw, UH (reprint author), Natl Cheng Kung Univ, Dept Elect Engn, 1 Univ Rd, Tainan 70101, Taiwan.
CR ANDERSON WW, 1983, J VAC SCI TECHNOL A, V1, P1730, DOI 10.1116/1.572213
   BAJAJ J, 1985, J VAC SCI TECHNOL A, V3, P192, DOI 10.1116/1.573198
   CELIK Z, 1985, IEEE T ELECTRON DEV, V32, P2797, DOI 10.1109/T-ED.1985.22418
   CELIKBUTLER Z, 1986, PHYS REV B, V33, P4898
   CHRISTEN.S, 1968, SOLID STATE ELECTRON, V11, P797, DOI 10.1016/0038-1101(68)90100-7
   CHUNG HK, 1985, J VAC SCI TECHNOL A, V3, P189, DOI 10.1116/1.573196
   HANAFI HI, 1978, PHYSICA B & C, V94, P351, DOI 10.1016/0378-4363(78)90041-4
   HANAFI HI, 1978, SOLID STATE ELECTRON, V21, P1019, DOI 10.1016/0038-1101(78)90178-8
   HANDEL PH, 1983, NOISE PHYSICAL SYSTE, P97
   HASLETT JW, 1972, SOLID STATE ELECTRON, V15, P117, DOI 10.1016/0038-1101(72)90072-X
   HSU ST, 1970, SOLID STATE ELECTRON, V13, P843, DOI 10.1016/0038-1101(70)90070-5
   Hung K. K., 1988, International Electron Devices Meeting. Technical Digest (IEEE Cat. No.88CH2528-8), P34, DOI 10.1109/IEDM.1988.32743
   JAYARAMAN R, 1989, IEEE T ELECTRON DEV, V36, P1773, DOI 10.1109/16.34242
   Kingston R H, 1957, SEMICONDUCTOR SURFAC
   KLEINPENNING TGM, 1985, J VAC SCI TECHNOL A, V3, P176, DOI 10.1116/1.573194
   RADFORD WA, 1985, J VAC SCI TECHNOL A, V3, P183, DOI 10.1116/1.573195
   SHARMA RN, 1969, THESIS U MINNESOTA
   SU YK, 1994, J APPL PHYS, V76, P4719, DOI 10.1063/1.357265
   SU YK, 1991, SOLID STATE ELECTRON, V34, P107, DOI 10.1016/0038-1101(91)90207-F
   SURYA C, 1987, PHYS REV B, V35, P6343, DOI 10.1103/PhysRevB.35.6343
   TOBIN SP, 1980, IEEE T ELECTRON DEV, V27, P43, DOI 10.1109/T-ED.1980.19817
   TU SL, 1989, JPN J APPL PHYS 2, V28, pL1874, DOI 10.1143/JJAP.28.L1874
   VANDERZIEL A, 1979, APPL PHYS LETT, V35, P942, DOI 10.1063/1.91014
   WU XL, 1987, IEEE T ELECTRON DEV, V34, P1971
   YANG MJ, 1989, APPL PHYS LETT, V54, P265, DOI 10.1063/1.100985
NR 25
TC 5
Z9 5
U1 3
U2 9
PU AMER INST PHYSICS
PI MELVILLE
PA 1305 WALT WHITMAN RD, STE 300, MELVILLE, NY 11747-4501 USA
SN 0021-8979
EI 1089-7550
J9 J APPL PHYS
JI J. Appl. Phys.
PD JUN 15
PY 1999
VL 85
IS 12
BP 8485
EP 8489
DI 10.1063/1.370630
PG 5
WC Physics, Applied
SC Physics
GA 200AR
UT WOS:000080517000069
DA 2018-12-27
ER

PT J
AU Fujii, Y
   Saitoh, Y
   Tanaka, H
   Toyooka, H
AF Fujii, Y
   Saitoh, Y
   Tanaka, H
   Toyooka, H
TI RETRACTED: Preoperative oral antiemetics for reducing postoperative
   vomiting after tonsillectomy in children: Granisetron versus
   perphenazine (Retracted article. See vol. 116, pg. 744, 2013)
SO ANESTHESIA AND ANALGESIA
LA English
DT Article; Retracted Publication
ID RECEPTOR ANTAGONIST; STRABISMUS SURGERY; ONDANSETRON; PREVENTION;
   EMESIS; NAUSEA
AB In a prospective, randomized, double-blinded trial, we evaluated the efficacy of two antiemetics given orally, granisetron and perphenazine, for preventing postoperative vomiting after tonsillectomy with or without adenoidectomy in children. One hundred pediatric patients, ASA physical status I, aged 4-10 yr, received either granisetron 40 mu g/kg or perphenazine 70 mu g/kg (n = 50 each) orally 1 h before surgery. We used a standard general anesthetic technique. The rate of complete response, defined as no emesis and no need for rescue antiemetic medication, during 0-3 h after anesthesia was 86% with granisetron and 60% with perphenazine; the corresponding rate 3-24 h after anesthesia was 86% and 62%, respectively (P < 0.05). No serious adverse events were observed in any of the groups. In conclusion, preoperative oral granisetron is more effective than perphenazine for preventing postoperative vomiting in children undergoing tonsillectomy with or without adenoidectomy. Implications: We compared the efficacy of granisetron and perphenazine given orally for preventing postoperative vomiting after tonsillectomy with or without adenoidectomy in children. Preoperative oral granisetron was more effective than perphenazine.
C1 Univ Tsukuba, Inst Clin Med, Dept Anesthesiol, Tsukuba, Ibaraki 305, Japan.
   Toride Kyodo Gen Hosp, Dept Anesthesiol, Toride, Ibaraki, Japan.
RP Fujii, Y (reprint author), Univ Tsukuba, Inst Clin Med, Dept Anesthesiol, 2-1-1 Amakubo, Tsukuba, Ibaraki 305, Japan.
CR ANDREWS PLR, 1992, EJC SUPPL, V28, P52
   ASPINALL RL, 1995, BRIT MED J, V311, P844, DOI 10.1136/bmj.311.7009.844
   BERMUDEZ J, 1988, BRIT J CANCER, V58, P644, DOI 10.1038/bjc.1988.277
   CARITHERS JS, 1987, LARYNGOSCOPE, V97, P422
   CARMICHAEL J, 1989, CANCER CHEMOTH PHARM, V24, P45
   Fujii Y, 1998, BRIT J ANAESTH, V81, P390, DOI 10.1093/bja/81.3.390
   Fujii Y, 1996, CAN J ANAESTH, V43, P660, DOI 10.1007/BF03017947
   Fujii Y, 1996, CAN J ANAESTH, V43, P35, DOI 10.1007/BF03015955
   FURST SR, 1994, ANESTHESIOLOGY, V81, P799, DOI 10.1097/00000542-199410000-00005
   LITMAN RS, 1994, ANESTH ANALG, V78, P478
   Maisano R, 1995, ANTICANCER RES, V15, P2287
   NAGANUMA G, 1962, NEW REMEDIES THER, V64, P14
   Splinter WM, 1998, BRIT J ANAESTH, V80, P155, DOI 10.1093/bja/80.2.155
   TRAMER M, 1995, BRIT J ANAESTH, V75, P556, DOI 10.1093/bja/75.5.556
   WATCHA MF, 1992, ANESTHESIOLOGY, V77, P162, DOI 10.1097/00000542-199207000-00023
NR 15
TC 9
Z9 10
U1 1
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0003-2999
J9 ANESTH ANALG
JI Anesth. Analg.
PD JUN
PY 1999
VL 88
IS 6
BP 1298
EP 1301
DI 10.1097/00000539-199906000-00018
PG 4
WC Anesthesiology
SC Anesthesiology
GA 199VV
UT WOS:000080505500018
PM 10357333
OA Bronze
DA 2018-12-27
ER

PT J
AU Fujii, Y
   Saitoh, Y
   Tanaka, H
   Toyooka, H
AF Fujii, Y
   Saitoh, Y
   Tanaka, H
   Toyooka, H
TI RETRACTED: Granisetron dexamethasone combination for reducing nausea and
   vomiting during and after spinal anesthesia for cesarean section
   (Retracted article. See vol. 116, pg. 744, 2013)
SO ANESTHESIA AND ANALGESIA
LA English
DT Article; Retracted Publication
ID ANTIEMETIC EFFICACY; POSTOPERATIVE NAUSEA; EPIDURAL-ANESTHESIA; RECEPTOR
   ANTAGONIST; DOUBLE-BLIND; METOCLOPRAMIDE; ONDANSETRON; DROPERIDOL;
   PREVENTION
AB We compared the efficacy of granisetron plus dexamethasone with that of granisetron alone for preventing nausea and vomiting in parturients undergoing cesarean section under spinal anesthesia. In a randomized, double-blinded manner, 120 patients received either granisetron 3 mg (Group I, n = 60) or granisetron 3 mg plus dexamethasone 8 mg (Group II, n = 60) TV immediately after clamping of the fetal umbilical cord. A complete response, defined as no emetic symptoms and no need for another rescue antiemetic medication in the intraoperative, postdelivery period was 83% in Group I and 98% in Group II (P = 0.008); the corresponding rates during the first 24 h after surgery was 85% and 98% (P = 0.016). No clinically serious adverse events were observed in any of the groups. In conclusion, the prophylactic use of a granisetron/dexamethasone combination is more effective than granisetron alone for reducing nausea and vomiting in patients during and after spinal anesthesia for cesarean section. Implications: Intraoperative, postdelivery, and postoperative nausea and vomiting are distressing to patients undergoing cesarean section under spinal anesthesia. The combination of granisetron plus dexamethasone was evaluated and found to be effective for preventing these emetic symptoms.
C1 Univ Tsukuba, Inst Clin Med, Dept Anesthesiol, Tsukuba, Ibaraki 305, Japan.
   Toride Kyodo Gen Hosp, Dept Anesthesiol, Toride, Ibaraki, Japan.
RP Fujii, Y (reprint author), Univ Tsukuba, Inst Clin Med, Dept Anesthesiol, 2-1-1 Amakubo, Tsukuba, Ibaraki 305, Japan.
CR AAPRO MS, 1984, J CLIN ONCOL, V2, P466, DOI 10.1200/JCO.1984.2.5.466
   Andrews PL, 1992, EJC SUPPL, V28A, P2
   ASPINALL RL, 1995, BRIT MED J, V311, P844, DOI 10.1136/bmj.311.7009.844
   BERMUDEZ J, 1988, BRIT J CANCER, V58, P644, DOI 10.1038/bjc.1988.277
   CARMICHAEL J, 1989, CANCER CHEMOTH PHARM, V24, P45
   CHESTNUT DH, 1987, ANESTHESIOLOGY, V66, P563, DOI 10.1097/00000542-198704000-00022
   DATTA S, 1982, ANESTHESIOLOGY, V56, P68, DOI 10.1097/00000542-198201000-00019
   Fujii Y, 1998, ACTA ANAESTH SCAND, V42, P312, DOI 10.1111/j.1399-6576.1998.tb04922.x
   Fujii Y, 1998, ACTA ANAESTH SCAND, V42, P921, DOI 10.1111/j.1399-6576.1998.tb05350.x
   LERMAN J, 1995, CAN J ANAESTH, V42, P263, DOI 10.1007/BF03010699
   LUSSOS SA, 1992, REGION ANESTH, V17, P126
   Pan PH, 1996, ANESTH ANALG, V83, P982, DOI 10.1097/00000539-199611000-00014
   Patra CK, 1972, BRIT J ANAESTH, V44, P1208
   SANTOS A, 1984, ANESTH ANALG, V63, P85
   SMITH DB, 1991, LANCET, V338, P487, DOI 10.1016/0140-6736(91)90555-4
   WATCHA MF, 1992, ANESTHESIOLOGY, V77, P162, DOI 10.1097/00000542-199207000-00023
   Watcha MF, 1997, ANESTHESIOLOGY, V86, P1170, DOI 10.1097/00000542-199705000-00021
   WHITE PF, 1993, ANESTHESIOLOGY, V78, P2, DOI 10.1097/00000542-199301000-00002
NR 18
TC 27
Z9 29
U1 4
U2 12
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0003-2999
J9 ANESTH ANALG
JI Anesth. Analg.
PD JUN
PY 1999
VL 88
IS 6
BP 1346
EP 1350
DI 10.1097/00000539-199906000-00028
PG 5
WC Anesthesiology
SC Anesthesiology
GA 199VV
UT WOS:000080505500028
PM 10357343
OA Bronze
DA 2018-12-27
ER

PT J
AU Khalil, S
   Elrabiehi, MM
AF Khalil, S
   Elrabiehi, MM
TI RETRACTED: Bromhexine-selective PVC membrane electrode based on
   bromhexinium tetraphenylborate (Retracted article. See vol. 96, pg. 422,
   2010)
SO MICROCHEMICAL JOURNAL
LA English
DT Article; Retracted Publication
DE bromhexine-selective electrode; response characteristics; selectivity
   coefficients
ID POTENTIOMETRIC TITRATION; HYDROCHLORIDE; ASSAY
AB A bromhexine ion-selective PVC membrane electrode based on bromhexinium tetraphenylborate has been prepared with dioctyl phthalate as plasticizer. The electrode showed a linear response with a slope factor of 57.5 mV/concentration decade at 20 degrees C over the concentration range from 4 X 10(-4) to 10(-1) M bromhexine. The effects of membrane composition, pH of the test solution, and the time of soaking on the electrode performance were studied. The electrode exhibited good selectivity for bromhexine with respect to a large number of inorganic cations and organic substances of biological importance. The standard addition method and potentiometric titrations were used to determine bromhexine concentrations in pure solutions and in a pharmaceutical preparation, with satisfactory results. (C) 1999 Academic Press.
C1 Cairo Univ, Fac Sci, Dept Chem, Faoyum Branch, Al Fayyum 63514, Egypt.
RP Khalil, S (reprint author), Teachers Coll Riyadh, Dept Chem, POB 4341, Riyadh 11491, Saudi Arabia.
CR ANZAI J, 1985, CHEM PHARM BULL, V33, P236
   ARAFAT T, 1990, ANAL LETT, V23, P311, DOI 10.1080/00032719008052446
   BADAWY SS, 1986, ANALYST, V111, P1363, DOI 10.1039/an9861101363
   BOWTLE WJ, 1981, ANALYST, V106, P478, DOI 10.1039/an9810600478
   Chi H, 1983, Yao Xue Xue Bao, V18, P278
   CHRISTOPOULOS TK, 1982, ANAL CHIM ACTA, V143, P143, DOI 10.1016/S0003-2670(01)95494-7
   COSOFRET VV, 1984, ANALYST, V109, P1321, DOI 10.1039/an9840901321
   DELAPUERTA CN, 1985, ANAL LETT, V18, P1887
   DELEENHEER AP, 1979, J PHARM SCI, V68, P999, DOI 10.1002/jps.2600680821
   DELEENHEER AP, 1979, J CHROMATOGR, V301, P1775
   DHINGBAL DM, 1985, INDIAN DRUGS, V22, P275
   EMMANUEL J, 1985, Indian Drugs, V22, P387
   GALA B, 1993, ANAL LETT, V26, P2607, DOI 10.1080/00032719308017978
   JONCKHEERE JAA, 1980, BIOMED MASS SPECTROM, V7, P582, DOI 10.1002/bms.1200071127
   KUMAR JL, 1982, J CHROMATOGR, V249, P373, DOI 10.1016/S0021-9673(00)86347-5
   LAU OW, 1990, ANALYST, V115, P1349, DOI 10.1039/an9901501349
   PALOMAR JC, 1983, ANAL LETT, V16, P237
   SANGHAVI NM, 1990, INDIAN DRUGS, V27, P486
   SANTORO MIRM, 1984, J ASSOC OFF ANA CHEM, V67, P532
   SHINGBAL D M, 1987, Indian Drugs, V24, P311
   SHINGBAL DM, 1987, INDIAN DRUGS, V24, P417
   YAO S, 1984, YAOWU FENXI ZAZHI, V4, P281
NR 22
TC 7
Z9 7
U1 4
U2 12
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0026-265X
EI 1095-9149
J9 MICROCHEM J
JI Microchem J.
PD JUN
PY 1999
VL 62
IS 2
BP 237
EP 243
DI 10.1006/mchj.1999.1723
PG 7
WC Chemistry, Analytical
SC Chemistry
GA 201XH
UT WOS:000080621800003
DA 2018-12-27
ER

PT J
AU Taub, J
   Lau, JF
   Ma, C
   Hahn, JH
   Hoque, R
   Rothblatt, J
   Chalfie, M
AF Taub, J
   Lau, JF
   Ma, C
   Hahn, JH
   Hoque, R
   Rothblatt, J
   Chalfie, M
TI RETRACTED: A cytosolic catalase is needed to extend adult lifespan in
   C-elegans daf-C and clk-1 mutants (Retracted Article. See, vol 421, pg
   764, 2003)
SO NATURE
LA English
DT Article; Retracted Publication
ID CAENORHABDITIS-ELEGANS; GUINEA-PIG; CYTOCHEMICAL DEMONSTRATION;
   OXIDATIVE STRESS; FAMILY-MEMBER; LONGEVITY; LIVER; GENE; OVEREXPRESSION;
   PEROXISOMES
AB The dauer larva is an alternative larval stage in Caenorhabditis elegans which allows animals to survive through periods of low food availability. Well-fed worms live for about three weeks, but dauer larvae can live for at least two months without affecting post-dauer lifespan(1). Mutations in daf-2 and age-1, which produce a dauer constitutive (Daf-C) phenotype, and in clk-1, which are believed to slow metabolism, markedly increase adult lifespan(2). Here we show that a ctl-1 mutation reduces adult lifespan in otherwise wild-type animals and eliminates the daf-c and clk-1-mediated extension of adult lifespan. ctl-1 encodes an unusual cytosolic catalase; a second gene, ctl-2, encodes a peroxisomal catalase. ctl-1 messenger RNA is increased in dauer larvae and adults with the daf-c mutations. We suggest that the ctl-1 catalase is needed during periods of starvation, as in the dauer larva, and that its misexpression in daf-c and clk-1 adults extends lifespan. Cytosolic catalase may have evolved to protect nematodes from oxidative damage produced during prolonged dormancy before reproductive maturity, or it may represent a general mechanism for permitting organisms to cope with the metabolic changes that accompany starvation.
C1 Columbia Univ, Dept Biol Sci, New York, NY 10027 USA.
   Dartmouth Coll, Dept Biol Sci, Gilman Lab 6044, Hanover, NH 03755 USA.
RP Chalfie, M (reprint author), Columbia Univ, Dept Biol Sci, 1212 Amsterdam Ave, New York, NY 10027 USA.
EM mc21@columbia.edu
CR AMSTAD P, 1991, BIOCHEMISTRY-US, V30, P9305, DOI 10.1021/bi00102a024
   Beckman KB, 1998, PHYSIOL REV, V78, P547
   BISSINGER PH, 1989, MOL CELL BIOL, V9, P1309, DOI 10.1128/MCB.9.3.1309
   Bulitta C, 1996, BBA-PROTEIN STRUCT M, V1293, P55, DOI 10.1016/0167-4838(95)00241-3
   Ewbank JJ, 1997, SCIENCE, V275, P980, DOI 10.1126/science.275.5302.980
   GOULD SJ, 1989, J CELL BIOL, V108, P1657, DOI 10.1083/jcb.108.5.1657
   HOSOKAWA H, 1994, MECH AGEING DEV, V74, P161, DOI 10.1016/0047-6374(94)90087-6
   KENYON C, 1997, C ELEGANS, V2, P791
   Kimura KD, 1997, SCIENCE, V277, P942, DOI 10.1126/science.277.5328.942
   KIRKWOOD TBL, 1991, PHILOS T R SOC B, V332, P15, DOI 10.1098/rstb.1991.0028
   LARSEN PL, 1995, GENETICS, V139, P1567
   Lin K, 1997, SCIENCE, V278, P1319, DOI 10.1126/science.278.5341.1319
   Loewen PC, 1997, OXIDATIVE STRESS MOL, P273
   MASORO EJ, 1991, ANN NY ACAD SCI, V621, P337
   Mello C, 1995, METHOD CELL BIOL, V48, P451
   Morris JZ, 1996, NATURE, V382, P536, DOI 10.1038/382536a0
   Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194
   ORR WC, 1994, SCIENCE, V263, P1128, DOI 10.1126/science.8108730
   Parkes TL, 1998, NAT GENET, V19, P171, DOI 10.1038/534
   PETERS TJ, 1972, J EXP MED, V136, P1117, DOI 10.1084/jem.136.5.1117
   Riddle DL, 1997, C ELEGANS, P739
   ROELS F, 1976, J HISTOCHEM CYTOCHEM, V24, P713, DOI 10.1177/24.6.950458
   ROELS F, 1977, J HISTOCHEM CYTOCHEM, V25, P157, DOI 10.1177/25.2.65420
   Ruis H., 1997, OXIDATIVE STRESS MOL, P309
   Sambrook J., 1989, MOL CLONING LAB MANU
   Scandalios JG, 1997, OXIDATIVE STRESS MOL, P343
   Sulston J. H., 1988, NEMATODE CAENORHABDI, P587
   VANFLETEREN JR, 1993, BIOCHEM J, V292, P605, DOI 10.1042/bj2920605
   WATERSTON R, 1992, NAT GENET, V1, P114, DOI 10.1038/ng0592-114
   YAMAMOTO K, 1988, EUR J CELL BIOL, V46, P129
NR 30
TC 188
Z9 201
U1 2
U2 17
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
J9 NATURE
JI Nature
PD MAY 13
PY 1999
VL 399
IS 6732
BP 162
EP 166
PG 5
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 196XU
UT WOS:000080335700053
PM 10335847
DA 2018-12-27
ER

PT J
AU Moneta, M
AF Moneta, M
TI RETRACTED: Energy loss of slow H- to Be-like ions in electron gas
   (Retracted Article. See Vol. 240, p. 665, 2003)
SO PHYSICA STATUS SOLIDI B-BASIC SOLID STATE PHYSICS
LA English
DT Article; Retracted Publication
ID PROJECTILES; COLLISIONS; CHARGE
AB The electronic stopping power and the energy loss straggling of low velocity H-, He-, Li- and Belike ions in the degenerate electron gas were calculated. The Hartree-Fock-Slater description of the ion and the dielectric function method were used. The stopping and straggling effective charges Z(eff) Of an ion were analysed. They are found to differ with each other and to depend on the electron gas density r(s), on the ion atomic number Z(i) and on N-i, the number of electrons carried by the ion.
C1 Univ Lodz, Katedra Fizyki Ciala Stalego, PL-90236 Lodz, Poland.
RP Moneta, M (reprint author), Univ Lodz, Katedra Fizyki Ciala Stalego, Pomorska 149, PL-90236 Lodz, Poland.
EM moneta@krysia.uni.lodz.pl
OI Moneta, Marek/0000-0002-3316-7371
CR CRAWFORD OH, 1989, PHYS REV A, V39, P4432, DOI 10.1103/PhysRevA.39.4432
   DEUTSCH C, 1989, PHYS REV A, V40, P3209, DOI 10.1103/PhysRevA.40.3209
   Firsov O.B., 1959, Zhurnal Eksperimental'noi i Teoreticheskoi Fiziki, V36, P1517
   HVELPLUND P, 1971, K DANSKE VID SELSK M, V38
   LINDHARD J, 1954, K DANSKE VID SELSK M, V28
   LINDHARD J, 1971, PHYS REV A, V4, P562
   LINDHARD J, 1953, K DANSKE VID SELSK M, V27
   LINDHARD J, 1964, K DANSKE VID SELSK M, V34
   McGuire EJ, 1998, PHYS REV A, V57, P2758, DOI 10.1103/PhysRevA.57.2758
   Moneta M, 1996, NUCL INSTRUM METH B, V115, P340, DOI 10.1016/0168-583X(95)01550-7
   Moneta M, 1997, ACTA PHYS POL A, V92, P1169, DOI 10.12693/APhysPolA.92.1169
   Moneta M, 1998, PHYS STATUS SOLIDI B, V206, P675, DOI 10.1002/(SICI)1521-3951(199804)206:2<675::AID-PSSB675>3.0.CO;2-3
   Moneta M, 1996, ACTA PHYS POL A, V89, P581, DOI 10.12693/APhysPolA.89.581
   TILININ IS, 1995, PHYS REV A, V51, P3058, DOI 10.1103/PhysRevA.51.3058
NR 14
TC 1
Z9 1
U1 2
U2 7
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 0370-1972
EI 1521-3951
J9 PHYS STATUS SOLIDI B
JI Phys. Status Solidi B-Basic Solid State Phys.
PD MAY
PY 1999
VL 213
IS 1
BP 153
EP 161
DI 10.1002/(SICI)1521-3951(199905)213:1<153::AID-PSSB153>3.0.CO;2-1
PG 9
WC Physics, Condensed Matter
SC Physics
GA 196VV
UT WOS:000080329500013
DA 2018-12-27
ER

PT J
AU Lee, BE
   Sung, JW
   Kim, DK
   Lee, JR
   Kim, ND
   Kang, SW
   Kim, DK
AF Lee, BE
   Sung, JW
   Kim, DK
   Lee, JR
   Kim, ND
   Kang, SW
   Kim, DK
TI RETRACTED: Functional studies on the interaction between human
   replication protein A and Xeroderma pigmentosum group A complementing
   protein (XPA) (Retracted Article. See vol 13, pg 157, 2002)
SO MOLECULES AND CELLS
LA English
DT Article; Retracted Publication
DE DNA repair; DNA replication; replication protein A; Xeroderma
   pigmentosum group A complementing protein (XPA)
ID DNA-BINDING-PROTEIN; NUCLEOTIDE EXCISION-REPAIR; IN-VITRO REPLICATION;
   SIMIAN-VIRUS-40 DNA; POLYMERASE-DELTA; PURIFIED PROTEINS; 70-KDA
   SUBUNIT; DAMAGED DNA; ORIGIN; IDENTIFICATION
AB The human replication protein A (RPA; also known as human single-stranded DNA binding protein, HSSB) is a multisubunit complex (70, 34 and 11 kDa subunits) involved in the three processes of DNA metabolism; replication, repair, recombination, We found that both 34 and 70 kDa subunits (p34 and p70, respectively), of RPA interacts with the Xeroderma pigmentosum group A complementing protein (XPA), a protein that specifically recognizes UV-damaged DNA, Our mutational analysis indicated that no particular domains of RPA p70 were essential for its interaction with XPA, We also examined the effect of this XPA-RPA interaction on in vitro simian virus 40 (SV40) DNA replication catalyzed by the crude extract and monopolymerase system. XPA inhibited SV40 DNA replication in vitro through its interaction with RPA, Taken together, these results suggest that there is a role for RPA in the regulation of DNA metabolism through its ability to modulate the interactions of proteins involved in the processes of DNA metabolism.
C1 Inje Univ, Dept Chem, Kimhae 621749, South Korea.
   Pusan Natl Univ, Dept Chem, Pusan 609735, South Korea.
   Pusan Natl Univ, Dept Pharm, Pusan 609735, South Korea.
RP Kim, DK (reprint author), Inje Univ, Dept Chem, Kimhae 621749, South Korea.
EM chemkdg@ijnc.inje.ac.kr
CR ALANI E, 1992, J MOL BIOL, V227, P54, DOI 10.1016/0022-2836(92)90681-9
   COVERLEY D, 1991, NATURE, V349, P538, DOI 10.1038/349538a0
   COVERLEY D, 1992, NUCLEIC ACIDS RES, V20, P3873, DOI 10.1093/nar/20.15.3873
   DORNREITER I, 1992, EMBO J, V11, P769, DOI 10.1002/j.1460-2075.1992.tb05110.x
   ERDILE LF, 1991, J BIOL CHEM, V266, P12090
   FAIRMAN MP, 1988, EMBO J, V7, P1211, DOI 10.1002/j.1460-2075.1988.tb02933.x
   GOMES XV, 1995, J BIOL CHEM, V270, P4534, DOI 10.1074/jbc.270.9.4534
   GUZDER SN, 1993, P NATL ACAD SCI USA, V90, P5433, DOI 10.1073/pnas.90.12.5433
   HEYER WD, 1990, EMBO J, V9, P2321, DOI 10.1002/j.1460-2075.1990.tb07404.x
   ISHIMI Y, 1988, J BIOL CHEM, V263, P19723
   JONES CJ, 1993, BIOCHEMISTRY-US, V32, P12096, DOI 10.1021/bi00096a021
   KENNY MK, 1989, P NATL ACAD SCI USA, V86, P9757, DOI 10.1073/pnas.86.24.9757
   Kim DK, 1996, J BIOL CHEM, V271, P15124, DOI 10.1074/jbc.271.25.15124
   LEE SH, 1995, J BIOL CHEM, V270, P12801, DOI 10.1074/jbc.270.21.12801
   LEE SH, 1995, J BIOL CHEM, V270, P21800, DOI 10.1074/jbc.270.37.21800
   LEE SH, 1991, J BIOL CHEM, V266, P594
   LEE SH, 1993, NUCLEIC ACIDS RES, V21, P1935, DOI 10.1093/nar/21.8.1935
   LI L, 1995, MOL CELL BIOL, V15, P5396
   LIU LF, 1981, P NATL ACAD SCI-BIOL, V78, P3487, DOI 10.1073/pnas.78.6.3487
   MATSUDA T, 1995, J BIOL CHEM, V270, P4152, DOI 10.1074/jbc.270.8.4152
   MIURA N, 1991, J BIOL CHEM, V266, P19786
   MIYAMOTO I, 1992, J BIOL CHEM, V267, P12182
   REARDON JT, 1993, COLD SPRING HARB SYM, V58, P605, DOI 10.1101/SQB.1993.058.01.067
   STIGGER E, 1994, P NATL ACAD SCI USA, V91, P579, DOI 10.1073/pnas.91.2.579
   WOBBE CR, 1987, P NATL ACAD SCI USA, V84, P1834, DOI 10.1073/pnas.84.7.1834
   WOBBE CR, 1985, P NATL ACAD SCI USA, V82, P5710, DOI 10.1073/pnas.82.17.5710
   WOLD MS, 1988, P NATL ACAD SCI USA, V85, P2523, DOI 10.1073/pnas.85.8.2523
   WOOD RD, 1993, COLD SPRING HARB SYM, V58, P625, DOI 10.1101/SQB.1993.058.01.069
NR 28
TC 8
Z9 8
U1 0
U2 8
PU KOREAN SOC MOLECULAR & CELLULAR  BIOLOGY
PI SEOUL
PA 635-4, YUCKSAM-DONG, GANGNAM-GU, SEOUL 135-703, SOUTH KOREA
SN 1016-8478
EI 0219-1032
J9 MOL CELLS
JI Mol. Cells
PD APR 30
PY 1999
VL 9
IS 2
BP 185
EP 190
PG 6
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 193RZ
UT WOS:000080151400012
PM 10340474
DA 2018-12-27
ER

PT J
AU Aoki, N
   Kawamura, M
   Yamaguchi-Aoki, Y
   Ohira, S
   Matsuda, T
AF Aoki, N
   Kawamura, M
   Yamaguchi-Aoki, Y
   Ohira, S
   Matsuda, T
TI RETRACTED: Down-regulation of protein tyrosine phosphatase gene
   expression in lactating mouse mammary gland (Retracted article. See vol.
   154, pg. 393, 2013)
SO JOURNAL OF BIOCHEMISTRY
LA English
DT Article; Retracted Publication
DE involution; lactation; mammary gland; prolactin signaling; protein
   tyrosine phosphatase
ID PHOSPHOTYROSINE PHOSPHATASE; SEQUENCE SIMILARITY; SIGNAL-TRANSDUCTION;
   POSITIVE REGULATOR; DNA-BINDING; PROLACTIN; ACTIVATION; INVOLUTION;
   INDUCTION; KINASES
AB Detailed analysis of protein tyrosine phosphatase (PTP) expression in mouse mammary gland and mammary epithelial cells using a set of degenerate primers corresponding to the PTP core domain sequence revealed the presence of 16 different receptor-type and intracellular PTPs, Northern blot and RT-PCR analyses revealed that some PTPs were up-regulated during gestation, suggesting that these enzymes are involved in development of mammary gland. However, expression of most PTPs dramatically decreased during lactation, whereas the p-casein gene expression was increased and remained at a high level. At the involution stage after weaning, most PTPs were up-regulated and their expression returned almost to the virgin level. Such up-regulation was also induced by forced weaning in lactating mother mice. These results suggest the possible contribution of PTPs to the development, involution, and remodeling of mammary gland and their possible inhibitory action on maintaining high expression of milk genes during lactation.
C1 Nagoya Univ, Grad Sch Bioagr Sci, Dept Appl Mol Biosci, Chikusa Ku, Nagoya, Aichi 4648601, Japan.
RP Aoki, N (reprint author), Nagoya Univ, Grad Sch Bioagr Sci, Dept Appl Mol Biosci, Chikusa Ku, Furo Cho, Nagoya, Aichi 4648601, Japan.
EM naoki@agr.nagoya-u.ac.jp
CR ADACHI M, 1992, FEBS LETT, V314, P335, DOI 10.1016/0014-5793(92)81500-L
   AHMAD S, 1993, P NATL ACAD SCI USA, V90, P2197, DOI 10.1073/pnas.90.6.2197
   Ali S, 1996, EMBO J, V15, P135, DOI 10.1002/j.1460-2075.1996.tb00341.x
   Aoki N, 1996, J BIOL CHEM, V271, P29422, DOI 10.1074/jbc.271.46.29422
   ATWOOD CS, 1995, BIOCHEM BIOPH RES CO, V207, P860, DOI 10.1006/bbrc.1995.1265
   BALL RK, 1988, EMBO J, V7, P2089, DOI 10.1002/j.1460-2075.1988.tb03048.x
   Berchtold S, 1998, MOL ENDOCRINOL, V12, P556, DOI 10.1210/me.12.4.556
   CHARBONNEAU H, 1992, ANNU REV CELL BIOL, V8, P463, DOI 10.1146/annurev.cellbio.8.1.463
   Cheng J, 1996, BLOOD, V88, P1156
   Daniel C. W., 1987, The mammary gland. Development, regulation, and function., P3
   Dosil M, 1996, BLOOD, V88, P4510
   FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088
   FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239
   Fuchs M, 1996, J BIOL CHEM, V271, P16712, DOI 10.1074/jbc.271.28.16712
   GOUILLEUX F, 1994, EMBO J, V13, P4361, DOI 10.1002/j.1460-2075.1994.tb06756.x
   GUENETTE RS, 1994, J MOL ENDOCRINOL, V12, P47, DOI 10.1677/jme.0.0120047
   Huang K, 1996, ONCOGENE, V13, P1567
   Kim YW, 1996, ONCOGENE, V13, P2275
   MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2396, DOI 10.1128/MCB.12.5.2396
   MAURO LJ, 1994, TRENDS BIOCHEM SCI, V19, P151, DOI 10.1016/0968-0004(94)90274-7
   Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4
   PLUTZKY J, 1992, P NATL ACAD SCI USA, V89, P1123, DOI 10.1073/pnas.89.3.1123
   RILLEMA JA, 1994, TRENDS ENDOCRIN MET, V5, P149, DOI 10.1016/1043-2760(94)90011-6
   SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463
   SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343
   Schaapveld RQJ, 1997, DEV BIOL, V188, P134, DOI 10.1006/dbio.1997.8630
   SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0
   STANDKE GJR, 1994, MOL ENDOCRINOL, V8, P469, DOI 10.1210/me.8.4.469
   SYMPSON CJ, 1994, J CELL BIOL, V125, P681, DOI 10.1083/jcb.125.3.681
   TALHOUK RS, 1992, J CELL BIOL, V118, P1271, DOI 10.1083/jcb.118.5.1271
   ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K
   VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217
   YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303
   YI TL, 1992, MOL CELL BIOL, V12, P836, DOI 10.1128/MCB.12.2.836
NR 34
TC 8
Z9 8
U1 5
U2 9
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0021-924X
EI 1756-2651
J9 J BIOCHEM
JI J. Biochem.
PD APR
PY 1999
VL 125
IS 4
BP 669
EP 675
DI 10.1093/oxfordjournals.jbchem.a022335
PG 7
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 184WP
UT WOS:000079637000004
PM 10101278
DA 2018-12-27
ER

PT J
AU Fujii, Y
   Tanaka, H
   Kobayashi, N
AF Fujii, Y
   Tanaka, H
   Kobayashi, N
TI RETRACTED: Granisetron, droperidol, and metoclopramide for preventing
   postoperative nausea and vomiting after thyroidectomy (Retracted
   article. See vol. 127, pg. E335, 2017)
SO LARYNGOSCOPE
LA English
DT Article; Retracted Publication
ID RECEPTOR ANTAGONIST
AB Objectives/Hypothesis: Patients undergoing thyroidectomy may be especially at risk of experiencing postoperative nausea and vomiting (PONV), This study was undertaken to compare the efficacy and safety of granisetron, droperidol, and metoclopramide for preventing PONV after thyroidectomy, Study Design Prospective randomized, double-blind study. Methods: One hundred twenty female patients received granisetron 40 mu g/kg, droperidol 20 mu g/kg, or metoclopramide 0.2 mg/kg (n = 40, each) intravenously (IV), immediately before the induction of anesthesia, A standardized general anesthetic technique was employed throughout the procedure. Results: The incidence of a complete response, that is, no PONV and no need for another rescue antiemetic during the first 3 hours (0 to 3 hours) after anesthesia was 90% with granisetron, 55% with droperidol, and 50% with metoclopramide, respectively; the corresponding incidence during the next 21 hours (3 to 24 hours) after anesthesia was 85%, 50%, and 45% (P <.05; overall Fisher's Exact probability test), No clinically important adverse events were observed in any of the groups, Conclusions: Prophylactic therapy with granisetron is superior to droperidol or metoclopramide for preventing PONV after thyroidectomy.
C1 Toride Kyodo Gen Hosp, Dept Anesthesiol, Toride, Ibaraki, Japan.
   Toride Kyodo Gen Hosp, Dept Otolaryngol, Toride, Ibaraki, Japan.
RP Fujii, Y (reprint author), Univ Tsukuba, Inst Clin Med, Dept Anesthesiol, 2-1-1 Amakubo, Tsukuba, Ibaraki 3050005, Japan.
CR Andrews PL, 1992, EJC SUPPL, V28A, P2
   BERMUDEZ J, 1988, BRIT J CANCER, V58, P644, DOI 10.1038/bjc.1988.277
   CARMICHAEL J, 1989, CANCER CHEMOTH PHARM, V24, P45
   COHEN SE, 1984, ANESTHESIOLOGY, V60, P67, DOI 10.1097/00000542-198401000-00015
   DEJONCKHEERE M, 1990, EUR J ANAESTH, V7, P421
   Ewalenko P, 1996, BRIT J ANAESTH, V77, P463, DOI 10.1093/bja/77.4.463
   Fujii Y, 1998, BRIT J ANAESTH, V81, P526, DOI 10.1093/bja/81.4.526
   FUJII Y, 1994, CAN J ANAESTH, V41, P291, DOI 10.1007/BF03009906
   Furue H, 1990, J CLIN THERAPEUTIC M, V6, P49
   KORTTILA K, 1979, ANESTH ANALG, V58, P396
   WATCHA MF, 1992, ANESTHESIOLOGY, V77, P162, DOI 10.1097/00000542-199207000-00023
NR 11
TC 19
Z9 19
U1 2
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0023-852X
EI 1531-4995
J9 LARYNGOSCOPE
JI Laryngoscope
PD APR
PY 1999
VL 109
IS 4
BP 664
EP 667
DI 10.1097/00005537-199904000-00028
PG 4
WC Medicine, Research & Experimental; Otorhinolaryngology
SC Research & Experimental Medicine; Otorhinolaryngology
GA 183EM
UT WOS:000079541100028
PM 10201761
DA 2018-12-27
ER

PT J
AU Geraghty, MT
   Bassett, D
   Morrell, JC
   Gatto, GJ
   Bai, JW
   Geisbrecht, BV
   Hieter, P
   Gould, SJ
AF Geraghty, MT
   Bassett, D
   Morrell, JC
   Gatto, GJ
   Bai, JW
   Geisbrecht, BV
   Hieter, P
   Gould, SJ
TI RETRACTED: Detecting patterns of protein distribution and gene
   expression in silico (Retracted Article. See vol 102, pg 516, 2005)
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article; Retracted Publication
DE peroxisomes; peroxisome biogenesis; membrane proteins; lysine synthesis;
   green fluorescent protein
ID SACCHAROMYCES-CEREVISIAE; PEROXISOME BIOGENESIS; BETA-OXIDATION;
   TRANSCRIPTION FACTORS; FATTY-ACIDS; MEMBRANE; PROLIFERATION; IMPORT;
   YEAST; ENCODES
AB Most biological information is contained within gene and genome sequences. However, current methods for analyzing these data are limited primarily to the prediction of coding regions and identification of sequence similarities. We have developed a computer algorithm, CoSMoS (for contest sensitive motif searches), which adds context sensitivity to sequence motif searches. CoSMoS was challenged to identify genes encoding peroxisome-associated and oleate-induced genes in the yeast Saccharomyces cerevisiae, Specifically, we searched for genes capable of encoding proteins with a type 1 or type 2 peroxisomal targeting signal and for genes containing the oleate-response element, a cis-acting element common to fatty acid-regulated genes. CoSMoS successfully identified 7 of 8 known PTS-containing peroxisomal proteins and 13 of 14 known oleate-regulated genes, More importantly, CoSMoS identified an additional 18 candidate peroxisomal proteins and 300 candidate oleate-regulated genes. Preliminary localization studies suggest that these include at least 10 previously unknown peroxisomal proteins. Phenotypic studies of selected gene disruption mutants suggests that several of these new peroxisomal proteins play roles in growth on fatty acids, one is involved in peroxisome biogenesis and at least two are required for synthesis of lysine, a heretofore unrecognized role for peroxisomes. These results expand our understanding of peroxisome content and function, demonstrate the utility of CoSMoS for context-sensitive motif scanning, and point to the benefits of improved in silico genome analysis.
C1 Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA.
   Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21205 USA.
   Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21205 USA.
RP Gould, SJ (reprint author), Johns Hopkins Univ, Sch Med, Dept Biol Chem, 725 N Wolfe St, Baltimore, MD 21205 USA.
EM stephen.gould@qmail.bs.jhu.edu
FU NIDDK NIH HHS [R01 DK045787, DK45787]
CR BAKERBRACHMANN C, 1998, YEAST, V14, P115
   Blobel F, 1996, EUR J BIOCHEM, V240, P468, DOI 10.1111/j.1432-1033.1996.0468h.x
   EINERHAND AWC, 1993, EUR J BIOCHEM, V214, P323, DOI 10.1111/j.1432-1033.1993.tb17927.x
   Elgersma Y, 1997, EMBO J, V16, P7326, DOI 10.1093/emboj/16.24.7326
   Elgersma Y, 1996, J BIOL CHEM, V271, P26375, DOI 10.1074/jbc.271.42.26375
   Geisbrecht BV, 1998, J BIOL CHEM, V273, P33184, DOI 10.1074/jbc.273.50.33184
   Gurvitz A, 1997, J BIOL CHEM, V272, P22140, DOI 10.1074/jbc.272.35.22140
   HELM R, 1995, NATURE, V373, P663
   Henke B, 1998, J BIOL CHEM, V273, P3702, DOI 10.1074/jbc.273.6.3702
   HOHFELD J, 1991, J CELL BIOL, V114, P1167, DOI 10.1083/jcb.114.6.1167
   Kalish JE, 1996, EMBO J, V15, P3275, DOI 10.1002/j.1460-2075.1996.tb00692.x
   Karpichev IV, 1997, MOL CELL BIOL, V17, P69, DOI 10.1128/MCB.17.1.69
   Karpichev IV, 1998, MOL CELL BIOL, V18, P6560, DOI 10.1128/MCB.18.11.6560
   KUNAU WH, 1993, BIOCHIMIE, V75, P209, DOI 10.1016/0300-9084(93)90079-8
   KUNAU WH, 1992, PROG CLIN BIOL RES, V375, P9
   LAZAROW PB, 1985, ANNU REV CELL BIOL, V1, P489, DOI 10.1146/annurev.cb.01.110185.002421
   LEWIN AS, 1990, MOL CELL BIOL, V10, P1399, DOI 10.1128/MCB.10.4.1399
   LIU H, 1995, J BIOL CHEM, V270, P10940, DOI 10.1074/jbc.270.18.10940
   Liu LX, 1997, J BIOL CHEM, V272, P13779, DOI 10.1074/jbc.272.21.13779
   LORENZ MC, 1995, GENE, V158, P113, DOI 10.1016/0378-1119(95)00144-U
   MULLERNEWEN G, 1995, EUR J BIOCHEM, V228, P68, DOI 10.1111/j.1432-1033.1995.tb20230.x
   Rottensteiner H, 1996, EMBO J, V15, P2924, DOI 10.1002/j.1460-2075.1996.tb00655.x
   Sambrook J., 1989, MOL CLONING LAB MANU
   Smith JJ, 1997, MOL CELL BIOL, V17, P2511, DOI 10.1128/MCB.17.5.2511
   SUBRAMANI S, 1993, ANNU REV CELL BIOL, V9, P445, DOI 10.1146/annurev.cb.09.110193.002305
   van Roermund CWT, 1998, EMBO J, V17, P677, DOI 10.1093/emboj/17.3.677
   VANDENBOSCH H, 1992, ANNU REV BIOCHEM, V61, P157, DOI 10.1146/annurev.bi.61.070192.001105
   VANROERMUND CWT, 1995, EMBO J, V14, P3480, DOI 10.1002/j.1460-2075.1995.tb07354.x
   Verleur N, 1997, EUR J BIOCHEM, V247, P972, DOI 10.1111/j.1432-1033.1997.00972.x
   Watanabe W, 1997, BIOCHEM BIOPH RES CO, V238, P234, DOI 10.1006/bbrc.1997.7217
   WATERHAM HR, 1994, J CELL BIOL, V127, P737, DOI 10.1083/jcb.127.3.737
   WINSTON F, 1995, YEAST, V11, P53, DOI 10.1002/yea.320110107
NR 32
TC 49
Z9 49
U1 2
U2 10
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD MAR 16
PY 1999
VL 96
IS 6
BP 2937
EP 2942
DI 10.1073/pnas.96.6.2937
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 177RH
UT WOS:000079224500069
PM 10077615
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Lorentz, O
   Suh, ER
   Taylor, JK
   Boudreau, F
   Traber, PG
AF Lorentz, O
   Suh, ER
   Taylor, JK
   Boudreau, F
   Traber, PG
TI RETRACTED: cAMP response element-binding protein interacts with the
   homeodomain protein Cdx2 and enhances transcriptional activity
   (Retracted Article. See vol 276, pg 10576, 2001)
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article; Retracted Publication
ID HOMEOBOX GENE; EPITHELIAL-CELLS; E1A PROTEINS; DIFFERENTIATION;
   ACTIVATION; EXPRESSION; CBP/P300; CREB; COACTIVATOR; TARGETS
AB Cdx-2 encodes for a homeodomain protein that is expressed in intestinal epithelial cells. The Cdx2 protein triggers intestinal differentiation in cell lines and is necessary for maintenance of the intestinal phenotype in mice. CBP (cAMP response element-binding protein) is a transcriptional co-activator that interacts with many transcription factors and components of the basal transcriptional machinery. In this study, we demonstrate that CBP is markedly induced upon differentiation of the Caco-2 intestinal cell line and augments Cdx2-dependent transcriptional activity. Cdx2 interacts with the amino-terminal domain of CBP, and the two proteins coexist in vivo within the same nuclear protein complex. Moreover, expression of the CBP domain that interacts with Cdx2 acts as a dominant-negative inhibitor of transcriptional activation by Cdx2. These findings demonstrate a direct interaction between an intestinal homeodomain protein and CBP and suggest that CBP participates in the network of transcriptional proteins that direct intestinal differentiation.
C1 Univ Penn, Dept Med, Div Gastroenterol, Philadelphia, PA 19104 USA.
RP Traber, PG (reprint author), Hosp Univ Penn, 100 Centrex,34th & Spruce St, Philadelphia, PA 19104 USA.
EM traberp@mail.med.upenn.edu
FU NIDDK NIH HHS [R01-DK46704, P30-DK50306]
CR ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0
   Basora N, 1998, INT J CANCER, V75, P738, DOI 10.1002/(SICI)1097-0215(19980302)75:5<738::AID-IJC12>3.0.CO;2-2
   Blobel GA, 1998, P NATL ACAD SCI USA, V95, P2061, DOI 10.1073/pnas.95.5.2061
   Chawengsaksophak K, 1997, NATURE, V386, P84, DOI 10.1038/386084a0
   Cheng XB, 1997, MOL CELL BIOL, V17, P1407, DOI 10.1128/MCB.17.3.1407
   Duluc I, 1997, J CELL SCI, V110, P1317
   Eckner R, 1996, BIOL CHEM, V377, P685
   Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153
   FOGH J, 1977, JNCI-J NATL CANCER I, V59, P221, DOI 10.1093/jnci/59.1.221
   Giles RH, 1998, TRENDS GENET, V14, P178, DOI 10.1016/S0168-9525(98)01438-3
   JAMES R, 1994, J BIOL CHEM, V269, P15229
   KIRSHENBAUM LA, 1995, J BIOL CHEM, V270, P7791, DOI 10.1074/jbc.270.14.7791
   KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0
   Lorentz O, 1997, J CELL BIOL, V139, P1553, DOI 10.1083/jcb.139.6.1553
   MYMRYK JS, 1992, MOL BIOL CELL, V3, P1107
   PINTO M, 1983, BIOL CELL, V47, P323
   SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539
   Shi Y, 1998, GENE DEV, V12, P943, DOI 10.1101/gad.12.7.943
   Suh E, 1996, MOL CELL BIOL, V16, P619
   SUH E, 1994, MOL CELL BIOL, V14, P7340, DOI 10.1128/MCB.14.11.7340
   Taylor JK, 1997, NUCLEIC ACIDS RES, V25, P2293, DOI 10.1093/nar/25.12.2293
   Taylor JK, 1997, DNA CELL BIOL, V16, P1419, DOI 10.1089/dna.1997.16.1419
   WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7
   WU GD, 1994, J BIOL CHEM, V269, P17080
   Xu L, 1998, NATURE, V395, P301
   ZAPPAVIGNA V, 1994, GENE DEV, V8, P732, DOI 10.1101/gad.8.6.732
NR 26
TC 19
Z9 19
U1 1
U2 7
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD MAR 12
PY 1999
VL 274
IS 11
BP 7196
EP 7199
DI 10.1074/jbc.274.11.7196
PG 4
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 175DV
UT WOS:000079078400052
PM 10066780
OA Bronze
DA 2018-12-27
ER

PT J
AU Mavoungou, E
   Sall, A
   Poaty-Mavoungou, V
   Toure, FS
   Yaba, P
   Delicat, A
   Lansoud-Soukate, J
AF Mavoungou, E
   Sall, A
   Poaty-Mavoungou, V
   Toure, FS
   Yaba, P
   Delicat, A
   Lansoud-Soukate, J
TI RETRACTED: Alloreactivity and association of human natural killer cells
   with the major histocompatibility complex (Retracted Article. See vol
   15, pg 735, 2008)
SO CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY
LA English
DT Article; Retracted Publication
ID ANCESTRAL HAPLOTYPES CARRY; TYROSINE-PHOSPHATASE 1C; MARROW
   GRAFT-REJECTION; HLA-C MOLECULES; CLASS-I; INHIBITORY RECEPTOR; NK
   CLONES; ANTIGEN RECEPTOR; TARGET-CELLS; LYSIS
AB All NK cells potentially lytic for autologous cells but not expressing self-major histocompatibility complex (MHC)-reactive receptors could be eliminated by a negative selection mechanism during ontogeny. This idea is based on the existence of a NK cell subset expressing a specific inhibitory receptor for allogeneic MHC alleles. As ancestral haplotypes of the MHC appear to define identical,MHC haplotypes in unrelated individuals, unrelated individuals having the same ancestral haplotype should also have the same NK defined allospecificities that have been shown to map to the human MHC. To test this prediction, multiple cell lines from unrelated individuals having the same ancestral haplotypes were tested for the NK-defined allospecificities. It was found that cells having the same ancestral haplotypes do have the same NK-defined specificities. Furthermore, the NK-defined phenotype of cells that possess two different ancestral haplotypes can be predicted from the NK-defined phenotypes of unrelated cells that are homozygous for the ancestral haplotypes concerned. Although the group 1 and 2 NK-defined allospecificities can be explained to some extent by HLA-C alleles, evidence is presented that additional genes may modify the phenotype conferred by HLA-C.
C1 Ctr Int Rech Med Franceville, Emerging & Reemerging Dis Unit, Franceville, Gabon.
RP Mavoungou, E (reprint author), Ctr Int Rech Med Franceville, Emerging & Reemerging Dis Unit, BP 769, Franceville, Gabon.
EM emavoung@cirmf.sci.ga
CR Apte RS, 1996, J IMMUNOL, V156, P2667
   BAKER E, 1995, CHROMOSOME RES, V3, P511
   BEATTY PG, 1993, BLOOD, V81, P249
   BENNETT M, 1972, TRANSPLANTATION, V14, P289, DOI 10.1097/00007890-197209000-00001
   BENNETT M, 1987, ADV IMMUNOL, V41, P333, DOI 10.1016/S0065-2776(08)60034-6
   BIASSONI R, 1995, J EXP MED, V182, P605, DOI 10.1084/jem.182.2.605
   Binstadt BA, 1996, IMMUNITY, V5, P629, DOI 10.1016/S1074-7613(00)80276-9
   Braud VM, 1998, NATURE, V391, P795, DOI 10.1038/35869
   Burshtyn DN, 1996, IMMUNITY, V4, P77, DOI 10.1016/S1074-7613(00)80300-3
   Campbell KS, 1996, J EXP MED, V184, P93, DOI 10.1084/jem.184.1.93
   CICCONE E, 1992, J EXP MED, V175, P709, DOI 10.1084/jem.175.3.709
   CICCONE E, 1992, J EXP MED, V176, P963, DOI 10.1084/jem.176.4.963
   CICCONE E, 1988, J EXP MED, V168, P2403, DOI 10.1084/jem.168.6.2403
   CICCONE E, 1990, P NATL ACAD SCI USA, V87, P9794, DOI 10.1073/pnas.87.24.9794
   CICCONE E, 1990, J EXP MED, V172, P47, DOI 10.1084/jem.172.1.47
   COLONNA M, 1992, P NATL ACAD SCI USA, V89, P7983, DOI 10.1073/pnas.89.17.7983
   COLONNA M, 1995, SCIENCE, V268, P405, DOI 10.1126/science.7716543
   COLONNA M, 1993, P NATL ACAD SCI USA, V90, P12000, DOI 10.1073/pnas.90.24.12000
   DAMBROSIO D, 1995, SCIENCE, V268, P293, DOI 10.1126/science.7716523
   DANDREA A, 1995, J IMMUNOL, V155, P2306
   DAWKINS RL, 1989, HUM IMMUNOL, V26, P91, DOI 10.1016/0198-8859(89)90094-3
   DEGLIESPOSTI MA, 1992, HUM IMMUNOL, V34, P242, DOI 10.1016/0198-8859(92)90023-G
   DEGLIESPOSTI MA, 1992, EUR J IMMUNOGENET, V19, P121, DOI 10.1111/j.1744-313X.1992.tb00051.x
   Dohring C, 1996, J IMMUNOL, V156, P3098
   FLEISCHHAUER K, 1990, NEW ENGL J MED, V323, P1818, DOI 10.1056/NEJM199012273232607
   Fry AM, 1996, J EXP MED, V184, P295, DOI 10.1084/jem.184.1.295
   GUMPERZ JE, 1995, J EXP MED, V181, P1133, DOI 10.1084/jem.181.3.1133
   LANIER LL, 1995, J IMMUNOL, V154, P3320
   LEELAYUWAT C, 1992, IMMUNOGENETICS, V36, P208, DOI 10.1007/BF00215049
   LETWIN V, 1994, J EXP MED, V180, P537
   Long EO, 1997, IMMUNOL REV, V155, P135, DOI 10.1111/j.1600-065X.1997.tb00946.x
   MANALTI MS, 1995, SCIENCE, V267, P1016
   Mandelboim O, 1996, J EXP MED, V184, P913, DOI 10.1084/jem.184.3.913
   MARSHALL B, 1993, GENOMICS, V17, P435, DOI 10.1006/geno.1993.1344
   MORETTA A, 1993, J EXP MED, V178, P597, DOI 10.1084/jem.178.2.597
   MORETTA L, 1992, IMMUNOL TODAY, V13, P300, DOI 10.1016/0167-5699(92)90042-6
   NAPPER C, 1995, EUR J IMMUNOL, V25, P1249
   OHLEN C, 1995, EUR J IMMUNOL, V25, P1286, DOI 10.1002/eji.1830250523
   Olcese L, 1996, J IMMUNOL, V156, P4531
   Pende D, 1996, J EXP MED, V184, P505, DOI 10.1084/jem.184.2.505
   REMBECKI RM, 1990, TRANSPLANTATION, V49, P633, DOI 10.1097/00007890-199003000-00030
   Scharenberg AM, 1996, CELL, V87, P961, DOI 10.1016/S0092-8674(00)81790-0
   SHIMIZU Y, 1989, EUR J IMMUNOL, V19, P447, DOI 10.1002/eji.1830190306
   STORKUS WJ, 1989, P NATL ACAD SCI USA, V86, P2361, DOI 10.1073/pnas.86.7.2361
   STORKUS WJ, 1991, P NATL ACAD SCI USA, V88, P5989, DOI 10.1073/pnas.88.14.5989
   THOMAS ML, 1995, J EXP MED, V181, P1953, DOI 10.1084/jem.181.6.1953
   THOMSEN M, 1993, HUM IMMUNOL, V38, P52, DOI 10.1016/0198-8859(93)90519-7
   WAGTMANN N, 1995, IMMUNITY, V2, P439, DOI 10.1016/1074-7613(95)90025-X
   WU XW, 1992, HUM IMMUNOL, V33, P89, DOI 10.1016/0198-8859(92)90058-U
   YU YYL, 1992, ANNU REV IMMUNOL, V10, P189, DOI 10.1146/annurev.immunol.10.1.189
   ZHANG WJ, 1990, J EXP MED, V171, P2101, DOI 10.1084/jem.171.6.2101
   ZHANG WJ, 1988, HUM IMMUNOL, V21, P165, DOI 10.1016/0198-8859(88)90068-7
NR 52
TC 1
Z9 4
U1 2
U2 4
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 1071-412X
J9 CLIN DIAGN LAB IMMUN
JI Clin. Diagn. Lab. Immunol.
PD MAR
PY 1999
VL 6
IS 2
BP 254
EP 259
PG 6
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 174QU
UT WOS:000079046800019
PM 10066663
DA 2018-12-27
ER

PT J
AU Hennein, HA
   Kiziltepe, U
   Barst, S
   Bocchieri, KA
   Hossain, A
   Call, DR
   Remick, DG
   Gold, JP
AF Hennein, HA
   Kiziltepe, U
   Barst, S
   Bocchieri, KA
   Hossain, A
   Call, DR
   Remick, DG
   Gold, JP
TI RETRACTED: Venovenous modified ultrafiltration after cardiopulmonary
   bypass in children: A prospective randomized study (Retracted article.
   See vol 119, pg 630, 2000)
SO JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY
LA English
DT Article; Proceedings Paper; Retracted Publication
CT 78th Annual Meeting of the American-Association-for-Thoracic-Surgery
CY MAY 03-06, 1998
CL BOSTON, MA
SP Amer Assoc Thorac Surg
ID PEDIATRIC CARDIAC-SURGERY; OPEN-HEART-SURGERY; INFLAMMATORY RESPONSE;
   PROINFLAMMATORY CYTOKINES; HEMOFILTRATION; COMPLEMENT; DYSFUNCTION;
   OPERATIONS; ISCHEMIA
AB Background: Cardiopulmonary bypass is associated with the production of both proinflammatory and anti-inflammatory cytokines, the balance of which leads to varying degrees of postoperative systemic inflammation. Arteriovenous modified ultrafiltration effectively reduces total body water and improves postoperative hemodynamic and homeostatic functions. Venovenous modified ultrafiltration is a modification of this technique, which has the potentially added advantage of eliminating the obligatory left-to-right shunt associated with arteriovenous modified ultrafiltration, We tested the hypothesis that venovenous modified ultrafiltration is a safe and effective method of achieving ultrafiltration in children after cardiopulmonary bypass, Methods: Thirty-eight pediatric patients were randomly assigned to undergo conventional, venovenous (n = 13), or no ultrafiltration venovenous (n = 13), and controls (n = 12), Perioperative, cardiopulmonary, and cytokine (tumor necrosis factor-a, interleukin-1 beta, interleukin-6, interleukin-8, and interleukin-10) data were collected for statistical analysis. Results: Compared with patients in the conventional ultrafiltration and control groups, patients undergoing venovenous modified ultrafiltration had the greatest volume of ultrafiltrate removed (46.9 +/- 8.4 mL/kg vs 20.1 +/- 5.0 mL/kg and 0 mL/kg for conventional ultrafiltration and control groups, respectively; P =.0001), least increase in total body water (1.91% +/- 1.49 % vs 3.90 % +/- 1.86 % and 8.24% +/- 3.41%; P =.05), greatest rise in hematocrit (39.7% +/- 1.7% vs 33.8% +/- 2.1% and 29.6% +/- 2.3%; P =.006), and shortest length of hospital stay (4.41 +/- 0.28 days vs 6.69 +/- 1.47 days and 8.38 +/- 1.11 days; P =.03, P =.03). Conclusions: Venovenous modified ultrafiltration is a safe and effective method of reducing the increase in total body water and duration of postoperative convalescence after cardiopulmonary bypass.
C1 Albert Einstein Coll Med, Long Isl Jewish Med Ctr, Schneider Childrens Hosp, Sect Pediat Cardiothorac Surg, New Hyde Pk, NY 11040 USA.
   Univ Michigan, Med Ctr, Ann Arbor, MI 48109 USA.
RP Hennein, HA (reprint author), Albert Einstein Coll Med, Long Isl Jewish Med Ctr, Schneider Childrens Hosp, Sect Pediat Cardiothorac Surg, New Hyde Pk, NY 11040 USA.
CR Ad N, 1996, ISRAEL J MED SCI, V32, P1326
   Ashraf S, 1997, ANN THORAC SURG, V64, P1790, DOI 10.1016/S0003-4975(97)00846-1
   BUTLER J, 1993, ANN THORAC SURG, V55, P552, DOI 10.1016/0003-4975(93)91048-R
   CASEY LC, 1993, ANN THORAC SURG, V56, pS92, DOI 10.1016/0003-4975(93)91143-B
   Davies MJ, 1998, J THORAC CARDIOV SUR, V115, P361, DOI 10.1016/S0022-5223(98)70280-6
   DEFORGE LE, 1991, BIOCHEM BIOPH RES CO, V174, P18, DOI 10.1016/0006-291X(91)90478-P
   DELIUS R, 1993, J THORAC CARDIOV SUR, V106, P329
   Draaisma AM, 1997, ANN THORAC SURG, V64, P521, DOI 10.1016/S0003-4975(97)00522-5
   ELLIOTT MJ, 1993, ANN THORAC SURG, V56, P1518, DOI 10.1016/0003-4975(93)90744-3
   Eppinger MJ, 1996, J THORAC CARDIOV SUR, V112, P1301, DOI 10.1016/S0022-5223(96)70144-7
   FRERING B, 1994, J THORAC CARDIOV SUR, V108, P636
   Friesen RH, 1997, ANN THORAC SURG, V64, P1787, DOI 10.1016/S0003-4975(97)00921-1
   HENNEIN HA, 1994, J THORAC CARDIOV SUR, V108, P626
   Joumois D, 1996, ANESTHESIOLOGY, V85, P965, DOI 10.1097/00000542-199611000-00003
   JOURNOIS D, 1994, ANESTHESIOLOGY, V81, P1181, DOI 10.1097/00000542-199411000-00011
   Khabar KSA, 1997, CLIN IMMUNOL IMMUNOP, V85, P97, DOI 10.1006/clin.1997.4413
   Koutlas TC, 1997, ANN THORAC SURG, V64, P37, DOI 10.1016/S0003-4975(97)00505-5
   MILLAR AB, 1993, ANN THORAC SURG, V56, P1499, DOI 10.1016/0003-4975(93)90740-9
   NAIK SK, 1991, CIRCULATION, V84, P422
   Saatvedt K, 1996, CARDIOVASC RES, V31, P596
   *SAS, 1991, SAS US MAN
   SKARYAK LA, 1995, J THORAC CARDIOV SUR, V109, P744, DOI 10.1016/S0022-5223(95)70357-8
   STEIN B, 1991, INTENS CARE MED, V17, P293, DOI 10.1007/BF01713941
   STEINBERG JB, 1993, J THORAC CARDIOV SUR, V106, P1008
   Wan S, 1997, CHEST, V112, P676, DOI 10.1378/chest.112.3.676
   Wan S, 1996, J THORAC CARDIOV SUR, V112, P806, DOI 10.1016/S0022-5223(96)70068-5
   Wan S, 1997, ANN THORAC SURG, V63, P269
   Wang MJ, 1996, ANN THORAC SURG, V61, P651, DOI 10.1016/0003-4975(95)00974-4
NR 28
TC 23
Z9 27
U1 1
U2 7
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0022-5223
EI 1097-685X
J9 J THORAC CARDIOV SUR
JI J. Thorac. Cardiovasc. Surg.
PD MAR
PY 1999
VL 117
IS 3
BP 496
EP 505
PG 10
WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery
SC Cardiovascular System & Cardiology; Respiratory System; Surgery
GA 172KB
UT WOS:000078921100011
PM 10047653
DA 2018-12-27
ER

PT J
AU Johnson, NE
AF Johnson, NE
TI RETRACTED: Nonmetropolitan sex-role ideologies: A longitudinal study
   (Retracted Article. See vol. 69, pg 302, 2004)
SO RURAL SOCIOLOGY
LA English
DT Article; Retracted Publication
ID TIME-SERIES MODELS; ROLE ATTITUDES; UNITED-STATES; METROPOLITAN;
   INEQUALITY; FERTILITY; AREAS; WOMEN; PANEL
AB Using the two waves (1987-1988 and 1992-1994) from the National Survey of Families and Households (NSFH), I focused on the 3,792 Main Respondents (MRs) living in sexual unions at Wave 1 who, along with the spouse or domestic partner, were successfully recontacted at Wave 2. MRs from both formal marriages and nonmarital cohabitations were included. An identically worded set of questions about proper roles for men and women was posed to each member of the pair at Wave 1 and again at Wave 2. An Exploratory Factor Analysis uncovered two factors. A conservative orientation on the Sexuality/Reproduction Factor (#1) defined legal marriage as the only acceptable domain for sexual intercourse, pregnancy, and childbirth. An orthodox perspective on the Childcare Factor (#2) assigned mothers the primary responsibility for the care of young children and men responsibility for earning the main living. In this study, we tested the hypotheses that nonmetro residents would be more conservative on both sex-role dimensions than metro residents at Wave 1, would be slower than metro residents to adopt more egalitarian attitudes, and thus would remain more traditional on both sex-role dimensions at Wave 2. The influence of nonmetro-to-metro and metro-to-nonmetro migration, as well as the sway over attitudes of the spouse/partner, was taken into account.
C1 Michigan State Univ, Dept Sociol, E Lansing, MI 48824 USA.
RP Johnson, NE (reprint author), Michigan State Univ, Dept Sociol, E Lansing, MI 48824 USA.
CR Cotter DA, 1996, RURAL SOCIOL, V61, P272
   FISCHER CS, 1975, AM J SOCIOL, V80, P1319, DOI 10.1086/225993
   Flora Cornelia B., 1978, RURAL US PERSISTENCE, P168
   FUGUITT GV, 1991, RURAL SOCIOL, V56, P475
   GRINGERI CE, 1993, RURAL SOCIOL, V58, P30
   Johnson DR, 1995, J MARRIAGE FAM, V57, P1065, DOI 10.2307/353423
   MASON KO, 1975, AM J SOCIOL, V80, P1212, DOI 10.1086/225951
   MCLAUGHLIN DK, 1993, J MARRIAGE FAM, V55, P827, DOI 10.2307/352765
   MONTGOMERY MR, 1993, POP STUD-J DEMOG, V47, P457, DOI 10.1080/0032472031000147246
   RICE TW, 1995, GENDER SOC, V9, P744, DOI 10.1177/089124395009006007
   Sayrs L., 1989, POOLED TIME SERIES A
   Smith JP, 1997, J GERONTOL B-PSYCHOL, V52, P74, DOI 10.1093/geronb/52B.Special_Issue.74
   Sweet J., 1988, 1 NSFH U WISC CTR DE
   THORNTON A, 1989, J MARRIAGE FAM, V51, P873, DOI 10.2307/353202
   THORNTON A, 1983, AM SOCIOL REV, V48, P211, DOI 10.2307/2095106
   THORNTON A, 1979, AM SOCIOL REV, V44, P831, DOI 10.2307/2094530
   WHITENER L, 1992, RURAL DEV PERSPECTIV, V8, P27
   WRIGHT MM, 1995, GENDER SOC, V9, P216, DOI 10.1177/089124395009002005
NR 18
TC 7
Z9 7
U1 3
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0036-0112
EI 1549-0831
J9 RURAL SOCIOL
JI Rural Sociol.
PD MAR
PY 1999
VL 64
IS 1
BP 44
EP 65
PG 22
WC Sociology
SC Sociology
GA 187AE
UT WOS:000079763100003
DA 2018-12-27
ER

PT J
AU Murthy, HMK
   Clum, S
   Padmanabhan, R
AF Murthy, HMK
   Clum, S
   Padmanabhan, R
TI RETRACTED: Dengue virus NS3 serine protease - Crystal structure and
   insights into interaction of the active site with substrates by
   molecular modeling and structural analysis of mutational effects
   (Retracted Article. See vol 284, pg 34468, 2009)
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article; Retracted Publication
ID HEPATITIS-C VIRUS; YELLOW-FEVER VIRUS; PUTATIVE NONSTRUCTURAL PROTEINS;
   POLYPROTEIN PRECURSOR; VIRAL POLYPROTEIN; NS2B-NS3 COMPLEX; CATALYTIC
   TRIAD; TYPE-2; CLEAVAGE; DOMAIN
AB The mosquito-borne dengue viruses are widespread human pathogens causing dengue fever, dengue hemorrhagic fever, and dengue shock syndrome, placing 40% of the world's population at risk with no effective treatment. The viral genome is a positive strand RNA that encodes a single polyprotein precursor. Processing of the polyprotein precursor into mature proteins is carried out by the host signal peptidase and by NS3 serine protease, which requires NS2B as a cofactor. We report here the crystal structure of the NS3 serine protease domain at 2.1 Angstrom resolution. This structure of the protease combined with modeling of peptide substrates into the active site suggests identities of residues involved in substrate recognition as well as providing a structural basis for several mutational effects on enzyme activity. This structure will be useful for development of specific inhibitors as therapeutics against dengue and other flaviviral proteases.
C1 Temple Univ, Fels Inst, Philadelphia, PA 19140 USA.
   Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, Kansas City, KS 66160 USA.
RP Murthy, HMK (reprint author), Univ Alabama Birmingham, CMC, 79-THT,MCLM-248,1918 Univ Blvd, Birmingham, AL 35294 USA.
EM murthy@onyx.cmc.uab.edu
FU NIAID NIH HHS [AI-32078]
CR ANGELIDES KJ, 1979, BIOCHEMISTRY-US, V18, P2363, DOI 10.1021/bi00578a035
   ARIAS CF, 1993, VIROLOGY, V193, P888, DOI 10.1006/viro.1993.1198
   Barrett AJ, 1986, RES MONOG CELL TISSU, V12, P515
   BARTENSCHLAGER R, 1993, J VIROL, V67, P3835
   BARTENSCHLAGER R, 1994, J VIROL, V68, P5045
   BAZAN JF, 1989, VIROLOGY, V171, P637, DOI 10.1016/0042-6822(89)90639-9
   BAZAN JF, 1989, FEBS LETT, V249, P5, DOI 10.1016/0014-5793(89)80003-1
   BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0
   BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355
   BRUNGER AT, 1990, XPLOR MANUAL VERSION
   BURLEY SK, 1988, ADV PROTEIN CHEM, V39, P125
   CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240
   CARTER P, 1988, NATURE, V332, P564, DOI 10.1038/332564a0
   CHAMBERS TJ, 1991, J VIROL, V65, P6042
   CHAMBERS TJ, 1993, J VIROL, V67, P6797
   CHAMBERS TJ, 1990, P NATL ACAD SCI USA, V87, P8898, DOI 10.1073/pnas.87.22.8898
   CHAMBERS TJ, 1990, ANNU REV MICROBIOL, V44, P649, DOI 10.1146/annurev.mi.44.100190.003245
   Clum S, 1997, J BIOL CHEM, V272, P30715, DOI 10.1074/jbc.272.49.30715
   CONNOLLY ML, 1983, SCIENCE, V221, P709, DOI 10.1126/science.6879170
   COREY DR, 1992, J AM CHEM SOC, V114, P1784, DOI 10.1021/ja00031a037
   Cowtan K, 1994, JOINT CCP4 ESF EACBM, V31, P34
   ECKART MR, 1993, BIOCHEM BIOPH RES CO, V192, P399, DOI 10.1006/bbrc.1993.1429
   FAILLA C, 1994, J VIROL, V68, P3753
   FALGOUT B, 1991, J VIROL, V65, P2467
   FALGOUT B, 1995, J VIROL, V69, P7232
   GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P3889, DOI 10.1093/nar/17.10.3889
   GRAKOUI A, 1993, J VIROL, V67, P2832
   GUBLER DJ, 1995, EMERG INFECT DIS, V1, P55
   HENDRICKSON WA, 1981, NATURE, V290, P107, DOI 10.1038/290107a0
   HIJIKATA M, 1993, P NATL ACAD SCI USA, V90, P10773, DOI 10.1073/pnas.90.22.10773
   HUANG QC, 1993, J MOL BIOL, V229, P1022, DOI 10.1006/jmbi.1993.1102
   IRIE K, 1989, GENE, V75, P197, DOI 10.1016/0378-1119(89)90266-7
   JAMES MNG, 1980, J MOL BIOL, V144, P43, DOI 10.1016/0022-2836(80)90214-4
   JAN LR, 1995, J GEN VIROL, V76, P573, DOI 10.1099/0022-1317-76-3-573
   JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224
   KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903
   KAPOOR M, 1995, J BIOL CHEM, V270, P19100, DOI 10.1074/jbc.270.32.19100
   Kautner I, 1997, J PEDIATR-US, V131, P516, DOI 10.1016/S0022-3476(97)70054-4
   Kim JL, 1996, CELL, V87, P343, DOI 10.1016/S0092-8674(00)81351-3
   KLEYWEGT GJ, 1995, STRUCTURE, V3, P535, DOI 10.1016/S0969-2126(01)00187-3
   KRAUT J, 1977, ANNU REV BIOCHEM, V46, P331, DOI 10.1146/annurev.bi.46.070177.001555
   KUNTZ ID, 1992, SCIENCE, V257, P1078, DOI 10.1126/science.257.5073.1078
   LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944
   LIN C, 1994, J VIROL, V68, P8147
   Love RA, 1996, CELL, V87, P331, DOI 10.1016/S0092-8674(00)81350-1
   MARKOFF L, 1989, J VIROL, V63, P3345
   MILLER RH, 1990, P NATL ACAD SCI USA, V87, P2057, DOI 10.1073/pnas.87.6.2057
   MONATH TP, 1994, P NATL ACAD SCI USA, V91, P2395, DOI 10.1073/pnas.91.7.2395
   Neurath H, 1989, PROTEOLYTIC ENZYMES
   NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407
   NOWAK T, 1989, VIROLOGY, V169, P365, DOI 10.1016/0042-6822(89)90162-1
   OTWINOWSKI Z, 1991, ISOMORPHOUS REPLACEM, P101
   Paetzel M, 1997, TRENDS BIOCHEM SCI, V22, P28, DOI 10.1016/S0968-0004(96)10065-7
   PERONA JJ, 1995, PROTEIN SCI, V4, P337
   PERONA JJ, 1993, SCIENCE, V261, P620, DOI 10.1126/science.8342029
   Pinheiro Fransisco P., 1997, World Health Statistics Quarterly, V50, P161
   PREUGSCHAT F, 1990, J VIROL, V64, P4364
   RANDOLPH VB, 1990, VIROLOGY, V174, P450, DOI 10.1016/0042-6822(90)90099-D
   READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622
   READ RJ, 1986, INTRO PROTEIN INHIBI, P301
   RicoHesse R, 1997, VIROLOGY, V230, P244, DOI 10.1006/viro.1997.8504
   SACK JS, 1988, J MOL GRAPHICS, V6, P224, DOI 10.1016/S0263-7855(98)80040-4
   SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X
   Steinkuhler C, 1996, J VIROL, V70, P6694
   STEITZ TA, 1982, ANNU REV BIOPHYS BIO, V11, P419, DOI 10.1146/annurev.bb.11.060182.002223
   SUZICH JA, 1993, J VIROL, V67, P6152
   SVITKIN YV, 1984, VIROLOGY, V135, P536, DOI 10.1016/0042-6822(84)90207-1
   TOMEI L, 1993, J VIROL, V67, P4017
   Valle RPC, 1998, J VIROL, V72, P624
   WESTAWAY EG, 1987, ADV VIRUS RES, V33, P45, DOI 10.1016/S0065-3527(08)60316-4
   Yan YW, 1998, PROTEIN SCI, V7, P837
   ZHANG LW, 1992, J VIROL, V66, P7549
   ACTA CRYSTALLOGR D, V50, P760
NR 73
TC 97
Z9 102
U1 1
U2 16
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD FEB 26
PY 1999
VL 274
IS 9
BP 5573
EP 5580
DI 10.1074/jbc.274.9.5573
PG 8
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 170KG
UT WOS:000078804400044
PM 10026173
OA Bronze
DA 2018-12-27
ER

PT J
AU LaCasse, RA
   Follis, KE
   Trahey, M
   Scarborough, JD
   Littman, DR
   Nunberg, JH
AF LaCasse, RA
   Follis, KE
   Trahey, M
   Scarborough, JD
   Littman, DR
   Nunberg, JH
TI RETRACTED: Fusion-competent vaccines broad neutralization of primary
   isolates of HIV (Retracted article. See vol 296, pg 1025, 2002)
SO SCIENCE
LA English
DT Article; Retracted Publication
ID HUMAN-IMMUNODEFICIENCY-VIRUS; MONOCLONAL-ANTIBODY; ENVELOPE
   GLYCOPROTEINS; TYPE-1; GP120; PREVENTION; SEROTYPES; BINDING;
   PATHOGENESIS; IMMUNIZATION
AB Current recombinant human immunodeficiency virus (HIV) gp120 protein vaccine candidates are unable to elicit antibodies capable of neutralizing infectivity of primary isolates from patients. Here, "fusion-competent" HIV vaccine immunogens were generated that capture the transient envelope-CD4-coreceptor structures that arise during HIV binding and fusion. In a transgenic mouse immunization model, these formaldehyde-fixed whole-cell vaccines elicited antibodies capable of neutralizing infectivity of 23 of 24 primary HIV isolates from diverse geographic locations and genetic clades A to E, Development of these fusion-dependent immunogens may Lead to a broadly effective HIV vaccine.
C1 Univ Montana, Montana Biotechnol Ctr, Missoula, MT 59812 USA.
   Univ Montana, Div Biol Sci, Missoula, MT 59812 USA.
   NYU Med Ctr, Skirball Inst Biomol Med, Howard Hughes Med Inst, New York, NY 10016 USA.
RP Nunberg, JH (reprint author), Univ Montana, Montana Biotechnol Ctr, Missoula, MT 59812 USA.
EM nunberg@selway.umt.edu
FU NIAID NIH HHS [AI41165, AI33856]
CR ARTHUR LO, 1992, SCIENCE, V258, P1935, DOI 10.1126/science.1470916
   BELSHE RB, 1994, JAMA-J AM MED ASSOC, V272, P475, DOI 10.1001/jama.272.6.475
   Berger EA, 1997, AIDS, V11, pS3
   BERGER EA, 1988, P NATL ACAD SCI USA, V85, P2357, DOI 10.1073/pnas.85.7.2357
   Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6
   COHEN J, 1994, SCIENCE, V264, P1839, DOI 10.1126/science.8009201
   COLLMAN R, 1992, J VIROL, V66, P7517
   Conley AJ, 1996, J VIROL, V70, P6751
   Connor RI, 1998, J VIROL, V72, P1552
   CRANAGE MP, 1993, AIDS RES HUM RETROV, V9, P13, DOI 10.1089/aid.1993.9.13
   Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0
   Doranz BJ, 1997, IMMUNOL RES, V16, P15, DOI 10.1007/BF02786321
   DSouza MP, 1997, J INFECT DIS, V175, P1056, DOI 10.1086/516443
   EMINI EA, 1992, NATURE, V355, P728, DOI 10.1038/355728a0
   Follis KE, 1998, J VIROL, V72, P7603
   Furuta RA, 1998, NAT STRUCT BIOL, V5, P276, DOI 10.1038/nsb0498-276
   Gauduin MC, 1997, NAT MED, V3, P1389, DOI 10.1038/nm1297-1389
   GERSHONI JM, 1993, FASEB J, V7, P1185
   Graham BS, 1998, J INFECT DIS, V177, P310, DOI 10.1086/514209
   GROENINK M, 1991, J VIROL, V65, P1968
   Guillon C, 1995, AIDS RES HUM RETROV, V11, P1537, DOI 10.1089/aid.1995.11.1537
   Hill CM, 1997, J VIROL, V71, P6296
   KAHN JO, 1994, J INFECT DIS, V170, P1288, DOI 10.1093/infdis/170.5.1288
   Kostrikis LG, 1996, J VIROL, V70, P445
   Krause RM, 1997, J INFECT DIS, V176, P549, DOI 10.1086/514074
   LaCasse RA, 1998, J VIROL, V72, P2491
   Langlois AJ, 1998, J VIROL, V72, P6950
   Lee S, 1997, J VIROL, V71, P6037
   Mascola JR, 1996, AIDS RES HUM RETROV, V12, P1319, DOI 10.1089/aid.1996.12.1319
   Mascola JR, 1996, J INFECT DIS, V173, P340, DOI 10.1093/infdis/173.2.340
   Montefiori DC, 1998, J VIROL, V72, P3427
   Moore J P, 1995, AIDS, V9 Suppl A, pS117
   Moore JP, 1997, CURR OPIN IMMUNOL, V9, P551, DOI 10.1016/S0952-7915(97)80110-0
   MOORE JP, 1989, AIDS, V3, P155, DOI 10.1097/00002030-198903000-00006
   Moore JP, 1996, J VIROL, V70, P427
   PRINCE AM, 1991, AIDS RES HUM RETROV, V7, P971, DOI 10.1089/aid.1991.7.971
   PUTKONEN P, 1993, J MED PRIMATOL, V22, P100
   Reimann KA, 1996, J VIROL, V70, P3198
   SCARBOROUGH JD, 1993, EMBO J, V12, P1547
   Sullivan N, 1998, J VIROL, V72, P4694
   TERSMETTE M, 1989, J VIROL, V63, P2118
   THALI M, 1993, J VIROL, V67, P3978
   Trkola A, 1998, J VIROL, V72, P1876
   VERSCHOOR EJ, 1995, VET IMMUNOL IMMUNOP, V46, P139, DOI 10.1016/0165-2427(94)07013-W
   Weber J, 1996, J VIROL, V70, P7827
   Weissenhorn W, 1998, P NATL ACAD SCI USA, V95, P6032, DOI 10.1073/pnas.95.11.6032
   Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0
   WILD C, 1992, P NATL ACAD SCI USA, V89, P10537, DOI 10.1073/pnas.89.21.10537
   WRIN T, 1995, J VIROL, V69, P39
   YAMAMOTO JK, 1991, AIDS RES HUM RETROV, V7, P911, DOI 10.1089/aid.1991.7.911
NR 50
TC 182
Z9 186
U1 1
U2 10
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
EI 1095-9203
J9 SCIENCE
JI Science
PD JAN 15
PY 1999
VL 283
IS 5400
BP 357
EP 362
DI 10.1126/science.283.5400.357
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 157MV
UT WOS:000078067000039
PM 9888845
DA 2018-12-27
ER

PT J
AU Gelband, CH
   Reaves, PY
   Evans, J
   Wang, HW
   Katovich, MJ
   Raizada, MK
AF Gelband, CH
   Reaves, PY
   Evans, J
   Wang, HW
   Katovich, MJ
   Raizada, MK
TI RETRACTED: Angiotensin II type 1 receptor antisense gene therapy
   prevents altered renal vascular calcium homeostasis in hypertension
   (Retracted Article. See vol 43, pg 292, 2004)
SO HYPERTENSION
LA English
DT Article; Proceedings Paper; Retracted Publication
CT 52nd Annual Fall Conference and Scientific Session of the
   American-Heart-Association
CY SEP 15-18, 1998
CL PHILADELPHIA, PA
SP Amer Heart Assoc
DE angiotensin II; arterioles; calcium, intracellular; Ca(2+) current;
   excitation-contraction coupling; gene therapy
ID HIGH BLOOD-PRESSURE; SMOOTH-MUSCLE; RAT; DELIVERY; CHANNELS; LOSARTAN
AB Intracellular Ca(2+) ([Ca(2+)](i)) homeostasis regulates vascular smooth muscle tone, and alteration in [Ca(2+)](i) handling is associated with the development and establishment of hypertension. We have previously established in the spontaneously hypertensive rat (SHR) that virally mediated delivery of angiotensin II type 1 receptor antisense (AT(1)R-AS) prevents the development of high blood pressure and some pathophysiology associated with hypertension for 120 days. In light of this, our objectives in this study were to determine whether AT(1)R-AS gene therapy (1) could have a longer duration in the prevention of hypertension and (2) would attenuate the alterations in renal vascular Ca(2+) homeostasis and therefore vasoconstriction, characteristics of hypertension, Intracardiac delivery of AT(1)R-AS in neonates prevented the development of hypertension in SHR for at least 210 days. At this time, untreated SHR renal resistance arterioles showed a significantly enhanced contractile response to KCl and angiotensin II (Ang II) when compared with normotensive Wistar-Kyoto rats. In addition, L-type Ca(2+) current density and Ang II-dependent increases in [Ca(2+)](i) were significantly increased in cells dissociated from renal resistance arterioles of the untreated SHR. AT(1)R-AS treatment prevented all of the above vascular alterations associated with the hypertensive state in SHR. Finally, Western blot analysis of L-type Ca(2+) channel (alpha(1C)) protein levels in renal resistance arterioles of untreated SHR showed no significant difference when compared with control. These results are novel and demonstrate that viral-mediated delivery of AT(1)R-AS not only attenuates the development of hypertension on a long-term basis but prevents changes in renal vascular Ca(2+) homeostasis associated with the disease.
C1 Univ Florida, Coll Med, Dept Physiol, Gainesville, FL 32610 USA.
   Univ Florida, Coll Pharm, Dept Pharmacodynam, Gainesville, FL 32610 USA.
RP Gelband, CH (reprint author), Univ Florida, Coll Med, Dept Physiol, POB 100274, Gainesville, FL 32610 USA.
EM Gelband@phys.med.ufl.edu
FU NHLBI NIH HHS [HL-52189, HL-56921]
CR BONNARDEAUX A, 1994, HYPERTENSION, V24, P63, DOI 10.1161/01.HYP.24.1.63
   BRUNNER HR, 1993, J HYPERTENS        S, V11, P553
   CURTIS JJ, 1983, NEW ENGL J MED, V309, P1009, DOI 10.1056/NEJM198310273091702
   HSUEH WA, 1995, ADV EXP MED BIOL, V377, P217
   Iyer SN, 1996, P NATL ACAD SCI USA, V93, P9960, DOI 10.1073/pnas.93.18.9960
   JEUNEMAITRE X, 1992, CELL, V71, P169, DOI 10.1016/0092-8674(92)90275-H
   Kaneko K, 1996, J HYPERTENS, V14, P645, DOI 10.1097/00004872-199605000-00015
   KANG PM, 1994, AM HEART J, V127, P1388, DOI 10.1016/0002-8703(94)90061-2
   KHALIL RA, 1990, HYPERTENSION PATHOPH, P547
   KURTZ TW, 1990, J CLIN INVEST, V85, P1328, DOI 10.1172/JCI114572
   Liao DF, 1996, CIRC RES, V79, P1007, DOI 10.1161/01.RES.79.5.1007
   Lu D, 1998, AM J PHYSIOL-HEART C, V274, pH719, DOI 10.1152/ajpheart.1998.274.2.H719
   Lu D, 1997, HYPERTENSION, V30, P363, DOI 10.1161/01.HYP.30.3.363
   Martens JR, 1998, P NATL ACAD SCI USA, V95, P2664, DOI 10.1073/pnas.95.5.2664
   Martens JR, 1996, CIRC RES, V79, P295, DOI 10.1161/01.RES.79.2.295
   Martens JR, 1998, P SOC EXP BIOL MED, V218, P192
   Oliverio MI, 1997, AM J PHYSIOL-RENAL, V272, pF515
   Phillips MI, 1997, HYPERTENSION, V29, P374, DOI 10.1161/01.HYP.29.1.374
   STAMLER J, 1993, ARCH INTERN MED, V153, P598, DOI 10.1001/archinte.153.5.598
   VOGT M, 1993, EUR HEART J, V14, P2, DOI 10.1093/eurheartj/14.suppl_D.2
   WHELTON PK, 1994, LANCET, V344, P101, DOI 10.1016/S0140-6736(94)91285-8
NR 21
TC 18
Z9 21
U1 2
U2 9
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0194-911X
J9 HYPERTENSION
JI Hypertension
PD JAN
PY 1999
VL 33
IS 1
SU S
BP 360
EP 365
DI 10.1161/01.HYP.33.1.360
PN 2
PG 6
WC Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 163AC
UT WOS:000078379200032
PM 9931130
OA Bronze
DA 2018-12-27
ER

PT J
AU Sato, Y
   Manabe, S
   Kuno, H
   Oizumi, K
AF Sato, Y
   Manabe, S
   Kuno, H
   Oizumi, K
TI RETRACTED: Amelioration of osteopenia and hypovitaminosis D by 1
   alpha-hydroxyvitamin D3 in elderly patients with Parkinson's disease
   (Retracted article. See vol. 89, 2018)
SO JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
LA English
DT Article; Retracted Publication
DE osteoporosis; Parkinson's disease; vitamin D
ID BONE-MINERAL DENSITY; POSTMENOPAUSAL OSTEOPOROSIS; SENILE OSTEOPOROSIS;
   HIP-FRACTURES; LONG-TERM; CALCIUM; ABSORPTIOMETRY; WOMEN;
   SUPPLEMENTATION; FALLS
AB Objectives-A high prevalence of hip and other fractures in elderly patients with Parkinson's disease has been linked to reduced bone mass arising from a defect of renal synthesis of 1, 25-dihydroxyvitamin D (1, 25-[OH](2)D). Treatment with 1 alpha-hydroxyvitamin D3 (1 alpha(OH)D3; an active form of vitamin D) was evaluated for maintaining bone mass and reducing the incidence of hip and other nonvertebral fractures in patients with Parkinson's disease.
   Methods-In a double blind, randomised trial, 86 elderly patients with Parkinson's disease (mean Hoehn and Yahr stage, 3; mean age 70.6 years) were randomised to receive either 1 mu g 1 alpha(OH)D-3 daily (treatment group, n=43) or a placebo (n=43) for 18 months. Bone mineral densities in the second metacarpals were determined by computed radiographic densitometry. Serum bone turnover indices were measured serially, and incidence of nonvertebral fractures was recorded.
   Results-Bone mineral densities decreased 1.2% in the treatment group compared with 6.7% in the placebo group during 18 months (p<0.0001). At baseline in both groups, the serum concentration of 1, 25-[OH](2)D was reduced. Parathyroid hormone was abnormally increased in 15 patients (17%) and correlated negatively with serum 25-hydroxyvitamin D, indicating compensatory hyperparathyroidism. Eight patients sustained fractures (six at the hip and two at other sites) in the placebo group, and one hip fracture occurred among treated patients (odds ratio 9.8; p=0.0028).
   Conclusion-By increasing serum 1, 25-[OH](2)D concentrations, treatment with 1 alpha(OH)D3 can reduce the risk of hip and other non-vertebral fractures in osteoporotic elderly patients with Parkinson's disease by slowing the loss of bone mineral densities.
C1 Futase Social Insurance Hosp, Dept Neurol, Iizuka, Fukuoka, Japan.
   Kurume Univ, Sch Med, Dept Internal Med 1, Kurume, Fukuoka 830, Japan.
RP Sato, Y (reprint author), Kurume Univ, Med Ctr, Dept Neurol, 155-1 Kokubumachi, Kurume, Fukuoka 8390863, Japan.
EM y-sato@ktarn.or.jp
CR CARANO A, 1990, J CLIN INVEST, V85, P456, DOI 10.1172/JCI114459
   CHAPUY MC, 1992, NEW ENGL J MED, V327, P1637, DOI 10.1056/NEJM199212033272305
   CHIU KY, 1992, J TRAUMA, V32, P584, DOI 10.1097/00005373-199205000-00008
   COUGHLIN L, 1980, CLIN ORTHOP RELAT R, P192
   DawsonHughes B, 1997, NEW ENGL J MED, V337, P670, DOI 10.1056/NEJM199709043371003
   DERISQUEBOURG T, 1994, CALCIFIED TISSUE INT, V54, P461, DOI 10.1007/BF00334323
   ERIKSEN EF, 1993, J BONE MINER RES, V8, P127
   EVENTOV I, 1983, J TRAUMA, V23, P98, DOI 10.1097/00005373-198302000-00004
   GARNERO P, 1994, J BONE MINER RES, V9, P255
   GRISSO JA, 1991, NEW ENGL J MED, V324, P1326, DOI 10.1056/NEJM199105093241905
   INOUE T, 1994, J BONE MINER MET, V12, P145
   ISHIZAKI F, 1993, MOVEMENT DISORD, V8, P507, DOI 10.1002/mds.870080416
   JOHNELL O, 1992, AGE AGEING, V21, P32, DOI 10.1093/ageing/21.1.32
   KAO CH, 1994, NUCL MED COMMUN, V15, P173, DOI 10.1097/00006231-199403000-00010
   KOLLER WC, 1989, CLIN NEUROPHARMACOL, V12, P98
   MASTUMOTO C, 1994, CALCIFIED TISSUE INT, V55, P324, DOI DOI 10.1007/BF00299308
   Matsumoto C, 1992, SEIKEIGEKA, V43, P1140
   MENCZEL J, 1994, CLIN ORTHOP RELAT R, P241
   ORIMO H, 1994, CALCIFIED TISSUE INT, V54, P370, DOI 10.1007/BF00305521
   ORIMO H, 1987, BONE MINER, V3, P47
   ORIMO H, 1982, VITAMIN D CHEM BIOCH, P1239
   POUILLES JM, 1991, J BONE MINER RES, V6, P997
   Sato Y, 1997, NEUROLOGY, V49, P1273, DOI 10.1212/WNL.49.5.1273
   Sato Y, 1997, STROKE, V28, P736, DOI 10.1161/01.STR.28.4.736
   SHIRAKI M, 1993, BONE MINER, V20, P223, DOI 10.1016/S0169-6009(08)80003-7
   SHIRAKI M, 1993, OSTEOPOROSIS INT, V3, pS176
   STAEHELI JW, 1988, J BONE JOINT SURG AM, V70A, P565, DOI 10.2106/00004623-198870040-00013
   STORM T, 1993, J BONE MINER RES, V8, P199
   TILYARD MW, 1992, NEW ENGL J MED, V326, P357, DOI 10.1056/NEJM199202063260601
   WIMALAWANSA SJ, 1993, CALCIFIED TISSUE INT, V52, P90, DOI 10.1007/BF00308314
NR 30
TC 85
Z9 86
U1 0
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0022-3050
EI 1468-330X
J9 J NEUROL NEUROSUR PS
JI J. Neurol. Neurosurg. Psychiatry
PD JAN
PY 1999
VL 66
IS 1
BP 64
EP 68
DI 10.1136/jnnp.66.1.64
PG 5
WC Clinical Neurology; Psychiatry; Surgery
SC Neurosciences & Neurology; Psychiatry; Surgery
GA 154DC
UT WOS:000077872500016
PM 9886454
OA Bronze
DA 2018-12-27
ER

PT J
AU Fujii, Y
   Saitoh, Y
   Tanaka, H
   Toyooka, H
AF Fujii, Y
   Saitoh, Y
   Tanaka, H
   Toyooka, H
TI RETRACTED: Prophylactic oral antiemetics for preventing postoperative
   nausea and vomiting: Granisetron versus domperidone (Retracted article.
   See vol. 116, pg. 743, 2013)
SO ANESTHESIA AND ANALGESIA
LA English
DT Article; Retracted Publication
ID RECEPTOR ANTAGONIST; EFFICACY
AB Ln this prospective, randomized, double-blinded study, we evaluated the efficacy of the oral antiemetics, granisetron and domperidone, for the prevention of postoperative nausea and vomiting (PONV) in 100 women undergoing major gynecologic surgery. Patients received either granisetron 2 mg or domperidone 20 mg (n = 50 in each group) orally 1 h before surgery. Standardized anesthetic techniques and postoperative analgesia regimens were used. Complete response (defined as no PONV and no administration of rescue antiemetic medication) for 0 -3 h after anesthesia was 88% with granisetron and 52% with domperidone; the corresponding incidence for 3-24 h after anesthesia was 86% and 48% (P < 0.05). No clinically important adverse events due to the drugs were observed in any of the groups. In conclusion, the efficacy of preoperative oral granisetron is superior to that of domperidone fur the prevention of PONV after major gynecologic surgery. Implications: We compared the efficacy of granisetron and domperidone administered orally for the prevention of postoperative nausea and vomiting in women undergoing gynecologic surgery. Preoperative oral granisetron was more effective than domperidone.
C1 Univ Tsukuba, Inst Clin Med, Dept Anesthesiol, Tsukuba, Ibaraki 305, Japan.
   Toride Kyodo Gen Hosp, Dept Anesthesiol, Toride, Ibaraki, Japan.
RP Fujii, Y (reprint author), Univ Tsukuba, Inst Clin Med, Dept Anesthesiol, 2-1-1 Amakubo, Tsukuba, Ibaraki 305, Japan.
CR ANDREWS P L R, 1992, European Journal of Cancer, V28A, pS2, DOI 10.1016/0959-8049(92)90628-F
   ASPINALL RL, 1995, BRIT MED J, V311, P844, DOI 10.1136/bmj.311.7009.844
   BERMUDEZ J, 1988, BRIT J CANCER, V58, P644, DOI 10.1038/bjc.1988.277
   BROGDEN RN, 1982, DRUGS, V24, P360, DOI 10.2165/00003495-198224050-00002
   CARMICHAEL J, 1989, CANCER CHEMOTH PHARM, V24, P45
   Fujii Y, 1998, ACTA ANAESTH SCAND, V42, P653, DOI 10.1111/j.1399-6576.1998.tb05297.x
   FUJII Y, 1994, CAN J ANAESTH, V41, P794, DOI 10.1007/BF03011585
   FUJII Y, 1994, CAN J ANAESTH, V41, P291, DOI 10.1007/BF03009906
   KUDOH S, 1993, JPN PHARMACOL THER, V21, P169
   Maisano R, 1995, ANTICANCER RES, V15, P2287
   WATCHA MF, 1992, ANESTHESIOLOGY, V77, P162, DOI 10.1097/00000542-199207000-00023
NR 11
TC 5
Z9 5
U1 1
U2 11
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0003-2999
J9 ANESTH ANALG
JI Anesth. Analg.
PD DEC
PY 1998
VL 87
IS 6
BP 1404
EP 1407
DI 10.1097/00000539-199812000-00037
PG 4
WC Anesthesiology
SC Anesthesiology
GA 142AP
UT WOS:000077178000037
PM 9842837
DA 2018-12-27
ER

PT J
AU Brigneti, G
   Voinnet, O
   Li, WX
   Ji, LH
   Ding, SW
   Baulcombe, DC
AF Brigneti, G
   Voinnet, O
   Li, WX
   Ji, LH
   Ding, SW
   Baulcombe, DC
TI RETRACTED: Viral pathogenicity determinants are suppressors of transgene
   silencing in Nicotiana benthamiana (Retracted article. See vol. 34, pg.
   2595, 2015)
SO EMBO JOURNAL
LA English
DT Article; Retracted Publication
DE cucumber mosaic virus; gene silencing; potato virus X; potato virus Y;
   virus resistance
ID POTATO VIRUS-X; GENE-EXPRESSION; GENOMIC RNA; PLANTS; RESISTANCE;
   POTYVIRUS; REPLICATION; MOVEMENT; STRAIN; DNA
AB Post-transcriptional gene silencing (PTGS) of a green fluorescent protein (GFP) transgene is suppressed in Nicotiana benthamiana plants infected with potato virus Y (PVY) or with cucumber mosaic virus (CMV), but not in plants infected with potato virus X (PVX). By expressing PVY and CMV-encoded proteins in a PVX vector we have shown that the viral suppressors of gene silencing are the HCPro of PVY and the 2b protein of CMV. The HCPro acts by blocking the maintenance of PTGS in tissues where silencing had already been set, whereas the 2b protein prevents initiation of gene silencing at the growing points of the plants. Combined with previous findings that viruses are both activators and targets of PTGS, these data provide compelling evidence that PTGS represents a natural mechanism for plant protection against viruses.
C1 John Innes Ctr Plant Sci Res, Sainsbury Lab, Norwich NR4 7UH, Norfolk, England.
   Natl Univ Singapore, Inst Mol Agrobiol, Mol Virol Lab, Singapore 117604, Singapore.
RP Baulcombe, DC (reprint author), John Innes Ctr Plant Sci Res, Sainsbury Lab, Colney Lane, Norwich NR4 7UH, Norfolk, England.
EM david.baulcombe@bbsrc.ac.uk
OI Baulcombe, David/0000-0003-0780-6878
CR ANANDALAKSHMI R, 1998, IN PRESS P NATL ACAD, V95
   BAULCOMBE DC, 1986, NATURE, V321, P446, DOI 10.1038/321446a0
   Baulcombe DC, 1996, PLANT CELL, V8, P1833
   BAULCOMBE DC, 1995, PLANT J, V7, P1045, DOI 10.1046/j.1365-313X.1995.07061045.x
   CHAPMAN S, 1992, PLANT J, V2, P549
   Cogoni C, 1997, TRENDS PLANT SCI, V2, P438, DOI 10.1016/S1360-1385(97)90028-5
   Covey SN, 1997, NATURE, V385, P781, DOI 10.1038/385781a0
   CRONIN S, 1995, PLANT CELL, V7, P549, DOI 10.1105/tpc.7.5.549
   DEPICKER A, 1997, CURR OPIN CELL BIOL, V9, P372
   DING SW, 1995, EMBO J, V14, P5762, DOI 10.1002/j.1460-2075.1995.tb00265.x
   English JJ, 1997, PLANT J, V12, P597, DOI 10.1046/j.1365-313X.1997.00597.x
   English JJ, 1996, PLANT CELL, V8, P179
   Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888
   Guo HS, 1997, MOL PLANT MICROBE IN, V10, P160, DOI 10.1094/MPMI.1997.10.2.160
   Hamilton CM, 1996, P NATL ACAD SCI USA, V93, P9975, DOI 10.1073/pnas.93.18.9975
   KASSCHAU KD, 1998, IN PRESS CELL, V95
   KAVANAGH T, 1992, VIROLOGY, V189, P609, DOI 10.1016/0042-6822(92)90584-C
   Kjemtrup S, 1998, PLANT J, V14, P91, DOI 10.1046/j.1365-313X.1998.00101.x
   KUMAGAI MH, 1995, P NATL ACAD SCI USA, V92, P1679, DOI 10.1073/pnas.92.5.1679
   LINDBO JA, 1993, PLANT CELL, V5, P1749, DOI 10.1105/tpc.5.12.1749
   Matthews REF, 1991, PLANT VIROLOGY
   MATZKE MA, 1995, PLANT PHYSIOL, V107, P6679
   MUELLER E, 1995, PLANT J, V7, P1001, DOI 10.1046/j.1365-313X.1995.07061001.x
   MURPHY JF, 1995, PHYTOPATHOLOGY, V85, P561, DOI 10.1094/Phyto-85-561
   Palauqui JC, 1997, EMBO J, V16, P4738, DOI 10.1093/emboj/16.15.4738
   PIORIBEIRO G, 1978, PHYTOPATHOLOGY, V68, P1260
   Pruss G, 1997, PLANT CELL, V9, P859, DOI 10.1105/tpc.9.6.859
   Ratcliff F, 1997, SCIENCE, V276, P1558, DOI 10.1126/science.276.5318.1558
   ROBAGLIA C, 1989, J GEN VIROL, V70, P935, DOI 10.1099/0022-1317-70-4-935
   Ruiz F, 1998, MOL BIOL CELL, V9, P931, DOI 10.1091/mbc.9.4.931
   Ruiz MT, 1998, PLANT CELL, V10, P937
   SMITH HA, 1994, PLANT CELL, V6, P1441
   THOLE V, 1993, GENE, V123, P149, DOI 10.1016/0378-1119(93)90118-M
   VANCE VB, 1991, VIROLOGY, V182, P486
   Voinnet O, 1997, NATURE, V389, P553, DOI 10.1038/39215
   VOINNET O, 1998, IN PRESS CELL, V95
NR 36
TC 813
Z9 898
U1 19
U2 155
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0261-4189
EI 1460-2075
J9 EMBO J
JI Embo J.
PD NOV 16
PY 1998
VL 17
IS 22
BP 6739
EP 6746
DI 10.1093/emboj/17.22.6739
PG 8
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 145WC
UT WOS:000077393700029
PM 9822616
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Schon, JH
   Kloc, C
   Laudise, RA
   Batlogg, B
AF Schon, JH
   Kloc, C
   Laudise, RA
   Batlogg, B
TI RETRACTED: Electrical properties of single crystals of rigid rodlike
   conjugated molecules (Retracted article. See vol B 66, art. no. 249904,
   2002)
SO PHYSICAL REVIEW B
LA English
DT Article; Retracted Publication
ID FIELD-EFFECT TRANSISTORS; ALKYL-SUBSTITUTED OLIGOTHIOPHENES; THIN-FILM;
   EFFECT MOBILITY; IODINE
AB Acceptor concentrations, carrier (hole) mobilities, and trap densities in single crystals of alpha-quaterthiophene, alpha-hexathiophene, and pentacene have been determined by temperature-dependent measurements of Ohmic and space-charge limited currents. Bulk mobilities of 0.06, 0.46, and 1.4 cm(2)/V s have been measured in these three materials along the crystallographic directions with best orbital overlap between molecules. The influence of reducing the oxidizing atmosphere during crystal growth and annealing was investigated. The trap density in these materials is minimized by growing the crystals in reducing atmospheres and increased by post-growth oxygen treatment. Residual dopant densities as low as similar to 10(11) cm(-3) could be achieved. Iodine, introduced during the crystal-growth process, enhances the conductivity up to 10(-3) S/cm. [S0163-1829(98)04443-9].
C1 AT&T Bell Labs, Lucent Technol, Murray Hill, NJ 07974 USA.
   Univ Konstanz, D-78434 Constance, Germany.
RP Schon, JH (reprint author), AT&T Bell Labs, Lucent Technol, 700 Mt Ave, Murray Hill, NJ 07974 USA.
RI Kloc, Christian/A-2255-2011
CR AKIMICHI H, 1991, APPL PHYS LETT, V58, P1500, DOI 10.1063/1.105158
   BARBE DF, 1970, J CHEM PHYS, V52, P4046, DOI 10.1063/1.1673607
   DODABALAPUR A, 1995, SCIENCE, V268, P270, DOI 10.1126/science.268.5208.270
   Garnier F, 1996, SYNTHETIC MET, V81, P163, DOI 10.1016/S0379-6779(96)03761-7
   Gutmann F., 1967, ORGANIC SEMICONDUCTO
   HADDON RC, 1995, J MATER CHEM, V5, P1719, DOI 10.1039/jm9950501719
   Hajlaoui R, 1997, ADV MATER, V9, P389, DOI 10.1002/adma.19970090504
   HOROWITZ G, 1995, J PHYS III, V5, P355, DOI 10.1051/jp3:1995132
   Horowitz G, 1996, ADV MATER, V8, P52, DOI 10.1002/adma.19960080109
   HOROWITZ G, 1989, SOLID STATE COMMUN, V72, P381, DOI 10.1016/0038-1098(89)90121-X
   HOTTA S, 1991, J MATER CHEM, V1, P835, DOI 10.1039/jm9910100835
   Kao K. C., 1981, ELECT TRANSPORT SOLI
   Katz HE, 1995, CHEM MATER, V7, P2235, DOI 10.1021/cm00060a007
   Kloc C, 1997, J CRYST GROWTH, V182, P416, DOI 10.1016/S0022-0248(97)00370-9
   Laquindanum JG, 1996, CHEM MATER, V8, P2542, DOI 10.1021/cm9603664
   LAUDISE RA, 1995, J CRYST GROWTH, V152, P241, DOI 10.1016/0022-0248(95)00134-4
   Laudise RA, 1998, J CRYST GROWTH, V187, P449, DOI 10.1016/S0022-0248(98)00034-7
   Lin Y-Y, 1996, 54 ANN DEV RES C DIG, P80
   Lin YY, 1997, 55TH ANNUAL DEVICE RESEARCH CONFERENCE, DIGEST - 1997, P60, DOI 10.1109/DRC.1997.612475
   MINAKATA T, 1991, J APPL PHYS, V69, P7354, DOI 10.1063/1.347594
   MINAKATA T, 1992, J APPL PHYS, V72, P4178, DOI 10.1063/1.352227
   PALOHEIMO J, 1990, APPL PHYS LETT, V56, P1157, DOI 10.1063/1.103182
   SCHEIN LB, 1977, PHYS REV B, V15, P1024, DOI 10.1103/PhysRevB.15.1024
   SIEGRIST T, 1998, ADV MATER, V10, P375
NR 24
TC 81
Z9 81
U1 2
U2 19
PU AMER PHYSICAL SOC
PI COLLEGE PK
PA ONE PHYSICS ELLIPSE, COLLEGE PK, MD 20740-3844 USA
SN 1098-0121
EI 1550-235X
J9 PHYS REV B
JI Phys. Rev. B
PD NOV 15
PY 1998
VL 58
IS 19
BP 12952
EP 12957
DI 10.1103/PhysRevB.58.12952
PG 6
WC Materials Science, Multidisciplinary; Physics, Applied; Physics,
   Condensed Matter
SC Materials Science; Physics
GA 144CE
UT WOS:000077295500070
DA 2018-12-27
ER

PT J
AU Fujii, Y
   Takahashi, S
   Toyooka, H
AF Fujii, Y
   Takahashi, S
   Toyooka, H
TI RETRACTED: The effects of milrinone and its mechanism in the fatigued
   diaphragm in dogs (Retracted article. See vol. 116, pg. 743, 2013)
SO ANESTHESIA AND ANALGESIA
LA English
DT Article; Retracted Publication
ID RESPIRATORY-FAILURE; CANINE DIAPHRAGM; MUSCLE FATIGUE; CONTRACTILITY;
   DOBUTAMINE; AMINOPHYLLINE; ACIDOSIS
AB We studied the effects of milrinone and its mechanism in nonfatigued and fatigued diaphragms in dogs. In Group Ia (n = 5), animals without fatigue, defined as the inability to sustain muscle force, received only maintenance fluids. Ln Group Ib (n = 5), dogs without fatigue were given a bolus injection (50 mu g/kg) followed by continuous infusion (0.5 mu g.kg(-1).min-(1)) of milrinone. In Groups IIa, IIb, and IIc (n = 8 in each), diaphragmatic fatigue was induced by intermittent supramaximal bilateral electrophrenic stimulation at a frequency of 20 Hz applied for 30 min. After producing fatigue, only maintenance fluids were administered (Group IIa); milrinone (50 mu g/kg loading dose plus 0.5 mu g.kg(-1).min(-1) maintenance dose) was administered (Group IIb); or nicardipine 5 mu g.kg(-1).min(-1) was infused simultaneously with milrinone (Group IIc). Diaphragmatic contractility was assessed with transdiaphragmatic pressure (Pdi). No differences in Pdi were observed in Groups Ia and Ib. After the fatigue-producing period, Pdi at low-frequency (20-Hz) stimulation decreased from the prefatigued values in Groups IIa, Ire, and IIc (P < 0.05), whereas the decrease was minimal at high-frequency (100-Hz) stimulation. Compared with Group IIa, Pdi to each stimulus increased during milrinone infusion in Group IIb, (P < 0.05). In Group IIc, the augmentation of Pdi in the fatigued diaphragm by milrinone was not abolished with an administration of nicardipine. In conclusion, milrinone improves contractility in the fatigued canine diaphragm but not via its effect on transmembrane calcium movement. Implications: Diaphragmatic fatigue may contribute to the development of respiratory failure. Milrinone increases contractility in the fatigued diaphragm and thereby may have an inotropic action on the improvement of diaphragmatic fatigue.
C1 Univ Tsukuba, Inst Clin Med, Dept Anesthesiol, Tsukuba, Ibaraki 305, Japan.
RP Fujii, Y (reprint author), Univ Tsukuba, Inst Clin Med, Dept Anesthesiol, 2-1-1 Amakubo, Tsukuba, Ibaraki 305, Japan.
CR ANSELL J, 1984, ARCH INTERN MED, V144, P949, DOI 10.1001/archinte.144.5.949
   AUBIER M, 1983, J APPL PHYSIOL, V54, P460
   AUBIER M, 1989, ANN INTERN MED, V110, P17, DOI 10.7326/0003-4819-110-1-17
   AUBIER M, 1986, J APPL PHYSIOL, V61, P1767
   COHEN CA, 1982, AM J MED, V73, P308, DOI 10.1016/0002-9343(82)90711-2
   COLUCCI WS, 1986, CIRCULATION, V73, P175
   EBATA T, 1992, CAN J ANAESTH, V39, P375, DOI 10.1007/BF03009049
   ESAU SA, 1989, AM REV RESPIR DIS, V139, P1410, DOI 10.1164/ajrccm/139.6.1410
   FUJII Y, 1995, CAN J ANAESTH, V42, P80, DOI 10.1007/BF03010577
   FUJII Y, 1993, CAN J ANAESTH, V40, P453, DOI 10.1007/BF03009517
   FUJII Y, 1994, CAN J ANAESTH, V41, P435, DOI 10.1007/BF03009869
   GRASSINO A, 1978, J APPL PHYSIOL, V44, P829
   HOWELL S, 1984, AM REV RESPIR DIS, V129, P118
   HOWELL S, 1985, J APPL PHYSIOL, V59, P1376
   IDE T, 1992, ANESTH ANALG, V74, P739
   KIKURA M, 1995, ANESTH ANALG, V81, P44, DOI 10.1097/00000539-199507000-00009
   MACKLEM PT, 1977, CLIN SCI MOL MED, V53, P419, DOI 10.1042/cs0530419
   ROBERTSON CH, 1977, J CLIN INVEST, V59, P31, DOI 10.1172/JCI108619
   ROSSING TH, 1987, AM REV RESPIR DIS, V136, P841, DOI 10.1164/ajrccm/136.4.841
   ROUSSOS C, 1982, NEW ENGL J MED, V307, P786, DOI 10.1056/NEJM198209233071304
   YOUNG RA, 1988, DRUGS, V36, P158, DOI 10.2165/00003495-198836020-00003
NR 21
TC 16
Z9 16
U1 2
U2 10
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0003-2999
J9 ANESTH ANALG
JI Anesth. Analg.
PD NOV
PY 1998
VL 87
IS 5
BP 1077
EP 1082
DI 10.1097/00000539-199811000-00018
PG 6
WC Anesthesiology
SC Anesthesiology
GA 133NH
UT WOS:000076692300018
PM 9806685
DA 2018-12-27
ER

PT J
AU Chen, MYM
   Ott, DJ
   Casolo, BJ
   Moghazy, KM
   Koufman, JA
AF Chen, MYM
   Ott, DJ
   Casolo, BJ
   Moghazy, KM
   Koufman, JA
TI RETRACTED: Correlation of laryngeal and pharyngeal carcinomas and
   24-hour pH monitoring of the esophagus and pharynx (Retracted article.
   See vol 121, pg 168, 1999)
SO OTOLARYNGOLOGY-HEAD AND NECK SURGERY
LA English
DT Article; Retracted Publication
ID GASTROESOPHAGEAL REFLUX DISEASE; OTOLARYNGOLOGIC MANIFESTATIONS;
   LARYNGITIS
AB The cause of laryngeal and pharyngeal carcinomas is likely multifactorial. Smoking is an important factor, but mucosal damage from gastroesophageal reflux may also contribute. The purpose of this study was to determine whether gastroesophageal reflux is more common in patients with laryngeal or pharyngeal carcinomas than in those without these malignancies, Over an 8-year period, we correlated the results of clinical and radiographic examinations of the pharynx and esophagus to pH monitoring results in 798 patients with a variety of upper aerodigestive tract symptoms and who underwent both pH monitoring and barium esophagography, In this group, 63 patients (52 men, 11 women) had laryngeal or pharyngeal carcinomas, and 735 patients (319 men, 416 women) had neither malignancy. Abnormal pH findings were defined as a total percentage of esophageal acid exposure time of 6% or more as determined with the esophageal probe, or any reflux event detected with the pharyngeal probe, Thirty-four of 63 patients with carcinomas (54%) had abnormal pH-monitoring results: Esophageal acid exposure was abnormal in 10 patients, pharyngeal acid exposure was abnormal in 7 patients, and acid exposure was abnormal in both areas in 17 patients. Of the 735 patients without malignancies, 365 (50%) had abnormal pH-monitoring results (p > 0.05). In this population of patients, abnormal results of pH monitoring were common, occurring in 399 (50%) of 798 patients, but no significant difference was found between results in those with and without laryngeal or pharyngeal carcinomas, Therefore, our study found that gastroesophageal reflux as shown by pH monitoring was not more common in patients with these malignancies.
C1 Wake Forest Univ, Bowman Gray Sch Med, Dept Radiol, Winston Salem, NC 27157 USA.
   Wake Forest Univ, Bowman Gray Sch Med, Dept Otolaryngol, Winston Salem, NC 27157 USA.
RP Chen, MYM (reprint author), Wake Forest Univ, Bowman Gray Sch Med, Dept Radiol, Med Ctr Blvd, Winston Salem, NC 27157 USA.
CR CANN CI, 1985, OTOLARYNG CLIN N AM, V18, P367
   CHEN MYM, 1992, RADIOLOGY, V185, P483, DOI 10.1148/radiology.185.2.1410359
   DEVENEY CW, 1993, ARCH SURG-CHICAGO, V128, P1021
   GAYNOR EB, 1991, AM J GASTROENTEROL, V86, P801
   HANSON DG, 1995, ANN OTO RHINOL LARYN, V104, P550, DOI 10.1177/000348949510400709
   KOUFMAN JA, 1991, LARYNGOSCOPE, V101, P1
   MORRISON MD, 1988, OTOLARYNG HEAD NECK, V99, P370, DOI 10.1177/019459988809900403
   OLSON NR, 1991, OTOLARYNG CLIN N AM, V24, P1201
   PRICE JC, 1990, ARCH OTOLARYNGOL, V116, P163
   STANCIU C, 1972, BRIT MED J, V3, P793, DOI 10.1136/bmj.3.5830.793
   WARD PH, 1988, LARYNGOSCOPE, V98, P1195
   WIENER GJ, 1987, GASTROENTEROLOGY, V92, P1694
   WILSON JA, 1989, ANN OTO RHINOL LARYN, V98, P405
NR 13
TC 33
Z9 36
U1 2
U2 7
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0194-5998
EI 1097-6817
J9 OTOLARYNG HEAD NECK
JI Otolaryngol. Head Neck Surg.
PD NOV
PY 1998
VL 119
IS 5
BP 460
EP 462
PG 3
WC Otorhinolaryngology; Surgery
SC Otorhinolaryngology; Surgery
GA 137JR
UT WOS:000076912000006
PM 9807069
DA 2018-12-27
ER

PT J
AU Chen, HC
   Yip, YK
   George, I
   Tyorkin, M
   Salik, E
   Sperber, K
AF Chen, HC
   Yip, YK
   George, I
   Tyorkin, M
   Salik, E
   Sperber, K
TI RETRACTED: Chronically HIV-1-infected monocytic cells induce apoptosis
   in cocultured T cells (Retracted Article. See vol 177, pg 6560, 2006)
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article; Retracted Publication
ID HUMAN-IMMUNODEFICIENCY-VIRUS; ACTIVATION-INDUCED APOPTOSIS; ENVELOPE
   GLYCOPROTEIN GP120; HUMAN MACROPHAGE HYBRIDOMAS; HIV-INFECTION; FAS
   ANTIGEN; CROSS-LINKING; PROTEASE INHIBITORS; INTERFERON-GAMMA;
   PROGRAMMED DEATH
AB We have previously developed a human macrophage hybridoma model system to study the effect of HIV-1 infection on monocytic function. Upon coculture of one chronically (35 days postinfection) HIV-1-infected human macrophage hybridoma cell line, 43(HIV), there was a dose-dependent decrease in the viability of cocultured Ag-stimulated T cells associated with an increase in DNA strand breaks. Enhanced apoptosis was determined by labeling with biotinylated dUTP and propidium iodide, increased staining with annexin V, increased side light scatter and expression of CD95, and decreased forward light scatter and expression of Bcl-2, There was also increased DNA strand breaks as determined by propidium iodide staining in unstimulated T cells cocultured with 43, and in T cells stimulated with anti-CD3 mAb and PHA, Pretreatment with 5145, a human polyclonal anti-gp120 Ab that recognizes the CD4 binding region, as well as with an anti-Fas ligand mAb blocked apoptosis in CD4(+) T cells but not in CD8(+) T cells. A soluble factor with a M-r below 10,000 Da was defined that induced apoptosis in CD4(+) and CD8(+) T cells and B cells. SDS-PAGE analysis of the active fractions revealed a band of 6000 Da that, after electroelution, had proapoptotic activity. The pI of the activity was estimated to be between 6.5 and 7.0, In conclusion, chronically HIV-1-infected monocytic cells induce apoptosis in bystander-, Ag-, anti-CD3-, and mitogen-stimulated T cells by multiple factors, which may contribute to the depletion of lymphocytes induced by HIV-1.
C1 Mt Sinai Med Ctr, Div Clin Immunol, New York, NY 10029 USA.
   CUNY Hunter Coll, Dept Biol Sci, New York, NY 10021 USA.
RP Sperber, K (reprint author), Mt Sinai Med Ctr, Div Clin Immunol, Box 1089,1 Gustave Levy Pl, New York, NY 10029 USA.
FU PHS HHS [R-29-256990]; NCRR NIH HHS [RR-03037]
CR Adachi Y, 1996, J IMMUNOL, V157, P4184
   AZIZ DC, 1989, NATURE, V338, P505, DOI 10.1038/338505a0
   Badley AD, 1996, J VIROL, V70, P199
   BANDA NK, 1992, J EXP MED, V176, P1099, DOI 10.1084/jem.176.4.1099
   CARBONARI M, 1994, BLOOD, V83, P1268
   CHIRMULE N, 1990, BLOOD, V75, P152
   CLEMENT MV, 1994, J EXP MED, V180, P557, DOI 10.1084/jem.180.2.557
   CLERICI M, 1994, P NATL ACAD SCI USA, V91, P11811, DOI 10.1073/pnas.91.25.11811
   COLLMAN R, 1992, J VIROL, V66, P7517
   DEBATIN KM, 1994, BLOOD, V83, P3101
   DIAMOND DC, 1988, J IMMUNOL, V141, P3715
   ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0
   FADOK VA, 1992, J IMMUNOL, V148, P2207
   FINKEL TH, 1995, NAT MED, V1, P129, DOI 10.1038/nm0295-129
   GARTNER S, 1986, SCIENCE, V233, P215, DOI 10.1126/science.3014648
   GENDELMAN HE, 1991, J VIROL, V65, P3853
   GENDELMAN HE, 1992, J IMMUNOL, V148, P422
   GENDELMAN HE, 1988, J EXP MED, V167, P1428, DOI 10.1084/jem.167.4.1428
   GRELL M, 1994, J IMMUNOL, V153, P1963
   GRIBBEN JG, 1995, P NATL ACAD SCI USA, V92, P811, DOI 10.1073/pnas.92.3.811
   GROUX H, 1993, EUR J IMMUNOL, V23, P1623, DOI 10.1002/eji.1830230734
   GROUX H, 1992, J EXP MED, V175, P331, DOI 10.1084/jem.175.2.331
   Himmelhoch S. R., 1971, METHOD ENZYMOL, V22, P273, DOI DOI 10.1016/0076-6879(71)22028-0
   HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0
   HUGHES MH, 1983, COMPUT PHYS COMMUN, V29, P59, DOI 10.1016/0010-4655(83)90027-9
   HUGIN AW, 1991, SCIENCE, V252, P424, DOI 10.1126/science.1850169
   ITOH N, 1993, J IMMUNOL, V151, P621
   JOHNSON BK, 1993, AIDS RES HUM RETROV, V9, P375, DOI 10.1089/aid.1993.9.375
   JUNE CH, 1994, IMMUNOL TODAY, V15, P321, DOI 10.1016/0167-5699(94)90080-9
   KABAYOSHI N, 1990, P NATL ACAD SCI USA, V90, P7573
   KLIMKAIT T, 1990, J VIROL, V64, P621
   KOOPMAN G, 1994, BLOOD, V84, P1415
   LEWIS DE, 1994, J IMMUNOL, V153, P412
   LIU Y, 1990, Journal of Experimental Medicine, V172, P1735, DOI 10.1084/jem.172.6.1735
   LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0
   MCCLOSKEY TW, 1995, CYTOMETRY, V22, P111, DOI 10.1002/cyto.990220206
   McCloskey TW, 1997, J IMMUNOL, V158, P1014
   MELTZER MS, 1990, IMMUNOL TODAY, V11, P217, DOI 10.1016/0167-5699(90)90086-O
   MEYAARD L, 1994, J CLIN INVEST, V93, P982, DOI 10.1172/JCI117105
   MEYAARD L, 1992, SCIENCE, V257, P217, DOI 10.1126/science.1352911
   MOSIER DE, 1993, SCIENCE, V260, P689, DOI 10.1126/science.8097595
   MUCHOCACHO CA, 1994, J IMMUNOL, V154, P5555
   Munn DH, 1996, J IMMUNOL, V156, P523
   NOVELLI F, 1994, J IMMUNOL, V152, P496
   OWENSCHAUB LB, 1992, CELL IMMUNOL, V140, P197, DOI 10.1016/0008-8749(92)90187-T
   OYAIZU N, 1993, BLOOD, V82, P3392
   Oyaizu N, 1997, J IMMUNOL, V158, P2456
   OYAIZU N, 1994, BLOOD, V84, P2622
   OYAIZU N, 1990, P NATL ACAD SCI USA, V87, P2379, DOI 10.1073/pnas.87.6.2379
   OYAIZU N, 1995, J CLIN IMMUNOL, V15, P217, DOI 10.1007/BF01540879
   PANTALEO G, 1991, P NATL ACAD SCI USA, V88, P9838, DOI 10.1073/pnas.88.21.9838
   PANTALEO G, 1993, NEW ENGL J MED, V328, P327
   PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0
   PINTER A, 1993, AIDS RES HUM RETROV, V9, P985, DOI 10.1089/aid.1993.9.985
   POLI G, 1992, AIDS RES HUM RETROV, V8, P191, DOI 10.1089/aid.1992.8.191
   Polyak S, 1997, J IMMUNOL, V159, P2177
   POPE M, 1994, CELL, V78, P389, DOI 10.1016/0092-8674(94)90418-9
   POPOVIC M, 1984, SCIENCE, V224, P497, DOI 10.1126/science.6200935
   SARIN A, 1994, J IMMUNOL, V153, P862
   SARIN A, 1993, J EXP MED, V178, P1693, DOI 10.1084/jem.178.5.1693
   SCHUITEMAKER H, 1993, J INFECT DIS, V168, P1140, DOI 10.1093/infdis/168.5.1140
   SHERRIS D, 1989, J IMMUNOL, V142, P2343
   Sperber K, 1998, INFLAMM BOWEL DIS, V4, P12, DOI 10.1097/00054725-199802000-00003
   SPERBER K, 1990, J CLIN LAB IMMUNOL, V31, P151
   SPERBER K, 1990, J IMMUNOL METHODS, V129, P31, DOI 10.1016/0022-1759(90)90417-T
   SPERBER K, 1993, AIDS RES HUM RETROV, V9, P657, DOI 10.1089/aid.1993.9.657
   Suss G, 1996, J EXP MED, V183, P1789, DOI 10.1084/jem.183.4.1789
   TALBOT PJ, 1984, J IMMUNOL METHODS, V73, P177, DOI 10.1016/0022-1759(84)90043-7
   WANG J, 1994, J IMMUNOL, V152, P3824
   WATANABE M, 1991, J VIROL, V65, P3344
   WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0
   WU X, 1994, P NATL ACAD SCI USA, V92, P1525
   WYSOCKI LJ, 1978, P NATL ACAD SCI USA, V75, P2844, DOI 10.1073/pnas.75.6.2844
   Yoo L, 1996, J IMMUNOL, V157, P1313
NR 74
TC 29
Z9 29
U1 0
U2 8
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
EI 1550-6606
J9 J IMMUNOL
JI J. Immunol.
PD OCT 15
PY 1998
VL 161
IS 8
BP 4257
EP 4267
PG 11
WC Immunology
SC Immunology
GA 127GV
UT WOS:000076343300061
PM 9780201
DA 2018-12-27
ER

PT J
AU Barbaro, G
   Di Lorenzo, G
   Grisorio, B
   Barbarini, G
AF Barbaro, G
   Di Lorenzo, G
   Grisorio, B
   Barbarini, G
CA Gruppo Italiano Studio Cardiologico Pazienti Af
TI RETRACTED: Incidence of dilated cardiomyopathy and detection of HIV in
   myocardial cells of HIV-positive patients (Retracted Article. See vol
   347, pg 140, 2002)
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article; Retracted Publication
ID ACQUIRED-IMMUNODEFICIENCY-SYNDROME; IMMUNE-DEFICIENCY-SYNDROME;
   TWO-DIMENSIONAL ECHOCARDIOGRAPHY; LEFT-VENTRICULAR DYSFUNCTION; SYNDROME
   AIDS; CONGESTIVE CARDIOMYOPATHY; CARDIAC MANIFESTATIONS;
   VIRUS-INFECTION; HEART
AB Background Human immunodeficiency virus (HIV) infection is increasingly recognized as an important cause of dilated cardiomyopathy. However, the pathogenesis of the heart-muscle disease in the acquired immunodeficiency syndrome is unclear.
   Methods We performed a prospective, long-term clinical and echocardiographic follow-up study of 952 asymptomatic HIV-positive patients to assess the incidence of dilated cardiomyopathy and to analyze the clinical variables associated with the development of cardiomyopathy. All patients with an echocardiographic diagnosis of dilated cardiomyopathy underwent endomyocardial biopsy for histologic, immunohistologic, and virologic assessment.
   Results During a mean (+/-SD) follow-up period of 60+/-5.3 months, an echocardiographic diagnosis of dilated cardiomyopathy was made in 76 patients (8 percent), with a mean annual incidence rate of 15.9 cases per 1000 patients. The incidence of dilated cardiomyopathy was higher in patients with a CD4 count of less than 400 cells per cubic millimeter (as compared with a CD4 count of greater than or equal to 400 cells per cubic millimeter) and in those who received therapy with zidovudine. A histologic diagnosis of myocarditis was made in 63 of the patients with dilated cardiomyopathy (83 percent). Inflammatory infiltrates were predominantly composed of CD3 and CD8 lymphocytes, with staining for major histocompatibility complex class I antigens in 71 percent of the patients. In the myocytes of 58 patients, HIV nucleic acid sequences were detected by in situ hybridization, and active myocarditis was documented in 36 of the 58. Among these 36 patients, 6 were also infected with coxsackievirus group B (17 percent), 2 with cytomegalovirus (6 percent), and 1 with Epstein-Barr virus (3 percent).
   Conclusions Dilated cardiomyopathy may be related either to a direct action of HIV on the myocardial tissue or to an autoimmune process induced by HIV, possibly in association with other cardiotropic viruses. (N Engl J Med 1998;339:1093-9,) (C) 1998. Massachusetts Medical Society.
C1 Univ Roma La Sapienza, Dept Emergency Med, Rome, Italy.
   Gen Hosp, Div Infect Dis, Foggia, Italy.
   Univ Pavia, Policlin San Matteo, Dept Infect & Trop Dis, I-27100 Pavia, Italy.
RP Barbaro, G (reprint author), Viale Anicio Gallo 63, I-00174 Rome, Italy.
CR ACIERNO LJ, 1989, J AM COLL CARDIOL, V13, P1144, DOI 10.1016/0735-1097(89)90277-5
   ANDERSON DW, 1988, J AM COLL CARDIOL, V11, P792, DOI 10.1016/0735-1097(88)90213-6
   Aretz H T, 1987, Am J Cardiovasc Pathol, V1, P3
   Armitage P., 1994, STAT METHODS MED RES
   Barbaro G, 1996, AIDS RES HUM RETROV, V12, P1559, DOI 10.1089/aid.1996.12.1559
   Barbaro G, 1996, Cardiologia, V41, P1199
   BAROLDI G, 1988, J AM COLL CARDIOL, V12, P463, DOI 10.1016/0735-1097(88)90420-2
   BESCHORNER WE, 1990, AM J PATHOL, V137, P1365
   BESTETTI RB, 1989, INT J CARDIOL, V22, P143, DOI 10.1016/0167-5273(89)90060-0
   BYRD BF, 1985, J AM COLL CARDIOL, V6, P1021, DOI 10.1016/S0735-1097(85)80304-1
   CALABRESE LH, 1987, ANN INTERN MED, V107, P691, DOI 10.7326/0003-4819-107-5-691
   Caves P K, 1973, Ann Thorac Surg, V16, P325
   COHEN IS, 1986, NEW ENGL J MED, V315, P628, DOI 10.1056/NEJM198609043151007
   DEAN AG, 1994, EPI INFO VERSION 6 M
   DOMANSKI MJ, 1995, J PEDIATR-US, V127, P137, DOI 10.1016/S0022-3476(95)70275-X
   FACTOR SM, 1989, J AM COLL CARDIOL, V13, P1037, DOI 10.1016/0735-1097(89)90257-X
   GRODY WW, 1990, AM J CARDIOL, V66, P203, DOI 10.1016/0002-9149(90)90589-S
   HERSKOWITZ A, 1993, CLIN IMMUNOL IMMUNOP, V68, P234, DOI 10.1006/clin.1993.1124
   HERSKOWITZ A, 1994, J AM COLL CARDIOL, V24, P1025, DOI 10.1016/0735-1097(94)90865-6
   HERSKOWITZ A, 1992, ANN INTERN MED, V116, P311, DOI 10.7326/0003-4819-116-4-311
   HIMELMAN RB, 1989, J AM COLL CARDIOL, V13, P1030, DOI 10.1016/0735-1097(89)90256-8
   KAUL S, 1991, AM HEART J, V122, P535, DOI 10.1016/0002-8703(91)91013-D
   LEVY WS, 1989, AM J CARDIOL, V63, P86, DOI 10.1016/0002-9149(89)91081-3
   REILLY JM, 1988, AM J CARDIOL, V62, P789, DOI 10.1016/0002-9149(88)91223-4
   SAHN DJ, 1978, CIRCULATION, V58, P1072, DOI 10.1161/01.CIR.58.6.1072
   WAHR DW, 1983, J AM COLL CARDIOL, V1, P863, DOI 10.1016/S0735-1097(83)80200-9
   WOODRUFF JF, 1980, AM J PATHOL, V101, P425
   WOODS GL, 1987, J VIROL METHODS, V18, P207, DOI 10.1016/0166-0934(87)90082-6
   1987, MMWR MORB MORTAL S1, V36, pS3
NR 29
TC 182
Z9 192
U1 2
U2 10
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD OCT 15
PY 1998
VL 339
IS 16
BP 1093
EP 1099
DI 10.1056/NEJM199810153391601
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA 129DP
UT WOS:000076448200001
PM 9770555
DA 2018-12-27
ER

PT J
AU Fujii, Y
   Toyooka, H
   Tanaka, H
AF Fujii, Y
   Toyooka, H
   Tanaka, H
TI RETRACTED: A granisetron-droperidol combination prevents postoperative
   vomiting in children (Retracted article. See vol. 116, pg. 743, 2013)
SO ANESTHESIA AND ANALGESIA
LA English
DT Article; Retracted Publication
ID RECEPTOR ANTAGONIST; TONSILLECTOMY; ONDANSETRON; NAUSEA; SURGERY; EMESIS
AB This study was performed to compare the efficacy of a granisetron-droperidol combination with each antiemetic alone to prevent postoperative vomiting after tonsillectomy with or without adenoidectomy in children. One hundred eighty pediatric patients, ASA physical status I, aged 4-10 yr, were enrolled in a prospective, randomized, double-blind investigation and assigned to one of three treatment regimens: granisetron 40 mu g/kg (Group G), droperidol 50 mu g/kg (Group D), or granisetron 40 mu g/kg Flus droperidol 50 mu g/kg (Group GD) (n = 60 in each group). These drugs were administered TV after an inhaled induction. The same standard general anesthetic technique and postoperative analgesia were used throughout. The rate of complete response, defined as no emesis and no need for rescue antiemetic, 0-3 h after anesthesia was 83% in Group G, 60% in Group D, and 97% in Group GD (P = 0.029 versus Group G, P = 0.001 versus Group D). The corresponding rates 3-24 h after anesthesia were 83%, 55%, and 97% (P = 0.029 versus Group G, P = 0.001 versus Group D). No clinically important adverse events were observed in any of the groups. Ln conclusion, a granisetron-droperidol combination is superior to each antiemetic alone in complete response in children undergoing general anesthesia for tonsillectomy. Implications: We compared the efficacy of granisetron plus droperidol with each antiemetic alone for the prevention of postoperative vomiting in children. The granisetron-droperidol combination was highly effective against postoperative emesis.
C1 Univ Tsukuba, Inst Clin Med, Dept Anesthesiol, Tsukuba 305, Japan.
   Toride Kyodo Gen Hosp, Dept Anesthesiol, Toride, Ibaraki, Japan.
RP Fujii, Y (reprint author), Univ Tsukuba, Inst Clin Med, Dept Anesthesiol, 2-1-1 Amakubo, Ibaraki 305, Japan.
CR Andrews PL, 1992, EJC SUPPL, V28A, P2
   ASPINALL RL, 1995, BRIT MED J, V311, P844, DOI 10.1136/bmj.311.7009.844
   BERMUDEZ J, 1988, BRIT J CANCER, V58, P644, DOI 10.1038/bjc.1988.277
   CARMICHAEL J, 1989, CANCER CHEMOTH PHARM, V24, P45
   COOK RJ, 1995, BRIT MED J, V310, P452, DOI 10.1136/bmj.310.6977.452
   Fujii Y, 1996, CAN J ANAESTH, V43, P660, DOI 10.1007/BF03017947
   Fujii Y, 1996, CAN J ANAESTH, V43, P35, DOI 10.1007/BF03015955
   FURST SR, 1994, ANESTHESIOLOGY, V81, P799, DOI 10.1097/00000542-199410000-00005
   GRUNWALD Z, 1994, PAEDIATRIC ANAESTHES, V4, P163
   LERMAN J, 1995, CAN J ANAESTH, V42, P263, DOI 10.1007/BF03010699
   LITMAN RS, 1994, ANESTH ANALG, V78, P478
   ROWBOTHAM DJ, 1992, BRIT J ANAESTH, V69, pS46, DOI 10.1093/bja/69.supplement_1.46S
   WATCHA MF, 1992, ANESTHESIOLOGY, V77, P162, DOI 10.1097/00000542-199207000-00023
   Watcha MF, 1997, ANESTHESIOLOGY, V86, P1170, DOI 10.1097/00000542-199705000-00021
   WHITE PF, 1993, ANESTHESIOLOGY, V78, P2, DOI 10.1097/00000542-199301000-00002
   YARKER YE, 1994, DRUGS, V48, P761, DOI 10.2165/00003495-199448050-00008
NR 16
TC 14
Z9 14
U1 1
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0003-2999
J9 ANESTH ANALG
JI Anesth. Analg.
PD OCT
PY 1998
VL 87
IS 4
BP 761
EP 765
DI 10.1097/00000539-199810000-00004
PG 5
WC Anesthesiology
SC Anesthesiology
GA 125JK
UT WOS:000076234300004
PM 9768766
DA 2018-12-27
ER

PT J
AU Deutsch, A
   Greshake, A
   Pesonan, LJ
   Pihlaja, P
AF Deutsch, A
   Greshake, A
   Pesonan, LJ
   Pihlaja, P
TI RETRACTED: Unaltered cosmic spherules in a 1.4-Gyr-old sandstone from
   Finland (Retracted Article. See vol 429, pg 322, 2004)
SO NATURE
LA English
DT Article; Retracted Publication
ID MICROMETEORITES; GREENLAND; COLLECTION; SEDIMENTS; DUST; ICE
AB Micrometeorites-submillimetre-sized particles derived from asteroids and comets(1-5)-occur in significant quantities in deep sea sediments(1,2,4), and the ice sheets of Greenland(6,7) and Antarctica(8,9). The most abundant micrometeorites are cosmic spherules(3), which contain nickel-rich spinels(10) that were crystallized and oxidized during atmospheric entry, therefore recording the oxygen content in the uppermost atmosphere(10-12). But the use of micrometeorites for detecting past changes in the flux of incoming extraterrestrial matter, and as probes of the evolution of the atmosphere, has been hampered by the fact that most objects with depositional ages higher than 0.5 Mpr show severe chemical alteration(2). Here we report the discovery of unaltered cosmic spherules in a 1.4-Gyr-old(13-15) sandstone(16,17) (red bed) from Finland. From this we infer that red beds, a common lithology in the Earth's history, map contain substantial unbiased populations of fossil micrometeorites, The study of such populations would allow systematic research on variations in the micrometeorite flux from the early Proterozoic era to recent times(9) (a time span of about 2.5 Gyr), and could help to better constrain the time when the atmospheric oxygen content was raised to its present level(18-20)
C1 Univ Munster, Inst Planetol, D-48149 Munster, Germany.
   Geol Survey Finland, FIN-02151 Espoo, Finland.
RP Deutsch, A (reprint author), Univ Munster, Inst Planetol, Wilhelm Klemm Str 10, D-48149 Munster, Germany.
EM deutsca@uni-muenster.de
CR AMATOV A, 1996, B GEOL SOC FINLAND, V21, P99
   BECKERLING W, 1995, PLANET SPACE SCI, V43, P435, DOI 10.1016/0032-0633(94)00175-Q
   BENCE AE, 1968, J GEOL, V76, P382, DOI 10.1086/627339
   BLANCHARD MB, 1980, EARTH PLANET SC LETT, V46, P178, DOI 10.1016/0012-821X(80)90004-7
   BROWNLEE DE, 1985, ANNU REV EARTH PL SC, V13, P147, DOI 10.1146/annurev.ea.13.050185.001051
   BROWNLEE DE, 1984, NATURE, V309, P693, DOI 10.1038/309693a0
   Brownlee DE, 1997, METEORIT PLANET SCI, V32, P157, DOI 10.1111/j.1945-5100.1997.tb01257.x
   BROWNLEE DE, 1981, SEA, V7, P733
   BROWNLEE DE, 1983, CHONDRULES THEIR ORI, P122
   GAYRAUD J, 1996, GEOL SOC AM SPEC PAP, V307, P425
   Goodwin A.M, 1991, PRECAMBRIAN GEOLOGY
   JEBANNO C, 1988, P LUNAR PLANET SCI C, V18, P623
   KASTING JF, 1993, SCIENCE, V259, P920, DOI 10.1126/science.11536547
   KERRIDGE JF, 1988, METEORITES EARLY SOL
   KOHONEN J, 1993, GEOL SURV FIN B, V369
   LOVE SG, 1991, ICARUS, V89, P26, DOI 10.1016/0019-1035(91)90085-8
   MARAIS DJD, 1992, NATURE, V359, P605, DOI 10.1038/359605a0
   MARTTILA E, 1969, THESIS U TURKU
   MARTTILA E, 1968, GEOLOGI, V20, P135
   MAURETTE M, 1991, NATURE, V351, P44, DOI 10.1038/351044a0
   MAURETTE M, 1987, NATURE, V328, P699, DOI 10.1038/328699a0
   Ohmoto H., 1997, GEOCHEM NEWS, V93, P12
   ROBIN E, 1992, EARTH PLANET SC LETT, V108, P181, DOI 10.1016/0012-821X(92)90021-M
   ROBIN E, 1990, EARTH PLANET SC LETT, V97, P162, DOI 10.1016/0012-821X(90)90106-8
   SOUMINEN V, 1991, GOEL SURV FIN B, V304
   STEELE IM, 1992, GEOCHIM COSMOCHIM AC, V56, P2923, DOI 10.1016/0016-7037(92)90368-S
   Taylor S, 1998, NATURE, V392, P899
   TAYLOR S, 1991, METEORITICS, V26, P203, DOI 10.1111/j.1945-5100.1991.tb01040.x
   THORSLUND P, 1981, NATURE, V289, P285, DOI 10.1038/289285a0
NR 29
TC 15
Z9 15
U1 5
U2 13
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
EI 1476-4687
J9 NATURE
JI Nature
PD SEP 10
PY 1998
VL 395
IS 6698
BP 146
EP 148
DI 10.1038/25943
PG 3
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 118GK
UT WOS:000075829900033
PM 9744272
DA 2018-12-27
ER

PT J
AU Gowen, LC
   Avrutskaya, AV
   Latour, AM
   Koller, BH
   Leadon, SA
AF Gowen, LC
   Avrutskaya, AV
   Latour, AM
   Koller, BH
   Leadon, SA
TI RETRACTED: BRCA1 required for transcription-coupled repair of oxidative
   DNA damage (Retracted article. See vol 300, pg 1657, June 13 2003)
SO SCIENCE
LA English
DT Article; Retracted Publication
ID RNA POLYMERASE-II; PREFERENTIAL REPAIR; OVARIAN-CANCER; STRAND; GENE;
   CELLS; BREAST
AB The breast and ovarian cancer susceptibility gene BRCA1 encodes a zinc finger protein of unknown function. Association of the BRCA1 protein with the DNA repair protein Rad51 and changes in the phosphorylation and cellular Localization of the protein after exposure to DNA-damaging agents are consistent with a role for BRCA1 in DNA repair. Here, it is shown that mouse embryonic stem cells deficient in BRCA1 are defective in the ability to tarry out transcription-coupled repair of oxidative DNA damage, and are hypersensitive to ionizing radiation and hydrogen peroxide. These results suggest that BRCA1 participates, directly or indirectly, in transcription-coupled repair of oxidative DNA damage.
C1 Univ N Carolina, Dept Radiat Oncol, Chapel Hill, NC 27599 USA.
   Univ N Carolina, Curriculum Genet & Mol Biol, Chapel Hill, NC 27599 USA.
   Univ N Carolina, Dept Med, Chapel Hill, NC 27599 USA.
RP Leadon, SA (reprint author), Univ N Carolina, Dept Radiat Oncol, Chapel Hill, NC 27599 USA.
EM saleadon@radonc.unc.edu
FU NCI NIH HHS [CA70490, CA40453, IP50CA58223]
CR CHRISTIANS FC, 1992, MUTAT RES, V274, P93, DOI 10.1016/0921-8777(92)90056-9
   Cooper PK, 1997, SCIENCE, V275, P990, DOI 10.1126/science.275.5302.990
   EASTON DF, 1993, AM J HUM GENET, V52, P678
   Friedberg EC, 1996, ANNU REV BIOCHEM, V65, P15
   Gowen LC, 1996, NAT GENET, V12, P191, DOI 10.1038/ng0296-191
   HANAWALT PC, 1994, SCIENCE, V266, P1957, DOI 10.1126/science.7801121
   HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0
   HTUN H, 1992, METHOD ENZYMOL, V212, P272
   LEADON SA, 1991, MUTAT RES, V255, P67, DOI 10.1016/0921-8777(91)90019-L
   LEADON SA, 1992, J BIOL CHEM, V267, P23175
   Leadon SA, 1997, CANCER RES, V57, P3784
   LEADON SA, 1993, P NATL ACAD SCI USA, V90, P10499, DOI 10.1073/pnas.90.22.10499
   MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6
   MELLON I, 1989, NATURE, V342, P95, DOI 10.1038/342095a0
   MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954
   Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4
   Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6
   Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605
   Snouwaert JN, 1998, CURRENT TOPICS ON BRCA1, P33, DOI 10.3233/BD-1998-101-206
   SWEDER KS, 1992, P NATL ACAD SCI USA, V89, P10696, DOI 10.1073/pnas.89.22.10696
   Thomas JE, 1997, CELL GROWTH DIFFER, V8, P801
   WARD JF, 1985, RADIAT RES, V103, P383, DOI 10.2307/3576760
NR 22
TC 416
Z9 426
U1 4
U2 28
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
EI 1095-9203
J9 SCIENCE
JI Science
PD AUG 14
PY 1998
VL 281
IS 5379
BP 1009
EP 1012
DI 10.1126/science.281.5379.1009
PG 4
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 110ZK
UT WOS:000075412700053
PM 9703501
DA 2018-12-27
ER

PT J
AU Haker, E
   Theodorsson, E
   Lundeberg, T
AF Haker, E
   Theodorsson, E
   Lundeberg, T
TI RETRACTED: An experimental model of tennis elbow in rats: A study of the
   contribution of the nervous system (Retracted Article. See vol 32, pg
   277, 2009)
SO INFLAMMATION
LA English
DT Article; Retracted Publication
ID GENE-RELATED PEPTIDE; CARRAGEENIN-INDUCED ARTHRITIS; SUBSTANCE-P;
   LATERAL EPICONDYLALGIA; NEUROKININ-A; KNEE-JOINT; CHROMATOGRAPHIC
   CHARACTERIZATION; NEUROGENIC INFLAMMATION; PROTEOGLYCAN SYNTHESIS;
   ARTICULAR-CARTILAGE
AB The contribution of the sensory and autonomic nervous system to experimentally induced tennis elbow or lateral epicondylalgia was investigated by analyses of the release of neuropeptides from sensory (substance P, SP neurokinin A, NKA, calcitonin gene-related peptide, CGRP) and sympathetic (neuropeptide Y, NPY) nerves. SP, CGRP, NKA, NPY-like immunoreactivity (-LI) was studied in rats cerebrospinal fluid (CSF), plasma and perfusates (PF) from the enthesis of the extensor carpi radialis brevis (ECRB) of the right elbow at 2, 6 and 24 h following 0.01 ml injection of either complete Freund adjuvans (FA) or 2% Carrageenan (CAR). The control group was injected with 0.01 ml saline. In general the changes of neuropeptide-LI in the CSF and plasma were similar for both treated groups compared with the controls, but they were more pronounced in the FA group than the CAR. SP-, NKA-, CGRP- and NPY-LI were significantly increased to a similar degree in the perfusates of the ECRBs of the treated groups with a greater increase in SP-LI in the FA than the CAR group compared with controls. When comparing the neuropeptide-LI in the CSF, plasma and PF between the 2 treated groups, there were thus few differences found. Generally a unilateral injection with either FA or CAR into the rat ECRB induced a similar alteration in the concentration of SP-, NKA-, CGRP- and NPY-LI in the CSF, plasma and PF at 2, 6 and 24 h following injection. However, the most pronounced changes in neuropeptide-LI occurred locally in the elbow ECRBs PF in both treated groups.
C1 Karolinska Inst, Dept Phys Therapy, Stockholm, Sweden.
   Linkoping Univ Hosp, Dept Clin Chem, S-58185 Linkoping, Sweden.
   Karolinska Hosp, Dept Phys Med & Rehabil, S-10401 Stockholm, Sweden.
RP Haker, E (reprint author), Karolinska Inst, Dept Phys Therapy, Stockholm, Sweden.
OI Theodorsson, Elvar/0000-0003-0756-7723
CR ALLANDER E, 1974, SCAND J RHEUMATOL, V3, P145, DOI 10.3109/03009747409097141
   BASBAUM AI, 1988, INT CONGR SER, V837, P41
   BECK PW, 1974, PFLUG ARCH EUR J PHY, V347, P209, DOI 10.1007/BF00592598
   BILEVICIUTE I, 1993, NEUROSCI LETT, V153, P37, DOI 10.1016/0304-3940(93)90071-R
   BINDER A, 1983, BRIT J RHEUMATOL, V22, P77
   BIRCH PJ, 1992, BRIT J PHARMACOL, V105, P508, DOI 10.1111/j.1476-5381.1992.tb09008.x
   BRODIN E, 1986, REGUL PEPTIDES, V13, P253, DOI 10.1016/0167-0115(86)90044-3
   Burton AK, 1988, MANUAL MED, V3, P141
   CARMICHAEL DJ, 1977, ARTHRITIS RHEUM, V20, P834, DOI 10.1002/art.1780200313
   CHAHL LA, 1977, BRIT J PHARMACOL, V59, P343, DOI 10.1111/j.1476-5381.1977.tb07498.x
   CHARD MD, 1994, ANN RHEUM DIS, V53, P30, DOI 10.1136/ard.53.1.30
   CHARD MD, 1989, BRIT J RHEUMATOL, V28, P186
   DEVEREAUX MD, 1985, CLIN EXP RHEUMATOL, V3, P333
   DIROSA M, 1971, J PATHOL, V104, P15, DOI 10.1002/path.1711040103
   EKBLAD E, 1984, REGUL PEPTIDES, V8, P225, DOI 10.1016/0167-0115(84)90064-8
   ERDOS EG, 1989, FASEB J, V3, P145
   Famaey J P, 1982, J Belge Med Phys Rehabil, V5, P55
   GAMSE R, 1987, ACTA PHYSIOL HUNG, V69, P343
   GILLARD GC, 1976, ARTHRITIS RHEUM, V19, P918, DOI 10.1002/art.1780190513
   GOLDIE I, 1964, ACTA CHIR SCAND S, V339
   HAKER E, 1990, CLIN J PAIN, V6, P221, DOI 10.1097/00002508-199009000-00009
   HAKER E, 1990, PAIN, V43, P243, DOI 10.1016/0304-3959(90)91078-W
   HAKER E, 1991, SCAND J REHABIL MED, V23, P115
   HAKER E, 1991, J PAIN SYMPTOM MANAG, V6, P241, DOI 10.1016/0885-3924(91)90014-U
   HAKER E, 1993, PAIN CLINIC, V62, P103
   Haker E, 1993, CRIT REV PHYS REHABI, V5, P129
   HAKER EHK, 1991, ARCH PHYS MED REHAB, V72, P984
   HOLSAPPLE MP, 1984, INFLAMMATION, V8, P223, DOI 10.1007/BF00916412
   HOPE PJ, 1990, BRAIN RES, V533, P292, DOI 10.1016/0006-8993(90)91352-H
   KIVI P, 1983, SCAND J REHABIL MED, V15, P37
   KONTTINEN YT, 1990, J RHEUMATOL, V17, P1586
   LAM FY, 1989, ANN RHEUM DIS, V48, P928, DOI 10.1136/ard.48.11.928
   LEHMAN L, 1974, CLIN ORTHOPED RELATE, V99, P220
   LOUIS SM, 1990, NEUROSCIENCE, V39, P727, DOI 10.1016/0306-4522(90)90256-4
   LOWTHER DA, 1978, ARTHRITIS RHEUM, V21, P675, DOI 10.1002/art.1780210611
   MORRIS M, 1987, J CARDIOVASC PHARM, V9, P541, DOI 10.1097/00005344-198705000-00006
   NADEL JA, 1991, EUR RESPIR J, V4, P745
   NEIL A, 1987, EXP BRAIN RES, V65, P343
   Nirschl R P, 1973, Orthop Clin North Am, V4, P787
   NIRSCHL RP, 1992, CLIN SPORT MED, V11, P851
   PERCY EC, 1981, MED SCI SPORT EXER, V13, P215, DOI 10.1249/00005768-198104000-00001
   SAARTOK T, 1986, ORTHOPEDICS, V9, P191
   SATOH M, 1992, PAIN, V49, P273, DOI 10.1016/0304-3959(92)90151-Z
   SCHAIBLE HG, 1990, BRAIN RES, V529, P214, DOI 10.1016/0006-8993(90)90830-5
   SOLVEBORN SA, 1990, P 4 C EUR SOC SURG S
   THEODORSSONNORHEIM E, 1985, BIOCHEM BIOPH RES CO, V131, P77, DOI 10.1016/0006-291X(85)91772-3
   THEODORSSONNORHEIM E, 1985, SCAND J CLIN LAB INV, V45, P355, DOI 10.3109/00365518509161019
   THEODORSSONNORHEIM E, 1987, LIFE SCI, V41, P845, DOI 10.1016/0024-3205(87)90177-9
   THEODORSSONNORHEIM E, 1984, REGUL PEPTIDES, V9, P229, DOI 10.1016/0167-0115(84)90075-2
   Thomas D, 1989, THERMOLOGY, V3, P132
   Thomas P K, 1992, Clin Auton Res, V2, P51, DOI 10.1007/BF01824213
   WEIHE E, 1991, ANN NY ACAD SCI, V632, P283, DOI 10.1111/j.1749-6632.1991.tb33116.x
   WIMALAWANSA SJ, 1990, MOL CELL ENDOCRINOL, V71, P13, DOI 10.1016/0303-7207(90)90069-K
   WIMALAWANSA SJ, 1988, PEPTIDES, V9, P407, DOI 10.1016/0196-9781(88)90276-8
   WOOLF C, 1986, NEUROSCI LETT, V66, P226, DOI 10.1016/0304-3940(86)90195-3
NR 55
TC 10
Z9 10
U1 1
U2 7
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0360-3997
EI 1573-2576
J9 INFLAMMATION
JI Inflammation
PD AUG
PY 1998
VL 22
IS 4
BP 435
EP 444
DI 10.1023/A:1022377001084
PG 10
WC Cell Biology; Immunology
SC Cell Biology; Immunology
GA ZZ744
UT WOS:000074762800008
PM 9675613
DA 2018-12-27
ER

PT J
AU Nam, HD
   Lee, BH
   Kim, SJ
   Jung, CH
   Lee, JH
   Park, S
AF Nam, HD
   Lee, BH
   Kim, SJ
   Jung, CH
   Lee, JH
   Park, S
TI RETRACTED: Preparation of ultrafine crystalline TiO2 powders from
   aqueous TiCl4 solution by precipitation(Retracted article. See vol. 56,
   Artn No. 069201, 2017)
SO JAPANESE JOURNAL OF APPLIED PHYSICS PART 1-REGULAR PAPERS BRIEF
   COMMUNICATIONS & REVIEW PAPERS
LA English
DT Article; Retracted Publication
DE ultrafine powders; TiO2; precipitation; rutile; anatase
ID OXIDATION; PHOTOCATALYSTS; HYDROLYSIS; PARTICLES; KINETICS
AB Ultrafine crystalline TiO2 powders were prepared by just heating and stirring aqueous TiOCl2 solution with a Ti+4 concentration of 0.5 mol/l at room temperature to 100 degrees C under one atmosphere. The crystallinity, the phase transformation and the par tide shape of ultrafine TiO2 powders obtained by this simple precipitation method were analyzed using an X-ray diffractometer (XRD), transmission electron microscopy (TEM), differential thermal analyzer (DTA), and scanning electron microscopy (SEM). TiO2 crystalline precipitates with a pure rutile phase were formed below 65 degrees C, then TiO2 crystalline precipitates with an anatase phase started forming at temperatures higher than 65 degrees C, which ends with the pure anatase phase at 100 degrees C. The direct formation of TiO2 crystalline precipitates from an aqueous TiOCl2 solution is due to the existence of the OH- ions in distilled water which cause the crystallization of TiOCl2 to TiO2 without hydrolyzation to Ti(OH)(4). Conventionally, rutile-phase TiO2 is obtained at much higher temperatures. However, in this study a stable rutile-phase TiO2 was obtained by a simple method at close to room temperature.
C1 Myongji Univ, Dept Inorgan Mat Engn, Yongin 449728, Kyunggi Do, South Korea.
   Korea Atom Energy Res Inst, Adv Nucl Mat Dev Team, Taejon 305600, South Korea.
   Sun Moon Univ, Dept Mat Sci & Engn, Asan 336840, Choongnam, South Korea.
RP Nam, HD (reprint author), Myongji Univ, Dept Inorgan Mat Engn, 38-2 San, Yongin 449728, Kyunggi Do, South Korea.
CR AKHTAR MK, 1991, J AEROSOL SCI, V22, pS35, DOI 10.1016/S0021-8502(05)80028-X
   BARRINGER EA, 1985, LANGMUIR, V1, P414, DOI 10.1021/la00064a005
   CHEN QW, 1995, MATER LETT, V22, P77, DOI 10.1016/0167-577X(94)00227-4
   CHENG HM, 1995, CHEM MATER, V7, P663, DOI 10.1021/cm00052a010
   DAWSON WJ, 1988, CERAM B, V67, P1673
   DING XZ, 1995, J MATER SCI LETT, V14, P21, DOI 10.1007/BF02565273
   FLOOD RU, 1995, J PHYS CHEM-US, V99, P8954, DOI 10.1021/j100022a004
   KAMAT PV, 1990, SOL ENERGY, V44, P83, DOI 10.1016/0038-092X(90)90070-S
   LARSON SA, 1994, APPL CATAL B-ENVIRON, V4, P325, DOI 10.1016/0926-3373(94)00030-1
   MATIJEVIC E, 1977, J COLLOID INTERF SCI, V61, P302, DOI 10.1016/0021-9797(77)90393-9
   MICHELI AL, 1984, AM CERAM SOC BULL, V63, P694
   PRATSINIS SE, 1990, J AM CERAM SOC, V73, P2158, DOI 10.1111/j.1151-2916.1990.tb05295.x
   SIEFERING KL, 1990, J ELECTROCHEM SOC, V137, P814, DOI 10.1149/1.2086561
   SUYAMA Y, 1985, J AM CERAM SOC, V68, pC154
NR 14
TC 72
Z9 81
U1 3
U2 25
PU JAPAN SOC APPLIED PHYSICS
PI TOKYO
PA KUDAN-KITA BUILDING 5TH FLOOR, 1-12-3 KUDAN-KITA, CHIYODA-KU, TOKYO,
   102-0073, JAPAN
SN 0021-4922
J9 JPN J APPL PHYS 1
JI Jpn. J. Appl. Phys. Part 1 - Regul. Pap. Brief Commun. Rev. Pap.
PD AUG
PY 1998
VL 37
IS 8
BP 4603
EP 4608
DI 10.1143/JJAP.37.4603
PG 6
WC Physics, Applied
SC Physics
GA 126UN
UT WOS:000076313100077
DA 2018-12-27
ER

PT J
AU Mavoungou, E
   Toure, FS
   Yaba, P
   Delicat, A
   Poaty-Mavoungou, V
AF Mavoungou, E
   Toure, FS
   Yaba, P
   Delicat, A
   Poaty-Mavoungou, V
TI RETRACTED: Peptide immunization restimulates the memory CD4 T cell
   response but fails to induce cytotoxic T lymphocytes in cynomolgus
   monkeys (Retracted Article. See vol 37, pg 215, 2008)
SO JOURNAL OF MEDICAL PRIMATOLOGY
LA English
DT Article; Retracted Publication
DE SIV; HIV; CTL; vaccine T helper epitope
ID HUMAN-IMMUNODEFICIENCY-VIRUS; IN-VIVO; RHESUS-MONKEYS; HIV; EPITOPES;
   VACCINE; HELPER; ENHANCEMENT; RECOGNITION; INFECTION
AB A potential strategy to induce peptide specific CTL in vivo was investigated. A synthetic vaccine consisting of an SIV-derived, HLA-A2.1-binding CTL epitope and a tetanus toxin-derived T helper epitope was evaluated for its capacity to induce peptide-specific CTL in monkeys. Thirteen animals were immunized and boosted twice with 150 mu g of CTL plus 250 mu g of the T helper peptide (p30). Peripheral blood mononuclear cells (PBMC) were regularly analysed for cytotoxic and proliferative responses before, between, and after the immunizations, and the serum was tested for anti-peptide antibodies. No unequivocal induction of SIV peptide-specific CTL in any of the monkeys was observed. However, a wide pattern of mild and transient side reactions were observed, ranging from local redness at the injection site to generalized exanthema, myalgias, arthralgias, and fever. The side-effects were related to the T helper epitope, as they were similar to the side-effects experienced after tetanus immunization, correlated to the magnitude of the p30-specific in vitro proliferative response, and occurred only if p30 was co-injected. No antibody against the SN-derived peptides nor against p30 was detectable in the serum after repeated immunizations. The data suggest that the CTL peptide, at the concentration used in this study, failed to induce a cytotoxic immune response in vivo, although the T helper peptide seems to be capable of restimulating the specific memory T cells.
C1 Ctr Int Rech Med Franceville, Immunol Unit, Franceville, Gabon.
   Ctr Int Rech Med Franceville, Unit Med Parasitol, Franceville, Gabon.
   Ctr Int Rech Med Franceville, Unit Retrovirol, Franceville, Gabon.
RP Mavoungou, E (reprint author), Ctr Int Rech Med Franceville, Immunol Unit, BP 769, Franceville, Gabon.
EM emavoung@cirmfrv.fr
CR AICHELE P, 1994, P NATL ACAD SCI USA, V91, P444, DOI 10.1073/pnas.91.2.444
   AUTRAN B, 1991, J ACQ IMMUNE DEFIC S, V2, P398
   BEDNAREK MA, 1991, J IMMUNOL METHODS, V139, P41, DOI 10.1016/0022-1759(91)90349-K
   Berzofsky J A, 1991, Biotechnol Ther, V2, P123
   BUSEYNE F, 1993, J IMMUNOL, V150, P3569
   CERNY A, 1995, J CLIN INVEST, V95, P521, DOI 10.1172/JCI117694
   Chenciner N, 1997, AIDS RES HUM RETROV, V13, P801, DOI 10.1089/aid.1997.13.801
   DADAGLIO G, 1991, J IMMUNOL, V147, P2302
   DEMOTZ S, 1989, J IMMUNOL, V142, P394
   DERES K, 1989, NATURE, V342, P561, DOI 10.1038/342561a0
   Fuller DH, 1997, VACCINE, V15, P924, DOI 10.1016/S0264-410X(96)00271-X
   Geretti AM, 1997, J GEN VIROL, V78, P821, DOI 10.1099/0022-1317-78-4-821
   GOTCH F, 1987, NATURE, V326, P881, DOI 10.1038/326881a0
   GUT J, 1993, PHARMACOL THERAPEUT, V581, P33
   JACOBSON S, 1990, NATURE, V348, P245, DOI 10.1038/348245a0
   KAST WM, 1991, P NATL ACAD SCI USA, V88, P2283, DOI 10.1073/pnas.88.6.2283
   KUWATA T, 1995, J GEN VIROL, V76, P2181, DOI 10.1099/0022-1317-76-9-2181
   LETVIN NL, 1993, NEW ENGL J MED, V329, P1400
   Lu S, 1996, J VIROL, V70, P3978
   MILLER MD, 1991, J IMMUNOL, V147, P320
   NIXON DF, 1992, IMMUNOLOGY, V76, P515
   NIXON DF, 1991, AIDS, V5, P1049
   NORMAN PS, 1995, J ALLERGY CLIN IMMUN, V95, P259
   NORMAN PS, 1994, ALLERGY CLIN IMMUNOL, V94, P231
   NOSIK NN, 1980, VOP VIRUSOL+, P473
   OHKAWA S, 1995, AIDS RES HUM RETROV, V11, P395, DOI 10.1089/aid.1995.11.395
   RAMMENSEE HG, 1993, CURR OPIN IMMUNOL, V5, P35, DOI 10.1016/0952-7915(93)90078-7
   SABIN AB, 1993, NATURE, V362, P212, DOI 10.1038/362212a0
   SAUZET JP, 1995, VACCINE, V13, P1339, DOI 10.1016/0264-410X(94)00087-4
   SHIRAI M, 1994, J IMMUNOL, V152, P549
   TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0
   VALMORI D, 1994, J IMMUNOL, V152, P2921
   VALMORI D, 1992, J IMMUNOL, V149, P717
   VALMORI D, 1994, EUR J IMMUNOL, V24, P1458, DOI 10.1002/eji.1830240633
   VITIELLO A, 1995, J CLIN INVEST, V95, P341, DOI 10.1172/JCI117662
   Voss G, 1996, J VIROL, V70, P7335
   WALKER BD, 1989, P NATL ACAD SCI USA, V86, P9514, DOI 10.1073/pnas.86.23.9514
   WALKER BD, 1987, NATURE, V328, P345, DOI 10.1038/328345a0
   WIDMANN C, 1992, J IMMUNOL METHODS, V155, P95, DOI 10.1016/0022-1759(92)90275-X
   WIDMANN C, 1991, J IMMUNOL, V147, P3745
   YASUTOMI Y, 1995, J IMMUNOL, V154, P2516
   YASUTOMI Y, 1995, J VIROL, V69, P2279
NR 42
TC 3
Z9 3
U1 2
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0047-2565
EI 1600-0684
J9 J MED PRIMATOL
JI J. Med. Primatol.
PD AUG
PY 1998
VL 27
IS 4
BP 202
EP 209
DI 10.1111/j.1600-0684.1998.tb00072.x
PG 8
WC Veterinary Sciences; Zoology
SC Veterinary Sciences; Zoology
GA 151ZX
UT WOS:000077751600004
PM 9879861
DA 2018-12-27
ER

PT J
AU Fujii, Y
   Saitoh, Y
   Tanaka, H
   Toyooka, H
AF Fujii, Y
   Saitoh, Y
   Tanaka, H
   Toyooka, H
TI RETRACTED: Prophylactic antiemetic therapy with granisetron-droperidol
   combination in patients undergoing laparoscopic cholecystectomy
   (Retracted article. See vol. 60, pg. 615, 2013)
SO CANADIAN JOURNAL OF ANAESTHESIA-JOURNAL CANADIEN D ANESTHESIE
LA English
DT Article; Retracted Publication
ID POSTOPERATIVE NAUSEA; RECEPTOR ANTAGONIST; METOCLOPRAMIDE; PREVENTION;
   ANESTHESIA
AB Purpose: A relatively high incidence of postoperative nausea and vomiting (PONV) occurs in patients undergoing laparoscopic cholecystectomy, This study was under-taken to compare the efficacy of granisetron-droperidol combination with each drug alone for the prevention of PONV after laparoscopic cholecystectomy,
   Methods: In a randomized, double-blind manner, 150 female inpatients received 3 mg granisetron (Group G), 1.25 mg droperidol (Group D) or 3 mg granisetron plus 1,25 mg droperidol (Group GD) (n = 50 for each) iv immediately before the induction of anaesthesia. The same standard general anaesthetic technique, which consisted of isoflurane and nitrous oxide in oxygen, was used, Nausea, vomiting and safety assessments were performed continuously during the first 24 hr after anaesthesia,
   Results: Complete response, defined as no PONV and no administration of rescue antiemetic medication, was 86% in Group G, 64% in Group D and 98% in Group GD (P = 0.03 vs Group G, P = 0.001 vs Group D). No clinically adverse events were observed in any group,
   Conclusion: Granisetron-droperidol combination is more effective than each antiemetic alone in the prevention of PONV after laparoscopic cholecystectomy.
C1 Univ Tsukuba, Inst Clin Med, Dept Anaesthesiol, Tsukuba, Ibaraki 305, Japan.
   Tokyo Med & Dent Univ, Sch Med, Dept Anaesthesiol & Crit Care Med, Bunkyo Ku, Tokyo 113, Japan.
   Toride Kyodo Gen Hosp, Dept Anaesthesiol, Toride, Ibaraki, Japan.
RP Fujii, Y (reprint author), Univ Tsukuba, Inst Clin Med, Dept Anaesthesiol, 2-1-1 Amakubo, Tsukuba, Ibaraki 305, Japan.
CR BERMUDEZ J, 1988, BRIT J CANCER, V58, P644, DOI 10.1038/bjc.1988.277
   CARMICHAEL J, 1989, CANCER CHEMOTH PHARM, V24, P45
   COHEN SE, 1984, ANESTHESIOLOGY, V60, P67, DOI 10.1097/00000542-198401000-00015
   Fujii Y, 1997, CAN J ANAESTH, V44, P396, DOI 10.1007/BF03014460
   Furue H, 1990, J CLIN THERAPEUTIC M, V6, P49
   Iitomi T, 1995, Masui, V44, P1627
   KORTTILA K, 1979, ANESTH ANALG, V58, P396
   LERMAN J, 1995, CAN J ANAESTH, V42, P263, DOI 10.1007/BF03010699
   McKenzie R, 1996, ANESTH ANALG, V83, P1218, DOI 10.1097/00000539-199612000-00015
   ROWBOTHAM DJ, 1992, BRIT J ANAESTH, V69, pS46, DOI 10.1093/bja/69.supplement_1.46S
   STANTON JM, 1991, ANAESTHESIA, V46, P317, DOI 10.1111/j.1365-2044.1991.tb11510.x
   WATCHA MF, 1992, ANESTHESIOLOGY, V77, P162, DOI 10.1097/00000542-199207000-00023
   WHITE PF, 1993, ANESTHESIOLOGY, V78, P2, DOI 10.1097/00000542-199301000-00002
NR 13
TC 21
Z9 21
U1 5
U2 11
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0832-610X
J9 CAN J ANAESTH
JI Can. J. Anaesth.-J. Can. Anesth.
PD JUN
PY 1998
VL 45
IS 6
BP 541
EP 544
DI 10.1007/BF03012704
PG 4
WC Anesthesiology
SC Anesthesiology
GA ZY710
UT WOS:000074651600007
PM 9669007
DA 2018-12-27
ER

PT J
AU Contreras, JL
   Wang, PX
   Eckhoff, DE
   Lobashevsky, AL
   Asiedu, C
   Frenette, L
   Robbin, ML
   Hubbard, WJ
   Cartner, S
   Nadler, S
   Cook, WJ
   Sharff, J
   Shiloach, J
   Thomas, FT
   Neville, DM
   Thomas, JM
AF Contreras, JL
   Wang, PX
   Eckhoff, DE
   Lobashevsky, AL
   Asiedu, C
   Frenette, L
   Robbin, ML
   Hubbard, WJ
   Cartner, S
   Nadler, S
   Cook, WJ
   Sharff, J
   Shiloach, J
   Thomas, FT
   Neville, DM
   Thomas, JM
TI RETRACTED: Peritransplant tolerance induction with anti-CD3-immunotoxin
   - A matter of proinflammatory cytokine control (Retracted article. See
   vol 85, pg. 920, 2008)
SO TRANSPLANTATION
LA English
DT Article; Retracted Publication
ID DONOR BONE-MARROW; TOTAL LYMPHOID IRRADIATION; NF-KAPPA-B;
   POSTTRANSPLANT ANTITHYMOCYTE GLOBULIN; INCOMPATIBLE ALLOGRAFT
   ACCEPTANCE; MIXED ALLOGENEIC CHIMERISM; RHESUS-MONKEYS; DENDRITIC CELLS;
   IFN-GAMMA; IN-VIVO
AB Background. Tolerance is gaining momentum as an approach to reduce lifelong immunosuppressive therapy while improving transplant longevity. Anti-CD3 immunotoxin (IT), FN18-CRM9, has potential to induce tolerance owing to its exceptional ability to deplete sessile lymph node T cells. However, if initiated at the time of transplantation, alpha-CD3-IT alone elicits a proinflammatory cytokine response, precluding establishment of tolerance.
   Methods. Four groups of rhesus monkeys received kidney allografts and immunosuppression, Three groups received alpha-CD3-IT alone or alpha-CD3-IT supplemented with 15-deoxyspergualin (DSG) and/or methylprednisolone (MP). One group received alpha-CD3-monoclonal antibody with DSG and MP. Cytokines were measured by enzyme-linked immunosorbent assay.
   Results. Supplementing peritransplant alpha-CD3-IT treatment with a brief course of DSG and IMP promoted rejection-free kidney allograft acceptance in 75% of macaques followed for up to 550 days. Among those given alpha-CD3-IT alone or with MP, none were long-term survivors, Tolerance developed after alpha-CD3-IT, DSG, and MP treatment, but not when the unconjugated alpha-CD3 monoclonal antibody was substituted for IT. Systemic production of proinflammatory cytokines interferon-gamma (IFN-gamma) and tumor necrosis factor-alpha induced after peritransplant alpha-CD3-IT was prevented only in animals given DSG. Despite high levels of interleukin (IL)-12 in the first month after transplant, tolerant recipients exhibited IL-12 resistance, rut evidenced by baseline plasma levels of IFN-gamma but elevated IL-4. DSG was shown to inhibit IL-la-driven IFN-gamma production by a mechanism associated with inhibition of nuclear factor kappa-B.
   Conclusions, In this model, peritransplant induction of tolerance is promoted by efficient elimination of sessile lymph node T cells and control of the proinflammatory IFN-gamma response by a mechanism that appears to involve resistance to IL-12.
C1 Univ Alabama Birmingham, UAB Transplant Ctr, Birmingham, AL 35294 USA.
   Univ Alabama Birmingham, Dept Surg, Div Transplantat Immunol, Birmingham, AL 35294 USA.
   Univ Alabama Birmingham, Dept Anesthesia, Birmingham, AL 35294 USA.
   Univ Alabama Birmingham, Dept Radiol, Birmingham, AL 35294 USA.
   Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA.
   Bristol Myers Squibb Co, Pharmaceut Res Inst, Seattle, WA 98121 USA.
   NIMH, Mol Biol Lab, NIH, Bethesda, MD USA.
   NIDDK, Cellular & Dev Biol Lab, Biotechnol Unit, NIH, Bethesda, MD USA.
RP Thomas, JM (reprint author), Univ Alabama Birmingham, UAB Transplant Ctr, Boshell Diabet Bldg 802,1808 7th St S, Birmingham, AL 35294 USA.
EM jthomas@uab.edu
FU NIAID NIH HHS [R0I AII22293, R0I AI39793]
CR ABBA IC, 1994, THER IMMUNOL, V1, P325
   AMEMIYA H, 1996, PRINCIPLES DRUG DEV, P383
   AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286
   BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141
   Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506
   BIEBER CP, 1979, TRANSPLANTATION, V28, P347, DOI 10.1097/00007890-197910000-00017
   Cella M, 1997, NATURE, V388, P782, DOI 10.1038/42030
   CHATENOUD L, 1994, TRANSPLANT P, V26, P3191
   Cobbold SP, 1996, IMMUNOL REV, V149, P5, DOI 10.1111/j.1600-065X.1996.tb00897.x
   Dorling Anthony, 1996, P355
   GATELY MK, 1994, INT IMMUNOL, V6, P157, DOI 10.1093/intimm/6.1.157
   HOEGER PH, 1994, J IMMUNOL, V153, P3908
   ILDSTAD ST, 1995, CHIMERISM TOLERANCE, P159
   Jacobson NG, 1996, ADV EXP MED BIOL, V409, P61
   KAWAI T, 1995, TRANSPLANTATION, V59, P256, DOI 10.1097/00007890-199501270-00018
   Kimikawa M, 1997, TRANSPLANTATION, V64, P709, DOI 10.1097/00007890-199709150-00008
   Knechtle SJ, 1997, TRANSPLANTATION, V63, P1, DOI 10.1097/00007890-199701150-00002
   Lakkis FG, 1997, J IMMUNOL, V158, P2443
   Larsen CP, 1996, NATURE, V381, P434, DOI 10.1038/381434a0
   Leonard AA, 1996, TRANSPLANTATION, V61, P1648, DOI 10.1097/00007890-199606150-00017
   MENG G, IN PRESS TRANSPLANT
   MONACO AP, 1995, TRANSPLANTATION IMMU, P247
   MONACO AP, 1995, CHIMERISM TOLERANCE, P99
   MOSES R, 1983, TRANSPLANTATION, V47, P435
   MYBURGH JA, 1980, TRANSPLANTATION, V29, P405, DOI 10.1097/00007890-198005000-00012
   NADLER SG, 1995, THER DRUG MONIT, V17, P700, DOI 10.1097/00007691-199512000-00026
   Naji A, 1996, CURR OPIN IMMUNOL, V8, P704, DOI 10.1016/S0952-7915(96)80089-6
   Nakamura T, 1997, J IMMUNOL, V158, P1085
   NEVILLE DM, 1992, P NATL ACAD SCI USA, V89, P2585, DOI 10.1073/pnas.89.7.2585
   Neville DM, 1996, J IMMUNOTHER, V19, P85, DOI 10.1097/00002371-199603000-00001
   NEVILLE DMJ, 1995, J CONTROL RELEASE, V24, P133
   Nickerson P, 1997, TRANSPLANTATION, V63, P489, DOI 10.1097/00007890-199702270-00001
   PENNOCK JL, 1981, TRANSPLANTATION, V32, P467, DOI 10.1097/00007890-198112000-00003
   Piccotti JR, 1997, TRANSPLANTATION, V63, P619, DOI 10.1097/00007890-199703150-00001
   Pierre P, 1997, NATURE, V388, P787, DOI 10.1038/42039
   RaisanenSokolowski A, 1997, J CLIN INVEST, V100, P2449, DOI 10.1172/JCI119787
   Ridge JP, 1996, SCIENCE, V271, P1723, DOI 10.1126/science.271.5256.1723
   Rogge L, 1997, J EXP MED, V185, P825, DOI 10.1084/jem.185.5.825
   Saleem S, 1996, TRANSPLANTATION, V62, P1908, DOI 10.1097/00007890-199612270-00039
   SIEGALL CB, 1994, P NATL ACAD SCI USA, V91, P9514, DOI 10.1073/pnas.91.20.9514
   SLIERENDREGT BL, 1992, HUM IMMUNOL, V35, P29, DOI 10.1016/0198-8859(92)90092-2
   SLIERENDREGT BL, 1994, J IMMUNOL, V152, P2298
   STEINMAN RM, 1991, ANNU REV IMMUNOL, V9, P271, DOI 10.1146/annurev.iy.09.040191.001415
   Strom TB, 1996, CURR OPIN IMMUNOL, V8, P688, DOI 10.1016/S0952-7915(96)80087-2
   Sykes M, 1997, NAT MED, V3, P783, DOI 10.1038/nm0797-783
   SYKES M, 1988, IMMUNOL TODAY, V9, P23, DOI 10.1016/0167-5699(88)91352-7
   Sykes M, 1996, CURR OPIN IMMUNOL, V8, P694, DOI 10.1016/S0952-7915(96)80088-4
   SYKES M, 1994, BONE MARROW TRANSPL, P204
   SZABO SJ, 1995, IMMUNITY, V2, P665, DOI 10.1016/1074-7613(95)90011-X
   Szabo SJ, 1997, J EXP MED, V185, P817, DOI 10.1084/jem.185.5.817
   TEPPER MA, 1995, J IMMUNOL, V155, P2427
   Tepper Mark A., 1996, P383
   THOMAS J, 1992, TRANSPLANTATION, V53, P247, DOI 10.1097/00007890-199202010-00001
   THOMAS J, 1987, TRANSPLANTATION, V43, P332, DOI 10.1097/00007890-198703000-00002
   THOMAS JM, 1989, TRANSPLANTATION, V47, P209, DOI 10.1097/00007890-198902000-00002
   THOMAS JM, 1995, TRANSPLANTATION, V59, P245, DOI 10.1097/00007890-199501270-00017
   THOMAS JM, 1994, TRANSPLANTATION, V57, P101, DOI 10.1097/00007890-199401000-00018
   THOMAS JM, 1991, TRANSPLANTATION, V51, P198, DOI 10.1097/00007890-199101000-00032
   Thomas JM, 1997, TRANSPLANTATION, V64, P124, DOI 10.1097/00007890-199707150-00022
   THOMAS JM, 1995, CHIMERISM TOLERANCE, P143
   THOMAS JM, 1996, PRINCIPLES DRUG DEV
   Tovey MG, 1996, J LEUKOCYTE BIOL, V59, P512
   TRINCHIERI G, 1995, ANNU REV IMMUNOL, V13, P251, DOI 10.1146/annurev.iy.13.040195.001343
   VOEST EE, 1995, J NATL CANCER I, V87, P581, DOI 10.1093/jnci/87.8.581
   WAAGA AM, 1990, TRANSPLANT P, V22, P1613
   WOOD KJ, 1995, CHIMERISM TOLERANCE, P15
NR 66
TC 70
Z9 71
U1 3
U2 12
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0041-1337
J9 TRANSPLANTATION
JI Transplantation
PD MAY 15
PY 1998
VL 65
IS 9
BP 1159
EP 1169
DI 10.1097/00007890-199805150-00003
PG 11
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA ZN734
UT WOS:000073676600003
PM 9603161
DA 2018-12-27
ER

PT J
AU Fujii, Y
   Saitoh, Y
   Tanaka, H
   Toyooka, H
AF Fujii, Y
   Saitoh, Y
   Tanaka, H
   Toyooka, H
TI RETRACTED: Effective dose of granisetron for the prevention of
   post-operative nausea and vomiting in patients undergoing laparoscopic
   cholecystectomy (Retracted article. See vol. 30, pg. 262, 2013)
SO EUROPEAN JOURNAL OF ANAESTHESIOLOGY
LA English
DT Article; Retracted Publication
DE complications, nausea, vomiting; drugs, antiemetics, granisetron;
   surgery, laparoscopic cholecystectomy
ID RECEPTOR ANTAGONIST; DOUBLE-BLIND; PLACEBO
AB This study was undertaken to determine the minimum effective dose of granisetron, a selective 5-hydroxytryptamine type 3 receptor antagonist, for the prevention of post-operative nausea and vomiting (PONV) in female patients undergoing elective laparoscopic cholecystectomy. In randomized, placebo-controlled, double-blind study, 120 women were assigned to receive either placebo (saline) or granisetron at three different doses (20 mu g kg(-1), 40 mu g kg(-1) or 80 mu g kg(-1)) intravenously immediately before the induction of anaesthesia. All patients received standardized anaesthesia consisting of isoflurane and nitrous oxide in oxygen. The incidence of PONV during the first 24 hours after anaesthesia was 43, 40, 13 and 13% after administration of placebo and granisetron 20 mu g kg(-1), 40 mu g kg(-1) and 80 mu g kg(-1), respectively (P<0.05, overall Fisher's exact probability test). Adverse effects postoperatively were not different among the groups. In conclusion, granisetron 40 mu g kg(-1) is the minimum effective dose in the prevention of PONV after laparoscopic cholecystectomy.
C1 Univ Tsukuba, Inst Clin Med, Dept Anaesthesiol, Tsukuba, Ibaraki 305, Japan.
RP Fujii, Y (reprint author), Univ Tsukuba, Inst Clin Med, Dept Anaesthesiol, Tsukuba, Ibaraki 305, Japan.
CR BERMUDEZ J, 1988, BRIT J CANCER, V58, P644, DOI 10.1038/bjc.1988.277
   CARMICHAEL J, 1989, CANCER CHEMOTH PHARM, V24, P45
   Fujii Y, 1998, EUR J ANAESTH, V15, P166, DOI 10.1111/j.0265-0215.1998.00267.x
   Furue H, 1990, J CLIN THERAPEUTIC M, V6, P49
   Iitomi T, 1995, Masui, V44, P1627
   Naguib M, 1996, CAN J ANAESTH, V43, P226, DOI 10.1007/BF03011739
   STANTON JM, 1991, ANAESTHESIA, V46, P317, DOI 10.1111/j.1365-2044.1991.tb11510.x
   WATCHA MF, 1992, ANESTHESIOLOGY, V77, P162, DOI 10.1097/00000542-199207000-00023
NR 8
TC 16
Z9 16
U1 4
U2 10
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0265-0215
EI 1365-2346
J9 EUR J ANAESTH
JI Eur. J. Anaesth.
PD MAY
PY 1998
VL 15
IS 3
BP 287
EP 291
DI 10.1017/S0265021598000556
PG 5
WC Anesthesiology
SC Anesthesiology
GA ZT366
UT WOS:000074077900007
PM 9649986
DA 2018-12-27
ER

PT J
AU Fujii, Y
   Toyooka, H
   Tanaka, H
AF Fujii, Y
   Toyooka, H
   Tanaka, H
TI RETRACTED: Efficacy of thoracic epidural analgesia following
   laparoscopic cholecystectomy (Retracted article. See vol. 30, pg. 262,
   2013)
SO EUROPEAN JOURNAL OF ANAESTHESIOLOGY
LA English
DT Article; Retracted Publication
DE surgery, laparoscopic cholecystectomy; analgesia, post-operative,
   epidural
ID POSTOPERATIVE PAIN; PULMONARY-FUNCTION; BUPIVACAINE; MORPHINE
AB This study was undertaken to determine whether epidural analgesia has any benefit for post-operative pain relief in patients undergoing laparoscopic cholecystectomy. Patients were randomly assigned to receive post-operative epidural analgesia with a morphine-bupivacaine combination (Group A, n=22) or placebo (saline) (Group B, n=22). The same standard general anaesthetic technique, which consists of nitrous oxide and isoflurane in oxygen was used. Analgesia was assessed using visual analogue pain scores (0-10 cm). The evaluation was carried out 24 and 48 h post-operatively. At 24 h after anaesthesia, pain scores in Group A (2.3+/-1.2) were lower than those in Group B (4.4+/-1.5) (P<0.05). However, at 48 h post-operatively, no difference in scores was observed between the two groups. in conclusion, epidural analgesia with a morphine-bupivacaine combination improves pain relief during the first 24 h following laparoscopic cholecystectomy.
C1 Univ Tsukuba, Inst Clin Med, Dept Anaesthesiol, Tsukuba, Ibaraki, Japan.
RP Fujii, Y (reprint author), Univ Tsukuba, Inst Clin Med, Dept Anaesthesiol, Tsukuba, Ibaraki, Japan.
CR BIGLER D, 1989, ACTA ANAESTH SCAND, V33, P561, DOI 10.1111/j.1399-6576.1989.tb02966.x
   CUNNINGHAM AJ, 1993, ANESTH ANALG, V76, P1120
   ERICE F, 1993, ANESTHESIOLOGY, V79, P966, DOI 10.1097/00000542-199311000-00015
   FISCHER RL, 1988, ANESTH ANALG, V67, P559
   FRAZEE RC, 1991, ANN SURG, V213, P651, DOI 10.1097/00000658-199106000-00016
   FREDMAN B, 1994, ANESTH ANALG, V79, P152
   GRACE PA, 1991, BRIT J SURG, V78, P160, DOI 10.1002/bjs.1800780209
   PUTENSENHIMMER G, 1992, ANESTHESIOLOGY, V77, P675, DOI 10.1097/00000542-199210000-00010
NR 8
TC 21
Z9 21
U1 2
U2 9
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0265-0215
EI 1365-2346
J9 EUR J ANAESTH
JI Eur. J. Anaesth.
PD MAY
PY 1998
VL 15
IS 3
BP 342
EP 344
DI 10.1097/00003643-199805000-00017
PG 3
WC Anesthesiology
SC Anesthesiology
GA ZT366
UT WOS:000074077900017
PM 9649996
DA 2018-12-27
ER

PT J
AU Fujii, Y
   Saitoh, Y
   Tanaka, H
   Toyooka, H
AF Fujii, Y
   Saitoh, Y
   Tanaka, H
   Toyooka, H
TI RETRACTED: Comparison of granisetron and droperidol in the prevention of
   vomiting after strabismus surgery or tonsillectomy in children
   (Retracted article. See vol. 23, pg. 377, 2013)
SO PAEDIATRIC ANAESTHESIA
LA English
DT Article; Retracted Publication
DE strabismus; tonsillectomy; complications; vomiting; antiemetics;
   droperidol, granisetron
ID RECEPTOR ANTAGONIST; EMESIS; NAUSEA
AB This prospective, randomized, double-blinded study evaluated the antiemetic efficacy of granisetron and droperidol in 80 ASA physical status I children, aged 4-10 years, undergoing strabismus surgery or tonsillectomy with or without adenoidectomy. After anaesthetic induction, the patients received either granisetron (40 mu g.kg(-1), n=40) or droperidol (50 mu g.kg(-1), n=40) intravenously. The incidence of vomiting during the first 24h after anaesthesia was 15% and 38% after administering granisetron and droperidol, respectively (P=0.02). The requirement for rescue antiemetic therapy for the treatment of two or more episodes of vomiting was 0% with granisetron and 18% with droperidol (P=0.001). In conclusion, granisetron was superior to droperidol in reducing the incidence and frequency of postoperative vomiting in paediatric patients.
C1 Univ Tsukuba, Inst Clin Med, Dept Anaesthesiol, Tsukuba, Ibaraki 305, Japan.
   Tokyo Med & Dent Univ, Dept Anaesthesiol & Crit Care Med, Bunkyo Ku, Tokyo 113, Japan.
   Toride Kyodo Gen Hosp, Dept Anaesthesiol, Ibaraki, Osaka, Japan.
RP Fujii, Y (reprint author), Univ Tsukuba, Inst Clin Med, Dept Anaesthesiol, Tsukuba, Ibaraki 305, Japan.
CR ABRAMOWITZ MD, 1983, ANESTHESIOLOGY, V59, P579, DOI 10.1097/00000542-198312000-00021
   ANDREWS PLR, 1992, EJC SUPPL, V28, P52
   BERMUDEZ J, 1988, BRIT J CANCER, V58, P644, DOI 10.1038/bjc.1988.277
   CARITHERS JS, 1987, LARYNGOSCOPE, V97, P422
   CARMICHAEL J, 1989, CANCER CHEMOTH PHARM, V24, P45
   CHRISTENSEN S, 1989, ANESTHESIOLOGY, V70, P251, DOI 10.1097/00000542-198902000-00012
   DUPRE LJ, 1980, BRIT J ANAESTH, V52, P831
   FALKSON G, 1989, CANCER CHEMOTH PHARM, V24, P193, DOI 10.1007/BF00300242
   Fujii Y, 1996, CAN J ANAESTH, V43, P660, DOI 10.1007/BF03017947
   Fujii Y, 1996, CAN J ANAESTH, V43, P35, DOI 10.1007/BF03015955
   Furue H, 1990, J CLIN THERAPEUTIC M, V6, P49
   GRUNWALD Z, 1994, PAEDIATRIC ANAESTHES, V4, P163
   LITMAN RS, 1994, ANESTH ANALG, V78, P478
   ROSE JB, 1994, ANESTH ANALG, V79, P486
   WATCHA MF, 1992, ANESTHESIOLOGY, V77, P162, DOI 10.1097/00000542-199207000-00023
NR 15
TC 10
Z9 10
U1 2
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1155-5645
J9 PAEDIATR ANAESTH
JI Paediatr. Anaesth.
PD MAY
PY 1998
VL 8
IS 3
BP 241
EP 244
DI 10.1046/j.1460-9592.1998.00206.x
PG 4
WC Anesthesiology; Pediatrics
SC Anesthesiology; Pediatrics
GA ZN707
UT WOS:000073673600011
PM 9608970
DA 2018-12-27
ER

PT J
AU Holscher, C
AF Holscher, C
TI RETRACTED: beta-amyloid induced reduction in synaptic transmission is
   reversed by inhibitors of nitric oxide synthase (Retracted article. See
   vol 9, pg U12, 1998)
SO NEUROREPORT
LA English
DT Article; Retracted Publication
DE Alzheimer's disease; amyloid; hippocampus; 7-NI; nitric oxide; rat;
   synaptic transmission; TRIM
ID ALZHEIMERS-DISEASE; APOPTOSIS
AB beta-AMYLOID has been shown to be neurotoxic in vivo and in vitro. Free radical production and subsequent lipid oxidation after beta-amyloid application have been observed in vitro and are considered to be factors that contribute to the neurotoxicity. Field recordings in the area CA1 for 3 weeks showed a dose-dependent effect on amplitude after intracerebroventricular (i.c.v.) injections of 1, 5 or 10 nmol beta-amyloid (25-35). The nitric oxide synthase inhibitors 7-nitro indazole (30 mg/kg, i.p.) and 1-(2-trifluoromethylphenyl)imidazole (150 nmol, i.c.v.) which preferentially inhibit the neuronal isoform prevented this beta-amyloid-induced decay of synaptic transmission. The protective effect of these inhibitors was reversed by L-arginine (200 mg/kg, i.p.). The results support the theory that nitric oxide production contributes to beta-amyloid-induced neuronal degeneration or reduction of neurotransmission. (C) 1998 Rapid Science Ltd.
C1 Univ Dublin Trinity Coll, Dept Physiol, Dublin 2, Ireland.
RP Holscher, C (reprint author), Univ Dublin Trinity Coll, Dept Physiol, Earlsfort Terrace, Dublin 2, Ireland.
CR Cullen WK, 1996, NEUROREPORT, V8, P87, DOI 10.1097/00001756-199612200-00018
   Good PF, 1996, AM J PATHOL, V149, P21
   Handy RLC, 1997, LIFE SCI, V60, pPL389, DOI 10.1016/S0024-3205(97)00295-6
   Handy RLC, 1996, BRIT J PHARMACOL, V119, P423, DOI 10.1111/j.1476-5381.1996.tb16003.x
   Holscher C, 1997, J NEUROSCI, V17, P6470
   HUANG ZH, 1994, SCIENCE, V265, P1883, DOI 10.1126/science.7522345
   LE WD, 1995, BRAIN RES, V686, P49, DOI 10.1016/0006-8993(95)00450-5
   Li YP, 1996, BRAIN RES, V738, P196, DOI 10.1016/S0006-8993(96)00733-0
   Lyras L, 1997, J NEUROCHEM, V68, P2061
   MACKENZIE GM, 1994, NEUROREPORT, V5, P1993, DOI 10.1097/00001756-199410000-00039
   Mark RJ, 1997, BRAIN RES, V756, P205, DOI 10.1016/S0006-8993(97)00196-0
   MATTSON MP, 1993, BRAIN RES, V621, P35, DOI 10.1016/0006-8993(93)90295-X
   SCHULZ JB, 1995, J NEUROCHEM, V64, P936, DOI 10.1046/j.1471-4159.1995.64020936.x
   Ueda K, 1997, J NEUROCHEM, V68, P265
   Vodovotz Y, 1996, J EXP MED, V184, P1425, DOI 10.1084/jem.184.4.1425
   Wu JQ, 1995, NEUROREPORT, V6, P2409, DOI 10.1097/00001756-199511270-00031
   YUN S, 1997, SOC NEUR ABSTR, V23
NR 17
TC 11
Z9 11
U1 2
U2 9
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0959-4965
EI 1473-558X
J9 NEUROREPORT
JI Neuroreport
PD APR 20
PY 1998
VL 9
IS 6
BP 1245
EP 1248
PG 4
WC Neurosciences
SC Neurosciences & Neurology
GA ZM026
UT WOS:000073497300055
PM 9601702
DA 2018-12-27
ER

PT J
AU Martens, JR
   Reaves, PY
   Lu, D
   Katovich, MJ
   Berecek, KH
   Bishop, SP
   Raizada, MK
   Gelband, CH
AF Martens, JR
   Reaves, PY
   Lu, D
   Katovich, MJ
   Berecek, KH
   Bishop, SP
   Raizada, MK
   Gelband, CH
TI RETRACTED: Prevention of renovascular and cardiac pathophysiological
   changes in hypertension by angiotensin II type 1 receptor antisense gene
   therapy (Retracted Article. See vol 101, pg 15271, 2004)
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article; Retracted Publication
ID HIGH BLOOD-PRESSURE; LEFT-VENTRICULAR HYPERTROPHY; SMOOTH-MUSCLE-CELLS;
   RENAL-TRANSPLANTATION; RESISTANCE ARTERIES; CORONARY-ARTERIES; VASCULAR
   MUSCLE; K+ CURRENT; RATS; ENDOTHELIUM
AB Hypertension produces pathophysiological changes that are often responsible for the mortality associated with the disease, However, it is unclear whether normalizing blood pressure (BP) with conventional therapy is effective in reversing the pathophysiological damage, The duration and initiation of treatment, site of administration, and agent used all appear to influence the reversal of the pathophysiological alterations associated with hypertension, We have previously established that retrovirally mediated delivery of angiotensin II type 1 receptor antisense (AT(1)R-AS) attenuates the development of high BP in the spontaneously hypertensive (SH) rat model of human essential hypertension, Our objective was to determine whether this attenuation of high BP is associated with prevention of other pathophysiological changes induced by the hypertensive state, Intracardiac delivery of AT(1)R-AS in neonates prevented the development of hypertension in SH rats for at least 120 days, Contractile experiments demonstrated an impaired endothelium-dependent vascular relaxation (acetylcholine) and an enhanced contractile response to vasoactive agents (phenylephrine and KCl) in the SH rat renal vasculature. In addition, the voltage-dependent K(+) current density, which is believed to contribute to smooth muscle resting membrane potential and basal tone, was decreased in renal resistance artery cells of the SH rat, AT(1)R-AS treatment prevented each of these renal vascular alterations, Finally, AT(1)R-AS delivery prevented the pathological alterations observed in the SH rat myocardium, including left ventricular hypertrophy, multifocal fibrosis, and perivascular fibrosis, These observations demonstrate that viral-mediated delivery of AT(1)R-AS attenuates the development of hypertension on a long term basis, and this is associated with prevention of pathophysiological changes in SH rats.
C1 Univ Florida, Coll Med, Dept Physiol, Gainesville, FL 32610 USA.
   Univ Florida, Coll Pharm, Dept Pharmacodynam, Gainesville, FL 32610 USA.
   Univ Alabama, Dept Physiol & Biophys, Birmingham, AL 35294 USA.
   Univ Alabama, Dept Pathol, Birmingham, AL 35294 USA.
RP Raizada, MK (reprint author), Univ Florida, Coll Med, Dept Physiol, POB 100274, Gainesville, FL 32610 USA.
EM mraizada@dean.med.ufl.edu
FU NHLBI NIH HHS [R01 HL056921, HL-52189, HL-56921]
CR BERECEK KH, 1987, AM J PHYSIOL, V252, pH796
   BERECEK KH, 1980, AM J PHYSIOL, V238, pH287
   BERECEK KH, 1995, ADV EXP MED BIOL, V377, P141
   BOHR DF, 1988, ANNU REV PHARMACOL, V28, P389
   CURTIS JJ, 1983, NEW ENGL J MED, V309, P1009, DOI 10.1056/NEJM198310273091702
   DAHL LK, 1972, P SOC EXP BIOL MED, V140, P852
   DEDIVITIIS O, 1993, EUR HEART J, V14, P22, DOI 10.1093/eurheartj/14.suppl_D.22
   ENGLAND SK, 1993, AM J PHYSIOL, V264, pH1337
   FLEISCHMANN BK, 1993, J PHYSIOL-LONDON, V469, P625, DOI 10.1113/jphysiol.1993.sp019834
   Fuchs LC, 1996, AM J HYPERTENS, V9, P475, DOI 10.1016/0895-7061(95)00441-6
   FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0
   GOLDBERG MR, 1995, HYPERTENSION, V25, P37, DOI 10.1161/01.HYP.25.1.37
   Guyton AC, 1990, HYPERTENSION PATHOPH, P1029
   HERMSMEYER K, 1976, CIRC RES, V38, P362, DOI 10.1161/01.RES.38.5.362
   Iyer SN, 1996, P NATL ACAD SCI USA, V93, P9960, DOI 10.1073/pnas.93.18.9960
   KANG PM, 1994, AM HEART J, V127, P1388, DOI 10.1016/0002-8703(94)90061-2
   KAWABE K, 1978, JPN HEART J, V19, P886
   KHALIL RA, 1990, HYPERTENSION PATHOPH, P547
   KNOT HJ, 1995, AM J PHYSIOL-HEART C, V269, pH348
   LI JY, 1993, CIRC RES, V72, P290, DOI 10.1161/01.RES.72.2.290
   LINZ W, 1989, CLIN EXP HYPERTENS A, V11, P1325, DOI 10.3109/10641968909038172
   LU D, 1995, P NATL ACAD SCI USA, V92, P1162, DOI 10.1073/pnas.92.4.1162
   Lu D, 1997, HYPERTENSION, V30, P363, DOI 10.1161/01.HYP.30.3.363
   LU D, 1995, P NATL ACAD SCI USA, V92, P2914, DOI 10.1073/pnas.92.7.2914
   LUSCHER TF, 1988, HYPERTENSION, V11, P573, DOI 10.1161/01.HYP.11.6.573
   MACGREGOR GA, 1992, AM J MED, V92, pS20, DOI 10.1016/0002-9343(92)90143-Y
   Martens JR, 1996, CIRC RES, V79, P295, DOI 10.1161/01.RES.79.2.295
   OHYA Y, 1993, CIRC RES, V73, P1090, DOI 10.1161/01.RES.73.6.1090
   PHILLIPS MI, 1987, ANNU REV PHYSIOL, V49, P413, DOI 10.1146/annurev.physiol.49.1.413
   RETTIG R, 1990, AM J PHYSIOL, V258, pF606
   RUILOPE LM, 1990, J HYPERTENS, V8, P525, DOI 10.1097/00004872-199006000-00005
   RUILOPE LM, 1994, HYPERTENSION, V23, P2
   RUSCH NJ, 1988, CIRC RES, V63, P997, DOI 10.1161/01.RES.63.6.997
   RUSCH NJ, 1994, HYPERTENSION, V23, P941, DOI 10.1161/01.HYP.23.6.941
   RUSCH NJ, 1992, HYPERTENSION, V19, P301, DOI 10.1161/01.HYP.19.4.301
   Schmieder RE, 1996, JAMA-J AM MED ASSOC, V275, P1507, DOI 10.1001/jama.275.19.1507
   Silva EG, 1996, BRIT J PHARMACOL, V118, P1367, DOI 10.1111/j.1476-5381.1996.tb15546.x
   SIMKO F, 1994, PHYSIOL RES, V43, P259
   TRIGGLE CR, 1985, CAN J PHYSIOL PHARM, V63, P355, DOI 10.1139/y85-065
   TSCHUDI MR, 1994, CIRCULATION, V89, P2212, DOI 10.1161/01.CIR.89.5.2212
   VANHOUTTE PM, 1986, ANNU REV PHYSIOL, V48, P307
   VANZWIETEN PA, 1992, J HYPERTENS, V10, pS1
   VOGT M, 1993, EUR HEART J, V14, P2, DOI 10.1093/eurheartj/14.suppl_D.2
   WILDE DW, 1994, HYPERTENSION, V24, P739, DOI 10.1161/01.HYP.24.6.739
   WU JN, 1993, HYPERTENSION, V22, P139, DOI 10.1161/01.HYP.22.2.139
NR 45
TC 48
Z9 51
U1 2
U2 13
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD MAR 3
PY 1998
VL 95
IS 5
BP 2664
EP 2669
DI 10.1073/pnas.95.5.2664
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA ZA471
UT WOS:000072366600130
PM 9482944
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Cho, ZH
   Chung, SC
   Jones, JP
   Park, JB
   Park, HJ
   Lee, HJ
   Wong, EK
   Min, BI
AF Cho, ZH
   Chung, SC
   Jones, JP
   Park, JB
   Park, HJ
   Lee, HJ
   Wong, EK
   Min, BI
TI RETRACTED: New findings of the correlation between acupoints and
   corresponding brain cortices using functional MRI (Retracted Article.
   See vol 103, pg 10527, 2006)
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article; Retracted Publication
DE acupuncture; MRI; correlation between visual and acupuncture stimulation
ID HUMAN VISUAL-CORTEX; SENSORY STIMULATION; EPI
AB A preliminary study of the correlation between acupuncture points (acupoints) for the treatment of eye disorders suggested by ancient Oriental literature and the corresponding brain localization for vision described by Western medicine was performed by using functional MRI (fMRI), The vision-related acupoint (VA1) is located in the lateral aspect of the foot, and when acupuncture stimulation is performed there, activation of occipital lobes is seen by fMRI. Stimulation of the eye by directly using light results in similar activation in the occipital lobes by fMRI, The experiment was conducted by using conventional checkerboard 8-Hz light-flash stimulation of the eye and observation of the time-course data, This was follow ed by stimulation of the VA1 by using the same time-course paradigm as visual light stimulation, Results obtained with 12 volunteers yielded very clean data and very close correlations between visual and acupuncture stimulation. We have also stimulated nonacupoints 2 to 5 cm away from the vision-related acupoints on the foot as a control, and activation in the occipital lobes was not observed, The results obtained demonstrate the correlation between activation of specific areas of brain cortices and corresponding acupoint stimulation predicted by ancient acupuncture literature.
C1 Univ Calif Irvine, Dept Radiol Sci, Irvine, CA 92697 USA.
   Univ Calif Irvine, Dept Psychiat, Irvine, CA 92697 USA.
   Univ Calif Irvine, Dept Human Behav, Irvine, CA 92697 USA.
   Univ Calif Irvine, Dept Ophthalmol, Irvine, CA 92697 USA.
   Korea Adv Inst Sci & Technol, Dept Elect Sci, Seoul 131, South Korea.
   Oriental Med Coll, Dept Meridianol, Seoul, South Korea.
   Kyung Hee Univ, Coll Med, Dept Physiol, Seoul, South Korea.
RP Cho, ZH (reprint author), Univ Calif Irvine, Dept Radiol Sci, Irvine, CA 92697 USA.
EM zcho@uci.edu
CR BANDETTINI PA, 1992, MAGNET RESON MED, V25, P390, DOI 10.1002/mrm.1910250220
   BANDETTINI PA, 1993, MAGNET RESON MED, V30, P161, DOI 10.1002/mrm.1910300204
   BLAMIRE AM, 1992, P NATL ACAD SCI USA, V89, P11069, DOI 10.1073/pnas.89.22.11069
   BUONOCORE MH, 1996, P ISMRM 4 ANN M NEW, P1840
   CHO ZH, 1992, MAGNET RESON MED, V28, P25, DOI 10.1002/mrm.1910280104
   Cho ZH, 1996, MAGNET RESON MED, V35, P1, DOI 10.1002/mrm.1910350102
   CHO ZH, 1976, IEEE T NUCL SCI, V23, P613, DOI 10.1109/TNS.1976.4328315
   Kaptchuk T, 1983, WEB HAS NO WEAVER
   KIM DH, 1987, ACUPUNCTURE MOXIBUST
   KIM SG, 1993, SCIENCE, V261, P615, DOI 10.1126/science.8342027
   KWONG K, 1995, INT J IMAG SYST TECH, V6, P131, DOI 10.1002/ima.1850060202
   KWONG KK, 1992, P NATL ACAD SCI USA, V89, P5675, DOI 10.1073/pnas.89.12.5675
   OGAWA S, 1992, P NATL ACAD SCI USA, V89, P5951, DOI 10.1073/pnas.89.13.5951
   PHELPS ME, 1985, SCIENCE, V228, P799, DOI 10.1126/science.2860723
   STUX G, 1987, ACUPUNCTURE
   TURNER R, 1993, MAGNET RESON MED, V29, P277, DOI 10.1002/mrm.1910290221
   TURNER R, 1993, P SMRM 12 ANN M NEW, P1411
   WU MT, 1997, P INT SOC MAGN RES M, P723
   YOSHIDA T, 1995, AM J CHINESE MED, V23, P319, DOI 10.1142/S0192415X95000389
NR 19
TC 280
Z9 344
U1 1
U2 41
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD MAR 3
PY 1998
VL 95
IS 5
BP 2670
EP 2673
DI 10.1073/pnas.95.5.2670
PG 4
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA ZA471
UT WOS:000072366600131
PM 9482945
OA Bronze, Green Published
DA 2018-12-27
ER

PT J
AU Fujii, Y
   Toyooka, H
   Tanaka, H
AF Fujii, Y
   Toyooka, H
   Tanaka, H
TI RETRACTED: Prevention of postoperative nausea and vomiting with a
   combination of granisetron and droperidol (Retracted article. See vol.
   116, pg. 743, 2013)
SO ANESTHESIA AND ANALGESIA
LA English
DT Article; Retracted Publication
ID RECEPTOR ANTAGONIST
AB In this randomized, double-blind study, we compared the efficacy and safety of granisetron plus droperidol with each antiemetic alone for preventing postoperative nausea and vomiting (PONV) in 150 female patients scheduled for elective major gynecological surgery. Patients were randomly assigned to receive IV either granisetron 2.5 mg (Group G), droperidol 1.25 mg (Group D), or granisetron 2.5 mg plus droperidol 1.25 mg (Group GD) immediately before the induction of anesthesia (n = 50 in each group). A standard anesthetic technique and postoperative analgesia were used. Complete response, defined as no PONV and no administration of rescue antiemetic medication during the first 24 h after anesthesia, was 84% in Group G, 54% in Group D, and 96% in Group GD (P = 0.046 versus Group G, P = 0.001 versus Group D). No clinically important adverse effects were observed in any group. Ln conclusion, the combination of granisetron and droperidol is more effective than each antiemetic alone for complete response in patients undergoing general anesthesia for major gynecological surgery. Implications: We compared the efficacy of granisetron plus droperidol with each antiemetic alone for the prevention of nausea and vomiting after gynecological surgery. The granisetron/droperidol combination was the most effective against these emetic symptoms.
C1 Univ Tsukuba, Inst Clin Med, Dept Anesthesiol, Tsukuba, Ibaraki 305, Japan.
   Toride Kyodo Gen Hosp, Dept Anesthesiol, Ibaraki, Osaka, Japan.
RP Fujii, Y (reprint author), Univ Tsukuba, Inst Clin Med, Dept Anesthesiol, 2-1-1 Amakubo, Tsukuba, Ibaraki 305, Japan.
CR ANDREWS P L R, 1992, European Journal of Cancer, V28A, pS2, DOI 10.1016/0959-8049(92)90628-F
   BELO S, 1994, ANESTH ANALG, V78, pU28
   BERMUDEZ J, 1988, BRIT J CANCER, V58, P644, DOI 10.1038/bjc.1988.277
   CARMICHAEL J, 1989, CANCER CHEMOTH PHARM, V24, P45
   CRESSMAN WA, 1973, ANESTHESIOLOGY, V38, P363, DOI 10.1097/00000542-197304000-00010
   FUJII Y, 1995, CAN J ANAESTH, V42, P852, DOI 10.1007/BF03011030
   FUJII Y, 1994, CAN J ANAESTH, V41, P794, DOI 10.1007/BF03011585
   FUJII Y, 1994, CAN J ANAESTH, V41, P291, DOI 10.1007/BF03009906
   Furue H, 1990, J CLIN THERAPEUTIC M, V6, P49
   KORTTILA K, 1979, ANESTH ANALG, V58, P396
   LERMAN J, 1995, CAN J ANAESTH, V42, P263, DOI 10.1007/BF03010699
   McKenzie R, 1996, ANESTH ANALG, V83, P1218, DOI 10.1097/00000539-199612000-00015
   MCKENZIE R, 1994, ANESTH ANALG, V79, P961
   ROWBOTHAM DJ, 1992, BR J ANAESTH, V69
   WATCHA MF, 1992, ANESTHESIOLOGY, V77, P162, DOI 10.1097/00000542-199207000-00023
   WHITE PF, 1993, ANESTHESIOLOGY, V78, P2, DOI 10.1097/00000542-199301000-00002
   YARKER YE, 1994, DRUGS, V48, P761, DOI 10.2165/00003495-199448050-00008
NR 17
TC 23
Z9 23
U1 1
U2 8
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0003-2999
J9 ANESTH ANALG
JI Anesth. Analg.
PD MAR
PY 1998
VL 86
IS 3
BP 613
EP 616
DI 10.1097/00000539-199803000-00033
PG 4
WC Anesthesiology
SC Anesthesiology
GA YZ516
UT WOS:000072261900033
PM 9495425
OA Bronze
DA 2018-12-27
ER

PT J
AU Leadon, SA
   Avrutskaya, AV
AF Leadon, SA
   Avrutskaya, AV
TI RETRACTED: Requirement for DNA mismatch repair proteins in the
   transcription-coupled repair of thymine glycols in Saccharomyces
   cerevisiae (Retracted article. see DNA Repair, vol 2, pg, 361, 2003)
SO MUTATION RESEARCH-DNA REPAIR
LA English
DT Article; Retracted Publication
DE transcription-coupled repair; mismatch repair; yeast; thymine glycol; UV
ID NUCLEOTIDE-EXCISION REPAIR; NONPOLYPOSIS COLON-CANCER; PREFERENTIAL
   REPAIR; COLORECTAL-CANCER; PYRIMIDINE DIMERS; COCKAYNE-SYNDROME; DHFR
   GENE; YEAST; STRAND; HOMOLOG
AB Defects in DNA mismatch repair have been shown to lead to increased genomic instability and mutability. We recently found that human cells defective in the DNA mismatch repair gene, hMSH2, were deficient in the transcription-coupled repair (TCR) of both oxidative DNA damage, including thymine glycols, and UV-induced DNA damage. However, in a hMLH1 mutant. only a reduction in the TCR of UV damage was observed. In this study, we examined whether TCR of thymine glycols in Sacchamomyces cerevisiae also requires the genes involved in DNA mismatch repair. We found that yeast cells containing mutations in MSH2 were deficient in the removal of thymine glycols from the transcribed strand of the RPB2 gene, while cells with mutations in either MLH1 or PMS1 alone showed near normal levels of TCR of thymine glycols. Interestingly, double mutants in the MLH1 and PMS1 genes were deficient in TCR of thymine glycols. Taken together, these results suggest that these two MutL homologues can act independently of each other, but that they have overlapping roles in TCR. Overall levels of thymine glycol removal were not reduced in the mismatch repair mutants. In contrast to the results with thymine glycols, no defects in TCR of pyrimidine dimers were found in cells with mutations in MSH2, MLH1, PMS1, and MLH1/PMS1. (C) 1998 Elsevier Science B.V.
C1 Univ N Carolina, Dept Radiat Oncol, Chapel Hill, NC 27599 USA.
RP Leadon, SA (reprint author), Univ N Carolina, Dept Radiat Oncol, Chapel Hill, NC 27599 USA.
EM saleadon@radonc.unc.edu
FU NCI NIH HHS [CA40453]
CR AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121
   ALANI E, 1994, GENETICS, V137, P19
   BOHR VA, 1985, CELL, V40, P359, DOI 10.1016/0092-8674(85)90150-3
   BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0
   Cooper PK, 1997, SCIENCE, V275, P990, DOI 10.1126/science.275.5302.990
   FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3
   Friedberg EC, 1996, ANNU REV BIOCHEM, V65, P15
   FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES
   HANAWALT PC, 1994, SCIENCE, V266, P1957, DOI 10.1126/science.7801121
   Johnson RE, 1996, J BIOL CHEM, V271, P27987, DOI 10.1074/jbc.271.45.27987
   KRAMER W, 1989, J BACTERIOL, V171, P5339, DOI 10.1128/jb.171.10.5339-5346.1989
   LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S
   LEADON SA, 1983, MUTAT RES, V112, P191, DOI 10.1016/0167-8817(83)90006-8
   LEADON SA, 1986, NUCLEIC ACIDS RES, V14, P8979, DOI 10.1093/nar/14.22.8979
   LEADON SA, 1995, MUTAT RES-DNA REPAIR, V337, P169, DOI 10.1016/0921-8777(95)00021-B
   LEADON SA, 1992, J BIOL CHEM, V267, P23175
   Leadon SA, 1997, CANCER RES, V57, P3784
   LEADON SA, 1993, P NATL ACAD SCI USA, V90, P10499, DOI 10.1073/pnas.90.22.10499
   LEADON SA, 1988, DNA REPAIR LAB MANUA, P311
   Marsischky GT, 1996, GENE DEV, V10, P407, DOI 10.1101/gad.10.4.407
   MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6
   Mellon I, 1996, SCIENCE, V272, P557, DOI 10.1126/science.272.5261.557
   Mellon I, 1996, P NATL ACAD SCI USA, V93, P1292, DOI 10.1073/pnas.93.3.1292
   Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533
   Mu D, 1997, MOL CELL BIOL, V17, P760, DOI 10.1128/MCB.17.2.760
   NEW L, 1993, MOL GEN GENET, V239, P97
   NICHOLS AF, 1992, NUCLEIC ACIDS RES, V20, P2441, DOI 10.1093/nar/20.10.2441
   Nouspikel T, 1997, P NATL ACAD SCI USA, V94, P3116, DOI 10.1073/pnas.94.7.3116
   PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251
   PROLLA TA, 1994, SCIENCE, V265, P1091, DOI 10.1126/science.8066446
   PROLLA TA, 1994, MOL CELL BIOL, V14, P407, DOI 10.1128/MCB.14.1.407
   REENAN RAG, 1992, GENETICS, V132, P975
   RISINGER JI, 1995, J BIOL CHEM, V270, P18183, DOI 10.1074/jbc.270.31.18183
   SELBY CP, 1991, P NATL ACAD SCI USA, V88, P8232, DOI 10.1073/pnas.88.18.8232
   SELBY CP, 1993, SCIENCE, V260, P53, DOI 10.1126/science.8465200
   SELBY CP, 1995, J BIOL CHEM, V270, P4890, DOI 10.1074/jbc.270.9.4890
   SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A
   STRAND M, 1993, NATURE, V365, P274, DOI 10.1038/365274a0
   SWEDER KS, 1992, P NATL ACAD SCI USA, V89, P10696, DOI 10.1073/pnas.89.22.10696
   Sweder KS, 1996, GENETICS, V143, P1127
   Umar A, 1996, CELL, V87, P65, DOI 10.1016/S0092-8674(00)81323-9
   VANGOOL AJ, 1994, EMBO J, V13, P5361, DOI 10.1002/j.1460-2075.1994.tb06871.x
   Verhage RA, 1996, MOL CELL BIOL, V16, P496
NR 43
TC 41
Z9 41
U1 2
U2 8
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0921-8777
J9 MUTAT RES-DNA REPAIR
JI Mutat. Res.-DNA Repair
PD MAR
PY 1998
VL 407
IS 2
BP 177
EP 187
DI 10.1016/S0921-8777(98)00007-X
PG 11
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Toxicology
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Toxicology
GA ZQ325
UT WOS:000073847200010
PM 9637246
DA 2018-12-27
ER

PT J
AU Wakefield, AJ
   Murch, SH
   Anthony, A
   Linnell, J
   Casson, DM
   Malik, M
   Berelowitz, M
   Dhillon, AP
   Thomson, MA
   Harvey, P
   Valentine, A
   Davies, SE
   Walker-Smith, JA
AF Wakefield, AJ
   Murch, SH
   Anthony, A
   Linnell, J
   Casson, DM
   Malik, M
   Berelowitz, M
   Dhillon, AP
   Thomson, MA
   Harvey, P
   Valentine, A
   Davies, SE
   Walker-Smith, JA
TI RETRACTED: Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and
   pervasive developmental disorder in children (Retracted article. See vol
   375, pg 445, 2010)
SO LANCET
LA English
DT Article; Retracted Publication
ID CROHNS-DISEASE; MEASLES VACCINATION; AUTISM
AB Background We investigated a consecutive series of children with chronic enterocolitis and regressive developmental disorder.
   Methods 12 children (mean age 6 years [range 3-10], 11 boys) were referred to a paediatric gastroenterology unit with a history of normal development followed by loss of acquired skills, including language, together with diarrhoea and abdominal pain. Children underwent gastroenterological, neurological, and developmental assessment and review of developmental records. Ileocolonoscopy and biopsy sampling, magnetic-resonance imaging (MRI), electroencephalography (EEG), and lumbar puncture were done under sedation. Barium follow-through radiography was done where possible. Biochemical, haematological, and immunological profiles were examined.
   Findings Onset of behavioural symptoms was associated, by the parents, with measles, mumps, and rubella vaccination in eight of the 12 children, with measles infection in one child, and otitis media in another. All 12 children had intestinal abnormalities, ranging from lymphoid nodular hyperplasia to aphthoid ulceration. Histology showed patchy chronic inflammation in the colon in 11 children and reactive ileal lymphoid hyperplasia in seven, but no granulomas. Behavioural disorders included autism (nine), disintegrative psychosis (one), and possible postviral or vaccinal encephalitis (two). There were no focal neurological abnormalities and MRI and EEG tests were normal. Abnormal laboratory results were significantly raised urinary methylmalonic acid compared with age-matched controls (p=0.003), low haemoglobin in four children, and a low serum IgA in four children.
   Interpretation We identified associated gastrointestinal disease and developmental regression in a group of previously normal children, which was generally associated in time with possible environmental triggers.
C1 Univ London Royal Free Hosp, Sch Med, Dept Med, Inflammatory Bowel Dis Study Grp, London NW3 2QG, England.
   Univ London Royal Free Hosp, Sch Med, Dept Histopathol, London NW3 2QG, England.
   Univ London Royal Free Hosp, Sch Med, Dept Paediat Gastroenterol, London NW3 2QG, England.
   Univ London Royal Free Hosp, Sch Med, Dept Child & Adolescent Psychiat, London NW3 2QG, England.
   Univ London Royal Free Hosp, Sch Med, Dept Neurol, London NW3 2QG, England.
   Univ London Royal Free Hosp, Sch Med, Dept Radiol, London NW3 2QG, England.
RP Wakefield, AJ (reprint author), Univ London Royal Free Hosp, Sch Med, Dept Med, Inflammatory Bowel Dis Study Grp, London NW3 2QG, England.
RI Dhillon, Amar/C-5619-2009
CR American Psychiatric Association, 1994, DIAGN STAT MAN MENT
   Asperger H., 1961, ANN PAEDIAT, V197, P146
   BHATT HR, 1982, CLIN CHIM ACTA, V118, P311, DOI 10.1016/0009-8981(82)90018-3
   DEufemia P, 1996, ACTA PAEDIATR, V85, P1076, DOI 10.1111/j.1651-2227.1996.tb14220.x
   DILLON MJ, 1974, CLIN SCI MOL MED, V47, P43, DOI 10.1042/cs0470043
   EKBOM A, 1994, LANCET, V344, P508, DOI 10.1016/S0140-6736(94)91898-8
   ENGLAND JM, 1980, LANCET, V2, P1072
   Fudenberg HH, 1996, BIOTHERAPY, V9, P13
   Fujimura Y, 1996, GUT, V38, P724, DOI 10.1136/gut.38.5.724
   Gupta S, 1996, P NATL AUTISM ASS CH, P455
   Kawashima H, 1996, ARCH VIROL, V141, P877, DOI 10.1007/BF01718162
   Lucarelli S, 1995, PANMINERVA MED, V37, P137
   Miller D, 1997, LANCET, V349, P730, DOI 10.1016/S0140-6736(05)60171-7
   MIYAMOTO H, 1995, J GASTROENTEROL, V30, P28, DOI 10.1007/BF01211371
   MURCH SH, 1993, LANCET, V341, P711, DOI 10.1016/0140-6736(93)90485-Y
   PANKSEPP J, 1979, TRENDS NEUROSCI, V2, P174, DOI 10.1016/0166-2236(79)90071-7
   Reichelt K L, 1981, Adv Biochem Psychopharmacol, V28, P627
   RUTTER M, CHILD ADOLESCENT PSY, P581
   SHATTOCK P, 1990, Brain Dysfunction, V3, P328
   THOMPSON NP, 1995, LANCET, V345, P1071, DOI 10.1016/S0140-6736(95)90816-1
   WALKERSMITH J, 1972, LANCET, V2, P883
   WARING RH, C P BIOL PERSP AUT U, pNAS35
   Warren RP, 1996, NEUROPSYCHOBIOLOGY, V34, P72, DOI 10.1159/000119295
   WARREN RP, 1991, CLIN EXP IMMUNOL, V83, P438
   Wing L, 1996, BRIT MED J, V312, P327
   WING L, 1996, AUTISTIC SPECTRUM, P68
NR 26
TC 1233
Z9 1267
U1 50
U2 586
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0140-6736
J9 LANCET
JI Lancet
PD FEB 28
PY 1998
VL 351
IS 9103
BP 637
EP 641
DI 10.1016/S0140-6736(97)11096-0
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA ZA447
UT WOS:000072364200010
PM 9500320
DA 2018-12-27
ER

PT J
AU Baglia, FA
   Walsh, PN
AF Baglia, FA
   Walsh, PN
TI RETRACTED: Prothrombin is a cofactor for the binding of factor XI to the
   platelet surface and for platelet-mediated factor XI activation by
   thrombin (Retracted Article. See vol 46, pg 12886, 2007)
SO BIOCHEMISTRY
LA English
DT Article; Retracted Publication
ID COAGULATION-FACTOR-XI; MOLECULAR-WEIGHT KININOGEN; WASHED
   HUMAN-PLATELETS; BLOOD-COAGULATION; HAGEMAN-FACTOR; PLASMA; SITE;
   IDENTIFICATION; DOMAIN; ANTIBODIES
AB To study the physiological significance of thrombin as an initiator of intrinsic blood coagulation, activated human platelets were compared with dextran sulfate as a surface for thrombin-catalyzed factor XI activation. Activated gel-filtered platelets promoted factor XI activation by thrombin at initial rates 2-5-fold greater than dextran sulfate in the presence of high molecular weight kininogen (HK, 45 nM), ZnCl2 (25 mu M), and CaCl2 (2 mM), conditions optimal for factor XI binding to platelets, Physiological concentrations of HK (636 nM) inhibited factor XI activation by thrombin in a concentration-dependent manner, and this inhibition was reversed by prothrombin (1-3 mu M) and by prothrombin fragment 1.2 (PF1.2), but not bq prothrombin fragment 1 (PF1). Since prothrombin and PF1.2 (but not PF1) also displaced HK from its binding site on the Apple 1 domain of factor XI, we conclude that the Kringle II domain of prothrombin competes with HK for binding to the Apple 1 domain of factor XI. Prothrombin (1-3 mu M) and PF1.2 (but not PF1) in the presence of CaCl2 (2 mM) were able to replace HK (45 nM) in the presence of:ZnCl2 (25 mu M) as a cofactor for the specific, reversible, high-affinity (K-d similar to 25 nM) binding of factor XI to 947 +/- 150 sites per platelet. This binding is mediated by residues Asn 235-Arg 266 in the Apple 3 domain since a conformationally constrained, synthetic peptide analogue of this sequence inhibits both factor XI binding to activated platelets and platelet-mediated, thrombin-catalyzed factor XI activation in the presence of prothrombin and CaCl2. Finally, prothrombin (1.2 mu M) and CaCl2 (2 mM) could substitute for HK (45 nM) and ZnCl2 (25 mu M) in promoting optimal rates of thrombin-catalyzed factor XI activation on the platelet surface, thereby initiating the intrinsic coagulation pathway by mechanisms completely independent of the contact phase proteins, factor XII, HK, and prekallikrein.
C1 Temple Univ, Sch Med, Sol Sherry Thrombosis Res Ctr, Philadelphia, PA 19140 USA.
   Temple Univ, Sch Med, Dept Med, Philadelphia, PA 19140 USA.
   Temple Univ, Sch Med, Dept Biochem, Philadelphia, PA 19140 USA.
RP Walsh, PN (reprint author), Temple Univ, Sch Med, Sol Sherry Thrombosis Res Ctr, 3400 N Broad St, Philadelphia, PA 19140 USA.
EM pnw@astro.ocis.temple.edu
FU NHLBI NIH HHS [HL56153, HL55407, HL46213]
CR BAGLIA FA, 1991, J BIOL CHEM, V266, P24190
   BAGLIA FA, 1995, J BIOL CHEM, V270, P6734, DOI 10.1074/jbc.270.12.6734
   BAGLIA FA, 1992, J BIOL CHEM, V267, P4247
   BAGLIA FA, 1990, J BIOL CHEM, V265, P4149
   Baglia FA, 1996, J BIOL CHEM, V271, P3652
   BAGLIA FA, 1993, J BIOL CHEM, V268, P3838
   BOUMA BN, 1977, J BIOL CHEM, V252, P6432
   BRUNNEE T, 1993, BLOOD, V81, P580
   Davie E W, 1979, Adv Enzymol Relat Areas Mol Biol, V48, P277
   FUJIKAWA K, 1986, BIOCHEMISTRY-US, V25, P2417, DOI 10.1021/bi00357a018
   GAILANI D, 1991, SCIENCE, V253, P909, DOI 10.1126/science.1652157
   GAILANI D, 1993, BLOOD, V82, P813
   GAILANI D, 1993, BLOOD COAGUL FIBRIN, V4, P15, DOI 10.1097/00001721-199304010-00003
   GREENGARD JS, 1984, BIOCHEMISTRY-US, V23, P6863, DOI 10.1021/bi00321a090
   GREENGARD JS, 1986, BIOCHEMISTRY-US, V25, P3884, DOI 10.1021/bi00361a022
   GRIFFIN JH, 1976, P NATL ACAD SCI USA, V73, P2554, DOI 10.1073/pnas.73.8.2554
   Habeeb A F, 1972, Methods Enzymol, V25, P457, DOI 10.1016/S0076-6879(72)25041-8
   HUI KY, 1992, BIOCHEM BIOPH RES CO, V184, P790, DOI 10.1016/0006-291X(92)90659-9
   KENT SBH, 1985, SYNTHETIC PEPTIDES B, P29
   KERBIRIOU DM, 1979, J BIOL CHEM, V254, P2020
   KURACHI K, 1980, BIOCHEMISTRY-US, V19, P1330, DOI 10.1021/bi00548a011
   KURACHI K, 1977, BIOCHEMISTRY-US, V16, P5831, DOI 10.1021/bi00645a030
   MCMULLEN BA, 1991, BIOCHEMISTRY-US, V30, P2056, DOI 10.1021/bi00222a008
   MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1
   NAITO K, 1991, J BIOL CHEM, V266, P7353
   PROCTOR RR, 1961, AM J CLIN PATHOL, V36, P212
   Scandura JM, 1996, BIOCHEMISTRY-US, V35, P8890, DOI 10.1021/bi9525029
   SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x
   SCOTT CF, 1984, BLOOD, V63, P42
   SCOTT CF, 1992, P NATL ACAD SCI USA, V89, P11189, DOI 10.1073/pnas.89.23.11189
   SINHA D, 1985, J BIOL CHEM, V260, P714
   THOMPSON RE, 1977, J CLIN INVEST, V60, P1376, DOI 10.1172/JCI108898
   VANDERGRAAF F, 1983, J BIOL CHEM, V258, P9669
   VONDEMBORNE PAK, 1994, THROMB HAEMOSTASIS, V72, P397
   VONDEMBORNE PAK, 1977, J CELL INVEST, V10, P2323
   WALSH PN, 1993, METHOD ENZYMOL, V222, P65
   WALSH PN, 1985, THROMB RES, V40, P257, DOI 10.1016/0049-3848(85)90337-8
   WALSH PN, 1981, BLOOD, V57, P106
NR 38
TC 82
Z9 82
U1 2
U2 13
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0006-2960
J9 BIOCHEMISTRY-US
JI Biochemistry
PD FEB 24
PY 1998
VL 37
IS 8
BP 2271
EP 2281
DI 10.1021/bi972113+
PG 11
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA YZ846
UT WOS:000072299900021
PM 9485373
DA 2018-12-27
ER

PT J
AU Taoka, Y
   Okajima, K
   Uchiba, M
   Murakami, K
   Harada, N
   Johno, M
   Naruo, M
AF Taoka, Y
   Okajima, K
   Uchiba, M
   Murakami, K
   Harada, N
   Johno, M
   Naruo, M
TI RETRACTED: Activated protein C reduces the severity of
   compression-induced spinal cord injury in rats by inhibiting activation
   of leukocytes (Retracted article. See vol. 31, pg. 8697, 2011)
SO JOURNAL OF NEUROSCIENCE
LA English
DT Article; Retracted Publication
DE activated protein C; post-traumatic spinal cord injury; leukocytes;
   motor disturbances; TNF-alpha; neutrophils
ID PULMONARY VASCULAR INJURY; INTRAVASCULAR COAGULATION; ADHESION;
   INFILTRATION; PATHOGENESIS; NEUTROPHILS; ENDOTOXIN; PATHWAY; GAMMA; LPS
AB Activated protein C (APC), an important inhibitor of the coagulation system, has recently been shown to prevent tissue injury by blocking the activation of leukocytes. To determine whether APC can also prevent post-traumatic spinal cord injury (SCI), a condition in which leukocytes play an important role, we tested the effects of APC on SCI induced in rats by compression trauma. Administration of APC, either before or after the induction of SCI, markedly reduced the motor disturbances in these animals. In contrast, neither an inactive derivative of activated factor X (DEG R-Xa), a selective inhibitor of thrombin generation, nor active site-blocked APC (DIP-APC) reduced the motor disturbances. Histological examination revealed that intramedullary hemorrhages, observed 24 hr after trauma, were significantly reduced in the animals administered APC. The increase in the tissue level of tumor necrosis factor-alpha (TNF-alpha) and the accumulation of neutrophils in the damaged segment of the spinal cord were significantly inhibited in the animals that had received APC, but these were not inhibited in those administered DIP-APC or DEGR-Xa. The induction of leukocytopenia had the same effect as APC, in that it significantly reduced motor disturbances, tissue levels of TNF-alpha, and neutrophil accumulation in the animals subjected to compressive SCI. These findings suggest that in SCI, APC reduces motor disturbances primarily by reducing the amount of TNF-alpha at the site of injury, thus inhibiting neutrophil accumulation and the resultant damage to the endothelial cells.
C1 Kumamoto Univ, Sch Med, Dept Lab Med, Kumamoto 860, Japan.
   Kumamoto Univ, Sch Med, Dept Dermatol, Kumamoto 860, Japan.
   Naruo Orthoped Hosp, Kumamoto 860, Japan.
RP Okajima, K (reprint author), Kumamoto Univ, Sch Med, Dept Lab Med, Honjo 1-1-1, Kumamoto 860, Japan.
CR BAJAJ SP, 1981, PREP BIOCHEM, V11, P397, DOI 10.1080/00327488108065531
   BLIGHT AR, 1992, J NEUROTRAUM, V9, pS83
   BRACKEN MB, 1990, NEW ENGL J MED, V322, P1405, DOI 10.1056/NEJM199005173222001
   CARLOS TM, 1994, BLOOD, V84, P2068
   DEMOPOULOS HB, 1978, SCAN ELECTRON MICROS, V2, P677
   ESMON CT, 1992, ARTERIOSCLER THROMB, V12, P135, DOI 10.1161/01.ATV.12.2.135
   GREY S, 1993, TRANSPLANT P, V25, P2913
   GREY ST, 1994, J IMMUNOL, V153, P3664
   GRINNELL BW, 1994, GLYCOBIOLOGY, V4, P221, DOI 10.1093/glycob/4.2.221
   Hamada Y, 1996, J NEUROCHEM, V66, P1525
   HARLAN JM, 1987, SEMIN THROMB HEMOST, V13, P434, DOI 10.1055/s-2007-1003520
   KATSUURA Y, 1994, THROMB RES, V76, P353, DOI 10.1016/0049-3848(94)90164-3
   KLEBANOFF SJ, 1986, J IMMUNOL, V136, P4220
   KUNKELBAGDEN E, 1993, EXP NEUROL, V119, P153, DOI 10.1006/exnr.1993.1017
   LUNDBERG C, 1983, INFLAMMATION, V7, P247, DOI 10.1007/BF00917262
   MEANS ED, 1983, J NEUROPATH EXP NEUR, V42, P707, DOI 10.1097/00005072-198311000-00009
   MULLERBERGHAUS G, 1975, BLOOD, V45, P631
   MULLIGAN MS, 1991, J CLIN INVEST, V88, P1396, DOI 10.1172/JCI115446
   Murakami K, 1997, AM J PHYSIOL-LUNG C, V272, pL197
   Murakami K, 1996, BLOOD, V87, P642
   NESHEIM ME, 1981, J BIOL CHEM, V256, P6537
   RIVLIN AS, 1977, J NEUROSURG, V47, P577, DOI 10.3171/jns.1977.47.4.0577
   STOVER SL, 1987, PARAPLEGIA, V25, P225, DOI 10.1038/sc.1987.40
   Taoka Y, 1997, NEUROSCIENCE, V79, P1177, DOI 10.1016/S0306-4522(97)00011-0
   Taoka Y, 1997, J NEUROSURG, V86, P1007, DOI 10.3171/jns.1997.86.6.1007
   TAOKA Y, 1995, PARAPLEGIA, V33, P450, DOI 10.1038/sc.1995.98
   WALKER FJ, 1979, BIOCHIM BIOPHYS ACTA, V571, P333, DOI 10.1016/0005-2744(79)90103-7
   Wang CX, 1996, J NEUROIMMUNOL, V69, P151
   XU J, 1990, J NEUROCHEM, V55, P907, DOI 10.1111/j.1471-4159.1990.tb04577.x
   YAKOVLEV AG, 1994, MOL CHEM NEUROPATHOL, V23, P179, DOI 10.1007/BF02815410
   Young W, 1988, J Neurotrauma, V5, P219, DOI 10.1089/neu.1988.5.219
   ZIMMERMAN BJ, 1990, AM J PHYSIOL, V259, pH390
NR 32
TC 103
Z9 107
U1 1
U2 7
PU SOC NEUROSCIENCE
PI WASHINGTON
PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA
SN 0270-6474
J9 J NEUROSCI
JI J. Neurosci.
PD FEB 15
PY 1998
VL 18
IS 4
BP 1393
EP 1398
PG 6
WC Neurosciences
SC Neurosciences & Neurology
GA YV453
UT WOS:000071825800020
PM 9454848
DA 2018-12-27
ER

PT J
AU Fujii, Y
   Saitoh, Y
   Tanaka, H
   Toyooka, H
AF Fujii, Y
   Saitoh, Y
   Tanaka, H
   Toyooka, H
TI RETRACTED: Prevention of PONV with granisetron, droperidol or
   metoclopramide in patients with postoperative emesis (Retracted article.
   See vol. 60, pg. 618, 2013)
SO CANADIAN JOURNAL OF ANAESTHESIA-JOURNAL CANADIEN D ANESTHESIE
LA English
DT Article; Retracted Publication
ID RECEPTOR ANTAGONIST; ANTIEMETIC EFFICACY; NAUSEA
AB Purpose: A high incidence of postoperative nausea and vomiting (PONV) has been noted in patients with a his tory of postoperative emesis. This study was undertaken to compare the efficacy of granisetron, droperidol and metoclopramide, in the prevention of PONV in such patients undergoing general anaesthesia for major gynaecological surgery.
   Methods: In a randomised, double-blind study, 90 female patients received 2.5 mg granisetron, 1.25 mg droperidol or 10 mg metoclopramide (n = 30 of each) iv immediately before induction of anaesthesia. The same standard general anaesthetic technique, which consisted of isoflurane in nitrous oxide and oxygen, was used. Nausea, vomiting and safety assessments were performed continuously during the first 24 hr after anaesthesia.
   Results: The incidence of PONV was 20% with granisetron, 57% with droperidol and 60% with metoclopramide (P < 0.05; overall Fisher's exact probability test). No clinically adverse events were observed in any group.
   Conclusion: Granisetron is more effective than droperidol or metoclopramide in preventing PONV in female patients with a history of postoperative emesis.
C1 Univ Tsukuba, Inst Clin Med, Dept Anaesthesiol, Tsukuba, Ibaraki 305, Japan.
   Tokyo Med & Dent Univ, Sch Med, Dept Anaesthesiol & Crit Care Med, Bunkyo Ku, Tokyo 113, Japan.
   Toride Kyodo Gen Hosp, Dept Anaesthesiol, Ibaraki, Osaka, Japan.
RP Fujii, Y (reprint author), Univ Tsukuba, Inst Clin Med, Dept Anaesthesiol, 2-1-1 Amakubo, Tsukuba, Ibaraki 305, Japan.
CR BERMUDEZ J, 1988, BRIT J CANCER, V58, P644, DOI 10.1038/bjc.1988.277
   CARMICHAEL J, 1989, CANCER CHEMOTH PHARM, V24, P45
   COHEN SE, 1984, ANESTHESIOLOGY, V60, P67, DOI 10.1097/00000542-198401000-00015
   Fujii Y, 1997, CAN J ANAESTH, V44, P273, DOI 10.1007/BF03015365
   FUJII Y, 1994, CAN J ANAESTH, V41, P794, DOI 10.1007/BF03011585
   FUJII Y, 1994, CAN J ANAESTH, V41, P291, DOI 10.1007/BF03009906
   Furue H, 1990, J CLIN THERAPEUTIC M, V6, P49
   KORTTILA K, 1979, ANESTH ANALG, V58, P396
   PURKIS I E, 1964, Can Anaesth Soc J, V11, P335, DOI 10.1007/BF03003420
   WATCHA MF, 1992, ANESTHESIOLOGY, V77, P162, DOI 10.1097/00000542-199207000-00023
   YARKER YE, 1994, DRUGS, V48, P761, DOI 10.2165/00003495-199448050-00008
NR 11
TC 19
Z9 19
U1 2
U2 8
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0832-610X
J9 CAN J ANAESTH
JI Can. J. Anaesth.-J. Can. Anesth.
PD FEB
PY 1998
VL 45
IS 2
BP 153
EP 156
DI 10.1007/BF03013255
PG 4
WC Anesthesiology
SC Anesthesiology
GA YY162
UT WOS:000072119500011
PM 9512851
DA 2018-12-27
ER

PT J
AU Fujii, Y
   Saitoh, Y
   Tanaka, H
   Toyooka, H
AF Fujii, Y
   Saitoh, Y
   Tanaka, H
   Toyooka, H
TI RETRACTED: Cardiovascular responses to tracheal extubation or LMA
   removal in children (Retracted article. See vol. 60, pg. 617, 2013)
SO CANADIAN JOURNAL OF ANAESTHESIA-JOURNAL CANADIEN D ANESTHESIE
LA English
DT Article; Retracted Publication
ID LARYNGEAL MASK AIRWAY; AWAKE
AB Purpose: This study was designed to investigate the cardiovascular effects related to tracheal extubation or laryngeal mask airway (LMA) removal in children.
   Methods: Sixty children, ASA physical status 1, 4-10 yr of age, undergoing minor elective surgery (inguinal hernia and phimosis) were allocated randomly to have their surgery performed with endotracheal intubation (Group ET, n = 30) or LMA (Group LMA, n = 30) and were studied for cardiovascular responses related to extubation or LMA removal. Changes in heart rate (HR), systolic blood pressure (SEP) and diastolic blood pressure (DBP) were measured before and 1, 2, 3, 5, and 10 min after tracheal extubation or LMA removal when the patients were awake.
   Results: The maximal changes in HR, SEP and DBP were less in Group LMA than in Group ET during the observation period (HR; 12 vs 26, SBP; 14 vs 28, DBP; 9 vs 13, median, P < 0.05).
   Conclusion: Laryngeal mask airway removal elicited less haemodynamic change than tracheal extubation in paediatric patients.
C1 Univ Tsukuba, Inst Clin Med, Dept Anaesthesiol, Tsukuba, Ibaraki 305, Japan.
   Tokyo Med & Dent Univ, Sch Med, Dept Anaesthesiol & Crit Care Med, Bunkyo Ku, Tokyo 113, Japan.
   Toride Kyodo Gen Hosp, Dept Anaesthesiol, Ibaraki, Osaka, Japan.
RP Fujii, Y (reprint author), Univ Tsukuba, Inst Clin Med, Dept Anaesthesiol, 2-1-1,Amakubo, Tsukuba, Ibaraki 305, Japan.
CR BRAIN AIJ, 1983, BRIT J ANAESTH, V55, P801, DOI 10.1093/bja/55.8.801
   BRAUDE N, 1989, ANAESTHESIA, V44, P551, DOI 10.1111/j.1365-2044.1989.tb11439.x
   Fujii Y, 1997, CAN J ANAESTH, V44, P1082, DOI 10.1007/BF03019230
   KUWASAKO Y, 1990, MASUI, V40, P586
   LOWRIE A, 1992, BRIT J ANAESTH, V68, P261, DOI 10.1093/bja/68.3.261
   MASON DG, 1990, ANAESTHESIA, V45, P760, DOI 10.1111/j.1365-2044.1990.tb14449.x
   MILLER KA, 1995, ANESTH ANALG, V80, P149, DOI 10.1097/00000539-199501000-00025
   PATEL RI, 1991, ANESTH ANALG, V73, P266
   PENNANT JH, 1993, ANESTHESIOLOGY, V79, P144
   POUNDER DR, 1991, ANESTHESIOLOGY, V74, P653, DOI 10.1097/00000542-199104000-00005
NR 10
TC 10
Z9 11
U1 4
U2 12
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0832-610X
J9 CAN J ANAESTH
JI Can. J. Anaesth.-J. Can. Anesth.
PD FEB
PY 1998
VL 45
IS 2
BP 178
EP 181
DI 10.1007/BF03013260
PG 4
WC Anesthesiology
SC Anesthesiology
GA YY162
UT WOS:000072119500016
PM 9512856
DA 2018-12-27
ER

PT J
AU Dhuley, JN
AF Dhuley, JN
TI RETRACTED: Antifungal antibiotic hamycin increases susceptibility of
   Candida albicans to phagocytosis by murine macrophages (Retracted
   Article. See vol 55, pg 112, 2009)
SO FEMS IMMUNOLOGY AND MEDICAL MICROBIOLOGY
LA English
DT Article; Retracted Publication
DE Candida albicans; hamycin; phagocytosis; macrophage
ID ADHERENCE; VIRULENCE; GROWTH
AB Hamycin is an antifungal antibiotic produced by Streptomyces pimprina Thirum. In the present study, the effect of hamycin on (a) the phagocytosis of Candida albicans by murine peritoneal macrophages and (b) the cell surface hydrophobicity (CSH) of C. albicans was investigated. Addition of hamycin to the culture of macrophages and Candida cells increased the susceptibility of Candida cells to the phagocytosis by macrophages. Pretreatment of Candida cells with hamycin increased their vulnerability to killing by macrophages. Examination of physico-chemical properties of Candida cell surface showed a significant decrease in the CSH. These findings suggest that the binding of hamycin to Candida cells induces biochemical/physico-chemical alterations of the surface, so that it becomes more susceptible to phagocytosis by murine macrophages. (C) 1998 Federation of European Microbiological Societies. Published by Elsevier Science B.V.
C1 Hindustan Antibiot Ltd, Res Ctr, Pharmacol & Toxicol Sect, Pune 411018, Maharashtra, India.
RP Dhuley, JN (reprint author), Hindustan Antibiot Ltd, Res Ctr, Pharmacol & Toxicol Sect, Pune 411018, Maharashtra, India.
CR ANTLEY PP, 1988, INFECT IMMUN, V56, P2884
   EVRON R, 1980, INFECT IMMUN, V28, P963
   GELFAND JA, 1988, CLIN RES, V36, P456
   GOKHALE B. B., 1963, Indian Practitioner, V16, P267
   GRANT K. B., 1964, HINDUSTAN ANTIBIOT BULL, V7, P63
   HAZEN KC, 1989, INFECT IMMUN, V57, P1894
   HIA JKS, 1989, J INFECT DIS, V158, P113
   Ichaporia R N, 1969, Hindustan Antibiot Bull, V12, P7
   KLOTZ SA, 1985, INFECT IMMUN, V50, P97
   MARODI L, 1991, J IMMUNOL, V146, P2783
   MCCOURTIE J, 1984, INFECT IMMUN, V45, P6
   PANDEY RC, 1977, J ANTIBIOT, V30, P158, DOI 10.7164/antibiotics.30.158
   RADHA TG, 1978, RESPIRATION, V36, P104
   SARTHOU P, 1986, J IMMUNOL, V137, P2156
   TANSHO S, 1994, MICROBIOL IMMUNOL, V38, P379, DOI 10.1111/j.1348-0421.1994.tb01794.x
   THIRUMALACHAR M. J., 1961, HINDUSTAN ANTIBIOT BULL, V3, P136
   Thirumalachar M. J., 1987, Recent trends in the discovery, development and evaluation of antifungal agents., P619
   UTZ JP, 1967, AM REV RESPIR DIS, V95, P506
   VANDERAUWERA P, 1988, CURR OPIN INFECT DIS, V1, P363, DOI 10.1097/00001432-198805000-00005
NR 19
TC 4
Z9 4
U1 2
U2 9
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0928-8244
J9 FEMS IMMUNOL MED MIC
JI FEMS Immunol. Med. Microbiol.
PD FEB
PY 1998
VL 20
IS 2
BP 153
EP 157
PG 5
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA ZB805
UT WOS:000072509800009
PM 9544783
DA 2018-12-27
ER

PT J
AU Van Parijs, L
   Peterson, DA
   Abbas, AK
AF Van Parijs, L
   Peterson, DA
   Abbas, AK
TI RETRACTED: The Fas/Fas ligand pathway and Bcl-2 regulate T cell
   responses to model self and foreign antigens (Retracted article. See
   vol. 30, pg. 611, 2009)
SO IMMUNITY
LA English
DT Article; Retracted Publication
ID RECEPTOR TRANSGENIC MICE; IN-VIVO; LYMPHOPROLIFERATIVE SYNDROME;
   PERIPHERAL TOLERANCE; NEGATIVE SELECTION; FAS ANTIGEN; B-CELLS;
   APOPTOSIS; DEATH; COSTIMULATION
AB We have examined the role of Fas and Bcl-2 in T cell survival and responses to antigen in vivo using T cells that express a transgenic antigen receptor specific for hen egg lysozyme (HEL) and that either lack functional Fas or Fas ligand (FasL) or overexpress Bcl-2 as a transgene. HEL-specific, Bcl-2-transgenic T cells showed prolonged responses to immunization with cognate peptide but were eliminated rapidly when exposed to HEL expressed systemically as a self antigen. In contrast, Fas- and FasL-defective T cells did not display exaggerated responses to immunization with HEL peptide, but did show increased expansion and survival in response to systemic self antigen and were able to activate anti-HEL (self) antibody-forming cells. Thus, Bcl-2 and Fas play different roles in the regulation of T cell responses to antigen in vivo and in self tolerance.
C1 Brigham & Womens Hosp, Dept Pathol, Div Immunol Res, Boston, MA 02115 USA.
   Harvard Univ, Sch Med, Boston, MA 02115 USA.
   Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA.
RP Abbas, AK (reprint author), Brigham & Womens Hosp, Dept Pathol, Div Immunol Res, 75 Francis St, Boston, MA 02115 USA.
EM aabbas@bustoff.bwh.harvard.edu
FU NIAID NIH HHS [AI32531, AI35297, AI22033]
CR Akbar AN, 1996, EUR J IMMUNOL, V26, P294, DOI 10.1002/eji.1830260204
   Akkaraju S, 1997, IMMUNITY, V7, P255, DOI 10.1016/S1074-7613(00)80528-2
   BOISE LH, 1995, IMMUNITY, V3, P87, DOI 10.1016/1074-7613(95)90161-2
   Borriello F, 1997, IMMUNITY, V6, P303, DOI 10.1016/S1074-7613(00)80333-7
   CHAO DT, 1995, J EXP MED, V182, P821, DOI 10.1084/jem.182.3.821
   COOKE MP, 1994, J EXP MED, V179, P425, DOI 10.1084/jem.179.2.425
   CORY S, 1995, ANNU REV IMMUNOL, V13, P513, DOI 10.1146/annurev.iy.13.040195.002501
   Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5
   delPeso L, 1997, SCIENCE, V278, P687
   FISHER GH, 1995, CELL, V81, P935, DOI 10.1016/0092-8674(95)90013-6
   GOODNOW CC, 1988, NATURE, V334, P676, DOI 10.1038/334676a0
   Henkart PA, 1996, IMMUNITY, V4, P195, DOI 10.1016/S1074-7613(00)80428-8
   HO WY, 1994, J EXP MED, V179, P1539, DOI 10.1084/jem.179.5.1539
   KEARNEY ER, 1994, IMMUNITY, V1, P327, DOI 10.1016/1074-7613(94)90084-1
   Kondo M, 1997, IMMUNITY, V7, P155, DOI 10.1016/S1074-7613(00)80518-X
   LENARDO MJ, 1991, NATURE, V353, P858, DOI 10.1038/353858a0
   LINETTE GP, 1994, IMMUNITY, V1, P197, DOI 10.1016/1074-7613(94)90098-1
   MOGIL RJ, 1995, INT IMMUNOL, V7, P1451, DOI 10.1093/intimm/7.9.1451
   Moreno MB, 1996, J IMMUNOL, V157, P3845
   NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326
   NAGATA S, 1995, IMMUNOL TODAY, V16, P39, DOI 10.1016/0167-5699(95)80069-7
   NUNEZ G, 1991, NATURE, V353, P71, DOI 10.1038/353071a0
   PEREZ VL, 1995, INT IMMUNOL, V7, P869, DOI 10.1093/intimm/7.5.869
   Perez VL, 1997, IMMUNITY, V6, P411, DOI 10.1016/S1074-7613(00)80284-8
   RIEUXLAUCAT F, 1995, SCIENCE, V268, P1347, DOI 10.1126/science.7539157
   SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2
   SINGER GG, 1994, CURR OPIN IMMUNOL, V6, P913, DOI 10.1016/0952-7915(94)90013-2
   SINGER GG, 1994, IMMUNITY, V1, P365, DOI 10.1016/1074-7613(94)90067-1
   SMITH KGC, 1994, IMMUNITY, V1, P803, DOI 10.1016/S1074-7613(94)80022-7
   STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3
   STRASSER A, 1995, CURR OPIN IMMUNOL, V7, P228, DOI 10.1016/0952-7915(95)80007-7
   STRASSER A, 1994, P NATL ACAD SCI USA, V91, P1376, DOI 10.1073/pnas.91.4.1376
   Strasser A, 1995, EMBO J, V14, P6136, DOI 10.1002/j.1460-2075.1995.tb00304.x
   TAKAHASHI T, 1994, CELL, V76, P969, DOI 10.1016/0092-8674(94)90375-1
   Tivol EA, 1996, CURR OPIN IMMUNOL, V8, P822, DOI 10.1016/S0952-7915(96)80011-2
   Van Parijs Luk, 1997, Journal of Experimental Medicine, V186, P1119
   VanParijs L, 1996, IMMUNITY, V4, P321, DOI 10.1016/S1074-7613(00)80440-9
   vanParijs L, 1996, CURR OPIN IMMUNOL, V8, P355, DOI 10.1016/S0952-7915(96)80125-7
   VanParijs L, 1997, J IMMUNOL, V158, P3738
   VANPARIJS L, 1998, IN PRESS J IMMUNOL
   VELLA AT, 1995, IMMUNITY, V2, P261, DOI 10.1016/1074-7613(95)90050-0
   WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0
   Weintraub JP, 1997, J IMMUNOL, V159, P4117
NR 43
TC 163
Z9 165
U1 4
U2 11
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1074-7613
J9 IMMUNITY
JI Immunity
PD FEB
PY 1998
VL 8
IS 2
BP 265
EP 274
DI 10.1016/S1074-7613(00)80478-1
PG 10
WC Immunology
SC Immunology
GA YY926
UT WOS:000072201800013
PM 9492007
OA Bronze
DA 2018-12-27
ER

PT J
AU Suzuki, M
   Murata, M
   Ikeda, M
   Miyoshi, T
   Imai, M
AF Suzuki, M
   Murata, M
   Ikeda, M
   Miyoshi, T
   Imai, M
TI RETRACTED: Primary structure and functional expression of a novel
   non-selective cation channel (Retracted Article. See vol 336, pg 729,
   2005)
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article; Retracted Publication
DE cloning; cDNA
ID PANCREATIC ACINAR-CELLS; SENSITIVE K+ CHANNEL; XENOPUS-OOCYTES;
   SODIUM-CHANNEL; CALCIUM; ACTIVATION; MEMBRANE; STRETCH; MESSENGER;
   CLONING
AB A non-selective cation channel is believed to play important roles in varous tissues, A novel complementary DNA encoding non-selective cation channel was isolated from MIN6, a mouse insulin secreting beta-cell line, This channel (mNSC1) conducts predominantly monovalent cations in Xenopus oocytes and is selective for cations over anions (P-K/P-Cl = 10) The current was completely blocked by lanthanum and niflumate, The mNSC1 of 423 amino acids contains a characteristic leucine repeat and unique membrane topology, The messenger RNA of this channel are abundant in the brain, heart, and lung, We may therefore conclude that studies with this channel will provide important information for understanding physiological functions of the excitable cells as well as non-excitable epithelia. (C) 1998 Academic Press.
C1 Jichi Med Sch, Dept Pharmacol, Minami Kawachi, Tochigi 32904, Japan.
RP Suzuki, M (reprint author), Jichi Med Sch, Dept Pharmacol, 3311-1 Yakushiji, Minami Kawachi, Tochigi 32904, Japan.
CR ASHCROFT FM, 1988, ANNU REV NEUROSCI, V11, P97, DOI 10.1146/annurev.ne.11.030188.000525
   BALDWIN TJ, 1991, NEURON, V7, P471, DOI 10.1016/0896-6273(91)90299-F
   BEAR CE, 1990, AM J PHYSIOL, V258, pC421
   BURCKHARDT BC, 1992, PFLUG ARCH EUR J PHY, V420, P83, DOI 10.1007/BF00378645
   CHRAIBI A, 1994, PFLUG ARCH EUR J PHY, V429, P90, DOI 10.1007/BF02584034
   CHRISTENSEN O, 1987, NATURE, V330, P66, DOI 10.1038/330066a0
   COLQUHOUN D, 1981, NATURE, V294, P752, DOI 10.1038/294752a0
   CONLEY EC, 1996, CAT CA ION CHANNEL F, V2, P248
   GIRARD S, 1993, SCIENCE, V260, P229, DOI 10.1126/science.8385801
   GOGELEIN H, 1990, FEBS LETT, V268, P79, DOI 10.1016/0014-5793(90)80977-Q
   KOZAK M, 1991, J BIOL CHEM, V266, P19867
   MARUYAMA Y, 1982, NATURE, V300, P61, DOI 10.1038/300061a0
   MCCORMACK K, 1991, P NATL ACAD SCI USA, V88, P2931, DOI 10.1073/pnas.88.7.2931
   MEYUHAS O, 1979, CELL, V16, P139, DOI 10.1016/0092-8674(79)90195-8
   MIYAZAKI JI, 1990, ENDOCRINOLOGY, V127, P126, DOI 10.1210/endo-127-1-126
   MOODY WJ, 1989, J MEMBRANE BIOL, V107, P179, DOI 10.1007/BF01871723
   NODA M, 1984, NATURE, V312, P121, DOI 10.1038/312121a0
   Rae J L, 1988, Ion Channels, V1, P283
   SIEMEN D, 1993, EXS, V66
   STRUGESS C, 1987, PFLUERS ARCH, V409, P607
   STUHMER W, 1989, NATURE, V339, P597, DOI 10.1038/339597a0
   STURGESS NC, 1986, FEBS LETT, V208, P397, DOI 10.1016/0014-5793(86)81056-0
   SUZUKI M, 1994, NATURE, V367, P642, DOI 10.1038/367642a0
   TANABE T, 1987, NATURE, V328, P313, DOI 10.1038/328313a0
   TEMPEL BL, 1988, NATURE, V332, P837, DOI 10.1038/332837a0
   THORN P, 1992, J GEN PHYSIOL, V100, P11, DOI 10.1085/jgp.100.1.11
   YANG XC, 1989, SCIENCE, V243, P1068, DOI 10.1126/science.2466333
   Zhu X, 1996, CELL, V85, P661, DOI 10.1016/S0092-8674(00)81233-7
NR 28
TC 17
Z9 17
U1 2
U2 12
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD JAN 6
PY 1998
VL 242
IS 1
BP 191
EP 196
DI 10.1006/bbrc.1997.7931
PG 6
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA YR970
UT WOS:000071550600035
PM 9439634
DA 2018-12-27
ER

PT J
AU Boldt, J
   Muller, M
   Mentges, D
   Papsdorf, M
   Hempelmann, G
AF Boldt, J
   Muller, M
   Mentges, D
   Papsdorf, M
   Hempelmann, G
TI RETRACTED: Volume therapy in the critically ill: is there a difference?
   (Retracted article. See vol. 40, pg. 145, 2014)
SO INTENSIVE CARE MEDICINE
LA English
DT Article; Retracted Publication
DE critically ill; sepsis; trauma; volume therapy; albumin;
   hydroxyethylstarch solution; macrocirculation; microcirculation;
   pulmonary function; renal function; coagulation
ID RISK SURGICAL PATIENTS; INTENSIVE-CARE-UNIT; HYDROXYETHYL STARCH; FLUID
   RESUSCITATION; REPERFUSION INJURY; HEMORRHAGIC-SHOCK; RANDOMIZED-TRIAL;
   CLINICAL-TRIAL; SEPTIC SHOCK; ALBUMIN
AB Objective-There are still several concerns about the extensive and prolonged use of hydroxyethylstarch solution (HES) in critically ill patients, The effects of volume replacement with HES over 5 days on hemodynamics, laboratory data, and organ function were compared with volume therapy using human albumin (HA).
   Design: Prospective, randomized study.
   Setting: Clinical investigations on a surgical intensive care unit (ICU) of a university hospital.
   Patients: 150 traumatized patients (injury severity score > 15) and 150 postoperative patients with sepsis were analyzed.
   Interventions: Either 10% low-molecular weight HES (HES-trauma, n = 75: HES-sepsis, n = 75) or 20 % HA (HA-trauma, n = 75; HA-sepsis, n = 75) was given for 5 days to maintain the pulmonary capillary wedge pressure (PCWP) between 12 and 15 torr. The entire management of therapy of the patients was performed by physicians who were not involved in the study and blinded to the infusion regimen.
   Measurements and results: In addition to extensive cardiorespiratory monitoring, several routine laboratory parameters for assessing pulmonary renal, hepatic, and coagulation function were analyzed from arterial blood samples on the day of admission to the ICU and on the day of sepsis diagnosis, respectively ("baseline" value) and daily over the following 5 days, Mortality during and after the study did not differ significantly between the infusion groups. There were also no differences between the incidence of pulmonary, renal, or hepatic failure in the two subgroups, Mean arterial pressure, heart rate, and PCWP were similar in both subgroups, whereas cardiac index, oxygen delivery index, oxygen consumption index, and the ratio between the partial pressure of oxygen in arterial blood and fractional inspired oxygen were higher in the HES- than in the HA-treated groups. Standard coagulation parameters did not differ, albumin concentration increased significantly in both HA groups, and lactate concentrations decreased only in the HES-sepsis patients (from 2.8 +/- 0.5 to 1.5 +/- 0.4 mg/dl). Volume replacement using albumin was significantly (p < 0.001) more costly than therapy with HES.
   Conclusions: Volume therapy with 10 % HES for 5 days in the ICU patient showed no disadvantages compared with an infusion regimen using 20 % albumin. Volume replacement using HES may even be associated with improved hemodynamics. HES appears to be a valuable and significantly cheaper alternative to albumin - even for prolonged volume therapy in the critically ill patient.
C1 Klinikum Stadt Ludwigshafen, Dept Anesthesiol & Intens Care Med, D-67063 Ludwigshafen, Germany.
   Univ Giessen, Dept Anesthesiol & Intens Care Med, Giessen, Germany.
RP Boldt, J (reprint author), Klinikum Stadt Ludwigshafen, Dept Anesthesiol & Intens Care Med, Bremserstr 79, D-67063 Ludwigshafen, Germany.
RI Mueller, Matthias/D-8560-2013
CR APELGREN KN, 1982, CRIT CARE MED, V10, P305, DOI 10.1097/00003246-198205000-00003
   BAKER SP, 1976, J TRAUMA, V16, P882, DOI 10.1097/00005373-197611000-00006
   BEARDS SC, 1994, CRIT CARE MED, V22, P600, DOI 10.1097/00003246-199404000-00015
   BERNARD GR, 1994, INTENS CARE MED, V20, P225, DOI 10.1007/BF01704707
   BLUMBERG N, 1990, Transfusion Medicine Reviews, V4, P24, DOI 10.1016/S0887-7963(90)70239-8
   Boldt J, 1996, INTENS CARE MED, V22, P1075, DOI 10.1007/s001340050216
   BONE RC, 1992, CRIT CARE MED, V20, P864
   BONE RC, 1992, CHEST, V101, P594, DOI 10.1378/chest.101.3.594
   BOYD O, 1993, JAMA-J AM MED ASSOC, V270, P2699, DOI 10.1001/jama.270.22.2699
   BRINKMEYER S, 1981, CRIT CARE MED, V9, P369, DOI 10.1097/00003246-198105000-00008
   Brutocao D, 1996, J CARDIOTHOR VASC AN, V10, P348, DOI 10.1016/S1053-0770(96)80095-4
   CHAUDRY IH, 1993, CURR OPINION ANESTH, V6, P385
   COLLIS RE, 1994, INTENS CARE MED, V20, P37, DOI 10.1007/BF02425053
   DAVIDSON I, 1989, CRITICAL CARE MED, V17, P1078
   FOLEY EF, 1990, ARCH SURG-CHICAGO, V125, P739
   GOLD MS, 1990, ANN SURG, V211, P482, DOI 10.1097/00000658-199004000-00016
   GRESSIER M, 1994, J CARDIOTHORAC VAS S, V43, P82
   HALJAMAE H, 1993, ACTA ANAESTH SCAND, V37, P25, DOI 10.1111/j.1399-6576.1991.tb05069.x
   HOLT ME, 1984, BRIT J EXP PATHOL, V65, P231
   KAPILA A, 1995, CLIN INTENSIVE CARE, V6, pA201
   LEE T, 1994, ANESTHESIOLOGY, V81, pA295
   NAPOLITANO LM, 1995, CRIT CARE MED, V23, P795, DOI 10.1097/00003246-199505000-00001
   OZ MC, 1991, AM J SURG, V162, P59, DOI 10.1016/0002-9610(91)90203-P
   Pocock SJ, 1983, CLIN TRIALS PRACTICA, P123
   PROUGH DS, 1989, ANESTH ANALG, V69, P699
   Sapijaszko MJA, 1996, CRIT CARE MED, V24, P601, DOI 10.1097/00003246-199604000-00009
   SCHELL RM, 1992, ANESTHESIOLOGY, V77, P86, DOI 10.1097/00000542-199207000-00013
   SCHMAND JF, 1995, CRIT CARE MED, V23, P806, DOI 10.1097/00003246-199505000-00006
   SHATNEY CH, 1983, ARCH SURG-CHICAGO, V118, P804
   SHOEMAKER WC, 1988, CHEST, V94, P1176, DOI 10.1378/chest.94.6.1176
   SIBBALD WJ, 1994, UPD INT CAR, V18, P266
   STOCKWELL MA, 1992, ANAESTHESIA, V47, P3, DOI 10.1111/j.1365-2044.1992.tb01941.x
   STRAUSS RG, 1985, TRANSFUSION, V25, P230, DOI 10.1046/j.1537-2995.1985.25385219903.x
   STRAUSS RG, 1988, J CARDIOTHORAC AN S1, V2, P24
   THIJS LG, 1995, UPD INT CAR, V19, P167
   VINCENT JL, 1991, CRIT CARE MED, V19, P316
   WEAVER DW, 1978, ARCH SURG-CHICAGO, V113, P387
NR 37
TC 86
Z9 94
U1 1
U2 6
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0342-4642
EI 1432-1238
J9 INTENS CARE MED
JI Intensive Care Med.
PD JAN
PY 1998
VL 24
IS 1
BP 28
EP 36
DI 10.1007/s001340050511
PG 11
WC Critical Care Medicine
SC General & Internal Medicine
GA YX779
UT WOS:000072076700006
PM 9503219
DA 2018-12-27
ER

PT J
AU Ichikawa, T
   Suzuki, Y
   Czaja, I
   Schommer, C
   Lessnick, A
   Schell, J
   Walden, R
AF Ichikawa, T
   Suzuki, Y
   Czaja, I
   Schommer, C
   Lessnick, A
   Schell, J
   Walden, R
TI RETRACTED: Identification and role of adenylyl cyclase in auxin
   signalling in higher plants (Retracted article. See vol 396, pg 390,
   1998)
SO NATURE
LA English
DT Article; Retracted Publication
ID SACCHAROMYCES-CEREVISIAE; INDEPENDENT GROWTH; CYCLIC-AMP; GENE;
   EXPRESSION; CELLS; TRANSDUCTION; ACTIVATION; SEQUENCE; PROTEINS
AB Cyclic AMP is an important signalling molecule in prokaryotes and eukaryotes(1), but its significance in higher plants has been generally doubted(2) because they have low adenylyl cyclase activity and barely detectable amounts of cAMP(3), Here we used activation T-DNA tagging to create tobacco cell lines that can proliferate in the absence of the phytohormone auxin in the culture media(4,5). The sequence tagged in one line, axi 141, was used to isolate a complementary DNA encoding adenylyl cyclase, the first from a higher plant. Sequence analysis reveals that the tobacco adenylyl cyclase is probably soluble, contains characteristic leucine-rich repeats, and bears similarity with adenylyl cyclase from the yeast Schizosaccharomyces pombe. Expression of the cDNA in Escherichia coli results in an increase in endogenous cAMP levels, and in yeast its expression functionally complements the cry1 mutation. Tobacco protoplasts treated with cAMP, or the adenylyl cyclase activator forskolin, no longer require auxin to divide. This finding, together with the observation that the adenylyl cyclase inhibitor dideoxyadenosine inhibits cell proliferation in the presence of auxin, suggests that cAMP is involved in auxin-triggered cell division in higher plants.
C1 MAX PLANCK INST ZUCHTUNGSFORSCH, D-50829 COLOGNE, GERMANY.
CR ARCHDEACON J, 1995, FEMS MICROBIOL LETT, V128, P177, DOI 10.1111/j.1574-6968.1995.tb07519.x
   ASSMANN SM, 1995, PLANT PHYSIOL, V108, P885, DOI 10.1104/pp.108.3.885
   FRANCIS SH, 1996, SIGNAL TRANSDUCTION, P223
   FRITZE K, 1994, PLANT J, V7, P101
   HARTZELL HC, 1991, NATURE, V351, P573, DOI 10.1038/351573a0
   HAYASHI H, 1992, SCIENCE, V258, P1350, DOI 10.1126/science.1455228
   HOLGATE ST, 1985, P NATL ACAD SCI USA, V77, P6800
   KATAGIRI F, 1989, NATURE, V340, P727, DOI 10.1038/340727a0
   KATAOKA T, 1985, CELL, V43, P493, DOI 10.1016/0092-8674(85)90179-5
   KROLL DJ, 1993, DNA CELL BIOL, V12, P441, DOI 10.1089/dna.1993.12.441
   LALLI E, 1994, J BIOL CHEM, V269, P17359
   LI WW, 1994, PLANT PHYSIOL, V106, P957, DOI 10.1104/pp.106.3.957
   Macdonald H, 1997, PHYSIOL PLANTARUM, V100, P423, DOI 10.1034/j.1399-3054.1997.1000303.x
   MATSUMOTO K, 1984, J BACTERIOL, V157, P277
   Millner PA, 1996, J EXP BOT, V47, P983, DOI 10.1093/jxb/47.8.983
   NAGATA T, 1970, PLANTA, V92, P301, DOI 10.1007/BF00385097
   Rohrig H, 1996, P NATL ACAD SCI USA, V93, P13389, DOI 10.1073/pnas.93.23.13389
   SEAMON KB, 1981, P NATL ACAD SCI-BIOL, V78, P3363, DOI 10.1073/pnas.78.6.3363
   STUDIER FW, 1990, METHOD ENZYMOL, V185, P60
   SUZUKI N, 1990, P NATL ACAD SCI USA, V87, P8711, DOI 10.1073/pnas.87.22.8711
   TAUSSIG R, 1995, J BIOL CHEM, V270, P1, DOI 10.1074/jbc.270.1.1
   TOPFER R, 1993, METHOD ENZYMOL, V217, P66
   TREWAVAS A, 1991, TRENDS GENET, V7, P356, DOI 10.1016/0168-9525(91)90255-O
   WALDEN R, 1993, PLANT CELL REP, V12, P551, DOI 10.1007/BF00233058
   WALDEN R, 1994, PLANT MOL BIOL, V26, P1521, DOI 10.1007/BF00016488
   WALDEN R, 1994, EMBO J, V13, P4729, DOI 10.1002/j.1460-2075.1994.tb06798.x
   YAMAWAKIKATAOKA Y, 1989, P NATL ACAD SCI USA, V86, P5693, DOI 10.1073/pnas.86.15.5693
NR 27
TC 34
Z9 36
U1 2
U2 22
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
EI 1476-4687
J9 NATURE
JI Nature
PD DEC 25
PY 1997
VL 390
IS 6661
BP 698
EP 701
PG 4
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA YM508
UT WOS:A1997YM50800035
PM 9414164
DA 2018-12-27
ER

PT J
AU Mandelboim, O
   Berke, G
   Fridkin, M
   Feldman, M
   Eisenstein, M
   Eisenbach, L
AF Mandelboim, O
   Berke, G
   Fridkin, M
   Feldman, M
   Eisenstein, M
   Eisenbach, L
TI RETRACTED: CTL induction by a tumour-associated antigen octapeptide
   derived from a murine lung carcinoma (vol 369, pg 67, 1994) (Retracted
   Article. See vol 392, pg 311, 1998)
SO NATURE
LA English
DT Correction; Retracted Publication
OI Eisenbach, Lea R/0000-0002-4816-1968
CR MANDELBOIM O, 1995, NAT MED, V1, P1179, DOI 10.1038/nm1195-1179
   MANDELBOIM O, 1994, NATURE, V369, P67, DOI 10.1038/369067a0
   ROSEN D, UNPUB J IMMUNOL
NR 3
TC 5
Z9 5
U1 1
U2 10
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
EI 1476-4687
J9 NATURE
JI Nature
PD DEC 11
PY 1997
VL 390
IS 6660
BP 643
EP 643
DI 10.1038/37678
PG 1
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA YK853
UT WOS:A1997YK85300059
PM 9767009
DA 2018-12-27
ER

PT J
AU Carvalho, CRO
   Thirone, ACP
   Gontijo, JAR
   Velloso, LA
   Saad, MJA
AF Carvalho, CRO
   Thirone, ACP
   Gontijo, JAR
   Velloso, LA
   Saad, MJA
TI RETRACTED: Effect of captopril, losartan, and bradykinin on early steps
   of insulin action (Retracted article. See vol. 65, pg. 1128, 2016)
SO DIABETES
LA English
DT Article; Retracted Publication
ID ANGIOTENSIN-CONVERTING ENZYME; PHOSPHATIDYLINOSITOL 3-KINASE ACTIVITY;
   DEPENDENT DIABETES-MELLITUS; RECEPTOR SUBSTRATE-1; SKELETAL-MUSCLE;
   TYROSINE PHOSPHORYLATION; ESSENTIAL-HYPERTENSION; GLUCOSE-TRANSPORTER;
   GLUT4 TRANSLOCATION; SIGNALING PATHWAY
AB Insulin initiates its metabolic and growth-promoting effects by binding to the a subunit of its receptor, thereby activating the kinase in the beta subunit. This event leads to tyrosyl phosphorylation of its cytosolic substrate, insulin receptor substrate 1 (IRS-1), which in turn associates with and activates phosphatidylinositol (PI) 3-kinase. The clinical use of ACE inhibitors has been associated with increased insulin sensitivity. However, the exact molecular mechanism is unknown. In the present study, we examined the phosphorylation status of the insulin receptor and IBS-I, as well as the association between IRS-1 and PI 3-kinase in the liver and muscle of 20-month-old rats treated acutely with captopril, using immunoprecipitation with antipeptide antibodies to the insulin receptor and IRS-1, and immunoblotting with antiphosphotyrosine and anti-PI 3-kinase antibodies. Insulin stimulation increased receptor autophosphorylation to 462 +/- 253% (P < 0.05) in the liver and 697 +/- 78% (P < 0.001) in the muscle of ACE inhibitor-treated rats. There were also increases to 250 +/- 17% (P < 0.001) and 280 +/- 50% (P < 0.05) in the insulin-stimulated IRS-1 phosphorylation levels in the liver and muscle, respectively, of animals treated with captopril. The insulin-stimulated IRS-1 association with PI 3-kinase rose to 305 +/- 20% (P < 0.001) in Liver and 267 +/- 48% (P < 0.05) in muscle. Losartan, an ANG receptor blocker, had no significant effect on insulin-stimulated IRS-1 phosphorylation in both tissues. The acute administration of bradykinin increased insulin-stimulated tyrosine phosphorylation of the insulin receptor and IRS-1 in the liver and muscle. These data demonstrate that ACE inhibitors modulate the early steps of insulin signaling, and that this effect may be simulated by the administration of bradykinin.
C1 UNIV ESTADUAL CAMPINAS, FCM, DEPT CLIN MED, BR-13081970 CAMPINAS, BRAZIL.
RI Gontijo, Jose/C-5128-2012; Carvalho, Carla/H-6476-2018
OI Carvalho, Carla/0000-0001-5824-8656; Gontijo, Jose/0000-0002-4658-385X
CR ARAUZPACHECO C, 1990, AM J MED, V89, P811, DOI 10.1016/0002-9343(90)90227-5
   BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x
   BERNE C, 1991, J INTERN MED, V229, P119
   BONORA E, 1989, J CLIN ENDOCR METAB, V68, P374, DOI 10.1210/jcem-68-2-374
   BOTTARI SP, 1993, FRONT NEUROENDOCRIN, V14, P123, DOI 10.1006/frne.1993.1005
   Carvalho CRO, 1996, ENDOCRINOLOGY, V137, P151, DOI 10.1210/en.137.1.151
   CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902
   CHOU CK, 1987, J BIOL CHEM, V262, P1842
   CLARKE JF, 1994, BIOCHEM J, V300, P631, DOI 10.1042/bj3000631
   DONNELLY R, 1992, J CARDIOVASC PHARM, V20, pS38, DOI 10.1097/00005344-199200111-00007
   DZAU VJ, 1993, J HYPERTENS, V11, pS13
   EBINA Y, 1987, P NATL ACAD SCI USA, V84, P704, DOI 10.1073/pnas.84.3.704
   FERRANNINI E, 1987, NEW ENGL J MED, V317, P350, DOI 10.1056/NEJM198708063170605
   FERRIERE M, 1985, ANN INTERN MED, V102, P134, DOI 10.7326/0003-4819-102-1-134_3
   FOLLI F, 1993, J CLIN INVEST, V92, P1787, DOI 10.1172/JCI116768
   GIORGETTI S, 1993, J BIOL CHEM, V268, P7358
   GOODYEAR LJ, 1995, J CLIN INVEST, V95, P2195, DOI 10.1172/JCI117909
   Gulati Kavita, 1996, Indian Journal of Experimental Biology, V34, P91
   HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415
   Haring HU, 1996, DIABETES, V45, pS115, DOI 10.2337/diab.45.1.S115
   HARUTA T, 1995, J BIOL CHEM, V270, P27991
   HENRIKSEN EJ, 1995, METABOLISM, V44, P267, DOI 10.1016/0026-0495(95)90276-7
   Henriksen EJ, 1996, DIABETES, V45, pS125, DOI 10.2337/diab.45.1.S125
   HERINGS RMC, 1995, LANCET, V345, P1195, DOI 10.1016/S0140-6736(95)91988-0
   HIROOKA Y, 1992, HYPERTENSION, V20, P175, DOI 10.1161/01.HYP.20.2.175
   Isami S, 1996, DIABETOLOGIA, V39, P412, DOI 10.1007/BF00400672
   JAUCH KW, 1987, EUR J CLIN INVEST, V17, P448, DOI 10.1111/j.1365-2362.1987.tb01141.x
   KELLY KL, 1993, J BIOL CHEM, V268, P4391
   KODAMA J, 1990, DIABETES CARE, V13, P1109, DOI 10.2337/diacare.13.11.1109
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   LAM K, 1994, J BIOL CHEM, V269, P20648
   LAMPHERE L, 1994, AM J PHYSIOL, V266, pE486
   LAVAN BE, 1992, J BIOL CHEM, V267, P11631
   MAEGAWA H, 1988, J BIOL CHEM, V261, P16597
   MOMOMURA K, 1988, BIOCHEM BIOPH RES CO, V155, P1181, DOI 10.1016/S0006-291X(88)81264-6
   MUKOYAMA M, 1993, J BIOL CHEM, V268, P24539
   NATALI A, 1991, HYPERTENSION, V17, P170, DOI 10.1161/01.HYP.17.2.170
   PACHECO CA, 1990, AM J MED, V89, P811
   PAOLISSO G, 1991, METABOLISM, V40, P972, DOI 10.1016/0026-0495(91)90075-8
   QUON MJ, 1994, J BIOL CHEM, V269, P27920
   Rett K, 1996, DIABETES, V45, pS66, DOI 10.2337/diab.45.1.S66
   RETT K, 1988, NEW ENGL J MED, V319, P1609
   SAAD MJA, 1995, BIOCHEM J, V310, P741, DOI 10.1042/bj3100741
   SAAD MJA, 1992, J CLIN INVEST, V90, P1839, DOI 10.1172/JCI116060
   SAAD MJA, 1995, FEBS LETT, V370, P131, DOI 10.1016/0014-5793(95)00809-N
   SANCHEZMARGALET V, 1994, BIOCHEM BIOPH RES CO, V204, P446, DOI 10.1006/bbrc.1994.2480
   SOUBRIER F, 1988, P NATL ACAD SCI USA, V85, P9386, DOI 10.1073/pnas.85.24.9386
   STEPHENS JM, 1995, ENDOCR REV, V16, P529, DOI 10.1210/er.16.4.529
   SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0
   Timmermans P B, 1996, Blood Press Suppl, V2, P53
   TOMIYAMA H, 1994, HYPERTENSION, V23, P450, DOI 10.1161/01.HYP.23.4.450
   TORLONE E, 1991, DIABETOLOGIA, V34, P119, DOI 10.1007/BF00500383
   TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350
   UEHARA M, 1994, DIABETOLOGIA, V37, P300, DOI 10.1007/s001250050109
   Velloso LA, 1996, P NATL ACAD SCI USA, V93, P12490, DOI 10.1073/pnas.93.22.12490
   WELSH GI, 1994, BIOCHEM J, V303, P15, DOI 10.1042/bj3030015
   WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0
   WHITE MF, 1994, J BIOL CHEM, V269, P1
   WINOCOUR P, 1986, LANCET, V2, P461
   YAMAUCHI K, 1995, P NATL ACAD SCI USA, V92, P664, DOI 10.1073/pnas.92.3.664
   YANG HYT, 1970, BIOCHIM BIOPHYS ACTA, V214, P374, DOI 10.1016/0005-2795(70)90017-6
   YEH JI, 1995, J BIOL CHEM, V270, P2107, DOI 10.1074/jbc.270.5.2107
NR 62
TC 99
Z9 104
U1 4
U2 8
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA
SN 0012-1797
EI 1939-327X
J9 DIABETES
JI Diabetes
PD DEC
PY 1997
VL 46
IS 12
BP 1950
EP 1957
DI 10.2337/diabetes.46.12.1950
PG 8
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA YH805
UT WOS:A1997YH80500005
PM 9392479
DA 2018-12-27
ER

PT J
AU Simmons, WA
   Roopenian, DC
   Summerfield, SG
   Jones, RC
   Galocha, B
   Christianson, GJ
   Maika, SD
   Zhou, M
   Gaskell, SJ
   Bordoli, RS
   Ploegh, HL
   Slaughter, CA
   Lindahl, KF
   Hammer, RE
   Taurog, JD
AF Simmons, WA
   Roopenian, DC
   Summerfield, SG
   Jones, RC
   Galocha, B
   Christianson, GJ
   Maika, SD
   Zhou, M
   Gaskell, SJ
   Bordoli, RS
   Ploegh, HL
   Slaughter, CA
   Lindahl, KF
   Hammer, RE
   Taurog, JD
TI RETRACTED: A new MHC locus that influences class I peptide presentation
   (Retracted article. See vol 11, pg U9, 1999)
SO IMMUNITY
LA English
DT Article; Retracted Publication
ID MAJOR HISTOCOMPATIBILITY COMPLEX; ANTIGEN PRESENTATION; INFLAMMATORY
   DISEASE; LINKED TRANSPORTER; TRANSGENIC MICE; CELL-LINE; T-CELLS; RAT;
   TAP; MOUSE
AB We have investigated the HLA-B27-restricted CTL response to HY minor histocompatibility antigens in rats and mice transgenic for HLA-B27 and human beta 2-microglobulin. A polymorphism was found at a locus within the H2 complex, producing two distinct but overlapping sets of B27-presented HY peptides. The locus, named Cim2, mapped between the K and Pb loci, and its product is therefore distinct from TAP, LMP, and tapasin. Identical findings in rats and mice, including identical HY peptide sequences and the failure of a rat Tap2A transgene to alter CTL recognition, suggest that a homologous locus with similar polymorphism exists in the rat. Cim2, or a closely linked locus, was found to exert a broad effect on peptide loading of both HLA-B27 and mouse class I alleles. The data thus establish a strong, previously unrecognized MHC-encoded influence on the class I antigen pathway.
C1 UNIV TEXAS, SW MED CTR, HAROLD C SIMMONS ARTHRIT RES CTR, DEPT INTERNAL MED, DALLAS, TX 75235 USA.
   UNIV TEXAS, SW MED CTR, HOWARD HUGHES MED INST, DEPT BIOCHEM, DALLAS, TX 75235 USA.
   UNIV TEXAS, SW MED CTR, DEPT MICROBIOL, DALLAS, TX 75235 USA.
   JACKSON LAB, BAR HARBOR, ME 04609 USA.
   UMIST, DEPT CHEM, MANCHESTER M60 1QD, LANCS, ENGLAND.
   MIT, CTR CANC RES, CAMBRIDGE, MA 02139 USA.
   MICROMASS UK LTD, MANCHESTER M23 9LE, LANCS, ENGLAND.
FU NIDDK NIH HHS [R01 DK47692]; NIAID NIH HHS [R01 AI28802]; NIAMS NIH HHS
   [R01 AR38319]
CR CARTER CA, 1991, IMMUNOGENETICS, V33, P202, DOI 10.1007/BF01719242
   CERUNDOLO V, 1995, EUR J IMMUNOL, V25, P554, DOI 10.1002/eji.1830250238
   delaSalle H, 1997, J IMMUNOL, V158, P4555
   DEVERSON EV, 1990, NATURE, V348, P738, DOI 10.1038/348738a0
   FEHLING HJ, 1994, SCIENCE, V265, P1234, DOI 10.1126/science.8066463
   Groettrup M, 1996, IMMUNOL TODAY, V17, P429, DOI 10.1016/0167-5699(96)10051-7
   HAMMER RE, 1990, CELL, V63, P1099, DOI 10.1016/0092-8674(90)90512-D
   HAMMOND C, 1995, CURR OPIN CELL BIOL, V7, P523, DOI 10.1016/0955-0674(95)80009-3
   HEEMELS MT, 1994, IMMUNITY, V1, P775, DOI 10.1016/S1074-7613(94)80019-7
   HEEMELS MT, 1993, SCIENCE, V262, P2059, DOI 10.1126/science.8266106
   HEEMELS MT, 1995, ANNU REV BIOCHEM, V64, P463, DOI 10.1146/annurev.bi.64.070195.002335
   JOLY E, 1994, IMMUNOGENETICS, V40, P45, DOI 10.1007/BF00163963
   KARLSSON L, 1992, J EXP MED, V176, P477, DOI 10.1084/jem.176.2.477
   KLEIN J, 1989, GENETIC VARIANTS STR, P747
   Klein J., 1986, NATURAL HIST MAJOR H
   Koopmann JO, 1997, CURR OPIN IMMUNOL, V9, P80, DOI 10.1016/S0952-7915(97)80163-X
   LEE DR, 1988, J EXP MED, V168, P1719, DOI 10.1084/jem.168.5.1719
   Lehner PJ, 1996, CURR OPIN IMMUNOL, V8, P59, DOI 10.1016/S0952-7915(96)80106-3
   LIVINGSTONE AM, 1991, IMMUNOGENETICS, V34, P157
   LIVINGSTONE AM, 1989, J EXP MED, V170, P777, DOI 10.1084/jem.170.3.777
   LOPEZ D, 1994, EUR J IMMUNOL, V24, P1194, DOI 10.1002/eji.1830240528
   Marusina K, 1997, J IMMUNOL, V158, P5251
   MOMBURG F, 1994, NATURE, V367, P648, DOI 10.1038/367648a0
   NAGATA T, 1995, IMMUNOGENETICS, V41, P83
   NEEFJES J, 1995, EUR J IMMUNOL, V25, P1133, DOI 10.1002/eji.1830250444
   OBST R, 1995, EUR J IMMUNOL, V25, P2170, DOI 10.1002/eji.1830250808
   Ortmann B, 1997, SCIENCE, V277, P1306, DOI 10.1126/science.277.5330.1306
   OZATO K, 1980, J IMMUNOL, V125, P2473
   PAZMANY L, 1992, J EXP MED, V175, P361, DOI 10.1084/jem.175.2.361
   PIRCHER H, 1989, EMBO J, V8, P719, DOI 10.1002/j.1460-2075.1989.tb03431.x
   POULETTY C, 1994, HUM IMMUNOL, V40, P218, DOI 10.1016/0198-8859(94)90072-8
   POWIS SJ, 1991, J EXP MED, V173, P913, DOI 10.1084/jem.173.4.913
   POWIS SJ, 1991, NATURE, V354, P528, DOI 10.1038/354528a0
   POWIS SJ, 1992, NATURE, V357, P211, DOI 10.1038/357211a0
   Powis SJ, 1996, IMMUNITY, V4, P159, DOI 10.1016/S1074-7613(00)80680-9
   RAMMENSEE HG, 1993, ANNU REV IMMUNOL, V11, P213, DOI 10.1146/annurev.iy.11.040193.001241
   RAMMENSEE HG, 1995, IMMUNOGENETICS, V41, P178, DOI 10.1007/BF00172063
   ROWLANDJONES SL, 1993, EUR J IMMUNOL, V23, P1999, DOI 10.1002/eji.1830230841
   SACHS DH, 1979, J IMMUNOL, V123, P1965
   Sadasivan B, 1996, IMMUNITY, V5, P103, DOI 10.1016/S1074-7613(00)80487-2
   SCHUMACHER TNM, 1994, P NATL ACAD SCI USA, V91, P13004, DOI 10.1073/pnas.91.26.13004
   Simmons WA, 1997, J IMMUNOL, V159, P2750
   Simmons WA, 1996, J IMMUNOL, V156, P1661
   SIMMONS WA, 1993, IMMUNOGENETICS, V38, P351
   TAUROG JD, 1988, J IMMUNOL, V141, P4020
   TAUROG JD, 1993, J IMMUNOL, V150, P4168
   TAUROG JD, 1990, TRANSGENIC MICE AND MUTANTS IN MHC RESEARCH, P268
   TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125
   UEMATSU Y, 1988, IMMUNOGENETICS, V27, P96, DOI 10.1007/BF00351082
   VANENDERT PM, 1994, IMMUNITY, V1, P491, DOI 10.1016/1074-7613(94)90091-4
   VANKAER L, 1992, CELL, V71, P1205
   VANKAER L, 1994, IMMUNITY, V1, P553
   VANSANTEN HM, 1995, J EXP MED, V181, P787, DOI 10.1084/jem.181.2.787
   Walter L, 1996, IMMUNOGENETICS, V44, P218, DOI 10.1007/s002510050114
   York IA, 1996, ANNU REV IMMUNOL, V14, P369, DOI 10.1146/annurev.immunol.14.1.369
NR 55
TC 14
Z9 14
U1 1
U2 8
PU CELL PRESS
PI CAMBRIDGE
PA 1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138
SN 1074-7613
J9 IMMUNITY
JI Immunity
PD NOV
PY 1997
VL 7
IS 5
BP 641
EP 651
DI 10.1016/S1074-7613(00)80385-4
PG 11
WC Immunology
SC Immunology
GA YH554
UT WOS:A1997YH55400007
PM 9390688
OA Bronze
DA 2018-12-27
ER

PT J
AU Parijs, LV
   Perez, VL
   Biuckians, A
   Maki, RG
   London, CA
   Abbas, AK
AF Parijs, LV
   Perez, VL
   Biuckians, A
   Maki, RG
   London, CA
   Abbas, AK
TI RETRACTED: Role of interleukin 12 and costimulators in T cell anergy in
   vivo (Retracted Article. See vol 206, pg 1207, 2009)
SO JOURNAL OF EXPERIMENTAL MEDICINE
LA English
DT Article; Retracted Publication
ID PANCREATIC BETA-CELLS; CLONAL EXPANSION; ANTIGEN RECEPTOR; IN-VIVO;
   TOLERANCE; CTLA-4; MICE; B7-1; UNRESPONSIVENESS; INVIVO
AB The induction of T cell anergy in vivo is thought to result from antigen recognition in the absence of co-stimulation and inflammation, and is associated with a block in T cell proliferation and Th1 differentiation. Here we have examined the role of interleukin (IL)-12, a potent inducer of Th1 responses, in regulating this process. T cell tolerance was induced by the administration of protein antigen without adjuvant in normal mice, and in recipients of adoptively transferred T cells from T cell receptor transgenic mice. The administration of IL-12 at the time of tolerance induction stimulates Th1 differentiation, but does not promote antigen-specific T cell proliferation. Conversely, inhibiting CTLA-4 engagement during anergy induction reverses the block in T cell proliferation, but does not promote full Th1 differentiation. T cells exposed to tolerogenic antigen in the presence of both IL-12 and anti-CTLA-4 antibody are not anergized, and behave identically to T cells which have encountered immunogenic antigen. These results suggest that two processes contribute to the induction of anergy in vivo; CTLA-4 engagement, which leads to a block in the ability of T cells to proliferate to antigen, and the absence of a prototypic inflammatory cytokine, IL-12, which prevents the differentiation of T cells into Th1 effector cells. The combination of IL-12 and anti-CTLA-4 antibody is sufficient to convert a normally tolerogenic stimulus to an immunogenic one.
C1 BRIGHAM & WOMENS HOSP, DEPT PATHOL, DIV IMMUNOL RES, BOSTON, MA 02115 USA.
   HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA.
RI London, Cheryl/E-6561-2012
CR Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0
   BURSTEIN HJ, 1993, J EXP MED, V177, P457, DOI 10.1084/jem.177.2.457
   BURSTEIN HJ, 1992, J IMMUNOL, V148, P3687
   DEWIT D, 1992, J EXP MED, V175, P9, DOI 10.1084/jem.175.1.9
   GUERDER S, 1994, IMMUNITY, V1, P155
   GUERDER S, 1994, P NATL ACAD SCI USA, V91, P5138, DOI 10.1073/pnas.91.11.5138
   HARLAN DM, 1994, P NATL ACAD SCI USA, V91, P3137, DOI 10.1073/pnas.91.8.3137
   HASKINS K, 1983, J EXP MED, V157, P1149, DOI 10.1084/jem.157.4.1149
   Kaplan MH, 1996, NATURE, V382, P174, DOI 10.1038/382174a0
   KEARNEY ER, 1995, J IMMUNOL, V155, P1032
   KEARNEY ER, 1994, IMMUNITY, V1, P327, DOI 10.1016/1074-7613(94)90084-1
   Kruisbeek AM, 1996, CURR OPIN IMMUNOL, V8, P233, DOI 10.1016/S0952-7915(96)80062-8
   Krummel MF, 1996, J EXP MED, V183, P2533, DOI 10.1084/jem.183.6.2533
   Lenschow DJ, 1996, ANNU REV IMMUNOL, V14, P233, DOI 10.1146/annurev.immunol.14.1.233
   LENSCHOW DJ, 1992, SCIENCE, V257, P789, DOI 10.1126/science.1323143
   LINSLEY PS, 1992, SCIENCE, V257, P792, DOI 10.1126/science.1496399
   Magram J, 1996, IMMUNITY, V4, P471, DOI 10.1016/S1074-7613(00)80413-6
   MCKNIGHT AJ, 1994, J IMMUNOL, V152, P2172
   MILICH DR, 1994, J IMMUNOL, V153, P429
   MILLER JFAP, 1992, ANNU REV IMMUNOL, V10, P51, DOI 10.1146/annurev.immunol.10.1.51
   MUELLER DL, 1995, CURR OPIN IMMUNOL, V7, P375, DOI 10.1016/0952-7915(95)80113-8
   MUELLER DL, 1989, ANNU REV IMMUNOL, V7, P445, DOI 10.1146/annurev.iy.07.040189.002305
   Perez VL, 1997, IMMUNITY, V6, P411, DOI 10.1016/S1074-7613(00)80284-8
   SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314
   Thierfelder WE, 1996, NATURE, V382, P171, DOI 10.1038/382171a0
   TIVOL EA, 1995, IMMUNITY, V3, P541, DOI 10.1016/1074-7613(95)90125-6
   TREMBLEAU S, 1995, IMMUNOL TODAY, V16, P383, DOI 10.1016/0167-5699(95)80006-9
   TRINCHIERI G, 1995, ANNU REV IMMUNOL, V13, P251, DOI 10.1146/annurev.iy.13.040195.001343
   TURKA LA, 1992, P NATL ACAD SCI USA, V89, P11102, DOI 10.1073/pnas.89.22.11102
   vonHerrath MG, 1995, IMMUNITY, V3, P727, DOI 10.1016/1074-7613(95)90062-4
   Walunas TL, 1996, J EXP MED, V183, P2541, DOI 10.1084/jem.183.6.2541
   WALUNAS TL, 1994, IMMUNITY, V1, P405, DOI 10.1016/1074-7613(94)90071-X
   WATERHOUSE P, 1995, SCIENCE, V270, P985, DOI 10.1126/science.270.5238.985
   WINDHAGEN A, 1995, J EXP MED, V182, P1985, DOI 10.1084/jem.182.6.1985
NR 34
TC 4
Z9 4
U1 2
U2 8
PU ROCKEFELLER UNIV PRESS
PI NEW YORK
PA 1114 FIRST AVE, 4TH FL, NEW YORK, NY 10021 USA
SN 0022-1007
J9 J EXP MED
JI J. Exp. Med.
PD OCT 6
PY 1997
VL 186
IS 7
BP 1119
EP 1128
DI 10.1084/jem.186.7.1119
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA YA580
UT WOS:A1997YA58000014
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Hunton, JE
   McEwen, RA
AF Hunton, JE
   McEwen, RA
TI RETRACTED: An assessment of the relation between analysts' earnings
   forecast accuracy, motivational incentives and cognitive information
   search strategy (Retracted article. See vol. 90, pg. 1717, 2015)
SO ACCOUNTING REVIEW
LA English
DT Article; Retracted Publication
DE analyst forecasts; forecast accuracy; cognitive search strategies;
   motivational incentives
ID DECISIONS
AB Prior research indicates that analysts' forecasts of earnings tend to be optimistic. Analysts' optimism may be attributed to experience, cognitive information search strategies, motivational incentives or some combination thereof. In this study, we conduct an experiment that uses a computerized eye-movement retinal imaging system to capture the cognitive search strategy of 60 professional financial analysts. We find that, within the experiment, more accurate analysts employ a directive information search strategy, whereas less accurate analysts employ a sequential search strategy. Experimental results also indicate that motivational incentives intensify the analysts' tendency to provide optimistic earnings forecasts. We also conduct an examination of ?he analysts' predictive accuracy outside the experimental setting. We find a significant relation between historical accuracy and the analysts' cognitive search strategy observed in the experiment. Post-experiment survey results provide insight into the linkage between specific accounting information used by the analysts and the accuracy of their forecasts.
C1 VIRGINIA COMMONWEALTH UNIV, RICHMOND, VA 23284 USA.
RP Hunton, JE (reprint author), UNIV S FLORIDA, TAMPA, FL 33620 USA.
CR ADELSON B, 1984, J EXP PSYCHOL LEARN, V10, P483, DOI 10.1037//0278-7393.10.3.483
   Affleck-Graves John, 1990, CONTEMP ACCOUNT RES, V6, P501
   ANDERSON MJ, 1988, ACCOUNT ORG SOC, V13, P431, DOI 10.1016/0361-3682(88)90015-3
   BIGGS SF, 1984, ACCOUNT ORG SOC, V9, P313, DOI 10.1016/0361-3682(84)90015-1
   Bouwman M. J., 1982, DECISION MAKING INTE, P134
   BOUWMAN MJ, 1987, ACCOUNT ORG SOC, V12, P1, DOI 10.1016/0361-3682(87)90013-4
   DUGAR A, 1995, CONTEMP ACCOUNT RES, V12, P131, DOI DOI 10.1111/J.1911-3846.1995.TB00484.X
   EINHORN HJ, 1981, ANNU REV PSYCHOL, V32, P53, DOI 10.1146/annurev.ps.32.020181.000413
   FRANCIS J, 1993, J ACCOUNTING RES, V31, P216, DOI 10.2307/2491271
   HAYES JR, 1982, DECISION MAKING INTE, P61
   LIN H, 1993, UNDERWRITING RELATIO
   Maines L. A., 1995, JUDGMENT DECISION MA
   MURPHY GL, 1984, J EXP PSYCHOL LEARN, V10, P144
   Schipper K., 1991, ACCOUNT HORIZ, V5, P105
   SCHMIDT FL, 1993, CURRENT DIRECTIO FEB, P8
   Simon H. A., 1977, NEW SCI MANAGEMENT D
   UNGSON GR, 1982, DECISION MAKING INTE
   WAGNER RK, 1987, J PERS SOC PSYCHOL, V52, P1236, DOI 10.1037/0022-3514.52.6.1236
   WAGNER RK, 1985, J PERS SOC PSYCHOL, V49, P436
   WAGNER RK, 1987, J BUSINESS PSYCH SUM, P301
   YATES F, 1990, JUDGMENT DECISION MA
NR 21
TC 78
Z9 78
U1 1
U2 23
PU AMER ACCOUNTING ASSOC
PI SARASOTA
PA 5717 BESSIE DR, SARASOTA, FL 34233 USA
SN 0001-4826
EI 1558-7967
J9 ACCOUNT REV
JI Account. Rev.
PD OCT
PY 1997
VL 72
IS 4
BP 497
EP 515
PG 19
WC Business, Finance
SC Business & Economics
GA YH388
UT WOS:A1997YH38800001
DA 2018-12-27
ER

PT J
AU Fujii, Y
   Tanaka, H
   Toyooka, H
AF Fujii, Y
   Tanaka, H
   Toyooka, H
TI RETRACTED: The effects of dexamethasone on antiemetics in female
   patients undergoing gynecologic surgery (Retracted article. See vol.
   115, pg. 920, 2012)
SO ANESTHESIA AND ANALGESIA
LA English
DT Article; Retracted Publication
ID ONDANSETRON PLUS DEXAMETHASONE; POSTOPERATIVE NAUSEA; GRANISETRON;
   PREVENTION; METOCLOPRAMIDE; DROPERIDOL; WOMEN
AB This randomized, double-blind study compared the effects of dexamethasone plus either droperidol, metoclopramide, or granisetron with each antiemetic alone for preventing postoperative nausea and vomiting (PONV) in 270 female patients undergoing general anesthesia for major gynecological surgery. Patients were randomly assigned to receive either droperidol 1.25 mg (Group D1, n = 45), droperidol 1.25 mg plus dexamethasone 8 mg (Group D2, n = 45), metoclopramide 10 mg (Group M1, n = 45), metoclopramide 10 mg plus dexamethasone 8 mg (Group M2, n = 45), granisetron 40 mu g/kg (Group G1, n = 45), or granisetron 40 mu g/kg plus dexamethasone 8 mg (Group G2, n = 45) immediately before the induction of anesthesia. A standard general anesthetic technique and postoperative analgesia were used throughout the study. Complete response, defined as no PONV and no administration of rescue antiemetic medication during the first 24 h after anesthesia, was 49% in Group D1, 60% in Group D2 (P = 0.199 versus Group D1), 51% in Group M1, 62% in Group M2 (P = 0.198 versus Group M1), 80% in Group G1, and 96% in Group G2 (P = 0.025 versus Group G1). Our results suggest that dexamethasone enhances the antiemetic efficacy of granisetron but does not potentiate the other antiemetics-droperidol and metoclopramide-in female patients undergoing major gynecological surgery. Implications: We compared the efficacy of dexamethasone plus three different antiemetics-droperidol, metoclopramide, and granisetron-for the prevention of nausea and vomiting after gynecologic surgery. The granisetron-dexamethasone combination was the most effective for preventing postoperative emetic symptoms.
C1 TORIDE KYODO GEN HOSP, DEPT ANESTHESIOL, TORIDE, IBARAKI, JAPAN.
RP Fujii, Y (reprint author), UNIV TSUKUBA, INST CLIN MED, DEPT ANESTHESIOL, 2-1-1 AMAKUBO, TSUKUBA, IBARAKI 305, JAPAN.
CR AAPRO MS, 1984, J CLIN ONCOL, V2, P466, DOI 10.1200/JCO.1984.2.5.466
   ANDREWS P L R, 1992, European Journal of Cancer, V28A, pS2, DOI 10.1016/0959-8049(92)90628-F
   CARMICHAEL J, 1989, CANCER CHEMOTH PHARM, V24, P45
   FUJII Y, 1995, CAN J ANAESTH, V42, P852, DOI 10.1007/BF03011030
   FUJII Y, 1994, CAN J ANAESTH, V41, P794, DOI 10.1007/BF03011585
   FUJII Y, 1994, CAN J ANAESTH, V41, P291, DOI 10.1007/BF03009906
   FUJII Y, 1995, CAN J ANAESTH, V42, P387, DOI 10.1007/BF03015482
   Furue H, 1990, J CLIN THERAPEUTIC M, V6, P49
   KHALIL SN, 1994, ANESTH ANALG, V79, P845
   LEESER J, 1991, ANESTH ANALG, V72, P751
   LERMAN J, 1995, CAN J ANAESTH, V42, P263, DOI 10.1007/BF03010699
   MADEJ TH, 1986, BRIT J ANAESTH, V58, P884, DOI 10.1093/bja/58.8.884
   MCKENZIE R, 1993, ANESTHESIOLOGY, V78, P21, DOI 10.1097/00000542-199301000-00005
   MCKENZIE R, 1994, ANESTH ANALG, V79, P961
   Rose JB, 1996, ANESTH ANALG, V82, P558, DOI 10.1097/00000539-199603000-00023
   SMITH DB, 1991, LANCET, V338, P487, DOI 10.1016/0140-6736(91)90555-4
   WATCHA MF, 1992, ANESTHESIOLOGY, V77, P162, DOI 10.1097/00000542-199207000-00023
   WHITE PF, 1993, ANESTHESIOLOGY, V78, P2, DOI 10.1097/00000542-199301000-00002
NR 18
TC 66
Z9 71
U1 2
U2 12
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0003-2999
J9 ANESTH ANALG
JI Anesth. Analg.
PD OCT
PY 1997
VL 85
IS 4
BP 913
EP 917
DI 10.1097/00000539-199710000-00036
PG 5
WC Anesthesiology
SC Anesthesiology
GA XY232
UT WOS:A1997XY23200036
PM 9322479
OA Bronze
DA 2018-12-27
ER

PT J
AU Abu-Akel, A
AF Abu-Akel, A
TI RETRACTED: A study of cohesive patterns and dynamic choices utilized by
   two schizophrenic patients in dialog, pre- and post-medication
   (Retracted Article. See Vol 46, Part 1, pg II, 2003)
SO LANGUAGE AND SPEECH
LA English
DT Article; Retracted Publication
DE systemic grammar; clozapine; phoricity (reference}; schizophrenia;
   speech functions
ID CLOZAPINE; CHILDREN; DISCOURSE; DISORDER
AB The present study evaluated the communicative deficits in the linguistic performance of two Arabic speaking schizophrenics having a first episode of disorganized schizophrenia. Two facets of the conversational performance of each patient prior to and following antipsychotic medication treatment were considered and compared to normals' performance of these two measures. These were the dynamic development of the interviews and selected cohesive devices.
   A description of the patients' aberrant conversational behavior and deficits in terms of systemic grammar is offered for profiling schizophrenics' discourse and measuring the effects of stimulant treatment. The neuroleptic clozapine led to both positive and negative changes in the socially appropriate use of language in the schizophrenics' conversations.
C1 UNIV CALIF LOS ANGELES, Dept TESL Appl Linguist, Los Angeles, CA 90095 USA.
RP Abu-Akel, A (reprint author), UNIV CALIF LOS ANGELES, Dept TESL Appl Linguist, Box 951531, Los Angeles, CA 90095 USA.
EM abu-akel@humnet.ucla.edu
CR ABUAKEL A, 1997, UNPUB PRAGMATIC VIEW
   ABUMANSOUR AH, 1986, THESIS U MICHIGAN AN
   American Psychiatric Association, 1994, DIAGN STAT MAN MENT
   BACCOUCHE B, 1984, CONVERSATION MODERN
   BALTAXE CAM, 1992, J AUTISM DEV DISORD, V22, P1, DOI 10.1007/BF01046399
   BARTOLUCCI G, 1987, APPL PSYCHOLINGUIST, V8, P67, DOI 10.1017/S0142716400000072
   BIRMAHER B, 1992, J AM ACAD CHILD PSY, V31, P160, DOI 10.1097/00004583-199201000-00024
   BISHOP DVM, 1989, BRIT J DISORD COMMUN, V24, P241
   BURKE MS, 1995, J AM ACAD CHILD PSY, V34, P127, DOI 10.1097/00004583-199502000-00005
   BUTLER CS, 1988, J PRAGMATICS, V12, P83, DOI 10.1016/0378-2166(88)90021-5
   CAPLAN R, 1993, J AM ACAD CHILD PSY, V32, P604, DOI 10.1097/00004583-199305000-00017
   Chaika E., 1990, UNDERSTANDING PSYCHO
   DOCHERTY N, 1988, J ABNORM PSYCHOL, V97, P437, DOI 10.1037/0021-843X.97.4.437
   FINE J, 1995, APPL PSYCHOLINGUIST, V16, P25, DOI 10.1017/S0142716400006408
   FINE J, 1994, J AUTISM DEV DISORD, V24, P315, DOI 10.1007/BF02172230
   FINE J, 1991, TREND LIN S, V55, P213
   FINE J, 1994, LANGUAGE WORKS COHES
   FINE J, 1988, PRAGMATICS TEXT SOME, P172
   GONZALEZ A, 1992, J AM ACAD CHILD PSY, V31, P1169
   GORDON CT, 1994, J AUTISM DEV DISORD, V24, P537, DOI 10.1007/BF02172134
   GOREN A, 1994, 5 IFNN C NEUR HELS
   GREEN AI, 1990, HOSP COMMUNITY PSYCH, V41, P379
   Grice H. P., 1975, SYNTAX SEMANTICS, V3, P41, DOI DOI 10.1017/S0022226700005296
   Halliday M. A. K., 1984, SEMIOTICS CULTURE LA, V1, P3
   Halliday M. A. K, 1976, COHESION ENGLISH
   KANE J, 1988, ARCH GEN PSYCHIAT, V45, P789
   Labov W., 1977, THERAPEUTIC DISCOURS
   LEVKOVITCH Y, 1995, J AM ACAD CHILD PSY, V34, P263, DOI 10.1097/00004583-199503000-00005
   LILES BZ, 1985, J SPEECH HEAR RES, V28, P123, DOI 10.1044/jshr.2801.123
   Martin J. R., 1985, SYSTEMIC PERSPECTIVE, V1, P248
   Martin J.R., 1992, ENGLISH TEXT SYSTEM
   *MED, 1993, MONTHL ETH DRUG IND
   MORICE RD, 1982, AUST NZ J PSYCHIAT, V16, P11, DOI 10.3109/00048678209161186
   Rochester S., 1977, DISCOURSE PRODUCTION, P245
   Rochester S, 1979, CRAZY TALK STUDY DIS
   SANDERS LM, 1995, APPL PSYCHOLINGUIST, V16, P325
   STERN RG, 1994, AM J PSYCHIAT, V151, P1817
   Ventola E., 1987, STRUCTURE SOCIAL INT
NR 38
TC 5
Z9 5
U1 1
U2 8
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0023-8309
EI 1756-6053
J9 LANG SPEECH
JI Lang. Speech
PD OCT-DEC
PY 1997
VL 40
BP 331
EP 351
DI 10.1177/002383099704000402
PN 4
PG 21
WC Audiology & Speech-Language Pathology; Linguistics; Psychology,
   Experimental
SC Audiology & Speech-Language Pathology; Linguistics; Psychology
GA ZT736
UT WOS:000074120000002
PM 9692323
DA 2018-12-27
ER

PT J
AU Simmons, WA
   Summerfield, SG
   Roopenian, DC
   Slaughter, CA
   Zuberi, AR
   Gaskell, SJ
   Bordoli, RS
   Hoyes, J
   Moomaw, CR
   Colbert, RA
   Leong, LYW
   Butcher, GW
   Hammer, RE
   Taurog, JD
AF Simmons, WA
   Summerfield, SG
   Roopenian, DC
   Slaughter, CA
   Zuberi, AR
   Gaskell, SJ
   Bordoli, RS
   Hoyes, J
   Moomaw, CR
   Colbert, RA
   Leong, LYW
   Butcher, GW
   Hammer, RE
   Taurog, JD
TI RETRACTED: Novel HY peptide antigens presented by HLA-B27 (Retracted
   article. See vol 163, pg 5741, 1999)
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article; Retracted Publication
ID MOUSE Y-CHROMOSOME; MINOR HISTOCOMPATIBILITY ANTIGENS; SEX-DETERMINING
   REGION; VERSUS-HOST DISEASE; SACCHAROMYCES-CEREVISIAE; INFLAMMATORY
   DISEASE; MASS-SPECTROMETRY; SEQUENCE IONS; T-LYMPHOCYTES; SIDE-CHAIN
AB We have identified two peptides corresponding to the male-specific HY minor histocompatibility Ags presented by HLA-B27 in transgenic rodents, isolated from whole cell extracts and from immunoprecipitated B27 molecules of male B27 rat spleen cells. HPLC peptide fractions that sensitized female B27 targets for lysis by B27-restricted anti-HY CTL were analyzed by electrospray tandem mass spectrometry using a new highly sensitive quadrupole/time-of-flight instrument. Two peptide sequences were obtained, KQYQKSTER and AVLNKSNREVR. Synthetic peptides corresponding to these sequences bound B27 in vitro and were recognized by distinct B27-restricted anti-HY CTL populations. Neither peptide sequence entirely matches known protein sequences or shows a resemblance to known Y chromosome genes, but both show homology to known autosomally encoded proteins. Both peptides were shown to be controlled by the Sxr(b) segment of the short arm of the mouse Y chromosome, a segment known to contain all previously identified HY Ags. Taken together, these findings suggest that the two peptides arise as a result of Y chromosome-regulated control of one or more autosomal gene products, Although arginine at position 2 is a dominant anchor residue for peptides bound to B27, neither B27-presented HY sequence contains this residue. These studies, employing sensitive new methodology for identification of MHC-bound peptides, significantly extend the complexity of the genetic basis of HY Ags and expand the repertoire of antigenically active peptides bound to B27.
C1 UNIV TEXAS, SW MED CTR, HAROLD C SIMMONS ARTHRITIS RES CTR, DALLAS, TX 75235 USA.
   UNIV TEXAS, SW MED CTR, DEPT INTERNAL MED, DALLAS, TX 75235 USA.
   UNIV TEXAS, SW MED CTR, HOWARD HUGHES MED INST, DALLAS, TX 75235 USA.
   UNIV TEXAS, SW MED CTR, DEPT BIOCHEM, DALLAS, TX 75235 USA.
   UNIV MANCHESTER, INST SCI & TECHNOL, DEPT CHEM, MANCHESTER M60 1QD, LANCS, ENGLAND.
   JACKSON LAB, BAR HARBOR, ME 04609 USA.
   MICROMASS UK LTD, ALTRINCHAM, ENGLAND.
   CHILDRENS HOSP, MED CTR, WILLIAM S ROWE DIV RHEUMATOL, CINCINNATI, OH 45229 USA.
   BABRAHAM INST, CAMBRIDGE, ENGLAND.
FU NIAMS NIH HHS [R01AR38319]; NIAID NIH HHS [R01AI28802]; NIDDK NIH HHS
   [R01DK47692]
CR AGULNIK AI, 1994, HUM MOL GENET, V3, P873, DOI 10.1093/hmg/3.6.873
   ALDRICH CJ, 1994, CELL, V79, P649, DOI 10.1016/0092-8674(94)90550-9
   ANDERSON KS, 1993, J IMMUNOL, V151, P3407
   BENASHER E, 1989, MOL GEN GENET, V215, P517
   Bhuyan PK, 1997, J IMMUNOL, V158, P3753
   BILLINGHAM RE, 1960, J IMMUNOL, V85, P14
   Boisgerault F, 1996, J CLIN INVEST, V98, P2764, DOI 10.1172/JCI119102
   BOON T, 1994, ANNU REV IMMUNOL, V12, P337, DOI 10.1146/annurev.immunol.12.1.337
   BROWN M, 1997, IN PRESS SPONDYLARTH
   Careless David J., 1995, Current Opinion in Rheumatology, V7, P290, DOI 10.1097/00002281-199507000-00005
   COLBERT RA, 1994, IMMUNITY, V1, P121, DOI 10.1016/1074-7613(94)90105-8
   DECASTRO JAL, 1995, CURR OPIN RHEUMATOL, V7, P270
   DENHAAN JMM, 1995, SCIENCE, V268, P1476, DOI 10.1126/science.7539551
   DICK LR, 1994, J IMMUNOL, V152, P3884
   Eicher EM, 1996, NAT GENET, V14, P206, DOI 10.1038/ng1096-206
   EICHWALD EJ, 1955, TRANSPLAN B, V2, P121
   EISEN HN, 1993, CELL, V75, P613, DOI 10.1016/0092-8674(93)90481-5
   Goulder PJR, 1997, NAT MED, V3, P212, DOI 10.1038/nm0297-212
   Goulmy E, 1996, CURR OPIN IMMUNOL, V8, P75, DOI 10.1016/S0952-7915(96)80108-7
   GRAFF RJ, 1973, TRANSPLANT REV-DENMA, V15, P26
   Greenfield A, 1996, NAT GENET, V14, P474, DOI 10.1038/ng1296-474
   GUBBAY J, 1990, NATURE, V346, P245, DOI 10.1038/346245a0
   HAMMER RE, 1990, CELL, V63, P1099, DOI 10.1016/0092-8674(90)90512-D
   HARLEY JB, 1997, ARTHRITIS ALLIED CON, P1347
   HILLENKAMP F, 1990, METHOD ENZYMOL, V193, P280, DOI 10.1016/0076-6879(90)93420-P
   Huang F, 1996, INFECT IMMUN, V64, P120
   HUET S, 1990, INT IMMUNOL, V2, P311, DOI 10.1093/intimm/2.4.311
   HUNT DF, 1992, SCIENCE, V255, P1261, DOI 10.1126/science.1546328
   JARDETZKY TS, 1991, NATURE, V353, P326, DOI 10.1038/353326a0
   JOHNSON RS, 1988, INT J MASS SPECTROM, V86, P137, DOI 10.1016/0168-1176(88)80060-0
   KentFirst MG, 1996, NAT GENET, V14, P128, DOI 10.1038/ng1096-128
   KING TR, 1994, GENOMICS, V24, P159, DOI 10.1006/geno.1994.1593
   KOOPMAN P, 1991, NATURE, V351, P117, DOI 10.1038/351117a0
   KRISHNA S, 1997, IN PRESS GENOMICS
   LISOWSKY T, 1990, MOL GEN GENET, V220, P186
   LOVELAND B, 1990, CELL, V60, P971, DOI 10.1016/0092-8674(90)90345-F
   LovellBadge R, 1995, PHILOS T ROY SOC B, V350, P205, DOI 10.1098/rstb.1995.0153
   MADDEN DR, 1992, CELL, V70, P1035, DOI 10.1016/0092-8674(92)90252-8
   MCLAREN A, 1984, NATURE, V312, P552, DOI 10.1038/312552a0
   MERTZ AKH, 1994, MOL MED, V1, P44
   MITCHELL MJ, 1992, GENOMICS, V12, P26, DOI 10.1016/0888-7543(92)90402-E
   Muller U, 1996, HUM GENET, V97, P701, DOI 10.1007/s004390050122
   PAGE DC, 1987, CELL, V51, P1091, DOI 10.1016/0092-8674(87)90595-2
   PARKER KC, 1994, BIOCHEMISTRY-US, V33, P7736, DOI 10.1021/bi00190a029
   Powis SJ, 1996, IMMUNITY, V4, P159, DOI 10.1016/S1074-7613(00)80680-9
   Raghavan M, 1996, PROTEIN SCI, V5, P2080, DOI 10.1002/pro.5560051014
   RAMMENSEE HG, 1993, ANNU REV IMMUNOL, V11, P213, DOI 10.1146/annurev.iy.11.040193.001241
   ROEPSTORFF P, 1984, BIOMED MASS SPECTROM, V11, P601, DOI 10.1002/bms.1200111109
   ROJO S, 1993, J EXP MED, V177, P613, DOI 10.1084/jem.177.3.613
   ROTZSCHKE O, 1990, SCIENCE, V249, P283, DOI 10.1126/science.1695760
   SCOFIELD RH, 1995, LANCET, V345, P1542, DOI 10.1016/S0140-6736(95)91089-1
   SCOTT DM, 1995, NATURE, V376, P695, DOI 10.1038/376695a0
   SIMMONS WA, 1993, IMMUNOGENETICS, V38, P351
   Simpson E, 1997, ANNU REV IMMUNOL, V15, P39, DOI 10.1146/annurev.immunol.15.1.39
   SIMPSON E, 1989, IMMUNOL LETT, V21, P39, DOI 10.1016/0165-2478(89)90009-6
   SIMPSON E, 1986, CELL, V44, P813, DOI 10.1016/0092-8674(86)90001-2
   SNELL GD, 1948, J GENET, V49, P87, DOI 10.1007/BF02986826
   SONG ZM, 1994, J EXP MED, V180, P1763, DOI 10.1084/jem.180.5.1763
   TAUROG JD, 1993, J IMMUNOL, V150, P4168
   TAYLOR JD, 1986, J MOL EVOL, V23, P242, DOI 10.1007/BF02115580
   THEOBALD M, 1995, CURR OPIN IMMUNOL, V7, P649, DOI 10.1016/0952-7915(95)80072-7
   UDAKA K, 1992, CELL, V69, P989, DOI 10.1016/0092-8674(92)90617-L
   VILLADANGOS JA, 1995, EUR J IMMUNOL, V25, P2370, DOI 10.1002/eji.1830250837
   WANG W, 1995, SCIENCE, V269, P1588, DOI 10.1126/science.7667640
   Wilm M, 1996, ANAL CHEM, V68, P1, DOI 10.1021/ac9509519
   ZUBERI AR, 1994, GENOMICS, V19, P273, DOI 10.1006/geno.1994.1058
NR 66
TC 27
Z9 27
U1 7
U2 15
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
EI 1550-6606
J9 J IMMUNOL
JI J. Immunol.
PD SEP 15
PY 1997
VL 159
IS 6
BP 2750
EP 2759
PG 10
WC Immunology
SC Immunology
GA XV750
UT WOS:A1997XV75000027
PM 9300696
DA 2018-12-27
ER

PT J
AU Bezouska, K
   Sklenar, J
   Dvorakova, J
   Havlicek, V
   Pospisil, M
   Thiem, J
   Kren, V
AF Bezouska, K
   Sklenar, J
   Dvorakova, J
   Havlicek, V
   Pospisil, M
   Thiem, J
   Kren, V
TI RETRACTED: NKR-P1A protein, an activating receptor of rat natural killer
   cells, binds to the chitobiose core of incompletely glycosylated
   N-linked glycans, and to linear chitooligomers (Retracted article. See
   vol. 453, 2014 & vol. 453, pg. 679, 2014)
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article; Retracted Publication
ID C-TYPE LECTINS; CARBOHYDRATE-RECOGNITION; LIGANDS; ANTIGEN; SITE
AB NKR-P1 represent a family of activating receptors in rodent natural killer cells related to C-type animal lectins. We identify here the elements involved in the reactivity of the major receptor of rat, NKR-P1A, with N-linked oligosaccharides of glycoproteins. Plate inhibition assays with isolated, structurally defined N-glycans as inhibitors of binding of NKR-P1A to GlcNAc(16-) BSA revealed that the removal of both the external sialic acids and the penultimate galactose residues resulted in attaining of significant inhibitory activities. Surprisingly, additional plate inhibition and glycoprotein overlay experiments brought evidence that the core chitobiose, depending on its substitution, can per se support the interaction with NKR-P1A. In a series of linear chitooligomers (n = 2-7), the inhibitory activities reached a maximum for the chitotetraose. The ability of NKR-P1 to recognize both the periphery and the core region of complex type oligosaccharides may define its dual specificity towards carbohydrate components of eukaryotic (e.g., tumor) cell surfaces, but also reflect an evolutionarily conserved reactivity with microbial saccharides important in immune recognition and signaling functions. (C) 1997 Academic Press.
C1 ACAD SCI CZECH REPUBL, INST MICROBIOL, CZ-14220 PRAGUE 4, CZECH REPUBLIC.
   UNIV HAMBURG, INST ORGAN CHEM, D-20146 HAMBURG, GERMANY.
RP Bezouska, K (reprint author), CHARLES UNIV, FAC SCI, DEPT BIOCHEM, HLAVOVA 8, CZ-12840 PRAGUE 2, CZECH REPUBLIC.
RI Kren, Vladimir/H-8461-2014
CR AHRENS PB, 1987, J BIOL CHEM, V262, P7575
   BANCROFT GJ, 1993, CURR OPIN IMMUNOL, V5, P503, DOI 10.1016/0952-7915(93)90030-V
   BEZOUSKA K, 1994, J BIOL CHEM, V269, P16945
   BEZOUSKA K, 1995, BIOCHEM BIOPH RES CO, V208, P68, DOI 10.1006/bbrc.1995.1306
   Bezouska K, 1996, BIOCHEM SOC T, V24, P156, DOI 10.1042/bst0240156
   BEZOUSKA K, 1994, NATURE, V372, P150, DOI 10.1038/372150a0
   BEZOUSKA K, 1992, MOL IMMUNOL, V29, P1437, DOI 10.1016/0161-5890(92)90217-L
   BRENNAN J, 1995, J BIOL CHEM, V270, P9691, DOI 10.1074/jbc.270.17.9691
   CERNY J, 1997, IN PRESS IMMUNOGENET
   DRICKAMER K, 1995, CURR OPIN STRUC BIOL, V5, P612, DOI 10.1016/0959-440X(95)80052-2
   DRICKAMER K, 1993, CURR OPIN STRUC BIOL, V3, P393, DOI 10.1016/S0959-440X(05)80112-5
   HIRANO H, 1992, J BIOCHEM-TOKYO, V111, P754, DOI 10.1093/oxfordjournals.jbchem.a123831
   KITAHATA S, 1992, BIOSCI BIOTECH BIOCH, V56, P1386, DOI 10.1271/bbb.56.1386
   Kometani T, 1996, BIOSCI BIOTECH BIOCH, V60, P1176
   KREN V, 1997, UNPUB
   KREN V, 1997, ENZYMATIC PREPARATIO
   PISKAREV VE, 1990, BIOCHEM J, V270, P755, DOI 10.1042/bj2700755
   Pueppke SG, 1996, CRIT REV BIOTECHNOL, V16, P1, DOI 10.3109/07388559609146599
   Ryan JC, 1997, IMMUNOL REV, V155, P79, DOI 10.1111/j.1600-065X.1997.tb00941.x
   Schauer R, 1978, Methods Enzymol, V50, P64
   SPAINK HP, 1997, REGULATION PLANT ANI
   THOMPSON EOP, 1978, AUST J BIOL SCI, V31, P443, DOI 10.1071/BI9780443
   TRINCHIERI G, 1989, ADV IMMUNOL, V47, P187, DOI 10.1016/S0065-2776(08)60664-1
   VLAHAS G, 1993, GLYCOCONJUGATE J, V10, P269, DOI 10.1007/BF01209952
NR 24
TC 28
Z9 29
U1 1
U2 11
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD SEP 8
PY 1997
VL 238
IS 1
BP 149
EP 153
DI 10.1006/bbrc.1997.7260
PG 5
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA XX890
UT WOS:A1997XX89000030
PM 9299469
DA 2018-12-27
ER

PT J
AU daSilva, EP
   Abboud, TK
   Lee, J
AF daSilva, EP
   Abboud, TK
   Lee, J
TI RETRACTED: Comparison of 0.07% ropivacaine plus sufentanil and 0.07%
   bupivacaine plus sufentanil for epidural anesthesia during labor and
   delivery. (Retracted article. See vol. 90, pg. 351, 1999)
SO ANESTHESIOLOGY
LA English
DT Meeting Abstract; Retracted Publication
C1 UNIV SO CALIF, LOS ANGELES CTY MED CTR, DEPT ANESTHESIOL, LOS ANGELES, CA 90089 USA.
CR McClure JH, 1996, BRIT J ANAESTH, V76, P300
   NAULTY J S, 1989, Anesthesiology (Hagerstown), V71, pA842
NR 2
TC 1
Z9 1
U1 1
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0003-3022
EI 1528-1175
J9 ANESTHESIOLOGY
JI Anesthesiology
PD SEP
PY 1997
VL 87
IS 3
SU S
BP A882
EP A882
DI 10.1097/00000542-199709001-00882
PG 1
WC Anesthesiology
SC Anesthesiology
GA XV636
UT WOS:A1997XV63600882
DA 2018-12-27
ER

PT J
AU Leadon, SA
   Avrutskaya, AV
AF Leadon, SA
   Avrutskaya, AV
TI RETRACTED: Differential involvement of the human mismatch repair
   proteins, hMLH1 and hMSH2, in transcription-coupled repair (Retracted
   Article. See vol 63, pg 3846, 2003)
SO CANCER RESEARCH
LA English
DT Article; Retracted Publication
ID NUCLEOTIDE-EXCISION REPAIR; NONPOLYPOSIS COLON-CANCER; RNA
   POLYMERASE-II; DNA-DAMAGE; MICROSATELLITE INSTABILITY;
   SACCHAROMYCES-CEREVISIAE; PREFERENTIAL REPAIR; IONIZING-RADIATION;
   ESCHERICHIA-COLI; TUMOR-CELLS
AB Defects in DNA mismatch repair have been associated with both hereditary and sporadic forms of cancer. Recently, it has been shown that human cell lines deficient in mismatch repair were also defective in the transcription-coupled repair (TCR) of UV-induced DNA damage. We examined whether TCR of ionizing radiation-iuduced DNA damage also requires the genes involved in DNA mismatch repair. Cells defective in the hMSH2 gene were deficient in the removal of oxidative damage, including thymine glycols, from the transcribed strand of an active gene. However, an hMLH1 mutant showed normal levels of TCR. By comparison, defects in either hMSH2 or hMLH1 resulted in reduced TCR of UV damage. Introducing chromosomes carrying either hMSH2 or hMLH1 into these cell lines restored their ability to carry out TCR. Deficiencies in either hMSH2 or hMLH1 did not result in decreased overall genomic Levels of repair or lead to an increased sensitivity to either UV Or ionizing radiation. Our results provide the first evidence for a protein that is absolutely required for the preferential removal of UV-induced DNA damage but not oxidative DNA damage from the transcribed strand of an active human gene.
RP Leadon, SA (reprint author), UNIV N CAROLINA, DEPT RADIAT ONCOL, CHAPEL HILL, NC 27599 USA.
FU NCI NIH HHS [CA40453]
CR AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121
   ALANI E, 1994, GENETICS, V137, P19
   BOYER JC, 1995, CANCER RES, V55, P6063
   BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0
   Cooper PK, 1997, SCIENCE, V275, P990, DOI 10.1126/science.275.5302.990
   DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264
   EELBY CP, 1995, J BIOL CHEM, V270, P4890
   FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3
   Friedberg EC, 1996, ANNU REV BIOCHEM, V65, P15
   FRIEDBERG EC, 1995, DNA REPAIR
   HANAWALT PC, 1994, SCIENCE, V266, P1957, DOI 10.1126/science.7801121
   HTUN H, 1992, METHOD ENZYMOL, V212, P272
   HUTCHINSON F, 1985, PROG NUCLEIC ACID RE, V32, P115, DOI 10.1016/S0079-6603(08)60347-5
   KOI M, 1994, CANCER RES, V54, P4308
   KRAMER W, 1989, J BACTERIOL, V171, P5339, DOI 10.1128/jb.171.10.5339-5346.1989
   KUNALA S, 1992, P NATL ACAD SCI USA, V89, P11031, DOI 10.1073/pnas.89.22.11031
   LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S
   LEADON SA, 1983, MUTAT RES, V112, P191, DOI 10.1016/0167-8817(83)90006-8
   LEADON SA, 1988, MOL CELL BIOL, V8, P5331, DOI 10.1128/MCB.8.12.5331
   LEADON SA, 1991, MUTAT RES, V255, P67, DOI 10.1016/0921-8777(91)90019-L
   LEADON SA, 1995, MUTAT RES-DNA REPAIR, V337, P169, DOI 10.1016/0921-8777(95)00021-B
   LEADON SA, 1992, J BIOL CHEM, V267, P23175
   LEADON SA, 1993, P NATL ACAD SCI USA, V90, P10499, DOI 10.1073/pnas.90.22.10499
   LEADON SA, 1988, DNA REPAIR LABORATOR, V3, P311
   LI GM, 1995, P NATL ACAD SCI USA, V92, P1950, DOI 10.1073/pnas.92.6.1950
   MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6
   MELLON I, 1989, NATURE, V342, P95, DOI 10.1038/342095a0
   Mellon I, 1996, SCIENCE, V272, P557, DOI 10.1126/science.272.5261.557
   Mellon I, 1996, P NATL ACAD SCI USA, V93, P1292, DOI 10.1073/pnas.93.3.1292
   Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533
   NICHOLS AF, 1992, NUCLEIC ACIDS RES, V20, P2441, DOI 10.1093/nar/20.10.2441
   Nouspikel T, 1997, P NATL ACAD SCI USA, V94, P3116, DOI 10.1073/pnas.94.7.3116
   PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251
   PROLLA TA, 1994, MOL CELL BIOL, V14, P407, DOI 10.1128/MCB.14.1.407
   REENAN RAG, 1992, GENETICS, V132, P975
   RISINGER JI, 1995, J BIOL CHEM, V270, P18183, DOI 10.1074/jbc.270.31.18183
   SELBY CP, 1991, P NATL ACAD SCI USA, V88, P8232, DOI 10.1073/pnas.88.18.8232
   SELBY CP, 1993, SCIENCE, V260, P53, DOI 10.1126/science.8465200
   SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A
   SMERDON MJ, 1990, CELL, V61, P675, DOI 10.1016/0092-8674(90)90479-X
   SMITH CA, 1981, DNA REPAIR LABORAT B, V1, P289
   STRAND M, 1993, NATURE, V365, P274, DOI 10.1038/365274a0
   SWEDER KS, 1992, P NATL ACAD SCI USA, V89, P10696, DOI 10.1073/pnas.89.22.10696
   Sweder KS, 1996, GENETICS, V143, P1127
   UMAR A, 1994, J BIOL CHEM, V269, P14367
   UMAR A, 1994, SCIENCE, V266, P814, DOI 10.1126/science.7973637
   Umar A, 1996, CELL, V87, P65, DOI 10.1016/S0092-8674(00)81323-9
   WARD JF, 1988, PROG NUCLEIC ACID RE, V35, P95, DOI 10.1016/S0079-6603(08)60611-X
NR 48
TC 78
Z9 78
U1 2
U2 9
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD SEP 1
PY 1997
VL 57
IS 17
BP 3784
EP 3791
PG 8
WC Oncology
SC Oncology
GA XU396
UT WOS:A1997XU39600030
PM 9288788
DA 2018-12-27
ER

PT J
AU Ymeri, HM
AF Ymeri, HM
TI RETRACTED: Exact analytical solution of the problem of two dielectric
   spheres in the uniform electrostatic field (Retracted article. See vol.
   96, pg. 95, 2014)
SO ELECTRICAL ENGINEERING
LA English
DT Article; Retracted Publication
AB In this paper, the exact analytical solution is derived in bispherical coordinates for the field due to two equal dielectric spheres, when this system is inclined at an arbitrary angle to a uniform electrostatic field. The method is based on the solution of a second order, inhomogeneous, linear difference equation using recurrence relations. Our procedure for solving this difference equation is straightforward, and analogous to the solution of second-order inhomogeneous linear ordinary differential equations in terms of Green's functions. The dipole moment of this system is evaluated as a function of separation. The numerical results obtained for the dipole moment of the system are shown in graphical form.
RP Ymeri, HM (reprint author), UNIV PRISHTINA, HIGHER TECH SCH, YU-38220 MITROVICE, KOSOVE, YUGOSLAVIA.
CR LEBEDEV NN, 1965, PROBLEMS MATH PHYSIC
   Milne-Thomson L M, 1960, CALCULUS FINITE DIFF
   Moon P., 1961, FIELD THEORY HDB
   MORSE PM, 1953, METHODS THEORETICA 2
   YMERI HM, 1992, B TU ISTANBUL
NR 5
TC 3
Z9 3
U1 2
U2 7
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0948-7921
EI 1432-0487
J9 ELECTR ENG
JI Electr. Eng.
PD AUG
PY 1997
VL 80
IS 4
BP 227
EP 233
DI 10.1007/BF01232794
PG 7
WC Engineering, Electrical & Electronic
SC Engineering
GA XT296
UT WOS:A1997XT29600003
DA 2018-12-27
ER

PT J
AU Gagneux, P
   Woodruff, DS
   Boesch, C
AF Gagneux, P
   Woodruff, DS
   Boesch, C
TI RETRACTED: Furtive mating in female chimpanzees (Retracted Article. See
   vol 414, pg 508, 2001)
SO NATURE
LA English
DT Letter; Retracted Publication
ID STRATEGIES; COMMUNITY
C1 UNIV CALIF SAN DIEGO, CTR MOL GENET, LA JOLLA, CA 92093 USA.
   UNIV BASEL, INST ZOOL, CH-4051 BASEL, SWITZERLAND.
RP Gagneux, P (reprint author), UNIV CALIF SAN DIEGO, DEPT BIOL, LA JOLLA, CA 92093 USA.
CR Birkhead T.R, 1992, SPERM COMPETITION BI
   Boesch Christophe, 1996, P101, DOI 10.1017/CBO9780511752414.010
   DUNBAR RIM, 1992, ANIM BEHAV, V44, P1171, DOI 10.1016/S0003-3472(05)80333-1
   Goodall J., 1986, CHIMPANZEES GOMBE PA
   MARTIN RD, 1992, PATERNITY IN PRIMATES : GENETIC TESTS AND THEORIES, P238
   MORIN PA, 1994, SCIENCE, V265, P1193, DOI 10.1126/science.7915048
   MORIN PA, 1994, MOL ECOL, V3, P469, DOI 10.1111/j.1365-294X.1994.tb00125.x
   Nishida T., 1990, CHIMPANZEES MAHALE M
   SUGIYAMA Y, 1993, PRIMATES, V34, P545, DOI 10.1007/BF02382665
   TUTIN CEG, 1979, BEHAV ECOL SOCIOBIOL, V6, P29, DOI 10.1007/BF00293242
NR 10
TC 56
Z9 61
U1 3
U2 17
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
EI 1476-4687
J9 NATURE
JI Nature
PD MAY 22
PY 1997
VL 387
IS 6631
BP 358
EP 359
DI 10.1038/387358a0
PG 2
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA XA496
UT WOS:A1997XA49600043
PM 9163418
DA 2018-12-27
ER

PT J
AU Aronica, SM
   Gingras, AC
   Sonenberg, N
   Cooper, S
   Hague, N
   Broxmeyer, HE
AF Aronica, SM
   Gingras, AC
   Sonenberg, N
   Cooper, S
   Hague, N
   Broxmeyer, HE
TI RETRACTED: Macrophage inflammatory protein-1 alpha and
   interferon-inducible protein 10 inhibit synergistically induced growth
   factor stimulation of MAP kinase activity and suppress phosphorylation
   of eukaryotic initiation factor 4E and 4E binding protein 1 (Retracted
   Article. See vol 107, pg 4713, 2006)
SO BLOOD
LA English
DT Article; Retracted Publication
ID HEMATOPOIETIC-CELL LINE; SMOOTH-MUSCLE CELLS; C-KIT LIGAND;
   MESSENGER-RNA; PHAS-I; PROLIFERATION; TRANSLATION; INSULIN; RAF-1;
   ASSOCIATION
AB Granulocyte-macrophage colony-stimulating factor (GM-CSF) and Steel factor (SLF) synergistically stimulate Raf-1 kinase activity, protein synthesis, and proliferation in hematopoietic MO7e cells; synergistic action, of these factors is blocked by the suppressive chemokines macrophage inflammatory protein-1 alpha (MIP-1 alpha) and interferon-inducible protein 10 (IP-10; Aronica et al, J Biol Chem 270:21998, 1995). We assessed the potential for both stimulatory and inhibitory factors to act through the MAP kinase signaling pathway by studying the effects of growth factors and chemokines on MAP kinase activation. Also, because activation of kinase signaling pathways and stimulation of protein synthesis by peptide growth factors are associated with increased phosphorylation of eukaryotic initiation factor 4E (eIF-4E) and the translational repressor 4E-binding protein 1 (4E-BP1) in some target cells, we investigated whether growth factor treatment could alter eIF-4E or 4E-BP1 phosphorylation state in MO7e cells, We report that treatment of MO7e cells with GM-CSF and SLF stimulated significant, greater-than-additive increases in MAP kinase activity and the phosphorylation of both eIF-4E and 4E-BP1, Increased 4E-BP1 phosphorylation correlated with a decrease in the association of 4E-BP1 with eIF-4E, Growth factor-induced phosphorylation of 4E-BP1 and dissociation of 4E-BP1 from eIF-4E was blocked in cells treated with rapamycin, wortmannin, or PD098059, Treatment of cells with IP-10 or MIP-1 alpha blocked the stimulatory effects of GM-CSF and SLF, resulting in suppression of MAP kinase activity, eIF-4E and 4E-BP1 phosphorylation, and eIF-4E/4E-BP1 dissociation, Our results suggest that GM-CSF and SLF exert part of their combined growth-promoting effects on MO7e cells through activation of MAP kinase and enhancement of eIF-4E and 4E-BP1 phosphorylation and dissociation and that suppression of growth factor-induced protein synthesis by MIP-1 alpha and IP-10 involves translational repression at the level of eIF-4E. (C) 1997 by The American Society of Hematology.
C1 INDIANA UNIV, SCH MED, DEPT MICROBIOL IMMUNOL, INDIANAPOLIS, IN 46202 USA.
   INDIANA UNIV, SCH MED, DEPT MED HEMATOL ONCOL, INDIANAPOLIS, IN 46202 USA.
   MCGILL UNIV, DEPT BIOCHEM, MONTREAL, PQ, CANADA.
RP Aronica, SM (reprint author), INDIANA UNIV, SCH MED, WALTHER ONCOL CTR, 975 W WALNUT ST, ROOM 501, INDIANAPOLIS, IN 46202 USA.
CR Aronica S M, 1996, Curr Opin Hematol, V3, P185
   ARONICA SM, 1995, J BIOL CHEM, V270, P21998, DOI 10.1074/jbc.270.37.21998
   BASHEY A, 1994, BLOOD, V83, P949
   BELKA C, 1995, LEUKEMIA, V9, P754
   Beretta L, 1996, EMBO J, V15, P658, DOI 10.1002/j.1460-2075.1996.tb00398.x
   Brown EJ, 1996, CELL, V86, P517, DOI 10.1016/S0092-8674(00)80125-7
   BROXMEYER HE, 1993, J IMMUNOL, V150, P3448
   BROXMEYER HE, 1995, HUMAN CYTOKINES THEI, P27
   BROXMEYER HE, 1996, BLOOD CEL B, V7, P121
   Bu X, 1996, EXP HEMATOL, V24, P423
   Carroll M. P., 1996, Blood, V88, p198A
   CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I
   DALY TJ, 1995, J BIOL CHEM, V270, P23282, DOI 10.1074/jbc.270.40.23282
   Flynn A, 1996, FEBS LETT, V389, P162, DOI 10.1016/0014-5793(96)00564-9
   Gingras AC, 1996, P NATL ACAD SCI USA, V93, P5578, DOI 10.1073/pnas.93.11.5578
   GRAVES LM, 1995, P NATL ACAD SCI USA, V92, P7222, DOI 10.1073/pnas.92.16.7222
   HALLEK M, 1992, J CELL PHYSIOL, V153, P176, DOI 10.1002/jcp.1041530122
   HENDRIE PC, 1991, EXP HEMATOL, V19, P1031
   JOSHIBARVE S, 1990, J BIOL CHEM, V265, P2979
   KASPAR RL, 1990, J BIOL CHEM, V265, P3619
   KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0
   LEJBKOWICZ F, 1992, P NATL ACAD SCI USA, V89, P9612, DOI 10.1073/pnas.89.20.9612
   LIN TA, 1995, J BIOL CHEM, V270, P18531, DOI 10.1074/jbc.270.31.18531
   LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721
   Liu R. Y., 1996, Blood, V88, p58A
   MANTEL C, 1995, J IMMUNOL, V154, P2342
   MERRICK WC, 1994, BIOCHIMIE, V76, P822, DOI 10.1016/0300-9084(94)90183-X
   MIYAZAWA K, 1991, EXP HEMATOL, V19, P1110
   PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0
   PROUD CG, 1994, NATURE, V371, P747, DOI 10.1038/371747a0
   RAO GN, 1994, J BIOL CHEM, V269, P7180
   RINKERSCHAEFFER CW, 1992, J BIOL CHEM, V267, P10659
   SARRIS AH, 1993, J EXP MED, V178, P1127, DOI 10.1084/jem.178.3.1127
   SONENBERG N, 1994, BIOCHIMIE, V76, P839, DOI 10.1016/0300-9084(94)90185-6
   SONENBERG N, 1996, TRANSLATIONAL CONTRO, P245
   vonManteuffel SR, 1996, P NATL ACAD SCI USA, V93, P4076, DOI 10.1073/pnas.93.9.4076
   Williamson E A, 1995, Curr Opin Hematol, V2, P29
NR 37
TC 25
Z9 25
U1 0
U2 4
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD MAY 15
PY 1997
VL 89
IS 10
BP 3582
EP 3595
PG 14
WC Hematology
SC Hematology
GA XD976
UT WOS:A1997XD97600011
PM 9160663
DA 2018-12-27
ER

PT J
AU Fujii, Y
   Tanaka, H
   Toyooka, H
AF Fujii, Y
   Tanaka, H
   Toyooka, H
TI RETRACTED: Granisetron reduces postoperative nausea and vomiting
   throughout menstrual cycle (Retracted article. See vol. 59, pg. 1165,
   2012)
SO CANADIAN JOURNAL OF ANAESTHESIA-JOURNAL CANADIEN D ANESTHESIE
LA English
DT Article; Retracted Publication
ID RECEPTOR ANTAGONIST; LAPAROSCOPY; PREVENTION
AB Purpose: The incidence of postoperative nausea and vomiting (PONV) is influenced by menstruation. This study was undertaken to assess the efficacy of granisetron, a selective 5-hydroxytryptamine type 3 receptor antagonist, for preventing PONV in patients during two different phases of menstrual cycle.
   Methods: One hundred twenty female patients undergoing general anaesthesia for major gynaecological surgery were divided according to the phase of menstrual cycle into two groups: day one to eight (menstrual) and day nine to end of the cycle (non-menstrual) groups. in a randomized, double-blind manner, the patients received placebo (saline) or 40 mu g.kg(-1) granisetron iv immediately before the induction of anaethesia. All patients received a standardized general and epidural anaesthesia and epidural morphine plus bupivacaine for postoperative analgesia. The incidence of PONV and other adverse events was recorded during the first 24 hr after anaesthesia.
   Results: The treatment groups were similar with respect to patient demographics, types of surgery, anaesthetics administered and analgesics used postoperatively. The incidence of PONV was 72% and 32% in patients during menstruation receiving placebo or granisetron (P < 0.05), and was 46% and 20% in those during non-menstruation, respectively (P < 0.05). No differences in the incidence of other adverse events were observed among the groups.
   Conclusion: Granisetron was effective in reducing the incidence of PONV in both phases of the menstrual cycle studied.
C1 TORIDE KYODO GEN HOSP, DEPT ANAESTHESIOL, TORIDE, IBARAKI, JAPAN.
   UNIV TSUKUBA, INST CLIN MED, DEPT ANAESTHESIOL, TSUKUBA, IBARAKI 305, JAPAN.
CR BEATTIE WS, 1991, CAN J ANAESTH, V38, P298, DOI 10.1007/BF03007618
   BEATTIE WS, 1993, ANESTHESIOLOGY, V78, P272, DOI 10.1097/00000542-199302000-00010
   BERMUDEZ J, 1988, BRIT J CANCER, V58, P644, DOI 10.1038/bjc.1988.277
   CARMICHAEL J, 1989, CANCER CHEMOTH PHARM, V24, P45
   FUJII Y, 1995, CAN J ANAESTH, V42, P852, DOI 10.1007/BF03011030
   FUJII Y, 1994, CAN J ANAESTH, V41, P794, DOI 10.1007/BF03011585
   FUJII Y, 1994, CAN J ANAESTH, V41, P291, DOI 10.1007/BF03009906
   Furue H, 1990, J CLIN THERAPEUTIC M, V6, P49
   LEESER J, 1991, ANESTH ANALG, V72, P751
   WATCHA MF, 1992, ANESTHESIOLOGY, V77, P162, DOI 10.1097/00000542-199207000-00023
NR 10
TC 12
Z9 13
U1 2
U2 8
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0832-610X
J9 CAN J ANAESTH
JI Can. J. Anaesth.-J. Can. Anesth.
PD MAY
PY 1997
VL 44
IS 5
BP 489
EP 493
DI 10.1007/BF03011936
PN 1
PG 5
WC Anesthesiology
SC Anesthesiology
GA WZ152
UT WOS:A1997WZ15200007
PM 9161742
OA Bronze
DA 2018-12-27
ER

PT J
AU Kim, CH
   Ryan, DE
   Marciniec, T
   Abelson, J
AF Kim, CH
   Ryan, DE
   Marciniec, T
   Abelson, J
TI RETRACTED: Site-specific deoxynucleotide substitutions in yeast U6 snRNA
   block splicing of pre-mRNA in vitro (Retracted article. See vol 18, pg
   2908, 1999)
SO EMBO JOURNAL
LA English
DT Article; Retracted Publication
DE group II intron; 2'-hydroxyl; spliceosome; stem-loop; U6 reconstitution
ID SMALL NUCLEAR RIBONUCLEOPROTEIN; BASE-PAIRING INTERACTION; PRECURSOR
   MESSENGER-RNA; TETRAHYMENA RIBOZYME; 2'-HYDROXYL GROUPS; ACTIVE-SITE;
   TERTIARY INTERACTIONS; CATALYTIC CORE; CROSS-LINKING; SPLICEOSOME
AB We have identified 2'-hydroxyl groups of the U6 phosphate-ribose backbone which are required for reconstitution of splicing activity in U6-depleted yeast extract. To screen the 2'-hydroxyls of yeast U6 at nucleotides 39-88, spanning the conserved central domain, synthetic U6 RNAs were constructed with deoxyribonucleotides incorporated site specifically. Only four individual deoxynucleotide substitutions blocked splicing activity: dA51 (in the ACAGAG sequence), dA62 (next to the AGC triad), and dU70 and dC72 (both in the loop of the 3' intramolecular stem-loop), Native gel analysis revealed that these deoxy-substituted U6 RNAs were competent for assembly of spliceosomes, Interestingly, a 2'-O-methyl substituent at A51, A62, U70 or C72 did not inhibit splicing activity, indicating that the essential 2'-OH groups at these positions in U6 act as hydrogen bond accepters or neutral coordinated ligands, The requisite 2'-hydroxyls at A62, U70 and C72 show both similarities and differences relative to the positions of essential 2'-hydroxyls of catalytic domain V of group II ribozymes. The identification of the essential 2'-hydroxyls at positions 62, 70 and 72 corroborates that the 3' intramolecular stem-loop in U6 plays an important role in pre-mRNA splicing.
C1 CALTECH, DIV BIOL 14775, PASADENA, CA 91125 USA.
OI Kim, Chang Hee/0000-0002-1032-5461
FU NIGMS NIH HHS [GM32637]
CR Abramovitz DL, 1996, SCIENCE, V271, P1410, DOI 10.1126/science.271.5254.1410
   ARES M, 1995, PROG NUCLEIC ACID RE, V50, P131, DOI 10.1016/S0079-6603(08)60813-2
   BAN C, 1994, J MOL BIOL, V236, P275, DOI 10.1006/jmbi.1994.1134
   BEVILACQUA PC, 1991, BIOCHEMISTRY-US, V30, P10632, DOI 10.1021/bi00108a005
   BRINGMANN P, 1984, EMBO J, V3, P1357, DOI 10.1002/j.1460-2075.1984.tb01977.x
   BROW DA, 1988, NATURE, V334, P213, DOI 10.1038/334213a0
   BROW DA, 1995, RNA, V1, P122
   CECH TR, 1987, SCIENCE, V236, P1532, DOI 10.1126/science.2438771
   CHANFREAU G, 1994, SCIENCE, V266, P1383, DOI 10.1126/science.7973729
   CHENG SC, 1987, GENE DEV, V1, P1014, DOI 10.1101/gad.1.9.1014
   COSTA M, 1995, EMBO J, V14, P1276, DOI 10.1002/j.1460-2075.1995.tb07111.x
   DATTA B, 1991, NATURE, V352, P821, DOI 10.1038/352821a0
   EGLI M, 1993, BIOCHEMISTRY-US, V32, P3221, DOI 10.1021/bi00064a004
   FABRIZIO P, 1989, GENE DEV, V3, P2137, DOI 10.1101/gad.3.12b.2137
   FABRIZIO P, 1992, NUCLEIC ACIDS RES, V20, P3659, DOI 10.1093/nar/20.14.3659
   FABRIZIO P, 1990, SCIENCE, V250, P404, DOI 10.1126/science.2145630
   FORTNER DM, 1994, GENE DEV, V8, P221, DOI 10.1101/gad.8.2.221
   FRANK DN, 1994, MOL CELL BIOL, V14, P2180, DOI 10.1128/MCB.14.3.2180
   HASHIMOTO C, 1984, NUCLEIC ACIDS RES, V12, P3283, DOI 10.1093/nar/12.7.3283
   HAUSNER TP, 1990, GENE DEV, V4, P2146, DOI 10.1101/gad.4.12a.2146
   HERSCHLAG D, 1993, BIOCHEMISTRY-US, V32, P8299, DOI 10.1021/bi00083a034
   HERSCHLAG D, 1993, BIOCHEMISTRY-US, V32, P8312, DOI 10.1021/bi00083a035
   KANDELSLEWIS S, 1993, SCIENCE, V262, P2035, DOI 10.1126/science.8266100
   Kim CH, 1996, RNA, V2, P995
   KLEPPE K, 1970, P NATL ACAD SCI USA, V67, P68, DOI 10.1073/pnas.67.1.68
   KONARSKA MM, 1987, CELL, V49, P763, DOI 10.1016/0092-8674(87)90614-3
   LAMOND AI, 1988, P NATL ACAD SCI USA, V85, P411, DOI 10.1073/pnas.85.2.411
   LESSER CF, 1993, SCIENCE, V262, P1982, DOI 10.1126/science.8266093
   LIN RJ, 1985, J BIOL CHEM, V260, P4780
   MADHANI HD, 1994, GENE DEV, V8, P1071, DOI 10.1101/gad.8.9.1071
   MADHANI HD, 1992, CELL, V71, P803, DOI 10.1016/0092-8674(92)90556-R
   MADHANI HD, 1990, GENE DEV, V4, P2264, DOI 10.1101/gad.4.12b.2264
   MADHANI HD, 1994, ANNU REV GENET, V28, P1
   MICHEL F, 1995, ANNU REV BIOCHEM, V64, P435, DOI 10.1146/annurev.bi.64.070195.002251
   MOORE M J, 1993, RNA WORLD, P303
   MOORE MJ, 1992, SCIENCE, V256, P992, DOI 10.1126/science.1589782
   MUSIERFORSYTH K, 1992, NATURE, V357, P513, DOI 10.1038/357513a0
   NEWMAN A, 1991, CELL, V65, P115, DOI 10.1016/0092-8674(91)90413-S
   NEWMAN AJ, 1992, CELL, V68, P743, DOI 10.1016/0092-8674(92)90149-7
   NILSEN TW, 1994, CELL, V78, P1, DOI 10.1016/0092-8674(94)90563-0
   PARKER R, 1987, CELL, V49, P229, DOI 10.1016/0092-8674(87)90564-2
   PERREAULT JP, 1992, J MOL BIOL, V226, P399, DOI 10.1016/0022-2836(92)90955-J
   PIKIELNY CW, 1986, NATURE, V324, P341, DOI 10.1038/324341a0
   PLEY HW, 1994, NATURE, V372, P68, DOI 10.1038/372068a0
   PYLE AM, 1991, NATURE, V350, P628, DOI 10.1038/350628a0
   PYLE AM, 1992, NATURE, V358, P123, DOI 10.1038/358123a0
   RINKE J, 1985, J MOL BIOL, V185, P721, DOI 10.1016/0022-2836(85)90057-9
   ROIHA H, 1989, GENE, V82, P137, DOI 10.1016/0378-1119(89)90038-3
   Sambrook J., 1989, MOL CLONING LAB MANU
   SAWA H, 1992, P NATL ACAD SCI USA, V89, P11269, DOI 10.1073/pnas.89.23.11269
   SAWA H, 1992, GENE DEV, V6, P244, DOI 10.1101/gad.6.2.244
   SHARP PA, 1994, ANGEW CHEM INT EDIT, V33, P1229, DOI 10.1002/anie.199412291
   SHUMYATSKY G, 1993, NUCLEIC ACIDS RES, V21, P3017, DOI 10.1093/nar/21.13.3017
   SMITH D, 1993, BIOCHEMISTRY-US, V32, P5273, DOI 10.1021/bi00071a001
   SONTHEIMER EJ, 1993, SCIENCE, V262, P1989, DOI 10.1126/science.8266094
   STROBEL SA, 1993, BIOCHEMISTRY-US, V32, P13593, DOI 10.1021/bi00212a027
   SUN JS, 1995, GENE DEV, V9, P843, DOI 10.1101/gad.9.7.843
   VANKAN P, 1990, EMBO J, V9, P3397, DOI 10.1002/j.1460-2075.1990.tb07541.x
   WASSARMAN DA, 1992, SCIENCE, V257, P1918, DOI 10.1126/science.1411506
   WINCOTT F, 1995, NUCLEIC ACIDS RES, V23, P2677, DOI 10.1093/nar/23.14.2677
   WOLFF T, 1992, EMBO J, V11, P345, DOI 10.1002/j.1460-2075.1992.tb05057.x
   WOLFF T, 1993, GENE DEV, V7, P1377, DOI 10.1101/gad.7.7b.1377
   WU J, 1991, NATURE, V352, P818, DOI 10.1038/352818a0
   WYATT JR, 1992, GENE DEV, V6, P2542, DOI 10.1101/gad.6.12b.2542
   Yan D, 1996, MOL CELL BIOL, V16, P818
   YEAN SL, 1991, MOL CELL BIOL, V11, P5571, DOI 10.1128/MCB.11.11.5571
   YU YT, 1995, RNA, V1, P46
NR 67
TC 6
Z9 6
U1 2
U2 10
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD, ENGLAND OX2 6DP
SN 0261-4189
J9 EMBO J
JI Embo J.
PD APR 15
PY 1997
VL 16
IS 8
BP 2119
EP 2129
DI 10.1093/emboj/16.8.2119
PG 11
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA WV896
UT WOS:A1997WV89600031
PM 9155037
OA Bronze, Green Published
DA 2018-12-27
ER

PT J
AU Fujii, Y
   Tanaka, H
   Toyooka, H
AF Fujii, Y
   Tanaka, H
   Toyooka, H
TI RETRACTED: Granisetron reduces the incidence and severity of nausea and
   vomiting after laparoscopic cholecystectomy (Retracted article. See vol.
   59, pg. 1166, 2012)
SO CANADIAN JOURNAL OF ANAESTHESIA-JOURNAL CANADIEN D ANESTHESIE
LA English
DT Article; Retracted Publication
ID POSTOPERATIVE NAUSEA; RECEPTOR ANTAGONIST; PREVENTION; METOCLOPRAMIDE;
   DOMPERIDONE; ANESTHESIA; DROPERIDOL
AB Purpose: Postoperative nausea and vomiting (PONV) are commonly observed undesirable consequences of laparoscopic cholecystectomy. This study was undertaken to compare granisetron, a selective 5-hydroxytryptamine mine type 3 receptor antagonist, with droperidol for reducing the incidence and severity of PONV after laparoscopic cholecystectomy.
   Methods: Eighty patients, aged 25-65 yr, scheduled for elective laparoscopic cholecystectomy were enrolled in a randomized, double-blinded investigation and assigned to one of three treatment regimens: placebo (saline), 1.25 mg droperidol (approximately 25 mu g.kg(-1)) or 3 mg granisetron (approximately 60 mu g.kg(-1)). The study drugs were administered iv immediately before the induction of anaesthesia, A standard general anaesthetic technique was employed throughout, Nausea, vomiting and safety assessments were performed continuously during the first 24 hr after anaesthesia.
   Results: The incidence of PONV was 46% with placebo, 41% with droperidol and 15% with granisetron (P < 0.05; overall chi(2) test). Four patients who had received placebo and two who had received droperidol required another rescue antiemetic, compared with none who had received granisetron (P < 0.05). Adverse events postoperatively were not different among the groups,
   Conclusion: Granisetron is more effective than droperidol and placebo for reducing the incidence and severity of PONV after laparoscopic cholecystectomy.
C1 TORIDE KYODO GEN HOSP, DEPT ANAESTHESIOL, TORIDE, IBARAKI, JAPAN.
RP Fujii, Y (reprint author), UNIV TSUKUBA, INST CLIN MED, DEPT ANAESTHESIOL, 2-1-1 AMAKUBO, TSUKUBA, IBARAKI 305, JAPAN.
CR ANDREWS P L R, 1992, European Journal of Cancer, V28A, pS2, DOI 10.1016/0959-8049(92)90628-F
   BERMUDEZ J, 1988, BRIT J CANCER, V58, P644, DOI 10.1038/bjc.1988.277
   CARMICHAEL J, 1989, CANCER CHEMOTH PHARM, V24, P45
   FUJII Y, 1994, CAN J ANAESTH, V41, P794, DOI 10.1007/BF03011585
   FUJII Y, 1994, CAN J ANAESTH, V41, P291, DOI 10.1007/BF03009906
   Furue H, 1990, J CLIN THERAPEUTIC M, V6, P49
   Iitomi T, 1995, Masui, V44, P1627
   KORTTILA K, 1979, ANESTH ANALG, V58, P396
   MADEJ TH, 1986, BRIT J ANAESTH, V58, P879, DOI 10.1093/bja/58.8.879
   Naguib M, 1996, CAN J ANAESTH, V43, P226, DOI 10.1007/BF03011739
   STANTON JM, 1991, ANAESTHESIA, V46, P317, DOI 10.1111/j.1365-2044.1991.tb11510.x
   WATCHA MF, 1992, ANESTHESIOLOGY, V77, P162, DOI 10.1097/00000542-199207000-00023
NR 12
TC 29
Z9 29
U1 3
U2 10
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0832-610X
J9 CAN J ANAESTH
JI Can. J. Anaesth.-J. Can. Anesth.
PD APR
PY 1997
VL 44
IS 4
BP 396
EP 400
DI 10.1007/BF03014460
PG 5
WC Anesthesiology
SC Anesthesiology
GA WT188
UT WOS:A1997WT18800010
PM 9104522
OA Bronze
DA 2018-12-27
ER

PT J
AU Zhang, JD
   Li, SK
AF Zhang, JD
   Li, SK
TI RETRACTED: Cancer mortality in a Chinese population exposed to
   hexavalent chromium in water (Retracted Article. See vol 48, pg 749,
   2006)
SO JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL MEDICINE
LA English
DT Article; Retracted Publication
AB This report is a clarification and further analysis of our previously published mortality study regarding groundwater contamination with hexavalent chromium (Cr+6) in the JinZhou area of China between 1965 and 1978, In our previous report, we stated that a significant excess of overall cancer mortality was observed (P = 0.04) in five Cr+6-contaminated villages combined. Further analysis revealed no clear statistical increase in cancer mortality in the three villages adjacent to the source of the contamination (P = 0.25), where 7% of the wells exceeded the European Community safe drinking water standard of 0.05 ppm Cr6+. These results do not indicate an association of cancer mortality with exposure to Cr+6-contaminated groundwater, but might reflect the influence of lifestyle or environmental factors not related to Cr+6. Further follow-up of this cohort is recommended.
C1 JINZHOU HLTH & ANTIEPIDEM STN, JINZHOU, PEOPLES R CHINA.
   BENXI HLTH & ANTIEPIDEM STN, BENXI, LIAO NING, PEOPLES R CHINA.
CR *AG TOX SUBST DIS, 1993, TOXIC PROF CHROM, P57
   BRESLOW NE, 1987, STAT METHODS CANC RE, V2
   *USEPA, 1991, FED REG         0130
   *WHO, 1987, ENV HLTH CRITERIA CH, V61, P44
   ZHANG J, 1979, STUDY EFFECT ENV POL
   Zhang J, 1987, J CHINESE PREVENTIVE, V21, P262
NR 6
TC 51
Z9 53
U1 1
U2 16
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1076-2752
EI 1536-5948
J9 J OCCUP ENVIRON MED
JI J. Occup. Environ. Med.
PD APR
PY 1997
VL 39
IS 4
BP 315
EP 319
DI 10.1097/00043764-199704000-00008
PG 5
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA WU655
UT WOS:A1997WU65500007
PM 9113601
DA 2018-12-27
ER

PT J
AU Shaukat, N
   Lear, J
   Lowy, A
   Fletcher, S
   deBono, DP
   Woods, KL
AF Shaukat, N
   Lear, J
   Lowy, A
   Fletcher, S
   deBono, DP
   Woods, KL
TI RETRACTED: First myocardial infarction in patients of Indian
   subcontinent and European origin: Comparison of risk factors,
   management, and long term outcome (Retracted article. See vol 316, pg
   116, 1998)
SO BRITISH MEDICAL JOURNAL
LA English
DT Article; Retracted Publication
ID CORONARY-ARTERY DISEASE; HEART-DISEASE; ASIANS; SURVIVAL; BIRMINGHAM;
   MORTALITY
AB Objectives: To compare long term outcome after first myocardial infarction amo
   Design: Matched pairs study
   Setting: Coronary care unit in central Leicester.
   Subjects: 238 pairs of patients admitted during 1987-93 matched for age (within 2 years), sex, date of admission (within 3 months), type of infarction (Q/non-Q), and site of infarction.
   Main outcome measures: Incidence of angina, reinfarction, or death during follow up of 1-7 years.
   Results: Patients of Indian subcontinent origin had a higher prevalence of diabetes (35% v 9% in patients of European origin, P<0.001), lower prevalence of smoking (39% v 63%, P < 0.001), longer median delay from symptom onset to admission (5 hours v 3 hows, P<0.01), and lower use of thrombolysis (50% v 66%, P<0.001). During long term follow up (median 39 months), mortality was higher in patients of Indian subcontinent origin (unadjusted hazard ratio=2.1, 95% confidence interval 1.3 to 5.4, P=0.002). After adjustment for smoking, history of diabetes, and thrombolysis the estimated hazard ratio fell slightly to 2.0 (1.1 to 3.6, P=0.02). Patients of Indian subcontinent origin had almost twice the incidence of angina (54% v 29%; P<0.001) and almost three times the risk of reinfarction during follow up (34% v 12.5% at 3 pars, P<0.001). The unadjusted hazard ratio for reinfarction in patients of Indian subcontinent origin was 2.8 (1.8 to 4.4, P<0.001). Adjustment for smoking, history of diabetes, and thrombolysis made little difference to die hazard ratio. Coronary angiography was performed with similar frequency in the two groups; triple vessel disease was the commonest finding in patients of Indian subcontinent origin and single vessel disease the commonest in Europeans (P<0.001).
   Conclusions: Patients of Indian subcontinent origin are at substantially higher risk of mortality and of further coronary events than Europeans after first myocardial infarction. This is probably due to their higher prevalence of diffuse coronary atheroma Their need for investigation with a view to coronary revascularisation is therefore greater History of diabetes is an inadequate surrogate for ethnic origin as a prognostic indicator.
C1 UNIV LEICESTER, DEPT MED & THERAPEUT & PUBL HLTH, LEICESTER, LEICS, ENGLAND.
RP Shaukat, N (reprint author), GEN HOSP KETTERING, NHS TRUST, DEPT CARDIOL, ROTHWELL RD, KETTERING NN16 8UZ, NORTHANTS, ENGLAND.
OI lear, john/0000-0002-2969-9922
CR BALARAJAN R, 1991, BMJ-BRIT MED J, V302, P560, DOI 10.1136/bmj.302.6776.560
   BALARAJAN R, 1992, HLTH TRENDS, V24, P113
   DHAWAN J, 1994, ATHEROSCLEROSIS, V105, P35, DOI 10.1016/0021-9150(94)90005-1
   FEEHALLY J, 1993, Q J MED, V86, P263
   HOLT JD, 1974, BIOMETRIKA, V61, P17, DOI 10.2307/2334281
   HUGHES LO, 1989, BRIT MED J, V298, P1345, DOI 10.1136/bmj.298.6684.1345
   LEAR JT, 1994, J ROY COLL PHYS LOND, V28, P143
   LOWRY PJ, 1984, BRIT HEART J, V52, P610
   LOWY AGJ, 1991, J PUBLIC HEALTH MED, V13, P276
   MCKEIGUE PM, 1988, BRIT HEART J, V60, P390
   MCKEIGUE PM, 1991, LANCET, V337, P382, DOI 10.1016/0140-6736(91)91164-P
   MUKHTAR HT, 1995, BRIT HEART J, V73, P122
   SHAUKAT N, 1993, BRIT MED J, V307, P717, DOI 10.1136/bmj.307.6906.717
   Wilkinson P, 1996, BRIT MED J, V312, P1330, DOI 10.1136/bmj.312.7042.1330
   WOODS KL, 1989, BRIT HEART J, V62, P118
   YUSUF S, 1994, LANCET, V344, P563, DOI 10.1016/S0140-6736(94)91963-1
NR 16
TC 22
Z9 22
U1 3
U2 14
PU BRITISH MED JOURNAL PUBL GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR
SN 0959-8138
J9 BRIT MED J
JI Br. Med. J.
PD MAR 1
PY 1997
VL 314
IS 7081
BP 639
EP 642
DI 10.1136/bmj.314.7081.639
PG 4
WC Medicine, General & Internal
SC General & Internal Medicine
GA WL418
UT WOS:A1997WL41800022
PM 9066475
OA Green Published
DA 2018-12-27
ER

PT J
AU Fujii, Y
   Tanaka, H
   Toyooka, H
AF Fujii, Y
   Tanaka, H
   Toyooka, H
TI RETRACTED: Prophylactic antiemetic efficacy of granisetron in patients
   with and without previous postoperative emesis (Retracted article. See
   vol. 59, pg. 1167, 2012)
SO CANADIAN JOURNAL OF ANAESTHESIA-JOURNAL CANADIEN D ANESTHESIE
LA English
DT Article; Retracted Publication
ID RECEPTOR ANTAGONIST; NAUSEA; PREVENTION; ONDANSETRON
AB Purpose: To evaluate the efficacy of granisetron, a selective antagonist of 5-hydroxytryptamine type 3 receptors, in the prevention of PONV in patients with and without previous postoperative emesis undergoing general anaesthesia for major gynaecological surgery.
   Methods: In a randomized, double-blind, placebo-controlled trial of 90 women with (n=40) and without (n=50) a history of PONV, the patients received either granisetron (40 mu g . kg(-1) or placebo (saline) iv immediately; before induction of anaesthesia, The same standard general anaesthetic technique, which consisted of isoflurane. in nitrous oxide and oxygen and avoided opioids, was used, Nausea, vomiting and safety assessments were per formed during the first 24 hr after anaesthesia,
   Results: The incidence of PONV was 70% and 25% after administration of placebo and granisetron in patients with previous PONV (P<0.05), and was 40% and 8% in patients without it,respectively(P<0.05). The incidence of adverse events postoperatively were not different among the treatment groups.
   Conclusion: Granisetron 40 mu g . kg(-1) given prior to anaesthesia reduces the incidence of PONV in patients with a history of PONV as well as in patients without it.
C1 TORIDE KYODO GEN HOSP, DEPT ANAESTHESIOL, TORIDE, IBARAKI, JAPAN.
RP Fujii, Y (reprint author), UNIV TSUKUBA, INST CLIN MED, DEPT ANAESTHESIOL, 2-1-1 AMAKUBO, TSUKUBA, IBARAKI 305, JAPAN.
CR ANDREWS P L R, 1992, European Journal of Cancer, V28A, pS2, DOI 10.1016/0959-8049(92)90628-F
   BERMUDEZ J, 1988, BRIT J CANCER, V58, P644, DOI 10.1038/bjc.1988.277
   BODNER M, 1991, ANESTH ANALG, V73, P250
   CARMICHAEL J, 1989, CANCER CHEMOTH PHARM, V24, P45
   DUPEYRON JP, 1993, ANAESTHESIA, V48, P214, DOI 10.1111/j.1365-2044.1993.tb06904.x
   Fujii Y, 1996, CAN J ANAESTH, V43, P110, DOI 10.1007/BF03011250
   FUJII Y, 1994, CAN J ANAESTH, V41, P794, DOI 10.1007/BF03011585
   FUJII Y, 1994, CAN J ANAESTH, V41, P291, DOI 10.1007/BF03009906
   Furue H, 1990, J CLIN THERAPEUTIC M, V6, P49
   KENNY GNC, 1992, BRIT J ANAESTH, V68, P466, DOI 10.1093/bja/68.5.466
   LEESER J, 1991, ANESTH ANALG, V72, P751
   LERMAN J, 1992, BRIT J ANAESTH, V69, pS24, DOI 10.1093/bja/69.supplement_1.24S
   MCKENZIE R, 1981, ANESTH ANALG, V60, P783
   PURKIS I E, 1964, Can Anaesth Soc J, V11, P335, DOI 10.1007/BF03003420
   WATCHA MF, 1992, ANESTHESIOLOGY, V77, P162, DOI 10.1097/00000542-199207000-00023
NR 15
TC 11
Z9 11
U1 2
U2 8
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0832-610X
J9 CAN J ANAESTH
JI Can. J. Anaesth.-J. Can. Anesth.
PD MAR
PY 1997
VL 44
IS 3
BP 273
EP 277
DI 10.1007/BF03015365
PG 5
WC Anesthesiology
SC Anesthesiology
GA WL920
UT WOS:A1997WL92000009
PM 9067046
OA Bronze
DA 2018-12-27
ER

PT J
AU Bassanezi, RC
   Leite, MBF
   Godoy, WAC
   VonZuben, CJ
   VonZuben, FJ
   dosReis, SF
AF Bassanezi, RC
   Leite, MBF
   Godoy, WAC
   VonZuben, CJ
   VonZuben, FJ
   dosReis, SF
TI RETRACTED: Diffusion model applied to postfeeding larval dispersal in
   blowflies (Diptera: Calliphoridae) (Retracted article. See vol. 108, pg.
   00, 2013)
SO MEMORIAS DO INSTITUTO OSWALDO CRUZ
LA English
DT Article; Retracted Publication
DE Chrysomya megacephala; Chrysomya putoria; Cochliomyia macellaria;
   diffusion model; larval dispersal; blowflies
ID POPULATION-DYNAMICS; COMPETITION; MOVEMENT
AB This paper presents a diffusion model of larval dispersal especifically designed to account for particular aspects of postfeeding larval dispersal from the food source in organisms such as blowflies. In these organisms the dispersal of immatures includes two groups of individuals, those that are actively migrating and those that have initiated the pupation process. The classical diffusion equation in one dimension was modified to incorporate a function which describes the burying of larvae to become pupae. The analytical solution of this equation predicts oscillatory and monotonic dispersal behaviors, which are observed in experimental populations of blowfly species.
C1 UNIV ESTADUAL CAMPINAS, DEPT PARASITOL, BR-13083970 CAMPINAS, SP, BRAZIL.
   UNIV ESTADUAL CAMPINAS, IMECC, DEPT MATEMAT APLICADA, BR-13083970 CAMPINAS, SP, BRAZIL.
   PONTIFICIA UNIV CATOLICA CAMPINAS, INST CIENCIAS EXATAS, CAMPINAS, SP, BRAZIL.
   UNIV ESTADUAL PAULISTA, DEPT PARASITOL, BOTUCATU, SP, BRAZIL.
   UNIV BRASILIA, DEPT ZOOL, BRASILIA, DF, BRAZIL.
   UNIV ESTADUAL CAMPINAS, DEPT ENGENHARIA COMP & AUTOMACAO IND, BR-13081970 CAMPINAS, SP, BRAZIL.
RI Von Zuben, Fernando J./K-5979-2017
OI Von Zuben, Fernando J./0000-0002-4128-5415
CR Andow D.A., 1993, P219
   [Anonymous], 1982, REVTA BRAS ZOOL, V1, P41
   BANKS HT, 1988, ENVIRON ENTOMOL, V17, P815, DOI 10.1093/ee/17.5.815
   BAUMGARTNER DL, 1984, J MED ENTOMOL, V21, P105, DOI 10.1093/jmedent/21.1.105
   BLACKITH RE, 1990, J NAT HIST, V24, P699, DOI 10.1080/00222939000770481
   BROADBENT SR, 1953, BIOMETRICS, V9, P460, DOI 10.2307/3001437
   CHRISTIE I, 1995, ECOL MODEL, V78, P219, DOI 10.1016/0304-3800(93)E0089-L
   DEJONG G, 1979, NETH J ZOOL, V29, P33, DOI 10.1163/002829679X00106
   GAINES SD, 1993, ECOLOGY, V74, P2430, DOI 10.2307/1939593
   GREENBERG B, 1984, ANN ENTOMOL SOC AM, V77, P488, DOI 10.1093/aesa/77.5.488
   GUIMARAES J H, 1978, Revista Brasileira de Entomologia, V22, P53
   Guimaraes J.H., 1979, Revista Brasileira de Entomologia, V23, P245
   GUIMARAES JH, 1984, AGROQUIMICA, V24, P8
   GURNEY WSC, 1975, J THEOR BIOL, V52, P441, DOI 10.1016/0022-5193(75)90011-9
   HELLAND IS, 1984, J CHEM ECOL, V10, P723, DOI 10.1007/BF00988539
   HOLMES EE, 1994, ECOLOGY, V75, P17, DOI 10.2307/1939378
   HOLMES EE, 1993, AM NAT, V142, P779, DOI 10.1086/285572
   IVES AR, 1991, ECOL MONOGR, V61, P75, DOI 10.2307/1943000
   KAREIVA P, 1982, ECOL MONOGR, V52, P261, DOI 10.2307/2937331
   KAREIVA PM, 1983, OECOLOGIA, V57, P322, DOI 10.1007/BF00377175
   KNEIDEL KA, 1984, J ANIM ECOL, V53, P849, DOI 10.2307/4663
   Murray JD, 1989, MATH BIOL
   NORRIS KR, 1959, BIOGEOGRAPHY ECOLOGY, V8, P514
   Okubo A., 1980, DIFFUSION ECOLOGICAL
   PESCHKE K, 1987, Zoologische Jahrbuecher Abteilung fuer Systematik Oekologie und Geographie der Tiere, V114, P241
   POSSINGHAM HP, 1990, ECOLOGY, V71, P973, DOI 10.2307/1937366
   PROUT T, 1985, AM NAT, V126, P521, DOI 10.1086/284436
   PUTMAN RJ, 1977, J ANIM ECOL, V46, P853, DOI 10.2307/3645
   ROUGHGARDEN J, 1988, SCIENCE, V241, P1460, DOI 10.1126/science.11538249
   Sereno Fabiana T. P. S., 1993, Anais da Sociedade Entomologica do Brasil, V22, P527
   ULLYETT GC, 1950, PHILOS T ROY SOC B, V234, P77, DOI 10.1098/rstb.1950.0001
NR 31
TC 9
Z9 11
U1 5
U2 14
PU FUNDACO OSWALDO CRUZ
PI RIO DE JANEIRO, RJ
PA AV BRASIL 4365, 21045-900 RIO DE JANEIRO, RJ, BRAZIL
SN 0074-0276
EI 1678-8060
J9 MEM I OSWALDO CRUZ
JI Mem. Inst. Oswaldo Cruz
PD MAR-APR
PY 1997
VL 92
IS 2
BP 281
EP 286
DI 10.1590/S0074-02761997000200025
PG 6
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA WR478
UT WOS:A1997WR47800025
PM 24159673
OA DOAJ Gold
DA 2018-12-27
ER

PT J
AU Cooper, PK
   Nouspikel, T
   Clarkson, SG
   Leadon, SA
AF Cooper, PK
   Nouspikel, T
   Clarkson, SG
   Leadon, SA
TI RETRACTED: Defective transcription-coupled repair of oxidative base
   damage in Cockayne syndrome patients from XP group G (Retracted Article.
   See vol 308, pg 1740, 2005)
SO SCIENCE
LA English
DT Article; Retracted Publication
ID PIGMENTOSUM GROUP-G; NUCLEOTIDE EXCISION-REPAIR; COMPLEMENTATION
   GROUP-G; RNA-POLYMERASE-II; DNA-REPAIR; IONIZING-RADIATION; PREFERENTIAL
   REPAIR; THYMINE GLYCOLS; ACTIVE GENES; YEAST RAD2
AB In normal human cells, damage due to ultraviolet light is preferentially removed from active genes by nucleotide excision repair (NER) in a transcription-coupled repair (TCR) process that requires the gene products defective in Cockayne syndrome (CS). Oxidative damage, including thymine glycols, is shown to be removed by TCR in cells from normal individuals and from xeroderma pigmentosum (XP)-A, XP-F, and XP-G patients who have NER defects but not from XP-G patients who have severe CS. Thus, TCR of oxidative damage requires an XPG function distinct from its NER endonuclease activity. These results raise the possibility that defective TCR of oxidative damage contributes to the developmental defects associated with CS.
C1 UNIV GENEVA, MED CTR, DEPT GENET & MICROBIOL, CH-1211 GENEVA 4, SWITZERLAND.
   UNIV N CAROLINA, SCH MED, DEPT RADIAT ONCOL, CHAPEL HILL, NC 27599 USA.
RP Cooper, PK (reprint author), UNIV CALIF BERKELEY, LAWRENCE BERKELEY NATL LAB, DIV LIFE SCI, BLDG 934, 1 CYCLOTRON RD, BERKELEY, CA 94720 USA.
FU NCI NIH HHS [CA40453, CA63503]
CR Brookman KW, 1996, MOL CELL BIOL, V16, P6553
   CHEN DS, 1994, ANN NY ACAD SCI, V726, P306, DOI 10.1111/j.1749-6632.1994.tb52834.x
   CLEAVER JE, 1989, METABOLIC BASIS INHE, V2, P2949
   DEMPLE B, 1994, ANNU REV BIOCHEM, V63, P915, DOI 10.1146/annurev.bi.63.070194.004411
   Friedberg EC, 1996, ANNU REV BIOCHEM, V65, P15
   Habraken Y, 1996, P NATL ACAD SCI USA, V93, P10718, DOI 10.1073/pnas.93.20.10718
   HABRAKEN Y, 1994, NUCLEIC ACIDS RES, V22, P3312, DOI 10.1093/nar/22.16.3312
   Hamel BCK, 1996, J MED GENET, V33, P607, DOI 10.1136/jmg.33.7.607
   HANAWALT PC, 1994, SCIENCE, V266, P1957, DOI 10.1126/science.7801121
   HATAHET Z, 1994, ANN NY ACAD SCI, V726, P346, DOI 10.1111/j.1749-6632.1994.tb52847.x
   HENNING KA, 1995, CELL, V82, P555, DOI 10.1016/0092-8674(95)90028-4
   HOEIJMAKERS JHJ, 1994, EUR J CANCER, V30A, P1912, DOI 10.1016/0959-8049(94)00381-E
   Iyer N, 1996, BIOCHEMISTRY-US, V35, P2157, DOI 10.1021/bi9524124
   JAEKEN J, 1989, HUM GENET, V83, P339
   KOW YW, 1990, MUTAT RES, V235, P147, DOI 10.1016/0921-8777(90)90068-G
   LASPIA MF, 1988, J BACTERIOL, V170, P3359, DOI 10.1128/jb.170.8.3359-3366.1988
   LEADON SA, 1995, MUTAT RES-DNA REPAIR, V337, P169, DOI 10.1016/0921-8777(95)00021-B
   LEADON SA, 1992, J BIOL CHEM, V267, P23175
   LEADON SA, 1993, P NATL ACAD SCI USA, V90, P10499, DOI 10.1073/pnas.90.22.10499
   LEADON SA, 1988, DNA REPAIR LABORATOR, V3, P311
   LEHMANN AR, 1995, TRENDS BIOCHEM SCI, V20, P402, DOI 10.1016/S0968-0004(00)89088-X
   MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6
   Mu D, 1996, J BIOL CHEM, V271, P8285, DOI 10.1074/jbc.271.14.8285
   MU D, 1995, J BIOL CHEM, V270, P2415, DOI 10.1074/jbc.270.6.2415
   NANCE MA, 1992, AM J MED GENET, V42, P68, DOI 10.1002/ajmg.1320420115
   NORRIS PG, 1987, BRIT J DERMATOL, V116, P861, DOI 10.1111/j.1365-2133.1987.tb04906.x
   NOUSPIKEL T, 1994, HUM MOL GENET, V3, P963, DOI 10.1093/hmg/3.6.963
   NOUSPIKEL T, IN PRESS P NATL ACAD
   ODONOVAN A, 1993, NATURE, V363, P185, DOI 10.1038/363185a0
   ODONOVAN A, 1994, J BIOL CHEM, V269, P15965
   ODONOVAN A, 1994, NATURE, V371, P432, DOI 10.1038/371432a0
   PARK CH, 1995, J BIOL CHEM, V270, P22657, DOI 10.1074/jbc.270.39.22657
   RILEY PA, 1994, INT J RADIAT BIOL, V65, P27, DOI 10.1080/09553009414550041
   Sancar A, 1996, ANNU REV BIOCHEM, V65, P43, DOI 10.1146/annurev.bi.65.070196.000355
   SATOH MS, 1993, P NATL ACAD SCI USA, V90, P6335, DOI 10.1073/pnas.90.13.6335
   SCHERLY D, 1993, NATURE, V363, P182, DOI 10.1038/363182a0
   SEEBERG E, 1995, TRENDS BIOCHEM SCI, V20, P391, DOI 10.1016/S0968-0004(00)89086-6
   Sijbers AM, 1996, CELL, V86, P811, DOI 10.1016/S0092-8674(00)80155-5
   TROELSTRA C, 1992, CELL, V71, P939, DOI 10.1016/0092-8674(92)90390-X
   VANHOFFEN A, 1993, NUCLEIC ACIDS RES, V21, P5890, DOI 10.1093/nar/21.25.5890
   VERMEULEN W, 1993, AM J HUM GENET, V53, P185
   VERMEULEN W, 1994, COLD SPRING HARB SYM, V59, P317, DOI 10.1101/SQB.1994.059.01.036
   WALKER LJ, 1994, NUCLEIC ACIDS RES, V22, P4884, DOI 10.1093/nar/22.23.4884
   WALLACE SS, 1988, ENVIRON MOL MUTAGEN, V12, P431, DOI 10.1002/em.2860120411
   WARD JF, 1988, PROG NUCLEIC ACID RE, V35, P95, DOI 10.1016/S0079-6603(08)60611-X
   Wood RD, 1996, ANNU REV BIOCHEM, V65, P135, DOI 10.1146/annurev.bi.65.070196.001031
NR 46
TC 270
Z9 270
U1 2
U2 16
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
EI 1095-9203
J9 SCIENCE
JI Science
PD FEB 14
PY 1997
VL 275
IS 5302
BP 990
EP 993
DI 10.1126/science.275.5302.990
PG 4
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA WH388
UT WOS:A1997WH38800049
PM 9020084
DA 2018-12-27
ER

PT J
AU Ymeri, HM
AF Ymeri, HM
TI RETRACTED: On the external field of an ideal toroid with arbitrary cross
   section (Retracted article. See vol. 96, pg. 97, 2014)
SO ELECTRICAL ENGINEERING
LA English
DT Article; Retracted Publication
AB The external magnetic field of an ideal toroid with arbitrary cross section vanishes for d.c. excitation but not for a.c. excitation. The external static field has a nonvanishing vector potential; the emf in a transformer winding is due to the time variation of this vector potential. An expression for the external magnetic field is derived, and it is shown that the external flux density is a negligible fraction of the flux density in the core.
RP Ymeri, HM (reprint author), UNIV PRISHTINA, HIGHER TECH SCH, YU-38220 MITROVICE, YUGOSLAVIA.
CR GOLEMI B, 1971, BAZAT TEORIKE TE ELE
   HOFMANN H, 1974, ELECTROMAGNETISCHE F
   Jones D- S, 1964, THEORY ELECTROMAGNET
NR 3
TC 1
Z9 1
U1 2
U2 4
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0948-7921
EI 1432-0487
J9 ELECTR ENG
JI Electr. Eng.
PD FEB
PY 1997
VL 80
IS 1
BP 1
EP 4
DI 10.1007/BF01235662
PG 4
WC Engineering, Electrical & Electronic
SC Engineering
GA WL376
UT WOS:A1997WL37600001
DA 2018-12-27
ER

PT J
AU Spycher, SE
   TabatabaVakili, S
   ODonnell, VB
   Palomba, L
   Azzi, A
AF Spycher, SE
   TabatabaVakili, S
   ODonnell, VB
   Palomba, L
   Azzi, A
TI RETRACTED: Aldose reductase induction: A novel response to oxidative
   stress of smooth muscle cells (Retracted article. See vol. 26, pg. 2719,
   2012)
SO FASEB JOURNAL
LA English
DT Article; Retracted Publication
DE hydrogen peroxide; 4-hydroxynonenal; differential display; gene
   expression
ID MESSENGER-RNA EXPRESSION; HUMAN-SKIN FIBROBLASTS; HYDROGEN-PEROXIDE;
   EPITHELIAL-CELLS; FREE-RADICALS; AUTOXIDATIVE GLYCOSYLATION;
   DIFFERENTIAL DISPLAY; ARACHIDONIC-ACID; HUMAN-TISSUES; ENZYME FORMS
AB Hydrogen peroxide (H2O2) or 4-hydroxy-2,3-trans-nonenal (HNE) treatment of rat vascular smooth muscle cells (A7r5) caused induction of aldose reductase mRNA. Induction was dose (10-100 mu M H2O2, 1-10 mu M HNE) and time dependent, reaching a maximum (three- to fourfold) after 7-12 h. Treatment of cells with actinomycin D confirmed de novo synthesis of aldose reductase mRNA. H2O2-induced expression was prevented by catalase but unaffected by Desferal, indicating that metal catalyzed degradation of peroxide was not involved, Induction of enzymatically active aldose reductase by H2O2 and HNE was confirmed using Western blotting and enzyme assays, Aldose reductase can metabolize several aldehyde compounds including HNE, a major toxic product of lipid peroxidation. Inclusion of Sorbinil, an aldose reductase inhibitor, in toxicity assays resulted in a significant (twofold) enhancement of HNE-mediated killing of A7r5 cells, suggesting a protective role of aldose reductase against HNE-induced cell death, These data indicate that the induction of aldose reductase during oxidative stress might represent an important cellular antioxidant defense mechanism.
C1 UNIV URBINO, IST FARMACOL & FARMACOGNOSIA, I-61029 URBINO, ITALY.
RP Spycher, SE (reprint author), UNIV BERN, INST BIOCHEM & MOL BIOL, BUHLSTR 28, CH-3012 BERN, SWITZERLAND.
RI O'Donnell, Valerie/C-6948-2012
CR BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   CAMERON NE, 1992, DIABETOLOGIA, V35, P1011, DOI 10.1007/BF02221675
   CAMMARATA PR, 1992, INVEST OPHTH VIS SCI, V33, P3572
   CAPPIELLO M, 1994, EXP EYE RES, V58, P491, DOI 10.1006/exer.1994.1042
   CHAUDHRI G, 1986, J IMMUNOL, V137, P2646
   Crawford DR, 1996, ARCH BIOCHEM BIOPHYS, V325, P256, DOI 10.1006/abbi.1996.0032
   DELCORSO A, 1989, ARCH BIOCHEM BIOPHYS, V270, P604, DOI 10.1016/0003-9861(89)90543-2
   DELCORSO A, 1989, J BIOL CHEM, V264, P17653
   DELCORSO A, 1993, ARCH BIOCHEM BIOPHYS, V300, P430, DOI 10.1006/abbi.1993.1058
   DELCORSO A, 1987, BIOCHEM BIOPH RES CO, V148, P369, DOI 10.1016/0006-291X(87)91120-X
   ECKL PM, 1993, MUTAT RES, V290, P183, DOI 10.1016/0027-5107(93)90158-C
   FLYNN TG, 1982, METHOD ENZYMOL, V89, P501
   GABBAY KH, 1966, SCIENCE, V151, P209, DOI 10.1126/science.151.3707.209
   GRAHAM C, 1991, GENE, V107, P259, DOI 10.1016/0378-1119(91)90326-7
   Grimshaw CE, 1996, ARCH BIOCHEM BIOPHYS, V327, P89, DOI 10.1006/abbi.1996.0096
   HUNT JV, 1990, DIABETES, V39, P1420, DOI 10.2337/diabetes.39.11.1420
   JAGT DLV, 1995, BBA-PROTEIN STRUCT M, V1249, P117
   JIANG ZY, 1991, BIOCHEM PHARMACOL, V42, P1273, DOI 10.1016/0006-2952(91)90265-7
   KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0
   KEYSE SM, 1989, P NATL ACAD SCI USA, V86, P99, DOI 10.1073/pnas.86.1.99
   KEYSE SM, 1987, J BIOL CHEM, V262, P14821
   KINOSHITA JH, 1988, DIABETES METAB REV, V4, P323, DOI 10.1002/dmr.5610040403
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   LARSSON R, 1988, J BIOL CHEM, V263, P17452
   LEE AYW, 1995, P NATL ACAD SCI USA, V92, P2780, DOI 10.1073/pnas.92.7.2780
   LI Y, 1994, EUR J BIOCHEM, V226, P31, DOI 10.1111/j.1432-1033.1994.tb20023.x
   LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393
   LIANG P, 1992, CANCER RES, V52, P6966
   MARANO CW, 1992, INVEST OPHTH VIS SCI, V33, P2619
   MEARS AB, 1984, DIABETES, V33, P604
   MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x
   MITCHELL DY, 1991, HEPATOLOGY, V13, P728, DOI 10.1002/hep.1840130420
   MURRELL GAC, 1990, BIOCHEM J, V265, P659, DOI 10.1042/bj2650659
   MYLARI BL, 1991, J MED CHEM, V34, P1011, DOI 10.1021/jm00107a020
   NGUYEN T, 1994, J BIOL CHEM, V269, P13656
   NISHIMURA C, 1988, BIOCHEM BIOPH RES CO, V153, P1051, DOI 10.1016/S0006-291X(88)81335-4
   OHTAKA M, 1992, DIABETOLOGIA, V35, P730
   OWENS GK, 1981, P NATL ACAD SCI-BIOL, V78, P7759, DOI 10.1073/pnas.78.12.7759
   PRESTERA T, 1995, P NATL ACAD SCI USA, V92, P8965, DOI 10.1073/pnas.92.19.8965
   RAO GN, 1992, CIRC RES, V70, P593, DOI 10.1161/01.RES.70.3.593
   RAO GN, 1993, ONCOGENE, V8, P2759
   RAO GN, 1993, NUCLEIC ACIDS RES, V21, P1259, DOI 10.1093/nar/21.5.1259
   ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0
   ROSSI MA, 1993, INT J TISSUE REACT, V15, P201
   SHI ST, 1992, MOL CELL BIOCHEM, V115, P27
   Srivastava S, 1995, BIOCHEM BIOPH RES CO, V217, P741, DOI 10.1006/bbrc.1995.2835
   TAWATA M, 1992, LIFE SCI, V51, P719, DOI 10.1016/0024-3205(92)90480-D
   TESFAMARIAM B, 1994, FREE RADICAL BIO MED, V16, P383, DOI 10.1016/0891-5849(94)90040-X
   Ullrich O, 1996, BIOCHEM J, V315, P705, DOI 10.1042/bj3150705
   VANDERJAGT DL, 1990, J BIOL CHEM, V265, P10912
   VONWARTBURG JP, 1982, METHOD ENZYMOL, V89, P506
   WERMUTH B, 1982, METHOD ENZYMOL, V89, P181
   WESTERHAUSEN A, 1982, METHOD ENZYMOL, V89, P497
   WIESE AG, 1995, ARCH BIOCHEM BIOPHYS, V318, P231, DOI 10.1006/abbi.1995.1225
   WOLFF SP, 1991, FREE RADICAL BIO MED, V10, P339, DOI 10.1016/0891-5849(91)90040-A
   WOLFF SP, 1987, BIOCHEM J, V245, P243, DOI 10.1042/bj2450243
   YOSHIOKA T, 1994, KIDNEY INT, V46, P405, DOI 10.1038/ki.1994.288
   ZARKOVIC N, 1993, CELL BIOCHEM FUNCT, V11, P279, DOI 10.1002/cbf.290110409
   ZOR U, 1993, BIOCHEM J, V295, P879, DOI 10.1042/bj2950879
NR 59
TC 141
Z9 146
U1 1
U2 8
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
EI 1530-6860
J9 FASEB J
JI Faseb J.
PD FEB
PY 1997
VL 11
IS 2
BP 181
EP 188
PG 8
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA WK509
UT WOS:A1997WK50900011
PM 9039961
DA 2018-12-27
ER

PT J
AU Haker, E
   Theodorsson, E
   Lundeberg, T
AF Haker, E
   Theodorsson, E
   Lundeberg, T
TI RETRACTED: An experimental study of the neurogenic and the immunological
   contribution to "tennis elbow" in rats (Retracted Article. See vol 32,
   pg 278, 2009)
SO INFLAMMATION
LA English
DT Article; Retracted Publication
ID GENE-RELATED PEPTIDE; ENDOPEPTIDASE 24.11 ENKEPHALINASE; Y-LIKE
   IMMUNOREACTIVITY; JOINT SYNOVIAL-FLUID; NEUROKININ-A-LIKE;
   SUBSTANCE-P-LIKE; NEUROPEPTIDE-Y; RHEUMATOID-ARTHRITIS; KNEE-JOINT;
   CHROMATOGRAPHIC CHARACTERIZATION
AB In the present study the content of substance P (SP)-, neurokinin A (NKA)-, calcitonin gene-related peptide (CGRP)- and neuropeptide Y (NPY)-like immunoreactivity (-LI) was measured in rats cerebrospinal fluid (CSF), plasma and perfusates (PF) from both elbow enthesis during acute inflammation. Either substance P, SP, (10-5 M, 0.01 ml) or human recombinant interleukin-1 alpha (hrIl-1 alpha, 0.01 ml) were injected into the right enthesis of the extensor carpi radialis brevis (ECRB). The left ECRB and both ECRBs of control rats, were injected with 0.01 mi saline. Samples of CSF, plasma and PF from both ECRBs were obtained at 2, 6, and 24 h following injection and neuropeptide-LI was analysed by specific radioimmunoassays. Neuopeptide-LI was compared with control values and between the treated groups. in both treated groups NKA- and CGRP-LI was increased in CSF and NKA-LI decreased in plasma, while CGRP- and NPY-LI were raised to a similarly significant degree in the enthesis of the ECRB. SP-LI was increased in ECRB PF in comparison with controls and NKA-LI levels were higher in the hrIl-1 alpha group both in comparison with controls and between treated groups. In summary an unilateral injection of either SP or hrIl-1 alpha into the enthesis of the ECRB of the rat showed a similar influence at 2, 6, and 24 h following injection. The most pronounced changes in neuropeptide-LI occurred in the ECRB PF of both treated groups.
C1 KAROLINSKA INST, DEPT PHYSIOL & PHARMACOL, STOCKHOLM, SWEDEN.
   LINKOPING UNIV HOSP, DEPT CLIN CHEM, S-58185 LINKOPING, SWEDEN.
   KAROLINSKA HOSP, DEPT PHYS MED & REHABIL, STOCKHOLM, SWEDEN.
RP Haker, E (reprint author), KAROLINSKA INST, DEPT PHYS THERAPY, STOCKHOLM, SWEDEN.
OI Theodorsson, Elvar/0000-0003-0756-7723
CR BARKLEY DEH, 1990, CLIN EXP IMMUNOL, V80, P25
   BASBAUM AL, 1988, ARTHRITIC RAT MODEL
   BILEVICIUTE I, 1994, NEUROSCI LETT, V167, P145, DOI 10.1016/0304-3940(94)91048-0
   BILEVICIUTE I, 1993, NEUROSCI LETT, V153, P37, DOI 10.1016/0304-3940(93)90071-R
   BILEVICIUTE I, 1993, 7 WORLD C PAIN
   BINDER AI, 1983, BRIT J RHEUMATOL, V22, P73
   BRAIN SD, 1985, NATURE, V313, P54, DOI 10.1038/313054a0
   BRODIN E, 1986, REGUL PEPTIDES, V13, P253, DOI 10.1016/0167-0115(86)90044-3
   CASINI A, 1989, N-S ARCH PHARMACOL, V339, P354
   CHARD MD, 1994, ANN RHEUM DIS, V53, P30, DOI 10.1136/ard.53.1.30
   CODERRE TJ, 1990, NEUROSCIENCE, V34, P521, DOI 10.1016/0306-4522(90)90160-6
   CONLON PJ, 1987, J IMMUNOL, V139, P98
   DALTON BJ, 1988, ARTHRITIS RHEUM, V32, P279
   DEMUCKADELL OBS, 1986, SCAND J GASTROENTERO, V21, P498, DOI 10.3109/00365528609015169
   DINARELLO CA, 1988, DIGEST DIS SCI, V33, pS25, DOI 10.1007/BF01538128
   DONNERER J, 1991, ANN NY ACAD SCI, V632, P296, DOI 10.1111/j.1749-6632.1991.tb33117.x
   DUFF G, 1988, BIOMED PHARMACOTHER, V43, P389
   ERDOS EG, 1989, FASEB J, V3, P145
   GAMSE R, 1987, ACTA PHYSIOL HUNG, V69, P343
   GOTO M, 1987, J CLIN INVEST, V80, P786, DOI 10.1172/JCI113135
   GOWEN M, 1983, NATURE, V306, P378, DOI 10.1038/306378a0
   GULBENKIAN S, 1986, J NEUROCYTOL, V15, P535, DOI 10.1007/BF01611735
   Haker E, 1993, CRIT REV PHYS REHABI, V5, P129
   HOPE PJ, 1990, BRAIN RES, V533, P292, DOI 10.1016/0006-8993(90)91352-H
   JOHNSON WJ, 1986, ARTHRITIS RHEUM, V29, P1122, DOI 10.1002/art.1780290910
   JONAKAIT GM, 1991, ANN NY ACAD SCI, V632, P19, DOI 10.1111/j.1749-6632.1991.tb33090.x
   KIDD B L, 1991, European Journal of Rheumatology and Inflammation, V11, P46
   KIMBALL ES, 1988, J IMMUNOL, V141, P3564
   KIRKHAM B, 1991, ANN RHEUM DIS, V50, P395, DOI 10.1136/ard.50.6.395
   LARSSON J, 1989, NEUROSCI LETT, V100, P326, DOI 10.1016/0304-3940(89)90707-6
   LARSSON J, 1991, SCAND J RHEUMATOL, V20, P326, DOI 10.3109/03009749109096808
   LEMBECK F, 1979, N-S ARCH PHARMACOL, V310, P175, DOI 10.1007/BF00500282
   LEVINE JD, 1986, J NEUROSCI, V6, P3423
   LEVINE JD, 1984, SCIENCE, V226, P547, DOI 10.1126/science.6208609
   LOTZ M, 1987, SCIENCE, V235, P893, DOI 10.1126/science.2433770
   LOTZ M, 1988, SCIENCE, V241, P1218, DOI 10.1126/science.2457950
   MCCACHREN SS, 1989, ARTHRITIS RHEUM, V32, P1539, DOI 10.1002/anr.1780321207
   MCGILLIS JP, 1987, FED PROC, V46, P196
   NAWA H, 1984, NATURE, V312, P729, DOI 10.1038/312729a0
   NONG YH, 1989, J IMMUNOL, V143, P45
   NUORI AME, 1984, CLIN EXP IMMUNOL, V55, P295
   OBYRNE EM, 1990, ARTHRITIS RHEUM, V33, P1023, DOI 10.1002/art.1780330715
   PAYAN DG, 1989, HOSP PRACT, V24, P67
   PERNOW J, 1987, LIFE SCI, V40, P47, DOI 10.1016/0024-3205(87)90251-7
   PETTIPHER ER, 1986, P NATL ACAD SCI USA, V83, P8749, DOI 10.1073/pnas.83.22.8749
   PIERART ME, 1988, J IMMUNOL, V140, P3808
   SAKLATVALA J, 1980, BIOCHEM BIOPH RES CO, V96, P1225, DOI 10.1016/0006-291X(80)90082-0
   SCHAIBLE HG, 1990, BRAIN RES, V529, P214, DOI 10.1016/0006-8993(90)90830-5
   SCICCHITANO R, 1988, IMMUNOLOGY, V63, P733
   SLUKA KA, 1995, PAIN FORUM, V4, P141
   SPIEGELMAN I, 1994, ANN NY ACAD SCI, V632, P220
   STIMPSON SA, 1988, J IMMUNOL, V140, P2964
   SUZUKI H, 1989, ARTHRITIS RHEUM, V32, P1528, DOI 10.1002/anr.1780321206
   THEODORSSONNORHEIM E, 1985, BIOCHEM BIOPH RES CO, V131, P77, DOI 10.1016/0006-291X(85)91772-3
   THEODORSSONNORHEIM E, 1985, SCAND J CLIN LAB INV, V45, P355, DOI 10.3109/00365518509161019
   THEODORSSONNORHEIM E, 1987, LIFE SCI, V41, P845, DOI 10.1016/0024-3205(87)90177-9
   THEODORSSONNORHEIM E, 1984, REGUL PEPTIDES, V9, P229, DOI 10.1016/0167-0115(84)90075-2
   THOMAS D, 1992, ANN RHEUM DIS, V51, P103, DOI 10.1136/ard.51.1.103
   UMEDA Y, 1988, BIOCHEM BIOPH RES CO, V154, P227, DOI 10.1016/0006-291X(88)90674-2
   WALKER MW, 1988, J NEUROSCI, V8, P2438
   YODLOWSKI ML, 1990, J RHEUMATOL, V17, P1600
NR 61
TC 3
Z9 3
U1 0
U2 6
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0360-3997
EI 1573-2576
J9 INFLAMMATION
JI Inflammation
PD FEB
PY 1997
VL 21
IS 1
BP 35
EP 44
DI 10.1023/A:1027386724444
PG 10
WC Cell Biology; Immunology
SC Cell Biology; Immunology
GA XC494
UT WOS:A1997XC49400004
PM 9179620
DA 2018-12-27
ER

PT J
AU Kikuchi, A
   Nishikawa, T
   Yamaguchi, K
AF Kikuchi, A
   Nishikawa, T
   Yamaguchi, K
TI RETRACTED: Absence of human T-cell lymphotropic virus type I in
   cutaneous T-cell lymphoma (Retracted article. See vol 340, pg 1837,
   1999)
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Letter; Retracted Publication
ID MYCOSIS-FUNGOIDES; BLOOD
C1 KUMAMOTO UNIV, SCH MED, KUMAMOTO 860, JAPAN.
RP Kikuchi, A (reprint author), KEIO UNIV, SCH MED, TOKYO 160, JAPAN.
CR BELJAARDS RC, 1989, AM J PATHOL, V135, P1169
   EDELSON RL, 1980, J AM ACAD DERMATOL, V2, P89, DOI 10.1016/S0190-9622(80)80385-9
   HALL WW, 1991, SCIENCE, V253, P317, DOI 10.1126/science.1857968
   MANCA N, 1994, J EXP MED, V180, P1973, DOI 10.1084/jem.180.5.1973
   MANCA N, 1995, J EXP MED, V181, P441
   PANCAKE BA, 1995, J CLIN INVEST, V95, P547, DOI 10.1172/JCI117697
NR 6
TC 4
Z9 4
U1 2
U2 9
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
EI 1533-4406
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD JAN 23
PY 1997
VL 336
IS 4
BP 296
EP 297
DI 10.1056/NEJM199701233360415
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA WE632
UT WOS:A1997WE63200026
PM 9005322
DA 2018-12-27
ER

PT J
AU Hegele, RA
AF Hegele, RA
TI RETRACTED: Candidate genes, small effects, and the prediction of
   atherosclerosis (Retracted article. See vol. 49, pg. 241, 2012)
SO CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES
LA English
DT Review; Retracted Publication
DE genetics; pathology; multifactorial disease; small effects; weak effects
ID CORONARY-ARTERY DISEASE; LOW-DENSITY-LIPOPROTEIN; CHOLESTEROL-FED
   RABBITS; ACID-BINDING PROTEIN; FACTOR-VII GENOTYPE; HEART-DISEASE;
   FAMILIAL HYPERCHOLESTEROLEMIA; PLASMA-LIPOPROTEINS; INSULIN-RESISTANCE;
   ADHESION MOLECULES
AB Atherogenesis is a complex process that involves the contributions of several pathophysiological subsystems. The dissection of the genetic component of atherosclerosis has become possible using current molecular technologies and analytical methods. Genetic factors are considered to determine the limits under which atherosclerosis develops and environmental factors are considered to position an individual's risk within these limits. Atherosclerosis proceeds through a well-characterized series of pathological stages that involve key cell types and the expression of particular gene products. Reductionist experimental models have helped to produce a list of several hundred candidate genes for the study of the genetic component of atherosclerosis. Within certain families and isolated communities, the effect of a single candidate gene on atherosclerosis susceptibility may be profound, as in the case of mutations in the gene encoding the low-density lipoprotein receptor, which produce familial hypercholesterolemia and premature atherosclerosis. However, particular candidate genes have small effects on atherosclerosis, or to one of its intermediate phenotypes, in whole populations. In addition, pleiotropy and epistasis can confound the identification of the genetic component of atherosclerosis. Despite these limitations, it might still be possible to use genetic information clinically in order to classify individuals who are susceptible to atherosclerosis, especially if as-yet undiscovered candidate genes, which are found to be important determinants of disease. However, it will be impossible to predict the onset of a clinical manifestation of atherosclerosis in a particular person. This is due to the confounding influence of other forces, such as variations in interindividual environmental landscape, nonlinear interactions between genes and environment, and even the possible influence of biological chaos.
C1 UNIV TORONTO, TORONTO, ON M5B 1W8, CANADA.
RP Hegele, RA (reprint author), ST MICHAELS HOSP, DNA RES LAB, DEPT MED & CLIN BIOCHEM, 30 BOND ST, TORONTO, ON M5B 1W8, CANADA.
CR Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518
   [Anonymous], 1993, Arterioscler Thromb, V13, P1291
   BAIER LJ, 1995, J CLIN INVEST, V95, P1281, DOI 10.1172/JCI117778
   BERLINER JA, 1995, CIRCULATION, V91, P2488, DOI 10.1161/01.CIR.91.9.2488
   Bernardi F, 1996, ARTERIOSCL THROM VAS, V16, P72
   BIREDALHANSEN H, 1995, CURR OPIN CELL BIOL, V7, P728
   BLACK DD, 1995, J PEDIATR GASTR NUTR, V20, P125, DOI 10.1097/00005176-199502000-00002
   BOCAN TMA, 1986, AM J PATHOL, V123, P413
   BRESLOW JL, 1994, ANNU REV PHYSIOL, V56, P797
   Breslow JL, 1996, SCIENCE, V272, P685, DOI 10.1126/science.272.5262.685
   BRESLOW JL, 1989, METABOLIC BASIS INHE, P1251
   BROWN BG, 1993, CIRCULATION, V87, P1781, DOI 10.1161/01.CIR.87.6.1781
   BU XD, 1994, HUM GENET, V93, P639, DOI 10.1007/BF00201563
   Candipan RC, 1996, ARTERIOSCL THROM VAS, V16, P44, DOI 10.1161/01.ATV.16.1.44
   Chung E, 1996, AM J HUM GENET, V58, P363
   COHEN JC, 1994, J CLIN INVEST, V94, P2377, DOI 10.1172/JCI117603
   CONSTANTINIDES P, 1990, PATHOBIOLOGY HUMAN A, P393
   DAMMERMAN M, 1995, CIRCULATION, V91, P505, DOI 10.1161/01.CIR.91.2.505
   DAVIGNON J, 1993, AM J CARDIOL, V72, pD6, DOI 10.1016/0002-9149(93)90003-U
   DEBAKEY ME, 1978, ATHEROSCLER REV, V3, P1
   EMESON EE, 1988, AM J PATHOL, V130, P369
   EMI M, 1991, ARTERIOSCLER THROMB, V11, P1349, DOI 10.1161/01.ATV.11.5.1349
   FALKNER B, 1996, ARTERIOSCLER THROMB, V15, P1795
   FELDMAN DL, 1984, ARCH PATHOL LAB MED, V108, P817
   Frenette PS, 1996, NEW ENGL J MED, V335, P43, DOI 10.1056/NEJM199607043350108
   Frenette PS, 1996, NEW ENGL J MED, V334, P1526, DOI 10.1056/NEJM199606063342308
   FUSTER V, 1992, NEW ENGL J MED, V326, P242
   FYFE AI, 1994, J CLIN INVEST, V94, P2516, DOI 10.1172/JCI117622
   GENEST JJ, 1992, CIRCULATION, V85, P2025, DOI 10.1161/01.CIR.85.6.2025
   GERRITY RG, 1981, AM J PATHOL, V103, P181
   GOWN AM, 1986, AM J PATHOL, V125, P191
   HANSSON GK, 1991, ARTERIOSCLER THROMB, V11, P745, DOI 10.1161/01.ATV.11.3.745
   HASEMAN JK, 1970, BEHAV GENET, V1, P11, DOI 10.1007/BF01067367
   HAWIGER J, 1994, HEMOSTASIS THROMBOSI, P762
   HAYDEN MR, 1995, NAT MED, V1, P22, DOI 10.1038/nm0195-22
   HEGELE RA, 1995, ARTERIOSCL THROM VAS, V15, P861, DOI 10.1161/01.ATV.15.7.861
   HEGELE RA, 1994, CIRCULATION, V90, P2207, DOI 10.1161/01.CIR.90.5.2207
   HEGELE RA, 1991, ARTERIOSCLER THROMB, V11, P1303, DOI 10.1161/01.ATV.11.5.1303
   HEGELE RA, 1989, AM J CARDIOL, V63, P109, DOI 10.1016/0002-9149(89)91089-8
   HEGELE RA, 1995, CIRCULATION, V92, P1089, DOI 10.1161/01.CIR.92.5.1089
   HEGELE RA, 1995, ARTERIOSCL THROM VAS, V15, P89, DOI 10.1161/01.ATV.15.1.89
   HEGELE RA, 1994, ARTERIOSCLER THROMB, V14, P671, DOI 10.1161/01.ATV.14.5.671
   HOFFMAN CJ, 1994, ARTERIOSCLER THROMB, V14, P1737, DOI 10.1161/01.ATV.14.11.1737
   HOPKINS PN, 1991, ARTERIOSCLER THROMB, V11, P1137, DOI 10.1161/01.ATV.11.5.1137
   HUMPHRIES SE, 1994, ARTERIOSCLER THROMB, V14, P193, DOI 10.1161/01.ATV.14.2.193
   KU G, 1992, J BIOL CHEM, V267, P14183
   LANDER ES, 1994, SCIENCE, V265, P2037, DOI 10.1126/science.8091226
   LEWIS GF, 1995, J CLIN INVEST, V95, P158, DOI 10.1172/JCI117633
   Li WW, 1995, J CLIN INVEST, V96, P2601, DOI 10.1172/JCI118324
   Mackness MI, 1996, CURR OPIN LIPIDOL, V7, P69, DOI 10.1097/00041433-199604000-00004
   MAHANEY MC, 1995, ARTERIOSCL THROM VAS, V15, P1730, DOI 10.1161/01.ATV.15.10.1730
   MARENBERG ME, 1994, NEW ENGL J MED, V330, P1041, DOI 10.1056/NEJM199404143301503
   MCMURRAY HF, 1993, J CLIN INVEST, V92, P1004, DOI 10.1172/JCI116605
   MEADE TW, 1986, LANCET, V2, P533
   Mehrabian M, 1992, MOL GENETICS CORONAR, P363
   MITCHELL BD, 1995, DIABETES, V44, P1046, DOI 10.2337/diabetes.44.9.1046
   Mitchell BD, 1996, ARTERIOSCL THROM VAS, V16, P281, DOI 10.1161/01.ATV.16.2.281
   Mlot C, 1996, SCIENCE, V272, P1422, DOI 10.1126/science.272.5267.1422
   NORDESTGAARD BG, 1995, ARTERIOSCL THROM VAS, V15, P534, DOI 10.1161/01.ATV.15.4.534
   OWENS GK, 1995, PHYSIOL REV, V75, P487
   PEDERSEN TR, 1994, LANCET, V344, P1383
   PUFFENBERGER EG, 1994, HUM MOL GENET, V3, P1217
   PURCELLHUYNH DA, 1995, J CLIN INVEST, V96, P1845, DOI 10.1172/JCI118230
   Reaven GM, 1996, NEW ENGL J MED, V334, P374, DOI 10.1056/NEJM199602083340607
   REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595
   Reue K, 1996, J LIPID RES, V37, P1387
   ROSE G, 1964, BRIT J PREV SOC MED, V18, P75
   ROSELAAR SE, 1995, J CLIN INVEST, V96, P1389, DOI 10.1172/JCI118174
   ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0
   RUIZ J, 1995, LANCET, V346, P869, DOI 10.1016/S0140-6736(95)92709-3
   SAHA N, 1994, ARTERIOSCLER THROMB, V14, P1923, DOI 10.1161/01.ATV.14.12.1923
   SCANU AM, 1990, J CLIN INVEST, V85, P1709, DOI 10.1172/JCI114625
   Serrato M, 1995, J CLIN INVEST, V96, P3005, DOI 10.1172/JCI118373
   Simon JA, 1996, HYPERTENSION, V27, P303, DOI 10.1161/01.HYP.27.2.303
   Sing C. F., 1995, ATHEROSCLEROSIS, P638
   Stafforini DM, 1996, J CLIN INVEST, V97, P2784, DOI 10.1172/JCI118733
   STARY HC, 1992, ARTERIOSCLER THROMB, V12, P120, DOI 10.1161/01.ATV.12.1.120
   Stary HC, 1990, PATHOBIOLOGY HUMAN A, P93
   STEINBERG D, 1989, NEW ENGL J MED, V320, P915
   STRONG JP, 1992, ARCH PATHOL LAB MED, V116, P1268
   URETSKY BF, 1987, CIRCULATION, V76, P827, DOI 10.1161/01.CIR.76.4.827
   *US DEP HHS PHS, 1990, US DEP HLTH HUM SERV
   VANE JR, 1990, NEW ENGL J MED, V323, P27
   VANHOUTTE PM, 1986, ANNU REV PHYSIOL, V48, P307
   WALDEN CC, 1994, ANN INTERN MED, V120, P1026, DOI 10.7326/0003-4819-120-12-199406150-00009
   Welch CL, 1996, J LIPID RES, V37, P1406
   WILLIAMS RR, 1986, JAMA-J AM MED ASSOC, V255, P219, DOI 10.1001/jama.255.2.219
   WynshawBoris A, 1996, NAT GENET, V13, P259, DOI 10.1038/ng0796-259
   XU QB, 1993, LANCET, V341, P255, DOI 10.1016/0140-6736(93)92613-X
   YAMAMOTO H, 1988, J CLIN INVEST, V81, P1752, DOI 10.1172/JCI113516
   ZEIHER AM, 1993, J CLIN INVEST, V92, P652, DOI 10.1172/JCI116634
NR 91
TC 24
Z9 25
U1 2
U2 8
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1040-8363
EI 1549-781X
J9 CRIT REV CL LAB SCI
JI Crit. Rev. Clin. Lab. Sci.
PY 1997
VL 34
IS 4
BP 343
EP 367
DI 10.3109/10408369708998097
PG 25
WC Medical Laboratory Technology
SC Medical Laboratory Technology
GA XU644
UT WOS:A1997XU64400002
PM 9288444
DA 2018-12-27
ER

PT J
AU Sato, Y
   Honda, Y
   Asoh, T
   Kikuyama, M
   Oizumi, K
AF Sato, Y
   Honda, Y
   Asoh, T
   Kikuyama, M
   Oizumi, K
TI RETRACTED: Hypovitaminosis D and decreased bone mineral density in
   amyotrophic lateral sclerosis (Retracted article. See vol. 79, pg. 229,
   2018)
SO EUROPEAN NEUROLOGY
LA English
DT Article; Retracted Publication
DE amyotrophic lateral sclerosis; bone mineral density; vitamin-D
   deficiency; hyperparathyroidism
ID VITAMIN-D DEFICIENCY; METABOLISM; CALCIUM; OSTEOPOROSIS; POPULATION;
   MASS
AB To assess the bone health of patients with amyotrophic lateral sclerosis (ALS), we evaluated the bone density and serum biochemical indices of bone metabolism in 11 ALS patients. The serum concentration of 25-hydroxyvitamin D (25-OHD) was significantly lower in patients (14.0 +/- 3.7 ng/ml) than in controls (25.2 +/- 4.0 ng/ml), at deficient levels (<10 ng/ml) in 2, and at insufficient levels (10-20 ng/ml) in 9 patients. Serum levels of parathyroid hormone (PTH) and ionized calcium were elevated in 8 and 6 patients, respectively. Dietary intake of vitamin D was below the recommended level (100 IU) in 10 patients, and 10 patients were in a sunlight-deprived state. The metacarpal bone density (MBD) and the metacarpal index (MCI) of the second metacarpal bone were measured by computed X-ray densitometry. Z scores of the MBD and the MCI were negative in 7 and 6 patients, respectively. The serum concentration of 25-OHD was positively correlated with the Z score of the MBD (p < 0.05, r = 0.727) and negatively with the PTH level (p < 0.05, r = -0.410). The degree of dysfunction of hand grip also correlated with the Z score of the MBD (p < 0.05, r = 0.749). These data underscore the importance of hypovitaminosis D and compensatory hyperparathyroidism in the development of osteopenia in patients with ALS.
C1 TEIJIN LTD, DIAGNOST EQUIPMENT DEPT, TOKYO, JAPAN.
   KURUME UNIV, SCH MED, DEPT INTERNAL MED 1, KURUME, FUKUOKA 830, JAPAN.
RP Sato, Y (reprint author), FUTASE SOCIAL INSURANCE HOSP, DEPT NEUROL, 1234 IKAWA, IIZUKA, FUKUOKA 820, JAPAN.
CR APPEL V, 1987, ANN NEUROL, V22, P328, DOI 10.1002/ana.410220308
   BEADLE PC, 1977, BRIT J DERMATOL, V97, P585
   BENSIMON G, 1994, NEW ENGL J MED, V330, P585, DOI 10.1056/NEJM199403033300901
   CHANTRAINE A, 1986, CALCIFIED TISSUE INT, V38, P323, DOI 10.1007/BF02555744
   DEITRICK JE, 1948, AM J MED, V4, P3, DOI 10.1016/0002-9343(48)90370-2
   GANU W, 1993, ACTA NEUROL SCAND, V88, P51
   GLOTH FM, 1995, JAMA-J AM MED ASSOC, V274, P1683, DOI 10.1001/jama.274.21.1683
   INOUE T, 1994, J BONE MINER MET, V12, P145
   KOBAYASHI T, 1989, NIPPON RINSHO, V47, P608
   KOMAR L, 1993, J AM GERIATR SOC, V41, P1057, DOI 10.1111/j.1532-5415.1993.tb06452.x
   LESTER E, 1980, SCAND J CLIN LAB INV, V40, P145, DOI 10.3109/00365518009093017
   MALLETTE LE, 1977, DIS NERV SYST, V38, P457
   MASTUMOTO C, 1994, CALCIFIED TISSUE INT, V55, P324, DOI DOI 10.1007/BF00299308
   NIEVES J, 1994, NEUROLOGY, V44, P1687, DOI 10.1212/WNL.44.9.1687
   PARFITT AM, 1982, AM J CLIN NUTR, V36, P1014, DOI 10.1093/ajcn/36.5.1014
   PLAITAKIS A, 1993, BRAIN RES BULL, V30, P381, DOI 10.1016/0361-9230(93)90269-H
   ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0
   SHERMAN SS, 1990, J CLIN ENDOCR METAB, V71, P405, DOI 10.1210/jcem-71-2-405
   SINAKI M, 1989, ARCH PHYS MED REHAB, V70, P220
   SOBUE I, 1976, CALCIUM STUDIES AMYO, P83
   VILLAREAL DT, 1991, J CLIN ENDOCR METAB, V72, P628, DOI 10.1210/jcem-72-3-628
   YANAGIHARA R, 1984, ANN NEUROL, V15, P42, DOI 10.1002/ana.410150108
NR 22
TC 38
Z9 38
U1 0
U2 2
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0014-3022
EI 1421-9913
J9 EUR NEUROL
JI Eur. Neurol.
PY 1997
VL 37
IS 4
BP 225
EP 229
DI 10.1159/000117447
PG 5
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA XC035
UT WOS:A1997XC03500006
PM 9208262
OA Bronze
DA 2018-12-27
ER

PT J
AU Fujii, Y
   Tanaka, H
   Toyooka, H
AF Fujii, Y
   Tanaka, H
   Toyooka, H
TI RETRACTED: Granisetron and dexamethasone provide more improved
   prevention of postoperative emesis than granisetron alone in children
   (Retracted article. See vol. 59, pg. 1168, 2012)
SO CANADIAN JOURNAL OF ANAESTHESIA-JOURNAL CANADIEN D ANESTHESIE
LA English
DT Article; Retracted Publication
DE anaesthesia, paediatric; complications, vomiting; vomiting, antiemetics;
   granisetron, dexamethasone; surgery, strabismus repair, tonsillectomy,
   adenoidectomy
ID ONDANSETRON PLUS DEXAMETHASONE; RECEPTOR ANTAGONIST; NAUSEA;
   TONSILLECTOMY
AB Purpose: Dexamethasone decreases chemotherapy-induced emesis when added to antiemetic regimens. This study was designed to compare the effectiveness of granisetron and dexamethasone with granisetron alone in the prevention of post operative vomiting after strabismus repair, tonsillectomy with or without adenoidectomy in children.
   Methods: In a randomized double-blind study, 60 healthy children, 4-10 yr of age, received either granisetron 40 mu g . kg(-1) and saline (Group S) or granisetron 40 mu g . kg(-1) and dexamethasone 4 mg (Group D) iv immediately after the induction of anaesthesia. All subjects received anaesthetics consisting of sevoflurane and nitrous oxide in oxygen. Postoperative pain was treated with acetaminophen pr or pentazocine iv. Postoperatively, during the first 24 hr after anaesthesia, the frequencies of retching and vomiting, and the incidence of adverse events were recorded by nursing staff.
   Results: There were no differences between the treatment groups with regard to demographics, surgical procedure, anaesthetic administered or analgesics used for postoperative pain. The frequency of the symptoms was 27% and 7% in Groups S and D, respectively (P < 0.05). The incidence of adverse events was comparable in the two groups.
   Conclusion: The prophylactic administration of granisetron and dexamethasone was mole effective than granisetron alone in the prevention of postoperative vomiting in paediatric subjects undergoing strabismus repair, tonsillectomy and adenoidectomy.
C1 TORIDE KYODO GEN HOSP, DEPT ANAESTHESIOL, IBARAKI, OSAKA, JAPAN.
RP Fujii, Y (reprint author), TOKYO MED & DENT UNIV, SCH MED, DEPT ANAESTHESIOL & CRIT CARE MED, TOKYO 113, JAPAN.
CR ABRAMOWITZ MD, 1983, ANESTHESIOLOGY, V59, P579, DOI 10.1097/00000542-198312000-00021
   ANDREWS P L R, 1992, European Journal of Cancer, V28A, pS2, DOI 10.1016/0959-8049(92)90628-F
   BERMUDEZ J, 1988, BRIT J CANCER, V58, P644, DOI 10.1038/bjc.1988.277
   CARITHERS JS, 1987, LARYNGOSCOPE, V97, P422
   CARMICHAEL J, 1989, CANCER CHEMOTH PHARM, V24, P45
   Fujii Y, 1996, CAN J ANAESTH, V43, P660, DOI 10.1007/BF03017947
   Fujii Y, 1996, CAN J ANAESTH, V43, P35, DOI 10.1007/BF03015955
   FUJII Y, 1995, CAN J ANAESTH, V42, P387, DOI 10.1007/BF03015482
   LERMAN J, 1995, CAN J ANAESTH, V42, P263, DOI 10.1007/BF03010699
   LITMAN RS, 1994, ANESTH ANALG, V78, P478
   MCKENZIE R, 1994, ANESTH ANALG, V79, P961
   ROSE JB, 1994, ANESTH ANALG, V79, P486
   SMITH DB, 1991, LANCET, V338, P487, DOI 10.1016/0140-6736(91)90555-4
   Splinter WM, 1996, CAN J ANAESTH, V43, P560, DOI 10.1007/BF03011766
   SPLINTER WM, 1995, CAN J ANAESTH, V42, P848, DOI 10.1007/BF03011029
   WATCHA MF, 1992, ANESTHESIOLOGY, V77, P162, DOI 10.1097/00000542-199207000-00023
   WHITE PF, 1993, ANESTHESIOLOGY, V78, P2, DOI 10.1097/00000542-199301000-00002
NR 17
TC 26
Z9 27
U1 2
U2 11
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0832-610X
J9 CAN J ANAESTH
JI Can. J. Anaesth.-J. Can. Anesth.
PD DEC
PY 1996
VL 43
IS 12
BP 1229
EP 1232
DI 10.1007/BF03013430
PG 4
WC Anesthesiology
SC Anesthesiology
GA VW212
UT WOS:A1996VW21200008
PM 8955972
OA Bronze
DA 2018-12-27
ER

PT J
AU Ansieau, S
   Scheffrahn, I
   Mosialos, G
   Brand, H
   Duyster, J
   Kaye, K
   Harada, J
   Dougall, B
   Hubinger, G
   Kieff, E
   Herrmann, F
   Leutz, A
   Gruss, HJ
AF Ansieau, S
   Scheffrahn, I
   Mosialos, G
   Brand, H
   Duyster, J
   Kaye, K
   Harada, J
   Dougall, B
   Hubinger, G
   Kieff, E
   Herrmann, F
   Leutz, A
   Gruss, HJ
TI RETRACTED: Tumor necrosis factor receptor-associated factor (TRAF)-1,
   TRAF-2, and TRAF-3 interact in vivo with the CD30 cytoplasmic domain;
   TRAF-2 mediates CD30-induced nuclear factor kappa B activation
   (Retracted article. See vol 94, pg 12732, 1997)
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article; Retracted Publication
DE Hodgkin disease; T-cell activation; cytokine receptor; signal
   transduction; protein motif
ID GROWTH-FACTOR RECEPTOR; RING FINGER PROTEIN; RNA-POLYMERASE-II; DEATH
   DOMAIN; SIGNAL-TRANSDUCTION; T-CELLS; TYROSINE PHOSPHORYLATION; HODGKINS
   LYMPHOMA; HIV EXPRESSION; CROSS-LINKING
AB CD30 is a member of the tumor necrosis factor receptor superfamily, which can transduce signals for proliferation, death, or nuclear factor kappa B (NF-kappa B) activation. Investigation of CD30 signaling pathways using a yeast two-hybrid interaction system trapped a cDNA encoding the tumor necrosis factor receptor-associated factor (TRAF)-2 TRAF homology domain. TRAF-1 and TRAF-3 also interacted with CD30, and >90% of in vitro-translated TRAF-1 or -2, or 50% of TRAF-3, bound to the CD30 cytoplasmic domain. TRAF-1, -2, and -3 bound mostly, but not exclusively, to the carboxyl-terminal 36 residues of CD30. The binding was strongly inhibited by a CD30 oligopeptide centered around a PXQXT (where X is any amino acid) motif shared with CD40 and the Epstein-Barr virus transforming protein LMP1, indicating that this motif in CD30 is an important determinant of TRAF-1, -2 or -3 interaction. At least 15% of TRAF-1, -2, or -3 associated with CD30 when coexpressed in 293 cells. The association was not affected by CD30 cross-linking. However, cross-linking of CD30 activated NF-kappa B. NF-kappa B activation was dependent on the carboxyl-terminal 36 amino acids of CD30 that mediate TRAF association. TRAF-2 has been previously shown to have a unique role in TRAF-mediated NF-kappa B activation, and NF-kappa B activation following CD30 cross-linking was blocked by a dominant negative TRAF-2 mutant. These data indicate that CD30 cross-linking-induced NF-kappa B activation is predominantly TRAF-2-mediated.
C1 UNIV ULM, MED CTR, DEPT INTERNAL MED 3, D-89072 ULM, GERMANY.
   MAX DELBRUCK CTR MOL MED, DEPT TUMOR DEV DIFFERENTIAT, D-13125 BERLIN, GERMANY.
   HARVARD UNIV, BRIGHAM & WOMENS HOSP, SCH MED, DEPT MICROBIOL & MOL GENET, BOSTON, MA 02115 USA.
   IMMUNEX RES & DEV CORP, DEPT MOL BIOL, SEATTLE, WA 98112 USA.
RI Leutz, Achim/K-9643-2013; Ansieau, Stephane/I-6195-2016
OI Leutz, Achim/0000-0001-8259-927X; 
FU NCI NIH HHS [CA47006, R01 CA047006, R35 CA047006]
CR Amakawa R, 1996, CELL, V84, P551, DOI 10.1016/S0092-8674(00)81031-4
   Baker SJ, 1996, ONCOGENE, V12, P1
   BERBERICH I, 1994, J IMMUNOL, V153, P4357
   BERBERICH I, 1996, EMBO J, V15, P95
   BISWAS P, 1995, IMMUNITY, V2, P587
   BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795
   Bowen MA, 1996, J IMMUNOL, V156, P442
   BRACH MA, 1993, J BIOL CHEM, V268, P8466
   Bradford MM, 1976, ANAL BIOCHEM, V72, P234
   CHENG GH, 1995, SCIENCE, V267, P1494, DOI 10.1126/science.7533327
   CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3
   DEVERGNE O, 1996, IN PRESS MOL CELL BI
   DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475
   DURKOP H, 1992, CELL, V68, P421, DOI 10.1016/0092-8674(92)90180-K
   DUYSTER J, 1995, P NATL ACAD SCI USA, V92, P1555, DOI 10.1073/pnas.92.5.1555
   ELLIS TM, 1993, J IMMUNOL, V151, P2380
   FALINI B, 1995, BLOOD, V85, P1
   FARIS M, 1994, J EXP MED, V179, P1923, DOI 10.1084/jem.179.6.1923
   FEINSTEIN E, 1995, TRENDS BIOCHEM SCI, V20, P342, DOI 10.1016/S0968-0004(00)89070-2
   Franken M, 1996, J VIROL, V70, P7819
   Gedrich RW, 1996, J BIOL CHEM, V271, P12852, DOI 10.1074/jbc.271.22.12852
   GRAVESTEIN LA, 1993, EUR J IMMUNOL, V23, P943, DOI 10.1002/eji.1830230427
   GRUSS HJ, 1994, BLOOD, V83, P2045
   Gruss HJ, 1996, BLOOD, V87, P2443
   GRUSS HJ, 1995, BLOOD, V85, P3378
   GRUSS HJ, 1996, IN PRESS J IMMUNOL
   HELLER RA, 1994, J CELL BIOL, V126, P5, DOI 10.1083/jcb.126.1.5
   HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5
   HU HM, 1994, J BIOL CHEM, V269, P30069
   INUI S, 1990, EUR J IMMUNOL, V20, P1747, DOI 10.1002/eji.1830200819
   KAYE MK, 1996, P NATL ACAD SCI USA, V93, P11085
   KIEFF E, 1996, VIROLOGY, P2343
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   Lee SY, 1996, J EXP MED, V183, P669, DOI 10.1084/jem.183.2.669
   MAGGI E, 1995, IMMUNITY, V3, P251, DOI 10.1016/1074-7613(95)90094-2
   MCDONALD PP, 1995, EUR J IMMUNOL, V25, P2870, DOI 10.1002/eji.1830251024
   MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1
   REN CL, 1994, J EXP MED, V179, P673, DOI 10.1084/jem.179.2.673
   Rickinson AB, 1996, VIROLOGY, P2397
   ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915
   ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0
   SATO T, 1995, FEBS LETT, V358, P113, DOI 10.1016/0014-5793(94)01406-Q
   SCHWAB U, 1982, NATURE, V299, P65, DOI 10.1038/299065a0
   SMITH CA, 1993, CELL, V73, P1349, DOI 10.1016/0092-8674(93)90361-S
   SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7
   SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4
   SONG HY, 1995, BIOCHEM J, V309, P825, DOI 10.1042/bj3090825
   STAMENKOVIC I, 1989, EMBO J, V8, P1403, DOI 10.1002/j.1460-2075.1989.tb03521.x
   STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1
   TORRES RM, 1992, J IMMUNOL, V148, P620
   UCKUN FM, 1991, J BIOL CHEM, V266, P17478
   Ware CF, 1996, J CELL BIOCHEM, V60, P47, DOI 10.1002/(SICI)1097-4644(19960101)60:1<47::AID-JCB8>3.3.CO;2-H
   WENDTNER CM, 1995, CANCER RES, V55, P4157
NR 53
TC 64
Z9 65
U1 2
U2 13
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD NOV 26
PY 1996
VL 93
IS 24
BP 14053
EP 14058
DI 10.1073/pnas.93.24.14053
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA VV467
UT WOS:A1996VV46700107
PM 8943059
OA Bronze
DA 2018-12-27
ER

PT J
AU Aoki, N
   YamaguchiAoki, Y
   Ullrich, A
AF Aoki, N
   YamaguchiAoki, Y
   Ullrich, A
TI RETRACTED: The novel protein-tyrosine phosphatase PTP20 is a positive
   regulator of PC12 cell neuronal differentiation (Retracted Article. See
   vol 285, 32678, 2010)
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article; Retracted Publication
ID NERVE GROWTH-FACTOR; INSULIN-RECEPTOR; CDNA CLONING; SH2 DOMAIN;
   EXPRESSION; KINASES; PRODUCT; GENE; RAS
AB A novel cytoplasmic protein-tyrosine phosphatase (PTPase) designated PTP20 was isolated from a PC12 cDNA Library and shown to positively regulate the differentiation process in PC12 cells. The PTP20 open reading frame of 453 amino acids contains a single tyrosine phosphatase catalytic domain and displays closest homology to members of the PTP-PEST protein-tyrosine phosphatase family. Transient expression of PTP20 in Rat-1 cells resulted in the expression of a 50-kDa protein which exhibited PTPase activity in vitro. Expression of the 2.3-kilobase PTP20 mRNA increased during differentiation of nerve growth factor (NGF)-stimulated PC12 cells. Consistent with this observation, stable overexpression of PTP20 in PC12 cells resulted in accelerated neurite formation following NGF treatment. These findings suggest a positive regulatory role of PTP20 in NGF-dependent neuronal differentiation of PC12 cells.
C1 MAX PLANCK INST BIOCHEM, DEPT MOL BIOL, D-82152 MARTINSRIED, GERMANY.
CR CHAO MV, 1992, CELL, V68, P995, DOI 10.1016/0092-8674(92)90068-N
   CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2
   CONNOLLY JL, 1984, J CELL BIOL, V98, P457, DOI 10.1083/jcb.98.2.457
   DIKIC I, 1994, CURR BIOL, V4, P702, DOI 10.1016/S0960-9822(00)00155-X
   GREENE LA, 1982, ADV CELL NEUROBIOL, V3, P373, DOI DOI 10.1016/B978-0-12-008303-9.50016-5
   HASHIMOTO N, 1992, BIOCHEM J, V284, P569, DOI 10.1042/bj2840569
   HEMPSTEAD BL, 1994, MOL CELL BIOL, V14, P1964, DOI 10.1128/MCB.14.3.1964
   KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549
   KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y
   KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488
   KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0
   LABBE D, 1994, FEBS LETT, V356, P351, DOI 10.1016/0014-5793(94)01305-5
   LONGO FM, 1993, J BIOL CHEM, V268, P26503
   MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2396, DOI 10.1128/MCB.12.5.2396
   MEI L, 1994, J BIOL CHEM, V269, P12254
   MORIYAMA T, 1994, FEBS LETT, V353, P305, DOI 10.1016/0014-5793(94)01064-1
   MORIYAMA T, 1992, BIOCHEM BIOPH RES CO, V188, P34, DOI 10.1016/0006-291X(92)92346-Y
   NEBREDA AR, 1991, SCIENCE, V252, P558, DOI 10.1126/science.1850550
   OBERMEIER A, 1994, EMBO J, V13, P1585, DOI 10.1002/j.1460-2075.1994.tb06421.x
   PAN MG, 1993, J BIOL CHEM, V268, P19284
   Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1
   SHARMA E, 1995, J BIOL CHEM, V270, P49, DOI 10.1074/jbc.270.1.49
   TAKEKAWA M, 1992, BIOCHEM BIOPH RES CO, V189, P1223, DOI 10.1016/0006-291X(92)92335-U
   THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N
   TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8
   ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K
   WALTON KM, 1993, ANNU REV BIOCHEM, V62, P101
   WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O
   WU YY, 1993, J CELL BIOL, V121, P409, DOI 10.1083/jcb.121.2.409
   YANG Q, 1993, J BIOL CHEM, V268, P6622
   YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303
NR 31
TC 39
Z9 39
U1 1
U2 7
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD NOV 15
PY 1996
VL 271
IS 46
BP 29422
EP 29426
DI 10.1074/jbc.271.46.29422
PG 5
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA VT052
UT WOS:A1996VT05200100
PM 8910608
OA Bronze
DA 2018-12-27
ER

PT J
AU Fujii, Y
   Toyooka, H
   Tanaka, H
AF Fujii, Y
   Toyooka, H
   Tanaka, H
TI RETRACTED: Antiemetic efficacy of granisetron and metoclopramide in
   children undergoing ophthalmic or ENT surgery (Retracted article. See
   vol. 59, pg. 1169, 2012)
SO CANADIAN JOURNAL OF ANAESTHESIA-JOURNAL CANADIEN D ANESTHESIE
LA English
DT Article; Retracted Publication
DE anaesthesia, paediatric; complications, vomiting; vomiting, antiemetics;
   metoclopramide, granisetron; surgery, strabismus repair, tonsillectomy
ID STRABISMUS SURGERY; POSTOPERATIVE NAUSEA; RECEPTOR ANTAGONIST;
   GENERAL-ANESTHESIA; DROPERIDOL; PREVENTION; TONSILLECTOMY
AB Purpose: The purpose of this Study was to compare the effectiveness of granisetron, metoclopramide and placebo in reducing the frequencies of retching and vomiting in children who had undergone strabismus repair and tonsillectomy with or without adenoidectomy.
   Methods: In a randomized, double-blind study, 70 healthy subjects, 4-10 yr of age, were given a single dose of either placebo (saline, n = 24), metoclopramide 0.25 mg . kg(-1) (n = 23) granisetron 40 mu g . kg(-1) (n = 23) iv over two to five minutes after the induction of anaesthesia. All subjects received inhalation anaesthesia with sevoflurane and nitrous oxide in oxygen. Rescue antiemetics were administered if two or more episodes of vomiting occurred Acetaminophen pr or pentazocine iv was given as needed for postoperative pain. All subjects remained in hospital for two days. During the first three and the next 21 hr after anaesthesia, the frequencies of retching and vomiting were recorded by nursing staff.
   Results: There was no difference among groups with regard to demographic characteristics, surgical procedures, anaesthetics administered, postoperative managements, or adverse effects. During 0-3 hr after anaesthesia, the frequencies of retching and vomiting were: placebo 62%, metoclopramide 22% and granisetron 13% (P < 0.05). The corresponding frequencies during 3-24 hr after anaesthesia were: placebo 50%, metoclopramide 39% and granisetron 13% (P < 0.05). Four children who had received placebo and three who had received metoclopramide required another rescue antiemetic.
   Conclusion: Granisetron 40 mu g . kg(-1) is more effective than either metoclopramide or placebo in reducing the frequencies of postoperative retching and vomiting during the first 24 hr after anaesthesia in children who have undergone strabismus surgery and tonsillectomy with or without adenoidectomy.
C1 TOKYO MED & DENT UNIV, SCH MED, DEPT ANAESTHESIOL & CRIT CARE MED, BUNKYO KU, TOKYO 113, JAPAN.
   TORIDE KYODO GEN HOSP, DEPT ANAESTHESIOL, TORIDE, IBARAKI 302, JAPAN.
CR ABRAMOWITZ MD, 1983, ANESTHESIOLOGY, V59, P579, DOI 10.1097/00000542-198312000-00021
   BERMUDEZ J, 1988, BRIT J CANCER, V58, P644, DOI 10.1038/bjc.1988.277
   BROADMAN LM, 1990, ANESTHESIOLOGY, V72, P245, DOI 10.1097/00000542-199002000-00006
   CARITHERS JS, 1987, LARYNGOSCOPE, V97, P422
   CARMICHAEL J, 1989, CANCER CHEMOTH PHARM, V24, P45
   COHEN SE, 1984, ANESTHESIOLOGY, V60, P67, DOI 10.1097/00000542-198401000-00015
   DUPRE LJ, 1980, BRIT J ANAESTH, V52, P831
   FALKSON G, 1989, CANCER CHEMOTH PHARM, V24, P193, DOI 10.1007/BF00300242
   FERRARI LR, 1992, ANESTH ANALG, V75, P351
   Fujii Y, 1996, CAN J ANAESTH, V43, P660, DOI 10.1007/BF03017947
   Fujii Y, 1996, CAN J ANAESTH, V43, P35, DOI 10.1007/BF03015955
   FUJII Y, 1994, CAN J ANAESTH, V41, P291, DOI 10.1007/BF03009906
   Furue H, 1990, J CLIN THERAPEUTIC M, V6, P49
   KILPATRICK GJ, 1988, NEUROSCI LETT, V94, P156, DOI 10.1016/0304-3940(88)90287-X
   KORTTILA K, 1979, ANESTH ANALG, V58, P396
   LIN DM, 1992, ANESTHESIOLOGY, V76, P357, DOI 10.1097/00000542-199203000-00006
   MELNICK B, 1989, ANESTH ANALG, V69, P748
   PANDIT UA, 1995, ANESTH ANALG, V80, P230, DOI 10.1097/00000539-199502000-00005
   WATCHA MF, 1992, ANESTHESIOLOGY, V77, P162, DOI 10.1097/00000542-199207000-00023
NR 19
TC 16
Z9 17
U1 2
U2 8
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0832-610X
J9 CAN J ANAESTH
JI Can. J. Anaesth.-J. Can. Anesth.
PD NOV
PY 1996
VL 43
IS 11
BP 1095
EP 1099
DI 10.1007/BF03011834
PG 5
WC Anesthesiology
SC Anesthesiology
GA VR156
UT WOS:A1996VR15600003
PM 8922763
OA Bronze
DA 2018-12-27
ER

PT J
AU Datta, BK
AF Datta, BK
TI RETRACTED: Analytic solution to the Lane-Emden equation (Retracted
   article. See vol. 124, pg. 257, 2009)
SO NUOVO CIMENTO DELLA SOCIETA ITALIANA DI FISICA B-BASIC TOPICS IN PHYSICS
LA English
DT Article; Retracted Publication
AB Analytical and numerical results are reported for the solution of the Lane-Emden (LE) equation by using the delta-perturbation technique. The Pade-approximants method is used to accelerate the convergence of the power series. Comparison with some known exact results shows the accuracy of the present solution.
RP Datta, BK (reprint author), CHAKDAHA COLL, DEPT MATH, CHAKDAHA 741222, WB, INDIA.
CR Adomian G, 1994, SOLVING FRONTIER PRO
   Baker GA, 1981, PADE APPROXIMANTS 1
   BROWN N, 1988, PHYS REV D, V38, P723, DOI 10.1103/PhysRevD.38.723
   Chandrasekhar S., 1967, INTRO STUDY STELLAR
   JONES HF, TH878821 IMP COLL
   LAURENZI BJ, 1990, J MATH PHYS, V31, P2535, DOI 10.1063/1.528998
   NOVOTNY E, 1967, INTRO STELLAR ATMOSP
   SHAWAGFEH NT, 1993, J MATH PHYS, V34, P4364, DOI 10.1063/1.530005
   YOTSUYANAGI I, DPKU8809 KAN U
NR 9
TC 13
Z9 13
U1 2
U2 10
PU SOC ITALIANA FISICA
PI BOLOGNA
PA VIA SARAGOZZA, 12, I-40123 BOLOGNA, ITALY
SN 2037-4895
EI 1594-9982
J9 NUOVO CIM B
JI Nouvo Cimento Soc. Ital. Fis. B-Basic Top. Phys.
PD NOV
PY 1996
VL 111
IS 11
BP 1385
EP 1388
DI 10.1007/BF02742511
PG 4
WC Physics, Multidisciplinary
SC Physics
GA VX330
UT WOS:A1996VX33000006
DA 2018-12-27
ER

PT J
AU Yu, SM
   Tsai, SY
   Guh, JH
   Ko, FN
   Teng, CM
   Ou, JT
AF Yu, SM
   Tsai, SY
   Guh, JH
   Ko, FN
   Teng, CM
   Ou, JT
TI RETRACTED: Mechanism of catecholamine-induced proliferation of vascular
   smooth muscle cells (Retracted article. See vol 98, pg 94, 1998)
SO CIRCULATION
LA English
DT Article; Retracted Publication
DE catecholamines; muscle, smooth; proteins
ID ACTIVATED PROTEIN-KINASE; ALPHA-1-ADRENERGIC RECEPTOR SUBTYPES; RAT
   THORACIC AORTA; SIGNAL-TRANSDUCTION; ANGIOTENSIN-II; MOLECULAR-CLONING;
   DNA-SYNTHESIS; MAP KINASE; EXPRESSION; ATHEROSCLEROSIS
AB Background Catecholamines have been shown to aggravate atherosclerosis in animals and humans, and abnormal proliferation of vascular smooth muscle cells (VSMC) is a key event in the early stage of atherosclerosis. Catecholamines may be involved in such cell growth. Therefore, a series of experiments using cultured VSMC was performed to elucidate their possible mitogenic effect.
   Methods and Results We examined the mitogenic effect of catecholamines using rat aortic smooth muscle cells (VSMC) by measuring [H-3]thymidine incorporation, checking with flow cytometry, and counting the cell number directly. Furthermore, the catecholamine-activated signal transduction pathway was assessed by measurement of the formation of inositol I, 4,5-triphosphate, intracellular Ca2+ concentration, mitogen-activated protein kinase (MAPK) activity, and mitogenic gene expression. Norepinephrine (NE) and phenylephrine stimulated [H-3]thymidine incorporation and cell growth. Clonidine and isoproterenol showed little of such effects. Prazosin was more effective than either yohimbine or propranolol in suppressing the mitogenic effect of NE, indicating that catecholamine-induced VSMC proliferation is mediated by alpha(1)-adrenoceptors. The alpha(1)-adrenoceptor activation was coupled to pertussis toxin-insensitive G(q)-protein and triggered phosphoinositide hydrolysis with subsequent activation of protein kinase C and MAPK in VSMC. In response to NE, both 42- and 44-kD MAPK were activated and tyrosine was phosphorylated. alpha(1)-Adrenoceptor stimulation with NE also caused accumulation of c-fos, c-jun, and c-myc mRNA. Chloroethylclonidine completely blocked the alpha(1)-adrenoceptor-mediated mitogenesis.
   Conclusions The effect of catecholamines appears to be mediated via the activation of the chloroethylclonidine-sensitive alpha(1)-adrenoceptors that triggers the phosphoinositide hydrolysis and activates the MAPK pathway, leading to DNA synthesis and cell proliferation.
C1 CHANG GUNG COLL MED & TECHNOL, DEPT MICROBIOL & IMMUNOL, TAYUAN, TAIWAN.
   NATL TAIWAN UNIV, COLL MED, INST PHARMACOL, TAIPEI 10764, TAIWAN.
RP Yu, SM (reprint author), CHANG GUNG COLL MED & TECHNOL, CARDIOVASC SCI LAB, DEPT PHARMACOL, 259 WEN HWA 1 RD, TAYUAN, TAIWAN.
OI GUH, JIH-HWA/0000-0002-6738-6054; TENG, CHE-MING/0000-0002-9719-7334
CR BAKER SJ, 1992, MOL CELL BIOL, V12, P4694, DOI 10.1128/MCB.12.10.4694
   BHATTACHARYA SK, 1974, ATHEROSCLEROSIS, V20, P241, DOI 10.1016/0021-9150(74)90009-4
   BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889
   CHOBANIAN AV, 1994, AM J HYPERTENS, V7, pS119, DOI 10.1093/ajh/7.10.119S
   CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2
   COTECCHIA S, 1990, J BIOL CHEM, V265, P63
   DAVIS RJ, 1993, J BIOL CHEM, V268, P14553
   DIMSDALE JE, 1980, JAMA-J AM MED ASSOC, V243, P340, DOI 10.1001/jama.243.4.340
   ERICKSON AK, 1990, J BIOL CHEM, V265, P19728
   FARAMELO C, 1989, AM J PHYSIOL, V256, pF875
   FARIVAR RS, 1995, HYPERTENSION, V25, P809, DOI 10.1161/01.HYP.25.4.809
   GOLDSTEIN DS, 1981, HYPERTENSION, V3, P48, DOI 10.1161/01.HYP.3.1.48
   GRANOT Y, 1993, J BIOL CHEM, V268, P9564
   GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440
   HAN C, 1987, NATURE, V329, P333, DOI 10.1038/329333a0
   HARRISON JK, 1991, TRENDS PHARMACOL SCI, V12, P62, DOI 10.1016/0165-6147(91)90499-I
   KARIN M, 1992, FASEB J, V6, P2581
   KUKREJA RS, 1981, ATHEROSCLEROSIS, V40, P291, DOI 10.1016/0021-9150(81)90139-8
   LOMASNEY JW, 1991, J BIOL CHEM, V266, P6365
   MARTINPERE J, 1983, P NATL ACAD SCI USA, V80, P929
   MINNEMAN KP, 1988, PHARMACOL REV, V40, P87
   MINNEMAN KP, 1988, MOL PHARMACOL, V33, P509
   MORINELLI TA, 1994, J BIOL CHEM, V269, P5693
   MORROW AL, 1986, MOL PHARMACOL, V29, P321
   NAKAKI T, 1990, MOL PHARMACOL, V37, P30
   NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J
   OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376
   OKAZAKI M, 1994, J CLIN INVEST, V94, P210, DOI 10.1172/JCI117309
   OMALLEY MK, 1989, BRIT J SURG, V76, P936, DOI 10.1002/bjs.1800760921
   PEREZ DM, 1991, MOL PHARMACOL, V40, P876
   POUYSSEGUR J, 1992, ANNU REV PHYSIOL, V54, P195, DOI 10.1146/annurev.ph.54.030192.001211
   ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806
   SCHORB W, 1993, CIRC RES, V72, P1245, DOI 10.1161/01.RES.72.6.1245
   SCHWINN DA, 1990, J BIOL CHEM, V265, P8183
   SETH A, 1992, J BIOL CHEM, V267, P24796
   SIMONSON MS, 1989, J CLIN INVEST, V83, P708, DOI 10.1172/JCI113935
   THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M
   TOBE K, 1991, J BIOL CHEM, V266, P24793
   VANKLEEF EM, 1992, CIRC RES, V70, P1122, DOI 10.1161/01.RES.70.6.1122
   YAMORI Y, 1987, CIRCULATION, V75, P92
   YU SM, 1995, BRIT J PHARMACOL, V114, P1227, DOI 10.1111/j.1476-5381.1995.tb13337.x
   YU SM, 1990, EUR J PHARMACOL, V187, P39
NR 42
TC 81
Z9 89
U1 2
U2 12
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0009-7322
EI 1524-4539
J9 CIRCULATION
JI Circulation
PD AUG 1
PY 1996
VL 94
IS 3
BP 547
EP 554
DI 10.1161/01.CIR.94.3.547
PG 8
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA UZ051
UT WOS:A1996UZ05100046
PM 8759101
DA 2018-12-27
ER

PT J
AU Fujii, Y
   Toyooka, H
   Tanaka, H
AF Fujii, Y
   Toyooka, H
   Tanaka, H
TI RETRACTED: Effective dose of granisetron for preventing postoperative
   emesis in children (Retracted article. See vol. 59, pg. 1170, 2012)
SO CANADIAN JOURNAL OF ANAESTHESIA-JOURNAL CANADIEN D ANESTHESIE
LA English
DT Article; Retracted Publication
DE complications, retching, vomiting; vomiting, antiemetics, granisetron;
   surgery, paediatric, strabismus repair, tonsillectomy
ID RECEPTOR ANTAGONIST; DROPERIDOL; SURGERY; NAUSEA
AB Purpose: This study Was to identify the minimum effective dose of granisetron, a selective 5-hydroxytryptamine type 3 receptor antagonist, to prevent postoperative vomiting in chil dren who have undergone strabismus repair, tonsillectomy or tonsillectomy with adenoidectomy.
   Methods: in a randomized double-blind fashion, 80 healthy children aged 4-10 yr were assigned to receive either placebo (saline) or granisetron in a dose of 20 40 or SO mu g . kg(-1) iv immediately following the induction of anaesthesia. All subjects received a standardized anaesthetic, which consisted of sevoflurane in nitrous oxide and oxygen. Rescue antiemetics were administered if two or more episodes of vomiting occurred. Postoperative pain was treated with acetaminophene pr or pentazocine iv, During the first 24 hr after anaesthesia, the frequencies of retching and vomiting were recorded in a standardized fashion by nursing staff while subjects were in a hospital.
   Results: There were no differences among four treatment groups With regard to subject characteristics, surgical procedures, anaesthetic and postoperative management or adverse effects. The frequencies of these symptoms Were as follows: 65%, 60%, 20% and 15% after administration of placebo, granisetron 20, 40 or 80 mu g . kg(-1). Three children who had received either placebo or granisetron 20 mu g . kg(-1) required another rescue antiemetic drug, whereas none who had received granisetron 40 or SO mu g . kg(-1) needed rescue drugs.
   Conclusion: Granisetron 40 mu g . kg(-1) is an effective antiemetic Sor preventing retching and vomiting following strabismus repair and tonsillectomy in children. Increasing the dose to 80 mu g . kg(-1) provided no demonstrable benefit in reducing postoperative emesis.
C1 TOKYO MED & DENT UNIV, SCH MED, DEPT ANAESTHESIOL & CRIT CARE MED, BUNKYO KU, TOKYO 113, JAPAN.
   TORIDE KYODO GEN HOSP, DEPT ANAESTHESIOL, IBARAKI, OSAKA 302, JAPAN.
CR ABRAMOWITZ MD, 1983, ANESTHESIOLOGY, V59, P579, DOI 10.1097/00000542-198312000-00021
   BERMUDEZ J, 1988, BRIT J CANCER, V58, P644, DOI 10.1038/bjc.1988.277
   CARITHERS JS, 1987, LARYNGOSCOPE, V97, P422
   CARMICHAEL J, 1989, CANCER CHEMOTH PHARM, V24, P45
   DUPRE LJ, 1980, BRIT J ANAESTH, V52, P831
   FALKSON G, 1989, CANCER CHEMOTH PHARM, V24, P193, DOI 10.1007/BF00300242
   Fujii Y, 1996, CAN J ANAESTH, V43, P35, DOI 10.1007/BF03015955
   FUJII Y, 1994, CAN J ANAESTH, V41, P794, DOI 10.1007/BF03011585
   FUJII Y, 1994, CAN J ANAESTH, V41, P291, DOI 10.1007/BF03009906
   Furue H, 1990, J CLIN THERAPEUTIC M, V6, P49
   LERMAN J, 1995, CAN J ANAESTH, V42, P263, DOI 10.1007/BF03010699
   LEUNG AKC, 1984, CURR THER RES CLIN E, V36, P911
   PANDIT UA, 1995, ANESTH ANALG, V80, P230, DOI 10.1097/00000539-199502000-00005
   WATCHA MF, 1992, ANESTHESIOLOGY, V77, P162, DOI 10.1097/00000542-199207000-00023
   WHITE PF, 1993, ANESTHESIOLOGY, V78, P2, DOI 10.1097/00000542-199301000-00002
NR 15
TC 26
Z9 26
U1 2
U2 9
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0832-610X
J9 CAN J ANAESTH
JI Can. J. Anaesth.-J. Can. Anesth.
PD JUL
PY 1996
VL 43
IS 7
BP 660
EP 664
DI 10.1007/BF03017947
PG 5
WC Anesthesiology
SC Anesthesiology
GA UU214
UT WOS:A1996UU21400003
PM 8807169
OA Bronze
DA 2018-12-27
ER

PT J
AU Cao, YZ
   Qin, LM
   Zhang, LQ
   Safrit, J
   Ho, DD
AF Cao, YZ
   Qin, LM
   Zhang, LQ
   Safrit, J
   Ho, DD
TI RETRACTED: Characterization of long-term survivors of human
   immunodeficiency virus type 1 infection (Retracted article. See vol 64,
   U5, 1998)
SO IMMUNOLOGY LETTERS
LA English
DT Article; Proceedings Paper; Retracted Publication
CT 1st International Summit on Immunological Correlates of Protection from
   HIV Infection and Disease
CY 1995
CL LE MT PELERIN, SWITZERLAND
SP EC Centralized Facil Preclin HIV 1 Vaccine Dev
DE HIV-1; long-term survivors; viral load; neutralizing antibody; CD8
   lymphocytes
ID HIV-1 INFECTION; MONONUCLEAR-CELLS; HOMOSEXUAL MEN; MESSENGER-RNA;
   T-LYMPHOCYTES; BISEXUAL MEN; REPLICATION; AIDS; INDIVIDUALS; PROGRESSION
AB A small population of HIV-l-infected individuals remains clinically healthy and immunologically normal for more than ten years. We have studied ten subjects who have been asymptomatic with normal and stable CD4(+) lymphocyte counts, despite 12 to 16 years of HIV-l infection, to gain information on the determinants of nonprogression. Multiple methods were used to determine the viral load in their blood. Plasma cultures were uniformly negative for infectious virus. However, particle-associated HIV-1 RNA was detectable in four subjects using a sensitive branched DNA amplification assay. In peripheral blood mononuclear cells (PBMC), infectious HIV-I was quantified in three subjects using a standard limiting-dilution culture method. Infectious virus was recovered from another subject using a CD8-depleted culture. In contrast, six subjects had no detectable infectious virus in PBMC. All had detectable viral DNA in PBMC by a quantitative polymerase chain reaction assay, but the copy numbers were low; ranging from 10 to 100 copies per 10(6) PBMC in all but two subjects. Overall, the viral burden in the plasma and PBMC of long-term survivors was orders of magnitude lower than those typically found in progressors. Possible mechanisms for low levels of HIV-1 in vivo were examined experimentally.
C1 NYU, SCH MED, AARON DIAMOND AIDS RES CTR, NEW YORK, NY 10016 USA.
FU NIAID NIH HHS [AI25541, AI32427, AI24030]
CR BAGASRA O, 1992, NEW ENGL J MED, V326, P1385, DOI 10.1056/NEJM199205213262103
   BUCHBINDER SP, 1994, AIDS, V8, P1123, DOI 10.1097/00002030-199408000-00014
   CAO YZ, 1995, AIDS RES HUM RETROV, V11, P353, DOI 10.1089/aid.1995.11.353
   COHEN J, 1993, SCIENCE, V262, P980, DOI 10.1126/science.8235635
   CONNOR RI, 1993, J VIROL, V67, P1772
   DAAR ES, 1991, NEW ENGL J MED, V324, P961, DOI 10.1056/NEJM199104043241405
   EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0
   FULTZ T, 1995, 2 NAT C HUM RETR REL
   GRAZIOSI C, 1994, 10 INT C AIDS YOK JA
   GREENOUGH TC, 1994, AIDS RES HUM RETROV, V10, P395, DOI 10.1089/aid.1994.10.395
   HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401
   HUANG Y, IN PRESS J VIROL
   JASON J, 1989, JAMA-J AM MED ASSOC, V261, P725, DOI 10.1001/jama.261.5.725
   JASSOY C, 1993, J VIROL, V67, P2844
   KANNAGI M, 1988, J IMMUNOL, V140, P2237
   KEET IPM, 1994, J INFECT DIS, V169, P1236, DOI 10.1093/infdis/169.6.1236
   KESTLER HW, 1991, CELL, V65, P651, DOI 10.1016/0092-8674(91)90097-I
   KOYANAGI Y, 1987, SCIENCE, V236, P819, DOI 10.1126/science.3646751
   LEARMONT J, 1992, LANCET, V340, P863, DOI 10.1016/0140-6736(92)93281-Q
   LIFSON AR, 1991, J INFECT DIS, V163, P959, DOI 10.1093/infdis/163.5.959
   LIFSON AR, 1988, J INFECT DIS, V158, P1360, DOI 10.1093/infdis/158.6.1360
   MICHAEL NL, 1992, J VIROL, V66, P310
   MUNOZ A, 1989, AM J EPIDEMIOL, V130, P530, DOI 10.1093/oxfordjournals.aje.a115367
   PACHL C, 1995, J ACQ IMMUN DEF SYND, V8, P446, DOI 10.1097/00042560-199504120-00003
   PANTALEO G, 1993, NEW ENGL J MED, V328, P327
   Pantaleo G., 1993, NATURE, V362, P335
   PATTERSON BK, 1993, SCIENCE, V260, P976, DOI 10.1126/science.8493534
   PIATAK M, 1993, SCIENCE, V259, P1749, DOI 10.1126/science.8096089
   RUTHERFORD GW, 1990, BRIT MED J, V301, P1183, DOI 10.1136/bmj.301.6762.1183
   SCHRAGER LK, 1994, AIDS S1, V8, pS95
   SHEPPARD HW, 1993, AIDS, V7, P1159, DOI 10.1097/00002030-199309000-00002
   SIMMONDS P, 1990, J VIROL, V64, P864
   SPIRA AI, UNPUB J VIROL
   WALKER CM, 1991, CELL IMMUNOL, V137, P420, DOI 10.1016/0008-8749(91)90090-X
   WALKER CM, 1986, SCIENCE, V234, P1563, DOI 10.1126/science.2431484
   WALKER CM, 1991, J VIROL, V65, P5921
   WILLIAMS LM, 1991, VIROLOGY, V184, P723, DOI 10.1016/0042-6822(91)90442-E
NR 37
TC 16
Z9 16
U1 2
U2 9
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0165-2478
J9 IMMUNOL LETT
JI Immunol. Lett.
PD JUN
PY 1996
VL 51
IS 1-2
BP 7
EP 13
DI 10.1016/0165-2478(96)02548-5
PG 7
WC Immunology
SC Immunology
GA UW653
UT WOS:A1996UW65300003
PM 8811338
DA 2018-12-27
ER

PT J
AU Baker, RJ
   VanDenBussche, RA
   Wright, AJ
   Wiggins, LE
   Hamilton, MJ
   Reat, EP
   Smith, MH
   Lomakin, MD
   Chesser, RK
AF Baker, RJ
   VanDenBussche, RA
   Wright, AJ
   Wiggins, LE
   Hamilton, MJ
   Reat, EP
   Smith, MH
   Lomakin, MD
   Chesser, RK
TI RETRACTED: High levels of genetic change in rodents of Chernobyl
   (Retracted article. See vol 390, pg 100, 1997)
SO NATURE
LA English
DT Article; Retracted Publication
ID MUTATIONS
AB BASE-PAIR substitution rates for the mitochondrial cytochrome b gene of free-living, native populations of voles collected next to reactor 4 at Chernobyl, Ukraine, were estimated by two independent methods to be in excess of 10(-4) nucleotides per site per generation. These estimates are hundreds of times greater than those typically found in mitochondria of vertebrates, suggesting that the environment resulting from this nuclear power plant disaster is having a measurable genetic impact on the organisms of that region. Despite these DNA changes, vole populations thrive and reproduce in the radioactive regions around the Chernobyl reactor.
C1 SAVANNAH RIVER ECOL LAB, AIKEN, SC 29802 USA.
   INT RES & DEV AGCY, KIEV 252001, UKRAINE.
RP Baker, RJ (reprint author), TEXAS TECH UNIV, DEPT BIOL SCI, LUBBOCK, TX 79409 USA.
CR Baker RJ, 1996, J MAMMAL, V77, P155, DOI 10.2307/1382717
   BAKER RJ, 1994, J MAMMAL, V75, P321, DOI 10.2307/1382550
   *BROOKH NAT LAB, 1961, FUND ASP RAD
   HOLLAENDER A, 1954, RAD BIOL, V1
   IRWIN DM, 1991, J MOL EVOL, V32, P128, DOI 10.1007/BF02515385
   KIMURA M, 1973, GENETICS, V73, P19
   LI WH, 1991, FUNDAMENTALS MOL EVO, P67
   LONGMIRE JL, 1992, AUK, V109, P522
   MADDISON WP, 1992, ANAL PHYLOGENY CHARA
   MEDVEDEV Z, 1990, LEGACY CHEMOBYL, P74
   Mourad R., 1987, Transactions of the American Nuclear Society, V54, P226
   Neel J. V., 1991, CHILDREN ATOMIC BOMB
   NEEL JV, 1986, P NATL ACAD SCI USA, V83, P389, DOI 10.1073/pnas.83.2.389
   POWERS DA, 1987, NUCL SAFETY, V28, P10
   SAVCHENKO VK, 1995, ECOLOGY CHEM CATASTR
   Schull WJ, 1995, EFFECTS ATOMIC RAD H
   SICH AR, 1994, NUCL SAFETY, V35, P1
   SMITH MF, 1991, MOL BIOL EVOL, V8, P85
   SOMMER SS, 1992, FASEB J, V6, P2767
   STAMATOYANNOPOULOS G, 1982, HUM GENET, V60, P181, DOI 10.1007/BF00569709
   SUGG DW, 1995, ENVIRON TOXICOL CHEM, V14, P661, DOI 10.1897/1552-8618(1995)14[661:TAODDT]2.0.CO;2
   SWOFFORD DL, 1991, PAUP PHYLOGENETIC AN
   VOGEL F, 1986, HUMAN GENETICS PROBL, P433
   WETTSTEIN PJ, 1995, MOL PHYLOGENET EVOL, V4, P150, DOI 10.1006/mpev.1995.1015
NR 24
TC 51
Z9 54
U1 3
U2 17
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
EI 1476-4687
J9 NATURE
JI Nature
PD APR 25
PY 1996
VL 380
IS 6576
BP 707
EP 708
PG 2
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA UG827
UT WOS:A1996UG82700049
PM 8614463
DA 2018-12-27
ER

PT J
AU Gruss, HJ
   Ulrich, D
   Dower, SK
   Herrmann, F
   Brach, MA
AF Gruss, HJ
   Ulrich, D
   Dower, SK
   Herrmann, F
   Brach, MA
TI RETRACTED: Activation of Hodgkin cells via the CD30 receptor induces
   autocrine secretion of interleukin-6 engaging the NF-kappa B
   transcription factor (Retracted article. See vol 93, pg 3573, 1999)
SO BLOOD
LA English
DT Article; Retracted Publication
ID REED-STERNBERG CELLS; TUMOR-NECROSIS-FACTOR; MONOCLONAL-ANTIBODY;
   LYMPHOID-CELLS; SERUM LEVELS; DISEASE; EXPRESSION; ANTIGEN; GENE;
   MOLECULE
AB The CD30 surface molecule is a recently identified member of the tumor necrosis factor/nerve growth factor receptor superfamily. Within the cytoplasmic signal transducing domain. CD30 shares no significant homology to other members of this family. Signaling events engaged via CD30 are still unknown. We here identify the NF-kappa B transcription factor as a target of the CD30-induced signal pathway in Hodgkin's disease (HD) cells. Exposure of HD cells to CD30 ligand induces release of interleukin-l (IL-6) that can be duplicated by cross-linking HD-cells to an agonistic anti-CD30 specific monoclonal antibody (alpha CD30). but not by cross-linking to an isotype-identical irrelevant monoclonal antibody. Crosslinking of HD cells to alpha CD30 leads to enhanced accumulation of IL-6 mRNA in a time-dependent fashion resulting from transcriptional activation of the IL-6 promoter. Transient transfection assays using a series of deleted IL-6 promoter constructs linked to the human growth hormone gene as a reporter gene furthermore indicate that transcriptional activation of the IL-6 promoter requires the presence of an intact NF-kappa B binding site. In addition. introduction of an NF-kappa B binding site appeared to be sufficient to confer inducibility of a heterologous promoter on activation of CD30 in HD cells. Cross-linking of CD30 promotes rapid and transient binding activity of nuclear proteins to the NF-kappa B recognition site of the IL-6 promoter. Supershift experiments using a series of monoclonal antibodies recognizing distinct members of the NF-kappa B transcription factor family furthermore indicate that in CD30 cross-linked HD cells p50. p65/Rel-A. and Rel-B are present. whereas the c-rel protein is not. (C) 1996 by The American Society of Hematology.
C1 MAX DELBRUCK CTR MOLEC MED, BERLIN, GERMANY.
   IMMUNEX RES & DEV CORP, DEPT BIOCHEM, SEATTLE, WA 98101 USA.
   IMMUNEX RES & DEV CORP, DEPT CELLULAR IMMUNOL, SEATTLE, WA 98101 USA.
RP Gruss, HJ (reprint author), HUMBOLDT UNIV BERLIN, VIRCHOW KLINIKUM, ABT MED ONKOL & ANGEWANDTE MOLEK BIOL, LINDENBERGER WEG 80, D-13122 BERLIN, GERMANY.
CR BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141
   BRACH MA, 1993, J BIOL CHEM, V268, P8466
   CHENG GH, 1995, SCIENCE, V267, P1494, DOI 10.1126/science.7533327
   DELABIE J, 1993, BLOOD, V82, P2845
   DREXLER HG, 1992, LEUKEMIA LYMPHOMA, V8, P283, DOI 10.3109/10428199209051008
   DURKOP H, 1992, CELL, V68, P421, DOI 10.1016/0092-8674(92)90180-K
   FALINI B, BLOOD, V85, P1005
   FOSS HD, 1993, BRIT J HAEMATOL, V84, P627, DOI 10.1111/j.1365-2141.1993.tb03138.x
   GAUSE A, 1991, BLOOD, V77, P1983
   GAUSE A, 1991, HEMATOL ONCOL, V9, P307
   GRUSS HJ, 1993, LEUKEMIA, V7, P1339
   GRUSS HJ, 1994, BLOOD, V83, P2045
   GRUSS HJ, 1992, BLOOD, V80, P2563
   GRUSS HJ, 1995, EUR J IMMUNOL, V25, P2083, DOI 10.1002/eji.1830250742
   GRUSS HJ, 1995, BLOOD, V85, P3378
   GRUSS HJ, 1992, CANCER RES, V52, P3353
   GRUSS HJ, 1994, ONCOGENESIS, V5, P23
   GRUSS HJ, 1995, LEUKEMIA LYMPHOMA, V18, P179
   GRUSS HJ, IN PRESS J IMMUNOL
   HECHT TT, 1985, J IMMUNOL, V134, P4231
   HERBST H, 1993, CRIT REV ONCOGENESIS, V4, P191
   HU HM, 1994, J BIOL CHEM, V269, P30069
   ISSHIKI H, 1990, MOL CELL BIOL, V10, P2757, DOI 10.1128/MCB.10.6.2757
   JUCKER M, 1991, BLOOD, V77, P2413
   KURZROCK R, 1993, CANCER RES, V53, P2118
   LIBERMANN TA, 1990, MOL CELL BIOL, V10, P2327, DOI 10.1128/MCB.10.5.2327
   MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1
   MUNRO JM, 1994, BLOOD, V83, P793
   NADALI G, 1994, J CLIN ONCOL, V12, P793, DOI 10.1200/JCO.1994.12.4.793
   PFREUNDSCHUH M, 1990, INT J CANCER, V45, P869, DOI 10.1002/ijc.2910450515
   PIZZOLO G, 1990, BRIT J HAEMATOL, V75, P282, DOI 10.1111/j.1365-2141.1990.tb02664.x
   ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915
   ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0
   RUCO LP, 1992, AM J PATHOL, V140, P1337
   SCHWAB U, 1982, NATURE, V299, P65, DOI 10.1038/299065a0
   SCHWARTING R, 1989, BLOOD, V74, P1678
   SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8
   SMITH CA, 1993, CELL, V73, P1349, DOI 10.1016/0092-8674(93)90361-S
   SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7
   STEIN H, 1985, BLOOD, V66, P848
   TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2
   TESCH H, 1992, LEUKEMIA LYMPHOMA, V7, P297, DOI 10.3109/10428199209049781
   WEIH F, 1995, CELL, V80, P331, DOI 10.1016/0092-8674(95)90416-6
   WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5
NR 44
TC 54
Z9 54
U1 0
U2 6
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD MAR 15
PY 1996
VL 87
IS 6
BP 2443
EP 2449
PG 7
WC Hematology
SC Hematology
GA UA957
UT WOS:A1996UA95700038
PM 8630409
DA 2018-12-27
ER

PT J
AU Attwood, GT
   Herrera, F
   Weissenstein, LA
   White, BA
AF Attwood, GT
   Herrera, F
   Weissenstein, LA
   White, BA
TI RETRACTED: An endo-beta-1,4-glucanase gene (celA) from the rumen
   anaerobe Ruminococcus albus 8: Cloning, sequencing, and transcriptional
   analysis (Retracted article. See vol 44, pg 312, 1998)
SO CANADIAN JOURNAL OF MICROBIOLOGY
LA English
DT Article; Retracted Publication
DE Ruminococcus albus; endoglucanase; transcription; hydrophobic cluster
   analysis
ID HYDROPHOBIC CLUSTER-ANALYSIS; BETA-GLUCOSIDASE GENE; MOLECULAR-CLONING;
   ESCHERICHIA-COLI; CELLULASE GENE; DNA-SEQUENCE; FLAVEFACIENS;
   EXPRESSION; PURIFICATION; FAMILIES
AB A genomic library of Ruminococcus albus 8 DNA was constructed in Escherichia toll using bacteriophage lambda ZapII. This library was screened for cellulase components and several Ostazin brilliant red/carboxymethyl cellulose positive clones were isolated. All of these clones contained a common 3.4-kb insert, which was recovered as a plasmid by helper phage excision. The carboxymethyl cellulase coding region was localized to a 1.4-kb region of DNA by nested deletions, and a clone containing the entire celA gene was sequenced. Analysis of the sequence revealed a 1231-bp open reading frame, coding for a protein of 411 amino acids with a predicted molecular weight of 45 747. This protein, designated CelA, showed extensive homology with family 5 endoglucanases by both primary amino acid sequence alignment and hydrophobic cluster analysis. Cell-free extracts of E. coli containing the celA clone demonstrated activity against carboxymethyl cellulose and acid swollen cellulose but not against any of the p-nitrophenol glycosides tested, indicating an endo-beta-1,4-glucanase type of activity. In vitro transcription-translation experiments showed that three proteins of 48 000, 44 000, and 23 000 molecular weight were produced by clones containing the celA gene. Northern analysis of RNA extracted from R, albus 8 grown on cellulose indicated a celA transcript of approximately 2700 bases, whereas when R. albus 8 was grown on cellobiose, celA transcripts of approximately 3000 and 600 bases were detected. Primer extension analysis of these RNAs revealed different transcription initiation sites for the celA gene when cells were grown with cellulose or cellobiose as the carbon source. These two sites differed by 370 bases in distance. A model, based on transcription and sequence data, is proposed for celA regulation.
C1 UNIV ILLINOIS, DEPT ANIM SCI, URBANA, IL 61801 USA.
CR BELAICH A, 1992, J BACTERIOL, V174, P4677
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   CHAMPION KM, 1988, CAN J MICROBIOL, V34, P1109, DOI 10.1139/m88-196
   CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2
   CUNNINGHAM C, 1991, MOL GEN GENET, V228, P320
   DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387
   GABORIAUD C, 1987, FEBS LETT, V224, P149, DOI 10.1016/0014-5793(87)80439-8
   GARDNER RM, 1987, J BACTERIOL, V169, P4581, DOI 10.1128/jb.169.10.4581-4588.1987
   HENRISSAT B, 1989, GENE, V81, P83, DOI 10.1016/0378-1119(89)90339-9
   HENRISSAT B, 1993, BIOCHEM J, V293, P781, DOI 10.1042/bj2930781
   HONDA H, 1988, ENZYME MICROB TECH, V10, P559, DOI 10.1016/0141-0229(88)90050-6
   HOWARD GT, 1988, APPL ENVIRON MICROB, V54, P1752
   KARITA S, 1993, J FERMENT BIOENG, V76, P439, DOI 10.1016/0922-338X(93)90237-3
   KAWAI S, 1987, AGR BIOL CHEM TOKYO, V51, P59, DOI 10.1080/00021369.1987.10867974
   LEMESLEVARLOOT L, 1990, BIOCHIMIE, V72, P555, DOI 10.1016/0300-9084(90)90120-6
   Maniatis T, 1982, MOL CLONING
   MARMUR J, 1961, J MOL BIOL, V3, P208, DOI 10.1016/S0022-2836(61)80047-8
   OHMIYA K, 1987, CARBOHYD RES, V166, P145, DOI 10.1016/0008-6215(87)80051-4
   OHMIYA K, 1989, J BACTERIOL, V171, P6771, DOI 10.1128/jb.171.12.6771-6775.1989
   OHMIYA K, 1988, APPL ENVIRON MICROB, V54, P1511
   OHMIYA K, 1985, J BACTERIOL, V161, P432
   OHMIYA K, 1990, NUCLEIC ACIDS RES, V18, P671, DOI 10.1093/nar/18.3.671
   POOLE DM, 1990, MOL GEN GENET, V223, P217
   QUIOCHO FA, 1986, ANNU REV BIOCHEM, V55, P287, DOI 10.1146/annurev.bi.55.070186.001443
   ROMANIEC MPM, 1989, LETT APPL MICROBIOL, V9, P101, DOI 10.1111/j.1472-765X.1989.tb00300.x
   SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463
   SEIDMAN CE, 1987, CURRENT PROTOCOLS MO
   TAKANO M, 1992, J FERMENT BIOENG, V73, P79, DOI 10.1016/0922-338X(92)90293-4
   TEATHER RM, 1982, APPL ENVIRON MICROB, V43, P777
   TRIEZENBERG SJ, 1992, CURRENT PROTOCOLS MO
   VERCOE PE, 1992, MOL GEN GENET, V233, P284, DOI 10.1007/BF00587590
   Vercoe PE, 1995, ANIM BIOTECHNOL, V6, P59, DOI 10.1080/10495399509525833
   WARE CE, 1989, J GEN MICROBIOL, V135, P921
   WARE CE, 1990, BIOCHEM BIOPH RES CO, V171, P777, DOI 10.1016/0006-291X(90)91214-D
   WATSON MEE, 1984, NUCLEIC ACIDS RES, V12, P5145, DOI 10.1093/nar/12.13.5145
   WHITE BA, 1991, RECENT ADV NUTR HERB, P217
NR 36
TC 9
Z9 9
U1 2
U2 7
PU CANADIAN SCIENCE PUBLISHING, NRC RESEARCH PRESS
PI OTTAWA
PA 65 AURIGA DR, SUITE 203, OTTAWA, ON K2E 7W6, CANADA
SN 0008-4166
EI 1480-3275
J9 CAN J MICROBIOL
JI Can. J. Microbiol.
PD MAR
PY 1996
VL 42
IS 3
BP 267
EP 278
DI 10.1139/m96-039
PG 12
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Immunology; Microbiology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Immunology; Microbiology
GA UA822
UT WOS:A1996UA82200008
PM 8868234
DA 2018-12-27
ER

PT J
AU Cin, VG
   Gok, H
   Kaptanoglu, B
AF Cin, VG
   Gok, H
   Kaptanoglu, B
TI RETRACTED: The prognostic value of serum troponin T in unstable angina
   (Retracted Article. See vol 145, pg E81, 2010)
SO INTERNATIONAL JOURNAL OF CARDIOLOGY
LA English
DT Article; Retracted Publication
DE troponin T; unstable angina
ID ACUTE MYOCARDIAL-INFARCTION; KINASE ISOENZYME-MB; CREATINE-KINASE;
   SKELETAL-MUSCLE; IDENTIFICATION; DEATH; IMMUNOASSAY; THROMBOSIS
AB Background: Cardiac troponin T is a regulatory contractile protein not normally found in blood. Its detection in the circulation has been shown to be a sensitive and specific marker for; myocardial cell damage. We used a newly developed enzyme immunoassay fbr troponin T to determine whether its presence in the serum of patients with unstable angina was a prognostic indicator. Methods: We screened 72 patients with unstable angina (Class III, acute unstable angina) for serum creatine kinase activity, creatine kinase myocardial band (isoenzyme M) activity, and troponin T, every 8 h for 2 days after admission to the hospital. The outcomes of interest during the hospitalization were death and myocardial infarction. Results: Troponin T was detected in the serum of 24 of the 72 patients (34%) with acute angina at rest. Only four of these patients had elevated creatine kinase M activity. Of the 24 patients who were positive for troponin T, 12 had myocardial infarction, and 6 of these died during hospitalization. In contrast, only 2 of the 48 patients with angina at rest who were negative for troponin T had an acute myocardial infarction, and these patients died. Thus, 12 of the 14 patients with myocardial infarctions had detectable levels of troponin T; only 2 had elevated creatine kinase M activity. Conclusions: Cardiac troponin T in serum appears to be a more sensitive indicator of myocardial-cell injury than serum creatine kinase MB activity, and its detection in the circulation may be a useful prognostic indicator in patients with unstable angina.
C1 SELCUK UNIV, SCH MED, DEPT BIOCHEM, KONYA 42151, TURKEY.
RP Cin, VG (reprint author), SELCUK UNIV, SCH MED, DEPT CARDIAC, KONYA 42151, TURKEY.
CR ARMSTRONG PW, 1982, AM J CARDIOL, V49, P1849, DOI 10.1016/0002-9149(82)90201-6
   BRAUNWALD E, 1989, CIRCULATION, V80, P410, DOI 10.1161/01.CIR.80.2.410
   BRIGGS MM, 1989, J MOL BIOL, V206, P245, DOI 10.1016/0022-2836(89)90538-X
   CUMMINS P, 1987, EUR J CLIN INVEST, V17, P317, DOI 10.1111/j.1365-2362.1987.tb02194.x
   DAVIES MJ, 1986, CIRCULATION, V73, P418, DOI 10.1161/01.CIR.73.3.418
   DILLON MC, 1982, ARCH INTERN MED, V142, P33, DOI 10.1001/archinte.142.1.33
   FALK E, 1985, CIRCULATION, V71, P699, DOI 10.1161/01.CIR.71.4.699
   FITZGERALD DJ, 1991, CIRCULATION, V83, P902
   FREEMAN GH, 1951, BIOMETRIKA, V38, P141, DOI 10.2307/2332323
   GAZES PC, 1973, CIRCULATION, V48, P331, DOI 10.1161/01.CIR.48.2.331
   GERHARDT W, 1991, CLIN CHEM, V37, P1405
   GOTTLIEB SO, 1986, NEW ENGL J MED, V314, P1214, DOI 10.1056/NEJM198605083141903
   GREASER ML, 1973, J BIOL CHEM, V248, P2125
   HAMM CW, 1987, J AM COLL CARDIOL, V10, P998, DOI 10.1016/S0735-1097(87)80336-4
   HAMM CW, 1992, NEW ENGL J MED, V327, P146, DOI 10.1056/NEJM199207163270302
   HAMM CW, 1987, DEUT MED WOCHENSCHR, V112, P1812, DOI 10.1055/s-2008-1068333
   HOLMES DR, 1981, BRIT HEART J, V45, P411
   JORGENSEN PJ, 1990, CLIN CHEM, V36, P1502
   KATUS HA, 1991, CIRCULATION, V83, P902, DOI 10.1161/01.CIR.83.3.902
   KATUS HA, 1989, J MOL CELL CARDIOL, V21, P1349, DOI 10.1016/0022-2828(89)90680-9
   KATUS HA, 1992, CLIN CHEM, V38, P386
   KATUS HA, 1990, UNSTABLE ANGINA /, P92
   MESSMER BJ, 1990, SURG TREATMENT ANGIN, P245
   MULCAHY R, 1981, AM J CARDIOL, V48, P525, DOI 10.1016/0002-9149(81)90083-7
   NORDLANDER R, 1979, BRIT HEART J, V41, P647
   OLSON HG, 1981, CIRCULATION, V64, P674, DOI 10.1161/01.CIR.64.4.674
   PEARLSTONE JR, 1986, J BIOL CHEM, V261, P6795
   SCLAROVSKY S, 1988, AM HEART J, V116, P933, DOI 10.1016/0002-8703(88)90143-3
   SEINO Y, 1993, LANCET, V342, P1236, DOI 10.1016/0140-6736(93)92216-G
   STAPRANS I, 1972, J BIOCHEM, V72, P723, DOI 10.1093/oxfordjournals.jbchem.a129951
   WAGNER GS, 1973, CIRCULATION, V47, P263, DOI 10.1161/01.CIR.47.2.263
   WHITE RD, 1985, AM J CARDIOL, V55, P1478, DOI 10.1016/0002-9149(85)90957-9
   WILLERSON JT, 1989, CIRCULATION, V80, P198, DOI 10.1161/01.CIR.80.1.198
   1993, EUR HEART J S, V14, P33
   1994, TURK KARDIYOL DRN AR, V22, P12
NR 35
TC 8
Z9 8
U1 3
U2 6
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0167-5273
EI 1874-1754
J9 INT J CARDIOL
JI Int. J. Cardiol.
PD MAR
PY 1996
VL 53
IS 3
BP 237
EP 244
PG 8
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA UR066
UT WOS:A1996UR06600007
DA 2018-12-27
ER

PT J
AU Stapel, DA
   Koomen, W
   vanderPligt, J
AF Stapel, DA
   Koomen, W
   vanderPligt, J
TI RETRACTED: The referents of trait inferences: The impact of trait
   concepts versus actor-trait links on subsequent judgments (Retracted
   article. See vol. 103, pg. 565, 2012)
SO JOURNAL OF PERSONALITY AND SOCIAL PSYCHOLOGY
LA English
DT Article; Retracted Publication
ID IMPRESSION-FORMATION; SOCIAL JUDGMENT; BEHAVIOR IDENTIFICATION;
   DISPOSITIONAL INFERENCE; PERSON MEMORY; CONTRAST; ASSIMILATION;
   CATEGORIZATION; ACCESSIBILITY; ORGANIZATION
AB The authors investigated the hypothesis that when trait inferences refer to abstract behavior labels they act as a general interpretation frame and lead to assimilation in subsequent judgments of an ambiguous target, whereas when they refer to a specific actor-trait link they will be used as a scale anchor and lead to contrast. Similar to G.B. Moskowitz and R.J. Roman's (1992) study, participants who were instructed to memorize trait-implying sentences showed assimilation, and participants who were instructed to form an impression of the actors in these sentences showed contrast. However, exposure to trait-implying sentences that described actors with real names and were accompanied with photos of the actors resulted in contrast under both memorization and impression instructions (Experiment 1). Furthermore, contrast ensued when trait-implying sentences were accompanied with information that suggested a person attribution, whereas assimilation ensued when that information suggested a situation attribution, independent of processing goals (Experiment 2). These findings are interpreted as support for referent-based explanations of the consequences of trait inferences.
RP Stapel, DA (reprint author), UNIV AMSTERDAM, DEPT SOCIAL PSYCHOL, ROETERSSTR 15, 1018 WB AMSTERDAM, NETHERLANDS.
CR BANAJI MR, 1993, J PERS SOC PSYCHOL, V65, P272, DOI 10.1037/0022-3514.65.2.272
   BARGH JA, 1988, COMMUNICATION SOCIAL, P9
   BASSILI JN, 1989, PERS SOC PSYCHOL B, V15, P285, DOI 10.1177/0146167289153001
   BASSILI JN, 1989, ON LINE COGNITION PE, P61
   BRUNER JS, 1957, PSYCHOL REV, V64, P123, DOI 10.1037/h0043805
   CARLSTON DE, 1994, J PERS SOC PSYCHOL, V66, P840, DOI 10.1037/0022-3514.66.5.840
   CLAEYS W, 1990, EUR J PERSONALITY, V4, P173, DOI 10.1002/per.2410040302
   CLARK LF, 1985, INFERENCES TEXT PROC, P95
   ERDLEY CA, 1988, J PERS SOC PSYCHOL, V54, P741, DOI 10.1037//0022-3514.54.5.741
   FORD TE, 1995, PERS SOC PSYCHOL B, V21, P950, DOI 10.1177/0146167295219009
   FORD TE, 1994, SOC COGNITION, V12, P149, DOI 10.1521/soco.1994.12.2.149
   HAMILTON DL, 1981, SOCIAL COGNITION ONT, V1, P135
   Helson H., 1964, ADAPTATION LEVEL THE
   HERR PM, 1986, J PERS SOC PSYCHOL, V51, P1106, DOI 10.1037//0022-3514.51.6.1106
   HIGGINS E T, 1989, P75
   HIGGINS ET, 1977, J EXP SOC PSYCHOL, V13, P141
   HILTON DJ, 1986, PSYCHOL REV, V93, P75, DOI 10.1037/0033-295X.93.1.75
   HOFFMAN C, 1981, J PERS SOC PSYCHOL, V40, P211, DOI 10.1037/0022-3514.40.2.211
   KAHNEMAN D, 1986, PSYCHOL REV, V93, P136, DOI 10.1037//0033-295X.93.2.136
   Kelley H. H., 1967, NEBRASKA S MOTIVATIO, V15, P192
   Leddo J., 1986, KNOWLEDGE STRUCTURES, P103
   LOMBARDI WJ, 1987, PERS SOC PSYCHOL B, V13, P411, DOI 10.1177/0146167287133009
   LUPFER MB, 1990, J PERS SOC PSYCHOL, V58, P239, DOI 10.1037/0022-3514.58.2.239
   MANIS M, 1991, J PERS SOC PSYCHOL, V61, P203, DOI 10.1037//0022-3514.61.2.203
   MARTIN LL, 1986, J PERS SOC PSYCHOL, V51, P493, DOI 10.1037/0022-3514.51.3.493
   MARTIN LL, 1990, J PERS SOC PSYCHOL, V59, P27, DOI 10.1037//0022-3514.59.1.27
   MOSKOWITZ GB, 1993, J PERS SOC PSYCHOL, V65, P132, DOI 10.1037/0022-3514.65.1.132
   MOSKOWITZ GB, 1992, J PERS SOC PSYCHOL, V62, P728, DOI 10.1037/0022-3514.62.5.728
   MOSKOWITZ GB, 1993, EUR J PERSONALITY, V7, P195, DOI 10.1002/per.2410070305
   NEWMAN LS, 1993, PERS SOC PSYCHOL B, V19, P513, DOI 10.1177/0146167293195004
   NEWMAN LS, 1990, PERS SOC PSYCHOL B, V16, P224, DOI 10.1177/0146167290162004
   PARDUCCI A, 1965, PSYCHOL REV, V72, P407, DOI 10.1037/h0022602
   PETTY RE, 1993, J EXP SOC PSYCHOL, V29, P137, DOI 10.1006/jesp.1993.1007
   READ SJ, 1987, J EXP SOC PSYCHOL, V23, P189, DOI 10.1016/0022-1031(87)90031-X
   SCHWARZ N, 1992, CONSTRUCTION OF SOCIAL JUDGMENTS, P217
   SEDIKIDES C, 1990, J PERS SOC PSYCHOL, V58, P397, DOI 10.1037/0022-3514.58.3.397
   SHERIF M, 1961, SOCIAL JUDGMENT
   SINCLAIR RC, 1987, PERS SOC PSYCHOL B, V13, P239, DOI 10.1177/0146167287132009
   SKOWRONSKI JJ, 1993, J EXP SOC PSYCHOL, V29, P17, DOI 10.1006/jesp.1993.1002
   Smith E. R., 1990, ADV SOCIAL COGNITION, P1
   SMITH ER, 1988, J EXP SOC PSYCHOL, V24, P490, DOI 10.1016/0022-1031(88)90048-0
   SRULL TK, 1983, J PERS SOC PSYCHOL, V44, P1157, DOI 10.1037/0022-3514.44.6.1157
   STAPEL DA, IN PRESS POLITICAL B
   STAPEL DA, 1995, UNPUB CATEGORIES CAT
   STAPEL DA, 1995, UNPUB DIFFERENTIAL C
   STAPEL DA, 1995, UNPUB WHEN FAR WHICH
   STAPEL DA, IN PRESS PERSONALITY
   STRACK F, 1993, EUR J SOC PSYCHOL, V23, P53, DOI 10.1002/ejsp.2420230105
   THOMPSON EP, 1994, J PERS SOC PSYCHOL, V66, P474, DOI 10.1037//0022-3514.66.3.474
   ULEMAN J S, 1989, P425
   ULEMAN JS, 1993, SOC COGNITION, V11, P321, DOI 10.1521/soco.1993.11.3.321
   ULEMAN JS, 1994, J PERS SOC PSYCHOL, V66, P490, DOI 10.1037/0022-3514.66.3.490
   ULEMAN JS, IN PRESS ADV EXPT SO, V29
   WHITNEY P, 1994, SOC COGNITION, V12, P19, DOI 10.1521/soco.1994.12.1.19
   WILSON TD, 1994, PSYCHOL BULL, V116, P117, DOI 10.1037/0033-2909.116.1.117
   WINTER L, 1984, J PERS SOC PSYCHOL, V47, P237, DOI 10.1037//0022-3514.47.2.237
   WINTER L, 1985, J PERS SOC PSYCHOL, V49, P904, DOI 10.1037/0022-3514.49.4.904
   WYER RS, 1984, HDB SOCIAL COGNITION, V2, P73
   WYER RS, 1989, MEMORY SOCIAL COGNIT
NR 59
TC 55
Z9 56
U1 1
U2 18
PU AMER PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA
SN 0022-3514
EI 1939-1315
J9 J PERS SOC PSYCHOL
JI J. Pers. Soc. Psychol.
PD MAR
PY 1996
VL 70
IS 3
BP 437
EP 450
DI 10.1037/0022-3514.70.3.437
PG 14
WC Psychology, Social
SC Psychology
GA TZ883
UT WOS:A1996TZ88300003
DA 2018-12-27
ER

PT J
AU Nihrane, A
   Fujita, K
   Willey, R
   Lyu, MS
   Silver, J
AF Nihrane, A
   Fujita, K
   Willey, R
   Lyu, MS
   Silver, J
TI RETRACTED: Murine leukemia virus envelope protein in transgenic-mouse
   serum blocks infection in vitro (Retracted article. See vol 72, pg 8462,
   1998)
SO JOURNAL OF VIROLOGY
LA English
DT Article; Retracted Publication
ID HUMAN-IMMUNODEFICIENCY-VIRUS; RECOMBINANT GP160; CELL-SURFACE; SOLUBLE
   CD4; FV-4 GENE; GLYCOPROTEIN; TYPE-1; MICE; EXPRESSION; IMMUNOGENICITY
AB Transgenic mice bearing a murine retroviral envelope transgene (Fv4) have Fv4 gp70(env) (SU) in their serum in amounts sufficient to block infection by ecotropic virus in vitro. Fv4 Env in serum is derived largely but not exclusively from hematopoietic cells. Tail cells from Fv4 mice and cell lines transduced with the Fv4 env transgene synthesize both components of the envelope protein (gp70 SU and p15E TM) but secrete the gp70 moiety, in the absence of retroviral particles. Blocking of the ecotropic viral receptor by secreted gp70 SU may contribute to resistance to retroviral infection in these mice.
C1 NIAID, MOLEC MICROBIOL LAB, BETHESDA, MD 20892 USA.
CR ANDERSON S, 1993, J VIROL, V67, P4923
   BANDA NK, 1992, J EXP MED, V176, P1099, DOI 10.1084/jem.176.4.1099
   BELSHE RB, 1993, J INFECT DIS, V168, P1387, DOI 10.1093/infdis/168.6.1387
   BRADY HJM, 1993, EMBO J, V12, P4923, DOI 10.1002/j.1460-2075.1993.tb06186.x
   BYRN RA, 1990, NATURE, V344, P667, DOI 10.1038/344667a0
   CAPON DJ, 1991, ANNU REV IMMUNOL, V9, P649
   CRISE B, 1990, J VIROL, V64, P5585
   DEEN KC, 1988, NATURE, V331, P82, DOI 10.1038/331082a0
   DELVILLANO BC, 1976, NATURE, V259, P497, DOI 10.1038/259497a0
   FISHER RA, 1988, NATURE, V331, P76, DOI 10.1038/331076a0
   GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3
   HUSSEY RE, 1988, NATURE, V331, P78, DOI 10.1038/331078a0
   IKEDA H, 1989, J VIROL, V63, P5405
   IKEDA H, 1983, VIROLOGY, V128, P127, DOI 10.1016/0042-6822(83)90324-0
   IKEDA H, 1984, VIROLOGY, V133, P65, DOI 10.1016/0042-6822(84)90426-4
   IKEDA H, COMMUNICATION
   JABBAR MA, 1990, J VIROL, V64, P6297
   JONES JS, 1993, J VIROL, V67, P67
   KADAN MJ, 1992, J VIROL, V66, P2281
   KAI K, 1986, VIROLOGY, V150, P509, DOI 10.1016/0042-6822(86)90315-6
   KID MJ, 1991, J VIROL, V65, P313
   KIM JW, 1993, J BIOL CHEM, V268, P16316
   KITAGAWA M, 1994, LEUKEMIA, V8, P2200
   KITAGAWA M, 1995, BLOOD, V86, P1557
   KOVACS JA, 1993, J CLIN INVEST, V92, P919, DOI 10.1172/JCI116667
   KOWALSKI M, 1987, SCIENCE, V237, P1351, DOI 10.1126/science.3629244
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   LANDER MR, 1978, J NATL CANCER I, V60, P477
   LEE MR, 1987, SCIENCE, V237, P1047, DOI 10.1126/science.3039662
   LERNER RA, 1976, J EXP MED, V143, P151, DOI 10.1084/jem.143.1.151
   LIMJOCO T, 1995, VIROLOGY, V208, P75, DOI 10.1006/viro.1995.1131
   LIMJOCO TI, 1993, J VIROL, V67, P4163
   LYERLY HK, 1987, P NATL ACAD SCI USA, V84, P4601, DOI 10.1073/pnas.84.13.4601
   MASUDA M, 1990, J VIROL, V64, P1033
   PINTER A, 1978, VIROLOGY, V91, P345, DOI 10.1016/0042-6822(78)90382-3
   REDFIELD RR, 1991, NEW ENGL J MED, V324, P1677, DOI 10.1056/NEJM199106133242401
   ROBINSON HL, 1981, J VIROL, V40, P745
   ROWE WP, 1970, VIROLOGY, V42, P1136, DOI 10.1016/0042-6822(70)90362-4
   RUBIN H, 1960, P NATL ACAD SCI USA, V46, P1105, DOI 10.1073/pnas.46.8.1105
   SPOUGE JL, 1994, J VIROL, V68, P1782
   WANG H, 1992, J BIOL CHEM, V267, P23617
   WILLEY RL, 1992, J VIROL, V66, P226
NR 42
TC 17
Z9 17
U1 1
U2 6
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
EI 1098-5514
J9 J VIROL
JI J. Virol.
PD MAR
PY 1996
VL 70
IS 3
BP 1882
EP 1889
PG 8
WC Virology
SC Virology
GA TV696
UT WOS:A1996TV69600066
PM 8627713
DA 2018-12-27
ER

PT J
AU Simmons, WA
   Leong, LYW
   Satumtira, N
   Butcher, GW
   Howard, JC
   Richardson, JA
   Slaughter, CA
   Hammer, RE
   Taurog, JD
AF Simmons, WA
   Leong, LYW
   Satumtira, N
   Butcher, GW
   Howard, JC
   Richardson, JA
   Slaughter, CA
   Hammer, RE
   Taurog, JD
TI RETRACTED: Rat MHC-linked peptide transporter alleles strongly influence
   peptide binding by HLA-B27 but not B27-associated inflammatory disease
   (Retracted article. See vol 163, pg 5741, 1999)
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article; Retracted Publication
ID CLASS-I MOLECULE; ANTIGEN; CIM
AB Rats transgenic for the human MHC molecule HLA-B27 were used to study the effect of two alleles, cim(a) and cim(b), which are associated with peptide transport by the MHC-encoded Tap2 transporter, on the function of HLA-B27 as a restriction element for CTL recognition of the male H-Y minor H Ag and on the multisystem inflammatory disease characteristic of B27 transgenic rats, Anti-H-Y CTL generated in cim(a) B27 transgenic rats lysed male B27 cim(b/b) targets significantly less well than cim(a/a) or cim(a/b) targets, Addition of exogenous H-Y peptides to male B27 cim(b/b) targets increased susceptibility to lysis to the level of cim(a/a) targets, Male B27 cim(b/b) cells were less efficient than cim(a/a) cells in competitively inhibiting CTL lysis of female B27 cim(a/a) targets sensitized with exogenous H-Y peptides, H-3-Labeled peptides eluted from 827 molecules of lymphoblasts from rats of two cim(b) and three cim(a) RT1 haplotypes showed that the cim(b) peptide pool favors comparatively longer and/or more hydrophobic peptides, These results indicate that RT1-linked Tap2 polymorphism in the rat strongly influences peptide loading of HLA-B27. Nonetheless, the prevalence and severity of multisystem inflammatory lesions were comparable in backcross rats bearing either cim(a/b) or cim(b/b). It thus appears either that binding of specific peptides to B27 is unimportant in the pathogenesis of B27-associated disease or that the critical peptides, unlike H-Y and many others, are not influenced by Tap transporter polymorphism.
C1 UNIV TEXAS, SW MED CTR, HAROLD C SIMMONS ARTHRITIS RES CTR, DALLAS, TX 75235 USA.
   UNIV TEXAS, SW MED CTR, DEPT INTERNAL MED, DALLAS, TX 75235 USA.
   UNIV TEXAS, SW MED CTR, GRAD PROGRAM IMMUNOL, DALLAS, TX 75235 USA.
   UNIV TEXAS, SW MED CTR, DEPT PATHOL, DALLAS, TX 75235 USA.
   UNIV TEXAS, SW MED CTR, HOWARD HUGHES MED INST, DALLAS, TX 75235 USA.
   UNIV TEXAS, SW MED CTR, DEPT BIOCHEM, DALLAS, TX 75235 USA.
   BABRAHAM INST, CAMBRIDGE CB2 4AT, ENGLAND.
OI Howard, Jonathan/0000-0003-2756-5143
FU NIDDK NIH HHS [DK47692]; NIAMS NIH HHS [AR38319]
CR BARRON KS, 1995, ARTHRITIS RHEUM, V38, P684, DOI 10.1002/art.1780380517
   BENJAMIN R, 1990, IMMUNOL TODAY, V11, P137, DOI 10.1016/0167-5699(90)90051-A
   BOWNESS P, 1994, EUR J IMMUNOL, V24, P2357, DOI 10.1002/eji.1830241015
   BREBAN M, 1993, J EXP MED, V178, P1606
   BREBAN M, IN PRESS J IMMUNOL
   BURMESTER GR, 1995, ANNU REV IMMUNOL, V13, P229, DOI 10.1146/annurev.immunol.13.1.229
   BUTCHER GW, 1987, J IMMUNOGENET, V14, P163
   CALIN A, 1984, SPONDYLARTHORPATHIES
   DAY PM, 1995, IMMUNITY, V2, P137, DOI 10.1016/S1074-7613(95)80014-X
   DECASTRO JAL, 1994, CURR OPIN RHEUMATOL, V6, P371
   DEVERSON EV, 1990, NATURE, V348, P738, DOI 10.1038/348738a0
   DICK LR, 1994, J IMMUNOL, V152, P3884
   ELLIOTT T, 1991, IMMUNOL TODAY, V12, P386
   ENGELHARD VH, 1994, ANNU REV IMMUNOL, V12, P181, DOI 10.1146/annurev.immunol.12.1.181
   FRUMENTO G, 1993, CELL IMMUNOL, V152, P623, DOI 10.1006/cimm.1993.1318
   HAMMER RE, 1990, CELL, V63, P1099, DOI 10.1016/0092-8674(90)90512-D
   HEEMELS MT, 1994, IMMUNITY, V1, P775, DOI 10.1016/S1074-7613(94)80019-7
   HEEMELS MT, 1993, SCIENCE, V262, P2059, DOI 10.1126/science.8266106
   Inman Robert D., 1994, Current Opinion in Rheumatology, V6, P360, DOI 10.1097/00002281-199407000-00003
   JARDETZKY TS, 1991, NATURE, V353, P326, DOI 10.1038/353326a0
   JOLY E, 1994, IMMUNOGENETICS, V40, P45, DOI 10.1007/BF00163963
   KHARE SD, 1995, J EXP MED, V182, P1153, DOI 10.1084/jem.182.4.1153
   LEIRISALOREPO M, 1987, CLIN RHEUMATOL S6, V2, P73
   LINSSEN A, 1988, ANN RHEUM DIS, V47, P431, DOI 10.1136/ard.47.5.431
   LIVINGSTONE AM, 1991, IMMUNOGENETICS, V34, P157
   LIVINGSTONE AM, 1989, J EXP MED, V170, P777, DOI 10.1084/jem.170.3.777
   MADDEN DR, 1991, NATURE, V353, P321, DOI 10.1038/353321a0
   MAKSYMOWYCH WP, 1994, J RHEUMATOL, V21, P665
   MALNATI MS, 1995, SCIENCE, V267, P1016, DOI 10.1126/science.7863326
   MOMBURG F, 1994, NATURE, V367, P648, DOI 10.1038/367648a0
   OBST R, 1995, EUR J IMMUNOL, V25, P2170, DOI 10.1002/eji.1830250808
   PARKER KC, 1994, BIOCHEMISTRY-US, V33, P7736, DOI 10.1021/bi00190a029
   POWIS SH, 1993, IMMUNOGENETICS, V37, P373, DOI 10.1007/BF00216802
   POWIS SJ, 1991, J EXP MED, V173, P913, DOI 10.1084/jem.173.4.913
   POWIS SJ, 1992, NATURE, V357, P211, DOI 10.1038/357211a0
   POWIS SP, 1996, IN PRESS IMMUNITY
   RAMMENSEE HG, 1995, CURR OPIN IMMUNOL, V7, P85, DOI 10.1016/0952-7915(95)80033-6
   RAMMENSEE HG, 1993, ANNU REV IMMUNOL, V11, P213, DOI 10.1146/annurev.iy.11.040193.001241
   SIMMONS WA, 1993, IMMUNOGENETICS, V38, P351
   TAUROG JD, 1993, J IMMUNOL, V150, P4168
   URBAN RG, 1994, P NATL ACAD SCI USA, V91, P1534, DOI 10.1073/pnas.91.4.1534
   VANBLEEK GM, 1990, NATURE, V348, P213
NR 42
TC 23
Z9 23
U1 0
U2 7
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD FEB 15
PY 1996
VL 156
IS 4
BP 1661
EP 1667
PG 7
WC Immunology
SC Immunology
GA TU692
UT WOS:A1996TU69200045
PM 8568273
DA 2018-12-27
ER

PT J
AU Fujii, Y
   Toyooka, H
   Tanaka, H
AF Fujii, Y
   Toyooka, H
   Tanaka, H
TI RETRACTED: Antiemetic effects of granisetron on postoperative nausea and
   vomiting in patients with and without motion sickness (Retracted
   article. See vol. 59, pg. 1171, 2012)
SO CANADIAN JOURNAL OF ANAESTHESIA-JOURNAL CANADIEN D ANESTHESIE
LA English
DT Article; Retracted Publication
DE complications, nausea, vomiting; surgery, gynaecological; vomiting,
   antiemetics, granisetron, incidence, motion sickness, nausea,
   postoperative
ID RECEPTOR ANTAGONIST; PREVENTION; ANESTHESIA
AB Purpose: This randomized, placebo-controlled, double-blind study was to evaluate the effects of granisetron, a selective 5-hydroxytryptamine type 3 receptor antagonist, for preventing postoperative nausea and vomiting in 110 patients with (n = 50) and without (n = 60) a history of motion sickness undergoing general anaesthesia for major gynaecological surgery.
   Methods:. The patients received a single dose of either granisetron (40 mu g . kg(-1)) or placebo (saline) iv over 2-5 min immediately before induction of anaesthesia. Postoperatively, during the first 24 hr after anaesthesia, the frequencies of nausea and vomiting were recorded.
   Results: Except for a positive history of motion sickness, the treatment groups were similar for patient characteristics, types of surgery, anaesthetics administered and opioids given. Postoperatively, the frequency of nausea was 44% and 16% after administration of placebo and granisetron in patients with motion sickness, and was 30% and 7% in patients without it, respectively; the corresponding frequencies of vomiting were 28%, 8%, 13% and 3%. The incidence of adverse events postoperatively were not different among the groups.
   Conclusion: These results suggest that preoperative prophylactic administration of granisetron is effective and safe for preventing postoperative nausea and vomiting in patients with motion sickness as well as in patients without it.
C1 TORIDE KYODO GEN HOSP, DEPT ANAESTHESIOL, TORIDE, IBARAKI 302, JAPAN.
RP Fujii, Y (reprint author), TOKYO MED & DENT UNIV, SCH MED, DEPT ANAESTHESIOL & CRIT CARE MED, BUNKYO KU, 1-5-45 YUSHIMA, TOKYO 113, JAPAN.
CR BERMUDEZ J, 1988, BRIT J CANCER, V58, P644, DOI 10.1038/bjc.1988.277
   CARMICHAEL J, 1989, CANCER CHEMOTH PHARM, V24, P45
   FUJII Y, 1995, CAN J ANAESTH, V42, P852, DOI 10.1007/BF03011030
   FUJII Y, 1994, CAN J ANAESTH, V41, P794, DOI 10.1007/BF03011585
   FUJII Y, 1994, CAN J ANAESTH, V41, P291, DOI 10.1007/BF03009906
   Furue H, 1990, J CLIN THERAPEUTIC M, V6, P49
   KAMATH B, 1990, BRIT J ANAESTH, V64, P728, DOI 10.1093/bja/64.6.728
   KORTTILA K, 1979, ANESTH ANALG, V58, P396
   LEESER J, 1991, ANESTH ANALG, V72, P751
   MCKENZIE R, 1981, ANESTH ANALG, V60, P783
   WATCHA MF, 1992, ANESTHESIOLOGY, V77, P162, DOI 10.1097/00000542-199207000-00023
NR 11
TC 14
Z9 15
U1 2
U2 10
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0832-610X
J9 CAN J ANAESTH
JI Can. J. Anaesth.-J. Can. Anesth.
PD FEB
PY 1996
VL 43
IS 2
BP 110
EP 114
DI 10.1007/BF03011250
PG 5
WC Anesthesiology
SC Anesthesiology
GA TT351
UT WOS:A1996TT35100004
PM 8825534
OA Bronze
DA 2018-12-27
ER

PT J
AU Fujii, Y
   Tanaka, H
   Toyooka, H
AF Fujii, Y
   Tanaka, H
   Toyooka, H
TI RETRACTED: Granisetron reduces vomiting after strabismus surgery and
   tonsillectomy in children (Retracted article. See vol. 59, pg. 1172,
   2012)
SO CANADIAN JOURNAL OF ANAESTHESIA-JOURNAL CANADIEN D ANESTHESIE
LA English
DT Article; Retracted Publication
DE anaesthesia, paediatric; complications, vomiting; vomiting, antiemetics;
   granisetron; surgery, strabismus repair, tonsillectomy
ID RECEPTOR ANTAGONIST; DROPERIDOL; METOCLOPRAMIDE; PREVENTION
AB Purpose: To evaluate the antiemetic efficacy of granisetron, a selective 5-hydroxytryptamine type 3 receptor antagonist on postoperative vomiting in children undergoing general anaesthesia for strabismus repair and tonsillectomy with or without adenoidectomy.
   Methods: In a randomized, placebo-controlled, double-blind study, fifty patients, 4-10 yr of age, were given a single dose of either placebo (saline, n = 25) or granisetron (40 mu g . kg(-1), n = 25) iv over 2-5 min after the induction of anaesthesia and prior to the surgical procedure. Postoperatively, during the first 24 hr after anaesthesia, the frequencies of retching and vomiting were recorded.
   Results: There were no differences between the two groups with regard to patient characteristics, surgical procedures and anaesthetic or postoperative management. The incidence of retching was 36% and 12% after administration of placebo or granisetron, respectively (P < 0.05); the corresponding frequencies of vomiting were 32% and 8% (P < 0.05). Four children who had received placebo required another rescue antiemetic drug, whereas none who had received granisetron needed this agent.
   Conclusion: Granisetron is effective in the prevention of retching and vomiting after strabismus repair and tonsillectomy in paediatric patients.
C1 TORIDE KYODO GEN HOSP, DEPT ANAESTHESIOL, TORIDE, IBARAKI 302, JAPAN.
RP Fujii, Y (reprint author), TOKYO MED & DENT UNIV, SCH MED, DEPT ANAESTHESIOL & CRIT CARE MED, BUNKYO KU, 1-5-45 YUSHIMA, TOKYO 113, JAPAN.
CR ABRAMOWITZ MD, 1983, ANESTHESIOLOGY, V59, P579, DOI 10.1097/00000542-198312000-00021
   ANDREWS P L R, 1992, European Journal of Cancer, V28A, pS2, DOI 10.1016/0959-8049(92)90628-F
   BERMUDEZ J, 1988, BRIT J CANCER, V58, P644, DOI 10.1038/bjc.1988.277
   CARITHERS JS, 1987, LARYNGOSCOPE, V97, P422
   CARMICHAEL J, 1989, CANCER CHEMOTH PHARM, V24, P45
   DUPRE LJ, 1980, BRIT J ANAESTH, V52, P831
   FUJII Y, 1994, CAN J ANAESTH, V41, P794, DOI 10.1007/BF03011585
   FUJII Y, 1994, CAN J ANAESTH, V41, P291, DOI 10.1007/BF03009906
   Furue H, 1990, J CLIN THERAPEUTIC M, V6, P49
   LEUNG AKC, 1984, CURR THER RES CLIN E, V36, P911
   LIN DM, 1992, ANESTHESIOLOGY, V76, P357, DOI 10.1097/00000542-199203000-00006
   WATCHA MF, 1992, ANESTHESIOLOGY, V77, P162, DOI 10.1097/00000542-199207000-00023
   WATCHA MF, 1995, ANESTHESIOLOGY, V82, P47, DOI 10.1097/00000542-199501000-00007
NR 13
TC 35
Z9 36
U1 2
U2 8
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0832-610X
J9 CAN J ANAESTH
JI Can. J. Anaesth.-J. Can. Anesth.
PD JAN
PY 1996
VL 43
IS 1
BP 35
EP 38
DI 10.1007/BF03015955
PG 4
WC Anesthesiology
SC Anesthesiology
GA TL090
UT WOS:A1996TL09000007
PM 8665632
DA 2018-12-27
ER

PT J
AU Matsuda, Y
   Katayama, T
   Kiyoda, S
   Ishiyama, T
   Asano, T
   Hosokawa, Y
   Toratani, H
   Ariyama, H
AF Matsuda, Y
   Katayama, T
   Kiyoda, S
   Ishiyama, T
   Asano, T
   Hosokawa, Y
   Toratani, H
   Ariyama, H
TI RETRACTED: Uptake and excretion of cobalt in the crustacean Portunus
   trituberculatus (Retracted article. See vol. 269, pg. 1168, 2011)
SO NUCLEAR INSTRUMENTS & METHODS IN PHYSICS RESEARCH SECTION B-BEAM
   INTERACTIONS WITH MATERIALS AND ATOMS
LA English
DT Article; Retracted Publication
AB An experimental study of the uptake of trace elements from water was undertaken to develop a technique for setting labelled crab (Portunus trituberculatus) fry free in the sea. Ten elements, Mn, Co, Cs, La, Pr, Sm, Eu, Gd, Dy and Ho, were used for the test. Three concentrations, 0.1, 0.01 and 0.001 ppm, were used for each element, and mixtures of all 10 elements with the same concentration were used. Fry were reared in water containing the 10 added elements for two weeks, living crabs were sampled just after the end of marking, and after one month natural rearing. The intake of elements was then studied by NAA. The intake of elements was successful and no effects on the survival rate and growth were detected. Just after the marking period and sample preparation, the concentrations of elements taken into and adsorbed onto living crabs reflect the concentrations applied, and after one month of natural rearing, there were no significant differences between the treated crabs and the controls. Marking crustacea with elements in this manner has not yet been shown to be unrealistic. It was found that there is a large volatile component of Co compounds that is missed by normal measurement methods in the early stages of neutron activation gamma-ray measurement. The non-volatile Co compound component reflected treated concentrations. The volatile Co compound component is thought to be derived from organic Co chelates (e.g., vitamin B-12) which are essential for living tissue. On the other hand, the non-volatile Co compound component is thought to originate from the inorganic Co compound CoCl2 which was added for the marking experiments.
C1 OSAKA PREFECTURAL FISHERIES EXPT STN, MISAKI, OSAKA 59903, JAPAN.
RP Matsuda, Y (reprint author), UNIV OSAKA PREFECTURE, ADV SCI & TECHNOL RES INST, 1-2 GAKUEN CHO, SAKAI, OSAKA 593, JAPAN.
CR BAYSTON JH, 1969, J AM CHEM SOC, V91, P2775, DOI 10.1021/ja01038a060
   CRUMBLISS AL, 1969, SCIENCE, V164, P1168, DOI 10.1126/science.164.3884.1168
   FUWA K, 1989, LIVING BODY HEAVY ME
   HALL LD, 1980, CARBOHYD RES, V83, pC5, DOI 10.1016/S0008-6215(00)85386-0
   KOLL G, 1970, J ANAL APPL PYROL, V17, P319
   MARTIN JH, 1970, LIMNOL OCEANOGR, V15, P756, DOI 10.4319/lo.1970.15.5.0756
   MATSUSIMA M, 1990, INORGANIC CHEM LIFE, P201
   RILEY JP, 1975, CHEM OCEANOGR, V1, P191
   SANO A, 1980, REPORT RESULTS STUDI, P416
   SCHRAUZER GN, 1970, J AM CHEM SOC, V92, P1551, DOI 10.1021/ja00709a020
   SHIBUYA M, 1978, NUCL ENG, V24, P23
   SHIBUYA M, 1981, REPORT RESULTS STUDI, P121
   Shibuya M., 1979, RADIOISOTOPES, V28, P64
   SHIBUYA M, 1977, ISOTOPE NEWS, V4, P6
   SUGIMURA Y, 1981, BUNSEKI, V3, P153
   VOGT LH, 1963, CHEM REV, V63, P269, DOI 10.1021/cr60223a004
   YANG JH, 1991, J INORG BIOCHEM, V41, P7, DOI 10.1016/0162-0134(91)85003-Y
   YONAMORI T, 1972, ISOTOPE NEWS, V7, P12
   1989, REPORT PROJECT STUDY
   1969, 163 FISH AG INT REP
NR 20
TC 1
Z9 1
U1 3
U2 8
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-583X
EI 1872-9584
J9 NUCL INSTRUM METH B
JI Nucl. Instrum. Methods Phys. Res. Sect. B-Beam Interact. Mater. Atoms
PD JAN
PY 1996
VL 108
IS 1-2
BP 188
EP 196
DI 10.1016/0168-583X(95)00853-5
PG 9
WC Instruments & Instrumentation; Nuclear Science & Technology; Physics,
   Atomic, Molecular & Chemical; Physics, Nuclear
SC Instruments & Instrumentation; Nuclear Science & Technology; Physics
GA TW709
UT WOS:A1996TW70900029
DA 2018-12-27
ER

PT J
AU Iosif, CS
AF Iosif, CS
TI RETRACTED: Laparoscopic surgery for stress urinary incontinence
   (Retracted article. See vol 61, pg 66, 1998)
SO UROLOGIA INTERNATIONALIS
LA English
DT Article; Retracted Publication
DE colpourethrocystopexy; female stress urinary incontinence; laparoscopy
ID BLADDER NECK SUSPENSION; RETROPUBIC URETHROPEXY; COLPOSUSPENSION
AB Retropubic bladder neck suspension can easily be performed laparoscopically giving the same therapeutic result as open surgery. Laparoscopy enables better visibility of the operative field, exact placement of paraurethral sutures and acceptable hemostasis. Patients who undergo laparoscopic retropubic suspension meet with less postoperative discomfort, fewer operative complications, a shorter hospital stay and less postoperative scars. The patients are allowed to drive and return to work 1-2 weeks after surgery.
RP Iosif, CS (reprint author), UNIV LUND HOSP, DEPT OBSTET & GYNECOL, S-22185 LUND, SWEDEN.
CR ALBALA DM, 1992, J ENDOUROL, V6, P137, DOI 10.1089/end.1992.6.137
   BERGMAN A, 1989, AM J OBSTET GYNECOL, V160, P1102, DOI 10.1016/0002-9378(89)90169-5
   BHATIA NN, 1985, OBSTET GYNECOL, V66, P255
   BOWEN LW, 1989, AM J OBSTET GYNECOL, V160, P452, DOI 10.1016/0002-9378(89)90471-7
   BURCH JC, 1968, AM J OBSTET GYNECOL, V100, P764, DOI 10.1016/S0002-9378(15)33576-6
   BURCH JC, 1961, AM J OBSTET GYNECOL, V81, P281, DOI 10.1016/S0002-9378(16)36367-0
   Harewood Laurence M., 1994, Journal of Urology, V151, p463A
   HERBERTSSON G, 1993, ACTA OBSTET GYN SCAN, V72, P298, DOI 10.3109/00016349309068041
   HOLLANDER JB, 1993, J ENDOUROL, V7, P461, DOI 10.1089/end.1993.7.461
   IOSIF CS, 1983, ARCH GYNECOL, V233, P93, DOI 10.1007/BF02114785
   IOSIF CS, 1994, ACTA OBSTET GYNECOL, V73, P91
   KORDA A, 1989, AUST NZ J OBSTET GYN, V29, P146, DOI 10.1111/j.1479-828X.1989.tb01705.x
   LIU CY, 1993, J AM ASSOC GYN LAP, V1, P31, DOI 10.1016/S1074-3804(05)80755-8
   LUI CY, 1993, J REPROD MED, V38, P526
   MARSHALL VF, 1949, SURG GYNECOL OBSTET, V88, P509
   MCDOUGALL EM, 1995, UROLOGY, V45, P641, DOI 10.1016/S0090-4295(99)80056-9
   McGuire E J, 1981, Prog Clin Biol Res, V78, P351
   POLASCIK TJ, 1995, UROLOGY, V45, P647, DOI 10.1016/S0090-4295(99)80057-0
   ROSENBERG MT, 1993, J ENDOUROL, V7, P5101
   SAND PK, 1987, OBSTET GYNECOL, V69, P399
   STANTON SL, 1979, BRIT J UROL, V51, P497, DOI 10.1111/j.1464-410X.1979.tb03586.x
   TANAGHO EA, 1976, J UROLOGY, V116, P751, DOI 10.1016/S0022-5347(17)58997-1
   Vancaillie T G, 1991, J Laparoendosc Surg, V1, P169, DOI 10.1089/lps.1991.1.169
NR 23
TC 3
Z9 3
U1 4
U2 12
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0042-1138
EI 1423-0399
J9 UROL INT
JI Urol.Int.
PY 1996
VL 57
IS 3
BP 180
EP 184
DI 10.1159/000282906
PG 5
WC Urology & Nephrology
SC Urology & Nephrology
GA VN575
UT WOS:A1996VN57500009
PM 8912448
DA 2018-12-27
ER

PT J
AU LIN, JC
   LIN, SC
   MAR, EC
   PELLETT, PE
   STAMEY, FR
   STEWART, JA
   SPIRA, TJ
AF LIN, JC
   LIN, SC
   MAR, EC
   PELLETT, PE
   STAMEY, FR
   STEWART, JA
   SPIRA, TJ
TI RETRACTED: IS KAPOSIS-SARCOMA-ASSOCIATED HERPESVIRUS DETECTABLE IN SEMEN
   OF HIV-INFECTED HOMOSEXUAL MEN (Retracted article. See vol. 351, pg.
   1365, 1998)
SO LANCET
LA English
DT Note; Retracted Publication
AB We explored a possible route of transmission of Kaposi's sarcoma-associated herpes virus (KSHV) with nested and unnested PCR techniques. We looked for KSHV DNA sequences in semen of HIV-positive homosexual men and HIV-negative healthy semen donors. With unnested primers we found KSHV sequences in 21 of 33 (64%) homosexual men and in none of 30 healthy donors. With a nested PCR assay, 30 of 33 (91%) specimens from the homosexual men and 7 of 30 (23%) specimens from healthy donors had detectable KSHV sequences. Over 5 years of follow-up, 13 of 30 KSHV-positive homosexual men (43%) developed KS compared with none of the 3 KSHV-negative homosexual men.
RP LIN, JC (reprint author), CTR DIS CONTROL & PREVENT, 1600 CLIFTON RD, MS-D10, ATLANTA, GA 30333 USA.
CR AMBROZIAK JA, 1995, SCIENCE, V268, P582, DOI 10.1126/science.7725108
   BERAL V, 1990, LANCET, V335, P123, DOI 10.1016/0140-6736(90)90001-L
   CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802
   CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879
   DUPIN N, 1995, LANCET, V345, P761, DOI 10.1016/S0140-6736(95)90642-8
   HUANG YQ, 1995, LANCET, V345, P759, DOI 10.1016/S0140-6736(95)90641-X
   LIN JC, 1993, BLOOD, V81, P3372
   MOORE PS, 1995, NEW ENGL J MED, V332, P1181, DOI 10.1056/NEJM199505043321801
   RADY PL, 1995, LANCET, V345, P1339
   SU IJ, 1995, LANCET, V345, P722, DOI 10.1016/S0140-6736(95)90893-5
NR 10
TC 102
Z9 103
U1 2
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0140-6736
EI 1474-547X
J9 LANCET
JI Lancet
PD DEC 16
PY 1995
VL 346
IS 8990
BP 1601
EP 1602
DI 10.1016/S0140-6736(95)91931-7
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA TK481
UT WOS:A1995TK48100012
PM 7500753
DA 2018-12-27
ER

PT J
AU BOLDT, J
   SCHINDLER, E
   WELTERS, I
   WITTSTOCK, M
   STERTMANN, WA
   HEMPELMANN, G
AF BOLDT, J
   SCHINDLER, E
   WELTERS, I
   WITTSTOCK, M
   STERTMANN, WA
   HEMPELMANN, G
TI RETRACTED: THE EFFECT OF THE ANTICOAGULATION REGIMEN ON
   ENDOTHELIAL-RELATED COAGULATION IN CARDIAC-SURGERY PATIENTS (Retracted
   article. See vol. 70, pg. 1104, 2015)
SO ANAESTHESIA
LA English
DT Article; Retracted Publication
DE SURGERY, CARDIAC, CARDIOPULMONARY BYPASS; ANTICOAGULATION, HEPARIN;
   COAGULATION, THROMBOMODULIN
ID CARDIOPULMONARY BYPASS; PLASMA THROMBOMODULIN; PROTEIN-C;
   HEPARIN-BINDING; INHIBITION; APROTININ
AB Heparin is still the most commonly used anticoagulant cardiac surgery necessitating cardiopulmonary bypass. In recent years, endothelial-related coagulation (e.g. thrombomodulin/protein C-system) has enlarged our knowledge of the regulation of haemostasis. In a controlled randomised study, the influence of different regimens of anticoagulation on the thrombomodulin/protein C-system was studied. Sixty patients undergoing elective coronary artery bypass grafting were randomly allocated into four groups (n = 15) to receive: 300 IU.kg(-1) of heparin before bypass; 600 IU.kg(-1) of heparin; 300 IU.kg(-1) of heparin as bolus followed by a continous infusion of 10 000 IU.h(-1) until the end of bypass; or 600 IU.kg(-1) of heparin plus 'high dose' aprotinin (2 million IU of aprotinin before bypass, 500 000 IU.h(-1) until the end of the operation and 2 million IU added to the bypass pump prime). Grouping was blinded for the surgeon and the anaesthetist. Plasma concentrations of thrombomodulin, protein C and (free) protein S as well as thrombin/antithrombin III were measured by enzyme-linked immunosorbent assays after induction of anaesthesia, during and after bypass, at the end of surgery, 5 h after bypass, and on the first postoperative day. Activated clotting time was significantly longer during bypass in group 2 (566 (60)s) and group 4 (655 (59)s, whereas standard coagulation parameters showed no differences between the four groups. Blood loss and use of homologous blood and blood products were highest in groups 2 and 3. Thrombomodulin plasma levels were similar (and normal) at baseline (<40 ng.l(-1)), decreased during bypass and reached baseline values postoperatively without showing significant group differences. Protein C did not show any differences among the groups within the investigation period. 'Free' protein S plasma levels were most reduced in group 1 (from 68 (8%) to 48 (9%) after bypass. Thrombin/antithrombin III plasma concentrations increased most in groups 1 (to 69 (14) mu g.l(-1) after bypass) and 2 (to 48 (7) mu g.l(-1) after bypass), whereas they remained significantly lower in groups 3 and 4. The thrombomodulin/protein C-system was not significantly influenced by the regimen of anticoagulation. Administration of 'high dose' heparin was associated with the highest blood loss, which could not be related to endothelial-associated coagulation.
C1 UNIV GIESSEN, DEPT CARDIOVASC SURG, D-35392 GIESSEN, GERMANY.
RP BOLDT, J (reprint author), UNIV GIESSEN, DEPT ANAESTHESIOL & INTENS CARE MED, D-35392 GIESSEN, GERMANY.
RI Schindler, Ehrenfried/A-1629-2015
CR AMANO K, 1992, THROMB HAEMOSTASIS, V68, P404
   AMIRAL J, 1991, THROMB HAEMOSTASIS, V65, P947
   BICK RL, 1985, SEMIN THROMB HEMOST, V11, P213, DOI 10.1055/s-2007-1004377
   BOFFA MC, 1991, NOUV REV FR HEMATOL, V33, P529
   CARDOSO PFG, 1991, J THORAC CARDIOV SUR, V101, P153
   CASEY LC, 1993, ANN THORAC SURG, V56, pS92, DOI 10.1016/0003-4975(93)91143-B
   CINES DB, 1986, CHEST, V89, P420, DOI 10.1378/chest.89.3.420
   COMP PC, 1984, NOUV REV FR HEMATOL, V26, P239
   COSTA P, 1984, INEFFECTIVENESS HEPA, P367
   DITTMAN WA, 1991, TRENDS CARDIOVAS MED, V1, P331, DOI 10.1016/1050-1738(91)90070-U
   ELLISON N, 1988, EFFECTIVE HEMOSTASIS, P1
   ESMON CT, 1989, J BIOL CHEM, V264, P4743
   FRESBELIUS S, 1990, BLOOD COAGUL FIBRIN, V1, P285
   Gravlee Glenn P., 1993, P340
   HATTON MWC, 1991, THROMB HAEMOSTASIS, V66, P208
   ISHII H, 1985, J CLIN INVEST, V76, P2178, DOI 10.1172/JCI112225
   JOBES DR, 1989, J CARDIOTHORACIC ANE, V2, P655
   JOHN LCH, 1993, J THORAC CARDIOV SUR, V105, P816
   JOHN LCH, 1993, ANN THORAC SURG, V55, P1175, DOI 10.1016/0003-4975(93)90029-H
   KAWASUJI M, 1993, ANN THORAC SURG, V55, P1205, DOI 10.1016/0003-4975(93)90035-G
   KNOBL PN, 1987, J THORAC CARDIOV SUR, V94, P600
   MANN KG, 1992, SEMIN HEMATOL, V29, P213
   MARUYAMA I, 1992, JPN CIRC J, V56, P187, DOI 10.1253/jcj.56.187
   METZ S, 1990, ANN THORAC SURG, V49, P440, DOI 10.1016/0003-4975(90)90251-Z
   OGAWA S, 1990, J CLIN INVEST, V85, P1090, DOI 10.1172/JCI114540
   PREISSNER KT, 1988, HAEMOSTASIS, V18, P271
   ROSENBERG RD, 1989, AM J MED S38, V87, pB3
   Royston D, 1992, J Cardiothorac Vasc Anesth, V6, P76, DOI 10.1016/1053-0770(91)90052-U
   SANDSET PM, 1988, THROMB RES, V50, P803, DOI 10.1016/0049-3848(88)90340-4
   SCHERER R, 1993, YB INTENSIVE CARE EM, P629
   STERN DM, 1991, DIABETES CARE, V14, P160, DOI 10.2337/diacare.14.2.160
   TAKANO S, 1990, BLOOD, V76, P2024
   Tanaka K, 1989, ASAIO Trans, V35, P373, DOI 10.1097/00002480-198907000-00065
   TEOH KHT, 1993, CIRCULATION, V88, P420
   THOMPSON EA, 1987, PROG HEMATOL, V15, P51
   UCHIYAMA H, 1992, THROMB RES, V65, P593, DOI 10.1016/0049-3848(92)90209-S
   WU KK, 1992, HOSP PRACT, V27, P145
NR 37
TC 14
Z9 14
U1 3
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0003-2409
EI 1365-2044
J9 ANAESTHESIA
JI Anaesthesia
PD NOV
PY 1995
VL 50
IS 11
BP 954
EP 960
DI 10.1111/j.1365-2044.1995.tb05927.x
PG 7
WC Anesthesiology
SC Anesthesiology
GA TD445
UT WOS:A1995TD44500008
PM 8678251
DA 2018-12-27
ER

PT J
AU VAUX, DL
AF VAUX, DL
TI RETRACTED: IMMUNOLOGY - WAYS AROUND REJECTION (RETRACTED ARTICLE. SEE
   VOL 394, PG 133, 1998)
SO NATURE
LA English
DT Editorial Material; Retracted Publication
ID APOPTOSIS; ANTIGEN; FAS
RP VAUX, DL (reprint author), ROYAL MELBOURNE HOSP, WALTER & ELIZA HALL INST MED RES, MELBOURNE, VIC 3050, AUSTRALIA.
RI Vaux, David/C-7249-2013
OI Vaux, David/0000-0003-2703-1651
CR ALDERSON MR, 1995, J EXP MED, V181, P71, DOI 10.1084/jem.181.1.71
   BARKER CF, 1977, ADV IMMUNOL, V25, P1
   BELLGRAU D, 1995, NATURE, V377, P630, DOI 10.1038/377630a0
   HEAD JR, 1983, TRANSPLANTATION, V35, P91, DOI 10.1097/00007890-198301000-00017
   ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5
   MCCURRY KR, 1995, NAT MED, V1, P423, DOI 10.1038/nm0595-423
   MIYAWAKI T, 1992, J IMMUNOL, V149, P3753
   NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326
   SELAWRY HP, 1993, CELL TRANSPLANT, V2, P123, DOI 10.1177/096368979300200206
   TAKAHASHI T, 1994, INT IMMUNOL, V6, P1567, DOI 10.1093/intimm/6.10.1567
NR 10
TC 19
Z9 20
U1 2
U2 8
PU MACMILLAN MAGAZINES LTD
PI LONDON
PA 4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF
SN 0028-0836
J9 NATURE
JI Nature
PD OCT 19
PY 1995
VL 377
IS 6550
BP 576
EP 577
DI 10.1038/377576a0
PG 2
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA TA275
UT WOS:A1995TA27500025
PM 7566165
DA 2018-12-27
ER

PT J
AU FUJII, Y
   TANAKA, H
   TOYOOKA, H
AF FUJII, Y
   TANAKA, H
   TOYOOKA, H
TI RETRACTED: PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING WITH
   GRANISETRON - A RANDOMIZED, DOUBLE-BLIND COMPARISON WITH DROPERIDOL
   (Retracted article. See vol. 59, pg. 1173, 2012)
SO CANADIAN JOURNAL OF ANAESTHESIA-JOURNAL CANADIEN D ANESTHESIE
LA English
DT Article; Retracted Publication
DE COMPLICATIONS, NAUSEA, VOMITING; VOMITING, ANTIEMETICS, GRANISETRON,
   DROPERIDOL, INCIDENCE, NAUSEA; SURGERY, GYNECOLOGICAL
ID RECEPTOR ANTAGONIST; METOCLOPRAMIDE; DOMPERIDONE
AB The effects of granisetron for preventing postoperative nausea and vomiting were investigated in a randomized, double-blind comparison with droperidol and placebo in 100 patients undergoing general anaesthesia for major gynaecological surgery. The patients received a single dose of either granisetron (40 mu g . kg(-1), 25), droperidol (1.25 mg, n = 25; 2.5 mg n = 25) or placebo (saline, n = 25) iv over two to five minutes immediately before induction of anaesthesia. The antiemetic effects of these drugs were evaluated during the first three and the next 21 hr after recovery from anaesthesia. During 0-3 hr after anaesthesia, the frequency of nausea and vomiting war; 60%, 12%, 16% and 12% after administration of placebo, granisetron, droperidol 1.25 mg or droperidol 2.5 mg, respectively. The corresponding frequencies during 3-24 hr after anaesthesia were 44%, 8%, 36% and 12%. The efficacy of granisetron in preventing postoperative nausea and vomiting was almost equal to that of droperidol 2.5 mg. The awakening time in the patients who had received droperidol 2.5 mg was prolonged by approximately three minutes compared with the placebo group (P < 0.05), and postoperative drowsiness/sedation was observed in these patients. In conclusion, preoperative prophylactic administration of granisetron is superior to that of droperidol in the prevention of postoperative nausea and vomiting after anaesthesia.
C1 TOKYO MED & DENT UNIV, SCH MED, DEPT ANAESTHESIOL & CRIT CARE MED, BUNKYO KU, TOKYO 113, JAPAN.
RP FUJII, Y (reprint author), TORIDE KYODO GEN HOSP, DEPT ANAESTHESIA, 2-1-1 HONGO, TORIDE, IBARAKI 302, JAPAN.
CR BERMUDEZ J, 1988, BRIT J CANCER, V58, P644, DOI 10.1038/bjc.1988.277
   CARMICHAEL J, 1989, CANCER CHEMOTH PHARM, V24, P45
   COHEN SE, 1984, ANESTHESIOLOGY, V60, P67, DOI 10.1097/00000542-198401000-00015
   CRESSMAN WA, 1973, ANESTHESIOLOGY, V38, P363, DOI 10.1097/00000542-197304000-00010
   FUJII Y, 1994, CAN J ANAESTH, V41, P794, DOI 10.1007/BF03011585
   FUJII Y, 1994, CAN J ANAESTH, V41, P291, DOI 10.1007/BF03009906
   Furue H, 1990, J CLIN THERAPEUTIC M, V6, P49
   KORTTILA K, 1979, ANESTH ANALG, V58, P396
   LEESER J, 1991, ANESTH ANALG, V72, P751
   MADEJ TH, 1986, BRIT J ANAESTH, V58, P879, DOI 10.1093/bja/58.8.879
   MCKENZIE R, 1981, ANESTH ANALG, V60, P783
   WATCHA MF, 1992, ANESTHESIOLOGY, V77, P162, DOI 10.1097/00000542-199207000-00023
NR 12
TC 25
Z9 29
U1 2
U2 8
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0832-610X
J9 CAN J ANAESTH
JI Can. J. Anaesth.-J. Can. Anesth.
PD OCT
PY 1995
VL 42
IS 10
BP 852
EP 856
DI 10.1007/BF03011030
PG 5
WC Anesthesiology
SC Anesthesiology
GA RX595
UT WOS:A1995RX59500003
PM 8706192
OA Bronze
DA 2018-12-27
ER

PT J
AU FUJII, Y
   TANAKA, H
   SAITOH, Y
   TOYOOKA, H
AF FUJII, Y
   TANAKA, H
   SAITOH, Y
   TOYOOKA, H
TI RETRACTED: EFFECTS OF CALCIUM-CHANNEL BLOCKERS ON CIRCULATORY RESPONSE
   TO TRACHEAL INTUBATION IN HYPERTENSIVE PATIENTS - NICARDIPINE VERSUS
   DILTIAZEM (Retracted article. See vol. 59, pg. 1174, 2012)
SO CANADIAN JOURNAL OF ANAESTHESIA-JOURNAL CANADIEN D ANESTHESIE
LA English
DT Article; Retracted Publication
DE INTUBATION, TRACHEAL, COMPLICATIONS; COMPLICATIONS, TACHYCARDIA,
   HYPERTENSION; PHARMACOLOGY, NICARDIPINE, DILTIAZEM
ID ENDOTRACHEAL INTUBATION; CARDIOVASCULAR-RESPONSE
AB We studied the circulatory responses to laryngoscopy and tracheal intubation in 37 hypertensive patients who received nicardipine 30 mu g . kg(-1) iv (Group N, n = 12), diltiazem 0.3 mg . kg(-1) (Group D, n = 12) or saline placebo (Group C, n = 13) 60 sec before the initiation of laryngoscopy. Anaesthesia was induced with thiopentone 5 mg . kg(-1) iv, and succinylcholine 2 mg . kg(-1) iv was used to facilitate tracheal intubation after precurarization with vecuronium 0.02 mg . kg(-1) iv. In patients in Group C heart rate (HR) increased from 79 +/- 14 (baseline) to 110 +/- 12 (P < 005) associated with tracheal intubation; mean arterial pressure (MAP) increased from 116 +/- 8 to 140 +/- 77 (P < 0.05) and rate-pressure product (RPP) increased from 13385 +/- 2393 to 21251 +/- 3883 (P < 0.05). The changes from baseline values in HR and RPP after tracheal intubation in Group D were less than those in Groups C and N (P < 0.05). The increase in in MAP following tracheal intubation in Groups N and D was lower than that in Group C (P < 0.05). We conclude that, compared with nicardipine, administration of diltiazem iv is associated with less circulatory response to tracheal intubation in hypertensive patients.
C1 TOKYO MED & DENT UNIV, SCH MED, DEPT ANAESTHESIOL & CRIT CARE MED, BUNKYO KU, TOKYO 113, JAPAN.
   TORIDE KYODO GEN HOSP, DEPT ANAESTHESIOL, TORIDE, IBARAKI 302, JAPAN.
CR COKKINOS DV, 1976, BRIT HEART J, V38, P39
   FOX EJ, 1977, ANESTHESIOLOGY, V47, P524, DOI 10.1097/00000542-197712000-00013
   Furuya Y, 1994, Masui, V43, P523
   Hasegawa J, 1992, Masui, V41, P356
   MIKAWA K, 1990, BRIT J ANAESTH, V64, P240
   MIKAWA K, 1990, ANAESTHESIA, V45, P289, DOI 10.1111/j.1365-2044.1990.tb14734.x
   OMOTE K, 1992, ANAESTHESIA, V47, P24, DOI 10.1111/j.1365-2044.1992.tb01947.x
   PRYSROBERTS C, 1971, BRIT J ANAESTH, V43, P531, DOI 10.1093/bja/43.6.531
   ROBINSON BF, 1967, CIRCULATION, V35, P1073, DOI 10.1161/01.CIR.35.6.1073
   STOELTING RK, 1977, ANESTHESIOLOGY, V47, P381, DOI 10.1097/00000542-197710000-00012
NR 10
TC 23
Z9 25
U1 4
U2 10
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0832-610X
J9 CAN J ANAESTH
JI Can. J. Anaesth.-J. Can. Anesth.
PD SEP
PY 1995
VL 42
IS 9
BP 785
EP 788
DI 10.1007/BF03011177
PG 4
WC Anesthesiology
SC Anesthesiology
GA RR615
UT WOS:A1995RR61500007
PM 7497558
OA Bronze
DA 2018-12-27
ER

PT J
AU Subramanian, G
   Trudell, ML
   Boyer, JH
AF Subramanian, G
   Trudell, ML
   Boyer, JH
TI RETRACTED: Dense energetic compounds of carbon, hydrogen, nitrogen, and
   oxygen atoms .5. 1,2,7,8-Bisfuroxano-3,4,9,10
   tetranitro-5,11-dehydro-5H,11H-benzotriazolo[2,1-a]benzotriazole
   (BTBB)(Retracted article. See vol 7, pg 163, 1996)
SO HETEROATOM CHEMISTRY
LA English
DT Article; Retracted Publication
AB A reaction between 2, 8-dichloro-4, 10-dinitro-5, 11-dehydro-5H, 11H-benzotriazolo[2, 1-a]-benzotriazole 8 and sodium azide in dimethyl sulfoxide produced 3, 9-diazido -4, 10-dinitro-5, 11-dehydro-5H, 11H-benzotriazolo [2, 1-a]benzotriazole 10 rather than the 2.8-diazido isomer 9 expected by direct displacement. Thermolytic elimination of nitrogen (2 moles) converted the dinitro diazide 10 to 3,4,9,10-bisfuroxano-5, 11-dehydro-5H, 11H-benzotriazolo[2, 1-a]benzotriazole 11 that was subsequently nitrated to give the 2, 8dinitro derivative 12. Similar nitration converted the dinitro diazide 9 to the trinitro 15 and tetranitro 14 derivatives: thermolysis of the latter gave 1,2,7,8-bisfuroxano-4, 10-dinitro-5, 11-dehydro-5H, 11H-benzotriazolo[2, 1-a]-benzotriazole 16. Nitration (100% HNO3, CF3SO3H) converted compound 16 to the 3,4,10-trinitro derivative 17, whereas a similar nitration (100% HNO3, FSO3H) gave the title compound BTBB, an insensitive high-energy, high-density (d 2. 03 g/cc) molecule. (C) 1995 John Wiley & Sons, Inc.
C1 UNIV NEW ORLEANS, DEPT CHEM, NEW ORLEANS, LA 70148 USA.
CR BAILEY AS, 1958, TETRAHEDRON, V3, P113, DOI 10.1016/0040-4020(58)80003-4
   BENSON FR, 1984, HIGH NITROGEN COMPOU, P6
   BERLIN JK, 1975, J HETEROCYCLIC CHEM, V12, P235, DOI 10.1002/jhet.5570120204
   BIFFIN MEC, 1971, CHEM AZIDO GROUP, P209
   CARBONI RA, 1967, J AM CHEM SOC, V89, P2626, DOI 10.1021/ja00987a021
   CHANG MS, 1985, Patent No. 4526980
   COON CL, 1973, J ORG CHEM, V38, P4243, DOI 10.1021/jo00964a007
   FEDEROFF BT, 1972, ENCY EXPLOSIVES RELA, V5, pD1184
   HARDER RJ, 1967, J AM CHEM SOC, V89, P2643, DOI 10.1021/ja00987a024
   KRASOVITSKII BM, 1988, ORGANIC LUMINESCENT, P17
   LU Q, 1993, HETEROATOM CHEM, V4, P91, DOI 10.1002/hc.520040114
   MEYER R, 1987, EXPLOSIVES, P332
   NIELSEN AT, 1991, CHEM ENERGETIC MAT, P95
   Rudolph A., 1959, US, Patent No. [2904544A, 2904544]
   STEVENS ED, COMMUNICATION
   URBANSKI T, 1978, J SCI IND RES INDIA, V37, P250
NR 16
TC 2
Z9 2
U1 3
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1042-7163
EI 1098-1071
J9 HETEROATOM CHEM
JI Heteroatom Chem.
PD SEP-OCT
PY 1995
VL 6
IS 5
BP 391
EP 395
DI 10.1002/hc.520060502
PG 5
WC Chemistry, Multidisciplinary
SC Chemistry
GA TR649
UT WOS:A1995TR64900001
DA 2018-12-27
ER

PT J
AU BRUGGER, W
   HEIMFELD, S
   BERENSON, RJ
   MERTELSANN, R
   KANZ, L
AF BRUGGER, W
   HEIMFELD, S
   BERENSON, RJ
   MERTELSANN, R
   KANZ, L
TI RETRACTED: RECONSTITUTION OF HEMATOPOIESIS AFTER HIGH-DOSE CHEMOTHERAPY
   BY AUTOLOGOUS PROGENITOR CELLS GENERATED EX-VIVO (RETRACTED ARTICLE. SEE
   VOL 345, PG 64, 2001)
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article; Retracted Publication
ID PLATELET RECOVERY; IFOSFAMIDE; CISPLATIN
AB Background. Autologous peripheral-blood progenitor cells can restore hematopoiesis after high-dose chemotherapy in patients with solid tumors or hematologic cancers. We investigated the ability of peripheral-blood progenitor cells generated ex vivo to restore hematopoiesis in patients with cancer who have undergone high-dose chemotherapy.
   Methods. Ten patients who had received high-dose chemotherapy were given transplants of autologous progenitor cells that had been generated ex vivo. We used 11 million CD34+ hematopoietic progenitor cells as the starting population for the cell growth. This number corresponds to less than 10 percent of the usual preparation of peripheral-blood CD34+ mononuclear cells used in leukapheresis. The CD34+ cells were grown in medium containing autologous plasma, recombinant human stem-cell factor, interleukin-1 beta, interleukin-3, interleukin-6, and erythropoietin.
   Results. No toxic effects were observed with the infusion of the generated cells. The cells promoted a rapid and sustained hematopoietic recovery when transplanted after treatment with high-dose etoposide (1500 mg per square meter of body-surface area), ifosfamide (12 g per square meter), carboplatin (750 mg per square meter), and epirubicin (150 mg per square meter), The pattern of hematopoietic reconstitution was identical to that in historical controls treated with unseparated mononuclear cells or positively selected CD34+ cells.
   Conclusions. A small number of peripheral-blood CD34+ cells, when grown ex vivo, can supply a population of hematopoietic precursors that have the ability to restore blood formation in patients treated with high doses of chemotherapy. This method, which requires only a small volume of the patient's blood, may reduce the risk of tumor-cell contamination, circumvent the need for leukapheresis, and allow repeated cycles of high-dose chemotherapy.
C1 UNIV FREIBURG, MED CTR, DEPT HEMATOL ONCOL, FREIBURG, GERMANY.
   CELLPRO CORP, BOTHELL, WA USA.
CR BRENNER MK, 1993, LANCET, V342, P1134, DOI 10.1016/0140-6736(93)92122-A
   BRUGGER W, 1992, J CLIN ONCOL, V10, P1452, DOI 10.1200/JCO.1992.10.9.1452
   BRUGGER W, 1993, BRIT J HAEMATOL, V84, P402, DOI 10.1111/j.1365-2141.1993.tb03093.x
   BRUGGER W, 1994, BLOOD, V83, P636
   BRUGGER W, 1993, BLOOD, V81, P2579
   BRUGGER W, 1994, BLOOD, V84, P1421
   DEISSEROTH AB, 1994, BLOOD, V83, P3068
   FISCH P, 1994, BLOOD, V84, pA228
   HENSCHLER R, 1994, BLOOD, V84, P2898
   KESSINGER A, 1991, BLOOD, V77, P211
   RILL DR, 1994, BLOOD, V84, P380
   SHERIDAN WP, 1992, LANCET, V339, P640, DOI 10.1016/0140-6736(92)90795-5
   SHPALL EJ, 1994, J CLIN ONCOL, V12, P28, DOI 10.1200/JCO.1994.12.1.28
   SHPALL EJ, 1994, BLOOD, V83, P623
NR 14
TC 339
Z9 341
U1 5
U2 13
PU MASS MEDICAL SOC
PI BOSTON
PA 10 SHATTUCK, BOSTON, MA 02115
SN 0028-4793
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD AUG 3
PY 1995
VL 333
IS 5
BP 283
EP 287
DI 10.1056/NEJM199508033330503
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA RL694
UT WOS:A1995RL69400003
PM 7541111
DA 2018-12-27
ER

PT J
AU CHAMBERLAIN, MC
   GRAFE, MR
AF CHAMBERLAIN, MC
   GRAFE, MR
TI RETRACTED: RECURRENT CHIASMATIC-HYPOTHALAMIC GLIOMA TREATED WITH ORAL
   ETOPOSIDE (Retracted article. See vol. 28, pg. 4018, 2010)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Article; Retracted Publication
ID OPTIC GLIOMA; CLINICAL-PHARMACOLOGY; RADIATION-THERAPY; NATURAL-HISTORY;
   SAN-FRANCISCO; MANAGEMENT; CHILDHOOD; NERVE; CHEMOTHERAPY; CHILDREN
AB Purpose: Chiasmatic-hypothalamic gliomas are not amenable to surgical resection and therefore are treated with either radiotherapy or chemotherapy. Here we report the use of etoposide (VP-16) administered on a chronic oral schedule as a novel chemotherapeutic approach.
   Patients and Methods: Fourteen patients, aged 2 to 15 years, were treated with VP-16 after clinical and neuroradiographic tumor progression. Thirteen patients had received prior radiotherapy, and 12 received prior nitrosourea-based chemotherapy. VP-16 was administered orally, each cycle consisting of 50 mg/m(2)/d on days 1 through 21 and 36 through 57. Clinical and neuroradiographic evaluations were performed during days 58 through 72 before initiation of each cycle of therapy. Complete blood counts were performed weekly.
   Results: Treatment-related complications included the following: partial alopecia (seven patients); diarrhea (six); weight loss (five); neutropenia (four); and thrombocytopenia (four). Three patients required transfusion (three RBC; two platelet), and one patient required antibiotic treatment of neutropenic fever. There were no treatment-related deaths. Fourteen patients were assessable, five of whom demonstrated a radiographic response (one complete and four partial); and three patients demonstrated stable disease, with a median duration of response of 8 months.
   Conclusion: Chronic oral VP-16 is well tolerated, produces modest toxicity, and has apparent activity in this small cohort of patients with recurrent chiasmatic-hypothalamic gliomas. (C) 1995 by American society of Clinical Oncology.
C1 UNIV CALIF SAN DIEGO, DEPT PATHOL, LA JOLLA, CA 92093 USA.
RP CHAMBERLAIN, MC (reprint author), UNIV CALIF SAN DIEGO, DEPT NEUROSCI, 9500 GILLMAN DR, MAIL CODE 0812, LA JOLLA, CA 92093 USA.
CR BATAINI JP, 1991, INT J RADIAT ONCOL, V21, P615, DOI 10.1016/0360-3016(91)90678-W
   CAPO H, 1991, NEUROL CLIN, V9, P179
   CHAMBERLAIN MC, 1989, CANCER, V63, P1681
   CHAMBERLAIN MC, 1993, J NEURO-ONCOL, V15, P133, DOI 10.1007/BF01053934
   CLARK PI, 1987, CLIN PHARMACOKINET, V12, P223, DOI 10.2165/00003088-198712040-00001
   CREAVEN PJ, 1982, CANCER CHEMOTH PHARM, V7, P133
   DANOFF BF, 1980, INT J RADIAT ONCOL, V6, P45, DOI 10.1016/0360-3016(80)90202-3
   DELOS A, 1992, J NEUROONCOL, V14, P151
   DOSORETZ DE, 1980, CANCER, V45, P1467, DOI 10.1002/1097-0142(19800315)45:6<1467::AID-CNCR2820450628>3.0.CO;2-#
   DUTTON JJ, 1991, NEUROL CLIN, V9, P163
   FLETCHER WA, 1986, J NEUROSURG, V65, P154, DOI 10.3171/jns.1986.65.2.0154
   GRECO FA, 1991, CANCER, V67, P303
   GRECO FA, 1991, CANCER, V67, P315
   HORWICH A, 1985, INT J RADIAT ONCOL, V11, P1067, DOI 10.1016/0360-3016(85)90052-5
   HOUSEPIAN EM, 1993, J NEURO-ONCOL, V15, P51, DOI 10.1007/BF01050263
   HOYT WF, 1969, BRIT J OPHTHALMOL, V53, P793, DOI 10.1136/bjo.53.12.793
   IMES RK, 1986, BRIT J OPHTHALMOL, V70, P179, DOI 10.1136/bjo.70.3.179
   IRACI G, 1981, CHILD BRAIN, V8, P326
   JANSS A, 1993, P AN M AM SOC CLIN, V12, P175
   KOVALIC JJ, 1990, INT J RADIAT ONCOL, V18, P927, DOI 10.1016/0360-3016(90)90418-J
   LANSKY LL, 1985, CANCER, V56, P1837, DOI 10.1002/1097-0142(19851001)56:7+<1837::AID-CNCR2820561324>3.0.CO;2-Z
   LISTERNICK R, 1989, J PEDIATR-US, V114, P778
   MEADOWS AT, 1985, J CLIN ONCOL, V3, P532, DOI 10.1200/JCO.1985.3.4.532
   MOGHRABI A, 1993, J NEUROSURG, V79, P223, DOI 10.3171/jns.1993.79.2.0223
   OXENHANDLER DC, 1978, J NEUROSURG, V48, P34, DOI 10.3171/jns.1978.48.1.0034
   PACKER RJ, 1983, CHILD BRAIN, V10, P393
   PACKER RJ, 1993, J CLIN ONCOL, V11, P850, DOI 10.1200/JCO.1993.11.5.850
   PACKER RJ, 1988, ANN NEUROL, V23, P79, DOI 10.1002/ana.410230113
   PACKER RJ, 1992, ANN NEUROL, V32, P48
   PETRONIO J, 1991, J NEUROSURG, V74, P701, DOI 10.3171/jns.1991.74.5.0701
   PIERCE SM, 1990, CANCER, V65, P45, DOI 10.1002/1097-0142(19900101)65:1<45::AID-CNCR2820650111>3.0.CO;2-Z
   RODRIGUEZ LA, 1990, NEUROSURGERY, V26, P242, DOI 10.1227/00006123-199002000-00010
   ROSENSTOCK JG, 1985, J NEUROSURG, V63, P862, DOI 10.3171/jns.1985.63.6.0862
   RUSH JA, 1982, OPHTHALMOLOGY, V89, P1213
   SLEVIN ML, 1991, CANCER, V67, P319, DOI 10.1002/1097-0142(19910101)67:1+<319::AID-CNCR2820671319>3.0.CO;2-D
   SPOOR TC, 1980, AM J OPHTHALMOL, V89, P284, DOI 10.1016/0002-9394(80)90126-9
   STERN J, 1979, NEUROSURGERY, V4, P524, DOI 10.1227/00006123-197906000-00006
   TENNY RT, 1982, J NEUROSURG, V57, P452, DOI 10.3171/jns.1982.57.4.0452
   WEISS L, 1987, CANCER, V59, P1000, DOI 10.1002/1097-0142(19870301)59:5<1000::AID-CNCR2820590525>3.0.CO;2-N
   WISOFF JH, 1990, J NEUROSURG, V73, P661, DOI 10.3171/jns.1990.73.5.0661
   WONG JYC, 1987, CANCER, V60, P1847, DOI 10.1002/1097-0142(19871015)60:8<1847::AID-CNCR2820600829>3.0.CO;2-E
NR 41
TC 52
Z9 52
U1 4
U2 10
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD AUG
PY 1995
VL 13
IS 8
BP 2072
EP 2076
DI 10.1200/JCO.1995.13.8.2072
PG 5
WC Oncology
SC Oncology
GA RM473
UT WOS:A1995RM47300031
PM 7636550
DA 2018-12-27
ER

PT J
AU GELBAND, CH
   HUME, JR
AF GELBAND, CH
   HUME, JR
TI RETRACTED: [CA2+](I) INHIBITION OF K+ CHANNELS IN CANINE RENAL-ARTERY -
   NOVEL MECHANISM FOR AGONIST-INDUCED MEMBRANE DEPOLARIZATION (Retracted
   Article. See vol. 94, pg E15, 2004)
SO CIRCULATION RESEARCH
LA English
DT Article; Retracted Publication
DE RENAL ARTERY; [CA2+](I); K+ CHANNELS; MEMBRANE POTENTIAL REGULATION
ID SMOOTH-MUSCLE CELLS; RECTIFIER POTASSIUM CHANNELS; RABBIT PORTAL-VEIN;
   PATCH-CLAMP; CALCIUM CHANNELS; CONDUCTANCE; SODIUM; NORADRENALINE;
   RECEPTOR; CURRENTS
AB The patch-clamp technique was used to examine the inhibition of delayed rectifier K+ channels by agents that release intracellular Ca2+. During voltage-clamp experiments on isolated myocytes with 4-aminopyridine (4-AP, 10 mmol/L) and niflumic acid (100 mu mol/L) present to inhibit delayed rectifier K+ current (I-K(dr)) and Ca2+-activated Cl- current (I-Cl(Ca)), angiotensin II (Ang II) and caffeine increased Ca2+- activated K+ current (I-K(Ca)) between -25 and 80 mV (n=5). Conversely, with charybdotoxin (ChTX, 100 nmol/L) and niflumic acid (100 mu mol/L) present to inhibit I-K(Ca) and I-Cl(Ca), Ang II and caffeine only caused inhibition of I-K(dr). Block was achieved within 15 seconds of drug application and was reversible upon washout (n=5). The effects of Ang II on I-K(Ca) and I-K(dr) were inhibited by the specific Ang II receptor antagonist losartan (1 mmol/L, n=3). Intracellular BAPTA (10 mmol/L) also abolished the effects of Ang II and caffeine on both I-K(Ca) and I-K(dr). In current-clamp experiments, the application of ChTX (100 nmol/L) and niflumic acid (100 mu mol/L) caused little change in resting membrane potential; however, subsequent application of caffeine (10 mmol/L) caused a 26+/-2.9 mV depolarization from -54+/-3.1 to -28+/-1.7 mV (n=6). 4-AP (10 mmol/L) blocked the caffeine-induced depolarization. When isolated cells were loaded with the Ca2+ indicator indo 1 (100 mu mol/L), Ang II, caffeine, and 4-AP increased [Ca2+](i) and depolarized the cells. Both Ang II and caffeine caused an increase in [Ca2+](i) that preceded membrane depolarization, whereas 4-AP depolarized the cell first and then caused an increase in [Ca2+](i) (n=4). In inside-out patches, with 200 nmol/L ChTX in the patch pipette to block large-conductance Ca2+-activated K+ channels, a 45+/-7-picosiemen 4-AP-sensitive K+ channel was identified that was sensitive to cytoplasmic Ca2+ (n=6). Increasing intracellular Ca2+ decreased channel opening probability [NxP(open), where N is the number of functional channels in a patch and P(open) is the opening probability] at all membrane potentials examined. At 0 mV, increasing Ca2+ from <5 to 200 and 600 nmol/L free Ca2+ decreased NxP(open) by 52+/-3% and 73+/-7%, respectively (n=6). The decrease in opening probability of the delayed rectifier K+ channel resulted from a concentration- and voltage-dependent decrease in mean open time. The decrease in mean open time reflected significant decreases and increases in open and closed time constants, respectively. These results suggest that agonist-induced changes in intracellular Ca2+ can alter vascular smooth muscle membrane potential through regulation of delayed rectifier K+ channels.
C1 UNIV NEVADA, SCH MED, DEPT PHYSIOL, RENO, NV 89557 USA.
FU NHLBI NIH HHS [HL-49254, HL-08531]; NIDDK NIH HHS [DK-41315]
CR ADAMS DJ, 1990, POTASSIUM CHANNELS S, P40
   BEECH DJ, 1989, BRIT J PHARMACOL, V98, P851, DOI 10.1111/j.1476-5381.1989.tb14614.x
   BENHAM CD, 1983, J PHYSIOL-LONDON, V340, P469, DOI 10.1113/jphysiol.1983.sp014774
   BENHAM CD, 1987, NATURE, V328, P275, DOI 10.1038/328275a0
   BEZANILLA F, 1972, J GEN PHYSIOL, V60, P588, DOI 10.1085/jgp.60.5.588
   BOYLE JP, 1992, J PHYSIOL-LONDON, V447, P329, DOI 10.1113/jphysiol.1992.sp019005
   BRAYDEN JE, 1992, SCIENCE, V256, P532, DOI 10.1126/science.1373909
   BYRNE NG, 1988, J PHYSIOL-LONDON, V404, P557, DOI 10.1113/jphysiol.1988.sp017306
   CARL A, 1995, J PHYSIOL-LONDON, V484, P339, DOI 10.1113/jphysiol.1995.sp020669
   CLAPP LH, 1992, AM J PHYSIOL, V262, pH916
   DAUT J, 1994, J CARDIOVASC ELECTR, V5, P154, DOI 10.1111/j.1540-8167.1994.tb01156.x
   DUBOIS JM, 1975, PFLUG ARCH EUR J PHY, V355, P361, DOI 10.1007/BF00579857
   EATON DC, 1980, J GEN PHYSIOL, V75, P727, DOI 10.1085/jgp.75.6.727
   FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463
   FLEISCHMANN BK, 1993, J PHYSIOL-LONDON, V469, P625, DOI 10.1113/jphysiol.1993.sp019834
   FRENCH RJ, 1977, J GEN PHYSIOL, V70, P707, DOI 10.1085/jgp.70.6.707
   GARCIA ML, 1991, J BIOENERG BIOMEMBR, V23, P615, DOI 10.1007/BF00785814
   GELBAND CH, 1993, CIRC RES, V73, P24, DOI 10.1161/01.RES.73.1.24
   GELBAND CH, 1992, CIRC RES, V71, P745, DOI 10.1161/01.RES.71.4.745
   GELBAND CH, 1994, BIOPHYS J, V66, pA328
   Gelband Craig H., 1995, Biophysical Journal, V68, pA252
   GREEN KA, 1991, BRIT J PHARMACOL, V102, P871, DOI 10.1111/j.1476-5381.1991.tb12269.x
   HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997
   ISHIKAWA T, 1993, J PHYSIOL-LONDON, V468, P379, DOI 10.1113/jphysiol.1993.sp019777
   KOMWATANA P, 1994, PFLUG ARCH EUR J PHY, V426, P320, DOI 10.1007/BF00374788
   LEBLANC N, 1990, SCIENCE, V248, P372, DOI 10.1126/science.2158146
   LOPATIN AN, 1994, J GEN PHYSIOL, V103, P203, DOI 10.1085/jgp.103.2.203
   NELSON MT, 1988, NATURE, V336, P382, DOI 10.1038/336382a0
   NELSON MT, 1990, AM J PHYSIOL, V259, pC3
   PACAUD P, 1989, PFLUG ARCH EUR J PHY, V413, P629, DOI 10.1007/BF00581813
   PEACH MJ, 1990, J CARDIOVASC PHARM, V16, pS25, DOI 10.1097/00005344-199016004-00007
   POST JM, 1995, CIRC RES, V77, P131, DOI 10.1161/01.RES.77.1.131
   QUAYLE JM, 1993, AM J PHYSIOL, V265, pC1363
   VANBREEMEN C, 1989, ANNU REV PHYSIOL, V51, P315, DOI 10.1146/annurev.physiol.51.1.315
   VOLK KA, 1993, AM J PHYSIOL, V264, pH1146
NR 35
TC 78
Z9 78
U1 3
U2 8
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0009-7330
J9 CIRC RES
JI Circ.Res.
PD JUL
PY 1995
VL 77
IS 1
BP 121
EP 130
DI 10.1161/01.RES.77.1.121
PG 10
WC Cardiac & Cardiovascular Systems; Hematology; Peripheral Vascular
   Disease
SC Cardiovascular System & Cardiology; Hematology
GA RG256
UT WOS:A1995RG25600016
PM 7788870
DA 2018-12-27
ER

PT J
AU UVA, JL
AF UVA, JL
TI RETRACTED: REVIEW - AUTOEROTIC ASPHYXIATION IN THE UNITED-STATES
   (RETRACTED ARTICLE. SEE VOL 40, PG 932, 1995)
SO JOURNAL OF FORENSIC SCIENCES
LA English
DT Review; Retracted Publication
DE PATHOLOGY AND BIOLOGY; AUTOEROTIC ASPHYXIA; ASPHYXIOPHILIA
ID DEATH; EPIDEMIOLOGY; FEATURES; BONDAGE
AB The purpose of this article is to define autoerotic asphyxia and present the enigma as a preventable problem. Articles published between 1856 and 1994 are identified through medline, referenced citations, and expert opinion. The literature selected were those most often cited and for which the methodological assumptions could be identified. interventional strategies deter mined included legislation/regulation, technology, and education. injury and death from autoerotic asphyxia can be controlled by pre-event, event, and post-event phase control. However, there are formidable barriers in the way.
RP UVA, JL (reprint author), WRIGHT STATE UNIV, SCH MED, DEPT EMERGENCY MED, 809 A PATTERSON RD, DAYTON, OH 45419 USA.
CR ALTER MJ, 1990, JAMA-J AM MED ASSOC, V263, P1218, DOI 10.1001/jama.263.9.1218
   [Anonymous], 1993, ICD10 CLASSIFICATION
   BASS M, 1970, J AMER MED ASSOC, V212, P2075, DOI 10.1001/jama.212.12.2075
   BECKETT S, 1954, WAITING FOR GODOT
   BERLYNE N, 1968, BRIT J PSYCHIAT, V114, P411, DOI 10.1192/bjp.114.509.411
   BLANCHARD R, 1991, BRIT J PSYCHIAT, V159, P371, DOI 10.1192/bjp.159.3.371
   BOGLIOLI LR, 1991, AM J FOREN MED PATH, V12, P64, DOI 10.1097/00000433-199103000-00012
   BRETTAIN R, 1968, GRADWOHLS LEGAL MED, P549
   Brierre de Boismont A., 1856, SUICIDE FOLIE SUICID
   BRODY JE, 1984, NY TIMES, P17
   BURGESS AW, 1983, AM J ORTHOPSYCHIAT, V53, P166, DOI 10.1111/j.1939-0025.1983.tb03361.x
   BYARD RW, 1988, AM J FOREN MED PATH, V9, P252, DOI 10.1097/00000433-198809000-00017
   BYARD RW, 1990, FORENSIC SCI INT, V48, P113, DOI 10.1016/0379-0738(90)90103-6
   BYARD RW, 1993, AM J FOREN MED PATH, V14, P70, DOI 10.1097/00000433-199303000-00017
   Camps F. E., 1976, GRADWOHLS LEGAL MED
   CESNIK JA, 1989, AM J PSYCHOTHER, V43, P277
   CORDNER SM, 1983, MED SCI LAW, V23, P54, DOI 10.1177/002580248302300109
   DANTO BL, 1980, AM J FOREN MED PATH, V1, P117, DOI 10.1097/00000433-198006000-00004
   DESADE, 1965, COMPLETE JUSTINE PHI
   DEVITA VT, 1989, CANCER PRINCIPLES PR, V1
   Diamond M, 1990, Hawaii Med J, V49, P11
   DIETZ PE, 1989, J FORENSIC SCI, V34, P528
   DITTO EW, 1981, AM J FOREN MED PATH, V2, P271, DOI 10.1097/00000433-198109000-00016
   ECKERT WG, 1991, AM J FOREN MED PATH, V12, P3, DOI 10.1097/00000433-199103000-00002
   EDMONDSON JS, 1972, BRIT J PSYCHIAT, V121, P437, DOI 10.1192/bjp.121.4.437
   EMSON HE, 1983, AM J FOREN MED PATH, V4, P337, DOI 10.1097/00000433-198312000-00011
   GOSNOLD JK, 1980, MED SCI LAW, V20, P54, DOI 10.1177/002580248002000111
   GWOZDZ F, 1970, FORENSIC SCI GAZETTE, V1, P2
   HADDON W, 1980, PUBLIC HEALTH REP, V95, P411
   HARBITZ F, 1943, TXB FORENSIC MED
   Hazelwood Robert R., 1983, AUTOEROTIC FATALITIE
   HENRY RD, 1971, MED LEGAL B, V214
   HENRY RD, 1955, MED LEGAL B, V58
   HERMAN SP, 1974, CLIN PEDIATR, V13, P854, DOI 10.1177/000992287401301008
   HIRSCHFIELD M, 1948, SEXUAL ANOMALIES
   HISS J, 1985, AM J FOREN MED PATH, V6, P250, DOI 10.1097/00000433-198509000-00016
   HOLLARAN RL, 1993, J FORENSIC SCI, V38, P359
   HUCKER SJ, 1985, PSYCHIAT CLIN N AM, V8, P323
   HUCKER SJ, 1985, UNPUB SUCCESSFUL TRE
   IKEDA N, 1988, MED SCI LAW, V28, P131, DOI 10.1177/002580248802800210
   IMAMI RH, 1988, AM J FOREN MED PATH, V9, P246, DOI 10.1097/00000433-198809000-00015
   JOHNSTONE JM, 1960, BRIT MED J, V2, P1714, DOI 10.1136/bmj.2.5214.1714
   LEADBEATTER S, 1988, AM J FOREN MED PATH, V9, P60, DOI 10.1097/00000433-198803000-00017
   LITMAN RE, 1972, ARCH GEN PSYCHIAT, V27, P80
   LOURIA DB, 1970, MED ASPECTS HUM SEX, V4, P89
   MCGINNIS JM, 1993, JAMA-J AM MED ASSOC, V270, P2207, DOI 10.1001/jama.270.18.2207
   MELVILLE H, 1928, B BUDD FORETOPMAN SH
   MICHAEL G, 1970, BRIT J PSYCHIAT, V117, P173
   Miller E C, 1983, Bull Am Acad Psychiatry Law, V11, P57
   MINYARD F, 1985, AM J FOREN MED PATH, V6, P151, DOI 10.1097/00000433-198506000-00008
   Money J, 1986, LOVEMAPS
   NELSON JH, 1989, CA-CANCER J CLIN, V39, P157, DOI 10.3322/canjclin.39.3.157
   POLSON CJ, 1973, ESSENTIALS FORENSIC
   RESNIK HLP, 1972, AM J PSYCHOTHER, V26, P4
   ROSENBLUM S, 1979, J AM ACAD CHILD PSY, V18, P546, DOI 10.1097/00004583-197922000-00012
   RUPP J C, 1973, Journal of Forensic Sciences, V18, P259
   SASS FA, 1975, J FORENSIC SCI, V2, P181
   SHANKEL LW, 1956, PSYCHIAT QUART, V30, P478, DOI 10.1007/BF01564363
   SIVALOGANATHAN S, 1984, MED SCI LAW, V24, P300, DOI 10.1177/002580248402400413
   SPITZ WU, 1980, MEDICOLEGAL INVESTIG, P345
   STEARNS A W, 1953, J Maine Med Assoc, V44, P16
   THIBAULT R, 1984, J FORENSIC SCI, V29, P679
   Walsh F M, 1977, Leg Med Annu, P155
   WESSELIUS CL, 1983, AM J FOREN MED PATH, V4, P341, DOI 10.1097/00000433-198312000-00012
   WILLIAMS WW, 1988, ANN INTERN MED, V108, P616, DOI 10.7326/0003-4819-108-4-616
   WILSON M, 1987, J SOC ISSUES, V43, P73, DOI 10.1111/j.1540-4560.1987.tb01296.x
   Wright R K, 1976, J Forensic Sci, V21, P387
   1987, AM J PREV MED, V3, P130
   1993, HIV AIDS SURVEILLANC
   1987, DSM III R
   1993, CANCER FACTS FIGURES
   1992, MMWR-MORBID MORTAL W, V41, P9
   1991, DSM IV
NR 73
TC 34
Z9 34
U1 2
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-1198
EI 1556-4029
J9 J FORENSIC SCI
JI J. Forensic Sci.
PD JUL
PY 1995
VL 40
IS 4
BP 574
EP 581
PG 8
WC Medicine, Legal
SC Legal Medicine
GA RL472
UT WOS:A1995RL47200012
PM 7595293
DA 2018-12-27
ER

PT J
AU KUDOH, Y
   NAGASE, T
   SASAKI, S
   TANAKA, M
AF KUDOH, Y
   NAGASE, T
   SASAKI, S
   TANAKA, M
TI RETRACTED: PHASE-F, A NEW HYDROUS MAGNESIUM-SILICATE SYNTHESIZED AT
   1000-DEGREES-C AND 17 GPA - CRYSTAL-STRUCTURE AND ESTIMATED BULK MODULUS
   (RETRACTED ARTICLE. SEE VOL 24, PG 601, 1997)
SO PHYSICS AND CHEMISTRY OF MINERALS
LA English
DT Article; Retracted Publication
ID TRANSITION ZONE
AB The structure of phase F, a non-stoichiometric hydrous silicate synthesized in a uniaxial, split-sphere, multi-anvil apparatus at conditions of 17 GPa and 1000 degrees C, has been solved and refined in space group P6(3)cm, using synchrotron X-ray data for a single crystal of a size 18 x 24 x 30 mu m. The composition and unit cell for phase F are Mg3.35Si5.51H7.26O18, a = 5.073(3) Angstrom c = 14.013(9) Angstrom, V = 312.3(5) Angstrom(3). The structure contains layers with many similarities to superhydrous phase B. The layers of oxygen atoms are stacked in the ABCBAC-type double cubic closest packing arrangement. The bulk modulus of phase F was estimated from the structural and compositional relationship to superhydrous phase B and periclase.
C1 TOKYO INST TECHNOL, ENGN MAT RES LAB, YOKOHAMA, KANAGAWA 227, JAPAN.
   NATL LAB HIGH ENERGY PHYS, PHOTON FACTORY, TSUKUBA, IBARAKI 305, JAPAN.
   TOKYO INST TECHNOL, DEPT INORGAN MAT, TOKYO 152, JAPAN.
RP KUDOH, Y (reprint author), TOHOKU UNIV, FAC SCI, INST MINERAL PETROL & ECON GEOL, SENDAI, MIYAGI 980, JAPAN.
RI Sasaki, Satoshi/F-7627-2014
CR BASS JD, 1991, T AM GEOPHYS UNION, V72, P499
   FAIRBAIRN HW, 1943, GEOL SOC AM BULL, V54, P1305
   FINGER LW, 1991, AM MINERAL, V76, P1
   GASPARIK T, 1990, J GEOPHYS RES-SOLID, V95, P15751, DOI 10.1029/JB095iB10p15751
   HAZEN RM, 1990, PHYS CHEM MINER, V17, P416
   HORIUCHI H, 1979, AM MINERAL, V64, P593
   KANZAKI M, 1991, PHYS EARTH PLANET IN, V66, P307, DOI 10.1016/0031-9201(91)90085-V
   KANZAKI M, 1989, EOS, V70, P508
   KUDOH Y, 1993, PHYS CHEM MINER, V19, P357
   KUDOH Y, 1994, HIGH-PRESSURE SCIENCE AND TECHNOLOGY - 1993, PTS 1 AND 2, P469, DOI 10.1063/1.46076
   PACALO REG, 1992, AM MINERAL, V77, P681
   RICHET P, 1989, J GEOPHYS RES-SOLID, V94, P3037, DOI 10.1029/JB094iB03p03037
   RINGWOOD AE, 1967, EARTH PLANET SC LETT, V2, P130, DOI 10.1016/0012-821X(67)90114-8
   SHANNON RD, 1969, ACTA CRYSTALL B-STRU, VB 25, P925, DOI 10.1107/S0567740869003220
   YAMAMOTO K, 1974, SOLID STATE CHEM J, V9, P187
   1974, INT TABLES XRAY CRYS
NR 16
TC 19
Z9 20
U1 0
U2 5
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0342-1791
EI 1432-2021
J9 PHYS CHEM MINER
JI Phys. Chem. Miner.
PD JUL
PY 1995
VL 22
IS 5
BP 295
EP 299
DI 10.1007/BF00202769
PG 5
WC Materials Science, Multidisciplinary; Mineralogy
SC Materials Science; Mineralogy
GA RK014
UT WOS:A1995RK01400003
DA 2018-12-27
ER

PT J
AU CHEN, W
   ZOLLMAN, S
   COUDERC, JL
   LASKI, FA
AF CHEN, W
   ZOLLMAN, S
   COUDERC, JL
   LASKI, FA
TI RETRACTED: THE BTB DOMAIN OF BRIC A BRAC MEDIATES DIMERIZATION IN-VITRO
   (RETRACTED ARTICLE. SEE VOL 17, PG 6772, 1997)
SO MOLECULAR AND CELLULAR BIOLOGY
LA English
DT Article; Retracted Publication
ID ACUTE PROMYELOCYTIC LEUKEMIA; FINGER ENCODING GENE; SHOPE FIBROMA VIRUS;
   SECONDARY-STRUCTURE; CONSERVED DOMAIN; VACCINIA VIRUS; ZINC FINGERS;
   DROSOPHILA; PROTEINS; FAMILY
AB The gene bric a brac (bab) is required for the proper development of the limbs and ovary in Drosophila melanogaster, bab encodes a BTB domain (also called a POZ domain), an similar to 115-amino-acid conserved motif found primarily in the N termini of zinc finger proteins. In this paper, we show that the BTB domain of bah can mediate protein dimerization in vitro. In addition, we demonstrate that the first 51 amino acids of the bah BTB domain are sufficient for dimerization, and we identify amino acids within this region that are required for binding.
C1 UNIV CALIF LOS ANGELES, INST MOLEC BIOL, LOS ANGELES, CA 90024 USA.
   UFR MED, BIOCHIM LAB, INSERM, U384, F-63001 CLERMONT FERRAND, FRANCE.
RP CHEN, W (reprint author), UNIV CALIF LOS ANGELES, DEPT BIOL, LOS ANGELES, CA 90024 USA.
CR Ausubel FM, 1989, CURRENT PROTOCOLS MO
   BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664
   BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769
   BULLER RML, 1991, MICROBIOL REV, V55, P80
   CHARDIN P, 1991, NUCLEIC ACIDS RES, V19, P1431, DOI 10.1093/nar/19.7.1431
   CHEN Z, 1994, P NATL ACAD SCI USA, V91, P1178, DOI 10.1073/pnas.91.3.1178
   CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x
   Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45
   DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387
   DIBELLO PR, 1991, GENETICS, V129, P385
   DORN R, 1993, P NATL ACAD SCI USA, V90, P11376, DOI 10.1073/pnas.90.23.11376
   GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8
   GODT D, 1993, DEVELOPMENT, V119, P799
   GODT D, 1995, DEVELOPMENT, V121, P173
   HARRISON SD, 1990, EMBO J, V9, P207, DOI 10.1002/j.1460-2075.1990.tb08097.x
   HOWARD ST, 1991, VIROLOGY, V180, P633, DOI 10.1016/0042-6822(91)90077-O
   JONGENS TA, 1992, CELL, V70, P569, DOI 10.1016/0092-8674(92)90427-E
   JONGENS TA, 1994, GENE DEV, V8, P2123, DOI 10.1101/gad.8.18.2123
   KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x
   KERCKAERT JP, 1993, NAT GENET, V5, P66, DOI 10.1038/ng0993-66
   KOONIN EV, 1992, TRENDS BIOCHEM SCI, V17, P213, DOI 10.1016/0968-0004(92)90379-N
   LAI ZC, 1992, CELL, V70, P609, DOI 10.1016/0092-8674(92)90430-K
   LIU QR, 1994, DEV BIOL, V165, P165, DOI 10.1006/dbio.1994.1243
   MIKI T, 1994, BLOOD, V83, P26
   NUMOTO M, 1993, NUCLEIC ACIDS RES, V21, P3767, DOI 10.1093/nar/21.16.3767
   READ D, 1992, EMBO J, V11, P1035, DOI 10.1002/j.1460-2075.1992.tb05142.x
   REES DC, 1989, ANNU REV BIOCHEM, V58, P607
   SAHUT L, IN PRESS DEV BIOL
   SENKEVICH TG, 1993, VIRUS RES, V30, P73, DOI 10.1016/0168-1702(93)90017-H
   SOELLER WC, 1993, MOL CELL BIOL, V13, P7961, DOI 10.1128/MCB.13.12.7961
   SUGAWARA MM, L16896 GENB ACC
   UPTON C, 1986, VIROLOGY, V152, P308, DOI 10.1016/0042-6822(86)90134-0
   WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0
   XUE FY, 1993, CELL, V72, P681, DOI 10.1016/0092-8674(93)90397-9
   YE BH, 1993, SCIENCE, V262, P747, DOI 10.1126/science.8235596
   ZELENT A, 1994, BRIT J HAEMATOL, V86, P451, DOI 10.1111/j.1365-2141.1994.tb04773.x
   ZHANG KYJ, 1994, PROTEIN SCI, V3, P687
   ZOLLMAN S, 1994, P NATL ACAD SCI USA, V91, P10717, DOI 10.1073/pnas.91.22.10717
NR 38
TC 74
Z9 75
U1 1
U2 4
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0270-7306
EI 1098-5549
J9 MOL CELL BIOL
JI Mol. Cell. Biol.
PD JUN
PY 1995
VL 15
IS 6
BP 3424
EP 3429
PG 6
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA QZ325
UT WOS:A1995QZ32500057
PM 7760839
DA 2018-12-27
ER

PT J
AU FUJII, Y
   TANAKA, H
   TOYOOKA, H
AF FUJII, Y
   TANAKA, H
   TOYOOKA, H
TI RETRACTED: GRANISETRON DEXAMETHASONE COMBINATION REDUCES POSTOPERATIVE
   NAUSEA AND VOMITING (Retracted article. See vol. 59, pg. 1175, 2012)
SO CANADIAN JOURNAL OF ANAESTHESIA-JOURNAL CANADIEN D ANESTHESIE
LA English
DT Article; Retracted Publication
DE COMPLICATIONS, NAUSEA, VOMITING; VOMITING, ANTIEMETICS, GRANISETRON,
   DEXAMETHASONE, INCIDENCE, NAUSEA; SURGERY, GYNECOLOGICAL
ID RECEPTOR ANTAGONIST
AB The prophylactic antiemetic efficacy of combined granisetron and dexamethasone was evaluated in a randomized double-blind manner in 88 patients undergoing general anaesthesia for major gynaecological surgery. Immediately after recovery from anaesthesia, patients received a single dose of either placebo (saline, n = 22), granisetron (20 mu g . kg(-1), n = 22), dexamethasone (8 mg, n = 22) or combined granisetron and dexamethasone (20 mu g . kg(-1) and 8 mg, respectively, n = 22) iv. The treatment groups were similar for patient demography, surgical procedures, anaesthetics administered and opioids given. Postoperatively, the frequency of nausea was 32%, 23%, 27% and 5% after administration of placebo, granisetron, dexamethasone and granisetron plus dexamethasone, respectively; the corresponding frequencies of vomiting were 23%, 23%, 23% and 5%. The incidence of adverse events postoperatively were not different among the groups. It ir concluded that prophylactic administration of combined granisetron and dexamethasone is effective in preventing postoperative nausea and vomiting after anaesthesia.
C1 TOKYO MED & DENT UNIV, SCH MED, DEPT ANAESTHESIOL & CRIT CARE MED, BUNKYO KU, TOKYO 113, JAPAN.
RP FUJII, Y (reprint author), TORIDE KYODO GEN HOSP, DEPT ANAESTHESIOL, 5901-1 TERADA, TORIDE, IBARAKI 302, JAPAN.
CR AAPRO MS, 1984, J CLIN ONCOL, V2, P466, DOI 10.1200/JCO.1984.2.5.466
   BERMUDEZ J, 1988, BRIT J CANCER, V58, P644, DOI 10.1038/bjc.1988.277
   CARMICHAEL J, 1989, CANCER CHEMOTH PHARM, V24, P45
   FUJII Y, 1994, CAN J ANAESTH, V41, P794, DOI 10.1007/BF03011585
   FUJII Y, 1994, CAN J ANAESTH, V41, P291, DOI 10.1007/BF03009906
   MCKENZIE R, 1981, ANESTH ANALG, V60, P783
   SMITH DB, 1991, LANCET, V338, P487, DOI 10.1016/0140-6736(91)90555-4
   WATCHA MF, 1992, ANESTHESIOLOGY, V77, P162, DOI 10.1097/00000542-199207000-00023
NR 8
TC 40
Z9 40
U1 3
U2 10
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0832-610X
J9 CAN J ANAESTH
JI Can. J. Anaesth.-J. Can. Anesth.
PD MAY
PY 1995
VL 42
IS 5
BP 387
EP 390
DI 10.1007/BF03015482
PN 1
PG 4
WC Anesthesiology
SC Anesthesiology
GA QW415
UT WOS:A1995QW41500006
PM 7614644
OA Bronze
DA 2018-12-27
ER

PT J
AU BIRD, J
AF BIRD, J
TI RETRACTED: ACADEMIC INTEGRITY - PROPER REVIEW MAKES FUNDING IRRELEVANT
   (RETRACTED ARTICLE. SEE VOL 311, PG 573, 1995)
SO BMJ-BRITISH MEDICAL JOURNAL
LA English
DT Letter; Retracted Publication
RP BIRD, J (reprint author), ST MARYS HOSP, LONDON W2 1NY, ENGLAND.
CR SMITH R, 1994, BRIT MED J, V309, P1597, DOI 10.1136/bmj.309.6969.1597
NR 1
TC 3
Z9 3
U1 2
U2 6
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 1756-1833
J9 BMJ-BRIT MED J
JI BMJ-British Medical Journal
PD APR 22
PY 1995
VL 310
IS 6986
BP 1068
EP 1069
DI 10.1136/bmj.310.6986.1068c
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA QV313
UT WOS:A1995QV31300050
PM 7728076
DA 2018-12-27
ER

PT J
AU MURRAY, N
   ZHENG, YC
   MANDEL, G
   BREHM, P
   BOLINGER, R
   REUER, Q
   KULLBERG, R
AF MURRAY, N
   ZHENG, YC
   MANDEL, G
   BREHM, P
   BOLINGER, R
   REUER, Q
   KULLBERG, R
TI RETRACTED: A SINGLE-SITE ON THE EPSILON-SUBUNIT IS RESPONSIBLE FOR THE
   CHANGE IN ACH RECEPTOR-CHANNEL CONDUCTANCE DURING SKELETAL-MUSCLE
   DEVELOPMENT (RETRACTED ARTICLE. SEE VOL 20, PG U9, 1998)
SO NEURON
LA English
DT Article; Retracted Publication
ID ACETYLCHOLINE-RECEPTOR; XENOPUS-LAEVIS; OPEN TIME; STRUCTURAL
   DETERMINANTS; AMINO-ACIDS; CULTURE; CELLS; EXPRESSION; RINGS
AB Four critically positioned amino acids on each of the alpha, beta, delta, and gamma subunits of the Torpedo nicotinic acetyl- choline receptor are determinants of channel conductance. Our results show that the gamma and epsilon subunits of Xenopus muscle receptors are identical at all four positions, despite the fact that alpha(2) beta delta epsilon receptors have a 50% greater conductance than alpha(2) beta delta gamma receptors. Instead, the functional difference is conferred by a single charged residue that lies extracellular to all four positions, corresponding to a location in the Torpedo receptor previously shown to have no influence on conductance. Substitution of a positively charged lysine residue in gamma by the neutral methionine in epsilon at this extracellular position is responsible for the increased conductance during maturation of the amphibian neuromuscular junction.
C1 UNIV ALASKA, DEPT BIOL, ANCHORAGE, AK 99508 USA.
RP MURRAY, N (reprint author), SUNY STONY BROOK, DEPT NEUROBIOL & BEHAV, STONY BROOK, NY 11794 USA.
FU NINDS NIH HHS [NS18205, NS24078]
CR BALDWIN TJ, 1988, J CELL BIOL, V106, P469, DOI 10.1083/jcb.106.2.469
   BREHM P, 1983, J NEUROSCI, V3, P101
   BREHM P, 1982, DEV BIOL, V91, P93, DOI 10.1016/0012-1606(82)90012-4
   BREHM P, 1984, J PHYSIOL-LONDON, V350, P631, DOI 10.1113/jphysiol.1984.sp015222
   BREHM P, 1984, J PHYSIOL-LONDON, V357, P203, DOI 10.1113/jphysiol.1984.sp015497
   CAMACHO P, 1993, J NEUROSCI, V13, P605
   FISCHBACH GD, 1980, J PHYSIOL-LONDON, V303, P125, DOI 10.1113/jphysiol.1980.sp013275
   GU Y, 1988, NEURON, V1, P117, DOI 10.1016/0896-6273(88)90195-X
   Higuchi R, 1990, PCR PROTOCOLS
   IMOTO K, 1988, NATURE, V335, P645, DOI 10.1038/335645a0
   JARAMILLO F, 1988, J PHYSIOL-LONDON, V396, P267, DOI 10.1113/jphysiol.1988.sp016962
   KIENKER P, 1994, BIOPHYS J, V66, P325, DOI 10.1016/S0006-3495(94)80781-7
   KONNO T, 1991, P ROY SOC B-BIOL SCI, V244, P69, DOI 10.1098/rspb.1991.0053
   KULLBERG RW, 1981, NATURE, V289, P411, DOI 10.1038/289411a0
   KULLBERG RW, 1994, RECEPTOR CHANNEL, V2, P23
   KULLBERG RW, 1977, DEV BIOL, V60, P101, DOI 10.1016/0012-1606(77)90113-0
   LEONARD RJ, 1984, SCIENCE, V226, P55, DOI 10.1126/science.6474189
   LIU Y, 1993, J PHYSIOL-LONDON, V470, P349, DOI 10.1113/jphysiol.1993.sp019862
   MISHINA M, 1986, NATURE, V321, P406, DOI 10.1038/321406a0
   OWENS J, 1993, RECEPTOR CHANNEL, V1, P173
   OWENS JL, 1989, J NEUROSCI, V9, P1018
   SAKMANN B, 1978, NATURE, V276, P401, DOI 10.1038/276401a0
   SAMBROOK J, 1989, MOL CLONING LABORATO
   SHEPHERD D, 1994, DEV BIOL, V162, P549, DOI 10.1006/dbio.1994.1108
   SIEGELBAUM SA, 1984, DEV BIOL, V104, P366, DOI 10.1016/0012-1606(84)90092-7
   WANG F, 1992, P ROY SOC B-BIOL SCI, V250, P11, DOI 10.1098/rspb.1992.0124
   WITZEMANN V, 1987, FEBS LETT, V223, P104, DOI 10.1016/0014-5793(87)80518-5
NR 27
TC 22
Z9 23
U1 2
U2 9
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 0896-6273
EI 1097-4199
J9 NEURON
JI Neuron
PD APR
PY 1995
VL 14
IS 4
BP 865
EP 870
DI 10.1016/0896-6273(95)90230-9
PG 6
WC Neurosciences
SC Neurosciences & Neurology
GA QU826
UT WOS:A1995QU82600020
PM 7718247
OA Bronze
DA 2018-12-27
ER

PT J
AU FRIEDMAN, AJ
   THOMAS, PP
AF FRIEDMAN, AJ
   THOMAS, PP
TI RETRACTED: DOES LOW-DOSE COMBINATION ORAL-CONTRACEPTIVE USE AFFECT
   UTERINE SIZE OR MENSTRUAL FLOW IN PREMENOPAUSAL WOMEN WITH LEIOMYOMAS
   (RETRACTED ARTICLE. SEE VOL 86, PG 728, 1995)
SO OBSTETRICS AND GYNECOLOGY
LA English
DT Article; Retracted Publication
ID HEALTH BENEFITS; FIBROIDS; VOLUME; RISK
AB Objective: To assess whether low-dose oral contraceptive (OC) use affects uterine size or menstrual flow in women with leiomyomas.
   Methods: Eighty-seven premenopausal women with leiomyomas were enrolled in a 1-year study. Fifty-five women took low-dose monophasic OCs, and 32 took no OCs or other hormonally active medications. Uterine size was assessed by bimanual and sonographic examinations before and after the study. Duration of menstrual flow and hematocrit were also assessed.
   Results: Fifty (91%) of 55 women completed 1 year of OC use. There was no significant difference in mean uterine size determined by bimanual examination or in uterine volume measured by sonography after 12 months of OC use. Likewise, there were no significant changes in these indices among the 32 women who did not take OCs. The mean duration of menstrual flow decreased significantly, from 5.8 to 4.4 days (P < .01), in the group of women taking OCs. The mean hematocrit increased significantly, from 35.8 to 37.8% (P = .014), in this group. In contrast, the women who did not take OCs had no significant changes in these indices.
   Conclusion: In most women with leiomyomas, low-dose OC use provides the noncontraceptive benefit of a reduction in the duration of menstrual flow, with resultant improvement in hematocrit, without increasing uterine size.
RP FRIEDMAN, AJ (reprint author), HARVARD UNIV, BRIGHAM & WOMENS HOSP, SCH MED, DEPT OBSTET & GYNECOL, 75 FRANCIS ST, BOSTON, MA 02115 USA.
FU NCRR NIH HHS [7-M01-RR02635-01]
CR BALDWIN RM, 1961, AM J OBSTET GYNECOL, V81, P739, DOI 10.1016/S0002-9378(15)33522-5
   Barer AP, 1938, AM J OBSTET GYNECOL, V35, P839, DOI 10.1016/S0002-9378(15)31658-6
   BUTTRAM VC, 1981, FERTIL STERIL, V36, P433
   CRAMER SF, 1990, AM J CLIN PATHOL, V94, P435, DOI 10.1093/ajcp/94.4.435
   FRIEDMAN AJ, 1994, HUM REPROD, V9, P1618, DOI 10.1093/oxfordjournals.humrep.a138762
   GOLDSTEIN SR, 1988, OBSTET GYNECOL, V72, P86
   HAYNES PJ, 1977, BRIT J OBSTET GYNAEC, V84, P763, DOI 10.1111/j.1471-0528.1977.tb12490.x
   HYTTEN FE, 1964, J OBSTET GYN BR COMM, V71, P255
   JOHN AH, 1971, J REPROD MED, V6, P56
   MISHELL DR, 1982, AM J OBSTET GYNECOL, V142, P809
   ORY HW, 1982, FAM PLANN PERSPECT, V14, P182, DOI 10.2307/2134636
   PARAZZINI F, 1992, OBSTET GYNECOL, V79, P430, DOI 10.1097/00006250-199203000-00021
   ROSS RK, 1986, BRIT MED J, V293, P359, DOI 10.1136/bmj.293.6543.359
   RYBO G, 1966, ACTA OBSTET GYN SCAN, VS 45, P25, DOI 10.3109/00016346609158477
   SAUER MV, 1988, J REPROD MED, V33, P612
NR 15
TC 34
Z9 36
U1 4
U2 8
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0029-7844
J9 OBSTET GYNECOL
JI Obstet. Gynecol.
PD APR
PY 1995
VL 85
IS 4
BP 631
EP 635
DI 10.1016/0029-7844(95)00007-E
PG 5
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA QN352
UT WOS:A1995QN35200027
PM 7898846
DA 2018-12-27
ER

PT J
AU HAJRA, A
   LIU, PP
   WANG, Q
   KELLEY, CA
   STACY, T
   ADELSTEIN, RS
   SPECK, NA
   COLLINS, FS
AF HAJRA, A
   LIU, PP
   WANG, Q
   KELLEY, CA
   STACY, T
   ADELSTEIN, RS
   SPECK, NA
   COLLINS, FS
TI RETRACTED: THE LEUKEMIC CORE BINDING-FACTOR BETA-SMOOTH MUSCLE MYOSIN
   HEAVY-CHAIN (CBF-BETA-SMMHC) CHIMERIC PROTEIN REQUIRES BOTH CBF-BETA AND
   MYOSIN HEAVY-CHAIN DOMAINS FOR TRANSFORMATION OF NIH 3T3 CELLS
   (RETRACTED ARTICLE. SEE VOL 93, PG 15523, 1996)
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article; Retracted Publication
ID ACUTE MYELOID-LEUKEMIA; POLYOMAVIRUS ENHANCER; NUCLEAR FACTOR; GENE;
   AML1; CHROMOSOME-16; ASSOCIATION; FUSION; REGION; DNA
AB An inversion of chromosome 16 associated with the M4Eo subtype of acute myeloid leukemia produces a chimeric protein fusing the beta subunit of the transcription factor core binding factor (CBF beta) to the tail region of smooth muscle myosin heavy chain (SMMHC). We investigated the oncogenic properties of this CBF beta-SMMHC chimeric protein using a 3T3 transformation assay. NIH 3T3 cells expressing CBF beta-SMMHC acquired a transformed phenotype, as indicated by their ability to form foci, grow in soft agarose, and form tumors in nude mice. Cells expressing normal CBF beta or the SMMHC tail domain did not become transformed. Electrophoretic mobility-shift assays showed that extracts from cells transformed by CBF beta-SMMHC no longer formed the normal CBF/DNA complex but instead formed a much larger complex that did not migrate into the gel, Analysis of CBF beta-SMMHC deletion mutants demonstrated that the chimeric protein was transforming only if two domains were both present: (i) CBF beta sequences necessary for association with the CBF alpha subunit, and (ii) SMMHC sequences important for the formation of multimeric filaments, These results are direct evidence that CBF beta-SMMHC can function as an oncoprotein.
C1 NIH, NATL CTR HUMAN GENOME RES, GENE TRANSFER LAB, BETHESDA, MD 20892 USA.
   UNIV MICHIGAN, SCH MED, DEPT HUMAN GENET, ANN ARBOR, MI 48109 USA.
   DARTMOUTH COLL, SCH MED, DEPT BIOCHEM, HANOVER, NH 03755 USA.
   NHLBI, MOLEC CARDIOL LAB, BETHESDA, MD 20892 USA.
RI Liu, Paul/A-7976-2012
OI Liu, Paul/0000-0002-6779-025X; Adelstein, Robert/0000-0002-8683-2144
FU NCI NIH HHS [CA58343-01]
CR ARTHUR DC, 1983, BLOOD, V61, P994
   ATKINSON SJ, 1991, J CELL SCI, V99, P823
   BAE SC, 1993, ONCOGENE, V8, P809
   CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745
   CLAXTON DF, 1994, BLOOD, V83, P1750
   ERICKSON P, 1992, BLOOD, V80, P1825
   GUMUCIO DL, 1988, MOL CELL BIOL, V8, P5310, DOI 10.1128/MCB.8.12.5310
   HARLOW E, 1988, ANTIBODIES LABORATOR
   HEBERT J, 1994, BLOOD, V84, P2291
   HERNANDEZMUNAIN C, 1994, MOL CELL BIOL, V14, P473, DOI 10.1128/MCB.14.1.473
   HODGE TP, 1992, J CELL BIOL, V118, P1085, DOI 10.1083/jcb.118.5.1085
   KAMACHI Y, 1990, J VIROL, V64, P4808
   KAMPS MP, 1991, GENE DEV, V5, P358, DOI 10.1101/gad.5.3.358
   KELLEY CA, 1992, J BIOL CHEM, V267, P2127
   LEBEAU MM, 1983, NEW ENGL J MED, V309, P630, DOI 10.1056/NEJM198309153091103
   LEVANON D, 1994, GENOMICS, V23, P425, DOI 10.1006/geno.1994.1519
   LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518
   LIU P, IN PRESS COLD SPRING
   MATSUOKA R, 1993, AM J MED GENET, V46, P61, DOI 10.1002/ajmg.1320460110
   MITANI K, 1994, EMBO J, V13, P504, DOI 10.1002/j.1460-2075.1994.tb06288.x
   MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431
   NISSON PE, 1992, CANCER GENET CYTOGEN, V63, P81, DOI 10.1016/0165-4608(92)90384-K
   NUCHPRAYOON I, 1994, MOL CELL BIOL, V14, P5558, DOI 10.1128/MCB.14.8.5558
   NUCIFORA G, 1994, P NATL ACAD SCI USA, V91, P4004, DOI 10.1073/pnas.91.9.4004
   OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859
   OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262
   PETRONI D, 1992, CARCINOGENESIS, V13, P883, DOI 10.1093/carcin/13.5.883
   REDONDO JM, 1992, MOL CELL BIOL, V12, P4817, DOI 10.1128/MCB.12.11.4817
   SATAKE M, 1988, ONCOGENE, V3, P69
   STRACESKI AJ, 1994, P NATL ACAD SCI USA, V91, P589, DOI 10.1073/pnas.91.2.589
   WANG SW, 1993, MOL CELL BIOL, V13, P3324, DOI 10.1128/MCB.13.6.3324
   WANG SW, 1992, MOL CELL BIOL, V12, P89, DOI 10.1128/MCB.12.1.89
   WOTTON D, 1994, MOL CELL BIOL, V14, P840, DOI 10.1128/MCB.14.1.840
NR 33
TC 27
Z9 27
U1 1
U2 5
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD MAR 14
PY 1995
VL 92
IS 6
BP 1926
EP 1930
DI 10.1073/pnas.92.6.1926
PG 5
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA QM408
UT WOS:A1995QM40800029
PM 7892201
OA Bronze, Green Published
DA 2018-12-27
ER

PT J
AU GOERTZEN, MJ
   CLAHSEN, H
   BURRIG, KF
   SCHULITZ, KP
AF GOERTZEN, MJ
   CLAHSEN, H
   BURRIG, KF
   SCHULITZ, KP
TI RETRACTED: STERILIZATION OF CANINE ANTERIOR CRUCIATE ALLOGRAFTS BY
   GAMMA-IRRADIATION IN ARGON (RETRACTED ARTICLE. SEE VOL 79B, PG 705,
   1997)
SO JOURNAL OF BONE AND JOINT SURGERY-BRITISH VOLUME
LA English
DT Article; Retracted Publication
ID LIGAMENT RECONSTRUCTION; BONE ALLOGRAFTS; TENDON; KNEE
AB Bone-ACL-bone allograft transplantation is a potential solution to the problem of reconstruction of the anterior cruciate ligament (ACL), but sterilisation by gamma irradiation or ethylene oxide causes degradation of the graft, We have studied the biomechanical and histological properties of deep-frozen canine bone-ACL-bone allografts sterilised by gamma irradiation (2.5;Mrad) under argon gas protection, Particular attention was paid to their collagen structure and neuroanatomy compared with those of non-irradiated allografts.
   We used 60 skeletally mature foxhounds. In 30 animals one ACL was replaced by an irradiated allograft and in the other 30 a non-irradiated graft was used. In both groups the graft was augmented by a Kennedy Ligament Augmentation Device. Examination of the allografts at 3, 6 and 12 months after implantation included mechanical testing, histology, collagen morphometry, neuroanatomical morphology (silver and gold chloride stain) and studies of the microvasculature (modified Spalteholz technique).
   At 12 months the irradiated ACL allografts failed at a mean mamimum load of 718.3 N, 63.8% of the strength of the normal canine ACL. The non-irradiated allografts failed at 780.1 N, 69.1% of normal. All the allografts showed a well-orientated collagen structure one year after transplantation and there was no difference between the irradiated grafts and the others, The silver staining technique demonstrated Golgi tendon organs and free nerve endings within both groups of allografts, As in the normal ACL these structures mere most commonly found near the surface of the graft and at its bony attachments. At 12 months the irradiated allografts showed slight hypervascularity compared with the non-irradiated grafts.
   We believe that cryopreserved ACL allografts have the potential to restore both the mechanical and the neurophysiological functions of the normal ACL.
C1 UNIV DUSSELDORF, INST ANAT, DEPT TOPOG ANAT & BIOMECH, D-40225 DUSSELDORF, GERMANY.
CR AICHROTH PM, 1986, J BONE JOINT SURG BR, V68, P841
   ANDRISH JT, 1984, CLIN ORTHOP RELAT R, V183, P298
   ARNOCZKY SP, 1979, J BONE JOINT SURG AM, V61, P1221, DOI 10.2106/00004623-197961080-00013
   AUGUSTINE RW, 1956, AM J SURG, V92, P380, DOI 10.1016/S0002-9610(56)80110-4
   BOLTON CW, 1985, CLIN ORTHOP RELAT R, V196, P202
   Bosworth DM, 1936, J BONE JOINT SURG, V18, P178
   Bruckner H, 1966, Chirurg, V37, P413
   CHO KO, 1975, J BONE JOINT SURG AM, V57, P608, DOI 10.2106/00004623-197557050-00003
   CLANCY WG, 1982, J BONE JOINT SURG AM, V64, P352, DOI 10.2106/00004623-198264030-00004
   COLEMAN HM, 1956, J BONE JOINT SURG BR, V38, P778
   DAHNERS LE, 1990, 36TH T M ORTH RES SO, P57
   ELLISON AE, 1980, CLIN ORTHOP RELAT R, V147, P51
   FRIEDLAENDER GE, 1982, J BONE JOINT SURG AM, V64, P307, DOI 10.2106/00004623-198264020-00031
   GIBBONS MJ, 1991, J ORTHOPAED RES, V9, P209, DOI 10.1002/jor.1100090209
   Groves EWH, 1917, LANCET, V2, P674
   HAUT RC, 1990, J ORTHOPAED RES, V8, P532, DOI 10.1002/jor.1100080409
   JACKSON DW, 1988, AM J SPORT MED, V16, P101, DOI 10.1177/036354658801600203
   JACKSON DW, 1987, AM J SPORT MED, V15, P528, DOI 10.1177/036354658701500602
   JACKSON DW, 1987, AM J SPORT MED, V15, P295, DOI 10.1177/036354658701500401
   JAGER M, 1978, UNFALLHEILKUNDE, V81, P172
   KENNEDY JC, 1982, AM J SPORT MED, V10, P329, DOI 10.1177/036354658201000601
   Matis U, 1973, Berl Munch Tierarztl Wochenschr, V86, P245
   MCMASTER WC, 1985, CLIN ORTHOP RELAT R, V196, P196
   NICHOLAS JA, 1973, J BONE JOINT SURG AM, VA 55, P899, DOI 10.2106/00004623-197355050-00001
   NOVOTNY GEK, 1988, STAIN TECHNOL, V63, P1
   ODONOGHUE DH, 1963, J BONE JOINT SURG AM, V45, P905, DOI 10.2106/00004623-196345050-00002
   PARRY MF, 1974, AM J MED, V57, P143, DOI 10.1016/0002-9343(74)90780-3
   PAULOS L, 1981, AM J SPORT MED, V9, P140, DOI 10.1177/036354658100900303
   PAULOS LE, 1987, T ORTHOP RES SOC, V12, P129
   PUDDU G, 1983, AM J SPORT MED, V11, P14, DOI 10.1177/036354658301100105
   SCHULTZ RA, 1984, J BONE JOINT SURG AM, V66A, P1072, DOI 10.2106/00004623-198466070-00014
   SCHUTTE MJ, 1987, J BONE JOINT SURG AM, V69A, P243, DOI 10.2106/00004623-198769020-00011
   SLOCUM DB, 1968, J BONE JOINT SURG AM, VA 50, P226, DOI 10.2106/00004623-196850020-00002
   TOMFORD WW, 1986, J BONE JOINT SURG AM, V68A, P534, DOI 10.2106/00004623-198668040-00008
   Tomford WW, 1983, CLIN ORTHOP RELAT R, V174, P15
   TRILLAT A, 1973, CHIRURGIE GENOU
   Zichner L, 1985, Unfallchirurgie, V11, P238, DOI 10.1007/BF02587970
   ZIMNY ML, 1985, STAIN TECHNOL, V60, P305, DOI 10.3109/10520298509113929
NR 38
TC 33
Z9 34
U1 2
U2 10
PU BRITISH EDITORIAL SOC BONE JOINT SURGERY
PI LONDON
PA 22 BUCKINGHAM STREET, LONDON WC2N 6ET, ENGLAND
SN 0301-620X
EI 2044-5377
J9 J BONE JOINT SURG BR
JI J. Bone Joint Surg.-Br. Vol.
PD MAR
PY 1995
VL 77B
IS 2
BP 205
EP 212
PG 8
WC Orthopedics; Surgery
SC Orthopedics; Surgery
GA QP824
UT WOS:A1995QP82400007
PM 7706332
DA 2018-12-27
ER

PT J
AU BERLINGIERI, MT
   MANFIOLETTI, G
   SANTORO, M
   BANDIERA, A
   VISCONTI, R
   GIANCOTTI, V
   FUSCO, A
AF BERLINGIERI, MT
   MANFIOLETTI, G
   SANTORO, M
   BANDIERA, A
   VISCONTI, R
   GIANCOTTI, V
   FUSCO, A
TI RETRACTED: INHIBITION OF HMGI-C PROTEIN-SYNTHESIS SUPPRESSES
   RETROVIRALLY INDUCED NEOPLASTIC TRANSFORMATION OF RAT-THYROID CELLS
   (Retracted article. See vol. 38, 2018)
SO MOLECULAR AND CELLULAR BIOLOGY
LA English
DT Article; Retracted Publication
ID EPITHELIAL-CELLS; MESSENGER-RNA; NUCLEAR PROTEINS; GENE-EXPRESSION;
   HISTONE H1; DNA; SEQUENCE; VIRUS; MOUSE; ONCOGENES
AB Elevated expression of the three high-mobility group I (HMGI) proteins (HMGI, HMGY, and HMGI-C) has previously been correlated with the presence of a highly malignant phenotype in epithelial and fibroblastic rat thyroid cells and in experimental thyroid, lung, mammary, and skin carcinomas. Northern (RNA) blot and run-on analyses demonstrated that the induction of HMGI genes in transformed thyroid cells occurs at the transcriptional level. An antisense methodology to block HMGI-C protein synthesis was then used to analyze the role of this protein in the process of thyroid cell transformation. Transfection of an antisense construct for the HMGI-C cDNA into normal thyroid cells, followed by infection with transforming myeloproliferative sarcoma virus or Kirsten murine sarcoma virus, generated cell lines that expressed significant levels of the retroviral transforming oncogenes v-mos or v-ras-Ki and removed the dependency on thyroid-stimulating hormones, However, in contrast with untransfected cells or cells transfected with the sense construct, those containing the antisense construct did not demonstrate the appearance of any malignant phenotypic markers (growth in soft agar and tumorigenicity in athymic mice). A great reduction of the HMGI-C protein levels and the absence of the HMGI(Y) proteins was observed in the HMGI-C antisense transfected, virally infected cells. Therefore, the HMGI-C protein seems to play a key role in the transformation of these thyroid cells.
C1 UNIV NAPLES, FAC MED & CHIRURG, CNR, CTR ENDOCRINOL & ONCOL SPERIMENTALE, I-80131 NAPLES, ITALY.
   UNIV TRIESTE, DIPARTIMENTO BIOCHIM BIOFIS & CHIM MACROMOLEC, I-34127 TRIESTE, ITALY.
   UNIV REGGIO CALABRIA, FAC MED & CHIRURG CATANZARO, DIPARTIMENTO MED SPERIMENTALE & CLIN, I-88100 CATANZARO, ITALY.
RI Visconti, Roberta/C-5299-2009
OI Fusco, Alfredo/0000-0003-3332-5197
CR AMBESIIMPIOMBATO FS, 1980, P NATL ACAD SCI-BIOL, V77, P3455, DOI 10.1073/pnas.77.6.3455
   ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9
   BERLINGIERI MT, 1990, BIOCHEM BIOPH RES CO, V173, P172, DOI 10.1016/S0006-291X(05)81037-X
   BERLINGIERI MT, 1989, EXP CELL RES, V183, P277, DOI 10.1016/0014-4827(89)90388-1
   BERLINGIERI MT, 1993, ONCOGENE, V8, P249
   BERLINGIERI MT, 1988, MOL CELL BIOL, V8, P2261, DOI 10.1128/MCB.8.5.2261
   BUSSEMAKERS MJG, 1991, CANCER RES, V51, P606
   CHIAPPETTA G, IN PRESS ONCOGENE
   DILAURO R, 1982, GENE, V19, P117, DOI 10.1016/0378-1119(82)90196-2
   DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6
   ECKNER R, 1989, NUCLEIC ACIDS RES, V17, P5947, DOI 10.1093/nar/17.15.5947
   ELLIS RW, 1981, NATURE, V292, P506, DOI 10.1038/292506a0
   ELTON TS, 1987, BIOCHEM BIOPH RES CO, V143, P260, DOI 10.1016/0006-291X(87)90659-0
   FASHENA SJ, 1992, MOL CELL BIOL, V12, P894, DOI 10.1128/MCB.12.2.894
   FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431
   FRIEDMANN M, 1993, NUCLEIC ACIDS RES, V21, P4259, DOI 10.1093/nar/21.18.4259
   FUSCO A, 1985, J VIROL, V56, P284
   FUSCO A, 1982, CANCER RES, V42, P618
   FUSCO A, 1987, MOL CELL BIOL, V7, P3365, DOI 10.1128/MCB.7.9.3365
   GIANCOTTI V, 1993, EUR J BIOCHEM, V213, P825, DOI 10.1111/j.1432-1033.1993.tb17825.x
   GIANCOTTI V, 1991, EUR J BIOCHEM, V198, P211, DOI 10.1111/j.1432-1033.1991.tb16003.x
   GIANCOTTI V, 1985, CANCER RES, V45, P6051
   GIANCOTTI V, 1989, EXP CELL RES, V184, P538, DOI 10.1016/0014-4827(89)90352-2
   GIANCOTTI V, 1987, EMBO J, V6, P1981, DOI 10.1002/j.1460-2075.1987.tb02461.x
   GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3
   GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0
   JOHNSON KR, 1989, MOL CELL BIOL, V9, P2114, DOI 10.1128/MCB.9.5.2114
   JOHNSON KR, 1988, J BIOL CHEM, V263, P18338
   KAWASAKI ES, 1990, PCR PROTOCOLS GUIDE, P21
   MACPHERSON I, 1964, VIROLOGY, V23, P291, DOI 10.1016/0042-6822(64)90301-0
   MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8
   MANFIOLETTI G, 1991, NUCLEIC ACIDS RES, V19, P6793, DOI 10.1093/nar/19.24.6793
   PATEL UA, 1994, BIOCHEM BIOPH RES CO, V201, P63, DOI 10.1006/bbrc.1994.1669
   RAM TG, 1993, CANCER RES, V53, P2655
   REEVES R, 1990, J BIOL CHEM, V265, P8573
   REEVES R, 1987, P NATL ACAD SCI USA, V84, P6531, DOI 10.1073/pnas.84.18.6531
   SAMBROOK J, 1989, MOL CLONING LABORATO
   SANTORO M, 1990, ONCOGENE, V5, P1595
   SKALNIK DG, 1992, BIOCHEM BIOPH RES CO, V187, P563, DOI 10.1016/0006-291X(92)91231-E
   SOLOMON MJ, 1986, P NATL ACAD SCI USA, V83, P1276, DOI 10.1073/pnas.83.5.1276
   STRAUSS F, 1984, CELL, V37, P889, DOI 10.1016/0092-8674(84)90424-0
   THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P
   TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9
   TOKUNAGA K, 1986, NUCLEIC ACIDS RES, V14, P2829
   TRONICK SR, 1979, P NATL ACAD SCI USA, V76, P6314, DOI 10.1073/pnas.76.12.6314
   YANGYEN HF, 1988, MOL CELL BIOL, V8, P3406, DOI 10.1128/MCB.8.8.3406
   ZHAO K, 1993, EMBO J, V12, P3237, DOI 10.1002/j.1460-2075.1993.tb05993.x
NR 47
TC 178
Z9 180
U1 2
U2 2
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0270-7306
EI 1098-5549
J9 MOL CELL BIOL
JI Mol. Cell. Biol.
PD MAR
PY 1995
VL 15
IS 3
BP 1545
EP 1553
PG 9
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA QH483
UT WOS:A1995QH48300044
PM 7862147
DA 2018-12-27
ER

PT J
AU KIEHNTOPF, M
   HERRMANN, F
   BRACH, MA
AF KIEHNTOPF, M
   HERRMANN, F
   BRACH, MA
TI RETRACTED: FUNCTIONAL NF-IL6/CCAAT ENHANCER-BINDING PROTEIN IS REQUIRED
   FOR TUMOR-NECROSIS-FACTOR ALPHA-INDUCIBLE EXPRESSION OF THE
   GRANULOCYTE-COLONY-STIMULATING FACTOR (CSF), BUT NOT THE
   GRANULOCYTE-MACROPHAGE CSF OR INTERLEUKIN-6 GENE IN HUMAN FIBROBLASTS
   (RETRACTED ARTICLE. SEE VOL 186, PG 171, 1997)
SO JOURNAL OF EXPERIMENTAL MEDICINE
LA English
DT Note; Retracted Publication
ID NF-KAPPA-B; TRANSCRIPTION FACTOR; NUCLEAR FACTOR; ACTIVATION; IL-6;
   PHOSPHORYLATION; CYTOKINES; ELEMENT; FAMILY; KINASE
AB Tumor necrosis factor (TNF) alpha participates in the regulation of the acute-phase, immune, and inflammatory responses. Target genes known to be transcriptionally activated by TNF-alpha include the granulocyte (G)-colony-stimulating factor (CSF) gene, the granulocyte/macrophage (GM)-CSF gene, as well as the interleukin (IL) 6 gene. Functional nuclear factor (NF)-IL6 recognition sites have been identified in regulatory regions of these genes by transient transfection studies using deleted promoter constructs. In addition, NF-IL6 is known to form heterodimeric complexes with the NF-kappa B transcription factor, which is also engaged in the transcriptional regulation of these genes. The indispensable importance of NF-IL6 for regulating gene expression of proinflammatory cytokine genes in response to inflammatory stimuli in vivo remains, however, unclear. We here report, by using both antisense (AS) oligodesoxyribonucleotide (ODN) and ribozyme (RZ)-mediated specific elimination of NF-IL6 transcripts in human fibroblasts, that TNF-alpha-induced synthesis of G-CSF, but not of GM-CSF or IL-6, is abolished in the absence of functional NF-IL6 in vivo. Both AS ODN and RZ targeting of the NF-IL6 transcript eliminate NF-IL6 protein, as shown in Western blot analysis and electrophoretic mobility shift assays. Similarly, fibroblasts exposed to either the AS NF-IL6 ODN or the NF-IL6 RZ, but not to the sense or nonsense ODN or a mutated ribozyme, also failed to respond with functional activation of NF-IL6 as assayed in transient transfection studies using heterologous promoter constructs harboring the NF-IL6 recognition site. In contrast, protein synthesis, DNA-binding activity, and transcriptional activation capacity of the NF-kappa B transcription factor is not impaired upon exposure to either ODN or RZ. Fibroblasts that had been cultured in the presence of the AS NF-IL6 ODN or the NF-IL6RZ failed to synthesize G-CSF protein in response to TNF-alpha, while TNF-alpha-inducible transcription and release of GM-CSF and IL-6 was preserved.
C1 FREE UNIV BERLIN, KLINIKUM RUDOLF VIRCHOW, ROBERT ROSSLE CANC CTR, DEPT MED ONCOL & APPL MOLEC BIOL, D-13122 BERLIN, GERMANY.
   MAX DELBRUCK CTR MOLEC MED, D-13122 BERLIN, GERMANY.
CR AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x
   AKIRA S, 1992, IMMUNOL REV, V127, P25, DOI 10.1111/j.1600-065X.1992.tb01407.x
   ARAI K, 1990, ANNU REV BIOCHEM, V59, P783, DOI 10.1146/annurev.biochem.59.1.783
   BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141
   BRACH MA, 1993, MOL CELL BIOL, V13, P4284, DOI 10.1128/MCB.13.7.4284
   BRACH MA, 1993, J BIOL CHEM, V268, P8466
   DUNN SM, 1994, BLOOD, V83, P2469
   GRUSS HJ, 1992, BLOOD, V80, P2563
   HIMES SR, 1993, ONCOGENE, V8, P3189
   ISSHIKI H, 1990, MOL CELL BIOL, V10, P2757, DOI 10.1128/MCB.10.6.2757
   KIEHNTOPF M, 1994, EMBO J, V13, P4645, DOI 10.1002/j.1460-2075.1994.tb06787.x
   KUCZEK ES, 1991, J IMMUNOL, V146, P2426
   LECLAIR KP, 1992, P NATL ACAD SCI USA, V89, P8145, DOI 10.1073/pnas.89.17.8145
   Liebermann TA, 1990, MOL CELL BIOL, V10, P2327
   MANTOVANI L, 1990, FEBS LETT, V270, P152, DOI 10.1016/0014-5793(90)81256-N
   MATSUSAKA T, 1993, P NATL ACAD SCI USA, V90, P10193, DOI 10.1073/pnas.90.21.10193
   NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207
   NISHIZAWA M, 1990, MOL CELL BIOL, V10, P2002, DOI 10.1128/MCB.10.5.2002
   POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R
   SCHRECK R, 1990, MOL CELL BIOL, V10, P1281, DOI 10.1128/MCB.10.3.1281
   Shannon M F, 1992, Growth Factors, V7, P181, DOI 10.3109/08977199209046923
   TSUBOI A, 1994, BIOCHEM BIOPH RES CO, V199, P1064, DOI 10.1006/bbrc.1994.1337
   VIETOR I, 1993, J BIOL CHEM, V268, P18994
   WANG CY, 1994, MOL CELL BIOL, V14, P1153, DOI 10.1128/MCB.14.2.1153
NR 24
TC 25
Z9 26
U1 3
U2 9
PU ROCKEFELLER UNIV PRESS
PI NEW YORK
PA 1114 FIRST AVE, 4TH FL, NEW YORK, NY 10021 USA
SN 0022-1007
J9 J EXP MED
JI J. Exp. Med.
PD FEB 1
PY 1995
VL 181
IS 2
BP 793
EP 798
DI 10.1084/jem.181.2.793
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA QD012
UT WOS:A1995QD01200037
PM 7530764
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU FUJII, Y
   TANAKA, H
   TOYOOKA, H
AF FUJII, Y
   TANAKA, H
   TOYOOKA, H
TI RETRACTED: CIRCULATORY RESPONSES TO LARYNGEAL MASK AIRWAY INSERTION OR
   TRACHEAL INTUBATION IN NORMOTENSIVE AND HYPERTENSIVE PATIENTS (Retracted
   article. See vol. 59, pg. 1177, 2012)
SO CANADIAN JOURNAL OF ANAESTHESIA-JOURNAL CANADIEN D ANESTHESIE
LA English
DT Article; Retracted Publication
DE EQUIPMENT, LARYNGEAL MASK AIRWAY; INTUBATION, TRACHEAL, COMPLICATIONS;
   COMPLICATIONS, TACHYCARDIA, HYPERTENSION
ID ENDOTRACHEAL INTUBATION; PRESSOR-RESPONSE; ANAESTHESIA; INDUCTION
AB The effects of laryngeal mask airway (LMA) insertion and tracheal intubation on circulatory responses were studied in normotensive (n = 24) and hypertensive (n = 22) patients. In a randomized, double-blind manner, LMA insertion or tracheal intubation was performed after induction of anaesthesia with thiopentone and muscle relaxation with succinyl choline. In both normotensive and hypertensive patients, heart rate (HR) mean arterial pressure (MAP) and rate-pressure product increased after tracheal intubation or LMA insertion compared with base-line (P < 0.05). The haemodynamic changes were greater after intubation than after LMA insertion (P < 0.05). Following intubation of the trachea or insertion of the LMA, HR increased more markedly in hypertensive patients than in normotensive patients (P < 0.05). Plasma adrenaline and noradrenaline concentrations after tracheal intubation or LMA insertion increased compared with baseline values (P < 0.05) in normotensive and hypertensive patients. The increase in noradrenaline concentration after tracheal intubation was greater than that after LMA insertion (P < 0.05). No patient revealed ECG evidence of myocardial ischaemia. We conclude that insertion of LMA is associated with less circulatory responses than tracheal intubation in both normotensive and hypertensive patients.
C1 TOKYO MED & DENT UNIV, SCH MED, DEPT ANAESTHESIOL & CRIT CARE MED, BUNKYO KU, TOKYO 113, JAPAN.
RP FUJII, Y (reprint author), TORIDE KYODO GEN HOSP, DEPT ANAESTHESIOL, 5901-1 TERADA, TORIDE, IBARAKI 302, JAPAN.
CR BRAIN AIJ, 1983, BRIT J ANAESTH, V55, P801, DOI 10.1093/bja/55.8.801
   BRAUDE N, 1989, ANAESTHESIA, V44, P551, DOI 10.1111/j.1365-2044.1989.tb11439.x
   COKKINOS DV, 1976, BRIT HEART J, V38, P39
   FORBES AM, 1970, BRIT J ANAESTH, V42, P618, DOI 10.1093/bja/42.7.618
   FOX EJ, 1977, ANESTHESIOLOGY, V47, P524, DOI 10.1097/00000542-197712000-00013
   HALLMAN H, 1978, LIFE SCI, V23, P1049, DOI 10.1016/0024-3205(78)90665-3
   PENNANT JH, 1993, ANESTHESIOLOGY, V79, P144
   PRYSROBERTS C, 1971, BRIT J ANAESTH, V43, P531, DOI 10.1093/bja/43.6.531
   ROBINSON BF, 1967, CIRCULATION, V35, P1073, DOI 10.1161/01.CIR.35.6.1073
   RUSSELL WJ, 1981, BRIT J ANAESTH, V53, P837, DOI 10.1093/bja/53.8.837
   WILSON IG, 1992, ANAESTHESIA, V47, P300, DOI 10.1111/j.1365-2044.1992.tb02168.x
NR 11
TC 46
Z9 49
U1 0
U2 8
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0832-610X
J9 CAN J ANAESTH
JI Can. J. Anaesth.-J. Can. Anesth.
PD JAN
PY 1995
VL 42
IS 1
BP 32
EP 36
DI 10.1007/BF03010568
PG 5
WC Anesthesiology
SC Anesthesiology
GA QL722
UT WOS:A1995QL72200007
PM 7534216
OA Bronze
DA 2018-12-27
ER

PT J
AU FUJII, Y
   TOYOOKA, H
   AMAHA, K
AF FUJII, Y
   TOYOOKA, H
   AMAHA, K
TI RETRACTED: AMRINONE IMPROVES CONTRACTILITY OF FATIGUED DIAPHRAGM IN DOGS
   (Retracted article. See vol. 59, pg. 1176, 2012)
SO CANADIAN JOURNAL OF ANAESTHESIA-JOURNAL CANADIEN D ANESTHESIE
LA English
DT Article; Retracted Publication
DE VENTILATION, DIAPHRAGM, FATIGUE; PHARMACOLOGY, AMRINONE
ID RESPIRATORY MUSCLES; CANINE DIAPHRAGM; BLOOD-FLOW; DOBUTAMINE;
   METABOLISM; ACIDOSIS; FAILURE; LACTATE; HEART
AB The effects of amrinone, a bipyridine derivative, on diaphragmatic contractility and fatigue were examined in 36 anaesthetized mechanically ventilated dogs divided into four groups. In Group Ia (n = 8), dogs without diaphragmatic fatigue were given a bolus injection (0.75 mg.kg(-1))followed by continuous infusion (10 mu g kg(-1).min(-1)) of amrinone iv. In Group Ib (n = 8), animals without fatigue received infusion only of maintenance fluid. In Group IIa (n = 10) and Group IIb (n = 10), diaphragmatic fatigue was induced by intermittent supramaximal bilateral electrophrenic stimulation at a frequency of 20 Hz applied for 30 min. After producing fatigue, amrinone (0.75 mg.kg(-1) loading dose plus 10 mu g.k(-1).min(-1) maintenance dose) iv were administered in Group IIa. Only maintenance fluids were administered in Group IIb during this period. diaphragmatic contractility was assessed in each group by measuring transdiaphragmatic pressure (Pdi). Compared with Group Ib, Pdi at any stimuli in Group lo did not differ. After producing fatigue, in Group IIa and Group IIB, Pdi decreased at low-frequency (10-30 Hz) stimulation (P < 0.05), whereas no change in Pdi was observed at high-frequency (50-100 Hz) stimulation. In Group IIa, Pdi to each stimulus increased during amrinone infusion compared with Group IIb (P < 0.05) In Group IIb, the speed of recovery from fatigue was relatively slower at low-frequency stimulation The integrated diaphragmatic electric activity (Edi) did not change throughout the experiment. These results indicate that amrinone improves contractility in the fatigued diaphragm.
C1 TOKYO MED & DENT UNIV, SCH MED, DEPT ANAESTHESIOL & CRIT CARE MED, BUNKYO KU, TOKYO 113, JAPAN.
RP FUJII, Y (reprint author), TORIDE KYODO GEN HOSP, DEPT ANAESTHESIOL, 5901-1 TERADA, TORIDE, IBARAKI 302, JAPAN.
CR AUBIER M, 1981, NEW ENGL J MED, V305, P249, DOI 10.1056/NEJM198107303050503
   AUBIER M, 1981, J APPL PHYSIOL, V50, P538
   AUBIER M, 1989, ANN INTERN MED, V110, P17, DOI 10.7326/0003-4819-110-1-17
   AUBIER M, 1986, J APPL PHYSIOL, V61, P1767
   BENOTTI J R, 1978, New England Journal of Medicine, V299, P1373
   EDWARDS RHT, 1978, CLIN SCI MOL MED, V54, P463, DOI 10.1042/cs0540463
   ENDOH M, 1982, J PHARMACOL EXP THER, V221, P775
   ESAU SA, 1989, AM REV RESPIR DIS, V139, P1410, DOI 10.1164/ajrccm/139.6.1410
   FUJII Y, 1993, CAN J ANAESTH, V40, P453, DOI 10.1007/BF03009517
   FUJII Y, 1991, MASUI, V5, P17
   GRASSINO A, 1978, J APPL PHYSIOL, V44, P829
   HOWELL S, 1984, AM REV RESPIR DIS, V129, P118
   HOWELL S, 1985, J APPL PHYSIOL, V59, P1376
   IDE T, 1992, ANESTH ANALG, V74, P739
   KLEIN NA, 1981, AM J CARDIOL, V48, P170, DOI 10.1016/0002-9149(81)90587-7
   Moxham J, 1981, Ciba Found Symp, V82, P197
   ROBERTSON CH, 1977, J CLIN INVEST, V59, P31, DOI 10.1172/JCI108619
   ROUSSOS C, 1982, NEW ENGL J MED, V307, P786, DOI 10.1056/NEJM198209233071304
   ROUSSOS CS, 1977, J APPL PHYSIOL, V43, P189
   SIDI A, 1993, ANESTH ANALG, V76, P1201, DOI 10.1213/00000539-199376060-00005
NR 20
TC 13
Z9 13
U1 2
U2 8
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0832-610X
J9 CAN J ANAESTH
JI Can. J. Anaesth.-J. Can. Anesth.
PD JAN
PY 1995
VL 42
IS 1
BP 80
EP 86
DI 10.1007/BF03010577
PG 7
WC Anesthesiology
SC Anesthesiology
GA QL722
UT WOS:A1995QL72200016
PM 7889590
OA Bronze
DA 2018-12-27
ER

PT J
AU BEZOUSKA, K
   YUEN, CT
   OBRIEN, J
   CHILDS, RA
   CHAI, WG
   LAWSON, AM
   DRBAL, K
   FISEROVA, A
   POSPISIL, M
   FEIZI, T
AF BEZOUSKA, K
   YUEN, CT
   OBRIEN, J
   CHILDS, RA
   CHAI, WG
   LAWSON, AM
   DRBAL, K
   FISEROVA, A
   POSPISIL, M
   FEIZI, T
TI RETRACTED: OLIGOSACCHARIDE LIGANDS FOR NKR-P1 PROTEIN ACTIVATE NK CELLS
   AND CYTOTOXICITY (Retracted article. See vol. 500, pg. 492, 2013)
SO NATURE
LA English
DT Article; Retracted Publication
ID NATURAL-KILLER-CELLS; MEDIATED CYTO-TOXICITY; GANGLIOSIDES; GLYCOLIPIDS;
   RECOGNITION; MOLECULE; MANNOSE; GLYCOPROTEINS; SPECIFICITY; ANTIBODIES
AB A diversity of high-affinity oligosaccharide ligands are Identified for NKR-P1, a membrane protein on natural killer (NH) cells which contains an extracellular Ca2+-dependent lectin domain. Interactions of such oligosaccharides on the target cell surface with NKR-P1 on the killer cell surface are crucial both for target cell recognition and for delivery of stimulatory or inhibitory signals linked to the NH cytolytic machinery. NK-resistant tumour cells are rendered susceptible by preincubation with liposomes expressing NKR-P1 ligands, suggesting that purging of tumour or virally infected cells in vivo may be a therapeutic possibility.
C1 NORTHWICK PK HOSP & CLIN RES CTR, GLYCOSCI LAB, GLYCOBIOL GRP, HARROW HA1 3UJ, MIDDX, ENGLAND.
   NORTHWICK PK HOSP & CLIN RES CTR, GLYCOSCI LAB, MASS SPECTROMETRY GRP, HARROW HA1 3UJ, MIDDX, ENGLAND.
   CHARLES UNIV, FAC SCI, DEPT BIOCHEM, CR-12840 PRAGUE 2, CZECH REPUBLIC.
   ACAD SCI CZECH REPUBL, INST MICROBIOL, DEPT IMMUNOL & GNOTOBIOL, CR-14220 PRAGUE 4, CZECH REPUBLIC.
CR ANDO I, 1987, INT J CANCER, V40, P12, DOI 10.1002/ijc.2910400104
   BEVILACQUA MP, 1993, J CLIN INVEST, V91, P379, DOI 10.1172/JCI116210
   BEZOUSKA K, 1994, J BIOL CHEM, V269, P16945
   BRUNNER KT, 1968, IMMUNOLOGY, V14, P181
   CHAMBERS WH, 1986, J IMMUNOL, V137, P1469
   CHAMBERS WH, 1989, J EXP MED, V169, P1373, DOI 10.1084/jem.169.4.1373
   CHAMBERS WH, 1993, GLYCOBIOLOGY, V3, P9, DOI 10.1093/glycob/3.1.9
   CHOU DKH, 1986, J BIOL CHEM, V261, P1717
   CHUSED TM, 1987, CYTOMETRY, V8, P396, DOI 10.1002/cyto.990080409
   DRICKAMER K, 1993, CURR OPIN STRUC BIOL, V3, P393, DOI 10.1016/S0959-440X(05)80112-5
   EBEL F, 1992, BIOCHEMISTRY-US, V31, P12190, DOI 10.1021/bi00163a031
   FEIZI T, 1989, CIBA F SYMP, V145, P62
   FEIZI T, 1987, BIOCHEM J, V245, P1
   FEIZI T, 1985, NATURE, V314, P53, DOI 10.1038/314053a0
   FEIZI T, 1994, METHOD ENZYMOL, V230, P484
   FEIZI T, 1979, J EXP MED, V149, P975, DOI 10.1084/jem.149.4.975
   Feizi Ten, 1993, Current Opinion in Structural Biology, V3, P701, DOI 10.1016/0959-440X(93)90053-N
   FORBES JT, 1981, P NATL ACAD SCI-BIOL, V78, P5797, DOI 10.1073/pnas.78.9.5797
   GIORDA R, 1990, SCIENCE, V249, P1298, DOI 10.1126/science.2399464
   GOOI HC, 1985, J BIOL CHEM, V260, P3218
   GRAYSON G, 1992, CELL IMMUNOL, V139, P18, DOI 10.1016/0008-8749(92)90096-8
   HAKOMORI S, 1985, CANCER RES, V45, P2405
   HAUBECK HD, 1985, J IMMUNOL, V134, P65
   KARLHOFER FM, 1992, NATURE, V358, P66, DOI 10.1038/358066a0
   KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.biochem.60.1.443
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   LARKIN M, 1992, J BIOL CHEM, V267, P13661
   LASKY LA, 1989, CELL, V56, P1045, DOI 10.1016/0092-8674(89)90637-5
   LOVELESS RW, 1992, EMBO J, V11, P813, DOI 10.1002/j.1460-2075.1992.tb05118.x
   MCCOY J P JR, 1991, Glycobiology, V1, P321, DOI 10.1093/glycob/1.4.321
   MCEVER RP, 1991, J CELL BIOCHEM, V45, P156, DOI 10.1002/jcb.240450206
   OHMORI K, 1989, BLOOD, V74, P255
   ROBINSON PJ, 1979, IMMUNOLOGICAL METHOD, V3, P125
   Ryan James C., 1992, Natural Immunity, V11, P279
   RYAN JC, 1992, J IMMUNOL, V149, P1631
   RYAN JC, 1991, J IMMUNOL, V147, P3244
   SCHWARZMANN G, 1987, METHOD ENZYMOL, V138, P319
   SCUDDER P, 1986, EUR J BIOCHEM, V157, P365, DOI 10.1111/j.1432-1033.1986.tb09678.x
   STOLL MS, 1988, BIOCHEM J, V256, P661, DOI 10.1042/bj2560661
   TRINCHIERI G, 1989, ADV IMMUNOL, V47, P187, DOI 10.1016/S0065-2776(08)60664-1
   VONFIGURA K, 1986, ANNU REV BIOCHEM, V55, P167, DOI 10.1146/annurev.biochem.55.1.167
   VUJANOVIC NL, 1988, J EXP MED, V167, P15, DOI 10.1084/jem.167.1.15
   WARD JM, 1983, AM J PATHOL, V111, P1
   YAMAMOTO H, 1985, CELL IMMUNOL, V96, P409, DOI 10.1016/0008-8749(85)90371-5
   YOGEESWARAN G, 1981, INT J CANCER, V28, P517, DOI 10.1002/ijc.2910280419
   YOKOYAMA WM, 1993, ANNU REV IMMUNOL, V11, P613, DOI 10.1146/annurev.iy.11.040193.003145
   YOKOYAMA WM, 1993, CURR OPIN IMMUNOL, V5, P67, DOI 10.1016/0952-7915(93)90083-5
   YOUNG WW, 1980, J IMMUNOL, V124, P199
   YOUNG WW, 1981, J IMMUNOL, V126, P1
   YUEN CT, 1994, J BIOL CHEM, V269, P1595
NR 50
TC 265
Z9 266
U1 4
U2 29
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
EI 1476-4687
J9 NATURE
JI Nature
PD NOV 10
PY 1994
VL 372
IS 6502
BP 150
EP 157
DI 10.1038/372150a0
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA PQ688
UT WOS:A1994PQ68800047
PM 7969447
DA 2018-12-27
ER

PT J
AU WALDEN, R
   HAYASHI, H
   LUBENOW, H
   CZAJA, I
   SCHELL, J
AF WALDEN, R
   HAYASHI, H
   LUBENOW, H
   CZAJA, I
   SCHELL, J
TI RETRACTED: AUXIN INDUCIBILITY AND DEVELOPMENTAL EXPRESSION OF AXI-1 - A
   GENE DIRECTING AUXIN INDEPENDENT GROWTH IN TOBACCO PROTOPLASTS
   (RETRACTED ARTICLE, SEE VOL 18, PG 2908, 1999)
SO EMBO JOURNAL
LA English
DT Article; Retracted Publication
DE AUXIN; CELL DIVISION; GENE EXPRESSION; PROTOPLASTS; T-DNA TAGGING;
   TOBACCO
ID T-DNA; MESOPHYLL PROTOPLASTS; NICOTIANA-SYLVESTRIS; SEQUENCE-ANALYSIS;
   HORMONE AUXIN; PLANT-GROWTH; PROTEIN; PROMOTER; TRANSCRIPTION;
   REGENERATION
AB We describe the characterization of axi 1, a tobacco gene isolated by activation T-DNA tagging which apparently plays a role in auxin action. Upon deregulated expression, axi 1 confers on protoplasts the ability to grow in culture not only in the absence of auxin but also in high auxin concentrations where maximal frequencies of cell division are not observed in wild-type protoplasts. In wild-type plants axi 1 is transcribed principally in root tissue. In the tagged plant line, axi 159, axi 1 RNA can be detected in all tissues tested. Freshly isolated wild-type protoplasts require auxin for the accumulation of detectable levels of axi 1 transcript and this precedes maximal levels of cell division. In contrast, axi 1 RNA appears in protoplasts isolated from axi 159 plants in the absence of auxin. axi 1 was localized to 6.2 kb of plant genomic DNA flanking the right T-DNA border sequence. axi 1 is interrupted by nine introns and in tobacco it is a member of a small gene family. Database searching reveals no similarity within the coding region with other genes. Sequences within the fourth intron are similar to those located in the non-coding regions of other plant genes, some of which are known to be auxin inducible. A DNA fragment containing the conserved sequence acts as an auxin responsive element in transient expression assays in wild-type protoplasts and this response is higher in axi 159 protoplasts. This suggests that auxin induced axi 1 expression may be mediated by a region contained within an intron sequence and that the axi 1 product might play a role in this induction.
RP WALDEN, R (reprint author), MAX PLANCK INST ZUCHTUNGSFORSCH, CARL VON LINNE WEG 10, D-50829 COLOGNE, GERMANY.
CR ADAM E, 1993, PLANT PHYSIOL, V101, P1407, DOI 10.1104/pp.101.4.1407
   BENFEY PN, 1990, SCIENCE, V250, P959, DOI 10.1126/science.250.4983.959
   CLINE MG, 1994, PHYSIOL PLANTARUM, V90, P230, DOI 10.1034/j.1399-3054.1994.900133.x
   DAVIES PJ, 1989, PLANT HORMONES THEIR
   Dellaporta SL, 1983, PLANT MOL BIOL REP, V14, P19, DOI DOI 10.1007/BF02712670
   DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387
   DROUIN G, 1990, J MOL EVOL, V31, P132, DOI 10.1007/BF02109482
   ESTELLE M, 1992, BIOESSAYS, V14, P439, DOI 10.1002/bies.950140703
   FROMM H, 1991, MOL GEN GENET, V229, P181, DOI 10.1007/BF00272154
   GOLDSMITH MHM, 1993, P NATL ACAD SCI USA, V90, P11442, DOI 10.1073/pnas.90.24.11442
   GOTTESMAN S, 1990, P NATL ACAD SCI USA, V87, P3513, DOI 10.1073/pnas.87.9.3513
   HAYASHI H, 1992, SCIENCE, V258, P1350, DOI 10.1126/science.1455228
   HENIKOFF S, 1987, METHOD ENZYMOL, V155, P156
   HENNIG J, 1993, PLANT J, V4, P481, DOI 10.1046/j.1365-313X.1993.04030481.x
   JACOBS WP, 1979, PLANT HORMONES DEV
   JEFFERSON RA, 1987, EMBO J, V6, P3901
   KAY R, 1987, SCIENCE, V236, P1299, DOI 10.1126/science.236.4806.1299
   KING J, 1988, TRENDS GENET, V229, P181
   KLEE H, 1991, ANNU REV PLANT PHYS, V42, P529, DOI 10.1146/annurev.arplant.42.1.529
   KORBER H, 1991, EMBO J, V10, P3983, DOI 10.1002/j.1460-2075.1991.tb04973.x
   LEYSER HMO, 1993, NATURE, V364, P161, DOI 10.1038/364161a0
   LINSMAIER EM, 1965, PHYSIOL PLANTARUM, V18, P100, DOI 10.1111/j.1399-3054.1965.tb06874.x
   LIU XJ, 1994, J BIOL CHEM, V269, P668
   LOGEMANN J, 1987, ANAL BIOCHEM, V163, P16, DOI 10.1016/0003-2697(87)90086-8
   MALIGA P, 1975, NATURE, V255, P401, DOI 10.1038/255401a0
   MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x
   NAGAO RT, 1993, PLANT MOL BIOL, V21, P1147, DOI 10.1007/BF00023610
   NAGATA T, 1970, PLANTA, V92, P301, DOI 10.1007/BF00385097
   NAGY JI, 1976, Z PFLANZENPHYSIOL, V78, P453, DOI 10.1016/S0044-328X(76)80093-1
   NAPIER RM, 1991, TRENDS BIOCHEM SCI, V16, P72
   NEGRUTIU I, 1987, PLANT MOL BIOL, V8, P363, DOI 10.1007/BF00015814
   OELLER PW, 1993, J MOL BIOL, V233, P789, DOI 10.1006/jmbi.1993.1555
   OHSHIMA M, 1990, NUCLEIC ACIDS RES, V18, P182, DOI 10.1093/nar/18.1.182
   PALME K, 1991, MECH DEVELOP, V33, P97, DOI 10.1016/0925-4773(91)90076-I
   PALME K, 1992, INT REV CYTOL, V132, P223, DOI 10.1016/S0074-7696(08)62457-2
   SAMBROOK J, 1989, MOL CLONING LABORATO
   SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463
   SPENA A, 1992, Current Opinion in Biotechnology, V3, P159, DOI 10.1016/0958-1669(92)90146-A
   VANBUUREN M, 1992, MOL GEN GENET, V232, P460, DOI 10.1007/BF00266251
   VANDERZAAL EJ, 1991, PLANT MOL BIOL, V16, P983, DOI 10.1007/BF00016071
   WALDEN R, 1993, PLANT CELL REP, V12, P551, DOI 10.1007/BF00233058
   WALDEN R, 1991, PLANT J, V1, P281, DOI 10.1046/j.1365-313X.1991.t01-6-00999.x
   WALDEN R, 1994, IN PRESS METODS PLAN
   WAREING PF, 1981, GROWTH DIFFERENTIATI
   Weisshaar B, 1991, Symp Soc Exp Biol, V45, P191
   WYATT RE, 1993, PLANT MOL BIOL, V22, P731, DOI 10.1007/BF00027361
   YOSHIOKA Y, 1993, P NATL ACAD SCI USA, V90, P6562, DOI 10.1073/pnas.90.14.6562
   YOSHIOKA Y, 1993, MOL MECHANISMS BACTE
NR 48
TC 21
Z9 21
U1 5
U2 15
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0261-4189
EI 1460-2075
J9 EMBO J
JI Embo J.
PD OCT 17
PY 1994
VL 13
IS 20
BP 4729
EP 4736
DI 10.1002/j.1460-2075.1994.tb06798.x
PG 8
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA PN994
UT WOS:A1994PN99400002
PM 7957043
DA 2018-12-27
ER

PT J
AU SOTT, C
   DORNER, B
   KARAWAJEW, L
   HERRMANN, F
   BRACH, MA
AF SOTT, C
   DORNER, B
   KARAWAJEW, L
   HERRMANN, F
   BRACH, MA
TI RETRACTED: TRANSFORMING GROWTH-FACTOR-BETA RELIEVES STEM-CELL
   FACTOR-INDUCED PROLIFERATION OF MYELOGENOUS LEUKEMIA-CELLS THROUGH
   INHIBITION OF BINDING OF THE TRANSCRIPTION FACTOR NF-JUN (RETRACTED
   ARTICLE. SEE VOL 93, PG. 3573, 1999)
SO BLOOD
LA English
DT Article; Retracted Publication
ID COLONY-STIMULATING FACTOR; HEMATOPOIETIC PROGENITOR CELLS; C-JUN;
   TGF-BETA; MESSENGER-RNA; RETINOBLASTOMA PROTEIN; EXPRESSION;
   FACTOR-BETA-1; TGF-BETA-1; ACTIVATION
AB Transforming growth factor-beta (TGF-beta) is a potent inhibitor of growth factor-stimulated hematopoiesis in normal and leukemic conditions. Using the factor-dependent myelogenous leukemia cell lines GF-D8 and Mo7, we show that TGF-beta interferes with stem cell factor (SCF)-induced proliferation by downmodulating c-jun gene expression, The ability of SCF to induce accumulation of c-jun transcripts was abolished when TGF-beta was present in culture. Transcriptional nuclear run-on assays indicated that TGF-beta relieved the capacity of SCF to enhance the transcriptional rate of the c-jun gene. Deletion analysis of the c-jun promoter furthermore showed that SCF was activating the c-jun promoter via the NF-jun transcription factor. Gel mobility shift assays showed that SCF increased the binding activity of NF-jun to its recognition site within 5 to 15 minutes. Binding activity peaked at 1 hour after exposure to SCF and declined to starting levels within 4 hours. The ability of SCF to enhance NF-jun binding activity was also dose-dependent in the range of 5 to 100 ng/mL. Exposure of GF-DB and Mo7 cells to TGF-beta before the addition of SCF antagonized SCF-induced NF-jun binding. Moreover, whereas SCF was capable of functionally activating a heterologous promoter containing the NF-jun binding site, pretreatment of GF-D8 cells with TGF-beta abolished transcriptional activation of this heterologous promoter. These findings indicate that SCF-mediated activation of c-jun via NF-jun is crucial for the SCF-inducible proliferative response and is inhibited by TGF-beta. In additional experiments, the antisense technique was used. Treatment of GF-D8 and Mo7 cells with an antisense oligodeoxyribonucleotide directed against the translation initiation site of c-jun abolished the capacity of SCF to induce a proliferative response, whereas sense and nonsense oligomers had no effect. Taken together, our data indicate that the counteracting modulation of the binding activity of NF-jun by SCF and TGF-beta regulates the expression of the c-jun gene and thereby the proliferative state of the GF-D8 and Mo7 target. (C) 1994 by The American Society of Hematology.
C1 MAX DELBRUCK CTR MOLEC MED, D-13122 BERLIN, GERMANY.
   FREE UNIV BERLIN, KLINIKUM RUDOLF VIRCHOW, DEPT MED ONCOL & APPL MOLEC BIOL, W-1000 BERLIN, GERMANY.
CR ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2
   AXELRAD AA, 1990, EXP HEMATOL, V18, P143
   BLATTI SP, 1992, CELL GROWTH DIFFER, V3, P429
   BOYD FT, 1989, J BIOL CHEM, V264, P2272
   BRACH MA, 1993, MOL CELL BIOL, V13, P4284, DOI 10.1128/MCB.13.7.4284
   BRACH MA, 1992, BLOOD, V79, P728
   BRACH MA, 1992, BLOOD, V80, P1224
   BRACH MA, 1992, EMBO J, V11, P1479, DOI 10.1002/j.1460-2075.1992.tb05192.x
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4
   CARTER R, 1991, ONCOGENE, V6, P229
   CHEN AR, 1993, BLOOD, V81, P2539
   DEVOS S, 1993, CANCER RES, V53, P3638
   DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475
   DUBOIS CM, 1990, J EXP MED, V172, P737, DOI 10.1084/jem.172.3.737
   EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4
   GAYNOR R, 1991, BLOOD, V77, P2618
   GRAHAM G J, 1990, Progress in Growth Factor Research, V2, P181, DOI 10.1016/0955-2235(90)90004-4
   GRAHAM GJ, 1990, NATURE, V344, P442, DOI 10.1038/344442a0
   HINO M, 1988, BRIT J HAEMATOL, V70, P143, DOI 10.1111/j.1365-2141.1988.tb02455.x
   JACOBSEN SEW, 1991, BLOOD, V77, P1706
   KELLER JR, 1988, J EXP MED, V168, P737, DOI 10.1084/jem.168.2.737
   KELLER JR, 1991, P NATL ACAD SCI USA, V88, P7190, DOI 10.1073/pnas.88.16.7190
   KIM SJ, 1990, MOL CELL BIOL, V10, P1492, DOI 10.1128/MCB.10.4.1492
   KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385
   LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9
   LI L, 1990, J BIOL CHEM, V265, P1556
   LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3
   MALTMAN J, 1993, J EXP MED, V178, P925, DOI 10.1084/jem.178.3.925
   MASSAGUE J, 1992, CELL, V69, P1067, DOI 10.1016/0092-8674(92)90627-O
   MOUTHON MA, 1992, EXP HEMATOL, V20, P909
   OHTA M, 1987, NATURE, V329, P539, DOI 10.1038/329539a0
   OKAZAKI R, 1992, J BONE MINER RES, V7, P1149
   OTTMANN OG, 1988, J IMMUNOL, V140, P2661
   PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K
   RAMBALDI A, 1993, BLOOD, V81, P1376
   RYDER K, 1988, P NATL ACAD SCI USA, V85, P8464, DOI 10.1073/pnas.85.22.8464
   RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0
   SEGARINI PR, 1992, J BIOL CHEM, V267, P1048
   SHAW RJ, 1990, J CELL BIOL, V111, P2139, DOI 10.1083/jcb.111.5.2139
   SING GK, 1988, BLOOD, V72, P1504
   TAETLE R, 1993, CANCER RES, V53, P3386
   YAN ZF, 1992, ONCOGENE, V7, P801
NR 43
TC 15
Z9 15
U1 1
U2 8
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD SEP 15
PY 1994
VL 84
IS 6
BP 1950
EP 1959
PG 10
WC Hematology
SC Hematology
GA PG388
UT WOS:A1994PG38800031
PM 7521696
DA 2018-12-27
ER

PT J
AU FUJII, Y
   TANAKA, H
   TOYOOKA, H
AF FUJII, Y
   TANAKA, H
   TOYOOKA, H
TI RETRACTED: OPTIMAL ANTIEMETIC DOSE OF GRANISETRON FOR PREVENTING
   POSTOPERATIVE NAUSEA AND VOMITING (Retracted article. See vol. 59, pg.
   1178, 2012)
SO CANADIAN JOURNAL OF ANAESTHESIA-JOURNAL CANADIEN D ANESTHESIE
LA English
DT Article; Retracted Publication
DE COMPLICATIONS, NAUSEA, VOMITING; VOMITING, ANTIEMETICS; GRANISETRON,
   INCIDENCE, NAUSEA; SURGERY, GYNECOLOGICAL
ID ANTAGONIST
AB In order to determine the optimal effective dose of granisetron for preventing postoperative nausea and vomiting, the drug was administered in doses of either 20, 40 or 60 mu g . kg(-1). The efficacy of granisetron was evaluated in a randomized, double-blind comparison with placebo in 100 patients undergoing general anaesthesia for major gynaecological surgery. The patients received a single dose of either graisetron or placebo (saline) iv immediately after recovery from anaesthesia. The effects were assessed during the 24 hr after recovery from anaesthesia by means of a nausea and vomiting scare; 0 = no emetic symptoms, 1 = nausea, 2 = vomiting. The treatment groups were similar for patient characteristics, surgical procedures and anaesthetics administered. The mean scores were 0.7, 0.6, 0.2 and 0.2 after administration of placebo granisetron 20, 40 and 60 mu g . kg(-1) respectively. Granisetron 40 mu g . kg(-1) was as effective as 60 mu g . kg(-1) and both resulted in reduction of the scores compared with placebo and granisetron 20 mu g . kg(-1) (P < 0.05). In conclusion, granisetron 40 mu g . kg(-1) is considered to be the appropriate dosage for preventing postoperative emesis after anaesthesia.
C1 TOKYO MED & DENT UNIV, SCH MED, DEPT ANAESTHESIOL & CRIT CARE MED, BUNKYO KU, TOKYO 113, JAPAN.
RP FUJII, Y (reprint author), TORIDE KYODO GEN HOSP, DEPT ANAESTHESIOL, 5901-1 TERADA, TORIDE, IBARAKI 302, JAPAN.
CR BERMUDEZ J, 1988, BRIT J CANCER, V58, P644, DOI 10.1038/bjc.1988.277
   CARMICHAEL J, 1989, CANCER CHEMOTH PHARM, V24, P45
   FALKSON G, 1989, CANCER CHEMOTH PHARM, V24, P193, DOI 10.1007/BF00300242
   FUJII Y, 1994, CAN J ANAESTH, V41, P291, DOI 10.1007/BF03009906
   Furue H, 1990, J CLIN THERAPEUTIC M, V6, P49
   WATCHA MF, 1992, ANESTHESIOLOGY, V77, P162, DOI 10.1097/00000542-199207000-00023
NR 6
TC 53
Z9 55
U1 2
U2 7
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0832-610X
J9 CAN J ANAESTH
JI Can. J. Anaesth.-J. Can. Anesth.
PD SEP
PY 1994
VL 41
IS 9
BP 794
EP 797
DI 10.1007/BF03011585
PG 4
WC Anesthesiology
SC Anesthesiology
GA PE608
UT WOS:A1994PE60800006
PM 7954995
OA Bronze
DA 2018-12-27
ER

PT J
AU DEWOLF, D
   RONDIA, G
   VERHAAREN, H
   MATTHYS, D
AF DEWOLF, D
   RONDIA, G
   VERHAAREN, H
   MATTHYS, D
TI RETRACTED: ADENOSINE-TRIPHOSPHATE TREATMENT FOR SUPRAVENTRICULAR
   TACHYCARDIA IN INFANTS (Retracted article. See vol. 174, pg. 1559, 2015)
SO EUROPEAN JOURNAL OF PEDIATRICS
LA English
DT Article; Retracted Publication
DE SVT; ATP; INFANTS
ID CHILDREN; ARRHYTHMIAS; MANAGEMENT; VERAPAMIL
AB Adenosine is an endogenous nucleoside acting on coronary perfusion and myocardial conduction. Although the anti-arrhythmic effects of adenosine have been known for decades, interest in the use of adenosine or adenosine triphosphate (ATP- a precursor of adenosine) in termination of supraventricular tachycardia (SVT) has been renewed. We studied the use of Striadyne (ATP and a mixture of other nucleosides including adenosine) in 22 infants younger than 6 months in order to evaluate efficacy and safety of the drug in this particular age group. Striadyne stopped SVT in 17 cases and was diagnostic in another 4 cases. Ten out of 17 successfully converted infants showed one or more reinitiations of SVT, which were easily controlled. The results support the efficacy of ATP for the termination of re-entry types of tachycardia, as well as its diagnostic value and its lack of serious side-effects.
C1 STATE UNIV GHENT HOSP, DEPT PAEDIAT, GHENT, BELGIUM.
RP DEWOLF, D (reprint author), FREE UNIV BRUSSELS, UNIV HOSP, DEPT PAEDIAT, LAARBEEKLAAN 101, B-1090 BRUSSELS, BELGIUM.
RI de wolf, daniel/F-7481-2013; de wolf, daniel/C-9057-2013
CR CAMM AJ, 1991, NEW ENGL J MED, V325, P1621
   CLARKE B, 1987, LANCET, V1, P299
   Drury AN, 1929, J PHYSIOL-LONDON, V68, P213, DOI 10.1113/jphysiol.1929.sp002608
   FAULDS D, 1991, DRUGS, V41, P596, DOI 10.2165/00003495-199141040-00007
   FLETCHER S, 1991, AM HEART J, V121, P1818, DOI 10.1016/0002-8703(91)90037-I
   FREILICH A, 1992, AM HEART J, V123, P1324, DOI 10.1016/0002-8703(92)91040-8
   GRECO R, 1982, CIRCULATION, V66, P504, DOI 10.1161/01.CIR.66.3.504
   Honey RM, 1930, Q J MED, V23, P485, DOI 10.1093/qjmed/os-23.92.485
   HOOD MA, 1992, AM HEART J, V123, P1543, DOI 10.1016/0002-8703(92)90807-8
   HUAULT G, 1993, PEDIATRIE URGENCE, P1062
   JOBE RL, 1991, AM HEART J, V121, P1239, DOI 10.1016/0002-8703(91)90692-B
   MCCABE JL, 1992, ANN EMERG MED, V21, P358, DOI 10.1016/S0196-0644(05)82650-2
   McDeed-Breault C, 1992, J Emerg Nurs, V18, P494
   MOSQUEDAGARCIA R, 1992, CLIN INVEST MED, V15, P445
   OVERHOLT ED, 1988, AM J CARDIOL, V61, P336, DOI 10.1016/0002-9149(88)90940-X
   RANKIN AC, 1992, AM J MED, V92, P655, DOI 10.1016/0002-9343(92)90784-9
   REYES G, 1992, ANN EMERG MED, V21, P1499, DOI 10.1016/S0196-0644(05)80069-1
   ROS S P, 1991, Pediatric Emergency Care, V7, P222, DOI 10.1097/00006565-199108000-00006
   ROSSI AF, 1992, CRIT CARE MED, V20, P1107, DOI 10.1097/00003246-199208000-00007
   SOMLO E, 1955, LANCET, V1, P1125
   STRASBURGER JF, 1991, DRUGS, V42, P974, DOI 10.2165/00003495-199142060-00006
   TILL J, 1989, BRIT HEART J, V62, P204
   TILL JA, 1991, ARCH DIS CHILD, V66, P647, DOI 10.1136/adc.66.5.647
NR 23
TC 4
Z9 4
U1 6
U2 13
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0340-6199
EI 1432-1076
J9 EUR J PEDIATR
JI Eur. J. Pediatr.
PD SEP
PY 1994
VL 153
IS 9
BP 668
EP 671
DI 10.1007/BF02190689
PG 4
WC Pediatrics
SC Pediatrics
GA PD811
UT WOS:A1994PD81100011
PM 7957427
DA 2018-12-27
ER

PT J
AU ASHFORD, MLJ
   BOND, CT
   BLAIR, TA
   ADELMAN, JP
AF ASHFORD, MLJ
   BOND, CT
   BLAIR, TA
   ADELMAN, JP
TI RETRACTED: CLONING AND FUNCTIONAL EXPRESSION OF A RAT-HEART K-ATP
   CHANNEL (RETRACTED ARTICLE. SEE VOL 378, PG 792, 1995)
SO NATURE
LA English
DT Article; Retracted Publication
ID POTASSIUM CHANNELS; VENTRICULAR MYOCYTES; MEMBRANE PATCHES; GUINEA-PIG;
   CELL; PINACIDIL
AB POTASSIUM channels that are ATP-sensitive (K-ATP) couple membrane potential to the metabolic status of the cell. K-ATP channels are inhibited by intracellular ATP and are stimulated by intracellular nucleotide diphosphates(1). K-ATP channel are important regulators of secretory processes and muscle contraction, and are targets for therapeutic treatment of type II diabetes by the inhibitory sulphonylureas(2) and for hypertension by activators such as pinacidil(3). In cardiac tissue, K-ATP channels are central regulators of post-ischaemic cardioprotection(4,5). Electrophysiological and pharmacological characteristics vary among K-ATP channels recorded from diverse tissues suggesting extensive molecular heterogeneity(1) A complementary DNA encoding a K-ATP channel was isolated from rat heart using the polymerase chain reaction. We report here that the expressed channels possess all of the essential features of native cardiac K-ATP channels, including sensitivity to intracellular nucleotides. In addition the cloned channels are activated by the potassium channel opener, pinacidil, but are not inhibited by the sulphonylurea, glibenclamide.
C1 OREGON HLTH SCI UNIV, VOLLUM INST, PORTLAND, OR 97201 USA.
   UNIV CAMBRIDGE, DEPT PHARMACOL, CAMBRIDGE CB2 1QJ, ENGLAND.
CR ALDRICH R, 1993, NATURE, V362, P107, DOI 10.1038/362107a0
   ASHCROFT FM, 1988, ANNU REV NEUROSCI, V11, P97, DOI 10.1146/annurev.ne.11.030188.000525
   BOND CT, IN PRESS RECEPT CHAN
   DASCAL N, 1993, P NATL ACAD SCI USA, V90, P6596, DOI 10.1073/pnas.90.14.6596
   Dempster J., 1993, COMPUTER ANAL ELECTR
   EDWARDS G, 1993, ANNU REV PHARMACOL, V33, P597, DOI 10.1146/annurev.pharmtox.33.1.597
   ESCANDE D, 1992, TRENDS PHARMACOL SCI, V13, P269, DOI 10.1016/0165-6147(92)90083-I
   FAN Z, 1990, J PHYSIOL-LONDON, V430, P273, DOI 10.1113/jphysiol.1990.sp018291
   FINDLAY I, 1992, J PHARMACOL EXP THER, V261, P540
   FINDLAY I, 1988, BIOCHIM BIOPHYS ACTA, V943, P297, DOI 10.1016/0005-2736(88)90561-5
   FRIEDEL HA, 1990, DRUGS, V39, P929, DOI 10.2165/00003495-199039060-00008
   FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998
   GOPALAKRISHNAN M, 1993, DRUG DEVELOP RES, V28, P95, DOI 10.1002/ddr.430280202
   HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997
   HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0
   KHAN RN, 1993, P ROY SOC B-BIOL SCI, V253, P225, DOI 10.1098/rspb.1993.0107
   KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0
   KUBO Y, 1993, NATURE, V364, P802, DOI 10.1038/364802a0
   LEDERER WJ, 1989, J PHYSIOL-LONDON, V419, P193, DOI 10.1113/jphysiol.1989.sp017869
   LEE K, 1994, BRIT J PHARMACOL, V111, P632, DOI 10.1111/j.1476-5381.1994.tb14783.x
   LYNCH JJ, 1992, FASEB J, V6, P2952
   SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F
   TRUBE G, 1984, PFLUG ARCH EUR J PHY, V401, P178, DOI 10.1007/BF00583879
   TUNG RT, 1991, J PHYSIOL-LONDON, V437, P239, DOI 10.1113/jphysiol.1991.sp018593
   ZILBERTER Y, 1988, PFLUG ARCH EUR J PHY, V411, P584, DOI 10.1007/BF00582382
NR 25
TC 189
Z9 191
U1 2
U2 6
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
EI 1476-4687
J9 NATURE
JI Nature
PD AUG 11
PY 1994
VL 370
IS 6489
BP 456
EP 459
DI 10.1038/370456a0
PG 4
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA PB407
UT WOS:A1994PB40700055
PM 8047164
DA 2018-12-27
ER

PT J
AU PEARCE, JM
   HAMID, RI
AF PEARCE, JM
   HAMID, RI
TI RETRACTED: RANDOMIZED CONTROLLED TRIAL OF THE USE OF HUMAN
   CHORIONIC-GONADOTROPIN IN RECURRENT MISCARRIAGE ASSOCIATED WITH
   POLYCYSTIC OVARIES (RETRACTED ARTICLE. SEE VOL 102, PG 853, 1995)
SO BRITISH JOURNAL OF OBSTETRICS AND GYNAECOLOGY
LA English
DT Article; Retracted Publication
ID ABORTION; WOMEN; INFERTILITY; OVULATION; DISEASE
AB Objective To determine whether the use of human chorionic gonadotrophin (hCG) would reduce the recurrent miscarriage rate in women with polycystic ovarian disease.
   Design Double-blind, prospective, randomised controlled trial.
   Setting A pregnancy loss clinic in a London teaching hospital.
   Subjects One hundred and ninety-one women with a history of three consecutive spontaneous first trimester miscarriages and polycystic ovary syndrome.
   Intervention 10000 i.u. of hCG or a placebo were given when the leading follicle was greater than or equal to 21 mm, then 5000 i.u. of hCG or a placebo were given twice weekly until miscarriage or the tenth week of pregnancy.
   Main outcome measure Miscarriage rate.
   Results Women with polycystic ovaries who received hCG treatment had a lower miscarriage rate (14 %) compared with women who received placebo (43 %). In women with follicular phase luteinising hormone > 10 iu/1, those who received hCG therapy had a miscarriage rate of 10 % compared with a rate of 44 % in women who received the placebo. When clomiphene was used for ovulation induction, women treated with hCG had a miscarriage rate of 14 % compared with a rate 47 % in women who received the placebo. There was no significant benefit from hCG therapy in natural cycles.
   Conclusion The use of hCG in women with recurrent miscarriage and polycystic ovary syndrome improves the pregnancy outcome.
RP PEARCE, JM (reprint author), ST GEORGE HOSP, DEPT OBSTET & GYNAECOL, BLACKSHAW RD, LONDON SW17 0QT, ENGLAND.
CR ADAMS J, 1986, BRIT MED J, V293, P355, DOI 10.1136/bmj.293.6543.355
   Alberman E., 1988, EARLY PREGNANCY LOSS, P9
   ARMAR NA, 1993, BRIT J OBSTET GYNAEC, V100, P161, DOI 10.1111/j.1471-0528.1993.tb15214.x
   GEIRSSON RT, 1983, PROGR OBSTETRICS GYN, V3, P3
   HAMILTONFAIRLEY D, 1991, HUM REPROD, V6, P1095, DOI 10.1093/oxfordjournals.humrep.a137491
   HARRISON RF, 1985, EUR J OBSTET GYN R B, V20, P159, DOI 10.1016/0028-2243(85)90015-2
   HARRISON RF, 1992, EUR J OBSTET GYN R B, V47, P175, DOI 10.1016/0028-2243(92)90147-Q
   JOHNSON P, 1990, BRIT MED J, V300, P154, DOI 10.1136/bmj.300.6718.154
   MACHIN D, 1987, STATISTICAL TABLES D
   PEARCE JM, 1993, CONT REV OBSTET GYNA, V5, P142
   REGAN L, 1990, LANCET, V336, P1141, DOI 10.1016/0140-6736(90)92765-A
   REGAN L, 1991, BMJ-BRIT MED J, V302, P543, DOI 10.1136/bmj.302.6776.543
   ROSSMANITH WG, 1991, CLIN ENDOCRINOL, V34, P223, DOI 10.1111/j.1365-2265.1991.tb00298.x
   SAGLE M, 1988, BMJ-BRIT MED J, V297, P1027, DOI 10.1136/bmj.297.6655.1027
   STERN JJ, 1992, AM J OBSTET GYNECOL, V166, P1844, DOI 10.1016/0002-9378(92)91576-V
   TUPPALA M, 1993, BRIT J OBSTET GYNAEC, V100, P348
NR 16
TC 9
Z9 9
U1 0
U2 6
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0306-5456
J9 BRIT J OBSTET GYNAEC
JI Br. J. Obstet. Gynaecol.
PD AUG
PY 1994
VL 101
IS 8
BP 685
EP 688
PG 4
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA PA237
UT WOS:A1994PA23700010
PM 7947503
DA 2018-12-27
ER

PT J
AU PEARCE, JM
   MANYONDA, IT
   CHAMBERLAIN, GVP
AF PEARCE, JM
   MANYONDA, IT
   CHAMBERLAIN, GVP
TI RETRACTED: TERM DELIVERY AFTER INTRAUTERINE RELOCATION OF AN ECTOPIC
   PREGNANCY (RETRACTED ARTICLE. SEE VOL 102, PG 853, 1995)
SO BRITISH JOURNAL OF OBSTETRICS AND GYNAECOLOGY
LA English
DT Note; Retracted Publication
RP PEARCE, JM (reprint author), ST GEORGE HOSP, SCH MED, DEPT OBSTET & GYNAECOL, CRANMER TERRACE, LONDON SW17, ENGLAND.
CR APLIN JD, 1991, J CELL SCI, V99, P681
   KIRBY DRS, 1960, NATURE, V187, P707, DOI 10.1038/187707a0
   KIRBY DRS, 1963, J REPROD FERTIL, V5, P1
   KIRBY DRS, 1963, J ANAT, V97, P119
   MANYONDA IT, 1994, CONT REV OBSTET GYNA, V6, P5
   PSYCHOYOS A, 1986, ANN NY ACAD SCI, V476, P36, DOI 10.1111/j.1749-6632.1986.tb20920.x
   ROTTEM S, 1991, ULTRASOUND OBST GYN, V1, P197, DOI 10.1046/j.1469-0705.1991.01030197.x
   SHETTLES LB, 1990, AM J OBSTET GYNECOL, V163, P2026, DOI 10.1016/0002-9378(90)90794-8
   WALLACE CJ, 1917, SURG GYNECOL OBSTET, V24, P578
NR 9
TC 13
Z9 13
U1 2
U2 7
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0306-5456
J9 BRIT J OBSTET GYNAEC
JI Br. J. Obstet. Gynaecol.
PD AUG
PY 1994
VL 101
IS 8
BP 716
EP 717
DI 10.1111/j.1471-0528.1994.tb13194.x
PG 2
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA PA237
UT WOS:A1994PA23700019
PM 7947511
DA 2018-12-27
ER

PT J
AU ROBSON, M
   HAMID, R
   MCPARLAND, P
   PEARCE, JM
AF ROBSON, M
   HAMID, R
   MCPARLAND, P
   PEARCE, JM
TI RETRACTED: DOPPLER ULTRASOUND OF THE UTEROPLACENTAL CIRCULATION IN THE
   PREDICTION OF PREGNANCY OUTCOME IN WOMEN WITH RAISED MATERNAL SERUM
   ALPHA-FETOPROTEIN (RETRACTED ARTICLE. SEE VOL 102, PG 853, 1995)
SO BRITISH JOURNAL OF OBSTETRICS AND GYNAECOLOGY
LA English
DT Article; Retracted Publication
ID BIRTH-WEIGHT; AFP
AB Objective To determine whether Doppler waveforms from the uteroplacental circulation could improve the prediction of pregnancy outcome in women with raised maternal serum alpha-fetoprotein and a structurally normal fetus. The study further attempts to determine whether the presence of an early diastolic notch would constitute a better screening test than waveform patterns.
   Design An observational study.
   Setting A tertiary referral obstetric service.
   Subjects All women referred to St George's Hospital with a raised maternal serum alpha-fetoprotein had waveform measurements from the uteroplacental circulation after exclusion of fetal abnormalities. Pregnancy outcome was determined by questionnaire sent to the referring clinicians.
   Main outcome measures Adverse perinatal outcome in the form of preterm labour, low birthweight and perinatal mortality.
   Results Data from 332 cases were available for analysis. Women with a normal pattern of uteroplacental waveforms had a perinatal mortality of 9.6/1000. Women with a uniform high resistance pattern had a perinatal mortality of 846/1000, and those with a mixed resistance pattern had a perinatal mortality of 268/1000. Overall there were 27 cases of placental abruption which accounted for eight of the 50 perinatal deaths. The remainder were due to prematurity or low birthweight or both. The presence of the early diastolic notch did not improve on the waveform patterns in the prediction of perinatal death.
   Conclusion Women with raised maternal serum alpha-fetoprotein and normal Doppler waveform patterns from the uteroplacental circulation can be reassured, but mixed or uniform high resistance patterns should encourage increased surveillance and a search for intervention therapies.
C1 ST GEORGE HOSP, SCH MED, DEPT OBSTET & GYNAECOL, LONDON SW17 0RE, ENGLAND.
CR ALTMAN DG, 1980, BRIT J OBSTET GYNAEC, V87, P81, DOI 10.1111/j.1471-0528.1980.tb04498.x
   ARISTIDOU A, 1990, BRIT J OBSTET GYNAEC, V97, P431, DOI 10.1111/j.1471-0528.1990.tb01831.x
   BOYD PA, 1986, PRENATAL DIAG, V6, P369, DOI 10.1002/pd.1970060505
   BOYD PA, 1992, BRIT J OBSTET GYNAEC, V99, P93, DOI 10.1111/j.1471-0528.1992.tb14461.x
   CHARD T, 1986, BRIT J OBSTET GYNAEC, V93, P36, DOI 10.1111/j.1471-0528.1986.tb07810.x
   HAMILTON MPR, 1985, OBSTET GYNECOL, V65, P465
   Katz V L, 1990, Obstet Gynecol Surv, V45, P719, DOI 10.1097/00006254-199011000-00001
   LOS FJ, 1985, PRENATAL DIAG, V5, P277, DOI 10.1002/pd.1970050405
   MCPARLAND P, 1991, DOPPLER ULTRASOUND P, P63
   MWAMBINGU FT, 1985, ACTA OBSTET GYN SCAN, V64, P275, DOI 10.3109/00016348509155128
   PEARCE JM, 1988, BRIT J OBSTET GYNAEC, V95, P248, DOI 10.1111/j.1471-0528.1988.tb06865.x
   SALAFIA CM, 1991, AM J OBSTET GYNECOL, V185, P1064
   STEEL SA, 1990, LANCET, V335, P1548, DOI 10.1016/0140-6736(90)91376-L
NR 13
TC 8
Z9 8
U1 2
U2 5
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0306-5456
J9 BRIT J OBSTET GYNAEC
JI Br. J. Obstet. Gynaecol.
PD JUN
PY 1994
VL 101
IS 6
BP 477
EP 480
DI 10.1111/j.1471-0528.1994.tb13144.x
PG 4
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA NQ222
UT WOS:A1994NQ22200005
PM 7517180
DA 2018-12-27
ER

PT J
AU HAMID, R
   ROBSON, M
   PEARCE, JM
AF HAMID, R
   ROBSON, M
   PEARCE, JM
TI RETRACTED: LOW-DOSE ASPIRIN IN WOMEN WITH RAISED MATERNAL SERUM
   ALPHA-FETOPROTEIN AND ABNORMAL DOPPLER WAVE-FORM PATTERNS FROM THE
   UTEROPLACENTAL CIRCULATION (RETRACTED ARTICLE. SEE VOL 102, PG 853,
   1995)
SO BRITISH JOURNAL OF OBSTETRICS AND GYNAECOLOGY
LA English
DT Article; Retracted Publication
ID BLEEDING-TIME; PREGNANCY; THROMBOXANE; FETAL
AB Objective To investigate the use of low dose aspirin in the reduction of perinatal morbidity and mortality in women with unexplained raised maternal serum alpha-fetoprotein and abnormal uteroplacental Doppler waveform patterns.
   Design Prospective randomised controlled trial.
   Setting A tertiary referral obstetric service.
   Subjects One hundred and sixty-four women referred to our unit with raised maternal serum alpha-fetoprotein and a structurally normal fetus had abnormal uteroplacental Doppler waveform patterns at 24 weeks of gestation.
   Intervention Women were randomly allocated to two groups, receiving either low dose aspirin 75 mg (n = 76) or placebo (n = 88) daily until delivery.
   Main outcome measures Preterm labour, low birthweight, the occurrence of placental abruptions and perinatal mortality.
   Results The frequency of severely small for gestational age infants (birthweight < 5th centile) was reduced in the aspirin treated group to 16% compared with 25 % in the placebo group (95 % CI-21% to 13 %). The frequency of delivery before 34 weeks of gestation was 26 % in the aspirin group and 42 % in the placebo group (95 % CI - 30 % to 1 %). The perinatal mortality was 240/1000 in the aspirin group and 320/1000 in the placebo group (95 % CI - 22 % to 6 %). None of these reductions was statistically significant. Although the frequency of placental abruptions was similar in the two groups, significantly more babies died from abruption in the aspirin treated group (91% versus 30 %, 95 % CI 28 % to 94 %). Low dose aspirin did cause a significant reduction (P = 0.008) in deaths from causes other than placental abruption.
   Conclusion This trial revealed a benefit of low dose aspirin therapy in women with raised maternal serum alpha-fetoprotein and abnormal uteroplacental Doppler waveform patterns, but the effect was smaller than expected. Although a reduction in deaths from small preterm babies was observed, there was an increase in the number of deaths following placental abruption without a significant increase in the number of abruptions. We recommend that this should be considered before giving aspirin to these high risk women and that other investigators should specifically look for this effect.
C1 ST GEORGE HOSP, SCH MED, DEPT OBSTET & GYNAECOL, LONDON SW17 0RE, ENGLAND.
CR ARISTIDOU A, 1990, BRIT J OBSTET GYNAEC, V97, P431, DOI 10.1111/j.1471-0528.1990.tb01831.x
   BENIGNI A, 1989, NEW ENGL J MED, V321, P357, DOI 10.1056/NEJM198908103210604
   BOYD PA, 1992, BRIT J OBSTET GYNAEC, V99, P93, DOI 10.1111/j.1471-0528.1992.tb14461.x
   DEKKER GA, 1993, AM J OBSTET GYNECOL, V168, P214, DOI 10.1016/S0002-9378(12)90917-5
   DESWIET M, 1990, J OBSTET GYNECOL, V10, P467
   FRITH PA, 1988, THROMB RES, V49, P463, DOI 10.1016/S0049-3848(98)90003-2
   ISIS-2 (Second International Study of Infarct Survival), 1988, LANCET, P349
   Katz V L, 1990, Obstet Gynecol Surv, V45, P719, DOI 10.1097/00006254-199011000-00001
   LOUDEN KA, 1992, CLIN PHARMACOKINET, V23, P90, DOI 10.2165/00003088-199223020-00002
   MCPARLAND P, 1990, LANCET, V335, P1552, DOI 10.1016/0140-6736(90)91377-M
   MCPARLAND P, 1991, DOPPLER ULTRASOUND P, P63
   PARAZZINI F, 1993, LANCET, V341, P396
   QUICK AJ, 1966, AM J MED SCI, V252, P265, DOI 10.1097/00000441-196609000-00003
   ROBSON M, 1994, BRIT J OBSTET GYNAEC, V101, P477, DOI 10.1111/j.1471-0528.1994.tb13144.x
   RODGERS RPC, 1990, SEMIN THROMB HEMOST, V16, P1, DOI 10.1055/s-2007-1002658
   SALAFIA CM, 1988, AM J OBSTET GYNECOL, V158, P1064, DOI 10.1016/0002-9378(88)90220-7
   STEEL SA, 1990, LANCET, V335, P1548, DOI 10.1016/0140-6736(90)91376-L
   TAGGART DP, 1990, ANN THORAC SURG, V50, P425, DOI 10.1016/0003-4975(90)90488-R
   THOMAS F, 1991, JAMA-J AM MED ASSOC, V266, P261
   THORP JA, 1988, AM J OBSTET GYNECOL, V159, P1381, DOI 10.1016/0002-9378(88)90560-1
   TRUDINGER BJ, 1988, AM J OBSTET GYNECOL, V159, P681, DOI 10.1016/S0002-9378(88)80034-6
   UZAN S, 1991, LANCET, V337, P1427, DOI 10.1016/0140-6736(91)93124-R
   WEISS HJ, 1968, J CLIN INVEST, V47, P2169, DOI 10.1172/JCI105903
NR 23
TC 11
Z9 11
U1 2
U2 9
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0306-5456
J9 BRIT J OBSTET GYNAEC
JI Br. J. Obstet. Gynaecol.
PD JUN
PY 1994
VL 101
IS 6
BP 481
EP 484
DI 10.1111/j.1471-0528.1994.tb13145.x
PG 4
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA NQ222
UT WOS:A1994NQ22200006
PM 7517181
DA 2018-12-27
ER

PT J
AU POEHLMAN, ET
   GARDNER, AW
   ARCIERO, P
   GORAN, MI
   CALLESESCANDON, J
AF POEHLMAN, ET
   GARDNER, AW
   ARCIERO, P
   GORAN, MI
   CALLESESCANDON, J
TI RETRACTED: EFFECTS OF ENDURANCE TRAINING ON TOTAL FAT OXIDATION IN
   ELDERLY PERSONS (RETRACTED ARTICLE. SEE VOL 99, PG 783, 2005)
SO JOURNAL OF APPLIED PHYSIOLOGY
LA English
DT Article; Retracted Publication
DE EXERCISE; SYMPATHETIC NERVOUS SYSTEM
ID METABOLIC-RATE; SKELETAL-MUSCLE; ENERGY-EXPENDITURE; ADIPOSE-TISSUE;
   OLDER INDIVIDUALS; PHYSICAL-ACTIVITY; LIPID OXIDATION; YOUNG-ADULT;
   WEIGHT-GAIN; EXERCISE
AB We examined the influence of 8 wk of endurance training on basal levels of fat oxidation and its association with changes in norepinephrine (NE) kinetics, resting metabolic rate (RMR), and body composition in 18 healthy elderly persons (66.1 +/- 1.4 yr; 10 men, 8 women). Fatty acid appearance rate and total body fat oxidation were determined from [C-14]palmitate infusion and indirect calorimetry, NE kinetics were determined from infusions of [H-3]NE, RMR was determined from the ventilated hood technique, and body composition was determined from underwater weighing. Endurance training increased peak oxygen consumption by 11% (1.9 +/- 0.1 to 2.1 +/- 0.1 l/min; P < 0.01) and increased RMR by 7% (1.20 +/- 0.02 to 1.28 +/- 0.02 kcal/min; P < 0.01). Endurance training increased NE appearance rate by 35% (0.51 +/- 0.04 to 0.69 +/- 0.04 mu g/min; P < 0.01), whereas no change in NE clearance was noted. Endurance training increased fat oxidation by 22% (201.0 +/- 11.2 vs. 244.0 +/- 15.2 mu mol/min; P < 0.01) but did not after fatty acid appearance rate. Approximately two-thirds of the variation (r(2) = 0.65) for the increase in fat oxidation was explained by increased NE appearance rate (r(2) = 0.51; P < 0.01) and changes in fat-free weight (r(2) = 0.14; P < 0.01). We conclude that 1) endurance training shifts in vivo basal substrate utilization toward greater fat oxidation in elderly individuals and 2) enhanced fat oxidation is associated with increased activity of the sympathetic nervous system and alterations in fat-free mass.
C1 VET AFFAIRS MED CTR, DIV GERONTOL, BALTIMORE, MD 21201 USA.
   UNIV MARYLAND, DEPT MED, BALTIMORE, MD 21201 USA.
   UNIV MARYLAND, CTR GERIATR RES EDUC & CLIN, BALTIMORE, MD 21201 USA.
   UNIV VERMONT, DEPT MED, BURLINGTON, VT 05405 USA.
FU NIA NIH HHS [NIA AG-05564, NIA AG-07857, NIA KO4-AG-00564]
CR ARNER P, 1988, DIABETES METAB REV, V4, P507
   CALLESESCANDON J, 1987, DIABETES, V36, P1167, DOI 10.2337/diabetes.36.10.1167
   COGGAN AR, 1992, J APPL PHYSIOL, V72, P1780
   COON PJ, 1992, METABOLISM, V41, P711, DOI 10.1016/0026-0495(92)90309-X
   CRAMPES F, 1986, J APPL PHYSIOL, V61, P25
   DESPRES JP, 1984, EUR J APPL PHYSIOL O, V53, P25, DOI 10.1007/BF00964685
   DESPRES JP, 1984, METABOLISM, V33, P235, DOI 10.1016/0026-0495(84)90043-X
   ESLER M, 1979, LIFE SCI, V25, P1461, DOI 10.1016/0024-3205(79)90371-0
   GALBO H, 1983, HORMONAL METABOLIC A
   GORAN MI, 1992, AM J PHYSIOL, V263, pE950
   GROOP LC, 1991, J CLIN INVEST, V87, P83, DOI 10.1172/JCI115005
   HAGENFEL.L, 1972, J CLIN INVEST, V51, P2324, DOI 10.1172/JCI107043
   HOLLOSZY JO, 1990, INT S SPORT, V21, P319
   HOLLOSZY JO, 1984, J APPL PHYSIOL, V56, P831
   HURLEY BF, 1986, J APPL PHYSIOL, V60, P562
   JANSSON E, 1987, J APPL PHYSIOL, V62, P999
   Jansson E, 1980, Acta Physiol Scand Suppl, V487, P1
   JENNINGS G, 1986, CIRCULATION, V73, P30, DOI 10.1161/01.CIR.73.1.30
   JENSEN MD, 1989, J CLIN INVEST, V83, P1168, DOI 10.1172/JCI113997
   KLEIN S, 1992, AM J PHYSIOL, V262, pE631
   KLEIN S, 1986, J CLIN INVEST, V78, P928, DOI 10.1172/JCI112682
   LONNQVIST F, 1990, J CLIN INVEST, V85, P1614, DOI 10.1172/JCI114612
   MILES JM, 1987, AM J PHYSIOL, V252, pE431
   MOLE PA, 1971, J CLIN INVEST, V50, P2323, DOI 10.1172/JCI106730
   ODEA K, 1982, METABOLISM, V31, P896, DOI 10.1016/0026-0495(82)90178-0
   POEHLMAN ET, 1991, AM J PHYSIOL, V261, pE233
   POEHLMAN ET, 1987, EUR J APPL PHYSIOL O, V56, P398, DOI 10.1007/BF00417766
   POEHLMAN ET, 1990, AM J PHYSIOL, V259, pE66
   POEHLMAN ET, 1992, METABOLISM, V41, P941, DOI 10.1016/0026-0495(92)90118-T
   POEHLMAN ET, 1989, CAN J PHYSIOL PHARM, V67, P10, DOI 10.1139/y89-003
   POEHLMAN ET, 1990, AM J PHYSIOL, V258, pE256
   POEHLMAN ET, 1991, CAN J PHYSIOL PHARM, V69, P320, DOI 10.1139/y91-049
   RAVUSSIN E, 1988, NEW ENGL J MED, V318, P467, DOI 10.1056/NEJM198802253180802
   ROMIJN JA, 1993, J APPL PHYSIOL, V75, P108
   SIRI W E, 1956, Adv Biol Med Phys, V4, P239
   SOYBEL D, 1983, J CLIN ENDOCR METAB, V56, P612, DOI 10.1210/jcem-56-3-612
   STARR JI, 1979, METHOD HORM RADIOIMM, P613
   TAYLOR HL, 1978, J CHRON DIS, V31, P741, DOI 10.1016/0021-9681(78)90058-9
   TOTH MJ, 1993, J APPL PHYSIOL, V75, P2288
   TREMBLAY A, 1992, CAN J PHYSIOL PHARM, V70, P1342, DOI 10.1139/y92-188
   ZURLO F, 1990, AM J PHYSIOL, V259, pE650
NR 41
TC 80
Z9 81
U1 4
U2 11
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 8750-7587
EI 1522-1601
J9 J APPL PHYSIOL
JI J. Appl. Physiol.
PD JUN
PY 1994
VL 76
IS 6
BP 2281
EP 2287
PG 7
WC Physiology; Sport Sciences
SC Physiology; Sport Sciences
GA NR916
UT WOS:A1994NR91600006
PM 7928848
DA 2018-12-27
ER

PT J
AU BARRY, MF
   CHRISTOFI, G
   BINDMAN, LJ
AF BARRY, MF
   CHRISTOFI, G
   BINDMAN, LJ
TI RETRACTED: POSTSYNAPTIC CONTROL OF THE DIRECTION OF CHANGES IN SYNAPTIC
   STRENGTH INDUCED BY NONASSOCIATIVE INTRACELLULAR CONDITIONING, IN
   ISOLATED SLICES OF RAT HIPPOCAMPUS (RETRACTED ARTICLE. SEE VOL 509P, PG
   207P, 1998)
SO JOURNAL OF PHYSIOLOGY-LONDON
LA English
DT Meeting Abstract; Retracted Publication
C1 UNIV LONDON UNIV COLL, DEPT PHYSIOL, LONDON WC1E 6BT, ENGLAND.
CR CHRISTOFI G, 1993, J PHYSIOL-LONDON, V473, pP31
   KULLMANN DM, 1992, NEURON, V9, P1175, DOI 10.1016/0896-6273(92)90075-O
NR 2
TC 0
Z9 0
U1 1
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-3751
EI 1469-7793
J9 J PHYSIOL-LONDON
JI J. Physiol.-London
PD JUN
PY 1994
VL 477P
BP P52
EP P53
PG 2
WC Neurosciences; Physiology
SC Neurosciences & Neurology; Physiology
GA NX999
UT WOS:A1994NX99900081
DA 2018-12-27
ER

PT J
AU FUJII, Y
   TOYOOKA, H
   AMAHA, K
AF FUJII, Y
   TOYOOKA, H
   AMAHA, K
TI RETRACTED: NICARDIPINE ENHANCES DIAPHRAGMATIC FATIGUE (Retracted
   article. See vol. 59, pg. 1179, 2012)
SO CANADIAN JOURNAL OF ANAESTHESIA-JOURNAL CANADIEN D ANESTHESIE
LA English
DT Article; Retracted Publication
DE MUSCLE, SKELETAL, DIAPHRAGM, FATIGUE; PHARMACOLOGY, NICARDIPINE
ID RESPIRATORY-FAILURE; CONTRACTILITY; THEOPHYLLINE; VERAPAMIL; MUSCLES;
   INVITRO
AB The effects of nicardipine, a calcium channel blocker, on diaphrogmatic fatigue were studied in 20 anaesthetized, mechanically ventilated dogs divided into two groups: control group (Group C, n = 10) and nicardipine group (Group N, n = 10). Diaphragmatic fatigue was induced by intermittent supramaximal electric stimulation to bilateral phrenic nerves at a frequency of 20 Hz for 30 min. In Group N, 5 mu g.kg(-1).min(-1) nicardipine iv was infused continuously during this fatigue-producing period. Transdiaphragmatic pressure (Pdi)produced by electrical stimulation (10-100 Hz) of the phrenic nerves was used as an index of diaphragmatic contractility. After a fatigue-producing period the Pdi in both groups decreased at low frequency (10-30 Hz) stimulation compared with pre-fatigue values (P < 0.05), whereas no change in Pdi was observed at high-frequency (50-100 Hz) stimulation. The decrease of Pdi at low;frequency stimulation was larger in Group N (P < 0.05). The integrated diaphragmatic electric activity (Edi) in both groups did not change at any frequency of stimulation throughout the experiment. We conclude that nicardipine enhances diaphragmatic fatigue.
C1 TOKYO MED & DENT UNIV, SCH MED, DEPT ANAESTHESIOL & CRIT CARE MED, BUNKYO KU, TOKYO 113, JAPAN.
RP FUJII, Y (reprint author), TORIDE KYODO GEN HOSP, DEPT ANAESTHESIOL, 5901-1 TERADA, TORIDE, IBARAKI 302, JAPAN.
CR AUBIER M, 1983, J APPL PHYSIOL, V54, P460
   AUBIER M, 1981, J APPL PHYSIOL, V50, P538
   AUBIER M, 1986, J ALLERGY CLIN IMMUN, V78, P787, DOI 10.1016/0091-6749(86)90062-X
   CHANG CC, 1989, CAN J PHYSIOL PHARM, V67, P1493, DOI 10.1139/y89-241
   EBATA T, 1992, CAN J ANAESTH, V39, P375, DOI 10.1007/BF03009049
   ESAU SA, 1988, AM J PHYSIOL, V254, pC365
   FUJJI Y, 1991, MATSUI, V5, P17
   FUJJI Y, 1991, HIROSHIMA J ANESTHES, V28, P211
   GRASSINO A, 1978, J APPL PHYSIOL, V44, P829
   HOWELL S, 1985, J APPL PHYSIOL, V59, P1376
   KRAYNACK BJ, 1983, CAN ANAESTH SOC J, V30, P242, DOI 10.1007/BF03013802
   MACKLEM PT, 1977, CLIN SCI MOL MED, V53, P419, DOI 10.1042/cs0530419
   MILLER MJ, 1989, LIFE SCI, V45, P2419, DOI 10.1016/0024-3205(89)90006-4
   Moxham J, 1981, Ciba Found Symp, V82, P197
   ROBERTSON CH, 1977, J CLIN INVEST, V59, P31, DOI 10.1172/JCI108619
   ROUSSOS C, 1982, NEW ENGL J MED, V307, P786, DOI 10.1056/NEJM198209233071304
NR 16
TC 8
Z9 8
U1 2
U2 8
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0832-610X
J9 CAN J ANAESTH
JI Can. J. Anaesth.-J. Can. Anesth.
PD MAY
PY 1994
VL 41
IS 5
BP 435
EP 439
DI 10.1007/BF03009869
PN 1
PG 5
WC Anesthesiology
SC Anesthesiology
GA NK867
UT WOS:A1994NK86700014
PM 8055614
OA Bronze
DA 2018-12-27
ER

PT J
AU AHLERS, A
   ENGEL, K
   SOTT, C
   GAESTEL, M
   HERRMANN, F
   BRACH, MA
AF AHLERS, A
   ENGEL, K
   SOTT, C
   GAESTEL, M
   HERRMANN, F
   BRACH, MA
TI RETRACTED: INTERLEUKIN-3 AND GRANULOCYTE-MACROPHAGE COLONY-STIMULATING
   FACTOR INDUCE ACTIVATION OF THE MAPKAP KINASE-2 RESULTING IN IN-VITRO
   SERINE PHOSPHORYLATION OF THE SMALL HEAT-SHOCK PROTEIN (HSP-27)
   (RETRACTED ARTICLE. SEE VOL 93, PG. 3573, 1999)
SO BLOOD
LA English
DT Article; Retracted Publication
ID MICROTUBULE-ASSOCIATED PROTEIN; MYELOID CELL-LINE; TYROSINE
   PHOSPHORYLATION; RAPID PHOSPHORYLATION; GROWTH-FACTORS; GM-CSF;
   NEUTROPHILS; EXPRESSION; HSP27; IDENTIFICATION
C1 FREE UNIV BERLIN, UNIVERSITATSKLINIKUM RUDOLF VIRCHOW, MAX DELBRUCK CTR MOLEC MED, D-13122 BERLIN, GERMANY.
   FREE UNIV BERLIN, UNIVERSITATSKLINIKUM RUDOLF VIRCHOW, DEPT MED ONCOL & APPL MOLEC BIOL, D-13122 BERLIN, GERMANY.
OI Gaestel, Matthias/0000-0002-4944-4652
CR ARRIGO AP, 1990, MOL CELL BIOL, V10, P1276, DOI 10.1128/MCB.10.3.1276
   AVANZI GC, 1987, BRIT J HAEMATOL, V359, P1988
   BRACH MA, 1990, BLOOD, V76, P1972
   BRACH MA, 1992, BLOOD, V80, P2920
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   CANNISTRA SA, 1988, SEMIN HEMATOL, V25, P173
   CLARK SC, 1987, SCIENCE, V236, P1229, DOI 10.1126/science.3296190
   EDER M, 1993, EMBO J, V12, P1647, DOI 10.1002/j.1460-2075.1993.tb05810.x
   ENGEL K, IN PRESS J BIOL CHEM
   GAESTEL M, 1991, J BIOL CHEM, V266, P14721
   GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0
   GOMEZ CJ, 1992, P NATL ACAD SCI USA, V89, P7551
   GRIFFIN JD, 1990, J IMMUNOL, V145, P576
   GUESDON F, 1991, J IMMUNOL, V147, P3402
   HANAZONO Y, 1993, EMBO J, V12, P1641, DOI 10.1002/j.1460-2075.1993.tb05809.x
   HERRMANN F, 1989, J CLIN ONCOL, V7, P159, DOI 10.1200/JCO.1989.7.2.159
   HERRMANN F, 1990, EUR J IMMUNOL, V20, P2513, DOI 10.1002/eji.1830201124
   HOSHI M, 1988, J BIOL CHEM, V263, P5396
   JAKOB U, 1993, J BIOL CHEM, V268, P1517
   KANAKURA Y, 1991, BLOOD, V77, P243
   KANAKURA Y, 1990, BLOOD, V76, P706
   KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   LANDRY J, 1992, J BIOL CHEM, V267, P794
   LINDEMANN A, 1988, EUR J IMMUNOL, V18, P369, DOI 10.1002/eji.1830180308
   MICHISHITA M, 1991, BIOCHEM BIOPH RES CO, V176, P979, DOI 10.1016/0006-291X(91)90378-K
   MIRON T, 1991, J CELL BIOL, V114, P255, DOI 10.1083/jcb.114.2.255
   MIYAZAWA K, 1991, EXP HEMATOL, V19, P1110
   OKUDA K, 1992, BLOOD, V79, P2880
   OSTER W, 1992, BLOOD, V79, P1260
   PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0
   RAINES MA, 1992, BLOOD, V79, P3350
   SAKLATVALA J, 1991, BIOCH J
   SHIINA N, 1992, EMBO J, V11, P3977, DOI 10.1002/j.1460-2075.1992.tb05491.x
   STOKOE D, 1992, FEBS LETT, V313, P307, DOI 10.1016/0014-5793(92)81216-9
   STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x
   WELHAM MJ, 1992, J IMMUNOL, V149, P1683
NR 37
TC 19
Z9 19
U1 0
U2 9
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD APR 1
PY 1994
VL 83
IS 7
BP 1791
EP 1798
PG 8
WC Hematology
SC Hematology
GA NE411
UT WOS:A1994NE41100011
PM 8142647
DA 2018-12-27
ER

PT J
AU FUJII, Y
   TANAKA, H
   TOYOOKA, H
AF FUJII, Y
   TANAKA, H
   TOYOOKA, H
TI RETRACTED: REDUCTION OF POSTOPERATIVE NAUSEA AND VOMITING WITH
   GRANISETRON (Retracted article. See vol. 59, pg. 1180, 2012)
SO CANADIAN JOURNAL OF ANAESTHESIA-JOURNAL CANADIEN D ANESTHESIE
LA English
DT Article; Retracted Publication
DE COMPLICATIONS, NAUSEA; VOMITING; VOMITING, ANTIEMETICS; GRANISETRON;
   METOCLOPRAMIDE; INCIDENCE; NAUSEA
ID METOCLOPRAMIDE; DOMPERIDONE; DROPERIDOL; PREVENTION
AB The antiemetic effects of granisetron, a selective 5-hydroxytryptamine type 3 receptor antagonist, on postoperative nausea and vomiting were studied and compared with placebo and metoclopramide in 60 patients undergoing general anaesthesia for major gynaecological surgery. The patients received a single iv dose of either granisetron (3 mg, n = 20) metoclopramide (10 mg, n = 20), or placebo (saline, n = 20) immediately after recovery from anaesthesia. The effects were assessed during the first three and the next 21 hr after recovery from anaesthesia by means of a nausea and vomiting score; 0 = no emetic symptoms, 1 = nausea, 2 = vomiting. The mean scores during 0-3 hr were 0.8, 0.1 and 0.1 after administration of placebo, metoclopramide and granisetron, respectively, the corresponding scores during 3-24 hr were 0.6, 0.5 and 0.1. The scores of the metoclopramide and the granisetron groups were different from the placebo group in the first three hours (P < 0.05). Although there were no differences in the scores during 0-3 hr between the metoclopramide and the granisetron groups, there were differences during 3-24 hr (P < 0.05). It is concluded that granisetron is superior to metoclopramide in the long-term prevention of postoperative nausea and vomiting after anaesthesia.
C1 TOKYO MED & DENT UNIV, SCH MED, DEPT ANAESTHESIOL & CRIT CARE MED, BUNKYO KU, TOKYO 113, JAPAN.
RP FUJII, Y (reprint author), TORIDE KYODO GEN HOSP, DEPT ANAESTHESIOL, 5901-1 TERADA, TORIDE, IBARAKI 302, JAPAN.
CR ANDREWS P L R, 1992, European Journal of Cancer, V28A, pS2, DOI 10.1016/0959-8049(92)90628-F
   BODNER M, 1991, ANESTH ANALG, V73, P250
   CARMICHAEL J, 1989, CANCER CHEMOTH PHARM, V24, P45
   Fujii Y, 1993, Masui, V42, P694
   Furue H, 1990, J CLIN THERAPEUTIC M, V6, P49
   KILPATRICK GJ, 1988, NEUROSCI LETT, V94, P156, DOI 10.1016/0304-3940(88)90287-X
   KORTTILA K, 1979, ANESTH ANALG, V58, P396
   MADEJ TH, 1986, BRIT J ANAESTH, V58, P879, DOI 10.1093/bja/58.8.879
   MCKENZIE R, 1981, ANESTH ANALG, V60, P783
   SCHELLER MS, 1987, ANESTH ANALG, V66, P274
NR 10
TC 51
Z9 54
U1 2
U2 9
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0832-610X
J9 CAN J ANAESTH
JI Can. J. Anaesth.-J. Can. Anesth.
PD APR
PY 1994
VL 41
IS 4
BP 291
EP 294
DI 10.1007/BF03009906
PG 4
WC Anesthesiology
SC Anesthesiology
GA ND953
UT WOS:A1994ND95300005
PM 8004733
OA Bronze
DA 2018-12-27
ER

PT J
AU GAREY, CE
   SCHWARZMAN, AL
   RISE, ML
   SEYFRIED, TN
AF GAREY, CE
   SCHWARZMAN, AL
   RISE, ML
   SEYFRIED, TN
TI RETRACTED: CERULOPLASMIN GENE DEFECT ASSOCIATED WITH EPILEPSY IN EL MICE
   (RETRACTED ARTICLE. SEE VOL 11, PG 104, 1995)
SO NATURE GENETICS
LA English
DT Article; Retracted Publication
ID E1 MOUSE; COPPER; DUPLICATION; DEFICIENCY; SUSCEPTIBILITY; FREQUENCY;
   DISEASE; CROSSES; ZINC; RAT
AB Epilepsy is a dominant trait in EL mice, a model for human complex partial seizures. We recently mapped the major gene, El-1, to chromosome 9 near the predicted location for the ceruloplasmin (Cp) gene. We now present evidence for a partial duplication in the Cp gene in EL mice. This Cp duplication is coinherited with seizures in backcross generations and is associated with enhanced expression of Cp mRNA and increased Cp oxidase activity. Moreover, the duplication is associated with an enhanced frequency of double recombinants, simulating negative interference. The findings are relevant to the basic mechanisms of epilepsy and to theories of genetic recombination and gene mapping.
C1 BOSTON COLL, DEPT BIOL, CHESTNUT HILL, MA 02167 USA.
FU NINDS NIH HHS [NS 23355]
CR Anderson V E, 1986, Adv Neurol, V44, P59
   ARAKI K, 1991, JPN J MED, V30, P383, DOI 10.2169/internalmedicine1962.30.383
   ARNATI P, 1965, GENETICS, V51, P369
   BINGLE CD, 1992, BIOCHIM BIOPHYS ACTA, V1139, P217, DOI 10.1016/0925-4439(92)90137-C
   BRIGANDE JV, 1992, J NEUROCHEM, V58, P752, DOI 10.1111/j.1471-4159.1992.tb09782.x
   CHASE M, 1958, GENETICS, V43, P332
   CHELLY J, 1993, NAT GENET, V5, P317, DOI 10.1038/ng1293-317
   CHUNG SH, 1983, BRAIN RES, V280, P323
   COLLIER S, 1993, NAT GENET, V3, P260, DOI 10.1038/ng0393-260
   DEVLIN RH, 1990, AM J HUM GENET, V46, P112
   DIETRICH W, 1992, GENETICS, V131, P423
   FLEMING RE, 1992, J BIOL CHEM, V267, P479
   FRIEDEN E, 1986, CLIN PHYSIOL BIOCH, V4, P11
   FUKAHORI M, 1990, BRAIN RES, V529, P16, DOI 10.1016/0006-8993(90)90806-M
   GAREY CE, 1993, T AM SOC NEUROCHEM, V24, P227
   GARNER I, 1986, EMBO J, V5, P2559, DOI 10.1002/j.1460-2075.1986.tb04535.x
   HARTMANN HA, 1992, MED HYPOTHESES, V38, P75, DOI 10.1016/0306-9877(92)90162-6
   HAUSER WA, 1982, GENETIC BASIS EPILEP, P3
   HOLLIDAY R, 1964, GENET RES, V5, P282, DOI 10.1017/S0016672300001233
   HU XY, 1990, AM J HUM GENET, V46, P682
   IMAIZUMI K, 1959, B EXP ANIM TOKYO, V8, P6
   ISHIDA N, 1993, BRAIN RES, V608, P52, DOI 10.1016/0006-8993(93)90773-G
   KORNREICH R, 1990, J BIOL CHEM, V265, P9319
   LANDER E S, 1987, Genomics, V1, P174, DOI 10.1016/0888-7543(87)90010-3
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   LUPSKI JR, 1991, CELL, V66, P219, DOI 10.1016/0092-8674(91)90613-4
   MANLY KF, 1991, MAMM GENOME, V1, P123, DOI 10.1007/BF02443789
   MEHES K, 1982, ARCH DIS CHILD, V57, P716, DOI 10.1136/adc.57.9.716
   MERCER JFB, 1986, FEBS LETT, V203, P185, DOI 10.1016/0014-5793(86)80739-6
   MOORE LA, 1993, J MOL EVOL, V36, P21, DOI 10.1007/BF02407303
   Muller HJ, 1916, AM NAT, V50, P284, DOI 10.1086/279541
   MURTI JR, 1992, MOL CELL BIOL, V12, P2545, DOI 10.1128/MCB.12.6.2545
   NARUSE H, 1992, NEUROSCIENCES-JPN S2, V18, P1
   NEUMANN PE, 1990, BEHAV GENET, V20, P307, DOI 10.1007/BF01067798
   PARKS RJ, 1991, J VIROL, V65, P1263
   PETERSON HM, 1963, P NATL ACAD SCI USA, V50, P126, DOI 10.1073/pnas.50.1.126
   PRITCHARD RH, 1960, GENET RES, V1, P1, DOI 10.1017/S0016672300000033
   PROHASKA JR, 1990, J NUTR BIOCHEM, V1, P149, DOI 10.1016/0955-2863(90)90015-D
   RICE EW, 1962, ANAL BIOCHEM, V3, P452, DOI 10.1016/0003-2697(62)90076-3
   RISE ML, 1991, SCIENCE, V253, P669, DOI 10.1126/science.1871601
   ROTHFELS KH, 1952, GENETICS, V37, P297
   SAMBROOK J, 1989, MOL CLONING LABORATO
   SHYAMALA V, 1990, EMBO J, V9, P939, DOI 10.1002/j.1460-2075.1990.tb08192.x
   SUZUKI J, 1977, ELECTROEN CLIN NEURO, V43, P299, DOI 10.1016/0013-4694(77)90253-X
   TARTOF KD, 1988, GENETICS, V120, P1
   WERTHER CA, 1986, DRUG NUTR INTERACT, V4, P269
   YAMADA T, 1992, BIOCHEM INT, V27, P243
   1992, MOUSE GENOME CONSOLI, V90
NR 48
TC 20
Z9 20
U1 3
U2 7
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1061-4036
EI 1546-1718
J9 NAT GENET
JI Nature Genet.
PD APR
PY 1994
VL 6
IS 4
BP 426
EP 431
DI 10.1038/ng0494-426
PG 6
WC Genetics & Heredity
SC Genetics & Heredity
GA ND870
UT WOS:A1994ND87000026
PM 7914452
DA 2018-12-27
ER

PT J
AU CAMPBELL, DA
   FIELD, M
   MCARDLE, CS
   COOKE, TG
   GALLAGHER, G
AF CAMPBELL, DA
   FIELD, M
   MCARDLE, CS
   COOKE, TG
   GALLAGHER, G
TI RETRACTED: POLYMORPHISM AT THE TUMOR-NECROSIS-FACTOR LOCUS - A MARKER OF
   GENETIC PREDISPOSITION TO COLORECTAL-CANCER (Retracted Article. See vol
   347, pg 1706, 1996)
SO LANCET
LA English
DT Letter; Retracted Publication
C1 UNIV GLASGOW, GLASGOW ROYAL INFIRM, DEPT MED, GLASGOW G31 2ER, SCOTLAND.
RP CAMPBELL, DA (reprint author), UNIV GLASGOW, GLASGOW ROYAL INFIRM, DEPT SURG, QUEEN ELIZABETH BLDG, GLASGOW G31 2ER, SCOTLAND.
CR ATKIN WS, 1993, LANCET, V341, P736, DOI 10.1016/0140-6736(93)90499-7
   DUNLOP MG, 1992, BRIT J SURG, V79, P488, DOI 10.1002/bjs.1800790606
   NAYLOR MS, 1990, CANCER RES, V50, P4436
   STEELE G, 1993, LANCET, V342, P1092, DOI 10.1016/0140-6736(93)92068-5
   UDALOVA IA, 1993, GENOMICS, V16, P180, DOI 10.1006/geno.1993.1156
   1993, SCI YB
NR 6
TC 11
Z9 11
U1 2
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0140-6736
EI 1474-547X
J9 LANCET
JI Lancet
PD JAN 29
PY 1994
VL 343
IS 8892
BP 293
EP 293
DI 10.1016/S0140-6736(94)91139-8
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA MT440
UT WOS:A1994MT44000038
PM 7905117
DA 2018-12-27
ER

PT J
AU FUJII, Y
   TANAKA, H
   TSURUOKA, S
   TOYOOKA, H
   AMAHA, K
AF FUJII, Y
   TANAKA, H
   TSURUOKA, S
   TOYOOKA, H
   AMAHA, K
TI RETRACTED: MIDDLE CEREBRAL ARTERIAL BLOOD-FLOW VELOCITY INCREASES DURING
   LAPAROSCOPIC CHOLECYSTECTOMY (Retracted article. See vol. 115, pg. 898,
   2012)
SO ANESTHESIA AND ANALGESIA
LA English
DT Article; Retracted Publication
ID NITROUS-OXIDE; DOPPLER; ISOFLURANE
AB The effects of intraperitoneal CO2 insufflation on middle cerebral arterial blood flow velocity were evaluated in 10 patients undergoing laparoscopic cholecystectomy under general anesthesia with nitrous oxide, oxygen, and isoflurane. Blood flow velocity was measured using transcranial Doppler ultrasonography. During CO2 insufflation, Paco(2) and the end-tidal CO2 concentration (PETCO(2)) increased significantly compared with the preinsufflation baseline value (P < 0.01) while ventilation was kept constant. Cerebral blood flow velocity also increased significantly in comparison with the baseline value (P < 0.01). These values still exceeded baseline values 10 min after deflation of the peritoneal cavity. A significant positive correlation was observed between blood flow velocity and Paco(2) (P < 0.001). Our results suggest that intraperitoneal COP insufflation during laparoscopic cholecystectomy increases cerebral blood flow and that this is probably due to an increased Paco(2).
C1 TORIDE KYODO GEN HOSP, DEPT ANESTHESIOL, IBARAKI, OSAKA, JAPAN.
   TORIDE KYODO GEN HOSP, DEPT NEUROSURG, IBARAKI, OSAKA, JAPAN.
   TOKYO MED & DENT UNIV, SCH MED, DEPT ANESTHESIOL & CRIT CARE MED, TOKYO 113, JAPAN.
CR AASLID R, 1982, J NEUROSURG, V57, P769, DOI 10.3171/jns.1982.57.6.0769
   ANDEL H, 1992, ANESTH ANALG, V74, pS8
   EGER EI, 1981, ANESTHESIOLOGY, V55, P559, DOI 10.1097/00000542-198111000-00014
   ENG C, 1992, ANESTHESIOLOGY, V77, P872, DOI 10.1097/00000542-199211000-00006
   HANSEN NB, 1983, PEDIATRICS, V72, P526
   HANSEN TD, 1989, BRIT J ANAESTH, V63, P290, DOI 10.1093/bja/63.3.290
   Lassen N., 1986, ANESTHESIA NEUROSURG, P1
   Liu S Y, 1991, J Laparoendosc Surg, V1, P241
   MARKWALDER TM, 1984, J CEREBR BLOOD F MET, V4, P368, DOI 10.1038/jcbfm.1984.54
   TODD MM, 1984, ANESTHESIOLOGY, V60, P276, DOI 10.1097/00000542-198404000-00002
   WIDDER B, 1989, J NEUROL NEUROSUR PS, V52, P38, DOI 10.1136/jnnp.52.1.38
NR 11
TC 39
Z9 44
U1 2
U2 8
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0003-2999
J9 ANESTH ANALG
JI Anesth. Analg.
PD JAN
PY 1994
VL 78
IS 1
BP 80
EP 83
PG 4
WC Anesthesiology
SC Anesthesiology
GA NA397
UT WOS:A1994NA39700014
PM 8267185
DA 2018-12-27
ER

PT J
AU ROBINSON, RA
   CLARK, JS
   HOLMES, AB
AF ROBINSON, RA
   CLARK, JS
   HOLMES, AB
TI RETRACTED: SYNTHESIS OF (+)-LAURENCIN (RETRACTED ARTICLE. SEE VOL 118,
   PG 6806, 1996)
SO JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Note; Retracted Publication
ID CIS-2-ETHYL-8-FORMYL-3,4,7,8-DIHYDRO-2H-OXOCIN-3-ONE 3-ETHYLENE ACETAL;
   8-MEMBERED CYCLIC ETHERS; RING ETHERS; INTRAMOLECULAR HYDROSILATION;
   CLAISEN REARRANGEMENT; ORGANIC-SYNTHESIS; CONSTRUCTION; CONVERSION;
   CYCLIZATIONS; OBTUSENYNE
C1 UNIV CAMBRIDGE, CHEM LAB, LENSFIELD RD, CAMBRIDGE CB2 1EW, ENGLAND.
CR BACH RD, 1992, J ORG CHEM, V57, P613, DOI 10.1021/jo00028a039
   BAUDAT R, 1979, HELV CHIM ACTA, V62, P1406, DOI 10.1002/hlca.19790620505
   BLUMENKOPF TA, 1990, J AM CHEM SOC, V112, P4399, DOI 10.1021/ja00167a042
   BLUMENKOPF TA, 1990, J AM CHEM SOC, V112, P4386, DOI 10.1021/ja00167a041
   CAMERON AF, 1969, J CHEM SOC B, P559, DOI 10.1039/j29690000559
   CARLING RW, 1986, J CHEM SOC CHEM COMM, P325, DOI 10.1039/c39860000325
   CARLING RW, 1986, J CHEM SOC CHEM COMM, P565, DOI 10.1039/c39860000565
   CARLING RW, 1986, TETRAHEDRON LETT, V27, P6133, DOI 10.1016/S0040-4039(00)85417-9
   CARLING RW, 1992, J CHEM SOC PERK T 1, P83, DOI 10.1039/p19920000083
   CLARK JS, 1988, TETRAHEDRON LETT, V29, P4333, DOI 10.1016/S0040-4039(00)80490-6
   CONGREVE MS, 1993, SYNLETT, P663
   CURTIS NR, 1991, TETRAHEDRON, V47, P7171, DOI 10.1016/S0040-4020(01)96169-1
   CURTIS NR, 1992, TETRAHEDRON LETT, V33, P675, DOI 10.1016/S0040-4039(00)92340-2
   CURTIS NR, 1992, TETRAHEDRON LETT, V33, P671, DOI 10.1016/S0040-4039(00)92339-6
   DAVIS FA, 1988, J AM CHEM SOC, V110, P8477, DOI 10.1021/ja00233a025
   DAVIS FA, 1989, TETRAHEDRON, V45, P5703, DOI 10.1016/S0040-4020(01)89102-X
   ERICKSON KL, 1983, MARINE NATURAL PRODU, V5, P131, DOI DOI 10.1016/B978-0-12-624005-4.50011-2
   FAULKNER DJ, 1991, NAT PROD REP, V8, P97, DOI 10.1039/np9910800097
   IMAMOTO T, 1989, J AM CHEM SOC, V111, P4392, DOI 10.1021/ja00194a037
   IRIE T, 1968, TETRAHEDRON, V24, P4193, DOI 10.1016/0040-4020(68)88180-3
   KOTSUKI H, 1992, SYNLETT, P97
   MASAMUNE T, 1979, B CHEM SOC JPN, V52, P127, DOI 10.1246/bcsj.52.127
   MASAMUNE T, 1979, B CHEM SOC JPN, V52, P135, DOI 10.1246/bcsj.52.135
   Moody C. J., 1992, STUDIES NATURAL PROD, V10, P201
   NICOLAOU KC, 1987, J AM CHEM SOC, V109, P2504, DOI 10.1021/ja00242a041
   NICOLAOU KC, 1990, J AM CHEM SOC, V112, P6263, DOI 10.1021/ja00173a013
   OVERMAN LE, 1988, J AM CHEM SOC, V110, P2248, DOI 10.1021/ja00215a040
   PAQUETTE LA, 1990, TETRAHEDRON, V46, P4487, DOI 10.1016/S0040-4020(01)85577-0
   PETRZILKA M, 1978, HELV CHIM ACTA, V61, P3075, DOI 10.1002/hlca.19780610833
   PINE SH, 1980, J AM CHEM SOC, V102, P3270, DOI 10.1021/ja00529a076
   RAVELO JL, 1992, TETRAHEDRON LETT, V33, P3389, DOI 10.1016/S0040-4039(00)92096-3
   SAITO S, 1984, CHEM LETT, P1389, DOI 10.1246/cl.1984.1389
   SCHMIDT SP, 1987, TETRAHEDRON LETT, V28, P767, DOI 10.1016/S0040-4039(01)80984-9
   TAKANO S, 1983, CHEM LETT, P1593, DOI 10.1246/cl.1983.1593
   TAMAO K, 1988, J AM CHEM SOC, V110, P3712, DOI 10.1021/ja00219a085
   TSUSHIMA K, 1992, TETRAHEDRON LETT, V33, P4345, DOI 10.1016/S0040-4039(00)74256-0
   TSUSHIMA K, 1990, CHEM LETT, P761, DOI 10.1246/cl.1990.761
   1993, J ORG CHEM, V58, pA11
NR 38
TC 44
Z9 44
U1 3
U2 17
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0002-7863
J9 J AM CHEM SOC
JI J. Am. Chem. Soc.
PD NOV 3
PY 1993
VL 115
IS 22
BP 10400
EP 10401
DI 10.1021/ja00075a082
PG 2
WC Chemistry, Multidisciplinary
SC Chemistry
GA MF517
UT WOS:A1993MF51700082
DA 2018-12-27
ER

PT J
AU SANDFORD, SA
   ALLAMANDOLA, LJ
   GEBALLE, TR
AF SANDFORD, SA
   ALLAMANDOLA, LJ
   GEBALLE, TR
TI RETRACTED: SPECTROSCOPIC DETECTION OF MOLECULAR-HYDROGEN FROZEN IN
   INTERSTELLAR ICES (RETRACTED ARTICLE. SEE VOL 287, PG 976, 2000)
SO SCIENCE
LA English
DT Article; Retracted Publication
ID DENSE CLOUDS; FEATURES; GAS
AB A weak infrared absorption feature near 4141 wavenumbers (2.415 micrometers) in the spectrum of WL5, an infrared source in the rho Ophiuchus cloud complex, has been detected. It is attributed to molecular hydrogen created by irradiation and frozen in situ into water-rich ices. A second, broader absorption at 4125 wavenumbers centimeters (2.424 micrometers) is probably due to methanol in the ices. The column densities of frozen molecular hydrogen and methanol are inferred to be about 2.5 x 10(18) and 3.0 x 10(19), respectively. There is about three times more frozen molecular hydrogen than frozen carbon monoxide along this line of sight.
C1 JOINT ASTRON CTR, HILO, HI 96720 USA.
RP SANDFORD, SA (reprint author), NASA, AMES RES CTR, MAIL STOP 245-6, MOFFETT FIELD, CA 94035 USA.
CR ALLAMANDOLA LJ, 1992, ASTROPHYS J, V399, P134, DOI 10.1086/171909
   ALLAMANDOLA LJ, 1988, DUST UNIVERSE, P229
   BRAND PWJL, 1993, J CHEM SOC FARADAY T, V89, P2131, DOI 10.1039/ft9938902131
   Brown G. N.  Jr., 1980, Advances in Cryogenic Engineering. Vol.25. Proceedings of the 1979 Cryogenic Engineering Conference, P662
   DEREMIGIS J, 1970, CAN J PHYS, V48, P1622
   DHENDECOURT LB, 1982, ASTRON ASTROPHYS, V109, pL12
   FLOWER DR, 1990, MON NOT R ASTRON SOC, V247, P500
   Hagen W., 1983, Astronomy & Astrophysics Supplement Series, V51, P389
   HOLLENBACH D, 1971, ASTROPHYS J, V163, P155, DOI 10.1086/150754
   HOLLENBACH D, 1970, J CHEM PHYS, V53, P79, DOI 10.1063/1.1673836
   HUDGINS DM, 1993, ASTROPHYS J SUPPL S, V86, P713, DOI 10.1086/191796
   HUDSON RL, 1992, J PHYS CHEM-US, V96, P6500, DOI 10.1021/j100194a072
   KERR TH, 1991, MON NOT R ASTRON SOC, V251, pP60, DOI 10.1093/mnras/251.1.60P
   KERR TH, UNPUB
   LEE TJ, 1971, NATURE-PHYS SCI, V231, P193, DOI 10.1038/physci231193a0
   LEE TJ, 1972, NATURE-PHYS SCI, V237, P99
   PIRRONELLO V, 1988, ASTRON ASTROPHYS, V196, P201
   SANDFORD SA, 1993, ASTROPHYS J, V409, pL65, DOI 10.1086/186861
   SANDFORD SA, 1992, FARADAY S, V28
   SANDFORD SA, UNPUB
   SANDFORD SA, IN PRESS ASTROPHYS J
   SCHUTTE WA, 1991, ASTRON ASTROPHYS, V244, P190
   SHULL JM, 1982, ANNU REV ASTRON ASTR, V20, P163, DOI 10.1146/annurev.aa.20.090182.001115
   SMITH GR, 1976, J CHEM PHYS, V65, P1591, DOI 10.1063/1.433218
   Souers P. C., 1986, HYDROGEN PROPERTIES
   TANAKA M, 1990, ASTROPHYS J, V352, P724, DOI 10.1086/168574
   Van de Hulst H. C., 1949, RECH ASTRON OBS UT 1, V11, P1
   WARREN JA, 1980, J CHEM PHYS, V72, P4901, DOI 10.1063/1.439774
   WILKING BA, 1983, ASTROPHYS J, V274, P698, DOI 10.1086/161482
NR 29
TC 61
Z9 61
U1 1
U2 12
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
EI 1095-9203
J9 SCIENCE
JI Science
PD OCT 15
PY 1993
VL 262
IS 5132
BP 400
EP 404
DI 10.1126/science.11542874
PG 5
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA MB859
UT WOS:A1993MB85900050
PM 11542874
DA 2018-12-27
ER

PT J
AU SAROEA, HG
AF SAROEA, HG
TI RETRACTED: COMMON COLDS - CAUSES, POTENTIAL CURES, AND TREATMENT
   (RETRACTED ARTICLE. SEE VOL 56, pg 413, 2010)
SO CANADIAN FAMILY PHYSICIAN
LA English
DT Article; Retracted Publication
AB Colds are a common clinical condition, caused by a variety of pathogens. This article reviews the etiology of the cold, proposed cures, symptomatic relief, method of transmission, and advice for patients. Transmission through indirect contact, or self-inoculation, seems more common than was once thought. Experimental antiviral agents hold some promise; in the meantime, symptomatic relief is available.
RP SAROEA, HG (reprint author), ROYAL ALEXANDRA HOSP, 10240 KINGSWAY, EDMONTON T5H 3V9, AB, CANADA.
NR 0
TC 6
Z9 6
U1 2
U2 5
PU COLL FAMILY PHYSICIANS CANADA
PI MISSISSAUGA
PA 2630 SKYMARK AVE, MISSISSAUGA, ONTARIO L4W 5A4, CANADA
SN 0008-350X
EI 1715-5258
J9 CAN FAM PHYSICIAN
JI Can. Fam. Phys.
PD OCT
PY 1993
VL 39
BP 2215
EP +
PG 1
WC Primary Health Care; Medicine, General & Internal
SC General & Internal Medicine
GA MC083
UT WOS:A1993MC08300023
PM 8219868
DA 2018-12-27
ER

PT J
AU FRIEDMAN, AJ
   HORNSTEIN, MD
AF FRIEDMAN, AJ
   HORNSTEIN, MD
TI RETRACTED: GONADOTROPIN-RELEASING-HORMONE AGONIST PLUS
   ESTROGEN-PROGESTIN ADD-BACK THERAPY FOR ENDOMETRIOSIS-RELATED PELVIC
   PAIN (RETRACTED ARTICLE. SEE VOL 65, PG 211, 1996)
SO FERTILITY AND STERILITY
LA English
DT Article; Retracted Publication
DE ENDOMETRIOSIS; GNRH AGONIST; LEUPROLIDE; STEROID ADD-BACK; ESTROGEN
   THRESHOLD HYPOTHESIS; PELVIC PAIN; ESTROGEN; PROGESTIN
ID SYMPTOMATIC ENDOMETRIOSIS; MEDROXYPROGESTERONE ACETATE; ORAL
   MEDROXYPROGESTERONE; THRESHOLD HYPOTHESIS; DEPOT LEUPROLIDE; GOSERELIN
   DEPOT; DENSITY LOSS; DANAZOL; WOMEN; NORETHINDRONE
AB Objective: To evaluate the safety and efficacy of leuprolide acetate depot (LA, Lupron; TAP Pharmaceuticals, Deerfield, IL) plus daily conjugated equine estrogens (Es, Premarin; Wyeth-Ayerst Laboratories, Philadelphia, PA), and medroxyprogesterone acetate (MPA, Provera; The Upjohn Company, Kalamazoo, MI) ''add-back'' treatment of endometriosis-associated pelvic pain.
   Design: Retrospective case series.
   Setting: Tertiary care, academic medical center.
   Patients: Eight patients with moderate to severe pelvic pain and laparoscopically documented endometriosis.
   Intervention: Leuprolide acetate depot 3.75 mg IM every 4 weeks for 24 months. Oral conjugated equine Es 0.625 mg/d plus MPA 2.5 mg/d were also taken from treatment months 3 through 24.
   Results: Six women completed the 2-year study. Mean revised endometriosis scores for implants, adhesions, and total values were significantly reduced at the conclusion of treatment from pretreatment scores. Self-reported pelvic pain scores were significantly lower at treatment months 3, 6, 12, 18, 24, and 6 months after therapy than pretreatment scores. Dual X-ray absorptiometry bone density measurements of the lumbar spine did not change significantly during the 24-month treatment period. The proportion of women experiencing hot flushes was significantly reduced after E-progestin add-back treatment from the proportion at treatment month 3.
   Conclusion: Treatment with LA depot plus conjugated equine Es and MPA for 2 years was a safe and effective therapy for women with endometriosis and pelvic pain in this small retrospective study.
RP FRIEDMAN, AJ (reprint author), HARVARD UNIV, BRIGHAM & WOMENS HOSP,SCH MED, DEPT OBSTET & GYNECOL,75 FRANCIS ST, ASBI-2-104, BOSTON, MA 02115 USA.
FU NCRR NIH HHS [7-M01-RR02635-01]
CR [Anonymous], 1985, Fertil Steril, V43, P351
   BARBIERI RL, 1992, AM J OBSTET GYNECOL, V166, P740, DOI 10.1016/0002-9378(92)91706-G
   CEDARS MI, 1990, OBSTET GYNECOL, V75, P641
   CUMMINGS SR, 1986, ANN INTERN MED, V104, P817, DOI 10.7326/0003-4819-104-6-817
   DAWOOD MY, 1989, FERTIL STERIL, V52, P21
   DLUGI AM, 1990, FERTIL STERIL, V54, P419
   DODIN S, 1991, OBSTET GYNECOL, V77, P410
   DOSWELL L, 1992, FERTIL STERIL, V57, P514
   FRIEDMAN AJ, 1993, J CLIN ENDOCR METAB, V76, P1439, DOI 10.1210/jc.76.6.1439
   FRIEDMAN AJ, 1990, AM J OBSTET GYNECOL, V163, P1114, DOI 10.1016/0002-9378(90)90667-V
   HENZL MR, 1988, NEW ENGL J MED, V318, P485, DOI 10.1056/NEJM198802253180805
   HORNSTEIN MD, 1993, FERTIL STERIL, V59, P1015
   KENNEDY SH, 1990, FERTIL STERIL, V53, P998
   LUCIANO AA, 1988, OBSTET GYNECOL, V72, P323
   MATTA WH, 1988, CLIN ENDOCRINOL, V29, P45, DOI 10.1111/j.1365-2265.1988.tb00248.x
   REICHEL RP, 1992, FERTIL STERIL, V57, P1197
   REID BA, 1992, BRIT J OBSTET GYNAEC, V99, P344, DOI 10.1111/j.1471-0528.1992.tb13737.x
   SCHIFF I, 1980, JAMA-J AM MED ASSOC, V244, P1443, DOI 10.1001/jama.244.13.1443
   SCHLAFF WD, 1990, OBSTET GYNECOL, V75, P646
   SHAW RW, 1992, FERTIL STERIL, V58, P265
   STEINGOLD KA, 1987, OBSTET GYNECOL, V69, P403
   SURREY ES, 1992, J CLIN ENDOCR METAB, V75, P558, DOI 10.1210/jc.75.2.558
   SURREY ES, 1990, FERTIL STERIL, V53, P620
   VENTURINI PL, 1990, FERTIL STERIL, V54, P1021
   WHEELER JM, 1992, AM J OBSTET GYNECOL, V167, P1367, DOI 10.1016/S0002-9378(11)91718-9
NR 25
TC 43
Z9 44
U1 1
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0015-0282
EI 1556-5653
J9 FERTIL STERIL
JI Fertil. Steril.
PD AUG
PY 1993
VL 60
IS 2
BP 236
EP 241
PG 6
WC Obstetrics & Gynecology; Reproductive Biology
SC Obstetrics & Gynecology; Reproductive Biology
GA LQ642
UT WOS:A1993LQ64200004
PM 8339817
DA 2018-12-27
ER

PT J
AU DUNKEL, EC
   DEFREITAS, D
   SCHEER, DI
   SIEGEL, ML
   ZHU, Q
   WHITLEY, RJ
   SCHAFFER, PA
   PAVANLANGSTON, D
AF DUNKEL, EC
   DEFREITAS, D
   SCHEER, DI
   SIEGEL, ML
   ZHU, Q
   WHITLEY, RJ
   SCHAFFER, PA
   PAVANLANGSTON, D
TI RETRACTED: A RABBIT MODEL FOR HUMAN CYTOMEGALOVIRUS-INDUCED
   CHORIORETINAL DISEASE (RETRACTED ARTICLE. SEE VOL 177, PG 1778, 1998)
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article; Retracted Publication
ID IMMUNE-DEFICIENCY SYNDROME; VIRUS RETINITIS; INTRAVITREAL GANCICLOVIR;
   MOLECULAR-CLONING; GUINEA-PIG; INFECTION; THERAPY; RETINOPATHY;
   ZIDOVUDINE; INVIVO
AB AD169, a well-characterized laboratory strain of human cytomegalovirus (HCMV), was used to establish an animal model of progressive HCMV chorioretinal disease by injection of 10(5) pfu into the rabbit vitreous. Chorioretinal, vitreous, and pulmonary disease were monitored by HCMV recovery, clinical observation, antigen localization, and histopathology. Vitritis and focal areas of immune cellular infiltrates were seen in inner retinal layers on days 2-4 after inoculation. Disease progressed with more severe vitritis and to involve the outer retinal layers in areas of mixed monocytic cellular infiltrates, retinal destruction, choroidal edema, and congestion. HCMV was recovered from chorioretinal cell sonicate cultures in titers ranging from 10(4) to 10(5) pfu during peak disease, and HCMV antigens were detected focally by immunofluorescence in retinal layers on days 2 and 4 after inoculation. A rabbit model of HCMV chorioretinitis similar to human CMV disease allows investigation of HCMV pathogenesis and new antiviral therapies and evaluation of immune system modulation of the HCMV ocular infection.
C1 HARVARD UNIV, SCH MED, DANA FARBER CANC INST, BOSTON, MA 02115 USA.
   SCHEER & CO, BRANFORD, CT USA.
   UNIV ALABAMA, DEPT PEDIAT, BIRMINGHAM, AL 35294 USA.
RP DUNKEL, EC (reprint author), HARVARD UNIV, SCH MED, SCHEPENS EYE RES INST, DEPT OPHTHALMOL, 20 STANIFORD ST, BOSTON, MA 02114 USA.
RI Freitas, Denise/G-9374-2015
OI Freitas, Denise/0000-0002-3389-6021
FU NEI NIH HHS [EY-08851]; NIAID NIH HHS [AI-15100]
CR ADLER SP, 1989, NEW ENGL J MED, V321, P1290, DOI 10.1056/NEJM198911093211903
   ANAND, 1993, ARCH OPHTHALMOL-CHIC, V111, P223
   AQUINODEJESUS MJC, 1989, ANTIVIR RES, V12, P181, DOI 10.1016/0166-3542(89)90028-4
   DAMICO DJ, 1988, ARCH OPHTHALMOL-CHIC, V106, P1168
   DUNKEL EC, 1992, INVEST OPHTH VIS SCI, V33, P788
   DUNKEL EC, 1984, INVEST OPHTH VIS SCI, V25, P525
   EBELING A, 1983, J VIROL, V47, P421
   EGBERT PR, 1980, ANN INTERN MED, V93, P664, DOI 10.7326/0003-4819-93-5-664
   FABER DW, 1992, INVEST OPHTH VIS SCI, V33, P2345
   FREITAS D, 1991, INVEST OPHTH VIS SCI, V32, P987
   GAO M, 1984, J VIROL, V52, P436
   GREEN MT, 1981, INFECT IMMUN, V34, P987
   GROSSNIKLAUS HE, 1987, OPHTHALMOLOGY, V94, P1601
   GUYER DR, 1989, ARCH OPHTHALMOL-CHIC, V107, P868, DOI 10.1001/archopht.1989.01070010890037
   HAYASHI K, 1985, INVEST OPHTH VIS SCI, V26, P486
   HEINEMANN MH, 1989, ARCH OPHTHALMOL-CHIC, V107, P1767, DOI 10.1001/archopht.1989.01070020849025
   HENDERLY DE, 1987, OPHTHALMOLOGY, V94, P425
   HENDERLY DE, 1987, AM J OPHTHALMOL, V103, P316
   JABS DA, 1989, ARCH OPHTHALMOL-CHIC, V107, P75, DOI 10.1001/archopht.1989.01070010077031
   KARNOVSKY MJ, 1965, J CELL BIOL, V27, pA137
   MATOBA AY, 1986, OPHTHALMOLOGY, V93, P746
   MEYERS JD, 1985, HERPESVIRUSES NEW YO, V4, P201
   MONTPLAISIR S, 1979, CAN J MICROBIOL, V25, P261, DOI 10.1139/m79-042
   PALESTINE AG, 1986, AM J OPHTHALMOL, V101, P95, DOI 10.1016/0002-9394(86)90470-8
   PASS RF, 1987, NEW ENGL J MED, V316, P1366, DOI 10.1056/NEJM198705283162203
   PAVANLANGSTON D, 1989, ARCH OPHTHALMOL-CHIC, V107, P1068, DOI 10.1001/archopht.1989.01070020130046
   PEPOSE JS, 1987, OPHTHALMOLOGY, V94, P414
   STAGNO S, 1985, NEW ENGL J MED, V313, P1270, DOI 10.1056/NEJM198511143132006
   USSERY FM, 1988, OPHTHALMOLOGY, V95, P640
   WALMSLEY SL, 1988, J INFECT DIS, V157, P569, DOI 10.1093/infdis/157.3.569
   1992, OPHTHALMOLOGY, V326, P213
NR 31
TC 12
Z9 12
U1 2
U2 10
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 5720 S WOODLAWN AVE, CHICAGO, IL 60637
SN 0022-1899
J9 J INFECT DIS
JI J. Infect. Dis.
PD AUG
PY 1993
VL 168
IS 2
BP 336
EP 344
DI 10.1093/infdis/168.2.336
PG 9
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA LN813
UT WOS:A1993LN81300012
PM 8393056
DA 2018-12-27
ER

PT J
AU FUJII, Y
   TOYOOKA, H
   EBATA, T
   AMAHA, K
AF FUJII, Y
   TOYOOKA, H
   EBATA, T
   AMAHA, K
TI RETRACTED: CONTRACTILITY OF FATIGUED DIAPHRAGM IS IMPROVED BY DOBUTAMINE
   (Retracted article. See vol. 59, pg. 1181, 2012)
SO CANADIAN JOURNAL OF ANAESTHESIA-JOURNAL CANADIEN D ANESTHESIE
LA English
DT Article; Retracted Publication
DE SYMPATHETIC NERVOUS SYSTEM, DOBUTAMINE; VENTILATION, DIAPHRAGM; FAILURE
ID RESPIRATORY-FAILURE; CANINE DIAPHRAGM; STRENGTH; ACIDOSIS; MUSCLES
AB The effects of dobutamine (DOB) on diaphragmatic fatigue were examined in 20 anaesthetized, mechanically ventilated dogs. Animals were divided into two groups: the DOB group (n = 10) and the control group (n = 10). Diaphragmatic fatigue was induced by intermittent supramaximal electric stimulation applied to bilateral phrenic nerves at a frequency of 20 Hz for 30 min. Diaphragmatic contractility was assessed with trans-diaphragmatic pressure (Pdi). After diaphragmatic fatigue, Pdi decreased at low-frequency (20 Hz) stimulation (P < 0.05), whereas the decrease was minimal at high-frequency (100 Hz) stimulation. In the DOB group, after producing fatigue, the continuous administration of 10 mug . kg-1 . min-1 dobutamine iv for 30 min produced an increased Pdi at both frequencies of stimulation (P < 0.05). The Pdi returned to pre-fatigue values after cessation of dobutamine administration. In the control group, the speed of recovery from fatigue was much slower at low-frequency stimulation. The integrated diaphragmatic electric activity (Edi) in the two groups did not change throughout the experiment at any frequency of stimulation. We conclude that dobutamine improves contractility in fatigued diaphragm.
C1 TOKYO MED & DENT UNIV, SCH MED, DEPT ANESTHESIOL & CRIT CARE MED, BUNKYO KU, TOKYO 113, JAPAN.
RP FUJII, Y (reprint author), TORIDE KYODO GEN HOSP, DEPT ANESTHESIOL, 5901-1 TERADA, TORIDE, IBARAKI 302, JAPAN.
CR AUBIER M, 1981, NEW ENGL J MED, V305, P249, DOI 10.1056/NEJM198107303050503
   AUBIER M, 1981, J APPL PHYSIOL, V50, P538
   AUBIER M, 1989, ANN INTERN MED, V110, P17, DOI 10.7326/0003-4819-110-1-17
   AUBIER M, 1986, J APPL PHYSIOL, V61, P1767
   EBATA T, 1992, CAN J ANAESTH, V39, P375, DOI 10.1007/BF03009049
   ESAU SA, 1989, AM REV RESPIR DIS, V139, P1410, DOI 10.1164/ajrccm/139.6.1410
   Fujii Y, 1991, J Anesth, V5, P17, DOI 10.1007/s0054010050017
   GRASSINO A, 1978, J APPL PHYSIOL, V44, P829
   HOWELL S, 1984, AM REV RESPIR DIS, V129, P118
   HOWELL S, 1985, J APPL PHYSIOL, V59, P1376
   MACKLEM PT, 1977, CLIN SCI MOL MED, V53, P419, DOI 10.1042/cs0530419
   Moxham J, 1981, Ciba Found Symp, V82, P197
   ROBERTSON CH, 1977, J CLIN INVEST, V59, P31, DOI 10.1172/JCI108619
   ROUSSOS C, 1982, NEW ENGL J MED, V307, P786, DOI 10.1056/NEJM198209233071304
NR 14
TC 15
Z9 15
U1 2
U2 9
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0832-610X
J9 CAN J ANAESTH
JI Can. J. Anaesth.-J. Can. Anesth.
PD MAY
PY 1993
VL 40
IS 5
BP 453
EP 458
DI 10.1007/BF03009517
PG 6
WC Anesthesiology
SC Anesthesiology
GA LF352
UT WOS:A1993LF35200012
PM 8513526
OA Bronze
DA 2018-12-27
ER

PT J
AU TAGHIAN, A
   GIOIOSO, D
   BUDACH, W
   SUIT, H
AF TAGHIAN, A
   GIOIOSO, D
   BUDACH, W
   SUIT, H
TI RETRACTED: IN VITRO SPLIT-DOSE RECOVERY OF GLIOBLASTOMA-MULTIFORME
   (RETRACTED ARTICLE. SEE VOL 146, PG 242, 1996)
SO RADIATION RESEARCH
LA English
DT Article; Retracted Publication
ID HUMAN-TUMOR CELLS; POTENTIALLY LETHAL DAMAGE; REPAIR; RADIOSENSITIVITY;
   RADIOCURABILITY; RADIORESISTANT; RADIOTHERAPY; PREDICT; LINES
RP TAGHIAN, A (reprint author), HARVARD UNIV, MASSACHUSETTS GEN HOSP, SCH MED, DEPT RADIAT ONCOL, EDWIN L STEELE LAB RADIAT BIOL, BOSTON, MA 02114 USA.
FU NCI NIH HHS [CA13311]
CR DESCHAVANNE PJ, 1990, RADIAT RES, V122, P29, DOI 10.2307/3577579
   ELKIND MM, 1959, NATURE, V184, P1293, DOI 10.1038/1841293a0
   FERTIL B, 1984, RADIAT RES, V99, P73, DOI 10.2307/3576448
   GUICHARD M, 1984, Radiotherapy and Oncology, V1, P263, DOI 10.1016/S0167-8140(84)80009-2
   HALL EJ, 1988, RADIAT RES, V114, P415, DOI 10.2307/3577115
   LITTLE JB, 1969, NATURE, V224, P804, DOI 10.1038/224804a0
   MALAISE EP, 1989, INT J RADIAT BIOL, V56, P597, DOI 10.1080/09553008914551801
   PEACOCK JH, 1988, INT J RADIAT BIOL, V54, P945, DOI 10.1080/09553008814552341
   SIEMANN DW, 1989, INT J RADIAT BIOL, V56, P567, DOI 10.1080/09553008914551751
   STEEL GG, 1987, RADIOTHER ONCOL, V9, P299
   TAGHIAN A, 1992, INT J RADIAT ONCOL, V23, P55, DOI 10.1016/0360-3016(92)90543-Q
   TAGHIAN A, 1993, INT J RADIAT ONCOL, V25, P243, DOI 10.1016/0360-3016(93)90345-V
   WEICHSELBAUM RR, 1986, P NATL ACAD SCI USA, V83, P2684, DOI 10.1073/pnas.83.8.2684
   WEICHSELBAUM RR, 1982, BRIT J CANCER, V45, P10, DOI 10.1038/bjc.1982.2
   WEICHSELBAUM RR, 1982, RADIOLOGY, V145, P511, DOI 10.1148/radiology.145.2.7134460
   WEICHSELBAUM RR, 1985, P NATL ACAD SCI USA, V82, P4732, DOI 10.1073/pnas.82.14.4732
   WEICHSELBAUM RR, 1987, INT J RADIAT ONCOL, V13, P709, DOI 10.1016/0360-3016(87)90289-6
   WEICHSELBAUM RR, 1986, INT J RADIAT ONCOL, V12, P637, DOI 10.1016/0360-3016(86)90073-8
NR 18
TC 16
Z9 16
U1 2
U2 6
PU RADIATION RESEARCH SOC
PI LAWRENCE
PA 810 E TENTH STREET, LAWRENCE, KS 66044 USA
SN 0033-7587
EI 1938-5404
J9 RADIAT RES
JI Radiat. Res.
PD APR
PY 1993
VL 134
IS 1
BP 16
EP 21
DI 10.2307/3578497
PG 6
WC Biology; Biophysics; Radiology, Nuclear Medicine & Medical Imaging
SC Life Sciences & Biomedicine - Other Topics; Biophysics; Radiology,
   Nuclear Medicine & Medical Imaging
GA KY744
UT WOS:A1993KY74400003
PM 8386388
DA 2018-12-27
ER

PT J
AU WILLIAMS, MH
   BOWIE, C
AF WILLIAMS, MH
   BOWIE, C
TI RETRACTED: EVIDENCE OF UNMET NEED IN THE CARE OF SEVERELY PHYSICALLY
   DISABLED ADULTS (RETRACTED ARTICLE. SEE VOL 316, PG 1700, 1998)
SO BMJ-BRITISH MEDICAL JOURNAL
LA English
DT Article; Retracted Publication
AB Objective-To identify unmet needs in the care of severely disabled people aged
   Design-Detailed personal interview and physical assessment of physically disabled adults; personal or telephone interview with carers.
   Setting-Somerset Health District.
   Subjects-181 severely disabled adults and their carers.
   Main outcome measures-Independence in activities of daily living; identity of requirements for assessing communication disorders; appropriate provision of services and allowances.
   Results-53 (29.3%) of the 181 disabled subjects had unmet needs for aids to allow independence in activities of daily living-namely, 43% of subjects (41/95) with progressive disorders and 14% of subjects (12/86) with non-progressive disorders. The prevalence of unmet need was higher among subjects whose sole regular professional contact was with health services personnel (48 (40.3%) of 119 subjects). Only 18 (31.6%) of the 57 subjects with communication disorders had ever been assessed by a speech therapist.
   Conclusions-This study shows that the needs of severely physically disabled adults in the community -especially those with progressive disorders-are being monitored inadequately by health professionals.
C1 SOMERSET HLTH AUTHOR, TAUNTON TA2 7PQ, ENGLAND.
RP WILLIAMS, MH (reprint author), UNIV BRISTOL, HLTH CARE EVALUAT UNIT, BRISTOL BS8 2PR, ENGLAND.
CR BEARDSHAW V, 1988, 3 RES REP
   BLAXTER M, 1979, CMND7615
   BRADSHAW J, 1972, PROBLMS PROGR MED CA
   BRECHIN A, 1981, LOOK IT THIS WAY NEW
   Buchan H, 1990, Health Serv J, V100, P240
   CAMPBELL MJ, 1984, J NEUROL SCI, V64, P65, DOI 10.1016/0022-510X(84)90056-X
   CANTRELL E, 1985, PRISONERS HANDICAP
   CULYER AJ, 1976, NEED NATIONAL HLTH S
   EDWARDS FC, 1990, HLTH SERVICES ADULTS
   Martin J., 1988, OPCS SURVEYS DISABIL
   Patrick D L, 1982, J R Coll Gen Pract, V32, P429
   ROBINSON T, 1978, WORLDS APART
   THOMAS A, 1985, DEV MED CHILD NEUR S, V4, P50
   WILLIAMS A., 1978, EC ASPECTS HLTH SERV
   1989, CARING PEOPLE
   1990, NHS COMMUNITY CARE A
NR 16
TC 21
Z9 21
U1 1
U2 14
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 1756-1833
J9 BMJ-BRIT MED J
JI BMJ-British Medical Journal
PD JAN 9
PY 1993
VL 306
IS 6870
BP 95
EP 98
DI 10.1136/bmj.306.6870.95
PG 4
WC Medicine, General & Internal
SC General & Internal Medicine
GA KG465
UT WOS:A1993KG46500017
PM 8435649
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU GRUSS, HJ
   BRACH, MA
   HERRMANN, F
AF GRUSS, HJ
   BRACH, MA
   HERRMANN, F
TI RETRACTED: INVOLVEMENT OF NUCLEAR FACTOR-KAPPA-B IN INDUCTION OF THE
   INTERLEUKIN-6 GENE BY LEUKEMIA INHIBITORY FACTOR (RETRACTED ARTICLE. SEE
   VOL 93, PG. 3573, 1999)
SO BLOOD
LA English
DT Article; Retracted Publication
ID DIFFERENTIATION-INDUCING FACTOR; NECROSIS FACTOR-ALPHA; STIMULATING
   FACTOR; CELLS; EXPRESSION; ACTIVATION; MICE; IMMUNOGLOBULIN; ELEMENT;
   IL-6
C1 UNIV FREIBURG, MED CTR, DEPT INTERNAL MED 1, HUGSTETTERSTR 55, W-7800 FREIBURG, GERMANY.
   FREE UNIV BERLIN, MAX DELBRUCK CTR MOLEC MED, UNIV CLIN RUDOLF VIRCHOW, W-1000 BERLIN 33, GERMANY.
CR ABE E, 1986, P NATL ACAD SCI USA, V83, P5958, DOI 10.1073/pnas.83.16.5958
   BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0
   BAUMANN H, 1989, J IMMUNOL, V143, P1163
   BRACH MA, 1992, BLOOD, V79, P728
   BRACH MA, 1990, FEBS LETT, V263, P349, DOI 10.1016/0014-5793(90)81411-G
   BRACH MA, 1991, J CLIN INVEST, V88, P691, DOI 10.1172/JCI115354
   BRACH MA, IN PRESS J BIOL CHEM
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X
   DEVARY Y, 1991, P NATL ACAD SCI USA, V11, P2804
   DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475
   GEARING DP, 1991, NEGATIVE REGULATORS, V628, P9
   GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0
   GROSSCHEDL R, 1985, CELL, V41, P885, DOI 10.1016/S0092-8674(85)80069-6
   HERRMANN F, 1991, ANN HEMATOL, V63, P229, DOI 10.1007/BF01703450
   HIRANO T, 1991, INT J CELL CLONING, V9, P166, DOI 10.1002/stem.5530090303
   HIRANO T, 1986, NATURE, V324, P73, DOI 10.1038/324073a0
   ISSHIKI H, 1990, MOL CELL BIOL, V10, P2757, DOI 10.1128/MCB.10.6.2757
   LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7
   LIBERMANN TA, 1990, MOL CELL BIOL, V10, P2327, DOI 10.1128/MCB.10.5.2327
   LOWE DG, 1989, DNA-J MOLEC CELL BIO, V8, P351, DOI 10.1089/dna.1.1989.8.351
   METCALF D, 1989, LEUKEMIA, V3, P847
   METCALF D, 1989, P NATL ACAD SCI USA, V86, P5948, DOI 10.1073/pnas.86.15.5948
   METCALF D, 1990, BLOOD, V76, P50
   MIYAURA C, 1989, BIOCHEM BIOPH RES CO, V158, P660, DOI 10.1016/0006-291X(89)92772-1
   MOREAU JF, 1988, NATURE, V336, P690, DOI 10.1038/336690a0
   MORI M, 1989, BIOCHEM BIOPH RES CO, V160, P1085, DOI 10.1016/S0006-291X(89)80114-7
   RAY A, 1988, P NATL ACAD SCI USA, V85, P6701, DOI 10.1073/pnas.85.18.6701
   RAY A, 1989, MOL CELL BIOL, V9, P5537, DOI 10.1128/MCB.9.12.5537
   SCHRECK R, 1990, MOL CELL BIOL, V10, P1281, DOI 10.1128/MCB.10.3.1281
   SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173
   SHAKHOV AN, 1990, J EXP MED, V171, P35, DOI 10.1084/jem.171.1.35
   SHIMIZU H, 1990, MOL CELL BIOL, V10, P561, DOI 10.1128/MCB.10.2.561
   SMITH AG, 1988, NATURE, V336, P688, DOI 10.1038/336688a0
   STEVENSON HC, 1984, METHOD ENZYMOL, V108, P242
   WILLIAMS RL, 1988, NATURE, V336, P684, DOI 10.1038/336684a0
   YAMAMORI T, 1989, SCIENCE, V246, P1412, DOI 10.1126/science.2512641
   YASUKAWA K, 1987, EMBO J, V6, P2939, DOI 10.1002/j.1460-2075.1987.tb02598.x
NR 38
TC 31
Z9 31
U1 0
U2 5
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD NOV 15
PY 1992
VL 80
IS 10
BP 2563
EP 2570
PG 8
WC Hematology
SC Hematology
GA JY677
UT WOS:A1992JY67700016
PM 1421375
DA 2018-12-27
ER

PT J
AU URADE, Y
   FUJITANI, Y
   ODA, K
   WATAKABE, T
   UMEMURA, I
   TAKAI, M
   OKADA, T
   SAKATA, K
   KARAKI, H
AF URADE, Y
   FUJITANI, Y
   ODA, K
   WATAKABE, T
   UMEMURA, I
   TAKAI, M
   OKADA, T
   SAKATA, K
   KARAKI, H
TI RETRACTED: AN ENDOTHELIN-B RECEPTOR-SELECTIVE ANTAGONIST - IRL-1038,
   [CYS(11)-CYS(15)]-ENDOTHELIN-1(11-21) (RETRACTED ARTICLE. SEE VOL 342,
   PG 103, 1994)
SO FEBS LETTERS
LA English
DT Article; Retracted Publication
DE ENDOTHELIN; RECEPTOR; ANTAGONIST; SMOOTH MUSCLE; CONTRACTION
AB In the inhibition of specific binding of [I-125]endothelins (ETs) to membranes from various tissues of rats, guinea pigs, pigs and humans, [Cys11-Cys15]-Et-1(11-21), IRL 1038, has a much higher affinity for ET(B) receptors (K(i) = 6-11 nM) than for ET(A) receptors (K(i) = 0.4-0.7 muM). In contraction assays, with ET-3 as a stimulant, 3 muM IRL 1038 antagonized the ET(B) receptor-mediated contraction of guinea pig ileal and tracheal smooth muscle without any significant agonistic activity, but did not effect the ET(A) receptor-mediated contraction of rat aortic smooth muscle. IRL 1038 is, therefore, considered to be the first antagonist selective to the ET(B) receptor.
C1 UNIV TOKYO, FAC AGR, DEPT VET PHARMACOL, BUNKYO KU, TOKYO 113, JAPAN.
RP URADE, Y (reprint author), CIBA GEIGY JAPAN LTD, INT RES LABS, 10-66 MIYUKI-CHO, TAKARAZUKA 665, JAPAN.
CR CANDENAS ML, 1992, EUR J PHARMACOL, V210, P291, DOI 10.1016/0014-2999(92)90418-4
   FUJIMOTO M, 1992, FEBS LETT, V305, P41, DOI 10.1016/0014-5793(92)80651-V
   FUJITANI Y, 1992, FEBS LETT, V298, P79, DOI 10.1016/0014-5793(92)80026-D
   GREENBERG DA, 1992, NEUROLOGY, V42, P25, DOI 10.1212/WNL.42.1.25
   IHARA M, 1991, BIOCHEM BIOPH RES CO, V178, P132, DOI 10.1016/0006-291X(91)91789-F
   INOUE A, 1989, P NATL ACAD SCI USA, V86, P2863, DOI 10.1073/pnas.86.8.2863
   KLOOG Y, 1988, SCIENCE, V242, P268, DOI 10.1126/science.2845579
   KOZUKA M, 1991, J BIOL CHEM, V266, P16892
   MACCUMBER MW, 1991, ARCH OPHTHALMOL-CHIC, V109, P705, DOI 10.1001/archopht.1991.01080050121041
   MIYASAKA N, 1992, ARTHRITIS RHEUM, V35, P397, DOI 10.1002/art.1780350406
   MIYATA S, 1992, J ANTIBIOT, V45, P74, DOI 10.7164/antibiotics.45.74
   MORELAND S, 1992, BIOCHEM BIOPH RES CO, V184, P100, DOI 10.1016/0006-291X(92)91163-K
   RUBANYI GM, 1991, FASEB J, V5, P2713
   SAKATA K, 1989, BRIT J PHARMACOL, V98, P483, DOI 10.1111/j.1476-5381.1989.tb12621.x
   SAKURAI T, 1992, TRENDS PHARMACOL SCI, V13, P103
   SPINELLA MJ, 1991, P NATL ACAD SCI USA, V88, P7443, DOI 10.1073/pnas.88.16.7443
   TAKAI M, 1992, BIOCHEM BIOPH RES CO, V184, P953, DOI 10.1016/0006-291X(92)90683-C
   TAKANASHI M, 1991, AM J PHYSIOL, V261, pH611
   YAMASHITA Y, 1991, J PHARMACOL EXP THER, V259, P1256
   YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0
NR 20
TC 127
Z9 127
U1 1
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1873-3468
J9 FEBS LETT
JI FEBS Lett.
PD OCT 12
PY 1992
VL 311
IS 1
BP 12
EP 16
DI 10.1016/0014-5793(92)81355-P
PG 5
WC Biochemistry & Molecular Biology; Biophysics; Cell Biology
SC Biochemistry & Molecular Biology; Biophysics; Cell Biology
GA JU076
UT WOS:A1992JU07600003
PM 1397285
DA 2018-12-27
ER

PT J
AU BRACH, MA
   BUHRING, HJ
   GRUSS, HJ
   ASHMAN, LK
   LUDWIG, WD
   MERTELSMANN, RH
   HERRMANN, F
AF BRACH, MA
   BUHRING, HJ
   GRUSS, HJ
   ASHMAN, LK
   LUDWIG, WD
   MERTELSMANN, RH
   HERRMANN, F
TI RETRACTED: FUNCTIONAL EXPRESSION OF C-KIT BY ACUTE MYELOGENOUS LEUKEMIA
   BLASTS IS ENHANCED BY TUMOR-NECROSIS-FACTOR-ALPHA THROUGH
   POSTTRANSCRIPTIONAL MESSENGER-RNA STABILIZATION BY A LABILE PROTEIN
   (RETRACTED ARTICLE. SEE VOL 93, PG. 3573, 1999)
SO BLOOD
LA English
DT Article; Retracted Publication
ID ACUTE MYELOBLASTIC-LEUKEMIA; COLONY-STIMULATING FACTOR; GM-CSF;
   SUSPENSION-CULTURE; MYELOID-LEUKEMIA; TYROSINE KINASE; GROWTH-FACTORS;
   MULTI-CSF; W-LOCUS; CELLS
C1 UNIV FREIBURG, MED CTR, DEPT INTERNAL MED 1, HUGSTETTER STR 55, W-7800 FREIBURG, GERMANY.
   UNIV TUBINGEN, DEPT INTERNAL MED 1, W-7400 TUBINGEN 1, GERMANY.
   FREE UNIV BERLIN, DEPT HEMATOL & ONCOL, W-1000 BERLIN 33, GERMANY.
   UNIV ADELAIDE, DEPT MICROBIOL & IMMUNOL, ADELAIDE, SA 5001, AUSTRALIA.
RI ASHMAN, LEONIE/G-7631-2013
OI ASHMAN, LEONIE/0000-0003-3559-3611
CR ASHMAN LK, 1988, LEUKEMIA RES, V12, P923, DOI 10.1016/0145-2126(88)90020-3
   BENNET JM, 1982, BRIT J HAEMATOL, V33, P451
   BROUDY VC, 1990, BLOOD, V76, pA134
   CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0
   CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005
   ELBAZ O, 1991, BLOOD, V77, P989
   FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9
   FORT R, 1989, NUCLEIC ACIDS RES, V13, P1431
   GLINIAK BC, 1990, CELL, V63, P1073, DOI 10.1016/0092-8674(90)90510-L
   GRIFFIN JD, 1986, BLOOD, V67, P1448
   Herrmann F, 1987, Haematol Blood Transfus, V31, P185
   HOANG T, 1989, J EXP MED, V170, P15, DOI 10.1084/jem.170.1.15
   HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V
   METCALF D, 1989, CANCER RES, V49, P2305
   MIYAUCHI J, 1988, J CELL PHYSIOL, V135, P55, DOI 10.1002/jcp.1041350108
   MIYAUCHI J, 1987, BLOOD, V70, P657
   OGAWA M, 1991, J EXP MED, V174, P63, DOI 10.1084/jem.174.1.63
   OSTER W, 1989, J CLIN INVEST, V84, P451, DOI 10.1172/JCI114186
   OSTER W, 1988, BLOOD CELLS, V14, P443
   WANG C, 1989, LEUKEMIA, V3, P699
   WEBER B, 1989, MOL CELL BIOL, V9, P769, DOI 10.1128/MCB.9.2.769
   WELHAM MJ, 1991, MOL CELL BIOL, V11, P2901, DOI 10.1128/MCB.11.5.2901
   WILLIAMS DE, 1990, CELL, V63, P167, DOI 10.1016/0092-8674(90)90297-R
   WONG GG, 1985, SCIENCE, V228, P810, DOI 10.1126/science.3923623
   YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x
NR 25
TC 30
Z9 30
U1 0
U2 6
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD SEP 1
PY 1992
VL 80
IS 5
BP 1224
EP 1230
PG 7
WC Hematology
SC Hematology
GA JL367
UT WOS:A1992JL36700019
PM 1381241
DA 2018-12-27
ER

PT J
AU POEHLMAN, ET
   GARDNER, AW
   GORAN, MI
AF POEHLMAN, ET
   GARDNER, AW
   GORAN, MI
TI RETRACTED: INFLUENCE OF ENDURANCE TRAINING ON ENERGY-INTAKE,
   NOREPINEPHRINE KINETICS, AND METABOLIC-RATE IN OLDER INDIVIDUALS
   (Retracted Article. See vol 54, pg 1267 & 1268, 2005)
SO METABOLISM-CLINICAL AND EXPERIMENTAL
LA English
DT Article; Retracted Publication
ID FOOD-INTAKE; BASAL METABOLISM; BODY-COMPOSITION; EXERCISE; WOMEN; OBESE;
   MEN; REQUIREMENTS; HUMANS
C1 UNIV VERMONT, DEPT NUTR SCI, BURLINGTON, VT 05405 USA.
RP POEHLMAN, ET (reprint author), UNIV VERMONT, COLL MED, DEPT MED, DIV ENDOCRINOL METAB & NUTR, GIVEN C-332, BURLINGTON, VT 05405 USA.
FU NIA NIH HHS [K04 AG 00564, AG-05564, AG-07857]
CR CHALLIS RAJ, 1984, BIOCHEM J, V221, P915, DOI 10.1042/bj2210915
   COHN SH, 1980, AM J PHYSIOL, V239, pE524
   DURRANT ML, 1982, PHYSIOL BEHAV, V29, P449, DOI 10.1016/0031-9384(82)90265-7
   ELAHI VK, 1983, J GERONTOL, V38, P162, DOI 10.1093/geronj/38.2.162
   ESLER M, 1979, LIFE SCI, V25, P1461, DOI 10.1016/0024-3205(79)90371-0
   GERSOVITZ M, 1982, AM J CLIN NUTR, V35, P6
   GORSKY RD, 1983, HUM BIOL, V55, P577
   HALLFRISCH J, 1990, J GERONTOL, V45, pM186, DOI 10.1093/geronj/45.6.M186
   KEIM NL, 1990, INT J OBESITY, V14, P335
   KEYS A, 1953, PHYSIOL REV, V33, P245
   KEYS A, 1973, METABOLISM, V22, P579, DOI 10.1016/0026-0495(73)90071-1
   KISSILEFF HR, 1990, AM J CLIN NUTR, V52, P240
   LANDSBERG L, 1990, UCLA SYM BI, V132, P81
   MCGANDY RB, 1966, J GERONTOL, V21, P581, DOI 10.1093/geronj/21.4.581
   MCGOWAN CR, 1986, APPETITE, V7, P97, DOI 10.1016/S0195-6663(86)80045-9
   MUNRO HN, 1987, ANNU REV NUTR, V7, P23
   NEWSHOLME EA, 1990, ANN MED, V22, P181, DOI 10.3109/07853899009147266
   OBARZANEK E, 1985, AM J CLIN NUTR, V42, P323
   PEOHLMAN ET, 1990, AM J PHYSIOL, V258, pE256
   PEOHLMAN ET, 1988, AM J CLIN NUTR, V48, P509
   PEOHLMAN ET, 1990, AM J PHYSIOL, V261, pE233
   Peryam D. R., 1957, FOOD TECHNOL       S, V11, P9, DOI DOI 10.1002/JSFA.6993
   POEHLMAN ET, 1990, AM J PHYSIOL, V259, pE66
   POEHLMAN ET, 1989, CAN J PHYSIOL PHARM, V67, P10, DOI 10.1139/y89-003
   PORIKOS KP, 1977, AM J CLIN NUTR, V30, P1638
   STARR JI, 1979, METHOD HORM RADIOIMM, P613
   STATEN MA, 1991, AM J CLIN NUTR, V53, P27
   THOMPSON DA, 1988, MED SCI SPORT EXER, V20, P222, DOI 10.1249/00005768-198806000-00002
   TZANKOFF SP, 1978, J APPL PHYSIOL, V45, P536
   UAUY R, 1982, AM J CLIN NUTR, V32, P779
   WEIR JBD, 1949, J PHYSIOL-LONDON, V109, P1
   WOO R, 1985, METABOLISM, V34, P836, DOI 10.1016/0026-0495(85)90108-8
   WOO R, 1982, AM J CLIN NUTR, V36, P470
   1985, USDA AGR HDB, V8
NR 34
TC 58
Z9 61
U1 1
U2 17
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0026-0495
J9 METABOLISM
JI Metab.-Clin. Exp.
PD SEP
PY 1992
VL 41
IS 9
BP 941
EP 948
DI 10.1016/0026-0495(92)90118-T
PG 8
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA JL947
UT WOS:A1992JL94700003
PM 1518423
DA 2018-12-27
ER

PT J
AU WEISER, WY
   POZZI, LAM
   TITUS, RG
   DAVID, JR
AF WEISER, WY
   POZZI, LAM
   TITUS, RG
   DAVID, JR
TI RETRACTED: RECOMBINANT HUMAN MIGRATION-INHIBITORY FACTOR HAS ADJUVANT
   ACTIVITY (RETRACTED ARTICLE. SEE VOL 94, PG 351, 1997)
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article; Retracted Publication
ID INTERFERON-GAMMA; MACROPHAGE-MIGRATION; LYMPHOCYTE MEDIATORS;
   LEISHMANIA-DONOVANI; IFN-GAMMA; INTERLEUKIN-1; HYPERSENSITIVITY;
   ENHANCEMENT; MICE
AB Recombinant human migration inhibitory factor (MIF), isolated through functional expression cloning in COS-1 cells, up-regulates expression of genes encoding HLA-DR and interleukin 1-beta (IL-1-beta) and elaboration of IL-1-beta by human monocyte-derived macrophages. Administration of soluble bovine serum albumin or human immunodeficiency virus 120-kDa glycoprotein (HIV gp120) to mice in the presence of recombinant MIF together with incomplete Freund's adjuvant induced a strong T-cell proliferative response comparable to that of complete Freund's adjuvant. Recombinant MIF also increased antibody production, especially of IgG1 and IgM, in mice. Taken together, these results indicate that recombinant MIF may be useful as an adjuvant in the development of vaccines.
C1 BRIGHAM & WOMENS HOSP, DEPT RHEUMATOL & IMMUNOL, BOSTON, MA 02115 USA.
   HARVARD UNIV, SCH PUBL HLTH, DEPT TROP PUBL HLTH, BOSTON, MA 02115 USA.
RP WEISER, WY (reprint author), HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02115 USA.
FU NIAID NIH HHS [AI22532, AI22801]
CR ADAMS DO, 1987, IMMUNOL REV, V97, P5, DOI 10.1111/j.1600-065X.1987.tb00514.x
   ANDERSON KP, 1988, J IMMUNOL, V140, P3599
   BLOOM BR, 1966, SCIENCE, V153, P80, DOI 10.1126/science.153.3731.80
   CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005
   COLLART MA, 1986, J EXP MED, V164, P2113, DOI 10.1084/jem.164.6.2113
   DAVID JR, 1966, P NATL ACAD SCI USA, V56, P72, DOI 10.1073/pnas.56.1.72
   DAVID JR, 1972, PROG ALLERGY, V16, P300, DOI 10.1159/000313176
   DINARELLO CA, 1988, FASEB J, V2, P108
   FOWLES RE, 1973, J EXP MED, V138, P952, DOI 10.1084/jem.138.4.952
   FRIEDMAN RM, 1983, ADV IMMUNOL, V34, P97, DOI 10.1016/S0065-2776(08)60378-8
   GONWA TA, 1986, J IMMUNOL, V137, P519
   HEATH AW, 1989, IMMUNOLOGY, V67, P520
   JUNGI TW, 1987, EUR J IMMUNOL, V17, P735, DOI 10.1002/eji.1830170526
   KLEINERMAN ES, 1986, J CANCER IMMUNOL IMM, V20, P151
   LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033
   MURRAY HW, 1983, J CLIN INVEST, V72, P1506, DOI 10.1172/JCI111107
   NATHAN CF, 1973, J EXP MED, V137, P275, DOI 10.1084/jem.137.2.275
   NATHAN CF, 1971, J EXP MED, V133, P1356, DOI 10.1084/jem.133.6.1356
   PIESSENS WF, 1975, J IMMUNOL, V114, P293
   PLAYFAIR JHL, 1987, CLIN EXP IMMUNOL, V67, P5
   POZZI LM, 1991, FASEB J, V5, pA4184
   ROCKLIN RE, 1970, NEW ENGL J MED, V282, P1340, DOI 10.1056/NEJM197006112822404
   SALATA RA, 1987, AM J TROP MED HYG, V37, P72, DOI 10.4269/ajtmh.1987.37.72
   SONNENFELD G, 1980, LYMPHOKINE REPORTS, V1, P113
   STARUCH MJ, 1983, J IMMUNOL, V130, P2191
   TITUS RG, 1984, J IMMUNOL, V133, P594
   WARREN HS, 1986, ANNU REV IMMUNOL, V4, P369, DOI 10.1146/annurev.iy.04.040186.002101
   WEISER WY, 1991, J IMMUNOL, V147, P2006
   WEISER WY, 1989, P NATL ACAD SCI USA, V86, P7522, DOI 10.1073/pnas.86.19.7522
   WEISER WY, 1991, FASEB J, V5, pA1487
NR 30
TC 22
Z9 22
U1 1
U2 7
PU NATL ACAD PRESS
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD SEP 1
PY 1992
VL 89
IS 17
BP 8049
EP 8052
DI 10.1073/pnas.89.17.8049
PG 4
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA JL614
UT WOS:A1992JL61400042
PM 1518830
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU AFAR, R
   CLARKE, PBS
   GOLDSTEIN, G
   QUIK, M
AF AFAR, R
   CLARKE, PBS
   GOLDSTEIN, G
   QUIK, M
TI RETRACTED: THYMOPOIETIN, A POLYPEPTIDE LIGAND FOR THE ALPHA-BUNGAROTOXIN
   BINDING-SITE IN BRAIN - AN AUTORADIOGRAPHIC STUDY (RETRACTED ARTICLE.
   SEE VOL 59, PG 789, 1994)
SO NEUROSCIENCE
LA English
DT Article; Retracted Publication
ID NICOTINIC ACETYLCHOLINE-RECEPTOR; CENTRAL NERVOUS-SYSTEM; CEREBRAL
   GLUCOSE-UTILIZATION; RAT-BRAIN; THYMIC POLYPEPTIDE; MOUSE-BRAIN;
   POSTNATAL-DEVELOPMENT; CILIARY GANGLION; CHROMAFFIN CELLS; H-3 NICOTINE
AB Thymopoietin, a 48-49-amino acid polypeptide present in the thymus gland, was investigated as a potential ligand for the neuronal nicotinic alpha-bungarotoxin binding site in rat brain. Binding of [I-125]alpha-bungarotoxin to whole rat brain sections was inhibited by thymopoietin in a concentration-dependent manner with an IC50 of 30.0 +/- 8.2 nM as compared to 1.1 +/- 0.3 nM for alpha-bungarotoxin. However, at concentrations of thymopoietin of up to 1-mu-M, [H-3]nicotine binding to high affinity sites was not inhibited. Thysplenin, a polypeptide with considerable homology to thymopoietin did not affect [I-125]alpha-bungarotoxin binding. These results suggest that thymopoietin selectively interacts with the nicotine alpha-bungarotoxin binding site labelled by [I-125]alpha-bungarotoxin rather than the neuronal nicotinice receptor(s) labelled by [H-3]nicotine.
   Autoradiographic studies revealed that 1-mu-M thymopoietin almost completely inhibited [I-125]alpha-bungarotoxin binding in all brain regions. Computer-assisted image analysis of displacement curves was performed on various brain areas rich in alpha-bungarotoxin binding, such as the dorsal endopiriform nucleus, fields 1 and 2 of Ammon's horn, the polymorph cell layer of the dentate gyrus and cortical layers 4 and 5. Thymopoietin inhibited [I-125]alpha-bungarotoxin binding with similar potency in all these regions, suggesting that it interacted at the same site in the different brain areas. The IC50 values averaged over the six regions were 24.6 +/- 2.8 nM for thymopoietin and 1.2 +/- 0.2 nM for alpha-bungarotoxin.
   These results show that thymopoietin specifically interacted with the alpha-bungarotoxin site with a similar potency in different brain regions. It is suggested that thymopoietin represents a selective ligand for alpha-bungarotoxin binding sites in brain.
C1 MCGILL UNIV, DEPT PHARMACOL & THERAPEUT, 3655 DRUMMOND ST, MONTREAL H3G 1Y6, QUEBEC, CANADA.
   IMMUNOBIOL RES INST, ANNANDALE, NJ 08801 USA.
CR AUDHYA T, 1984, P NATL ACAD SCI-BIOL, V81, P2847, DOI 10.1073/pnas.81.9.2847
   AUDHYA T, 1987, P NATL ACAD SCI USA, V84, P3545, DOI 10.1073/pnas.84.11.3545
   BASCH RS, 1974, P NATL ACAD SCI USA, V71, P1474, DOI 10.1073/pnas.71.4.1474
   BROWN RH, 1986, BRAIN RES, V381, P237, DOI 10.1016/0006-8993(86)90072-7
   CARBONETTO ST, 1978, P NATL ACAD SCI USA, V75, P1016, DOI 10.1073/pnas.75.2.1016
   CHANGEUX JP, 1987, TRENDS NEUROSCI, V10, P245, DOI 10.1016/0166-2236(87)90167-6
   CLARKE PBS, 1985, J NEUROSCI, V5, P1307
   COUTURIER S, 1990, NEURON, V5, P847, DOI 10.1016/0896-6273(90)90344-F
   DELAGARZA R, 1987, NEUROSCIENCE, V23, P887, DOI 10.1016/0306-4522(87)90165-5
   DENERIS ES, 1991, TRENDS PHARMACOL SCI, V12, P34, DOI 10.1016/0165-6147(91)90486-C
   Falkeborn Y, 1983, Int J Dev Neurosci, V1, P289, DOI 10.1016/0736-5748(83)90031-X
   FIEDLER EP, 1990, INT J DEV NEUROSCI, V8, P533, DOI 10.1016/0736-5748(90)90045-4
   FIEDLER EP, 1987, J NEUROCHEM, V49, P983, DOI 10.1111/j.1471-4159.1987.tb00990.x
   FREEMAN JA, 1977, NATURE, V269, P218, DOI 10.1038/269218a0
   GALZI JL, 1991, ANNU REV PHARMACOL, V31, P37, DOI 10.1146/annurev.pa.31.040191.000345
   GOLDSTEI.G, 1968, LANCET, V2, P119
   GOLDSTEI.G, 1974, NATURE, V247, P11, DOI 10.1038/247011a0
   GOTTI C, 1991, P NATL ACAD SCI USA, V88, P3258, DOI 10.1073/pnas.88.8.3258
   GRUNWALD F, 1987, BRAIN RES, V400, P232, DOI 10.1016/0006-8993(87)90622-6
   HAMILL GS, 1986, J COMP NEUROL, V251, P398, DOI 10.1002/cne.902510310
   HENDERSON C, 1989, J HISTOTECHNOL, V12, P123
   HUNT S, 1979, NEUROSCIENCE, V4, P585, DOI 10.1016/0306-4522(79)90135-0
   HUNT S, 1978, BRAIN RES, V157, P213, DOI 10.1016/0006-8993(78)90025-2
   JACOB MH, 1983, J NEUROSCI, V3, P260
   LINDSTROM J, 1987, MOL NEUROBIOL, V1, P281, DOI 10.1007/BF02935740
   LIPTON SA, 1988, SCIENCE, V239, P1293, DOI 10.1126/science.3344435
   LONDON ED, 1988, J NEUROSCI, V8, P3920
   LORING RH, 1985, NEUROSCIENCE, V14, P645, DOI 10.1016/0306-4522(85)90316-1
   LUETJE CW, 1990, J NEUROCHEM, V55, P632, DOI 10.1111/j.1471-4159.1990.tb04180.x
   LUETJE CW, 1990, FASEB J, V4, P2754
   LUKAS RJ, 1990, MOL PHARMACOL, V38, P887
   MARKS MJ, 1982, MOL PHARMACOL, V22, P554
   MCLANE KE, 1990, J BIOL CHEM, V265, P9816
   MCNAMARA D, 1990, J CEREBR BLOOD F MET, V10, P48, DOI 10.1038/jcbfm.1990.7
   MEEKER RB, 1986, J NEUROSCI, V6, P1866
   Morel E, 1988, Ann N Y Acad Sci, V540, P298, DOI 10.1111/j.1749-6632.1988.tb27080.x
   NORDBERG A, 1985, INT J DEV NEUROSCI, V3, P473, DOI 10.1016/0736-5748(85)90230-8
   OSWALD RE, 1981, NEUROSCIENCE, V6, P1, DOI 10.1016/0306-4522(81)90239-6
   PATRICK J, 1977, J BIOL CHEM, V252, P8629
   QUIK M, 1986, BRAIN RES, V372, P11
   QUIK M, 1990, MOL PHARMACOL, V37, P90
   QUIK M, 1982, BRAIN RES, V245, P57, DOI 10.1016/0006-8993(82)90339-0
   QUIK M, 1982, BRAIN RES, V238, P385, DOI 10.1016/0006-8993(82)90112-3
   QUIK M, 1990, J PHARMACOL EXP THER, V254, P1113
   QUIK M, 1988, CAN J PHYSIOL PHARM, V66, P971, DOI 10.1139/y88-160
   QUIK M, 1989, J NEUROCHEM, V53, P1320, DOI 10.1111/j.1471-4159.1989.tb07431.x
   QUIK M, 1991, P NATL ACAD SCI USA, V88, P2603, DOI 10.1073/pnas.88.6.2603
   QUIK M, 1991, MOL PHARMACOL, V39, P324
   REVAH F, 1987, P NATL ACAD SCI USA, V84, P3477, DOI 10.1073/pnas.84.10.3477
   SCHOEPFER R, 1990, NEURON, V5, P35, DOI 10.1016/0896-6273(90)90031-A
   SCHULZ DW, 1991, J NEUROSCI, V11, P287
   SEGAL M, 1978, BRAIN RES, V148, P105, DOI 10.1016/0006-8993(78)90381-5
   STEINBACH JH, 1989, ANNU REV PHYSIOL, V51, P353, DOI 10.1146/annurev.ph.51.030189.002033
   STEINBACH JH, 1989, TRENDS NEUROSCI, V12, P3, DOI 10.1016/0166-2236(89)90145-8
   SUNSHINE GH, 1978, J IMMUNOL, V120, P1594
   SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111
   TWOMEY JJ, 1977, P NATL ACAD SCI USA, V74, P2541, DOI 10.1073/pnas.74.6.2541
   VENKATASUBRAMANIAN K, 1986, P NATL ACAD SCI USA, V83, P3171, DOI 10.1073/pnas.83.10.3171
   WHITING P, 1987, P NATL ACAD SCI USA, V84, P595, DOI 10.1073/pnas.84.2.595
   WHITING PJ, 1987, J NEUROSCI, V7, P4005
   WONNACOTT S, 1986, J NEUROCHEM, V47, P1706, DOI 10.1111/j.1471-4159.1986.tb13078.x
   WONNACOTT S, 1988, NICOTINIC ACETYLCHOL, P3
   ZATZ M, 1981, BRAIN RES, V213, P438, DOI 10.1016/0006-8993(81)90250-X
NR 63
TC 6
Z9 6
U1 3
U2 6
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0306-4522
EI 1873-7544
J9 NEUROSCIENCE
JI Neuroscience
PD JUN
PY 1992
VL 48
IS 3
BP 641
EP 653
DI 10.1016/0306-4522(92)90408-T
PG 13
WC Neurosciences
SC Neurosciences & Neurology
GA HV396
UT WOS:A1992HV39600011
PM 1603334
DA 2018-12-27
ER

PT J
AU SUN, WD
   CHANTLER, PD
AF SUN, WD
   CHANTLER, PD
TI RETRACTED: CLONING OF THE CDNA-ENCODING A NEURONAL MYOSIN HEAVY-CHAIN
   FROM MAMMALIAN BRAIN AND ITS DIFFERENTIAL EXPRESSION WITHIN THE
   CENTRAL-NERVOUS-SYSTEM (RETRACTED ARTICLE. SEE VOL 268, PG 585, 1997)
SO JOURNAL OF MOLECULAR BIOLOGY
LA English
DT Article; Retracted Publication
DE CELLULAR MYOSIN; NEURONAL MYOSIN; MYOSIN HEAVY CHAIN CDNA; MYOSIN
   SEQUENCE COMPARISONS; MYOSIN DISTRIBUTION
ID AMINO-ACID-SEQUENCE; MESSENGER-RNA; GROWTH CONES; DNA-SEQUENCE; ACTIN;
   CELLS; GENE; PROTEIN; MUSCLE; KINASE
C1 MED COLL PENN, DEPT ANAT & NEUROBIOL, 3200 HENRY AVE, PHILADELPHIA, PA 19129 USA.
FU NIAMS NIH HHS [AR-32858]
CR AUSUBEL FM, 1991, CURRENT PROTOCOLS MO, V1
   BERL S, 1973, SCIENCE, V179, P441, DOI 10.1126/science.179.4072.441
   BLITZ AL, 1974, P NATL ACAD SCI USA, V71, P4472, DOI 10.1073/pnas.71.11.4472
   BRAY D, 1988, SCIENCE, V239, P883, DOI 10.1126/science.3277283
   BRIDGMAN PC, 1989, J CELL BIOL, V108, P95, DOI 10.1083/jcb.108.1.95
   BURKE M, 1990, FEBS LETT, V262, P185, DOI 10.1016/0014-5793(90)80185-L
   CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2
   CONTI MA, 1991, BIOCHEMISTRY-US, V30, P966, DOI 10.1021/bi00218a012
   DECAMILLI P, 1990, ANNU REV PHYSIOL, V52, P625, DOI 10.1146/annurev.ph.52.030190.003205
   DELOZANNE A, 1987, SCIENCE, V236, P1086, DOI 10.1126/science.3576222
   DIEDERICH KW, 1989, HUM GENET, V81, P214
   EMERSON CP, 1987, ANNU REV BIOCHEM, V56, P695, DOI 10.1146/annurev.biochem.56.1.695
   ETO M, 1990, J BIOCHEM-TOKYO, V108, P499, DOI 10.1093/oxfordjournals.jbchem.a123228
   KARN J, 1983, P NATL ACAD SCI-BIOL, V80, P4253, DOI 10.1073/pnas.80.14.4253
   KARSCHMIZRACHI I, 1990, GENE, V89, P289, DOI 10.1016/0378-1119(90)90020-R
   KATSURAGAWA Y, 1989, EUR J BIOCHEM, V184, P611, DOI 10.1111/j.1432-1033.1989.tb15057.x
   KAWAMOTO S, 1991, J CELL BIOL, V112, P915, DOI 10.1083/jcb.112.5.915
   KERRICK WGL, 1984, P NATL ACAD SCI-BIOL, V81, P165, DOI 10.1073/pnas.81.1.165
   KORN ED, 1988, ANNU REV BIOPHYS BIO, V17, P23
   LUDOWYKE RI, 1989, J BIOL CHEM, V264, P12492
   MABUCHI I, 1977, J CELL BIOL, V74, P251, DOI 10.1083/jcb.74.1.251
   MCLACHLAN AD, 1982, NATURE, V299, P226, DOI 10.1038/299226a0
   MCNALLY EM, 1989, J MOL BIOL, V210, P665, DOI 10.1016/0022-2836(89)90141-1
   MILLER M, 1992, NEURON, V8, P25, DOI 10.1016/0896-6273(92)90106-N
   MORALES M, 1989, J COMP NEUROL, V279, P666, DOI 10.1002/cne.902790412
   MURAKAMI N, 1990, J BIOL CHEM, V265, P1041
   MURAKAMI N, 1991, FEBS LETT, V278, P23, DOI 10.1016/0014-5793(91)80074-D
   PASTERNAK C, 1989, NATURE, V341, P549, DOI 10.1038/341549a0
   PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0
   SAEZ CG, 1990, P NATL ACAD SCI USA, V87, P1164, DOI 10.1073/pnas.87.3.1164
   SAMBROOK J, 1989, MOL CLONING LABORATO
   SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463
   SHOHET RV, 1989, P NATL ACAD SCI USA, V86, P7726, DOI 10.1073/pnas.86.20.7726
   SINARD JH, 1989, CELL MOTIL CYTOSKEL, V12, P42, DOI 10.1002/cm.970120106
   SMITH SJ, 1988, SCIENCE, V242, P708, DOI 10.1126/science.3055292
   SPUDICH JA, 1989, CELL REGUL, V1, P1
   STEDMAN HH, 1990, J BIOL CHEM, V265, P3568
   SUN W-D, 1991, Journal of Cell Biology, V115, p329A
   SUN WD, 1991, BIOCHEM BIOPH RES CO, V175, P244, DOI 10.1016/S0006-291X(05)81226-4
   TITUS MA, 1989, CELL REGUL, V1, P55
   YANAGISAWA M, 1987, J MOL BIOL, V198, P143, DOI 10.1016/0022-2836(87)90302-0
NR 41
TC 25
Z9 25
U1 1
U2 6
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0022-2836
EI 1089-8638
J9 J MOL BIOL
JI J. Mol. Biol.
PD APR 20
PY 1992
VL 224
IS 4
BP 1185
EP 1193
DI 10.1016/0022-2836(92)90482-Y
PG 9
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA HT233
UT WOS:A1992HT23300028
PM 1569576
DA 2018-12-27
ER

PT J
AU OSTER, W
   BRACH, MA
   GRUSS, HJ
   MERTELSMANN, R
   HERRMANN, F
AF OSTER, W
   BRACH, MA
   GRUSS, HJ
   MERTELSMANN, R
   HERRMANN, F
TI RETRACTED: INTERLEUKIN-1-BETA (IL-1-BETA) EXPRESSION IN HUMAN BLOOD
   MONONUCLEAR PHAGOCYTES IS DIFFERENTIALLY REGULATED BY
   GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR (GM-CSF), M-CSF, AND
   IL-3 (RETRACTED ARTICLE. SEE VOL 93, PG. 3573, 1999)
SO BLOOD
LA English
DT Article; Retracted Publication
ID TUMOR NECROSIS FACTOR; RIBONUCLEIC-ACID; HUMAN-MONOCYTES; MESSENGER-RNA;
   GROWTH-FACTOR; FACTOR-ALPHA; IFN-GAMMA; CELLS; SECRETION; TRANSCRIPTION
C1 UNIV FREIBURG, MED CTR, DEPT HEMATOL & ONCOL, HUGSTETTER STR 55, W-7800 FREIBURG, GERMANY.
   BEHRINGWERKE AG, W-3550 MARBURG, GERMANY.
CR AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408
   BRACH MA, 1990, FEBS LETT, V263, P349, DOI 10.1016/0014-5793(90)81411-G
   CANNISTRA SA, 1988, BLOOD, V71, P672
   CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005
   COLLART MA, 1990, MOL CELL BIOL, V10, P1498, DOI 10.1128/MCB.10.4.1498
   DINARELLO CA, 1986, J EXP MED, V163, P1433, DOI 10.1084/jem.163.6.1433
   DINARELLO CA, 1987, J IMMUNOL, V139, P1902
   FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9
   FRENDL G, 1990, J IMMUNOL, V144, P3400
   GLINIAK BC, 1990, CELL, V63, P1073, DOI 10.1016/0092-8674(90)90510-L
   HART PH, 1988, J IMMUNOL, V141, P1516
   HERRMANN F, 1988, J CLIN INVEST, V81, P1415, DOI 10.1172/JCI113471
   HERRMANN F, 1989, J IMMUNOL, V142, P139
   LEARY AG, 1988, BLOOD, V71, P1759
   LINDEMANN A, 1988, EUR J IMMUNOL, V18, P369, DOI 10.1002/eji.1830180308
   LINDEMANN A, 1989, J CLIN INVEST, V83, P1308, DOI 10.1172/JCI114016
   LINDEMANN A, 1988, J IMMUNOL, V140, P837
   MARCH CJ, 1985, NATURE, V315, P641, DOI 10.1038/315641a0
   MOCHIZUKI DY, 1987, P NATL ACAD SCI USA, V84, P5267, DOI 10.1073/pnas.84.15.5267
   MOORE RN, 1980, J IMMUNOL, V125, P1302
   MORRISSEY PJ, 1988, J IMMUNOL, V140, P1910
   SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419
   SCHWARTZ RJ, 1980, BIOCHEMISTRY-US, V19, P5883, DOI 10.1021/bi00566a034
   SHANNON MF, 1990, MOL CELL BIOL, V10, P2950, DOI 10.1128/MCB.10.6.2950
   SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7
   SISSON SD, 1988, BLOOD, V72, P1368
   THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201
   VELLENGA E, 1988, BLOOD, V71, P1529
NR 28
TC 40
Z9 40
U1 0
U2 7
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD MAR 1
PY 1992
VL 79
IS 5
BP 1260
EP 1265
PG 6
WC Hematology
SC Hematology
GA HF638
UT WOS:A1992HF63800022
PM 1536949
DA 2018-12-27
ER

PT J
AU BRACH, MA
   HERRMANN, F
   KUFE, DW
AF BRACH, MA
   HERRMANN, F
   KUFE, DW
TI RETRACTED: ACTIVATION OF THE AP-1 TRANSCRIPTION FACTOR BY
   ARABINOFURANOSYLCYTOSINE IN MYELOID-LEUKEMIA CELLS (RETRACTED ARTICLE.
   SEE VOL 93, PG. 3573, 1999)
SO BLOOD
LA English
DT Article; Retracted Publication
ID NECROSIS-FACTOR-ALPHA; C-JUN; DNA-SYNTHESIS; GENE-EXPRESSION;
   PROTO-ONCOGENE; 1-BETA-D-ARABINOFURANOSYLCYTOSINE INCORPORATION;
   MAMMALIAN-CELLS; ARA-CTP; INHIBITORS; ELEMENTS
C1 HARVARD UNIV, SCH MED,DANA FARBER CANC INST,CLIN PHARMACOL LAB, 44 BINNEY ST, BOSTON, MA 02115 USA.
   UNIV FREIBURG, DEPT HEMATOL & ONCOL, W-7800 FREIBURG, GERMANY.
FU NCI NIH HHS [CA29431]
CR ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2
   ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0
   BIRD P, 1987, J CELL BIOL, V105, P2905, DOI 10.1083/jcb.105.6.2905
   BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349
   BRACH MA, 1990, LEUKEMIA, V4, P646
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0
   CHIU R, 1987, NATURE, V329, P648, DOI 10.1038/329648a0
   CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1
   COZZARELLI NR, 1977, ANNU REV BIOCHEM, V46, P641, DOI 10.1146/annurev.bi.46.070177.003233
   DATTA R, 1990, MOL PHARMACOL, V38, P435
   DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804
   DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475
   FRAM RJ, 1982, CANCER RES, V42, P4050
   FREI E, 1969, CANCER RES, V29, P1325
   FURTH JJ, 1968, CANCER RES, V28, P2061
   GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044
   GRAHAM FL, 1970, CANCER RES, V30, P2627
   GRIFFIN J, 1982, EXP HEMATOL, V10, P774
   GROSSCHEDL R, 1985, CELL, V41, P885, DOI 10.1016/S0092-8674(85)80069-6
   GRUSS HJ, IN PRESS FEBS LETT
   HUBERMAN JA, 1981, CELL, V23, P647, DOI 10.1016/0092-8674(81)90426-8
   KHARBANDA S, 1991, BIOCHEMISTRY-US, V30, P7947, DOI 10.1021/bi00246a011
   KHARBANDA SM, 1990, J CLIN INVEST, V86, P1517, DOI 10.1172/JCI114870
   KUFE D, 1984, BLOOD, V64, P54
   KUFE DW, 1984, MOL PHARMACOL, V26, P128
   KUFE DW, 1980, J BIOL CHEM, V255, P8997
   LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0
   LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X
   MAJOR PP, 1981, P NATL ACAD SCI-BIOL, V78, P3235, DOI 10.1073/pnas.78.5.3235
   MAJOR PP, 1982, BIOCHEM PHARMACOL, V31, P2937, DOI 10.1016/0006-2952(82)90266-0
   MANTOVANI L, 1990, FEBS LETT, V270, P152, DOI 10.1016/0014-5793(90)81256-N
   Maxam A M, 1980, Methods Enzymol, V65, P499
   MITCHELL T, 1986, MOL PHARMACOL, V30, P398
   NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8
   OHNO Y, 1988, CANCER RES, V48, P1494
   RUBIN E, 1991, MOL PHARMACOL, V39, P697
   RYDER K, 1988, P NATL ACAD SCI USA, V85, P8464, DOI 10.1073/pnas.85.22.8464
   RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0
   SHERMAN ML, 1990, J BIOL CHEM, V265, P3320
   SHERMAN ML, 1990, P NATL ACAD SCI USA, V87, P5663, DOI 10.1073/pnas.87.15.5663
   STEIN B, 1989, MOL CELL BIOL, V9, P5169, DOI 10.1128/MCB.9.11.5169
   SUNDARALINGAM M, 1975, ANN NY ACAD SCI, V255, P3, DOI 10.1111/j.1749-6632.1975.tb29211.x
   TAKEDA K, 1982, CANCER RES, V42, P5152
   TOWNSEND AJ, 1987, MOL PHARMACOL, V32, P330
NR 45
TC 47
Z9 48
U1 1
U2 7
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD FEB 1
PY 1992
VL 79
IS 3
BP 728
EP 734
PG 7
WC Hematology
SC Hematology
GA HB533
UT WOS:A1992HB53300025
PM 1310062
DA 2018-12-27
ER

PT J
AU ISMAEEL, NA
AF ISMAEEL, NA
TI RETRACTED: CLINICAL ISOLATES OF ENTEROCOCCI WITH HIGH-LEVEL RESISTANCE
   TO CURRENTLY AVAILABLE AMINOGLYCOSIDES (RETRACTED ARTICLE. SEE VOL. 72,
   PG. 95, 2009)
SO JOURNAL OF HOSPITAL INFECTION
LA English
DT Article; Retracted Publication
DE ENTEROCOCCI; RESISTANCE TO AMINOGLYCOSIDES; HIGH-LEVEL GENTAMICIN
   RESISTANCE
ID GROUP-D STREPTOCOCCI; FAECALIS; GENTAMICIN; ENDOCARDITIS; ANTIBIOTICS;
   BACTEREMIA; SYNERGISM; INFECTION
RP ISMAEEL, NA (reprint author), KING ABDULAZIZ UNIV, COLL MED & ALLIED SCI, DEPT MICROBIOL, POB 9029, JEDDAH 21413, SAUDI ARABIA.
CR CHEN HY, 1985, J MED MICROBIOL, V20, P187, DOI 10.1099/00222615-20-2-187
   COURVALIN P, 1980, J BACTERIOL, V143, P541
   FACKLAM RR, 1985, MANUAL CLIN MICROBIO, P154
   HERZSTEIN J, 1984, AM J MED, V76, P186, DOI 10.1016/0002-9343(84)90772-1
   HORODNICEANU T, 1979, ANTIMICROB AGENTS CH, V16, P686, DOI 10.1128/AAC.16.5.686
   HUNTER TH, 1947, AM J MED, V2, P436, DOI 10.1016/0002-9343(47)90088-0
   IKEDA DP, 1984, DIAGN MICR INFEC DIS, V2, P171, DOI 10.1016/0732-8893(84)90027-0
   JAWETZ E, 1950, SCIENCE, V111, P254, DOI 10.1126/science.111.2880.254
   KAYE D, 1982, ARCH INTERN MED, V142, P2006, DOI 10.1001/archinte.142.11.2006
   MAKI DG, 1981, AM J MED, V70, P719, DOI 10.1016/0002-9343(81)90603-3
   MANDELL GL, 1970, ARCH INTERN MED, V125, P258, DOI 10.1001/archinte.125.2.258
   MANDELL GL, 1984, ANN INTERN MED, V100, P904
   MEDERSKISAMORAJ BD, 1983, J INFECT DIS, V147, P751, DOI 10.1093/infdis/147.4.751
   MOELLERING RC, 1979, J INFECT DIS, V140, P203, DOI 10.1093/infdis/140.2.203
   MOELLERING RC, 1974, AM J MED, V57, P239, DOI 10.1016/0002-9343(74)90448-3
   MOELLERING RC, 1982, REV INFECT DIS, V4, pS708
   MOELLERING RC, 1982, T AM CLIN CLIMAT ASS, V94, P55
   MOELLERING RC, 1970, ANTIMICROB AGENTS CH, V19, P335
   MOELLERING RC, 1979, MICROBIOLOGY 1979, P293
   MURRAY BE, 1983, ANTIMICROB AGENTS CH, V23, P799, DOI 10.1128/AAC.23.6.799
   Rantz LA, 1943, ARCH INTERN MED, V71, P516, DOI 10.1001/archinte.1943.00210040075008
   SAHM DF, 1988, J CLIN MICROBIOL, V26, P250
   SELIGMAN SJ, 1974, J INFECT DIS, V129, pS213, DOI 10.1093/infdis/129.Supplement_2.S213
   SPENGLER RF, 1978, JOHNS HOPKINS MED J, V142, P77
   STANDIFORD HD, 1970, ARCH INTERN MED, V126, P255, DOI 10.1001/archinte.126.2.255
   TOALA P, 1969, AM J MED SCI, V258, P416, DOI 10.1097/00000441-196912000-00006
   TOFTE RW, 1984, ANTIMICROB AGENTS CH, V25, P532, DOI 10.1128/AAC.25.4.532
   WHITESIDE M, 1983, AM J INFECT CONTROL, V11, P125, DOI 10.1016/0196-6553(83)90028-7
   ZERVOS MJ, 1987, ANN INTERN MED, V106, P687, DOI 10.7326/0003-4819-106-5-687
   ZERVOS MJ, 1986, J INFECT DIS, V153, P1075, DOI 10.1093/infdis/153.6.1075
   1985, STANDARD METHODS DIL
NR 31
TC 7
Z9 7
U1 3
U2 8
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0195-6701
EI 1532-2939
J9 J HOSP INFECT
JI J. Hosp. Infect.
PD JAN
PY 1992
VL 20
IS 1
BP 35
EP 42
DI 10.1016/0195-6701(92)90059-U
PG 8
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA HD364
UT WOS:A1992HD36400004
PM 1348070
DA 2018-12-27
ER

PT J
AU PRAKASH, K
   RANGANATHAN, PN
   METTUS, R
   REDDY, P
   SRINIVASAN, A
   PLOTKIN, S
AF PRAKASH, K
   RANGANATHAN, PN
   METTUS, R
   REDDY, P
   SRINIVASAN, A
   PLOTKIN, S
TI RETRACTED: GENERATION OF DELETION MUTANTS OF SIMIAN IMMUNODEFICIENCY
   VIRUS INCAPABLE OF PROVIRAL INTEGRATION (RETRACTED ARTICLE. SEE VOL 67,
   PG 6916, 1993)
SO JOURNAL OF VIROLOGY
LA English
DT Article; Retracted Publication
ID INFECTION; DNA; CHIMPANZEES; RECOMBINANT; PROTECTION; SEQUENCE; MONKEY;
   CELLS
AB Deletion mutants of simian immunodeficiency virus (SIVmac) which were unable to integrate into host cells were generated by removing a portion of the integrase (IN) domain of the pol gene. The resulting plasmid was transfected into HUT-78 and human rhabdomyosarcoma cells. In comparison with the parental plasmid DNA transfected in parallel, the deletion mutant was found to direct efficient production of virus in both cell systems. Viruses derived from wild-type and mutant proviral DNAs were also tested for their relative replicative abilities in HUT-78 and U937 cells, and the kinetics of virus production was found to vary between these two cell systems. Analysis of DNA from infected cell nuclei showed that the deletion mutant lacked the ability to integrate despite being able to produce infectious virus. Using the sensitive polymerase chain reaction technique, we have clearly demonstrated the absence of the IN domain in the deletion mutant after infection and replication in HUT-78 cells. Such mutants might form the basis for the development of an experimental live attenuated vaccine.
C1 WISTAR INST, PHILADELPHIA, PA 19104 USA.
RP PRAKASH, K (reprint author), CHILDRENS HOSP PHILADELPHIA, DIV INFECT DIS & IMMUNOL, 34TH ST & CIV CTR BLVD, PHILADELPHIA, PA 19104 USA.
FU PHS HHS [25822]
CR BERMAN PW, 1988, P NATL ACAD SCI USA, V85, P5200, DOI 10.1073/pnas.85.14.5200
   CHAKRABARTI L, 1987, NATURE, V328, P543, DOI 10.1038/328543a0
   DESROSIERS RC, 1989, P NATL ACAD SCI USA, V86, P6353, DOI 10.1073/pnas.86.16.6353
   FUKASAWA M, 1988, NATURE, V333, P457, DOI 10.1038/333457a0
   GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3
   HARRIS JD, 1984, P NATL ACAD SCI-BIOL, V81, P7212, DOI 10.1073/pnas.81.22.7212
   HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5
   HU SL, 1987, NATURE, V328, P721, DOI 10.1038/328721a0
   JOHNSON MS, 1986, P NATL ACAD SCI USA, V83, P7648, DOI 10.1073/pnas.83.20.7648
   LEVINE AM, 1989, SCI SOCIAL CHALLENGE
   MOUS J, 1988, J VIROL, V62, P1433
   MURPHEYCORB M, 1989, SCIENCE, V246, P1293, DOI 10.1126/science.2555923
   PANGANIBAN AT, 1983, NATURE, V306, P155, DOI 10.1038/306155a0
   POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415
   SCHWARTZBERG P, 1984, CELL, V37, P1043, DOI 10.1016/0092-8674(84)90439-2
   SOMASUNDARAN M, 1988, SCIENCE, V242, P1554, DOI 10.1126/science.3201245
   SOMPAYRAC LM, 1981, P NATL ACAD SCI-BIOL, V78, P7575, DOI 10.1073/pnas.78.12.7575
   SRINIVASAN A, 1988, ARCH VIROL, V99, P21, DOI 10.1007/BF01311020
   STEVENSON M, 1990, J VIROL, V64, P2421
NR 19
TC 8
Z9 8
U1 1
U2 4
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
J9 J VIROL
JI J. Virol.
PD JAN
PY 1992
VL 66
IS 1
BP 167
EP 171
PG 5
WC Virology
SC Virology
GA GU971
UT WOS:A1992GU97100021
PM 1727479
DA 2018-12-27
ER

PT J
AU RAMESH, G
   DESHPANDE, MS
   MAGGIRWAR, SB
   HEGDE, MV
   RALE, VB
AF RAMESH, G
   DESHPANDE, MS
   MAGGIRWAR, SB
   HEGDE, MV
   RALE, VB
TI RETRACTED: ALPHA-GLUCOSIDASE SYNTHESIS IN BATCH AND CONTINUOUS CULTURE
   OF SACCHAROMYCES-CEREVISIAE (RETRACTED ARTICLE. SEE VOL 10, PG 9, 1994)
SO WORLD JOURNAL OF MICROBIOLOGY & BIOTECHNOLOGY
LA English
DT Article; Retracted Publication
DE SACCHAROMYCES-CEREVISIAE; MALTOSE INDUCTION; CATABOLITE REPRESSION;
   CHEMOSTAT; ALPHA-GLUCOSIDASE; PERMEASE
AB Glucose prevented maltose utilization in batch culture of Saccharomyces cerevisiae whereas in a mixed carbohydrate-limited system, maltose and glucose were consumed simultaneously. The specific activity of alpha-glucosidase depended on the dilution rate as well as the proportion of maltose in the mixture. The chemostat provides a way of reaching the low residual concentrations of glucose in the broth that are necessary to release catabolite repression and permit maltose induction of alpha-glucosidase.
C1 UNIV POONA, DEPT MICROBIOL, POONA 411007, MAHARASHTRA, INDIA.
NR 0
TC 1
Z9 1
U1 2
U2 10
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0959-3993
EI 1573-0972
J9 WORLD J MICROB BIOT
JI World J. Microbiol. Biotechnol.
PD JAN
PY 1992
VL 8
IS 1
BP 42
EP 44
DI 10.1007/BF01200682
PG 3
WC Biotechnology & Applied Microbiology
SC Biotechnology & Applied Microbiology
GA HA889
UT WOS:A1992HA88900007
PM 24425332
DA 2018-12-27
ER

PT J
AU KAWABATA, S
   HIGGINS, GA
   GORDON, JW
AF KAWABATA, S
   HIGGINS, GA
   GORDON, JW
TI RETRACTED: AMYLOID PLAQUES, NEUROFIBRILLARY TANGLES AND NEURONAL LOSS IN
   BRAINS OF TRANSGENIC MICE OVEREXPRESSING A C-TERMINAL FRAGMENT OF HUMAN
   AMYLOID PRECURSOR PROTEIN (RETRACTED ARTICLE. SEE VOL 356, PG 265, 1992)
SO NATURE
LA English
DT Article; Retracted Publication
ID ALZHEIMERS-DISEASE; DIFFERENTIAL REGULATION; GENE-EXPRESSION;
   DOWNS-SYNDROME; MOUSE EMBRYOS; THY-1 GENE; DNA; INJECTION; RECEPTOR
AB ALZHEIMER's disease (AD) affects more than 30% of people over 80 years of age 1,2. The aetiology and pathogenesis of this progressive dementia is poorly understood, but symptomatic disease is associated histopathologically with amyloid plaques, neurofibrillary tangles and neuronal loss primarily in the temporal lobe and neocortex of the brain. The core of the extracellular plaque is a derivative of the amyloid precursor protein (App) 3, referred to as beta/A4 (refs 4-6), and contains the amino-acid residues 29-42 that are normally embedded in the membrane-spanning region of the precursor 3. The cellular source of APP and the relationship of its deposition to the neuropathology of AD is unknown. To investigate the relationship between APP overexpression and amyloidogenesis, we have developed a vector to drive expression specifically in neurons of a C-terminal fragment of APP that contains the beta/A4 region, and have used a transgenic mouse system 7,8 to insert and express this construct. We report here that overexpression of this APP transgene in neurons is sufficient to produce extracellular dense-core amyloid plaques, neurofibrillary tangles and neuronal degeneration similar to that in the AD brain.
C1 MT SINAI MED CTR, DEPT GERIATR & ADULT DEV, 2056 ANNENBERG, NEW YORK, NY 10029 USA.
   MT SINAI MED CTR, DEPT OBSTET GYNECOL & REPROD SCI, NEW YORK, NY 10029 USA.
   YAMANOUCHI PHARMACEUT CO LTD, TOKYO 103, JAPAN.
   NIA, GERONTOL RES CTR, BALTIMORE, MD 21224 USA.
RP GORDON, JW (reprint author), MT SINAI MED CTR, DEPT GERIATR & ADULT DEV, 2056 ANNENBERG, NEW YORK, NY 10029 USA.
CR Bielschowsky M, 1904, J PSYCHOL NEUROL, V3, P169
   EVANS DA, 1989, JAMA-J AM MED ASSOC, V262, P2551, DOI 10.1001/jama.262.18.2551
   GIACCONE G, 1989, NEUROSCI LETT, V97, P232, DOI 10.1016/0304-3940(89)90169-9
   GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4
   GLISIN V, 1974, BIOCHEMISTRY-US, V13, P2633, DOI 10.1021/bi00709a025
   GORDON JW, 1987, CELL, V50, P445, DOI 10.1016/0092-8674(87)90498-3
   GORDON JW, 1983, METHOD ENZYMOL, V101, P411
   GORDON JW, 1980, P NATL ACAD SCI-BIOL, V77, P7380, DOI 10.1073/pnas.77.12.7380
   GORDON JW, 1981, SCIENCE, V214, P1244, DOI 10.1126/science.6272397
   GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831
   HIGGINS GA, 1990, NEUROBIOL AGING, V11, P61, DOI 10.1016/0197-4580(90)90064-7
   HIGGINS GA, 1988, P NATL ACAD SCI USA, V85, P1297, DOI 10.1073/pnas.85.4.1297
   HIGGINS GA, 1989, NEURON, V3, P247, DOI 10.1016/0896-6273(89)90038-X
   JOACHIM CL, 1988, BRAIN RES, V474, P100, DOI 10.1016/0006-8993(88)90673-7
   JOACHIM CL, 1989, AM J PATHOL, V135, P309
   KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0
   KATZMAN R, 1991, FASEB J, V5, P278
   KOLLIAS G, 1987, P NATL ACAD SCI USA, V84, P1492, DOI 10.1073/pnas.84.6.1492
   MANN DMA, 1989, NEUROBIOL AGING, V10, P397, DOI 10.1016/0197-4580(89)90073-0
   MASTERS CL, 1985, EMBO J, V4, P2757, DOI 10.1002/j.1460-2075.1985.tb04000.x
   MOTTE J, 1989, ACTA NEUROPATHOL, V77, P535, DOI 10.1007/BF00687256
   QUON D, 1991, NATURE, V352, P239, DOI 10.1038/352239a0
   RUMBLE B, 1989, NEW ENGL J MED, V320, P1446, DOI 10.1056/NEJM198906013202203
   SIMAN R, 1989, NEURON, V3, P275, DOI 10.1016/0896-6273(89)90252-3
   SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0
   TSURUSHITA N, 1988, GENE, V62, P135, DOI 10.1016/0378-1119(88)90587-2
   WIRAK DO, 1991, SCIENCE, V253, P323, DOI 10.1126/science.1857970
   WISNIEWSKI HM, 1989, CAN J NEUROL SCI, V16, P535
   YAMAGUCHI H, 1989, AM J PATHOL, V135, P593
   YANKNER BA, 1989, SCIENCE, V245, P417, DOI 10.1126/science.2474201
NR 30
TC 86
Z9 88
U1 3
U2 13
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
J9 NATURE
JI Nature
PD DEC 12
PY 1991
VL 354
IS 6353
BP 476
EP 478
DI 10.1038/354476a0
PG 3
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA GV078
UT WOS:A1991GV07800059
PM 1793460
DA 2018-12-27
ER

PT J
AU LANTZ, M
   THYSELL, H
   NILSSON, E
   OLSSON, I
AF LANTZ, M
   THYSELL, H
   NILSSON, E
   OLSSON, I
TI RETRACTED: ON THE BINDING OF TUMOR-NECROSIS-FACTOR (TNF) TO HEPARIN AND
   THE RELEASE INVIVO OF THE TNF-BINDING PROTEIN-I BY HEPARIN (RETRACTED
   ARTICLE. SEE VOL 91, PG 737, 1993)
SO JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Article; Retracted Publication
DE INFLAMMATION; ENDOTOXIN; GLOMERULAR FILTRATION; LYMPHOTOXIN; GROWTH
   FACTORS
ID HUMAN BIOLOGICAL-FLUIDS; LIPOPROTEIN-LIPASE; ENDOTHELIAL-CELLS; SOLUBLE
   FORM; FACTOR-ALPHA; RECEPTOR; ENDOTOXIN; INHIBITOR; SURFACE; SULFATE
AB Tumor necrosis factor (TNF), a protein released by activated macrophages, is a central mediator of the host response to infection and inflammation. The TNF-binding protein I (TNF-BP-I) is a soluble fragment of the p60 transmembrane TNF receptor and an antagonist to TNF. The level of serum TNF-BP-I was found to be increased in patients with renal insufficiency as a result of a decrease in the glomerular filtration rate. During hemodialysis of patients with renal failure there was a rapid but transient increase in serum TNF-BP-I. This increase was found to be caused by heparin given before dialysis and a similar dose-dependent response to heparin was observed also in healthy individuals. The finding of a repeated release of TNF-BP-I into the circulation with intermittent injections of heparin indicates that TNF-BP-I is present both in a storage pool and in a circulating pool. The mechanism for the heparin-mediated release of TNF-BP-I was not explained; TNF-BP did not show affinity for heparin. On the other hand, TNF was found to have affinity for heparin and it could also be dissociated from heparin by TNF-BP-I. It is suggested that heparin-like molecules of the extracellular matrix can retain TNF in physical proximity with target cells and restrict the actions of TNF and protect against systemic harmful manifestations.
C1 UNIV LUND HOSP, DEPT MED, DIV HEMATOL, S-22185 LUND, SWEDEN.
   UNIV LUND HOSP, DEPT NEPHROL, S-22185 LUND, SWEDEN.
RP LANTZ, M (reprint author), LUND HOSP, RES DEPT 2, E-BLOCK, S-22185 LUND, SWEDEN.
CR BEUTLER B, 1985, SCIENCE, V229, P869, DOI 10.1126/science.3895437
   BROCHNER.J, 1972, SCAND J CLIN LAB INV, V30, P271, DOI 10.3109/00365517209084290
   CARSWELL EA, 1975, P NATL ACAD SCI USA, V72, P3666, DOI 10.1073/pnas.72.9.3666
   ENGELMANN H, 1989, J BIOL CHEM, V264, P11974
   ENGELMANN H, 1990, J BIOL CHEM, V265, P1531
   FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664
   HEINEGAR.D, 1973, CLIN CHIM ACTA, V43, P305, DOI 10.1016/0009-8981(73)90466-X
   HIMMLER A, 1990, DNA CELL BIOL, V9, P705, DOI 10.1089/dna.1990.9.705
   LANTZ M, 1990, J CLIN INVEST, V86, P1396, DOI 10.1172/JCI114853
   LI Q, BIOCHEM BIOPH RES CO, V166, P557
   LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V
   LOFBERG H, 1979, SCAND J CLIN LAB INV, V39, P619, DOI 10.3109/00365517909108866
   NOPHAR Y, 1990, EMBO J, V9, P3269, DOI 10.1002/j.1460-2075.1990.tb07526.x
   OLD LJ, 1987, NATURE, V326, P330, DOI 10.1038/326330a0
   OLIVECRONA T, 1977, FED PROC, V36, P60
   OLSSON I, 1989, EUR J HAEMATOL, V42, P270, DOI 10.1111/j.1600-0609.1989.tb00111.x
   PEETRE C, 1988, EUR J HAEMATOL, V41, P414
   ROBERTS R, 1988, NATURE, V332, P376, DOI 10.1038/332376a0
   ROBINSONWHITE A, 1985, J CLIN INVEST, V76, P93, DOI 10.1172/JCI111983
   SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W
   SECKINGER P, 1988, J EXP MED, V167, P1511, DOI 10.1084/jem.167.4.1511
   SECKINGER P, 1989, J BIOL CHEM, V264, P11966
   SHERRY B, 1988, J CELL BIOL, V107, P1269, DOI 10.1083/jcb.107.4.1269
   SHIMADA K, 1981, J CLIN INVEST, V68, P995, DOI 10.1172/JCI110354
   TRACEY KJ, 1987, NATURE, V330, P662, DOI 10.1038/330662a0
NR 25
TC 155
Z9 155
U1 2
U2 6
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 2015 MANCHESTER RD, ANN ARBOR, MI 48104 USA
SN 0021-9738
EI 1558-8238
J9 J CLIN INVEST
JI J. Clin. Invest.
PD DEC
PY 1991
VL 88
IS 6
BP 2026
EP 2031
DI 10.1172/JCI115530
PG 6
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA GU967
UT WOS:A1991GU96700032
PM 1752960
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU HERRMANN, F
   ANDREEFF, M
   GRUSS, HJ
   BRACH, MA
   LUBBERT, M
   MERTELSMANN, R
AF HERRMANN, F
   ANDREEFF, M
   GRUSS, HJ
   BRACH, MA
   LUBBERT, M
   MERTELSMANN, R
TI RETRACTED: INTERLEUKIN-4 INHIBITS GROWTH OF MULTIPLE MYELOMAS BY
   SUPPRESSING INTERLEUKIN-6 EXPRESSION (RETRACTED ARTICLE. SEE VOL 93, PG.
   3573, 1999)
SO BLOOD
LA English
DT Article; Retracted Publication
ID TUMOR NECROSIS FACTOR; COLONY-STIMULATING FACTOR; FACTOR-ALPHA;
   HUMAN-MONOCYTES; CELL GROWTH; AUTOCRINE; IL-6; RNA; LEUKEMIA;
   DIFFERENTIATION
C1 UNIV TEXAS, MD ANDERSON CANC CTR, HOUSTON, TX 77030 USA.
RP HERRMANN, F (reprint author), UNIV FREIBURG, MED CTR, DEPT HEMATOL & ONCOL, HUGSTETTER STR 55, W-7800 FREIBURG, GERMANY.
CR BANCHEREAU J, 1990, HEMATOPOIETIC GROWTH, P433
   BRACH MA, 1990, BLOOD, V76, P1972
   CANNISTRA SA, 1986, J CLIN INVEST, V77, P13, DOI 10.1172/JCI112267
   CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2
   CICCO NA, 1990, BLOOD, V75, P2049
   CORDINGLEY FT, 1988, LANCET, V1, P969
   DURIE BGM, 1975, CANCER, V36, P842, DOI 10.1002/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U
   ESSNER R, 1989, J IMMUNOL, V142, P3857
   FIEDLER W, 1990, LEUKEMIA, V4, P462
   FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431
   HART PH, 1989, P NATL ACAD SCI USA, V86, P3803, DOI 10.1073/pnas.86.10.3803
   HENSCHLER R, 1990, BRIT J HAEMATOL, V76, P7, DOI 10.1111/j.1365-2141.1990.tb07829.x
   HERRMANN F, 1990, BLUT, V61, P226, DOI 10.1007/BF01744136
   HIRANO T, 1986, NATURE, V324, P73, DOI 10.1038/324073a0
   HOWARD M, 1982, J EXP MED, V155, P914, DOI 10.1084/jem.155.3.914
   ISAKSON PC, 1982, J EXP MED, V155, P734, DOI 10.1084/jem.155.3.734
   KAWANO M, 1988, NATURE, V332, P83, DOI 10.1038/332083a0
   KLEIN B, 1989, BLOOD, V73, P517
   MIKI S, 1989, FEBS LETT, V250, P607, DOI 10.1016/0014-5793(89)80805-1
   OSTER W, 1989, J CLIN INVEST, V84, P451, DOI 10.1172/JCI114186
   RIEDEL D, 1990, LEUKEMIA, V4, P786
   STANDIFORD TJ, 1990, J IMMUNOL, V145, P1435
   TAYLOR CW, 1990, BLOOD, V75, P1114
   TEVELDE AA, 1990, BLOOD, V76, P1392
   THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201
   WIESER M, 1989, BLOOD, V73, P1105
   WIJDENES J, 1990, LYMPHOKINE RES, V9, P593
   YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546
   ZHANG XG, 1989, BLOOD, V74, P11
NR 29
TC 63
Z9 63
U1 0
U2 7
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD OCT 15
PY 1991
VL 78
IS 8
BP 2070
EP 2074
PG 5
WC Hematology
SC Hematology
GA GK542
UT WOS:A1991GK54200024
PM 1912585
DA 2018-12-27
ER

PT J
AU SWEDAK, JAM
   FORER, A
AF SWEDAK, JAM
   FORER, A
TI RETRACTED: KINETOCHORE FUNCTION CAN BE ALTERED BY ULTRAVIOLET MICROBEAM
   IRRADIATION WITHOUT LOSS OF THE ASSOCIATED BIREFRINGENT SPINDLE FIBER
   (RETRACTED ARTICLE. SEE VOL 107, PG U2, 1994)
SO JOURNAL OF CELL SCIENCE
LA English
DT Article; Retracted Publication
DE KINETOCHORE; SPINDLE FIBER; BIREFRINGENCE
ID CRANE-FLY SPERMATOCYTES; CHROMOSOME MOVEMENT; ANAPHASE; MICROTUBULES;
   POLEWARD; FIBERS; CELLS; COMPONENTS; METAPHASE; ENDS
AB We have irradiated kinetochores of chromosomes in spermatocytes of crane flies (Nephrotoma abbreviata (Loew) and Nephrotoma suturalis (Loew)), while observing the cells using polarization microscopy. Irradiation of a kinetochore of one sex chromosome with 0.106 ergs mu-m-2, the minimum dose needed to stop movement, had no effect on the birefringence of the irradiated kinetochore's spindle fibre. Irradiation of the kinetochore of an autosomal half-bivalent in anaphase, with the same dose, had no effect on the birefringence of the irradiated kinetochore's spindle fibre, but nonetheless the anaphase movements of all six autosomal half-bivalents were stopped, temporarily, for up to 20 min. Irradiations of the kinetochores of an autosomal half-bivalent with higher doses (0.301 ergs mu-m-2) caused loss of birefringence of the irradiated kinetochore's spindle fibre, and the movements of all six autosomal half-bivalents were stopped permanently. We argue that the ultraviolet microbeam differentially affects two functions of the kinetochore: (1) a 'signalling' function, and (2) microtubule attachment, with the signalling function being altered at doses lower than that of microtubule attachment.
RP SWEDAK, JAM (reprint author), YORK UNIV, DEPT BIOL, N YORK M3J 1P3, ONTARIO, CANADA.
CR BAJER A, 1961, EXP CELL RES, V25, P251, DOI 10.1016/0014-4827(61)90277-4
   Bajer A, 1972, CHROMOSOMES TODAY, V3, P63
   BAUER H, 1961, CHROMOSOMA, V12, P116, DOI 10.1007/BF00328918
   Cornman I, 1944, AM NAT, V78, P410, DOI 10.1086/281214
   DIETZ R, 1969, NATURWISSENSCHAFTEN, V56, P237, DOI 10.1007/BF00633917
   FORER A, 1982, METHOD CELL BIOL, V25, P227, DOI 10.1016/S0091-679X(08)61427-2
   FORER A, 1973, CHROMOSOMA, V40, P417, DOI 10.1007/BF00399432
   FORER A, 1966, CHROMOSOMA, V19, P44, DOI 10.1007/BF00332793
   FUGE H, 1973, CHROMOSOMA, V43, P109, DOI 10.1007/BF00483375
   GORBSKY GJ, 1988, J CELL BIOL, V106, P1185, DOI 10.1083/jcb.106.4.1185
   GORBSKY GJ, 1987, J CELL BIOL, V104, P9, DOI 10.1083/jcb.104.1.9
   HAYS TS, 1990, J CELL BIOL, V110, P391, DOI 10.1083/jcb.110.2.391
   INOUE S, 1981, J CELL BIOL, V91, pS131, DOI 10.1083/jcb.91.3.131s
   IZUTSU K, 1988, Protoplasma Supplementum, V1, P122
   Izutsu K., 1961, MIE MED J, V11, P213
   IZUTSU KOSAKU, 1959, MIE MED JOUR, V9, P15
   JANICKE MA, 1984, J CELL BIOL, V98, P859, DOI 10.1083/jcb.98.3.859
   MCINTOSH JR, 1985, ANEUPLOIDY ETIOLOGY, P197
   MCNEILL PA, 1981, J CELL BIOL, V88, P543, DOI 10.1083/jcb.88.3.543
   NICKLAS RB, 1989, J CELL BIOL, V109, P2245, DOI 10.1083/jcb.109.5.2245
   NICKLAS RB, 1988, CHROMOSOME STRUCTURE, P53
   RIEDER CL, 1990, J CELL BIOL, V110, P81, DOI 10.1083/jcb.110.1.81
   SCHRADER F, 1953, MITOSIS
   SILLERS PJ, 1981, CAN J BIOCHEM CELL B, V59, P777, DOI 10.1139/o81-108
   STEFFEN W, 1985, CYTOBIOS, V43, P199
   SWEDAK JAM, 1987, J CELL SCI, V88, P441
   SWEDAK JAM, 1990, J CELL BIOL, V111
   WADSWORTH P, 1989, J CELL BIOL, V109, P2257, DOI 10.1083/jcb.109.5.2257
   WILSON P, 1987, BIOCHEM CELL BIOL, V65, P363, DOI 10.1139/o87-046
   WILSON PJ, 1988, J CELL SCI, V91, P455
   ZIRKLE RE, 1970, J CELL BIOL, V47, pA235
NR 31
TC 7
Z9 7
U1 6
U2 12
PU COMPANY OF BIOLOGISTS LTD
PI CAMBRIDGE
PA BIDDER BUILDING CAMBRIDGE COMMERCIAL PARK COWLEY RD, CAMBRIDGE CB4 4DL,
   CAMBS, ENGLAND
SN 0021-9533
EI 1477-9137
J9 J CELL SCI
JI J. Cell Sci.
PD OCT
PY 1991
VL 100
BP 261
EP 268
PN 2
PG 8
WC Cell Biology
SC Cell Biology
GA GM252
UT WOS:A1991GM25200003
PM 1757486
DA 2018-12-27
ER

PT J
AU SWEDAK, JAM
   LEGGIADRO, C
   FORER, A
AF SWEDAK, JAM
   LEGGIADRO, C
   FORER, A
TI RETRACTED: ELECTRON-MICROSCOPIC AND IMMUNOCHEMICAL ANALYSIS OF
   KINETOCHORE MICROTUBULES AFTER ULTRAVIOLET MICROBEAM IRRADIATION OF
   KINETOCHORES (RETRACTED ARTICLE. SEE VOL 107, PG U2, 1994)
SO JOURNAL OF CELL SCIENCE
LA English
DT Article; Retracted Publication
DE KINETOCHORES; ULTRAVIOLET MICROBEAM; SPINDLES
ID CRANE-FLY SPERMATOCYTES; NEPHROTOMA-SUTURALIS; 3-DIMENSIONAL
   ARCHITECTURE; SPINDLE MICROTUBULES; CHROMOSOME FIBERS; MEIOTIC DIVISION;
   PALES-FERRUGINEA; ANAPHASE-I; BIREFRINGENCE; METAPHASE
AB We used an ultraviolet microbeam to irradiate kinetochores of chromosomes in crane-fly spermatocytes. We used one of two doses, low (0.106 erg mu-m-2) or high (0.301 erg mu-m-2), and then studied the microtubules in those spindles using electron microscopy or immunofluorescence microscopy. After irradiation with low doses microtubules are present as usual, with normal fluorescence and in normal numbers. After irradiation with high doses microtubules are no longer associated with the irradiated kinetochore. After irradiation with either dose, non-kinetochore microtubules are in smaller numbers in the irradiated half-spindle than in the non-irradiated half-spindle or in non-irradiated cells. Since irradiation with low doses alters interchromosomal 'signals', but microtubules remain attached to the kinetochore, we argue that low doses of ultraviolet light damage a signal-related function of kinetochores without altering the ability of the kinetochores to bind microtubules.
RP SWEDAK, JAM (reprint author), YORK UNIV, DEPT BIOL, N YORK M3J 1P3, ONTARIO, CANADA.
CR BEHNKE O, 1966, CR TRAV LAB CARLSB, V35, P437
   CZABAN BB, 1985, J CELL SCI, V79, P1
   FORER A, 1982, METHOD CELL BIOL, V25, P227, DOI 10.1016/S0091-679X(08)61427-2
   FORER A, 1977, CAN J GENET CYTOL, V19, P503, DOI 10.1139/g77-054
   FUGE H, 1973, CHROMOSOMA, V43, P109, DOI 10.1007/BF00483375
   FUGE H, 1971, Z ZELLFORSCH MIK ANA, V120, P579, DOI 10.1007/BF00340590
   FUGE H, 1985, CHROMOSOMA, V91, P322, DOI 10.1007/BF00328228
   FUGE H, 1984, CHROMOSOMA, V90, P323, DOI 10.1007/BF00294158
   FUGE H, 1974, CHROMOSOMA, V45, P245
   HAMEROFF SR, 1986, DYNAMIC ASPECTS MICR, P949
   HUGHES K, 1988, J CELL SCI, V91, P469
   KORUGA DL, 1986, DYNAMIC ASPECTS MICR, P953
   LAFOUNTAIN JR, 1974, J ULTRA MOL STRUCT R, V46, P268, DOI 10.1016/S0022-5320(74)80061-4
   LAFOUNTAIN JR, 1976, J ULTRA MOL STRUCT R, V54, P333, DOI 10.1016/S0022-5320(76)80020-2
   NICKLAS RB, 1982, J CELL BIOL, V95, P91, DOI 10.1083/jcb.95.1.91
   RIEDER CL, 1990, J CELL BIOL, V110, P81, DOI 10.1083/jcb.110.1.81
   SWEDAK JAM, 1987, J CELL SCI, V88, P441
   SWEDAK JAM, 1991, J CELL SCI, V100
   WILSON PJ, 1988, J CELL SCI, V91, P455
   WILSON PJ, 1989, CELL MOTIL CYTOSKEL, V14, P237, DOI 10.1002/cm.970140210
NR 20
TC 5
Z9 5
U1 3
U2 10
PU COMPANY OF BIOLOGISTS LTD
PI CAMBRIDGE
PA BIDDER BUILDING CAMBRIDGE COMMERCIAL PARK COWLEY RD, CAMBRIDGE CB4 4DL,
   CAMBS, ENGLAND
SN 0021-9533
EI 1477-9137
J9 J CELL SCI
JI J. Cell Sci.
PD OCT
PY 1991
VL 100
BP 269
EP 277
PN 2
PG 9
WC Cell Biology
SC Cell Biology
GA GM252
UT WOS:A1991GM25200004
PM 1757487
DA 2018-12-27
ER

PT J
AU ELLEMANNJENSEN, P
AF ELLEMANNJENSEN, P
TI RETRACTED: THE SOCIAL COSTS OF SMOKING REVISITED (RETRACTED ARTICLE. SEE
   VOL 96, PG 1099, 2001)
SO BRITISH JOURNAL OF ADDICTION
LA English
DT Note; Retracted Publication
ID PREVENTION
AB This article may be read as a comment on and extension to the recent survey of studies of the social costs of smoking in this journal by Markandya & Pearce (1989), covering some aspects of the literature not included in that survey. Inevitably, there is a considerable amount of overlap with the material in several of the listed references, including the Markandya & Pearce (1989) survey. The article argues that the published studies based on the incidence approach to the costs of smoking, even on their own terms and accepting the stated assumptions, are erroneous, yielding cost estimates that are too high. In the appendix a simple model of the use of taxation to correct for informational error concerning a risky good is presented.
RP ELLEMANNJENSEN, P (reprint author), ODENSE UNIV, DEPT ECON, 55 CAMPUSVEJ, DK-5230 ODENSE, DENMARK.
CR ATKINSON AB, 1974, J ROY STAT SOC A STA, V137, P297, DOI 10.2307/2344952
   ATKINSON AB, 1974, EC HLTH MED CARE, P428
   BECKER GS, 1988, J POLIT ECON, V96, P675, DOI 10.1086/261558
   BERGER MC, 1987, SOUTHERN ECON J, V53, P967, DOI 10.2307/1059689
   BESLEY T, 1988, J PUBLIC ECON, V35, P371, DOI 10.1016/0047-2727(88)90038-2
   BUTLER JRG, 1981, SCOT J POLIT ECON, V28, P196, DOI 10.1111/j.1467-9485.1981.tb00085.x
   ELLEMANNJENSEN P, 1986, ANAL SAMFUNDSCKONOMI
   EMERY AE, 1988, ELEMENTS MED GENETIC
   GODDEERIS JH, 1983, J HEALTH ECON, V2, P149, DOI 10.1016/0167-6296(83)90004-8
   HJALTE K, 1984, ROKNINGENS EFFEKTER, V4
   HJALTE K, 1984, ROKNING EKONOMISK AN, V6
   HJALTE K, 1984, EC BENEFITS GIVING S, V5
   HJALTE K, 1985, LAKARTIDNINGEN, V82, P2978
   HJALTE K, 1985, EKONOMISK DEBATT, V2, P125
   JONESLEE MH, 1989, EC SAFETY PHYSICAL R
   LEU RE, 1983, SOC SCI MED, V17, P1907, DOI 10.1016/0277-9536(83)90168-5
   MARKANDYA A, 1989, BRIT J ADDICT, V84, P1139
   OSTER G, 1986, AM J PUBLIC HEALTH, V76, P647, DOI 10.2105/AJPH.76.6.647
   OSTER G, 1984, EC COSTS SMOKING BEN
   RICE DP, 1986, MILBANK Q, V64, P489, DOI 10.2307/3349924
   SANDMO A, 1983, ECONOMICA, V50, P19, DOI 10.2307/2554118
   WAGSTAFF A, 1987, BRIT J ADDICT, V82, P461
NR 22
TC 3
Z9 3
U1 1
U2 5
PU CARFAX PUBLISHING-TAYLOR & FRANCIS GROUP
PI BASINGSTOKE
PA RANKINE RD, BASINGSTOKE RG24 8PR, HANTS, ENGLAND
SN 0952-0481
J9 BRIT J ADDICT
PD AUG
PY 1991
VL 86
IS 8
BP 957
EP 966
PG 10
WC Substance Abuse; Psychiatry
SC Substance Abuse; Psychiatry
GA FX591
UT WOS:A1991FX59100003
PM 1912750
DA 2018-12-27
ER

PT J
AU HOWARD, SL
AF HOWARD, SL
TI RETRACTED: LOW-ENERGY THRESHOLD OF THE FINE-STRUCTURE TRANSITION IN
   RARE-GAS CHARGE-TRANSFER (RETRACTED ARTICLE. SEE VOL 201, PG 574, 1993)
SO CHEMICAL PHYSICS LETTERS
LA English
DT Article; Retracted Publication
ID CROSSED-BEAM TECHNIQUE
AB Data from previous crossed-beam experiments have demonstrated a low-energy threshold of the endoergic fine-structure transition in the charge-transfer reaction of rare gases. Correlation of the spin-orbit energies within this group of the periodic table with the threshold collision energy from these experiments demonstrates that theoretical calculations require three-dimensional analysis instead of one-dimensional at these energies.
RP HOWARD, SL (reprint author), USA, BALLIST RES LABS, ABERDEEN PROVING GROUND, MD 21005 USA.
CR ATKINS PW, 1983, MOL QUANTUM MECHANIC, pCH3
   HILL TL, 1960, INTRO STATISTICAL TH, pCH4
   HOWARD SL, 1990, CHEM PHYS LETT, V170, P99, DOI 10.1016/0009-2614(90)87096-A
   HOWARD SL, 1989, J CHEM PHYS, V91, P2922, DOI 10.1063/1.456962
   HOWARD SL, 1987, CAN J PHYS, V65, P1077, DOI 10.1139/p87-178
   JOHNSON RE, 1972, J PHYS SOC JPN, V32, P1612, DOI 10.1143/JPSJ.32.1612
   JOHNSON RE, 1970, J PHYS PT B ATOM M P, V3, P539, DOI 10.1088/0022-3700/3/4/009
   MOTT NF, 1965, THEORY ATOMIC COLLIS, P662
   NIKITIN EE, 1965, OPT SPECTROSC-USSR, V19, P91
NR 9
TC 2
Z9 2
U1 3
U2 8
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0009-2614
EI 1873-4448
J9 CHEM PHYS LETT
JI Chem. Phys. Lett.
PD JUN 28
PY 1991
VL 181
IS 4
BP 298
EP 300
DI 10.1016/0009-2614(91)80074-8
PG 3
WC Chemistry, Physical; Physics, Atomic, Molecular & Chemical
SC Chemistry; Physics
GA FW190
UT WOS:A1991FW19000004
DA 2018-12-27
ER

PT J
AU REYNAUD, A
   FEDERIGHI, M
   LICOIS, D
   GUILLOT, JF
   JOLY, B
AF REYNAUD, A
   FEDERIGHI, M
   LICOIS, D
   GUILLOT, JF
   JOLY, B
TI RETRACTED: R-PLASMID IN ESCHERICHIA-COLI O103 CODING FOR COLONIZATION OF
   THE RABBIT INTESTINAL-TRACT (RETRACTED ARTICLE. SEE VOL 61, PG 4533,
   1993)
SO INFECTION AND IMMUNITY
LA English
DT Article; Retracted Publication
ID WEANLING RABBITS; WEANED RABBITS; AF/R1 PILI; STRAINS; DIARRHEA; RDEC-1;
   ENTEROTOXIN; INFECTIONS; ADHESION; GENES
AB One rabbit pathogenic Escherichia coli strain, belonging to serogroup O103, harbors a self-transferable 117-kb plasmid (pREC-1) encoding resistance to several antibiotics. The role of this R plasmid in the colonization of the digestive tract in specific-pathogen-free (E. coli O103-free) rabbits was studied. Five-week-old rabbits were inoculated with the wild-type strain, with its variant cured of the plasmid, with an E. coli K-12 strain, or with an untypeable E. coli strain from a healthy rabbit. No symptoms and no mortality were observed in animals inoculated with strains without the plasmid pREC-1, but 87.5% of the rabbits infected by the wild strain died, generally with bloody diarrhea, between days 5 and 15 postinfection. The weight gain of animals was strongly reduced. Transfer of the plasmid to the cured strain or to nonvirulent strains led these strains to induce the same pathology but with a lower mortality. Colonization of the gut by the O103 strain and symptoms of bloody diarrhea are thus related to the presence of the pREC-1 plasmid. The GV strain, which does not produce classical heat-labile enterotoxin or heat-stable enterotoxin and is not invasive, could be considered an enteropathagenic E. coli-like strain. The presence of a conjugative plasmid such as pREC-1 encoding both antibiotic resistance and virulence determinants in O103 E. coli from rabbits could represent a prominent epidemiological hazard under selective pressure by antibiotic therapy.
C1 INRA TOURS NOUZILLY, UNITE PATHOL LAPIN, F-37380 MONNAIE, FRANCE.
   UNIV TOURS, F-37000 TOURS, FRANCE.
   FAC PHARM CLERMONT FERRAND, SERV BACTERIOL, F-63001 CLERMONT FERRAND, FRANCE.
RP REYNAUD, A (reprint author), DEPT PUY DOME, ANAL VET & BIOL LAB, RN 89, BP 42, F-63000 CLERMONT FERRAND, FRANCE.
CR BALDINI MM, 1983, J PEDIATR GASTR NUTR, V2, P534, DOI 10.1097/00005176-198302030-00023
   BOUANCHAUD D H, 1969, Journal of General Microbiology, V54, P417
   CAMGUILHEM R, 1986, ANN RECH VET, V17, P409
   CAMGUILHEM R, 1986, REV MED VET-TOULOUSE, V137, P205
   CAMGUILHEM R, 1989, J CLIN MICROBIOL, V27, P743
   CANTEY JR, 1977, J INFECT DIS, V135, P454, DOI 10.1093/infdis/135.3.454
   CHENEY CP, 1983, J INFECT DIS, V147, P711, DOI 10.1093/infdis/147.4.711
   COUDERT P, 1979, Z PARASITENKD, V60, P37
   COUDERT P, 1988, 4TH P C WORLD RABB S, V2, P137
   CRAVIOTO A, 1979, CURR MICROBIOL, V3, P95, DOI 10.1007/BF02602439
   GIANNELLA RA, 1976, INFECT IMMUN, V14, P95
   GUILLOT JF, 1977, ANTIMICROB AGENTS CH, V12, P697, DOI 10.1128/AAC.12.6.697
   GYLES CL, 1977, SCIENCE, V198, P198, DOI 10.1126/science.333581
   KADO CI, 1981, J BACTERIOL, V145, P1365
   LIN ECC, 1987, ESCHERICHIA COLI SAL, V1, P244
   MILON A, 1990, INFECT IMMUN, V58, P2690
   MOON HW, 1983, INFECT IMMUN, V41, P1340
   OBRIEN AD, 1982, J INFECT DIS, V146, P763, DOI 10.1093/infdis/146.6.763
   OKERMAN L, 1987, VET MICROBIOL, V14, P33, DOI 10.1016/0378-1135(87)90050-2
   PEETERS JE, 1985, VET PATHOL, V22, P54, DOI 10.1177/030098588502200109
   PEETERS JE, 1984, J COMP PATHOL, V94, P521, DOI 10.1016/0021-9975(84)90056-2
   PEETERS JE, 1984, J CLIN MICROBIOL, V20, P34
   RENAULT L, 1983, B ACAD VET FRANCE, V56, P387
   Reynaud A., 1987, Cuni-Sciences, V4, P1
   ROSAS SB, 1983, J BACTERIOL, V155, P402
   ROTHBAUM R, 1982, GASTROENTEROLOGY, V83, P441
   SERENY B., 1957, ACTA MICROBIOL ACAD SCI HUNGARICAE, V4, P367
   Stanisich VA., 1988, METHOD MICROBIOL, V21, P11
   STREUN A, 1979, Z PARASITENKD, V60, P37, DOI 10.1007/BF00928970
   TAKEUCHI A, 1978, INFECT IMMUN, V19, P686
   TAYLOR CJ, 1986, J PEDIATR GASTR NUTR, V5, P70, DOI 10.1097/00005176-198601000-00013
   TAYLOR J, 1961, J EXP PATHOL, V42, P43
   ULSHEN MH, 1980, GUT, V26, P270
   WATANABE T, 1961, J BACTERIOL, V81, P669
   WOLF MK, 1990, INFECT IMMUN, V58, P1124
   WOLF MK, 1988, INFECT IMMUN, V56, P1846
NR 36
TC 14
Z9 14
U1 2
U2 7
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0019-9567
EI 1098-5522
J9 INFECT IMMUN
JI Infect. Immun.
PD JUN
PY 1991
VL 59
IS 6
BP 1888
EP 1892
PG 5
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA FN775
UT WOS:A1991FN77500003
PM 2037350
DA 2018-12-27
ER

PT J
AU CHEONG, WE
AF CHEONG, WE
TI RETRACTED: THE ECONOMIC-FUTURE OF HONG-KONG - MUSHKAT,M (RETRACTED
   ARTICLE. SEE VOL 65, PG 386, 1992)
SO PACIFIC AFFAIRS
LA English
DT Book Review; Retracted Publication
RP CHEONG, WE (reprint author), UNIV HONG KONG, HONG KONG, HONG KONG.
CR MUSHKAT M, 1990, EC FUTURE HONG KONG
NR 1
TC 1
Z9 1
U1 2
U2 493
PU PACIFIC AFFAIRS UNIV BRITISH COLUMBIA
PI VANCOUVER
PA #164-1855 WEST MALL, VANCOUVER, BC V6T 1Z2, CANADA
SN 0030-851X
EI 1715-3379
J9 PAC AFF
JI Pac. Aff.
PD SUM
PY 1991
VL 64
IS 2
BP 246
EP 247
DI 10.2307/2759970
PG 2
WC Area Studies
SC Area Studies
GA GD721
UT WOS:A1991GD72100015
DA 2018-12-27
ER

PT J
AU DUNKEL, EC
AF DUNKEL, EC
TI RETRACTED: HCMV-INDUCED CHORIORETINITIS IN THE RABBIT (RETRACTED
   ARTICLE. SEE VOL 27, PG 3582, 1995)
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article; Retracted Publication
ID CYTOMEGALO-VIRUS RETINITIS; HERPES-SIMPLEX VIRUS; INTRAVITREAL
   GANCICLOVIR
C1 HARVARD UNIV, SCH MED, DEPT OPHTHALMOL, BOSTON, MA 02115 USA.
RP DUNKEL, EC (reprint author), HARVARD UNIV, SCH MED, EYE RES INST, 20 STANFORD ST, BOSTON, MA 02115 USA.
CR GREEN MT, 1987, EXP EYE RES, V45, P375, DOI 10.1016/S0014-4835(87)80124-0
   HEINEMANN MH, 1989, ARCH OPHTHALMOL-CHIC, V107, P1767, DOI 10.1001/archopht.1989.01070020849025
   HENDERLY DE, 1987, AM J OPHTHALMOL, V103, P316
   JABS DA, 1989, ARCH OPHTHALMOL-CHIC, V107, P75, DOI 10.1001/archopht.1989.01070010077031
   LEWIS ML, 1989, OPHTHALMOLOGY, V96, P875
   PAVANLANGSTON D, 1989, ARCH OPHTHALMOL-CHIC, V107, P1068, DOI 10.1001/archopht.1989.01070020130046
   USSERY FM, 1988, OPHTHALMOLOGY, V95, P640
NR 7
TC 4
Z9 4
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
J9 TRANSPL P
JI Transplant. Proc.
PD JUN
PY 1991
VL 23
IS 3
SU 3
BP 25
EP 28
PG 4
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA FQ909
UT WOS:A1991FQ90900007
PM 1648830
DA 2018-12-27
ER

PT J
AU QUIK, M
   ELBIZRI, H
   AUDHYA, T
   GOLDSTEIN, G
AF QUIK, M
   ELBIZRI, H
   AUDHYA, T
   GOLDSTEIN, G
TI RETRACTED: THYMOPOIETIN, A POTENT ANTAGONIST AT NICOTINIC RECEPTORS IN
   C2 MUSCLE-CELL CULTURES (RETRACTED ARTICLE. SEE VOL 44, PG 680, 1993)
SO MOLECULAR PHARMACOLOGY
LA English
DT Article; Retracted Publication
ID ACETYLCHOLINE-RECEPTOR; ALPHA-BUNGAROTOXIN; POLYPEPTIDE HORMONE; THYMIC
   POLYPEPTIDE; MYASTHENIA-GRAVIS; SKELETAL-MUSCLE; ION CHANNEL; BINDING;
   SERUM; LINE
AB Recent work has shown that thymopoietin, a polypeptide with actions in the immune and nervous systems, potently binds to the alpha-bungarotoxin (alpha-BGT) receptor. The present study was done to characterize the interaction of thymopoietin at the nicotinic alpha-BGT binding site in cultured muscle cells and to correlate these findings with the effects of the polypeptide on nicotinic receptor-mediated function. Inhibition studies showed that thymopoietin potently inhibited I-125-alpha-BGT binding in C2 muscle cells in culture, with an lC50 of 1.1 nM, a value similar to that for alpha-BGT. Thymopoietin bound to the alpha-BGT receptor in the cells in culture relatively slowly; at 10(-8) M thymopoietin, maximal inhibition occurred after 45 to 75 min of exposure to the polypeptide. Dissociation of thymopoietin from the receptor exhibited a much longer time course; recovery of alpha-BGT binding to control values after exposure to 10(-8) M thymopoietin occurred approximately 16 hr after removal of the polypeptide. The effects of thymopoietin on I-125-alpha-BGT binding correlated well with those on nicotinic function. Thymopoietin potently inhibited nicotinic receptor-mediated Na-22 uptake in muscle cells in culture, with an lC50 of 2 nM. This effect was dependent on the length of the preincubation period with thymopoietin, with maximal inhibition occurring after 60 min of exposure to the polypeptide. Recovery of the functional response after thymopoietin (10(-8) M) exposure required about 16 hr. The mode of inhibition of receptor-mediated ion flux by thymopoietin was similar to that observed with alpha-BGT but distinct from that obtained with d-tubocurarine and gallamine. To conclude, thymopoietin, a thymic polypeptide associated with the immune system, potently inhibited both I-125-alpha-BGT binding and nicotinic receptor-mediated function in C2 muscle cells. These findings may have implications for myasthenia gravis and/or other neuromuscular disorders.
C1 IMMUNOBIOL RES INST, ANNANDALE, NJ 08801 USA.
RP QUIK, M (reprint author), MCGILL UNIV, DEPT PHARMACOL, MCINTYRE MED BLDG, 3655 DRUMMOND ST, MONTREAL H3G 1Y6, QUEBEC, CANADA.
CR AUDHYA T, 1981, BIOCHEMISTRY-US, V20, P6195, DOI 10.1021/bi00524a044
   AUDHYA T, 1984, P NATL ACAD SCI-BIOL, V81, P2847, DOI 10.1073/pnas.81.9.2847
   AUDHYA T, 1987, P NATL ACAD SCI USA, V84, P3545, DOI 10.1073/pnas.84.11.3545
   BASCH RS, 1974, P NATL ACAD SCI USA, V71, P1474, DOI 10.1073/pnas.71.4.1474
   BASCH RS, 1975, CELL IMMUNOL, V20, P218, DOI 10.1016/0008-8749(75)90099-4
   BROWN RH, 1986, BRAIN RES, V381, P237, DOI 10.1016/0006-8993(86)90072-7
   CATTERALL WA, 1975, J BIOL CHEM, V250, P1776
   CHANGEUX JP, 1987, TRENDS PHARMACOL SCI, V8, P459, DOI 10.1016/0165-6147(87)90039-3
   COLQUHOUN D, 1987, TRENDS PHARMACOL SCI, V8, P465, DOI 10.1016/0165-6147(87)90040-X
   GOLDSTEI.G, 1974, NATURE, V247, P11, DOI 10.1038/247011a0
   GOLDSTEIN G, 1966, LANCET, V2, P1164
   GOLDSTEIN G, 1975, LANCET, V2, P256
   GOLDSTEIN G, 1987, IMMUNE REGULATION CH, P51
   GRIESMANN GE, 1990, J NEUROCHEM, V54, P1541, DOI 10.1111/j.1471-4159.1990.tb01202.x
   GU Y, 1985, J NEUROSCI, V5, P1909
   GUY HR, 1987, TRENDS NEUROSCI, V10, P318, DOI 10.1016/0166-2236(87)90087-7
   INESTROSA NC, 1983, EXP CELL RES, V147, P393, DOI 10.1016/0014-4827(83)90221-5
   LENTZ TL, 1988, INT REV NEUROBIOL, V29, P117, DOI 10.1016/S0074-7742(08)60085-9
   LUKAS RJ, 1990, MOL PHARMACOL, V38, P887
   MARICQ AV, 1985, J NEUROSCI, V5, P1917
   MILLER JB, 1984, EXP CELL RES, V154, P256, DOI 10.1016/0014-4827(84)90685-2
   MOREL E, 1987, EUR J IMMUNOL, V17, P1109, DOI 10.1002/eji.1830170806
   OCHOA ELM, 1988, CELL MOL NEUROBIOL, V8, P325, DOI 10.1007/BF00711174
   QUIK M, 1990, MOL PHARMACOL, V37, P90
   QUIK M, 1982, BRAIN RES, V245, P57, DOI 10.1016/0006-8993(82)90339-0
   QUIK M, 1982, BRAIN RES, V238, P385, DOI 10.1016/0006-8993(82)90112-3
   QUIK M, 1990, J PHARMACOL EXP THER, V254, P1113
   QUIK M, 1990, NEUROSCIENCE, V39, P139, DOI 10.1016/0306-4522(90)90228-V
   QUIK M, 1989, J NEUROCHEM, V53, P1320, DOI 10.1111/j.1471-4159.1989.tb07431.x
   REVAH F, 1987, P NATL ACAD SCI USA, V84, P3477, DOI 10.1073/pnas.84.10.3477
   SARVEY JM, 1978, MEMBRANE BIOCHEM, V1, P131, DOI 10.3109/09687687809064163
   SCHMIDT J, 1977, MOL PHARMACOL, V13, P283
   STALLCUP WB, 1976, EXP CELL RES, V98, P277, DOI 10.1016/0014-4827(76)90439-0
   STEINBACH JH, 1989, ANNU REV PHYSIOL, V51, P353, DOI 10.1146/annurev.ph.51.030189.002033
   SUNSHINE GH, 1978, J IMMUNOL, V120, P1594
   TWOMEY JJ, 1979, AM J MED, V66, P639, DOI 10.1016/0002-9343(79)91175-6
   VENKATASUBRAMANIAN K, 1986, P NATL ACAD SCI USA, V83, P3171, DOI 10.1073/pnas.83.10.3171
NR 37
TC 11
Z9 11
U1 1
U2 6
PU AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA
SN 0026-895X
EI 1521-0111
J9 MOL PHARMACOL
JI Mol. Pharmacol.
PD MAR
PY 1991
VL 39
IS 3
BP 324
EP 331
PG 8
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA FD156
UT WOS:A1991FD15600009
PM 2005877
DA 2018-12-27
ER

PT J
AU QUIK, M
   BABU, U
   AUDHYA, T
   GOLDSTEIN, G
AF QUIK, M
   BABU, U
   AUDHYA, T
   GOLDSTEIN, G
TI RETRACTED: EVIDENCE FOR THYMOPOIETIN AND THYMOPOIETIN ALPHA-BUNGAROTOXIN
   NICOTINIC RECEPTORS WITHIN THE BRAIN (RETRACTED ARTICLE. SEE VOL 90, PG
   10409, 1993)
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article; Retracted Publication
ID CENTRAL NERVOUS-SYSTEM; ACETYLCHOLINE-RECEPTOR; BINDING-SITES;
   RAT-BRAIN; THYMIC POLYPEPTIDE; CILIARY GANGLION; CHROMAFFIN CELLS;
   PURIFICATION; LOCALIZATION; SPLENIN
AB Thymopoietin, a polypeptide hormone of the thymus that has pleiotropic actions on the immune, endocrine, and nervous systems, potently interacts with the neuromuscular nicotinic acetylcholine receptor. Thymopoietin binds to the nicotinic alpha-bungarotoxin (alpha-BGT) receptor in muscle and, like alpha-BGT, inhibits cholinergic transmission at this site. Evidence is given that radiolabeled thymopoietin similarly binds to a nicotinic alpha-BGT-binding site within the brain and does so with the characteristics of a specific receptor ligand. Thus specific binding to neuronal membranes was saturable, of high affinity (K(d) = 8 nM), linear with increased tissue concentration, and readily reversible; half-time was almost-equal-to 5 min for association and 10 min for dissociation. Binding of I-125-labeled thymopoietin was displaced not only by unlabeled thymopoietin but also by alpha-BGT and the nicotinic receptor ligands d-tubocurarine and nicotine; various other receptor ligands (muscarinic, adrenergic, and dopaminergic) did not affect binding of I-125-labeled thymopoietin. Thymopoietin was shown by ELISA to be present in brain extracts, displacement curves of thymus and brain extracts being parallel to the standard thymopoietin curve, and Western (immuno) blot identified in brain and thymus extracts a thymopoietin-immunoreactive polypeptide of the same molecular mass as purified thymopoietin polypeptide. We conclude that thymopoietin and thymopoietin-binding sites are present within the brain and that the receptor for thymopoietin is the previously identified nicotinic alpha-BGT-binding site of neuronal tissue.
C1 IMMUNOBIOL RES INST, ANNANDALE, NJ 08801 USA.
RP QUIK, M (reprint author), MCGILL UNIV, DEPT PHARMACOL, MCINTYRE MED BLDG, 3655 DRUMMOND ST, MONTREAL H3G 1Y6, QUEBEC, CANADA.
CR AUDHYA T, 1984, ARCH BIOCHEM BIOPHYS, V234, P167, DOI 10.1016/0003-9861(84)90338-2
   AUDHYA T, 1981, BIOCHEMISTRY-US, V20, P6195, DOI 10.1021/bi00524a044
   AUDHYA T, 1984, P NATL ACAD SCI-BIOL, V81, P2847, DOI 10.1073/pnas.81.9.2847
   AUDHYA T, 1987, P NATL ACAD SCI USA, V84, P3545, DOI 10.1073/pnas.84.11.3545
   BERG DK, 1988, NATURE, V334, P384, DOI 10.1038/334384a0
   BOULTER J, 1987, P NATL ACAD SCI USA, V84, P7763, DOI 10.1073/pnas.84.21.7763
   BOULTER J, 1986, NATURE, V319, P368, DOI 10.1038/319368a0
   BOULTER J, 1990, J BIOL CHEM, V265, P4472
   BROWN RH, 1986, BRAIN RES, V381, P237, DOI 10.1016/0006-8993(86)90072-7
   CLARKE PBS, 1985, J NEUROSCI, V5, P1307
   DUVOISIN RM, 1989, NEURON, V3, P487, DOI 10.1016/0896-6273(89)90207-9
   GOLDSTEI.G, 1974, NATURE, V247, P11, DOI 10.1038/247011a0
   GOLDSTEIN G, 1987, IMMUNE REGULATION CH, P51
   GOTTI C, 1989, NEUROSCIENCE, V32, P759, DOI 10.1016/0306-4522(89)90296-0
   JACOB MH, 1983, J NEUROSCI, V3, P260
   KEMP G, 1987, MOL PHARMACOL, V32, P356
   KEMP G, 1985, BRAIN RES, V347, P274, DOI 10.1016/0006-8993(85)90187-8
   LINDSTROM J, 1987, MOL NEUROBIOL, V1, P281, DOI 10.1007/BF02935740
   LORING RH, 1985, NEUROSCIENCE, V14, P645, DOI 10.1016/0306-4522(85)90316-1
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   LUKAS RJ, 1990, MOL PHARMACOL, V38, P887
   MARKS MJ, 1983, J PHARMACOL EXP THER, V226, P817
   MITSUKA M, 1983, J NEUROSCI, V3, P1785
   MORLEY BJ, 1979, LIFE SCI, V24, P859, DOI 10.1016/0024-3205(79)90335-7
   OSWALD RE, 1981, NEUROSCIENCE, V6, P1, DOI 10.1016/0306-4522(81)90239-6
   QUIK M, 1986, BRAIN RES, V372, P11
   QUIK M, 1990, MOL PHARMACOL, V37, P90
   QUIK M, 1982, BRAIN RES, V238, P385, DOI 10.1016/0006-8993(82)90112-3
   QUIK M, 1990, J PHARMACOL EXP THER, V254, P1113
   QUIK M, 1988, CAN J PHYSIOL PHARM, V66, P971, DOI 10.1139/y88-160
   QUIK M, 1989, J NEUROCHEM, V53, P1320, DOI 10.1111/j.1471-4159.1989.tb07431.x
   QUIK M, 1987, MOL PHARMACOL, V31, P385
   REVAH F, 1987, P NATL ACAD SCI USA, V84, P3477, DOI 10.1073/pnas.84.10.3477
   STEINBACH JH, 1989, TRENDS NEUROSCI, V12, P3, DOI 10.1016/0166-2236(89)90145-8
   TALLE MA, 1991, IN PRESS THYMUS
   VENKATASUBRAMANIAN K, 1986, P NATL ACAD SCI USA, V83, P3171, DOI 10.1073/pnas.83.10.3171
   WHITING P, 1987, P NATL ACAD SCI USA, V84, P595, DOI 10.1073/pnas.84.2.595
NR 37
TC 16
Z9 16
U1 1
U2 7
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD MAR
PY 1991
VL 88
IS 6
BP 2603
EP 2607
DI 10.1073/pnas.88.6.2603
PG 5
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA FC216
UT WOS:A1991FC21600119
PM 1848710
OA Bronze, Green Published
DA 2018-12-27
ER

PT J
AU SUN, WD
   CHANTLER, PD
AF SUN, WD
   CHANTLER, PD
TI RETRACTED: A UNIQUE CELLULAR MYOSIN II EXHIBITING DIFFERENTIAL
   EXPRESSION IN THE CEREBRAL-CORTEX (RETRACTED ARTICLE. SEE VOL 235, PG
   268, 1997)
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article; Retracted Publication
ID AMINO-ACID SEQUENCES; BRAIN MYOSIN; HEAVY-CHAIN; PHOSPHORYLATION;
   TISSUES; PROTEINS
C1 MED COLL PENN, EASTERN PENN PSYCHIAT INST DIV, DEPT ANAT & NEUROBIOL, PHILADELPHIA, PA 19129 USA.
FU NIAMS NIH HHS [AR 32858]
CR BARYLKO B, 1983, EMBO J, V2, P369, DOI 10.1002/j.1460-2075.1983.tb01432.x
   BARYLKO B, 1986, EUR J BIOCHEM, V158, P271, DOI 10.1111/j.1432-1033.1986.tb09747.x
   BERL S, 1970, BIOCHEMISTRY-US, V9, P2058, DOI 10.1021/bi00812a005
   BURRIDGE K, 1975, J MOL BIOL, V99, P1, DOI 10.1016/S0022-2836(75)80154-9
   CHANTLER PD, 1988, 4TH INT C CELL BIOL, P265
   CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2
   CONTI MA, 1990, BIOPHYS J, V57, pA332
   ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541
   JACKSON RJ, 1990, CELL, V62, P15, DOI 10.1016/0092-8674(90)90235-7
   KATSURAGAWA Y, 1989, EUR J BIOCHEM, V184, P611, DOI 10.1111/j.1432-1033.1989.tb15057.x
   KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0
   MATSUMURA S, 1988, J BIOCHEM-TOKYO, V103, P237, DOI 10.1093/oxfordjournals.jbchem.a122254
   MATSUMURA S, 1985, J BIOL CHEM, V260, P1959
   MURAKAMI N, 1990, J BIOL CHEM, V265, P1041
   PUSZKIN S, 1968, SCIENCE, V161, P170, DOI 10.1126/science.161.3837.170
   SAEZ CG, 1990, P NATL ACAD SCI USA, V87, P1164, DOI 10.1073/pnas.87.3.1164
   SAMBROOK J, 1989, MOL CLONING LABORATO
   SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463
   SHOHET RV, 1989, P NATL ACAD SCI USA, V86, P7726, DOI 10.1073/pnas.86.20.7726
   SMITH SJ, 1988, SCIENCE, V242, P708, DOI 10.1126/science.3055292
   TRIFARO JM, 1978, NEUROSCIENCE, V3, P1, DOI 10.1016/0306-4522(78)90150-1
NR 21
TC 14
Z9 14
U1 1
U2 6
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD FEB 28
PY 1991
VL 175
IS 1
BP 244
EP 249
DI 10.1016/S0006-291X(05)81226-4
PG 6
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA EZ636
UT WOS:A1991EZ63600036
PM 1998509
DA 2018-12-27
ER

PT J
AU HENSCHLER, R
   BRENNSCHEIDT, U
   MERTELSMANN, R
   HERRMANN, F
AF HENSCHLER, R
   BRENNSCHEIDT, U
   MERTELSMANN, R
   HERRMANN, F
TI RETRACTED: INDUCTION OF C-JUN EXPRESSION IN THE MYELOID-LEUKEMIA
   CELL-LINE KG-1 BY 1-BETA-D-ARABINOFURANOSYLCYTOSINE (Retracted Article.
   See vol 71, pg 388, 2007)
SO MOLECULAR PHARMACOLOGY
LA English
DT Article; Retracted Publication
ID DNA-BINDING; MESSENGER-RNA; RIBONUCLEIC-ACID; GENE-EXPRESSION; ONCOGENE
   JUN; FOS; SEQUENCE; PROTEIN; AP-1; DIFFERENTIATION
AB c-Jun/AP-1 is a transcription factor commonly induced in mammalian cells by serum, phorbol compounds, or peptide growth factors. We show that c-Jun/AP-1 is inducible as well as coordinately regulated, in the human acute myelogenous leukemia cell line KG-1, by the cytostatic drug 1-beta-D-arabinofuranosylcytosine (Ara-C). Concomitantly with Ara-C treatment, growth inhibition and loss of clonogenic survival of KG-1 cells were observed. Whereas KG-1 cells displayed only barely detectable amounts of c-jun transcripts when cultured in the presence of serum, Ara-C at concentrations of 1 to 50-mu-M induced c-jun transcripts in a dose-dependent fashion. Time course studies showed that 10-mu-M Ara-C induced c-jun transcripts 6 hr after initiation of culture. Induction of c-jun mRNA was independent of de novo protein synthesis, because the protein synthesis inhibitor cycloheximide failed to alter Ara-C-induced c-jun mRNA accumulation. Furthermore, cycloheximide did not induce c-jun transcripts, ruling out the possibility of posttranscriptional stabilization of c-jun mRNA by labile proteins, as has been previously reported for a variety of serum-inducible protooncogenes and early response genes. Moreover, nuclear run-on analysis disclosed that c-jun induction by Ara-C in KG-1 cells took place at a transcriptional level. Taken together, these findings indicate that c-jun mRNA, unlike its rapid (within minutes) induction by serum in fibroblasts, is induced by Ara-C in KG-1 cells following a much more prolonged time course and is regulated essentially at a transcriptional level.
C1 UNIV FREIBURG, MED CTR, DEPT HEMATOL & ONCOL, HUGSTETTER STR 55, W-7800 FREIBURG, GERMANY.
CR ALITALO K, 1983, P NATL ACAD SCI-BIOL, V80, P1707, DOI 10.1073/pnas.80.6.1707
   ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0
   BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349
   BRACH M, 1990, EXP HEMATOL, V18, P748
   BRENNER DA, 1989, DNA-J MOLEC CELL BIO, V8, P279, DOI 10.1089/dna.1.1989.8.279
   CHIEN LT, 1973, SELECTIVE INHIBITORS, P227
   CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005
   CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4
   DIXIT VM, 1989, J BIOL CHEM, V264, P16905
   FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9
   HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X
   KOUZARIDES T, 1989, NATURE, V340, P568, DOI 10.1038/340568a0
   MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848
   MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136
   MITCHELL T, 1986, MOL PHARMACOL, V30, P398
   PERTOVAARA L, 1989, MOL CELL BIOL, V9, P1255, DOI 10.1128/MCB.9.3.1255
   PINTO A, 1988, MED ONCOL TUMOR PHAR, V5, P91
   QUANTIN B, 1988, NATURE, V334, P538, DOI 10.1038/334538a0
   RYDER K, 1988, P NATL ACAD SCI USA, V85, P8464, DOI 10.1073/pnas.85.22.8464
   SARIBAN E, 1988, MOL CELL BIOL, V8, P340, DOI 10.1128/MCB.8.1.340
   SCHWARTZ RJ, 1980, BIOCHEMISTRY-US, V19, P5883, DOI 10.1021/bi00566a034
   SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7
   SHERMAN ML, 1990, J BIOL CHEM, V265, P3320
   VOGT PK, 1987, P NATL ACAD SCI USA, V84, P3316, DOI 10.1073/pnas.84.10.3316
   WEBER B, 1989, MOL CELL BIOL, V9, P769, DOI 10.1128/MCB.9.2.769
   WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0
   WU BY, 1989, J BIOL CHEM, V264, P9000
NR 27
TC 16
Z9 16
U1 0
U2 7
PU AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA
SN 0026-895X
EI 1521-0111
J9 MOL PHARMACOL
JI Mol. Pharmacol.
PD FEB
PY 1991
VL 39
IS 2
BP 171
EP 176
PG 6
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA EY502
UT WOS:A1991EY50200012
PM 1996082
DA 2018-12-27
ER

PT J
AU BANERJEE, AK
   PETERS, TJ
AF BANERJEE, AK
   PETERS, TJ
TI RETRACTED: EXPERIMENTAL NONSTEROIDAL ANTIINFLAMMATORY DRUG-INDUCED
   ENTEROPATHY IN THE RAT - SIMILARITIES TO INFLAMMATORY BOWEL-DISEASE AND
   EFFECT OF THROMBOXANE SYNTHETASE INHIBITORS (RETRACTED ARTICLE. SEE VOL
   48, PG 286, 2001)
SO GUT
LA English
DT Article; Retracted Publication
ID INDUCED INTESTINAL INFLAMMATION; CROHNS-DISEASE; CYCLOOXYGENASE
   INHIBITION; PROSTACYCLIN BIOSYNTHESIS; TEMPORAL RELATIONSHIP;
   ARACHIDONIC-ACID; PERMEABILITY; INDOMETHACIN; SULFASALAZINE;
   PATHOGENESIS
AB We have validated an established animal model of acute inflammatory bowel disease in indomethacin-treated rats. Studies in both in vitro and in vivo chromium-51-labelled ethylenediamine tetra-acetate (Cr-51-EDTA) permeability and tissue myeloperoxidase activity, a marker of inflammatory cell invasion, showed increased permeability and enzyme levels, respectively, in treated animals compared to controls (in vitro Cr-51-EDTA permeability: (mean (SE)) control 0.10 (0.02)-mu-l/mg per tissue, experimental 0.17 (0.02) (p < 0.01, 2 way analysis of variance); in vivo Cr-51-EDTA permeability: control 3.9 (1.3) (% dose recovered), experimental 12.1 (1.5) (p < 0.01); tissue myeloperoxidase: control 10.8 (0.4) mU/mg, experimental 17.2 (0.5) (p < 0.01). Pretreatment or simultaneous treatment of indomethacin-treated animals with glucocorticoids, sulphasalazine, or tetracycline reduced the permeability changes and the tissue inflammatory response (in vitro CR-51-EDTA permeability: (mean (SE)) sulphasalazine+indomethacin 0.11 (0.2)-mu-l/mg tissue (p < 0.01), prednisolone +/- indomethacin 0.12 (0.02) (p < 0.01), tetracycline+indomethacin 0.12 (0.02) (p < 0.01)). Glucocorticoids and sulphasalazine, but not tetracycline, administered after the indomethacin also partially corrected the permeability and inflammatory changes induced by indomethacin (in vitro Cr-51-EDTA permeability: sulphasalazine 0.15 (0.02)-mu-l/mg, p < 0.02; prednisolone 0.12 (0.02)-mu-l/mg, p < 0.01). This approach was used to investigate the effects of two different thromboxane synthetase inhibitors in indomethacin-treated animals. Simultaneous treatment with thromboxane synthetase inhibitors and indomethacin prevented the Cr-51-EDTA permeability and tissue myeloperoxidase increases induced by indomethacin alone (in vitro Cr-51-EDTA permeability: thromboxane synthetase inhibitors+indomethacin 0.11 (0.1) mu-l/mg (p0.01); tissue myeloperoxidase: 11 (0.4) mU/mg, (p < 0.01). Thromboxane synthetase inhibitors administered after the indomethacin also partially corrected the permeability and inflammatory changes induced by indomethacin (in vitro Cr-51-EDTA permeability: thromboxane synthetase inhibitors 0.12 (0.02) mU/mg (p < 0.01); tissue myeloperoxidase 13.8 (0.5) (p < 0.01). These studies indicate that thromboxane synthetase inhibitors partially correct the intestinal lesion nonsteroidal anti-inflammatory drug enteropathy, and may therefore be of use in inflammatory bowel diseases in humans.
RP BANERJEE, AK (reprint author), KINGS COLL HOSP, DEPT CLIN BIOCHEM, LONDON SE5 9PJ, ENGLAND.
CR BANERJEE AK, 1989, LANCET, V2, P1459
   BANERJEE AK, 1989, BRIT MED J, V298, P1539, DOI 10.1136/bmj.298.6687.1539
   BANERJEE AK, 1988, GUT, V29, P1152, DOI 10.1136/gut.29.8.1152
   BJARNASON I, 1988, GASTROENTEROLOGY, V94, pA38
   BJARNASON I, 1983, GASTROENTEROLOGY, V85, P318
   BJARNASON I, 1984, LANCET, V1, P179
   BJARNASON I, 1987, GASTROENTEROLOGY, V93, P480, DOI 10.1016/0016-5085(87)90909-7
   BJARNASON I, 1984, GUT, V25, P145, DOI 10.1136/gut.25.2.145
   BJARNASON I, 1985, GUT, V26, P579, DOI 10.1136/gut.26.6.579
   BJARNASON I, 1988, SCAND J GASTROENTERO, V94, P1737
   BJARNASON I, 1972, DIGEST DIS SCI, V72, P1027
   BJARNASON I, 1988, GASTROENTEROLOGY, V94, P1937
   BOUGHTONSMITH NK, 1985, GASTROENTEROLOGY, V88, P1332
   BOUGHTONSMITH NK, 1985, BRIT J PHARMACOL, V86, P439, DOI 10.1111/j.1476-5381.1985.tb08913.x
   BRADLEY PP, 1982, BLOOD, V60, P618
   CRONQUIST AG, 1975, INT J APPL RADIAT IS, V26, P89, DOI 10.1016/0020-708X(75)90108-8
   CROSS PE, 1986, J MED CHEM, V29, P342, DOI 10.1021/jm00153a007
   CROSS PE, 1984, SPECIAL PUBLICATION, V50, P268
   FANG WF, 1977, AM J DIG DIS, V22, P749, DOI 10.1007/BF01694504
   HAWKEY CJ, 1985, DIGEST DIS SCI, V30, P1161, DOI 10.1007/BF01314051
   HOLLANDER D, 1986, ANN INTERN MED, V105, P883, DOI 10.7326/0003-4819-105-6-883
   KANE SP, 1979, CLIN SCI, V57, P295, DOI 10.1042/cs0570295
   KENT TH, 1969, AM J PATHOL, V54, P237
   LIGUMSKY M, 1981, GASTROENTEROLOGY, V81, P444
   MITCHELL DN, 1970, LANCET, V2, P168
   ROBERT A, 1977, PROSTAGLANDINS, V14, P333, DOI 10.1016/0090-6980(77)90178-2
   SHARON P, 1985, GASTROENTEROLOGY, V88, P55, DOI 10.1016/S0016-5085(85)80132-3
   WAKEFIELD AJ, 1989, LANCET, V2, P1057
   WHITTLE BJR, 1981, GASTROENTEROLOGY, V80, P94
   WILLIAMS JG, 1989, BIOCHEM PHARMACOL, V38, P149, DOI 10.1016/0006-2952(89)90161-5
NR 30
TC 53
Z9 53
U1 1
U2 8
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0017-5749
EI 1468-3288
J9 GUT
JI Gut
PD DEC
PY 1990
VL 31
IS 12
BP 1358
EP 1364
DI 10.1136/gut.31.12.1358
PG 7
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA EP405
UT WOS:A1990EP40500006
PM 1979954
OA Bronze, Green Published
DA 2018-12-27
ER

PT J
AU DUTT, P
   VINAYAK, VK
AF DUTT, P
   VINAYAK, VK
TI RETRACTED: EVALUATION OF ELISA FOR DETECTION OF GIARDIA-LAMBLIA-SPECIFIC
   COPRO-ANTIGEN EMPLOYING MONOSPECIFIC ANTIBODIES (RETRACTED ARTICLE. SEE
   VOL 45, PG 163, 1992)
SO JAPANESE JOURNAL OF MEDICAL SCIENCE & BIOLOGY
LA English
DT Article; Retracted Publication
ID LINKED IMMUNOSORBENT-ASSAY; GSA 65; DIAGNOSIS; FECES;
   COUNTERIMMUNOELECTROPHORESIS; COPRODIAGNOSIS; PROTEINS
AB An enzyme linked immunosorbent assay (ELISA) system, using monospecific antibodies for the detection of Giardia lamblia specific 66 kDa copro-antigen has been developed and evaluated. The assay detected the antigen in stool eluates of all the 24 microscopically confirmed cases of giardiasis and in 17 (68%) of the 25 microscopy-negative clinically suspected cases of giardiasis. None of stool eluates from 20 subjects infected with other protozoal / helminthic intestinal parasites or from 20 apparently healthy subjects had G. lamblia-specific copro-antigen. The ELISA employing monospecific antibodies is a sensitive and specific tool for the diagnosis of giardiasis and is especially useful for confirming microscopy-negative suspected cases of giardiasis.
RP DUTT, P (reprint author), POSTGRAD INST MED EDUC & RES, DEPT EXPTL MED, DIV EXPTL PARASITOL & PARASIT IMMUNOL, CHANDIGARH 160012, INDIA.
CR BURKE JA, 1977, CRC CR REV CL LAB SC, V7, P373, DOI 10.3109/10408367709151690
   BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5
   CRAFT JC, 1982, J INFECT DIS, V145, P499, DOI 10.1093/infdis/145.4.499
   DIAMOND LS, 1968, J PARASITOL, V54, P1047, DOI 10.2307/3277143
   DIXON M, 1953, BIOCHEM J, V54, P457, DOI 10.1042/bj0540457
   DUTTP, 1991, IN PRESS J MED MICRO, V33
   GREEN EL, 1985, LANCET, V2, P691
   HOSKINS LC, 1967, GASTROENTEROLOGY, V53, P265
   HUDSON L, 1980, PRACTICAL IMMUNOLOGY, P165
   KHANNA RKK, 1988, T ROY SOC TROP MED H, V82, P439
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   MOORE GT, 1969, NEW ENGL J MED, V281, P402, DOI 10.1056/NEJM196908212810802
   NAIK SR, 1978, ANN TROP MED PARASIT, V72, P491, DOI 10.1080/00034983.1978.11719350
   ROSOFF JD, 1986, J CLIN MICROBIOL, V23, P905
   ROSOFF JD, 1986, J CLIN MICROBIOL, V24, P1079
   ROSOFF JD, 1989, J CLIN MICROBIOL, V27, P1997
   UNGAR BLP, 1984, J INFECT DIS, V149, P90, DOI 10.1093/infdis/149.1.90
   VINAYAK VK, 1967, INDIAN J MED RES, V55, P134
   VINAYAK VK, 1985, PEDIATR INFECT DIS J, V4, P383, DOI 10.1097/00006454-198507000-00010
   WRIGHT SG, 1977, GUT, V18, P343, DOI 10.1136/gut.18.5.343
NR 20
TC 1
Z9 1
U1 2
U2 6
PU NATL INST INFECTIOUS DISEASES
PI TOKYO
PA JPN J INFECT DIS ED OFF NATL INST INFECTIOUS DISEASES TOYAMA 1-23-1,
   SHINJUKU-KU, TOKYO, 162-8640, JAPAN
SN 0021-5112
J9 JPN J MED SCI BIOL
JI Jpn. J. Med. Sci. Biol.
PD DEC
PY 1990
VL 43
IS 6
BP 209
EP 217
DI 10.7883/yoken1952.43.209
PG 9
WC Medicine, General & Internal
SC General & Internal Medicine
GA EZ345
UT WOS:A1990EZ34500002
PM 2101137
OA Bronze
DA 2018-12-27
ER

PT J
AU ELMER, LW
   BLACK, JA
   WAXMAN, SG
   ANGELIDES, KJ
AF ELMER, LW
   BLACK, JA
   WAXMAN, SG
   ANGELIDES, KJ
TI RETRACTED: THE VOLTAGE-DEPENDENT SODIUM-CHANNEL IN MAMMALIAN CNS AND PNS
   - ANTIBODY CHARACTERIZATION AND IMMUNOCYTOCHEMICAL LOCALIZATION
   (RETRACTED ARTICLE. SEE VOL 761, PG 2, 1997)
SO BRAIN RESEARCH
LA English
DT Article; Retracted Publication
C1 BAYLOR UNIV, DEPT MOLEC PHYSIOL & BIOPHYS, 1 BAYLOR PLAZA, HOUSTON, TX 77030 USA.
   YALE UNIV, SCH MED, DEPT NEUROL, NEW HAVEN, CT 06510 USA.
   VET ADM MED CTR, CTR NEUROSCI & REGENERAT RES, PVA EPVA, W HAVEN, CT 06516 USA.
FU NINDS NIH HHS [NS-24931, NS-01218, NS-24606]
CR ANGELIDES KJ, 1988, J CELL BIOL, V106, P1911, DOI 10.1083/jcb.106.6.1911
   BARCHI RL, 1983, J NEUROCHEM, V40, P1377, DOI 10.1111/j.1471-4159.1983.tb13580.x
   BARRES BA, 1989, NEURON, V2, P1375, DOI 10.1016/0896-6273(89)90076-7
   BERHANIN J, 1976, EMBO J, V2, P915
   BLACK JA, 1989, GLIA, V2, P353, DOI 10.1002/glia.440020508
   BLACK JA, 1989, PROC R SOC SER B-BIO, V238, P39, DOI 10.1098/rspb.1989.0065
   BOUDIER JL, 1988, J NEUROSCI, V8, P1469
   BRUCK C, 1982, J IMMUNOL METHODS, V53, P313, DOI 10.1016/0022-1759(82)90178-8
   CASADEI JM, 1984, P NATL ACAD SCI-BIOL, V81, P6227, DOI 10.1073/pnas.81.19.6227
   CASADEI JM, 1986, J BIOL CHEM, V261, P4318
   CATTERALL WA, 1981, J NEUROSCI, V1, P777
   CAU P, 1985, BRAIN RES, V334, P9, DOI 10.1016/0006-8993(85)90561-X
   CHIU SY, 1987, J PHYSIOL-LONDON, V386, P181, DOI 10.1113/jphysiol.1987.sp016529
   COSTA MRC, 1984, J BIOL CHEM, V259, P8210
   CRUZ LJ, 1985, J BIOL CHEM, V260, P9280
   DESTGROTH SF, 1980, J IMMUNOL METHODS, V35, P1, DOI 10.1016/0022-1759(80)90146-5
   EDELSTEIN NG, 1988, BIOCHEMISTRY-US, V27, P1818, DOI 10.1021/bi00406a003
   ELLISMAN MH, 1982, P NATL ACAD SCI-BIOL, V79, P6707, DOI 10.1073/pnas.79.21.6707
   ELMER LW, 1985, BIOCHEMISTRY-US, V24, P8128, DOI 10.1021/bi00348a044
   FRITZ LC, 1983, J NEUROSCI, V3, P2300
   GORDON D, 1987, P NATL ACAD SCI USA, V84, P8682, DOI 10.1073/pnas.84.23.8682
   GRISHIN EV, 1984, BIOL MEMBRANY, V1, P858
   HAIMOVICH B, 1984, J NEUROSCI, V4, P2259
   HARTSHORNE RP, 1984, J BIOL CHEM, V259, P1667
   HOEFSMIT ECM, 1986, J MICROSC-OXFORD, V143, P161, DOI 10.1111/j.1365-2818.1986.tb02774.x
   JOHO RH, 1990, MOL BRAIN RES, V7, P105, DOI 10.1016/0169-328X(90)90087-T
   JONES OT, 1989, SCIENCE, V244, P1189, DOI 10.1126/science.2543080
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   MERRIL CR, 1981, ANAL BIOCHEM, V110, P201, DOI 10.1016/0003-2697(81)90136-6
   MILLER JA, 1983, BIOCHEMISTRY-US, V22, P462, DOI 10.1021/bi00271a032
   MOURRE C, 1988, BRAIN RES, V448, P128, DOI 10.1016/0006-8993(88)91109-2
   NODA M, 1986, NATURE, V322, P826, DOI 10.1038/322826a0
   NODA M, 1984, NATURE, V312, P121, DOI 10.1038/312121a0
   NODA M, 1986, NATURE, V320, P188, DOI 10.1038/320188a0
   SRINIVASAN Y, 1988, NATURE, V333, P177, DOI 10.1038/333177a0
   SUZUKI H, 1988, FEBS LETT, V228, P195, DOI 10.1016/0014-5793(88)80615-X
   TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350
   TRIMMER JS, 1989, NEURON, V3, P33, DOI 10.1016/0896-6273(89)90113-X
   WAXMAN SG, 1985, SCIENCE, V228, P1502, DOI 10.1126/science.2409596
   WESTENBROEK RE, 1989, NEURON, V3, P695, DOI 10.1016/0896-6273(89)90238-9
   WOLLNER DA, 1985, BRAIN RES, V331, P145, DOI 10.1016/0006-8993(85)90724-3
   WOLLNER DA, 1987, J BIOL CHEM, V262, P14709
NR 42
TC 28
Z9 28
U1 4
U2 8
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0006-8993
EI 1872-6240
J9 BRAIN RES
JI Brain Res.
PD NOV 5
PY 1990
VL 532
IS 1-2
BP 222
EP 231
DI 10.1016/0006-8993(90)91763-7
PG 10
WC Neurosciences
SC Neurosciences & Neurology
GA EK059
UT WOS:A1990EK05900031
PM 2178033
DA 2018-12-27
ER

PT J
AU BOLDT, J
   KLING, D
   ZICKMANN, B
   JACOBI, M
   DAPPER, F
   HEMPELMANN, G
AF BOLDT, J
   KLING, D
   ZICKMANN, B
   JACOBI, M
   DAPPER, F
   HEMPELMANN, G
TI RETRACTED: ACUTE PREOPERATIVE PLASMAPHERESIS AND ESTABLISHED BLOOD
   CONSERVATION TECHNIQUES(Retracted article. See vol. 103, pg. 369, 2017)
SO ANNALS OF THORACIC SURGERY
LA English
DT Article; Retracted Publication
C1 UNIV GIESSEN, DIV CARDIOVASC SURG, W-6300 GIESSEN, GERMANY.
RP BOLDT, J (reprint author), UNIV GIESSEN, DEPT ANESTHESIOL & INTENS CARE MED, KLINIKSTR 29, W-6300 GIESSEN, GERMANY.
CR BERMAN IR, 1976, J TRAUMA, V16, P471, DOI 10.1097/00005373-197606000-00006
   BIDSTRUP B P, 1988, Perfusion (London), V3, P171, DOI 10.1177/026765918800300302
   BOLDT J, 1989, J THORAC CARDIOV SUR, V97, P832
   BOLDT J, IN PRESS ANESTHESIOL
   CHENOWETH DE, 1981, NEW ENGL J MED, V304, P497, DOI 10.1056/NEJM198102263040901
   CRADDOCK PR, 1977, NEW ENGL J MED, V296, P769, DOI 10.1056/NEJM197704072961401
   EBERT JP, 1985, ANESTHESIOLOGY, V63, P104, DOI 10.1097/00000542-198507000-00018
   FRITZ H, 1980, CIBA F S, V75, P351
   GIODORNO GF, 1988, ANN THORAC SURG, V46, P416
   GUYTON AC, 1979, PULMONARY EDEMA, P65
   HARKE H, 1977, ANAESTHESIST, V26, P64
   HARKER LA, 1986, NEW ENGL J MED, V314, P1446, DOI 10.1056/NEJM198605293142209
   HIRATZKA L F, 1986, Perfusion (London), V1, P239, DOI 10.1177/026765918600100402
   LOWENSTEIN E, 1981, CLEVELAND CLIN Q, V48, P112, DOI 10.3949/ccjm.48.1.112
   MAGILLIGAN DJ, 1984, ANN THORAC SURG, V37, P33, DOI 10.1016/S0003-4975(10)60706-0
   MALIK AB, 1985, LUNG, V163, P193, DOI 10.1007/BF02713821
   MAYER ED, 1985, SCAND J THORAC CARD, V19, P165, DOI 10.3109/14017438509102713
   MESSMER K, 1973, BIBL ANAT, P327
   Nelson RL, 1983, PATHOPHYSIOLOGY TECH, V2, P229
   PETERMAN TA, 1987, WORLD J SURG, V11, P36, DOI 10.1007/BF01658457
   Rommelsheim K, 1987, Anasth Intensivther Notfallmed, V22, P3, DOI 10.1055/s-2007-1002499
   Starling E H, 1896, J Physiol, V19, P312
   TAMARI Y, 1983, J EXTRA-CORP TECHNOL, V15, P126
   VONFINCK M, 1985, ANAESTHESIST, V34, P675
   WEIL MH, 1979, CRIT CARE MED, V7, P113, DOI 10.1097/00003246-197903000-00006
   WESTABY S, 1987, INTENS CARE MED, V13, P89
   Wright G, 1986, CARDIOPULMONARY BYPA, P249
   YOUNG JA, 1983, TECHNIQUE PATHOPHYSI, V2, P88
NR 28
TC 10
Z9 10
U1 2
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0003-4975
EI 1552-6259
J9 ANN THORAC SURG
JI Ann. Thorac. Surg.
PD JUL
PY 1990
VL 50
IS 1
BP 62
EP 68
DI 10.1016/0003-4975(90)90088-N
PG 7
WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery
SC Cardiovascular System & Cardiology; Respiratory System; Surgery
GA DQ420
UT WOS:A1990DQ42000012
PM 2369230
DA 2018-12-27
ER

PT J
AU LONDON, JA
AF LONDON, JA
TI RETRACTED: OPTICAL-RECORDING OF ACTIVITY IN THE HAMSTER GUSTATORY CORTEX
   ELICITED BY ELECTRICAL-STIMULATION OF THE TONGUE (RETRACTED ARTICLE. SEE
   VOL 22, PG 599, 1997)
SO CHEMICAL SENSES
LA English
DT Note; Retracted Publication
RP LONDON, JA (reprint author), UNIV CONNECTICUT, CTR HLTH, DEPT BIOSTRUCT & FUNCT, FARMINGTON, CT 06032 USA.
CR BENJAMIN RM, 1959, J COMP NEUROL, V111, P231, DOI 10.1002/cne.901110203
   BENJAMIN RM, 1955, J NEUROPHYSIOL, V18, P56
   BUJAS Z, 1979, SENS PROCESS, V3, P353
   CECHETTO DF, 1987, J COMP NEUROL, V262, P27, DOI 10.1002/cne.902620104
   Cohen L B, 1986, Soc Gen Physiol Ser, V40, P71
   GANCHROW D, 1972, BRAIN RES, V36, P289, DOI 10.1016/0006-8993(72)90736-6
   HANAMORI T, 1987, ANN NY ACAD SCI, V510, P338
   HERNESS MS, 1988, CHEM SENSES, V13, P697
   HYMAN AM, 1980, J GEN PHYSIOL, V76, P125, DOI 10.1085/jgp.76.2.125
   HYMAN AM, 1980, J GEN PHYSIOL, V76, P143, DOI 10.1085/jgp.76.2.143
   KEVETTER GA, 1981, J COMP NEUROL, V197, P99, DOI 10.1002/cne.901970108
   KONNERTH A, 1986, NEUROSCI LETT, V66, P49, DOI 10.1016/0304-3940(86)90164-3
   KONNERTH A, 1988, GLIA, V1, P225, DOI 10.1002/glia.440010308
   KOSAR E, 1986, BRAIN RES, V379, P329, DOI 10.1016/0006-8993(86)90787-0
   LONDON J A, 1988, Society for Neuroscience Abstracts, V14, P1186
   LONDON J A, 1987, Society for Neuroscience Abstracts, V13, P365
   LONDON JA, 1988, CHEM SENSES, V13, P709
   LONDON JA, 1986, BIOL BULL, V171, P496
   LONDON JA, 1988, EUROPEAN NEUROSCIENC, V1, P61
   LONDON JA, 1986, FLUORESCENCE BIOL SC, P423
   MCPHEETERS M, 1987, Society for Neuroscience Abstracts, V13, P360
   MILLER IJ, 1984, PHYSIOL BEHAV, V32, P275, DOI 10.1016/0031-9384(84)90142-2
   NEWMAN R, 1980, J COMP NEUROL, V191, P193, DOI 10.1002/cne.901910204
   ORBACH HS, 1985, J NEUROSCI, V5, P1886
   REEP RL, 1982, NEUROSCIENCE, V7, P1265, DOI 10.1016/0306-4522(82)91133-2
   REEP RL, 1982, NEUROSCIENCE, V7, P2609, DOI 10.1016/0306-4522(82)90087-2
   SMITH DV, 1975, PHYSIOL BEHAV, V15, P303, DOI 10.1016/0031-9384(75)90098-0
   TRAVERS JB, 1979, SENS PROCESS, V3, P1
   TRAVERS SP, 1984, J GEN PHYSIOL, V84, P221, DOI 10.1085/jgp.84.2.221
   Van Hoosier G.L., 1984, LABORATORY ANIMAL ME, P124
   WHITEHEAD MC, 1983, J COMP NEUROL, V220, P378, DOI 10.1002/cne.902200403
   WHITEHEAD MC, 1988, J COMP NEUROL, V276, P547, DOI 10.1002/cne.902760409
   WHITEHEAD MC, 1983, SOC NEUR ABSTR, V9, P1021
   YAMAMOTO T, 1972, PHYSIOL BEHAV, V9, P789, DOI 10.1016/0031-9384(72)90053-4
   YAMAMOTO T, 1980, J NEUROPHYSIOL, V44, P440
   YAMAMOTO T, 1980, EXP BRAIN RES, V40, P63
   Yamamoto T., 1987, Umami: a basic taste. Physiology, biochemistry, nutrition, food science, P441
NR 37
TC 8
Z9 8
U1 4
U2 7
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0379-864X
EI 1464-3553
J9 CHEM SENSES
JI Chem. Senses
PD FEB
PY 1990
VL 15
IS 1
BP 137
EP 143
DI 10.1093/chemse/15.1.137
PG 7
WC Behavioral Sciences; Food Science & Technology; Neurosciences;
   Physiology
SC Behavioral Sciences; Food Science & Technology; Neurosciences &
   Neurology; Physiology
GA CU415
UT WOS:A1990CU41500009
DA 2018-12-27
ER

PT J
AU FOWLER, PA
   RACEY, PA
AF FOWLER, PA
   RACEY, PA
TI RETRACTED: EFFECT OF MELATONIN ADMINISTRATION AND LONG DAY-LENGTH ON
   ENDOCRINE CYCLES IN THE HEDGEHOG ERINACEUS-EUROPAEUS (Retracted article.
   See vol. 59, pg. 402, 2015)
SO JOURNAL OF PINEAL RESEARCH
LA English
DT Article; Retracted Publication
C1 UNIV ABERDEEN, DEPT ZOOL, ABERDEEN AB9 2ZD, SCOTLAND.
RI Fowler, Paul/A-5644-2008
OI Fowler, Paul/0000-0002-4831-9075
CR ALMEIDA OFX, 1984, BIOL REPROD, V30, P143, DOI 10.1095/biolreprod30.1.143
   BITTMAN EL, 1978, SCIENCE, V202, P648, DOI 10.1126/science.568311
   BLANK JL, 1984, BIOL REPROD, V30, P410, DOI 10.1095/biolreprod30.2.410
   DAVIS DE, 1975, J MAMMAL, V56, P199, DOI 10.2307/1379616
   DUTOURNE B, 1983, GEN COMP ENDOCR, V50, P324, DOI 10.1016/0016-6480(83)90233-2
   ELOMARI B, 1989, J REPROD FERTIL, V86, P145
   FOWLER PA, 1987, J REPROD FERTIL, V81, P567
   FOWLER PA, 1988, J REPROD FERTIL, V84, P259
   FOWLER PA, 1988, J REPROD FERTIL, V82, P285
   FOWLER PA, 1986, THESIS U ABERDEEN
   GIROD C, 1967, ANN ENDOCRINOL-PARIS, V28, P581
   GLASS JD, 1979, J THERM BIOL, V4, P149, DOI 10.1016/0306-4565(79)90029-9
   HOFFMAN RA, 1983, GROWTH, V47, P109
   IRBY DC, 1984, J REPROD FERTIL, V70, P657
   KRISTOFFERSSON R, 1964, ANN ACAD SCI FENN A, V80, P5
   LINCOLN GA, 1989, J REPROD FERTIL, V85, P687
   LYNCH GR, 1978, PHYSIOL ZOOL, V51, P289, DOI 10.1086/physzool.51.3.30155746
   MALPAUX B, 1988, NEUROENDOCRINOLOGY, V48, P264, DOI 10.1159/000125021
   MROSOVSKY N, 1977, SCIENCE, V196, P902, DOI 10.1126/science.860123
   PEVET P, 1974, EXPERIENTIA, V30, P1069, DOI 10.1007/BF01939015
   PHILLIPS JA, 1980, CAN J ZOOL, V58, P2150, DOI 10.1139/z80-294
   PHILLIPS JA, 1982, J COMP PHYSIOL, V146, P501, DOI 10.1007/BF00609446
   Reiter R. J., 1985, The hamster - reproduction and behavior., P99
   REITER RJ, 1983, PINEAL GLAND ITS END, P303
   SABOUREA.M, 1973, CR SOC BIOL, V167, P712
   SABOUREAU M, 1979, J INTERDISCIPL CYCLE, V10, P249
   SABOUREAU M, 1984, CR ACAD SCI III-VIE, V299, P239
   SABOUREAU M, 1979, THESIS U TOURS
   SABOUREAU M, 1981, PHOTOPERIODISM REPRO, P319
   SAURE L, 1969, Aquilo Ser Zoologica, V9, P1
   SNEDECOR GW, 1980, STATISTICAL METHODS, P149
   TUREK FW, 1975, SCIENCE, V190, P280, DOI 10.1126/science.1179207
   VRIEND J, 1984, J PINEAL RES, V1, P15, DOI 10.1111/j.1600-079X.1984.tb00191.x
   VRIEND J, 1985, ENDOCRINOLOGY, V117, P2402, DOI 10.1210/endo-117-6-2402
   VRIEND J, 1983, PINEAL RES REV, V1, P183
   WALIN T, 1968, Annales Zoologici Fennici, V5, P227
   ZAR JH, 1984, BIOSTAT ANAL, P162
NR 37
TC 3
Z9 3
U1 3
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0742-3098
EI 1600-079X
J9 J PINEAL RES
JI J. Pineal Res.
PY 1990
VL 8
IS 3
BP 193
EP 204
DI 10.1111/j.1600-079X.1990.tb00679.x
PG 12
WC Endocrinology & Metabolism; Neurosciences; Physiology
SC Endocrinology & Metabolism; Neurosciences & Neurology; Physiology
GA DJ796
UT WOS:A1990DJ79600001
PM 2380905
DA 2018-12-27
ER

PT J
AU QUIK, M
   COHEN, R
   AUDHYA, T
   GOLDSTEIN, G
AF QUIK, M
   COHEN, R
   AUDHYA, T
   GOLDSTEIN, G
TI RETRACTED: THYMOPOIETIN INTERACTS AT THE ALPHA-BUNGAROTOXIN SITE OF AND
   INDUCES PROCESS FORMATION IN PC12 PHEOCHROMOCYTOMA CELLS (RETRACTED
   ARTICLE. SEE VOL 59, PG 789, 1994)
SO NEUROSCIENCE
LA English
DT Article; Retracted Publication
C1 IMMUNOBIOL RES INST, ANNANDALE, NJ 08801 USA.
RP QUIK, M (reprint author), MCGILL UNIV, DEPT PHARMACOL, 3655 DRUMMOND ST, MONTREAL H3G 1Y6, QUEBEC, CANADA.
CR AUDHYA T, 1981, BIOCHEMISTRY-US, V20, P6195, DOI 10.1021/bi00524a044
   AUDHYA T, 1984, P NATL ACAD SCI-BIOL, V81, P2847, DOI 10.1073/pnas.81.9.2847
   AUDHYA T, 1987, P NATL ACAD SCI USA, V84, P3545, DOI 10.1073/pnas.84.11.3545
   BALLIVET M, 1988, NEURON, V1, P847, DOI 10.1016/0896-6273(88)90132-8
   BASCH RS, 1974, P NATL ACAD SCI USA, V71, P1474, DOI 10.1073/pnas.71.4.1474
   BERG DK, 1988, NATURE, V334, P384, DOI 10.1038/334384a0
   BREDER CD, 1988, SCIENCE, V240, P321, DOI 10.1126/science.3258444
   BROWN RH, 1986, BRAIN RES, V381, P237, DOI 10.1016/0006-8993(86)90072-7
   CHIAPPINELLI VA, 1978, NEUROCHEM RES, V3, P465, DOI 10.1007/BF00966328
   CONTITRONCONI BM, 1985, P NATL ACAD SCI USA, V82, P5208, DOI 10.1073/pnas.82.15.5208
   DELAGARZA R, 1987, NEUROSCIENCE, V23, P887, DOI 10.1016/0306-4522(87)90165-5
   DENERIS ES, 1988, NEURON, V1, P45, DOI 10.1016/0896-6273(88)90208-5
   DENERIS ES, 1989, J BIOL CHEM, V264, P6268
   FARRAR WL, 1987, IMMUNOL REV, V100, P361, DOI 10.1111/j.1600-065X.1987.tb00539.x
   FARRAR WL, 1987, J IMMUNOL, V139, P459
   FIELDER EP, 1987, J NEUROCHEM, V49, P983
   FREEMAN JA, 1977, NATURE, V269, P218, DOI 10.1038/269218a0
   GOLDSTEI.G, 1974, NATURE, V247, P11, DOI 10.1038/247011a0
   GOLDSTEIN G, 1975, LANCET, V2, P256
   GOLDSTEIN G, 1987, IMMUNE REGULATION CH, P51
   GREENE LA, 1982, ADV CELL NEUROBIOL, V3, P373, DOI DOI 10.1016/B978-0-12-008303-9.50016-5
   HALVORSEN SW, 1989, J NEUROSCI, V9, P3673
   HENLEY JM, 1988, J BIOL CHEM, V263, P9686
   KEMP G, 1987, MOL PHARMACOL, V32, P356
   KEMP G, 1985, BRAIN RES, V347, P274, DOI 10.1016/0006-8993(85)90187-8
   LINDSTROM J, 1987, MOL NEUROBIOL, V1, P281, DOI 10.1007/BF02935740
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   LUKAS RJ, 1986, J NEUROCHEM, V47, P1768, DOI 10.1111/j.1471-4159.1986.tb13087.x
   MARKS MJ, 1982, MOL PHARMACOL, V22, P554
   MARTIN M, 1988, TRENDS PHARMACOL SCI, V9, P171, DOI 10.1016/0165-6147(88)90033-8
   MORLEY BJ, 1979, LIFE SCI, V24, P859, DOI 10.1016/0024-3205(79)90335-7
   NEF P, 1988, EMBO J, V7, P595, DOI 10.1002/j.1460-2075.1988.tb02852.x
   OSWALD RE, 1981, NEUROSCIENCE, V6, P1, DOI 10.1016/0306-4522(81)90239-6
   PATRICK J, 1977, J BIOL CHEM, V252, P8629
   QUIK M, 1990, MOL PHARMACOL, V37, P90
   QUIK M, 1988, CAN J PHYSIOL PHARM, V66, P971, DOI 10.1139/y88-160
   QUIK M, 1989, J NEUROCHEM, V53, P1320, DOI 10.1111/j.1471-4159.1989.tb07431.x
   REVAH F, 1987, P NATL ACAD SCI USA, V84, P3477, DOI 10.1073/pnas.84.10.3477
   SAPOLSKY R, 1987, SCIENCE, V238, P522, DOI 10.1126/science.2821621
   SCHMIDT J, 1977, MOL PHARMACOL, V13, P283
   SCHWARTZ RD, 1982, MOL PHARMACOL, V22, P56
   STEINBACH JH, 1989, TRENDS NEUROSCI, V12, P3, DOI 10.1016/0166-2236(89)90145-8
   SUNSHINE GH, 1978, J IMMUNOL, V120, P1594
   TWOMEY JJ, 1979, AM J MED, V66, P639, DOI 10.1016/0002-9343(79)91175-6
   VENKATASUBRAMANIAN K, 1986, P NATL ACAD SCI USA, V83, P3171, DOI 10.1073/pnas.83.10.3171
   WADA E, 1989, J COMP NEUROL, V284, P314, DOI 10.1002/cne.902840212
   WADA K, 1988, SCIENCE, V240, P330, DOI 10.1126/science.2832952
   WALICKE PA, 1989, ANNU REV NEUROSCI, V12, P103, DOI 10.1146/annurev.ne.12.030189.000535
   WHITING P, 1987, P NATL ACAD SCI USA, V84, P595, DOI 10.1073/pnas.84.2.595
   WONNACOTT S, 1986, J NEUROCHEM, V47, P1706, DOI 10.1111/j.1471-4159.1986.tb13078.x
NR 50
TC 13
Z9 13
U1 3
U2 5
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0306-4522
EI 1873-7544
J9 NEUROSCIENCE
JI Neuroscience
PY 1990
VL 39
IS 1
BP 139
EP 150
DI 10.1016/0306-4522(90)90228-V
PG 12
WC Neurosciences
SC Neurosciences & Neurology
GA EK590
UT WOS:A1990EK59000012
PM 2089274
DA 2018-12-27
ER

PT J
AU CHANDRA, RK
   PURI, S
   HAMED, A
AF CHANDRA, RK
   PURI, S
   HAMED, A
TI RETRACTED: INFLUENCE OF MATERNAL DIET DURING LACTATION AND USE OF
   FORMULA FEEDS ON DEVELOPMENT OF ATOPIC ECZEMA IN HIGH-RISK INFANTS
   (Retracted article. See vol. 351, h5682, 2015)
SO BMJ-BRITISH MEDICAL JOURNAL
LA English
DT Article; Retracted Publication
RP CHANDRA, RK (reprint author), MEM UNIV NEWFOUNDLAND, JANEWAY CHILD HLTH CTR, ST JOHNS A1A 1R8, NEWFOUNDLAND, CANADA.
CR ATHERTON DJ, 1988, CLIN ALLERGY, V18, P215, DOI 10.1111/j.1365-2222.1988.tb02863.x
   BJORKSTEN B, 1983, IMMUNOL TODAY, V4, P215, DOI 10.1016/0167-5699(83)90029-4
   BOCK SA, 1982, J ALLERGY CLIN IMMUN, V69, P173, DOI 10.1016/0091-6749(82)90096-3
   CANT AJ, 1986, BRIT MED J, V293, P231, DOI 10.1136/bmj.293.6541.231
   CHANDRA RK, 1989, NUTR RES, V9, P1, DOI 10.1016/S0271-5317(89)80098-3
   CHANDRA RK, 1978, NUTR REV, V36, P265
   CHANDRA RK, 1985, CLIN ALLERGY, V15, P517, DOI 10.1111/j.1365-2222.1985.tb02304.x
   CHANDRA RK, 1987, FOOD ALLERGY, P373
   CHANDRA RK, IN PRESS ANN ALLERGY
   CHANDRA RK, 1986, CLIN ALLERGY, V16, P565
   DEWEY K, 1987, HUMAN LACTATION, V3, P361
   JAKOBSSON I, 1985, ACTA PAEDIATR SCAND, V74, P341
   MATHEW DJ, 1977, LANCET, V1, P321
   MISKELLY FG, 1988, ARCH DIS CHILD, V63, P388, DOI 10.1136/adc.63.4.388
   PEARSON DJ, 1989, CLIN EXP ALLERGY, V19, P83, DOI 10.1111/j.1365-2222.1989.tb02350.x
   SAARINEN UM, 1984, CLIN REV ALLERG, V2, P151
   ZIEGER RS, 1986, J ALLERGY CLIN IMMUN, V78, P24
NR 17
TC 169
Z9 173
U1 2
U2 10
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 1756-1833
J9 BMJ-BRIT MED J
JI BMJ-British Medical Journal
PD JUL 22
PY 1989
VL 299
IS 6693
BP 228
EP 230
DI 10.1136/bmj.299.6693.228
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA AG617
UT WOS:A1989AG61700016
PM 2504375
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU GUTMAN, D
   GOLDENBERG, CJ
AF GUTMAN, D
   GOLDENBERG, CJ
TI RETRACTED: VIRUS-SPECIFIC SPLICING INHIBITOR IN EXTRACTS FROM CELLS
   INFECTED WITH HIV-1 (RETRACTED ARTICLE. SEE VOL 243, PG 12, 1989)
SO SCIENCE
LA English
DT Article; Retracted Publication
C1 UNIV MIAMI, DEPT MICROBIOL & IMMUNOL, MIAMI, FL 33101 USA.
FU NIAID NIH HHS [AI-24479]
CR ALDOVINI A, 1986, P NATL ACAD SCI USA, V83, P6672, DOI 10.1073/pnas.83.18.6672
   ARYA SK, 1985, SCIENCE, V229, P69, DOI 10.1126/science.2990040
   BREITBART RE, 1985, CELL, V41, P67, DOI 10.1016/0092-8674(85)90062-5
   CHEN ISY, 1986, CELL, V47, P1, DOI 10.1016/0092-8674(86)90359-4
   CHOI YD, 1986, SCIENCE, V231, P1534, DOI 10.1126/science.3952495
   CULLEN BR, 1986, CELL, V46, P973, DOI 10.1016/0092-8674(86)90696-3
   DAYTON AI, 1986, CELL, V44, P941, DOI 10.1016/0092-8674(86)90017-6
   FEINBERG MB, 1986, CELL, V46, P807, DOI 10.1016/0092-8674(86)90062-0
   FISHER AG, 1986, NATURE, V320, P367, DOI 10.1038/320367a0
   FRENDEWEY D, 1985, CELL, V42, P355, DOI 10.1016/S0092-8674(85)80131-8
   GOH WC, 1986, J VIROL, V59, P181
   GRABOWSKI PJ, 1985, CELL, V42, P345, DOI 10.1016/S0092-8674(85)80130-6
   GREEN MR, 1986, ANNU REV GENET, V20, P671
   HAUBER J, 1987, P NATL ACAD SCI USA, V84, P6364, DOI 10.1073/pnas.84.18.6364
   HWANG LHS, 1984, MOL CELL BIOL, V4, P2289, DOI 10.1128/MCB.4.11.2289
   KALTWASSER G, 1986, NUCLEIC ACIDS RES, V14, P3687, DOI 10.1093/nar/14.9.3687
   KAO SY, 1987, NATURE, V330, P489, DOI 10.1038/330489a0
   KRAMER A, 1984, CELL, V38, P299, DOI 10.1016/0092-8674(84)90551-8
   MILLER CK, 1986, J VIROL, V58, P75
   MOUNT SM, 1983, CELL, V33, P509, DOI 10.1016/0092-8674(83)90432-4
   MUESING MA, 1987, CELL, V48, P691, DOI 10.1016/0092-8674(87)90247-9
   NEVINS JR, 1981, NATURE, V290, P113, DOI 10.1038/290113a0
   PETERLIN BM, 1986, P NATL ACAD SCI USA, V83, P9734, DOI 10.1073/pnas.83.24.9734
   RATNER L, 1985, NATURE, V313, P277, DOI 10.1038/313277a0
   ROSEN CA, 1985, CELL, V41, P813, DOI 10.1016/S0092-8674(85)80062-3
   ROSEN CA, 1986, NATURE, V319, P555, DOI 10.1038/319555a0
   SADAIE MR, 1988, SCIENCE, V239, P910, DOI 10.1126/science.3277284
   SODROSKI J, 1986, NATURE, V321, P412, DOI 10.1038/321412a0
   SODROSKI J, 1985, SCIENCE, V229, P74, DOI 10.1126/science.2990041
   WOLLENZIEN PL, 1987, NUCLEIC ACIDS RES, V15, P9279, DOI 10.1093/nar/15.22.9279
   WRIGHT CM, 1986, SCIENCE, V234, P988, DOI 10.1126/science.3490693
NR 31
TC 6
Z9 6
U1 3
U2 6
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
EI 1095-9203
J9 SCIENCE
JI Science
PD SEP 16
PY 1988
VL 241
IS 4872
BP 1492
EP 1495
DI 10.1126/science.3047873
PG 4
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA Q0479
UT WOS:A1988Q047900037
PM 3047873
DA 2018-12-27
ER

PT J
AU BAILIN, SC
AF BAILIN, SC
TI RETRACTED: A NORMALIZATION THEOREM FOR SET-THEORY (Retracted article.
   See vol. 76, pg. 1096, 2011)
SO JOURNAL OF SYMBOLIC LOGIC
LA English
DT Article; Retracted Publication
RP BAILIN, SC (reprint author), COMP TECHNOL ASSOCIATES, 14900 SWEITZER LANE, SUITE 201, LAUREL, MD 20707 USA.
CR Barendregt H. P., 1981, LAMBDA CALCULUS ITS
   GIRARD JY, 1971, 2ND P SCAND LOG S, P63
   HALLNAS L, 1983, THESIS U STOCKHOLM S
   Prawitz Dag, 1965, NATURAL DEDUCTION PR
   STATMAN R, 1974, THESIS STANFORD U ST
NR 5
TC 8
Z9 8
U1 2
U2 8
PU ASSOC SYMBOLIC LOGIC, INC
PI POUGHKEEPSIE
PA 124 RAYMOND AVENUE, POUGHKEEPSIE, NY 12604-0001 USA
SN 0022-4812
J9 J SYMBOLIC LOGIC
JI J. Symb. Log.
PD SEP
PY 1988
VL 53
IS 3
BP 673
EP 695
DI 10.2307/2274565
PG 23
WC Mathematics; Logic
SC Mathematics; Science & Technology - Other Topics
GA Q3464
UT WOS:A1988Q346400001
DA 2018-12-27
ER

PT J
AU HERRMANN, F
   BAMBACH, T
   BONIFER, R
   LINDEMANN, A
   RIEDEL, D
   OSTER, W
   MERTELSMANN, R
AF HERRMANN, F
   BAMBACH, T
   BONIFER, R
   LINDEMANN, A
   RIEDEL, D
   OSTER, W
   MERTELSMANN, R
TI RETRACTED: THE SUPPRESSIVE EFFECTS OF RECOMBINANT HUMAN-TUMOR NECROSIS
   FACTOR-ALPHA ON NORMAL AND MALIGNANT MYELOPOIESIS - SYNERGISM WITH
   INTERFERON-GAMMA (RETRACTED ARTICLE. SEE VOL 17, PG 241, 1999)
SO INTERNATIONAL JOURNAL OF CELL CLONING
LA English
DT Article; Retracted Publication
RP HERRMANN, F (reprint author), UNIV MAINZ, DEPT HEMATOL, LANGENBECKSTR 1, D-6500 MAINZ, FED REP GER.
CR AGGARWAL BB, 1985, NATURE, V318, P665, DOI 10.1038/318665a0
   BLICK M, 1987, CANCER RES, V47, P2986
   BROUDY VC, 1986, P NATL ACAD SCI USA, V83, P7467, DOI 10.1073/pnas.83.19.7467
   BROXMEYER HE, 1986, J IMMUNOL, V136, P4487
   BROXMEYER HE, 1985, J IMMUNOL, V135, P2502
   DEGLIANTONI G, 1985, J EXP MED, V162, P1512, DOI 10.1084/jem.162.5.1512
   FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9
   FRASSONI F, 1982, BRIT J HAEMATOL, V50, P647, DOI 10.1111/j.1365-2141.1982.tb01965.x
   GRIFFIN JD, 1982, BLOOD, V60, P30
   HAHN CJ, 1986, J LEUKOCYTE BIOL, V40, P21
   Herrmann F, 1987, Haematol Blood Transfus, V31, P185
   HERRMANN F, 1986, MUNCHEN MED WOCHEN, V128, P630
   HERRMANN F, 1986, J IMMUNOL, V136, P1629
   HERRMANN F, 1988, IN PRESS J CLIN ONCO
   JACOBSEN N, 1979, CELL TISSUE KINET, V12, P213, DOI 10.1111/j.1365-2184.1979.tb00127.x
   KURZROCK R, 1987, BLOOD, V70, P943
   MAMUS SW, 1985, J CLIN INVEST, V75, P1496, DOI 10.1172/JCI111853
   MAMUS SW, 1985, BLOOD S, V66, pA510
   MANIATIS T, 1982, MOL CLONING LABORATO
   MCGLAVE PB, 1986, CLIN RES, V34, pA464
   MUNKER R, 1986, NATURE, V323, P79, DOI 10.1038/323079a0
   MURPHY M, 1986, J EXP MED, V164, P263, DOI 10.1084/jem.164.1.263
   OLD LJ, 1985, SCIENCE, V230, P630, DOI 10.1126/science.2413547
   OSTER W, 1987, BLOOD, V70, P1700
   PETERS PM, 1986, J IMMUNOL, V137, P2592
   PHILIP R, 1986, NATURE, V323, P86, DOI 10.1038/323086a0
   PIKE BL, 1970, J CELL PHYSIOL, V76, P77, DOI 10.1002/jcp.1040760111
   RIGBY WFC, 1985, BLOOD, V65, P858
   RUGGIERO V, 1986, J IMMUNOL, V136, P2445
   SHALABY MR, 1985, J IMMUNOL, V135, P2069
   SHIRAI T, 1985, NATURE, V313, P803, DOI 10.1038/313803a0
   SIEFF CA, 1985, SCIENCE, V230, P1171, DOI 10.1126/science.3877981
   SUGARMAN BJ, 1985, SCIENCE, V230, P943, DOI 10.1126/science.3933111
   TAKEDA K, 1986, NATURE, V323, P338, DOI 10.1038/323338a0
   TRINCHIERI G, 1986, J EXP MED, V164, P1206, DOI 10.1084/jem.164.4.1206
   TSUJIMOTO M, 1986, J IMMUNOL, V136, P2441
   URBAN JL, 1986, P NATL ACAD SCI USA, V83, P5233, DOI 10.1073/pnas.83.14.5233
NR 37
TC 29
Z9 30
U1 2
U2 8
PU ALPHAMED PRESS
PI DURHAM
PA 318 BLACKWELL ST, STE 260, DURHAM, NC 27701-2884 USA
SN 0737-1454
J9 INT J CELL CLONING
PD JUL
PY 1988
VL 6
IS 4
BP 241
EP 261
DI 10.1002/stem.5530060403
PG 21
WC Biotechnology & Applied Microbiology
SC Biotechnology & Applied Microbiology
GA P4322
UT WOS:A1988P432200002
PM 3138311
OA Bronze
DA 2018-12-27
ER

PT J
AU BLANTON, R
   LOULA, EC
   PARKER, J
AF BLANTON, R
   LOULA, EC
   PARKER, J
TI RETRACTED: TWO HEAT-INDUCED PROTEINS ARE ASSOCIATED WITH TRANSFORMATION
   OF SCHISTOSOMA-MANSONI CERCARIAE TO SCHISTOSOMULA (RETRACTED ARTICLE.
   SEE VOL 86, PG 6650, 1989)
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article; Retracted Publication
C1 UNIV HOSP CLEVELAND, CLEVELAND, OH 44106 USA.
RP BLANTON, R (reprint author), CASE WESTERN RESERVE UNIV, DEPT MED, DIV GEOG MED, CLEVELAND, OH 44106 USA.
OI Blanton, Ronald/0000-0001-6655-7336
FU NIAID NIH HHS [AI00608]; NHLBI NIH HHS [HL07592]
CR ATKINSON KH, 1981, MOL BIOCHEM PARASIT, V4, P205, DOI 10.1016/0166-6851(81)90019-0
   Belding D.L., 1965, TXB PARASITOLOGY
   CHAPPELL L H, 1974, International Journal for Parasitology, V4, P361, DOI 10.1016/0020-7519(74)90043-5
   COUSIN CE, 1986, J PARASITOL, V72, P609, DOI 10.2307/3281521
   DUVALL RH, 1967, AM J TROP MED HYG, V16, P483, DOI 10.4269/ajtmh.1967.16.483
   GOFF SA, 1984, P NATL ACAD SCI-BIOL, V81, P6647, DOI 10.1073/pnas.81.21.6647
   GOFF SA, 1985, CELL, V41, P587, DOI 10.1016/S0092-8674(85)80031-3
   GRAZIOSI G, 1980, J EXP ZOOL, V214, P141, DOI 10.1002/jez.1402140203
   KELLEY PM, 1982, MOL CELL BIOL, V2, P267, DOI 10.1128/MCB.2.3.267
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   LAWRENCE F, 1985, P NATL ACAD SCI USA, V82, P4414, DOI 10.1073/pnas.82.13.4414
   LINDQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151, DOI 10.1146/annurev.bi.55.070186.005443
   Mahmoud A. A. F., 1984, Tropical and geographical medicine., P443
   NAGAI Y, 1977, COMP BIOCHEM PHYS B, V57, P27, DOI 10.1016/0305-0491(77)90077-3
   PITCHFOR.RJ, 1965, B WORLD HEALTH ORGAN, V32, P83
   RAMALHOPINTO FJ, 1974, EXP PARASITOL, V36, P360, DOI 10.1016/0014-4894(74)90076-9
   ROCCHERI MC, 1981, DEV BIOL, V83, P173, DOI 10.1016/S0012-1606(81)80020-6
   SCHMIDT GD, 1981, F PARASITOLOGY
   SHIFF CJ, 1974, J PARASITOL, V60, P578, DOI 10.2307/3278710
   Stirewalt M.A., 1974, Advances Parasit, V12, P115, DOI 10.1016/S0065-308X(08)60388-7
   STIREWALT MA, 1983, EXP PARASITOL, V56, P358, DOI 10.1016/0014-4894(83)90081-4
   STIREWALT MA, 1969, EXP PARASITOL, V26, P17, DOI 10.1016/0014-4894(69)90091-5
   STIREWALT MA, 1974, ASPECTS BIOL SYMBIOS, P1
   VANDERPLOEG LHT, 1985, SCIENCE, V228, P1443, DOI 10.1126/science.4012301
   VELAZQUEZ JM, 1984, CELL, V36, P655, DOI 10.1016/0092-8674(84)90345-3
NR 25
TC 14
Z9 14
U1 1
U2 8
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD DEC
PY 1987
VL 84
IS 24
BP 9011
EP 9014
DI 10.1073/pnas.84.24.9011
PG 4
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA L7601
UT WOS:A1987L760100054
PM 3321064
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU FUSCO, A
   BERLINGIERI, MT
   DIFIORE, PP
   PORTELLA, G
   GRIECO, M
   VECCHIO, G
AF FUSCO, A
   BERLINGIERI, MT
   DIFIORE, PP
   PORTELLA, G
   GRIECO, M
   VECCHIO, G
TI RETRACTED: ONE-STEP AND 2-STEP TRANSFORMATIONS OF RAT-THYROID
   EPITHELIAL-CELLS BY RETROVIRAL ONCOGENES (Retracted article. See vol.
   38, 2018)
SO MOLECULAR AND CELLULAR BIOLOGY
LA English
DT Note; Retracted Publication
RP FUSCO, A (reprint author), UNIV NAPLES, L CALIFANO FAC MED & CHIRURG 2, DIPARTIMENTO BIOL & PATOL, CNR, I-80131 NAPLES, ITALY.
RI Di Fiore, Pier Paolo/K-2130-2012
OI Di Fiore, Pier Paolo/0000-0002-2252-0950; Fusco,
   Alfredo/0000-0003-3332-5197
CR AARONSON SA, 1978, J VIROL, V27, P366
   ADAMS SL, 1977, P NATL ACAD SCI USA, V74, P3399, DOI 10.1073/pnas.74.8.3399
   AMBESIIMPIOMBATO FS, 1980, P NATL ACAD SCI-BIOL, V77, P3455, DOI 10.1073/pnas.77.6.3455
   ANDERSON SM, 1983, J VIROL, V46, P594
   BECHADE C, 1985, NATURE, V316, P559, DOI 10.1038/316559a0
   CAIRNS J, 1983, NATURE, V34, P582
   CHIRIGOS MA, 1968, INT J CANCER, V3, P223, DOI 10.1002/ijc.2910030207
   COLLETTA G, 1983, MOL CELL BIOL, V3, P2099, DOI 10.1128/MCB.3.11.2099
   DELORBE WJ, 1980, J VIROL, V36, P50
   ELLIS RW, 1981, NATURE, V292, P506, DOI 10.1038/292506a0
   FRANZ T, 1985, NATURE, V315, P149, DOI 10.1038/315149a0
   FUSCO A, 1985, J VIROL, V56, P284
   FUSCO A, 1981, INT J CANCER, V28, P655, DOI 10.1002/ijc.2910280519
   FUSCO A, 1982, CANCER RES, V42, P618
   Fusco A, 1985, ONCOGENES TUMOR ANTI, P17
   GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3
   HARVEY JJ, 1964, NATURE, V204, P1104, DOI 10.1038/2041104b0
   KAPLAN PL, 1983, CELL, V33, P931, DOI 10.1016/0092-8674(83)90036-3
   KIRSTEN WH, 1967, J NATL CANCER I, V39, P311
   LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0
   MACPHERSON I, 1964, VIROLOGY, V23, P291, DOI 10.1016/0042-6822(64)90301-0
   NISHIKURA K, 1983, P NATL ACAD SCI-BIOL, V80, P4822, DOI 10.1073/pnas.80.15.4822
   PETERS RL, 1974, J NATL CANCER I, V53, P1725
   RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218
   RAPP UR, 1983, J VIROL, V45, P914
   RASHEED S, 1978, P NATL ACAD SCI USA, V75, P2972, DOI 10.1073/pnas.75.6.2972
   SPANDIDOS DA, 1984, NATURE, V310, P469, DOI 10.1038/310469a0
   SPANDIDOS DA, 1985, ANTICANCER RES, V5, P485
   THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201
   VECCHIO G, 1982, EXPRESSION DIFFERENT, P501
   VECCHIO G, 1981, ADV THYROID NEOPLASI, P11
   WATSON DK, 1983, P NATL ACAD SCI-BIOL, V80, P3642, DOI 10.1073/pnas.80.12.3642
NR 32
TC 258
Z9 259
U1 1
U2 3
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0270-7306
EI 1098-5549
J9 MOL CELL BIOL
JI Mol. Cell. Biol.
PD SEP
PY 1987
VL 7
IS 9
BP 3365
EP 3370
DI 10.1128/MCB.7.9.3365
PG 6
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA J7164
UT WOS:A1987J716400049
PM 3670314
OA Bronze, Green Published
DA 2018-12-27
ER

PT J
AU AUDHYA, T
   SCHLESINGER, DH
   GOLDSTEIN, G
AF AUDHYA, T
   SCHLESINGER, DH
   GOLDSTEIN, G
TI RETRACTED: ISOLATION AND COMPLETE AMINO-ACID-SEQUENCE OF HUMAN
   THYMOPOIETIN AND SPLENIN (RETRACTED ARTICLE. SEE VOL 91, PG 6249, 1994)
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article; Retracted Publication
C1 NYU MED CTR, DEPT MED & CELL BIOL, NEW YORK, NY 10016 USA.
RP AUDHYA, T (reprint author), ORTHO PHARMACEUT CORP, BIOTECH DIV, DEPT IMMUNOBIOL, POB 300, RARITAN, NJ 08869 USA.
CR AUDHYA T, 1984, ARCH BIOCHEM BIOPHYS, V234, P167, DOI 10.1016/0003-9861(84)90338-2
   AUDHYA T, 1981, BIOCHEMISTRY-US, V20, P6195, DOI 10.1021/bi00524a044
   AUDHYA T, 1984, P NATL ACAD SCI-BIOL, V81, P2847, DOI 10.1073/pnas.81.9.2847
   BASCH RS, 1974, P NATL ACAD SCI USA, V71, P1474, DOI 10.1073/pnas.71.4.1474
   BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529
   CHU AC, 1983, J INVEST DERMATOL, V81, P194, DOI 10.1111/1523-1747.ep12517686
   GOLDSTEI.G, 1974, NATURE, V247, P11, DOI 10.1038/247011a0
   GOLDSTEIN G, 1976, J IMMUNOL, V117, P690
   GOLDSTEIN G, 1979, SCIENCE, V204, P1309, DOI 10.1126/science.451537
   HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P399
   LISI PJ, 1980, CLIN CHIM ACTA, V107, P111, DOI 10.1016/0009-8981(80)90420-9
   MALAISE MG, 1987, IMMUNE REGULATION CH, P111
   RANGES GE, 1982, J EXP MED, V156, P1057, DOI 10.1084/jem.156.4.1057
   SCHEID MP, 1975, SCIENCE, V190, P1211, DOI 10.1126/science.1081736
   SCHEID MP, 1978, J EXP MED, V147, P1727, DOI 10.1084/jem.147.6.1727
   SCHLESINGER DH, 1983, METHOD ENZYMOL, V91, P494
   SCHREIER PH, 1981, P NATL ACAD SCI-BIOL, V78, P4495, DOI 10.1073/pnas.78.7.4495
   SPACKMAN DH, 1958, ANAL CHEM, V30, P1190, DOI 10.1021/ac60139a006
   STEINER DF, 1967, P NATL ACAD SCI USA, V57, P473, DOI 10.1073/pnas.57.2.473
   STEINMETZ M, 1983, SCIENCE, V222, P727, DOI 10.1126/science.6356354
   SUNSHINE GH, 1978, J IMMUNOL, V120, P1594
   VENKATASUBRAMANIAN K, 1986, P NATL ACAD SCI USA, V83, P3171, DOI 10.1073/pnas.83.10.3171
   VIAMONTES GI, 1986, CELL IMMUNOL, V100, P305, DOI 10.1016/0008-8749(86)90031-6
NR 23
TC 42
Z9 43
U1 2
U2 8
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD JUN
PY 1987
VL 84
IS 11
BP 3545
EP 3549
DI 10.1073/pnas.84.11.3545
PG 5
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA H6030
UT WOS:A1987H603000003
PM 3473468
OA Bronze, Green Published
DA 2018-12-27
ER

PT J
AU REVAH, F
   MULLE, C
   PINSET, C
   AUDHYA, T
   GOLDSTEIN, G
   CHANGEUX, JP
AF REVAH, F
   MULLE, C
   PINSET, C
   AUDHYA, T
   GOLDSTEIN, G
   CHANGEUX, JP
TI RETRACTED: CALCIUM-DEPENDENT EFFECT OF THE THYMIC POLYPEPTIDE
   THYMOPOIETIN ON THE DESENSITIZATION OF THE NICOTINIC
   ACETYLCHOLINE-RECEPTOR (RETRACTED ARTICLE. SEE VOL 90, PG 10409, 1993)
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article; Retracted Publication
C1 INST PASTEUR, CNRS, UNITE INTERACT MOLEC & CELLULAIRES 041149, F-75724 PARIS 15, FRANCE.
   ORTHO PHARMACEUT CORP, DIV BIOTECH, RARITAN, NJ 08869 USA.
RP REVAH, F (reprint author), INST PASTEUR, UNITE NEUROBIOL MOLEC, 25 RUE DR ROUX, F-75724 PARIS 15, FRANCE.
OI Mulle, Christophe/0000-0003-2709-6615
CR AGUAYO LG, 1986, P NATL ACAD SCI USA, V83, P3523, DOI 10.1073/pnas.83.10.3523
   AUDHYA T, 1981, BIOCHEMISTRY-US, V20, P6195, DOI 10.1021/bi00524a044
   AUDHYA T, 1987, IN PRESS P NATL ACAD
   BOYD ND, 1980, BIOCHEMISTRY-US, V19, P5353, DOI 10.1021/bi00564a032
   CHANGEUX JP, 1986, J PHYSIOL-LONDON, V378, P497, DOI 10.1113/jphysiol.1986.sp016232
   CHANGEUX JP, 1984, SCIENCE, V225, P1335, DOI 10.1126/science.6382611
   COLQUHOUN D, 1981, NATURE, V294, P464, DOI 10.1038/294464a0
   FUCCELLO A, 1984, ARCH BIOCHEM BIOPHYS, V228, P292, DOI 10.1016/0003-9861(84)90070-5
   GOLDSTEI.G, 1969, CLIN EXP IMMUNOL, V4, P181
   GOLDSTEI.G, 1974, NATURE, V247, P11, DOI 10.1038/247011a0
   GOLDSTEIN G, 1966, LANCET, V2, P1164
   GOLDSTEIN G, 1966, LANCET, V2, P315
   GOLDSTEIN G, 1974, ANN NY ACAD SCI, V183, P230
   Grossman S, 1974, Methods Biochem Anal, V22, P177, DOI 10.1002/9780470110423.ch4
   HAMMILL OP, 1981, PFLUGERS ARCH, V391, P85
   HEIDMANN T, 1983, BIOCHEMISTRY-US, V22, P3112, DOI 10.1021/bi00282a014
   HEIDMANN T, 1982, CR ACAD SCI III-VIE, V295, P665
   HEIDMANN T, 1979, EUR J BIOCHEM, V94, P255, DOI 10.1111/j.1432-1033.1979.tb12893.x
   HUGANIR RL, 1986, NATURE, V321, P774, DOI 10.1038/321774a0
   LINDSTROM JM, 1976, NEUROLOGY, V26, P1054, DOI 10.1212/WNL.26.11.1054
   MARLAS G, 1982, EUR J BIOCHEM, V125, P157, DOI 10.1111/j.1432-1033.1982.tb06663.x
   MIDDLETON P, 1986, P NATL ACAD SCI USA, V83, P4967, DOI 10.1073/pnas.83.13.4967
   MILEDI R, 1980, J PHYSIOL-LONDON, V300, P197, DOI 10.1113/jphysiol.1980.sp013158
   MISHINA M, 1986, NATURE, V321, P406, DOI 10.1038/321406a0
   NEUBIG RR, 1979, P NATL ACAD SCI USA, V76, P690, DOI 10.1073/pnas.76.2.690
   SAKMANN B, 1980, NATURE, V286, P71, DOI 10.1038/286071a0
   SOBEL A, 1977, EUR J BIOCHEM, V80, P215, DOI 10.1111/j.1432-1033.1977.tb11874.x
   VENKATASUBRAMANIAN K, 1986, P NATL ACAD SCI USA, V83, P3171, DOI 10.1073/pnas.83.10.3171
   VIAMONTES GI, 1986, CELL IMMUNOL, V100, P305, DOI 10.1016/0008-8749(86)90031-6
NR 29
TC 41
Z9 42
U1 2
U2 7
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD MAY
PY 1987
VL 84
IS 10
BP 3477
EP 3481
DI 10.1073/pnas.84.10.3477
PG 5
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA H3882
UT WOS:A1987H388200083
PM 2437580
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU KOSZINOWSKI, J
AF KOSZINOWSKI, J
TI RETRACTED: DIFFUSION AND SOLUBILITY OF N-ALKANES IN POLYOLEFINS
   (Retracted article. See vol. 133, 2016)
SO JOURNAL OF APPLIED POLYMER SCIENCE
LA English
DT Article; Retracted Publication
RP KOSZINOWSKI, J (reprint author), FRAUNHOFER INST LEBENSMITTELTECHNOL & VERPACKUNG, SCHRAGENHOFSTR 35, D-8000 MUNCHEN 50, FED REP GER.
CR AVEYARD R, 1970, T FARADAY SOC, V66, P37, DOI 10.1039/tf9706600037
   Barrer RM, 1939, T FARADAY SOC, V35, P0628, DOI 10.1039/tf9393500628
   BARRER RM, 1946, P PHYS SOC LOND, V58, P321, DOI 10.1088/0959-5309/58/3/313
   BARRER RM, 1968, DIFFUSION SOLIDS
   BECKER K, 1983, DTSCH LEBENSM RDSCHA, V8, P257
   CHEN SP, 1980, POLYM ENG SCI, V20, P40, DOI 10.1002/pen.760200108
   Crank J., 1968, DIFFUSION POLYM
   CRATIN PD, 1968, IND ENG CHEM, V60, P14, DOI 10.1021/ie50705a005
   DAVIES M, 1951, J CHEM SOC, P1249, DOI 10.1039/jr9510001249
   DEWAN RK, 1963, J CHEM PHYS, V39, P1820, DOI 10.1063/1.1734536
   DOUGLASS DC, 1958, J PHYS CHEM-US, V62, P1102, DOI 10.1021/j150567a020
   EGGERT J, 1960, LEHRBUCH PHYSIKALISC, P377
   Einstein A., 1956, INVESTIGATIONS THEOR
   Glasstone S., 1941, THEORY RATE PROCESSE
   GOODMAN DS, 1958, J AM CHEM SOC, V80, P3887, DOI 10.1021/ja01548a023
   JOHNSON M, 1975, J APPL POLYM SCI, V19, P1745, DOI 10.1002/app.1975.070190624
   KIECKBUSCH TG, 1979, J CHROMATOGR SCI, V17, P273, DOI 10.1093/chromsci/17.5.273
   KUMINS CA, 1961, J POLYM SCI, V55, P629
   LAWSON AW, 1960, J CHEM PHYS, V32, P131, DOI 10.1063/1.1700886
   MEARES P, 1954, J AM CHEM SOC, V76, P3415, DOI 10.1021/ja01642a015
   MICHAELS AS, 1964, J APPL PHYS, V35, P3165, DOI 10.1063/1.1713195
   MUKERJEE P, 1965, J PHYS CHEM-US, V69, P2821, DOI 10.1021/j100893a003
   PEETERS H, 1979, J CHEM TECHNOL BIOT, V29, P581
   Roseveare WE, 1941, J APPL PHYS, V12, P669, DOI 10.1063/1.1712959
   SPACEK P, 1967, J POLYMER SCI      C, V16, P705
   Sutherland W, 1905, PHILOS MAG, V9, P781, DOI 10.1080/14786440509463331
   VONMEERWALL E, 1979, J APPL POLYM SCI, V23, P877, DOI 10.1002/app.1979.070230322
   WESTLAKE JF, 1975, J APPL POLYM SCI, V19, P319, DOI 10.1002/app.1975.070190201
NR 28
TC 2
Z9 2
U1 3
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0021-8995
EI 1097-4628
J9 J APPL POLYM SCI
JI J. Appl. Polym. Sci.
PD OCT
PY 1986
VL 32
IS 5
BP 4765
EP 4786
DI 10.1002/app.1986.070320501
PG 22
WC Polymer Science
SC Polymer Science
GA E3188
UT WOS:A1986E318800001
DA 2018-12-27
ER

PT J
AU GLUECK, CJ
   MELLIES, MJ
   DINE, M
   PERRY, T
   LASKARZEWSKI, P
AF GLUECK, CJ
   MELLIES, MJ
   DINE, M
   PERRY, T
   LASKARZEWSKI, P
TI RETRACTED: SAFETY AND EFFICACY OF LONG-TERM DIET AND DIET PLUS BILE
   ACID-BINDING RESIN CHOLESTEROL-LOWERING THERAPY IN 73 CHILDREN
   HETEROZYGOUS FOR FAMILIAL HYPERCHOLESTEROLEMIA (Retracted article. See
   vol. 80, pg. 617, 1987)
SO PEDIATRICS
LA English
DT Article; Retracted Publication
C1 UNIV CINCINNATI, COLL MED, CTR LIPID RES, CINCINNATI, OH 45221 USA.
   UNIV CINCINNATI, COLL MED, GEN CLIN RES CTR, CINCINNATI, OH 45221 USA.
   UNIV CINCINNATI, COLL MED, GEN CLIN RES CLINFO CTR, CINCINNATI, OH 45221 USA.
   UNIV CINCINNATI, COLL MED, DEPT MED, CINCINNATI, OH 45221 USA.
   UNIV CINCINNATI, COLL MED, DEPT PEDIAT, CINCINNATI, OH 45221 USA.
FU PHS HHS [68-25, 00068-3-5]; NHLBI NIH HHS [HV2417-L]
CR ARNTZENIUS AC, 1985, NEW ENGL J MED, V312, P805, DOI 10.1056/NEJM198503283121301
   BERENSON GS, 1983, PREV MED, V12, P741, DOI 10.1016/0091-7435(83)90259-1
   BERNSTEIN MJ, 1985, JAMA-J AM MED ASSOC, V253, P2080
   DINE MS, 1981, PEDIATRICS, V67, P506
   DINE MS, 1979, PEDIATRICS, V63, P1
   ENOS WF, 1953, JAMA-J AM MED ASSOC, V152, P1090, DOI 10.1001/jama.1953.03690120006002
   FARAH JR, 1977, LANCET, V1, P59
   FOMON SJ, 1984, PEDIATR RES, V18, P1233, DOI 10.1203/00006450-198412000-00001
   FREDRICKSON DS, 1974, US DHEW NIH73112 PUB
   FRIEDMAN G, 1976, PEDIATRICS, V58, P655
   GLUECK CJ, 1977, AM J DIS CHILD, V131, P162, DOI 10.1001/archpedi.1977.02120150044009
   GLUECK CJ, 1974, PEDIATRICS, V54, P51
   GLUECK CJ, 1973, PEDIATRICS, V52, P669
   GLUECK CJ, 1977, PEDIATRICS, V59, P433
   GLUECK CJ, 1976, PEDIATRICS, V57, P68
   GLUECK CJ, 1980, CHILDHOOD PREVENTION, P155
   GLUECK CJ, 1980, PEDIATRICS PEDIATRIC, V2, P131
   Glueck CJ, 1977, HYPERLIPIDEMIA DIAGN, P17
   GLUECK CJ, 1986, REDUCTION CARDIOVASC
   HJERMANN I, 1981, LANCET, V2, P1303
   HOLMAN RL, 1961, AM J CLIN NUTR, V9, P565, DOI 10.1093/ajcn/9.5.565
   JUDSON JJ, 1971, J AMER MED ASSOC, V216, P1185
   KAGAN AR, 1976, B WORLD HEALTH ORGAN, V53, P485
   KAUFMANN NA, 1982, ISRAEL J MED SCI, V18, P1167
   KWITEROVICH PO, 1986, PEDIATRICS, V78, P349
   LARSEN R, 1974, AM J DIS CHILD, V128, P67, DOI 10.1001/archpedi.1974.02110260069012
   LASKARZEWSKI P, 1980, AM J EPIDEMIOL, V111, P395, DOI 10.1093/oxfordjournals.aje.a112914
   LEVY RI, 1984, CIRCULATION, V69, P325, DOI 10.1161/01.CIR.69.2.325
   MAUER AM, 1985, PEDIATRICS, V76, P125
   MORDASINI R, 1978, MONATSSCHR KINDERH, V126, P436
   NEWMAN WP, 1986, NEW ENGL J MED, V314, P138, DOI 10.1056/NEJM198601163140302
   PUSKA P, 1982, PREV MED, V11, P550, DOI 10.1016/0091-7435(82)90068-8
   RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P351
   ROY CC, 1985, PEDIATR CLIN N AM, V32, P517
   Snedecor G.W., 1967, STATISTICAL METHODS
   STRONG JP, 1968, LAB INVEST, V18, P527
   STRONG JP, 1962, AM J PATHOL, V40, P37
   TELL GS, 1982, PROMOTING ADOLESCENT, P381
   The Lipid Research Clinics Coronary Primary Prevention Trial results II, 1984, JAMA-J AM MED ASSOC, V251, P365
   TSANG RC, 1978, PEDIATR RES, V12, P980, DOI 10.1203/00006450-197810000-00006
   VAUGHAN VC, 1979, NELSON TXB PEDIATRIC, P37
   WEST RJ, 1980, LANCET, V2, P873
   WISSLER RW, 1983, PREV MED, V12, P868, DOI 10.1016/0091-7435(83)90269-4
   1974, US DHEW NIH75678 PUB
   1985, CLIN RES, V33, pA520
   1980, NIH801527 US DEP HLT
NR 46
TC 37
Z9 37
U1 0
U2 4
PU AMER ACAD PEDIATRICS
PI ELK GROVE VILLAGE
PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA
SN 0031-4005
EI 1098-4275
J9 PEDIATRICS
JI Pediatrics
PD AUG
PY 1986
VL 78
IS 2
BP 338
EP 348
PG 11
WC Pediatrics
SC Pediatrics
GA D4187
UT WOS:A1986D418700025
PM 3526270
DA 2018-12-27
ER

PT J
AU BOLDT, J
   VONBORMANN, B
   KLING, D
   BORNER, U
   MULCH, J
   HEMPELMANN, G
AF BOLDT, J
   VONBORMANN, B
   KLING, D
   BORNER, U
   MULCH, J
   HEMPELMANN, G
TI RETRACTED: VOLUME REPLACEMENT WITH A NEW HYDROXYETHYLSTARCH IN
   CARDIAC-SURGERY (Retracted article. See vol. 42, pg. 266, 2015)
SO INFUSIONSTHERAPIE UND KLINISCHE ERNAHRUNG
LA German
DT Article; Retracted Publication
C1 UNIV GIESSEN, HERZ & GEFASSCHIRURG KLIN, D-6300 GIESSEN, GERMANY.
RP BOLDT, J (reprint author), UNIV GIESSEN, ANAESTHESIOL & OPERAT INTENS MED ABT, KLIN STR 29, D-6300 GIESSEN, GERMANY.
CR AHNEFELD F W, 1965, Anaesthesist, V14, P137
   BAMBAUER R, 1984, INFUS KLIN ERN, V11, P157
   BERGMANN H, 1979, ANASTH INTENSIVMED, V16, P156
   CHINARD FP, 1962, CIRC RES, V10, P473, DOI 10.1161/01.RES.10.3.473
   GLINZ W, 1972, HELV CHIR ACTA, V39, P103
   HALMAGYI M, 1984, ANAESTHESIST, V33, P73
   HARKE H, 1980, ANAESTHESIST, V29, P71
   KHOSROPOUR R, 1980, ANAESTHESIST, V29, P616
   KILIAN J, 1981, AKTUELLER UBERBLICK, V8, P2
   KOHLER H, 1982, KLIN WOCHENSCHR, V60, P293, DOI 10.1007/BF01716806
   KOHLER H, 1977, ANAESTHESIST, V26, P623
   KOHLER H, 1978, ANAESTHESIST, V27, P421
   LAMKE L-O, 1976, Resuscitation, V5, P93, DOI 10.1016/0300-9572(76)90029-0
   LEE WH, 1968, J TRAUMA, V8, P121
   LEWIS FR, 1978, SURG FORUM, V29, P182
   LUCAS CE, 1980, J TRAUMA, V20, P446, DOI 10.1097/00005373-198006000-00002
   LUTZ H, 1980, PLASMAERSATZMITTEL
   MESSMER K, 1978, INFUSIONSTHERAPIE, V5, P169
   Messmer K, 1975, Klin Anasthesiol Intensivther, V9, P1
   MIHM FG, 1982, ANESTHESIOLOGY, V57, P116, DOI 10.1097/00000542-198208000-00009
   MITTERMAYER C, 1977, Intensivmedizin, V14, P252
   MOGGIO RA, 1983, CRIT CARE MED, V11, P943, DOI 10.1097/00003246-198312000-00009
   MOLLMANN HW, 1984, ANASTH INTENSIV NOTF, V19, P99, DOI 10.1055/s-2007-1003422
   MOSS GS, 1981, SURGERY, V89, P434
   POKAR H, 1976, VOLUMENREGULATION FL, P59
   RACKOW EC, 1977, CHEST, V72, P709, DOI 10.1378/chest.72.6.709
   Ratcliff NB, 1973, J THORAC CARDIOVASC, V65, P425
   RING J, 1977, ANAESTHESIST, V26, P279
   RING J, 1978, ANASTH INTENSIVMED, V111, P1
   ROSENTHAL M H, 1981, Anesthesiology (Hagerstown), V55, pA81
   SCHONING B, 1975, ANAESTHESIST, V24, P507
   STURM JA, 1984, BEITR INTENSIV NOTFA, V2, P113
   Sunder-Plassmann L, 1972, Z Prakt Anasth Wiederbeleb Intensivther, V7, P95
   UTLEY JR, 1981, ANN THORAC SURG, V31, P121, DOI 10.1016/S0003-4975(10)61530-5
   VIRGILIO RW, 1979, SURGERY, V85, P129
   VONBORMANN B, 1985, ANAESTHESIST, V34, P265
   WEIL MH, 1979, CRIT CARE MED, V7, P113, DOI 10.1097/00003246-197903000-00006
NR 37
TC 25
Z9 25
U1 3
U2 5
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0378-0791
J9 INFUS KLIN ERN
PD JUN
PY 1986
VL 13
IS 3
BP 145
EP 151
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA D1812
UT WOS:A1986D181200006
PM 2427448
DA 2018-12-27
ER

PT J
AU SIDDIQUI, FA
AF SIDDIQUI, FA
TI RETRACTED: PURIFICATION AND IMMUNOLOGICAL CHARACTERIZATION OF DNA
   POLYMERASE-ALPHA FROM HUMAN ACUTE LYMPHOBLASTIC-LEUKEMIA CELLS
   (RETRACTED ARTICLE. SEE VOL 1338, PG 145, 1997)
SO BIOCHIMICA ET BIOPHYSICA ACTA
LA English
DT Article; Retracted Publication
C1 NEW YORK STATE DEPT HLTH, ROSWELL PK MEM INST, GRACE CANC DRUG CTR, BUFFALO, NY 14263 USA.
   NEW YORK STATE DEPT HLTH, ROSWELL PK MEM INST, DEPT EXPTL THERAPEUT, BUFFALO, NY 14263 USA.
CR Alberts B, 1971, METHOD ENZYMOL, V21, P198
   BERGER NA, 1979, BIOCHEM BIOPH RES CO, V89, P218, DOI 10.1016/0006-291X(79)90966-5
   Bollum F J, 1975, Prog Nucleic Acid Res Mol Biol, V15, P109, DOI 10.1016/S0079-6603(08)60118-X
   BOLLUM FJ, 1960, J BIOL CHEM, V235, P2399
   FISHER PA, 1977, J BIOL CHEM, V252, P6528
   GROSSE F, 1981, BIOCHEMISTRY-US, V20, P5470, DOI 10.1021/bi00522a019
   HANAOKA F, 1979, BIOCHEM BIOPH RES CO, V87, P575, DOI 10.1016/0006-291X(79)91833-3
   HOLMES AM, 1975, FEBS LETT, V60, P233, DOI 10.1016/0014-5793(75)80721-6
   HOLMES AM, 1976, EUR J BIOCHEM, V62, P229, DOI 10.1111/j.1432-1033.1976.tb10152.x
   IKEGAMI S, 1978, NATURE, V275, P458, DOI 10.1038/275458a0
   KROKAN H, 1979, BIOCHEMISTRY-US, V18, P4431, DOI 10.1021/bi00587a025
   LOEB LA, 1974, ENZYMES, V10, P173
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   MARTIN RG, 1961, J BIOL CHEM, V236, P1372
   MATSUKAGE A, 1976, BIOCHEMISTRY-US, V15, P5305, DOI 10.1021/bi00669a017
   NOZAKI Y, 1976, BIOCHEMISTRY-US, V15, P3884, DOI 10.1021/bi00662a036
   ONO Y, 1978, GANN, V69, P207
   OTTO B, 1978, NUCLEIC ACIDS RES, V5, P1715, DOI 10.1093/nar/5.5.1715
   SIDDIQUI FA, 1978, BIOCHIM BIOPHYS ACTA, V517, P150, DOI 10.1016/0005-2787(78)90042-4
   SPADARI S, 1975, P NATL ACAD SCI USA, V72, P503, DOI 10.1073/pnas.72.2.503
   SRIVASTAVA BIS, 1980, J BIOCHEM BIOPH METH, V2, P1
   TANABE K, 1976, J BIOCHEM-TOKYO, V79, P85, DOI 10.1093/oxfordjournals.jbchem.a131061
   TANFORD C, 1974, BIOCHEMISTRY-US, V13, P2369, DOI 10.1021/bi00708a021
   WAQAR MA, 1978, NUCLEIC ACIDS RES, V5, P1933, DOI 10.1093/nar/5.6.1933
   Warburg O, 1942, BIOCHEM Z, V310, P384
   WEISSBACH A, 1975, EUR J BIOCHEM, V59, P1, DOI 10.1111/j.1432-1033.1975.tb02416.x
   WEISSBACH A, 1975, SCIENCE, V190, P401, DOI 10.1126/science.1179222
   WEISSBACH A, 1975, CELL, V5, P101, DOI 10.1016/0092-8674(75)90017-3
   YOSHIDA S, 1974, BIOCHIM BIOPHYS ACTA, V353, P463, DOI 10.1016/0005-2787(74)90052-5
NR 29
TC 4
Z9 4
U1 3
U2 8
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0006-3002
J9 BIOCHIM BIOPHYS ACTA
JI Biochim. Biophys. Acta
PY 1983
VL 745
IS 2
BP 154
EP 161
DI 10.1016/0167-4838(83)90044-4
PG 8
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA QY453
UT WOS:A1983QY45300006
PM 6405790
DA 2018-12-27
ER

PT J
AU SWIFT, IE
   MILBORROW, BV
AF SWIFT, IE
   MILBORROW, BV
TI RETRACTED: RETENTION OF THE 4-PRO-R HYDROGEN-ATOM OF MEVALONATE AT
   C-2,2' OF BACTERIORUBERIN IN HALOBACTERIUM-HALOBIUM (Retracted Article.
   See vol 389, pg 919, 2005)
SO BIOCHEMICAL JOURNAL
LA English
DT Article; Retracted Publication
RP SWIFT, IE (reprint author), UNIV NEW S WALES, SCH BIOCHEM, KENSINGTON 2033, NEW S WALES, AUSTRALIA.
CR ANDREWES AG, 1975, ACTA CHEM SCAND B, V29, P884, DOI 10.3891/acta.chem.scand.29b-0884
   ANDREWES AG, 1974, ACTA CHEM SCAND B, VB 28, P737, DOI 10.3891/acta.chem.scand.28b-0737
   BAXTER RM, 1960, CAN J MICROBIOL, V6, P417, DOI 10.1139/m60-047
   BRITTON G, 1977, J CHEM SOC CHEM COMM, P655, DOI 10.1039/c39770000655
   DAVIES BH, 1970, BIOCHEM J, V116, P101, DOI 10.1042/bj1160101
   Davies BH, 1976, CHEMISTRY BIOCHEMIST, P38
   DAVIS JB, 1966, J CHEM SOC C, P2154, DOI 10.1039/j39660002154
   EUGSTER CH, 1969, HELV CHIM ACTA, V52, P1729, DOI 10.1002/hlca.19690520627
   FAHEY D, 1978, PHYTOCHEMISTRY, V17, P2077, DOI 10.1016/S0031-9422(00)89284-5
   Goodwin T.W., 1971, CAROTENOIDS, P577
   GOODWIN TW, 1965, BIOCHEM J, V97, pC28, DOI 10.1042/bj0970028C
   JOHANSEN JE, 1977, TETRAHEDRON, V33, P381, DOI 10.1016/0040-4020(77)80090-2
   KELLY M, 1970, ACTA CHEM SCAND, V24, P2169, DOI 10.3891/acta.chem.scand.24-2169
   LIAAEN-JENSEN S, 1969, Pure and Applied Chemistry, V20, P421, DOI 10.1351/pac196920040421
   LIAAENJENSEN S, 1976, PURE APPL CHEM, V47, P129, DOI 10.1351/pac197647020129
   LIAAENJENSEN S, 1960, ACTA CHEM SCAND, V14, P950
   MARSHALL CL, 1968, BIOCHEM J, V110, P441, DOI 10.1042/bj1100441
   MILBORROW BV, 1972, BIOCHEM J, V128, P1135, DOI 10.1042/bj1281135
   WILLIAMS RJ, 1967, BIOCHEM J, V105, P99, DOI 10.1042/bj1050099
NR 19
TC 8
Z9 8
U1 3
U2 11
PU PORTLAND PRESS LTD
PI LONDON
PA CHARLES DARWIN HOUSE, 12 ROGER STREET, LONDON WC1N 2JU, ENGLAND
SN 0264-6021
EI 1470-8728
J9 BIOCHEM J
JI Biochem. J.
PY 1980
VL 187
IS 1
BP 261
EP 264
DI 10.1042/bj1870261
PG 4
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA JL394
UT WOS:A1980JL39400030
PM 7406867
DA 2018-12-27
ER

EF